{
  "file_name": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
  "total_pages": 129,
  "pdf_type": "normal",
  "font_analysis": {
    "font_sizes_frequency": {
      "26.03999900817871": 3,
      "23.03999900817871": 1,
      "18.0": 1,
      "17.03999900817871": 2,
      "11.039999961853027": 243,
      "15.0": 1483,
      "14.039999961853027": 9,
      "12.0": 1511,
      "9.960000038146973": 232,
      "32.040000915527344": 2,
      "20.03999900817871": 12,
      "15.960000038146973": 32,
      "12.960000038146973": 129,
      "8.279999732971191": 2,
      "9.59999942779541": 3,
      "8.759956359863281": 3,
      "10.199999809265137": 6,
      "7.679999828338623": 2,
      "59.3115234375": 1,
      "58.88851547241211": 1,
      "7.079999923706055": 7
    },
    "heading_sizes": [
      32.040000915527344,
      26.03999900817871,
      20.03999900817871,
      17.03999900817871,
      15.960000038146973,
      15.0,
      14.039999961853027,
      12.960000038146973
    ]
  },
  "table_analysis": {
    "total_tables": 21,
    "tables_info": [
      {
        "bbox": [
          68.04000091552734,
          185.26429748535156,
          531.6412353515625,
          768.50830078125
        ],
        "num_rows": 8,
        "num_cols": 2
      },
      {
        "bbox": [
          62.63999938964844,
          167.75999450683594,
          533.3519897460938,
          344.03997802734375
        ],
        "num_rows": 8,
        "num_cols": 2
      },
      {
        "bbox": [
          69.47999572753906,
          439.55999755859375,
          523.9199829101562,
          717.7200317382812
        ],
        "num_rows": 7,
        "num_cols": 2
      },
      {
        "bbox": [
          63.47999954223633,
          407.8800048828125,
          149.16000366210938,
          460.67999267578125
        ],
        "num_rows": 3,
        "num_cols": 2
      },
      {
        "bbox": [
          66.23999786376953,
          212.1599884033203,
          536.1599731445312,
          746.6400146484375
        ],
        "num_rows": 3,
        "num_cols": 2
      },
      {
        "bbox": [
          105.83999633789062,
          589.6799926757812,
          536.2319946289062,
          645.1199951171875
        ],
        "num_rows": 3,
        "num_cols": 2
      },
      {
        "bbox": [
          74.87999725341797,
          337.91998291015625,
          527.760009765625,
          738.7200317382812
        ],
        "num_rows": 12,
        "num_cols": 4
      },
      {
        "bbox": [
          74.87999725341797,
          167.27999877929688,
          527.760009765625,
          727.5599975585938
        ],
        "num_rows": 10,
        "num_cols": 4
      },
      {
        "bbox": [
          73.19999694824219,
          163.0800018310547,
          522.3599853515625,
          745.6799926757812
        ],
        "num_rows": 15,
        "num_cols": 4
      },
      {
        "bbox": [
          75.0,
          166.55999755859375,
          536.3999633789062,
          704.52001953125
        ],
        "num_rows": 16,
        "num_cols": 3
      },
      {
        "bbox": [
          75.0,
          153.47999572753906,
          536.3999633789062,
          669.6000366210938
        ],
        "num_rows": 13,
        "num_cols": 3
      },
      {
        "bbox": [
          67.43999481201172,
          165.59999084472656,
          530.5199584960938,
          739.4400024414062
        ],
        "num_rows": 11,
        "num_cols": 4
      },
      {
        "bbox": [
          68.04000091552734,
          296.3999938964844,
          532.0800170898438,
          429.1199951171875
        ],
        "num_rows": 11,
        "num_cols": 5
      },
      {
        "bbox": [
          67.08000183105469,
          116.39999389648438,
          530.1599731445312,
          210.71998596191406
        ],
        "num_rows": 6,
        "num_cols": 4
      },
      {
        "bbox": [
          62.39999771118164,
          291.6000061035156,
          534.0,
          734.6400146484375
        ],
        "num_rows": 17,
        "num_cols": 3
      },
      {
        "bbox": [
          62.39999771118164,
          122.03999328613281,
          534.0,
          749.760009765625
        ],
        "num_rows": 24,
        "num_cols": 4
      },
      {
        "bbox": [
          62.39999771118164,
          124.55999755859375,
          534.0,
          612.9600219726562
        ],
        "num_rows": 18,
        "num_cols": 3
      },
      {
        "bbox": [
          73.79999542236328,
          310.1925048828125,
          529.0800170898438,
          690.4762573242188
        ],
        "num_rows": 11,
        "num_cols": 3
      },
      {
        "bbox": [
          67.43999481201172,
          170.63999938964844,
          507.47998046875,
          746.0282592773438
        ],
        "num_rows": 3,
        "num_cols": 3
      },
      {
        "bbox": [
          66.23999786376953,
          171.239990234375,
          527.8800048828125,
          662.8800048828125
        ],
        "num_rows": 11,
        "num_cols": 2
      },
      {
        "bbox": [
          97.43999481201172,
          419.7599792480469,
          530.7601928710938,
          532.1279907226562
        ],
        "num_rows": 5,
        "num_cols": 3
      }
    ]
  },
  "text_blocks": [
    {
      "text": "우울장애 개선 디지털치료기기",
      "font_size": 26.03999900817871,
      "font_name": "H2hdrM",
      "bbox": [
        122.39999389648438,
        236.6072998046875,
        472.91595458984375,
        262.6473083496094
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성·성능 평가 및 임상시험계획서",
      "font_size": 26.03999900817871,
      "font_name": "H2hdrM",
      "bbox": [
        70.08000183105469,
        278.1272888183594,
        525.1204223632812,
        304.16729736328125
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "작성 가이드라인(민원인 안내서)",
      "font_size": 26.03999900817871,
      "font_name": "H2hdrM",
      "bbox": [
        108.0,
        319.7673034667969,
        487.218017578125,
        345.80731201171875
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2022. 12.",
      "font_size": 23.03999900817871,
      "font_name": "T2",
      "bbox": [
        261.8399963378906,
        475.4399719238281,
        353.3540954589844,
        503.06494140625
      ],
      "page_num": 1,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의 료 기 기 심 사 부",
      "font_size": 18.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        195.59999084472656,
        715.88916015625,
        419.6399841308594,
        739.83056640625
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지침서ᆞ안내서 제ᆞ개정 점검표",
      "font_size": 17.03999900817871,
      "font_name": "H2hdrM",
      "bbox": [
        168.0,
        93.37289428710938,
        423.0,
        110.41288757324219
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명칭",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        82.55999755859375,
        137.50430297851562,
        103.08004760742188,
        152.18836975097656
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        132.72000122070312,
        128.62429809570312,
        531.6412353515625,
        143.30836486816406
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인(민원인 안내서)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        132.72000122070312,
        146.26429748535156,
        266.5113220214844,
        160.9483642578125
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아래에 해당하는 사항에 체크하여 주시기 바랍니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        165.0,
        165.7042999267578,
        426.3693542480469,
        180.38836669921875
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등록대상",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        70.79999542236328,
        327.58428955078125,
        114.83966064453125,
        342.26837158203125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "여부",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        81.83999633789062,
        345.2242736816406,
        103.91999816894531,
        359.9083557128906
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        185.26429748535156,
        450.76171875,
        199.9483642578125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서가 있습니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        151.67999267578125,
        200.62429809570312,
        294.8779602050781,
        215.30836486816406
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        185.26429748535156,
        506.6396484375,
        215.30836486816406
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        185.26429748535156,
        506.6396484375,
        215.30836486816406
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        220.06430053710938,
        527.760009765625,
        234.7483673095703
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "으로 고려하시기 바랍니다. 그럼에도 불구하고 동 지침서ㆍ안내서의 제정이",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.63999938964844,
        235.54429626464844,
        531.6412353515625,
        265.5883483886719
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.63999938964844,
        235.54429626464844,
        531.6412353515625,
        265.5883483886719
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(사유 :                                                                )",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        266.2642822265625,
        525.4837646484375,
        280.9483642578125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 법령(법ㆍ시행령ㆍ시행규칙) 또는",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        282.94427490234375,
        314.6809997558594,
        297.62835693359375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.87998962402344,
        299.5042724609375,
        415.72100830078125,
        330.74835205078125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나열한 것입니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.87998962402344,
        299.5042724609375,
        415.72100830078125,
        330.74835205078125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        291.82427978515625,
        506.6396484375,
        321.86834716796875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        291.82427978515625,
        506.6396484375,
        321.86834716796875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        332.624267578125,
        506.6396484375,
        362.7883605957031
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        332.624267578125,
        506.6396484375,
        362.7883605957031
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        332.624267578125,
        506.6396484375,
        362.7883605957031
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 일회성 지시ㆍ명령에 해당하는 내용입니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        367.5442810058594,
        506.6396484375,
        397.5883483886719
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        367.5442810058594,
        506.6396484375,
        397.5883483886719
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        367.5442810058594,
        506.6396484375,
        397.5883483886719
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 외국 규정을 단순 번역하거나 설명하는 내용입니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        402.4642639160156,
        506.6396484375,
        432.50836181640625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        402.4642639160156,
        506.6396484375,
        432.50836181640625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        402.4642639160156,
        506.6396484375,
        432.50836181640625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        437.2642822265625,
        438.88092041015625,
        451.9483642578125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정리한 자료입니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.16000366210938,
        452.7442626953125,
        251.56101989746094,
        467.4283447265625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        437.2642822265625,
        506.6396484375,
        467.4283447265625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        437.2642822265625,
        506.6396484375,
        467.4283447265625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        472.18426513671875,
        525.7349853515625,
        502.2283630371094
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        472.18426513671875,
        525.7349853515625,
        502.2283630371094
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.23999786376953,
        531.1043090820312,
        122.52259063720703,
        545.788330078125
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구분",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        81.83999633789062,
        548.7443237304688,
        103.91999816894531,
        563.4283447265625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        507.1042785644531,
        446.8798522949219,
        521.788330078125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준이나 절차를 제시하는 것입니까? (공무원용)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.27999877929688,
        522.4642944335938,
        375.3637390136719,
        537.1483154296875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예(☞지침서)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        507.1042785644531,
        527.7637329101562,
        537.1483154296875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        507.1042785644531,
        527.7637329101562,
        537.1483154296875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        541.904296875,
        450.76129150390625,
        556.5883178710938
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        150.72000122070312,
        557.38427734375,
        450.7612609863281,
        587.4283447265625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기술하는 것입니까? (민원인용)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        150.72000122070312,
        557.38427734375,
        450.7612609863281,
        587.4283447265625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 예(☞안내서)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        549.5842895507812,
        531.6412353515625,
        579.7483520507812
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        549.5842895507812,
        531.6412353515625,
        579.7483520507812
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기타 확인",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        68.04000091552734,
        608.5042724609375,
        117.5999984741211,
        623.1882934570312
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사항",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        81.83999633789062,
        626.144287109375,
        103.91999816894531,
        640.8283081054688
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        592.184326171875,
        450.7625427246094,
        606.8683471679688
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민원인을 구속하는 내용이 있습니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        151.67999267578125,
        607.664306640625,
        338.1979675292969,
        622.3483276367188
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        592.184326171875,
        506.6396484375,
        622.3483276367188
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        592.184326171875,
        506.6396484375,
        622.3483276367188
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        624.2243041992188,
        527.7615356445312,
        638.9083251953125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안내서 제ㆍ개정 절차를 진행하시기 바랍니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.52000427246094,
        639.7042846679688,
        382.81500244140625,
        654.3883056640625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상기 사항에 대하여 확인하였음.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        213.239990234375,
        664.7843017578125,
        379.08935546875,
        679.4683227539062
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2022년  12월  14일",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        238.79998779296875,
        704.9843139648438,
        342.1199951171875,
        719.6683349609375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "담당자",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        276.239990234375,
        739.5443115234375,
        350.9913024902344,
        768.50830078125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확  인(부서장)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        276.239990234375,
        739.5443115234375,
        350.9913024902344,
        768.50830078125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "양 승 하",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        475.1999816894531,
        737.8643188476562,
        519.9599609375,
        752.54833984375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 원 규",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        475.1999816894531,
        755.5042724609375,
        519.9599609375,
        770.1882934570312
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제·개정 이력",
      "font_size": 17.03999900817871,
      "font_name": "MalgunGothicBold",
      "bbox": [
        249.0,
        93.05402374267578,
        346.20001220703125,
        115.71855163574219
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애 개선 디지털치료기기 안전성·성능 평가 및",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        119.75999450683594,
        143.03431701660156,
        480.71343994140625,
        162.98548889160156
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험계획서 작성 가이드라인(민원인 안내서)",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        131.75999450683594,
        165.5943145751953,
        464.1286315917969,
        185.5454864501953
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제·개정번호",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        82.91999816894531,
        216.07916259765625,
        440.3994140625,
        234.7534637451172
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "승인일자",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        82.91999816894531,
        216.07916259765625,
        440.3994140625,
        234.7534637451172
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주요 내용",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        82.91999816894531,
        216.07916259765625,
        440.3994140625,
        234.7534637451172
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안내서-1258-01",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        262.6391296386719,
        259.7549133300781,
        281.3134460449219
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "’22.12.14.",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        262.6391296386719,
        259.7549133300781,
        281.3134460449219
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "우울장애 개선 디지털치료기기 안전성·성능",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        287.1600036621094,
        246.25946044921875,
        533.4187622070312,
        298.22039794921875
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가 및 임상시험계획서 작성 가이드라인",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        287.1600036621094,
        246.25946044921875,
        533.4187622070312,
        298.22039794921875
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(민원인 안내서) 제정",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        287.1600036621094,
        246.25946044921875,
        533.4187622070312,
        298.22039794921875
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 안내서는 우울장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        69.5999984741211,
        92.0594482421875,
        534.0187377929688,
        108.0203857421875
      ],
      "page_num": 5,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "작성에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        69.5999984741211,
        116.0594482421875,
        526.7849731445312,
        132.0203857421875
      ],
      "page_num": 5,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        69.5999984741211,
        140.0594482421875,
        529.7999877929688,
        156.0203857421875
      ],
      "page_num": 5,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        69.5999984741211,
        164.0594482421875,
        534.0187377929688,
        180.0203857421875
      ],
      "page_num": 5,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아님을 알려드립니다. 또한, 본 안내서는 2022년 12월 현재의 과학적ㆍ기술적 사실",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        69.5999984741211,
        188.0594482421875,
        534.0187377929688,
        204.0203857421875
      ],
      "page_num": 5,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정법규 내용 및 구체적인",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        69.5999984741211,
        212.0594482421875,
        534.0187377929688,
        228.0203857421875
      ],
      "page_num": 5,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        69.5999984741211,
        236.0594482421875,
        390.2250061035156,
        252.0203857421875
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설명하거나",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        74.5199966430664,
        265.6397399902344,
        528.2615966796875,
        278.8872985839844
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품의약품안전처 지침서 등의",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        87.83999633789062,
        281.5997619628906,
        528.2620239257812,
        294.8473205566406
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관리에 관한 규정 제2조)",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        87.83999633789062,
        299.3597412109375,
        200.07467651367188,
        312.6072998046875
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 관련 규정",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        357.72747802734375,
        140.87998962402344,
        370.38372802734375
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 「의료기기법」 제2조 (정의)",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        381.72747802734375,
        254.6699981689453,
        394.38372802734375
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 「의료기기법」 제3조 (등급분류와 지정)",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        405.72747802734375,
        320.66998291015625,
        418.38372802734375
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 「의료기기법」 제10조 (임상시험계획의 승인 등)",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        429.72747802734375,
        368.66998291015625,
        442.38372802734375
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 「의료기기법 시행규칙」 제9조 (기술문서 등의 심사)",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        453.72747802734375,
        392.66998291015625,
        466.38372802734375
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(5) 「의료기기법 시행규칙」 제20조 (임상시험계획의 승인 등)",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        477.72747802734375,
        422.66998291015625,
        490.38372802734375
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 「의료기기법 시행규칙」 제24조 (임상시험 실시기준 등)",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        501.72747802734375,
        410.66998291015625,
        514.3837280273438
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(7) 「의료기기 허가·신고·심사 등에 관한 규정」",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        525.7274780273438,
        361.1999816894531,
        538.3837280273438
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(8) 「의료기기 임상시험계획 승인에 관한 규정」",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        549.7274780273438,
        349.1999816894531,
        562.3837280273438
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 문의처",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        621.7274780273438,
        122.87999725341797,
        634.3837280273438
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식품의약품안전처 식품의약품안전평가원 의료기기심사부 첨단의료기기과",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        645.7274780273438,
        485.6399841308594,
        658.3837280273438
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화 : (043) 719-3912",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        669.7274780273438,
        202.44000244140625,
        682.3837280273438
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "FAX : (043) 719-3900",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.63999938964844,
        693.7274780273438,
        201.83999633789062,
        706.3837280273438
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "목",
      "font_size": 32.040000915527344,
      "font_name": "T6",
      "bbox": [
        240.1199951171875,
        107.04000091552734,
        352.20001220703125,
        145.48800659179688
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "차",
      "font_size": 32.040000915527344,
      "font_name": "T6",
      "bbox": [
        240.1199951171875,
        107.04000091552734,
        352.20001220703125,
        145.48800659179688
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅰ. 개 요 ········································································ 1",
      "font_size": 20.03999900817871,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        192.41812133789062,
        538.5,
        213.55406188964844
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 배경 및 목적 ················································································ 1",
      "font_size": 15.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        232.5243682861328,
        538.4999389648438,
        249.357177734375
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 적용 범위 ······················································································ 1",
      "font_size": 15.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        264.5643615722656,
        538.4999389648438,
        281.3971862792969
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 용어 설명 ······················································································ 3",
      "font_size": 15.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        296.6043701171875,
        538.4999389648438,
        313.43719482421875
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 현황 ································································································ 4",
      "font_size": 15.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        328.52435302734375,
        538.4999389648438,
        345.357177734375
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅱ. 안전성·성능 평가 ·············································· 29",
      "font_size": 20.03999900817871,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        376.4981384277344,
        538.4998779296875,
        397.6340637207031
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 국내외 관련 규격 및 가이드라인 ·········································· 29",
      "font_size": 15.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        416.6043395996094,
        538.5006103515625,
        433.4371643066406
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 안전성 평가 항목 ······································································ 33",
      "font_size": 15.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        448.52435302734375,
        538.5006103515625,
        465.357177734375
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 성능 평가 항목 ·········································································· 44",
      "font_size": 15.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        480.5643615722656,
        538.5006103515625,
        497.3971862792969
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅲ. 임상시험계획서 작성 시 고려사항 및 예시 ·· 46",
      "font_size": 20.03999900817871,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        528.4181518554688,
        538.4998779296875,
        549.5540771484375
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅳ. 참고문헌 ······························································ 119",
      "font_size": 20.03999900817871,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        600.4181518554688,
        538.499755859375,
        621.5540771484375
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 1 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        803.6103515625,
        311.7449951171875,
        813.5703125
      ],
      "page_num": 8,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅰ",
      "font_size": 20.03999900817871,
      "font_name": "T9",
      "bbox": [
        68.4000015258789,
        91.31999969482422,
        168.3599853515625,
        115.36800384521484
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개 요",
      "font_size": 20.03999900817871,
      "font_name": "H2hdrM",
      "bbox": [
        68.4000015258789,
        91.31999969482422,
        168.3599853515625,
        115.36800384521484
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 배경 및 목적",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        145.05995178222656,
        181.19970703125,
        161.01995849609375
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식품의약품안전처는 정부 지원 과제 중 디지털치료기기에 특화된",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        188.349365234375,
        546.0599975585938,
        204.169677734375
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과제의 제품 설계부터 제품화에 필요한 안전성·성능 평가 및 임상시험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        218.349365234375,
        538.5599975585938,
        234.169677734375
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "계획서 작성 방법 제공을 통한 신속 제품화 지원을 하고 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        248.349365234375,
        488.0029602050781,
        264.169677734375
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 가이드라인은 “우울장애 개선 디지털치료기기”의 안전성 및 성능",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        278.349365234375,
        546.0599975585938,
        294.169677734375
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가 방법, 임상시험계획서 작성 시 고려사항 및 예시를 구체적으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        308.349365234375,
        545.9400024414062,
        324.169677734375
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시하여 신속 제품화를 위한 맞춤형 기술 지원을 목적으로 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        338.349365234375,
        510.5629577636719,
        354.169677734375
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 적용 범위",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        66.0,
        406.8999328613281,
        158.52000427246094,
        422.85992431640625
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 가이드라인에서 다루는 우울장애 개선 디지털치료기기는 「의료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        450.1893615722656,
        538.5599975585938,
        466.0096740722656
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기 품목 및 품목별 등급에 관한 규정(식약처 고시 제2021-83호)」의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        480.1893615722656,
        545.9400024414062,
        496.0096740722656
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품목 분류에 따라 정서장애치료소프트웨어(2등급, E06070.01) 의료기기로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        510.18939208984375,
        546.0599975585938,
        526.0097045898438
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분류된다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        540.1893920898438,
        125.81999969482422,
        556.0097045898438
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단, 추후 우울장애 외 동반된 정신과적 증상에 대한 평가 또는 치료를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        570.1893920898438,
        546.0599975585938,
        586.0097045898438
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동시에 목적으로 한다면 심리평가소프트웨어(2등급, E06050.01) 또는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        600.1893310546875,
        546.0599975585938,
        616.0096435546875
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인지치료소프트웨어(2등급, E06060.02)의 의료기기 분류를 추가하여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        630.1893310546875,
        546.0599975585938,
        646.0096435546875
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조합의료기기로 분류할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        660.1893310546875,
        278.1229553222656,
        676.0096435546875
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 2 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        803.6103515625,
        311.7449951171875,
        813.5703125
      ],
      "page_num": 9,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품목명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        79.68000030517578,
        123.83999633789062,
        454.67999267578125,
        138.239990234375
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영문명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        79.68000030517578,
        123.83999633789062,
        454.67999267578125,
        138.239990234375
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등급",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        79.68000030517578,
        123.83999633789062,
        454.67999267578125,
        138.239990234375
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분류번호",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        79.68000030517578,
        123.83999633789062,
        454.67999267578125,
        138.239990234375
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품목정의",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        79.68000030517578,
        123.83999633789062,
        454.67999267578125,
        138.239990234375
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인지치료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.63999938964844,
        167.75999450683594,
        122.63999938964844,
        182.1599884033203
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.63999938964844,
        186.95999145507812,
        128.63999938964844,
        201.3599853515625
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Cognitive",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        157.3199920654297,
        158.16000366210938,
        204.86399841308594,
        172.55999755859375
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "therapy",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        162.1199951171875,
        177.36000061035156,
        200.1119842529297,
        191.75999450683594
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "software",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        159.47999572753906,
        196.55999755859375,
        202.70399475097656,
        210.95999145507812
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        236.51998901367188,
        177.36000061035156,
        315.8399963378906,
        191.75999450683594
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "E06060.02",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        236.51998901367188,
        177.36000061035156,
        315.8399963378906,
        191.75999450683594
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인지기능을 개선하는 데 사용하는 소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        326.6399841308594,
        167.75999450683594,
        531.239990234375,
        182.1599884033203
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가상·증강(VR·AR) 기반 소프트웨어를 포함",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        326.6399841308594,
        186.95999145507812,
        531.47998046875,
        201.3599853515625
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "심리평가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.63999938964844,
        239.0399932861328,
        122.63999938964844,
        253.4399871826172
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.63999938964844,
        258.239990234375,
        128.63999938964844,
        272.6399841308594
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Psychological",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        146.27999877929688,
        229.4399871826172,
        215.9399871826172,
        243.83998107910156
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "assessment",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        150.36000061035156,
        248.63998413085938,
        211.739990234375,
        263.03997802734375
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "software",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        159.47999572753906,
        267.8399963378906,
        202.70399475097656,
        282.239990234375
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        236.51998901367188,
        239.0399932861328,
        533.3519897460938,
        263.03997802734375
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "E06050.01",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        236.51998901367188,
        239.0399932861328,
        533.3519897460938,
        263.03997802734375
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료인이 환자의 심리적 상태를 평가,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        236.51998901367188,
        239.0399932861328,
        533.3519897460938,
        263.03997802734375
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결정하는 데 사용하기 위한 소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        326.6399841308594,
        258.239990234375,
        533.0399780273438,
        272.6399841308594
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정서장애치료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        62.63999938964844,
        310.44000244140625,
        134.63999938964844,
        324.8399963378906
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.63999938964844,
        329.6399841308594,
        128.63999938964844,
        344.03997802734375
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Affective",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        159.36000061035156,
        291.239990234375,
        202.82400512695312,
        305.6399841308594
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "disorder",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.55999755859375,
        310.44000244140625,
        201.72000122070312,
        324.8399963378906
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "therapy",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        162.1199951171875,
        329.6399841308594,
        200.1119842529297,
        344.03997802734375
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "software",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        159.47999572753906,
        348.8399963378906,
        202.70399475097656,
        363.239990234375
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        236.51998901367188,
        320.03997802734375,
        315.8399963378906,
        334.4399719238281
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "E06070.01",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        236.51998901367188,
        320.03997802734375,
        315.8399963378906,
        334.4399719238281
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정서장애(우울장애 등)를 개선하는데 사",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        326.6399841308594,
        300.8399963378906,
        533.3999633789062,
        315.239990234375
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용하는 소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        326.6399841308594,
        320.03997802734375,
        426.47998046875,
        334.4399719238281
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가상ㆍ증강(VRㆍAR) 기반 소프트웨어를 포함",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        326.6399841308594,
        339.239990234375,
        532.7999877929688,
        353.6399841308594
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표 1. 우울장애 개선 디지털치료기기 관련 의료기기 품목(식약처 고시 제2021-83호)",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        60.959999084472656,
        95.15999603271484,
        533.4417724609375,
        110.71199798583984
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 본 가이드라인에서 다루는 우울장애 개선 디지털치료기기는 소프트웨어 의료",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        56.63999938964844,
        393.3599853515625,
        538.4400024414062,
        408.9119873046875
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기로서, 사용 시 필요한 범용 장비(스마트폰 또는 태블릿 PC 등)는 적용",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        419.3999938964844,
        538.4400024414062,
        434.9519958496094
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "범위에 포함되지 않으나, 반드시 함께 병용해야 하므로 전기용품 안전 인증과",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        445.32000732421875,
        538.439453125,
        460.87200927734375
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전자파 적합성 인증을 통과한 제품을 사용해야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        471.3599853515625,
        397.8551940917969,
        486.9119873046875
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 실생활 습관을 추적 관찰하기 위해 기타 웨어러블 의료기기를 추가로 사용하는",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        56.63999938964844,
        497.3999938964844,
        538.4400024414062,
        512.9519653320312
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우는 별도의 안전성과 성능 시험을 통과한 제품의 사용을 권고한다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        523.3199462890625,
        478.7351989746094,
        538.8719482421875
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 3 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        803.6103515625,
        311.7449951171875,
        813.5703125
      ],
      "page_num": 10,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 용어 설명",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        66.0,
        93.4599609375,
        158.52000427246094,
        109.41996002197266
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 소프트웨어 의료기기(Software as a Medical Device, SaMD)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        134.70936584472656,
        487.6875,
        150.52967834472656
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하드웨어에 종속되지 않고 의료기기의 사용 목적에 부합하는 기능을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        164.70936584472656,
        546.0599975585938,
        180.52967834472656
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가지며 독립적인 형태의 소프트웨어만으로 이루어진 의료기기이다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        194.70936584472656,
        538.04296875,
        210.52967834472656
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 디지털치료기기(Digital Therapeutics)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        224.70936584472656,
        332.4075012207031,
        240.52967834472656
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인(민원인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        254.70938110351562,
        538.5599975585938,
        270.5296936035156
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방, 관리, 치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        284.7093811035156,
        538.4400024414062,
        300.5296936035156
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하기 위해 환자에게 근거 기반의 치료적 개입을 제공하는 소프트웨어",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        314.7093811035156,
        546.0599975585938,
        330.5296936035156
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기(SaMD)이다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        344.7093811035156,
        215.60296630859375,
        360.5296936035156
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 정신질환의 진단 및 통계 편람(Diagnostic and Statistical Manual of",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        374.7093811035156,
        545.9400024414062,
        390.5296936035156
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Mental Disorders, Fifth Edition, DSM-5)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.04000091552734,
        404.7093505859375,
        350.4075012207031,
        420.5296630859375
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미국 정신의학협회(American Psychiatric Association, APA)에서 발행한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        434.7093505859375,
        546.0599975585938,
        450.5296630859375
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정신질환의 신뢰할 만한 진단이 가능하도록 고안된 관련 기준들을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        464.7093505859375,
        546.0599975585938,
        480.5296630859375
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통칭하는 정신질환 분류법이다. DSM-5는 2013년도의 새로운 업데이트",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        494.7093505859375,
        546.0599975585938,
        510.5296630859375
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "버전이다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        524.7093505859375,
        140.00296020507812,
        540.5296630859375
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 4 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        803.6103515625,
        311.7449951171875,
        813.5703125
      ],
      "page_num": 11,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 현황",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        93.4599609375,
        117.1199951171875,
        109.41996002197266
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 우울장애 인구학적 특성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        136.74937438964844,
        248.1599884033203,
        152.56968688964844
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질병관리청에서 실시한 2020년 국민건강영양조사에 따르면 전국",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        166.74937438964844,
        546.0599975585938,
        182.56968688964844
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "만 19세 이상 성인을 대상으로 조사한 우울장애 유병률은 5.3%이었다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        196.74937438964844,
        545.9400024414062,
        212.56968688964844
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "남성이 4.4%, 여성이 6.2%로 남성보다 여성이 우울장애 유병률이 약",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        226.74937438964844,
        545.9400024414062,
        242.56968688964844
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1.4배 더 높다. 연령별로 유병률을 살펴보면 전 연령층에서 우울장애가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        256.7493591308594,
        546.0599975585938,
        272.5696716308594
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발병하나, 19~29세에서 유병률이 8.3%로 가장 높고, 30~39세 6.8%,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        286.7493591308594,
        545.9400024414062,
        302.5696716308594
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "40~49세 4.9%, 50~59세 2.4%, 60~69세 4.3%, 70세 이상 5.3%로 연령이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        316.7493591308594,
        545.9400024414062,
        332.5696716308594
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증가할수록 유병률이 감소하다가 50대 이후 다시 증가하는 U자형",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        346.7493591308594,
        546.0599975585938,
        362.5696716308594
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모양이다. 성별 기준으로는 남성 30~39세 6.5%, 여성 19~29세에서",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        376.7493591308594,
        545.9400024414062,
        392.5696716308594
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "11.3%로 가장 우울장애 유병률이 높다. 다만 우울장애 의사 진단",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        406.7493591308594,
        545.9400024414062,
        422.5696716308594
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경험률은 4.9%이며, 남성이 3.0%, 여성이 6.8%로 여성이 2.3배 높다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        436.7493591308594,
        546.0599975585938,
        452.5696716308594
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "70세 이상에서 6.6%로 우울장애 의사 진단 경험률이 가장 높으며,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        466.7493591308594,
        545.9400024414062,
        482.5696716308594
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연령별로는 유병률과 마찬가지로 U자형 모양를 띄고 있다. 성별 기준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        496.7493591308594,
        538.5599975585938,
        512.5697021484375
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로는 남성은 19~29세 4.7%, 여성은 60~69세 8.8%로 우울장애 의사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        526.7493896484375,
        546.0599975585938,
        542.5697021484375
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단 경험률이 가장 높다. 2008년 우울장애 의사 진단 경험률이 2.9%에서",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        556.7493896484375,
        545.9400024414062,
        572.5697021484375
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2020년 4.9%에 이르기까지 우울장애 의사 진단 경험률이 꾸준하게 증가하고",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        586.7493896484375,
        546.0599975585938,
        602.5697021484375
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있으며, 이와 더불어 자살 계획률과 정신 문제 상담 경험률도 증가하고",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        616.7493896484375,
        545.9400024414062,
        632.5697021484375
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        646.7493896484375,
        90.68296813964844,
        662.5697021484375
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애는 다른 정신질환과 동반 위험이 크다. 대표적으로 알코올",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        676.7493896484375,
        546.0599975585938,
        692.5697021484375
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중독과 같은 물질 사용 장애(substance use disorder), 공황장애(panic",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        706.7493286132812,
        546.0599975585938,
        722.5696411132812
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "disorder)를 비롯해 불안장애(anxiety disorder), 강박장애(obsessive-",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        736.7493286132812,
        546.0599975585938,
        752.5696411132812
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 5 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        803.6103515625,
        311.7449951171875,
        813.5703125
      ],
      "page_num": 12,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "compulsive disorder), 사회불안장애(social anxiety disorder)등과 동반",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        545.9400024414062,
        100.72968292236328
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이환 위험성이 높다. 이러한 동반 질환은 진단과 치료에 부정적인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        114.90937042236328,
        546.0599975585938,
        130.72967529296875
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영향을 끼치며, 동반 질환도 함께 치료해야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        144.9093780517578,
        401.72296142578125,
        160.7296905517578
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 우울장애 진단 절차/과정",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        204.90936279296875,
        252.83999633789062,
        220.72967529296875
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DSM-5에서 기분장애(mood disorder)를 양극성 및 관련 장애(bipolar",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        234.90936279296875,
        546.0599975585938,
        250.72967529296875
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and related disorder)와 우울장애(depressive disorder)로 분류하고 있으며,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        264.90936279296875,
        546.0599975585938,
        280.72967529296875
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애는 주요우울장애(major depressive disorder), 지속성 우울장애",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        294.90936279296875,
        538.5599975585938,
        310.72967529296875
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(persistent depressive disorder), 월경 전 불쾌감 장애(premenstrual",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        324.90936279296875,
        546.0599975585938,
        340.72967529296875
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "dysphoric",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        354.90936279296875,
        546.0599975585938,
        370.72967529296875
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "disorder)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        354.90936279296875,
        546.0599975585938,
        370.72967529296875
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        354.90936279296875,
        546.0599975585938,
        370.72967529296875
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구분하고",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        354.90936279296875,
        546.0599975585938,
        370.72967529296875
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        354.90936279296875,
        546.0599975585938,
        370.72967529296875
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Patient",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        354.90936279296875,
        546.0599975585938,
        370.72967529296875
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Health",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        354.90936279296875,
        546.0599975585938,
        370.72967529296875
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Questionnaire-9 (PHQ-9)과 같은 우울장애 선별도구로 선별 검사할 수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        384.90936279296875,
        545.9400024414062,
        400.72967529296875
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있으며, 진단은 DSM-5의 진단기준을 적용한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        414.90936279296875,
        372.3229675292969,
        430.72967529296875
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요우울장애 진단을 위해서는 다음의 증상 중 5가지 이상이 2주일",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        444.90936279296875,
        545.9400024414062,
        460.72967529296875
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상 지속되었는지 확인해야 한다. (1) 주관적 보고나 타인에 의한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        474.90936279296875,
        546.0599975585938,
        490.72967529296875
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관찰로 나타난 거의 매일 또는 거의 하루 내내 우울한 기분, (2) 거의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        504.90936279296875,
        545.9400024414062,
        520.7296752929688
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "매일, 하루 대부분 활동에서 현저히 감소한 흥미, (3) 식이요법을 하지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        534.9093627929688,
        545.9400024414062,
        550.7296752929688
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않는 중에 의미 있는 체중 감량과 체중증가 또는 거의 매일의 식욕의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        564.9093627929688,
        546.0599975585938,
        580.7296752929688
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "감소 또는 증가, (4) 거의 매일 불면 또는 과수면, (5) 거의 매일 정신",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        594.9093627929688,
        538.4400024414062,
        610.7296752929688
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "운동 흥분 또는 지체, (6) 거의 매일 피로 또는 에너지 상실, (7) 거의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        624.9093627929688,
        546.0599975585938,
        640.7296752929688
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "매일 무가치감 또는 과도하고 부적절한 죄책감을 느낌, (8) 거의 매일",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        654.9093627929688,
        545.9400024414062,
        670.7296752929688
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사고와 집중 능력의 감퇴 또는 결정 논란, (9) 반복적인 죽음에 관한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        684.9093627929688,
        545.9400024414062,
        700.7296752929688
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생각 또는 구체적인 계획이 없는 반복적 자살 사고나 자살 시도 또는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        714.9093627929688,
        545.9400024414062,
        730.7296752929688
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자살하려는 구체적 계획 등이 나타나며, 적어도 하나의 증상이 해당해야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        744.9093627929688,
        546.0599975585938,
        760.7296752929688
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 6 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        803.6103515625,
        311.7449951171875,
        813.5703125
      ],
      "page_num": 13,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한 증상이 임상적으로 의미 있는 고통을 일으키거나 사회적, 직업적,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        546.0599975585938,
        100.72968292236328
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 중요한 기능 영역에서 손상을 일으키며, 증상이 물질에 대한 직접적",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        114.90937042236328,
        545.9400024414062,
        130.72967529296875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생리적 효과 또는 일반적 의학적 상태 때문이 아니어야 한다. 환자의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        144.9093780517578,
        546.0599975585938,
        160.7296905517578
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증상이 조현정동장애, 조현병, 조현 형장에, 망상장애, 혹은 기타 정신병적",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        174.9093780517578,
        546.0599975585938,
        190.7296905517578
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장애로 잘 설명되지 않아야 하며, 과거 조증 혹은 경조증 삽화가 없어야",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        204.90936279296875,
        545.9400024414062,
        220.72967529296875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        234.90936279296875,
        90.08296966552734,
        250.72967529296875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지속성 우울장애는 기분저하증 혹은 감정 부전 장애로도 불리며, 최소",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        264.90936279296875,
        546.0599975585938,
        280.72967529296875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2년 동안 주관적, 객관적으로 거의 종일 우울한 기분이 지속된다. 진단을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        294.90936279296875,
        545.9400024414062,
        310.72967529296875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해서는 우울한 기간 다음의 증상 6가지 중 2가지 이상이 존재하는지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        324.90936279296875,
        546.0599975585938,
        340.72967529296875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인해야 한다. (1) 식욕 저하 혹은 과식, (2) 불면 혹은 과수면, (3) 기력",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        354.90936279296875,
        545.9400024414062,
        370.72967529296875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "저하 혹은 피로, (4) 낮은 자존감, (5) 집중 감소 또는 결정 내리기 어려움,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        384.90936279296875,
        545.9400024414062,
        400.72967529296875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(6) 절망감 등의 증상이 이에 해당한다. 조증 삽화, 혼합성 삽화, 또는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        414.90936279296875,
        546.0599975585938,
        430.72967529296875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경조증 삽화를 만족시킨 적이 없어야 하며 순환성 장애를 만족시킨 적이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        444.90936279296875,
        545.9400024414062,
        460.72967529296875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없어야 한다. 만성적인 정신병적 증상의 경과 중에 발생한 것이 아니어야",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        474.90936279296875,
        545.9400024414062,
        490.72967529296875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하며, 물질이나 내과적 상태 때문이 아니어야 한다. 이러한 증상으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        504.90936279296875,
        546.0599975585938,
        520.7296752929688
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인해 사회적, 직업적, 기타 기능 영역에서 임상적으로 현저한 고통이나",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        534.9093627929688,
        545.9400024414062,
        550.7296752929688
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "손상을 초래하는지 확인해야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        564.9093627929688,
        288.2029724121094,
        580.7296752929688
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애는 특정 양상(specifier)에 따라 분류할 수 있으며 각각의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        594.9093627929688,
        545.9400024414062,
        610.7296752929688
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성이 달라 약물 선택 등의 치료 방향 결정을 다르게 해야 한다. 크게",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        624.9093627929688,
        546.0599975585938,
        640.7296752929688
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불안증(anxious distress) 동반, 혼재성 양상(mixed features) 동반, 멜랑",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        654.9093627929688,
        538.5599975585938,
        670.7296752929688
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "콜리아 양상(melancholic features) 동반, 비전형적 양상(atypical features)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        684.9093627929688,
        546.0599975585938,
        700.7296752929688
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동반, 정신병적 양상(psychotic features) 동반, 긴장증(catatonia) 동반,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        714.9093627929688,
        546.0599975585938,
        730.7296752929688
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주산기 발병(peripartum onset) 동반, 계절성(seasonal patterns) 동반으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        744.9093627929688,
        546.0599975585938,
        760.7296752929688
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 7 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        803.6103515625,
        311.7449951171875,
        813.5703125
      ],
      "page_num": 14,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        163.40296936035156,
        100.72968292236328
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애 환자는 기분 증상 외에도 사고 증상, 인지 증상, 정신운동",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        114.90937042236328,
        545.9400024414062,
        130.72967529296875
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증상, 신체 증상, 정신병적 증상 등이 다양하게 나타나기 때문에 복잡한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        144.9093780517578,
        545.9400024414062,
        160.7296905517578
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "감별이 있을 수 있다. 인지 증상의 저하로 인한 가성치매로 인해 치매",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        174.9093780517578,
        545.9400024414062,
        190.7296905517578
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자와 감별해야 하며, 정신병적 증상이 조현병 또는 우울장애 때문인지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        204.90936279296875,
        545.9400024414062,
        220.72967529296875
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "감별해야 하며, 환자가 호소하는 여러 가지 신체 증상이 기질적인 문제",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        234.90936279296875,
        545.9400024414062,
        250.72967529296875
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "때문인지 감별할 필요가 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        264.90936279296875,
        266.3399963378906,
        280.72967529296875
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 8 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        803.6103515625,
        311.7449951171875,
        813.5703125
      ],
      "page_num": 15,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(출처 : 일차 의료용 근거 기반 우울장애 임상진료지침(대한의학회, 2022))",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        95.87999725341797,
        549.1199951171875,
        499.3320007324219,
        563.52001953125
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 9 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        803.6103515625,
        311.7449951171875,
        813.5703125
      ],
      "page_num": 16,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 우울장애 비약물 치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        240.6599884033203,
        100.72968292236328
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애 비약물 치료에는 인지행동치료(Cognitive Behavioral Therapy,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        114.90937042236328,
        545.9400024414062,
        130.72967529296875
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CBT), 대인관계 정신치료(Interpersonal Therapy, ITP), 마음 챙김 인지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        144.9093780517578,
        538.4400024414062,
        160.7296905517578
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료(Mindfulness-Based Cognitive therapy, MBCT) 등이 증상을 경감",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        174.9093780517578,
        538.4400024414062,
        190.7296905517578
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시키는데 효과적인 방법이며, 경증 또는 중등도 우울장애에서는 비약물",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        204.90936279296875,
        546.0599975585938,
        220.72967529296875
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료를 우선하여 고려할 수 있다. 비약물 치료 중 대표적으로 인지행동",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        234.90936279296875,
        538.4400024414062,
        250.72967529296875
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료(CBT)가 권고되고 있으며, 임상에서 개인치료 또는 집단치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        264.90936279296875,
        546.0599975585938,
        280.72967529296875
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "형식으로 활발하게 사용되고 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        294.90936279296875,
        295.6429748535156,
        310.72967529296875
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애 인지행동치료(Cognitive Behavioral Therapy for Depression,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        324.90936279296875,
        545.9400024414062,
        340.72967529296875
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CBT-D)는 단기적으로는 약물치료와 그 효과가 유사하며 장기적인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        354.90936279296875,
        545.9400024414062,
        370.72967529296875
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "효과는 약물치료보다 우수한 것으로 밝혀져 있으며, 이러한 효과",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        384.90936279296875,
        545.9400024414062,
        400.72967529296875
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "입증을 통해 일차 치료로 권장되고 있다(Churchill et al., 2013, Van",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        414.90936279296875,
        545.9400024414062,
        430.72967529296875
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Hees et al., 2013). 선행 연구에 의하면, 약물치료나 비약물 치료를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        444.90936279296875,
        545.9400024414062,
        460.72967529296875
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단독으로 사용하기보다는 병용하면 우울장애에 대한 치료 효과가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        474.90936279296875,
        545.9400024414062,
        490.72967529296875
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "더 우수한 것으로 나타났다(Cuijpers et al., 2013, Kriston et al., 2014).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        504.90936279296875,
        533.9629516601562,
        520.7296752929688
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애 인지행동치료는 우울장애 환자의 역기능 사고로 인해",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        534.9093627929688,
        546.0599975585938,
        550.7296752929688
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발생하고 유지된다는 이론 근거를 기반으로 하며, 이러한 역기능 사고를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        564.9093627929688,
        546.0599975585938,
        580.7296752929688
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발견하고 수정하는 것을 치료 목표로 한다. 우울장애 환자의 자기, 환경,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        594.9093627929688,
        546.0599975585938,
        610.7296752929688
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미래에 대한 비합리적인 믿음과 왜곡된 태도가 우울한 영향을 영속",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        624.9093627929688,
        538.5599975585938,
        640.7296752929688
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시키고 기능을 훼손한다고 가정한다. 우울장애 인지행동치료는 환자의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        654.9093627929688,
        545.9400024414062,
        670.7296752929688
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신념과 태도를 도전하고 뒤집으며 실생활에서 부적응 선입견과 행동을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        684.9093627929688,
        545.9400024414062,
        700.7296752929688
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자가 바꾸도록 유도함으로써 우울장애 증상을 줄이고자 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        714.9093627929688,
        493.739990234375,
        730.7296752929688
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애와 관련된 역기능 사고는 두 가지 수준으로 구분이 되는데,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        744.9093627929688,
        545.9400024414062,
        760.7296752929688
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 10 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 17,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하나는 자동 사고이며, 다른 하나는 핵심 신념이다. 자동 사고는 특정",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        545.9400024414062,
        100.72968292236328
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상황과 관련하여 자동으로 떠오르는 생각으로, 주의를 약간 기울이면",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        114.90937042236328,
        546.0599975585938,
        130.72967529296875
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "쉽게 의식화할 수 있다. 반면 핵심 신념은 자동 사고보다는 추상화되어",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        144.9093780517578,
        545.9400024414062,
        160.7296905517578
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있으며, 일상생활 경험을 조직화한다. 우울장애 인지행동치료는 우울한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        174.9093780517578,
        545.9400024414062,
        190.7296905517578
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기분에 대한 자동 사고를 수정하고 궁극적으로는 핵심 신념 변화를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        204.90936279296875,
        546.0599975585938,
        220.72967529296875
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통해 우울장애 재발을 막고자 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        234.90936279296875,
        308.1000061035156,
        250.72967529296875
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애 인지행동치료는 행동 기법과 인지 기법으로 구분할 수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        264.90936279296875,
        545.9400024414062,
        280.72967529296875
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다. 우울장애 환자는 일상생활과 관련된 기능이 많이 떨어져 있을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        294.90936279296875,
        545.9400024414062,
        310.72967529296875
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있으므로 행동 기법을 먼저 적용하는 것이 도움이 된다. 행동 기법은",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        324.90936279296875,
        546.0599975585938,
        340.72967529296875
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 활동 계획(activity scheduling), ② 점진적 과업 주기(graded task",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        354.90936279296875,
        545.9400024414062,
        370.72967529296875
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "assignments), ③ 자기강화(self-reinforcement) 등이 있으며, 이를 통해",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        384.90936279296875,
        545.9400024414062,
        400.72967529296875
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애 환자의 자기효능감을 향상하는 데 도움을 줄 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        414.90936279296875,
        502.97998046875,
        430.72967529296875
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인지행동치료 인지 기법으로는 ① 자동 사고 파악하기, ② 인지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        444.90936279296875,
        546.0599975585938,
        460.72967529296875
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "오류 찾기 등이 있다. 우울한 기분과 관련성이 높은 자동 사고를 확인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        474.90936279296875,
        538.4400024414062,
        490.72967529296875
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하기 위해서는 자동 사고가 무엇인지 알려주고, 우울감을 심하게 느낀",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        504.90936279296875,
        545.9400024414062,
        520.7296752929688
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상황을 이야기해봄으로써 자동 사고를 파악한다. 우울장애 환자에게는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        534.9093627929688,
        545.9400024414062,
        550.7296752929688
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 흑백논리(all-or-nothing thinking), ② 과잉 일반화(overgeneralization),",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        564.9093627929688,
        545.9400024414062,
        580.7296752929688
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "③ 평가절하 사고(disqualifying the positive), ④ 성급한 결론(jumping",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        594.9093627929688,
        546.0599975585938,
        610.7296752929688
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "to conclusions), ⑤ 사고 확대와 추론(magnification or minimization)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        624.9093627929688,
        546.0599975585938,
        640.7296752929688
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등과 같은 인지 오류가 자주 발생한다. 따라서 자동 사고에 나타난",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        654.9093627929688,
        546.0599975585938,
        670.7296752929688
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인지 오류를 검토하게 함으로써 자동 사고를 변화시킬 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        684.9093627929688,
        512.3399658203125,
        700.7296752929688
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 11 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 18,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구분",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        69.47999572753906,
        109.79999542236328,
        354.3599853515625,
        124.19999694824219
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제목",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        69.47999572753906,
        109.79999542236328,
        354.3599853515625,
        124.19999694824219
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        69.47999572753906,
        109.79999542236328,
        354.3599853515625,
        124.19999694824219
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "행동",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        69.47999572753906,
        420.3599853515625,
        93.47999572753906,
        434.7599792480469
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개입",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        69.47999572753906,
        439.55999755859375,
        93.47999572753906,
        453.9599914550781
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전략",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        69.47999572753906,
        458.7599792480469,
        93.47999572753906,
        473.15997314453125
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "활동",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        119.15999603271484,
        233.39999389648438,
        143.16000366210938,
        247.79998779296875
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        119.15999603271484,
        252.60000610351562,
        143.16000366210938,
        267.0
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(activity",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        112.19999694824219,
        271.79998779296875,
        150.07199096679688,
        286.1999816894531
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "schedul",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        111.36000061035156,
        291.0,
        150.77999877929688,
        305.3999938964844
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ing",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        123.5999984741211,
        310.1999816894531,
        138.58799743652344,
        324.5999755859375
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 먼저 우울장애 환자의 현재 활동 정도와 그에 따른 감정 상태를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        147.0,
        523.7999877929688,
        161.39999389648438
      ],
      "page_num": 18,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정한다. 다음 단계로, 우울장애 환자가 자신의 활동 계획에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        166.1999969482422,
        523.7999877929688,
        180.59999084472656
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함하고 싶은 일, 수행하여야 할 일, 특히 즐거움을 주는 활동",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        185.39999389648438,
        523.7999877929688,
        199.79998779296875
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "등을 일일이 열거하게 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        204.59999084472656,
        325.8599853515625,
        218.99998474121094
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 우울장애 환자와 함께 활동을 채택하고, 채택된 활동을 하기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        223.79998779296875,
        523.7999877929688,
        238.19998168945312
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위한 구체적인 시간표를 짜서 매일 이것을 실행하게 한다. 이러한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        243.0,
        523.9199829101562,
        257.3999938964844
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "활동은 즐거움을 주는 활동뿐 아니라 무언가를 수행해야 하는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        262.1999816894531,
        523.7999877929688,
        276.5999755859375
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "활동도 함께 포함된다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        281.3999938964844,
        293.4599914550781,
        295.79998779296875
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 계획된 각각의 활동에서 기대되는 즐거움 혹은 성취 정도를 예측",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        300.6000061035156,
        523.7999877929688,
        315.0
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하면 도움이 된다. 이러한 활동에 장애를 예상해보고 그에 대한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        319.79998779296875,
        523.7999877929688,
        334.1999816894531
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해결책을 미리 논의해도 좋다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        339.0,
        331.3800048828125,
        353.3999938964844
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 계획된 활동을 통해 실제로 얻은 즐거움 혹은 수행 능력 정도를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        358.1999816894531,
        523.7999877929688,
        372.5999755859375
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기록하게 하는 등 자신의 행동을 스스로 관찰, 기록하도록",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        377.3999938964844,
        523.7999877929688,
        391.79998779296875
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        396.6000061035156,
        200.8199920654297,
        411.0
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "점진적",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        113.15999603271484,
        439.55999755859375,
        149.16000366210938,
        453.9599914550781
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "과업",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        119.15999603271484,
        458.7599792480469,
        143.16000366210938,
        473.15997314453125
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        119.15999603271484,
        477.9599914550781,
        143.16000366210938,
        492.3599853515625
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(graded",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        111.5999984741211,
        497.1600036621094,
        150.6119842529297,
        511.55999755859375
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "task",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        120.5999984741211,
        516.3599853515625,
        141.5159912109375,
        530.760009765625
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "assign",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.5999984741211,
        535.5599975585938,
        147.58799743652344,
        549.9600219726562
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ments)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        113.75999450683594,
        554.760009765625,
        148.45199584960938,
        569.1600341796875
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 즐거움을 주는 일이나 수행 능력을 키울 과업을 선택하고 계획",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        449.1600036621094,
        523.7999877929688,
        463.55999755859375
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하는 데 있어, 환자의 수행 성공 가능성이 최대화될 수 있도록",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        468.3599853515625,
        523.7999877929688,
        482.7599792480469
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하는 계획이 중요하다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        487.55999755859375,
        295.8599853515625,
        501.9599914550781
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 수행 가능성 최대화를 위해 과업으로 주는 활동을 수행하기 가장",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        506.760009765625,
        523.7999877929688,
        521.1600341796875
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "쉬운 활동부터 점차 어려운 활동으로 옮겨가는 방법이 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        525.9599609375,
        523.8599853515625,
        540.3599853515625
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이를 위해 때때로 과업이 세분화되고 단순화될 필요가 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        545.1599731445312,
        505.8599853515625,
        559.5599975585938
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        119.15999603271484,
        626.5199584960938,
        143.16000366210938,
        640.9199829101562
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "강화",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        119.15999603271484,
        645.719970703125,
        143.16000366210938,
        660.1199951171875
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(self-re",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        112.43999481201172,
        664.9199829101562,
        149.78399658203125,
        679.3200073242188
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "inforce",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.0,
        684.1199951171875,
        148.2239990234375,
        698.52001953125
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ment)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        116.63999938964844,
        703.3200073242188,
        145.57199096679688,
        717.7200317382812
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 어떤 목표를 성공적으로 달성하는 데에서 오는 자기 보상은 점차",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        607.3200073242188,
        523.7999877929688,
        621.7200317382812
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "활동을 늘리게 하고 그것을 유지케 하는 효과적인 수단이 된다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        626.5199584960938,
        516.8999633789062,
        640.9199829101562
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 목표 설정과 수행에 강력한 합리성을 제공하고, 확실하게 정의된",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        645.719970703125,
        523.7999877929688,
        660.1199951171875
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구체적이고 달성 가능한 목표를 세우도록 고무하며, 환자가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        664.9199829101562,
        523.7999877929688,
        679.3200073242188
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "강화 받을 수 있는 활동을 찾아 선택하게 하고, 목표를 정한 후에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        684.1199951171875,
        523.7999877929688,
        698.52001953125
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "즉각적으로 강화를 받을 수 있는 활동에 참여하도록 하고, 변화",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        703.3200073242188,
        523.9199829101562,
        717.7200317382812
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상황을 관찰 기록함으로써 환자의 자기강화를 도와줄 수 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        722.5199584960938,
        517.8599853515625,
        736.9199829101562
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 2. 우울장애 인지행동치료 구성",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        185.63999938964844,
        83.15999603271484,
        399.2405700683594,
        98.71199798583984
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 12 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 19,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구분",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        69.47999572753906,
        88.31999969482422,
        354.3599853515625,
        102.72000122070312
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제목",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        69.47999572753906,
        88.31999969482422,
        354.3599853515625,
        102.72000122070312
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        69.47999572753906,
        88.31999969482422,
        354.3599853515625,
        102.72000122070312
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인지적",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        63.47999954223633,
        407.8800048828125,
        99.47999572753906,
        422.2799987792969
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개입",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        69.47999572753906,
        427.0799865722656,
        93.47999572753906,
        441.47998046875
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전략",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        69.47999572753906,
        446.2799987792969,
        93.47999572753906,
        460.67999267578125
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자동적",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        113.15999603271484,
        369.47998046875,
        149.16000366210938,
        383.8799743652344
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사고와",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        113.15999603271484,
        388.67999267578125,
        149.16000366210938,
        403.0799865722656
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "왜곡된",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        113.15999603271484,
        407.8800048828125,
        149.16000366210938,
        422.2799987792969
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인지",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        119.15999603271484,
        427.0799865722656,
        143.16000366210938,
        441.47998046875
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "변화를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        113.15999603271484,
        446.2799987792969,
        149.16000366210938,
        460.67999267578125
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        119.15999603271484,
        465.47998046875,
        143.16000366210938,
        479.8799743652344
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전략",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        119.15999603271484,
        484.67999267578125,
        143.16000366210938,
        499.0799865722656
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험 구상(designing experiments)",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        160.9199981689453,
        110.27999877929688,
        353.7720031738281,
        124.68000030517578
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 우울장애 환자가 자신의 자동적 사고를 실증적 검증이 가능한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        129.47999572753906,
        523.7999877929688,
        143.87998962402344
      ],
      "page_num": 19,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과학적인 가정으로 간주하도록 고무한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        148.67999267578125,
        397.8599853515625,
        163.07998657226562
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 아이디어를 구상하는 방법은 가정된 자동적 사고를 지지하거나",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        167.87998962402344,
        523.7999877929688,
        182.2799835205078
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반박할 수 있는 증거를 생각해 내는 것이다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        187.0800018310547,
        415.8599853515625,
        201.47999572753906
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 예를 들어, “내가 아는 모든 사람은 나를 싫어한다”라는 자동적",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        206.27999877929688,
        523.7999877929688,
        220.67999267578125
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사고를 시험하기 위해서 먼저, 사람이 어떤 사람을 싫어할 때",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        225.47999572753906,
        523.7999877929688,
        239.87998962402344
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적으로 하는 행동을 생각해볼 수 있다. 다음으로 무작위로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        244.67999267578125,
        523.7999877929688,
        259.0799865722656
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "선정된 아는 사람을 만나 그들이 실제로 우울장애 환자에게",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        263.8800048828125,
        523.7999877929688,
        278.2799987792969
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인사를 하는지 하지 않는지 볼 수 있도록 실험을 구상한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        283.0799865722656,
        499.8599853515625,
        297.47998046875
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 일련의 실험은 자신의 자동적 사고에 대한 비합리성을 인식하게",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        302.2799987792969,
        523.7999877929688,
        316.67999267578125
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하고, 더 합리적인 사고로 변화 필요성을 깨닫게 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        321.47998046875,
        472.3800048828125,
        335.8799743652344
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부정적 단어 정의(operationalizing negative constructs)",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        160.9199981689453,
        359.8800048828125,
        476.052001953125,
        374.2799987792969
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 우울장애 환자의 자동적 사고는 때때로 절대적이고 흑백 논리적",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        379.0799865722656,
        523.7999877929688,
        393.47998046875
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "으로 나타난다. 어떤 특정 부정적 단어가 자기 자신에게 어느",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        172.9199981689453,
        398.2799987792969,
        523.7999877929688,
        412.67999267578125
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정도 해당이 되는지 그 정도를 알게 하는 방법으로 이러한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        417.47998046875,
        523.7999877929688,
        431.8799743652344
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부정적인 단어를 정확히 정의해보게 할 수 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        436.67999267578125,
        447.8999938964844,
        451.0799865722656
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 다음으로 우울장애 환자와 함께 그 개념의 정도를 나타내는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        455.8799743652344,
        523.7999877929688,
        470.27996826171875
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "등급을 만들고 정의에 자신이 얼마나 부합하는지 정도를 나타",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        475.0799865722656,
        523.7999877929688,
        489.47998046875
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내게 한다. 환자 자신이 가지고 있는 부정적인 사고에 자신이",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        494.2799987792969,
        523.9199829101562,
        508.67999267578125
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당하지 않는다는 사실을 발견하게 되고 보다 합리적인 사고를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        513.47998046875,
        523.7999877929688,
        527.8800048828125
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "할 수 있게 된다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        532.6799926757812,
        265.8599853515625,
        547.0800170898438
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "귀결 분석(consequential analysis)",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        160.9199981689453,
        571.0800170898438,
        354.85198974609375,
        585.4800415039062
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 귀결 분석은 감정 저하를 일으키는 잠재된 두려움, 사고, 가정",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        590.2799682617188,
        523.7999877929688,
        604.6799926757812
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "등을 이해하기 위한 유용한 수단이 된다. “만약...라면?”이라는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        609.47998046875,
        523.9199829101562,
        623.8800048828125
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "질문을 통해 환자의 잠재된 사고에 이를 수 있도록 유도한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        628.6799926757812,
        511.8599853515625,
        643.0800170898438
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "재귀인(reattribution)",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        160.9199981689453,
        667.0799560546875,
        273.73199462890625,
        681.47998046875
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 부정적인 사건 원인을 더 다양하게 생각해 내도록 도와주어야",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        686.2799682617188,
        523.7999877929688,
        700.6799926757812
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한다. 불쾌한 사건을 상상하게 하고, 자신이 생각하는 사건이",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        705.47998046875,
        523.7999877929688,
        719.8800048828125
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일어난 이유를 설명하게 한 다음, 보다 합리적이고 현실적인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        724.6799926757812,
        523.7999877929688,
        739.0800170898438
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대안적 이유를 생각해 낸다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        743.8800048828125,
        325.8599853515625,
        758.280029296875
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 13 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 20,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(출처: Beck, J.S.(1995), 권정혜 & 이재우(2001), 이삼연(1999))",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.63999938964844,
        492.47998046875,
        400.0920104980469,
        506.8799743652344
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구분",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        69.47999572753906,
        88.31999969482422,
        354.3599853515625,
        102.72000122070312
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제목",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        69.47999572753906,
        88.31999969482422,
        354.3599853515625,
        102.72000122070312
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        69.47999572753906,
        88.31999969482422,
        354.3599853515625,
        102.72000122070312
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비기능",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        113.15999603271484,
        235.3199920654297,
        149.16000366210938,
        249.71998596191406
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        119.15999603271484,
        254.51998901367188,
        143.16000366210938,
        268.91998291015625
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "핵심",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        119.15999603271484,
        273.7200012207031,
        143.16000366210938,
        288.1199951171875
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신념",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        119.15999603271484,
        292.91998291015625,
        143.16000366210938,
        307.3199768066406
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "변화를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        113.15999603271484,
        312.1199951171875,
        149.16000366210938,
        326.5199890136719
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        119.15999603271484,
        331.32000732421875,
        143.16000366210938,
        345.7200012207031
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전략",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        119.15999603271484,
        350.5199890136719,
        143.16000366210938,
        364.91998291015625
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "과거력 조사(historical exploration)",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        160.9199981689453,
        129.72000122070312,
        356.4119873046875,
        144.1199951171875
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 비기능적 신념은 때때로 고통스러운 과거 경험을 왜곡되게",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        148.9199981689453,
        523.7999877929688,
        163.3199920654297
      ],
      "page_num": 20,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해석함으로써 생길 수 있다. 이러한 상황을 재점검해봄으로써",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        168.1199951171875,
        523.7999877929688,
        182.51998901367188
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "환자는 이와 같은 오류나 왜곡을 깨닫게 되고 그들을 수정하려고",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        187.3199920654297,
        523.9199829101562,
        201.71998596191406
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "노력하게 된다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        206.51998901367188,
        253.86000061035156,
        220.91998291015625
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "손익 분석(cost-benefit analysis)",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        160.9199981689453,
        244.91998291015625,
        345.1319885253906,
        259.3199768066406
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 비기능적 핵심 신념이 발견되고 비합리성이 밝혀졌음에도 이러한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        264.1199951171875,
        523.7999877929688,
        278.5199890136719
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신념이 자기 보호기능을 해왔거나 혹은 그것을 가짐으로써",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        283.32000732421875,
        523.7999877929688,
        297.7200012207031
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이점이 있을 때 잘못된 신념을 포기하지 않으려 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        302.5199890136719,
        478.8599853515625,
        316.91998291015625
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 이런 경우 그 같은 신념을 유지함으로써 오는 손해와 이익을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        321.7200012207031,
        523.7999877929688,
        336.1199951171875
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하나하나 나열하여 비교해 보도록 하는 방법이 있다. 변화된",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        340.91998291015625,
        523.7999877929688,
        355.3199768066406
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신념에 대해 손해와 이익 분석도 이와 같은 방식으로 행해질",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        172.9199981689453,
        360.1199951171875,
        523.7999877929688,
        374.5199890136719
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        379.3199768066406,
        217.86000061035156,
        393.719970703125
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "법칙을 깨는 실험(rule-breaking experiments)",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        160.9199981689453,
        417.7200012207031,
        419.8919982910156,
        432.1199951171875
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 잘못된 신념을 변화시키는 방법으로 환자가 이러한 신념을 깨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        436.91998291015625,
        523.7999877929688,
        451.3199768066406
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "버릴 수 있는 실험을 구상하는 방법이다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        456.1199951171875,
        395.5799865722656,
        470.5199890136719
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 14 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 21,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라. 우울장애 약물치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        210.72000122070312,
        100.72968292236328
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애 인지행동치료를 적용하기가 어렵거나, 적용하더라도 효과가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        114.90937042236328,
        546.0599975585938,
        130.72967529296875
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없으면 약물적 치료를 통해 우울장애를 개선할 수 있다. <표 3>은 일차",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        144.9093780517578,
        545.9400024414062,
        160.7296905517578
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료용 근거 기반 우울장애 임상진료지침(대한의학회, 2022)의 항우울제",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        174.9093780517578,
        546.0599975585938,
        190.7296905517578
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "권고 요약표를 정리하였다. 우울장애 약물치료는 임상 양상, 공존 질환,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        204.90936279296875,
        546.0599975585938,
        220.72967529296875
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이전 약물치료 병력, 부작용, 약물 상호작용, 환자 기호 등을 종합하여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        234.90936279296875,
        545.9400024414062,
        250.72967529296875
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상황에 맞게 각 임상의가 적절하게 판단하여 사용하여야 한다. 단, 이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        264.90936279296875,
        545.9400024414062,
        280.72967529296875
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부분은 본 의료기기의 주요부문이 아니므로 더 서술하지 않되, 환자의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        294.90936279296875,
        546.0599975585938,
        310.72967529296875
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절한 치료를 위해 우울 증상을 파악하고 개선한다는 점에서, 약물",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        324.90936279296875,
        545.9400024414062,
        340.72967529296875
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "복용력을 고려하는 디지털치료기기라면 환자의 상태를 파악하기를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        354.90936279296875,
        546.0599975585938,
        370.72967529296875
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "권고한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        384.90936279296875,
        128.82000732421875,
        400.72967529296875
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "종류",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        143.52000427246094,
        436.1999816894531,
        519.2520141601562,
        450.5999755859375
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기전",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        143.52000427246094,
        436.1999816894531,
        519.2520141601562,
        450.5999755859375
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용량(mg)",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        143.52000427246094,
        436.1999816894531,
        519.2520141601562,
        450.5999755859375
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제1차 약제",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        87.72000122070312,
        450.9599914550781,
        150.1199951171875,
        465.3599853515625
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아고멜라틴(agomelatine)",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        465.9599914550781,
        494.88031005859375,
        479.2080078125
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MT1 and MT2 agonist; 5-HT2 antagonist",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        465.9599914550781,
        494.88031005859375,
        479.2080078125
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "25-50",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        465.9599914550781,
        494.88031005859375,
        479.2080078125
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부프로피온(bupropion)",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        479.7599792480469,
        505.91998291015625,
        493.00799560546875
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NDRI",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        81.72000122070312,
        479.7599792480469,
        505.91998291015625,
        493.00799560546875
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "150-300",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        479.7599792480469,
        505.91998291015625,
        493.00799560546875
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시탈로프람(citalopram)",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        493.5599670410156,
        494.8799743652344,
        506.8079833984375
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SSRI",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        81.72000122070312,
        493.5599670410156,
        494.8799743652344,
        506.8079833984375
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20-40",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        493.5599670410156,
        494.8799743652344,
        506.8079833984375
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데스벤라팍신(desvenlafaxine)",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        507.3599548339844,
        500.40032958984375,
        520.6079711914062
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SNRI",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        81.72000122070312,
        507.3599548339844,
        500.40032958984375,
        520.6079711914062
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "50-100",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        507.3599548339844,
        500.40032958984375,
        520.6079711914062
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "듀록세틴(duloxetine)",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        521.280029296875,
        478.1999816894531,
        534.5280151367188
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SNRI",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        81.72000122070312,
        521.280029296875,
        478.1999816894531,
        534.5280151367188
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "60",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        521.280029296875,
        478.1999816894531,
        534.5280151367188
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에스시탈로프람(escitalopram)",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        535.0800170898438,
        494.88031005859375,
        548.3280029296875
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SSRI",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        81.72000122070312,
        535.0800170898438,
        494.88031005859375,
        548.3280029296875
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10-20",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        535.0800170898438,
        494.88031005859375,
        548.3280029296875
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "플루옥세틴(fluoxetine)",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        548.8800048828125,
        494.88031005859375,
        562.1279907226562
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SSRI",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        81.72000122070312,
        548.8800048828125,
        494.88031005859375,
        562.1279907226562
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20-60",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        548.8800048828125,
        494.88031005859375,
        562.1279907226562
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "플루복사민(fluvoxamine)",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        562.6799926757812,
        505.91998291015625,
        575.927978515625
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SSRI",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        81.72000122070312,
        562.6799926757812,
        505.91998291015625,
        575.927978515625
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "100-300",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        562.6799926757812,
        505.91998291015625,
        575.927978515625
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "밀나시프란(milnacipran)",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        576.47998046875,
        483.719970703125,
        589.7279663085938
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SNRI",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        81.72000122070312,
        576.47998046875,
        483.719970703125,
        589.7279663085938
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "100",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        576.47998046875,
        483.719970703125,
        589.7279663085938
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "멀타자핀(mirtazapine)",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        590.280029296875,
        494.8799743652344,
        603.5280151367188
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "α2-Adrenergic agonist; 5-HT2 antagonist",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        590.280029296875,
        494.8799743652344,
        603.5280151367188
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15-45",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        590.280029296875,
        494.8799743652344,
        603.5280151367188
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "파록세틴(paroxetine)",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        604.2000122070312,
        494.88031005859375,
        617.447998046875
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SSRI",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        81.72000122070312,
        604.2000122070312,
        494.88031005859375,
        617.447998046875
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20-50",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        604.2000122070312,
        494.88031005859375,
        617.447998046875
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설트랄린(sertraline)",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        618.0,
        500.40032958984375,
        631.2479858398438
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SSRI",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        81.72000122070312,
        618.0,
        500.40032958984375,
        631.2479858398438
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "50-200",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        618.0,
        500.40032958984375,
        631.2479858398438
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "벤라팍신(venlafaxine)",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        631.7999877929688,
        500.40032958984375,
        645.0479736328125
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SNRI",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        81.72000122070312,
        631.7999877929688,
        500.40032958984375,
        645.0479736328125
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "75-225",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        631.7999877929688,
        500.40032958984375,
        645.0479736328125
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보티오섹틴(vortioxetine)",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        645.6000366210938,
        494.88031005859375,
        669.8880004882812
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Serotonin reuptake inhibitor; 5-HT1A agonist; 5-HT1B",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        81.72000122070312,
        645.6000366210938,
        494.88031005859375,
        669.8880004882812
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "partial agonist; 5-HT1D, 5-HT3A, and 5-HT7 antagonist",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        645.6000366210938,
        494.88031005859375,
        669.8880004882812
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10-20",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        645.6000366210938,
        494.88031005859375,
        669.8880004882812
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제2차 약제",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        87.72000122070312,
        670.3200073242188,
        150.1199951171875,
        684.7200317382812
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아미트립틀린(amitriptyline)",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        685.2000122070312,
        494.88031005859375,
        698.447998046875
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TCA",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        685.2000122070312,
        494.88031005859375,
        698.447998046875
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "25-50",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        685.2000122070312,
        494.88031005859375,
        698.447998046875
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이미프라민 (imipramine)",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        699.1199951171875,
        505.91998291015625,
        712.3679809570312
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TCA",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        699.1199951171875,
        505.91998291015625,
        712.3679809570312
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "150-300",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        699.1199951171875,
        505.91998291015625,
        712.3679809570312
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "노르트립틸린(nortriptyline)",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        712.9199829101562,
        494.8799743652344,
        726.16796875
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TCA",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        712.9199829101562,
        494.8799743652344,
        726.16796875
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20-40",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        712.9199829101562,
        494.8799743652344,
        726.16796875
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "트라조돈(trazodone)",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        726.7200317382812,
        500.40032958984375,
        739.968017578125
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Serotonin reuptake inhibitor; 5-HT2 antagonist",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        726.7200317382812,
        500.40032958984375,
        739.968017578125
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "50-100",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        726.7200317382812,
        500.40032958984375,
        739.968017578125
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모노클로베미드(monoclobemide)",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        740.52001953125,
        478.1999816894531,
        753.7680053710938
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Reversible inhibitor of MAO-A",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        740.52001953125,
        478.1999816894531,
        753.7680053710938
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "60",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        740.52001953125,
        478.1999816894531,
        753.7680053710938
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(출처: 대한의학회(2022), 일차 의료용 근거기반 우울장애 임상진료지침)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        81.72000122070312,
        754.2000122070312,
        473.2919921875,
        768.6000366210938
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표 3. 항우울제 권고 요약표",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        215.27999877929688,
        413.1600036621094,
        387.96063232421875,
        428.7120056152344
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 15 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 22,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마. 우울장애 비약물 치료의 임상 권고 사항",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        360.6000061035156,
        100.72968292236328
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미국정신의학회(APA), 캐나다 기분·불안 치료 네트워크(Canadian",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        114.90937042236328,
        546.0599975585938,
        130.72967529296875
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Network for Mood and Anxiety Treatments, CANMAT), 영국정신의학회",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        144.9093780517578,
        538.4400024414062,
        160.7296905517578
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(British Association for Psychopharmacology, BAP) 등은 우울장애 치료를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        174.9093780517578,
        545.9400024414062,
        190.7296905517578
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해 인지행동치료(CBT)를 먼저 권고한다. 또한 대한의학회 ‘일차 의료용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        204.90936279296875,
        545.9400024414062,
        220.72967529296875
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "근거 기반 우울장애 임상진료지침(2022)’에서도 경증 혹은 중등도 수준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        234.90936279296875,
        545.9400024414062,
        250.72967529296875
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애에서는 인지행동치료 등 정신사회 치료를 먼저 고려하도록",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        264.90936279296875,
        546.0599975585938,
        280.72967529296875
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "권장하고 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        294.90936279296875,
        158.1229705810547,
        310.72967529296875
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진료지침*",
      "font_size": 8.279999732971191,
      "font_name": "T10",
      "bbox": [
        107.04000091552734,
        360.47998046875,
        483.3605651855469,
        377.11199951171875
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "권고등급**",
      "font_size": 8.279999732971191,
      "font_name": "T10",
      "bbox": [
        107.04000091552734,
        360.47998046875,
        483.3605651855469,
        377.11199951171875
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "근거 수준",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        107.04000091552734,
        360.47998046875,
        483.3605651855469,
        377.11199951171875
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "APA 진료지침(2010)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.19999694824219,
        383.5199890136719,
        499.6919860839844,
        397.91998291015625
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Strong",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.19999694824219,
        383.5199890136719,
        499.6919860839844,
        397.91998291015625
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "High (Substantial)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.19999694824219,
        383.5199890136719,
        499.6919860839844,
        397.91998291015625
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "BAP 진료지침(2014)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.19999694824219,
        403.55999755859375,
        489.73199462890625,
        417.9599914550781
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Strong (A등급)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.19999694824219,
        403.55999755859375,
        489.73199462890625,
        417.9599914550781
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "High (Level I)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.19999694824219,
        403.55999755859375,
        489.73199462890625,
        417.9599914550781
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CANMAT 진료지침(2016)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        69.36000061035156,
        423.5999755859375,
        491.2919921875,
        437.9999694824219
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Strong (First-line)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        69.36000061035156,
        423.5999755859375,
        491.2919921875,
        437.9999694824219
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "High (Level 1)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        69.36000061035156,
        423.5999755859375,
        491.2919921875,
        437.9999694824219
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* APA: American Psychiatric Association, BAP: British Association for Psychopharmacology,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        61.79999923706055,
        441.0,
        527.7120361328125,
        455.3999938964844
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CANMAT: Canadian Network for Mood and Anxiety Treatments",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        72.72000122070312,
        456.5999755859375,
        393.1199951171875,
        470.9999694824219
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "** 진료지침별 권고 등급의 수준이 상이하여 재분류함",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        61.79999923706055,
        472.1999816894531,
        358.67999267578125,
        486.5999755859375
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표 4. 진료지침별 우울장애 인지행동치료의 권고등급 및 근거 수준",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        86.04000091552734,
        335.1600036621094,
        502.8005676269531,
        350.7120056152344
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미국정신의학협회(APA) 진료지침(2010)은 대수롭지 않거나 중등도",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        514.2693481445312,
        546.0599975585938,
        530.0896606445312
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수준 우울장애이면 초기 치료로 인지행동치료를 제안한다(권고등급,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        544.2693481445312,
        545.9400024414062,
        560.0896606445312
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Strong). 캐나다 기분·불안 치료 네트워크(CANMAT) 진료지침(2016)은",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        574.2693481445312,
        545.9400024414062,
        590.0896606445312
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "급성기 치료(Acute Treatment) 및 유지 치료(Maintenance Treatment)에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        604.2693481445312,
        546.0599975585938,
        620.0896606445312
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해 인지행동치료가 효과가 있으며, 근거 수준이 높다고 제안한다(권고",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        634.2693481445312,
        538.5599975585938,
        650.0896606445312
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등급, Strong [First-line]). 전화를 활용한 인지행동치료, 인터넷이나",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        664.2693481445312,
        546.0599975585938,
        680.0896606445312
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "컴퓨터를 활용한 급성기 치료(Acute Treatment)는 권고등급을 Strong",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        694.2693481445312,
        546.0599975585938,
        710.0896606445312
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[Second-line]으로 제안한다. 마음챙김 기반 인지치료(Mindfulness-based",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        724.2693481445312,
        546.0599975585938,
        740.0896606445312
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "cognitive therapy, MBCT)은 유지 치료(Maintenance Treatment) 단계에서",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        754.2693481445312,
        545.9400024414062,
        770.0896606445312
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 16 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 23,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활용하도록 권고한다(권고등급, Strong [First-line]).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        404.2429504394531,
        100.72968292236328
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영국정신의학회(BAP) 진료지침은 경증(mild)에서 중등도(moderate)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        114.90937042236328,
        546.0599975585938,
        130.72967529296875
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애를 위한 급성 치료는 인지행동치료(CBT), 대인관계 정신치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        144.9093780517578,
        538.5599975585938,
        160.7296905517578
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Interpersonal psychotherapy, IPT), 행동 활성화(Behavioural activation,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        174.9093780517578,
        545.9400024414062,
        190.7296905517578
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "BA)가 항우울제 대안이라고 제안하며(권고등급 Strong [A]), 재발성 우울",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        204.90936279296875,
        538.5599975585938,
        220.72967529296875
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장애에 대해서 단독 요법으로 심리치료 할 때는 인지행동 치료를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        234.90936279296875,
        545.9400024414062,
        250.72967529296875
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "권고한다(권고등급 B). 심각한 우울장애는 비약물 치료 단독보다",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        264.90936279296875,
        546.0599975585938,
        280.72967529296875
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항우울제 치료에 추가로 활용하기를 권장한다. 다만, 우울장애 인지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        294.90936279296875,
        538.5599975585938,
        310.72967529296875
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "행동치료는 시간과 비용에 제약이 있고, 약물치료보다 효과가 늦기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        324.90936279296875,
        545.9400024414062,
        340.72967529296875
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "때문에 모든 환자에게 같게 적용하는 데 제한이 있을 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        354.90936279296875,
        504.6600036621094,
        370.72967529296875
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바. 디지털 기반 우울장애 치료 관련 선행연구",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        414.90936279296875,
        375.6000061035156,
        430.72967529296875
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디지털 기반 우울장애 인지행동치료는 웹 또는 모바일 앱 등을 이용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        444.90936279296875,
        538.5599975585938,
        460.72967529296875
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여 병원에 내원하지 않고도 인지행동치료를 시행 받게 되어 치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        474.90936279296875,
        546.0599975585938,
        490.72967529296875
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접근성 개선을 기대하게 한다. 또한 디지털 기반 치료로, 환자가 대부분",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        504.90936279296875,
        545.9400024414062,
        520.7296752929688
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로그램을 수행하고 피드백을 받을 수 있으므로 치료자 관점에서 비용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        534.9093627929688,
        546.0599975585938,
        550.7296752929688
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대비 효용성도 증가한다. 따라서, 환자가 병원에 매주 내원해야 시행이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        564.9093627929688,
        545.9400024414062,
        580.7296752929688
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능한 전통적인 치료 공간 접근성과 시간 자원 여부에 따른 치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        594.9093627929688,
        545.9400024414062,
        610.7296752929688
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제약을 개선할 수 있다(Andrews, 2018).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        624.9093627929688,
        328.52294921875,
        640.7296752929688
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "먼저, 독일에서 개발한 Deprexis를 활용하여 우울장애 디지털 치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        654.9093627929688,
        538.5599975585938,
        670.7296752929688
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기 효과성을 검증한 많은 연구가 진행되었다(Fischer et al., 2015,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        684.9093627929688,
        546.0599975585938,
        700.7296752929688
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Berger et al., 2011, Klein et al., 2016, Beevers et al., 2017, Moritz et",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        714.9093627929688,
        546.0599975585938,
        730.7296752929688
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "al., 2015). Deprexis의 효과성 검증을 위해 Beck Depression Inventory",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        744.9093627929688,
        545.9400024414062,
        760.7296752929688
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 17 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 24,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(BDI-II) 척도 13점 이상이고 연령은 18세 이상인 우울장애 환자 98명을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        545.9400024414062,
        100.72968292236328
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대상으로 무작위배정 임상시험을 진행하였다(Berger et al., 2018).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        114.90937042236328,
        546.0599975585938,
        130.72967529296875
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실험군(51명)은 기존 심리상담과 함께 웹 기반 우울장애 프로그램인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        144.9093780517578,
        546.0599975585938,
        160.7296905517578
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Deprexis를 사용하였고, 대조군(47명)은 심리상담만을 진행하였다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        174.9093780517578,
        546.0599975585938,
        190.7296905517578
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Deprexis는 주로 인지행동 심리치료를 기반으로 하는 정신교육 정보와",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        204.90936279296875,
        546.0599975585938,
        220.72967529296875
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "운동 정보 등을 제공하는 10개 콘텐츠 모듈을 제공하여 환자가 사용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        234.90936279296875,
        538.4400024414062,
        250.72967529296875
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "할 수 있도록 했다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        264.90936279296875,
        195.6599884033203,
        280.72967529296875
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 연구에서 일차 유효성 평가지표는 BDI-II를 사용하였으며, 이차",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        294.90936279296875,
        546.0599975585938,
        310.72967529296875
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효성 지표로는 불안 증상을 측정하기 위한 Generalized Anxiety",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        324.90936279296875,
        546.0599975585938,
        340.72967529296875
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Disorder Scale(GAD-7), 신체 증상을 측정하기 위한 Patient Health",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        354.90936279296875,
        545.9400024414062,
        370.72967529296875
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Questionnaire(PHQ-15), 삶의 질을 확인하기 위한 Short-Form Health",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        384.90936279296875,
        545.9400024414062,
        400.72967529296875
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Survey(SF-12)을 사용하였다. 웹 기반 프로그램을 함께 사용한 치료가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        414.90936279296875,
        546.0599975585938,
        430.72967529296875
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "심리치료 단독 수행보다 우울장애를 개선하는 효과가 더 있었고",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        444.90936279296875,
        538.4400024414062,
        460.72967529296875
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Cohen’s d=0.51), 이차 유효성 변수도 개선하는 효과가 있었다",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        474.90936279296875,
        538.5599975585938,
        490.72967529296875
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(SF-12 physical subscale Cohen’s d=0.07, SF-12 mental health",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        504.90936279296875,
        546.0599975585938,
        520.7296752929688
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Cohen’s d=0.55).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        534.9093627929688,
        177.44296264648438,
        550.7296752929688
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "18세 이상인 경증에서 중등도 수준 우울 증상(PHQ-9 5점~14점)이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        564.9093627929688,
        545.9400024414062,
        580.7296752929688
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 총 1,013명을 대상으로 Deprexis 효과성을 검증하는 다기관 무작위",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        594.9093627929688,
        538.4400024414062,
        610.7296752929688
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "배정 임상시험도 진행되었다(Klein et al., 2016). 대조군(504명)은 일반적인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        624.9093627929688,
        546.0599975585938,
        640.7296752929688
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료 서비스를 받았고, 실험군(509명)은 Deprexis 프로그램에 대한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        654.9093627929688,
        546.0599975585938,
        670.7296752929688
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "권한을 받아서 사용하였다. 프로그램은 CBT 기반 12주 프로그램이고,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        684.9093627929688,
        546.0599975585938,
        700.7296752929688
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인지 재구성, 행동 활성화, 수용 및 마음챙김 등과 같은 내용을 포함",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        714.9093627929688,
        538.5599975585938,
        730.7296752929688
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 10개 모듈로 구성되어 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        744.9093627929688,
        293.1000061035156,
        760.7296752929688
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 18 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 25,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구에서는 PHQ-9를 일차 유효성 평가지표로 사용하였으며, 5점이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        84.90937042236328,
        546.0599975585938,
        100.72968292236328
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "감소 되었을 때 임상적으로 중요한 개선이 있다고 정의하였다. 이차 유",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        114.90937042236328,
        538.4400024414062,
        130.72967529296875
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "효성 평가지표는 Hamilton Depression Rating Scale(HDRS-24), Quick",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        144.9093780517578,
        546.0599975585938,
        160.7296905517578
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Inventory of Depressive Symptomatology(QIDS-C16)가 사용되었다. 지표는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        174.9093780517578,
        546.0599975585938,
        190.7296905517578
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구 시작 시(Baseline), 3개월(평가 후) 및 6개월(추적)에 측정하였다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        204.90936279296875,
        536.9400024414062,
        220.72967529296875
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3개월 후 측정된 결과에 의하면, 점수는 두 집단 모두에서 감소하",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        234.90936279296875,
        538.4400024414062,
        250.72967529296875
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "였는데, PHQ-9 변화는 집단 간에 유의하게 달랐다(t=6.12, p<0.001).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        264.90936279296875,
        546.0599975585938,
        280.72967529296875
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "PHQ-9 점수는 대조군보다 평균 1.57점(95% confidence intervals [CI]:",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        294.90936279296875,
        545.9400024414062,
        310.72967529296875
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1.07-2.07) 포인트 더 많이 감소했다. 3개월 후 집단 간 효과 크기는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        324.90936279296875,
        546.0599975585938,
        340.72967529296875
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "0.39(95% CI: 0.13-0.64)였으며, 6개월 후도 효과 크기는 0.32(95% CI:",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        354.90936279296875,
        546.0599975585938,
        370.72967529296875
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "0.06-0.69)로 안정적이었다. 임상적으로 중요한 PHQ-9 변화를 경험한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        384.90936279296875,
        545.9400024414062,
        400.72967529296875
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참가자 비율도 실험군이 대조군에 비해 높았다(35.6 vs. 20.2%).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        414.90936279296875,
        490.1629638671875,
        430.72967529296875
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 선행 연구에서는 단극성 우울장애에 대해 Selfapy라는 웹 기반",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        444.90936279296875,
        546.0599975585938,
        460.72967529296875
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중재 효과성을 평가하는 무작위배정 임상시험을 실시하였다 (Krämer",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        474.90936279296875,
        546.0599975585938,
        490.72967529296875
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "et al., 2021). 특히 심리치료사 가이드 여부에 따른 효과성도 확인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        504.90936279296875,
        538.4400024414062,
        520.7296752929688
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고자 세 그룹으로 구분하여 실험을 진행하였다. 18~65세이며 BDI-II가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        534.9093627929688,
        545.9400024414062,
        550.7296752929688
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "13점 이상인 우울장애가 있는 환자(401명)를 모집하였으며, 가이드 그룹",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        564.9093627929688,
        538.5599975585938,
        580.7296752929688
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(151명), 가이드가 없는 그룹(150명), 대조군(100명)으로 무작위 할당",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        594.9093627929688,
        538.5599975585938,
        610.7296752929688
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하였다. 가이드 그룹은 매주 25분 동안 전화로 개인 지도를 받았고,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        624.9093627929688,
        545.9400024414062,
        640.7296752929688
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드가 없는 그룹은 Selfapy만 사용하였다. 대조군은 이메일을 통해",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        654.9093627929688,
        546.0599975585938,
        670.7296752929688
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표준화된 마음챙김 훈련을 받았다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        684.9093627929688,
        300.6600036621094,
        700.7296752929688
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로그램은 인지행동치료 등을 근거로 하고 있으며, 6개 핵심 중재",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        714.9093627929688,
        546.0599975585938,
        730.7296752929688
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모듈과 6개 추가적인 심층 모듈로 구성되어 12주 동안 제공되었다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        744.9093627929688,
        545.9400024414062,
        760.7296752929688
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 19 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 26,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일차 유효성 평가지표는 BDI-II를 사용하여 우울 증상에 대해 측정",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        538.4400024414062,
        100.72968292236328
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하였으며, QIDS-SR-16, HRSD-24가 이차 유효성 평가지표로 사용되었다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        114.90937042236328,
        546.0599975585938,
        130.72967529296875
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구 시작 시(Baseline), 중재 중(6주), 중재 종료(12주), 추적 관찰(6개월) 시",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        144.9093780517578,
        546.0599975585938,
        160.7296905517578
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울 증상을 평가했다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        174.9093780517578,
        210.68296813964844,
        190.7296905517578
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "BDI-II 변화는 중재 후 그룹 간에 유의한 차이가 있었다(F2,398",
      "font_size": 9.59999942779541,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        204.90936279296875,
        543.239990234375,
        221.47499084472656
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "=37.20, P<.001). 가이드 또는 가이드가 없는 그룹에서 BDI-II 점수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        234.90936279296875,
        546.0599975585938,
        250.72967529296875
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "감소는 그룹 간 효과 크기가 대조군보다 더 컸다(guided vs control:",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        264.90936279296875,
        545.9400024414062,
        280.72967529296875
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "d=1.63, 95% CI 1.37-1.93; unguided vs control: d=1.47, 95% CI",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        294.90936279296875,
        546.0599975585938,
        310.72967529296875
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1.22-1.73). 반면, 가이드 또는 가이드가 없는 그룹 간 유의미한 차이가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        324.90936279296875,
        546.0599975585938,
        340.72967529296875
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발견되지는 않았다. 추적 관찰(6개월)에서 치료 효과는 두 중재 그룹",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        354.90936279296875,
        546.0599975585938,
        370.72967529296875
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모두에서",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        384.90936279296875,
        546.0599975585938,
        401.4750061035156
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유지되었습니다(guided:",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        384.90936279296875,
        546.0599975585938,
        401.4750061035156
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "F1,194=0.62,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        384.90936279296875,
        546.0599975585938,
        401.4750061035156
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "P>.999;",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        384.90936279296875,
        546.0599975585938,
        401.4750061035156
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "unguided:",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        384.90936279296875,
        546.0599975585938,
        401.4750061035156
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "F1,176=0.13, P>.999).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        414.90936279296875,
        191.6999969482422,
        431.4749755859375
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또 다른 선행 연구에서는 인터넷 기반 우울장애 인지행동치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        444.90936279296875,
        546.0599975585938,
        460.72967529296875
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로그램인 Thrive 효과성을 검증하는 무작위배정 임상시험을 실시",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        474.90936279296875,
        538.5599975585938,
        490.72967529296875
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하였다(Schure et al., 2019). 우울 증상(PHQ-9 5점 이상)이 있는 18세 이상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        504.90936279296875,
        546.0599975585938,
        520.7296752929688
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성인 343명을 모집하고, Trive를 활용한 실험군(181명)과 대조군(162명)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        534.9093627929688,
        538.447509765625,
        550.7296752929688
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 무작위 할당하였다. 실험군은 완전 자동화된 프로그램인 Thrive를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        564.9093627929688,
        545.9400024414062,
        580.7296752929688
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "웹 브라우저 및 모바일 앱을 사용하였다. 콘텐츠는 비디오를 통해 전달",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        594.9093627929688,
        538.4400024414062,
        610.7296752929688
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되며, 행동 활성화, 인지 재구조화, 사회 기술 훈련에 중점을 둔 세",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        624.9093627929688,
        545.9400024414062,
        640.7296752929688
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가지 대화형 모듈을 제공하였다. 사용자 입력 및 사용자 패턴을 기반",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        654.9093627929688,
        538.4400024414062,
        670.7296752929688
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 알고리즘을 사용하여 개인에 맞게 피드백을 제공했다. 대조군은",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        684.9093627929688,
        546.0599975585938,
        700.7296752929688
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반 우울장애 정보에 대한 링크를 받았다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        714.9093627929688,
        353.1229553222656,
        730.7296752929688
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 20 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 27,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일차 유효성 변수는 환자가 직접 보고한 PHQ-9 점수였으며, 불안",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        84.90937042236328,
        545.9400024414062,
        100.72968292236328
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증상 심각성(GAD-7), 일상 기능(Work and Social Adjustment Scale,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        114.90937042236328,
        546.0599975585938,
        130.72967529296875
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "WSAS), 회복력(Conner-Davidson Resilience Scale, CD-RISC-10), 자살에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        144.9093780517578,
        545.9400024414062,
        160.7296905517578
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관한 생각 등이 이차 유효성 변수로 활용되었다. 평가지표는 연구 시작 시",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        174.9093780517578,
        538.4400024414062,
        190.7296905517578
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Baseline), 4주 및 8주에 측정하였다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        204.90936279296875,
        315.7799987792969,
        220.72967529296875
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실험군은 대조군보다 우울장애 증상 중증도가 유의하게 낮았고",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        234.90936279296875,
        538.5599975585938,
        250.72967529296875
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(F1,248=28.67, P<.001), 치료 효과 크기(d=0.63)를 확인하였다. 그룹 평균",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        264.90936279296875,
        545.9400024414062,
        281.4750061035156
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "패턴은 실험군 우울장애 심각도(8주 개입 후)가 대조군 그룹보다 유의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        294.90936279296875,
        538.5599975585938,
        310.72967529296875
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하게 낮았다(7.702 [Standard Error, SE 0.336] vs 10.224 [SE 0.328],",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        324.90936279296875,
        545.9400024414062,
        340.72967529296875
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "adjusted P<.001; d=0.63).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        354.90936279296875,
        222.68296813964844,
        370.72967529296875
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 21 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 28,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사. 우울장애 개선 디지털치료기기의 국외 사례",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        383.1600036621094,
        100.72968292236328
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "현재 국외에서 우울장애 개선 디지털치료기기로서, 허가된 제품 및",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        114.90937042236328,
        545.9400024414062,
        130.72967529296875
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인지행동치료(CBT)를 이용한 제품은 다음과 같다 <표 5>.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        144.9093780517578,
        450.4429626464844,
        160.7296905517578
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연번",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        66.23999786376953,
        212.1599884033203,
        90.83999633789062,
        226.5599822998047
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품명(제조업체)",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        135.36000061035156,
        201.83999633789062,
        231.01199340820312,
        216.239990234375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품설명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        379.79998779296875,
        212.1599884033203,
        429.5999755859375,
        226.5599822998047
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품외형",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        158.27999877929688,
        222.47999572753906,
        208.0800018310547,
        236.87998962402344
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.83999633789062,
        369.47998046875,
        81.83999633789062,
        383.8799743652344
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Deprexis",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        158.51998901367188,
        248.63998413085938,
        207.71998596191406,
        263.03997802734375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(GAIA)",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        164.87998962402344,
        267.8399963378906,
        201.4919891357422,
        282.239990234375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- Deprexis는 18세 이상인 우울장애 및 우울한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        244.67999267578125,
        536.1599731445312,
        259.0799865722656
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기분이 있는 환자를 위한 치료를 지원하는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.32000732421875,
        263.8800048828125,
        536.1599731445312,
        278.2799987792969
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대화형 온라인 기반 자조 프로그램으로 인지",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.32000732421875,
        283.0799865722656,
        536.1599731445312,
        297.47998046875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행동치료(CBT)를 기반으로 하며, 21년 2월 20일에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.32000732421875,
        302.2799987792969,
        536.1599731445312,
        316.67999267578125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "독일 DiGA 디렉터리에 등록되었다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.32000732421875,
        321.47998046875,
        478.5,
        335.8799743652344
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 인지행동치료 기반 행동의 활성화, 인지 재구",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        340.67999267578125,
        536.1599731445312,
        355.0799865722656
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조화, 이완, 수용과 마음챙김 등의 프로그램을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        285.8399963378906,
        359.8800048828125,
        536.1599731445312,
        374.2799987792969
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제공한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        285.8399963378906,
        379.0799865722656,
        336.7799987792969,
        393.47998046875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- Deprexis는 인공 지능을 사용하여 사용자와",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        398.2799987792969,
        536.1599731445312,
        412.67999267578125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상호 작용하고 질문에 대한 응답을 분석하여",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        285.8399963378906,
        417.47998046875,
        536.1599731445312,
        431.8799743652344
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "우울장애 증상을 관리하는 데 도움이 되는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        285.8399963378906,
        436.67999267578125,
        536.1599731445312,
        451.0799865722656
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "맞춤형 피드백과 전략을 제공한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        285.8399963378906,
        455.8799743652344,
        474.7799987792969,
        470.27996826171875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 최초 등록 후 90일 동안 사용을 할 수 있으며,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        475.0799865722656,
        536.2319946289062,
        489.47998046875
      ],
      "page_num": 28,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "매주 30분 동안 주 1~2회의 사용을 권장한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        285.8399963378906,
        494.2799987792969,
        529.8599853515625,
        508.67999267578125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(출처: Deprexis",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        111.23999786376953,
        439.0799865722656,
        255.6719970703125,
        453.47998046875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "홈페이지,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        111.23999786376953,
        439.0799865722656,
        255.6719970703125,
        453.47998046875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "https://uk.deprexis.com/)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        121.68000030517578,
        458.2799987792969,
        245.2919921875,
        472.67999267578125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.83999633789062,
        631.6799926757812,
        81.83999633789062,
        646.0800170898438
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Selfapy",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        162.36000061035156,
        513.719970703125,
        203.95199584960938,
        528.1199951171875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Selfapy GmbH)",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        137.52000427246094,
        532.9199829101562,
        536.1599731445312,
        550.0800170898438
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- Selfapy는 근거 기반 이론과 인지 행동 치료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        137.52000427246094,
        532.9199829101562,
        536.1599731445312,
        550.0800170898438
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기술을 기반으로 우울장애 환자에게 개별 온라인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        287.2799987792969,
        554.8800048828125,
        536.1599731445312,
        569.280029296875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "과정을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        287.2799987792969,
        574.0800170898438,
        536.1599731445312,
        588.4800415039062
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제공하며,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        287.2799987792969,
        574.0800170898438,
        536.1599731445312,
        588.4800415039062
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20년",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        287.2799987792969,
        574.0800170898438,
        536.1599731445312,
        588.4800415039062
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6월",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        287.2799987792969,
        574.0800170898438,
        536.1599731445312,
        588.4800415039062
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12일에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        287.2799987792969,
        574.0800170898438,
        536.1599731445312,
        588.4800415039062
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "독일",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        287.2799987792969,
        574.0800170898438,
        536.1599731445312,
        588.4800415039062
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "DiGA 디렉터리에 등록되었다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        287.2799987792969,
        593.2799682617188,
        449.4599914550781,
        607.6799926757812
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 부정적인 생각 다루기, 긍정적인 일상 구조",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        273.8399963378906,
        612.47998046875,
        536.1599731445312,
        626.8800048828125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "만들기, 이완 기술, 수면 문제 및 재발 방지",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        288.239990234375,
        631.6799926757812,
        536.1599731445312,
        646.0800170898438
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전략과 같은 주제에 대한 프로그램을 제공하며,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        288.239990234375,
        650.8800048828125,
        536.2319946289062,
        665.280029296875
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개인적인 상황에 맞게 조정하여 제공한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        288.239990234375,
        670.0799560546875,
        519.1799926757812,
        684.47998046875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 최소 30분 동안 지속되는 1~2회 세션으로 매주",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        689.2799682617188,
        536.1599731445312,
        703.6799926757812
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최소 1개의 수업을 완료하는 것을 권장하며,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.32000732421875,
        708.47998046875,
        536.2319946289062,
        722.8800048828125
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과정은 총 3개월 동안 사용할 수 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.32000732421875,
        727.6799926757812,
        499.2599792480469,
        742.0800170898438
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(출처: Selfapy 홈페이지,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        117.83999633789062,
        713.0399780273438,
        249.07199096679688,
        727.4400024414062
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "https://www.selfapy.com/)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        118.68000030517578,
        732.239990234375,
        248.2919921875,
        746.6400146484375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 5. 국외 우울장애 개선 디지털치료기기 허가 제품 및 관련 제품의 개발 동향(2022. 11. 기준)",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        59.63999938964844,
        176.0399932861328,
        540.4017944335938,
        191.5919952392578
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 22 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 29,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        75.83999633789062,
        223.55999755859375,
        81.83999633789062,
        237.95999145507812
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Thrive",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        165.83999633789062,
        96.0,
        200.4239959716797,
        110.4000015258789
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Waypoint)",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        153.239990234375,
        115.19999694824219,
        213.01199340820312,
        129.59999084472656
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "-",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        137.16000366210938,
        536.1599731445312,
        151.55999755859375
      ],
      "page_num": 29,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Thrive는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        137.16000366210938,
        536.1599731445312,
        151.55999755859375
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인지행동치료(CBT)의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        137.16000366210938,
        536.1599731445312,
        151.55999755859375
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모범",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        137.16000366210938,
        536.1599731445312,
        151.55999755859375
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사례를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        137.16000366210938,
        536.1599731445312,
        151.55999755859375
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바탕으로 구조화된 디지털 커리큘럼을 통해",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        289.79998779296875,
        156.36000061035156,
        536.1599731445312,
        170.75999450683594
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공하는 우울장애 디지털 프로그램이다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        289.79998779296875,
        175.55999755859375,
        514.739990234375,
        189.95999145507812
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 행동 활성화, 인지 재구성 및 사회적 기술 훈련",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        273.8399963378906,
        194.75999450683594,
        536.1599731445312,
        209.1599884033203
      ],
      "page_num": 29,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술을 기반으로 하는 세 가지 CBT 모듈이",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.32000732421875,
        213.95999145507812,
        536.1599731445312,
        228.3599853515625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "포함되어있고, 각 모듈은 10개의 강의로 구성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.32000732421875,
        233.1599884033203,
        536.1599731445312,
        247.5599822998047
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "되어 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.32000732421875,
        252.3599853515625,
        343.260009765625,
        266.7599792480469
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- Thrive는 PHQ-9(Patient Health Questionnaire)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        271.55999755859375,
        536.1719970703125,
        285.9599914550781
      ],
      "page_num": 29,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애 평가를 사용하여 사용자와 임상의가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        287.3999938964844,
        290.7599792480469,
        536.1599731445312,
        305.15997314453125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진행 상황을 추적할 수 있도록 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        287.3999938964844,
        309.9599914550781,
        488.3399963378906,
        324.3599853515625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(출처: Thrive 홈페이지,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        120.95999908447266,
        284.6399841308594,
        245.95199584960938,
        299.03997802734375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "https://play.google.com/store/a",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        105.83999633789062,
        303.8399963378906,
        261.1679992675781,
        318.239990234375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "pps/details?id=com.waypointh",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        107.39999389648438,
        323.03997802734375,
        259.5480041503906,
        337.4399719238281
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ealth.thrive&hl=ko)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        136.67999267578125,
        342.239990234375,
        230.17198181152344,
        356.6399841308594
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        75.83999633789062,
        520.2000122070312,
        81.83999633789062,
        534.6000366210938
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Novego: Coping with",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        122.63999938964844,
        387.47998046875,
        243.58799743652344,
        401.8799743652344
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Depression",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        151.44000244140625,
        406.67999267578125,
        214.7880096435547,
        421.0799865722656
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(IVPNetworks)",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        143.16000366210938,
        425.8800048828125,
        223.2119903564453,
        440.2799987792969
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- Novego의 우울장애 프로그램은 전신 치료 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        273.8399963378906,
        395.3999938964844,
        536.1599731445312,
        409.79998779296875
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마음챙김 훈련의 일부 및 입증된 인지행동치료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.1999816894531,
        414.5999755859375,
        536.1599731445312,
        428.9999694824219
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방법을 제공하며, 심리적으로 스트레스가 많은",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.1999816894531,
        433.79998779296875,
        536.1599731445312,
        448.1999816894531
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생활 상황(예: 우울장애, 불안, 소진, 스트레스)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.1999816894531,
        453.0,
        536.1719970703125,
        467.3999938964844
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 인한 질병의 증상을 완화하거나 예방하기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.1999816894531,
        472.1999816894531,
        536.1599731445312,
        486.5999755859375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해 고안된 온라인 자조 프로그램을 제공한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.1999816894531,
        491.3999938964844,
        534.0599975585938,
        505.79998779296875
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 21년 10월 10일 독일 DiGA 디렉터리에 포함",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        510.5999755859375,
        536.1599731445312,
        525.0
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "되었으며, 12주의 정규 프로그램 기간 이후",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        287.0400085449219,
        529.7999877929688,
        536.1599731445312,
        544.2000122070312
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추가 12개월 동안 참가자에게 제공한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        287.0400085449219,
        549.0,
        505.97998046875,
        563.4000244140625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 참가자는 내용과 운동에 대해 질문이 있는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        568.2000122070312,
        536.1599731445312,
        582.6000366210938
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경우 일주일에 한 번 메시지로 Novego 심리",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        288.7200012207031,
        587.3999633789062,
        536.1599731445312,
        601.7999877929688
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "학자 팀에 직접 연락할 수 있고, 심각한 위기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        288.7200012207031,
        606.5999755859375,
        536.1599731445312,
        621.0
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상황의 경우 프로그램과 함께 24시간 위기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        288.7200012207031,
        625.7999877929688,
        536.1599731445312,
        640.2000122070312
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "핫라인을 이용할 수 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        288.7200012207031,
        645.0,
        429.6600036621094,
        659.4000244140625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(출처: NOVEGO 홈페이지,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        111.36000061035156,
        589.2000122070312,
        255.43199157714844,
        603.6000366210938
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "https://www.novego.de//)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        120.83999633789062,
        608.3999633789062,
        246.13198852539062,
        622.7999877929688
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 23 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 30,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.83999633789062,
        227.63999938964844,
        81.83999633789062,
        242.0399932861328
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SparkRx",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        159.47999572753906,
        96.0,
        206.87998962402344,
        110.4000015258789
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Limbix)",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        161.16000366210938,
        115.19999694824219,
        205.0919952392578,
        129.59999084472656
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- SparkRx는 13세에서 22세 사이의 우울장애",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        102.83999633789062,
        536.1599731445312,
        117.23999786376953
      ],
      "page_num": 30,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자에게",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        288.9599914550781,
        122.03999328613281,
        536.1599731445312,
        136.4399871826172
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인지행동치료를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        288.9599914550781,
        122.03999328613281,
        536.1599731445312,
        136.4399871826172
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공하는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        288.9599914550781,
        122.03999328613281,
        536.1599731445312,
        136.4399871826172
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디지털",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        288.9599914550781,
        122.03999328613281,
        536.1599731445312,
        136.4399871826172
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료제이며,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        288.9599914550781,
        141.239990234375,
        536.1599731445312,
        155.63998413085938
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미국",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        288.9599914550781,
        141.239990234375,
        536.1599731445312,
        155.63998413085938
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "FDA에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        288.9599914550781,
        141.239990234375,
        536.1599731445312,
        155.63998413085938
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아직",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        288.9599914550781,
        141.239990234375,
        536.1599731445312,
        155.63998413085938
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "승인되지는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        288.9599914550781,
        141.239990234375,
        536.1599731445312,
        155.63998413085938
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않았지만, COVID-19로 인해 정신 장애를 치료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        288.9599914550781,
        160.44000244140625,
        536.1599731445312,
        174.83999633789062
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 디지털 건강 장치에 대한 FDA 비상",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        288.9599914550781,
        179.63999938964844,
        536.1599731445312,
        194.0399932861328
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지침에 따라 처방전 없이 제공할 수 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        288.9599914550781,
        198.83999633789062,
        519.8999633789062,
        213.239990234375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 우울장애를 이해하는 데 도움이 되는 상호작용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        218.0399932861328,
        536.1599731445312,
        232.4399871826172
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프로그램을 수행하며, 활동 일정, 마음챙김,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.44000244140625,
        237.239990234375,
        536.2319946289062,
        251.63998413085938
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기분 추적을 포함하여 증상을 관리하는 대처",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.44000244140625,
        256.44000244140625,
        536.1599731445312,
        270.8399963378906
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기술을 배우고 그 과정에서 보상을 받는다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.44000244140625,
        275.6399841308594,
        523.3800048828125,
        290.03997802734375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 프로그램은 5가지 레벨로 구성되어 있으며,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        294.8399963378906,
        536.2319946289062,
        309.239990234375
      ],
      "page_num": 30,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "매주",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        288.7200012207031,
        314.03997802734375,
        536.1599731445312,
        328.4399719238281
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1레벨을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        288.7200012207031,
        314.03997802734375,
        536.1599731445312,
        328.4399719238281
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "완료하도록",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        288.7200012207031,
        314.03997802734375,
        536.1599731445312,
        328.4399719238281
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "권장하지만",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        288.7200012207031,
        314.03997802734375,
        536.1599731445312,
        328.4399719238281
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7주",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        288.7200012207031,
        314.03997802734375,
        536.1599731445312,
        328.4399719238281
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "동안 프로그램 액세스가 가능하다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        288.7200012207031,
        333.239990234375,
        477.6600036621094,
        347.6399841308594
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(출처: SparkRx 홈페이지,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        332.1600036621094,
        252.07199096679688,
        346.55999755859375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "https://www.sparkrx.com)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        119.63999938964844,
        351.3599853515625,
        247.3319854736328,
        365.7599792480469
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.83999633789062,
        522.47998046875,
        81.83999633789062,
        536.8800048828125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SilverCloud",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        151.0800018310547,
        390.9599914550781,
        215.2919921875,
        405.3599853515625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(SilverCloud)",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        147.0,
        410.1600036621094,
        219.25198364257812,
        424.55999755859375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- SilverCloud의 우울장애 프로그램은 경증에서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        397.67999267578125,
        536.1599731445312,
        412.0799865722656
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중증도의 우울장애를 겪는 개인에게 인지행동",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        287.5199890136719,
        416.8800048828125,
        536.1599731445312,
        431.2799987792969
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "치료 기반의 서비스가 제공되도록 설계되었으며,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        287.5199890136719,
        436.0799865722656,
        536.2319946289062,
        450.47998046875
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자기 기분과 유발 요인을 잘 이해하고 가르치기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        287.5199890136719,
        455.2799987792969,
        536.1599731445312,
        469.67999267578125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위한 유연한 사고방식과 전략을 개발할 수",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        287.5199890136719,
        474.47998046875,
        536.1599731445312,
        488.8799743652344
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있도록 돕는다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        287.5199890136719,
        493.67999267578125,
        368.4599914550781,
        508.0799865722656
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        512.8800048828125,
        536.1599731445312,
        527.280029296875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "영국의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        512.8800048828125,
        536.1599731445312,
        527.280029296875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상의가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        512.8800048828125,
        536.1599731445312,
        527.280029296875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "환자를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        512.8800048828125,
        536.1599731445312,
        527.280029296875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의뢰하면",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        512.8800048828125,
        536.1599731445312,
        527.280029296875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "무료로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        512.8800048828125,
        536.1599731445312,
        527.280029296875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "플랫폼에 접근할 수 있는 권한을 주어지며,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        289.67999267578125,
        532.0800170898438,
        536.2319946289062,
        546.4800415039062
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가입 후 서포터가 배정되어 목표를 설정한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        289.67999267578125,
        551.2799682617188,
        535.97998046875,
        565.6799926757812
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        570.47998046875,
        536.1599731445312,
        584.8800048828125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상적으로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        570.47998046875,
        536.1599731445312,
        584.8800048828125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "입증된",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        570.47998046875,
        536.1599731445312,
        584.8800048828125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "디지털",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        570.47998046875,
        536.1599731445312,
        584.8800048828125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인지행동치료를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        570.47998046875,
        536.1599731445312,
        584.8800048828125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용하며 전체 과정은 8주 동안 지원이 되며,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        290.1600036621094,
        589.6799926757812,
        536.2319946289062,
        604.0800170898438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하루에 15분, 일주일에 3~4번 정도 사용하는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        290.1600036621094,
        608.8800048828125,
        536.1599731445312,
        623.280029296875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "것을 권장하고 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        290.1600036621094,
        628.0799560546875,
        401.1000061035156,
        642.47998046875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(출처: SilverCloud 홈페이지,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        107.63999938964844,
        592.3200073242188,
        259.2720031738281,
        606.7200317382812
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "https://health.colostate.edu/silv",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        105.83999633789062,
        611.5199584960938,
        261.1080017089844,
        625.9199829101562
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ercloud/)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        161.39999389648438,
        630.719970703125,
        205.45199584960938,
        645.1199951171875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 24 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 31,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아. 디지털치료기기의 정의와 국내 가이드라인별 적용 기준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        465.5999755859375,
        100.72968292236328
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 디지털치료기기 정의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        114.90937042236328,
        233.87998962402344,
        130.72967529296875
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        144.9093780517578,
        546.0599975585938,
        160.7296905517578
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(민원인 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        94.07999420166016,
        174.9093780517578,
        545.9400024414062,
        190.7296905517578
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리, 치료하기 위해 환자에게 근거 기반의 치료적 개입을 제공",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        94.07999420166016,
        204.90936279296875,
        538.4400024414062,
        220.72967529296875
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 소프트웨어 의료기기(SaMD)이다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        94.07999420166016,
        234.90936279296875,
        361.8599853515625,
        250.72967529296875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ “예방, 관리”의 범위는 치료적 개입이 필요한 “환자”를 대상으로 함",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        99.95999908447266,
        263.1600036621094,
        519.0,
        278.7120056152344
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 국내 가이드라인별 적용 기준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        320.9493713378906,
        293.7599792480469,
        336.7696838378906
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 디지털치료기기 허가·심사 가이드라인(민원인 안내서)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        350.9493713378906,
        485.6474914550781,
        366.7696838378906
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "디지털치료기기는 「의료기기법」 제2조에 따른 사용 목적에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        380.9493713378906,
        545.9400024414062,
        396.7696838378906
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당해야 하며, <그림 1>과 같이 소프트웨어 의료기기로써 범용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        410.9493713378906,
        546.0599975585938,
        426.7696838378906
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하드웨어에 설치되고, 질병을 예방, 관리 또는 치료하기 위한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        440.9493713378906,
        546.0599975585938,
        456.7696838378906
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목적으로 환자에게 적용되어야 한다. 또한, 치료 작용기전의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        470.9493713378906,
        546.0599975585938,
        486.7696838378906
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과학적(임상적) 근거에 해당하는 자료가 있어야 한다. 여기서",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        500.9493408203125,
        545.9400024414062,
        516.7696533203125
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질병이란 국제질병분류코드(International Classification of Disease,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        530.9493408203125,
        546.0599975585938,
        546.7696533203125
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ICD)에 기반한 한국표준질병사인분류에 독립적으로 분류 가능한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        560.9493408203125,
        546.0599975585938,
        576.7696533203125
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질환으로 정의한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        590.9493408203125,
        240.56295776367188,
        606.7696533203125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "디지털 우울장애 인지행동치료(CBT)는 우울장애 인지행동치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        620.9493408203125,
        546.0599975585938,
        636.7696533203125
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반의 콘텐츠를 범용 스마트폰이나 태블릿 PC에 설치되어",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        650.9493408203125,
        546.0599975585938,
        666.7696533203125
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공하므로 소프트웨어 의료기기에 해당한다. 또한 한국표준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        680.9493408203125,
        538.4400024414062,
        696.7696533203125
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질병사인분류에 따라 우울장애를 의사에게 진단받은 환자들을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        710.9493408203125,
        545.9400024414062,
        726.7696533203125
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대상으로 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        740.9493408203125,
        210.56295776367188,
        756.7696533203125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 25 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 32,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미국, 영국, 캐나다 등 많은 학회에서 개발한 임상진료지침을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        84.90937042236328,
        545.9400024414062,
        100.72968292236328
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비롯하여, 국내 대한의학회의 한국형 우울장애 치료지침서에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        114.90937042236328,
        546.0599975585938,
        130.72967529296875
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따르면, 우울장애의 비약물치료로써 인지행동치료(CBT)를 시행",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        144.9093780517578,
        538.5599975585938,
        160.7296905517578
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하기를 권고하고 있다. 또한 다수의 동료검토 선행연구",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        174.9093780517578,
        538.5599975585938,
        190.7296905517578
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Peer-reviewed Journal)에서 임상시험을 통해 디지털 우울장애",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        204.90936279296875,
        546.0599975585938,
        220.72967529296875
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인지행동치료의 치료 효과성을 입증된 바 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        234.90936279296875,
        422.72296142578125,
        250.72967529296875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위와 같이 디지털 우울장애 인지행동치료(Digital CBT)는 디지털",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        264.90936279296875,
        538.5599975585938,
        280.72967529296875
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료기기 대상 여부 판단기준 및 절차를 충족하므로 디지털",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        294.90936279296875,
        538.5599975585938,
        310.72967529296875
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료기기 대상이라고 판단할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        324.90936279296875,
        370.7629699707031,
        340.72967529296875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "그림 1. 디지털 치료기기 대상여부 판단 기준 및 절차",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        111.1199951171875,
        710.5199584960938,
        446.0400390625,
        726.0719604492188
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[출처: 식품의약품안전처(2020.08), 디지털치료기기 허가·심사 가이드라인(민원인 안내서)]",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        56.63999938964844,
        730.2000122070312,
        501.156005859375,
        744.6000366210938
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 26 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나) 의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        84.90937042236328,
        525.1275024414062,
        100.72968292236328
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디지털치료기기는 식품의약품안전처‘의료기기의 사이버보안",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        114.90937042236328,
        546.0599975585938,
        130.72967529296875
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허가·심사 가이드라인(민원인 안내서)’에 근거하여 보안성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        144.9093780517578,
        546.0599975585938,
        160.7296905517578
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영역은 가용성(Availability), 기밀성(Confidentiality), 무결성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        174.9093780517578,
        538.5599975585938,
        190.7296905517578
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Integrity)을 고려하여 평가한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        204.90936279296875,
        327.8029479980469,
        220.72967529296875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가용성은 데이터가 승인된 사용자에게 즉시 제공되어야 하며,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        234.90936279296875,
        545.9400024414062,
        250.72967529296875
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요한 때에 필요한 곳에서 필요한 형태로 존재되어야 함을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        264.90936279296875,
        545.9400024414062,
        280.72967529296875
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의미한다. 기밀성은 데이터가 허가되지 않은 사람에게 공개",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        294.90936279296875,
        538.4400024414062,
        310.72967529296875
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되거나, 허가되지 않은 용도로 사용되지 않아야 함을 의미하며,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        324.90936279296875,
        545.9400024414062,
        340.72967529296875
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무결성은 데이터가 허가되지 않은 방법으로 변환되거나 파괴",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        354.90936279296875,
        538.5599975585938,
        370.72967529296875
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되지 않아야 함을 의미한다. 유·무선 통신이 가능하거나 통신",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        384.90936279296875,
        546.0599975585938,
        400.72967529296875
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경로가 존재하는 의료기기는 정보의 위변조, 오작동 또는 의료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        414.90936279296875,
        538.5599975585938,
        430.72967529296875
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기에 승인되지 않은 접근 등을 방지하기 위한 대책을 마련",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        444.90936279296875,
        538.4400024414062,
        460.72967529296875
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        474.90936279296875,
        195.56295776367188,
        490.72967529296875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사이버보안 침해로 인한 위해도는 의료기기의 잠재적 결함",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        504.90936279296875,
        538.5599975585938,
        520.7296752929688
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 인해 사용자에게 발생할 수 있는 위해(harm)의 정도, 의료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        534.9093627929688,
        538.4400024414062,
        550.7296752929688
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기의 통신방법 및 사용환경을 종합적으로 고려하여 ‘상’,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        564.9093627929688,
        546.0599975585938,
        580.7296752929688
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘중’, ‘하’로 결정되고, 그에 따른 사이버보안 요구사항을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        594.9093627929688,
        546.0599975585938,
        610.7296752929688
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적용한다. 일반적으로 디지털 치료기기는 ‘치료’를 목적으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        624.9093627929688,
        546.0599975585938,
        640.7296752929688
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 2등급 이상의 의료기기로 품목 분류되므로 사이버보안",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        654.9093627929688,
        546.0599975585938,
        670.7296752929688
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성에서‘하’등급의 분류가 불가능하다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        684.9093627929688,
        404.2429504394531,
        700.7296752929688
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 27 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 34,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그림 2. 데이터 보호 및 보안성 영역 연구의 흐름",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        143.39999389648438,
        296.0400085449219,
        451.08056640625,
        311.5920104980469
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 의료기기의 소프트웨어 허가·심사 가이드라인(민원인 안내서)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        362.7093811035156,
        538.0874633789062,
        378.5296936035156
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어 의료기기도 일반 의료기기와 마찬가지로 제조 및",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        392.7093811035156,
        545.9400024414062,
        408.5296936035156
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품질관리체계의 기준과 위험관리 프로세스가 조화를 이루는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        422.7093505859375,
        545.9400024414062,
        438.5296630859375
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "범위 내에서 개발 및 유지가 되어야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        452.7093505859375,
        398.0029602050781,
        468.5296630859375
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식품의약품안전처‘의료기기 소프트웨어 허가·심사 가이드라인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        482.7093505859375,
        546.0599975585938,
        498.5296630859375
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(민원인 안내서)’를 기준으로 디지털치료기기의 위험성 관리",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        512.7093505859375,
        546.0599975585938,
        528.5296630859375
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로세스는 의료기기에서 발생하는 위험분석(risk analysis), 위험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        542.7093505859375,
        538.4400024414062,
        558.5296630859375
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가(risk evaluation), 위험통제(risk control), 잔여 위험 허용평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        572.7093505859375,
        538.5599975585938,
        588.5296630859375
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(evaluation of overall residual risk acceptability), 위험관리 보고서",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        602.7093505859375,
        538.4400024414062,
        618.5296630859375
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(risk management report), 생산 및 생산 후 정보(production",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        632.7093505859375,
        545.9400024414062,
        648.5296630859375
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and post-production information)로 구분한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        662.7093505859375,
        418.7629699707031,
        678.5296630859375
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 소프트웨어 안전성 등급은 고장 또는 잠재적 결함으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        692.7093505859375,
        545.9400024414062,
        708.5296630859375
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인해 환자나 사용자에게 미치는 위해의 영향에 따라 분류한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        722.7093505859375,
        545.9400024414062,
        738.5296630859375
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기 소프트웨어 사용으로 건강상의 상해 또는 손상이 없는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        752.7093505859375,
        545.9400024414062,
        768.5296630859375
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 28 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 35,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우 A등급, 심각하지 않은 상해의 가능성 있으면 B등급, 심각한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        84.90937042236328,
        546.0599975585938,
        100.72968292236328
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상해 또는 사망의 가능성이 있는 경우 C등급으로 구분한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        114.90937042236328,
        506.2429504394531,
        130.72967529296875
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기 소프트웨어는 안전성 등급이 결정될 때까지 초기에는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        144.9093780517578,
        546.0599975585938,
        160.7296905517578
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "C등급 요구사항이 적용되며, 소프트웨어 시스템의 실패가 위험한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        174.9093780517578,
        546.0599975585938,
        190.7296905517578
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상황을 발생하지 않으면 안전성 등급은 A등급에 해당한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        204.90936279296875,
        492.8029479980469,
        220.72967529296875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "그림 3. 소프트웨어의 안전성 평가 관련 연구의 흐름",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        132.95999145507812,
        475.32000732421875,
        461.52056884765625,
        490.87200927734375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인(민원인 안내서)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        535.1493530273438,
        538.5675048828125,
        550.9696655273438
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디지털치료기기는 실사용증거(Real World Evidence, RWE)를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        565.1493530273438,
        546.0599975585938,
        580.9696655273438
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용하여 의료기기의 사전 및 사후와 관련된 안전성 및 유효성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        595.1493530273438,
        546.0599975585938,
        610.9696655273438
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "입증 근거로 제시할 수 있으며, 이에 따른 기간 및 비용을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        625.1493530273438,
        545.9400024414062,
        640.9696655273438
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "절약할 수 있다.1)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        655.1062622070312,
        237.05999755859375,
        670.9696655273438
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실사용증거 수집은 데이터의 타당성 및 신뢰성 확보를 위해",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        685.1493530273438,
        545.9400024414062,
        700.9696655273438
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 실사용데이터(RWD)는 기존의 중재적 방법에 의한 임상시험으로부터 수집되지 않은 다양한 유형의 의료데이터에 대한 포괄적인",
      "font_size": 8.759956359863281,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        733.1456298828125,
        542.7031860351562,
        742.6378173828125
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용어이다. 실사용증거(RWE)는 RWD를 분석하여 파생된 증거로써, RWD 분석을 통해 얻은 의료기기의 사용 결과나 잠재적 이익",
      "font_size": 8.759956359863281,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.91999816894531,
        747.5455932617188,
        542.7031860351562,
        757.0377807617188
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 위험성에 관한 임상적 근거를 말한다. 또한, 임상 문헌을 분석하여 파생된 새로운 증거도 포함한다.",
      "font_size": 8.759956359863281,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.91999816894531,
        761.9456176757812,
        458.298095703125,
        771.4378051757812
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 29 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 36,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품질, 수집 및 분석 방법, 수집한 인력의 역량을 입증할 수 있는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        84.90937042236328,
        546.0599975585938,
        100.72968292236328
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "객관적인 사항이 반드시 포함되어야 한다. 또한 실사용증거는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        114.90937042236328,
        545.9400024414062,
        130.72967529296875
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적용 목적, 수집 및 분석 정보, 분석 결과에 대한 사항을 제시",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        144.9093780517578,
        538.5599975585938,
        160.7296905517578
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        174.9093780517578,
        180.56295776367188,
        190.7296905517578
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 30 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 37,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅱ",
      "font_size": 20.03999900817871,
      "font_name": "T9",
      "bbox": [
        68.4000015258789,
        91.31999969482422,
        288.3600158691406,
        115.36800384521484
      ],
      "page_num": 37,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성·성능 평가",
      "font_size": 20.03999900817871,
      "font_name": "H2hdrM",
      "bbox": [
        68.4000015258789,
        91.31999969482422,
        288.3600158691406,
        115.36800384521484
      ],
      "page_num": 37,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 국내외 관련 규격 및 가이드라인",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        147.09996032714844,
        325.19940185546875,
        163.05996704101562
      ],
      "page_num": 37,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 국내외 규격",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        190.38937377929688,
        165.72000122070312,
        206.20968627929688
      ],
      "page_num": 37,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디지털치료기기 관련 국내외 규격은 <표 6>과 같다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        220.38937377929688,
        433.1629638671875,
        236.20968627929688
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "번호",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.27999877929688,
        280.0799865722656,
        527.760009765625,
        294.47998046875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표준 번호",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.27999877929688,
        280.0799865722656,
        527.760009765625,
        294.47998046875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "규격 명칭",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.27999877929688,
        280.0799865722656,
        527.760009765625,
        294.47998046875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주요 내용",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.27999877929688,
        280.0799865722656,
        527.760009765625,
        294.47998046875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.27999877929688,
        280.0799865722656,
        527.760009765625,
        294.47998046875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.87999725341797,
        337.91998291015625,
        159.95999145507812,
        352.3199768066406
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ISO 13485",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.87999725341797,
        337.91998291015625,
        159.95999145507812,
        352.3199768066406
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Medical devices",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        209.39999389648438,
        309.1199951171875,
        293.5199890136719,
        323.5199890136719
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "– Quality management",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        188.27999877929688,
        328.32000732421875,
        314.5799865722656,
        342.7200012207031
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "systems – Requirements for",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        173.16000366210938,
        347.5199890136719,
        329.7599792480469,
        361.91998291015625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "regulatory purposes",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        199.55999755859375,
        366.7200012207031,
        303.3600158691406,
        381.1199951171875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 품질관리 (Quality",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        341.8800048828125,
        318.7200012207031,
        488.47198486328125,
        333.1199951171875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Management)에 대한 국제",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        343.91998291015625,
        337.91998291015625,
        486.47998046875,
        352.3199768066406
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "규격",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        403.1999816894531,
        357.1199951171875,
        427.1999816894531,
        371.5199890136719
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국외",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        503.7599792480469,
        337.91998291015625,
        527.760009765625,
        352.3199768066406
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.87999725341797,
        427.3199768066406,
        159.95999145507812,
        441.719970703125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ISO 14971",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.87999725341797,
        427.3199768066406,
        159.95999145507812,
        441.719970703125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Medical devices",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        209.39999389648438,
        408.1199951171875,
        293.5199890136719,
        422.5199890136719
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "– Application of risk",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        202.55999755859375,
        427.3199768066406,
        300.2760009765625,
        441.719970703125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "management to medical devices",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        176.51998901367188,
        446.5199890136719,
        326.3999938964844,
        460.91998291015625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 위험관리",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        342.47998046875,
        408.1199951171875,
        487.95599365234375,
        422.5199890136719
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Risk",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        342.47998046875,
        408.1199951171875,
        487.95599365234375,
        422.5199890136719
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Management)에 대한 국제",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        343.91998291015625,
        427.3199768066406,
        486.47998046875,
        441.719970703125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "규격",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        403.1999816894531,
        446.5199890136719,
        427.1999816894531,
        460.91998291015625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국외",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        503.7599792480469,
        427.3199768066406,
        527.760009765625,
        441.719970703125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        74.87999725341797,
        507.1199951171875,
        324.239990234375,
        531.1199951171875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IEC 62304",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        74.87999725341797,
        507.1199951171875,
        324.239990234375,
        531.1199951171875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Medical device software –",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        74.87999725341797,
        507.1199951171875,
        324.239990234375,
        531.1199951171875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Software life cycle processes",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        173.51998901367188,
        526.3200073242188,
        329.3999938964844,
        540.7200317382812
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 소프트웨어의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        352.1999816894531,
        487.91998291015625,
        478.1999816894531,
        502.3199768066406
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개발부터 유지보수를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        358.1999816894531,
        507.1199951171875,
        472.1999816894531,
        521.52001953125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "포함하여 전주기에 대한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        349.1999816894531,
        526.3200073242188,
        481.1999816894531,
        540.7200317382812
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국제 규격",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        388.1999816894531,
        545.5199584960938,
        442.1999816894531,
        559.9199829101562
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국외",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        503.7599792480469,
        516.719970703125,
        527.760009765625,
        531.1199951171875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        74.87999725341797,
        606.1199951171875,
        80.87999725341797,
        620.52001953125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IEC/TR",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        113.27999877929688,
        596.5199584960938,
        150.98399353027344,
        610.9199829101562
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "80002-1",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        111.0,
        615.719970703125,
        153.239990234375,
        630.1199951171875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Medical device software –",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        178.55999755859375,
        577.3200073242188,
        324.239990234375,
        591.7200317382812
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Part 1: Guidance on the",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        185.63999938964844,
        596.5199584960938,
        317.1839904785156,
        610.9199829101562
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "application of ISO 14971 to",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        177.83999633789062,
        615.719970703125,
        325.0679931640625,
        630.1199951171875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "medical device software",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        187.55999755859375,
        634.9199829101562,
        315.2640075683594,
        649.3200073242188
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 소프트웨어의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        352.1999816894531,
        586.9199829101562,
        478.1999816894531,
        601.3200073242188
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험관리 방법에 대한 국제",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        340.1999816894531,
        606.1199951171875,
        490.1999816894531,
        620.52001953125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "규격",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        403.1999816894531,
        625.3200073242188,
        427.1999816894531,
        639.7200317382812
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국외",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        503.7599792480469,
        606.1199951171875,
        527.760009765625,
        620.52001953125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.87999725341797,
        705.1199951171875,
        80.87999725341797,
        719.52001953125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IEC",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        122.5199966430664,
        695.5199584960938,
        141.70799255371094,
        709.9199829101562
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "80001-1",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        111.0,
        714.719970703125,
        153.239990234375,
        729.1199951171875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Application of risk",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        205.79998779296875,
        666.719970703125,
        297.1559753417969,
        681.1199951171875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "management for IT-networks",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        177.1199951171875,
        685.9199829101562,
        325.79998779296875,
        700.3200073242188
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "incorporating medical devices",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        176.27999877929688,
        705.1199951171875,
        326.6400146484375,
        719.52001953125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "– Part 1: Roles,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        207.1199951171875,
        724.3200073242188,
        295.7519836425781,
        738.7200317382812
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "responsibilities, and activities",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        178.44000244140625,
        743.5199584960938,
        324.4800109863281,
        757.9199829101562
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "네트워크로 연결되는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        358.1999816894531,
        685.9199829101562,
        472.1999816894531,
        700.3200073242188
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기의 위험관리",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        358.1999816894531,
        705.1199951171875,
        472.1999816894531,
        719.52001953125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방법에 대한 국제 규격",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        352.1999816894531,
        724.3200073242188,
        478.1999816894531,
        738.7200317382812
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국외",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        503.7599792480469,
        705.1199951171875,
        527.760009765625,
        719.52001953125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 6. 디지털치료기기 관련 국내/외 규격",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        171.59999084472656,
        251.3999786376953,
        423.1205749511719,
        266.9519958496094
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 31 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 국내외 가이드라인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        472.8693542480469,
        210.72000122070312,
        488.6896667480469
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디지털치료기기 관련 국내외 가이드라인은 <표 7>과 같다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        502.869384765625,
        478.1629638671875,
        518.689697265625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "번호",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.27999877929688,
        93.23999786376953,
        527.760009765625,
        107.63999938964844
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표준 번호",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.27999877929688,
        93.23999786376953,
        527.760009765625,
        107.63999938964844
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규격 명칭",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.27999877929688,
        93.23999786376953,
        527.760009765625,
        107.63999938964844
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요 내용",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.27999877929688,
        93.23999786376953,
        527.760009765625,
        107.63999938964844
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비고",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.27999877929688,
        93.23999786376953,
        527.760009765625,
        107.63999938964844
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.87999725341797,
        186.47999572753906,
        80.87999725341797,
        200.87998962402344
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IEC/TR",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        113.27999877929688,
        176.87998962402344,
        150.98399353027344,
        191.2799835205078
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "80001-2-1",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        104.87999725341797,
        196.0800018310547,
        159.36000061035156,
        210.47999572753906
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Application of risk",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        205.79998779296875,
        128.87998962402344,
        297.1559753417969,
        143.2799835205078
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "management for IT-networks",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        177.1199951171875,
        148.0800018310547,
        325.79998779296875,
        162.47999572753906
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "incorporating medical devices",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        176.27999877929688,
        167.27999877929688,
        326.6400146484375,
        181.67999267578125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "– Part 2-1: Step by step",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        183.59999084472656,
        186.47999572753906,
        319.3800048828125,
        200.87998962402344
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "risk management of medical",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        178.55999755859375,
        205.67999267578125,
        324.29998779296875,
        220.07998657226562
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IT-networks – Practical",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        189.239990234375,
        224.87998962402344,
        313.739990234375,
        239.2799835205078
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "applications and examples",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        183.83999633789062,
        244.07998657226562,
        319.08001708984375,
        258.47998046875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "네트워크로 연결되는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        358.1999816894531,
        167.27999877929688,
        472.1999816894531,
        181.67999267578125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기의 위험관리",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        358.1999816894531,
        186.47999572753906,
        472.1999816894531,
        200.87998962402344
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방법에 대한 국제 규격",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        352.1999816894531,
        205.67999267578125,
        478.1999816894531,
        220.07998657226562
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국외",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        503.7599792480469,
        186.47999572753906,
        527.760009765625,
        200.87998962402344
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.87999725341797,
        349.55999755859375,
        80.87999725341797,
        363.9599914550781
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IEC/TR",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        113.27999877929688,
        339.9599914550781,
        150.98399353027344,
        354.3599853515625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "80001-2-2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        104.87999725341797,
        359.1600036621094,
        159.36000061035156,
        373.55999755859375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Application of risk management",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        174.1199951171875,
        291.9599914550781,
        328.739990234375,
        306.3599853515625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "for IT-networks incorporating",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        180.72000122070312,
        311.1600036621094,
        322.18798828125,
        325.55999755859375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "medical devices",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        212.51998901367188,
        330.3599853515625,
        290.3999938964844,
        344.7599792480469
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "– Part 2-2: Guidance for the",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        176.63999938964844,
        349.55999755859375,
        326.3039855957031,
        363.9599914550781
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "disclosure and communication",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        177.83999633789062,
        368.7599792480469,
        325.0679931640625,
        383.15997314453125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "of medical device security",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        187.3199920654297,
        387.9599914550781,
        315.552001953125,
        402.3599853515625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "needs, risks and controls",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        189.36000061035156,
        407.1600036621094,
        313.55999755859375,
        421.55999755859375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "네트워크로 연결되는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        358.1999816894531,
        330.3599853515625,
        472.1999816894531,
        344.7599792480469
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기의 위험관리",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        358.1999816894531,
        349.55999755859375,
        472.1999816894531,
        363.9599914550781
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방법에 대한 국제 규격",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        352.1999816894531,
        368.7599792480469,
        478.1999816894531,
        383.15997314453125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국외",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        503.7599792480469,
        349.55999755859375,
        527.760009765625,
        363.9599914550781
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "번호",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        66.5999984741211,
        562.5599975585938,
        522.3599853515625,
        576.9600219726562
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가이드라인 명칭",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        66.5999984741211,
        562.5599975585938,
        522.3599853515625,
        576.9600219726562
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주요 내용",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        66.5999984741211,
        562.5599975585938,
        522.3599853515625,
        576.9600219726562
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        66.5999984741211,
        562.5599975585938,
        522.3599853515625,
        576.9600219726562
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        611.8800048828125,
        259.44000244140625,
        635.8800048828125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "디지털치료기기 허가·심사",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        611.8800048828125,
        259.44000244140625,
        635.8800048828125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가이드라인(민원인 안내서)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        115.68000030517578,
        631.0799560546875,
        260.5320129394531,
        645.47998046875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "「의료기기법」 및 「의료기기법시행",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        583.0800170898438,
        483.7200012207031,
        597.4800415039062
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "규칙」,「의료기기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        602.2799682617188,
        483.7200012207031,
        616.6799926757812
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가·신고·심사",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        602.2799682617188,
        483.7200012207031,
        616.6799926757812
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "등에 관한 규정」 기반, 디지털치료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        621.47998046875,
        483.7200012207031,
        635.8800048828125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기기에 해당하는 제품의 범위, 판단",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        640.6799926757812,
        483.7200012207031,
        655.0800170898438
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준, 허가·심사 방안 등 제시",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        659.8800048828125,
        445.79998779296875,
        674.280029296875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국내",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        498.3599853515625,
        621.47998046875,
        522.3599853515625,
        635.8800048828125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        693.9599609375,
        82.19999694824219,
        708.3599853515625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        131.16000366210938,
        674.760009765625,
        245.1599884033203,
        689.1600341796875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "밸리데이션 가이드라인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        125.15999603271484,
        693.9599609375,
        251.1599884033203,
        708.3599853515625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(민원인 안내서)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        145.67999267578125,
        713.1599731445312,
        230.531982421875,
        727.5599975585938
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        674.760009765625,
        483.7200012207031,
        689.1600341796875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        674.760009765625,
        483.7200012207031,
        689.1600341796875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "밸리데이션에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        674.760009765625,
        483.7200012207031,
        689.1600341796875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대하여 알기 쉽게 설명하거나 식품",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        693.9599609375,
        483.7200012207031,
        708.3599853515625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의약품안전처의 입장을 기술",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        282.239990234375,
        713.1599731445312,
        438.239990234375,
        727.5599975585938
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국내",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        498.3599853515625,
        693.9599609375,
        522.3599853515625,
        708.3599853515625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 7. 디지털치료기기 관련 국내외 가이드라인",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        151.3199920654297,
        533.8799438476562,
        439.5617980957031,
        549.4319458007812
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 32 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 39,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        66.5999984741211,
        93.23999786376953,
        522.3599853515625,
        107.63999938964844
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인 명칭",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        66.5999984741211,
        93.23999786376953,
        522.3599853515625,
        107.63999938964844
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요 내용",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        66.5999984741211,
        93.23999786376953,
        522.3599853515625,
        107.63999938964844
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비고",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        66.5999984741211,
        93.23999786376953,
        522.3599853515625,
        107.63999938964844
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        76.19999694824219,
        163.0800018310547,
        82.19999694824219,
        177.47999572753906
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        131.16000366210938,
        143.87998962402344,
        245.1599884033203,
        158.2799835205078
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허가심사 가이드라인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        131.16000366210938,
        163.0800018310547,
        245.1599884033203,
        177.47999572753906
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(민원인 안내서)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        145.67999267578125,
        182.27999877929688,
        230.531982421875,
        196.67999267578125
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 소프트웨어의 기술문서 작성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        115.07999420166016,
        483.7200012207031,
        129.47999572753906
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        134.27999877929688,
        483.7200012207031,
        148.67999267578125
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대하여",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        134.27999877929688,
        483.7200012207031,
        148.67999267578125
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상세히",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        134.27999877929688,
        483.7200012207031,
        148.67999267578125
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술하고",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        134.27999877929688,
        483.7200012207031,
        148.67999267578125
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘의료기기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        153.47999572753906,
        483.7200012207031,
        167.87998962402344
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        153.47999572753906,
        483.7200012207031,
        167.87998962402344
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적합성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        153.47999572753906,
        483.7200012207031,
        167.87998962402344
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        153.47999572753906,
        483.7200012207031,
        167.87998962402344
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보고서’, ‘의료기기 소프트웨어 검증",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        172.67999267578125,
        483.7200012207031,
        187.07998657226562
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 유효성 확인’ 자료 등 허가·심사 시",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        191.87998962402344,
        483.7200012207031,
        206.2799835205078
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제출해야 할 첨부 자료에 대하여 제시",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        211.0800018310547,
        482.2799987792969,
        225.47999572753906
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국내",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        498.3599853515625,
        163.0800018310547,
        522.3599853515625,
        177.47999572753906
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        76.19999694824219,
        257.5199890136719,
        82.19999694824219,
        271.91998291015625
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기의 사이버보안",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        125.15999603271484,
        238.3199920654297,
        251.1599884033203,
        252.71998596191406
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가·심사 가이드라인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        128.87998962402344,
        257.5199890136719,
        247.4399871826172,
        271.91998291015625
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(민원인 안내서)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        145.67999267578125,
        276.7200012207031,
        230.531982421875,
        291.1199951171875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        228.72000122070312,
        483.7200012207031,
        243.1199951171875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가·심사",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        228.72000122070312,
        483.7200012207031,
        243.1199951171875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        228.72000122070312,
        483.7200012207031,
        243.1199951171875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용자의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        228.72000122070312,
        483.7200012207031,
        243.1199951171875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "건강에 직접적인 영향을 미칠 수 있는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        247.91998291015625,
        483.7200012207031,
        262.3199768066406
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사이버보안 위협에 적용할 수 있는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        267.1199951171875,
        483.7200012207031,
        281.5199890136719
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최소한의 권고 사항 등 제시",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        286.32000732421875,
        438.239990234375,
        300.7200012207031
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국내",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        498.3599853515625,
        257.5199890136719,
        522.3599853515625,
        271.91998291015625
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        323.1600036621094,
        82.19999694824219,
        337.55999755859375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기의 사이버보안",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        125.15999603271484,
        303.9599914550781,
        251.1599884033203,
        318.3599853515625
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용방법 및 사례집",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        134.16000366210938,
        323.1600036621094,
        242.1599884033203,
        337.55999755859375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(민원인 안내서)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        145.67999267578125,
        342.3599853515625,
        230.531982421875,
        356.7599792480469
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        303.9599914550781,
        483.7200012207031,
        318.3599853515625
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사이버보안",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        303.9599914550781,
        483.7200012207031,
        318.3599853515625
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        303.9599914550781,
        483.7200012207031,
        318.3599853515625
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방법과",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        303.9599914550781,
        483.7200012207031,
        318.3599853515625
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가신청 시 제출하는 자료의 작성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        323.1600036621094,
        483.7200012207031,
        337.55999755859375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시를 제시",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        342.3599853515625,
        348.239990234375,
        356.7599792480469
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국내",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        498.3599853515625,
        323.1600036621094,
        522.3599853515625,
        337.55999755859375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        376.67999267578125,
        82.19999694824219,
        391.0799865722656
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Off-The-Shelf Software Use in",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        105.36000061035156,
        367.0799865722656,
        270.8279724121094,
        381.47998046875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Medical Devices",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        145.0800018310547,
        386.2799987792969,
        231.1199951171875,
        400.67999267578125
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기에서의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        367.0799865722656,
        483.7200012207031,
        381.47998046875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기성품",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        367.0799865722656,
        483.7200012207031,
        381.47998046875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        367.0799865722656,
        483.7200012207031,
        381.47998046875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용에 대한 가이드",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        386.2799987792969,
        390.239990234375,
        400.67999267578125
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미국",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        498.3599853515625,
        376.67999267578125,
        522.3599853515625,
        391.0799865722656
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        459.0,
        82.19999694824219,
        473.3999938964844
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Information for Healthcare",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        119.39999389648438,
        411.0,
        256.823974609375,
        425.3999938964844
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Organizations about FDA’S",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        115.79999542236328,
        430.1999816894531,
        260.35198974609375,
        444.5999755859375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "“Guidance for Industry:",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        127.07999420166016,
        449.3999938964844,
        249.08399963378906,
        463.79998779296875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Cybersecurity for Networked",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        113.27999877929688,
        468.5999755859375,
        262.9320068359375,
        482.9999694824219
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Medical Devices Containing",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        487.79998779296875,
        261.4679870605469,
        502.1999816894531
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Off-The-Shelf(OTS) Software”",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        108.47999572753906,
        507.0,
        267.7799987792969,
        521.4000244140625
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "네트워크를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        449.3999938964844,
        483.7200012207031,
        463.79998779296875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "활용하는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        449.3999938964844,
        483.7200012207031,
        463.79998779296875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        449.3999938964844,
        483.7200012207031,
        463.79998779296875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사이버보안에 대한 정보 가이드라인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        459.0,
        522.3599853515625,
        482.9999694824219
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미국",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        282.239990234375,
        459.0,
        522.3599853515625,
        482.9999694824219
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        76.19999694824219,
        553.4400024414062,
        82.19999694824219,
        567.8400268554688
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Guidance for the Content of",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        112.19999694824219,
        524.6400146484375,
        264.05999755859375,
        539.0400390625
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Premarket Submissions for",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        116.63999938964844,
        543.8399658203125,
        259.55999755859375,
        558.239990234375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Software Contained in Medical",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        106.43999481201172,
        563.0399780273438,
        269.8199768066406,
        577.4400024414062
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Devices",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        167.75999450683594,
        582.239990234375,
        208.55999755859375,
        596.6400146484375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        543.8399658203125,
        483.7200012207031,
        558.239990234375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "포함하는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        543.8399658203125,
        483.7200012207031,
        558.239990234375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        543.8399658203125,
        483.7200012207031,
        558.239990234375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 시판 전 제출에 대한 가이드라인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        553.4400024414062,
        522.3599853515625,
        577.4400024414062
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미국",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        282.239990234375,
        553.4400024414062,
        522.3599853515625,
        577.4400024414062
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        76.19999694824219,
        619.0799560546875,
        82.19999694824219,
        633.47998046875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Deciding When to Submit a",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        113.27999877929688,
        599.8800048828125,
        262.9679870605469,
        614.280029296875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "510(k) for a Software Change",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        108.36000061035156,
        619.0799560546875,
        267.8639831542969,
        633.47998046875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "to an Existing Device",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        130.55999755859375,
        638.2799682617188,
        245.66400146484375,
        652.6799926757812
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 내 소프트웨어 변경에 따른",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        609.47998046875,
        483.7200012207031,
        623.8800048828125
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침 가이드라인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        628.6799926757812,
        372.239990234375,
        643.0800170898438
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미국",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        498.3599853515625,
        619.0799560546875,
        522.3599853515625,
        633.47998046875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        73.19999694824219,
        675.1199951171875,
        85.19999694824219,
        689.52001953125
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Postmarket Management of",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        655.9199829101562,
        261.41998291015625,
        670.3200073242188
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Cybersecurity in Medical",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        123.36000061035156,
        675.1199951171875,
        252.89999389648438,
        689.52001953125
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Devices",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        167.75999450683594,
        694.3200073242188,
        208.55999755859375,
        708.7200317382812
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        665.5199584960938,
        483.7200012207031,
        679.9199829101562
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사이버보안의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        665.5199584960938,
        483.7200012207031,
        679.9199829101562
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시판",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        282.239990234375,
        665.5199584960938,
        483.7200012207031,
        679.9199829101562
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "후",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        665.5199584960938,
        483.7200012207031,
        679.9199829101562
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관리에 대한 가이드라인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        675.1199951171875,
        522.3599853515625,
        699.1199951171875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미국",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        282.239990234375,
        675.1199951171875,
        522.3599853515625,
        699.1199951171875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "11",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        73.19999694824219,
        721.6799926757812,
        85.19999694824219,
        736.0800170898438
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Guidance on Cybersecurity for",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        106.79999542236328,
        712.0799560546875,
        269.3999938964844,
        726.47998046875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "medical devices",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        146.0399932861328,
        721.6799926757812,
        522.3599853515625,
        745.6799926757812
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 사이버보안에 대한 가이드라인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        146.0399932861328,
        721.6799926757812,
        522.3599853515625,
        745.6799926757812
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유럽",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        146.0399932861328,
        721.6799926757812,
        522.3599853515625,
        745.6799926757812
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 33 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 안전성 평가 항목",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        93.4599609375,
        213.1199951171875,
        109.41996002197266
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 소프트웨어 검증 및 유효성 확인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        136.74937438964844,
        308.1600036621094,
        152.56968688964844
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 개요",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        166.74937438964844,
        121.31999969482422,
        182.56968688964844
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기에 포함되는 소프트웨어 또는 의료기기 자체가 소프트",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        196.74937438964844,
        538.4400024414062,
        212.56968688964844
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "웨어면 ‘의료기기 제조 및 품질관리 기준’ 및 ‘의료기기 위험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        226.74937438964844,
        538.5599975585938,
        242.56968688964844
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리 시스템’과 조화를 이루는 범위에서 개발, 유지되고 사용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        256.7493591308594,
        538.4400024414062,
        272.5696716308594
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되어야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        286.7493591308594,
        173.1229705810547,
        302.5696716308594
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 검증 및 유효성 확인은 의료기기로서의 소프트웨어의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        316.7493591308594,
        546.0599975585938,
        332.5696716308594
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신뢰도를 높이고 환자 또는 사용자에 대한 위험을 낮추기 위한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        346.7493591308594,
        545.9400024414062,
        362.5696716308594
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활동으로, 국제 표준 IEC 62304, ISO 14971 및 ‘의료기기 소프트",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        376.7493591308594,
        538.5599975585938,
        392.5696716308594
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "웨어 밸리데이션 가이드라인(민원인 안내서)’에 따라 수행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        406.7493591308594,
        527.3629760742188,
        422.5696716308594
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 소프트웨어 개발 및 위험관리",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        436.7493591308594,
        293.7599792480469,
        452.5696716308594
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 제조업체는 ‘의료기기 제조 및 품질관리 기준’에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        466.7493591308594,
        545.9400024414062,
        482.5696716308594
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규정된 바와 같이 수립된 품질시스템에서 관련 절차에 따라 소프트",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        496.7493591308594,
        538.4400024414062,
        512.5697021484375
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "웨어의 개발 및 유지를 위한 활동을 수행하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        526.7493896484375,
        458.0029602050781,
        542.5697021484375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 소프트웨어의 위험관리는 소프트웨어 개발 활동의 일부이며,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        556.7493896484375,
        546.0599975585938,
        572.5697021484375
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동시에 의료기기의 전체 수명주기의 위험관리 일부로 수행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        586.7493896484375,
        495.3229675292969,
        602.5697021484375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 소프트웨어 위험관리를 통해 의료기기에 포함된 소프트",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        616.7493896484375,
        538.5599975585938,
        632.5697021484375
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "웨어 사용에 따른 허용 불가능한 위험이 발생하지 않고, 의료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        646.7493896484375,
        538.4400024414062,
        662.5697021484375
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기로서의 사용 목적을 달성할 수 있음을 증명해야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        676.7493896484375,
        488.0029602050781,
        692.5697021484375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 개발 및 위험관리는 <표 8>와 같이 IEC 62304 프로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        706.7493286132812,
        538.5599975585938,
        722.5696411132812
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세스에 따른다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        736.7493286132812,
        188.1229705810547,
        752.5696411132812
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 34 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 41,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.4000015258789,
        109.07999420166016,
        185.51998901367188,
        133.07998657226562
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "IEC 62304",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.4000015258789,
        109.07999420166016,
        185.51998901367188,
        133.07998657226562
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로세스",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        130.9199981689453,
        128.27999877929688,
        180.72000122070312,
        142.67999267578125
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어 개발",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        256.44000244140625,
        118.67999267578125,
        525.5999755859375,
        133.07998657226562
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어 위험관리",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        256.44000244140625,
        118.67999267578125,
        525.5999755859375,
        133.07998657226562
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.0,
        176.1599884033203,
        81.0,
        190.5599822998047
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        102.5999984741211,
        409.0799865722656,
        138.60000610351562,
        423.47998046875
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        108.5999984741211,
        428.2799987792969,
        132.60000610351562,
        442.67999267578125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개발",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        108.5999984741211,
        447.47998046875,
        132.60000610351562,
        461.8799743652344
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        108.5999984741211,
        466.67999267578125,
        132.60000610351562,
        481.0799865722656
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "세스",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        108.5999984741211,
        485.8799743652344,
        132.60000610351562,
        500.27996826171875
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        150.47999572753906,
        166.55999755859375,
        210.0,
        180.95999145507812
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개발 계획",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        153.47999572753906,
        185.75999450683594,
        207.0,
        200.1599884033203
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개발 소프트웨어의 범위, 규모",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        220.79998779296875,
        147.36000061035156,
        386.2799987792969,
        161.75999450683594
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 소프트웨어 안전에 적합한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        166.55999755859375,
        386.2799987792969,
        180.95999145507812
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개발 활동을 위하여 소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        185.75999450683594,
        386.2799987792969,
        200.1599884033203
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개발 계획을 수립한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        204.95999145507812,
        336.5400085449219,
        219.3599853515625
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어의 개발 계획을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        156.95999145507812,
        536.3999633789062,
        171.3599853515625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수립하면서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        176.1599884033203,
        536.3999633789062,
        190.5599822998047
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "동시에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        176.1599884033203,
        536.3999633789062,
        190.5599822998047
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        176.1599884033203,
        536.3999633789062,
        190.5599822998047
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관리 계획을 수립한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        195.36000061035156,
        519.4199829101562,
        209.75999450683594
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.0,
        300.9599914550781,
        81.0,
        315.3599853515625
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        150.239990234375,
        281.7599792480469,
        210.239990234375,
        296.15997314453125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "요구사항",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        156.239990234375,
        300.9599914550781,
        204.239990234375,
        315.3599853515625
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        168.239990234375,
        320.1600036621094,
        192.239990234375,
        334.55999755859375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어가 어떤(what) 기능을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        262.55999755859375,
        386.2799987792969,
        276.9599914550781
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "어떻게(how) 수행할 것인지에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        281.7599792480469,
        386.2799987792969,
        296.15997314453125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대하여, 소프트웨어가 수행할 수",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        300.9599914550781,
        386.2799987792969,
        315.3599853515625
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있는 논리적이고 물리적인 표현",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        320.1600036621094,
        386.2799987792969,
        334.55999755859375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "으로 정의한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        339.3599853515625,
        301.739990234375,
        353.7599792480469
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어의 정상 상태 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        396.47998046875,
        233.75999450683594,
        536.3999633789062,
        248.1599884033203
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고장",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        252.95999145507812,
        536.3999633789062,
        267.3599853515625
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상태에서의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        252.95999145507812,
        536.3999633789062,
        267.3599853515625
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재적",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        252.95999145507812,
        536.3999633789062,
        267.3599853515625
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결함을 고려하여 위험을 분석",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        396.47998046875,
        272.1600036621094,
        536.3999633789062,
        286.55999755859375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하고, 해당 위험을 통제하기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        291.3599853515625,
        536.3999633789062,
        305.7599792480469
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위한 조치를 결정한다. 이 중",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        310.55999755859375,
        536.3999633789062,
        324.9599914550781
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 설계에 해당하는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        329.7599792480469,
        536.3999633789062,
        344.15997314453125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통제 조치를 소프트웨어 요구",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        348.9599914550781,
        536.3999633789062,
        363.3599853515625
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사항에 반영한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        368.1600036621094,
        482.2200012207031,
        382.55999755859375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        75.0,
        464.6399841308594,
        81.0,
        479.03997802734375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        150.239990234375,
        455.03997802734375,
        210.239990234375,
        469.4399719238281
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아키텍처",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        156.239990234375,
        474.239990234375,
        204.239990234375,
        488.6399841308594
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 요구사항을 소프트",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        397.44000244140625,
        386.2799987792969,
        411.8399963378906
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "웨어 구조로 설명하며 소프트",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        416.6399841308594,
        386.2799987792969,
        431.03997802734375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "웨어 항목(item)을 식별하는 아키",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        435.8399963378906,
        386.2799987792969,
        450.239990234375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "텍처로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        455.03997802734375,
        386.2799987792969,
        469.4399719238281
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "변환한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        455.03997802734375,
        386.2799987792969,
        469.4399719238281
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        455.03997802734375,
        386.2799987792969,
        469.4399719238281
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "항목과 소프트웨어 항목 외부의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        474.239990234375,
        386.2799987792969,
        488.6399841308594
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구성요소 간의 연계성과 소프트",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        493.44000244140625,
        386.2799987792969,
        507.8399963378906
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "웨어 항목 간 연계성을 위한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        512.6400146484375,
        386.2799987792969,
        527.0400390625
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아키텍처를 개발한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        531.8399658203125,
        334.3800048828125,
        546.239990234375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        435.8399963378906,
        536.3999633789062,
        450.239990234375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "요구사항에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        435.8399963378906,
        536.3999633789062,
        450.239990234375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반영한 위험 통제 조치가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        455.03997802734375,
        536.3999633789062,
        469.4399719238281
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실현될 수 있도록 안전한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        474.239990234375,
        536.3999633789062,
        488.6399841308594
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구조를 갖추어 설계한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        493.44000244140625,
        531.4199829101562,
        507.8399963378906
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        75.0,
        642.1199951171875,
        210.239990234375,
        666.1199951171875
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.0,
        642.1199951171875,
        210.239990234375,
        666.1199951171875
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상세 설계",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        153.239990234375,
        661.3200073242188,
        207.239990234375,
        675.7200317382812
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 아키텍처를 소프트",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        555.719970703125,
        386.2799987792969,
        570.1199951171875
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "웨어 유닛으로 표현할 수 있을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        574.9199829101562,
        386.2799987792969,
        589.3200073242188
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "때까지",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        594.1199951171875,
        386.2799987792969,
        608.52001953125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분해하고,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        594.1199951171875,
        386.2799987792969,
        608.52001953125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "각",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        594.1199951171875,
        386.2799987792969,
        608.52001953125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유닛에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        594.1199951171875,
        386.2799987792969,
        608.52001953125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        613.3200073242188,
        386.2200012207031,
        627.7200317382812
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상세",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        613.3200073242188,
        386.2200012207031,
        627.7200317382812
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설계를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        613.3200073242188,
        386.2200012207031,
        627.7200317382812
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수행한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        613.3200073242188,
        386.2200012207031,
        627.7200317382812
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또한 소프트웨어 유닛 및 외부",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        632.5199584960938,
        386.2799987792969,
        646.9199829101562
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구성요인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        651.719970703125,
        386.2799987792969,
        666.1199951171875
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사이의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        651.719970703125,
        386.2799987792969,
        666.1199951171875
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연계성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        651.719970703125,
        386.2799987792969,
        666.1199951171875
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        220.79998779296875,
        651.719970703125,
        386.2799987792969,
        666.1199951171875
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 유닛 사이의 연계성을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        670.9199829101562,
        386.2799987792969,
        685.3200073242188
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        690.1199951171875,
        386.2200012207031,
        704.52001953125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상세",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        690.1199951171875,
        386.2200012207031,
        704.52001953125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설계를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        690.1199951171875,
        386.2200012207031,
        704.52001953125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수행한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        690.1199951171875,
        386.2200012207031,
        704.52001953125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상세 설계를 바탕으로 코딩을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        709.3200073242188,
        386.2799987792969,
        723.7200317382812
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하며 코드는 정확하고 요구사항에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        728.5199584960938,
        386.2799987792969,
        742.9199829101562
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부합한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        747.719970703125,
        265.9800109863281,
        762.1199951171875
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 위험 통제 조치를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        613.3200073242188,
        536.3999633789062,
        627.7200317382812
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품에 구현한다. 이때 코드는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        632.5199584960938,
        536.3999633789062,
        646.9199829101562
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험관리 프로세스에서 식별한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        651.719970703125,
        536.3999633789062,
        666.1199951171875
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        670.9199829101562,
        536.3999633789062,
        685.3200073242188
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "요구사항을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        670.9199829101562,
        536.3999633789062,
        685.3200073242188
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정확하게",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        670.9199829101562,
        536.3999633789062,
        685.3200073242188
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실현할 수 있어야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        690.1199951171875,
        508.97998046875,
        704.52001953125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 8. 소프트웨어 개발 및 위험관리",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        190.1999969482422,
        86.04000091552734,
        410.1612243652344,
        101.59200286865234
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 35 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 42,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.4000015258789,
        87.47999572753906,
        185.51998901367188,
        111.47999572753906
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "IEC 62304",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.4000015258789,
        87.47999572753906,
        185.51998901367188,
        111.47999572753906
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로세스",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        130.9199981689453,
        106.68000030517578,
        180.72000122070312,
        121.08000183105469
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어 개발",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        256.44000244140625,
        97.07999420166016,
        525.5999755859375,
        111.47999572753906
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어 위험관리",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        256.44000244140625,
        97.07999420166016,
        525.5999755859375,
        111.47999572753906
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.0,
        163.0800018310547,
        81.0,
        177.47999572753906
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        150.239990234375,
        153.47999572753906,
        210.239990234375,
        167.87998962402344
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유닛 검증",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        153.239990234375,
        172.67999267578125,
        207.239990234375,
        187.07998657226562
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "각 유닛에 대한 코드를 검증하는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        134.27999877929688,
        386.2799987792969,
        148.67999267578125
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것으로 코드 실행 전에 오류를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        153.47999572753906,
        386.2799987792969,
        167.87998962402344
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "파악할 수 있는 “static test” 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        220.79998779296875,
        172.67999267578125,
        386.2799987792969,
        187.07998657226562
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "“white-box” 방법으로 수행한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        191.87998962402344,
        376.8599853515625,
        206.2799835205078
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 요구사항에서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        204.83999633789062,
        536.3999633789062,
        219.239990234375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정의한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        224.0399932861328,
        536.3999633789062,
        238.4399871826172
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험통제",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        224.0399932861328,
        536.3999633789062,
        238.4399871826172
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조치가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        224.0399932861328,
        536.3999633789062,
        238.4399871826172
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실제 제품에 올바르게 반영",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        396.47998046875,
        243.239990234375,
        536.3999633789062,
        257.6399841308594
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "되었으며, 위험이 효과적",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        262.44000244140625,
        536.3999633789062,
        276.8399963378906
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "으로 통제되어 잔여 위험이",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        281.6399841308594,
        536.3999633789062,
        296.03997802734375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허용 가능함을 검증한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        300.8399963378906,
        531.4199829101562,
        315.239990234375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.0,
        261.0,
        81.0,
        275.3999938964844
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        150.239990234375,
        251.39999389648438,
        210.239990234375,
        265.79998779296875
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통합 검증",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        153.239990234375,
        270.6000061035156,
        207.239990234375,
        285.0
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통합계획에 따라 소프트웨어를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        232.1999969482422,
        386.2799987792969,
        246.59999084472656
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통합하고",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        251.39999389648438,
        386.2799987792969,
        265.79998779296875
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통합한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        251.39999389648438,
        386.2799987792969,
        265.79998779296875
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        251.39999389648438,
        386.2799987792969,
        265.79998779296875
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "항목이",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        270.6000061035156,
        386.2799987792969,
        285.0
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의도한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        270.6000061035156,
        386.2799987792969,
        285.0
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        270.6000061035156,
        386.2799987792969,
        285.0
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기능을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        270.6000061035156,
        386.2799987792969,
        285.0
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발휘하는지 확인한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        289.79998779296875,
        337.739990234375,
        304.1999816894531
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.0,
        350.6399841308594,
        81.0,
        365.03997802734375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        150.239990234375,
        331.44000244140625,
        210.239990234375,
        345.8399963378906
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시스템",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        162.239990234375,
        350.6399841308594,
        198.239990234375,
        365.03997802734375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        168.239990234375,
        369.8399963378906,
        192.239990234375,
        384.239990234375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전체 소프트웨어 시스템이 요구",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        341.03997802734375,
        386.2799987792969,
        355.4399719238281
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사항을 충족하는지 확인한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        360.239990234375,
        373.5,
        374.6399841308594
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        75.0,
        473.1600036621094,
        81.0,
        487.55999755859375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        102.5999984741211,
        515.8800048828125,
        138.60000610351562,
        530.280029296875
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        108.5999984741211,
        535.0800170898438,
        132.60000610351562,
        549.4800415039062
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유지",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        108.5999984741211,
        554.2799682617188,
        132.60000610351562,
        568.6799926757812
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "활동",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        108.5999984741211,
        573.47998046875,
        132.60000610351562,
        587.8800048828125
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        108.5999984741211,
        592.6799926757812,
        132.60000610351562,
        607.0800170898438
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "세스",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        108.5999984741211,
        611.8800048828125,
        132.60000610351562,
        626.280029296875
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        150.239990234375,
        463.55999755859375,
        210.239990234375,
        477.9599914550781
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "형상 관리",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        153.239990234375,
        482.7599792480469,
        207.239990234375,
        497.15997314453125
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어의 출시 후에 발생",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        434.7599792480469,
        386.2799987792969,
        449.15997314453125
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하는 피드백에 적절히 대응하고",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        453.9599914550781,
        386.2799987792969,
        468.3599853515625
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        473.1600036621094,
        386.2799987792969,
        487.55999755859375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "항목의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        473.1600036621094,
        386.2799987792969,
        487.55999755859375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일관성을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        473.1600036621094,
        386.2799987792969,
        487.55999755859375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유지하면서 설계 변경 및 소프트",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        492.3599853515625,
        386.2799987792969,
        506.7599792480469
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "웨어 형상을 유지한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        511.55999755859375,
        332.94000244140625,
        525.9600219726562
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "새로운 위험의 발생 또는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        415.55999755859375,
        536.3999633789062,
        429.9599914550781
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기존에 식별한 위험 평가의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        434.7599792480469,
        536.3999633789062,
        449.15997314453125
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "변경이 필요한 경우, 소프트",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        453.9599914550781,
        536.3999633789062,
        468.3599853515625
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "웨어 형상의 변경이 위해",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        473.1600036621094,
        536.3999633789062,
        487.55999755859375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "요인이 될 수 있는 경우",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        492.3599853515625,
        536.3999633789062,
        506.7599792480469
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험관리 프로세스의 입력",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        511.55999755859375,
        536.3999633789062,
        525.9600219726562
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "으로 식별한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        530.760009765625,
        477.41998291015625,
        545.1600341796875
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        75.0,
        636.0,
        210.239990234375,
        660.0
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.0,
        636.0,
        210.239990234375,
        660.0
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "문제해결",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        156.239990234375,
        655.2000122070312,
        204.239990234375,
        669.6000366210938
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시판 후 소프트웨어에 문제가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        607.2000122070312,
        386.2799987792969,
        621.6000366210938
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생하거나 개선의 필요성 때문에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        626.3999633789062,
        386.2799987792969,
        640.7999877929688
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품 또는 관련 문서가 수정되는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        645.5999755859375,
        386.2799987792969,
        660.0
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경우 문제점과 그 영향 등을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        664.7999877929688,
        386.2799987792969,
        679.2000122070312
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분석하여 변경해야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        684.0,
        349.1399841308594,
        698.4000244140625
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시판 후 발견된 문제점을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        578.3999633789062,
        536.3999633789062,
        592.7999877929688
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분석하고",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        597.5999755859375,
        536.3999633789062,
        612.0
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전과",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        597.5999755859375,
        536.3999633789062,
        612.0
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관련된",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        597.5999755859375,
        536.3999633789062,
        612.0
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "항목은 위험관리 프로세스의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        616.7999877929688,
        536.3999633789062,
        631.2000122070312
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "입력으로 식별한다. 문제",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        636.0,
        536.3999633789062,
        650.4000244140625
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해결 및 설계 변경은 위험",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        655.2000122070312,
        536.3999633789062,
        669.6000366210938
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통제 조치가 될 수 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        674.3999633789062,
        536.4599609375,
        688.7999877929688
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요시 규제 당국에 안전성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        693.5999755859375,
        536.3999633789062,
        708.0
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련 보고를 시행한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        712.7999877929688,
        519.4199829101562,
        727.2000122070312
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 36 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 소프트웨어 안전성 등급",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        84.90937042236328,
        256.32000732421875,
        100.72968292236328
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기 소프트웨어의 고장 또는 잠재적 결함으로 인해 환자나",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        114.90937042236328,
        546.0599975585938,
        130.72967529296875
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용자에게 미치는 위해의 영향에 따라 안전성 등급을 <표 9>과",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        144.9093780517578,
        546.0599975585938,
        160.7296905517578
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같이 분류한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        174.9093780517578,
        195.6599884033203,
        190.7296905517578
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "등급",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        119.87999725341797,
        231.83999633789062,
        373.3199768066406,
        246.239990234375
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설명",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        119.87999725341797,
        231.83999633789062,
        373.3199768066406,
        246.239990234375
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A등급",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        116.15999603271484,
        250.91998291015625,
        450.41998291015625,
        265.3199768066406
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부상이나 신체적 피해가 발생할 가능성이 없다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        116.15999603271484,
        250.91998291015625,
        450.41998291015625,
        265.3199768066406
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "B등급",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        116.15999603271484,
        268.55999755859375,
        469.2599792480469,
        282.9599914550781
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "심각하지 않은 부상(경상)이 발생할 가능성이 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        116.15999603271484,
        268.55999755859375,
        469.2599792480469,
        282.9599914550781
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "C등급",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        115.68000030517578,
        286.1999816894531,
        456.41998291015625,
        300.5999755859375
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "심각한 부상 또는 사망이 발생할 가능성이 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        115.68000030517578,
        286.1999816894531,
        456.41998291015625,
        300.5999755859375
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 9. 소프트웨어 안전성 등급",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        215.39999389648438,
        206.0399932861328,
        401.76055908203125,
        221.5919952392578
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 안전성 등급은 위험통제 후 잔여 위험의 심각도를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        341.58935546875,
        546.0599975585938,
        357.40966796875
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "토대로 분류할 수 있다. 이때, 발생 가능성은 안전성 등급 결정 시",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        371.58935546875,
        545.9400024414062,
        387.40966796875
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려하지 않는다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        401.58935546875,
        203.1229705810547,
        417.40966796875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어가 여러 개의 독립적인 모듈이 모여서 구성된 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        431.58935546875,
        546.0599975585938,
        447.40966796875
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각 모듈에 대해 별도로 안전성 등급을 부여할 수 있다. 이때 전체",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        461.58935546875,
        545.9400024414062,
        477.40966796875
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어의 안전성 등급은 개별 모듈의 안전성 등급 중 가장",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        491.58935546875,
        545.9400024414062,
        507.40966796875
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "높은 등급이 된다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        521.58935546875,
        210.56295776367188,
        537.40966796875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 의료기기의 사이버 보안",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        581.58935546875,
        248.1599884033203,
        597.40966796875
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 개요",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        611.58935546875,
        121.31999969482422,
        627.40966796875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유·무선 통신이 가능하거나 통신 경로가 존재하는 제품의 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        641.58935546875,
        546.0599975585938,
        657.40966796875
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사이버보안에 대한 요구사항을 준수해야 한다. 제조자는 이를 확인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        671.58935546875,
        538.4400024414062,
        687.40966796875
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "할 수 있도록 ‘의료기기 사이버보안 요구사항 체크리스트’와",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        701.58935546875,
        546.0599975585938,
        717.40966796875
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요구사항을 실제로 검증한 자료를 제출하여야 한다. 다만, 제조사의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        731.58935546875,
        545.9400024414062,
        747.40966796875
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 37 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 44,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위험분석을 통해 요구사항 일부를 제외하거나 수정하여 적용할 때는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        84.90937042236328,
        545.9400024414062,
        100.72968292236328
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험규격 및 그 설정 근거를 제출하여야 하며 해당 자료로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        114.90937042236328,
        545.9400024414062,
        130.72967529296875
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘사이버보안 위험관리문서’를 제출할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        144.9093780517578,
        430.282958984375,
        160.7296905517578
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사이버보안 요구사항은 ‘의료기기의 사이버보안 허가·심사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        174.9093780517578,
        560.9400024414062,
        190.7296905517578
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인(민원인 안내서)’에 따른다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        204.90936279296875,
        362.96295166015625,
        220.72967529296875
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 사이버보안 요구사항",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        234.90936279296875,
        233.87998962402344,
        250.72967529296875
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‘의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)’",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        264.90936279296875,
        538.5599975585938,
        280.72967529296875
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에는 보안통신, 데이터 보호, 기기 무결성, 사용자 인증, 소프트웨어",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        294.90936279296875,
        546.0599975585938,
        310.72967529296875
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유지보수, 물리적 접근, 신뢰성 및 가용성 등에 대한 요구사항을 제시",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        324.90936279296875,
        538.5599975585938,
        340.72967529296875
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고 있다. 본 요구사항은 제품의 사이버보안 안전성 등급 및",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        354.90936279296875,
        545.9400024414062,
        370.72967529296875
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 적용한다. 해당 가이드라인에 따라 제품에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        384.90936279296875,
        546.0599975585938,
        400.72967529296875
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적합한 통신 개략도와 사이버보안 적용 사항을 기재한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        414.90936279296875,
        480.5629577636719,
        430.72967529296875
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 사이버보안 위험관리",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        444.90936279296875,
        233.87998962402344,
        460.72967529296875
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 위험관리에는 사이버보안에 대한 위험관리 항목이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        474.90936279296875,
        560.9400024414062,
        490.72967529296875
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함되어야 하며, 소프트웨어 위험관리와 동일한 방식으로 위험관리",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        84.95999908447266,
        504.90936279296875,
        546.0599975585938,
        520.7296752929688
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과가 검증되어야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        84.95999908447266,
        534.9093627929688,
        257.48297119140625,
        550.7296752929688
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 위험분석",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        564.9093627929688,
        168.83999633789062,
        580.7296752929688
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‘위해요인 식별’에서는 관련 자료(규격, 가이드라인, 국내외",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        594.9093627929688,
        545.9400024414062,
        610.7296752929688
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상 사례 등)에 근거하여 의료기기의 정상 및 고장상태에서",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        105.0,
        624.9093627929688,
        546.0599975585938,
        640.7296752929688
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이미 알고 있거나 예측 가능한 의료기기 사이버보안 측면의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        105.0,
        654.9093627929688,
        546.0599975585938,
        670.7296752929688
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해요인에 대해 <표 10>과 같이 기록한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        105.0,
        684.9093627929688,
        409.0199890136719,
        700.7296752929688
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‘위험산정’에서는 위해상황을 초래할 수 있는 예측 가능한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        714.9093627929688,
        546.0599975585938,
        730.7296752929688
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사건들을 조합하여 각 위해요인에 대한 위험을 산정한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        105.0,
        744.9093627929688,
        498.9229431152344,
        760.7296752929688
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 38 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 45,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해요인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        102.23999786376953,
        110.15999603271484,
        428.6399841308594,
        134.1599884033203
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구체적인 예시",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        102.23999786376953,
        110.15999603271484,
        428.6399841308594,
        134.1599884033203
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용자 또는 환자에게",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        102.23999786376953,
        110.15999603271484,
        428.6399841308594,
        134.1599884033203
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발생 가능한 손상",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        320.6399841308594,
        129.36000061035156,
        416.6399841308594,
        143.75999450683594
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        470.7599792480469,
        119.75999450683594,
        518.760009765625,
        134.1599884033203
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비 인가된",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        99.23999786376953,
        165.59999084472656,
        153.239990234375,
        179.99998474121094
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용자의 접근",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        87.23999786376953,
        184.8000030517578,
        165.239990234375,
        199.1999969482422
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비 인가된 사용자의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        178.55999755859375,
        156.0,
        286.55999755859375,
        170.39999389648438
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접근으로 인해 환자",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        178.55999755859375,
        175.1999969482422,
        286.55999755859375,
        189.59999084472656
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데이터 손실",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        199.55999755859375,
        194.39999389648438,
        265.55999755859375,
        208.79998779296875
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오진, 잘못된 치료 수행",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        304.1999816894531,
        165.59999084472656,
        433.0799865722656,
        179.99998474121094
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또는 치료기회 박탈",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        314.6399841308594,
        184.8000030517578,
        422.6399841308594,
        199.1999969482422
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국내·외",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        474.47998046875,
        165.59999084472656,
        515.0399780273438,
        179.99998474121094
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이상사례",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        470.7599792480469,
        184.8000030517578,
        518.760009765625,
        199.1999969482422
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 10. 위해요인 식별 예시",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        228.47999572753906,
        86.04000091552734,
        394.6805725097656,
        101.59200286865234
      ],
      "page_num": 45,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나) 위험평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        268.02935791015625,
        176.33999633789062,
        283.84967041015625
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식별한 각 위해요인에 대하여 위험관리 계획서에 정의한 위험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.95999908447266,
        298.02935791015625,
        525.8399658203125,
        313.84967041015625
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허용 기준을 사용하여 위험 감소가 필요한지 결정한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        105.0,
        328.02935791015625,
        491.3399963378906,
        343.84967041015625
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식별한 모든 위험에 대하여 위험의 평가 결과를 ‘위험을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        105.0,
        358.02935791015625,
        545.9400024414062,
        373.84967041015625
      ],
      "page_num": 45,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허용할 수 없는 영역(unacceptable)’과‘합리적으로 실현할",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        105.0,
        388.02935791015625,
        546.0599975585938,
        403.84967041015625
      ],
      "page_num": 45,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있는 가장 낮은 영역(As Low As Reasonably Practicable,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        105.0,
        418.02935791015625,
        545.9400024414062,
        433.84967041015625
      ],
      "page_num": 45,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ALARP)’, ‘허용할 수 있는 영역(acceptable)’의 3단계 또는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        105.0,
        448.02935791015625,
        546.0599975585938,
        463.84967041015625
      ],
      "page_num": 45,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘위험을 허용할 수 없는 영역(unacceptable)’과 ‘허용할 수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        105.0,
        478.02935791015625,
        546.0599975585938,
        493.84967041015625
      ],
      "page_num": 45,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 영역(Acceptable)’의 2단계로 구분할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        105.0,
        508.02935791015625,
        461.1229553222656,
        523.8496704101562
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험분석",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        236.39999389648438,
        566.2799682617188,
        523.4400024414062,
        580.6799926757812
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험평가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        236.39999389648438,
        566.2799682617188,
        523.4400024414062,
        580.6799926757812
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해요인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        67.43999481201172,
        604.5599975585938,
        115.43999481201172,
        618.9600219726562
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생 가능한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        138.47999572753906,
        594.9599609375,
        204.47999572753906,
        609.3599853515625
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사례",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        159.47999572753906,
        604.5599975585938,
        354.3599853515625,
        628.5599975585938
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해상황",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        159.47999572753906,
        604.5599975585938,
        354.3599853515625,
        628.5599975585938
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        159.47999572753906,
        604.5599975585938,
        354.3599853515625,
        628.5599975585938
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        391.3199768066406,
        585.3599853515625,
        415.3199768066406,
        599.760009765625
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가능",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        391.3199768066406,
        604.5599975585938,
        415.3199768066406,
        618.9600219726562
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        397.3199768066406,
        623.760009765625,
        409.3199768066406,
        638.1600341796875
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "심각",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        429.9599914550781,
        594.9599609375,
        453.9599914550781,
        609.3599853515625
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        435.9599914550781,
        614.1599731445312,
        447.9599914550781,
        628.5599975585938
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        468.47998046875,
        594.9599609375,
        492.47998046875,
        609.3599853515625
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "도",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.47998046875,
        604.5599975585938,
        530.5199584960938,
        628.5599975585938
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.47998046875,
        604.5599975585938,
        530.5199584960938,
        628.5599975585938
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        85.43999481201172,
        657.8399658203125,
        97.43999481201172,
        672.239990234375
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인가된",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        73.43999481201172,
        677.0399780273438,
        109.43999481201172,
        691.4400024414062
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용자의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        67.43999481201172,
        696.239990234375,
        115.43999481201172,
        710.6400146484375
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접근",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        79.43999481201172,
        715.4400024414062,
        103.43999481201172,
        729.8400268554688
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용자 구분을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        132.47999572753906,
        648.239990234375,
        210.47999572753906,
        662.6400146484375
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하지 않고",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        144.47999572753906,
        667.4400024414062,
        198.47999572753906,
        681.8400268554688
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "누구나 환자의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        132.47999572753906,
        686.6400146484375,
        210.47999572753906,
        701.0400390625
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데이터에 접근",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        132.47999572753906,
        705.8399658203125,
        210.47999572753906,
        720.239990234375
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하도록 한 경우",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        129.47999572753906,
        725.0399780273438,
        213.47999572753906,
        739.4400024414062
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조작된 환자",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        226.9199981689453,
        648.239990234375,
        292.91998291015625,
        662.6400146484375
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        247.9199981689453,
        667.4400024414062,
        271.91998291015625,
        681.8400268554688
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데이터로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        235.9199981689453,
        686.6400146484375,
        283.91998291015625,
        701.0400390625
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전문의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        241.9199981689453,
        705.8399658203125,
        277.91998291015625,
        720.239990234375
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진료수행",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        235.9199981689453,
        725.0399780273438,
        283.91998291015625,
        739.4400024414062
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오진, 잘못 된",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        305.5199890136719,
        648.239990234375,
        379.1999816894531,
        662.6400146484375
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "치료 수행",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        315.3599853515625,
        667.4400024414062,
        369.3599853515625,
        681.8400268554688
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        330.3599853515625,
        686.6400146484375,
        354.3599853515625,
        701.0400390625
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "치료기회",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        318.3599853515625,
        705.8399658203125,
        366.3599853515625,
        720.239990234375
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "박탈",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        330.3599853515625,
        725.0399780273438,
        354.3599853515625,
        739.4400024414062
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        400.3199768066406,
        686.6400146484375,
        483.47998046875,
        701.0400390625
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        400.3199768066406,
        686.6400146484375,
        483.47998046875,
        701.0400390625
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        400.3199768066406,
        686.6400146484375,
        483.47998046875,
        701.0400390625
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ALA",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        507.7200012207031,
        677.0399780273438,
        529.343994140625,
        691.4400024414062
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "RP",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        510.47998046875,
        696.239990234375,
        526.5239868164062,
        710.6400146484375
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 11. 위험평가 예시",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        231.95999145507812,
        539.0399780273438,
        364.3200378417969,
        554.5919799804688
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 39 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다) 위험통제",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        84.90937042236328,
        176.33999633789062,
        100.72968292236328
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조자는 위험평가 결과 중 ‘위험을 허용할 수 없는 영역",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        114.90937042236328,
        538.5599975585938,
        130.72967529296875
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(unacceptable)’과‘합리적으로 실현할 수 있는 가장 낮은 영역",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        144.9093780517578,
        538.5599975585938,
        160.7296905517578
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(ALARP)’을 허용 가능한 수준까지 감소시키기 위하여 위험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        174.9093780517578,
        546.0599975585938,
        190.7296905517578
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통제 조치를 식별하고, <표 12>와 같이 위험통제 활동을 수행",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        204.90936279296875,
        538.5599975585938,
        220.72967529296875
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        234.90936279296875,
        195.56295776367188,
        250.72967529296875
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 전체 잔여위험 허용 가능성 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        481.7493591308594,
        341.2200012207031,
        497.5696716308594
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모든 위험통제 조치를 하고 검증한 뒤 위험관리 계획에서 정",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        511.7493896484375,
        538.4400024414062,
        527.5697021484375
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의한 위험허용 기준을 사용하여 해당 의료기기에서 식별한 전체",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        541.7493896484375,
        546.0599975585938,
        557.5697021484375
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잔여위험이 허용 가능한지 아닌지를 결정하고 <표 13>과 같이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        571.7493896484375,
        546.0599975585938,
        587.5697021484375
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기록한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        601.7493896484375,
        173.1229705810547,
        617.5697021484375
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험통제 조치",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.04000091552734,
        315.6000061035156,
        146.0399932861328,
        330.0
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험통제",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        171.95999145507812,
        306.0,
        219.95999145507812,
        320.3999938964844
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조치실행",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        171.95999145507812,
        325.1999816894531,
        219.95999145507812,
        339.5999755859375
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잔여위험평가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        250.9199981689453,
        289.0799865722656,
        322.91998291015625,
        303.47998046875
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        360.47998046875,
        315.6000061035156,
        384.47998046875,
        330.0
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험/",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        418.55999755859375,
        296.3999938964844,
        445.71600341796875,
        310.79998779296875
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이득",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        420.1199951171875,
        315.6000061035156,
        444.1199951171875,
        330.0
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분석",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        420.1199951171875,
        334.79998779296875,
        444.1199951171875,
        349.1999816894531
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        466.3199768066406,
        296.3999938964844,
        490.3199768066406,
        310.79998779296875
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        466.3199768066406,
        315.6000061035156,
        490.3199768066406,
        330.0
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        466.3199768066406,
        334.79998779296875,
        490.3199768066406,
        349.1999816894531
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통제",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        508.0799865722656,
        306.0,
        532.0800170898438,
        320.3999938964844
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "완료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        508.0799865722656,
        325.1999816894531,
        532.0800170898438,
        339.5999755859375
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        245.51998901367188,
        303.8399963378906,
        269.5199890136719,
        318.239990234375
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가능",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        245.51998901367188,
        323.03997802734375,
        269.5199890136719,
        337.4399719238281
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        251.51998901367188,
        342.239990234375,
        263.5199890136719,
        356.6399841308594
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "심",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        287.8800048828125,
        303.8399963378906,
        299.8800048828125,
        318.239990234375
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "각",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        287.8800048828125,
        323.03997802734375,
        299.8800048828125,
        337.4399719238281
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        287.8800048828125,
        342.239990234375,
        299.8800048828125,
        356.6399841308594
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        317.2799987792969,
        303.8399963378906,
        329.2799987792969,
        318.239990234375
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "험",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        317.2799987792969,
        323.03997802734375,
        329.2799987792969,
        337.4399719238281
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "도",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        317.2799987792969,
        342.239990234375,
        329.2799987792969,
        356.6399841308594
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설계 변경을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.04000091552734,
        366.7200012207031,
        140.0399932861328,
        381.1199951171875
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통한 사용자별",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.04000091552734,
        385.91998291015625,
        146.0399932861328,
        400.3199768066406
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접근통제 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        74.04000091552734,
        405.1199951171875,
        140.0399932861328,
        419.5199890136719
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인증 기능 구현",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        65.04000091552734,
        424.3199768066406,
        149.0399932861328,
        438.719970703125
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        165.95999145507812,
        357.1199951171875,
        225.95999145507812,
        371.5199890136719
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 자료로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        162.95999145507812,
        376.3199768066406,
        228.95999145507812,
        390.719970703125
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접근통제 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        162.95999145507812,
        395.5199890136719,
        228.95999145507812,
        409.91998291015625
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인증 기능",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        168.95999145507812,
        414.7200012207031,
        222.95999145507812,
        429.1199951171875
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구현 확인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        168.95999145507812,
        433.91998291015625,
        222.95999145507812,
        448.3199768066406
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        254.51998901367188,
        395.5199890136719,
        400.8240051269531,
        409.91998291015625
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        254.51998901367188,
        395.5199890136719,
        400.8240051269531,
        409.91998291015625
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        254.51998901367188,
        395.5199890136719,
        400.8240051269531,
        409.91998291015625
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Acceptable",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        254.51998901367188,
        395.5199890136719,
        400.8240051269531,
        409.91998291015625
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험 <",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        413.6399841308594,
        385.91998291015625,
        450.635986328125,
        400.3199768066406
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이득",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        420.1199951171875,
        405.1199951171875,
        444.1199951171875,
        419.5199890136719
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        466.3199768066406,
        376.3199768066406,
        490.3199768066406,
        390.719970703125
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사항",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        466.3199768066406,
        395.5199890136719,
        490.3199768066406,
        409.91998291015625
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        466.3199768066406,
        414.7200012207031,
        490.3199768066406,
        429.1199951171875
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "완료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        508.0799865722656,
        395.5199890136719,
        532.0800170898438,
        409.91998291015625
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 12. 위험통제 예시",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        232.9199981689453,
        266.0400085449219,
        365.40057373046875,
        281.5920104980469
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 40 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잔여위험평가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.19999694824219,
        109.07999420166016,
        154.1999969482422,
        123.47999572753906
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        202.1999969482422,
        126.0,
        311.2799987792969,
        149.99998474121094
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험/이득",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        202.1999969482422,
        126.0,
        311.2799987792969,
        149.99998474121094
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분석",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        273.7200012207031,
        145.1999969482422,
        297.7200012207031,
        159.59999084472656
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        328.91998291015625,
        116.39999389648438,
        352.91998291015625,
        130.79998779296875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        328.91998291015625,
        135.59999084472656,
        352.91998291015625,
        149.99998474121094
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        328.91998291015625,
        154.8000030517578,
        352.91998291015625,
        169.1999969482422
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통제",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        376.3199768066406,
        126.0,
        400.3199768066406,
        140.39999389648438
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "완료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        376.3199768066406,
        145.1999969482422,
        400.3199768066406,
        159.59999084472656
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전체 잔여위험 허용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        422.1600036621094,
        116.39999389648438,
        530.1599731445312,
        130.79998779296875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가능성 평가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        443.1600036621094,
        135.59999084472656,
        509.1600036621094,
        149.99998474121094
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(허용 가능/불가)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        432.239990234375,
        154.8000030517578,
        520.2119750976562,
        169.1999969482422
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        67.08000183105469,
        123.83999633789062,
        91.08000183105469,
        138.239990234375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가능",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        67.08000183105469,
        143.0399932861328,
        91.08000183105469,
        157.4399871826172
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        73.08000183105469,
        162.239990234375,
        85.08000183105469,
        176.63998413085938
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "심각",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        106.19999694824219,
        133.44000244140625,
        130.1999969482422,
        147.83999633789062
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        112.19999694824219,
        152.63999938964844,
        124.19999694824219,
        167.0399932861328
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        145.44000244140625,
        133.44000244140625,
        169.44000244140625,
        147.83999633789062
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "도",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        151.44000244140625,
        152.63999938964844,
        163.44000244140625,
        167.0399932861328
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.08000183105469,
        186.72000122070312,
        304.2359924316406,
        210.71998596191406
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.08000183105469,
        186.72000122070312,
        304.2359924316406,
        210.71998596191406
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.08000183105469,
        186.72000122070312,
        304.2359924316406,
        210.71998596191406
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Acceptable",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.08000183105469,
        186.72000122070312,
        304.2359924316406,
        210.71998596191406
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험 <",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        76.08000183105469,
        186.72000122070312,
        304.2359924316406,
        210.71998596191406
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이득",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        273.7200012207031,
        205.9199981689453,
        297.7200012207031,
        220.3199920654297
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        328.91998291015625,
        177.1199951171875,
        352.91998291015625,
        191.51998901367188
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사항",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        328.91998291015625,
        196.3199920654297,
        352.91998291015625,
        210.71998596191406
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        328.91998291015625,
        215.51998901367188,
        352.91998291015625,
        229.91998291015625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "완료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        376.3199768066406,
        196.3199920654297,
        500.1600036621094,
        210.71998596191406
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허용가능",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        376.3199768066406,
        196.3199920654297,
        500.1600036621094,
        210.71998596191406
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 13. 전체 잔여위험 허용 가능성 평가 예시",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        157.55999755859375,
        86.04000091552734,
        438.7205810546875,
        101.59200286865234
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4) 사이버보안 적용 방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        278.349365234375,
        241.3199920654297,
        294.169677734375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‘의료기기 사이버보안 요구사항 체크리스트’는 의료기기 사이버",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        308.349365234375,
        538.5599975585938,
        324.169677734375
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보안 요구사항에 대한 적합성 여부를 확인할 수 있는 자료로 제조자는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        79.91999816894531,
        338.349365234375,
        545.9400024414062,
        354.169677734375
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체크리스트의 질의 사항을 확인하여 요구사항의 적용여부 등을 확인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        79.91999816894531,
        368.349365234375,
        538.5599975585938,
        384.169677734375
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        79.91999816894531,
        398.349365234375,
        159.80296325683594,
        414.169677734375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용되는 통신기술(유·무선 통신 방식 등), 사용환경(병원 내/외",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        428.349365234375,
        546.0599975585938,
        444.169677734375
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용, 공용 네트워크망 사용 등) 등 통신 특성을 확인할 수 있는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        79.91999816894531,
        458.349365234375,
        545.9400024414062,
        474.169677734375
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항을 기재한다. 이를 기반으로 체크리스트에 따라 요구사항 적용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        79.91999816894531,
        488.349365234375,
        538.4400024414062,
        504.169677734375
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여부, 적합성 입증방법, 첨부자료 또는 문서번호를 기재한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        79.91999816894531,
        518.349365234375,
        488.0999755859375,
        534.169677734375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 41 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<예시> - 의료기기 사이버보안 요구사항 체크리스트",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        412.91998291015625,
        100.72968292236328
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "< 의료기기 사이버보안 특성 기재 >",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        80.87999725341797,
        133.82249450683594,
        295.32000732421875,
        147.49124145507812
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 사용되는 통신 기술 : 유선 통신(LAN), 무선통신(Wi-fi, 블루투스)",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        80.87999725341797,
        159.8625030517578,
        485.489990234375,
        173.53125
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 사용 환경 : 병원 내 사용, 병원 외 사용",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        80.87999725341797,
        185.78250122070312,
        338.7599792480469,
        199.4512481689453
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 공용 네트워크 망 사용여부 : Y",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        80.87999725341797,
        211.82249450683594,
        285.5474853515625,
        225.49124145507812
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사이버보안 요구사항",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        143.27999877929688,
        291.6000061035156,
        397.1999816894531,
        315.5999755859375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당기기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        143.27999877929688,
        291.6000061035156,
        397.1999816894531,
        315.5999755859375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용여부",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        349.1999816894531,
        310.79998779296875,
        397.1999816894531,
        325.1999816894531
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적합성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        291.6000061035156,
        453.239990234375,
        306.0
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "입증 방법",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        310.79998779296875,
        462.239990234375,
        325.1999816894531
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        492.0,
        272.3999938964844,
        516.0,
        286.79998779296875
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "첨부자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        480.0,
        291.6000061035156,
        528.0,
        306.0
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        492.0,
        310.79998779296875,
        516.0,
        325.1999816894531
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "문서번호",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        480.0,
        330.0,
        528.0,
        344.3999938964844
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보안",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.4000015258789,
        488.6399841308594,
        92.4000015258789,
        503.03997802734375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통신",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.4000015258789,
        507.8399658203125,
        92.4000015258789,
        522.239990234375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 의료기기가 다른 기기나 네트워크와",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        346.1999816894531,
        338.8800048828125,
        360.5999755859375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "어떻게 접속(유·무선 통신 등)하여야 할지를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        365.3999938964844,
        338.8800048828125,
        379.79998779296875
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고려하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        384.6000061035156,
        202.13999938964844,
        399.0
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예: Wi-Fi, 이더넷, 블루투스, USB 등",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        115.19999694824219,
        403.79998779296875,
        335.3999938964844,
        418.1999816894531
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        375.0,
        385.1999816894531,
        389.3999938964844
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        346.1999816894531,
        462.8399963378906,
        360.5999755859375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        414.239990234375,
        365.3999938964844,
        456.239990234375,
        379.79998779296875
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        384.6000061035156,
        453.239990234375,
        399.0
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        403.79998779296875,
        462.239990234375,
        418.1999816894531
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        365.3999938964844,
        534.0,
        379.79998779296875
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        384.6000061035156,
        530.1719970703125,
        399.0
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        421.44000244140625,
        338.8800048828125,
        435.8399963378906
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내·외부의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        421.44000244140625,
        338.8800048828125,
        435.8399963378906
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모든",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        109.19999694824219,
        421.44000244140625,
        338.8800048828125,
        435.8399963378906
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "입력에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        421.44000244140625,
        338.8800048828125,
        435.8399963378906
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        421.44000244140625,
        338.8800048828125,
        435.8399963378906
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성을 확인하는 설계 특성을 고려하여야",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        440.6399841308594,
        338.8800048828125,
        455.03997802734375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하며, 보안이 취약한 통신(예. 가정용 네트",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        459.8399963378906,
        338.8800048828125,
        474.239990234375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "워크 혹은 기존 기기)만을 지원하는 기기 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        109.19999694824219,
        479.03997802734375,
        338.8800048828125,
        493.4399719238281
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "환경에서 이루어지는 통신도 고려한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        498.239990234375,
        322.1399841308594,
        512.6400146484375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        459.8399963378906,
        385.1999816894531,
        474.239990234375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        431.03997802734375,
        462.8399963378906,
        445.4399719238281
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        414.239990234375,
        450.239990234375,
        456.239990234375,
        464.6399841308594
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        469.44000244140625,
        453.239990234375,
        483.8399963378906
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        488.6399841308594,
        462.239990234375,
        503.03997802734375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        450.239990234375,
        534.0,
        464.6399841308594
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        469.44000244140625,
        530.1719970703125,
        483.8399963378906
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 비인가 접근/변경/반복을 방지하기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        515.8800048828125,
        338.8800048828125,
        530.280029296875
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위한 의료기기의 보안이 보장된(secured)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        535.0800170898438,
        338.8919982910156,
        549.4800415039062
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데이터 송·수신 방법을 고려하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        554.2799682617188,
        332.6999816894531,
        568.6799926757812
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예: 기기/시스템 간 통신 시 상호인증",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        115.19999694824219,
        573.47998046875,
        338.8800048828125,
        587.8800048828125
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방법, 암호화 필요 여부, 과거에 전송된",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        115.19999694824219,
        592.6799926757812,
        338.8800048828125,
        607.0800170898438
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "명령어 및 데이터의 비인가 반복에 대한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        115.19999694824219,
        611.8800048828125,
        338.8800048828125,
        626.280029296875
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방지, 사전에 정의된 통신 종료 시점의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        115.19999694824219,
        631.0799560546875,
        338.8800048828125,
        645.47998046875
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적절성 여부 등",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        115.19999694824219,
        650.2799682617188,
        199.1999969482422,
        664.6799926757812
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        583.0800170898438,
        385.1999816894531,
        597.4800415039062
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        554.2799682617188,
        462.8399963378906,
        568.6799926757812
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        414.239990234375,
        573.47998046875,
        456.239990234375,
        587.8800048828125
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        592.6799926757812,
        453.239990234375,
        607.0800170898438
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        611.8800048828125,
        462.239990234375,
        626.280029296875
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        573.47998046875,
        534.0,
        587.8800048828125
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        592.6799926757812,
        530.1719970703125,
        607.0800170898438
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데이터",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        62.39999771118164,
        701.0399780273438,
        98.4000015258789,
        715.4400024414062
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보호",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        68.4000015258789,
        720.239990234375,
        92.4000015258789,
        734.6400146484375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 안전(safety)과 관련된 데이터가 저장",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        672.239990234375,
        338.8800048828125,
        686.6400146484375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "되거나 기기와 송·수신될 때 암호화와 같은",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        691.4400024414062,
        338.8800048828125,
        705.8400268554688
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일정 수준의 보호가 요구되는지 고려하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        710.6399536132812,
        336.17999267578125,
        725.0399780273438
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예: 비밀번호(passwords)는 암호화된 보안",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        729.8399658203125,
        338.8800048828125,
        744.239990234375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(secure)이 확보된 해쉬(hash)로 저장되어야 함",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        749.0399780273438,
        336.239990234375,
        763.4400024414062
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        710.6399536132812,
        385.1999816894531,
        725.0399780273438
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        681.8399658203125,
        462.8399963378906,
        696.239990234375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        414.239990234375,
        701.0399780273438,
        456.239990234375,
        715.4400024414062
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        720.239990234375,
        453.239990234375,
        734.6400146484375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        739.4400024414062,
        462.239990234375,
        753.8400268554688
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        701.0399780273438,
        534.0,
        715.4400024414062
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        720.239990234375,
        530.1719970703125,
        734.6400146484375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 42 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조자는 기밀성에 대한 위험통제 수단이",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        93.23999786376953,
        338.8800048828125,
        107.63999938964844
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요구될 때, 통신 프로토콜의 컨트롤(control)/",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        109.19999694824219,
        112.43999481201172,
        338.9159851074219,
        126.83999633789062
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시퀀싱(sequencing) 필드의 메시지를 보호",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        109.19999694824219,
        131.63999938964844,
        338.8800048828125,
        146.0399932861328
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하거나 암호화의 키 관련 자료가 손상되는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        150.83999633789062,
        338.8800048828125,
        165.239990234375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "것을 방지하도록 고려하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        170.0399932861328,
        290.6999816894531,
        184.4399871826172
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        131.63999938964844,
        385.1999816894531,
        146.0399932861328
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        102.83999633789062,
        462.8399963378906,
        117.23999786376953
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        414.239990234375,
        122.03999328613281,
        456.239990234375,
        136.4399871826172
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        141.239990234375,
        453.239990234375,
        155.63998413085938
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        160.44000244140625,
        462.239990234375,
        174.83999633789062
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        122.03999328613281,
        534.0,
        136.4399871826172
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        141.239990234375,
        530.1719970703125,
        155.63998413085938
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.4000015258789,
        308.7599792480469,
        92.4000015258789,
        323.15997314453125
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "무결성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        62.39999771118164,
        327.9599914550781,
        98.4000015258789,
        342.3599853515625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 데이터 부인방지(non-repudiation)를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        198.95999145507812,
        338.8800048828125,
        213.3599853515625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보장하기 위한 설계 특성이 필요한지를 결정",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        218.1599884033203,
        338.8800048828125,
        232.5599822998047
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하기 위해 시스템 레벨에서의 아키텍쳐를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        237.36000061035156,
        338.8800048828125,
        251.75999450683594
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        256.55999755859375,
        196.74000549316406,
        270.9599914550781
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예: 감사 로그 기록 기능 제공",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        275.7599792480469,
        287.5199890136719,
        290.15997314453125
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        237.36000061035156,
        385.1999816894531,
        251.75999450683594
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        208.55999755859375,
        462.8399963378906,
        222.95999145507812
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        414.239990234375,
        227.75999450683594,
        456.239990234375,
        242.1599884033203
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        246.95999145507812,
        453.239990234375,
        261.3599853515625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        266.1600036621094,
        462.239990234375,
        280.55999755859375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        227.75999450683594,
        534.0,
        242.1599884033203
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        246.95999145507812,
        530.1719970703125,
        261.3599853515625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 기기 소프트웨어의 비인가된 변경과",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        308.7599792480469,
        338.8800048828125,
        323.15997314453125
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "같은 기기의 무결성에 대한 위험을 고려해야",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        327.9599914550781,
        338.8800048828125,
        342.3599853515625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        347.1600036621094,
        134.6999969482422,
        361.55999755859375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        327.9599914550781,
        385.1999816894531,
        342.3599853515625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        299.1600036621094,
        462.8399963378906,
        313.55999755859375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        414.239990234375,
        318.3599853515625,
        456.239990234375,
        332.7599792480469
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        337.55999755859375,
        453.239990234375,
        351.9599914550781
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        356.7599792480469,
        462.239990234375,
        371.15997314453125
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        318.3599853515625,
        534.0,
        332.7599792480469
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        337.55999755859375,
        530.1719970703125,
        351.9599914550781
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 바이러스, 스파이웨어, 랜섬웨어 등",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        380.03997802734375,
        338.8800048828125,
        394.4399719238281
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기기에서 실행될 수 있는 악성코드를 막기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        399.239990234375,
        338.8800048828125,
        413.6399841308594
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해 안티 멀웨어 프로그램과 같은 통제",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        418.44000244140625,
        338.8800048828125,
        432.8399963378906
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조치를 고려하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        437.6399841308594,
        242.8199920654297,
        452.03997802734375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        408.8399963378906,
        385.1999816894531,
        423.239990234375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        380.03997802734375,
        462.8399963378906,
        394.4399719238281
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        414.239990234375,
        399.239990234375,
        456.239990234375,
        413.6399841308594
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        418.44000244140625,
        453.239990234375,
        432.8399963378906
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        437.6399841308594,
        462.239990234375,
        452.03997802734375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        399.239990234375,
        534.0,
        413.6399841308594
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        418.44000244140625,
        530.1719970703125,
        432.8399963378906
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용자",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        62.39999771118164,
        524.1599731445312,
        98.4000015258789,
        538.5599975585938
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인증",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.4000015258789,
        543.3599853515625,
        92.4000015258789,
        557.760009765625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 기기의 사용이 입증된 사용자이거나,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        466.55999755859375,
        338.8320007324219,
        480.9599914550781
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다른 역할의 사용자에게 사용권한을 부여를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        485.7599792480469,
        338.8800048828125,
        500.15997314453125
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허용하거나, 응급상황에서 접근을 허용하는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        504.9599609375,
        338.8800048828125,
        519.3599853515625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용자 접근통제에 대해 고려하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        524.1599731445312,
        338.82000732421875,
        538.5599975585938
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추가로 동일한 자격증명은 기기와 고객들에게",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        543.3599853515625,
        338.8800048828125,
        557.760009765625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "공유되지 않아야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        562.5599975585938,
        224.94000244140625,
        576.9600219726562
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 접근 통제의 예: 비밀번호, 하드웨어 키,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        581.760009765625,
        338.8320007324219,
        596.1600341796875
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생체인증 등",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        600.9599609375,
        177.59999084472656,
        615.3599853515625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        533.760009765625,
        385.1999816894531,
        548.1600341796875
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        504.9599609375,
        462.8399963378906,
        519.3599853515625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        414.239990234375,
        524.1599731445312,
        456.239990234375,
        538.5599975585938
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        543.3599853515625,
        453.239990234375,
        557.760009765625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        562.5599975585938,
        462.239990234375,
        576.9600219726562
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        524.1599731445312,
        534.0,
        538.5599975585938
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        543.3599853515625,
        530.1719970703125,
        557.760009765625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        62.39999771118164,
        660.719970703125,
        98.4000015258789,
        675.1199951171875
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.4000015258789,
        679.9199829101562,
        92.4000015258789,
        694.3200073242188
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유지",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.4000015258789,
        699.1199951171875,
        92.4000015258789,
        713.52001953125
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보수",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.4000015258789,
        718.3200073242188,
        92.4000015258789,
        732.7200317382812
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 주기적인 업데이트의 구현과 배포를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        643.5599975585938,
        338.8800048828125,
        657.9600219726562
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위한 수행절차를 수립하고 통보하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        662.760009765625,
        337.739990234375,
        677.1600341796875
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        653.1599731445312,
        385.1999816894531,
        667.5599975585938
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        624.3599853515625,
        462.8399963378906,
        638.760009765625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        414.239990234375,
        643.5599975585938,
        456.239990234375,
        657.9600219726562
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        662.760009765625,
        453.239990234375,
        677.1600341796875
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        681.9599609375,
        462.239990234375,
        696.3599853515625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        643.5599975585938,
        534.0,
        657.9600219726562
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        662.760009765625,
        530.1719970703125,
        677.1600341796875
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 운영 체제(OS) 소프트웨어, 제3자",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        706.5599975585938,
        338.8800048828125,
        720.9600219726562
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어, 오픈 소스 소프트웨어가 업데이트나",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        725.760009765625,
        338.8800048828125,
        740.1600341796875
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통제될 경우에 대해 고려하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        744.9599609375,
        303.8999938964844,
        759.3599853515625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        725.760009765625,
        385.1999816894531,
        740.1600341796875
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        696.9599609375,
        462.8399963378906,
        711.3599853515625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        414.239990234375,
        716.1599731445312,
        456.239990234375,
        730.5599975585938
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        735.3599853515625,
        453.239990234375,
        749.760009765625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        754.5599975585938,
        462.239990234375,
        768.9600219726562
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        716.1599731445312,
        534.0,
        730.5599975585938
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        735.3599853515625,
        530.1719970703125,
        749.760009765625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 43 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 50,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한 제조자는 외부의 통제에 의한 소프트",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        95.75999450683594,
        338.8800048828125,
        110.15999603271484
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "웨어의 업데이트나 운영환경 만료에 대한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        114.95999908447266,
        338.8800048828125,
        129.36000061035156
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대응 계획을 수립하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        134.16000366210938,
        264.41998291015625,
        148.55999755859375
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예: 보안이 보장되지 않은(unsecure) 운영",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        114.83999633789062,
        153.36000061035156,
        338.8800048828125,
        167.75999450683594
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "체제 버전에서 운영되는 의료기기 소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        172.55999755859375,
        338.03997802734375,
        186.95999145507812
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        134.16000366210938,
        385.1999816894531,
        148.55999755859375
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        105.36000061035156,
        462.8399963378906,
        119.76000213623047
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        414.239990234375,
        124.55999755859375,
        456.239990234375,
        138.95999145507812
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        143.75999450683594,
        453.239990234375,
        158.1599884033203
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        162.95999145507812,
        462.239990234375,
        177.3599853515625
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        124.55999755859375,
        534.0,
        138.95999145507812
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        143.75999450683594,
        530.1719970703125,
        158.1599884033203
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 새로운 사이버보안 취약성에 대응할",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        209.39999389648438,
        338.8800048828125,
        223.79998779296875
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 업데이트 방안을 고려하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        228.59999084472656,
        337.739990234375,
        242.99998474121094
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예: 업데이트 시 사용자 개입/ 자동 업",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        247.79998779296875,
        338.7599792480469,
        262.1999816894531
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데이트 여부, 기기의 안전(safety)과 성능에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        267.0,
        338.8800048828125,
        281.3999938964844
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "영향을 보장할 수 있는 업데이트 유효성 검증",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        286.1999816894531,
        338.03997802734375,
        300.5999755859375
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        247.79998779296875,
        385.1999816894531,
        262.1999816894531
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        219.0,
        462.8399963378906,
        233.39999389648438
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        414.239990234375,
        238.1999969482422,
        456.239990234375,
        252.59999084472656
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        257.3999938964844,
        453.239990234375,
        271.79998779296875
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        276.6000061035156,
        462.239990234375,
        291.0
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        238.1999969482422,
        534.0,
        252.59999084472656
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        257.3999938964844,
        530.1719970703125,
        271.79998779296875
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 업데이트의 수행하기 위해 어떤",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        324.239990234375,
        338.8800048828125,
        338.6399841308594
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연결이 필요한지와 코드 서명 및 기타 비슷한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        343.44000244140625,
        338.8800048828125,
        357.8399963378906
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수단을 통한 연결이나 업데이트의 진본성을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        362.6399841308594,
        338.8800048828125,
        377.03997802734375
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고려하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        381.8399963378906,
        196.74000549316406,
        396.239990234375
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        353.03997802734375,
        385.1999816894531,
        367.4399719238281
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        324.239990234375,
        462.8399963378906,
        338.6399841308594
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        414.239990234375,
        343.44000244140625,
        456.239990234375,
        357.8399963378906
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        362.6399841308594,
        453.239990234375,
        377.03997802734375
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        381.8399963378906,
        462.239990234375,
        396.239990234375
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        343.44000244140625,
        534.0,
        357.8399963378906
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        362.6399841308594,
        530.1719970703125,
        377.03997802734375
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "물리적",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        62.39999771118164,
        454.3199768066406,
        98.4000015258789,
        468.719970703125
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접근",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.4000015258789,
        473.5199890136719,
        92.4000015258789,
        487.91998291015625
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 비인가 된 개인이 의료기기에 접근",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        415.91998291015625,
        338.8800048828125,
        430.3199768066406
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하는 것을 방지하기 위한 통제 수단을 고려",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        435.1199951171875,
        338.8800048828125,
        449.5199890136719
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        454.3199768066406,
        174.17999267578125,
        468.719970703125
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예: 물리적 잠금 혹은 포트(port) 접근의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        473.5199890136719,
        338.8800048828125,
        487.91998291015625
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "물리적 제한, 인증이 필요 없는 물리적 케",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        492.7200012207031,
        338.8800048828125,
        507.1199951171875
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이블의 접근제한 등",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        511.91998291015625,
        217.0800018310547,
        526.3200073242188
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        463.91998291015625,
        385.1999816894531,
        478.3199768066406
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성능 시험",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        425.5199890136719,
        462.239990234375,
        439.91998291015625
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        444.7200012207031,
        462.8399963378906,
        459.1199951171875
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        414.239990234375,
        463.91998291015625,
        456.239990234375,
        478.3199768066406
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        483.1199951171875,
        453.239990234375,
        497.5199890136719
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        502.32000732421875,
        462.239990234375,
        516.7200317382812
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        454.3199768066406,
        534.0,
        468.719970703125
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        473.5199890136719,
        530.1719970703125,
        487.91998291015625
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신뢰성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        62.39999771118164,
        550.5599975585938,
        98.4000015258789,
        564.9600219726562
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        74.4000015258789,
        569.760009765625,
        86.4000015258789,
        584.1600341796875
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가용성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        62.39999771118164,
        588.9599609375,
        98.4000015258789,
        603.3599853515625
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 의료기기가 필수 성능을 유지하기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        540.9599609375,
        338.8800048828125,
        555.3599853515625
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해 사이버보안 공격을 탐지, 저항, 대응",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        109.19999694824219,
        560.1599731445312,
        338.8800048828125,
        574.5599975585938
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 복구하도록 허용하는 설계 특성을 고려",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        579.3599853515625,
        338.8800048828125,
        593.760009765625
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        598.5599975585938,
        174.17999267578125,
        612.9600219726562
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        569.760009765625,
        385.1999816894531,
        584.1600341796875
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        540.9599609375,
        462.8399963378906,
        555.3599853515625
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        414.239990234375,
        560.1599731445312,
        456.239990234375,
        574.5599975585938
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        579.3599853515625,
        453.239990234375,
        593.760009765625
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        598.5599975585938,
        462.239990234375,
        612.9600219726562
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        560.1599731445312,
        534.0,
        574.5599975585938
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        579.3599853515625,
        530.1719970703125,
        593.760009765625
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 44 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 51,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 성능 평가 항목",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        63.119998931884766,
        92.01995849609375,
        195.72000122070312,
        107.97996520996094
      ],
      "page_num": 51,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애 개선 디지털치료기기의 성능 평가 항목은 제품의 주요",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        134.94937133789062,
        545.9400024414062,
        150.76968383789062
      ],
      "page_num": 51,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기능을 근거로 설정하며, 시험 기준 및 시험 방법은 제품의 특성을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        164.94937133789062,
        546.0599975585938,
        180.76968383789062
      ],
      "page_num": 51,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려하여 가능한 정량적이고 구체적으로 작성한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        194.94937133789062,
        405.5629577636719,
        210.76968383789062
      ],
      "page_num": 51,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 주요 기능 선정 시 아래 고려사항을 참고하여 선정한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        224.94937133789062,
        523.0199584960938,
        240.76968383789062
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 제품의 사용목적상 필요한 기능(능력) 요구사항",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        254.94937133789062,
        437.6399841308594,
        270.7696838378906
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 소프트웨어 기반 알람, 경고, 연산 메시지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        284.9493713378906,
        399.239990234375,
        300.7696838378906
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 데이터베이스 요구사항",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        314.9493713378906,
        272.6399841308594,
        330.7696838378906
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 운영방법 및 유지보수 방법과 관련된 요구사항",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        344.9493713378906,
        435.7200012207031,
        360.7696838378906
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 45 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 52,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 예시는 이해를 돕기 위하여 작성된 것으로 실제 신청하려는 제품의 내용과 상이",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.55999755859375,
        104.39999389648438,
        528.0,
        118.79999542236328
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "할 수 있다. 본 예시는 대표적인 예를 작성한 것으로 실제 시험규격에 대해 작성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        128.39999389648438,
        528.1199951171875,
        142.79998779296875
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시에는 해당 제품의 특성 및 주요 기능을 고려하여 작성하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        152.39999389648438,
        445.5,
        166.79998779296875
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        232.2693634033203,
        91.32749938964844,
        248.0896759033203
      ],
      "page_num": 52,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.55999755859375,
        267.9674987792969,
        463.55999755859375,
        280.6237487792969
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험 항목",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.55999755859375,
        267.9674987792969,
        463.55999755859375,
        280.6237487792969
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험기준",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.55999755859375,
        267.9674987792969,
        463.55999755859375,
        280.6237487792969
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험 방법",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.55999755859375,
        267.9674987792969,
        463.55999755859375,
        280.6237487792969
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        310.1925048828125,
        275.5199890136719,
        321.83624267578125
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최소 응답시간",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        310.1925048828125,
        275.5199890136719,
        321.83624267578125
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "OO초 미만일 것",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        310.1925048828125,
        275.5199890136719,
        321.83624267578125
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "OOO 기능이 구현되도록 입력값을",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        292.6725158691406,
        528.9592895507812,
        304.3162536621094
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "입력한 후 그에 대한 응답시간을",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        310.1925048828125,
        529.0796508789062,
        321.83624267578125
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "측정",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        327.83251953125,
        371.6400146484375,
        339.47625732421875
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        373.4324951171875,
        172.07965087890625,
        385.07623291015625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "메모리 크기",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        373.4324951171875,
        172.07965087890625,
        385.07623291015625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "App memory size는 최소",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        364.552490234375,
        344.8796691894531,
        376.19622802734375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "OO MB 이상일 것",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        382.1925048828125,
        285.1199951171875,
        393.83624267578125
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설치될 기기의 메모리 공간을",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        355.7925109863281,
        529.0800170898438,
        367.4362487792969
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인한다.",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        373.4324951171875,
        396.57562255859375,
        385.07623291015625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(ex:설정→애플리케이션→메모리)",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        390.9525146484375,
        513.5700073242188,
        402.59625244140625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        427.7925109863281,
        172.07965087890625,
        439.4362487792969
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경고 메시지",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        427.7925109863281,
        172.07965087890625,
        439.4362487792969
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‘OOOOO’ 경고푸시 알림이",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        418.9125061035156,
        344.8799743652344,
        430.5562438964844
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생할 것",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        436.552490234375,
        243.239990234375,
        448.19622802734375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 알림이 발생하는 조건 정하고,",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        418.9125061035156,
        529.0800170898438,
        430.5562438964844
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실제 제품에 구현시킨다.",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        436.552490234375,
        473.49560546875,
        448.19622802734375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        482.1524963378906,
        174.8393096923828,
        502.5562438964844
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데이터베이스",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        482.1524963378906,
        174.8393096923828,
        502.5562438964844
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "송수신",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        125.27999877929688,
        499.7925109863281,
        158.39999389648438,
        511.4362487792969
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데이터베이스 저장했던 정보와",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        473.3924865722656,
        344.8799743652344,
        485.0362243652344
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다시 호출한 정보가 일치",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        490.9125061035156,
        339.3601379394531,
        502.5562438964844
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "할 것",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        508.552490234375,
        221.2799835205078,
        520.1962280273438
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "네트워크 API를 통해 데이터",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        464.51251220703125,
        523.5598754882812,
        476.15625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "베이스로 미리 정해진 데이터를 송신",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        482.1524963378906,
        529.0800170898438,
        493.7962341308594
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 저장한 후, 해당 데이터를 다시",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        499.7925109863281,
        528.9596557617188,
        511.4362487792969
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불러오기 한다.",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        517.3125,
        424.05560302734375,
        528.9562377929688
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        580.552490234375,
        79.31999206542969,
        592.1962280273438
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중복 로그인",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.5999984741211,
        571.6724853515625,
        172.07965087890625,
        583.3162231445312
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방지",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        130.8000030517578,
        589.3125,
        152.87998962402344,
        600.9562377929688
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다른 디바이스에서 같은 휴대폰",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        545.2725219726562,
        339.3598937988281,
        556.916259765625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "번호로 동시에 로그인을 시도",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        562.9124755859375,
        339.3600769042969,
        574.5562133789062
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "했을 때, 기존 로그인되어",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        580.552490234375,
        344.87933349609375,
        592.1962280273438
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있던 기기에서는 로그아웃",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        598.072509765625,
        339.35943603515625,
        609.7162475585938
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "되어야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        615.7125244140625,
        257.1356201171875,
        627.3562622070312
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한기기에 시험용 정보로 로그인을",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        562.9124755859375,
        529.0796508789062,
        574.5562133789062
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 후, 다른 기기에서 같은 정보로",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        580.552490234375,
        528.9596557617188,
        592.1962280273438
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "로그인을 시도한다.",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        598.072509765625,
        446.0155944824219,
        609.7162475585938
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        661.3125,
        172.0796661376953,
        681.7162475585938
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "우울 증상",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        661.3125,
        172.0796661376953,
        681.7162475585938
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정확도",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        125.27999877929688,
        678.83251953125,
        158.39999389648438,
        690.4762573242188
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "우울 증상 예상값 대비 결과값",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        661.3125,
        344.8799743652344,
        672.9562377929688
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "차이는 ± 1% 이내일 것",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        678.83251953125,
        317.3999938964844,
        690.4762573242188
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "우울 증상 임의의 시험용 수명",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        652.4324951171875,
        523.5594482421875,
        664.0762329101562
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "입력정보를 입력했을 때, 산출되는",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        670.072509765625,
        528.9592895507812,
        681.7162475585938
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과값과 예상값을 비교한다.",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        687.7125244140625,
        495.5755920410156,
        699.3562622070312
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 46 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 53,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅲ",
      "font_size": 20.03999900817871,
      "font_name": "T9",
      "bbox": [
        68.4000015258789,
        97.07999420166016,
        508.32000732421875,
        121.12799835205078
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험계획서 작성 시 고려사항 및 예시",
      "font_size": 20.03999900817871,
      "font_name": "H2hdrM",
      "bbox": [
        68.4000015258789,
        97.07999420166016,
        508.32000732421875,
        121.12799835205078
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "「의료기기법 시행규칙」제20조(임상시험계획의 승인 등) 제2항에 따라",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        162.3093719482422,
        545.9400024414062,
        178.1296844482422
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험계획서에 포함되어야 할 사항은 다음과 같다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        192.3093719482422,
        439.04296875,
        208.1296844482422
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 임상시험의 제목",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        222.2624969482422,
        195.0,
        235.93124389648438
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 임상시험기관의 명칭 및 소재지",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        243.1425018310547,
        285.9599914550781,
        256.8112487792969
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 임상시험의 책임자ㆍ담당자 및 공동연구자의 성명 및 직명",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        263.9024963378906,
        448.4399719238281,
        277.5712585449219
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 임상시험용 의료기기를 관리하는 관리자의 성명 및 직명",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        284.6624755859375,
        435.4804992675781,
        298.33123779296875
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5. 임상시험을 하려는 자의 성명 및 주소",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        305.54248046875,
        324.9599914550781,
        319.21124267578125
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6. 임상시험의 목적 및 배경",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        326.302490234375,
        246.9600067138672,
        339.97125244140625
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7. 임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다)",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        347.0624694824219,
        503.2499694824219,
        360.7312316894531
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8. 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되어 임상시험에",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        367.9424743652344,
        539.9999389648438,
        381.6112365722656
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참여하는 사람(피험자)의 선정기준ㆍ제외기준ㆍ인원 및 그 근거",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.79999542236328,
        388.7024841308594,
        467.6399841308594,
        402.3712463378906
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9. 임상시험기간",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        409.46246337890625,
        175.56105041503906,
        423.1312255859375
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10. 임상시험방법(사용량ㆍ사용방법ㆍ사용기간ㆍ병용요법 등을 포함한다)",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        430.34246826171875,
        496.16998291015625,
        444.01123046875
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "11. 관찰항목ㆍ임상검사항목 및 관찰검사방법",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        451.10247802734375,
        344.5205078125,
        464.771240234375
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "12. 예측되는 부작용 및 사용 시 주의사항",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        471.86248779296875,
        324.96051025390625,
        485.53125
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "13. 중지ㆍ탈락 기준",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        492.7424621582031,
        195.1205291748047,
        506.4112243652344
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "14. 유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 따른다)",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        513.5025024414062,
        480.6899719238281,
        527.1712646484375
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "15. 부작용을 포함한 안전성의 평가기준ㆍ평가방법 및 보고방법",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        534.262451171875,
        455.0404968261719,
        547.9312133789062
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "16. 피험자동의서 서식",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        555.1424560546875,
        208.0800018310547,
        568.8112182617188
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "17. 피해자 보상에 대한 규약",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        575.9024658203125,
        247.08053588867188,
        589.5712280273438
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "18. 임상시험 후 피험자의 진료에 관한 사항",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        596.6624755859375,
        338.0404968261719,
        610.3312377929688
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "19. 피험자의 안전보호에 관한 대책",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        617.54248046875,
        286.08050537109375,
        631.2112426757812
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "20. 그 밖에 임상시험을 안전하고 과학적으로 실시하기 위하여 필요한 사항",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        638.302490234375,
        497.1601867675781,
        651.9712524414062
      ],
      "page_num": 53,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 본 장에서 제시한 항목 및 예시는 참고용으로 작성한 것으로 사안에",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        70.08000183105469,
        682.199951171875,
        531.359619140625,
        697.751953125
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "따라 변경될 수 있으며, 제품의 특성에 따라 타당한 근거를 제시할 경우",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        92.15999603271484,
        708.1199340820312,
        531.3598022460938,
        723.6719360351562
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설정 변경이 가능하다.",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        92.15999603271484,
        734.1599731445312,
        229.73519897460938,
        749.7119750976562
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 47 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 54,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 임상시험의 제목",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        59.52000045776367,
        99.09996032714844,
        200.16000366210938,
        115.0599594116211
      ],
      "page_num": 54,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험용 ‘우울장애 개선 디지털치료기기’의 안전성과 유효성을 증명하고자",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        78.1199951171875,
        159.47999572753906,
        529.9204711914062,
        175.03199768066406
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하는 임상시험의 목적을 구체적으로 알 수 있도록 기입한다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        65.15999603271484,
        185.51998901367188,
        425.0951843261719,
        201.07199096679688
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        412.67431640625,
        94.91999816894531,
        432.62548828125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "우울장애 진단환자의 우울 증상을 개선하기 위해서 사용되는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        448.9893798828125,
        545.9400024414062,
        464.8096923828125
      ],
      "page_num": 54,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "OOO 디지털치료기기의 안전성 및 유효성을 평가하기 위한 전향적",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        79.08000183105469,
        478.9893493652344,
        545.9400024414062,
        494.8096618652344
      ],
      "page_num": 54,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무작위 확증 임상시험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        79.08000183105469,
        508.9893798828125,
        227.63999938964844,
        524.8096923828125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 대상 질환 : [F32] Depressive episode - 우울에피소드",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        538.9893798828125,
        459.5999755859375,
        554.8096923828125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 의료기기의 사용 목적 : 환자의 우울 증상을 정량적으로 개선",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        568.9893798828125,
        515.280029296875,
        584.8096923828125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 임상시험용 의료기기 : 우울장애 개선 디지털치료기기(OOO)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        598.9893798828125,
        504.36749267578125,
        614.8096923828125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 임상시험 평가 내용 : 우울장애 심각도 척도(Depressive Severity Index)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        628.9893798828125,
        536.7675170898438,
        644.8096923828125
      ],
      "page_num": 54,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5) 임상시험 디자인 : 단일(다)기관, 무작위배정, 전향적 임상시험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        658.9893798828125,
        517.6799926757812,
        674.8096923828125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 48 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 55,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 임상시험기관의 명칭 및 소재지",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        93.4599609375,
        317.1596984863281,
        109.41996002197266
      ],
      "page_num": 55,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처장은 [의료법]에 따른 의료기관 중 임상시험에 필요한 시설, 인력 및 기구를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.55999755859375,
        144.239990234375,
        528.1199951171875,
        158.63998413085938
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "갖춘",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        64.55999755859375,
        168.239990234375,
        528.1199951171875,
        182.63998413085938
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기관을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        168.239990234375,
        528.1199951171875,
        182.63998413085938
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험기관으로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        168.239990234375,
        528.1199951171875,
        182.63998413085938
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지정하여",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        168.239990234375,
        528.1199951171875,
        182.63998413085938
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "운영하고",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        168.239990234375,
        528.1199951171875,
        182.63998413085938
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있으며, 임상시험기관은",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        168.239990234375,
        528.1199951171875,
        182.63998413085938
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[의료기기 임상시험기관 지정에 관한 규정(식약처 고시)]에 따라 식약처장으로부터",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        192.239990234375,
        528.0,
        206.63998413085938
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 임상시험기관으로 지정받은 곳이어야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        216.239990234375,
        355.5,
        230.63998413085938
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        283.4342956542969,
        94.91999816894531,
        303.3854675292969
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험기관",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        321.90936279296875,
        154.13999938964844,
        337.72967529296875
      ],
      "page_num": 55,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기관명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        100.07999420166016,
        357.3599853515625,
        488.1600036621094,
        371.7599792480469
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소재지",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        100.07999420166016,
        357.3599853515625,
        488.1600036621094,
        371.7599792480469
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        100.07999420166016,
        357.3599853515625,
        488.1600036621094,
        371.7599792480469
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "팩스",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        100.07999420166016,
        357.3599853515625,
        488.1600036621094,
        371.7599792480469
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○병원",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        89.04000091552734,
        377.7599792480469,
        521.280029296875,
        392.15997314453125
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○시 ○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        89.04000091552734,
        377.7599792480469,
        521.280029296875,
        392.15997314453125
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        89.04000091552734,
        377.7599792480469,
        521.280029296875,
        392.15997314453125
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        89.04000091552734,
        377.7599792480469,
        521.280029296875,
        392.15997314453125
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○병원",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        89.04000091552734,
        398.2799987792969,
        521.280029296875,
        412.67999267578125
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○시 ○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        89.04000091552734,
        398.2799987792969,
        521.280029296875,
        412.67999267578125
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        89.04000091552734,
        398.2799987792969,
        521.280029296875,
        412.67999267578125
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        89.04000091552734,
        398.2799987792969,
        521.280029296875,
        412.67999267578125
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 49 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 56,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 임상시험 책임자·담당자 및 공동연구자의 성명 및 직명",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        93.4599609375,
        501.1199951171875,
        109.41996002197266
      ],
      "page_num": 56,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.79999542236328,
        139.3199920654297,
        442.0199890136719,
        153.71998596191406
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        70.79999542236328,
        163.3199920654297,
        531.0,
        177.71998596191406
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "으로서, 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        83.27999877929688,
        187.3199920654297,
        531.0,
        201.71998596191406
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하기에 충분한 경험이 있는 자가 선정되어야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        83.27999877929688,
        211.3199920654297,
        373.2599792480469,
        225.71998596191406
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 담당",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        70.79999542236328,
        235.3199920654297,
        531.0,
        249.71998596191406
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상시험에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        83.27999877929688,
        259.32000732421875,
        531.0,
        273.7200012207031
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관여하는 사람을 말한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        83.27999877929688,
        283.32000732421875,
        222.17999267578125,
        297.7200012207031
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 공동연구자는 의학통계 전문가, 의료기기 전문가 등을 말한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.79999542236328,
        307.32000732421875,
        438.8999938964844,
        321.7200012207031
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 각 임상시험기관의 적절한 임상시험의 수행을 위하여 임상시험기관 및 시험자의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.79999542236328,
        331.32000732421875,
        531.1199951171875,
        345.7200012207031
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의견을 조정하기 위하여 조정위원회를 설치하고 임상시험 조정자를 선정할 수 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        83.27999877929688,
        355.3199768066406,
        529.739990234375,
        369.719970703125
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        408.59429931640625,
        94.91999816894531,
        428.54547119140625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 시험책임자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        435.90936279296875,
        158.16000366210938,
        451.72967529296875
      ],
      "page_num": 56,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        468.47998046875,
        486.8399963378906,
        482.8799743652344
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소속기관명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        468.47998046875,
        486.8399963378906,
        482.8799743652344
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전공",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        468.47998046875,
        486.8399963378906,
        482.8799743652344
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "직위",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        468.47998046875,
        486.8399963378906,
        482.8799743652344
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        468.47998046875,
        486.8399963378906,
        482.8799743652344
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        486.1199951171875,
        519.9599609375,
        500.5199890136719
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○병원",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        86.87999725341797,
        486.1199951171875,
        519.9599609375,
        500.5199890136719
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        486.1199951171875,
        519.9599609375,
        500.5199890136719
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        486.1199951171875,
        519.9599609375,
        500.5199890136719
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        486.1199951171875,
        519.9599609375,
        500.5199890136719
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 시험담당자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        518.9493408203125,
        158.16000366210938,
        534.7696533203125
      ],
      "page_num": 56,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        551.5199584960938,
        486.8399963378906,
        565.9199829101562
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소속기관명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        551.5199584960938,
        486.8399963378906,
        565.9199829101562
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전공",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        551.5199584960938,
        486.8399963378906,
        565.9199829101562
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "직위",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        551.5199584960938,
        486.8399963378906,
        565.9199829101562
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        551.5199584960938,
        486.8399963378906,
        565.9199829101562
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        569.1599731445312,
        519.9599609375,
        583.5599975585938
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○병원",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        86.87999725341797,
        569.1599731445312,
        519.9599609375,
        583.5599975585938
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        569.1599731445312,
        519.9599609375,
        583.5599975585938
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        569.1599731445312,
        519.9599609375,
        583.5599975585938
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        569.1599731445312,
        519.9599609375,
        583.5599975585938
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 공동연구자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        602.109375,
        158.16000366210938,
        617.9296875
      ],
      "page_num": 56,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        634.6799926757812,
        486.8399963378906,
        649.0800170898438
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소속기관명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        634.6799926757812,
        486.8399963378906,
        649.0800170898438
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전공",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        634.6799926757812,
        486.8399963378906,
        649.0800170898438
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "직위",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        634.6799926757812,
        486.8399963378906,
        649.0800170898438
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        634.6799926757812,
        486.8399963378906,
        649.0800170898438
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        652.3200073242188,
        519.9599609375,
        666.7200317382812
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○병원",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        86.87999725341797,
        652.3200073242188,
        519.9599609375,
        666.7200317382812
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        652.3200073242188,
        519.9599609375,
        666.7200317382812
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        652.3200073242188,
        519.9599609375,
        666.7200317382812
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        652.3200073242188,
        519.9599609375,
        666.7200317382812
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 임상시험 조정자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        685.2693481445312,
        195.72000122070312,
        701.0896606445312
      ],
      "page_num": 56,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        717.8399658203125,
        486.8399963378906,
        732.239990234375
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소속기관명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        717.8399658203125,
        486.8399963378906,
        732.239990234375
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전공",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        717.8399658203125,
        486.8399963378906,
        732.239990234375
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "직위",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        717.8399658203125,
        486.8399963378906,
        732.239990234375
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        717.8399658203125,
        486.8399963378906,
        732.239990234375
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        735.47998046875,
        519.9599609375,
        749.8800048828125
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○병원",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        86.87999725341797,
        735.47998046875,
        519.9599609375,
        749.8800048828125
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        735.47998046875,
        519.9599609375,
        749.8800048828125
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        735.47998046875,
        519.9599609375,
        749.8800048828125
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        735.47998046875,
        519.9599609375,
        749.8800048828125
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 50 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 임상시험용 의료기기를 관리하는 관리자의 성명 및 직명",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        93.4599609375,
        501.1199951171875,
        109.41996002197266
      ],
      "page_num": 57,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험용 의료기기 관리자는 임상시험기관에서 임상시험용 해당 의료기기를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.55999755859375,
        143.0399932861328,
        528.239990234375,
        157.4399871826172
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보관, 관리하는 임상의, 의료기사 또는 간호사 등으로 임상시험기관의 장이 지정한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        167.0399932861328,
        528.239990234375,
        181.4399871826172
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자를 말하며, 임상시험용 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        191.0399932861328,
        528.239990234375,
        205.4399871826172
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "할 경우 이를 함께 관리한다. 임상시험용 의료기기 관리자의 성명, 소속 기관명 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        64.55999755859375,
        215.0399932861328,
        528.239990234375,
        229.4399871826172
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "직명 등 인적사항을 기재한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        239.0399932861328,
        231.17999267578125,
        253.4399871826172
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        310.0743103027344,
        94.91999816894531,
        330.0254821777344
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 관리자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        337.3893737792969,
        169.0800018310547,
        353.2096862792969
      ],
      "page_num": 57,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        371.3999938964844,
        486.8399963378906,
        385.79998779296875
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소속기관명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        371.3999938964844,
        486.8399963378906,
        385.79998779296875
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전공",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        371.3999938964844,
        486.8399963378906,
        385.79998779296875
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "직위",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        371.3999938964844,
        486.8399963378906,
        385.79998779296875
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        371.3999938964844,
        486.8399963378906,
        385.79998779296875
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        391.79998779296875,
        519.9599609375,
        406.1999816894531
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○병원",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        86.87999725341797,
        391.79998779296875,
        519.9599609375,
        406.1999816894531
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        391.79998779296875,
        519.9599609375,
        406.1999816894531
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        391.79998779296875,
        519.9599609375,
        406.1999816894531
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        391.79998779296875,
        519.9599609375,
        406.1999816894531
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 51 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 58,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5. 임상시험을 하려는 자의 성명 및 주소",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        99.09996032714844,
        365.15997314453125,
        115.0599594116211
      ],
      "page_num": 58,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 의뢰자는 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.79999542236328,
        154.67999267578125,
        533.6400146484375,
        169.07998657226562
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 의료기기의 제조업자 또는 수입업자가 해당된다. 의뢰자는 임상시험 모니터",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        178.67999267578125,
        533.6400146484375,
        193.07998657226562
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "요원을 지정하여야 한다. 임상시험 모니터요원의 선정, 자격기준, 수행임무 등에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        202.67999267578125,
        533.760009765625,
        217.07998657226562
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 사항은 「의료기기법 시행규칙」별표3 “의료기기의 임상시험 관리기준” 제8호",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        64.55999755859375,
        226.67999267578125,
        533.760009765625,
        241.07998657226562
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "머목(모니터링)에서 정하고 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        250.67999267578125,
        247.6199951171875,
        265.0799865722656
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        316.7943115234375,
        94.91999816894531,
        336.7454833984375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 의뢰자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        343.9893798828125,
        128.16000366210938,
        359.8096923828125
      ],
      "page_num": 58,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        378.0,
        461.2799987792969,
        392.3999938964844
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대표이사",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        378.0,
        461.2799987792969,
        392.3999938964844
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소재지",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        378.0,
        461.2799987792969,
        392.3999938964844
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        378.0,
        461.2799987792969,
        392.3999938964844
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㈜○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        78.0,
        398.5199890136719,
        506.5199890136719,
        412.91998291015625
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        78.0,
        398.5199890136719,
        506.5199890136719,
        412.91998291015625
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○ ○○시 ○○구",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        78.0,
        398.5199890136719,
        506.5199890136719,
        412.91998291015625
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○- ○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        78.0,
        398.5199890136719,
        506.5199890136719,
        412.91998291015625
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 모니터요원",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        432.78936767578125,
        158.16000366210938,
        448.60968017578125
      ],
      "page_num": 58,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        466.79998779296875,
        461.2799987792969,
        481.1999816894531
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대표이사",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        466.79998779296875,
        461.2799987792969,
        481.1999816894531
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소재지",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        466.79998779296875,
        461.2799987792969,
        481.1999816894531
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        466.79998779296875,
        461.2799987792969,
        481.1999816894531
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㈜○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        78.0,
        487.3199768066406,
        506.5199890136719,
        501.719970703125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        78.0,
        487.3199768066406,
        506.5199890136719,
        501.719970703125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○ ○○시 ○○구",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        78.0,
        487.3199768066406,
        506.5199890136719,
        501.719970703125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○- ○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        78.0,
        487.3199768066406,
        506.5199890136719,
        501.719970703125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 임상시험 수탁업체",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        521.58935546875,
        210.72000122070312,
        537.40966796875
      ],
      "page_num": 58,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        555.5999755859375,
        461.2799987792969,
        570.0
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대표이사",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        555.5999755859375,
        461.2799987792969,
        570.0
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소재지",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        555.5999755859375,
        461.2799987792969,
        570.0
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        555.5999755859375,
        461.2799987792969,
        570.0
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㈜○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        78.0,
        576.1199951171875,
        506.5199890136719,
        590.52001953125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        78.0,
        576.1199951171875,
        506.5199890136719,
        590.52001953125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○ ○○시 ○○구",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        78.0,
        576.1199951171875,
        506.5199890136719,
        590.52001953125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○- ○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        78.0,
        576.1199951171875,
        506.5199890136719,
        590.52001953125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 임상시험 수탁기관(Contact Research Organization, CRO)이 있는 경우 해당",
      "font_size": 12.960000038146973,
      "font_name": "T14",
      "bbox": [
        56.63999938964844,
        608.6399536132812,
        538.4400024414062,
        624.1919555664062
      ],
      "page_num": 58,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용을 기재함",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        634.5599365234375,
        160.55999755859375,
        650.1119384765625
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 52 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 59,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6. 임상시험의 목적 및 배경",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        93.4599609375,
        269.1600036621094,
        109.41996002197266
      ],
      "page_num": 59,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.55999755859375,
        143.51998901367188,
        530.8800048828125,
        157.91998291015625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기술하는 것을 말하며, 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        167.51998901367188,
        530.8800048828125,
        181.91998291015625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적인 사항, 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        191.51998901367188,
        530.8800048828125,
        205.91998291015625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "디자인 특성, 원자재 및 성능, 새로운 제조방법 등에 대한 특이성을 함께 기재한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        215.51998901367188,
        523.3800048828125,
        229.91998291015625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 임상시험의 목적",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        285.54937744140625,
        195.72000122070312,
        301.36968994140625
      ],
      "page_num": 59,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        314.8742980957031,
        94.91999816894531,
        334.8254699707031
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[목적]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        351.1893615722656,
        110.64468383789062,
        367.0096740722656
      ],
      "page_num": 59,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 임상시험용 디지털치료기기의 우울장애 치료에 대한 안전성 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        79.91999816894531,
        381.1893615722656,
        543.8999633789062,
        397.0096740722656
      ],
      "page_num": 59,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 임상시험용 디지털치료기기의 우울장애 치료에 대한 유효성 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        79.91999816894531,
        411.1893615722656,
        543.8999633789062,
        427.0096740722656
      ],
      "page_num": 59,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최근 우울장애로 치료받는 환자의 숫자가 급격히 증가하는 추세로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        471.1893615722656,
        545.9400024414062,
        487.0096740722656
      ],
      "page_num": 59,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애를 치료하는 방법들 또한 많은 주목을 받고 있다(우울장애",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        501.18939208984375,
        545.9400024414062,
        517.0097045898438
      ],
      "page_num": 59,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상진료지침, 2022, ICSI, 2016). 임상에서 우울장애 환자들에게 주로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        531.1893920898438,
        545.9400024414062,
        547.0097045898438
      ],
      "page_num": 59,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용되는 치료는 약물치료이다. 약물치료는 우울장애의 단기 치료에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        561.1893920898438,
        546.0599975585938,
        577.0097045898438
      ],
      "page_num": 59,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있어서 유용성이 확립되어 있으나 성기능장애, 졸림(진정 작용), 체중증가,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        591.1893310546875,
        545.9400024414062,
        607.0096435546875
      ],
      "page_num": 59,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수면장애(불면), 소화기장애(오심, 구토) 등의 부작용의 위험성이 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        621.1893310546875,
        537.3229370117188,
        637.0096435546875
      ],
      "page_num": 59,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한 약물치료의 단점들을 보완해줄 수 있는 치료는 우울장애",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        651.1893310546875,
        545.9400024414062,
        667.0096435546875
      ],
      "page_num": 59,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인지행동치료(CBT-D)이다. 우울장애 인지행동치료(CBT-D)는 단기적으로는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        681.1893310546875,
        546.0599975585938,
        697.0096435546875
      ],
      "page_num": 59,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약물치료와 그 효과가 유사하며 장기적인 효과는 약물치료보다 우수한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        711.1893310546875,
        545.9400024414062,
        727.0096435546875
      ],
      "page_num": 59,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것으로 밝혀져 있으며, 이러한 효과의 입증을 통해 우울증의 일차",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        741.1893310546875,
        546.0599975585938,
        757.0096435546875
      ],
      "page_num": 59,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 53 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료로 권장되고 있다(Van Hees et al., 2013).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        384.17999267578125,
        100.72968292236328
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하지만 실제 임상에서 우울장애 인지행동치료(CBT-D)가 처방되는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        114.90937042236328,
        546.0599975585938,
        130.72967529296875
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비율은 약물치료보다 현저히 낮다. 우울장애 인지행동치료(CBT-D)가 약물",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        144.9093780517578,
        538.5599975585938,
        160.7296905517578
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료에 비해 많은 장점이 있음에도 널리 시행되지 않는 이유는 첫째,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        174.9093780517578,
        545.9400024414062,
        190.7296905517578
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애 인지행동치료(CBT-D)를 위해 환자들이 병원에 매주 내원",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        204.90936279296875,
        538.5599975585938,
        220.72967529296875
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여야 하므로 병원에의 공간적 접근성, 치료를 위해 확보할 수 있는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        234.90936279296875,
        545.9400024414062,
        250.72967529296875
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시간 자원 여부에 따른 치료적 제약이 생기기 때문이다. 둘째, 특히",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        264.90936279296875,
        546.0599975585938,
        280.72967529296875
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고령 환자이거나, 기타 내과 질환으로 인해 이동이 힘든 환자들의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        294.90936279296875,
        546.0599975585938,
        310.72967529296875
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우, 혹은 직장인이라 매주 시간을 내기 어려운 환자들의 경우 본인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        324.90936279296875,
        538.4400024414062,
        340.72967529296875
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "들이 원하더라도 우울장애 인지행동치료(CBT-D)를 받기 어려운 것이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        354.90936279296875,
        545.9400024414062,
        370.72967529296875
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "현실이다. 셋째, 치료진 관점에서 약물치료와 비교해 우울장애 인지행동",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        384.90936279296875,
        538.5599975585938,
        400.72967529296875
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료(CBT-D)를 시행하는 것이 시간 대비 효용성이 높지 않으므로 선호도가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        414.90936279296875,
        545.9400024414062,
        430.72967529296875
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "떨어지는 경향이 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        444.90936279296875,
        210.68296813964844,
        460.72967529296875
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한 단점들을 보완하기 위해 디지털로 수행하는 우울장애 인지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        474.90936279296875,
        538.4400024414062,
        490.72967529296875
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "행동치료(Digital CBT-D)가 개발되고 있다. 디지털 우울장애 인지행동",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        504.90936279296875,
        538.5599975585938,
        520.7296752929688
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료(Digital CBT-D)의 개념은 2005년에 처음으로 등장하였으며, 인터넷을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        534.9093627929688,
        546.0599975585938,
        550.7296752929688
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이용하여 병원에 내원하지 않고도 우울장애 인지행동치료(CBT-D)를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        564.9093627929688,
        546.0599975585938,
        580.7296752929688
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시행 받을 수 있도록 하는 것이다(Andersson et al. 2005). 이를 통해",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        594.9093627929688,
        546.0599975585938,
        610.7296752929688
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자들이 직접 집에서 컴퓨터, 혹은 스마트폰을 이용하여 치료를 시행",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        624.9093627929688,
        546.0599975585938,
        640.7296752929688
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "받을 수 있으므로 시·공간의 제약에서 자유롭게 될 것이며, 치료 대",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        654.9093627929688,
        538.4400024414062,
        670.7296752929688
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부분을 환자가 프로그램을 통해 수행하고 피드백을 받을 수 있으므로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        684.9093627929688,
        545.9400024414062,
        700.7296752929688
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료자 입장에서 비용 대비 효용성 또한 증가하게 될 것으로 기대된다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        714.9093627929688,
        537.5629272460938,
        730.7296752929688
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디지털 우울장애 인지행동치료(Digital CBT-D)가 등장한지도 약 15년이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        744.9093627929688,
        546.0599975585938,
        760.7296752929688
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 54 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 61,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되어 치료 효과에 관한 여러 연구 결과들이 발표되고 있다. 특히, 최근",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        545.9400024414062,
        100.72968292236328
      ],
      "page_num": 61,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구들은 단순히 우울장애 인지행동치료(CBT-D)를 디지털 환경으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        114.90937042236328,
        546.0599975585938,
        130.72967529296875
      ],
      "page_num": 61,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "옮기는 것에서 발전하여, 애플리케이션을 통하여 환자에게 바로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        144.9093780517578,
        546.0599975585938,
        160.7296905517578
      ],
      "page_num": 61,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피드백을 제공함으로써 의사나 치료자가 직접적인 가이드를 주지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        174.9093780517578,
        545.9400024414062,
        190.7296905517578
      ],
      "page_num": 61,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않더라도 치료 효과를 볼 수 있게 하는 “디지털치료기기(Digital",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        204.90936279296875,
        546.0599975585938,
        220.72967529296875
      ],
      "page_num": 61,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Therapeutics, DTx)”의 개념을 추구하고 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        234.90936279296875,
        376.6429748535156,
        250.72967529296875
      ],
      "page_num": 61,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 임상 시험을 통해 우울장애가 있는 환자들을 대상으로 개발된 우울",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        264.90936279296875,
        538.5599975585938,
        280.72967529296875
      ],
      "page_num": 61,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장애 개선 디지털치료기기의 작용기전에 대한 안전성(Safety)과 유효성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        294.90936279296875,
        538.4400024414062,
        310.72967529296875
      ],
      "page_num": 61,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(effectiveness)을 검증하고자 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        324.90936279296875,
        300.29998779296875,
        340.72967529296875
      ],
      "page_num": 61,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 55 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 62,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 임상시험의 배경",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        195.72000122070312,
        100.72968292236328
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디지털치료기기란 질병이나 장애를 예방, 관리, 치료하기 위해 환자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        114.90937042236328,
        538.5599975585938,
        130.72967529296875
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에게 근거 기반의 치료적 중재(evidence-based therapeutic intervention)를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        144.9093780517578,
        546.0599975585938,
        160.7296905517578
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공하는 고도화된 소프트웨어 의료기기를 가리킨다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        174.9093780517578,
        410.0029602050781,
        190.7296905517578
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "독일 GAIA 社에서 제공하는 Deprexis™는 CE 승인을 받은 우울장애",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        201.74998474121094,
        545.9400024414062,
        221.24998474121094
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개선 디지털치료기기로서, 실제 임상에서 사용되고 있다. Deprexis™는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        232.9499969482422,
        545.9400024414062,
        250.72967529296875
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여러 무작위배정 임상시험을 통해 그 효용성 또한 입증된 바 있으며,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        264.90936279296875,
        545.9400024414062,
        280.72967529296875
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울과 관련된 변수들을 포함하여 신체적 건강, 심리적 웰빙 및 우울",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        294.90936279296875,
        546.0599975585938,
        310.72967529296875
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련 지표 또한 호전되었다는 것이 밝혀진 바 있다(Twomey et al., 2020.).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        324.90936279296875,
        543.5399780273438,
        340.72967529296875
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "12개의 Deprexis RCT(총 피험자=2,901명)에 대한 메타분석은 우울",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        354.90936279296875,
        538.4400024414062,
        370.72967529296875
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장애 감소에 대한 Deprexis™의 효과를 확인하였다(g = 0.51, 95% CI:",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        382.9499816894531,
        545.9400024414062,
        400.72967529296875
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "0.40–0.62, I2 = 26%). 임상 연구의 질, 선별 및 무작위배정 절차를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        412.9499816894531,
        546.0599975585938,
        430.72967529296875
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려할 때 결과는 유사하였다. 임상 연구의 지도, 개발자 참여, 환경",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        444.90936279296875,
        538.4400024414062,
        460.72967529296875
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(지역사회 대 임상) 및 초기 증상 심각도는 효과 크기에 통계적으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        474.90936279296875,
        545.9400024414062,
        490.72967529296875
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유의한 영향을 미치지 않았으며 출판 편향의 증거도 없었다. 따라서",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        504.90936279296875,
        545.9400024414062,
        520.7296752929688
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한 결과는 Deprexis가 8-12주에 걸쳐 임상적으로 관련된 우울",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        534.9093627929688,
        546.0599975585938,
        550.7296752929688
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증상의 개선할 수 있음을 확인하였다, 아래의 <그림 4>는 우울장애",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        564.9093627929688,
        545.9400024414062,
        580.7296752929688
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개선 디지털치료기기와 관련하여 수행한 임상시험의 선행 연구의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        594.9093627929688,
        545.9400024414062,
        610.7296752929688
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "메타분석 결과이다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        624.9093627929688,
        188.8429718017578,
        640.7296752929688
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한 디지털치료기기는 기존의 우울장애 개선을 위한 웰니스",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        654.9093627929688,
        546.0599975585938,
        670.7296752929688
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로그램과 다음과 같은 차이점을 가진다. 첫째, 일방적인 콘텐츠",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        684.9093627929688,
        546.0599975585938,
        700.7296752929688
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공을 넘어 쌍방향적인 피드백을 제공한다. 피험자의 우울과 관련된",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        714.9093627929688,
        545.9400024414062,
        730.7296752929688
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변수를 지속해서 수집하고, 이에 대해 다음 목표를 제시함으로써 치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        744.9093627929688,
        546.0599975585938,
        760.7296752929688
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 56 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 63,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "효과를 극대화한다. 이 과정에서 피험자는 단순히 콘텐츠를 소비하는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        396.3093566894531,
        546.0599975585938,
        412.1296691894531
      ],
      "page_num": 63,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것을 넘어서, 스스로 콘텐츠에 참여하고 있다는 느낌을 받을 수 있다.",
      "font_size": 15.0,
      "font_name": "Haansoft Batang",
      "bbox": [
        56.63999938964844,
        426.3093566894531,
        538.5,
        442.1296691894531
      ],
      "page_num": 63,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "둘째, 피험자 맞춤형 콘텐츠 제공이 가능하다. 모든 콘텐츠를 같은",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        456.3093566894531,
        545.9400024414062,
        472.1296691894531
      ],
      "page_num": 63,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비율로 제공하는 것에 그치지 않고 피험자의 정보를 수집함으로써 취",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        486.3093566894531,
        538.4400024414062,
        502.1296691894531
      ],
      "page_num": 63,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약한 부분에 대한 집중적인 맞춤형 콘텐츠 제공을 하는 것이 가능하다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        516.3093872070312,
        546.0599975585938,
        532.1296997070312
      ],
      "page_num": 63,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "셋째, 일정 시간 동안의 꾸준한 사용을 독려하며 치료 효과에 대한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        546.3093872070312,
        546.0599975585938,
        562.1296997070312
      ],
      "page_num": 63,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모니터링이 가능하다. 일반적으로 디지털치료기기는 모든 콘텐츠를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        576.3093872070312,
        545.9400024414062,
        592.1296997070312
      ],
      "page_num": 63,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한 번에 제공하지 않고 일정 기간 순차적인 콘텐츠 제공을 함으로써",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        606.3093872070312,
        546.0599975585938,
        622.1296997070312
      ],
      "page_num": 63,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용기간을 조정한다. 이에 따라 피험자들은 치료 기간 중 자신의 우울",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        636.3093872070312,
        538.4400024414062,
        652.1296997070312
      ],
      "page_num": 63,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장애 증상이 어떻게 변화하는지 실제 체감하고, 또한 디지털치료기기를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        666.3093872070312,
        546.0599975585938,
        682.1296997070312
      ],
      "page_num": 63,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통한 모니터링을 받을 수 있어 치료 동기 부여에 긍정적으로 작용할",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        696.3093872070312,
        546.0599975585938,
        712.1296997070312
      ],
      "page_num": 63,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        726.3093872070312,
        120.65999603271484,
        742.1296997070312
      ],
      "page_num": 63,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그림 4. 우울장애 개선 디지털치료기기 임상시험 선행 연구 결과",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        95.63999938964844,
        343.44000244140625,
        498.840576171875,
        358.99200439453125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(출처: Twomey et al., 2020.)",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        243.1199951171875,
        363.0,
        421.7236022949219,
        378.552001953125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 57 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 64,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 연구에서는 국내에서 개발된 디지털 우울장애 인지행동치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        84.90937042236328,
        546.0599975585938,
        100.72968292236328
      ],
      "page_num": 64,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "애플리케이션을 무작위배정 임상시험을 통해 효과성과 안전성 검증을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        114.90937042236328,
        545.9400024414062,
        130.72967529296875
      ],
      "page_num": 64,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함으로써 해당 애플리케이션을 실제 국내 임상에서 활용할 수 있는지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        144.9093780517578,
        545.9400024414062,
        160.7296905517578
      ],
      "page_num": 64,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인을 할 수 있겠으며 국내 우울장애 환자들에게 새로운 치료의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        174.9093780517578,
        545.9400024414062,
        190.7296905517578
      ],
      "page_num": 64,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선택지를 열어주고자 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        204.90936279296875,
        241.64295959472656,
        220.72967529296875
      ],
      "page_num": 64,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 58 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7. 임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증 포함)",
      "font_size": 14.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        99.09996032714844,
        524.1658935546875,
        115.0599594116211
      ],
      "page_num": 65,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 임상시험용 의료기기 사용 목적",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        143.46937561035156,
        300.6000061035156,
        159.28968811035156
      ],
      "page_num": 65,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 대상질환 또는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        180.36000061035156,
        530.8800048828125,
        194.75999450683594
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적응증을 포함하도록 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        204.36000061035156,
        212.94000244140625,
        218.75999450683594
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        268.914306640625,
        94.91999816894531,
        288.865478515625
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[사용목적]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        300.1893615722656,
        126.24468231201172,
        316.0096740722656
      ],
      "page_num": 65,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모바일 애플리케이션 형태의 우울장애 인지행동치료 기반 콘텐츠를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        330.1893615722656,
        546.0599975585938,
        346.0096740722656
      ],
      "page_num": 65,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "범용 장비(스마트폰 또는 태블릿 PC)를 통해 제공하는 소프트웨어 의료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        360.1893615722656,
        538.5599975585938,
        376.0096740722656
      ],
      "page_num": 65,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기이다. 임상시험용 기기는 우울장애 인지행동치료(CBT-D)를 제공하여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        390.1893615722656,
        546.0599975585938,
        406.0096740722656
      ],
      "page_num": 65,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대조군(우울장애 일기 작성 권고 및 간단한 우울장애 교육 제공) 대비",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        420.1893615722656,
        546.0599975585938,
        436.0096740722656
      ],
      "page_num": 65,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애 증상을 개선하는 것을 목표로 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        450.1893615722656,
        375.53997802734375,
        466.0096740722656
      ],
      "page_num": 65,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 의료기기는 의사에게 우울장애* 진단을 받은 환자들을 대상으로 하며,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        478.22998046875,
        546.0599975585938,
        496.0096740722656
      ],
      "page_num": 65,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추후 추가적인 적응증 확대는 가능하나 우울장애에 대한 의사 진단을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        510.18939208984375,
        545.9400024414062,
        526.0097045898438
      ],
      "page_num": 65,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반으로 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        540.1893920898438,
        157.1629638671875,
        556.0097045898438
      ],
      "page_num": 65,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "* [F32] Depressive episode (우울에피소드))",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        68.5199966430664,
        568.43994140625,
        301.2422790527344,
        583.991943359375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 59 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 임상시험용 의료기기 정보",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        263.15997314453125,
        100.72968292236328
      ],
      "page_num": 66,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 임상시험용 의료기기 및 대조시험용 의료기기의 품목명, 제조회사, 원재료, 모양,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        77.87999725341797,
        121.80000305175781,
        532.6320190429688,
        136.1999969482422
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구조, 성능 등을 구체적으로 기재하도록 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        66.5999984741211,
        145.8000030517578,
        305.94000244140625,
        160.1999969482422
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        197.27430725097656,
        94.91999816894531,
        217.22547912597656
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 임상시험용 의료기기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        224.58937072753906,
        233.87998962402344,
        240.40968322753906
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 시험기기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        254.58935546875,
        168.83999633789062,
        270.40966796875
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 품목명(품목분류번호, 등급): 정서장애치료소프트웨어(E06070.01, 2등급)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.07999420166016,
        284.58935546875,
        537.1275024414062,
        300.40966796875
      ],
      "page_num": 66,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 모델명: ○○○",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        314.58935546875,
        217.1999969482422,
        330.40966796875
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 제조회사: ㈜○○○",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        344.58935546875,
        246.95999145507812,
        360.40966796875
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 원재료: (임상시험용 의료기기의 원재료에 대한 특성 기술)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        374.58935546875,
        515.6474609375,
        390.40966796875
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 독립형 소프트웨어 제품은 소프트웨어 명칭, 버전, 운영환경 기재",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        121.43999481201172,
        402.8399963378906,
        522.4805297851562,
        418.3919982910156
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 모양 및 구조: (임상시험용 의료기기의 모양 및 구조 기술)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        430.6293640136719,
        515.6474609375,
        446.4496765136719
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 성능: (임상시험용 의료기기의 성능 기술)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        460.6293640136719,
        396.9674987792969,
        476.4496765136719
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 대조기기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        490.6293640136719,
        168.83999633789062,
        506.4496765136719
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 대조 시험용 의료기기의 구체적인 정보를 ‘가)’를 참고하여 작성한다. 대조",
      "font_size": 12.960000038146973,
      "font_name": "T14",
      "bbox": [
        84.95999908447266,
        518.7599487304688,
        538.4400024414062,
        534.3119506835938
      ],
      "page_num": 66,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험용 의료기기가 설정되지 않았을 경우 생략할 수 있으며, 설정하지",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        104.39999389648438,
        544.7999877929688,
        538.43896484375,
        560.3519897460938
      ],
      "page_num": 66,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않으면 이에 대한 사유와 근거 등을 제시해야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        104.39999389648438,
        570.8399658203125,
        409.9751892089844,
        586.3919677734375
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 임상시험용 의료기기 사용 방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        628.6293334960938,
        300.6000061035156,
        644.4496459960938
      ],
      "page_num": 66,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        657.9542846679688,
        94.91999816894531,
        677.9054565429688
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 사용 전 준비사항",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        685.2693481445312,
        211.3199920654297,
        701.0896606445312
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 치료에 앞서 범용장비(스마트폰, 태블릿, PC 등)에 OOO 디지털",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        715.2693481445312,
        538.5599975585938,
        731.0896606445312
      ],
      "page_num": 66,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료기기를 설치한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        745.2693481445312,
        253.1629638671875,
        761.0896606445312
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 60 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 사용 방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        84.90937042236328,
        158.87998962402344,
        100.72968292236328
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가) OOO 디지털치료기기를 실행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        114.90937042236328,
        340.04296875,
        130.72967529296875
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나) 회원가입 및 초기 우울장애 평가를 시행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        144.9093780517578,
        420.3229675292969,
        160.7296905517578
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 초기 평가에는 최소 다음의 사항이 포함되어야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        174.9093780517578,
        476.72296142578125,
        190.7296905517578
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": 성별, 연령, 항우울제 복용 여부, 우울 증상에 대한 기초 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        204.90936279296875,
        536.1599731445312,
        220.72967529296875
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 디지털치료기기를 통한 우울과 관련된 행동의 교정을 수행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        234.90936279296875,
        546.0599975585938,
        250.72967529296875
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 내용은 과학적 근거에 기반하여야 하며, 우울장애 인지행동치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        108.23999786376953,
        264.90936279296875,
        538.5599975585938,
        280.72967529296875
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(CBT-D)를 기반으로 하였을 경우 다음 사항이 포함되어야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        108.23999786376953,
        294.90936279296875,
        532.282958984375,
        310.72967529296875
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 자극 조절법: 우울장애와 각성 자극이 연관된 상태를 해소하기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.5999984741211,
        324.90936279296875,
        546.0599975585938,
        340.72967529296875
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위한 행동 치료를 수행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        135.47999572753906,
        354.90936279296875,
        319.52294921875,
        370.72967529296875
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 우울 일기 및 동등한 수준으로 우울에 대한 평가가 가능한 도구:",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.5999984741211,
        384.90936279296875,
        546.0599975585938,
        400.72967529296875
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애에 대한 평가 및 피드백을 할 수 있게 하려면",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        135.47999572753906,
        414.90936279296875,
        546.0599975585938,
        430.72967529296875
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울에 대한 평가를 해야 하며, 우울장애 인지행동치료를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        135.47999572753906,
        444.90936279296875,
        546.0599975585938,
        460.72967529296875
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반으로 하였을 경우 일반적으로 우울장애 일기가 사용된다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        135.47999572753906,
        474.90936279296875,
        545.7000122070312,
        490.72967529296875
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라) 디지털치료기기를 통한 우울과 관련된 인지의 교정을 수행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        504.90936279296875,
        546.0599975585938,
        520.7296752929688
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 내용은 과학적 근거에 기반하여야 하며, 우울장애 인지행동",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        108.83999633789062,
        534.9093627929688,
        538.5599975585938,
        550.7296752929688
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료를 기반으로 하였을 경우 우울과 관련된 왜곡된 인지의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        108.83999633789062,
        564.9093627929688,
        545.9400024414062,
        580.7296752929688
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "교정 및 기저 불안을 줄이는 내용이 포함되어야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        108.83999633789062,
        594.9093627929688,
        480.2029724121094,
        610.7296752929688
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마) 상술한 치료의 경우 환자의 순응도를 높이기 위한 전략이 포함",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        624.9093627929688,
        538.5599975585938,
        640.7296752929688
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되어야 하며(콘텐츠 제공 방식의 다양화, 알림 제공, 보상 방안",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.31999969482422,
        654.9093627929688,
        545.9400024414062,
        670.7296752929688
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등을 포함) 환자가 입력한 정보에 따른 피드백이 제공되어야",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.31999969482422,
        684.9093627929688,
        545.9400024414062,
        700.7296752929688
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고 환자가 스스로 입력한 정보를 모니터링할 수 있도록",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.31999969482422,
        714.9093627929688,
        545.9400024414062,
        730.7296752929688
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.31999969482422,
        744.9093627929688,
        198.2029571533203,
        760.7296752929688
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 61 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8. 피험자의 선정기준·제외기준·인원 및 그 근거",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        99.09996032714844,
        437.15997314453125,
        115.0599594116211
      ],
      "page_num": 68,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 피험자의 선정·제외 기준, 인원 및 근거",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        182.51998901367188,
        288.7200012207031,
        196.91998291015625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자(Subject)란 임상시험에 참여하는 임상시험용 또는 대조시험용 의료기기의 적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.19999694824219,
        206.51998901367188,
        533.760009765625,
        220.91998291015625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상이 되는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄격한 피험자의 선정",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.31999969482422,
        230.51998901367188,
        533.760009765625,
        244.91998291015625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준과 제외 기준을 제시하여야 한다. 이 때 임상시험 참여와 연관된 이익을 기대",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.31999969482422,
        254.51998901367188,
        533.6400146484375,
        268.91998291015625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 불이익을 우려하여 자발적인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.31999969482422,
        278.5199890136719,
        533.6400146484375,
        292.91998291015625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참여 결정에 영향을 받을 소지가 있는 등 취약한 환경에 있는 피험자 (Vulnerable",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.31999969482422,
        302.5199890136719,
        533.6639404296875,
        316.91998291015625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Subjects)는 선정대상에서 제외한다. 또한, 시험군과 대조군을 포함한 피험자 수는 해당",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        82.31999969482422,
        326.5199890136719,
        533.6400146484375,
        340.91998291015625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기의 특성, 임상시험 디자인, 근거를 통한 시험에서 기대하는 연구결과의 사전",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.31999969482422,
        350.5199890136719,
        533.6400146484375,
        364.91998291015625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예측, 통계적 유의성, 검정 방법, 탈락률 등을 반영하여 통계학 적으로 타당하게 제시",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.31999969482422,
        374.5199890136719,
        533.6400146484375,
        388.91998291015625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "되어야 하며, 임상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.31999969482422,
        398.5199890136719,
        533.7000122070312,
        412.91998291015625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 피험자 수: 시험대상수 산출시 일반적인 고려사항",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        64.55999755859375,
        446.5199890136719,
        341.3999938964844,
        460.91998291015625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상연구에서 피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 수가 보장",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.19999694824219,
        470.5199890136719,
        533.6400146484375,
        484.91998291015625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "되어야 하며, 일반적으로 1차 유효성 평가변수를 기준으로 정해지고, 연구 계획서상에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.31999969482422,
        494.5199890136719,
        533.760009765625,
        508.91998291015625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정확한 피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.31999969482422,
        518.5199584960938,
        433.8599853515625,
        532.9199829101562
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 62 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        84.35431671142578,
        94.91999816894531,
        104.30548858642578
      ],
      "page_num": 69,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 피험자 선정기준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        111.54936981201172,
        195.47999572753906,
        127.36968231201172
      ],
      "page_num": 69,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ": 선정기준 모두를 만족하는 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.04000091552734,
        141.54937744140625,
        302.4599914550781,
        157.36968994140625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 만 19세 이상 성인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        171.54937744140625,
        218.87998962402344,
        187.36968994140625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) DSM-5의 주요우울장애 진단기준을 만족하거나 ICD-10의 우울",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        201.54937744140625,
        538.5599975585938,
        217.36968994140625
      ],
      "page_num": 69,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에피소드 진단(F32)을 받은 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.43999481201172,
        231.5493621826172,
        299.0400085449219,
        247.3696746826172
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 우울장애 심각도 척도(BDI-II)에서 14점 이상 점수를 가진 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        261.54937744140625,
        506.5199890136719,
        277.36968994140625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ BDI-II에서 14점 이상의 점수를 가져 mild depression 이상 수준의 임상적",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        84.95999908447266,
        289.79998779296875,
        538.43896484375,
        305.35198974609375
      ],
      "page_num": 69,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울이 있다고 판단할 수 있는 자, 혹은 이외 유사한, 과학적 근거를 가진",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        104.39999389648438,
        315.8399963378906,
        538.4402465820312,
        331.3919982910156
      ],
      "page_num": 69,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울 척도 검사상 mild depression 이상 수준의 임상적 우울이 있다고",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        104.39999389648438,
        341.8800048828125,
        538.4403076171875,
        357.4320068359375
      ],
      "page_num": 69,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "판단할 수 있는 자",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        104.39999389648438,
        367.79998779296875,
        215.760009765625,
        383.35198974609375
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 한국어를 읽고 쓰는 데 어려움이 없는 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        395.58935546875,
        376.1999816894531,
        411.40966796875
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 범용 장비(스마트폰 또는 태블릿 PC 등)를 이용하여 모바일",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        425.58935546875,
        545.9400024414062,
        441.40966796875
      ],
      "page_num": 69,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "애플리케이션을 사용하는 데에 어려움이 없는 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        455.58935546875,
        428.7599792480469,
        471.40966796875
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) 본 임상시험에 대해 충분한 설명을 듣고 이해한 후, 스스로 참여를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        485.58935546875,
        545.9400024414062,
        501.40966796875
      ],
      "page_num": 69,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결정하고 주의사항을 준수하기로 서면 동의한 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.07999420166016,
        515.58935546875,
        415.67999267578125,
        531.40966796875
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 피험자 제외기준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        569.58935546875,
        203.5800018310547,
        585.40966796875
      ],
      "page_num": 69,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ": 제외기준 중 어느 하나라도 해당하는 항목이 있는 경우 본",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.63999938964844,
        599.58935546875,
        546.0599975585938,
        615.40966796875
      ],
      "page_num": 69,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험에서 배제",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.63999938964844,
        629.58935546875,
        223.13999938964844,
        645.40966796875
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 양극성 장애 또는 조현병과 같은 심각한 정신질환을 앓고 있는 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        659.58935546875,
        535.3200073242188,
        675.40966796875
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 스크리닝 시점 3개월 이내에 자살 시도를 한 바 있으며, 정신과",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        689.58935546875,
        546.0599975585938,
        705.40966796875
      ],
      "page_num": 69,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전문의에 의해 자살 고위험군으로 판단되는 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        719.58935546875,
        413.7599792480469,
        735.40966796875
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 콜롬비아 자살 위험성 스케일(Columbia Suicide Severity Rating Scale,",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        84.95999908447266,
        747.8399658203125,
        538.5068969726562,
        763.3919677734375
      ],
      "page_num": 69,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 63 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "C-SSRS) 혹은 이와 유사한 과학적 근거를 가진 자살 위험성 평가상 자",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        104.39999389648438,
        83.15999603271484,
        538.4400024414062,
        98.71199798583984
      ],
      "page_num": 70,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "살 고위험군으로 평가되는 자",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        104.39999389648438,
        109.19999694824219,
        279.8399963378906,
        124.75199890136719
      ],
      "page_num": 70,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 스크리닝 시점 1년 동안 제대로 치료받지 못한 간질, 심각한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        136.98936462402344,
        545.9400024414062,
        152.80967712402344
      ],
      "page_num": 70,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정신질환 또는 정신과 입원 이력이 있는 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.55999755859375,
        166.98936462402344,
        397.44000244140625,
        182.80967712402344
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 스크리닝 이전 1주일 이내에 평균 알코올 섭취량이 1일 20g을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        196.98936462402344,
        546.0599975585938,
        212.80967712402344
      ],
      "page_num": 70,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "초과하는 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        226.98936462402344,
        173.87998962402344,
        242.80967712402344
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 스크리닝 시점 3개월 이내에 우울장애에 대한 다른 비약물적인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        256.9893798828125,
        546.0599975585938,
        272.8096923828125
      ],
      "page_num": 70,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료요법을 이미 받는 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.19999694824219,
        286.9893798828125,
        260.2799987792969,
        302.8096923828125
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) 최근 1개월 이내 사용하는 신경정신과 관련 약물의 종류 및 용량에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        316.9893798828125,
        545.9400024414062,
        332.8096923828125
      ],
      "page_num": 70,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변화가 있는 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.07999420166016,
        346.9893798828125,
        192.47999572753906,
        362.8096923828125
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 최근 1개월 이내 (필요시 처방을 포함하여) 복용 약물의 종류 및 용량이",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        84.95999908447266,
        375.1199951171875,
        538.4400024414062,
        390.6719970703125
      ],
      "page_num": 70,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같으면 배제기준에 해당하지 않는다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        104.39999389648438,
        401.1600036621094,
        322.01519775390625,
        416.7120056152344
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7) 기타 사유로 인하여 시험자가 임상시험 참여에 부적합하다고",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        428.9493713378906,
        546.0599975585938,
        444.7696838378906
      ],
      "page_num": 70,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "판단한 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        458.9493713378906,
        158.87998962402344,
        474.7696838378906
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 피험자 선정기준 및 제외기준은 의료기기의 특성, 내용 구성 등을",
      "font_size": 15.0,
      "font_name": "T11",
      "bbox": [
        60.0,
        512.8800048828125,
        538.4400024414062,
        530.8800048828125
      ],
      "page_num": 70,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려하여 적절한 기준을 설정함",
      "font_size": 15.0,
      "font_name": "T11",
      "bbox": [
        82.43999481201172,
        542.8800048828125,
        299.8800048828125,
        560.8800048828125
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 64 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 목표대상자 수 및 그 근거",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        263.15997314453125,
        100.72968292236328
      ],
      "page_num": 71,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자 수는 임상시험 방법에 따라 식약처의 ‘의료기기 임상시험 관련 통계기법",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.55999755859375,
        121.80000305175781,
        533.6400146484375,
        136.1999969482422
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인’을 참고하여 임상시험 피험자 수 산출 방식을 적용한다. 피험자 수를 결정",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        141.0,
        533.760009765625,
        155.39999389648438
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하기 위해서는 사전 정보가 필요한데, 여기에 포함되어야 할 필수 정보로는 다음이 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        160.1999969482422,
        531.7799682617188,
        174.59999084472656
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 연구가설",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.5199966430664,
        179.39999389648438,
        137.8800048828125,
        193.79998779296875
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 유의수준",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        74.5199966430664,
        198.59999084472656,
        137.8800048828125,
        212.99998474121094
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 통계적 검정 방법",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.5199966430664,
        217.79998779296875,
        185.87998962402344,
        232.19998168945312
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 사용될 통계적 분석 방법(즉, 연구디자인과도 관련)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.5199966430664,
        237.0,
        369.73199462890625,
        251.39999389648438
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이(및 표준편차)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.5199966430664,
        256.1999816894531,
        456.73199462890625,
        270.5999755859375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        322.7943115234375,
        94.91999816894531,
        342.7454833984375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 목표 대상자 수: 총 110명 (군당 55명)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        350.109375,
        352.2074890136719,
        365.9296875
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 본 가이드라인에 작성된 산출 방법은 공개된 선행연구 결과를 기반으로",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        98.63999938964844,
        378.3599853515625,
        538.4396362304688,
        393.9119873046875
      ],
      "page_num": 71,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "작성된 예시이며, 목표 대상자 수는 개발 제품 특성과 탐색 임상시험 등",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        118.19999694824219,
        404.2799987792969,
        538.4400024414062,
        419.8320007324219
      ],
      "page_num": 71,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품별 선행연구 결과에 따라 다르므로, 개발 제품의 선행연구 결과",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        118.19999694824219,
        430.32000732421875,
        538.4400634765625,
        445.87200927734375
      ],
      "page_num": 71,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 참고문헌을 기준으로 산출한다. 이때, 그 근거(가설, 변수, 성공",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        118.19999694824219,
        456.3599853515625,
        538.4395141601562,
        471.9119873046875
      ],
      "page_num": 71,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기준)를 함께 제시하여야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        118.19999694824219,
        482.2799987792969,
        307.4952087402344,
        497.8320007324219
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 목표 대상자 수 산정의 추정 공식 예시",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        536.109375,
        361.1999816894531,
        551.9296875
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 일차목적 및 가설",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        566.109375,
        235.44000244140625,
        581.9296875
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 시험의 일차목적: 우울장애 진단환자의 우울장애 심각도",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        596.109375,
        545.9400024414062,
        611.9296875
      ],
      "page_num": 71,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "척도(BDI) 변화량이 대조군과 비교해 시험군에서 치료 전과",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        626.109375,
        546.0599975585938,
        641.9296875
      ],
      "page_num": 71,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비교하여 우월하게 개선되는 것을 확증하는 것이다. 변화량은",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        656.109375,
        546.0599975585938,
        671.9296875
      ],
      "page_num": 71,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료 시작 전 평가지표 Baseline 조사에서 수집한 정보와 대비",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        686.109375,
        538.5599975585938,
        701.9296875
      ],
      "page_num": 71,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여 치료 종료 후(Post-treatment) 수집한 정보와의 차이를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        716.109375,
        545.9400024414062,
        731.9296875
      ],
      "page_num": 71,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의미하며, 이에 대한 가설은 아래와 같다. 이 가설의 평균 차이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        746.109375,
        545.9400024414062,
        761.9296875
      ],
      "page_num": 71,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 65 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검정에서 통계학적으로 유의하면 임상시험 성공으로 평가한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        84.90937042236328,
        536.3629760742188,
        100.72968292236328
      ],
      "page_num": 72,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "    ",
      "font_size": 10.199999809265137,
      "font_name": "HyhwpEQ",
      "bbox": [
        216.20489501953125,
        145.0682830810547,
        407.8427429199219,
        164.50827026367188
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "    ≠",
      "font_size": 10.199999809265137,
      "font_name": "HyhwpEQ",
      "bbox": [
        216.20489501953125,
        145.0682830810547,
        407.8427429199219,
        164.50827026367188
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": 시험군의 치료 전 대비 post-treatment 후 평균 우울장애 심각도",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        77.15999603271484,
        208.38937377929688,
        545.9400024414062,
        226.67202758789062
      ],
      "page_num": 72,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "척도(BDI) 변화량",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.43999481201172,
        241.38937377929688,
        215.39999389648438,
        257.2096862792969
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": 대조군의 치료 전 대비 post-treatment 후 평균 우울장애 심각도",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        77.15999603271484,
        271.5093688964844,
        545.9400024414062,
        289.91204833984375
      ],
      "page_num": 72,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "척도(BDI) 변화량",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.43999481201172,
        304.6293640136719,
        215.39999389648438,
        320.4496765136719
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "19세 이상 우울장애 환자를 대상으로 한 국외 인터넷 기반",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        358.6293640136719,
        546.0599975585938,
        374.4496765136719
      ],
      "page_num": 72,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애 인지행동치료(Web-based CBT-D) 선행 연구를 검토한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        388.6293640136719,
        546.0599975585938,
        404.4496765136719
      ],
      "page_num": 72,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과, 대조군 대비 인터넷 기반 우울장애 인지행동치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        418.6293640136719,
        538.5599975585938,
        434.4496765136719
      ],
      "page_num": 72,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Web-based CBT-D)의 치료 전 대비 Post-treatment 후 우울장애",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        448.6293640136719,
        546.0599975585938,
        464.4496765136719
      ],
      "page_num": 72,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "심각도 척도(BDI)의 effect size는 0.65, 1.17로 조사되었다. 이에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        478.6293640136719,
        545.9400024414062,
        494.4496765136719
      ],
      "page_num": 72,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 연구에서의 예상되는 effect size는 보수적으로 조사된 결과",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        508.62933349609375,
        546.0599975585938,
        524.4496459960938
      ],
      "page_num": 72,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중 작은 수치에 해당하는 0.65로 정하고자 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        538.6293334960938,
        452.0999755859375,
        554.4496459960938
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 66 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선행연구",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        99.1199951171875,
        127.55998992919922,
        410.998291015625,
        150.3599853515625
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "군",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        99.1199951171875,
        127.55998992919922,
        410.998291015625,
        150.3599853515625
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        99.1199951171875,
        127.55998992919922,
        410.998291015625,
        150.3599853515625
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "BDI 변화량1)",
      "font_size": 7.679999828338623,
      "font_name": "T10",
      "bbox": [
        99.1199951171875,
        127.55998992919922,
        410.998291015625,
        150.3599853515625
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Effect size2)",
      "font_size": 7.679999828338623,
      "font_name": "T10",
      "bbox": [
        462.8399963378906,
        135.0,
        530.7582397460938,
        150.3599853515625
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Mean",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        321.239990234375,
        143.39999389648438,
        422.7959899902344,
        157.79998779296875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SD",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        321.239990234375,
        143.39999389648438,
        422.7959899902344,
        157.79998779296875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Meyer et al.(2009)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.43999481201172,
        170.63999938964844,
        172.2119903564453,
        185.0399932861328
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CBTi",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        204.83999633789062,
        160.67999267578125,
        428.2799987792969,
        175.07998657226562
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "159",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        204.83999633789062,
        160.67999267578125,
        428.2799987792969,
        175.07998657226562
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6.85",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        204.83999633789062,
        160.67999267578125,
        428.2799987792969,
        175.07998657226562
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10.99",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        204.83999633789062,
        160.67999267578125,
        428.2799987792969,
        175.07998657226562
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0.65",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        486.47998046875,
        170.63999938964844,
        507.47998046875,
        185.0399932861328
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "WL",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        208.9199981689453,
        180.47999572753906,
        428.2799987792969,
        194.87998962402344
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "57",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        208.9199981689453,
        180.47999572753906,
        428.2799987792969,
        194.87998962402344
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-0.04",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        208.9199981689453,
        180.47999572753906,
        428.2799987792969,
        194.87998962402344
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9.54",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        208.9199981689453,
        180.47999572753906,
        428.2799987792969,
        194.87998962402344
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Vernmark et al.(2010)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        67.43999481201172,
        210.239990234375,
        181.0919952392578,
        224.63998413085938
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CBTi",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        204.83999633789062,
        200.39999389648438,
        428.2799987792969,
        214.79998779296875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "30",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        204.83999633789062,
        200.39999389648438,
        428.2799987792969,
        214.79998779296875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "11.90",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        204.83999633789062,
        200.39999389648438,
        428.2799987792969,
        214.79998779296875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5.25",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        204.83999633789062,
        200.39999389648438,
        428.2799987792969,
        214.79998779296875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1.17",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        486.47998046875,
        210.239990234375,
        507.47998046875,
        224.63998413085938
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "WL",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        208.9199981689453,
        220.1999969482422,
        428.2799987792969,
        234.59999084472656
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "29",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        208.9199981689453,
        220.1999969482422,
        428.2799987792969,
        234.59999084472656
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.48",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        208.9199981689453,
        220.1999969482422,
        428.2799987792969,
        234.59999084472656
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7.34",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        208.9199981689453,
        220.1999969482422,
        428.2799987792969,
        234.59999084472656
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) BDI 변화량 = Baseline 시점의 BDI 점수 – Post-treatment 시점의 BDI 점수",
      "font_size": 9.960000038146973,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        237.83998107910156,
        473.3999938964844,
        262.87200927734375
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) Effect size = (시험군의 평균 BDI 변화량 –대조군의 평균 BDI 변화량) / 합동표준편차",
      "font_size": 9.960000038146973,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        237.83998107910156,
        473.3999938964844,
        262.87200927734375
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 14. 치료 전 대비 Post-treatment 후 우울장애 심각도 척도(BDI) 변화량",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        82.31999969482422,
        86.04000091552734,
        516.720458984375,
        101.59200286865234
      ],
      "page_num": 73,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비교결과",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        304.67999267578125,
        105.47999572753906,
        355.6801452636719,
        121.03199768066406
      ],
      "page_num": 73,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 연구에서는 가설의 평균 변화량 차이 검정에 대해 최소",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        341.4693603515625,
        545.9400024414062,
        357.2896728515625
      ],
      "page_num": 73,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요한 피험자 수를 산출하기 위해 effect size는 0.65를 가정",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        371.4693603515625,
        538.5599975585938,
        387.2896728515625
      ],
      "page_num": 73,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하였고, 양측 유의수준 5%, 검정력 80%를 만족하는 데 필요한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        401.4693603515625,
        545.9400024414062,
        417.2896728515625
      ],
      "page_num": 73,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자 수(군당 1:1 배정)를 산출한 결과, 한 군당 38명이었다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        431.4693603515625,
        546.0599975585938,
        447.2896728515625
      ],
      "page_num": 73,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이에 중도 탈락을 30%를 고려하여 목표 피험자 수는 총 110명",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        461.4693603515625,
        538.5599975585938,
        477.2896728515625
      ],
      "page_num": 73,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(군당 55명)으로 결정하였다. 두 군의 평균 차이 검정에 대한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        491.4693603515625,
        545.9400024414062,
        507.2896728515625
      ],
      "page_num": 73,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자 수 산출 공식은 아래와 같다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        521.4693603515625,
        365.48297119140625,
        537.2896728515625
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 기존 CBTi 연구에서는 병원 방문 없이 온라인 수집으로만",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        551.4693603515625,
        545.9400024414062,
        567.2896728515625
      ],
      "page_num": 73,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한 경우 40% 정도의 중도 탈락을 보였다. 그러나, 본",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        151.9199981689453,
        581.4693603515625,
        545.9400024414062,
        597.2896728515625
      ],
      "page_num": 73,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구에서는 병원 방문으로 이보다는 더 적게 탈락할 것",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        151.9199981689453,
        611.4693603515625,
        538.4400024414062,
        627.2896728515625
      ],
      "page_num": 73,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 예상하여 30%로 정하고자 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        151.9199981689453,
        641.4693603515625,
        407.2429504394531,
        657.2896728515625
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": " ",
      "font_size": 59.3115234375,
      "font_name": "HyhwpEQ",
      "bbox": [
        171.1199951171875,
        717.5882568359375,
        317.181884765625,
        746.0282592773438
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "",
      "font_size": 10.199999809265137,
      "font_name": "HyhwpEQ",
      "bbox": [
        171.1199951171875,
        717.5882568359375,
        317.181884765625,
        746.0282592773438
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "     ",
      "font_size": 10.199999809265137,
      "font_name": "HyhwpEQ",
      "bbox": [
        202.1999969482422,
        702.1119995117188,
        315.7799987792969,
        723.9482421875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "",
      "font_size": 58.88851547241211,
      "font_name": "HyhwpEQ",
      "bbox": [
        319.67999267578125,
        717.5882568359375,
        451.9552307128906,
        746.0282592773438
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "",
      "font_size": 10.199999809265137,
      "font_name": "HyhwpEQ",
      "bbox": [
        319.67999267578125,
        717.5882568359375,
        451.9552307128906,
        746.0282592773438
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": " ",
      "font_size": 10.199999809265137,
      "font_name": "HyhwpEQ",
      "bbox": [
        338.6399841308594,
        705.3519897460938,
        450.5400085449219,
        723.5882568359375
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": " ",
      "font_size": 15.0,
      "font_name": "HyhwpEQ",
      "bbox": [
        454.44000244140625,
        717.5882568359375,
        504.05999755859375,
        733.3082885742188
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 67 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ": 한 군당 필요한 피험자 수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        117.23999786376953,
        85.14937591552734,
        318.239990234375,
        100.96968841552734
      ],
      "page_num": 74,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ": 제1종 오류 0.05 (유의수준)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        117.23999786376953,
        115.14936828613281,
        324.9674987792969,
        130.9696807861328
      ],
      "page_num": 74,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ": 제2종 오류 0.20",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        117.23999786376953,
        145.1493682861328,
        246.5399932861328,
        160.9696807861328
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": 군간 예상되는 effect size",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        117.23999786376953,
        175.1493682861328,
        313.4915466308594,
        190.9696807861328
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 본 임상시험의 경우 임상시험 설계 시 중도 탈락율은 약 10∼30%",
      "font_size": 12.960000038146973,
      "font_name": "T18",
      "bbox": [
        99.95999908447266,
        233.1599884033203,
        538.5162963867188,
        248.7119903564453
      ],
      "page_num": 74,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "범위로 고려할 것을 권고한다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        119.39999389648438,
        259.20001220703125,
        301.7351989746094,
        274.75201416015625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 68 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        246.35430908203125,
        94.91999816894531,
        266.30548095703125
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자의 모집 기간, 임상 관찰 및 수행 기간, 통계분석 기간, 결과",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        273.54937744140625,
        538.4400024414062,
        289.36968994140625
      ],
      "page_num": 75,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보고서 작성 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        303.54937744140625,
        546.0599975585938,
        319.36968994140625
      ],
      "page_num": 75,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려하도록 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        333.54937744140625,
        168.68296813964844,
        349.36968994140625
      ],
      "page_num": 75,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 식품의약품안전처의 임상 계획 승인일로부터 00개월",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        363.54937744140625,
        461.2799987792969,
        379.36968994140625
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 대상자 모집 기간: 00개월",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        393.54937744140625,
        277.91998291015625,
        409.36968994140625
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 임상시험 수행 기간: 00개월",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        423.54937744140625,
        292.91998291015625,
        439.36968994140625
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 통계처리 및 결과보고서 작성 기간: 00개월",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        453.54937744140625,
        397.79998779296875,
        469.36968994140625
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9. 임상시험기간",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        93.4599609375,
        181.1994171142578,
        109.41996002197266
      ],
      "page_num": 75,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자의 모집 기간, 임상 관찰 및 시험 수행 기간, 통계 처리 기간, 결과보고서 작성 기간,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.47999572753906,
        146.87998962402344,
        530.83203125,
        161.2799835205078
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험심사위원회 심사 기간 등 충분한 기간을 고려하여 “식품의약품안전처의 임상 계획",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        170.87998962402344,
        530.8800048828125,
        185.2799835205078
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "승인일로부터 OO 개월”로 표시하고 근거자료를 제출한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        194.87998962402344,
        361.739990234375,
        209.2799835205078
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 69 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        263.6343078613281,
        94.91999816894531,
        283.5854797363281
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 시험방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        290.8293762207031,
        150.66000366210938,
        306.6496887207031
      ],
      "page_num": 76,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 시험기기 및 대조기기 정보",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        320.8293762207031,
        278.7599792480469,
        336.6496887207031
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 시험기기: 디지털 우울장애 인지행동치료 애플리케이션",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        350.8293762207031,
        487.44000244140625,
        366.6496887207031
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(예) 무작위배정 이후, 8주 동안 치료 기간이 종결된 직후에 방문",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        108.47999572753906,
        380.8293762207031,
        538.4400024414062,
        396.6496887207031
      ],
      "page_num": 76,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Post-treatment)하여 임상 평가를 받고, 디지털 우울장애 인지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        108.47999572753906,
        410.8293762207031,
        538.5599975585938,
        426.6496887207031
      ],
      "page_num": 76,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "행동치료를 처방받아 치료를 수행하는 군(Conal et al., 2020)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        108.47999572753906,
        440.8293762207031,
        515.887451171875,
        456.6496887207031
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 대조기기: 위약 대조군(sham)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        470.8293762207031,
        313.1399841308594,
        486.6496887207031
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(예) 우울 일기기능과 기록 알림 기능만 탑재된 애플리케이션 등",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        108.23999786376953,
        500.829345703125,
        535.4400024414062,
        516.649658203125
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 단, 본 연구에서는 연구설계에 따라 비처치대조군(wait-list)*의 적용도",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        98.63999938964844,
        528.1199340820312,
        538.4400024414062,
        544.6319580078125
      ],
      "page_num": 76,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능하다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        118.19999694824219,
        555.1199951171875,
        173.335205078125,
        570.6719970703125
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 비처치대조군: 치료 기간 동안 아무런 처치를 받지 않고 대기하는 군",
      "font_size": 12.960000038146973,
      "font_name": "T18",
      "bbox": [
        123.5999984741211,
        581.1599731445312,
        538.4400024414062,
        596.7119750976562
      ],
      "page_num": 76,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이다. 다만, 맹검을 유지하는 수준의 최소한 치료가 제공되어야 하며,",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        135.0,
        607.0799560546875,
        538.5081787109375,
        622.6319580078125
      ],
      "page_num": 76,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이에는 과학적인 근거가 있어야 한다. 우울장애 인지행동치료를 기반으로 한",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        135.0,
        633.1199340820312,
        538.4400024414062,
        648.6719360351562
      ],
      "page_num": 76,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디지털치료기기의 경우 서면 형태로 된 우울장애 교육 자료 등이 이에",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        135.0,
        659.1599731445312,
        538.439697265625,
        674.7119750976562
      ],
      "page_num": 76,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당한다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        135.0,
        685.0799560546875,
        190.13519287109375,
        700.6319580078125
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 우울장애 개선 디지털치료기기 허가제품이 출시된 이후에는 기허가",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        98.63999938964844,
        711.1199340820312,
        538.4400024414062,
        726.6719360351562
      ],
      "page_num": 76,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품과 비교시험 하는 동등성 검정 혹은 비열등성 검정 등을 시행하여",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        118.19999694824219,
        737.1599731445312,
        538.43896484375,
        752.7119750976562
      ],
      "page_num": 76,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10. 임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)",
      "font_size": 14.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        93.4599609375,
        490.3258361816406,
        109.41996002197266
      ],
      "page_num": 76,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 방법은 해당 의료기기에 대한 모양, 구조 및 사용 전 준비사항/피험자에 대한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        77.87999725341797,
        144.36000061035156,
        532.7999877929688,
        158.75999450683594
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각 단계별 조작 순서, 병용 요법",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        66.5999984741211,
        168.36000061035156,
        532.7999877929688,
        182.75999450683594
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "등을 기술한다. 임상시험을 위한 피험자 동의 및 준비, 치료절차, 관찰 및 평가 절차 등을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        66.5999984741211,
        192.36000061035156,
        532.7999877929688,
        206.75999450683594
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상세히 시험방법을 기술한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        66.5999984741211,
        216.36000061035156,
        217.6199951171875,
        230.75999450683594
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 70 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 77,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 성능을 증명할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        118.19999694824219,
        83.15999603271484,
        290.2152099609375,
        98.71199798583984
      ],
      "page_num": 77,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "* 비열등성/동등성 시험(Non-inferiority, equivalence trial): 비교 연구에 있어",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        136.44000244140625,
        109.19999694824219,
        538.4396362304688,
        124.75199890136719
      ],
      "page_num": 77,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대조기기와 비교해 시험기기의 성능이 열등하지 않음을 보이거나,",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        148.3199920654297,
        135.83999633789062,
        538.5081787109375,
        151.39199829101562
      ],
      "page_num": 77,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동등함을 보이는 연구시험이다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        148.3199920654297,
        162.47999572753906,
        333.4151916503906,
        178.03199768066406
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 디지털치료기기 치료 기간: 총 8주",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        217.50936889648438,
        335.3399963378906,
        233.32968139648438
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 총 4회의 외래 방문을 통한 조사: 방문 1(Screening), 방문",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        248.2293701171875,
        545.9400024414062,
        264.0496826171875
      ],
      "page_num": 77,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2(Baseline), 방문 3(Post-treatment), 방문 4(Follow-up, 3개월 후)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        279.0693664550781,
        531.7274780273438,
        294.8896789550781
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 방문 4(Follow-up, 3개월 후)는 필요시 애플리케이션, 이메일, 문자,",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        98.63999938964844,
        308.0400085449219,
        538.5081787109375,
        323.5920104980469
      ],
      "page_num": 77,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "SNS 등을 통해 수집할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        118.19999694824219,
        334.67999267578125,
        309.2951965332031,
        350.23199462890625
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 층화무작위배정: 기관별 성별(남/여), 연령(oo세 미만, oo세 이상)을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        363.0693664550781,
        545.9400024414062,
        378.8896789550781
      ],
      "page_num": 77,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "층화하여 층내 시험군, 대조군 1:1 배정",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.9199981689453,
        393.78936767578125,
        479.3999938964844,
        409.60968017578125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 시험 방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        424.6293640136719,
        158.87998962402344,
        440.4496765136719
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 스크리닝, 선정·제외 기준 확인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        455.349365234375,
        330.3599853515625,
        471.169677734375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 기관별로 내원한 환자 중 선정, 제외 기준에 따라 적합한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        486.0693664550781,
        546.0599975585938,
        501.8896789550781
      ],
      "page_num": 77,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구 군을 선별한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        516.9093627929688,
        258.5629577636719,
        532.7296752929688
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 피험자 동의 및 준비",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        547.6293334960938,
        251.27999877929688,
        563.4496459960938
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        578.349365234375,
        546.0599975585938,
        594.169677734375
      ],
      "page_num": 77,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용을 피험자 본인 또는 대리인에게 설명하고, 피험자 또는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        609.1893310546875,
        545.9400024414062,
        625.0096435546875
      ],
      "page_num": 77,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대리인이 내용을 잘 이해한 것을 확인한 다음, 자유의사에 따른",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        639.9093627929688,
        546.0599975585938,
        655.7296752929688
      ],
      "page_num": 77,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 참가의 동의를 문서로 받는다. 또한 동의에 서명한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        670.6293334960938,
        545.9400024414062,
        686.4496459960938
      ],
      "page_num": 77,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연월일을 기록하며, 동의서 사본을 환자에게 제공하여 환자가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        701.4693603515625,
        545.9400024414062,
        717.2896728515625
      ],
      "page_num": 77,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지속해서 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        732.1893310546875,
        538.282958984375,
        748.0096435546875
      ],
      "page_num": 77,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 71 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 78,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다) 인구학적 조사, 병력조사 요법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        84.90937042236328,
        315.3599853515625,
        100.72968292236328
      ],
      "page_num": 78,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        114.90937042236328,
        545.9400024414062,
        130.72967529296875
      ],
      "page_num": 78,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등에 대하여 차트 확인 및 애플리케이션 내 질문 등을 통하여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        144.9093780517578,
        545.9400024414062,
        160.7296905517578
      ],
      "page_num": 78,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "점검하고 증례 기록서에 기록한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        174.9093780517578,
        350.60296630859375,
        190.7296905517578
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 인구학적 정보: 성별, 연령, 직업, 업무 생산성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.5999984741211,
        204.90936279296875,
        452.03997802734375,
        220.72967529296875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 병력조사: 동반 질환 여부",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.5999984741211,
        234.90936279296875,
        312.47998046875,
        250.72967529296875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 병용약물: 복용 여부 및 종류",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.5999984741211,
        264.90936279296875,
        335.03997802734375,
        280.72967529296875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 피험자 식별코드 부여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        294.90936279296875,
        258.8399963378906,
        310.72967529296875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 피험자에게 서명하고 동의를 받은 후 동의 취득 순서에 따라",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.5999984741211,
        324.90936279296875,
        545.9400024414062,
        340.72967529296875
      ],
      "page_num": 78,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "스크리닝 번호를 부여하며 피험자가 참여를 종료할 때까지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        136.0800018310547,
        354.90936279296875,
        545.9400024414062,
        370.72967529296875
      ],
      "page_num": 78,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자 식별코드를 부여한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        136.0800018310547,
        384.90936279296875,
        335.0029602050781,
        400.72967529296875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 피험자 적합성 평가: 피험자 선정 및 제외 기준에 적합한지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.5999984741211,
        414.90936279296875,
        546.0599975585938,
        430.72967529296875
      ],
      "page_num": 78,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        135.83999633789062,
        444.90936279296875,
        198.56295776367188,
        460.72967529296875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 피험자 식별코드는 아래의 방법에 따라 기입한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.5999984741211,
        474.90936279296875,
        470.0029602050781,
        490.72967529296875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 피험자 식별코드: 실시기관 코드 - 등록된 순",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        140.87998962402344,
        503.1600036621094,
        421.91998291015625,
        518.7119750976562
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마) 외래 방문마다 유효성 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        530.9493408203125,
        296.2799987792969,
        546.7696533203125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 일차와 이차 유효성 평가 관련된 목록을 작성한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        560.9493408203125,
        461.84295654296875,
        576.7696533203125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 일차 유효성 평가지표: 한국판 우울장애 심각도 척도 제2판(BDI-II)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.5999984741211,
        590.9493408203125,
        533.7675170898438,
        606.7696533203125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 일차 유효성 평가지표로는 우울장애의 증상 개선을 확인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        620.9493408203125,
        538.5599975585938,
        636.7696533203125
      ],
      "page_num": 78,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고자 하는 연구에서 널리 사용되고 있는 우울장애 심각도 척도",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        144.59999084472656,
        650.9493408203125,
        545.9400024414062,
        666.7696533203125
      ],
      "page_num": 78,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제2판(Beck Depression Inventory, BDI-II)를 이용하도록 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        144.59999084472656,
        680.9493408203125,
        518.1229858398438,
        696.7696533203125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 필요하면 과학적인 근거를 가진 기타 우울에 대한 주관적 보고",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        710.9493408203125,
        546.0599975585938,
        726.7696533203125
      ],
      "page_num": 78,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "척도로 대체할 수 있다(e.g. Patient Health Questionnaire-9, PHQ-9).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        142.67999267578125,
        740.9493408203125,
        536.1229858398438,
        756.7696533203125
      ],
      "page_num": 78,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 72 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 79,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 이차 유효성 평가지표",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.5999984741211,
        84.90937042236328,
        280.0799865722656,
        100.72968292236328
      ],
      "page_num": 79,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 일차 유효성 평가지표를 통해 유효성을 검증하는 것이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        114.90937042236328,
        546.0599975585938,
        130.72967529296875
      ],
      "page_num": 79,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기본적인 원칙이지만, 이외 필요하면 변수를 이차 유효성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        145.55999755859375,
        144.9093780517578,
        545.9400024414062,
        160.7296905517578
      ],
      "page_num": 79,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가지표로 사용할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        145.55999755859375,
        174.9093780517578,
        336.4429626464844,
        190.7296905517578
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 과학적인 근거를 가진 변수이되, 기존 우울 증상 개선 시",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        204.90936279296875,
        545.9400024414062,
        220.72967529296875
      ],
      "page_num": 79,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함께 개선될 수 있다고 여겨진 영역에 한정한다(우울장애",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        144.59999084472656,
        234.90936279296875,
        545.9400024414062,
        250.72967529296875
      ],
      "page_num": 79,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개선, 삶의 질, 직업적 혹은 사회적 기능, 우울과 불안을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        144.59999084472656,
        264.90936279296875,
        545.9400024414062,
        280.72967529296875
      ],
      "page_num": 79,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함한 정신건강의학과적 증상 등)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        144.59999084472656,
        294.90936279296875,
        380.7674865722656,
        310.72967529296875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 관찰 시기를 표기한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        324.90936279296875,
        296.60296630859375,
        340.72967529296875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 방문 2(Baseline), 방문 3(Post-treatment,), 방문 4",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        144.95999145507812,
        354.90936279296875,
        546.0599975585938,
        370.72967529296875
      ],
      "page_num": 79,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Follow-up, 3개월 후)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        159.95999145507812,
        384.90936279296875,
        306.9674987792969,
        400.72967529296875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "측정도구",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        105.23999786376953,
        455.03997802734375,
        379.0799865722656,
        469.4399719238281
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        105.23999786376953,
        455.03997802734375,
        379.0799865722656,
        469.4399719238281
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "우울장애 선별 도구",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.43999481201172,
        507.1199951171875,
        184.44000244140625,
        521.52001953125
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Patient Health",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        91.55999755859375,
        526.3200073242188,
        169.18800354003906,
        540.7200317382812
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Questionnaire-9, PHQ-9)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        545.5199584960938,
        196.2119903564453,
        559.9199829101562
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PHQ-9은 다른 우울장애 평가척도와 유의한 공존 타당도를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        478.3199768066406,
        527.760009765625,
        492.719970703125
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나타내고 우울장애를 평가하고 선별하는 척도로써 신뢰도와",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        497.5199890136719,
        527.760009765625,
        511.91998291015625
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "타당도가 입증되었다. PHQ-9의 경우 기존 우울장애 평가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        516.719970703125,
        527.760009765625,
        531.1199951171875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "도구보다 문항 수가 적고 작성 시간이 적게 걸려 일차 진료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        535.9199829101562,
        527.8800048828125,
        550.3200073242188
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "과정에서도 적용하기 쉬워 우울장애를 선별하는데 유용한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        555.1199951171875,
        527.760009765625,
        569.52001953125
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "도구이다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        574.3200073242188,
        257.4599914550781,
        588.7200317382812
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 15. 우울장애 이차 유효성 평가 지표 측정도구 예시",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        124.79999542236328,
        432.0,
        466.9205627441406,
        447.552001953125
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 73 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 80,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정도구",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        105.23999786376953,
        87.47999572753906,
        379.0799865722656,
        101.87999725341797
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        105.23999786376953,
        87.47999572753906,
        379.0799865722656,
        101.87999725341797
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "몽고메리-아스버그",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        79.31999969482422,
        165.59999084472656,
        181.55999755859375,
        179.99998474121094
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "우울장애 척도",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        91.43999481201172,
        184.8000030517578,
        169.44000244140625,
        199.1999969482422
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Montgomery-˚Asberg",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        73.68000030517578,
        204.0,
        187.06800842285156,
        218.39999389648438
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Depression Rating",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        81.95999908447266,
        223.1999969482422,
        178.7880096435547,
        237.59999084472656
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Scale, MADRS)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        89.15999603271484,
        242.39999389648438,
        171.6119842529297,
        256.79998779296875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MADRS는 우울장애를 측정하는 문항 총 10개로 구성되어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        117.59999084472656,
        527.760009765625,
        131.99998474121094
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있다. 문항은 겉으로 드러나는 슬픔, 스스로 보고하는 슬픔,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        136.8000030517578,
        527.7120361328125,
        151.1999969482422
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내적 긴장감, 수면저하, 식욕 저하, 집중의 어려움, 나태(권태),",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        156.0,
        527.83203125,
        170.39999389648438
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "느낌의 상실, 비관적 사고, 자살 사고와 같은 특징적인 우울",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        175.1999969482422,
        527.760009765625,
        189.59999084472656
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장애에 관한 것이다. 이들 문항 중 10개는 증상이 없는 것",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        194.39999389648438,
        527.760009765625,
        208.79998779296875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에서 증가하여 심각도 수준(0~6)도 구성되어 있다. 점수는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        213.59999084472656,
        527.760009765625,
        227.99998474121094
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최대 60점이 나오고 점수가 높을수록 우울장애가 심각함을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        232.79998779296875,
        527.760009765625,
        247.19998168945312
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나타낸다. 현재 MADRS에 대한 우울 점수에 따라, 정상(0~7점),",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        252.0,
        527.83203125,
        266.3999938964844
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경미(8~15점), 중간(16~25점), 심각(26~30점), 매우 심각(31점",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        271.1999816894531,
        527.760009765625,
        285.5999755859375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이상)을 나타낸다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        290.3999938964844,
        302.82000732421875,
        304.79998779296875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해밀톤 우울장애 척도",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.43999481201172,
        341.3999938964844,
        190.44000244140625,
        355.79998779296875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Hamilton Depression",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.15999603271484,
        360.6000061035156,
        186.58799743652344,
        375.0
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Rating Scale, HDRS)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.27999877929688,
        379.79998779296875,
        186.6119842529297,
        394.1999816894531
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HDRS는 우울장애와 관련된 증상을 총 17문항으로 구성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        331.79998779296875,
        527.760009765625,
        346.1999816894531
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "되었다. 전체 문항 점수를 합산하며, 11점 이하는 우울하지",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        351.0,
        527.760009765625,
        365.3999938964844
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "않음, 11~16점은 경미한 우울, 17~25점은 중등도 우울, 26점",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        370.1999816894531,
        527.760009765625,
        384.5999755859375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이상은 심한 우울장애로 구분한다.",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        206.51998901367188,
        389.3999938964844,
        398.7167663574219,
        403.79998779296875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "역학용 우울 척도",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.43999481201172,
        436.44000244140625,
        178.44000244140625,
        450.8399963378906
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(The Center for",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        92.5199966430664,
        455.6399841308594,
        168.239990234375,
        470.03997802734375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Epidemiological Studies",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        73.68000030517578,
        474.8399963378906,
        187.1999969482422,
        489.239990234375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Depression Scale, CES-D)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        65.04000091552734,
        494.03997802734375,
        195.73199462890625,
        508.4399719238281
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CES-D는 총 20개 문항으로 우울 정서, 긍정적 정서, 신체적",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        426.8399963378906,
        527.760009765625,
        441.239990234375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증상 및 둔화된 행동, 대인관계 요인 4개로 구성되었다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        446.03997802734375,
        527.7000122070312,
        460.4399719238281
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CES-D는 18세 이상 65세 이하 성인에게 적용 가능하며, 5,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        465.239990234375,
        527.83203125,
        479.6399841308594
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10, 15번은 긍정 질문으로 역 채점하여 총점을 산출한다. 원래",
      "font_size": 12.0,
      "font_name": "T18",
      "bbox": [
        206.51998901367188,
        484.44000244140625,
        527.760009765625,
        498.8399963378906
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CES-D는 16점을 절단 점수로 사용한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        503.6400146484375,
        427.739990234375,
        518.0400390625
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "쯍 우울 척도",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        94.43999481201172,
        573.8399658203125,
        166.44000244140625,
        588.239990234375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Zung’s Self-Rating",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        79.08000183105469,
        593.0399780273438,
        181.66799926757812,
        607.4400024414062
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Depression Scale, SDS)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        66.1199951171875,
        612.239990234375,
        194.65199279785156,
        626.6400146484375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SDS는 긍정 문항 10개, 부정 문항 10개 총 20개의 문항에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        545.0399780273438,
        527.760009765625,
        559.4400024414062
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대해 4점 척도로 응답하도록 구성되어 있다. 일반인을 대상",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        564.239990234375,
        527.760009765625,
        578.6400146484375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "으로 우울장애를 선별하고자 할 때 적용 가능하며, 채점은",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        583.4400024414062,
        527.760009765625,
        597.8400268554688
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "문항 점수를 합산한다. SDS에서 50점 이상은 경미, 60점",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        602.6400146484375,
        527.760009765625,
        617.0400390625
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이상은 중증도, 70점 이상을 고도의 심각성으로 분류할 것을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        621.8399658203125,
        527.760009765625,
        636.239990234375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제한하였다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        641.0399780273438,
        269.4599914550781,
        655.4400024414062
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 74 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 81,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정도구",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        105.23999786376953,
        87.47999572753906,
        379.0799865722656,
        101.87999725341797
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        105.23999786376953,
        87.47999572753906,
        379.0799865722656,
        101.87999725341797
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한국인 우울",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        97.43999481201172,
        171.239990234375,
        163.44000244140625,
        185.63998413085938
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "척도(Korean Depression",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        66.23999786376953,
        190.44000244140625,
        194.6280059814453,
        204.83999633789062
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Scale, KDS )",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        95.15999603271484,
        209.63999938964844,
        165.6119842529297,
        224.0399932861328
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "KDS는 한국인 우울장애 환자들이 호소하는 증상과 생활사건에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        113.63999938964844,
        527.760009765625,
        128.0399932861328
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 내용분석을 통해 문항을 구성하였다는 것에 의미가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        132.83999633789062,
        527.760009765625,
        147.239990234375
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있는 국내 제작 척도이다. 총 30문항에 대해 5점 척도로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        152.0399932861328,
        527.760009765625,
        166.4399871826172
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "응답하도록 구성되었으며, 우울 증상은 미래에 대한 부정적",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        171.239990234375,
        527.760009765625,
        185.63998413085938
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생각, 자기에 대한 부정적 생각, 우울 기분, 신체화 증상, 의욕",
      "font_size": 12.0,
      "font_name": "T18",
      "bbox": [
        206.51998901367188,
        190.44000244140625,
        527.8800048828125,
        204.83999633789062
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상실 총 6 요인이다. 18세 이상의 일반 성인과 우울장애",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        209.63999938964844,
        527.760009765625,
        224.0399932861328
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "환자에게 적용할 수 있다. 문항 점수의 총점은 규준에 근거",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        228.83999633789062,
        527.760009765625,
        243.239990234375
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하여 해석한다. 전체 남자는 T점수 65, 전체 여자는 T점수",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        248.04000854492188,
        527.760009765625,
        262.44000244140625
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "70으로 우울장애를 분류할 경우, 진단적 효율성은 73.1%이다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        267.239990234375,
        527.8200073242188,
        281.6399841308594
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "병원 불안 우울 척도",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        73.43999481201172,
        343.0799865722656,
        187.44000244140625,
        357.47998046875
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Hospital Anxiety and",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.04000091552734,
        362.2799987792969,
        186.85198974609375,
        376.67999267578125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Depression Scale,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.68000030517578,
        381.47998046875,
        178.15199279785156,
        395.8799743652344
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HADS)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        112.79999542236328,
        400.67999267578125,
        147.97198486328125,
        415.0799865722656
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HADS는 병원을 방문한 환자의 불안, 우울 정도와 감정",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        304.67999267578125,
        527.760009765625,
        319.0799865722656
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상태의 변화를 매우 신속하게 간단하게 평가하고자 고안",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        323.8800048828125,
        527.760009765625,
        338.2799987792969
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하였으며 선별도구로 사용된다. HADS는 불안과 우울을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        343.0799865722656,
        527.760009765625,
        357.47998046875
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "측정하는 총 14개의 문항에 대해 4점 척도로 응답하도록",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        362.2799987792969,
        527.760009765625,
        376.67999267578125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구성되어 있다. 18세에서 65세 성인에게 적용할 수 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        381.47998046875,
        527.7000122070312,
        395.8799743652344
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "우울 하위척도를 8점으로 절단할 때 민감도 89.2%, 특이도",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        400.67999267578125,
        527.760009765625,
        415.0799865722656
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "82.5%이며, 불안 하위척도를 8점으로 절단할 때 민감도",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        419.8800048828125,
        527.760009765625,
        434.2799987792969
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "78.8%, 특이도 82.5%로 나타났다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        439.0799865722656,
        389.1000061035156,
        453.47998046875
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "노인 우울 척도",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        88.43999481201172,
        486.239990234375,
        172.44000244140625,
        500.6399841308594
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Geriatric Depression",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.23999786376953,
        505.44000244140625,
        185.50799560546875,
        519.8400268554688
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Scale, GDS)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        97.43999481201172,
        524.6400146484375,
        163.3319854736328,
        539.0400390625
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "GDS는 노인 우울장애를 측정하기 위해 간단하고 신속하게",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        476.6399841308594,
        527.760009765625,
        491.03997802734375
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "측정할 수 있도록 고안하였다. GDS는 총 30문항에 대해",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        495.8399963378906,
        527.760009765625,
        510.239990234375
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‘예, 아니요’의 단순 형식으로 응답하도록 구성되어 있어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        515.0399780273438,
        527.760009765625,
        529.4400024414062
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "노인에게 시행하기에 적합하다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        534.239990234375,
        377.4599914550781,
        548.6400146484375
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "무망감 질문지",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        91.43999481201172,
        590.8800048828125,
        169.44000244140625,
        605.280029296875
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Hopelessness",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        92.63999938964844,
        610.0799560546875,
        168.239990234375,
        624.47998046875
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Depression Symptom",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.04000091552734,
        629.2799682617188,
        186.7080078125,
        643.6799926757812
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Questionnaire, HDSQ)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        72.1199951171875,
        648.47998046875,
        188.77198791503906,
        662.8800048828125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HDSQ는 무망감",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        571.6799926757812,
        527.7120361328125,
        586.0800170898438
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이론(Hopelessness",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        571.6799926757812,
        527.7120361328125,
        586.0800170898438
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Theory)에 기초하여,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        571.6799926757812,
        527.7120361328125,
        586.0800170898438
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "우울장애 관련 요소로서 무망감을 측정하기 위해 고안된",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        590.8800048828125,
        527.760009765625,
        605.280029296875
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "것이다. HDSQ는 32문항에 4점 척도로 구성되었으며 하위",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        610.0799560546875,
        527.760009765625,
        624.47998046875
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "요인으로 8 요인(동기적 결핍, 대인관계의 의존성, 정신",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        629.2799682617188,
        527.760009765625,
        643.6799926757812
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "운동 지체, 에너지 없음, 냉담/무 쾌락, 불면증, 집중 곤란/",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        206.51998901367188,
        648.47998046875,
        527.7960205078125,
        662.8800048828125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반추, 자살에 관한 생각)이 확인되었다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        667.6799926757812,
        419.6999816894531,
        682.0800170898438
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 75 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 82,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정도구",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        105.23999786376953,
        87.47999572753906,
        379.0799865722656,
        101.87999725341797
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        105.23999786376953,
        87.47999572753906,
        379.0799865722656,
        101.87999725341797
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "벡 자살 사고 척도",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        79.43999481201172,
        191.51998901367188,
        181.44000244140625,
        205.91998291015625
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Beck Suicidal ideation",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.19999694824219,
        210.72000122070312,
        190.54800415039062,
        225.1199951171875
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Scale, BSS)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        98.5199966430664,
        229.9199981689453,
        162.25198364257812,
        244.3199920654297
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "BSS는 우울장애 관련 구성개념의 하나로, 자살 위험의 지침인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        105.1199951171875,
        527.760009765625,
        119.5199966430664
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자살 사고를 평가하기 위해 고안된 자기보고 질문지이다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        124.31999206542969,
        527.7000122070312,
        138.71998596191406
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "BSS는 총 21개 문항으로 구성되어 있으며 이 중 19개 문항은",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        143.51998901367188,
        527.760009765625,
        157.91998291015625
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자살 소망, 자살 태도, 자살 계획에 대해 0~2점으로 응답",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        206.51998901367188,
        162.72000122070312,
        527.760009765625,
        177.1199951171875
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하게 되어 있다. 나머지 2개 문항은 이전 자살시도의 횟수와",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        181.9199981689453,
        527.760009765625,
        196.3199920654297
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마지막 시도의 심각성을 평가하지만 점수에는 포함되지",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        201.1199951171875,
        527.760009765625,
        215.51998901367188
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "않는다. BSS는 현재 자살 욕구를 질문하는 4, 5번 문항에서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        220.3199920654297,
        527.760009765625,
        234.71998596191406
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‘아니오’로 응답하면 20, 21번 문항을 넘어가도록 되어 있고,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        239.51998901367188,
        527.7120361328125,
        253.91998291015625
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‘예’로 응답하면 6번 이하의 문항에 대해 계속 응답하도록",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        258.7200012207031,
        527.760009765625,
        273.1199951171875
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "되어 있다. BSS는 자살 사고 내용 뿐만 아니라 구체적인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        277.91998291015625,
        527.760009765625,
        292.3199768066406
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자살 특징(실제 자살 계획)까지도 확인할 수 있는 장점이",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        297.1199951171875,
        527.760009765625,
        311.5199890136719
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        316.32000732421875,
        233.45999145507812,
        330.7200012207031
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "역기능적 태도 척도",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.43999481201172,
        365.6399841308594,
        184.44000244140625,
        380.03997802734375
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Dysfunctional Attitude",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        72.36000061035156,
        384.8399963378906,
        188.4239959716797,
        399.239990234375
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Scale, DAS)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        98.15999603271484,
        404.03997802734375,
        162.6119842529297,
        418.4399719238281
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "DAS는 우울장애 관련 구성개념 중 부적응적 사고 유형과",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        336.8399963378906,
        527.760009765625,
        351.239990234375
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "역기능적인지를 평가하기 위해 고안하였다. 원래 DAS는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        356.03997802734375,
        527.760009765625,
        370.4399719238281
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "우울장애와",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        375.239990234375,
        527.760009765625,
        389.6399841308594
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관련",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        206.51998901367188,
        375.239990234375,
        527.760009765625,
        389.6399841308594
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        375.239990234375,
        527.760009765625,
        389.6399841308594
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "역기능적인지를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        375.239990234375,
        527.760009765625,
        389.6399841308594
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가하기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        375.239990234375,
        527.760009765625,
        389.6399841308594
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        375.239990234375,
        527.760009765625,
        389.6399841308594
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고안된 100개의 문항으로 구성되었다. 그러나 임상적으로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        394.44000244140625,
        527.760009765625,
        408.8399963378906
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "손쉽게 활용하기 위해 40문항으로 단축하였으며, 성취지향,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        413.6399841308594,
        527.7120361328125,
        428.03997802734375
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대인관계지향 2개 요인으로 구성되었다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        432.8399963378906,
        425.4599914550781,
        447.239990234375
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "36항 건강수준 척도",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.43999481201172,
        501.3599853515625,
        184.44000244140625,
        515.760009765625
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Short Form-36 Health",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        69.95999908447266,
        520.5599975585938,
        190.7880096435547,
        534.9600219726562
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Survey, SF-36 )",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        88.68000030517578,
        539.760009765625,
        172.0919952392578,
        554.1600341796875
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SF-36는 신체적 및 정신적 건강 관련 삶의 질에 대한 35개",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        453.3599853515625,
        527.760009765625,
        467.7599792480469
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "문항과 건강 상태 변화에 대한 1개 문항으로 총 36개",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        472.55999755859375,
        527.760009765625,
        486.9599914550781
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "문항으로 구성. 건강 관련 삶의 질은 8개의 하부영역으로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        491.7599792480469,
        527.760009765625,
        506.15997314453125
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구성되었고, 이는 신체적 건강 관련 삶의 질과 정신적 건강",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        510.9599609375,
        527.760009765625,
        525.3599853515625
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관련 삶의 질로 구성. 점수 산정은 각각의 8개 하위 척도에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        530.1599731445312,
        527.760009765625,
        544.5599975585938
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "속하는 세부 항목들을 점수화 한 뒤 합산하여 0점부터",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        549.3599853515625,
        527.760009765625,
        563.760009765625
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "100점 사이의 점수로 변환시키는데, 0점은 가장 나쁜 건강",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        568.5599975585938,
        527.760009765625,
        582.9600219726562
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상태를 의미하며, 100점은 가장 좋은 건강 상태를 의미이다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        587.760009765625,
        526.3800048828125,
        602.1600341796875
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생산성 손실 점수",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.43999481201172,
        636.9599609375,
        178.44000244140625,
        651.3599853515625
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Work Productivity and",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.43999481201172,
        656.1599731445312,
        190.3319854736328,
        670.5599975585938
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Activity Impairment,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        79.55999755859375,
        675.3599853515625,
        181.27198791503906,
        689.760009765625
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "WPAI)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.23999786376953,
        694.5599975585938,
        146.65199279785156,
        708.9600219726562
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "= (건강 문제로 인해 손실된 시간의 비율) + [(1 - 건강 문제로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        608.1599731445312,
        527.760009765625,
        622.5599975585938
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인해 손실된 시간의 비율) × 건강 문제로 인해 일하는 동안",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        627.3599853515625,
        527.760009765625,
        641.760009765625
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생한 장애(impairment) 비율]",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        206.51998901367188,
        646.5599975585938,
        368.916015625,
        660.9600219726562
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "= 건강 문제로 일을 빠진 시간/(건강 문제로 일을 빠진 시간+",
      "font_size": 12.0,
      "font_name": "T18",
      "bbox": [
        206.51998901367188,
        665.760009765625,
        527.7359619140625,
        680.1600341796875
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실제 일한 시간) + [(1 - 건강 문제로 일을 빠진 시간/(건강",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        684.9599609375,
        527.760009765625,
        699.3599853515625
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "문제로 일을 빠진 시간+실제 일한 시간)] × 건강 문제로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        206.51998901367188,
        704.1599731445312,
        527.760009765625,
        718.5599975585938
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인해 일하는 동안 발생한 작업 능률 점수/10]",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        206.51998901367188,
        723.3599853515625,
        452.6759948730469,
        737.760009765625
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(출처: 우울장애 임상지료지침, 2022, H.J. Cho et al., 2007, VA/DoD, 2016",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        742.0799560546875,
        465.47998046875,
        756.47998046875
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 76 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 83,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바) 순응도 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        84.90937042236328,
        191.27999877929688,
        100.72968292236328
      ],
      "page_num": 83,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 치료기간 동안 어플리케이션 사용 시간 및 활용 여부를 수집한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        114.90937042236328,
        534.5629272460938,
        130.72967529296875
      ],
      "page_num": 83,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사) 이상반응 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        144.9093780517578,
        206.27999877929688,
        160.7296905517578
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        174.9093780517578,
        545.9400024414062,
        190.7296905517578
      ],
      "page_num": 83,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        204.90936279296875,
        538.4400024414062,
        220.72967529296875
      ],
      "page_num": 83,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        234.90936279296875,
        546.0599975585938,
        250.72967529296875
      ],
      "page_num": 83,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용을 기록한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        264.90936279296875,
        231.92295837402344,
        280.72967529296875
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아) 병용약물 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        294.90936279296875,
        206.27999877929688,
        310.72967529296875
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 외래 방문마다 병용약물을 수집하여 기록한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        324.90936279296875,
        432.2029724121094,
        340.72967529296875
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자) 관찰 및 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        354.90936279296875,
        198.83999633789062,
        370.72967529296875
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 각 관찰 항목에 대한 평가 도구 및 평가 방법에 대한 자세한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        384.90936279296875,
        545.9400024414062,
        400.72967529296875
      ],
      "page_num": 83,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용을 기재한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        414.90936279296875,
        233.1229705810547,
        430.72967529296875
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 77 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 84,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 설계 방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        150.72000122070312,
        100.72968292236328
      ],
      "page_num": 84,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        119.63999938964844,
        529.7999877929688,
        134.0399932861328
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있다. 피험자 배정과",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        63.71999740600586,
        143.63999938964844,
        529.7999877929688,
        158.0399932861328
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "처리 할당에 있어 편향(Bias)을 줄이기 위해 무작위배정(Randomization)과 눈가림",
      "font_size": 12.0,
      "font_name": "T18",
      "bbox": [
        63.71999740600586,
        167.63999938964844,
        529.7999877929688,
        182.0399932861328
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Blinding) 전략이 잘 포함되어야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        63.71999740600586,
        191.63999938964844,
        275.82000732421875,
        206.0399932861328
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        237.1143035888672,
        94.91999816894531,
        257.06549072265625
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 대상자군",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        273.42938232421875,
        161.39999389648438,
        289.24969482421875
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험군 : 디지털 우울장애 인지행동치료군",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        303.42938232421875,
        402.7200012207031,
        319.24969482421875
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 대조군 : 디지털 우울장애 위약군(sham군)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        333.42938232421875,
        401.0474853515625,
        349.24969482421875
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 무작위배정 방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        363.4293518066406,
        212.75999450683594,
        379.2496643066406
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 연구자는 선정·제외 기준을 합격한 피험자의 순서대로 배정일에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        393.4293518066406,
        546.0599975585938,
        409.2496643066406
      ],
      "page_num": 84,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "쌍방향 웹반응시스템(Interactive Web Response System,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        423.4293518066406,
        546.0599975585938,
        439.2496643066406
      ],
      "page_num": 84,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "IWRS)을 통해서 시험군 혹은 대조군으로 1:1 배정한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        453.4293518066406,
        490.52294921875,
        469.2496643066406
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 본 연구와 독립된 통계학자가 SAS 통계 패키지를 가지고 층화",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        483.4293518066406,
        545.9400024414062,
        499.2496643066406
      ],
      "page_num": 84,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "순열화 블록 무작위배정법(stratified permuted block randomization)을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        513.4293823242188,
        546.0599975585938,
        529.2496948242188
      ],
      "page_num": 84,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이용하여 발행된 난수표를 적용한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        543.4293823242188,
        365.48297119140625,
        559.2496948242188
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 층: 성별(남/여), 연령(oo세 미만, oo세 이상)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.5999984741211,
        573.4293823242188,
        432.72747802734375,
        589.2496948242188
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 맹검 방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        603.4293823242188,
        168.83999633789062,
        619.2496948242188
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 연구의 특성상 단일 맹검을 지향하되, 필요시 비맹검 임상시험을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        633.4293823242188,
        545.9400024414062,
        649.2496948242188
      ],
      "page_num": 84,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수행할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        663.4293823242188,
        224.48297119140625,
        679.2496948242188
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 단일맹검인 경우, 임상시험 도중 응급상황 발생 등으로 인하여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        693.4293823242188,
        545.9400024414062,
        709.2496948242188
      ],
      "page_num": 84,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자의 눈가림을 해제할 수 있다. 이 경우, 사유와 해제일,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        723.4293823242188,
        545.9400024414062,
        739.2496948242188
      ],
      "page_num": 84,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "열람자, 해제 후 조치사항 등에 대한 문서를 기록·보관한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        753.4293823242188,
        532.6429443359375,
        769.2496948242188
      ],
      "page_num": 84,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 78 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 85,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "11. 관찰항목·임상검사항목 및 관찰검사방법",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        99.09996032714844,
        398.5194091796875,
        115.0599594116211
      ],
      "page_num": 85,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 임상시험 전, 중, 후에 관찰해야 할 항목들을 나열한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.55999755859375,
        146.0399932861328,
        385.6199951171875,
        160.4399871826172
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험 전 피험자 선정 과정에서의 확인해야 할 사항, 임상검사, 피험자 동의서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.55999755859375,
        170.0399932861328,
        533.2799682617188,
        184.4399871826172
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유/무, 피험자 기초정보, 병력조사, 선정 및 제외 기준, 식별코드 부여 등에 대해서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        83.5199966430664,
        194.0399932861328,
        533.2799682617188,
        208.4399871826172
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기술한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        83.5199966430664,
        218.0399932861328,
        134.4600067138672,
        232.4399871826172
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자의 방문 일에 따른 관찰 시기별 관찰 항목, 임상 검사 항목과 관찰검사방법을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.55999755859375,
        242.0399932861328,
        533.2799682617188,
        256.44000244140625
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "명시한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.0,
        266.0400085449219,
        133.02000427246094,
        280.44000244140625
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험 중 관찰 항목을 기술한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.55999755859375,
        290.03997802734375,
        277.739990234375,
        304.4399719238281
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험 후 이상반응 확인에 대해서 기술한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.55999755859375,
        314.03997802734375,
        343.739990234375,
        328.4399719238281
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        344.2743225097656,
        94.91999816894531,
        364.2254943847656
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험 일정표",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        380.58935546875,
        168.1199951171875,
        396.40966796875
      ],
      "page_num": 85,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "스크리닝 및",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        191.75999450683594,
        419.7599792480469,
        254.51998901367188,
        433.00799560546875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검사일",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        206.0399932861328,
        431.8799743652344,
        240.2397003173828,
        445.12799072265625
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Screening)1)",
      "font_size": 7.079999923706055,
      "font_name": "T10",
      "bbox": [
        190.55999755859375,
        443.0400085449219,
        255.78968811035156,
        457.24798583984375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "치료 시작일",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        276.7200012207031,
        425.7599792480469,
        339.4797058105469,
        439.00799560546875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Baseline)",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        282.6000061035156,
        437.8799743652344,
        333.7030334472656,
        451.12799072265625
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "치료 기간 종료",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        356.7599792480469,
        419.7599792480469,
        438.18963623046875,
        457.24798583984375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1주 후(8주+1주)",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        356.7599792480469,
        419.7599792480469,
        438.18963623046875,
        457.24798583984375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Post-treatment)3)3)3)",
      "font_size": 7.079999923706055,
      "font_name": "T10",
      "bbox": [
        356.7599792480469,
        419.7599792480469,
        438.18963623046875,
        457.24798583984375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(선택)",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        475.91998291015625,
        413.6399841308594,
        505.9022216796875,
        426.88800048828125
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "치료 기간 종료",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        450.9599914550781,
        425.7599792480469,
        530.7601928710938,
        439.00799560546875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3개월 후",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        468.0,
        437.8799743652344,
        513.719970703125,
        451.12799072265625
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Follow up)4)",
      "font_size": 7.079999923706055,
      "font_name": "T10",
      "bbox": [
        458.3999938964844,
        449.1600036621094,
        523.7496948242188,
        463.24798583984375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4)",
      "font_size": 7.079999923706055,
      "font_name": "T10",
      "bbox": [
        458.3999938964844,
        449.1600036621094,
        523.7496948242188,
        463.24798583984375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4)",
      "font_size": 7.079999923706055,
      "font_name": "T10",
      "bbox": [
        458.3999938964844,
        449.1600036621094,
        523.7496948242188,
        463.24798583984375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방문일",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        103.19999694824219,
        467.03997802734375,
        504.9599914550781,
        480.2879943847656
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방문1",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        103.19999694824219,
        467.03997802734375,
        504.9599914550781,
        480.2879943847656
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방문2",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        103.19999694824219,
        467.03997802734375,
        504.9599914550781,
        480.2879943847656
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방문3",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        103.19999694824219,
        467.03997802734375,
        504.9599914550781,
        480.2879943847656
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방문4",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        103.19999694824219,
        467.03997802734375,
        504.9599914550781,
        480.2879943847656
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경과일수",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        97.43999481201172,
        486.47998046875,
        493.99871826171875,
        499.7279968261719
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "D-28 이내",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        97.43999481201172,
        486.47998046875,
        493.99871826171875,
        499.7279968261719
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "DAY1",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        97.43999481201172,
        486.47998046875,
        493.99871826171875,
        499.7279968261719
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        97.43999481201172,
        486.47998046875,
        493.99871826171875,
        499.7279968261719
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        97.43999481201172,
        486.47998046875,
        493.99871826171875,
        499.7279968261719
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관찰형태",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        97.43999481201172,
        506.7599792480469,
        324.9599914550781,
        526.1279907226562
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내원",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        97.43999481201172,
        506.7599792480469,
        324.9599914550781,
        526.1279907226562
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내원과",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        97.43999481201172,
        506.7599792480469,
        324.9599914550781,
        526.1279907226562
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "애플리케이션",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        275.3999938964844,
        518.8800048828125,
        341.3999938964844,
        532.1279907226562
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내원과",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        381.1199951171875,
        506.7599792480469,
        414.1199951171875,
        520.0079956054688
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "애플리케이션",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        364.67999267578125,
        518.8800048828125,
        430.67999267578125,
        532.1279907226562
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내원 또는 앱,",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        460.44000244140625,
        506.7599792480469,
        521.8358154296875,
        520.0079956054688
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이메일, 문자, SNS",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        452.7599792480469,
        518.8800048828125,
        529.501220703125,
        532.1279907226562
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구 참여 동의서 취득",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        64.55999755859375,
        538.4400024414062,
        493.99871826171875,
        551.68798828125
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        64.55999755859375,
        538.4400024414062,
        493.99871826171875,
        551.68798828125
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        538.4400024414062,
        493.99871826171875,
        551.68798828125
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        538.4400024414062,
        493.99871826171875,
        551.68798828125
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        538.4400024414062,
        493.99871826171875,
        551.68798828125
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "선정/제외기준 확인",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        69.83999633789062,
        556.3200073242188,
        493.99871826171875,
        569.5679931640625
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        69.83999633789062,
        556.3200073242188,
        493.99871826171875,
        569.5679931640625
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        69.83999633789062,
        556.3200073242188,
        493.99871826171875,
        569.5679931640625
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        69.83999633789062,
        556.3200073242188,
        493.99871826171875,
        569.5679931640625
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        69.83999633789062,
        556.3200073242188,
        493.99871826171875,
        569.5679931640625
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인구학적 정보",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        83.04000091552734,
        574.2000122070312,
        493.99871826171875,
        587.447998046875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        83.04000091552734,
        574.2000122070312,
        493.99871826171875,
        587.447998046875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        83.04000091552734,
        574.2000122070312,
        493.99871826171875,
        587.447998046875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        83.04000091552734,
        574.2000122070312,
        493.99871826171875,
        587.447998046875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        83.04000091552734,
        574.2000122070312,
        493.99871826171875,
        587.447998046875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "과거병력 조사",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        83.04000091552734,
        592.2000122070312,
        493.99871826171875,
        605.447998046875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        83.04000091552734,
        592.2000122070312,
        493.99871826171875,
        605.447998046875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        83.04000091552734,
        592.2000122070312,
        493.99871826171875,
        605.447998046875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        83.04000091552734,
        592.2000122070312,
        493.99871826171875,
        605.447998046875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        83.04000091552734,
        592.2000122070312,
        493.99871826171875,
        605.447998046875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험 의료기기 적용",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        64.55999755859375,
        610.0800170898438,
        495.34893798828125,
        623.3280029296875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        64.55999755859375,
        610.0800170898438,
        495.34893798828125,
        623.3280029296875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        64.55999755859375,
        610.0800170898438,
        495.34893798828125,
        623.3280029296875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        64.55999755859375,
        610.0800170898438,
        495.34893798828125,
        623.3280029296875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        64.55999755859375,
        610.0800170898438,
        495.34893798828125,
        623.3280029296875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가지표 Baseline 수집",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        64.55999755859375,
        625.9199829101562,
        493.99871826171875,
        639.16796875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(O)",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        625.9199829101562,
        493.99871826171875,
        639.16796875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        64.55999755859375,
        625.9199829101562,
        493.99871826171875,
        639.16796875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        625.9199829101562,
        493.99871826171875,
        639.16796875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        625.9199829101562,
        493.99871826171875,
        639.16796875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가지표 수집 및 분석2)",
      "font_size": 7.079999923706055,
      "font_name": "T10",
      "bbox": [
        64.55999755859375,
        640.9199829101562,
        495.34893798828125,
        655.0079956054688
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2)2)",
      "font_size": 7.079999923706055,
      "font_name": "T10",
      "bbox": [
        64.55999755859375,
        640.9199829101562,
        495.34893798828125,
        655.0079956054688
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        64.55999755859375,
        640.9199829101562,
        495.34893798828125,
        655.0079956054688
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        64.55999755859375,
        640.9199829101562,
        495.34893798828125,
        655.0079956054688
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        64.55999755859375,
        640.9199829101562,
        495.34893798828125,
        655.0079956054688
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        64.55999755859375,
        640.9199829101562,
        495.34893798828125,
        655.0079956054688
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이상반응 확인",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        83.04000091552734,
        659.760009765625,
        495.34893798828125,
        673.0079956054688
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        83.04000091552734,
        659.760009765625,
        495.34893798828125,
        673.0079956054688
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        83.04000091552734,
        659.760009765625,
        495.34893798828125,
        673.0079956054688
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        83.04000091552734,
        659.760009765625,
        495.34893798828125,
        673.0079956054688
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        83.04000091552734,
        659.760009765625,
        495.34893798828125,
        673.0079956054688
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "병용약물 조사",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        83.04000091552734,
        677.6400146484375,
        495.34893798828125,
        690.8880004882812
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        83.04000091552734,
        677.6400146484375,
        495.34893798828125,
        690.8880004882812
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        83.04000091552734,
        677.6400146484375,
        495.34893798828125,
        690.8880004882812
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        83.04000091552734,
        677.6400146484375,
        495.34893798828125,
        690.8880004882812
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        83.04000091552734,
        677.6400146484375,
        495.34893798828125,
        690.8880004882812
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "순응도 조사",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        88.91999816894531,
        695.52001953125,
        495.34893798828125,
        708.7680053710938
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        88.91999816894531,
        695.52001953125,
        495.34893798828125,
        708.7680053710938
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        88.91999816894531,
        695.52001953125,
        495.34893798828125,
        708.7680053710938
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        88.91999816894531,
        695.52001953125,
        495.34893798828125,
        708.7680053710938
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T14",
      "bbox": [
        88.91999816894531,
        695.52001953125,
        495.34893798828125,
        708.7680053710938
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 스크리닝 및 검사일은 치료 시작일 전 28일 이내에 시작한다.",
      "font_size": 9.960000038146973,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        711.5999755859375,
        504.7601623535156,
        753.552001953125
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 수집하는 지표에 따라 수집이 다를 경우 나누어 표현한다. (예: BDI는 스크리닝에도 수집함)",
      "font_size": 9.960000038146973,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        711.5999755859375,
        504.7601623535156,
        753.552001953125
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 우울장애 개선 디지털치료기기 제품의 치료 기간에 따라 전체 치료 기간은 변경될 수 있다.",
      "font_size": 9.960000038146973,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        711.5999755859375,
        504.7601623535156,
        753.552001953125
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4) 임상시험 설계에 따른 선택사항이므로 치료 기간 종료 후 추적 관찰 기간은 변경될 수 있다.",
      "font_size": 9.960000038146973,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        711.5999755859375,
        504.7601623535156,
        753.552001953125
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 79 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 86,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 임상시험 절차",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        180.72000122070312,
        100.72968292236328
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 방문 1 (스크리닝 및 검사일, Screening)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        114.90937042236328,
        364.2074890136719,
        130.72967529296875
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가) 임상시험 설명 및 동의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        144.9093780517578,
        266.2799987792969,
        160.7296905517578
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        174.9093780517578,
        545.9400024414062,
        190.7296905517578
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대상자 또는 법정대리인에게 상세히 설명한다. 서명 일자를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        204.90936279296875,
        546.0599975585938,
        220.72967529296875
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정확히 기재하여야 하며, 작성된 동의서 원본은 시험자가 보관",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        234.90936279296875,
        538.5599975585938,
        250.72967529296875
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고 사본은 시험대상자 또는 법정대리인에게 내준다. 대상자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        264.90936279296875,
        538.5599975585938,
        280.72967529296875
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에게 동의를 받은 후 동의 취득 순서에 따라 스크리닝 번호를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        294.90936279296875,
        545.9400024414062,
        310.72967529296875
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부여한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        324.90936279296875,
        180.68296813964844,
        340.72967529296875
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 선정/제외 기준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        354.90936279296875,
        210.95999145507812,
        370.72967529296875
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        384.90936279296875,
        545.9400024414062,
        400.72967529296875
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위임자가 모든 선정 및 제외 기준을 검토해야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        414.90936279296875,
        469.282958984375,
        430.72967529296875
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 인구학적 정보",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        444.90936279296875,
        206.27999877929688,
        460.72967529296875
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 인구학적 정보로 대상자 이니셜, 만 나이, 성별, 직업, 그리고",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        474.90936279296875,
        546.0599975585938,
        490.72967529296875
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "업무 생산성을 조사하며 기초 문진에 필요한 환자들의 의학적",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        504.90936279296875,
        545.9400024414062,
        520.7296752929688
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성에 대한 정보들을 수집한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        534.9093627929688,
        335.84295654296875,
        550.7296752929688
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 과거 병력 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        564.9093627929688,
        213.83999633789062,
        580.7296752929688
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 병력 등을 문진과 과거 진료 기록을 통해 조사한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        594.9093627929688,
        469.282958984375,
        610.7296752929688
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 병력조사에 포함되어야 하는 내용은 다음과 같다. 치매, 인지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        624.9093627929688,
        546.0599975585938,
        640.7296752929688
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기능 장애, 정신증, 양극성 장애 및 현재 주요 우울 삽화",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        654.9093627929688,
        538.5599975585938,
        670.7296752929688
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(current major depressive episode) 등 스크리닝 확인해야 할",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        684.9093627929688,
        546.0599975585938,
        700.7296752929688
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질병군 등의 과거력 및 현 병력, 발생 시기, 치료와 진행여부",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        714.9093627929688,
        545.9400024414062,
        730.7296752929688
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 내용 등을 기재한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        744.9093627929688,
        276.4429626464844,
        760.7296752929688
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 80 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 동의서 취득일 기준으로 최근 5년 이내 과거 및 현재 병력을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        84.90937042236328,
        545.9400024414062,
        100.72968292236328
      ],
      "page_num": 87,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조사한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        114.90937042236328,
        180.0829620361328,
        130.72967529296875
      ],
      "page_num": 87,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마) 우울장애 심각도 척도(BDI-II) 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        144.9093780517578,
        344.03997802734375,
        160.7296905517578
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자 선정을 위한 한국판 우울장애 심각도 척도 정보를 수집",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        174.9093780517578,
        538.5599975585938,
        190.7296905517578
      ],
      "page_num": 87,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        204.90936279296875,
        149.48297119140625,
        220.72967529296875
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 필요시 본 단계에서 수집한 정보를 Baseline 지표로 활용할",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        234.90936279296875,
        546.0599975585938,
        250.72967529296875
      ],
      "page_num": 87,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        264.90936279296875,
        180.05999755859375,
        280.72967529296875
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바) 병용약물 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        294.90936279296875,
        206.27999877929688,
        310.72967529296875
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 약물 복용력 등을 문진과 과거 진료기록을 통해 조사한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        324.90936279296875,
        513.802978515625,
        340.72967529296875
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        354.90936279296875,
        538.5599975585938,
        370.72967529296875
      ],
      "page_num": 87,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        384.90936279296875,
        545.9400024414062,
        400.72967529296875
      ],
      "page_num": 87,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기간, 목적을 확인한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        414.90936279296875,
        273.0829772949219,
        430.72967529296875
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 방문 2 (치료시작일, Baseline)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        474.90936279296875,
        301.5,
        490.72967529296875
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) Baseline 유효성 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        504.90936279296875,
        253.0800018310547,
        520.7296752929688
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 일차 유효성 평가지표, 이차 임상 변수를 평가하기 위해 우울장애",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        534.9093627929688,
        545.9400024414062,
        550.7296752929688
      ],
      "page_num": 87,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "심각도 척도(BDI) 및 해당하는 자가 보고를 작성하도록 하여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        564.9093627929688,
        545.9400024414062,
        580.7296752929688
      ],
      "page_num": 87,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지참하게 하거나, 애플리케이션 등을 통해 평가지표에 대한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        594.9093627929688,
        546.0599975585938,
        610.7296752929688
      ],
      "page_num": 87,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Baseline 정보를 수집한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        624.9093627929688,
        298.739990234375,
        640.7296752929688
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 필요에 따라 방문 1(스크리닝 단계)에서 측정한 우울장애 심각도",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        654.9093627929688,
        546.0599975585938,
        670.7296752929688
      ],
      "page_num": 87,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "척도(BDI) 정보를 Baseline 지표로 활용할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        684.9093627929688,
        455.1229553222656,
        700.7296752929688
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 무작위 배정",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        714.9093627929688,
        198.77999877929688,
        730.7296752929688
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험군 혹은 대조군에 무작위배정을 통해 배치한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        744.9093627929688,
        476.8199768066406,
        760.7296752929688
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 81 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 88,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다) 임상시험 의료기기 시험방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        84.90937042236328,
        303.8399963378906,
        100.72968292236328
      ],
      "page_num": 88,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- OOO 애플리케이션을 실행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        114.90937042236328,
        330.5629577636719,
        130.72967529296875
      ],
      "page_num": 88,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 회원가입 및 초기 증상 평가를 시행한다(7가지 기본 입력 정보:",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        144.9093780517578,
        546.0599975585938,
        160.7296905517578
      ],
      "page_num": 88,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성별, 나이, 우울장애 증상의 정도, 우울장애 증상의 양상, 동반",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        174.9093780517578,
        538.5599975585938,
        190.7296905517578
      ],
      "page_num": 88,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증상 여부, 직업, 업무 생산성).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        204.90936279296875,
        325.282958984375,
        220.72967529296875
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 정해진 기간에 상술 된 방식으로 디지털치료기기 콘텐츠를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        234.90936279296875,
        545.9400024414062,
        250.72967529296875
      ],
      "page_num": 88,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통한 우울장애 치료를 수행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        264.90936279296875,
        335.84295654296875,
        280.72967529296875
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 대조군 검사 시험방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        294.90936279296875,
        258.8399963378906,
        310.72967529296875
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 우울장애 교육/우울장애 일기(예: Sham, 대면교육, 교육책자 등)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        324.90936279296875,
        545.9400024414062,
        340.72967529296875
      ],
      "page_num": 88,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "애플리케이션을 실행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        354.90936279296875,
        286.282958984375,
        370.72967529296875
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 회원가입 및 초기 우울 증상 평가를 시행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        384.90936279296875,
        432.2029724121094,
        400.72967529296875
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 정해진 기간에 환자에게 해가 되지 않는 내용으로 과학적 근거에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        414.90936279296875,
        545.9400024414062,
        430.72967529296875
      ],
      "page_num": 88,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반한 정보를 제공한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        444.90936279296875,
        283.8829650878906,
        460.72967529296875
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 실험 설계에 따라 대조군에 Sham을 적용하지 않고 wait-list로 대체할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        90.0,
        473.1600036621094,
        536.4551391601562,
        488.7120056152344
      ],
      "page_num": 88,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마) 이상반응 확인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        500.9493408203125,
        206.27999877929688,
        516.7696533203125
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        530.9493408203125,
        545.9400024414062,
        546.7696533203125
      ],
      "page_num": 88,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상 반응 여부를 방문일에 진찰을 통해 관찰하고, 임상시험용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        560.9493408203125,
        545.9400024414062,
        576.7696533203125
      ],
      "page_num": 88,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기와의 인과관계에 대하여 증례 기록지에 기록한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        590.9493408203125,
        513.802978515625,
        606.7696533203125
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        90.0,
        619.199951171875,
        538.4400024414062,
        634.751953125
      ],
      "page_num": 88,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대체 수집할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        109.43999481201172,
        645.1199340820312,
        236.09519958496094,
        660.6719360351562
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바) 병용약물 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        672.9093627929688,
        206.27999877929688,
        688.7296752929688
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        702.9093627929688,
        521.2429809570312,
        718.7296752929688
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        732.9093627929688,
        538.5599975585938,
        748.7296752929688
      ],
      "page_num": 88,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 82 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 89,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        84.90937042236328,
        545.9400024414062,
        100.72968292236328
      ],
      "page_num": 89,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기간, 목적을 확인한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        114.90937042236328,
        273.0829772949219,
        130.72967529296875
      ],
      "page_num": 89,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사) 순응도 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        144.9093780517578,
        191.27999877929688,
        160.7296905517578
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 치료기간 동안 어플리케이션 사용도 및 컨텐츠 이용도를 수집",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        174.9093780517578,
        538.4400024414062,
        190.7296905517578
      ],
      "page_num": 89,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여 순응도를 조사한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        204.90936279296875,
        282.0829772949219,
        220.72967529296875
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 방문 3 (치료 기간 종료 1주 후, Post-treatment)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        264.90936279296875,
        422.0474853515625,
        280.72967529296875
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 치료 후 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        294.90936279296875,
        198.83999633789062,
        310.72967529296875
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 치료 후 평가 및 일차 유효성 평가지표, 이차 유효성 평가지표의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        324.90936279296875,
        546.0599975585938,
        340.72967529296875
      ],
      "page_num": 89,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변화를 검증하기 위해 우울장애 심각도 척도 및 해당하는 자가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        354.90936279296875,
        545.9400024414062,
        370.72967529296875
      ],
      "page_num": 89,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보고를 작성하도록 하여 지참하게 하거나, 애플리케이션을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        384.90936279296875,
        545.9400024414062,
        400.72967529296875
      ],
      "page_num": 89,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통해 정보를 수집한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        414.90936279296875,
        273.6600036621094,
        430.72967529296875
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 디지털치료기기에 대한 사용자 반응 평가를 함께 수행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        444.90936279296875,
        521.2429809570312,
        460.72967529296875
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 이상 반응 확인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        474.90936279296875,
        213.83999633789062,
        490.72967529296875
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        504.90936279296875,
        545.9400024414062,
        520.7296752929688
      ],
      "page_num": 89,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        534.9093627929688,
        538.4400024414062,
        550.7296752929688
      ],
      "page_num": 89,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        564.9093627929688,
        546.0599975585938,
        580.7296752929688
      ],
      "page_num": 89,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용을 기록한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        594.9093627929688,
        229.88296508789062,
        610.7296752929688
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        99.95999908447266,
        623.1599731445312,
        538.439697265625,
        638.7119750976562
      ],
      "page_num": 89,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대체 수집할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        119.39999389648438,
        649.199951171875,
        242.21519470214844,
        664.751953125
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 병용약물 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        676.9893798828125,
        206.27999877929688,
        692.8096923828125
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        706.9893798828125,
        521.2429809570312,
        722.8096923828125
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        736.9893798828125,
        538.5599975585938,
        752.8096923828125
      ],
      "page_num": 89,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 83 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 90,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        84.90937042236328,
        545.9400024414062,
        100.72968292236328
      ],
      "page_num": 90,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기간, 목적을 확인한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        114.90937042236328,
        273.0829772949219,
        130.72967529296875
      ],
      "page_num": 90,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라) 순응도 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        144.9093780517578,
        191.27999877929688,
        160.7296905517578
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        174.9093780517578,
        545.9400024414062,
        190.7296905517578
      ],
      "page_num": 90,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "순응도를 조사한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        204.90936279296875,
        241.76296997070312,
        220.72967529296875
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 방문 4 (치료 기간 종료 3개월 후, Follow up)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        264.90936279296875,
        410.6999816894531,
        280.72967529296875
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 장기 효과 검증",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        294.90936279296875,
        213.83999633789062,
        310.72967529296875
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 장기 효과 확인을 위한 일차 유효성 평가지표, 이차 유효성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        324.90936279296875,
        546.0599975585938,
        340.72967529296875
      ],
      "page_num": 90,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가지표의 변화를 검증하기 위해 우울장애 심각도 척도 및",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        354.90936279296875,
        545.9400024414062,
        370.72967529296875
      ],
      "page_num": 90,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당하는 자가 보고를 작성하도록 하여 지참하게 하거나,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        384.90936279296875,
        546.0599975585938,
        400.72967529296875
      ],
      "page_num": 90,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "애플리케이션, 이메일, 문자, SNS 등을 통해 수집한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        414.90936279296875,
        502.4029541015625,
        430.72967529296875
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 내원은 필수가 아니며 앱, 이메일, 문자 등을 통해 수집할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        101.63999938964844,
        443.1600036621094,
        520.4951782226562,
        458.7120056152344
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 디지털치료기기에 대한 장기 사용자 반응 평가를 함께 수행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        470.9493713378906,
        536.0029296875,
        486.7696838378906
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 이상 반응 확인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        500.9493408203125,
        213.83999633789062,
        516.7696533203125
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        530.9493408203125,
        545.9400024414062,
        546.7696533203125
      ],
      "page_num": 90,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        560.9493408203125,
        538.4400024414062,
        576.7696533203125
      ],
      "page_num": 90,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        590.9493408203125,
        545.9400024414062,
        606.7696533203125
      ],
      "page_num": 90,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용을 기록한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        620.9493408203125,
        226.282958984375,
        636.7696533203125
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 단, 이상반응 여부는 필요시 온라인(앱, 이메일, 문자, SNS 등)으로 대체",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        98.63999938964844,
        649.199951171875,
        538.4402465820312,
        664.751953125
      ],
      "page_num": 90,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수집할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        118.19999694824219,
        675.1199340820312,
        210.41519165039062,
        690.6719360351562
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 병용약물 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        702.9093627929688,
        206.27999877929688,
        718.7296752929688
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        732.9093627929688,
        521.2429809570312,
        748.7296752929688
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 84 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 91,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        84.90937042236328,
        538.5599975585938,
        100.72968292236328
      ],
      "page_num": 91,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        114.90937042236328,
        546.0599975585938,
        130.72967529296875
      ],
      "page_num": 91,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기간, 목적을 확인한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        144.9093780517578,
        270.0829772949219,
        160.7296905517578
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 순응도 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        174.9093780517578,
        191.27999877929688,
        190.7296905517578
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        204.90936279296875,
        545.9400024414062,
        220.72967529296875
      ],
      "page_num": 91,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "순응도를 조사한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        234.90936279296875,
        241.76296997070312,
        250.72967529296875
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 85 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 92,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "12. 예측되는 부작용 및 사용 시 주의사항",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        99.09996032714844,
        374.5196838378906,
        115.0599594116211
      ],
      "page_num": 92,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        77.4000015258789,
        151.9199981689453,
        516.719970703125,
        166.3199920654297
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "등을 제시한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        175.9199981689453,
        148.6199951171875,
        190.3199920654297
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        244.19430541992188,
        94.91999816894531,
        264.1454772949219
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 예측되는 부작용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        280.5093688964844,
        195.72000122070312,
        296.3296813964844
      ],
      "page_num": 92,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 연구에서 적용하는 치료는 디지털 우울장애 인지행동치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        310.5093688964844,
        538.5599975585938,
        326.3296813964844
      ],
      "page_num": 92,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Digital CBT-D)는 행동 요법 또는 인지 요법을 포함한 교육 이외 기타",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        340.5093688964844,
        545.9400024414062,
        356.3296813964844
      ],
      "page_num": 92,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "침습적이거나, 환자에게 유해를 끼칠 수 있는 내용은 포함되어 있지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        370.5093688964844,
        546.0599975585938,
        386.3296813964844
      ],
      "page_num": 92,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않다. 다만, 일반적인 우울장애 인지행동치료(CBT-D)의 부작용에 준하는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        400.5093688964844,
        545.9400024414062,
        416.3296813964844
      ],
      "page_num": 92,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부작용 또는 범용장비 사용으로 인한 부작용을 예상할 수 있고, 이는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        430.5093688964844,
        545.9400024414062,
        446.3296813964844
      ],
      "page_num": 92,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다음과 같다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        460.5093688964844,
        141.44296264648438,
        476.3296813964844
      ],
      "page_num": 92,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 우울장애 인지행동치료(CBT-D)의 행동 요법 중 밤 시간의 집중",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        490.5093688964844,
        546.0599975585938,
        506.3296813964844
      ],
      "page_num": 92,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "저하를 불러일으킬 수 있어 3교대자 등 밤 시간 우울장애가 큰",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        520.5093383789062,
        545.9400024414062,
        536.3296508789062
      ],
      "page_num": 92,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피해를 가져올 수 있는 직업군의 환자의 경우 임상시험에서",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        550.5093383789062,
        546.0599975585938,
        566.3296508789062
      ],
      "page_num": 92,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제외한다. 이외에도 치료 시작 시점에서 밤 시간 우울장애가 악화",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        580.5093383789062,
        538.4400024414062,
        596.3296508789062
      ],
      "page_num": 92,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "될 수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통하여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        610.5093383789062,
        545.9400024414062,
        626.3296508789062
      ],
      "page_num": 92,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        640.5093383789062,
        491.6999816894531,
        656.3296508789062
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 우울장애 인지행동치료(CBT-D)의 인지 요법 중 왜곡된 인지 교정의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        670.5093383789062,
        545.9400024414062,
        686.3296508789062
      ],
      "page_num": 92,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우 일시적인 불안감 악화를 가져올 수 있다. 치료 시작 시점에서",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        700.5093383789062,
        545.9400024414062,
        716.3296508789062
      ],
      "page_num": 92,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일시적인 불안감 악화가 나타날 수 있음을 알리고, 24시간 연락",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        730.5093383789062,
        546.0599975585938,
        746.3296508789062
      ],
      "page_num": 92,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 86 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 93,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능한 연구자 번호를 통하여 즉시 상담과 필요하면 의료진 연결이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        84.90937042236328,
        546.0599975585938,
        100.72968292236328
      ],
      "page_num": 93,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능하도록 조치한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        114.90937042236328,
        237.92295837402344,
        130.72967529296875
      ],
      "page_num": 93,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 디지털 우울장애 인지행동치료(Digital CBT-D를 위한 범용 장비",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        144.9093780517578,
        538.5599975585938,
        160.7296905517578
      ],
      "page_num": 93,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(스마트폰 또는 태블릿 PC 등) 사용으로 두통, 눈의 피로, 눈 또는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.55999755859375,
        174.9093780517578,
        546.0599975585938,
        190.7296905517578
      ],
      "page_num": 93,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "근육경련, 눈의 불수의운동, 메스꺼움, 어지럼증, 머리 또는 눈의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.55999755859375,
        204.90936279296875,
        546.0599975585938,
        220.72967529296875
      ],
      "page_num": 93,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불쾌감 또는 통증, 졸림, 피로감과 같은 부작용이 발생할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.55999755859375,
        234.90936279296875,
        546.0599975585938,
        250.72967529296875
      ],
      "page_num": 93,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 경우 24시간 연락 가능한 연구자 번호를 통하여 즉시 상담과",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.55999755859375,
        264.90936279296875,
        545.9400024414062,
        280.72967529296875
      ],
      "page_num": 93,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요하면 의료진 연결이 가능하도록 조치한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.55999755859375,
        294.90936279296875,
        417.2029724121094,
        310.72967529296875
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 연구에서 진행되는 평가는 자가 보고 설문지, 면담 등 모두",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        336.1893615722656,
        545.9400024414062,
        352.0096740722656
      ],
      "page_num": 93,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비침습적인 검사로 이루어져 있으므로 예측되는 부작용은 없다.",
      "font_size": 15.0,
      "font_name": "Haansoft Batang",
      "bbox": [
        56.63999938964844,
        366.1893615722656,
        517.3950805664062,
        382.0096740722656
      ],
      "page_num": 93,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 사용 시 주의사항",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        418.7493591308594,
        203.1599884033203,
        434.5696716308594
      ],
      "page_num": 93,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 연구에서 적용하는 우울장애 개선 디지털치료기기의 부작용,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        448.7493591308594,
        545.9400024414062,
        464.5696716308594
      ],
      "page_num": 93,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반적 주의, 적용상의 주의는 다음과 같다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        478.7493591308594,
        376.3800048828125,
        494.5696716308594
      ],
      "page_num": 93,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 부작용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        508.7493896484375,
        141.36000061035156,
        524.5697021484375
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 제품을 사용한 후 제품에 대한 부적합 반응이 전부 배제될",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        538.7493896484375,
        545.9400024414062,
        554.5697021484375
      ],
      "page_num": 93,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수는 없으며, 이상 반응 문제가 생길 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        568.7493896484375,
        418.5,
        584.5697021484375
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 일반적 주의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        598.7493896484375,
        178.8000030517578,
        614.5697021484375
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사이버 보안과 관련된 사고 발생 시 임상시험 관리자 긴급",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        628.7493896484375,
        545.9400024414062,
        644.5697021484375
      ],
      "page_num": 93,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호로 연락하고 관리자가 조치할 때까지 대기한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.1199951171875,
        658.7493896484375,
        455.48297119140625,
        674.5697021484375
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 적용상의 주의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        688.7493896484375,
        188.75999450683594,
        704.5697021484375
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용 시간, 사용 횟수, 결과 작성 등 임상시험 책임자와 담당자가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        718.7493286132812,
        545.9400024414062,
        734.5696411132812
      ],
      "page_num": 93,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요구한 사용 방법을 준수하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.1199951171875,
        748.7493286132812,
        342.4429626464844,
        764.5696411132812
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 87 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 94,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "13. 중지·탈락 기준",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        99.09996032714844,
        214.44000244140625,
        115.0599594116211
      ],
      "page_num": 94,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 부작용, 이상반응 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상 시험의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.55999755859375,
        162.47999572753906,
        530.8800048828125,
        176.87998962402344
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진행이 피험자의 안전 보호를 위협하여 그 진행을 멈추는 것을 ‘중지’라 하며, 임상",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.23999786376953,
        186.47999572753906,
        530.8800048828125,
        200.87998962402344
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험 개시에서 완료까지 중지될 수 있는 세부 사항을 ‘중지 기준’에 제시한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.23999786376953,
        210.47999572753906,
        530.8200073242188,
        224.87998962402344
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‘중지 처리’에는 각 중지 기준에 대한 유효성 평가 통계 처리 시 그 산입 여부와",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.23999786376953,
        234.47999572753906,
        530.8800048828125,
        248.87998962402344
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자별 중지 사유를 포함한 관련 임상시험 자료의 처리 방법을 제시한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.23999786376953,
        258.47998046875,
        501.17999267578125,
        272.8799743652344
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- ‘탈락’ 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        71.04000091552734,
        282.47998046875,
        530.8800048828125,
        296.8799743652344
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험이 완료되지 못한 경우를 말하며, 그 분류기준을 ‘탈락 기준’에, 탈락의 사유와",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.23999786376953,
        306.47998046875,
        530.8800048828125,
        320.8799743652344
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관련 임상자료의 처리 방법을 ‘탈락 처리’에 구체적으로 제시한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.23999786376953,
        330.47998046875,
        446.5799865722656,
        344.8799743652344
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        402.11431884765625,
        94.91999816894531,
        422.06549072265625
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 중지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        438.4293518066406,
        113.15999603271484,
        454.2496643066406
      ],
      "page_num": 94,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 중지 기준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        468.4293518066406,
        158.87998962402344,
        484.2496643066406
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        498.4293518066406,
        546.0599975585938,
        514.2496337890625
      ],
      "page_num": 94,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 일시 중지시킬 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        528.4293823242188,
        309.8029479980469,
        544.2496948242188
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        558.4293823242188,
        545.9400024414062,
        574.2496948242188
      ],
      "page_num": 94,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것에 무리가 있다고 판단될 때는 임상시험을 중지할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        588.4293823242188,
        523.8829345703125,
        604.2496948242188
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 심각한 부작용 발생으로 조기 종료시킬 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        618.4293823242188,
        447.08294677734375,
        634.2496948242188
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 중지 처리",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        648.4293823242188,
        158.87998962402344,
        664.2496948242188
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        678.4293823242188,
        546.0599975585938,
        694.2496948242188
      ],
      "page_num": 94,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 일시 중지시킬 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        708.4293823242188,
        309.8029479980469,
        724.2496948242188
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 중지 시점까지의 검사 결과 관련 자료는 성능과 안전성 평가를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        738.4293823242188,
        546.0599975585938,
        754.2496948242188
      ],
      "page_num": 94,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 88 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 95,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위한 통계처리 시 삽입할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        84.90937042236328,
        350.60296630859375,
        100.72968292236328
      ],
      "page_num": 95,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 임상시험을 통해 얻은 자료는 성능 및 안전성 분석을 위한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        114.90937042236328,
        546.0599975585938,
        130.72967529296875
      ],
      "page_num": 95,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "데이터가 정해져야 하며, 만약 자료에 결함이 생기면 적절한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        144.9093780517578,
        545.9400024414062,
        160.7296905517578
      ],
      "page_num": 95,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보정 방법을 임상시험계획서에 제시하고 보정 후 분석을 시행",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        174.9093780517578,
        538.4400024414062,
        190.7296905517578
      ],
      "page_num": 95,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하도록 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        204.90936279296875,
        202.282958984375,
        220.72967529296875
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 탈락",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        264.90936279296875,
        113.15999603271484,
        280.72967529296875
      ],
      "page_num": 95,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 탈락 기준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        294.90936279296875,
        158.87998962402344,
        310.72967529296875
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험자는 다음과 같은 경우에 연구 참여 대상자를 시험에서",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        324.90936279296875,
        546.0599975585938,
        340.72967529296875
      ],
      "page_num": 95,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "탈락시킬 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.55999755859375,
        354.90936279296875,
        215.60296630859375,
        370.72967529296875
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자가 임상시험 중 임상시험 참여 중단을 요구하거나 시험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        384.90936279296875,
        538.4400024414062,
        400.72967529296875
      ],
      "page_num": 95,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참여 동의를 철회하는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        414.90936279296875,
        300.3599853515625,
        430.72967529296875
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 3개월 이내에 자살 시도를 한 바 있으며, 정신과 전문의에 의해",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        444.90936279296875,
        545.9400024414062,
        460.72967529296875
      ],
      "page_num": 95,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자살 고위험군으로 판단되는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        474.90936279296875,
        346.79998779296875,
        490.72967529296875
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 콜롬비아 자살 위험성 스케일(C-SSRS) 혹은 이와 유사한 과학적",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        114.95999908447266,
        503.1600036621094,
        538.4405517578125,
        518.7119750976562
      ],
      "page_num": 95,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "근거를 가진 자살 위험성 평가상 자살 고위험군으로 평가되는 자",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        134.39999389648438,
        529.199951171875,
        524.2799682617188,
        544.751953125
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자의 부작용(예: 두통, 눈의 피로, 눈 또는 근육경련, 눈의 불",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        556.9893798828125,
        538.5599365234375,
        572.8096923828125
      ],
      "page_num": 95,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수의운동, 메스꺼움, 어지럼증 등)으로 인하여 임상시험 책임자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        586.9893798828125,
        546.0599975585938,
        602.8096923828125
      ],
      "page_num": 95,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 담당자가 임상시험 수행이 불가능한 것으로 판단한 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        616.9893798828125,
        535.2000122070312,
        632.8096923828125
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자가 임상시험 중 임상시험용 의료기기 비교 평가하는 데",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        646.9893798828125,
        545.9400024414062,
        662.8096923828125
      ],
      "page_num": 95,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영향을 줄 것으로 예상하는 약물을 임의로 복용한 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        676.9893798828125,
        495.1199951171875,
        692.8096923828125
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자의 임상시험 중 임상시험용 의료기기 비교 평가하는 데",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        706.9893798828125,
        545.9400024414062,
        722.8096923828125
      ],
      "page_num": 95,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영향을 줄 수 있는 약물의 사용량이 변경된 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        736.9893798828125,
        450.5999755859375,
        752.8096923828125
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 89 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 96,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 임상시험 중 선정/제외 기준 위반 등 중대한 계획서 위반 사항이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        84.90937042236328,
        545.9400024414062,
        100.72968292236328
      ],
      "page_num": 96,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발견되는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        114.90937042236328,
        213.239990234375,
        130.72967529296875
      ],
      "page_num": 96,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 피험자가 제때 방문을 안 하며 연락이 안 되는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        144.9093780517578,
        472.79998779296875,
        160.7296905517578
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 기타 사유로 인하여 임상시험 책임자 또는 담당자가 임상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        174.9093780517578,
        538.5599975585938,
        190.7296905517578
      ],
      "page_num": 96,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험을 중지해야 한다고 판단한 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        204.90936279296875,
        378.7200012207031,
        220.72967529296875
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 우울 증상이 지나치게 악화되어 다른 건강 결과 악화가 예상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        234.90936279296875,
        538.4400024414062,
        250.72967529296875
      ],
      "page_num": 96,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        264.90936279296875,
        183.59999084472656,
        280.72967529296875
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 탈락 처리",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        294.90936279296875,
        158.87998962402344,
        310.72967529296875
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 중도 탈락 시, 시험자는 대상자의 임상시험 조기 탈락의 주요",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        324.90936279296875,
        545.9400024414062,
        340.72967529296875
      ],
      "page_num": 96,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사유를 평가하여 증례 기록서 임상시험 완료 란에 해당 정보를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        354.90936279296875,
        546.0599975585938,
        370.72967529296875
      ],
      "page_num": 96,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기재한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        384.90936279296875,
        176.9629669189453,
        400.72967529296875
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 참여 중단 의사를 밝히지 않고 방문에 출석하지 않아 현재",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        414.90936279296875,
        546.0599975585938,
        430.72967529296875
      ],
      "page_num": 96,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상태가 불분명한 대상자의 경우에 시험자는 대상자와 전화",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        444.90936279296875,
        546.0599975585938,
        460.72967529296875
      ],
      "page_num": 96,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통화를 하여 탈락의 주요 사유를 파악하도록 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        474.90936279296875,
        469.282958984375,
        490.72967529296875
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 90 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 97,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "14. 유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 의함)",
      "font_size": 14.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        93.4599609375,
        524.0458374023438,
        109.41996002197266
      ],
      "page_num": 97,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 해당 의료기기의 임상시험에 따른 유효성 평가는 사용된 모든 의료기기를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        71.04000091552734,
        145.1999969482422,
        530.6400146484375,
        159.59999084472656
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능 평가 기준을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.95999908447266,
        169.1999969482422,
        530.5199584960938,
        183.59999084472656
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제시한다. 그 밖에 임상시험 결과의 사용 범위에 따른 성능 평가를 위하여",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.95999908447266,
        193.1999969482422,
        530.6400146484375,
        207.59999084472656
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이차 유효성 평가변수를 제시하여 각 임상 검사 항목 및 검사 방법에 대한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.95999908447266,
        217.1999969482422,
        530.5199584960938,
        231.59999084472656
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준을 제시한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.95999908447266,
        241.1999969482422,
        184.25999450683594,
        255.59999084472656
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 성능 평가방법은 임상시험 기간 동안 일차/이차 유효성 평가변수에 대한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        71.04000091552734,
        265.1999816894531,
        530.6400146484375,
        279.5999755859375
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험군과 대조군간의 비교 분석 방법을 통계적으로 타당하게 제시한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        85.91999816894531,
        289.1999816894531,
        510.05999755859375,
        303.5999755859375
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 통계 분석 방법에 따른 통계적 유의성에 대한 평가 방법과 기준을 제시한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        71.04000091552734,
        313.1999816894531,
        530.5800170898438,
        327.5999755859375
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험을 복수의 임상시험 기관에서 실시하는 경우에는 기관에 따라 임상시험",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.47999572753906,
        337.1999816894531,
        530.6400146484375,
        351.5999755859375
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과에 차이가 있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.47999572753906,
        361.1999816894531,
        530.5199584960938,
        375.5999755859375
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "차이를 보정할 수 있는 경우는 이를 반영하여 분석 결과를 제시해야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.47999572753906,
        385.1999816894531,
        528.0599975585938,
        399.5999755859375
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 유효성의 평가 기준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        454.8693542480469,
        218.1599884033203,
        470.6896667480469
      ],
      "page_num": 97,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        484.1943054199219,
        94.91999816894531,
        504.1454772949219
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[일차 유효성 평가변수]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        511.50933837890625,
        222.05999755859375,
        527.3296508789062
      ],
      "page_num": 97,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료 전 대비 8주 후 우울장애 심각도 척도(BDI) 변화량",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        541.5093383789062,
        469.0199890136719,
        557.3296508789062
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": (치료 8주 후 BDI 점수) – (치료 전 BDI 점수)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        571.5093383789062,
        406.97998046875,
        587.3296508789062
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[이차 유효성 평가변수]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        601.5093383789062,
        214.56468200683594,
        617.3296508789062
      ],
      "page_num": 97,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 치료 전 대비 3개월 후 우울장애 심각도 척도(BDI) 변화량",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        631.5093383789062,
        491.1600036621094,
        647.3296508789062
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 치료 전 대비 8주 및 3개월 후 우울장애 선별 도구 척도(PHQ-9) 변화량",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        661.5093383789062,
        537.719970703125,
        677.3296508789062
      ],
      "page_num": 97,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 치료 전 대비 8주 및 3개월 후 관해율*",
      "font_size": 9.59999942779541,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        689.5499877929688,
        358.5599670410156,
        707.3296508789062
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 관해 정의: 우울장애 심각도 척도(BDI) 13점 이하",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        82.55999755859375,
        719.7599487304688,
        384.72052001953125,
        735.3119506835938
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 91 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 98,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4) 치료 전 대비 8주 및 3개월 후 반응률*",
      "font_size": 9.59999942779541,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        82.94999694824219,
        358.5599670410156,
        100.72968292236328
      ],
      "page_num": 98,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "* 반응 정의: 기저점 대비 일차 유효성 변수(우울장애 심각도 척도[BDI]) 변화량의",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        82.55999755859375,
        113.15999603271484,
        538.4400024414062,
        128.7119903564453
      ],
      "page_num": 98,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비율이 50% 이상이면 반응(호전)이 있는 것으로 평가",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        94.07999420166016,
        139.1999969482422,
        399.4804382324219,
        154.7519989013672
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 삶의 질",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        166.98936462402344,
        143.75999450683594,
        182.80967712402344
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) 사용자 반응 평가(순응도, 만족도, 난이도, 개선점 등)",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        196.98936462402344,
        424.8899841308594,
        212.80967712402344
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7) 기타 이차 유효성 평가변수*들의 치료 전 대비 변화량",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        358.9893798828125,
        471.239990234375,
        374.8096923828125
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 기타 이차 유효성 평가지표 예시는 다음과 같다 <표 17>.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        82.55999755859375,
        387.239990234375,
        436.9751892089844,
        402.7919921875
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "측정 질문 (0점-10점, 시각아날로그척도 사용)",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        181.67999267578125,
        251.87998962402344,
        466.60174560546875,
        267.4320068359375
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        93.47999572753906,
        271.55999755859375,
        516.5399780273438,
        285.9599914550781
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나는 디지털치료기기를 통해 우울장애에 대한 이해도가 더 증가하였다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        93.47999572753906,
        271.55999755859375,
        516.5399780273438,
        285.9599914550781
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        93.47999572753906,
        291.239990234375,
        507.53997802734375,
        305.6399841308594
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나는 다시 우울장애가 심해지면, 이 디지털치료기기를 사용할 것이다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        93.47999572753906,
        291.239990234375,
        507.53997802734375,
        305.6399841308594
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        93.47999572753906,
        309.7200012207031,
        521.3399658203125,
        324.1199951171875
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나는 내 주변의 우울장애 환자에게, 이 디지털치료기기를 추천할 것이다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        93.47999572753906,
        309.7200012207031,
        521.3399658203125,
        324.1199951171875
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 16. 사용자 반응 평가 지표 예시",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        192.1199951171875,
        227.99998474121094,
        412.2005615234375,
        243.55198669433594
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "측정 지표",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        297.6000061035156,
        439.9200134277344,
        357.9605712890625,
        455.4720153808594
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        96.83999633789062,
        459.239990234375,
        530.4119873046875,
        473.6399841308594
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "몽고메리-아스버그 우울장애 척도(Montgomery-As˚ - berg Depression Rating Scale, MADRS)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        96.83999633789062,
        459.239990234375,
        530.4119873046875,
        473.6399841308594
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        96.83999633789062,
        479.03997802734375,
        476.6520080566406,
        493.4399719238281
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해밀톤 우울장애 척도(Hamilton Depression Rating Scale, HDRS)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        96.83999633789062,
        479.03997802734375,
        476.6520080566406,
        493.4399719238281
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        96.83999633789062,
        498.9599914550781,
        347.03997802734375,
        513.3599853515625
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "역학용 우울 척도(The Center for Epidemioloꠓ",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        96.83999633789062,
        498.9599914550781,
        347.03997802734375,
        513.3599853515625
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "gical Studies Depression Scale, CES-D)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        345.9599914550781,
        498.9599914550781,
        524.052001953125,
        513.3599853515625
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        96.83999633789062,
        518.760009765625,
        434.8919982910156,
        533.1600341796875
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "쯍 우울 척도(Zung’s Self-Rating Depression Scale, SDS)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        96.83999633789062,
        518.760009765625,
        434.8919982910156,
        533.1600341796875
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        96.83999633789062,
        538.5599975585938,
        396.61199951171875,
        552.9600219726562
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한국인 우울 척도(Korean Depression Scale, KDS)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        96.83999633789062,
        538.5599975585938,
        396.61199951171875,
        552.9600219726562
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        96.83999633789062,
        558.47998046875,
        318.3599853515625,
        572.8800048828125
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "병원 불안 우울 척도(Hospital Anxiꠓ",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        96.83999633789062,
        558.47998046875,
        318.3599853515625,
        572.8800048828125
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ety and Depression Scale, HADS)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        318.3599853515625,
        558.47998046875,
        501.37200927734375,
        572.8800048828125
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        96.83999633789062,
        578.2799682617188,
        397.9320068359375,
        592.6799926757812
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "노인 우울 척도 (Geriatric Depression Scale, GDS)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        96.83999633789062,
        578.2799682617188,
        397.9320068359375,
        592.6799926757812
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        96.83999633789062,
        598.0799560546875,
        520.81201171875,
        612.47998046875
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "무망감 질문지(Hopelessness Depression Symptom Questionnaire, HDSQ)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        96.83999633789062,
        598.0799560546875,
        520.81201171875,
        612.47998046875
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        96.83999633789062,
        618.0,
        417.85198974609375,
        632.4000244140625
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "벡 자살 사고 척도(Beck Suicidal ideation Scale, BSS)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        96.83999633789062,
        618.0,
        417.85198974609375,
        632.4000244140625
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        93.47999572753906,
        637.7999877929688,
        420.37200927734375,
        652.2000122070312
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "역기능적 태도 척도(Dysfunctional Attitude Scale, DAS)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        93.47999572753906,
        637.7999877929688,
        420.37200927734375,
        652.2000122070312
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "11",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        93.47999572753906,
        657.5999755859375,
        441.37200927734375,
        672.0
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "36항 건강수준 척도(Short Form-36 Health Survey, SF-36)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        93.47999572753906,
        657.5999755859375,
        441.37200927734375,
        672.0
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        93.47999572753906,
        677.5199584960938,
        487.81201171875,
        691.9199829101562
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생산성 손실 점수(Work Productivity and Activity Impairment, WPAI)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        93.47999572753906,
        677.5199584960938,
        487.81201171875,
        691.9199829101562
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "13",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        93.47999572753906,
        697.3200073242188,
        305.7599792480469,
        711.7200317382812
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "우울장애 일기를 통한 우울 양상",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        93.47999572753906,
        697.3200073242188,
        305.7599792480469,
        711.7200317382812
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        93.47999572753906,
        717.1199951171875,
        272.7599792480469,
        731.52001953125
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "우울, 불안 관련 증상 유무",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        93.47999572753906,
        717.1199951171875,
        272.7599792480469,
        731.52001953125
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        93.47999572753906,
        737.0399780273438,
        261.0,
        751.4400024414062
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "직업적/사회적 기능 상태",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        93.47999572753906,
        737.0399780273438,
        261.0,
        751.4400024414062
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 17. 우울장애 이차 유효성 평가 지표 예시",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        166.55999755859375,
        416.0400085449219,
        447.7205810546875,
        431.5920104980469
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 92 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 99,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 검사 방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        150.72000122070312,
        100.72968292236328
      ],
      "page_num": 99,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 우울장애 심각도 척도(Beck Depression Inventory, BDI-II)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        114.90937042236328,
        482.4075012207031,
        130.72967529296875
      ],
      "page_num": 99,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애 심각도 척도(BDI-II)는 우울장애의 증상 심각도에 대한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        144.9093780517578,
        545.9400024414062,
        160.7296905517578
      ],
      "page_num": 99,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가를 수행할 수 있으며 질환의 호전 여부를 판단할 수 있는,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        174.9093780517578,
        545.9400024414062,
        190.7296905517578
      ],
      "page_num": 99,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과학적으로 검증된 자가 보고식 설문이다(Beck, 1961). 우울장애",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        204.90936279296875,
        545.9400024414062,
        220.72967529296875
      ],
      "page_num": 99,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "심각도 척도는 DSM-5의 우울장애 진단기준에 근거하여 우울장애를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        234.90936279296875,
        546.0599975585938,
        250.72967529296875
      ],
      "page_num": 99,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정하는 문항 총 21개로 구성되어 있다. 문항은 슬픔, 죄의식, 자살",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        264.90936279296875,
        546.0599975585938,
        280.72967529296875
      ],
      "page_num": 99,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사고, 흥미 결여와 같은 특징적인 우울장애에 관한 것이다. 이들 문항",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        294.90936279296875,
        546.0599975585938,
        310.72967529296875
      ],
      "page_num": 99,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중 19개는 증상이 없는 것에서부터 증가하여 심각도 수준(0~3)을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        324.90936279296875,
        546.0599975585938,
        340.72967529296875
      ],
      "page_num": 99,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나타내며, 나머지 2문항은 행동의 변화(식욕 및 수면)에 대해 반응",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        354.90936279296875,
        538.4400024414062,
        370.72967529296875
      ],
      "page_num": 99,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하도록 구성되어 있다. 21문항에서 인지-정서적 요인과 신체화 요인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        384.90936279296875,
        546.0599975585938,
        400.72967529296875
      ],
      "page_num": 99,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2 요인이 확인되었다. 우울장애 심각도 척도(BDI-II)는 13세 이상의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        414.90936279296875,
        545.9400024414062,
        430.72967529296875
      ],
      "page_num": 99,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "청소년과 성인을 대상으로 실시하며, 점수는 최대 63점이 나오고",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        444.90936279296875,
        546.0599975585938,
        460.72967529296875
      ],
      "page_num": 99,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "점수가 높을수록 우울장애가 심각함을 나타낸다. 현재 BDI-II에 대한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        474.90936279296875,
        546.0599975585938,
        490.72967529296875
      ],
      "page_num": 99,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울 점수에 따라, 약간의 우울(0~13점), 경미한 우울(14~19점), 중증도",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        504.90936279296875,
        546.0599975585938,
        520.7296752929688
      ],
      "page_num": 99,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울(20~28점), 심각한 우울(29~63점)을 나타낸다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        534.9093627929688,
        418.6199951171875,
        550.7296752929688
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 연구에서는 일차 유효성 지표에 대한 검증을 위해 방문 1, 방문 2,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        564.9093627929688,
        546.0599975585938,
        580.7296752929688
      ],
      "page_num": 99,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방문 3, 방문 4에 각각 우울장애 심각도 척도(BDI-II) 자가 보고 설문을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        594.9093627929688,
        545.9400024414062,
        610.7296752929688
      ],
      "page_num": 99,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수행할 예정이다. 단, 필요에 따라 방문 1(스크리닝 단계)에서 측정한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        624.9093627929688,
        545.9400024414062,
        640.7296752929688
      ],
      "page_num": 99,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애 심각도 척도(BDI-II) 정보를 방문 2의 baseline 지표로 활용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        654.9093627929688,
        538.4400024414062,
        670.7296752929688
      ],
      "page_num": 99,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "할 수 있다. 방문 1의 경우 연구자가 직접 피험자와 대면하여 연구에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        684.9093627929688,
        546.0599975585938,
        700.7296752929688
      ],
      "page_num": 99,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 설명을 수행하고 서면동의를 얻은 뒤, 독립된 방에서 설문지를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        714.9093627929688,
        545.9400024414062,
        730.7296752929688
      ],
      "page_num": 99,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공하고 피험자가 스스로 설문에 답하게 5-10분간의 시간을 제공",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        744.9093627929688,
        538.4400024414062,
        760.7296752929688
      ],
      "page_num": 99,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 93 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 100,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "할 예정이며, 이는 방문 2, 3, 4에서도 동일하게 진행될 예정이다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        84.90937042236328,
        545.9400024414062,
        100.72968292236328
      ],
      "page_num": 100,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다만 방문 2, 3의 경우 애플리케이션을 통해 우울장애 심각도 척도",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        114.90937042236328,
        538.4400024414062,
        130.72967529296875
      ],
      "page_num": 100,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(BDI-II) 정보를 수집할 수 있으며, 방문 4는 내원, 애플리케이션,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        144.9093780517578,
        545.9400024414062,
        160.7296905517578
      ],
      "page_num": 100,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이메일, 문자, SNS를 이용하여 설문지를 제공한 뒤 회신받는 것으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        174.9093780517578,
        546.0599975585938,
        190.7296905517578
      ],
      "page_num": 100,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "갈음할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        204.90936279296875,
        193.13999938964844,
        220.72967529296875
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방문 1의 설문에서 13점 이하를 기록할 때 연구 대상에서 제외",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        234.90936279296875,
        538.4400024414062,
        250.72967529296875
      ],
      "page_num": 100,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되게 된다. 방문 3, 4의 설문 점수는 방문 1의 점수와 비교 분석",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        264.90936279296875,
        538.4400024414062,
        280.72967529296875
      ],
      "page_num": 100,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되어 유효성에 대한 검증을 위해 사용될 예정이다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        294.90936279296875,
        435.8029479980469,
        310.72967529296875
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 우울장애 선별 도구(Patient Health Questionnaire-9, PHQ-9)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        340.9893798828125,
        501.12750244140625,
        356.8096923828125
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "우울장애 선별 도구(PHQ-9)란 다른 우울장애 평가척도와 유의한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        370.9893798828125,
        546.0599975585938,
        386.8096923828125
      ],
      "page_num": 100,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공존 타당도를 나타내고 우울장애를 평가하고 선별하는 척도로서의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        400.9893798828125,
        545.9400024414062,
        416.8096923828125
      ],
      "page_num": 100,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신뢰도와 타당도가 입증되었다. PHQ-9의 경우 기존 우울장애 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        430.9893798828125,
        538.4400024414062,
        446.8096923828125
      ],
      "page_num": 100,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "도구보다 문항 수가 적고 작성 시간이 적게 걸려 일차 진료 과정",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        460.9893493652344,
        538.4400024414062,
        476.8096618652344
      ],
      "page_num": 100,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에서도 적용하기 쉬워 우울장애를 선별하는데 유용한 도구이다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        490.9893493652344,
        515.6029663085938,
        506.8096618652344
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "현재 BDI에 대한 우울 점수에 따라, 경도 우울(10~14점), 중등도",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        520.9893798828125,
        553.5,
        536.8096923828125
      ],
      "page_num": 100,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울(15~19점), 심각도 우울(20점 이상)을 나타낸다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        550.9893798828125,
        433.5,
        566.8096923828125
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 기타 이차 유효성 평가변수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        610.9893798828125,
        286.2599792480469,
        626.8096923828125
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "삶의 질, 우울/불안 관련 증상 유무, 직업적/사회적 기능 상태,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        640.9893798828125,
        545.9400024414062,
        656.8096923828125
      ],
      "page_num": 100,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등의 항목에 있어서는 자가 보고 설문 혹은 연구자와 대면 인터뷰를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        670.9893798828125,
        546.0599975585938,
        686.8096923828125
      ],
      "page_num": 100,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통해 측정할 수 있다. 자가 보고 설문의 경우 우울장애 심각도",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        700.9893798828125,
        545.9400024414062,
        716.8096923828125
      ],
      "page_num": 100,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "척도(BDI-II)와 동등한 방식으로 측정할 수 있다. 연구자와 대면",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        730.9893798828125,
        546.0599975585938,
        746.8096923828125
      ],
      "page_num": 100,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 94 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 101,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인터뷰 또한 우울장애 심각도 척도(BDI-II)와 유사한 방식으로 하되,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        84.90937042236328,
        546.0599975585938,
        100.72968292236328
      ],
      "page_num": 101,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자가 보고 설문 대신 연구자와의 인터뷰를 통해 진행되는 방식으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        114.90937042236328,
        546.0599975585938,
        130.72967529296875
      ],
      "page_num": 101,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        144.9093780517578,
        185.60296630859375,
        160.7296905517578
      ],
      "page_num": 101,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용자 반응 평가에 대해서는 애플리케이션 사용 후 측정이 진행",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        174.9093780517578,
        538.4400024414062,
        190.7296905517578
      ],
      "page_num": 101,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되어야 하므로 방문 3, 방문 4에 측정을 수행하여야 한다. 여기에는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        204.90936279296875,
        545.9400024414062,
        220.72967529296875
      ],
      "page_num": 101,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용자의 순응도, 만족도, 난이도, 개선점 등이 포함되어야 하며",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        234.90936279296875,
        546.0599975585938,
        250.72967529296875
      ],
      "page_num": 101,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자가 보고 설문 혹은 연구자와 대면 인터뷰를 통해 측정할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        264.90936279296875,
        545.9400024414062,
        280.72967529296875
      ],
      "page_num": 101,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이외 기타 치료 관련 변수와 같은 방식으로 측정할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        294.90936279296875,
        487.2599792480469,
        310.72967529296875
      ],
      "page_num": 101,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 통계분석방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        354.90936279296875,
        173.16000366210938,
        370.72967529296875
      ],
      "page_num": 101,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 분석대상군",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        384.90936279296875,
        166.3199920654297,
        400.72967529296875
      ],
      "page_num": 101,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 모든 분석 대상자군(Full Analysis Set, FAS)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        414.90936279296875,
        408.60748291015625,
        430.72967529296875
      ],
      "page_num": 101,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "배정된 대로 분석(Intention-to-treat, ITT) 원칙을 따르며,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        444.90936279296875,
        546.0599975585938,
        460.72967529296875
      ],
      "page_num": 101,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무작위배정된 모든 피험자군 중 주요한 선정기준을 위배하거나",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        474.90936279296875,
        546.0599975585938,
        490.72967529296875
      ],
      "page_num": 101,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무작위배정된 후 우울장애 개선 디지털치료기기를 로그인하여,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        504.90936279296875,
        545.9400024414062,
        520.7296752929688
      ],
      "page_num": 101,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한 번이라도 사용한 로그가 존재하지 않거나, 무작위배정 이후",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        534.9093627929688,
        546.0599975585938,
        550.7296752929688
      ],
      "page_num": 101,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일차 유효성 평가자료가 전혀 없는 경우는 제외한다. 1차/2차",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        564.9093627929688,
        545.9400024414062,
        580.7296752929688
      ],
      "page_num": 101,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효성 평가는 모든 분석 대상자군(Full Analysis Set, FAS)를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        594.9093627929688,
        545.9400024414062,
        610.7296752929688
      ],
      "page_num": 101,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요분석군으로 분석한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        624.9093627929688,
        288.2029724121094,
        640.7296752929688
      ],
      "page_num": 101,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 계획서 순응 임상시험대상자군(Per-protocol Set, PPS)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        654.9093627929688,
        479.5274963378906,
        670.7296752929688
      ],
      "page_num": 101,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모든 분석 대상자군(FAS)에 속한 피험자이면서 임상시험 일정",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        684.9093627929688,
        538.5599975585938,
        700.7296752929688
      ],
      "page_num": 101,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대로 모든 수행을 완료하고, 아래의 주요한 임상시험계획 위반이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        714.9093627929688,
        545.9400024414062,
        730.7296752929688
      ],
      "page_num": 101,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없는 피험자로 정의한다. 1차/2차 유효성 평가는 계획서 순응",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        744.9093627929688,
        546.0599975585938,
        760.7296752929688
      ],
      "page_num": 101,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 95 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 102,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험대상자군(PPS)를 보조분석군으로 분석한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        84.90937042236328,
        459.5629577636719,
        100.72968292236328
      ],
      "page_num": 102,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 임상시험 불순응*으로 판단되는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.5999984741211,
        112.94999694824219,
        388.3199768066406,
        130.72967529296875
      ],
      "page_num": 102,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 우울장애 관련한 약물을 복용한 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.5999984741211,
        144.9093780517578,
        390.9599914550781,
        160.7296905517578
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 정신과적 전문치료를 시작한 것으로 판단되는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.5999984741211,
        174.9093780517578,
        488.3999938964844,
        190.7296905517578
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 임상시험 참여 중 심적/신체적 환경 변화로 있는 것으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.5999984741211,
        204.90936279296875,
        545.9400024414062,
        220.72967529296875
      ],
      "page_num": 102,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "판단되는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        136.0800018310547,
        234.90936279296875,
        233.51998901367188,
        250.72967529296875
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 순응도란 어플리케이션 치료 기간 내 총 노출된 모듈 횟수를 통해",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        121.43999481201172,
        263.1600036621094,
        538.4405517578125,
        278.7120056152344
      ],
      "page_num": 102,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가한다. 총 모듈 횟수 중 75% 미만(예, 총 12주의 경우 9주 미만)",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        134.52000427246094,
        289.20001220703125,
        538.4817504882812,
        304.75201416015625
      ],
      "page_num": 102,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 노출되면 ‘불순응’으로 판단한다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        134.52000427246094,
        315.1199951171875,
        357.89520263671875,
        330.6719970703125
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 안전성 자료(Safety Set, SS)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        342.90936279296875,
        302.2875061035156,
        358.72967529296875
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "우울장애 개선 디지털치료기기로 한 번이라도 치료를 받은",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        372.90936279296875,
        546.0599975585938,
        388.72967529296875
      ],
      "page_num": 102,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든 피험자로 정의한다. 안전성 평가는 안전성 자료를 대상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        402.90936279296875,
        538.4400024414062,
        418.72967529296875
      ],
      "page_num": 102,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 분석한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        432.90936279296875,
        209.1229705810547,
        448.72967529296875
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 일차 유효성 평가변수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        492.90936279296875,
        241.3199920654297,
        508.72967529296875
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 치료 전 대비 Post-treatment 후 우울장애 심각도 척도(BDI)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        522.9093627929688,
        546.0599975585938,
        538.7296752929688
      ],
      "page_num": 102,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변화량",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        552.9093627929688,
        162.239990234375,
        568.7296752929688
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": 각 시점에서의 우울장애 심각도 척도(BDI) 총점수와 Post-",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        582.9093627929688,
        546.0599975585938,
        598.7296752929688
      ],
      "page_num": 102,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "treatment 후 변화량의 평균과 표준편차를 제시한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        126.23999786376953,
        612.9093627929688,
        487.52294921875,
        628.7296752929688
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": Post-treatment 후 변화량의 군간 차이 검정은 기저치를 공",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        642.9093627929688,
        538.5599975585938,
        658.7296752929688
      ],
      "page_num": 102,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변량으로 한 공분산분석(ANCOVA)을 적용한다. P-value와",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        126.23999786376953,
        672.9093627929688,
        546.0599975585938,
        688.7296752929688
      ],
      "page_num": 102,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함께 양측 95% 신뢰구간을 제시한다. 대조군 대비 시험군의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        126.23999786376953,
        702.9093627929688,
        546.0599975585938,
        718.7296752929688
      ],
      "page_num": 102,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평균 변화량이 우월한 방향에 있고 P-value가 유의수준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        126.23999786376953,
        732.9093627929688,
        545.9400024414062,
        748.7296752929688
      ],
      "page_num": 102,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 96 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 103,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "0.05에서 작으면 통계적으로 우월하다고 판단한다. 또한,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        126.23999786376953,
        84.90937042236328,
        545.9400024414062,
        100.72968292236328
      ],
      "page_num": 103,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과에 대한 임상적 평가를 제시한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        126.23999786376953,
        114.90937042236328,
        385.282958984375,
        130.72967529296875
      ],
      "page_num": 103,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 이차 유효성 평가변수:",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        174.9093780517578,
        252.89999389648438,
        190.7296905517578
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 치료 전 대비 3개월 후 우울장애 심각도 척도(BDI), 8주 후",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        204.90936279296875,
        545.9400024414062,
        220.72967529296875
      ],
      "page_num": 103,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 3개월 후 우울장애 선별 도구(PHQ-9) 변화량",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        234.90936279296875,
        444.239990234375,
        250.72967529296875
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": 각 유효성 평가변수의 각 시점의 변화량에 대해 기저치, 성,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        264.90936279296875,
        545.9400024414062,
        280.72967529296875
      ],
      "page_num": 103,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연령을 포함한 공분산분석을 적용하여 다른 변수를 통제한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        294.90936279296875,
        545.9400024414062,
        310.72967529296875
      ],
      "page_num": 103,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "후 배정군간 평균 변화량 차이가 있는지 양측 유의수준 0.05",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        324.90936279296875,
        538.5,
        340.72967529296875
      ],
      "page_num": 103,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에서 통계적 우월성을 평가한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        354.90936279296875,
        343.0199890136719,
        370.72967529296875
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 치료 전 대비 8주 후 및 3개월 후 관해율, 반응율",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        384.90936279296875,
        454.55999755859375,
        400.72967529296875
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": 치료 전 대비 치료 후 각 시점에서 군간 관해율 및 반응율",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        414.90936279296875,
        546.0599975585938,
        430.72967529296875
      ],
      "page_num": 103,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "차이는 카이제곱검정(Chi-square test) 혹은 피셔정확검정",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        444.90936279296875,
        538.5599975585938,
        460.72967529296875
      ],
      "page_num": 103,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Fisher’s exact test; 전체 셀의 20% 이상에서 기대빈도 5",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        474.90936279296875,
        545.9400024414062,
        490.72967529296875
      ],
      "page_num": 103,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미만인 경우)을 통해 양측 유의수준 0.05에서 통계적 우월성을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        504.90936279296875,
        545.9400024414062,
        520.7296752929688
      ],
      "page_num": 103,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        534.9093627929688,
        178.04296875,
        550.7296752929688
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 삶의 질",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        564.9093627929688,
        168.72000122070312,
        580.7296752929688
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": 일차 유효성 평가변수와 동일한 방법을 적용한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        594.9093627929688,
        467.0029602050781,
        610.7296752929688
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 사용자 반응 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        624.9093627929688,
        235.44000244140625,
        640.7296752929688
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": 각 시점에서 군간 답변 차이는 카이제곱검정 혹은 피셔정확",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        654.9093627929688,
        538.4400024414062,
        670.7296752929688
      ],
      "page_num": 103,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검정을 통해 양측 유의수준 0.05에서 통계적 우월성을 평가한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        684.9093627929688,
        535.04296875,
        700.7296752929688
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 우울/불안 관련 증상 유무 및 직업적/사회적 기능 상태",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        714.9093627929688,
        489.47998046875,
        730.7296752929688
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": 각 시점에서 군간 응답 빈도와 비율을 제시하고 필요 시 카이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        744.9093627929688,
        538.4400024414062,
        760.7296752929688
      ],
      "page_num": 103,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 97 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 104,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제곱검정 혹은 피셔정확검정을 통해 유의수준 0.05에서 통계적",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        84.90937042236328,
        546.0599975585938,
        100.72968292236328
      ],
      "page_num": 104,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가를 수행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        114.90937042236328,
        220.40296936035156,
        130.72967529296875
      ],
      "page_num": 104,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4) 결측값 처리",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        174.9093780517578,
        173.87998962402344,
        190.7296905517578
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 모든 분석 대상자군(Full Analysis Set, FAS)에서 중도 탈락 등의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        204.90936279296875,
        545.9400024414062,
        220.72967529296875
      ],
      "page_num": 104,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사유로 치료 후 시점에서 발생하는 결측치는 일차/이차 유효성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        234.90936279296875,
        546.0599975585938,
        250.72967529296875
      ],
      "page_num": 104,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가변수에 대해서는 마지막 관측값 선행 대체법(Last Observation",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        264.90936279296875,
        545.9400024414062,
        280.72967529296875
      ],
      "page_num": 104,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Carried Forward, LOCF) 방법으로 대치한다. 그 외 자료는 대치",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        294.90936279296875,
        545.9400024414062,
        310.72967529296875
      ],
      "page_num": 104,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "처리 없이 수집된 자료로 분석한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        324.90936279296875,
        341.36297607421875,
        340.72967529296875
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 이상치 처리",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        354.90936279296875,
        173.87998962402344,
        370.72967529296875
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 각 변수에 대해 이상치는 별도로 고려하지 않는다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        384.90936279296875,
        461.84295654296875,
        400.72967529296875
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) 하위 분석",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        414.90936279296875,
        158.87998962402344,
        430.72967529296875
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 1차 유효성 평가 결과가 피험자의 하위집단(성별, 연령별 등)에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        444.90936279296875,
        545.9400024414062,
        460.72967529296875
      ],
      "page_num": 104,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라 차이가 있는지를 확인하기 위해 하위 분석을 제시한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        474.90936279296875,
        528.6829833984375,
        490.72967529296875
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7) 민감도분석",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        504.90936279296875,
        166.3199920654297,
        520.7296752929688
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 1차 유효성 평가 결과가 기관에 따라 차이가 있는지를 확인하기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        534.9093627929688,
        545.9400024414062,
        550.7296752929688
      ],
      "page_num": 104,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해 기관 및 기관과 그룹 간 상호작용을 공분산 분석 모형에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        564.9093627929688,
        546.0599975585938,
        580.7296752929688
      ],
      "page_num": 104,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함하여 기관에 따른 군간 차이가 있는지 분석하여 제시한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        594.9093627929688,
        535.4029541015625,
        610.7296752929688
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 대치 처리하지 않고 결측치를 고려한 반복 측정 혼합 모형을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        624.9093627929688,
        545.9400024414062,
        640.7296752929688
      ],
      "page_num": 104,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적용하여 주요 결과와 차이가 있는지 분석하여 제시한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        654.9093627929688,
        506.3629455566406,
        670.7296752929688
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8) 중간 분석",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        684.9093627929688,
        158.87998962402344,
        700.7296752929688
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 본 연구는 중간 분석을 수행하지 않는다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        714.9093627929688,
        395.1229553222656,
        730.7296752929688
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 98 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 105,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "9) 안전성 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        84.90937042236328,
        173.87998962402344,
        100.72968292236328
      ],
      "page_num": 105,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 안전성 평가에서는 수집된 이상 사례의 유형, 임상시험용 의료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        114.90937042236328,
        538.4400024414062,
        130.72967529296875
      ],
      "page_num": 105,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기와의 인과성, 중대성 등을 발생한 환자 수, 발생 빈도 수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        144.9093780517578,
        545.9400024414062,
        160.7296905517578
      ],
      "page_num": 105,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 백분율을 군별로 제시한다. 필요하면 카이제곱검정(Chi-square",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        174.9093780517578,
        545.9400024414062,
        190.7296905517578
      ],
      "page_num": 105,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "test) 혹은 피셔정확검정(Fisher’s exact test; 전체 셀의 20%",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        204.90936279296875,
        545.9400024414062,
        220.72967529296875
      ],
      "page_num": 105,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상에서 기대빈도 5 미만인 경우)을 통해 발생 환자 비율의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        234.90936279296875,
        546.0599975585938,
        250.72967529296875
      ],
      "page_num": 105,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "차이가 있는지 평가한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        264.90936279296875,
        283.8829650878906,
        280.72967529296875
      ],
      "page_num": 105,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 99 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        803.6103515625,
        314.625,
        813.5703125
      ],
      "page_num": 106,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "15. 부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        99.09996032714844,
        525.96044921875,
        115.0599594116211
      ],
      "page_num": 106,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생 시",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.91999816894531,
        150.239990234375,
        530.6400146484375,
        164.63998413085938
      ],
      "page_num": 106,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‘의료기기 임상시험 관리기준’(의료기기법 시행규칙 [별표3])에 의거, 정한 기간",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        174.239990234375,
        530.5199584960938,
        188.63998413085938
      ],
      "page_num": 106,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내에 가능한 신속한 보고가 되어야 하며, 이상반응 등에 대한 의학적 소견·",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        198.239990234375,
        530.6520385742188,
        212.63998413085938
      ],
      "page_num": 106,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정도와",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        222.239990234375,
        530.6400146484375,
        236.63998413085938
      ],
      "page_num": 106,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        222.239990234375,
        530.6400146484375,
        236.63998413085938
      ],
      "page_num": 106,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기와의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        222.239990234375,
        530.6400146484375,
        236.63998413085938
      ],
      "page_num": 106,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인과관계를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        222.239990234375,
        530.6400146484375,
        236.63998413085938
      ],
      "page_num": 106,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가하여",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        222.239990234375,
        530.6400146484375,
        236.63998413085938
      ],
      "page_num": 106,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증례기록서에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        222.239990234375,
        530.6400146484375,
        236.63998413085938
      ],
      "page_num": 106,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기록",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        222.239990234375,
        530.6400146484375,
        236.63998413085938
      ],
      "page_num": 106,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하여야",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        246.239990234375,
        530.5199584960938,
        260.6399841308594
      ],
      "page_num": 106,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한다. 따라서 이상반응에 대한 임상시험용 의료기기와의 인과관계에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        246.239990234375,
        530.5199584960938,
        260.6399841308594
      ],
      "page_num": 106,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 평가 기준을 제시하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        270.239990234375,
        276.8999938964844,
        284.6399841308594
      ],
      "page_num": 106,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        316.7943115234375,
        94.91999816894531,
        336.7454833984375
      ],
      "page_num": 106,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 피험자 안전성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        343.9893798828125,
        180.72000122070312,
        359.8096923828125
      ],
      "page_num": 106,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 임상시험은 저위험(low-risk) 치료용 의료기기의 임상적 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        373.9893798828125,
        538.5599975585938,
        389.8096923828125
      ],
      "page_num": 106,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이므로 피험자가 직접적으로 받는 인체의 위해도가 없을 수도 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        403.9893798828125,
        546.0599975585938,
        419.8096923828125
      ],
      "page_num": 106,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하지만, 치료 도중 피험자한테 문제(예: 낮 시간 졸음이 과도한 현상 등)가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        433.9893798828125,
        546.0599975585938,
        449.8096923828125
      ],
      "page_num": 106,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발생하면 임상시험 담당 연구진에게 연락할 수 있는 긴급 연락망을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        463.9893493652344,
        546.0599975585938,
        479.8096618652344
      ],
      "page_num": 106,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공하고, 디지털 기기(애플리케이션) 사용 관련한 문제(예: 버그 문제,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        493.9893493652344,
        546.0599975585938,
        509.8096618652344
      ],
      "page_num": 106,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로그인 실패 등)가 발생하면 회사 측 고객센터로 연락할 수 있는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        523.9893798828125,
        545.9400024414062,
        539.8096923828125
      ],
      "page_num": 106,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "별도의 연락망을 제공한다. 긴급 연락망과 방문을 통해 이상 반응을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        553.9893798828125,
        546.0599975585938,
        569.8096923828125
      ],
      "page_num": 106,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수집한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        583.9893798828125,
        120.68296813964844,
        599.8096923828125
      ],
      "page_num": 106,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 시험자 안전성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        643.9893798828125,
        180.72000122070312,
        659.8096923828125
      ],
      "page_num": 106,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 임상시험용 의료기기는 소프트웨어에 속하며 비침습적이며 짧은",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        673.9893798828125,
        546.0599975585938,
        689.8096923828125
      ],
      "page_num": 106,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기간 동안 임상시험에 참여하기 때문에 안전에 대한 위험은 없다고",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        703.9893798828125,
        546.0599975585938,
        719.8096923828125
      ],
      "page_num": 106,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        733.9893798828125,
        135.68296813964844,
        749.8096923828125
      ],
      "page_num": 106,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 100 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        803.6103515625,
        317.5050048828125,
        813.5703125
      ],
      "page_num": 107,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 이상 사례의 정의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        203.1599884033203,
        100.72968292236328
      ],
      "page_num": 107,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 이상 사례(Adverse Event, AE)란 임상시험 중 피험자에게 발생한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        114.90937042236328,
        546.0599975585938,
        130.72967529296875
      ],
      "page_num": 107,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든 의도하지 않은 증후(sign), 증상(symptom) 또는 질병을 말하며,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        144.9093780517578,
        546.0599975585938,
        160.7296905517578
      ],
      "page_num": 107,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 임상시험용 의료기기와 반드시 인과관계를 가져야 하는 것은",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        174.9093780517578,
        546.0599975585938,
        190.7296905517578
      ],
      "page_num": 107,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아니다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        204.90936279296875,
        140.3629608154297,
        220.72967529296875
      ],
      "page_num": 107,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 의료기기 이상 반응(Adverse Device Effect, ADE)이란 임상시험용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        234.90936279296875,
        546.0599975585938,
        250.72967529296875
      ],
      "page_num": 107,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기로 인하여 발생한 모든 유해하고 의도하지 않은 반응으로서",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.07999420166016,
        264.90936279296875,
        545.9400024414062,
        280.72967529296875
      ],
      "page_num": 107,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험용 의료기기와의 인과관계를 부정할 수 없는 경우를 말한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.07999420166016,
        294.90936279296875,
        536.2429809570312,
        310.72967529296875
      ],
      "page_num": 107,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○ 의료기기의 오류(결함)로 인한 오진률 발생 가능성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        324.90936279296875,
        460.79998779296875,
        340.72967529296875
      ],
      "page_num": 107,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 이상 사례의 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        364.7493591308594,
        203.1599884033203,
        380.5696716308594
      ],
      "page_num": 107,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 임상시험용 의료기기와의 인과관계 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        394.7493591308594,
        368.7599792480469,
        410.5696716308594
      ],
      "page_num": 107,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이상 사례 발현 시 임상시험용 의료기기와의 관련성 여부는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        424.7493591308594,
        545.9400024414062,
        440.5696716308594
      ],
      "page_num": 107,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험자가 다음 기준에 의하여 평가하며, 시험자의 의견을 기술",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        94.07999420166016,
        454.7493591308594,
        538.5599975585938,
        470.5696716308594
      ],
      "page_num": 107,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        94.07999420166016,
        484.7493591308594,
        128.12295532226562,
        500.5696716308594
      ],
      "page_num": 107,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○ 관련성이 명백함(Definitely related)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        514.7493896484375,
        353.16748046875,
        530.5697021484375
      ],
      "page_num": 107,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        544.7493896484375,
        546.0599975585938,
        560.5697021484375
      ],
      "page_num": 107,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "순서가 타당한 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        574.7493896484375,
        255.1199951171875,
        590.5697021484375
      ],
      "page_num": 107,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 이상 반응이 다른 어떤 이유보다 임상시험용 의료기기의 사용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        604.7493896484375,
        545.9400024414062,
        620.5697021484375
      ],
      "page_num": 107,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "때문에 가장 개연성이 있게 설명되는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        634.7493896484375,
        406.0799865722656,
        650.5697021484375
      ],
      "page_num": 107,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 사용 중단으로 이상 반응이 없어지는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        664.7493896484375,
        406.0799865722656,
        680.5697021484375
      ],
      "page_num": 107,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 재사용(재사용이 가능한 경우에만 실시) 결과가 양성인 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        694.7493896484375,
        526.6799926757812,
        710.5697021484375
      ],
      "page_num": 107,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 이상 반응이 임상시험용 의료기기 또는 동일 계열의 의료기기에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        724.7493286132812,
        545.9400024414062,
        740.5696411132812
      ],
      "page_num": 107,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해 이미 알려진 정보와 일관된 양상을 보이는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        754.7493286132812,
        480.239990234375,
        770.5696411132812
      ],
      "page_num": 107,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 101 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        803.6103515625,
        317.5050048828125,
        813.5703125
      ],
      "page_num": 108,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○ 관련성이 많음(Probably related)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        84.90937042236328,
        334.3274841308594,
        100.72968292236328
      ],
      "page_num": 108,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 임상시험용 의료기기를 사용하였다는 증거가 있는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        113.46937561035156,
        495.1199951171875,
        129.28968811035156
      ],
      "page_num": 108,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        143.46937561035156,
        545.9400024414062,
        159.28968811035156
      ],
      "page_num": 108,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "타당한 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        173.46937561035156,
        196.44000244140625,
        189.28968811035156
      ],
      "page_num": 108,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 이상 반응이 다른 원인보다 임상시험용 의료기기의 사용으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        203.46937561035156,
        546.0599975585938,
        219.28968811035156
      ],
      "page_num": 108,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "더욱 개연성이 있게 설명되는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        233.46937561035156,
        347.6399841308594,
        249.28968811035156
      ],
      "page_num": 108,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험용 의료기기의 사용 중단으로 이상 반응이 사라지는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        263.4693603515625,
        546.0599975585938,
        279.2896728515625
      ],
      "page_num": 108,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        293.4693603515625,
        146.52000427246094,
        309.2896728515625
      ],
      "page_num": 108,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○ 관련성이 의심됨(Possibly related)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        323.4693603515625,
        341.16748046875,
        339.2896728515625
      ],
      "page_num": 108,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험용 의료기기를 사용하였다는 증거가 있는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        353.4693603515625,
        495.1199951171875,
        369.2896728515625
      ],
      "page_num": 108,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        383.4693603515625,
        545.9400024414062,
        399.2896728515625
      ],
      "page_num": 108,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "타당한 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        413.4693603515625,
        196.44000244140625,
        429.2896728515625
      ],
      "page_num": 108,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 이상 반응이 다른 가능성이 있는 원인과 같은 수준으로 임상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        443.4693603515625,
        538.4400024414062,
        459.2896728515625
      ],
      "page_num": 108,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험용 의료기기의 사용에 기인한다고 판단되는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        473.4693603515625,
        476.5199890136719,
        489.2896728515625
      ],
      "page_num": 108,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험용 의료기기의 사용 중단으로(실시된 경우) 이상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        503.4693603515625,
        546.0599975585938,
        519.2896728515625
      ],
      "page_num": 108,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반응이 사라지는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        533.4693603515625,
        269.5199890136719,
        549.2896728515625
      ],
      "page_num": 108,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○ 관련성이 적음(Probably not related)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        563.4693603515625,
        360.36749267578125,
        579.2896728515625
      ],
      "page_num": 108,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험용 의료기기를 사용하였다는 증거가 있는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        593.4693603515625,
        495.1199951171875,
        609.2896728515625
      ],
      "page_num": 108,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 이상 반응에 대해 보다 가능성 있는 원인이 있는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        623.4693603515625,
        487.67999267578125,
        639.2896728515625
      ],
      "page_num": 108,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험용 의료기기의 사용 중단 결과(실시된 경우)가 음성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        653.4693603515625,
        538.5599975585938,
        669.2896728515625
      ],
      "page_num": 108,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이거나 모호한 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        683.4693603515625,
        250.3199920654297,
        699.2896728515625
      ],
      "page_num": 108,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험용 의료기기의 재사용(실시된 경우) 결과가 음성이거나",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        713.4693603515625,
        546.0599975585938,
        729.2896728515625
      ],
      "page_num": 108,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모호한 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        743.4693603515625,
        196.44000244140625,
        759.2896728515625
      ],
      "page_num": 108,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 102 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        803.6103515625,
        317.5050048828125,
        813.5703125
      ],
      "page_num": 109,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○ 관련성이 없음(Definitely not related)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        84.90937042236328,
        366.72747802734375,
        100.72968292236328
      ],
      "page_num": 109,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 임상시험용 의료기기를 사용하지 않은 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        114.90937042236328,
        413.5199890136719,
        130.72967529296875
      ],
      "page_num": 109,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 임상시험용 의료기기의 사용과 이상 반응 발현과의 시간적",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        144.9093780517578,
        545.9400024414062,
        160.7296905517578
      ],
      "page_num": 109,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "순서가 타당하지 않은 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        174.9093780517578,
        302.2799987792969,
        190.7296905517578
      ],
      "page_num": 109,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 이상 반응에 대해 다른 명백한 원인이 있는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        204.90936279296875,
        450.5999755859375,
        220.72967529296875
      ],
      "page_num": 109,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○ 평가 불가능(Unknown)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        234.90936279296875,
        269.7674865722656,
        250.72967529296875
      ],
      "page_num": 109,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 정보가 불충분하거나 상충하여 판단할 수 없고 이를 보완",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        264.90936279296875,
        538.4400024414062,
        280.72967529296875
      ],
      "page_num": 109,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하거나 확인할 수 없는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        294.90936279296875,
        309.6000061035156,
        310.72967529296875
      ],
      "page_num": 109,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마. 안전성의 평가 기준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        354.90936279296875,
        218.1599884033203,
        370.72967529296875
      ],
      "page_num": 109,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 임상시험에서 이상 반응은 임상시험 시작 전에 관찰되지 않은",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        384.90936279296875,
        545.9400024414062,
        400.72967529296875
      ],
      "page_num": 109,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증상이 발생하는 모든 바람직하지 않은 의학적ㆍ물리적 소견을 이상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        414.90936279296875,
        546.0599975585938,
        430.72967529296875
      ],
      "page_num": 109,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반응으로 분류한다. 예측되는 부작용도 이상 반응으로 분류한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        444.90936279296875,
        499.6429443359375,
        460.72967529296875
      ],
      "page_num": 109,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바. 이상 사례 보고 방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        504.90936279296875,
        225.59999084472656,
        520.7296752929688
      ],
      "page_num": 109,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 이상 사례 교육",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.5999984741211,
        534.9093627929688,
        191.27999877929688,
        550.7296752929688
      ],
      "page_num": 109,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○ 시험책임자는 시험담당자 또는 임상의 등에게 임상시험용 의료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        564.9093627929688,
        538.5599975585938,
        580.7296752929688
      ],
      "page_num": 109,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기 사용 후 나타날 수 있는 모든 이상 사례에 대하여 교육을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.39999389648438,
        594.9093627929688,
        546.0599975585938,
        610.7296752929688
      ],
      "page_num": 109,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고 사용 후 나타나는 모든 현상에 대하여 보고하도록 교육을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.39999389648438,
        624.9093627929688,
        545.9400024414062,
        640.7296752929688
      ],
      "page_num": 109,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.39999389648438,
        654.9093627929688,
        144.44296264648438,
        670.7296752929688
      ],
      "page_num": 109,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 중대한 이상사례·의료기기 이상반응 보고",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.5999984741211,
        684.9093627929688,
        378.8399963378906,
        700.7296752929688
      ],
      "page_num": 109,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※",
      "font_size": 12.960000038146973,
      "font_name": "T13",
      "bbox": [
        56.63999938964844,
        713.1599731445312,
        538.4400024414062,
        728.7119750976562
      ],
      "page_num": 109,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 내용은「의료기기법 시행규칙」별표 3“의료기기 임상시험 관리기준” 제8호",
      "font_size": 12.960000038146973,
      "font_name": "T14",
      "bbox": [
        56.63999938964844,
        713.1599731445312,
        538.4400024414062,
        728.7119750976562
      ],
      "page_num": 109,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "러목(의료기기이상반응의 보고)에 따른다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        82.68000030517578,
        739.199951171875,
        327.1752014160156,
        754.751953125
      ],
      "page_num": 109,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 103 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        803.6103515625,
        317.5050048828125,
        813.5703125
      ],
      "page_num": 110,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○ 이외에도 시험자가 중대하다고 간주하거나, 임상시험용 의료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        84.90937042236328,
        538.4400024414062,
        100.72968292236328
      ],
      "page_num": 110,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기와의 사용과 연관 지을 수 있는 유의한 위험, 금기, 부작용,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.23999786376953,
        114.90937042236328,
        545.9400024414062,
        130.72967529296875
      ],
      "page_num": 110,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주의사항을 시사하는 사건 등도 중대한 이상사례/의료기기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.23999786376953,
        144.9093780517578,
        545.9400024414062,
        160.7296905517578
      ],
      "page_num": 110,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상반응으로 기록하고 사망을 초래하거나 생명을 위협할 때는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.23999786376953,
        174.9093780517578,
        546.0599975585938,
        190.7296905517578
      ],
      "page_num": 110,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의뢰자가 이 사실을 보고받거나 알게 된 날로부터 7일 이내,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.23999786376953,
        204.90936279296875,
        546.0599975585938,
        220.72967529296875
      ],
      "page_num": 110,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 경우 상세한 정보를 최초 보고일로부터 8일 이내에 추가로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.23999786376953,
        234.90936279296875,
        546.0599975585938,
        250.72967529296875
      ],
      "page_num": 110,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보고 하여야 한다. 그 밖의 중대하거나 예상하지 못한 모든",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.23999786376953,
        264.90936279296875,
        545.9400024414062,
        280.72967529296875
      ],
      "page_num": 110,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상 반응이 나타났을 때 의뢰자가 이 사실을 보고 받거나",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.23999786376953,
        294.90936279296875,
        545.9400024414062,
        310.72967529296875
      ],
      "page_num": 110,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알게 된 날로부터 15일 이내 보고한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.23999786376953,
        324.90936279296875,
        387.5629577636719,
        340.72967529296875
      ],
      "page_num": 110,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 104 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        803.6103515625,
        317.5050048828125,
        813.5703125
      ],
      "page_num": 111,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "16. 피험자 동의서 서식",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        93.4599609375,
        238.44000244140625,
        109.41996002197266
      ],
      "page_num": 111,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험책임자는 의료기기법 시행규칙 제24조 제1항 제4호의 규정에 따라 임상",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.91999816894531,
        143.16000366210938,
        530.5199584960938,
        157.55999755859375
      ],
      "page_num": 111,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화할 때, 헬싱키 선언에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        167.1599884033203,
        530.5199584960938,
        181.5599822998047
      ],
      "page_num": 111,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 서식,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        191.1599884033203,
        530.592041015625,
        205.5599822998047
      ],
      "page_num": 111,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        215.1599884033203,
        530.5800170898438,
        229.5599822998047
      ],
      "page_num": 111,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행규칙",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        64.55999755859375,
        239.1599884033203,
        530.6400146484375,
        253.5599822998047
      ],
      "page_num": 111,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[별표 3])에서 정하고 있다. 이에 따른 피험자 동의서 서식을 제시하여야 하며, 피험자",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        263.1600036621094,
        530.6400146484375,
        277.55999755859375
      ],
      "page_num": 111,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설명서에는 동 기준의 제7호 아목의 10)을 포함하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        287.1600036621094,
        404.94000244140625,
        301.55999755859375
      ],
      "page_num": 111,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        324.23431396484375,
        94.91999816894531,
        344.18548583984375
      ],
      "page_num": 111,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 피험자 동의서에 반드시 포함되어야 하는 사항",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        360.54937744140625,
        405.6000061035156,
        376.36968994140625
      ],
      "page_num": 111,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 임상시험의 연구목적으로 수행된다는 사실",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        390.54937744140625,
        383.7599792480469,
        406.36968994140625
      ],
      "page_num": 111,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 임상시험의 목적",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        420.54937744140625,
        203.87998962402344,
        436.36968994140625
      ],
      "page_num": 111,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 임상시험용 의료기기에 관한 정보 및 시험군 또는 대조군에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        450.54937744140625,
        546.0599975585938,
        466.36968994140625
      ],
      "page_num": 111,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무작위배정 될 확률",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        480.54937744140625,
        226.3199920654297,
        496.36968994140625
      ],
      "page_num": 111,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 침습적 시술(invasive procedure)을 포함하여 임상시험에서 피험자가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        510.54937744140625,
        545.9400024414062,
        526.3696899414062
      ],
      "page_num": 111,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "받게 될 각종 검사나 절차",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        540.5493774414062,
        271.32000732421875,
        556.3696899414062
      ],
      "page_num": 111,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 피험자가 준수하여야 할 사항",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        570.5493774414062,
        293.7599792480469,
        586.3696899414062
      ],
      "page_num": 111,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) 검증되지 않은 임상시험이라는 사실",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        600.5493774414062,
        338.7599792480469,
        616.3696899414062
      ],
      "page_num": 111,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7) 피험자에게 미칠 것으로 예상되는 위험이나 불편",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        630.5493774414062,
        428.7599792480469,
        646.3696899414062
      ],
      "page_num": 111,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8) 기대되는 이익이 있거나 피험자에게 기대되는 이익이 없을 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        660.5493774414062,
        545.9400024414062,
        676.3696899414062
      ],
      "page_num": 111,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그 사실",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        690.5493774414062,
        143.87998962402344,
        706.3696899414062
      ],
      "page_num": 111,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9) 피험자가 선택할 수 있는 다른 치료방법이나 종류 및 그 치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        720.5493774414062,
        545.9400024414062,
        736.3696899414062
      ],
      "page_num": 111,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법의 잠재적 위험과 이익",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        750.5493774414062,
        278.7599792480469,
        766.3696899414062
      ],
      "page_num": 111,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 105 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        803.6103515625,
        317.5050048828125,
        813.5703125
      ],
      "page_num": 112,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10) 임상시험과 관련한 손상이 발생하였을 경우 피험자에게 주어질",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        84.90937042236328,
        545.9400024414062,
        100.72968292236328
      ],
      "page_num": 112,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보상이나 치료방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        114.90937042236328,
        233.8199920654297,
        130.72967529296875
      ],
      "page_num": 112,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "11) 피험자가 임상시험에 참여함으로써 받게 될 금전적 보상이 있는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        144.9093780517578,
        545.9400024414062,
        160.7296905517578
      ],
      "page_num": 112,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우 예상 금액 및 이 금액이 임상시험 참여의 정도나 기간에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        174.9093780517578,
        546.0599975585938,
        190.7296905517578
      ],
      "page_num": 112,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라 조정될 것이라고 하는 것",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        204.90936279296875,
        308.7599792480469,
        220.72967529296875
      ],
      "page_num": 112,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12) 임상시험에 참여함으로써 피험자에게 예상되는 비용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        234.90936279296875,
        454.91998291015625,
        250.72967529296875
      ],
      "page_num": 112,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "13) 피험자의 임상시험 참여 여부 결정은 자발적이어야 하며,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        264.90936279296875,
        545.9400024414062,
        280.72967529296875
      ],
      "page_num": 112,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자가 원래 받을 수 있는 이익에 대한 손실 없이 임상시험의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        294.90936279296875,
        546.0599975585938,
        310.72967529296875
      ],
      "page_num": 112,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참여를 거부하거나 임상시험 도중 언제라도 참여를 포기할 수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        324.90936279296875,
        545.9400024414062,
        340.72967529296875
      ],
      "page_num": 112,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다는 사실",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        354.90936279296875,
        181.3199920654297,
        370.72967529296875
      ],
      "page_num": 112,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14) 제8호 항목에 따른 모니터 요원, 제8호 항목에 따른 점검을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        384.90936279296875,
        546.0599975585938,
        400.72967529296875
      ],
      "page_num": 112,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실시하는 자, 임상시험심사위원회 및 식품의약품안전처장이 관계",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        414.90936279296875,
        546.0599975585938,
        430.72967529296875
      ],
      "page_num": 112,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "법령에 따라 임상시험의 실시 절차와 자료의 품질을 검증하기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        444.90936279296875,
        545.9400024414062,
        460.72967529296875
      ],
      "page_num": 112,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위하여 피험자의 신상에 관한 비밀이 보호되는 범위에서 피험자의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        474.90936279296875,
        545.9400024414062,
        490.72967529296875
      ],
      "page_num": 112,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의무기록을 열람할 수 있다는 사실과 피험자 또는 피험자 대리인의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        504.90936279296875,
        546.0599975585938,
        520.7296752929688
      ],
      "page_num": 112,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서명이 이러한 자료의 열람을 허용하게 된다는 사실",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        534.9093627929688,
        458.7599792480469,
        550.7296752929688
      ],
      "page_num": 112,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15) 피험자의 신상을 파악할 수 있는 기록은 비밀로 보호될 것이며",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        564.9093627929688,
        546.0599975585938,
        580.7296752929688
      ],
      "page_num": 112,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험의 결과가 출관될 경우 피험자의 신상은 비밀로 보호",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        594.9093627929688,
        538.4400024414062,
        610.7296752929688
      ],
      "page_num": 112,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "될 것이라는 사실",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        624.9093627929688,
        218.87998962402344,
        640.7296752929688
      ],
      "page_num": 112,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "16) 피험자의 임상시험 계속 참여 여부에 영향을 줄 수 있는 새로운",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        654.9093627929688,
        546.0599975585938,
        670.7296752929688
      ],
      "page_num": 112,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정보를 취득하면 적시에 피험자 또는 피험자의 대리인에게 알릴",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        684.9093627929688,
        546.0599975585938,
        700.7296752929688
      ],
      "page_num": 112,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이라는 사실",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        714.9093627929688,
        196.3199920654297,
        730.7296752929688
      ],
      "page_num": 112,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "17) 임상시험과 피험자의 권익에 관하여 추가적인 정보를 얻고자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        744.9093627929688,
        545.9400024414062,
        760.7296752929688
      ],
      "page_num": 112,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 106 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        803.6103515625,
        317.5050048828125,
        813.5703125
      ],
      "page_num": 113,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하거나 임상시험과 관련이 있는 손상이 발생하면 연락해야 하는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        84.90937042236328,
        545.9400024414062,
        100.72968292236328
      ],
      "page_num": 113,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사람",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        114.90937042236328,
        128.8800048828125,
        130.72967529296875
      ],
      "page_num": 113,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "18) 임상시험 도중 피험자의 임상시험 참여가 중지되는 경우 및 그",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        144.9093780517578,
        546.0599975585938,
        160.7296905517578
      ],
      "page_num": 113,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사유",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        174.9093780517578,
        128.8800048828125,
        190.7296905517578
      ],
      "page_num": 113,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "19) 피험자의 임상시험 예상 참여 기간",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        204.90936279296875,
        338.7599792480469,
        220.72967529296875
      ],
      "page_num": 113,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20) 임상시험에 참여하는 대략의 피험자 수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        234.90936279296875,
        368.7599792480469,
        250.72967529296875
      ],
      "page_num": 113,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 피험자 동의의 일반적 요건",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        294.90936279296875,
        270.5999755859375,
        310.72967529296875
      ],
      "page_num": 113,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 연구자는 연구를 시작하기 전에 임상시험심사위원회(Institutional",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        324.90936279296875,
        546.0599975585938,
        340.72967529296875
      ],
      "page_num": 113,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Review Board, IRB)로부터 피험자에게 제공될 설명서 및 동의서,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        354.90936279296875,
        546.0599975585938,
        370.72967529296875
      ],
      "page_num": 113,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기타 문서화된 정보의 사전 서면승인을 받아야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        384.90936279296875,
        455.2429504394531,
        400.72967529296875
      ],
      "page_num": 113,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 연구자는 임상시험심사위원회 승인 직인이 찍힌 동의서 등을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        414.90936279296875,
        546.0599975585938,
        430.72967529296875
      ],
      "page_num": 113,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자 또는 피험자의 대리인에게 제공해야 하며, 피험자(또는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        444.90936279296875,
        545.9400024414062,
        460.72967529296875
      ],
      "page_num": 113,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대리인)와 동의를 받은 책임연구자(또는 책임연구자의 위임을 받은",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        474.90936279296875,
        546.0599975585938,
        490.72967529296875
      ],
      "page_num": 113,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자)는 동의서 서식에 서명하고, 자필로 해당 날짜를 기재하여야",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        504.90936279296875,
        545.9400024414062,
        520.7296752929688
      ],
      "page_num": 113,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        534.9093627929688,
        125.36296844482422,
        550.7296752929688
      ],
      "page_num": 113,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 연구자는 서명된 동의서를 보관해야 하며, 사본을 피험자(또는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        564.9093627929688,
        545.9400024414062,
        580.7296752929688
      ],
      "page_num": 113,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대리인)에게 제공해야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        594.9093627929688,
        280.04296875,
        610.7296752929688
      ],
      "page_num": 113,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 동의서를 받는 과정에서 연구자는 피험자 또는 대리인에게 강제나",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        624.9093627929688,
        546.0599975585938,
        640.7296752929688
      ],
      "page_num": 113,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부당한 영향을 미치지 않아야 하며, 피험자 또는 대리인이 연구의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        654.9093627929688,
        546.0599975585938,
        670.7296752929688
      ],
      "page_num": 113,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든 정보를 이해할 수 있는 용어 및 언어로 작성된 동의서 등을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        684.9093627929688,
        546.0599975585938,
        700.7296752929688
      ],
      "page_num": 113,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공하여 설명하고 질문에 대하여 대답한 후 충분히 생각할",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        714.9093627929688,
        546.0599975585938,
        730.7296752929688
      ],
      "page_num": 113,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기회를 제공하여 동의를 얻어야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        744.9093627929688,
        350.36297607421875,
        760.7296752929688
      ],
      "page_num": 113,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 107 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        803.6103515625,
        317.5050048828125,
        813.5703125
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5) 피험자 동의서에는 피험자 또는 대리인의 법적 권리를 포기나",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        84.90937042236328,
        546.0599975585938,
        100.72968292236328
      ],
      "page_num": 114,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제한, 연구자/의뢰자/기관 및 기관장의 과실 책임의 면제를 암시",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        114.90937042236328,
        538.4400024414062,
        130.72967529296875
      ],
      "page_num": 114,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 내용이 포함되어서는 안된다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        144.9093780517578,
        327.8029479980469,
        160.7296905517578
      ],
      "page_num": 114,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) 피험자의 동의에 영향을 줄 수 있는 새로운 연구 관련정보가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        174.9093780517578,
        545.9400024414062,
        190.7296905517578
      ],
      "page_num": 114,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수집되면 동의서 서식, 피험자 설명서 및 기타 문서화된 정보는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        204.90936279296875,
        545.9400024414062,
        220.72967529296875
      ],
      "page_num": 114,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이에 따라 수정되어야 하며, 사용 전에 반드시 위원회의 승인을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        234.90936279296875,
        545.9400024414062,
        250.72967529296875
      ],
      "page_num": 114,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "받아야 한다. 피험자의 지속적인 연구 참여 의지에 영향을 줄 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        264.90936279296875,
        545.9400024414062,
        280.72967529296875
      ],
      "page_num": 114,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구 책임자는 피험자 또는 대리인에게 즉시 알리고, 이러한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        294.90936279296875,
        545.9400024414062,
        310.72967529296875
      ],
      "page_num": 114,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고지와 관련된 모든 사항을 문서화해야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        324.90936279296875,
        402.8029479980469,
        340.72967529296875
      ],
      "page_num": 114,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7) 피험자 또는 대리인이 동의서 등을 읽을 수 없는 경우에는 공정한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        354.90936279296875,
        545.9400024414062,
        370.72967529296875
      ],
      "page_num": 114,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "입회자가 동의를 얻는 전 과정에 참석하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        384.90936279296875,
        436.52294921875,
        400.72967529296875
      ],
      "page_num": 114,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 임상시험 실시 도중 피험자 설명문 등이 변경되었을 때 재동의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        444.90936279296875,
        508.79998779296875,
        460.72967529296875
      ],
      "page_num": 114,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 실시 도중 동의서 서식이 변경되거나, 피험자에게 제공된",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        474.90936279296875,
        545.9400024414062,
        490.72967529296875
      ],
      "page_num": 114,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "문서 정보의 변경이 있는 경우에는 변경일 기준 다음 방문일에 변경",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        504.90936279296875,
        545.9400024414062,
        520.7296752929688
      ],
      "page_num": 114,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용을 피험자에게 충분히 설명하고, 시험책임자(또는 시험담당의사)와",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        534.9093627929688,
        545.9400024414062,
        550.7296752929688
      ],
      "page_num": 114,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자는 변경동의서에 서명하고 해당 날짜를 자필로 적어야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        564.9093627929688,
        513.2030029296875,
        580.7296752929688
      ],
      "page_num": 114,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라. 피험자의 대리인이 피험자를 대신하여 임상시험 참여에 동의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        624.9093627929688,
        477.47998046875,
        640.7296752929688
      ],
      "page_num": 114,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자의 이해능력, 의사표현능력의 결여 등의 사유로 동의를 받을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        654.9093627929688,
        545.9400024414062,
        670.7296752929688
      ],
      "page_num": 114,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 없는 경우에는 대리인의 동의를 받을 수 있으며, 이와 같은 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        684.9093627929688,
        538.4400024414062,
        700.7296752929688
      ],
      "page_num": 114,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에도 피험자는 피험자 자신이 이해할 수 있는 정도까지 임상시험에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        714.9093627929688,
        546.0599975585938,
        730.7296752929688
      ],
      "page_num": 114,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관한 정보를 제공 받아야하며, 가능하다면 피험자는 동의서 서식에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        744.9093627929688,
        545.9400024414062,
        760.7296752929688
      ],
      "page_num": 114,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 108 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        803.6103515625,
        317.5050048828125,
        813.5703125
      ],
      "page_num": 115,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서명하고 자필로 날짜를 기재하여야 한다. 또한, 피험자의 대리인임을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        545.9400024414062,
        100.72968292236328
      ],
      "page_num": 115,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인할 수 있는 근거자료 등을 확보하고, 피험자 동의 설명서 등에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        114.90937042236328,
        546.0599975585938,
        130.72967529296875
      ],
      "page_num": 115,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대리인의 동의 사유를 구체적으로 기술할 것을 권장한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        144.9093780517578,
        450.5629577636719,
        160.7296905517578
      ],
      "page_num": 115,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 109 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        803.6103515625,
        317.5050048828125,
        813.5703125
      ],
      "page_num": 116,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "17. 피해자 보상에 대한 규약",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        99.09996032714844,
        278.5196838378906,
        115.0599594116211
      ],
      "page_num": 116,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료 방법 등을 제공",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.43999481201172,
        164.27999877929688,
        530.8800048828125,
        178.67999267578125
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하는 원칙과 절차를 수립하여 제시한다. 피해자 보상에 대한 규약에는 보상원칙과 보상이",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        188.27999877929688,
        530.8800048828125,
        202.67999267578125
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        212.27999877929688,
        425.4599914550781,
        226.67999267578125
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        287.99432373046875,
        94.91999816894531,
        307.94549560546875
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험용 의료기기가 직접적 원인이 되어 피험자에게 손상이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        315.1893615722656,
        546.0599975585938,
        331.0096740722656
      ],
      "page_num": 116,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발생하여 응급조치가 필요한 경우 시험책임자가 가입한 보험에 의해",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        345.1893615722656,
        546.0599975585938,
        361.0096740722656
      ],
      "page_num": 116,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보상한다. 본 임상시험과 관련이 없는 부작용이 발생한 경우에도",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        375.1893615722656,
        546.0599975585938,
        391.0096740722656
      ],
      "page_num": 116,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 과와의 긴밀한 협조를 통하여 신속한 검사와 처치를 시행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        405.1893615722656,
        526.4029541015625,
        421.0096740722656
      ],
      "page_num": 116,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예상된 의료기기 이상반응에 대하여 당사자들 간에 미리 합의한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        435.1893615722656,
        545.9400024414062,
        451.0096740722656
      ],
      "page_num": 116,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보상액 또는 조치가 있는 경우, 당해 기준에 따라 이를 보상한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        465.1893615722656,
        546.0599975585938,
        481.0096740722656
      ],
      "page_num": 116,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그 외의 경우에는 신체손상의 정도, 성격, 지속기간, 유사사례 등을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        495.1893615722656,
        546.0599975585938,
        511.0096740722656
      ],
      "page_num": 116,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "종합적으로 고려하여 당사자들 간에 합의한 보상방법에 따라 이를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        525.1893920898438,
        545.9400024414062,
        541.0097045898438
      ],
      "page_num": 116,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보상한다. 당사자들 간에 전항의 합의가 이루어지지 아니한 경우에는,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        555.1893920898438,
        546.0599975585938,
        571.0097045898438
      ],
      "page_num": 116,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "법원의 판결 및 이에 준하는 결정의 확정내용에 따라 보상한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        585.1893920898438,
        495.5629577636719,
        601.0097045898438
      ],
      "page_num": 116,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 110 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        803.6103515625,
        317.5050048828125,
        813.5703125
      ],
      "page_num": 117,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "18. 임상시험 후 피험자의 진료에 관한 사항",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        99.09996032714844,
        390.47998046875,
        115.0599594116211
      ],
      "page_num": 117,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상반응 등에 대하여 임상",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.79999542236328,
        151.3199920654297,
        530.8800048828125,
        165.71998596191406
      ],
      "page_num": 117,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        175.3199920654297,
        530.8800048828125,
        189.71998596191406
      ],
      "page_num": 117,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하는 원칙과 절차를 수립하여 제시한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        199.3199920654297,
        287.82000732421875,
        213.71998596191406
      ],
      "page_num": 117,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        261.9543151855469,
        94.91999816894531,
        281.9054870605469
      ],
      "page_num": 117,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 OO병원",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        289.2693786621094,
        538.5599975585938,
        305.0896911621094
      ],
      "page_num": 117,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에서 진행하던 치료절차가 임상시험 참여 전과 다름없이 진행되며,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        319.2693786621094,
        545.9400024414062,
        335.0896911621094
      ],
      "page_num": 117,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이후의 치료비는 피험자가 지불하여야 한다. 다만, 부작용 발생 시",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        349.2693786621094,
        545.9400024414062,
        365.0896911621094
      ],
      "page_num": 117,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험에 사용된 의료기기와의 인과관계 유무를 확인한 후,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        379.2693786621094,
        546.0599975585938,
        395.0896911621094
      ],
      "page_num": 117,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 임상시험에 사용된 의료기기로 인하여 부작용이 발생한 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        409.2693786621094,
        546.0599975585938,
        425.0896911621094
      ],
      "page_num": 117,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㈜OOO에서 치료에 관한 부작용이 소실될 때까지 치료비를 지불한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        439.2693786621094,
        535.1629638671875,
        455.0896911621094
      ],
      "page_num": 117,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 111 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        803.6103515625,
        317.5050048828125,
        813.5703125
      ],
      "page_num": 118,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "19. 피험자의 안전보호에 대한 대책",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        93.4599609375,
        326.5196838378906,
        109.41996002197266
      ],
      "page_num": 118,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 및",
      "font_size": 12.0,
      "font_name": "T14",
      "bbox": [
        76.08000183105469,
        147.47999572753906,
        533.760009765625,
        161.87998962402344
      ],
      "page_num": 118,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        171.47999572753906,
        410.6999816894531,
        185.87998962402344
      ],
      "page_num": 118,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        231.95431518554688,
        94.91999816894531,
        251.90548706054688
      ],
      "page_num": 118,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 임상시험 실시기관",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        259.1493835449219,
        210.72000122070312,
        274.9696960449219
      ],
      "page_num": 118,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 실시기관의 장은 해당 임상시험의 실시에 필요한 임상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        289.14935302734375,
        538.4400024414062,
        304.96966552734375
      ],
      "page_num": 118,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험실, 설비와 전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        319.14935302734375,
        546.0599975585938,
        334.96966552734375
      ],
      "page_num": 118,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "취할 수 있도록 하는 등 해당 임상시험을 적절하게 실시할 수 있도록",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        349.14935302734375,
        545.9400024414062,
        364.96966552734375
      ],
      "page_num": 118,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        379.14935302734375,
        143.1229705810547,
        394.96966552734375
      ],
      "page_num": 118,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 임상시험심사위원회",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        439.14935302734375,
        218.1599884033203,
        454.96966552734375
      ],
      "page_num": 118,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 임상시험심사위원회는 국내 법규/관례에 따라 구성되어 있어야",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        469.14935302734375,
        546.0599975585938,
        484.96966552734375
      ],
      "page_num": 118,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다. 임상시험심사위원회는 피험자의 권리, 안전, 복지를 보호해야",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        499.14935302734375,
        546.0599975585938,
        514.9696655273438
      ],
      "page_num": 118,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        529.1493530273438,
        546.0599975585938,
        544.9696655273438
      ],
      "page_num": 118,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그 이유의 타당성을 면밀히 검토하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        559.1493530273438,
        402.8029479980469,
        574.9696655273438
      ],
      "page_num": 118,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        589.1493530273438,
        538.4400024414062,
        604.9696655273438
      ],
      "page_num": 118,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동의가 적절하게 얻어지지 않았거나 임상시험이 임상시험계획서에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        619.1493530273438,
        546.0599975585938,
        634.9696655273438
      ],
      "page_num": 118,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라 진행되지 않은 경우 또는 중대한 이상사례/의료기기 이상반응이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        649.1493530273438,
        545.9400024414062,
        664.9696655273438
      ],
      "page_num": 118,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나타난 경우에는 임상시험의 일부 또는 전부에 대하여 중지 명령",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        679.1493530273438,
        545.9400024414062,
        694.9696655273438
      ],
      "page_num": 118,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등 필요한 조치를 시험책임자에게 하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        709.1493530273438,
        417.8029479980469,
        724.9696655273438
      ],
      "page_num": 118,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 112 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        803.6103515625,
        317.5050048828125,
        813.5703125
      ],
      "page_num": 119,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 시험자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        128.16000366210938,
        100.72968292236328
      ],
      "page_num": 119,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 시험자(Investigator)란 시험책임자, 시험담당자, 임상시험조정자를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        114.90937042236328,
        546.0599975585938,
        130.72967529296875
      ],
      "page_num": 119,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "말한다. 시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        144.9093780517578,
        538.4400024414062,
        160.7296905517578
      ],
      "page_num": 119,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품안전처장의 승인을 득한 임상시험 계획서를 준수하여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        174.9093780517578,
        545.9400024414062,
        190.7296905517578
      ],
      "page_num": 119,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험을 실시하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        204.90936279296875,
        290.36297607421875,
        220.72967529296875
      ],
      "page_num": 119,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        234.90936279296875,
        546.0599975585938,
        250.72967529296875
      ],
      "page_num": 119,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 시험실적 검사치의 이상을 포함하여 임상시험에서 발생한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        264.90936279296875,
        546.0599975585938,
        280.72967529296875
      ],
      "page_num": 119,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든 이상반응에 대해 피험자가 적절한 의학적 처치를 받을 수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        294.90936279296875,
        546.0599975585938,
        310.72967529296875
      ],
      "page_num": 119,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있도록 조치하여야 하고, 시험자가 알게 된 피험자의 병발질환에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        324.90936279296875,
        546.0599975585938,
        340.72967529296875
      ],
      "page_num": 119,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해 의학적 처치가 필요한 경우 이를 피험자에게 알려주어야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        354.90936279296875,
        536.8429565429688,
        370.72967529296875
      ],
      "page_num": 119,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        384.90936279296875,
        546.0599975585938,
        400.72967529296875
      ],
      "page_num": 119,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "문제점을 적극적으로 대응한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        414.90936279296875,
        305.36297607421875,
        430.72967529296875
      ],
      "page_num": 119,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 의뢰자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        474.90936279296875,
        128.16000366210938,
        490.72967529296875
      ],
      "page_num": 119,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        504.90936279296875,
        545.9400024414062,
        520.7296752929688
      ],
      "page_num": 119,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통상의료기기 임상시험의 경우 의료기기 제조업자(수입자를 포함",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        534.9093627929688,
        538.5599975585938,
        550.7296752929688
      ],
      "page_num": 119,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다)를 말한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        564.9093627929688,
        197.60296630859375,
        580.7296752929688
      ],
      "page_num": 119,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        594.9093627929688,
        538.5599975585938,
        610.7296752929688
      ],
      "page_num": 119,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험계획서의 절차에 따라 이루어지도록 하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        624.9093627929688,
        462.8029479980469,
        640.7296752929688
      ],
      "page_num": 119,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        654.9093627929688,
        538.5599975585938,
        670.7296752929688
      ],
      "page_num": 119,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험의 종류와 복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        684.9093627929688,
        546.0599975585938,
        700.7296752929688
      ],
      "page_num": 119,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정도 및 이미 확인된 임상시험 실시상의 문제점 등에 따라 결정",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        714.9093627929688,
        538.5599975585938,
        730.7296752929688
      ],
      "page_num": 119,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되어야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        744.9093627929688,
        177.92295837402344,
        760.7296752929688
      ],
      "page_num": 119,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 113 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        803.6103515625,
        317.5050048828125,
        813.5703125
      ],
      "page_num": 120,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마. 모니터링",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        143.16000366210938,
        100.72968292236328
      ],
      "page_num": 120,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 모니터링(Monitoring)이란 임상시험 진행 과정을 감독하고, 해당",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        114.90937042236328,
        545.9400024414062,
        130.72967529296875
      ],
      "page_num": 120,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험이 임상시험계획서, 표준작업지침서, 임상시험 실시 기준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        144.9093780517578,
        545.9400024414062,
        160.7296905517578
      ],
      "page_num": 120,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 관련 규정에 따라 실시, 기록되는지 여부를 검토, 확인하는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        174.9093780517578,
        545.9400024414062,
        190.7296905517578
      ],
      "page_num": 120,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활동을 말한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        204.90936279296875,
        192.92295837402344,
        220.72967529296875
      ],
      "page_num": 120,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 임상시험에 대한 모니터링은 임상시험모니터요원의 정기적인 임상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        234.90936279296875,
        538.5599975585938,
        250.72967529296875
      ],
      "page_num": 120,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험 실시기관 방문과 전화 등을 통해서 이루어질 것이다. 방문 시",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        264.90936279296875,
        545.9400024414062,
        280.72967529296875
      ],
      "page_num": 120,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모니터는 환자기록 원본, 임상시험용 의료기기 관리 기록, 자료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        294.90936279296875,
        538.4400024414062,
        310.72967529296875
      ],
      "page_num": 120,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보관(연구파일) 등을 확인한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        324.90936279296875,
        299.72296142578125,
        340.72967529296875
      ],
      "page_num": 120,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 또한 임상시험모니터 요원은 임상시험 진행과정을 잘 살피고,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        354.90936279296875,
        546.0599975585938,
        370.72967529296875
      ],
      "page_num": 120,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "문제가 있을 경우 시험자와 상의한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        384.90936279296875,
        350.36297607421875,
        400.72967529296875
      ],
      "page_num": 120,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바. 임상시험계획서의 변경",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        444.90936279296875,
        240.72000122070312,
        460.72967529296875
      ],
      "page_num": 120,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        474.90936279296875,
        538.5599975585938,
        490.72967529296875
      ],
      "page_num": 120,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로부터 승인받은 후, 시험절차가 광범위해지거나 위험도가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        504.90936279296875,
        545.9400024414062,
        520.7296752929688
      ],
      "page_num": 120,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "높아지거나 피험자 선정기준에 변화가 있거나 추가적인 안전성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        534.9093627929688,
        546.0599975585938,
        550.7296752929688
      ],
      "page_num": 120,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정보로 인해 임사시험계획서를 변경하는 경우에는 임상시험심사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        564.9093627929688,
        538.4400024414062,
        580.7296752929688
      ],
      "page_num": 120,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위원회 및 식품의약품안전처장의 승인을 받아야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        594.9093627929688,
        462.8029479980469,
        610.7296752929688
      ],
      "page_num": 120,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        624.9093627929688,
        546.0599975585938,
        640.7296752929688
      ],
      "page_num": 120,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용 등을 기록하여 보관하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        654.9093627929688,
        350.36297607421875,
        670.7296752929688
      ],
      "page_num": 120,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        684.9093627929688,
        545.9400024414062,
        700.7296752929688
      ],
      "page_num": 120,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우를 제외하고는, 임상시험심사위원회- 및 식품의약품안전처장의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        714.9093627929688,
        546.0599975585938,
        730.7296752929688
      ],
      "page_num": 120,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변경 승인 이전에는 계획서와 다르게 임상시험을 실시하여서는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        744.9093627929688,
        546.0599975585938,
        760.7296752929688
      ],
      "page_num": 120,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 114 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        803.6103515625,
        317.5050048828125,
        813.5703125
      ],
      "page_num": 121,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안 된다. 만일 피험자에게 발생한 즉각적 위험요소를 제거하기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        84.90937042236328,
        545.9400024414062,
        100.72968292236328
      ],
      "page_num": 121,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        114.90937042236328,
        538.5599975585938,
        130.72967529296875
      ],
      "page_num": 121,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        144.9093780517578,
        545.9400024414062,
        160.7296905517578
      ],
      "page_num": 121,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대하여 임상시험심사위원회(사후검토 승인을 위함), 의뢰자, 식품",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        174.9093780517578,
        538.4400024414062,
        190.7296905517578
      ],
      "page_num": 121,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품안전처장에게 제출하여야 한다. 그리고 임상시험심사위원회",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        204.90936279296875,
        546.0599975585938,
        220.72967529296875
      ],
      "page_num": 121,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위원장이나 간사가 승인한 문서를 의뢰자에게 보내야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        234.90936279296875,
        500.2429504394531,
        250.72967529296875
      ],
      "page_num": 121,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        264.90936279296875,
        546.0599975585938,
        280.72967529296875
      ],
      "page_num": 121,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반드시 필요한 것은 아니며 행정상 변경이 필요하다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        294.90936279296875,
        455.2429504394531,
        310.72967529296875
      ],
      "page_num": 121,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사. 피험자 동의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        354.90936279296875,
        165.72000122070312,
        370.72967529296875
      ],
      "page_num": 121,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 피험자 동의(Informed consent)라 함은 피험자가 임상시험 참여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        384.90936279296875,
        546.0599975585938,
        400.72967529296875
      ],
      "page_num": 121,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유무를 결정하기 전에 피험자를 위한 설명서를 통해 해당 임상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        414.90936279296875,
        538.5599975585938,
        430.72967529296875
      ],
      "page_num": 121,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험과 관련된 모든 정보를 제공받고, 서명과 서명 날짜가 포함된",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        444.90936279296875,
        546.0599975585938,
        460.72967529296875
      ],
      "page_num": 121,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "문서를 통해 본인이 자발적으로 임상시험에 참여함을 확인하는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        474.90936279296875,
        546.0599975585938,
        490.72967529296875
      ],
      "page_num": 121,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "절차를 말한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        504.90936279296875,
        192.92295837402344,
        520.7296752929688
      ],
      "page_num": 121,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 피험자 본인 또는 대리인이 동의서 서식, 피험자 설명서 및 기타",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        534.9093627929688,
        546.0599975585938,
        550.7296752929688
      ],
      "page_num": 121,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "문서화된 정보를 읽을 수 없는 경우에는 공정한 입회자가 동의를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        564.9093627929688,
        545.9400024414062,
        580.7296752929688
      ],
      "page_num": 121,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "얻는 전 과정에 참석하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        594.9093627929688,
        320.36297607421875,
        610.7296752929688
      ],
      "page_num": 121,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        624.9093627929688,
        546.0599975585938,
        640.7296752929688
      ],
      "page_num": 121,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세부 사항에 대해 질문하고 해당 임상시험의 참여 여부를 결정",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        654.9093627929688,
        538.5599975585938,
        670.7296752929688
      ],
      "page_num": 121,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "할 수 있도록 충분한 시간과 기회를 주어야 하며, 모든 임상시험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        684.9093627929688,
        546.0599975585938,
        700.7296752929688
      ],
      "page_num": 121,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련 질문에 대해 피험자 또는 대리인이 만족할 수 있도록 대답",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        714.9093627929688,
        538.5599975585938,
        730.7296752929688
      ],
      "page_num": 121,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해주어야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        744.9093627929688,
        192.92295837402344,
        760.7296752929688
      ],
      "page_num": 121,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 115 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        803.6103515625,
        317.5050048828125,
        813.5703125
      ],
      "page_num": 122,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아. 피험자 기록의 비밀보장",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        248.1599884033203,
        100.72968292236328
      ],
      "page_num": 122,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        114.90937042236328,
        545.9400024414062,
        130.72967529296875
      ],
      "page_num": 122,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험의 결과가 출관 될 경우에도 피험자의 신원을 비밀상태로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        144.9093780517578,
        546.0599975585938,
        160.7296905517578
      ],
      "page_num": 122,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유지한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        174.9093780517578,
        155.3629608154297,
        190.7296905517578
      ],
      "page_num": 122,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        204.90936279296875,
        546.0599975585938,
        220.72967529296875
      ],
      "page_num": 122,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모니터링과 점검 및 진행사항 관리를 위한 목적으로 피험자의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        234.90936279296875,
        546.0599975585938,
        250.72967529296875
      ],
      "page_num": 122,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기록을 열람할 수 있다. 시험자는 본 임상시험 계획서에 서명함",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        264.90936279296875,
        538.4400024414062,
        280.72967529296875
      ],
      "page_num": 122,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로써, 국내의 법규와 윤리적 측면에서 임상시험 의뢰자 또는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        294.90936279296875,
        545.9400024414062,
        310.72967529296875
      ],
      "page_num": 122,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모니터 및 점검자가 피험자의 차트와 증례기록서 기록을 검증하기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        324.90936279296875,
        546.0599975585938,
        340.72967529296875
      ],
      "page_num": 122,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        354.90936279296875,
        545.9400024414062,
        370.72967529296875
      ],
      "page_num": 122,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한 정보들은 기밀로 보관되어야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        384.90936279296875,
        380.3629455566406,
        400.72967529296875
      ],
      "page_num": 122,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 증례기록서 등 임상시험에 관련된 모든 서류에는 피험자 이름이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        414.90936279296875,
        545.9400024414062,
        430.72967529296875
      ],
      "page_num": 122,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아닌 피험자 식별코드(일반적으로 피험자 이니셜)로 기록하고",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        444.90936279296875,
        546.0599975585938,
        460.72967529296875
      ],
      "page_num": 122,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구분한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        474.90936279296875,
        155.3629608154297,
        490.72967529296875
      ],
      "page_num": 122,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자. 기록의 보존",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        534.9093627929688,
        165.72000122070312,
        550.7296752929688
      ],
      "page_num": 122,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        564.9093627929688,
        545.9400024414062,
        580.7296752929688
      ],
      "page_num": 122,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여야 하며 보안을 유지하도록 한다. 제조허가/수입허가 또는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        594.9093627929688,
        545.9400024414062,
        610.7296752929688
      ],
      "page_num": 122,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그 변경 허가를 위한 임상시험 관련 자료는 허가일로부터 3년간",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        624.9093627929688,
        546.0599975585938,
        640.7296752929688
      ],
      "page_num": 122,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보존하도록 하고, 그 밖의 임상시험 관련 자료는 임상시험이 끝난",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        654.9093627929688,
        546.0599975585938,
        670.7296752929688
      ],
      "page_num": 122,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "날부터 3년간 보존하도록 한다. 다만, 식품의약품안전처장이 지시",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        684.9093627929688,
        538.5599975585938,
        700.7296752929688
      ],
      "page_num": 122,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        714.9093627929688,
        545.9400024414062,
        730.7296752929688
      ],
      "page_num": 122,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연장할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        744.9093627929688,
        200.3629608154297,
        760.7296752929688
      ],
      "page_num": 122,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 116 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        803.6103515625,
        317.5050048828125,
        813.5703125
      ],
      "page_num": 123,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "20. 그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        93.4599609375,
        523.3199462890625,
        109.41996002197266
      ],
      "page_num": 123,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례기록서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        144.83999633789062,
        530.8800048828125,
        159.239990234375
      ],
      "page_num": 123,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험책임자의 이력",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        168.83999633789062,
        530.8800048828125,
        183.239990234375
      ],
      "page_num": 123,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 의료기기의 공급과",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        192.83999633789062,
        530.8800048828125,
        207.239990234375
      ],
      "page_num": 123,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "취급에 관한 사항을 추가로 확보할 수 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        216.83999633789062,
        300.17999267578125,
        231.239990234375
      ],
      "page_num": 123,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        275.6343078613281,
        94.91999816894531,
        295.5854797363281
      ],
      "page_num": 123,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 자료 처리",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        311.9493713378906,
        150.72000122070312,
        327.7696838378906
      ],
      "page_num": 123,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 근거 자료/문서의 직접 열람",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        341.9493713378906,
        283.44000244140625,
        357.7696838378906
      ],
      "page_num": 123,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 임상시험에 관련된 모니터 및 점검자는 본 임상시험의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        371.9493713378906,
        545.9400024414062,
        387.7696838378906
      ],
      "page_num": 123,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모니터링과 점검 및 진행사항 관리를 위한 목적으로 대상자의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        401.9493713378906,
        545.9400024414062,
        417.7696838378906
      ],
      "page_num": 123,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기록을 열람할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        431.9493713378906,
        248.1229705810547,
        447.7696838378906
      ],
      "page_num": 123,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 증례기록서의 작성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        461.9493713378906,
        218.87998962402344,
        477.7696838378906
      ],
      "page_num": 123,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험용 의료기기와 연관된 유의한 위험, 금기, 부작용, 주의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        491.9493713378906,
        545.9400024414062,
        507.7696838378906
      ],
      "page_num": 123,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항을 시사하는 사건 등을 포함하며, 발생시간, 정도, 처치, 경과,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        521.9493408203125,
        546.0599975585938,
        537.7696533203125
      ],
      "page_num": 123,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험용 의료기기와의 인과관계 등에 대한 정보를 증례기록서에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        551.9493408203125,
        546.0599975585938,
        567.7696533203125
      ],
      "page_num": 123,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기록한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        581.9493408203125,
        150.68296813964844,
        597.7696533203125
      ],
      "page_num": 123,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 법규준수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        641.9493408203125,
        143.16000366210938,
        657.7696533203125
      ],
      "page_num": 123,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험자는 서명록에 서명함으로써, 본 임상시험계획서, 의료기기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        671.9493408203125,
        546.0599975585938,
        687.7696533203125
      ],
      "page_num": 123,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 관리기준, 국내의 모든 관련 법규와 임상시험 수행에 관련된",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        701.9493408203125,
        545.9400024414062,
        717.7696533203125
      ],
      "page_num": 123,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규칙 및 규정에 따라서 효과적이고 성실하게 연구를 수행할 것에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        731.9493408203125,
        545.9400024414062,
        747.7696533203125
      ],
      "page_num": 123,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 117 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        803.6103515625,
        317.5050048828125,
        813.5703125
      ],
      "page_num": 124,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동의하게 된다. 임상시험 담당자 및 참여 연구진은 임상시험계획을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        545.9400024414062,
        100.72968292236328
      ],
      "page_num": 124,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정확히 분석, 숙지하도록 하며 시험책임자는 예기치 않은 이상반응",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        114.90937042236328,
        545.9400024414062,
        130.72967529296875
      ],
      "page_num": 124,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등의 출현에 대한 충분한 대처와 필요에 따른 보고, 시험참여 연구진에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        144.9093780517578,
        545.9400024414062,
        160.7296905517578
      ],
      "page_num": 124,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 충분한 교육 등 사전조치를 취한다. 임상시험의 진행은 의료기기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        174.9093780517578,
        538.4400024414062,
        190.7296905517578
      ],
      "page_num": 124,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 관리 기준에 합당하게 진행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        204.90936279296875,
        345.5629577636719,
        220.72967529296875
      ],
      "page_num": 124,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 임상시험 자료의 보관 및 열람",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        264.90936279296875,
        293.1600036621094,
        280.72967529296875
      ],
      "page_num": 124,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 자료는 기밀로 보관되고 열람은 본 임상시험의 모니터링과",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        294.90936279296875,
        546.0599975585938,
        310.72967529296875
      ],
      "page_num": 124,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "점검 및 진행 사항 관리를 위한 목적으로 대상자의 기록을 열람할 수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        324.90936279296875,
        545.9400024414062,
        340.72967529296875
      ],
      "page_num": 124,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        354.90936279296875,
        90.68296813964844,
        370.72967529296875
      ],
      "page_num": 124,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라. 점검 및 실태조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        414.90936279296875,
        203.1599884033203,
        430.72967529296875
      ],
      "page_num": 124,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험의 중요도, 대상자 수, 임상시험의 종류와 복잡성, 대상자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        444.90936279296875,
        538.4400024414062,
        460.72967529296875
      ],
      "page_num": 124,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        474.90936279296875,
        545.9400024414062,
        490.72967529296875
      ],
      "page_num": 124,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실시상의 문제점 등에 따라 결정된다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        504.90936279296875,
        315.5629577636719,
        520.7296752929688
      ],
      "page_num": 124,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마. 임상시험용 의료기기의 사용 및 관리",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        564.9093627929688,
        338.1600036621094,
        580.7296752929688
      ],
      "page_num": 124,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        594.9093627929688,
        546.0599975585938,
        610.7296752929688
      ],
      "page_num": 124,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리한다. 임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        624.9093627929688,
        545.9400024414062,
        640.7296752929688
      ],
      "page_num": 124,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "저장하며 “임상시험용”이라는 문구가 있어야 한다. 임상시험용 의료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        654.9093627929688,
        538.5599975585938,
        670.7296752929688
      ],
      "page_num": 124,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기 관리자는 임상시험에 사용되는 의료기기에 대해 인수, 재고관리,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        684.9093627929688,
        546.0599975585938,
        700.7296752929688
      ],
      "page_num": 124,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반납 등의 업무를 수행하고 관련 기록을 유지하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        714.9093627929688,
        453.8029479980469,
        730.7296752929688
      ],
      "page_num": 124,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 118 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        803.6103515625,
        317.5050048828125,
        813.5703125
      ],
      "page_num": 125,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바. 임상시험용 의료기기의 공급과 취급",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        84.90937042236328,
        330.6000061035156,
        100.72968292236328
      ],
      "page_num": 125,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 의뢰자는 임상시험계획서에 대한 심사위원회와 청장의 승인을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        114.90937042236328,
        545.9400024414062,
        130.72967529296875
      ],
      "page_num": 125,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        144.9093780517578,
        545.9400024414062,
        160.7296905517578
      ],
      "page_num": 125,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아니 된다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        174.9093780517578,
        162.92295837402344,
        190.7296905517578
      ],
      "page_num": 125,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 의뢰자는 관리자 등이 임상시험용 의료기기를 취급하고 보관하는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        204.90936279296875,
        546.0599975585938,
        220.72967529296875
      ],
      "page_num": 125,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법에 대해 문서화된 절차를 가지고 있어야 하며, 이 절차에는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        234.90936279296875,
        545.9400024414062,
        250.72967529296875
      ],
      "page_num": 125,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절하고 안전한 수, 취급, 보관, 미사용 임상시험용 의료기기의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        264.90936279296875,
        546.0599975585938,
        280.72967529296875
      ],
      "page_num": 125,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자로부터의 반납 및 의뢰자에 대한 반납 등에 대한 방법이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        294.90936279296875,
        546.0599975585938,
        310.72967529296875
      ],
      "page_num": 125,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함된다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        324.90936279296875,
        155.3629608154297,
        340.72967529296875
      ],
      "page_num": 125,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        354.90936279296875,
        538.5599975585938,
        370.72967529296875
      ],
      "page_num": 125,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로의 공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        384.90936279296875,
        545.9400024414062,
        400.72967529296875
      ],
      "page_num": 125,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 폐기에 관한 기록을 유지하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        414.90936279296875,
        372.8029479980469,
        430.72967529296875
      ],
      "page_num": 125,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        444.90936279296875,
        538.5599975585938,
        460.72967529296875
      ],
      "page_num": 125,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험의 종료 또는 사용기간의 만료 등에 의한 임상시험용 의료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        474.90936279296875,
        538.4400024414062,
        490.72967529296875
      ],
      "page_num": 125,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기의 회수체계를 확립하고 이를 문서화하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        504.90936279296875,
        462.8029479980469,
        520.7296752929688
      ],
      "page_num": 125,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 119 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        803.6103515625,
        317.5050048828125,
        813.5703125
      ],
      "page_num": 126,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅳ",
      "font_size": 20.03999900817871,
      "font_name": "T9",
      "bbox": [
        68.4000015258789,
        91.31999969482422,
        198.35975646972656,
        115.36800384521484
      ],
      "page_num": 126,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참고문헌",
      "font_size": 20.03999900817871,
      "font_name": "H2hdrM",
      "bbox": [
        68.4000015258789,
        91.31999969482422,
        198.35975646972656,
        115.36800384521484
      ],
      "page_num": 126,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 2020년 국민건강영양조사, 질병관리청, 2020.12",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        145.640625,
        282.3001403808594,
        156.1453094482422
      ],
      "page_num": 126,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 일차 의료용 근거 기반 우울장애 임상진료지침, 대한의학회, 2022",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        161.6006317138672,
        369.6597595214844,
        172.10531616210938
      ],
      "page_num": 126,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 권정혜, & 이재우. (2001). 우울증의 인지행동치료. 인지행동치료, 1, 1-22.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        177.6806182861328,
        407.0840759277344,
        188.185302734375
      ],
      "page_num": 126,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 이삼연. (1999). 인지-행동치료의 우울증 사정과 개입전략. 한국가족복지학, 4, 189-218.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        193.640625,
        466.72381591796875,
        204.1453094482422
      ],
      "page_num": 126,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5. Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., ... & CANMAT",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        209.60061645507812,
        543.4210815429688,
        220.1053009033203
      ],
      "page_num": 126,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Depression Work Group. (2016). Canadian Network for Mood and Anxiety Treatments (CANMAT)",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.36000061035156,
        225.6806182861328,
        543.4210205078125,
        236.185302734375
      ],
      "page_num": 126,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2016 clinical guidelines for the management of adults with major depressive disorder: section 3.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.36000061035156,
        241.640625,
        543.420166015625,
        252.1453094482422
      ],
      "page_num": 126,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Pharmacological treatments. The Canadian Journal of Psychiatry, 61(9), 540-560.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.36000061035156,
        257.6006164550781,
        438.5238342285156,
        268.1053161621094
      ],
      "page_num": 126,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6. Gelenberg, A. J., Freeman, M. P., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H.,",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        273.68060302734375,
        543.4203491210938,
        284.185302734375
      ],
      "page_num": 126,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "& Van Rhoads, R. S. (2010). American Psychiatric Association practice guidelines for the treatment",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.36000061035156,
        289.6405944824219,
        543.4191284179688,
        300.1452941894531
      ],
      "page_num": 126,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of patients with major depressive disorder. Am J Psychiatry, 167(Suppl 10), 9-118.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.36000061035156,
        305.6006164550781,
        448.0038146972656,
        316.1053161621094
      ],
      "page_num": 126,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7. Anderson, I. M., Ferrier, I. N., Baldwin, R. C., Cowen, P. J., Howard, L., Lewis, G., ... & Tylee, A.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        321.68060302734375,
        543.4208374023438,
        332.185302734375
      ],
      "page_num": 126,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2008). Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.36000061035156,
        337.6405944824219,
        543.4198608398438,
        348.1452941894531
      ],
      "page_num": 126,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "the 2000 British Association for Psychopharmacology guidelines. Journal of psychopharmacology,",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.36000061035156,
        353.6006164550781,
        543.4192504882812,
        364.1053161621094
      ],
      "page_num": 126,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "22(4), 343-396.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.36000061035156,
        369.68060302734375,
        136.00381469726562,
        380.185302734375
      ],
      "page_num": 126,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8. Andrews, G., Basu, A., Cuijpers, P., Craske, M. G., McEvoy, P., English, C. L., & Newby, J. M.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        385.6405944824219,
        543.4201049804688,
        396.1452941894531
      ],
      "page_num": 126,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2018). Computer therapy for the anxiety and depression disorders is effective, acceptable and",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.36000061035156,
        401.6006164550781,
        543.5398559570312,
        412.1053161621094
      ],
      "page_num": 126,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "practical health care: an updated meta-analysis. Journal of anxiety disorders, 55, 70-78.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.36000061035156,
        417.68060302734375,
        474.8838195800781,
        428.185302734375
      ],
      "page_num": 126,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9. Fischer, A., Schröder, J., Vettorazzi, E., Wolf, O. T., Pöttgen, J., Lau, S., ... & Gold, S. M. (2015). An",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        433.6405944824219,
        543.540283203125,
        444.1452941894531
      ],
      "page_num": 126,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "online programme to reduce depression in patients with multiple sclerosis: a randomised controlled",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.36000061035156,
        449.6006164550781,
        543.5405883789062,
        460.1053161621094
      ],
      "page_num": 126,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "trial. The Lancet Psychiatry, 2(3), 217-223.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.36000061035156,
        465.68060302734375,
        266.3238220214844,
        476.185302734375
      ],
      "page_num": 126,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10. Berger, T., Hämmerli, K., Gubser, N., Andersson, G., & Caspar, F. (2011). Internet-based treatment",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        481.6405944824219,
        543.4191284179688,
        492.1452941894531
      ],
      "page_num": 126,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of depression: a randomized controlled trial comparing guided with unguided self-help. Cognitive",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        497.6006164550781,
        543.540283203125,
        508.1053161621094
      ],
      "page_num": 126,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "behaviour therapy, 40(4), 251-266.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        513.6806030273438,
        231.2838134765625,
        524.185302734375
      ],
      "page_num": 126,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "11. Klein, J. P., Berger, T., Schröder, J., Späth, C., Meyer, B., Caspar, F., ... & Hohagen, F. (2016).",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        529.640625,
        543.4208374023438,
        540.1453247070312
      ],
      "page_num": 126,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Effects of a psychological internet intervention in the treatment of mild to moderate depressive",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        545.6005859375,
        543.4204711914062,
        556.1052856445312
      ],
      "page_num": 126,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "symptoms: results of the EVIDENT study, a randomized controlled trial. Psychotherapy and",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        561.6806030273438,
        543.5398559570312,
        572.185302734375
      ],
      "page_num": 126,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "psychosomatics, 85(4), 218-228.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        577.640625,
        215.92381286621094,
        588.1453247070312
      ],
      "page_num": 126,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12. Beevers, C. G., Pearson, R., Hoffman, J. S., Foulser, A. A., Shumake, J., & Meyer, B. (2017).",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        593.6005859375,
        543.4208374023438,
        604.1052856445312
      ],
      "page_num": 126,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Effectiveness of an internet intervention (Deprexis) for depression in a united states adult sample:",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        609.6806030273438,
        543.4214477539062,
        620.185302734375
      ],
      "page_num": 126,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "A parallel-group pragmatic randomized controlled trial. Journal of consulting and clinical psychology,",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        625.640625,
        543.421142578125,
        636.1453247070312
      ],
      "page_num": 126,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "85(4), 367.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        641.6005859375,
        121.0038070678711,
        652.1052856445312
      ],
      "page_num": 126,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "13. Meyer, B., Bierbrodt, J., Schröder, J., Berger, T., Beevers, C. G., Weiss, M., ... & Klein, J. P.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        657.6806030273438,
        543.4202880859375,
        668.185302734375
      ],
      "page_num": 126,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2015). Effects of an Internet intervention (Deprexis) on severe depression symptoms: randomized",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        673.640625,
        543.5405883789062,
        684.1453247070312
      ],
      "page_num": 126,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "controlled trial. Internet Interventions, 2(1), 48-59.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        689.6005859375,
        304.8438415527344,
        700.1052856445312
      ],
      "page_num": 126,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14. Krämer, R., & Köhler, S. (2021). Evaluation of the online-based self-help programme “Selfapy” in",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        705.6806030273438,
        543.419677734375,
        716.185302734375
      ],
      "page_num": 126,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "patients with unipolar depression: study protocol for a randomized, blinded parallel group",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        721.640625,
        543.4202880859375,
        732.1453247070312
      ],
      "page_num": 126,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "dismantling study. Trials, 22(1), 1-10.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        737.6005859375,
        243.404052734375,
        748.1052856445312
      ],
      "page_num": 126,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15. Schure, M. B., Lindow, J. C., Greist, J. H., Nakonezny, P. A., Bailey, S. J., Bryan, W. L., & Byerly,",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        753.6806030273438,
        543.420654296875,
        764.185302734375
      ],
      "page_num": 126,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 120 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        803.6103515625,
        317.5050048828125,
        813.5703125
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "M. J. (2019). Use of a fully automated internet-based cognitive behavior therapy intervention in a",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        85.0406265258789,
        543.4197387695312,
        95.5453109741211
      ],
      "page_num": 127,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "community population of adults with depression symptoms: randomized controlled trial. Journal of",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        101.00062561035156,
        543.4198608398438,
        111.50531005859375
      ],
      "page_num": 127,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "medical Internet research, 21(11), e14754.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        117.08062744140625,
        265.1241149902344,
        127.58531188964844
      ],
      "page_num": 127,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "16. Deprexis  홈페이지, https://uk.deprexis.com/",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        133.04061889648438,
        274.5552978515625,
        143.54530334472656
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "17. Selfapy 홈페이지, https://www.selfapy.com/",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        149.00062561035156,
        269.5141906738281,
        159.50531005859375
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "18. Thrive 홈페이지, https://play.google.com/store/apps/details?id=com.waypointhealth.thrive&hl=ko",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        165.08062744140625,
        499.9779357910156,
        175.58531188964844
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "19. NOVEGO 홈페이지, https://www.novego.de",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        181.04061889648438,
        267.89471435546875,
        191.54530334472656
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "20. SparkRx 홈페이지, https://www.sparkrx.com",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        197.00062561035156,
        271.6985778808594,
        207.50531005859375
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "21. SilverCloud 홈페이지, https://health.colostate.edu/silvercloud/",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        213.08062744140625,
        347.2748718261719,
        223.58531188964844
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "22. 디지털치료기기 허가·심사 가이드라인 민원인 안내서, 식품의약품안전처 2020.08",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        229.04061889648438,
        449.6996765136719,
        239.54530334472656
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "23. 의료기기의 사이버 보안 허가·심사 가이드라인 민원인안내서 2022.1. 21",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        245.00062561035156,
        409.6202392578125,
        255.50531005859375
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "24. 의료기기 소프트웨어 허가·심사 가이드라인, 식품의약품안전처, 2018.06",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        261.0805969238281,
        407.3396911621094,
        271.5852966308594
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "25. 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인 민원인 안내서 2019. 02.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        277.0406188964844,
        438.0440673828125,
        287.5453186035156
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "26. 의료기기 소프트웨어 밸리데이션 가이드라인, 식품의약품안전처, 2007.03",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        293.0006103515625,
        407.3396911621094,
        303.50531005859375
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "27. 소프트웨어 밸리데이션 규격 안내서, 디지털헬스케어 소프트웨어 시험평가센터, 2018.07",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        309.0805969238281,
        477.3001403808594,
        319.5852966308594
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "28. 니코틴 사용장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        325.0406188964844,
        538.4400024414062,
        335.5453186035156
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인 안내서, 식품의약품안전처, 2021.12",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        341.0006103515625,
        247.3796844482422,
        351.50531005859375
      ],
      "page_num": 127,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "29. 알코올 사용장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        357.0805969238281,
        538.4400024414062,
        367.5852966308594
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인 안내서, 식품의약품안전처, 2021.12",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        373.0406188964844,
        247.3796844482422,
        383.5453186035156
      ],
      "page_num": 127,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "30. 불면증 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원인 안내서,",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        389.0006103515625,
        543.5399169921875,
        399.50531005859375
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식품의약품안전처, 2021.12",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        405.0805969238281,
        194.69967651367188,
        415.5852966308594
      ],
      "page_num": 127,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "31. Van Hees, M. L., Rotter, T., Ellermann, T., & Evers, S. M. (2013). The effectiveness of individual",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        421.04058837890625,
        543.4197387695312,
        431.5452880859375
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "interpersonal psychotherapy as a treatment for major depressive disorder in adult outpatients: a",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        437.0006103515625,
        543.540283203125,
        447.50531005859375
      ],
      "page_num": 127,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "systematic review. BMC psychiatry, 13(1), 1-10.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        453.0805969238281,
        292.24407958984375,
        463.5852966308594
      ],
      "page_num": 127,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "32. Andersson, G., Bergström, J., Holländare, F., Carlbring, P. E. R., Kaldo, V., & Ekselius, L. (2005).",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        469.04058837890625,
        543.5398559570312,
        479.5452880859375
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Internet-based self-help for depression: randomised controlled trial. The British Journal of",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        485.0006103515625,
        543.4198608398438,
        495.50531005859375
      ],
      "page_num": 127,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Psychiatry, 187(5), 456-461.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        501.0805969238281,
        199.2438201904297,
        511.5852966308594
      ],
      "page_num": 127,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "33. Twomey, C., O’Reilly, G., Bültmann, O., & Meyer, B. (2020). Effectiveness of a tailored,",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        517.0405883789062,
        543.4194946289062,
        527.5452880859375
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "integrative Internet intervention (deprexis) for depression: Updated meta-analysis. PLoS One, 15(1),",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        533.0006103515625,
        543.4210815429688,
        543.5053100585938
      ],
      "page_num": 127,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "e0228100.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        549.0806274414062,
        117.28359985351562,
        559.5853271484375
      ],
      "page_num": 127,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "34. Meyer, B., Berger, T., Caspar, F., Beevers, C., Andersson, G., & Weiss, M. (2009). Effectiveness of",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        565.0405883789062,
        543.5404052734375,
        575.5452880859375
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "a novel integrative online treatment for depression (Deprexis): randomized controlled trial. Journal",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        581.0006103515625,
        543.540771484375,
        591.5053100585938
      ],
      "page_num": 127,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of medical Internet research, 11(2), e1151.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        597.0806274414062,
        269.2043151855469,
        607.5853271484375
      ],
      "page_num": 127,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "35. Vernmark, K., Lenndin, J., Bjärehed, J., Carlsson, M., Karlsson, J., Öberg, J., ... & Andersson, G.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        613.0405883789062,
        543.4199829101562,
        623.5452880859375
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2010). Internet administered guided self-help versus individualized e-mail therapy: A randomized",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        629.0006103515625,
        543.4186401367188,
        639.5053100585938
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "trial of two versions of CBT for major depression. Behaviour research and therapy, 48(5), 368-376.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        645.0806274414062,
        533.8037719726562,
        655.5853271484375
      ],
      "page_num": 127,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "36. Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., & Erbaugh, J. (1961). An inventory for",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        661.0405883789062,
        543.5394897460938,
        671.5452880859375
      ],
      "page_num": 127,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "measuring depression. Archives of general psychiatry, 4(6), 561-571.",
      "font_size": 9.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        74.27999877929688,
        677.0006103515625,
        388.12384033203125,
        687.5053100585938
      ],
      "page_num": 127,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "우울장애 개선 디지털치료기기 안전성·성능 평가 및",
      "font_size": 15.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        107.87999725341797,
        421.5894775390625,
        492.930908203125,
        442.8175048828125
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험계획서 작성 가이드라인(민원인 안내서)",
      "font_size": 15.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        120.7199935913086,
        447.14947509765625,
        475.2722473144531,
        468.37750244140625
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        475.8797607421875,
        354.59857177734375,
        489.1273193359375
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        475.8797607421875,
        354.59857177734375,
        489.1273193359375
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "처 식품의약품안전처 식품의약품안전평가원",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        64.91999816894531,
        475.8797607421875,
        354.59857177734375,
        489.1273193359375
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        502.8797302246094,
        253.8000030517578,
        516.1273193359375
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        502.8797302246094,
        253.8000030517578,
        516.1273193359375
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일 2022년 12월 14일",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        64.91999816894531,
        502.8797302246094,
        253.8000030517578,
        516.1273193359375
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        529.8796997070312,
        199.6795196533203,
        543.1273193359375
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        529.8796997070312,
        199.6795196533203,
        543.1273193359375
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        529.8796997070312,
        199.6795196533203,
        543.1273193359375
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "서경원",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        64.91999816894531,
        529.8796997070312,
        199.6795196533203,
        543.1273193359375
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "편 집 위 원 장 이정림",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        64.91999816894531,
        556.7597045898438,
        199.6795196533203,
        570.00732421875
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "편",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        586.1597290039062,
        381.4809265136719,
        599.4073486328125
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "집",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        586.1597290039062,
        381.4809265136719,
        599.4073486328125
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        586.1597290039062,
        381.4809265136719,
        599.4073486328125
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "원",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        586.1597290039062,
        381.4809265136719,
        599.4073486328125
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이원규, 박종호, 양승하, 한영민, 김건소, 채형래",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        64.91999816894531,
        586.1597290039062,
        381.4809265136719,
        599.4073486328125
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "문",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        666.19970703125,
        159.36000061035156,
        679.4473266601562
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        666.19970703125,
        159.36000061035156,
        679.4473266601562
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "처",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        666.19970703125,
        159.36000061035156,
        679.4473266601562
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "28159 충북 청주시 흥덕구 오송읍 오송생명2로 187",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        169.67999267578125,
        618.19970703125,
        409.2854309082031,
        631.4473266601562
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오송보건의료행정타운",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        169.67999267578125,
        634.2797241210938,
        269.6385498046875,
        647.52734375
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식품의약품안전처 식품의약품안전평가원",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        169.67999267578125,
        650.2396850585938,
        354.59857177734375,
        663.4873046875
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기심사부 첨단의료기기과",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        169.67999267578125,
        666.19970703125,
        314.6390380859375,
        679.4473266601562
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화: 043-719-3912",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        169.67999267578125,
        698.2396850585938,
        260.2435607910156,
        711.4873046875
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "팩스: 043-719-3900",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        169.67999267578125,
        714.19970703125,
        260.2435607910156,
        727.4473266601562
      ],
      "page_num": 128,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "28159 충북 청주시 흥덕구 오송읍 오송생명2로 187",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        144.83999633789062,
        399.86248779296875,
        450.36053466796875,
        413.53125
      ],
      "page_num": 129,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오송보건의료행정타운",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        232.55999755859375,
        420.6224670410156,
        362.5215759277344,
        434.2912292480469
      ],
      "page_num": 129,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식품의약품안전처 식품의약품안전평가원",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        177.36000061035156,
        441.3824768066406,
        417.841552734375,
        455.0512390136719
      ],
      "page_num": 129,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기심사부 첨단의료기기과",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        203.39999389648438,
        462.2624816894531,
        391.801025390625,
        475.9312438964844
      ],
      "page_num": 129,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TEL : 043) 719-3912   FAX : 043) 719-3900",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.51998901367188,
        483.0224914550781,
        430.5610656738281,
        496.6912536621094
      ],
      "page_num": 129,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "https://www.nifds.go.kr",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        231.83999633789062,
        503.782470703125,
        363.4131164550781,
        517.4512329101562
      ],
      "page_num": 129,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[부패·공익신고 안내] ※ 신고자 및 신고내용은 보호됩니다.",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        156.95999145507812,
        693.0,
        469.7447814941406,
        706.2479858398438
      ],
      "page_num": 129,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‣ 식약처 홈페이지 “국민소통 > 신고센터 > 부패·공익신고 상담”코너",
      "font_size": 11.039999961853027,
      "font_name": "T18",
      "bbox": [
        156.95999145507812,
        710.6400146484375,
        512.0399780273438,
        723.8880004882812
      ],
      "page_num": 129,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    }
  ],
  "markdown_content": "<!-- PAGE_1 -->\n## 우울장애 개선 디지털치료기기\n\n<!-- PAGE_1 -->\n## 안전성·성능 평가 및 임상시험계획서\n\n<!-- PAGE_1 -->\n## 작성 가이드라인(민원인 안내서)\n\n- 2022. 12.\n의 료 기 기 심 사 부\n\n<!-- PAGE_3 -->\n#### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n우울장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n**[표 시작]**\n\n| 소프트웨어 | 6 | 1 | 2 | 2 | Acceptable | 위험 < | 2) 사용 환경 : 병원 내 사용, 병원 외 사용 | 으로서, 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시 | 진행이 피험자의 안전 보호를 위협하여 그 진행을 멈추는 것을 ‘중지’라 하며, 임상 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 개발 계획 | 포함하고 싶은 일, 수행하여야 할 일, 특히 즐거움을 주는 활동 | 반박할 수 있는 증거를 생각해 내는 것이다. | 환자는 이와 같은 오류나 왜곡을 깨닫게 되고 그들을 수정하려고 | – Part 2-1: Step by step | 개발 활동을 위하여 소프트웨어 | 가상·증강(VR·AR) 기반 소프트웨어를 포함 | 의료기기의 위험관리 | □ 예 | ■ 아니오 | 국외 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 벡 자살 사고 척도 | 생각, 자기에 대한 부정적 생각, 우울 기분, 신체화 증상, 의욕 | “white-box” 방법으로 수행한다. | 및 유효성 확인’ 자료 등 허가·심사 시 |\n| 6) 사용자 반응 평가(순응도, 만족도, 난이도, 개선점 등) | 제시한다. 그 밖에 임상시험 결과의 사용 범위에 따른 성능 평가를 위하여 | 80001-2-1 | software | 데이터 손실 | 장애에 관한 것이다. 이들 문항 중 10개는 증상이 없는 것 | 사항 | 완료 | 허용가능 | 관리 계획을 수립한다. |\n| 2) 유의수준 | 제조자는 데이터 부인방지(non-repudiation)를 | 제품명(제조업체) | 지침서ㆍ안내서가 있습니까? | CBTi | 30 | 11.90 | 5.25 | 마지막 시도의 심각성을 평가하지만 점수에는 포함되지 | 지침에 따라 처방전 없이 제공할 수 있다. |\n| 19) 피험자의 임상시험 예상 참여 기간 | (Montgomery-˚Asberg | 가이드라인(민원인 안내서)’에 따른다. | 갈음할 수 있다. | 아니다. | 임상시험을 실시하여야 한다. | 활동을 말한다. | 따라 조정될 것이라고 하는 것 | - 이상 반응에 대해 다른 명백한 원인이 있는 경우 | (Integrity)을 고려하여 평가한다. | 상황을 발생하지 않으면 안전성 등급은 A등급에 해당한다. | (1) 인구학적 정보: 성별, 연령, 직업, 업무 생산성 | 한다. | 증상 여부, 직업, 업무 생산성). | 하여 순응도를 조사한다. | 순응도를 조사한다. | 하도록 한다. | 시험을 중지해야 한다고 판단한 경우 | - 예를 들어, “내가 아는 모든 사람은 나를 싫어한다”라는 자동적 | 등을 일일이 열거하게 한다. | 노력하게 된다. | risk management of medical | 표 9. 소프트웨어 안전성 등급 | 개발 계획을 수립한다. | 이득 | 방법에 대한 국제 규격 |\n| (Beck Suicidal ideation | 3) 공용 네트워크 망 사용여부 : Y | 하기에 충분한 경험이 있는 자가 선정되어야 한다. | 시험 개시에서 완료까지 중지될 수 있는 세부 사항을 ‘중지 기준’에 제시한다. | Scale, KDS ) | 제조자는 새로운 사이버보안 취약성에 대응할 | 상실 총 6 요인이다. 18세 이상의 일반 성인과 우울장애 | 제출해야 할 첨부 자료에 대하여 제시 | 제품설명 | 소프트웨어 | 1.17 |\n| 제·개정번호 | 승인일자 | 주요 내용 | 이차 유효성 평가변수를 제시하여 각 임상 검사 항목 및 검사 방법에 대한 | 에서 증가하여 심각도 수준(0~6)도 구성되어 있다. 점수는 | 없음 |\n| 2) 디지털치료기기 치료 기간: 총 8주 | 3) 통계적 검정 방법 | 디지털치료기기 관련 국내외 규격은 <표 6>과 같다. | 기술한다. | 보장하기 위한 설계 특성이 필요한지를 결정 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | 제품외형 | 않는다. BSS는 현재 자살 욕구를 질문하는 4, 5번 문항에서 | WL | 29 | 4.48 | 7.34 | 소프트웨어 |\n| 1) 임상시험용 의료기기 | 3 | 제품의 주요 기능 선정 시 아래 고려사항을 참고하여 선정한다. | Depression Rating | 초과하는 자 | - 우울장애 환자와 함께 활동을 채택하고, 채택된 활동을 하기 | 사고를 시험하기 위해서 먼저, 사람이 어떤 사람을 싫어할 때 | IT-networks – Practical |\n| 5 | 에피소드 진단(F32)을 받은 자 | Scale, BSS) | 의료기기 업데이트 방안을 고려하여야 한다. | 등급 | 설명 | Psychological | 표 16. 사용자 반응 평가 지표 예시 | 환자에게 적용할 수 있다. 문항 점수의 총점은 규준에 근거 | 통합계획에 따라 소프트웨어를 | 의료기기 | 허가·심사 | 시 | 사용자의 | 검증 및 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다. | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 담당 | 2) 사이버보안 요구사항 | 12) 임상시험에 참여함으로써 피험자에게 예상되는 비용 | 20) 임상시험에 참여하는 대략의 피험자 수 | 4) 사용될 통계적 분석 방법(즉, 연구디자인과도 관련) | ‘중지 처리’에는 각 중지 기준에 대한 유효성 평가 통계 처리 시 그 산입 여부와 | ○ 평가 불가능(Unknown) | 위원장이나 간사가 승인한 문서를 의뢰자에게 보내야 한다. | 하는 소프트웨어 의료기기(SaMD)이다. | 인지행동치료의 치료 효과성을 입증된 바 있다. | 하여야 한다. | 하기 위해 시스템 레벨에서의 아키텍쳐를 | (2) 병력조사: 동반 질환 여부 | 비기능 | 순응도를 조사한다. | 및 3개월 후 우울장애 선별 도구(PHQ-9) 변화량 | 더욱 개연성이 있게 설명되는 경우 | 활동 | 판단되는 경우 | 으로 고려하시기 바랍니다. 그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 | 필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다. | 최대 60점이 나오고 점수가 높을수록 우울장애가 심각함을 | 적용 |\n| 심리평가 | 기준을 제시한다. | Scale, MADRS) | 척도(BDI) 변화량 | 의료기기의 사이버보안 | ‘아니오’로 응답하면 20, 21번 문항을 넘어가도록 되어 있고, | 검증 및 |\n| 손익 분석(cost-benefit analysis) | 위한 구체적인 시간표를 짜서 매일 이것을 실행하게 한다. 이러한 | 일반적으로 하는 행동을 생각해볼 수 있다. 다음으로 무작위로 | applications and examples | 유효성 | (AB-1234) |\n| ※ 예: 업데이트 시 사용자 개입/ 자동 업 | A등급 | 부상이나 신체적 피해가 발생할 가능성이 없다. | 소프트웨어 | assessment | Deprexis | 표 6. 디지털치료기기 관련 국내/외 규격 | 측정 질문 (0점-10점, 시각아날로그척도 사용) | 나타낸다. 현재 MADRS에 대한 우울 점수에 따라, 정상(0~7점), | 하여 해석한다. 전체 남자는 T점수 65, 전체 여자는 T점수 | 통합하고 | 통합한 | 소프트웨어 | 건강에 직접적인 영향을 미칠 수 있는 | 되어 있다. | 적용 |\n| 5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이(및 표준편차) | 가) 시험기기 | - 제품의 사용목적상 필요한 기능(능력) 요구사항 | 평가하여야 한다. | 계획 | 적인 | 유효성 | (AB-1234) |\n| 소프트웨어 | Pharmacological treatments. The Canadian Journal of Psychiatry, 61(9), 540-560. | 3) 우울장애 심각도 척도(BDI-II)에서 14점 이상 점수를 가진 자 | 6 | 4 | 하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상시험에 | 피험자별 중지 사유를 포함한 관련 임상시험 자료의 처리 방법을 제시한다. | 범위로 고려할 것을 권고한다. | 허가·심사 가이드라인 | 활동은 즐거움을 주는 활동뿐 아니라 무언가를 수행해야 하는 | ‘예’로 응답하면 6번 이하의 문항에 대해 계속 응답하도록 | 국내 |\n| 안내서-1258-01 | ’22.12.14. | - 성능 평가방법은 임상시험 기간 동안 일차/이차 유효성 평가변수에 대한 | 3) 방문 3 (치료 기간 종료 1주 후, Post-treatment) | 4) 방문 4 (치료 기간 종료 3개월 후, Follow up) | ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설명하거나 | 명시한다. | ※ “예방, 관리”의 범위는 치료적 개입이 필요한 “환자”를 대상으로 함 | (3) 병용약물: 복용 여부 및 종류 | 데이트 여부, 기기의 안전(safety)과 성능에 | 내용을 기록한다. | 수 있다. | 통한 우울장애 치료를 수행한다. | 되는 경우 | 차이가 있는지 평가한다. | (사유 :                                                                ) | - 비기능적 핵심 신념이 발견되고 비합리성이 밝혀졌음에도 이러한 | 선정된 아는 사람을 만나 그들이 실제로 우울장애 환자에게 | 70으로 우울장애를 분류할 경우, 진단적 효율성은 73.1%이다. | 소프트웨어가 어떤(what) 기능을 | 표 12. 위험통제 예시 | 사이버보안 위협에 적용할 수 있는 | 확인 자료 |\n| 나) 위험평가 | 1 | 나는 디지털치료기기를 통해 우울장애에 대한 이해도가 더 증가하였다. | (activity | B등급 | 심각하지 않은 부상(경상)이 발생할 가능성이 있다. | 통합 검증 | software | (GAIA) | 경미(8~15점), 중간(16~25점), 심각(26~30점), 매우 심각(31점 | 항목이 | 의도한 | 대로 | 기능을 | 해당 |\n| 1) 대상자군 | ※ 예: 감사 로그 기록 기능 제공 | 핵심 | (민원인 안내서) | 기술을 배우고 그 과정에서 보상을 받는다. | 확인 자료 |\n| - ‘탈락’ 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상 | 4) 사이버보안 적용 방법 | 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품의약품안전처 지침서 등의 | 소프트웨어 | 활동도 함께 포함된다. | 되어 있다. BSS는 자살 사고 내용 뿐만 아니라 구체적인 | 어떻게(how) 수행할 것인지에 |\n| 관여하는 사람을 말한다. | 되어야 한다. | 치료요법을 이미 받는 자 | - 소프트웨어 기반 알람, 경고, 연산 메시지 | 영향을 보장할 수 있는 업데이트 유효성 검증 | C등급 | 심각한 부상 또는 사망이 발생할 가능성이 있다. | (출처: Thrive 홈페이지, | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 인사를 하는지 하지 않는지 볼 수 있도록 실험을 구상한다. | 신념이 자기 보호기능을 해왔거나 혹은 그것을 가짐으로써 | 최소한의 권고 사항 등 제시 |\n| - 임상시험 중 관찰 항목을 기술한다. | 시험군과 대조군간의 비교 분석 방법을 통계적으로 타당하게 제시한다. | 2 | 나는 다시 우울장애가 심해지면, 이 디지털치료기기를 사용할 것이다. | schedul | 사이버보안 요구사항 | 해당기기 | Affective | Application of risk management | 이상)을 나타낸다. | 발휘하는지 확인한다. | 잔여위험평가 | 적합성 | □ 예 | ■ 아니오 | 첨부자료 |\n| 1) 탈락 기준 | 2) 탈락 처리 | 되어 유효성에 대한 검증을 위해 사용될 예정이다. | 이외 기타 치료 관련 변수와 같은 방식으로 측정할 수 있다. | 라) 피험자 식별코드 부여 | 아) 병용약물 조사 | 바) 병용약물 조사 | 라) 대조군 검사 시험방법 | 가) 치료 후 평가 | 가) 장기 효과 검증 | 반드시 필요한 것은 아니며 행정상 변경이 필요하다. | 필요하면 의료진 연결이 가능하도록 조치한다. | 경우 | 하거나 확인할 수 없는 경우 | 신념 | 그림 2. 데이터 보호 및 보안성 영역 연구의 흐름 | 포함한 정신건강의학과적 증상 등) | 자살 특징(실제 자살 계획)까지도 확인할 수 있는 장점이 | OOO 기능이 구현되도록 입력값을 | 위험/ | 추가 |\n| 식별한 각 위해요인에 대하여 위험관리 계획서에 정의한 위험 | 2 | 관리에 관한 규정 제2조) | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? | 요구사항 | - 계획된 각각의 활동에서 기대되는 즐거움 혹은 성취 정도를 예측 | - 일련의 실험은 자신의 자동적 사고에 대한 비합리성을 인식하게 | 대하여, 소프트웨어가 수행할 수 | 허용 가능함을 검증한다. | 소프트웨어 |\n| of patients with major depressive disorder. Am J Psychiatry, 167(Suppl 10), 9-118. | - 공동연구자는 의학통계 전문가, 의료기기 전문가 등을 말한다. | 시험이 완료되지 못한 경우를 말하며, 그 분류기준을 ‘탈락 기준’에, 탈락의 사유와 | - 시험군 : 디지털 우울장애 인지행동치료군 | 척도(BDI) 변화량 | https://play.google.com/store/a | 의료기기의 사이버보안 | 위험통제 | 이점이 있을 때 잘못된 신념을 포기하지 않으려 한다. | HADS는 병원을 방문한 환자의 불안, 우울 정도와 감정 | 발생 | 의료기기 | 사이버보안 | 적용 | 방법과 | 심 | 위 |\n| 기기 | 1 | 최소 응답시간 | OO초 미만일 것 | 3 | 나는 내 주변의 우울장애 환자에게, 이 디지털치료기기를 추천할 것이다. | 제조자는 기기 소프트웨어의 비인가된 변경과 | 변화를 | ing | disorder | for IT-networks incorporating | Medical devices | 진행 상황을 추적할 수 있도록 한다. | 적용여부 | 입력한 후 그에 대한 응답시간을 | 입증 방법 | 또는 |\n| 위험통제 조치 | - 임상시험 후 이상반응 확인에 대해서 기술한다. | - 통계 분석 방법에 따른 통계적 유의성에 대한 평가 방법과 기준을 제시한다. | - 데이터베이스 요구사항 | - 모델명: ○○○ | 으로 노출되면 ‘불순응’으로 판단한다. | 있다. | 결과 | 이득 | 발생 |\n| 2) 국내 가이드라인별 적용 기준 | 1) 시험기기 및 대조기기 정보 | - 이런 경우 그 같은 신념을 유지함으로써 오는 손해와 이익을 | 정의 | 하면 도움이 된다. 이러한 활동에 장애를 예상해보고 그에 대한 | 하고, 더 합리적인 사고로 변화 필요성을 깨닫게 한다. | 있는 논리적이고 물리적인 표현 | 2 | E06070.01 | 독일 DiGA 디렉터리에 등록되었다. | 용하는 소프트웨어 | 의료기기 품질관리 (Quality | 검증 및 |\n| 5 | · 관찰 시기를 표기한다. | ○ 의료기기의 오류(결함)로 인한 오진률 발생 가능성 | ○ 관련성이 의심됨(Possibly related) | 고지와 관련된 모든 사항을 문서화해야 한다. | 보관(연구파일) 등을 확인한다. | 포함된다. | - 외래 방문마다 병용약물을 수집하여 기록한다. | - 약물 복용력 등을 문진과 과거 진료기록을 통해 조사한다. | pps/details?id=com.waypointh | 치료기기 대상이라고 판단할 수 있다. | 제조자는 업데이트의 수행하기 위해 어떤 | 알게 된 날로부터 15일 이내 보고한다. | 부여한다. | 처리 없이 수집된 자료로 분석한다. | 적용방법 및 사례집 | 조치실행 | 상태의 변화를 매우 신속하게 간단하게 평가하고자 고안 | 가능 | 허가신청 시 제출하는 자료의 작성 | 각 | 험 | 소프트웨어 | 국내 |\n| 소프트웨어 | 등록대상 | - 각 임상시험기관의 적절한 임상시험의 수행을 위하여 임상시험기관 및 시험자의 | 관련 임상자료의 처리 방법을 ‘탈락 처리’에 구체적으로 제시한다. | 허용 기준을 사용하여 위험 감소가 필요한지 결정한다. | 같은 기기의 무결성에 대한 위험을 고려해야 | (출처: SparkRx 홈페이지, | 위한 | 소프트웨어 | therapy | – Quality management | HDRS는 우울장애와 관련된 증상을 총 17문항으로 구성 | medical devices | 측정 | 네트워크로 연결되는 | 적용 | 문서번호 |\n| 임상시험을 복수의 임상시험 기관에서 실시하는 경우에는 기관에 따라 임상시험 | 표 4. 진료지침별 우울장애 인지행동치료의 권고등급 및 근거 수준 | - 대조군 : 디지털 우울장애 위약군(sham군) | SNS 등을 통해 수집할 수 있다. | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? | □ 예 | ■ 아니오 | DAS는 우울장애 관련 구성개념 중 부적응적 사고 유형과 | 동안 프로그램 액세스가 가능하다. | 분석 | 위험 |\n| 해밀톤 우울장애 척도 | 2) 우울장애 선별 도구(Patient Health Questionnaire-9, PHQ-9) | 1) 근거 자료/문서의 직접 열람 | 인 안내서, 식품의약품안전처, 2021.12 | 1 | ISO 13485 | IEC/TR | ealth.thrive&hl=ko) | (민원인 안내서) | 해결책을 미리 논의해도 좋다. | 하나하나 나열하여 비교해 보도록 하는 방법이 있다. 변화된 | 으로 정의한다. | 전체 소프트웨어 시스템이 요구 | 성 | 예시를 제시 | 성 | 도 | Management)에 대한 국제 | 유효성 | (AB-1234) | 국외 |\n| 병원 불안 우울 척도 | 의료기기(SaMD)이다. | 여부 | 변화가 있는 자 | 그림 4. 우울장애 개선 디지털치료기기 임상시험 선행 연구 결과 | - 운영방법 및 유지보수 방법과 관련된 요구사항 | - 제조회사: ㈜○○○ | - 안전성 자료(Safety Set, SS) | 제조자는 의료기기가 다른 기기나 네트워크와 | 한다. | 연결이 필요한지와 코드 서명 및 기타 비슷한 | 하였으며 선별도구로 사용된다. HADS는 불안과 우울을 | 소프트웨어 | 검증 및 |\n| 1) 목표 대상자 수: 총 110명 (군당 55명) | 7 | 7 | 가) 디지털치료기기 허가·심사 가이드라인(민원인 안내서) | 가) 시험기기: 디지털 우울장애 인지행동치료 애플리케이션 | 전략 | https://www.sparkrx.com) | software | 시스템 | systems – Requirements for | – Part 2-2: Guidance for the | 되었다. 전체 문항 점수를 합산하며, 11점 이하는 우울하지 | 의료기기의 위험관리 | 국외 |\n| 5) 이상치 처리 | 자) 관찰 및 평가 | 나) 선정/제외 기준 | 의견을 조정하기 위하여 조정위원회를 설치하고 임상시험 조정자를 선정할 수 있다. | 탈락시킬 수 있다. | 있다는 사실 | 기관명 | 소재지 | 전화 | 팩스 | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 에서 통계적 우월성을 평가한다. | 애플리케이션을 실행한다. | 위한 행동 치료를 수행한다. | 소프트웨어 | 역기능적인지를 평가하기 위해 고안하였다. 원래 DAS는 | 설치될 기기의 메모리 공간을 | 적용 | 규격 | 확인 자료 |\n| 1. 관련 규정 | (Hospital Anxiety and | (Hamilton Depression | 7) 기타 이차 유효성 평가변수*들의 치료 전 대비 변화량 | 결과에 차이가 있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 | 80001-2-2 | 진료지침* | 권고등급** | 근거 수준 | - 계획된 활동을 통해 실제로 얻은 즐거움 혹은 수행 능력 정도를 | 부정적 단어 정의(operationalizing negative constructs) | 신념에 대해 손해와 이익 분석도 이와 같은 방식으로 행해질 | 측정하는 총 14개의 문항에 대해 4점 척도로 응답하도록 | 사항을 충족하는지 확인한다. |\n| 설계 변경을 | 역기능적 태도 척도 | 1) 식품의약품안전처의 임상 계획 승인일로부터 00개월 | 2) 무작위배정 방법 | Off-The-Shelf Software Use in | 어떻게 접속(유·무선 통신 등)하여야 할지를 | 수단을 통한 연결이나 업데이트의 진본성을 | App memory size는 최소 | regulatory purposes | (출처: Twomey et al., 2020.) | 의료기기에서의 | 기성품 | 소프트웨어 | 검증 및 | 유효성 | (AB-1234) |\n| 22(4), 343-396. | 1 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 판단할 수 있는 자 | 자동적 | □ 일회성 지시ㆍ명령에 해당하는 내용입니까? | □ 예 | ■ 아니오 | 검증 | disclosure and communication | 않음, 11~16점은 경미한 우울, 17~25점은 중등도 우울, 26점 | 방법에 대한 국제 규격 | 사항에 반영한다. |\n| 2 | 메모리 크기 | 인 안내서, 식품의약품안전처, 2021.12 | 6 | - 원재료: (임상시험용 의료기기의 원재료에 대한 특성 기술) | 검증 자료로 | 기록하게 하는 등 자신의 행동을 스스로 관찰, 기록하도록 | 우울장애와 | 관련 | 있는 | 역기능적인지를 | 평가하기 | 위해 | 확인한다. | 적용 | 해당 | 미국 |\n| (1) 「의료기기법」 제2조 (정의) | Rating Scale, HDRS) | Depression Scale, | 회사명 | 대표이사 | 소재지 | 전화 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 제조자는 바이러스, 스파이웨어, 랜섬웨어 등 | 고려하여야 한다. | - 우울장애 환자의 자동적 사고는 때때로 절대적이고 흑백 논리적 | 수 있다. | OO MB 이상일 것 | 구성되어 있다. 18세에서 65세 성인에게 적용할 수 있다. | 제공한다. | 소프트웨어 | 확인 자료 |\n| 통한 사용자별 | 1) 분석대상군 | (Dysfunctional Attitude | APA 진료지침(2010) | Strong | High (Substantial) | * 기타 이차 유효성 평가지표 예시는 다음과 같다 <표 17>. | 차이를 보정할 수 있는 경우는 이를 반영하여 분석 결과를 제시해야 한다. | 기타 문서화된 정보의 사전 서면승인을 받아야 한다. | 입회자가 동의를 얻는 전 과정에 참석하여야 한다. | 문제가 있을 경우 시험자와 상의한다. | 이러한 정보들은 기밀로 보관되어야 한다. | - 회원가입 및 초기 우울 증상 평가를 시행한다. | - 치료 전 대비 8주 후 및 3개월 후 관해율, 반응율 | - 각 변수에 대해 이상치는 별도로 고려하지 않는다. | 고려하여야 한다. | 기재한다. | Novego: Coping with | 피험자 식별코드를 부여한다. | Medical Devices | (Follow-up, 3개월 후) | 사용에 대한 가이드 | 위험 < | 유효성 | (AB-1234) |\n| 1) 임상시험의 연구목적으로 수행된다는 사실 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 참여하는 사람(피험자)의 선정기준ㆍ제외기준ㆍ인원 및 그 근거 | 사고와 | SilverCloud | of medical device security | 이상은 심한 우울장애로 구분한다. | (ex:설정→애플리케이션→메모리) |\n| 4) 한국어를 읽고 쓰는 데 어려움이 없는 자 | 1) 임상시험용 의료기기와의 인과관계 평가 | 2) 대상자 모집 기간: 00개월 | 접근통제 및 | 한다. | 고안된 100개의 문항으로 구성되었다. 그러나 임상적으로 | 층화하여 층내 시험군, 대조군 1:1 배정 | 소프트웨어 요구사항을 소프트 | 1 | 2 | 2 | Acceptable | 사항 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 할 수 있다. | 고려하지 않는다. | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 같으면 배제기준에 해당하지 않는다. | 기기에서 실행될 수 있는 악성코드를 막기 | HADS) | □ 외국 규정을 단순 번역하거나 설명하는 내용입니까? | □ 예 | ■ 아니오 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | 으로 나타난다. 어떤 특정 부정적 단어가 자기 자신에게 어느 | 우울 하위척도를 8점으로 절단할 때 민감도 89.2%, 특이도 | 검증 및 |\n| (2) 「의료기기법」 제3조 (등급분류와 지정) | 접근통제 및 | 식품의약품안전처, 2021.12 | BAP 진료지침(2014) | Strong (A등급) | High (Level I) | Mental Disorders, Fifth Edition, DSM-5) | 웨어 밸리데이션 가이드라인(민원인 안내서)’에 따라 수행한다. | Scale, DAS) | ※ 예: Wi-Fi, 이더넷, 블루투스, USB 등 | * 독립형 소프트웨어 제품은 소프트웨어 명칭, 버전, 운영환경 기재 | Depression | needs, risks and controls | 확인 자료 | 이득 |\n| 소프트 | 왜곡된 | Information for Healthcare | (SilverCloud) | Medical devices | 의료기기 위험관리 | (Risk | 적용 |\n| 6) 하위 분석 | 적합한 통신 개략도와 사이버보안 적용 사항을 기재한다. | 문제점을 적극적으로 대응한다. | 및 폐기에 관한 기록을 유지하여야 한다. | - 모든 분석 대상자군(Full Analysis Set, FAS) | 제조자는 비인가 된 개인이 의료기기에 접근 | 내용을 기재한다. | 위임자가 모든 선정 및 제외 기준을 검토해야 한다. | 기간, 목적을 확인한다. | 통해 정보를 수집한다. | 애플리케이션, 이메일, 문자, SNS 등을 통해 수집한다. | 참여 동의를 철회하는 경우 | 타당한 경우 | 표 17. 우울장애 이차 유효성 평가 지표 예시 | 인증 기능 | 정도 해당이 되는지 그 정도를 알게 하는 방법으로 이러한 | 손쉽게 활용하기 위해 40문항으로 단축하였으며, 성취지향, | 표 3. 항우울제 권고 요약표 | 웨어 구조로 설명하며 소프트 | 없음 | (선택) |\n| practical health care: an updated meta-analysis. Journal of anxiety disorders, 55, 70-78. | 행동 | 2) 임상시험의 목적 | 우울장애 개선 디지털치료기기 안전성·성능 평가 및 | 제조자는 | 내·외부의 | 모든 | 입력에 | 대한 | 위해 안티 멀웨어 프로그램과 같은 통제 | 법칙을 깨는 실험(rule-breaking experiments) | 스크리닝 및 | ‘OOOOO’ 경고푸시 알림이 | 82.5%이며, 불안 하위척도를 8점으로 절단할 때 민감도 | 오송보건의료행정타운 | 해당 알림이 발생하는 조건 정하고, | 치료 기간 종료 | 1주 후(8주+1주) | (Post-treatment)3)3)3) | 유효성 | (AB-1234) |\n| CANMAT 진료지침(2016) | Strong (First-line) | High (Level 1) | 개입 | 5) 시험 방법 | 2 | ISO 14971 | 3) 임상시험 수행 기간: 00개월 | 인지 | (IVPNetworks) | – Application of risk | CES-D는 총 20개 문항으로 우울 정서, 긍정적 정서, 신체적 | 치료 시작일 | Management)에 대한 국제 | 성능 시험 | 치료 기간 종료 | 국외 |\n| (3) 「의료기기법」 제10조 (임상시험계획의 승인 등) | 3 | 경고 메시지 | 기록을 열람할 수 있다. | - 모양 및 구조: (임상시험용 의료기기의 모양 및 구조 기술) | 웨어 | Organizations about FDA’S | 표 15. 우울장애 이차 유효성 평가 지표 측정도구 예시 | 검사일 | 소프트웨어 |\n| 2) 소프트웨어 개발 및 위험관리 | 역학용 우울 척도 | 으로 분석한다. | 하는 것을 방지하기 위한 통제 수단을 고려 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 종류 | 기전 | 용량(mg) | - 잘못된 신념을 변화시키는 방법으로 환자가 이러한 신념을 깨어 | 구현 확인 | 부정적인 단어를 정확히 정의해보게 할 수 있다. | 발생할 것 | 대인관계지향 2개 요인으로 구성되었다. | 웨어 항목(item)을 식별하는 아키 | 소프트웨어의 출시 후에 발생 | 실제 제품에 구현시킨다. | □ 예 | ■ 아니오 |\n| 개입 | 행동치료를 처방받아 치료를 수행하는 군(Conal et al., 2020) | 유효성을 확인하는 설계 특성을 고려하여야 | 조치를 고려하여야 한다. | (출처: Deprexis | 홈페이지, | 점진적 | 식품의약품안전처 식품의약품안전평가원 | 78.8%, 특이도 82.5%로 나타났다. | (Baseline) | 측정 지표 | 확인 자료 | 3개월 후 |\n| 전략 | 3) 사이버보안 위험관리 | 다) 인구학적 정보 | - 디지털치료기기에 대한 사용자 반응 평가를 함께 수행한다. | ※ 내원은 필수가 아니며 앱, 이메일, 문자 등을 통해 수집할 수 있다. | 개발 | 변화를 | 기반한 정보를 제공한다. | 임상시험계획서 작성 가이드라인(민원인 안내서) | 평가한다. | management to medical devices | (Screening)1) | 증상 및 둔화된 행동, 대인관계 요인 4개로 구성되었다. | 규격 | 소프트웨어 |\n| 제1차 약제 | “Guidance for Industry: | - 즐거움을 주는 일이나 수행 능력을 키울 과업을 선택하고 계획 | 네트워크를 | 활용하는 | 의료기기의 | 검증 및 | (Follow up)4) | 4) | 4) |\n| (4) 「의료기기법 시행규칙」 제9조 (기술문서 등의 심사) | CANMAT: Canadian Network for Mood and Anxiety Treatments | systematic review. BMC psychiatry, 13(1), 1-10. | 4) 통계처리 및 결과보고서 작성 기간: 00개월 | 가) 스크리닝, 선정·제외 기준 확인 | 애플리케이션을 사용하는 데에 어려움이 없는 자 | (The Center for | 측정도구 | 설명 | 범위 내에서 개발 및 유지가 되어야 한다. | 하여야 한다. | IWRS)을 통해서 시험군 혹은 대조군으로 1:1 배정한다. | 정리한 자료입니까? | 소프트웨어 | - 다음으로 우울장애 환자와 함께 그 개념의 정도를 나타내는 | 버릴 수 있는 실험을 구상하는 방법이다. | SF-36는 신체적 및 정신적 건강 관련 삶의 질에 대한 35개 | 텍처로 | 변환한다. | 소프트웨어 | 하는 피드백에 적절히 대응하고 | 맞춤형 피드백과 전략을 제공한다. |\n| 전략 | 2) 증례기록서의 작성 | 7 | 판단한 자 | 1 | 몽고메리-아스버그 우울장애 척도(Montgomery-As˚ - berg Depression Rating Scale, MADRS) | - 성능: (임상시험용 의료기기의 성능 기술) | 하며, 보안이 취약한 통신(예. 가정용 네트 | 과업 | https://uk.deprexis.com/) | 의료기기심사부 첨단의료기기과 | 사이버보안에 대한 정보 가이드라인 | 미국 | 적용 |\n| trial. The Lancet Psychiatry, 2(3), 217-223. | 3 | 아고멜라틴(agomelatine) | MT1 and MT2 agonist; 5-HT2 antagonist | 25-50 | 회사명 | 대표이사 | 소재지 | 전화 | 방문일 | 방문1 | 방문2 | 방문3 | 방문4 | 프로 | 제조자는 기기의 사용이 입증된 사용자이거나, | 위한 | 소프트웨어 | CES-D는 18세 이상 65세 이하 성인에게 적용 가능하며, 5, | 네트워크 API를 통해 데이터 | 적용 | 검증 및 |\n| 1) 중지 기준 | 전자파 적합성 인증을 통과한 제품을 사용해야 한다. | 나) 대조기기: 위약 대조군(sham) | 성명 | 소속기관명 | 전공 | 직위 | 전화 | Cybersecurity for Networked | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. | 하는 데 있어, 환자의 수행 성공 가능성이 최대화될 수 있도록 | 유효성 | (AB-1234) |\n| 접근 | 2) 방문 2 (치료시작일, Baseline) | Epidemiological Studies | 8 | 나) 이상 반응 확인 | 구분한다. | 하여야 한다. | (3) 피험자 식별코드는 아래의 방법에 따라 기입한다. | ※ 예: 물리적 잠금 혹은 포트(port) 접근의 | 자살 고위험군으로 판단되는 경우 | 통화를 하여 탈락의 주요 사유를 파악하도록 한다. | 따라 차이가 있는지를 확인하기 위해 하위 분석을 제시한다. | 시험용 의료기기의 사용에 기인한다고 판단되는 경우 | 그림 3. 소프트웨어의 안전성 평가 관련 연구의 흐름 | 아키텍처 | 등급을 만들고 정의에 자신이 얼마나 부합하는지 정도를 나타 | 데이터베이스 저장했던 정보와 | GDS는 노인 우울장애를 측정하기 위해 간단하고 신속하게 | 문항과 건강 상태 변화에 대한 1개 문항으로 총 36개 | 항목과 소프트웨어 항목 외부의 | 소프트웨어 | 항목의 | 일관성을 | (AB-1234) |\n| (5) 「의료기기법 시행규칙」 제20조 (임상시험계획의 승인 등) | 4 | 데이터베이스 | 라) 전체 잔여위험 허용 가능성 평가 | 부프로피온(bupropion) | NDRI | 150-300 | 무작위배정 될 확률 | 2 | 해밀톤 우울장애 척도(Hamilton Depression Rating Scale, HDRS) | 워크 혹은 기존 기기)만을 지원하는 기기 및 | 기준)를 함께 제시하여야 한다. | 주기 | PHQ-9은 다른 우울장애 평가척도와 유의한 공존 타당도를 | 베이스로 미리 정해진 데이터를 송신 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 노인 우울 척도 | 한다. | 경과일수 | D-28 이내 | DAY1 | - | - | 세스 | 다른 역할의 사용자에게 사용권한을 부여를 | 전략 | 형상 관리 | TEL : 043) 719-3912   FAX : 043) 719-3900 | 10, 15번은 긍정 질문으로 역 채점하여 총점을 산출한다. 원래 | 유효성 |\n| 보안 | (출처: Beck, J.S.(1995), 권정혜 & 이재우(2001), 이삼연(1999)) | 에서도 적용하기 쉬워 우울장애를 선별하는데 유용한 도구이다. | 나) 대조기기 | Medical Devices Containing | 하는 계획이 중요하다. | 다시 호출한 정보가 일치 | 문항으로 구성. 건강 관련 삶의 질은 8개의 하부영역으로 | 유지하면서 설계 변경 및 소프트 | 의료기기 소프트웨어의 | 확인 자료 |\n| 2) 일차 유효성 평가변수 | 시탈로프람(citalopram) | SSRI | 20-40 | (graded | 물리적 제한, 인증이 필요 없는 물리적 케 | 내게 한다. 환자 자신이 가지고 있는 부정적인 사고에 자신이 | 측정할 수 있도록 고안하였다. GDS는 총 30문항에 대해 | 구성요소 간의 연계성과 소프트 | 매주 30분 동안 주 1~2회의 사용을 권장한다. | 있도록 돕는다. | 구조를 갖추어 설계한다. |\n| (6) 「의료기기법 시행규칙」 제24조 (임상시험 실시기준 등) | Psychiatry, 187(5), 456-461. | 36항 건강수준 척도 | 마) 이상반응 확인 | 나) 이상 반응 확인 | 3 | 역학용 우울 척도(The Center for Epidemioloꠓ | 환경에서 이루어지는 통신도 고려한다. | 송수신 | 나타내고 우울장애를 평가하고 선별하는 척도로써 신뢰도와 | gical Studies Depression Scale, CES-D) | 및 저장한 후, 해당 데이터를 다시 | 확인 자료 |\n| 7) 민감도분석 | 3 | IEC 62304 | Medical device software – | (Geriatric Depression | 우울장애 선별 도구 | 디지털치료기기 관련 국내외 가이드라인은 <표 7>과 같다. | 가) Baseline 유효성 평가 | 데스벤라팍신(desvenlafaxine) | SNRI | 50-100 | 절차를 말한다. | 기기의 회수체계를 확립하고 이를 문서화하여야 한다. | 관찰형태 | 내원 | 내원과 | Off-The-Shelf(OTS) Software” | 허용하거나, 응급상황에서 접근을 허용하는 | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | * 피험자 식별코드: 실시기관 코드 - 등록된 순 | - 수행 가능성 최대화를 위해 과업으로 주는 활동을 수행하기 가장 | CES-D는 16점을 절단 점수로 사용한다. | https://www.nifds.go.kr | 개발부터 유지보수를 | 내원과 | 소프트웨어 | □ 예(☞지침서) | ■ 아니오 | 내원 또는 앱, |\n| 통신 | 1) 부작용 | 무작위 확증 임상시험 | 있는 영역(Acceptable)’의 2단계로 구분할 수 있다. | 이블의 접근제한 등 | 할 것 | 구성되었고, 이는 신체적 건강 관련 삶의 질과 정신적 건강 | 웨어 형상을 유지한다. |\n| behaviour therapy, 40(4), 251-266. | ○ 관련성이 명백함(Definitely related) | 결정하고 주의사항을 준수하기로 서면 동의한 자 | 소프트 | 제조자는 비인가 접근/변경/반복을 방지하기 | 연구 군을 선별한다. | task | Selfapy | 해당하지 않는다는 사실을 발견하게 되고 보다 합리적인 사고를 | 타당도가 입증되었다. PHQ-9의 경우 기존 우울장애 평가 | ‘예, 아니요’의 단순 형식으로 응답하도록 구성되어 있어 | 웨어 항목 간 연계성을 위한 | 불러오기 한다. | 국외 |\n| (Short Form-36 Health | 4 | 6 | 여부, 적합성 입증방법, 첨부자료 또는 문서번호를 기재한다. | 듀록세틴(duloxetine) | SNRI | 60 | 정확한 피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 한다. | 높은 등급이 된다. | 4 | 쯍 우울 척도(Zung’s Self-Rating Depression Scale, SDS) | 피험자 수 산출 공식은 아래와 같다. | 기준이나 절차를 제시하는 것입니까? (공무원용) | 애플리케이션 | 애플리케이션 | 이메일, 문자, SNS |\n| (7) 「의료기기 허가·신고·심사 등에 관한 규정」 | 경우는 별도의 안전성과 성능 시험을 통과한 제품의 사용을 권고한다. | 버전이다. | 웨어의 개발 및 유지를 위한 활동을 수행하여야 한다. | (Patient Health | Scale, GDS) | 사용자 접근통제에 대해 고려하여야 한다. | Guidance for the Content of | 쉬운 활동부터 점차 어려운 활동으로 옮겨가는 방법이 있다. | Software life cycle processes | 포함하여 전주기에 대한 | 검증 및 |\n| 마) 외래 방문마다 유효성 평가 | 또는 일시 중지시킬 수 있다. | 근거를 가진 자살 위험성 평가상 자살 고위험군으로 평가되는 자 | 관련 삶의 질로 구성. 점수 산정은 각각의 8개 하위 척도에 | 아키텍처를 개발한다. | 으로 식별한다. |\n| 1) 목표 대상자 수 산정의 추정 공식 예시 | 우울(20~28점), 심각한 우울(29~63점)을 나타낸다. | 에스시탈로프람(escitalopram) | SSRI | 10-20 | 결과가 검증되어야 한다. | 한다. | 서명이 이러한 자료의 열람을 허용하게 된다는 사실 | 웨어 | 위한 의료기기의 보안이 보장된(secured) | 평가한다. | assign | 특성에 대한 정보들을 수집한다. | 반응이 사라지는 경우 | 표 7. 디지털치료기기 관련 국내외 가이드라인 | 할 수 있게 된다. | 도구보다 문항 수가 적고 작성 시간이 적게 걸려 일차 진료 | 노인에게 시행하기에 적합하다. | 적용 |\n| 1) 대상 질환 : [F32] Depressive episode - 우울에피소드 | 치료 전 대비 8주 후 우울장애 심각도 척도(BDI) 변화량 | Survey, SF-36 ) | 받게 될 각종 검사나 절차 | 5 | 한국인 우울 척도(Korean Depression Scale, KDS) | 제조자는 의료기기가 필수 성능을 유지하기 | 중 작은 수치에 해당하는 0.65로 정하고자 한다. | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 표 11. 위험평가 예시 | 소프트웨어 |\n| 인증 | 고려하여 적절한 기준을 설정함 | 추가로 동일한 자격증명은 기기와 고객들에게 | Premarket Submissions for | 이용하여 발행된 난수표를 적용한다. | 이를 위해 때때로 과업이 세분화되고 단순화될 필요가 있다. | 다른 디바이스에서 같은 휴대폰 | SDS는 긍정 문항 10개, 부정 문항 10개 총 20개의 문항에 | 소프트웨어를 | 포함하는 | 의료기기에 | 국제 규격 | 유효성 | (AB-1234) |\n| (8) 「의료기기 임상시험계획 승인에 관한 규정」 | e0228100. | 우울(15~19점), 심각도 우울(20점 이상)을 나타낸다. | 나) 피험자 동의 및 준비 | 플루옥세틴(fluoxetine) | SSRI | 20-60 | 구분 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | (출처 : 일차 의료용 근거 기반 우울장애 임상진료지침(대한의학회, 2022)) | 속하는 세부 항목들을 점수화 한 뒤 합산하여 0점부터 | 추가 12개월 동안 참가자에게 제공한다. | ■ 예(☞안내서) | □ 아니오 |\n| 선정/제외기준 확인 | O | O | - | - | 8 | 회사명 | 대표이사 | 소재지 | 전화 | 유지 | 데이터 송·수신 방법을 고려하여야 한다. | ments) | 변화량 | 가능하다. | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까? (민원인용) | 과정에서도 적용하기 쉬워 우울장애를 선별하는데 유용한 | 소프트웨어 아키텍처를 소프트 | 대한 시판 전 제출에 대한 가이드라인 | 미국 | 소프트웨어 |\n| 그 이유의 타당성을 면밀히 검토하여야 한다. | 6 | 병원 불안 우울 척도(Hospital Anxiꠓ | - 일차와 이차 유효성 평가 관련된 목록을 작성한다. | 위해 사이버보안 공격을 탐지, 저항, 대응 | ety and Depression Scale, HADS) | 검증 및 |\n| ○ 관련성이 적음(Probably not related) | 가) 위험분석 | 라) 과거 병력 조사 | 플루복사민(fluvoxamine) | SSRI | 100-300 | 한다)를 말한다. | - 일차목적 및 가설 | - 삶의 질 | Software Contained in Medical | 공유되지 않아야 한다. | 번호로 동시에 로그인을 시도 | 대해 4점 척도로 응답하도록 구성되어 있다. 일반인을 대상 | 위험분석 | 위험평가 | 한기기에 시험용 정보로 로그인을 | 확인 자료 |\n| * [F32] Depressive episode (우울에피소드)) | 2) 의료기기의 사용 목적 : 환자의 우울 증상을 정량적으로 개선 | 5) 피험자가 준수하여야 할 사항 | 및 | : (치료 8주 후 BDI 점수) – (치료 전 BDI 점수) | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 수는 없으며, 이상 반응 문제가 생길 수 있다. | 않으면 이에 대한 사유와 근거 등을 제시해야 한다. | 중복 로그인 | 귀결 분석(consequential analysis) | HDSQ는 무망감 | 이론(Hopelessness | Theory)에 기초하여, | 100점 사이의 점수로 변환시키는데, 0점은 가장 나쁜 건강 | 적용 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 밀나시프란(milnacipran) | SNRI | 100 | 인구학적 정보 | O | - | - | - | 쯍 우울 척도 | 활동 | · 층: 성별(남/여), 연령(oo세 미만, oo세 이상) | ※ 예: 기기/시스템 간 통신 시 상호인증 | 순서가 타당한 경우 | Medical device software – | 도구이다. | 웨어 유닛으로 표현할 수 있을 | 검증 및 |\n| 5 | psychosomatics, 85(4), 218-228. | 기록한다. | 7 | 노인 우울 척도 (Geriatric Depression Scale, GDS) | 및 복구하도록 허용하는 설계 특성을 고려 | ※ 접근 통제의 예: 비밀번호, 하드웨어 키, | Devices | 했을 때, 기존 로그인되어 | 한 후, 다른 기기에서 같은 정보로 | 유효성 | (AB-1234) |\n| 동시에 의료기기의 전체 수명주기의 위험관리 일부로 수행한다. | 으로 우울장애를 선별하고자 할 때 적용 가능하며, 채점은 | 「의료기기법」 및 「의료기기법시행 | 의료기기 소프트웨어의 | 적용 | 발생 |\n| 멀타자핀(mirtazapine) | α2-Adrenergic agonist; 5-HT2 antagonist | 15-45 | 과거병력 조사 | O | - | - | - | 무망감 질문지 | (출처: SilverCloud 홈페이지, | 질환으로 정의한다. | (출처: NOVEGO 홈페이지, | 의료기기와의 인과관계에 대하여 증례 기록지에 기록한다. | 것에 무리가 있다고 판단될 때는 임상시험을 중지할 수 있다. | 방지 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | - 귀결 분석은 감정 저하를 일으키는 잠재된 두려움, 사고, 가정 | 우울장애 관련 요소로서 무망감을 측정하기 위해 고안된 | 상태를 의미하며, 100점은 가장 좋은 건강 상태를 의미이다. | □ 예 | ■ 아니오 |\n| of medical Internet research, 11(2), e1151. | : 일차 유효성 평가변수와 동일한 방법을 적용한다. | (Zung’s Self-Rating | 대리인)에게 제공해야 한다. | 위원회 및 식품의약품안전처장의 승인을 받아야 한다. | 얻는 전 과정에 참석하여야 한다. | - 병력 등을 문진과 과거 진료 기록을 통해 조사한다. | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 프로 | 교정 및 기저 불안을 줄이는 내용이 포함되어야 한다. | IEC/TR | 방법, 암호화 필요 여부, 과거에 전송된 | 내용을 기록한다. | 발생 가능한 | Part 1: Guidance on the | 때까지 | 분해하고, | 각 | 유닛에 | DiGA 디렉터리에 등록되었다. | 유효성 | 심각 | 위험 | (AB-1234) |\n| 3) 임상시험용 의료기기 : 우울장애 개선 디지털치료기기(OOO) | 6) 검증되지 않은 임상시험이라는 사실 | 2) 일반적 주의 | 8 | 무망감 질문지(Hopelessness Depression Symptom Questionnaire, HDSQ) | 기록한다. | 하여야 한다. | Deciding When to Submit a | 생체인증 등 | 있던 기기에서는 로그아웃 | 규칙」,「의료기기 | 허가·신고·심사 | 로그인을 시도한다. | 확인 자료 |\n| 4 | 3) 맹검 방법 | 파록세틴(paroxetine) | SSRI | 20-50 | 사례 | 위해상황 | 위해 | - 어떤 목표를 성공적으로 달성하는 데에서 오는 자기 보상은 점차 | 문항 점수를 합산한다. SDS에서 50점 이상은 경미, 60점 | 시판 후 소프트웨어에 문제가 | 위험관리 방법에 대한 국제 | 가능 | 도 | 결과 | 국외 |\n| 기타 확인 | 1) 개요 | 3) 기타 이차 유효성 평가변수 | 1 | 디지털치료기기 허가·심사 | (Hopelessness | https://health.colostate.edu/silv | 세스 | 명령어 및 데이터의 비인가 반복에 대한 | https://www.novego.de//) | 민원인을 구속하는 내용이 있습니까? | 등을 이해하기 위한 유용한 수단이 된다. “만약...라면?”이라는 | 것이다. HDSQ는 32문항에 4점 척도로 구성되었으며 하위 | = (건강 문제로 인해 손실된 시간의 비율) + [(1 - 건강 문제로 | 의료기기 내 소프트웨어 변경에 따른 | 확인 자료 |\n| 80002-1 | treatment 후 변화량의 평균과 표준편차를 제시한다. | application of ISO 14971 to | 되어야 한다. | 대한 | 상세 | 설계를 | 수행한다. | 성 |\n| 2. 문의처 | 9 | 설트랄린(sertraline) | SSRI | 50-200 | 9 | 벡 자살 사고 척도(Beck Suicidal ideation Scale, BSS) | - 심각한 부작용 발생으로 조기 종료시킬 수 있다. | 510(k) for a Software Change | 내용을 기록한다. | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | 이상은 중증도, 70점 이상을 고도의 심각성으로 분류할 것을 | 등에 관한 규정」 기반, 디지털치료 | 국내 | 미국 |\n| 사항 | 시험계획서의 절차에 따라 이루어지도록 하여야 한다. | 될 것이라는 사실 | - 사용자 반응 평가 | - 이상 반응에 대해 보다 가능성 있는 원인이 있는 경우 | 주요분석군으로 분석한다. | Baseline 정보를 수집한다. | 자기 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 활동을 늘리게 하고 그것을 유지케 하는 효과적인 수단이 된다. | 인해 손실된 시간의 비율) × 건강 문제로 인해 일하는 동안 | 발생하거나 개선의 필요성 때문에 | 성 | 규격 | 소프트웨어 |\n| 1) 치료 전 대비 3개월 후 우울장애 심각도 척도(BDI) 변화량 | 7) 피험자에게 미칠 것으로 예상되는 위험이나 불편 | Depression Symptom | 2 | 벤라팍신(venlafaxine) | SNRI | 75-225 | 임상시험에서 배제 | 방지, 사전에 정의된 통신 종료 시점의 | 가이드라인(민원인 안내서) | ercloud/) | 질문을 통해 환자의 잠재된 사고에 이를 수 있도록 유도한다. | 요인으로 8 요인(동기적 결핍, 대인관계의 의존성, 정신 | 지침 가이드라인 | 것을 권장하고 있다. |\n| 9 | 소프트웨어 | 내용을 기재함 | 생산성 손실 점수 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 때문에 가장 개연성이 있게 설명되는 경우 | 오송보건의료행정타운 | medical device software | 또한 소프트웨어 유닛 및 외부 |\n| 85(4), 367. | 4 | 소프트웨어 | 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다. | 10 | 역기능적 태도 척도(Dysfunctional Attitude Scale, DAS) | to an Existing Device | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다. | 으로 예상하여 30%로 정하고자 한다. | 제한하였다. | 기기에 해당하는 제품의 범위, 판단 |\n| 식품의약품안전처 식품의약품안전평가원 의료기기심사부 첨단의료기기과 | 보티오섹틴(vortioxetine) | Serotonin reuptake inhibitor; 5-HT1A agonist; 5-HT1B | partial agonist; 5-HT1D, 5-HT3A, and 5-HT7 antagonist | 10-20 | 제조자는 주기적인 업데이트의 구현과 배포를 | 대체 수집할 수 있다. | 강화 | - 목표 설정과 수행에 강력한 합리성을 제공하고, 확실하게 정의된 | 발생한 장애(impairment) 비율] | 제품 또는 관련 문서가 수정되는 | 핫라인을 이용할 수 있다. | 검증 및 |\n| 2) 중지 처리 | Questionnaire, HDSQ) | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 적절성 여부 등 | 대체 수집할 수 있다. | 사용자 구분을 | 식품의약품안전처 식품의약품안전평가원 | 운동 지체, 에너지 없음, 냉담/무 쾌락, 불면증, 집중 곤란/ | 구성요인 | 사이의 | 연계성 | 및 | 조작된 환자 | 오진, 잘못 된 | 우울 증상 임의의 시험용 수명 |\n| (Work Productivity and | 내용 등을 기록하여 보관하여야 한다. | - 계획서 순응 임상시험대상자군(Per-protocol Set, PPS) | 절약할 수 있다.1) | 한다. | Postmarket Management of | 적용하여 주요 결과와 차이가 있는지 분석하여 제시한다. | 문제해결 | 적용 |\n| 5) 임상시험 디자인 : 단일(다)기관, 무작위배정, 전향적 임상시험 | 6 | 우울 증상 | 이상반응 확인 | - | O | O | O | 비 | 11 | 36항 건강수준 척도(Short Form-36 Health Survey, SF-36) | 번호로 연락하고 관리자가 조치할 때까지 대기한다. | 상세 설계 | 우울 증상 예상값 대비 결과값 | 기준, 허가·심사 방안 등 제시 |\n| - 사용 중단으로 이상 반응이 없어지는 경우 | and post-production information)로 구분한다. | 위한 수행절차를 수립하고 통보하여야 한다. | (self-re | 수행할 수 있다. | 하지 않고 | 재귀인(reattribution) | 의료기기심사부 첨단의료기기과 | 구체적이고 달성 가능한 목표를 세우도록 고무하며, 환자가 | Application of risk | = 건강 문제로 일을 빠진 시간/(건강 문제로 일을 빠진 시간+ | 상기 사항에 대하여 확인하였음. | 경우 문제점과 그 영향 등을 | 결과 | 의료기기 | 사이버보안의 | 시판 | 후 | 치료 수행 | 유효성 | (AB-1234) |\n| 전화 : (043) 719-3912 | 제2차 약제 | 제조자는 안전(safety)과 관련된 데이터가 저장 | 반추, 자살에 관한 생각)이 확인되었다. | 소프트웨어 유닛 사이의 연계성을 | 개인적인 상황에 맞게 조정하여 제공한다. | 입력정보를 입력했을 때, 산출되는 |\n| 10 | 인가된 | measuring depression. Archives of general psychiatry, 4(6), 561-571. | Activity Impairment, | 바) 병용약물 조사 | 다) 병용약물 조사 | 기기로서의 사용 목적을 달성할 수 있음을 증명해야 한다. | 영향을 줄 것으로 예상하는 약물을 임의로 복용한 경우 | 수집할 수 있다. | Cybersecurity in Medical | 의료기기 소프트웨어 | 의료기기 | 소프트웨어 | 밸리데이션에 | 관리에 대한 가이드라인 | 미국 | ALA |\n| 웨어 | ※ 본 장에서 제시한 항목 및 예시는 참고용으로 작성한 것으로 사안에 | 병용약물 조사 | O | O | O | O | 12 | 생산성 손실 점수(Work Productivity and Activity Impairment, WPAI) | 정확도 | 제2판(Beck Depression Inventory, BDI-II)를 이용하도록 한다. | 차이는 ± 1% 이내일 것 | 소프트웨어 | 확인 자료 |\n| 1) 사용 전 준비사항 | 8) 중간 분석 | 아미트립틀린(amitriptyline) | TCA | 25-50 | 위해요인에 대해 <표 10>과 같이 기록한다. | 안전성에서‘하’등급의 분류가 불가능하다. | inforce | 척도(BDI) 정보를 Baseline 지표로 활용할 수 있다. | 이거나 모호한 경우 | 누구나 환자의 | 해당한다. | - 부정적인 사건 원인을 더 다양하게 생각해 내도록 도와주어야 | 강화 받을 수 있는 활동을 찾아 선택하게 하고, 목표를 정한 후에 | management for IT-networks | 실제 일한 시간) + [(1 - 건강 문제로 일을 빠진 시간/(건강 | 분석하여 변경해야 한다. | 데이터로 | 또는 | 네트워크로 연결되는 | 3 | 2 | 6 |\n| 3) 적용상의 주의 | 3) 치료 전 대비 8주 및 3개월 후 관해율* | controlled trial. Internet Interventions, 2(1), 48-59. | 그 사실 | 되거나 기기와 송·수신될 때 암호화와 같은 | 위한 | 상세 | 설계를 | 수행한다. | 결과값과 예상값을 비교한다. | 실현할 수 있어야 한다. |\n| 2 | FAX : (043) 719-3900 | 순응도 조사 | - | O | O | O | 13 | 우울장애 일기를 통한 우울 양상 | - 재사용(재사용이 가능한 경우에만 실시) 결과가 양성인 경우 | WPAI) | IEC | 밸리데이션 가이드라인 | [부패·공익신고 안내] ※ 신고자 및 신고내용은 보호됩니다. | Devices | 대하여 알기 쉽게 설명하거나 식품 | 소프트웨어 | 국내 | RP |\n| 유지 | 이미프라민 (imipramine) | TCA | 150-300 | 전화: 043-719-3912 |       | 검증 및 |\n| 5 | 다) 병용약물 조사 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. | 제조자는 운영 체제(OS) 소프트웨어, 제3자 | ment) | 데이터에 접근 | 즉각적으로 강화를 받을 수 있는 활동에 참여하도록 하고, 변화 | 한다. 불쾌한 사건을 상상하게 하고, 자신이 생각하는 사건이 | incorporating medical devices | 문제로 일을 빠진 시간+실제 일한 시간)] × 건강 문제로 | 2022년  12월  14일 | 전문의 | 치료기회 |   | 의료기기의 위험관리 | 국외 |\n| 등 필요한 조치를 시험책임자에게 하여야 한다. | 따라 변경될 수 있으며, 제품의 특성에 따라 타당한 근거를 제시할 경우 | Guidance on Cybersecurity for | 일정 수준의 보호가 요구되는지 고려하여야 한다. | 그림 1. 디지털 치료기기 대상여부 판단 기준 및 절차 | 또는 일시 중지시킬 수 있다. | ‣ 식약처 홈페이지 “국민소통 > 신고센터 > 부패·공익신고 상담”코너 | 상세 설계를 바탕으로 코딩을 | 적용 |\n| 접근 | 나) 무작위 배정 | 노르트립틸린(nortriptyline) | TCA | 20-40 | 14 | 우울, 불안 관련 증상 유무 | 것이라는 사실 | - 우울/불안 관련 증상 유무 및 직업적/사회적 기능 상태 | - 본 연구는 중간 분석을 수행하지 않는다. | 80001-1 | (출처: Selfapy 홈페이지, | (민원인 안내서) | 팩스: 043-719-3900 | 의약품안전처의 입장을 기술 | 관련 보고를 시행한다. | 검증 및 |\n| 보호 | 보수 | 11 | * 관해 정의: 우울장애 심각도 척도(BDI) 13점 이하 | 전문의에 의해 자살 고위험군으로 판단되는 자 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | medical devices | 의료기기 사이버보안에 대한 가이드라인 | 유럽 |   |  |  |  | 유효성 |   | (AB-1234) |\n| 트라조돈(trazodone) | Serotonin reuptake inhibitor; 5-HT2 antagonist | 50-100 | 소프트웨어, 오픈 소스 소프트웨어가 업데이트나 | 하도록 한 경우 | 상황을 관찰 기록함으로써 환자의 자기강화를 도와줄 수 있다. | 일어난 이유를 설명하게 한 다음, 보다 합리적이고 현실적인 | 인해 일하는 동안 발생한 작업 능률 점수/10] | – Part 1: Roles, | 진료수행 | 박탈 | 방법에 대한 국제 규격 | 적용 |\n| ※ 예: 비밀번호(passwords)는 암호화된 보안 | https://www.selfapy.com/) | 하며 코드는 정확하고 요구사항에 | 과정은 총 3개월 동안 사용할 수 있다. |\n| 세스에 따른다. | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 설정 변경이 가능하다. | 15 | 직업적/사회적 기능 상태 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. | 영향을 줄 수 있는 약물의 사용량이 변경된 경우 | 유효성 | (AB-1234) |\n| dismantling study. Trials, 22(1), 1-10. | 모노클로베미드(monoclobemide) | Reversible inhibitor of MAO-A | 60 | 러목(의료기기이상반응의 보고)에 따른다. | 대상으로 한다. | 담당자 | 확  인(부서장) | 확인 자료 | 양 승 하 |\n| 기회를 제공하여 동의를 얻어야 한다. | 되어야 한다. | 해주어야 한다. | 연장할 수 있다. | - 시험군 혹은 대조군에 무작위배정을 통해 배치한다. | 사건들을 조합하여 각 위해요인에 대한 위험을 산정한다. | 치료기기를 설치한다. | 통제될 경우에 대해 고려하여야 한다. | 하여야 한다. | 및 내용 등을 기재한다. | 모호한 경우 | 대안적 이유를 생각해 낸다. | responsibilities, and activities |\n| 방법의 잠재적 위험과 이익 | 요구한 사용 방법을 준수하여야 한다. | (secure)이 확보된 해쉬(hash)로 저장되어야 함 | 부합한다. |\n\n**[표 끝]**\n\n지침서ㆍ안내서\n\n이 원 규\n\n<!-- PAGE_4 -->\n#### 제·개정 이력\n\n<!-- PAGE_4 -->\n###### 우울장애 개선 디지털치료기기 안전성·성능 평가 및\n\n<!-- PAGE_4 -->\n###### 임상시험계획서 작성 가이드라인(민원인 안내서)\n\n우울장애 개선 디지털치료기기 안전성·성능\n\n평가 및 임상시험계획서 작성 가이드라인\n\n(민원인 안내서) 제정\n\n이 안내서는 우울장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서\n\n작성에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이\n\n아님을 알려드립니다. 또한, 본 안내서는 2022년 12월 현재의 과학적ㆍ기술적 사실\n\n및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정법규 내용 및 구체적인\n\n<!-- PAGE_7 -->\n# 목\n\n<!-- PAGE_7 -->\n# 차\n\n<!-- PAGE_7 -->\n### Ⅰ. 개 요 ········································································ 1\n\n<!-- PAGE_7 -->\n##### 1. 배경 및 목적 ················································································ 1\n\n<!-- PAGE_7 -->\n##### 2. 적용 범위 ······················································································ 1\n\n<!-- PAGE_7 -->\n##### 3. 용어 설명 ······················································································ 3\n\n<!-- PAGE_7 -->\n##### 4. 현황 ································································································ 4\n\n<!-- PAGE_7 -->\n### Ⅱ. 안전성·성능 평가 ·············································· 29\n\n<!-- PAGE_7 -->\n##### 1. 국내외 관련 규격 및 가이드라인 ·········································· 29\n\n<!-- PAGE_7 -->\n##### 2. 안전성 평가 항목 ······································································ 33\n\n<!-- PAGE_7 -->\n##### 3. 성능 평가 항목 ·········································································· 44\n\n<!-- PAGE_7 -->\n### Ⅲ. 임상시험계획서 작성 시 고려사항 및 예시 ·· 46\n\n<!-- PAGE_7 -->\n### Ⅳ. 참고문헌 ······························································ 119\n\n- - 1 -\n<!-- PAGE_8 -->\n### Ⅰ\n\n<!-- PAGE_8 -->\n### 개 요\n\n<!-- PAGE_8 -->\n##### 1. 배경 및 목적\n\n<!-- PAGE_8 -->\n###### 식품의약품안전처는 정부 지원 과제 중 디지털치료기기에 특화된\n\n<!-- PAGE_8 -->\n###### 과제의 제품 설계부터 제품화에 필요한 안전성·성능 평가 및 임상시험\n\n<!-- PAGE_8 -->\n###### 계획서 작성 방법 제공을 통한 신속 제품화 지원을 하고 있다.\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 “우울장애 개선 디지털치료기기”의 안전성 및 성능\n\n<!-- PAGE_8 -->\n###### 평가 방법, 임상시험계획서 작성 시 고려사항 및 예시를 구체적으로\n\n<!-- PAGE_8 -->\n###### 제시하여 신속 제품화를 위한 맞춤형 기술 지원을 목적으로 한다.\n\n<!-- PAGE_8 -->\n##### 2. 적용 범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인에서 다루는 우울장애 개선 디지털치료기기는 「의료\n\n<!-- PAGE_8 -->\n###### 기기 품목 및 품목별 등급에 관한 규정(식약처 고시 제2021-83호)」의\n\n<!-- PAGE_8 -->\n###### 품목 분류에 따라 정서장애치료소프트웨어(2등급, E06070.01) 의료기기로\n\n<!-- PAGE_8 -->\n###### 분류된다.\n\n<!-- PAGE_8 -->\n###### 단, 추후 우울장애 외 동반된 정신과적 증상에 대한 평가 또는 치료를\n\n<!-- PAGE_8 -->\n###### 동시에 목적으로 한다면 심리평가소프트웨어(2등급, E06050.01) 또는\n\n<!-- PAGE_8 -->\n###### 인지치료소프트웨어(2등급, E06060.02)의 의료기기 분류를 추가하여\n\n<!-- PAGE_8 -->\n###### 조합의료기기로 분류할 수 있다.\n\n- - 2 -\n품목명\n\n영문명\n\n등급\n\n분류번호\n\n품목정의\n\n**[표 시작]**\n\n| 갖춘 | 의료기관을 | 임상시험기관으로 | 지정하여 | 운영하고 | 있으며, 임상시험기관은 | 임상시험심사위원회 심사 기간 등 충분한 기간을 고려하여 “식품의약품안전처의 임상 계획 | 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시한다. | (Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험책임자의 이력 | 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각 단계별 조작 순서, 병용 요법 | - 임상시험 전 피험자 선정 과정에서의 확인해야 할 사항, 임상검사, 피험자 동의서 | 1) 만 19세 이상 성인 | 인지치료 | Meyer et al.(2009) | 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능 평가 기준을 | 한국인 우울 | 것을 방지하도록 고려하여야 한다. | - 아이디어를 구상하는 방법은 가정된 자동적 사고를 지지하거나 | 해석함으로써 생길 수 있다. 이러한 상황을 재점검해봄으로써 | 응답하도록 구성되었으며, 우울 증상은 미래에 대한 부정적 | 인지기능을 개선하는 데 사용하는 소프트웨어 | 0.65 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 등을 제시한다. | ‘의료기기 임상시험 관리기준’(의료기기법 시행규칙 [별표3])에 의거, 정한 기간 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | 3) 이차 유효성 평가변수: | 4) 결측값 처리 | 1 | 라) 순응도 조사 | 같이 분류한다. | 유지한다. | 아니 된다. | 사유 | - 초기 평가에는 최소 다음의 사항이 포함되어야 한다. | 해야 한다. | (3) 정신과적 전문치료를 시작한 것으로 판단되는 경우 | IEC/TR | 체제 버전에서 운영되는 의료기기 소프트웨어 | 점검하고 증례 기록서에 기록한다. | 타당한 경우 | 순서가 타당하지 않은 경우 | : 군간 예상되는 effect size | 평가지표로 사용할 수 있다. | 유닛 검증 | therapy | 접근으로 인해 환자 | 느낌의 상실, 비관적 사고, 자살 사고와 같은 특징적인 우울 | 파악할 수 있는 “static test” 및 | 2 | E06060.02 | 보고서’, ‘의료기기 소프트웨어 검증 | 제공하는 우울장애 디지털 프로그램이다. | 해당 |\n| 1) 연구가설 | 해당 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 대상질환 또는 | (민원인 안내서) | 하게 되어 있다. 나머지 2개 문항은 이전 자살시도의 횟수와 | WL | 57 | -0.04 | 9.54 |\n| ※ 피험자의 선정·제외 기준, 인원 및 근거 | 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입한다. | 사용자의 접근 | 우울장애 척도 | 또는 치료기회 박탈 | 이상사례 |\n| (Blinding) 전략이 잘 포함되어야 한다. | [의료기기 임상시험기관 지정에 관한 규정(식약처 고시)]에 따라 식약처장으로부터 | 자를 말하며, 임상시험용 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용 | 일반적인 사항, 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 서식, | 하는 원칙과 절차를 수립하여 제시한다. 피해자 보상에 대한 규약에는 보상원칙과 보상이 | 척도(Korean Depression | 등을 기술한다. 임상시험을 위한 피험자 동의 및 준비, 치료절차, 관찰 및 평가 절차 등을 |\n| 승인일로부터 OO 개월”로 표시하고 근거자료를 제출한다. | 사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 의료기기의 공급과 | 예시 | 유/무, 피험자 기초정보, 병력조사, 선정 및 제외 기준, 식별코드 부여 등에 대해서 |\n| 내에 가능한 신속한 보고가 되어야 하며, 이상반응 등에 대한 의학적 소견· | 하는 원칙과 절차를 수립하여 제시한다. |\n**적응증을 포함하도록 한다.**\n| 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함한다. | 연번 | Vernmark et al.(2010) |\n| 의료기기 임상시험기관으로 지정받은 곳이어야 한다. | 할 경우 이를 함께 관리한다. 임상시험용 의료기기 관리자의 성명, 소속 기관명 및 | 디자인 특성, 원자재 및 성능, 새로운 제조방법 등에 대한 특이성을 함께 기재한다. | 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 한다. | 취급에 관한 사항을 추가로 확보할 수 있다. | 상세히 시험방법을 기술한다. |\n| 정도와 | 임상시험용 | 의료기기와의 | 인과관계를 | 평가하여 | 증례기록서에 | 기록 |\n**예시**\n**예시**\n| 직명 등 인적사항을 기재한다. | 1) BDI 변화량 = Baseline 시점의 BDI 점수 – Post-treatment 시점의 BDI 점수 | 2) Effect size = (시험군의 평균 BDI 변화량 –대조군의 평균 BDI 변화량) / 합동표준편차 | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행규칙 | - 피험자의 방문 일에 따른 관찰 시기별 관찰 항목, 임상 검사 항목과 관찰검사방법을 | 2 | E06050.01 | 의료인이 환자의 심리적 상태를 평가, |\n| 하여야 | 한다. 따라서 이상반응에 대한 임상시험용 의료기기와의 인과관계에 | 예시 | 예시 |\n**머목(모니터링)에서 정하고 있다.**\n| 예시 | 결정하는 데 사용하기 위한 소프트웨어 |\n| [별표 3])에서 정하고 있다. 이에 따른 피험자 동의서 서식을 제시하여야 하며, 피험자 | 예시 |\n| 번호 | 시험 항목 | 시험기준 | 시험 방법 | 대한 평가 기준을 제시하여야 한다. | 예시 |\n**예시**\n| 번호 | 표준 번호 | 규격 명칭 | 주요 내용 | 비고 | 2(Baseline), 방문 3(Post-treatment), 방문 4(Follow-up, 3개월 후) |\n| 설명서에는 동 기준의 제7호 아목의 10)을 포함하여야 한다. | 예시 |\n**예시**\n**(CBT-D)를 기반으로 하였을 경우 다음 사항이 포함되어야 한다.**\n**통제**\n| 정서장애치료 | 예시 |\n| 예시 | 예시 | 예시 |\n| 예시 | 완료 |\n\n**[표 끝]**\n\nCognitive\n\n정서장애(우울장애 등)를 개선하는데 사\n\n가상ㆍ증강(VRㆍAR) 기반 소프트웨어를 포함\n\n<!-- PAGE_9 -->\n###### 표 1. 우울장애 개선 디지털치료기기 관련 의료기기 품목(식약처 고시 제2021-83호)\n\n<!-- PAGE_9 -->\n###### ※ 본 가이드라인에서 다루는 우울장애 개선 디지털치료기기는 소프트웨어 의료\n\n<!-- PAGE_9 -->\n###### 기기로서, 사용 시 필요한 범용 장비(스마트폰 또는 태블릿 PC 등)는 적용\n\n<!-- PAGE_9 -->\n###### 범위에 포함되지 않으나, 반드시 함께 병용해야 하므로 전기용품 안전 인증과\n\n<!-- PAGE_9 -->\n###### ※ 실생활 습관을 추적 관찰하기 위해 기타 웨어러블 의료기기를 추가로 사용하는\n\n- - 3 -\n<!-- PAGE_10 -->\n##### 3. 용어 설명\n\n<!-- PAGE_10 -->\n###### 가. 소프트웨어 의료기기(Software as a Medical Device, SaMD)\n\n<!-- PAGE_10 -->\n###### 하드웨어에 종속되지 않고 의료기기의 사용 목적에 부합하는 기능을\n\n<!-- PAGE_10 -->\n###### 가지며 독립적인 형태의 소프트웨어만으로 이루어진 의료기기이다.\n\n<!-- PAGE_10 -->\n###### 나. 디지털치료기기(Digital Therapeutics)\n\n<!-- PAGE_10 -->\n###### 식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인(민원인\n\n<!-- PAGE_10 -->\n###### 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방, 관리, 치료\n\n<!-- PAGE_10 -->\n###### 하기 위해 환자에게 근거 기반의 치료적 개입을 제공하는 소프트웨어\n\n<!-- PAGE_10 -->\n###### 다. 정신질환의 진단 및 통계 편람(Diagnostic and Statistical Manual of\n\n<!-- PAGE_10 -->\n###### 미국 정신의학협회(American Psychiatric Association, APA)에서 발행한\n\n<!-- PAGE_10 -->\n###### 정신질환의 신뢰할 만한 진단이 가능하도록 고안된 관련 기준들을\n\n<!-- PAGE_10 -->\n###### 통칭하는 정신질환 분류법이다. DSM-5는 2013년도의 새로운 업데이트\n\n- - 4 -\n<!-- PAGE_11 -->\n##### 4. 현황\n\n<!-- PAGE_11 -->\n###### 가. 우울장애 인구학적 특성\n\n<!-- PAGE_11 -->\n###### 질병관리청에서 실시한 2020년 국민건강영양조사에 따르면 전국\n\n<!-- PAGE_11 -->\n###### 만 19세 이상 성인을 대상으로 조사한 우울장애 유병률은 5.3%이었다.\n\n<!-- PAGE_11 -->\n###### 남성이 4.4%, 여성이 6.2%로 남성보다 여성이 우울장애 유병률이 약\n\n<!-- PAGE_11 -->\n###### 1.4배 더 높다. 연령별로 유병률을 살펴보면 전 연령층에서 우울장애가\n\n<!-- PAGE_11 -->\n###### 발병하나, 19~29세에서 유병률이 8.3%로 가장 높고, 30~39세 6.8%,\n\n<!-- PAGE_11 -->\n###### 40~49세 4.9%, 50~59세 2.4%, 60~69세 4.3%, 70세 이상 5.3%로 연령이\n\n<!-- PAGE_11 -->\n###### 증가할수록 유병률이 감소하다가 50대 이후 다시 증가하는 U자형\n\n<!-- PAGE_11 -->\n###### 모양이다. 성별 기준으로는 남성 30~39세 6.5%, 여성 19~29세에서\n\n<!-- PAGE_11 -->\n###### 11.3%로 가장 우울장애 유병률이 높다. 다만 우울장애 의사 진단\n\n<!-- PAGE_11 -->\n###### 경험률은 4.9%이며, 남성이 3.0%, 여성이 6.8%로 여성이 2.3배 높다.\n\n<!-- PAGE_11 -->\n###### 70세 이상에서 6.6%로 우울장애 의사 진단 경험률이 가장 높으며,\n\n<!-- PAGE_11 -->\n###### 연령별로는 유병률과 마찬가지로 U자형 모양를 띄고 있다. 성별 기준\n\n<!-- PAGE_11 -->\n###### 으로는 남성은 19~29세 4.7%, 여성은 60~69세 8.8%로 우울장애 의사\n\n<!-- PAGE_11 -->\n###### 진단 경험률이 가장 높다. 2008년 우울장애 의사 진단 경험률이 2.9%에서\n\n<!-- PAGE_11 -->\n###### 2020년 4.9%에 이르기까지 우울장애 의사 진단 경험률이 꾸준하게 증가하고\n\n<!-- PAGE_11 -->\n###### 있으며, 이와 더불어 자살 계획률과 정신 문제 상담 경험률도 증가하고\n\n<!-- PAGE_11 -->\n###### 있다.\n\n<!-- PAGE_11 -->\n###### 우울장애는 다른 정신질환과 동반 위험이 크다. 대표적으로 알코올\n\n<!-- PAGE_11 -->\n###### 중독과 같은 물질 사용 장애(substance use disorder), 공황장애(panic\n\n<!-- PAGE_11 -->\n###### disorder)를 비롯해 불안장애(anxiety disorder), 강박장애(obsessive-\n\n- - 5 -\n<!-- PAGE_12 -->\n###### compulsive disorder), 사회불안장애(social anxiety disorder)등과 동반\n\n<!-- PAGE_12 -->\n###### 이환 위험성이 높다. 이러한 동반 질환은 진단과 치료에 부정적인\n\n<!-- PAGE_12 -->\n###### 영향을 끼치며, 동반 질환도 함께 치료해야 한다.\n\n<!-- PAGE_12 -->\n###### 나. 우울장애 진단 절차/과정\n\n<!-- PAGE_12 -->\n###### DSM-5에서 기분장애(mood disorder)를 양극성 및 관련 장애(bipolar\n\n<!-- PAGE_12 -->\n###### and related disorder)와 우울장애(depressive disorder)로 분류하고 있으며,\n\n<!-- PAGE_12 -->\n###### 우울장애는 주요우울장애(major depressive disorder), 지속성 우울장애\n\n<!-- PAGE_12 -->\n###### (persistent depressive disorder), 월경 전 불쾌감 장애(premenstrual\n\n<!-- PAGE_12 -->\n###### dysphoric\n\n<!-- PAGE_12 -->\n###### disorder)\n\n<!-- PAGE_12 -->\n###### 등으로\n\n<!-- PAGE_12 -->\n###### 구분하고\n\n<!-- PAGE_12 -->\n###### 있다.\n\n<!-- PAGE_12 -->\n###### Patient\n\n<!-- PAGE_12 -->\n###### Health\n\n<!-- PAGE_12 -->\n###### Questionnaire-9 (PHQ-9)과 같은 우울장애 선별도구로 선별 검사할 수\n\n<!-- PAGE_12 -->\n###### 있으며, 진단은 DSM-5의 진단기준을 적용한다.\n\n<!-- PAGE_12 -->\n###### 주요우울장애 진단을 위해서는 다음의 증상 중 5가지 이상이 2주일\n\n<!-- PAGE_12 -->\n###### 이상 지속되었는지 확인해야 한다. (1) 주관적 보고나 타인에 의한\n\n<!-- PAGE_12 -->\n###### 관찰로 나타난 거의 매일 또는 거의 하루 내내 우울한 기분, (2) 거의\n\n<!-- PAGE_12 -->\n###### 매일, 하루 대부분 활동에서 현저히 감소한 흥미, (3) 식이요법을 하지\n\n<!-- PAGE_12 -->\n###### 않는 중에 의미 있는 체중 감량과 체중증가 또는 거의 매일의 식욕의\n\n<!-- PAGE_12 -->\n###### 감소 또는 증가, (4) 거의 매일 불면 또는 과수면, (5) 거의 매일 정신\n\n<!-- PAGE_12 -->\n###### 운동 흥분 또는 지체, (6) 거의 매일 피로 또는 에너지 상실, (7) 거의\n\n<!-- PAGE_12 -->\n###### 매일 무가치감 또는 과도하고 부적절한 죄책감을 느낌, (8) 거의 매일\n\n<!-- PAGE_12 -->\n###### 사고와 집중 능력의 감퇴 또는 결정 논란, (9) 반복적인 죽음에 관한\n\n<!-- PAGE_12 -->\n###### 생각 또는 구체적인 계획이 없는 반복적 자살 사고나 자살 시도 또는\n\n<!-- PAGE_12 -->\n###### 자살하려는 구체적 계획 등이 나타나며, 적어도 하나의 증상이 해당해야 한다.\n\n- - 6 -\n<!-- PAGE_13 -->\n###### 이러한 증상이 임상적으로 의미 있는 고통을 일으키거나 사회적, 직업적,\n\n<!-- PAGE_13 -->\n###### 다른 중요한 기능 영역에서 손상을 일으키며, 증상이 물질에 대한 직접적\n\n<!-- PAGE_13 -->\n###### 생리적 효과 또는 일반적 의학적 상태 때문이 아니어야 한다. 환자의\n\n<!-- PAGE_13 -->\n###### 증상이 조현정동장애, 조현병, 조현 형장에, 망상장애, 혹은 기타 정신병적\n\n<!-- PAGE_13 -->\n###### 장애로 잘 설명되지 않아야 하며, 과거 조증 혹은 경조증 삽화가 없어야\n\n<!-- PAGE_13 -->\n###### 한다.\n\n<!-- PAGE_13 -->\n###### 지속성 우울장애는 기분저하증 혹은 감정 부전 장애로도 불리며, 최소\n\n<!-- PAGE_13 -->\n###### 2년 동안 주관적, 객관적으로 거의 종일 우울한 기분이 지속된다. 진단을\n\n<!-- PAGE_13 -->\n###### 위해서는 우울한 기간 다음의 증상 6가지 중 2가지 이상이 존재하는지\n\n<!-- PAGE_13 -->\n###### 확인해야 한다. (1) 식욕 저하 혹은 과식, (2) 불면 혹은 과수면, (3) 기력\n\n<!-- PAGE_13 -->\n###### 저하 혹은 피로, (4) 낮은 자존감, (5) 집중 감소 또는 결정 내리기 어려움,\n\n<!-- PAGE_13 -->\n###### (6) 절망감 등의 증상이 이에 해당한다. 조증 삽화, 혼합성 삽화, 또는\n\n<!-- PAGE_13 -->\n###### 경조증 삽화를 만족시킨 적이 없어야 하며 순환성 장애를 만족시킨 적이\n\n<!-- PAGE_13 -->\n###### 없어야 한다. 만성적인 정신병적 증상의 경과 중에 발생한 것이 아니어야\n\n<!-- PAGE_13 -->\n###### 하며, 물질이나 내과적 상태 때문이 아니어야 한다. 이러한 증상으로\n\n<!-- PAGE_13 -->\n###### 인해 사회적, 직업적, 기타 기능 영역에서 임상적으로 현저한 고통이나\n\n<!-- PAGE_13 -->\n###### 손상을 초래하는지 확인해야 한다.\n\n<!-- PAGE_13 -->\n###### 우울장애는 특정 양상(specifier)에 따라 분류할 수 있으며 각각의\n\n<!-- PAGE_13 -->\n###### 특성이 달라 약물 선택 등의 치료 방향 결정을 다르게 해야 한다. 크게\n\n<!-- PAGE_13 -->\n###### 불안증(anxious distress) 동반, 혼재성 양상(mixed features) 동반, 멜랑\n\n<!-- PAGE_13 -->\n###### 콜리아 양상(melancholic features) 동반, 비전형적 양상(atypical features)\n\n<!-- PAGE_13 -->\n###### 동반, 정신병적 양상(psychotic features) 동반, 긴장증(catatonia) 동반,\n\n<!-- PAGE_13 -->\n###### 주산기 발병(peripartum onset) 동반, 계절성(seasonal patterns) 동반으로\n\n- - 7 -\n<!-- PAGE_14 -->\n###### 진단할 수 있다.\n\n<!-- PAGE_14 -->\n###### 우울장애 환자는 기분 증상 외에도 사고 증상, 인지 증상, 정신운동\n\n<!-- PAGE_14 -->\n###### 증상, 신체 증상, 정신병적 증상 등이 다양하게 나타나기 때문에 복잡한\n\n<!-- PAGE_14 -->\n###### 감별이 있을 수 있다. 인지 증상의 저하로 인한 가성치매로 인해 치매\n\n<!-- PAGE_14 -->\n###### 환자와 감별해야 하며, 정신병적 증상이 조현병 또는 우울장애 때문인지\n\n<!-- PAGE_14 -->\n###### 감별해야 하며, 환자가 호소하는 여러 가지 신체 증상이 기질적인 문제\n\n<!-- PAGE_14 -->\n###### 때문인지 감별할 필요가 있다.\n\n- - 8 -\n- - 9 -\n<!-- PAGE_16 -->\n###### 다. 우울장애 비약물 치료\n\n<!-- PAGE_16 -->\n###### 우울장애 비약물 치료에는 인지행동치료(Cognitive Behavioral Therapy,\n\n<!-- PAGE_16 -->\n###### CBT), 대인관계 정신치료(Interpersonal Therapy, ITP), 마음 챙김 인지\n\n<!-- PAGE_16 -->\n###### 치료(Mindfulness-Based Cognitive therapy, MBCT) 등이 증상을 경감\n\n<!-- PAGE_16 -->\n###### 시키는데 효과적인 방법이며, 경증 또는 중등도 우울장애에서는 비약물\n\n<!-- PAGE_16 -->\n###### 치료를 우선하여 고려할 수 있다. 비약물 치료 중 대표적으로 인지행동\n\n<!-- PAGE_16 -->\n###### 치료(CBT)가 권고되고 있으며, 임상에서 개인치료 또는 집단치료\n\n<!-- PAGE_16 -->\n###### 형식으로 활발하게 사용되고 있다.\n\n<!-- PAGE_16 -->\n###### 우울장애 인지행동치료(Cognitive Behavioral Therapy for Depression,\n\n<!-- PAGE_16 -->\n###### CBT-D)는 단기적으로는 약물치료와 그 효과가 유사하며 장기적인\n\n<!-- PAGE_16 -->\n###### 효과는 약물치료보다 우수한 것으로 밝혀져 있으며, 이러한 효과\n\n<!-- PAGE_16 -->\n###### 입증을 통해 일차 치료로 권장되고 있다(Churchill et al., 2013, Van\n\n<!-- PAGE_16 -->\n###### Hees et al., 2013). 선행 연구에 의하면, 약물치료나 비약물 치료를\n\n<!-- PAGE_16 -->\n###### 단독으로 사용하기보다는 병용하면 우울장애에 대한 치료 효과가\n\n<!-- PAGE_16 -->\n###### 더 우수한 것으로 나타났다(Cuijpers et al., 2013, Kriston et al., 2014).\n\n<!-- PAGE_16 -->\n###### 우울장애 인지행동치료는 우울장애 환자의 역기능 사고로 인해\n\n<!-- PAGE_16 -->\n###### 발생하고 유지된다는 이론 근거를 기반으로 하며, 이러한 역기능 사고를\n\n<!-- PAGE_16 -->\n###### 발견하고 수정하는 것을 치료 목표로 한다. 우울장애 환자의 자기, 환경,\n\n<!-- PAGE_16 -->\n###### 미래에 대한 비합리적인 믿음과 왜곡된 태도가 우울한 영향을 영속\n\n<!-- PAGE_16 -->\n###### 시키고 기능을 훼손한다고 가정한다. 우울장애 인지행동치료는 환자의\n\n<!-- PAGE_16 -->\n###### 신념과 태도를 도전하고 뒤집으며 실생활에서 부적응 선입견과 행동을\n\n<!-- PAGE_16 -->\n###### 환자가 바꾸도록 유도함으로써 우울장애 증상을 줄이고자 한다.\n\n<!-- PAGE_16 -->\n###### 우울장애와 관련된 역기능 사고는 두 가지 수준으로 구분이 되는데,\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 하나는 자동 사고이며, 다른 하나는 핵심 신념이다. 자동 사고는 특정\n\n<!-- PAGE_17 -->\n###### 상황과 관련하여 자동으로 떠오르는 생각으로, 주의를 약간 기울이면\n\n<!-- PAGE_17 -->\n###### 쉽게 의식화할 수 있다. 반면 핵심 신념은 자동 사고보다는 추상화되어\n\n<!-- PAGE_17 -->\n###### 있으며, 일상생활 경험을 조직화한다. 우울장애 인지행동치료는 우울한\n\n<!-- PAGE_17 -->\n###### 기분에 대한 자동 사고를 수정하고 궁극적으로는 핵심 신념 변화를\n\n<!-- PAGE_17 -->\n###### 통해 우울장애 재발을 막고자 한다.\n\n<!-- PAGE_17 -->\n###### 우울장애 인지행동치료는 행동 기법과 인지 기법으로 구분할 수\n\n<!-- PAGE_17 -->\n###### 있다. 우울장애 환자는 일상생활과 관련된 기능이 많이 떨어져 있을\n\n<!-- PAGE_17 -->\n###### 수 있으므로 행동 기법을 먼저 적용하는 것이 도움이 된다. 행동 기법은\n\n<!-- PAGE_17 -->\n###### ① 활동 계획(activity scheduling), ② 점진적 과업 주기(graded task\n\n<!-- PAGE_17 -->\n###### assignments), ③ 자기강화(self-reinforcement) 등이 있으며, 이를 통해\n\n<!-- PAGE_17 -->\n###### 우울장애 환자의 자기효능감을 향상하는 데 도움을 줄 수 있다.\n\n<!-- PAGE_17 -->\n###### 인지행동치료 인지 기법으로는 ① 자동 사고 파악하기, ② 인지\n\n<!-- PAGE_17 -->\n###### 오류 찾기 등이 있다. 우울한 기분과 관련성이 높은 자동 사고를 확인\n\n<!-- PAGE_17 -->\n###### 하기 위해서는 자동 사고가 무엇인지 알려주고, 우울감을 심하게 느낀\n\n<!-- PAGE_17 -->\n###### 상황을 이야기해봄으로써 자동 사고를 파악한다. 우울장애 환자에게는\n\n<!-- PAGE_17 -->\n###### ① 흑백논리(all-or-nothing thinking), ② 과잉 일반화(overgeneralization),\n\n<!-- PAGE_17 -->\n###### ③ 평가절하 사고(disqualifying the positive), ④ 성급한 결론(jumping\n\n<!-- PAGE_17 -->\n###### to conclusions), ⑤ 사고 확대와 추론(magnification or minimization)\n\n<!-- PAGE_17 -->\n###### 등과 같은 인지 오류가 자주 발생한다. 따라서 자동 사고에 나타난\n\n<!-- PAGE_17 -->\n###### 인지 오류를 검토하게 함으로써 자동 사고를 변화시킬 수 있다.\n\n- - 11 -\n구분\n\n제목\n\n내용\n\n- - 먼저 우울장애 환자의 현재 활동 정도와 그에 따른 감정 상태를\n측정한다. 다음 단계로, 우울장애 환자가 자신의 활동 계획에\n\n<!-- PAGE_18 -->\n###### 표 2. 우울장애 인지행동치료 구성\n\n- - 12 -\n구분\n\n제목\n\n내용\n\n**[표 시작]**\n\n| 인지적 | 예시 |\n| --- | --- |\n**예시**\n**인증 기능 구현**\n\n**[표 끝]**\n\n시험 구상(designing experiments)\n\n- - 우울장애 환자가 자신의 자동적 사고를 실증적 검증이 가능한\n과학적인 가정으로 간주하도록 고무한다.\n\n- - 13 -\n구분\n\n제목\n\n내용\n\n과거력 조사(historical exploration)\n\n- - 비기능적 신념은 때때로 고통스러운 과거 경험을 왜곡되게\n- - 14 -\n<!-- PAGE_21 -->\n###### 라. 우울장애 약물치료\n\n<!-- PAGE_21 -->\n###### 우울장애 인지행동치료를 적용하기가 어렵거나, 적용하더라도 효과가\n\n<!-- PAGE_21 -->\n###### 없으면 약물적 치료를 통해 우울장애를 개선할 수 있다. <표 3>은 일차\n\n<!-- PAGE_21 -->\n###### 의료용 근거 기반 우울장애 임상진료지침(대한의학회, 2022)의 항우울제\n\n<!-- PAGE_21 -->\n###### 권고 요약표를 정리하였다. 우울장애 약물치료는 임상 양상, 공존 질환,\n\n<!-- PAGE_21 -->\n###### 이전 약물치료 병력, 부작용, 약물 상호작용, 환자 기호 등을 종합하여\n\n<!-- PAGE_21 -->\n###### 상황에 맞게 각 임상의가 적절하게 판단하여 사용하여야 한다. 단, 이\n\n<!-- PAGE_21 -->\n###### 부분은 본 의료기기의 주요부문이 아니므로 더 서술하지 않되, 환자의\n\n<!-- PAGE_21 -->\n###### 적절한 치료를 위해 우울 증상을 파악하고 개선한다는 점에서, 약물\n\n<!-- PAGE_21 -->\n###### 복용력을 고려하는 디지털치료기기라면 환자의 상태를 파악하기를\n\n<!-- PAGE_21 -->\n###### 권고한다.\n\n(출처: 대한의학회(2022), 일차 의료용 근거기반 우울장애 임상진료지침)\n\n- - 15 -\n<!-- PAGE_22 -->\n###### 마. 우울장애 비약물 치료의 임상 권고 사항\n\n<!-- PAGE_22 -->\n###### 미국정신의학회(APA), 캐나다 기분·불안 치료 네트워크(Canadian\n\n<!-- PAGE_22 -->\n###### Network for Mood and Anxiety Treatments, CANMAT), 영국정신의학회\n\n<!-- PAGE_22 -->\n###### (British Association for Psychopharmacology, BAP) 등은 우울장애 치료를\n\n<!-- PAGE_22 -->\n###### 위해 인지행동치료(CBT)를 먼저 권고한다. 또한 대한의학회 ‘일차 의료용\n\n<!-- PAGE_22 -->\n###### 근거 기반 우울장애 임상진료지침(2022)’에서도 경증 혹은 중등도 수준\n\n<!-- PAGE_22 -->\n###### 우울장애에서는 인지행동치료 등 정신사회 치료를 먼저 고려하도록\n\n<!-- PAGE_22 -->\n###### 권장하고 있다.\n\n* APA: American Psychiatric Association, BAP: British Association for Psychopharmacology,\n\n** 진료지침별 권고 등급의 수준이 상이하여 재분류함\n\n<!-- PAGE_22 -->\n###### 미국정신의학협회(APA) 진료지침(2010)은 대수롭지 않거나 중등도\n\n<!-- PAGE_22 -->\n###### 수준 우울장애이면 초기 치료로 인지행동치료를 제안한다(권고등급,\n\n<!-- PAGE_22 -->\n###### Strong). 캐나다 기분·불안 치료 네트워크(CANMAT) 진료지침(2016)은\n\n<!-- PAGE_22 -->\n###### 급성기 치료(Acute Treatment) 및 유지 치료(Maintenance Treatment)에\n\n<!-- PAGE_22 -->\n###### 대해 인지행동치료가 효과가 있으며, 근거 수준이 높다고 제안한다(권고\n\n<!-- PAGE_22 -->\n###### 등급, Strong [First-line]). 전화를 활용한 인지행동치료, 인터넷이나\n\n<!-- PAGE_22 -->\n###### 컴퓨터를 활용한 급성기 치료(Acute Treatment)는 권고등급을 Strong\n\n<!-- PAGE_22 -->\n###### [Second-line]으로 제안한다. 마음챙김 기반 인지치료(Mindfulness-based\n\n<!-- PAGE_22 -->\n###### cognitive therapy, MBCT)은 유지 치료(Maintenance Treatment) 단계에서\n\n- - 16 -\n<!-- PAGE_23 -->\n###### 활용하도록 권고한다(권고등급, Strong [First-line]).\n\n<!-- PAGE_23 -->\n###### 영국정신의학회(BAP) 진료지침은 경증(mild)에서 중등도(moderate)\n\n<!-- PAGE_23 -->\n###### 우울장애를 위한 급성 치료는 인지행동치료(CBT), 대인관계 정신치료\n\n<!-- PAGE_23 -->\n###### (Interpersonal psychotherapy, IPT), 행동 활성화(Behavioural activation,\n\n<!-- PAGE_23 -->\n###### BA)가 항우울제 대안이라고 제안하며(권고등급 Strong [A]), 재발성 우울\n\n<!-- PAGE_23 -->\n###### 장애에 대해서 단독 요법으로 심리치료 할 때는 인지행동 치료를\n\n<!-- PAGE_23 -->\n###### 권고한다(권고등급 B). 심각한 우울장애는 비약물 치료 단독보다\n\n<!-- PAGE_23 -->\n###### 항우울제 치료에 추가로 활용하기를 권장한다. 다만, 우울장애 인지\n\n<!-- PAGE_23 -->\n###### 행동치료는 시간과 비용에 제약이 있고, 약물치료보다 효과가 늦기\n\n<!-- PAGE_23 -->\n###### 때문에 모든 환자에게 같게 적용하는 데 제한이 있을 수 있다.\n\n<!-- PAGE_23 -->\n###### 바. 디지털 기반 우울장애 치료 관련 선행연구\n\n<!-- PAGE_23 -->\n###### 디지털 기반 우울장애 인지행동치료는 웹 또는 모바일 앱 등을 이용\n\n<!-- PAGE_23 -->\n###### 하여 병원에 내원하지 않고도 인지행동치료를 시행 받게 되어 치료\n\n<!-- PAGE_23 -->\n###### 접근성 개선을 기대하게 한다. 또한 디지털 기반 치료로, 환자가 대부분\n\n<!-- PAGE_23 -->\n###### 프로그램을 수행하고 피드백을 받을 수 있으므로 치료자 관점에서 비용\n\n<!-- PAGE_23 -->\n###### 대비 효용성도 증가한다. 따라서, 환자가 병원에 매주 내원해야 시행이\n\n<!-- PAGE_23 -->\n###### 가능한 전통적인 치료 공간 접근성과 시간 자원 여부에 따른 치료\n\n<!-- PAGE_23 -->\n###### 제약을 개선할 수 있다(Andrews, 2018).\n\n<!-- PAGE_23 -->\n###### 먼저, 독일에서 개발한 Deprexis를 활용하여 우울장애 디지털 치료\n\n<!-- PAGE_23 -->\n###### 기기 효과성을 검증한 많은 연구가 진행되었다(Fischer et al., 2015,\n\n<!-- PAGE_23 -->\n###### Berger et al., 2011, Klein et al., 2016, Beevers et al., 2017, Moritz et\n\n<!-- PAGE_23 -->\n###### al., 2015). Deprexis의 효과성 검증을 위해 Beck Depression Inventory\n\n- - 17 -\n<!-- PAGE_24 -->\n###### (BDI-II) 척도 13점 이상이고 연령은 18세 이상인 우울장애 환자 98명을\n\n<!-- PAGE_24 -->\n###### 대상으로 무작위배정 임상시험을 진행하였다(Berger et al., 2018).\n\n<!-- PAGE_24 -->\n###### 실험군(51명)은 기존 심리상담과 함께 웹 기반 우울장애 프로그램인\n\n<!-- PAGE_24 -->\n###### Deprexis를 사용하였고, 대조군(47명)은 심리상담만을 진행하였다.\n\n<!-- PAGE_24 -->\n###### Deprexis는 주로 인지행동 심리치료를 기반으로 하는 정신교육 정보와\n\n<!-- PAGE_24 -->\n###### 운동 정보 등을 제공하는 10개 콘텐츠 모듈을 제공하여 환자가 사용\n\n<!-- PAGE_24 -->\n###### 할 수 있도록 했다.\n\n<!-- PAGE_24 -->\n###### 해당 연구에서 일차 유효성 평가지표는 BDI-II를 사용하였으며, 이차\n\n<!-- PAGE_24 -->\n###### 유효성 지표로는 불안 증상을 측정하기 위한 Generalized Anxiety\n\n<!-- PAGE_24 -->\n###### Disorder Scale(GAD-7), 신체 증상을 측정하기 위한 Patient Health\n\n<!-- PAGE_24 -->\n###### Questionnaire(PHQ-15), 삶의 질을 확인하기 위한 Short-Form Health\n\n<!-- PAGE_24 -->\n###### Survey(SF-12)을 사용하였다. 웹 기반 프로그램을 함께 사용한 치료가\n\n<!-- PAGE_24 -->\n###### 심리치료 단독 수행보다 우울장애를 개선하는 효과가 더 있었고\n\n<!-- PAGE_24 -->\n###### (Cohen’s d=0.51), 이차 유효성 변수도 개선하는 효과가 있었다\n\n<!-- PAGE_24 -->\n###### (SF-12 physical subscale Cohen’s d=0.07, SF-12 mental health\n\n<!-- PAGE_24 -->\n###### Cohen’s d=0.55).\n\n<!-- PAGE_24 -->\n###### 18세 이상인 경증에서 중등도 수준 우울 증상(PHQ-9 5점~14점)이\n\n<!-- PAGE_24 -->\n###### 있는 총 1,013명을 대상으로 Deprexis 효과성을 검증하는 다기관 무작위\n\n<!-- PAGE_24 -->\n###### 배정 임상시험도 진행되었다(Klein et al., 2016). 대조군(504명)은 일반적인\n\n<!-- PAGE_24 -->\n###### 의료 서비스를 받았고, 실험군(509명)은 Deprexis 프로그램에 대한\n\n<!-- PAGE_24 -->\n###### 권한을 받아서 사용하였다. 프로그램은 CBT 기반 12주 프로그램이고,\n\n<!-- PAGE_24 -->\n###### 인지 재구성, 행동 활성화, 수용 및 마음챙김 등과 같은 내용을 포함\n\n<!-- PAGE_24 -->\n###### 하는 10개 모듈로 구성되어 있다.\n\n- - 18 -\n<!-- PAGE_25 -->\n###### 연구에서는 PHQ-9를 일차 유효성 평가지표로 사용하였으며, 5점이\n\n<!-- PAGE_25 -->\n###### 감소 되었을 때 임상적으로 중요한 개선이 있다고 정의하였다. 이차 유\n\n<!-- PAGE_25 -->\n###### 효성 평가지표는 Hamilton Depression Rating Scale(HDRS-24), Quick\n\n<!-- PAGE_25 -->\n###### Inventory of Depressive Symptomatology(QIDS-C16)가 사용되었다. 지표는\n\n<!-- PAGE_25 -->\n###### 연구 시작 시(Baseline), 3개월(평가 후) 및 6개월(추적)에 측정하였다.\n\n<!-- PAGE_25 -->\n###### 3개월 후 측정된 결과에 의하면, 점수는 두 집단 모두에서 감소하\n\n<!-- PAGE_25 -->\n###### 였는데, PHQ-9 변화는 집단 간에 유의하게 달랐다(t=6.12, p<0.001).\n\n<!-- PAGE_25 -->\n###### PHQ-9 점수는 대조군보다 평균 1.57점(95% confidence intervals [CI]:\n\n<!-- PAGE_25 -->\n###### 1.07-2.07) 포인트 더 많이 감소했다. 3개월 후 집단 간 효과 크기는\n\n<!-- PAGE_25 -->\n###### 0.39(95% CI: 0.13-0.64)였으며, 6개월 후도 효과 크기는 0.32(95% CI:\n\n<!-- PAGE_25 -->\n###### 0.06-0.69)로 안정적이었다. 임상적으로 중요한 PHQ-9 변화를 경험한\n\n<!-- PAGE_25 -->\n###### 참가자 비율도 실험군이 대조군에 비해 높았다(35.6 vs. 20.2%).\n\n<!-- PAGE_25 -->\n###### 다른 선행 연구에서는 단극성 우울장애에 대해 Selfapy라는 웹 기반\n\n<!-- PAGE_25 -->\n###### 중재 효과성을 평가하는 무작위배정 임상시험을 실시하였다 (Krämer\n\n<!-- PAGE_25 -->\n###### et al., 2021). 특히 심리치료사 가이드 여부에 따른 효과성도 확인\n\n<!-- PAGE_25 -->\n###### 하고자 세 그룹으로 구분하여 실험을 진행하였다. 18~65세이며 BDI-II가\n\n<!-- PAGE_25 -->\n###### 13점 이상인 우울장애가 있는 환자(401명)를 모집하였으며, 가이드 그룹\n\n<!-- PAGE_25 -->\n###### (151명), 가이드가 없는 그룹(150명), 대조군(100명)으로 무작위 할당\n\n<!-- PAGE_25 -->\n###### 하였다. 가이드 그룹은 매주 25분 동안 전화로 개인 지도를 받았고,\n\n<!-- PAGE_25 -->\n###### 가이드가 없는 그룹은 Selfapy만 사용하였다. 대조군은 이메일을 통해\n\n<!-- PAGE_25 -->\n###### 표준화된 마음챙김 훈련을 받았다.\n\n<!-- PAGE_25 -->\n###### 프로그램은 인지행동치료 등을 근거로 하고 있으며, 6개 핵심 중재\n\n<!-- PAGE_25 -->\n###### 모듈과 6개 추가적인 심층 모듈로 구성되어 12주 동안 제공되었다.\n\n- - 19 -\n<!-- PAGE_26 -->\n###### 일차 유효성 평가지표는 BDI-II를 사용하여 우울 증상에 대해 측정\n\n<!-- PAGE_26 -->\n###### 하였으며, QIDS-SR-16, HRSD-24가 이차 유효성 평가지표로 사용되었다.\n\n<!-- PAGE_26 -->\n###### 연구 시작 시(Baseline), 중재 중(6주), 중재 종료(12주), 추적 관찰(6개월) 시\n\n<!-- PAGE_26 -->\n###### 우울 증상을 평가했다.\n\nBDI-II 변화는 중재 후 그룹 간에 유의한 차이가 있었다(F2,398\n\n<!-- PAGE_26 -->\n###### =37.20, P<.001). 가이드 또는 가이드가 없는 그룹에서 BDI-II 점수\n\n<!-- PAGE_26 -->\n###### 감소는 그룹 간 효과 크기가 대조군보다 더 컸다(guided vs control:\n\n<!-- PAGE_26 -->\n###### d=1.63, 95% CI 1.37-1.93; unguided vs control: d=1.47, 95% CI\n\n<!-- PAGE_26 -->\n###### 1.22-1.73). 반면, 가이드 또는 가이드가 없는 그룹 간 유의미한 차이가\n\n<!-- PAGE_26 -->\n###### 발견되지는 않았다. 추적 관찰(6개월)에서 치료 효과는 두 중재 그룹\n\n<!-- PAGE_26 -->\n###### 모두에서\n\n<!-- PAGE_26 -->\n###### 유지되었습니다(guided:\n\n<!-- PAGE_26 -->\n###### F1,194=0.62,\n\n<!-- PAGE_26 -->\n###### P>.999;\n\n<!-- PAGE_26 -->\n###### unguided:\n\n<!-- PAGE_26 -->\n###### F1,176=0.13, P>.999).\n\n<!-- PAGE_26 -->\n###### 또 다른 선행 연구에서는 인터넷 기반 우울장애 인지행동치료\n\n<!-- PAGE_26 -->\n###### 프로그램인 Thrive 효과성을 검증하는 무작위배정 임상시험을 실시\n\n<!-- PAGE_26 -->\n###### 하였다(Schure et al., 2019). 우울 증상(PHQ-9 5점 이상)이 있는 18세 이상\n\n<!-- PAGE_26 -->\n###### 성인 343명을 모집하고, Trive를 활용한 실험군(181명)과 대조군(162명)\n\n<!-- PAGE_26 -->\n###### 으로 무작위 할당하였다. 실험군은 완전 자동화된 프로그램인 Thrive를\n\n<!-- PAGE_26 -->\n###### 웹 브라우저 및 모바일 앱을 사용하였다. 콘텐츠는 비디오를 통해 전달\n\n<!-- PAGE_26 -->\n###### 되며, 행동 활성화, 인지 재구조화, 사회 기술 훈련에 중점을 둔 세\n\n<!-- PAGE_26 -->\n###### 가지 대화형 모듈을 제공하였다. 사용자 입력 및 사용자 패턴을 기반\n\n<!-- PAGE_26 -->\n###### 으로 알고리즘을 사용하여 개인에 맞게 피드백을 제공했다. 대조군은\n\n<!-- PAGE_26 -->\n###### 일반 우울장애 정보에 대한 링크를 받았다.\n\n- - 20 -\n<!-- PAGE_27 -->\n###### 일차 유효성 변수는 환자가 직접 보고한 PHQ-9 점수였으며, 불안\n\n<!-- PAGE_27 -->\n###### 증상 심각성(GAD-7), 일상 기능(Work and Social Adjustment Scale,\n\n<!-- PAGE_27 -->\n###### WSAS), 회복력(Conner-Davidson Resilience Scale, CD-RISC-10), 자살에\n\n<!-- PAGE_27 -->\n###### 관한 생각 등이 이차 유효성 변수로 활용되었다. 평가지표는 연구 시작 시\n\n<!-- PAGE_27 -->\n###### (Baseline), 4주 및 8주에 측정하였다.\n\n<!-- PAGE_27 -->\n###### 실험군은 대조군보다 우울장애 증상 중증도가 유의하게 낮았고\n\n<!-- PAGE_27 -->\n###### (F1,248=28.67, P<.001), 치료 효과 크기(d=0.63)를 확인하였다. 그룹 평균\n\n<!-- PAGE_27 -->\n###### 패턴은 실험군 우울장애 심각도(8주 개입 후)가 대조군 그룹보다 유의\n\n<!-- PAGE_27 -->\n###### 하게 낮았다(7.702 [Standard Error, SE 0.336] vs 10.224 [SE 0.328],\n\n<!-- PAGE_27 -->\n###### adjusted P<.001; d=0.63).\n\n- - 21 -\n<!-- PAGE_28 -->\n###### 사. 우울장애 개선 디지털치료기기의 국외 사례\n\n<!-- PAGE_28 -->\n###### 현재 국외에서 우울장애 개선 디지털치료기기로서, 허가된 제품 및\n\n<!-- PAGE_28 -->\n###### 인지행동치료(CBT)를 이용한 제품은 다음과 같다 <표 5>.\n\n**[표 시작]**\n\n**기술을 기반으로 하는 세 가지 CBT 모듈이**\n**- 우울장애를 이해하는 데 도움이 되는 상호작용**\n| 대상이 되는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄격한 피험자의 선정 | 시험보고서 |\n**포함되어있고, 각 모듈은 10개의 강의로 구성**\n**시험보고서**\n**- Deprexis는 18세 이상인 우울장애 및 우울한**\n| 기준과 제외 기준을 제시하여야 한다. 이 때 임상시험 참여와 연관된 이익을 기대 | 기분 추적을 포함하여 증상을 관리하는 대처 |\n**기분이 있는 환자를 위한 치료를 지원하는**\n**하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 불이익을 우려하여 자발적인**\n**대화형 온라인 기반 자조 프로그램으로 인지**\n**우울장애 평가를 사용하여 사용자와 임상의가**\n**행동치료(CBT)를 기반으로 하며, 21년 2월 20일에**\n**참여 결정에 영향을 받을 소지가 있는 등 취약한 환경에 있는 피험자 (Vulnerable**\n| 매주 | 1레벨을 | 완료하도록 | 권장하지만 | 7주 |\n**시험보고서**\n**Subjects)는 선정대상에서 제외한다. 또한, 시험군과 대조군을 포함한 피험자 수는 해당**\n**- 인지행동치료 기반 행동의 활성화, 인지 재구**\n**시험보고서**\n**의료기기의 특성, 임상시험 디자인, 근거를 통한 시험에서 기대하는 연구결과의 사전**\n**조화, 이완, 수용과 마음챙김 등의 프로그램을**\n**시험보고서**\n**예측, 통계적 유의성, 검정 방법, 탈락률 등을 반영하여 통계학 적으로 타당하게 제시**\n| - Novego의 우울장애 프로그램은 전신 치료 및 | 완료 |\n| 되어야 하며, 임상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 한다. | - Deprexis는 인공 지능을 사용하여 사용자와 | - SilverCloud의 우울장애 프로그램은 경증에서 | 시험보고서 |\n| 상호 작용하고 질문에 대한 응답을 분석하여 | 마음챙김 훈련의 일부 및 입증된 인지행동치료 | 중증도의 우울장애를 겪는 개인에게 인지행동 |\n| 우울장애 증상을 관리하는 데 도움이 되는 | 방법을 제공하며, 심리적으로 스트레스가 많은 |\n**시험보고서**\n| 자기 기분과 유발 요인을 잘 이해하고 가르치기 | 시험보고서 |\n| - 임상연구에서 피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 수가 보장 | - 디지털치료기기에 대한 장기 사용자 반응 평가를 함께 수행한다. | 으로 인한 질병의 증상을 완화하거나 예방하기 |\n**위한 유연한 사고방식과 전략을 개발할 수**\n**위해 고안된 온라인 자조 프로그램을 제공한다.**\n**되어야 하며, 일반적으로 1차 유효성 평가변수를 기준으로 정해지고, 연구 계획서상에**\n**(예) 우울 일기기능과 기록 알림 기능만 탑재된 애플리케이션 등**\n**- 21년 10월 10일 독일 DiGA 디렉터리에 포함**\n| - | 영국의 | 임상의가 | 환자를 | 의뢰하면 | 무료로 |\n**시험보고서**\n**되었으며, 12주의 정규 프로그램 기간 이후**\n| 1) 이상 사례 교육 | (Selfapy GmbH) | - Selfapy는 근거 기반 이론과 인지 행동 치료 |\n**가입 후 서포터가 배정되어 목표를 설정한다.**\n**기술을 기반으로 우울장애 환자에게 개별 온라인**\n**시험보고서**\n| 번호 | 가이드라인 명칭 | 주요 내용 | 비고 |\n| - 참가자는 내용과 운동에 대해 질문이 있는 | - | 임상적으로 | 입증된 | 디지털 | 인지행동치료를 |\n| 과정을 | 제공하며, | 20년 | 6월 | 12일에 | 독일 | 시험보고서 |\n**경우 일주일에 한 번 메시지로 Novego 심리**\n**(1) 일차 유효성 평가지표: 한국판 우울장애 심각도 척도 제2판(BDI-II)**\n**포함하여 기관에 따른 군간 차이가 있는지 분석하여 제시한다.**\n| 위해요인 | 학자 팀에 직접 연락할 수 있고, 심각한 위기 |\n| - 부정적인 생각 다루기, 긍정적인 일상 구조 | 하루에 15분, 일주일에 3~4번 정도 사용하는 |\n**또는 담당자가 임상시험 수행이 불가능한 것으로 판단한 경우**\n**상황의 경우 프로그램과 함께 24시간 위기**\n**만들기, 이완 기술, 수면 문제 및 재발 방지**\n| trial of two versions of CBT for major depression. Behaviour research and therapy, 48(5), 368-376. | 시험보고서 |\n**1) 양극성 장애 또는 조현병과 같은 심각한 정신질환을 앓고 있는 자**\n| 1) 중대한 이상사례·의료기기 이상반응 보고 | 검정을 통해 양측 유의수준 0.05에서 통계적 우월성을 평가한다. |\n**- 최소 30분 동안 지속되는 1~2회 세션으로 매주**\n**사용자의**\n**시험보고서**\n**시험보고서**\n\n**[표 끝]**\n\n- - 최초 등록 후 90일 동안 사용을 할 수 있으며,\n전략과 같은 주제에 대한 프로그램을 제공하며,\n\n최소 1개의 수업을 완료하는 것을 권장하며,\n\n<!-- PAGE_28 -->\n###### 표 5. 국외 우울장애 개선 디지털치료기기 허가 제품 및 관련 제품의 개발 동향(2022. 11. 기준)\n\n- - 22 -\nThrive\n\n(Waypoint)\n\n- -\nThrive는\n\n인지행동치료(CBT)의\n\n모범\n\n사례를\n\n바탕으로 구조화된 디지털 커리큘럼을 통해\n\n- - 행동 활성화, 인지 재구성 및 사회적 기술 훈련\n- - Thrive는 PHQ-9(Patient Health Questionnaire)\n생활 상황(예: 우울장애, 불안, 소진, 스트레스)\n\n- - 23 -\nSparkRx\n\n(Limbix)\n\n- - SparkRx는 13세에서 22세 사이의 우울장애\n환자에게\n\n인지행동치료를\n\n제공하는\n\n디지털\n\n치료제이며,\n\n미국\n\nFDA에\n\n아직\n\n승인되지는\n\n않았지만, COVID-19로 인해 정신 장애를 치료\n\n하는 디지털 건강 장치에 대한 FDA 비상\n\n프로그램을 수행하며, 활동 일정, 마음챙김,\n\n- - 프로그램은 5가지 레벨로 구성되어 있으며,\n치료 기반의 서비스가 제공되도록 설계되었으며,\n\n플랫폼에 접근할 수 있는 권한을 주어지며,\n\n**[표 시작]**\n\n**사용하며 전체 과정은 8주 동안 지원이 되며,**\n\n**[표 끝]**\n\n- - 24 -\n<!-- PAGE_31 -->\n###### 아. 디지털치료기기의 정의와 국내 가이드라인별 적용 기준\n\n<!-- PAGE_31 -->\n###### 1) 디지털치료기기 정의\n\n<!-- PAGE_31 -->\n###### 식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인\n\n<!-- PAGE_31 -->\n###### (민원인 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방,\n\n<!-- PAGE_31 -->\n###### 관리, 치료하기 위해 환자에게 근거 기반의 치료적 개입을 제공\n\n<!-- PAGE_31 -->\n###### 디지털치료기기는 「의료기기법」 제2조에 따른 사용 목적에\n\n<!-- PAGE_31 -->\n###### 해당해야 하며, <그림 1>과 같이 소프트웨어 의료기기로써 범용\n\n<!-- PAGE_31 -->\n###### 하드웨어에 설치되고, 질병을 예방, 관리 또는 치료하기 위한\n\n<!-- PAGE_31 -->\n###### 목적으로 환자에게 적용되어야 한다. 또한, 치료 작용기전의\n\n<!-- PAGE_31 -->\n###### 과학적(임상적) 근거에 해당하는 자료가 있어야 한다. 여기서\n\n<!-- PAGE_31 -->\n###### 질병이란 국제질병분류코드(International Classification of Disease,\n\n<!-- PAGE_31 -->\n###### ICD)에 기반한 한국표준질병사인분류에 독립적으로 분류 가능한\n\n<!-- PAGE_31 -->\n###### 디지털 우울장애 인지행동치료(CBT)는 우울장애 인지행동치료\n\n<!-- PAGE_31 -->\n###### 기반의 콘텐츠를 범용 스마트폰이나 태블릿 PC에 설치되어\n\n<!-- PAGE_31 -->\n###### 제공하므로 소프트웨어 의료기기에 해당한다. 또한 한국표준\n\n<!-- PAGE_31 -->\n###### 질병사인분류에 따라 우울장애를 의사에게 진단받은 환자들을\n\n- - 25 -\n<!-- PAGE_32 -->\n###### 미국, 영국, 캐나다 등 많은 학회에서 개발한 임상진료지침을\n\n<!-- PAGE_32 -->\n###### 비롯하여, 국내 대한의학회의 한국형 우울장애 치료지침서에\n\n<!-- PAGE_32 -->\n###### 따르면, 우울장애의 비약물치료로써 인지행동치료(CBT)를 시행\n\n<!-- PAGE_32 -->\n###### 하기를 권고하고 있다. 또한 다수의 동료검토 선행연구\n\n<!-- PAGE_32 -->\n###### (Peer-reviewed Journal)에서 임상시험을 통해 디지털 우울장애\n\n<!-- PAGE_32 -->\n###### 위와 같이 디지털 우울장애 인지행동치료(Digital CBT)는 디지털\n\n<!-- PAGE_32 -->\n###### 치료기기 대상 여부 판단기준 및 절차를 충족하므로 디지털\n\n[출처: 식품의약품안전처(2020.08), 디지털치료기기 허가·심사 가이드라인(민원인 안내서)]\n\n- - 26 -\n<!-- PAGE_33 -->\n###### 나) 의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)\n\n<!-- PAGE_33 -->\n###### 디지털치료기기는 식품의약품안전처‘의료기기의 사이버보안\n\n<!-- PAGE_33 -->\n###### 허가·심사 가이드라인(민원인 안내서)’에 근거하여 보안성\n\n<!-- PAGE_33 -->\n###### 영역은 가용성(Availability), 기밀성(Confidentiality), 무결성\n\n<!-- PAGE_33 -->\n###### 가용성은 데이터가 승인된 사용자에게 즉시 제공되어야 하며,\n\n<!-- PAGE_33 -->\n###### 필요한 때에 필요한 곳에서 필요한 형태로 존재되어야 함을\n\n<!-- PAGE_33 -->\n###### 의미한다. 기밀성은 데이터가 허가되지 않은 사람에게 공개\n\n<!-- PAGE_33 -->\n###### 되거나, 허가되지 않은 용도로 사용되지 않아야 함을 의미하며,\n\n<!-- PAGE_33 -->\n###### 무결성은 데이터가 허가되지 않은 방법으로 변환되거나 파괴\n\n<!-- PAGE_33 -->\n###### 되지 않아야 함을 의미한다. 유·무선 통신이 가능하거나 통신\n\n<!-- PAGE_33 -->\n###### 경로가 존재하는 의료기기는 정보의 위변조, 오작동 또는 의료\n\n<!-- PAGE_33 -->\n###### 기기에 승인되지 않은 접근 등을 방지하기 위한 대책을 마련\n\n<!-- PAGE_33 -->\n###### 사이버보안 침해로 인한 위해도는 의료기기의 잠재적 결함\n\n<!-- PAGE_33 -->\n###### 으로 인해 사용자에게 발생할 수 있는 위해(harm)의 정도, 의료\n\n<!-- PAGE_33 -->\n###### 기기의 통신방법 및 사용환경을 종합적으로 고려하여 ‘상’,\n\n<!-- PAGE_33 -->\n###### ‘중’, ‘하’로 결정되고, 그에 따른 사이버보안 요구사항을\n\n<!-- PAGE_33 -->\n###### 적용한다. 일반적으로 디지털 치료기기는 ‘치료’를 목적으로\n\n<!-- PAGE_33 -->\n###### 하는 2등급 이상의 의료기기로 품목 분류되므로 사이버보안\n\n- - 27 -\n<!-- PAGE_34 -->\n###### 다) 의료기기의 소프트웨어 허가·심사 가이드라인(민원인 안내서)\n\n<!-- PAGE_34 -->\n###### 소프트웨어 의료기기도 일반 의료기기와 마찬가지로 제조 및\n\n<!-- PAGE_34 -->\n###### 품질관리체계의 기준과 위험관리 프로세스가 조화를 이루는\n\n<!-- PAGE_34 -->\n###### 식품의약품안전처‘의료기기 소프트웨어 허가·심사 가이드라인\n\n<!-- PAGE_34 -->\n###### (민원인 안내서)’를 기준으로 디지털치료기기의 위험성 관리\n\n<!-- PAGE_34 -->\n###### 프로세스는 의료기기에서 발생하는 위험분석(risk analysis), 위험\n\n<!-- PAGE_34 -->\n###### 평가(risk evaluation), 위험통제(risk control), 잔여 위험 허용평가\n\n<!-- PAGE_34 -->\n###### (evaluation of overall residual risk acceptability), 위험관리 보고서\n\n<!-- PAGE_34 -->\n###### (risk management report), 생산 및 생산 후 정보(production\n\n<!-- PAGE_34 -->\n###### 의료기기 소프트웨어 안전성 등급은 고장 또는 잠재적 결함으로\n\n<!-- PAGE_34 -->\n###### 인해 환자나 사용자에게 미치는 위해의 영향에 따라 분류한다.\n\n<!-- PAGE_34 -->\n###### 의료기기 소프트웨어 사용으로 건강상의 상해 또는 손상이 없는\n\n- - 28 -\n<!-- PAGE_35 -->\n###### 경우 A등급, 심각하지 않은 상해의 가능성 있으면 B등급, 심각한\n\n<!-- PAGE_35 -->\n###### 상해 또는 사망의 가능성이 있는 경우 C등급으로 구분한다.\n\n<!-- PAGE_35 -->\n###### 의료기기 소프트웨어는 안전성 등급이 결정될 때까지 초기에는\n\n<!-- PAGE_35 -->\n###### C등급 요구사항이 적용되며, 소프트웨어 시스템의 실패가 위험한\n\n<!-- PAGE_35 -->\n###### 라) 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인(민원인 안내서)\n\n<!-- PAGE_35 -->\n###### 디지털치료기기는 실사용증거(Real World Evidence, RWE)를\n\n<!-- PAGE_35 -->\n###### 사용하여 의료기기의 사전 및 사후와 관련된 안전성 및 유효성\n\n<!-- PAGE_35 -->\n###### 입증 근거로 제시할 수 있으며, 이에 따른 기간 및 비용을\n\n<!-- PAGE_35 -->\n###### 실사용증거 수집은 데이터의 타당성 및 신뢰성 확보를 위해\n\n1) 실사용데이터(RWD)는 기존의 중재적 방법에 의한 임상시험으로부터 수집되지 않은 다양한 유형의 의료데이터에 대한 포괄적인\n\n용어이다. 실사용증거(RWE)는 RWD를 분석하여 파생된 증거로써, RWD 분석을 통해 얻은 의료기기의 사용 결과나 잠재적 이익\n\n또는 위험성에 관한 임상적 근거를 말한다. 또한, 임상 문헌을 분석하여 파생된 새로운 증거도 포함한다.\n\n- - 29 -\n<!-- PAGE_36 -->\n###### 품질, 수집 및 분석 방법, 수집한 인력의 역량을 입증할 수 있는\n\n<!-- PAGE_36 -->\n###### 객관적인 사항이 반드시 포함되어야 한다. 또한 실사용증거는\n\n<!-- PAGE_36 -->\n###### 적용 목적, 수집 및 분석 정보, 분석 결과에 대한 사항을 제시\n\n- - 30 -\n<!-- PAGE_37 -->\n### Ⅱ\n\n<!-- PAGE_37 -->\n### 안전성·성능 평가\n\n<!-- PAGE_37 -->\n##### 1. 국내외 관련 규격 및 가이드라인\n\n<!-- PAGE_37 -->\n###### 가. 국내외 규격\n\n- - 31 -\n<!-- PAGE_38 -->\n###### 나. 국내외 가이드라인\n\n번호\n\n표준 번호\n\n규격 명칭\n\n주요 내용\n\n비고\n\nApplication of risk\n\nmanagement for IT-networks\n\n**[표 시작]**\n\n| incorporating medical devices | 네트워크로 연결되는 |\n| --- | --- |\n\n**[표 끝]**\n\n- - 32 -\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n**[표 시작]**\n\n| 5 | 3 | 몽고메리-아스버그 | 정신질환 또는 정신과 입원 이력이 있는 자 | 비 인가된 | 허가심사 가이드라인 | 소프트웨어 | 및 소프트웨어 안전에 적합한 | 오진, 잘못된 치료 수행 | 국내·외 | 국내 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n\n**[표 끝]**\n\n의료기기 소프트웨어\n\n의료기기 소프트웨어의 기술문서 작성\n\n방법에\n\n대하여\n\n상세히\n\n기술하고\n\n‘의료기기\n\n소프트웨어\n\n적합성\n\n확인\n\n- - 33 -\n<!-- PAGE_40 -->\n##### 2. 안전성 평가 항목\n\n<!-- PAGE_40 -->\n###### 가. 소프트웨어 검증 및 유효성 확인\n\n<!-- PAGE_40 -->\n###### 1) 개요\n\n<!-- PAGE_40 -->\n###### 의료기기에 포함되는 소프트웨어 또는 의료기기 자체가 소프트\n\n<!-- PAGE_40 -->\n###### 웨어면 ‘의료기기 제조 및 품질관리 기준’ 및 ‘의료기기 위험\n\n<!-- PAGE_40 -->\n###### 관리 시스템’과 조화를 이루는 범위에서 개발, 유지되고 사용\n\n<!-- PAGE_40 -->\n###### 소프트웨어 검증 및 유효성 확인은 의료기기로서의 소프트웨어의\n\n<!-- PAGE_40 -->\n###### 신뢰도를 높이고 환자 또는 사용자에 대한 위험을 낮추기 위한\n\n<!-- PAGE_40 -->\n###### 활동으로, 국제 표준 IEC 62304, ISO 14971 및 ‘의료기기 소프트\n\n<!-- PAGE_40 -->\n###### 의료기기 제조업체는 ‘의료기기 제조 및 품질관리 기준’에\n\n<!-- PAGE_40 -->\n###### 규정된 바와 같이 수립된 품질시스템에서 관련 절차에 따라 소프트\n\n<!-- PAGE_40 -->\n###### 의료기기 소프트웨어의 위험관리는 소프트웨어 개발 활동의 일부이며,\n\n<!-- PAGE_40 -->\n###### 제조자는 소프트웨어 위험관리를 통해 의료기기에 포함된 소프트\n\n<!-- PAGE_40 -->\n###### 웨어 사용에 따른 허용 불가능한 위험이 발생하지 않고, 의료\n\n<!-- PAGE_40 -->\n###### 소프트웨어 개발 및 위험관리는 <표 8>와 같이 IEC 62304 프로\n\n- - 34 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n개발 소프트웨어의 범위, 규모\n\n소프트웨어의 개발 계획을\n\n**[표 시작]**\n\n| 수립하면서 | 동시에 | 위험 |\n| --- | --- | --- |\n| : 성별, 연령, 항우울제 복용 여부, 우울 증상에 대한 기초 평가 | 소프트웨어 요구사항에서 |\n| 정의한 | 위험통제 | 조치가 |\n**소프트웨어의 정상 상태 및**\n**실제 제품에 올바르게 반영**\n| 고장 | 상태에서의 | 잠재적 |\n**되었으며, 위험이 효과적**\n**결함을 고려하여 위험을 분석**\n**으로 통제되어 잔여 위험이**\n**하고, 해당 위험을 통제하기**\n**임상시험용 의료기기와의 인과관계를 부정할 수 없는 경우를 말한다.**\n**위한 조치를 결정한다. 이 중**\n**소프트웨어 설계에 해당하는**\n**통제 조치를 소프트웨어 요구**\n**새로운 위험의 발생 또는**\n| 소프트웨어 | 요구사항에 | 기존에 식별한 위험 평가의 |\n| 반영한 위험 통제 조치가 | 변경이 필요한 경우, 소프트 |\n| 실현될 수 있도록 안전한 | 웨어 형상의 변경이 위해 |\n**요인이 될 수 있는 경우**\n**위험관리 프로세스의 입력**\n**시판 후 발견된 문제점을**\n| 분석하고 | 안전과 | 관련된 |\n| 소프트웨어 위험 통제 조치를 | 항목은 위험관리 프로세스의 |\n| 제품에 구현한다. 이때 코드는 | 입력으로 식별한다. 문제 |\n**위험관리 프로세스에서 식별한**\n**해결 및 설계 변경은 위험**\n| 안전 | 요구사항을 | 정확하게 |\n\n**[표 끝]**\n\n<!-- PAGE_41 -->\n###### 표 8. 소프트웨어 개발 및 위험관리\n\n- - 35 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n**[표 시작]**\n\n| 임상시험 의뢰자는 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 | 소프트웨어 | 비 인가된 사용자의 | 내적 긴장감, 수면저하, 식욕 저하, 집중의 어려움, 나태(권태), | 것으로 코드 실행 전에 오류를 | 위험 | (허용 가능/불가) |\n| --- | --- | --- | --- | --- | --- | --- |\n| 임상시험용 ‘우울장애 개선 디지털치료기기’의 안전성과 유효성을 증명하고자 | 1) 사용되는 통신 기술 : 유선 통신(LAN), 무선통신(Wi-fi, 블루투스) | 동등함을 보이는 연구시험이다. | CBTi | 159 | 6.85 | 10.99 | 확인 자료 |\n| 임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료 방법 등을 제공 | 자살 소망, 자살 태도, 자살 계획에 대해 0~2점으로 응답 | 확인 자료 |\n\n**[표 끝]**\n\n각 유닛에 대한 코드를 검증하는\n\n통제 조치가 될 수 있다.\n\n필요시 규제 당국에 안전성\n\n- - 36 -\n<!-- PAGE_43 -->\n###### 3) 소프트웨어 안전성 등급\n\n<!-- PAGE_43 -->\n###### 의료기기 소프트웨어의 고장 또는 잠재적 결함으로 인해 환자나\n\n<!-- PAGE_43 -->\n###### 사용자에게 미치는 위해의 영향에 따라 안전성 등급을 <표 9>과\n\n<!-- PAGE_43 -->\n###### 소프트웨어 안전성 등급은 위험통제 후 잔여 위험의 심각도를\n\n<!-- PAGE_43 -->\n###### 토대로 분류할 수 있다. 이때, 발생 가능성은 안전성 등급 결정 시\n\n<!-- PAGE_43 -->\n###### 소프트웨어가 여러 개의 독립적인 모듈이 모여서 구성된 경우\n\n<!-- PAGE_43 -->\n###### 각 모듈에 대해 별도로 안전성 등급을 부여할 수 있다. 이때 전체\n\n<!-- PAGE_43 -->\n###### 소프트웨어의 안전성 등급은 개별 모듈의 안전성 등급 중 가장\n\n<!-- PAGE_43 -->\n###### 나. 의료기기의 사이버 보안\n\n<!-- PAGE_43 -->\n###### 유·무선 통신이 가능하거나 통신 경로가 존재하는 제품의 경우\n\n<!-- PAGE_43 -->\n###### 사이버보안에 대한 요구사항을 준수해야 한다. 제조자는 이를 확인\n\n<!-- PAGE_43 -->\n###### 할 수 있도록 ‘의료기기 사이버보안 요구사항 체크리스트’와\n\n<!-- PAGE_43 -->\n###### 요구사항을 실제로 검증한 자료를 제출하여야 한다. 다만, 제조사의\n\n- - 37 -\n<!-- PAGE_44 -->\n###### 위험분석을 통해 요구사항 일부를 제외하거나 수정하여 적용할 때는\n\n<!-- PAGE_44 -->\n###### 시험규격 및 그 설정 근거를 제출하여야 하며 해당 자료로\n\n<!-- PAGE_44 -->\n###### ‘사이버보안 위험관리문서’를 제출할 수 있다.\n\n<!-- PAGE_44 -->\n###### 사이버보안 요구사항은 ‘의료기기의 사이버보안 허가·심사\n\n<!-- PAGE_44 -->\n###### ‘의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)’\n\n<!-- PAGE_44 -->\n###### 에는 보안통신, 데이터 보호, 기기 무결성, 사용자 인증, 소프트웨어\n\n<!-- PAGE_44 -->\n###### 유지보수, 물리적 접근, 신뢰성 및 가용성 등에 대한 요구사항을 제시\n\n<!-- PAGE_44 -->\n###### 하고 있다. 본 요구사항은 제품의 사이버보안 안전성 등급 및\n\n<!-- PAGE_44 -->\n###### 제품의 특성에 따라 적용한다. 해당 가이드라인에 따라 제품에\n\n<!-- PAGE_44 -->\n###### 소프트웨어 위험관리에는 사이버보안에 대한 위험관리 항목이\n\n<!-- PAGE_44 -->\n###### 포함되어야 하며, 소프트웨어 위험관리와 동일한 방식으로 위험관리\n\n<!-- PAGE_44 -->\n###### ‘위해요인 식별’에서는 관련 자료(규격, 가이드라인, 국내외\n\n<!-- PAGE_44 -->\n###### 이상 사례 등)에 근거하여 의료기기의 정상 및 고장상태에서\n\n<!-- PAGE_44 -->\n###### 이미 알고 있거나 예측 가능한 의료기기 사이버보안 측면의\n\n<!-- PAGE_44 -->\n###### ‘위험산정’에서는 위해상황을 초래할 수 있는 예측 가능한\n\n- - 38 -\n위해요인\n\n구체적인 예시\n\n사용자 또는 환자에게\n\n발생 가능한 손상\n\n관련자료\n\n<!-- PAGE_45 -->\n###### 표 10. 위해요인 식별 예시\n\n<!-- PAGE_45 -->\n###### 식별한 모든 위험에 대하여 위험의 평가 결과를 ‘위험을\n\n<!-- PAGE_45 -->\n###### 허용할 수 없는 영역(unacceptable)’과‘합리적으로 실현할\n\n<!-- PAGE_45 -->\n###### 수 있는 가장 낮은 영역(As Low As Reasonably Practicable,\n\n<!-- PAGE_45 -->\n###### ALARP)’, ‘허용할 수 있는 영역(acceptable)’의 3단계 또는\n\n<!-- PAGE_45 -->\n###### ‘위험을 허용할 수 없는 영역(unacceptable)’과 ‘허용할 수\n\n- - 39 -\n<!-- PAGE_46 -->\n###### 다) 위험통제\n\n<!-- PAGE_46 -->\n###### 제조자는 위험평가 결과 중 ‘위험을 허용할 수 없는 영역\n\n<!-- PAGE_46 -->\n###### (unacceptable)’과‘합리적으로 실현할 수 있는 가장 낮은 영역\n\n<!-- PAGE_46 -->\n###### (ALARP)’을 허용 가능한 수준까지 감소시키기 위하여 위험\n\n<!-- PAGE_46 -->\n###### 통제 조치를 식별하고, <표 12>와 같이 위험통제 활동을 수행\n\n<!-- PAGE_46 -->\n###### 모든 위험통제 조치를 하고 검증한 뒤 위험관리 계획에서 정\n\n<!-- PAGE_46 -->\n###### 의한 위험허용 기준을 사용하여 해당 의료기기에서 식별한 전체\n\n<!-- PAGE_46 -->\n###### 잔여위험이 허용 가능한지 아닌지를 결정하고 <표 13>과 같이\n\n- - 40 -\n잔여위험평가\n\n**[표 시작]**\n\n| medical Internet research, 21(11), e14754. | 추가 | 전체 잔여위험 허용 |\n| --- | --- | --- |\n| 임상시험 디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고 | MADRS는 우울장애를 측정하는 문항 총 10개로 구성되어 | 검증 및 |\n| 발생 | 결과 | 위험/이득 | 자살 사고를 평가하기 위해 고안된 자기보고 질문지이다. | 통제 | 검증 및 |\n| 선행연구 | 군 | N | BDI 변화량1) | 시퀀싱(sequencing) 필드의 메시지를 보호 | 적용 |\n| < 의료기기 사이버보안 특성 기재 > | 심각 | 대응 계획을 수립하여야 한다. | 위험 | 있다. 문항은 겉으로 드러나는 슬픔, 스스로 보고하는 슬픔, | 대한 내용분석을 통해 문항을 구성하였다는 것에 의미가 | 발생 | 적용 | 가능성 평가 |\n| - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함한다. | : 선정기준 모두를 만족하는 자 | 비율이 50% 이상이면 반응(호전)이 있는 것으로 평가 | 유효성 |\n| 가능 | - 임상시험 전, 중, 후에 관찰해야 할 항목들을 나열한다. | 식약처장은 [의료법]에 따른 의료기관 중 임상시험에 필요한 시설, 인력 및 기구를 | 임상시험용 의료기기 관리자는 임상시험기관에서 임상시험용 해당 의료기기를 | 측정할 수 있다. | 나) 회원가입 및 초기 우울장애 평가를 시행한다. | 사) 이상반응 조사 | 가) 임상시험 설명 및 동의 | 마) 우울장애 심각도 척도(BDI-II) 조사 | 사) 순응도 조사 | 라) 순응도 조사 | 하는 내용이 포함되어서는 안된다. | - 피험자가 제때 방문을 안 하며 연락이 안 되는 경우 | (2) 우울장애 관련한 약물을 복용한 경우 | 기간, 목적을 확인한다. | : 제2종 오류 0.20 | BSS는 총 21개 문항으로 구성되어 있으며 이 중 19개 문항은 |      |     ≠ | 분석 | Mean | SD | 완료 | 유효성 |\n| 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 | 하거나 암호화의 키 관련 자료가 손상되는 | 있는 국내 제작 척도이다. 총 30문항에 대해 5점 척도로 |\n| 성 | ※ 예: 보안이 보장되지 않은(unsecure) 운영 | 도 |\n**성**\n\n**[표 끝]**\n\n<!-- PAGE_47 -->\n###### 표 13. 전체 잔여위험 허용 가능성 평가 예시\n\n<!-- PAGE_47 -->\n###### ‘의료기기 사이버보안 요구사항 체크리스트’는 의료기기 사이버\n\n<!-- PAGE_47 -->\n###### 보안 요구사항에 대한 적합성 여부를 확인할 수 있는 자료로 제조자는\n\n<!-- PAGE_47 -->\n###### 체크리스트의 질의 사항을 확인하여 요구사항의 적용여부 등을 확인\n\n<!-- PAGE_47 -->\n###### 사용되는 통신기술(유·무선 통신 방식 등), 사용환경(병원 내/외\n\n<!-- PAGE_47 -->\n###### 사용, 공용 네트워크망 사용 등) 등 통신 특성을 확인할 수 있는\n\n<!-- PAGE_47 -->\n###### 사항을 기재한다. 이를 기반으로 체크리스트에 따라 요구사항 적용\n\n- - 41 -\n<!-- PAGE_48 -->\n###### <예시> - 의료기기 사이버보안 요구사항 체크리스트\n\n**[표 시작]**\n\n**예시**\n**무결성**\n**예시**\n**예시**\n**※ 피험자 수: 시험대상수 산출시 일반적인 고려사항**\n**물리적**\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 |\n**예시**\n**Depression Scale, CES-D)**\n| 발 | 행 | 일 2022년 12월 14일 |\n**사용자**\n| 발 | 행 | 인 | 서경원 |\n| 연구 참여 동의서 취득 | O | - | - | - |\n**Questionnaire-9, PHQ-9)**\n**신뢰성**\n**편 집 위 원 장 이정림**\n| 편 | 집 | 위 | 원 | 이원규, 박종호, 양승하, 한영민, 김건소, 채형래 |\n**가용성**\n| 임상시험 의료기기 적용 | O | O | O | O | Depression Scale, SDS) |\n| 평가지표 Baseline 수집 | (O) | O | - | - |\n| 평가지표 수집 및 분석2) | 2)2) | O | O | O | O |\n| 소프트 | 예시 |\n| 문 | 의 | 처 |\n**데이터**\n\n**[표 끝]**\n\n- - 42 -\n제조자는 기밀성에 대한 위험통제 수단이\n\n요구될 때, 통신 프로토콜의 컨트롤(control)/\n\n소프트웨어\n\n**[표 시작]**\n\n**시험보고서**\n**시험보고서**\n**할 수 있다. 본 예시는 대표적인 예를 작성한 것으로 실제 시험규격에 대해 작성**\n**Effect size2)**\n| 가이드라인’을 참고하여 임상시험 피험자 수 산출 방식을 적용한다. 피험자 수를 결정 | (AB-1234) |\n| 그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있다. 피험자 배정과 | 구조, 성능 등을 구체적으로 기재하도록 한다. | - 해당 의료기기의 임상시험에 따른 유효성 평가는 사용된 모든 의료기기를 | 피험자의 모집 기간, 임상 관찰 및 시험 수행 기간, 통계 처리 기간, 결과보고서 작성 기간, | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 및 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례기록서 | 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | 시험책임자는 의료기기법 시행규칙 제24조 제1항 제4호의 규정에 따라 임상 | 임상시험 방법은 해당 의료기기에 대한 모양, 구조 및 사용 전 준비사항/피험자에 대한 | (AB-1234) |\n| 시에는 해당 제품의 특성 및 주요 기능을 고려하여 작성하여야 한다. | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상반응 등에 대하여 임상 | 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생 시 |\n| 하기 위해서는 사전 정보가 필요한데, 여기에 포함되어야 할 필수 정보로는 다음이 있다. | - 부작용, 이상반응 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상 시험의 |\n| 보관, 관리하는 임상의, 의료기사 또는 간호사 등으로 임상시험기관의 장이 지정한 | 시험을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화할 때, 헬싱키 선언에 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람 |\n| 처리 할당에 있어 편향(Bias)을 줄이기 위해 무작위배정(Randomization)과 눈가림 | 기술하는 것을 말하며, 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 |\n**해당 의료기기의 제조업자 또는 수입업자가 해당된다. 의뢰자는 임상시험 모니터**\n| 요원을 지정하여야 한다. 임상시험 모니터요원의 선정, 자격기준, 수행임무 등에 | - 피험자(Subject)란 임상시험에 참여하는 임상시험용 또는 대조시험용 의료기기의 적용 |\n**대한 사항은 「의료기기법 시행규칙」별표3 “의료기기의 임상시험 관리기준” 제8호**\n\n**[표 끝]**\n\n확인 자료\n\n- - 43 -\n또한 제조자는 외부의 통제에 의한 소프트\n\n웨어의 업데이트나 운영환경 만료에 대한\n\n소프트웨어\n\n- - 44 -\n<!-- PAGE_51 -->\n##### 3. 성능 평가 항목\n\n<!-- PAGE_51 -->\n###### 우울장애 개선 디지털치료기기의 성능 평가 항목은 제품의 주요\n\n<!-- PAGE_51 -->\n###### 기능을 근거로 설정하며, 시험 기준 및 시험 방법은 제품의 특성을\n\n<!-- PAGE_51 -->\n###### 고려하여 가능한 정량적이고 구체적으로 작성한다.\n\n- - 45 -\n본 예시는 이해를 돕기 위하여 작성된 것으로 실제 신청하려는 제품의 내용과 상이\n\n<!-- PAGE_52 -->\n###### 예시)\n\n- - 46 -\n<!-- PAGE_53 -->\n### Ⅲ\n\n<!-- PAGE_53 -->\n### 임상시험계획서 작성 시 고려사항 및 예시\n\n<!-- PAGE_53 -->\n###### 「의료기기법 시행규칙」제20조(임상시험계획의 승인 등) 제2항에 따라\n\n<!-- PAGE_53 -->\n###### 임상시험계획서에 포함되어야 할 사항은 다음과 같다.\n\n<!-- PAGE_53 -->\n###### 1. 임상시험의 제목\n\n<!-- PAGE_53 -->\n###### 2. 임상시험기관의 명칭 및 소재지\n\n<!-- PAGE_53 -->\n###### 3. 임상시험의 책임자ㆍ담당자 및 공동연구자의 성명 및 직명\n\n<!-- PAGE_53 -->\n###### 4. 임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n<!-- PAGE_53 -->\n###### 5. 임상시험을 하려는 자의 성명 및 주소\n\n<!-- PAGE_53 -->\n###### 6. 임상시험의 목적 및 배경\n\n<!-- PAGE_53 -->\n###### 7. 임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다)\n\n<!-- PAGE_53 -->\n###### 8. 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되어 임상시험에\n\n<!-- PAGE_53 -->\n###### 9. 임상시험기간\n\n<!-- PAGE_53 -->\n###### 10. 임상시험방법(사용량ㆍ사용방법ㆍ사용기간ㆍ병용요법 등을 포함한다)\n\n<!-- PAGE_53 -->\n###### 11. 관찰항목ㆍ임상검사항목 및 관찰검사방법\n\n<!-- PAGE_53 -->\n###### 12. 예측되는 부작용 및 사용 시 주의사항\n\n<!-- PAGE_53 -->\n###### 13. 중지ㆍ탈락 기준\n\n<!-- PAGE_53 -->\n###### 14. 유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 따른다)\n\n<!-- PAGE_53 -->\n###### 15. 부작용을 포함한 안전성의 평가기준ㆍ평가방법 및 보고방법\n\n<!-- PAGE_53 -->\n###### 16. 피험자동의서 서식\n\n<!-- PAGE_53 -->\n###### 17. 피해자 보상에 대한 규약\n\n<!-- PAGE_53 -->\n###### 18. 임상시험 후 피험자의 진료에 관한 사항\n\n<!-- PAGE_53 -->\n###### 19. 피험자의 안전보호에 관한 대책\n\n<!-- PAGE_53 -->\n###### 20. 그 밖에 임상시험을 안전하고 과학적으로 실시하기 위하여 필요한 사항\n\n- - 47 -\n<!-- PAGE_54 -->\n##### 1. 임상시험의 제목\n\n<!-- PAGE_54 -->\n###### 우울장애 진단환자의 우울 증상을 개선하기 위해서 사용되는\n\n<!-- PAGE_54 -->\n###### OOO 디지털치료기기의 안전성 및 유효성을 평가하기 위한 전향적\n\n<!-- PAGE_54 -->\n###### 4) 임상시험 평가 내용 : 우울장애 심각도 척도(Depressive Severity Index)\n\n- - 48 -\n<!-- PAGE_55 -->\n##### 2. 임상시험기관의 명칭 및 소재지\n\n<!-- PAGE_55 -->\n###### 임상시험기관\n\n- - 49 -\n<!-- PAGE_56 -->\n##### 3. 임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n<!-- PAGE_56 -->\n###### 가. 시험책임자\n\n<!-- PAGE_56 -->\n###### 나. 시험담당자\n\n<!-- PAGE_56 -->\n###### 다. 공동연구자\n\n<!-- PAGE_56 -->\n###### 라. 임상시험 조정자\n\n- - 50 -\n<!-- PAGE_57 -->\n##### 4. 임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n<!-- PAGE_57 -->\n###### 의료기기 관리자\n\n- - 51 -\n<!-- PAGE_58 -->\n##### 5. 임상시험을 하려는 자의 성명 및 주소\n\n<!-- PAGE_58 -->\n###### 가. 의뢰자\n\n<!-- PAGE_58 -->\n###### 나. 모니터요원\n\n<!-- PAGE_58 -->\n###### 다. 임상시험 수탁업체\n\n<!-- PAGE_58 -->\n###### ※ 임상시험 수탁기관(Contact Research Organization, CRO)이 있는 경우 해당\n\n- - 52 -\n<!-- PAGE_59 -->\n##### 6. 임상시험의 목적 및 배경\n\n<!-- PAGE_59 -->\n###### 가. 임상시험의 목적\n\n<!-- PAGE_59 -->\n###### [목적]\n\n<!-- PAGE_59 -->\n###### 1) 임상시험용 디지털치료기기의 우울장애 치료에 대한 안전성 평가\n\n<!-- PAGE_59 -->\n###### 2) 임상시험용 디지털치료기기의 우울장애 치료에 대한 유효성 평가\n\n<!-- PAGE_59 -->\n###### 최근 우울장애로 치료받는 환자의 숫자가 급격히 증가하는 추세로\n\n<!-- PAGE_59 -->\n###### 우울장애를 치료하는 방법들 또한 많은 주목을 받고 있다(우울장애\n\n<!-- PAGE_59 -->\n###### 임상진료지침, 2022, ICSI, 2016). 임상에서 우울장애 환자들에게 주로\n\n<!-- PAGE_59 -->\n###### 사용되는 치료는 약물치료이다. 약물치료는 우울장애의 단기 치료에\n\n<!-- PAGE_59 -->\n###### 있어서 유용성이 확립되어 있으나 성기능장애, 졸림(진정 작용), 체중증가,\n\n<!-- PAGE_59 -->\n###### 수면장애(불면), 소화기장애(오심, 구토) 등의 부작용의 위험성이 있다.\n\n<!-- PAGE_59 -->\n###### 이러한 약물치료의 단점들을 보완해줄 수 있는 치료는 우울장애\n\n<!-- PAGE_59 -->\n###### 인지행동치료(CBT-D)이다. 우울장애 인지행동치료(CBT-D)는 단기적으로는\n\n<!-- PAGE_59 -->\n###### 약물치료와 그 효과가 유사하며 장기적인 효과는 약물치료보다 우수한\n\n<!-- PAGE_59 -->\n###### 것으로 밝혀져 있으며, 이러한 효과의 입증을 통해 우울증의 일차\n\n- - 53 -\n<!-- PAGE_60 -->\n###### 치료로 권장되고 있다(Van Hees et al., 2013).\n\n<!-- PAGE_60 -->\n###### 하지만 실제 임상에서 우울장애 인지행동치료(CBT-D)가 처방되는\n\n<!-- PAGE_60 -->\n###### 비율은 약물치료보다 현저히 낮다. 우울장애 인지행동치료(CBT-D)가 약물\n\n<!-- PAGE_60 -->\n###### 치료에 비해 많은 장점이 있음에도 널리 시행되지 않는 이유는 첫째,\n\n<!-- PAGE_60 -->\n###### 우울장애 인지행동치료(CBT-D)를 위해 환자들이 병원에 매주 내원\n\n<!-- PAGE_60 -->\n###### 하여야 하므로 병원에의 공간적 접근성, 치료를 위해 확보할 수 있는\n\n<!-- PAGE_60 -->\n###### 시간 자원 여부에 따른 치료적 제약이 생기기 때문이다. 둘째, 특히\n\n<!-- PAGE_60 -->\n###### 고령 환자이거나, 기타 내과 질환으로 인해 이동이 힘든 환자들의\n\n<!-- PAGE_60 -->\n###### 경우, 혹은 직장인이라 매주 시간을 내기 어려운 환자들의 경우 본인\n\n<!-- PAGE_60 -->\n###### 들이 원하더라도 우울장애 인지행동치료(CBT-D)를 받기 어려운 것이\n\n<!-- PAGE_60 -->\n###### 현실이다. 셋째, 치료진 관점에서 약물치료와 비교해 우울장애 인지행동\n\n<!-- PAGE_60 -->\n###### 치료(CBT-D)를 시행하는 것이 시간 대비 효용성이 높지 않으므로 선호도가\n\n<!-- PAGE_60 -->\n###### 떨어지는 경향이 있다.\n\n<!-- PAGE_60 -->\n###### 이러한 단점들을 보완하기 위해 디지털로 수행하는 우울장애 인지\n\n<!-- PAGE_60 -->\n###### 행동치료(Digital CBT-D)가 개발되고 있다. 디지털 우울장애 인지행동\n\n<!-- PAGE_60 -->\n###### 치료(Digital CBT-D)의 개념은 2005년에 처음으로 등장하였으며, 인터넷을\n\n<!-- PAGE_60 -->\n###### 이용하여 병원에 내원하지 않고도 우울장애 인지행동치료(CBT-D)를\n\n<!-- PAGE_60 -->\n###### 시행 받을 수 있도록 하는 것이다(Andersson et al. 2005). 이를 통해\n\n<!-- PAGE_60 -->\n###### 환자들이 직접 집에서 컴퓨터, 혹은 스마트폰을 이용하여 치료를 시행\n\n<!-- PAGE_60 -->\n###### 받을 수 있으므로 시·공간의 제약에서 자유롭게 될 것이며, 치료 대\n\n<!-- PAGE_60 -->\n###### 부분을 환자가 프로그램을 통해 수행하고 피드백을 받을 수 있으므로\n\n<!-- PAGE_60 -->\n###### 치료자 입장에서 비용 대비 효용성 또한 증가하게 될 것으로 기대된다.\n\n<!-- PAGE_60 -->\n###### 디지털 우울장애 인지행동치료(Digital CBT-D)가 등장한지도 약 15년이\n\n- - 54 -\n<!-- PAGE_61 -->\n###### 되어 치료 효과에 관한 여러 연구 결과들이 발표되고 있다. 특히, 최근\n\n<!-- PAGE_61 -->\n###### 연구들은 단순히 우울장애 인지행동치료(CBT-D)를 디지털 환경으로\n\n<!-- PAGE_61 -->\n###### 옮기는 것에서 발전하여, 애플리케이션을 통하여 환자에게 바로\n\n<!-- PAGE_61 -->\n###### 피드백을 제공함으로써 의사나 치료자가 직접적인 가이드를 주지\n\n<!-- PAGE_61 -->\n###### 않더라도 치료 효과를 볼 수 있게 하는 “디지털치료기기(Digital\n\n<!-- PAGE_61 -->\n###### Therapeutics, DTx)”의 개념을 추구하고 있다.\n\n<!-- PAGE_61 -->\n###### 본 임상 시험을 통해 우울장애가 있는 환자들을 대상으로 개발된 우울\n\n<!-- PAGE_61 -->\n###### 장애 개선 디지털치료기기의 작용기전에 대한 안전성(Safety)과 유효성\n\n<!-- PAGE_61 -->\n###### (effectiveness)을 검증하고자 한다.\n\n- - 55 -\n<!-- PAGE_62 -->\n###### 나. 임상시험의 배경\n\n<!-- PAGE_62 -->\n###### 디지털치료기기란 질병이나 장애를 예방, 관리, 치료하기 위해 환자\n\n<!-- PAGE_62 -->\n###### 에게 근거 기반의 치료적 중재(evidence-based therapeutic intervention)를\n\n<!-- PAGE_62 -->\n###### 제공하는 고도화된 소프트웨어 의료기기를 가리킨다.\n\n<!-- PAGE_62 -->\n###### 독일 GAIA 社에서 제공하는 Deprexis™는 CE 승인을 받은 우울장애\n\n<!-- PAGE_62 -->\n###### 개선 디지털치료기기로서, 실제 임상에서 사용되고 있다. Deprexis™는\n\n<!-- PAGE_62 -->\n###### 여러 무작위배정 임상시험을 통해 그 효용성 또한 입증된 바 있으며,\n\n<!-- PAGE_62 -->\n###### 우울과 관련된 변수들을 포함하여 신체적 건강, 심리적 웰빙 및 우울\n\n<!-- PAGE_62 -->\n###### 관련 지표 또한 호전되었다는 것이 밝혀진 바 있다(Twomey et al., 2020.).\n\n<!-- PAGE_62 -->\n###### 12개의 Deprexis RCT(총 피험자=2,901명)에 대한 메타분석은 우울\n\n<!-- PAGE_62 -->\n###### 장애 감소에 대한 Deprexis™의 효과를 확인하였다(g = 0.51, 95% CI:\n\n<!-- PAGE_62 -->\n###### 0.40–0.62, I2 = 26%). 임상 연구의 질, 선별 및 무작위배정 절차를\n\n<!-- PAGE_62 -->\n###### 고려할 때 결과는 유사하였다. 임상 연구의 지도, 개발자 참여, 환경\n\n<!-- PAGE_62 -->\n###### (지역사회 대 임상) 및 초기 증상 심각도는 효과 크기에 통계적으로\n\n<!-- PAGE_62 -->\n###### 유의한 영향을 미치지 않았으며 출판 편향의 증거도 없었다. 따라서\n\n<!-- PAGE_62 -->\n###### 이러한 결과는 Deprexis가 8-12주에 걸쳐 임상적으로 관련된 우울\n\n<!-- PAGE_62 -->\n###### 증상의 개선할 수 있음을 확인하였다, 아래의 <그림 4>는 우울장애\n\n<!-- PAGE_62 -->\n###### 개선 디지털치료기기와 관련하여 수행한 임상시험의 선행 연구의\n\n<!-- PAGE_62 -->\n###### 메타분석 결과이다.\n\n<!-- PAGE_62 -->\n###### 이러한 디지털치료기기는 기존의 우울장애 개선을 위한 웰니스\n\n<!-- PAGE_62 -->\n###### 프로그램과 다음과 같은 차이점을 가진다. 첫째, 일방적인 콘텐츠\n\n<!-- PAGE_62 -->\n###### 제공을 넘어 쌍방향적인 피드백을 제공한다. 피험자의 우울과 관련된\n\n<!-- PAGE_62 -->\n###### 변수를 지속해서 수집하고, 이에 대해 다음 목표를 제시함으로써 치료\n\n- - 56 -\n<!-- PAGE_63 -->\n###### 효과를 극대화한다. 이 과정에서 피험자는 단순히 콘텐츠를 소비하는\n\n<!-- PAGE_63 -->\n###### 것을 넘어서, 스스로 콘텐츠에 참여하고 있다는 느낌을 받을 수 있다.\n\n<!-- PAGE_63 -->\n###### 둘째, 피험자 맞춤형 콘텐츠 제공이 가능하다. 모든 콘텐츠를 같은\n\n<!-- PAGE_63 -->\n###### 비율로 제공하는 것에 그치지 않고 피험자의 정보를 수집함으로써 취\n\n<!-- PAGE_63 -->\n###### 약한 부분에 대한 집중적인 맞춤형 콘텐츠 제공을 하는 것이 가능하다.\n\n<!-- PAGE_63 -->\n###### 셋째, 일정 시간 동안의 꾸준한 사용을 독려하며 치료 효과에 대한\n\n<!-- PAGE_63 -->\n###### 모니터링이 가능하다. 일반적으로 디지털치료기기는 모든 콘텐츠를\n\n<!-- PAGE_63 -->\n###### 한 번에 제공하지 않고 일정 기간 순차적인 콘텐츠 제공을 함으로써\n\n<!-- PAGE_63 -->\n###### 사용기간을 조정한다. 이에 따라 피험자들은 치료 기간 중 자신의 우울\n\n<!-- PAGE_63 -->\n###### 장애 증상이 어떻게 변화하는지 실제 체감하고, 또한 디지털치료기기를\n\n<!-- PAGE_63 -->\n###### 통한 모니터링을 받을 수 있어 치료 동기 부여에 긍정적으로 작용할\n\n<!-- PAGE_63 -->\n###### 수 있다.\n\n- - 57 -\n<!-- PAGE_64 -->\n###### 본 연구에서는 국내에서 개발된 디지털 우울장애 인지행동치료\n\n<!-- PAGE_64 -->\n###### 애플리케이션을 무작위배정 임상시험을 통해 효과성과 안전성 검증을\n\n<!-- PAGE_64 -->\n###### 함으로써 해당 애플리케이션을 실제 국내 임상에서 활용할 수 있는지\n\n<!-- PAGE_64 -->\n###### 확인을 할 수 있겠으며 국내 우울장애 환자들에게 새로운 치료의\n\n<!-- PAGE_64 -->\n###### 선택지를 열어주고자 한다.\n\n- - 58 -\n<!-- PAGE_65 -->\n###### 7. 임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증 포함)\n\n<!-- PAGE_65 -->\n###### 가. 임상시험용 의료기기 사용 목적\n\n<!-- PAGE_65 -->\n###### [사용목적]\n\n<!-- PAGE_65 -->\n###### 모바일 애플리케이션 형태의 우울장애 인지행동치료 기반 콘텐츠를\n\n<!-- PAGE_65 -->\n###### 범용 장비(스마트폰 또는 태블릿 PC)를 통해 제공하는 소프트웨어 의료\n\n<!-- PAGE_65 -->\n###### 기기이다. 임상시험용 기기는 우울장애 인지행동치료(CBT-D)를 제공하여\n\n<!-- PAGE_65 -->\n###### 대조군(우울장애 일기 작성 권고 및 간단한 우울장애 교육 제공) 대비\n\n<!-- PAGE_65 -->\n###### 우울장애 증상을 개선하는 것을 목표로 한다.\n\n<!-- PAGE_65 -->\n###### 본 의료기기는 의사에게 우울장애* 진단을 받은 환자들을 대상으로 하며,\n\n<!-- PAGE_65 -->\n###### 추후 추가적인 적응증 확대는 가능하나 우울장애에 대한 의사 진단을\n\n<!-- PAGE_65 -->\n###### 기반으로 한다.\n\n- - 59 -\n<!-- PAGE_66 -->\n###### 나. 임상시험용 의료기기 정보\n\n해당 임상시험용 의료기기 및 대조시험용 의료기기의 품목명, 제조회사, 원재료, 모양,\n\n<!-- PAGE_66 -->\n###### - 품목명(품목분류번호, 등급): 정서장애치료소프트웨어(E06070.01, 2등급)\n\n<!-- PAGE_66 -->\n###### ※ 대조 시험용 의료기기의 구체적인 정보를 ‘가)’를 참고하여 작성한다. 대조\n\n<!-- PAGE_66 -->\n###### 시험용 의료기기가 설정되지 않았을 경우 생략할 수 있으며, 설정하지\n\n<!-- PAGE_66 -->\n###### 다. 임상시험용 의료기기 사용 방법\n\n<!-- PAGE_66 -->\n###### - 치료에 앞서 범용장비(스마트폰, 태블릿, PC 등)에 OOO 디지털\n\n- - 60 -\n<!-- PAGE_67 -->\n###### 2) 사용 방법\n\n<!-- PAGE_67 -->\n###### 가) OOO 디지털치료기기를 실행한다.\n\n<!-- PAGE_67 -->\n###### 다) 디지털치료기기를 통한 우울과 관련된 행동의 교정을 수행한다.\n\n<!-- PAGE_67 -->\n###### 이 내용은 과학적 근거에 기반하여야 하며, 우울장애 인지행동치료\n\n<!-- PAGE_67 -->\n###### (1) 자극 조절법: 우울장애와 각성 자극이 연관된 상태를 해소하기\n\n<!-- PAGE_67 -->\n###### (2) 우울 일기 및 동등한 수준으로 우울에 대한 평가가 가능한 도구:\n\n<!-- PAGE_67 -->\n###### 우울장애에 대한 평가 및 피드백을 할 수 있게 하려면\n\n<!-- PAGE_67 -->\n###### 우울에 대한 평가를 해야 하며, 우울장애 인지행동치료를\n\n<!-- PAGE_67 -->\n###### 기반으로 하였을 경우 일반적으로 우울장애 일기가 사용된다.\n\n<!-- PAGE_67 -->\n###### 라) 디지털치료기기를 통한 우울과 관련된 인지의 교정을 수행한다.\n\n<!-- PAGE_67 -->\n###### 이 내용은 과학적 근거에 기반하여야 하며, 우울장애 인지행동\n\n<!-- PAGE_67 -->\n###### 치료를 기반으로 하였을 경우 우울과 관련된 왜곡된 인지의\n\n<!-- PAGE_67 -->\n###### 마) 상술한 치료의 경우 환자의 순응도를 높이기 위한 전략이 포함\n\n<!-- PAGE_67 -->\n###### 되어야 하며(콘텐츠 제공 방식의 다양화, 알림 제공, 보상 방안\n\n<!-- PAGE_67 -->\n###### 등을 포함) 환자가 입력한 정보에 따른 피드백이 제공되어야\n\n<!-- PAGE_67 -->\n###### 하고 환자가 스스로 입력한 정보를 모니터링할 수 있도록\n\n- - 61 -\n<!-- PAGE_68 -->\n##### 8. 피험자의 선정기준·제외기준·인원 및 그 근거\n\n- - 62 -\n<!-- PAGE_69 -->\n###### 예시\n\n<!-- PAGE_69 -->\n###### 가. 피험자 선정기준\n\n<!-- PAGE_69 -->\n###### 2) DSM-5의 주요우울장애 진단기준을 만족하거나 ICD-10의 우울\n\n<!-- PAGE_69 -->\n###### ※ BDI-II에서 14점 이상의 점수를 가져 mild depression 이상 수준의 임상적\n\n<!-- PAGE_69 -->\n###### 우울이 있다고 판단할 수 있는 자, 혹은 이외 유사한, 과학적 근거를 가진\n\n<!-- PAGE_69 -->\n###### 우울 척도 검사상 mild depression 이상 수준의 임상적 우울이 있다고\n\n<!-- PAGE_69 -->\n###### 5) 범용 장비(스마트폰 또는 태블릿 PC 등)를 이용하여 모바일\n\n<!-- PAGE_69 -->\n###### 6) 본 임상시험에 대해 충분한 설명을 듣고 이해한 후, 스스로 참여를\n\n<!-- PAGE_69 -->\n###### 나. 피험자 제외기준\n\n<!-- PAGE_69 -->\n###### : 제외기준 중 어느 하나라도 해당하는 항목이 있는 경우 본\n\n<!-- PAGE_69 -->\n###### 2) 스크리닝 시점 3개월 이내에 자살 시도를 한 바 있으며, 정신과\n\n<!-- PAGE_69 -->\n###### ※ 콜롬비아 자살 위험성 스케일(Columbia Suicide Severity Rating Scale,\n\n- - 63 -\n<!-- PAGE_70 -->\n###### C-SSRS) 혹은 이와 유사한 과학적 근거를 가진 자살 위험성 평가상 자\n\n<!-- PAGE_70 -->\n###### 살 고위험군으로 평가되는 자\n\n<!-- PAGE_70 -->\n###### 3) 스크리닝 시점 1년 동안 제대로 치료받지 못한 간질, 심각한\n\n<!-- PAGE_70 -->\n###### 4) 스크리닝 이전 1주일 이내에 평균 알코올 섭취량이 1일 20g을\n\n<!-- PAGE_70 -->\n###### 5) 스크리닝 시점 3개월 이내에 우울장애에 대한 다른 비약물적인\n\n<!-- PAGE_70 -->\n###### 6) 최근 1개월 이내 사용하는 신경정신과 관련 약물의 종류 및 용량에\n\n<!-- PAGE_70 -->\n###### ※ 최근 1개월 이내 (필요시 처방을 포함하여) 복용 약물의 종류 및 용량이\n\n<!-- PAGE_70 -->\n###### 7) 기타 사유로 인하여 시험자가 임상시험 참여에 부적합하다고\n\n<!-- PAGE_70 -->\n###### ※ 피험자 선정기준 및 제외기준은 의료기기의 특성, 내용 구성 등을\n\n- - 64 -\n<!-- PAGE_71 -->\n###### 다. 목표대상자 수 및 그 근거\n\n피험자 수는 임상시험 방법에 따라 식약처의 ‘의료기기 임상시험 관련 통계기법\n\n<!-- PAGE_71 -->\n###### ※ 본 가이드라인에 작성된 산출 방법은 공개된 선행연구 결과를 기반으로\n\n<!-- PAGE_71 -->\n###### 작성된 예시이며, 목표 대상자 수는 개발 제품 특성과 탐색 임상시험 등\n\n<!-- PAGE_71 -->\n###### 제품별 선행연구 결과에 따라 다르므로, 개발 제품의 선행연구 결과\n\n<!-- PAGE_71 -->\n###### 및 참고문헌을 기준으로 산출한다. 이때, 그 근거(가설, 변수, 성공\n\n<!-- PAGE_71 -->\n###### 본 시험의 일차목적: 우울장애 진단환자의 우울장애 심각도\n\n<!-- PAGE_71 -->\n###### 척도(BDI) 변화량이 대조군과 비교해 시험군에서 치료 전과\n\n<!-- PAGE_71 -->\n###### 비교하여 우월하게 개선되는 것을 확증하는 것이다. 변화량은\n\n<!-- PAGE_71 -->\n###### 치료 시작 전 평가지표 Baseline 조사에서 수집한 정보와 대비\n\n<!-- PAGE_71 -->\n###### 하여 치료 종료 후(Post-treatment) 수집한 정보와의 차이를\n\n<!-- PAGE_71 -->\n###### 의미하며, 이에 대한 가설은 아래와 같다. 이 가설의 평균 차이\n\n- - 65 -\n<!-- PAGE_72 -->\n###### 검정에서 통계학적으로 유의하면 임상시험 성공으로 평가한다.\n\n<!-- PAGE_72 -->\n###### : 시험군의 치료 전 대비 post-treatment 후 평균 우울장애 심각도\n\n<!-- PAGE_72 -->\n###### : 대조군의 치료 전 대비 post-treatment 후 평균 우울장애 심각도\n\n<!-- PAGE_72 -->\n###### 19세 이상 우울장애 환자를 대상으로 한 국외 인터넷 기반\n\n<!-- PAGE_72 -->\n###### 우울장애 인지행동치료(Web-based CBT-D) 선행 연구를 검토한\n\n<!-- PAGE_72 -->\n###### 결과, 대조군 대비 인터넷 기반 우울장애 인지행동치료\n\n<!-- PAGE_72 -->\n###### (Web-based CBT-D)의 치료 전 대비 Post-treatment 후 우울장애\n\n<!-- PAGE_72 -->\n###### 심각도 척도(BDI)의 effect size는 0.65, 1.17로 조사되었다. 이에\n\n<!-- PAGE_72 -->\n###### 본 연구에서의 예상되는 effect size는 보수적으로 조사된 결과\n\n- - 66 -\n<!-- PAGE_73 -->\n###### 표 14. 치료 전 대비 Post-treatment 후 우울장애 심각도 척도(BDI) 변화량\n\n<!-- PAGE_73 -->\n###### 비교결과\n\n<!-- PAGE_73 -->\n###### 본 연구에서는 가설의 평균 변화량 차이 검정에 대해 최소\n\n<!-- PAGE_73 -->\n###### 필요한 피험자 수를 산출하기 위해 effect size는 0.65를 가정\n\n<!-- PAGE_73 -->\n###### 하였고, 양측 유의수준 5%, 검정력 80%를 만족하는 데 필요한\n\n<!-- PAGE_73 -->\n###### 피험자 수(군당 1:1 배정)를 산출한 결과, 한 군당 38명이었다.\n\n<!-- PAGE_73 -->\n###### 이에 중도 탈락을 30%를 고려하여 목표 피험자 수는 총 110명\n\n<!-- PAGE_73 -->\n###### (군당 55명)으로 결정하였다. 두 군의 평균 차이 검정에 대한\n\n<!-- PAGE_73 -->\n###### · 기존 CBTi 연구에서는 병원 방문 없이 온라인 수집으로만\n\n<!-- PAGE_73 -->\n###### 한 경우 40% 정도의 중도 탈락을 보였다. 그러나, 본\n\n<!-- PAGE_73 -->\n###### 연구에서는 병원 방문으로 이보다는 더 적게 탈락할 것\n\n- - 67 -\n<!-- PAGE_74 -->\n###### : 한 군당 필요한 피험자 수\n\n<!-- PAGE_74 -->\n###### : 제1종 오류 0.05 (유의수준)\n\n<!-- PAGE_74 -->\n###### ※ 본 임상시험의 경우 임상시험 설계 시 중도 탈락율은 약 10∼30%\n\n- - 68 -\n<!-- PAGE_75 -->\n###### 피험자의 모집 기간, 임상 관찰 및 수행 기간, 통계분석 기간, 결과\n\n<!-- PAGE_75 -->\n###### 보고서 작성 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을\n\n<!-- PAGE_75 -->\n###### 고려하도록 한다.\n\n<!-- PAGE_75 -->\n##### 9. 임상시험기간\n\n- - 69 -\n<!-- PAGE_76 -->\n###### 가. 시험방법\n\n<!-- PAGE_76 -->\n###### (예) 무작위배정 이후, 8주 동안 치료 기간이 종결된 직후에 방문\n\n<!-- PAGE_76 -->\n###### (Post-treatment)하여 임상 평가를 받고, 디지털 우울장애 인지\n\n<!-- PAGE_76 -->\n###### ※ 단, 본 연구에서는 연구설계에 따라 비처치대조군(wait-list)*의 적용도\n\n<!-- PAGE_76 -->\n###### * 비처치대조군: 치료 기간 동안 아무런 처치를 받지 않고 대기하는 군\n\n<!-- PAGE_76 -->\n###### 이다. 다만, 맹검을 유지하는 수준의 최소한 치료가 제공되어야 하며,\n\n<!-- PAGE_76 -->\n###### 이에는 과학적인 근거가 있어야 한다. 우울장애 인지행동치료를 기반으로 한\n\n<!-- PAGE_76 -->\n###### 디지털치료기기의 경우 서면 형태로 된 우울장애 교육 자료 등이 이에\n\n<!-- PAGE_76 -->\n###### ※ 우울장애 개선 디지털치료기기 허가제품이 출시된 이후에는 기허가\n\n<!-- PAGE_76 -->\n###### 제품과 비교시험 하는 동등성 검정 혹은 비열등성 검정 등을 시행하여\n\n<!-- PAGE_76 -->\n###### 10. 임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n- - 70 -\n<!-- PAGE_77 -->\n###### 해당 성능을 증명할 수 있다.\n\n<!-- PAGE_77 -->\n###### * 비열등성/동등성 시험(Non-inferiority, equivalence trial): 비교 연구에 있어\n\n<!-- PAGE_77 -->\n###### 대조기기와 비교해 시험기기의 성능이 열등하지 않음을 보이거나,\n\n<!-- PAGE_77 -->\n###### 3) 총 4회의 외래 방문을 통한 조사: 방문 1(Screening), 방문\n\n<!-- PAGE_77 -->\n###### ※ 방문 4(Follow-up, 3개월 후)는 필요시 애플리케이션, 이메일, 문자,\n\n<!-- PAGE_77 -->\n###### 4) 층화무작위배정: 기관별 성별(남/여), 연령(oo세 미만, oo세 이상)을\n\n<!-- PAGE_77 -->\n###### - 기관별로 내원한 환자 중 선정, 제외 기준에 따라 적합한\n\n<!-- PAGE_77 -->\n###### - 본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한\n\n<!-- PAGE_77 -->\n###### 내용을 피험자 본인 또는 대리인에게 설명하고, 피험자 또는\n\n<!-- PAGE_77 -->\n###### 대리인이 내용을 잘 이해한 것을 확인한 다음, 자유의사에 따른\n\n<!-- PAGE_77 -->\n###### 임상시험 참가의 동의를 문서로 받는다. 또한 동의에 서명한\n\n<!-- PAGE_77 -->\n###### 연월일을 기록하며, 동의서 사본을 환자에게 제공하여 환자가\n\n<!-- PAGE_77 -->\n###### 지속해서 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n- - 71 -\n<!-- PAGE_78 -->\n###### 다) 인구학적 조사, 병력조사 요법\n\n<!-- PAGE_78 -->\n###### - 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력\n\n<!-- PAGE_78 -->\n###### 등에 대하여 차트 확인 및 애플리케이션 내 질문 등을 통하여\n\n<!-- PAGE_78 -->\n###### (1) 피험자에게 서명하고 동의를 받은 후 동의 취득 순서에 따라\n\n<!-- PAGE_78 -->\n###### 스크리닝 번호를 부여하며 피험자가 참여를 종료할 때까지\n\n<!-- PAGE_78 -->\n###### (2) 피험자 적합성 평가: 피험자 선정 및 제외 기준에 적합한지\n\n<!-- PAGE_78 -->\n###### · 일차 유효성 평가지표로는 우울장애의 증상 개선을 확인\n\n<!-- PAGE_78 -->\n###### 하고자 하는 연구에서 널리 사용되고 있는 우울장애 심각도 척도\n\n<!-- PAGE_78 -->\n###### · 필요하면 과학적인 근거를 가진 기타 우울에 대한 주관적 보고\n\n<!-- PAGE_78 -->\n###### 척도로 대체할 수 있다(e.g. Patient Health Questionnaire-9, PHQ-9).\n\n- - 72 -\n<!-- PAGE_79 -->\n###### (2) 이차 유효성 평가지표\n\n<!-- PAGE_79 -->\n###### · 일차 유효성 평가지표를 통해 유효성을 검증하는 것이\n\n<!-- PAGE_79 -->\n###### 기본적인 원칙이지만, 이외 필요하면 변수를 이차 유효성\n\n<!-- PAGE_79 -->\n###### · 과학적인 근거를 가진 변수이되, 기존 우울 증상 개선 시\n\n<!-- PAGE_79 -->\n###### 함께 개선될 수 있다고 여겨진 영역에 한정한다(우울장애\n\n<!-- PAGE_79 -->\n###### 개선, 삶의 질, 직업적 혹은 사회적 기능, 우울과 불안을\n\n<!-- PAGE_79 -->\n###### - 방문 2(Baseline), 방문 3(Post-treatment,), 방문 4\n\n- - 73 -\n측정도구\n\n설명\n\n- - 74 -\n측정도구\n\n설명\n\nKDS는 한국인 우울장애 환자들이 호소하는 증상과 생활사건에\n\n- - 75 -\n측정도구\n\n설명\n\nBSS는 우울장애 관련 구성개념의 하나로, 자살 위험의 지침인\n\n(출처: 우울장애 임상지료지침, 2022, H.J. Cho et al., 2007, VA/DoD, 2016\n\n- - 76 -\n<!-- PAGE_83 -->\n###### 바) 순응도 조사\n\n<!-- PAGE_83 -->\n###### - 치료기간 동안 어플리케이션 사용 시간 및 활용 여부를 수집한다.\n\n<!-- PAGE_83 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_83 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_83 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_83 -->\n###### - 각 관찰 항목에 대한 평가 도구 및 평가 방법에 대한 자세한\n\n- - 77 -\n<!-- PAGE_84 -->\n###### 나. 설계 방법\n\n<!-- PAGE_84 -->\n###### - 연구자는 선정·제외 기준을 합격한 피험자의 순서대로 배정일에\n\n<!-- PAGE_84 -->\n###### 쌍방향 웹반응시스템(Interactive Web Response System,\n\n<!-- PAGE_84 -->\n###### - 본 연구와 독립된 통계학자가 SAS 통계 패키지를 가지고 층화\n\n<!-- PAGE_84 -->\n###### 순열화 블록 무작위배정법(stratified permuted block randomization)을\n\n<!-- PAGE_84 -->\n###### - 연구의 특성상 단일 맹검을 지향하되, 필요시 비맹검 임상시험을\n\n<!-- PAGE_84 -->\n###### - 단일맹검인 경우, 임상시험 도중 응급상황 발생 등으로 인하여\n\n<!-- PAGE_84 -->\n###### 피험자의 눈가림을 해제할 수 있다. 이 경우, 사유와 해제일,\n\n<!-- PAGE_84 -->\n###### 열람자, 해제 후 조치사항 등에 대한 문서를 기록·보관한다.\n\n- - 78 -\n<!-- PAGE_85 -->\n##### 11. 관찰항목·임상검사항목 및 관찰검사방법\n\n<!-- PAGE_85 -->\n###### 임상시험 일정표\n\n1) 스크리닝 및 검사일은 치료 시작일 전 28일 이내에 시작한다.\n\n2) 수집하는 지표에 따라 수집이 다를 경우 나누어 표현한다. (예: BDI는 스크리닝에도 수집함)\n\n3) 우울장애 개선 디지털치료기기 제품의 치료 기간에 따라 전체 치료 기간은 변경될 수 있다.\n\n4) 임상시험 설계에 따른 선택사항이므로 치료 기간 종료 후 추적 관찰 기간은 변경될 수 있다.\n\n- - 79 -\n<!-- PAGE_86 -->\n###### 가. 임상시험 절차\n\n<!-- PAGE_86 -->\n###### 1) 방문 1 (스크리닝 및 검사일, Screening)\n\n<!-- PAGE_86 -->\n###### - 임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여\n\n<!-- PAGE_86 -->\n###### 대상자 또는 법정대리인에게 상세히 설명한다. 서명 일자를\n\n<!-- PAGE_86 -->\n###### 정확히 기재하여야 하며, 작성된 동의서 원본은 시험자가 보관\n\n<!-- PAGE_86 -->\n###### 하고 사본은 시험대상자 또는 법정대리인에게 내준다. 대상자\n\n<!-- PAGE_86 -->\n###### 에게 동의를 받은 후 동의 취득 순서에 따라 스크리닝 번호를\n\n<!-- PAGE_86 -->\n###### - 대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그\n\n<!-- PAGE_86 -->\n###### - 인구학적 정보로 대상자 이니셜, 만 나이, 성별, 직업, 그리고\n\n<!-- PAGE_86 -->\n###### 업무 생산성을 조사하며 기초 문진에 필요한 환자들의 의학적\n\n<!-- PAGE_86 -->\n###### - 병력조사에 포함되어야 하는 내용은 다음과 같다. 치매, 인지\n\n<!-- PAGE_86 -->\n###### 기능 장애, 정신증, 양극성 장애 및 현재 주요 우울 삽화\n\n<!-- PAGE_86 -->\n###### (current major depressive episode) 등 스크리닝 확인해야 할\n\n<!-- PAGE_86 -->\n###### 질병군 등의 과거력 및 현 병력, 발생 시기, 치료와 진행여부\n\n- - 80 -\n<!-- PAGE_87 -->\n###### - 동의서 취득일 기준으로 최근 5년 이내 과거 및 현재 병력을\n\n<!-- PAGE_87 -->\n###### 조사한다.\n\n<!-- PAGE_87 -->\n###### - 피험자 선정을 위한 한국판 우울장애 심각도 척도 정보를 수집\n\n<!-- PAGE_87 -->\n###### - 필요시 본 단계에서 수집한 정보를 Baseline 지표로 활용할\n\n<!-- PAGE_87 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n<!-- PAGE_87 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_87 -->\n###### - 일차 유효성 평가지표, 이차 임상 변수를 평가하기 위해 우울장애\n\n<!-- PAGE_87 -->\n###### 심각도 척도(BDI) 및 해당하는 자가 보고를 작성하도록 하여\n\n<!-- PAGE_87 -->\n###### 지참하게 하거나, 애플리케이션 등을 통해 평가지표에 대한\n\n<!-- PAGE_87 -->\n###### - 필요에 따라 방문 1(스크리닝 단계)에서 측정한 우울장애 심각도\n\n- - 81 -\n<!-- PAGE_88 -->\n###### 다) 임상시험 의료기기 시험방법\n\n<!-- PAGE_88 -->\n###### - OOO 애플리케이션을 실행한다.\n\n<!-- PAGE_88 -->\n###### - 회원가입 및 초기 증상 평가를 시행한다(7가지 기본 입력 정보:\n\n<!-- PAGE_88 -->\n###### 성별, 나이, 우울장애 증상의 정도, 우울장애 증상의 양상, 동반\n\n<!-- PAGE_88 -->\n###### - 정해진 기간에 상술 된 방식으로 디지털치료기기 콘텐츠를\n\n<!-- PAGE_88 -->\n###### - 우울장애 교육/우울장애 일기(예: Sham, 대면교육, 교육책자 등)\n\n<!-- PAGE_88 -->\n###### - 정해진 기간에 환자에게 해가 되지 않는 내용으로 과학적 근거에\n\n<!-- PAGE_88 -->\n###### ※ 실험 설계에 따라 대조군에 Sham을 적용하지 않고 wait-list로 대체할 수 있다.\n\n<!-- PAGE_88 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_88 -->\n###### 이상 반응 여부를 방문일에 진찰을 통해 관찰하고, 임상시험용\n\n<!-- PAGE_88 -->\n###### ※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n<!-- PAGE_88 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n- - 82 -\n<!-- PAGE_89 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_89 -->\n###### 기간, 목적을 확인한다.\n\n<!-- PAGE_89 -->\n###### - 치료기간 동안 어플리케이션 사용도 및 컨텐츠 이용도를 수집\n\n<!-- PAGE_89 -->\n###### - 치료 후 평가 및 일차 유효성 평가지표, 이차 유효성 평가지표의\n\n<!-- PAGE_89 -->\n###### 변화를 검증하기 위해 우울장애 심각도 척도 및 해당하는 자가\n\n<!-- PAGE_89 -->\n###### 보고를 작성하도록 하여 지참하게 하거나, 애플리케이션을\n\n<!-- PAGE_89 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_89 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_89 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_89 -->\n###### ※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n<!-- PAGE_89 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n- - 83 -\n<!-- PAGE_90 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_90 -->\n###### 기간, 목적을 확인한다.\n\n<!-- PAGE_90 -->\n###### - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n\n<!-- PAGE_90 -->\n###### - 장기 효과 확인을 위한 일차 유효성 평가지표, 이차 유효성\n\n<!-- PAGE_90 -->\n###### 평가지표의 변화를 검증하기 위해 우울장애 심각도 척도 및\n\n<!-- PAGE_90 -->\n###### 해당하는 자가 보고를 작성하도록 하여 지참하게 하거나,\n\n<!-- PAGE_90 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_90 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_90 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_90 -->\n###### ※ 단, 이상반응 여부는 필요시 온라인(앱, 이메일, 문자, SNS 등)으로 대체\n\n- - 84 -\n<!-- PAGE_91 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n<!-- PAGE_91 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_91 -->\n###### - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n\n- - 85 -\n<!-- PAGE_92 -->\n##### 12. 예측되는 부작용 및 사용 시 주의사항\n\n<!-- PAGE_92 -->\n###### 가. 예측되는 부작용\n\n<!-- PAGE_92 -->\n###### 본 연구에서 적용하는 치료는 디지털 우울장애 인지행동치료\n\n<!-- PAGE_92 -->\n###### (Digital CBT-D)는 행동 요법 또는 인지 요법을 포함한 교육 이외 기타\n\n<!-- PAGE_92 -->\n###### 침습적이거나, 환자에게 유해를 끼칠 수 있는 내용은 포함되어 있지\n\n<!-- PAGE_92 -->\n###### 않다. 다만, 일반적인 우울장애 인지행동치료(CBT-D)의 부작용에 준하는\n\n<!-- PAGE_92 -->\n###### 부작용 또는 범용장비 사용으로 인한 부작용을 예상할 수 있고, 이는\n\n<!-- PAGE_92 -->\n###### 다음과 같다.\n\n<!-- PAGE_92 -->\n###### 1) 우울장애 인지행동치료(CBT-D)의 행동 요법 중 밤 시간의 집중\n\n<!-- PAGE_92 -->\n###### 저하를 불러일으킬 수 있어 3교대자 등 밤 시간 우울장애가 큰\n\n<!-- PAGE_92 -->\n###### 피해를 가져올 수 있는 직업군의 환자의 경우 임상시험에서\n\n<!-- PAGE_92 -->\n###### 제외한다. 이외에도 치료 시작 시점에서 밤 시간 우울장애가 악화\n\n<!-- PAGE_92 -->\n###### 될 수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통하여\n\n<!-- PAGE_92 -->\n###### 2) 우울장애 인지행동치료(CBT-D)의 인지 요법 중 왜곡된 인지 교정의\n\n<!-- PAGE_92 -->\n###### 경우 일시적인 불안감 악화를 가져올 수 있다. 치료 시작 시점에서\n\n<!-- PAGE_92 -->\n###### 일시적인 불안감 악화가 나타날 수 있음을 알리고, 24시간 연락\n\n- - 86 -\n<!-- PAGE_93 -->\n###### 가능한 연구자 번호를 통하여 즉시 상담과 필요하면 의료진 연결이\n\n<!-- PAGE_93 -->\n###### 가능하도록 조치한다.\n\n<!-- PAGE_93 -->\n###### 3) 디지털 우울장애 인지행동치료(Digital CBT-D를 위한 범용 장비\n\n<!-- PAGE_93 -->\n###### (스마트폰 또는 태블릿 PC 등) 사용으로 두통, 눈의 피로, 눈 또는\n\n<!-- PAGE_93 -->\n###### 근육경련, 눈의 불수의운동, 메스꺼움, 어지럼증, 머리 또는 눈의\n\n<!-- PAGE_93 -->\n###### 불쾌감 또는 통증, 졸림, 피로감과 같은 부작용이 발생할 수 있다.\n\n<!-- PAGE_93 -->\n###### 해당 경우 24시간 연락 가능한 연구자 번호를 통하여 즉시 상담과\n\n<!-- PAGE_93 -->\n###### 본 연구에서 진행되는 평가는 자가 보고 설문지, 면담 등 모두\n\n<!-- PAGE_93 -->\n###### 비침습적인 검사로 이루어져 있으므로 예측되는 부작용은 없다.\n\n<!-- PAGE_93 -->\n###### 나. 사용 시 주의사항\n\n<!-- PAGE_93 -->\n###### 본 연구에서 적용하는 우울장애 개선 디지털치료기기의 부작용,\n\n<!-- PAGE_93 -->\n###### 일반적 주의, 적용상의 주의는 다음과 같다.\n\n<!-- PAGE_93 -->\n###### 본 제품을 사용한 후 제품에 대한 부적합 반응이 전부 배제될\n\n<!-- PAGE_93 -->\n###### 사이버 보안과 관련된 사고 발생 시 임상시험 관리자 긴급\n\n<!-- PAGE_93 -->\n###### 사용 시간, 사용 횟수, 결과 작성 등 임상시험 책임자와 담당자가\n\n- - 87 -\n<!-- PAGE_94 -->\n##### 13. 중지·탈락 기준\n\n<!-- PAGE_94 -->\n###### 가. 중지\n\n<!-- PAGE_94 -->\n###### - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n\n<!-- PAGE_94 -->\n###### - 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는\n\n<!-- PAGE_94 -->\n###### - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n\n<!-- PAGE_94 -->\n###### - 중지 시점까지의 검사 결과 관련 자료는 성능과 안전성 평가를\n\n- - 88 -\n<!-- PAGE_95 -->\n###### 위한 통계처리 시 삽입할 수 있다.\n\n<!-- PAGE_95 -->\n###### - 임상시험을 통해 얻은 자료는 성능 및 안전성 분석을 위한\n\n<!-- PAGE_95 -->\n###### 데이터가 정해져야 하며, 만약 자료에 결함이 생기면 적절한\n\n<!-- PAGE_95 -->\n###### 보정 방법을 임상시험계획서에 제시하고 보정 후 분석을 시행\n\n<!-- PAGE_95 -->\n###### 나. 탈락\n\n<!-- PAGE_95 -->\n###### 시험자는 다음과 같은 경우에 연구 참여 대상자를 시험에서\n\n<!-- PAGE_95 -->\n###### - 피험자가 임상시험 중 임상시험 참여 중단을 요구하거나 시험\n\n<!-- PAGE_95 -->\n###### - 3개월 이내에 자살 시도를 한 바 있으며, 정신과 전문의에 의해\n\n<!-- PAGE_95 -->\n###### ※ 콜롬비아 자살 위험성 스케일(C-SSRS) 혹은 이와 유사한 과학적\n\n<!-- PAGE_95 -->\n###### - 피험자의 부작용(예: 두통, 눈의 피로, 눈 또는 근육경련, 눈의 불\n\n<!-- PAGE_95 -->\n###### 수의운동, 메스꺼움, 어지럼증 등)으로 인하여 임상시험 책임자\n\n<!-- PAGE_95 -->\n###### - 피험자가 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n\n<!-- PAGE_95 -->\n###### - 피험자의 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n\n- - 89 -\n<!-- PAGE_96 -->\n###### - 임상시험 중 선정/제외 기준 위반 등 중대한 계획서 위반 사항이\n\n<!-- PAGE_96 -->\n###### 발견되는 경우\n\n<!-- PAGE_96 -->\n###### - 기타 사유로 인하여 임상시험 책임자 또는 담당자가 임상\n\n<!-- PAGE_96 -->\n###### - 우울 증상이 지나치게 악화되어 다른 건강 결과 악화가 예상\n\n<!-- PAGE_96 -->\n###### - 중도 탈락 시, 시험자는 대상자의 임상시험 조기 탈락의 주요\n\n<!-- PAGE_96 -->\n###### 사유를 평가하여 증례 기록서 임상시험 완료 란에 해당 정보를\n\n<!-- PAGE_96 -->\n###### - 참여 중단 의사를 밝히지 않고 방문에 출석하지 않아 현재\n\n<!-- PAGE_96 -->\n###### 상태가 불분명한 대상자의 경우에 시험자는 대상자와 전화\n\n- - 90 -\n<!-- PAGE_97 -->\n###### 14. 유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 의함)\n\n<!-- PAGE_97 -->\n###### 가. 유효성의 평가 기준\n\n<!-- PAGE_97 -->\n###### [일차 유효성 평가변수]\n\n<!-- PAGE_97 -->\n###### [이차 유효성 평가변수]\n\n<!-- PAGE_97 -->\n###### 2) 치료 전 대비 8주 및 3개월 후 우울장애 선별 도구 척도(PHQ-9) 변화량\n\n- - 91 -\n4) 치료 전 대비 8주 및 3개월 후 반응률*\n\n<!-- PAGE_98 -->\n###### * 반응 정의: 기저점 대비 일차 유효성 변수(우울장애 심각도 척도[BDI]) 변화량의\n\n**[표 시작]**\n\n**5) 삶의 질**\n\n**[표 끝]**\n\n- - 92 -\n<!-- PAGE_99 -->\n###### 나. 검사 방법\n\n<!-- PAGE_99 -->\n###### 1) 우울장애 심각도 척도(Beck Depression Inventory, BDI-II)\n\n<!-- PAGE_99 -->\n###### 우울장애 심각도 척도(BDI-II)는 우울장애의 증상 심각도에 대한\n\n<!-- PAGE_99 -->\n###### 평가를 수행할 수 있으며 질환의 호전 여부를 판단할 수 있는,\n\n<!-- PAGE_99 -->\n###### 과학적으로 검증된 자가 보고식 설문이다(Beck, 1961). 우울장애\n\n<!-- PAGE_99 -->\n###### 심각도 척도는 DSM-5의 우울장애 진단기준에 근거하여 우울장애를\n\n<!-- PAGE_99 -->\n###### 측정하는 문항 총 21개로 구성되어 있다. 문항은 슬픔, 죄의식, 자살\n\n<!-- PAGE_99 -->\n###### 사고, 흥미 결여와 같은 특징적인 우울장애에 관한 것이다. 이들 문항\n\n<!-- PAGE_99 -->\n###### 중 19개는 증상이 없는 것에서부터 증가하여 심각도 수준(0~3)을\n\n<!-- PAGE_99 -->\n###### 나타내며, 나머지 2문항은 행동의 변화(식욕 및 수면)에 대해 반응\n\n<!-- PAGE_99 -->\n###### 하도록 구성되어 있다. 21문항에서 인지-정서적 요인과 신체화 요인\n\n<!-- PAGE_99 -->\n###### 2 요인이 확인되었다. 우울장애 심각도 척도(BDI-II)는 13세 이상의\n\n<!-- PAGE_99 -->\n###### 청소년과 성인을 대상으로 실시하며, 점수는 최대 63점이 나오고\n\n<!-- PAGE_99 -->\n###### 점수가 높을수록 우울장애가 심각함을 나타낸다. 현재 BDI-II에 대한\n\n<!-- PAGE_99 -->\n###### 우울 점수에 따라, 약간의 우울(0~13점), 경미한 우울(14~19점), 중증도\n\n<!-- PAGE_99 -->\n###### 본 연구에서는 일차 유효성 지표에 대한 검증을 위해 방문 1, 방문 2,\n\n<!-- PAGE_99 -->\n###### 방문 3, 방문 4에 각각 우울장애 심각도 척도(BDI-II) 자가 보고 설문을\n\n<!-- PAGE_99 -->\n###### 수행할 예정이다. 단, 필요에 따라 방문 1(스크리닝 단계)에서 측정한\n\n<!-- PAGE_99 -->\n###### 우울장애 심각도 척도(BDI-II) 정보를 방문 2의 baseline 지표로 활용\n\n<!-- PAGE_99 -->\n###### 할 수 있다. 방문 1의 경우 연구자가 직접 피험자와 대면하여 연구에\n\n<!-- PAGE_99 -->\n###### 대한 설명을 수행하고 서면동의를 얻은 뒤, 독립된 방에서 설문지를\n\n<!-- PAGE_99 -->\n###### 제공하고 피험자가 스스로 설문에 답하게 5-10분간의 시간을 제공\n\n- - 93 -\n<!-- PAGE_100 -->\n###### 할 예정이며, 이는 방문 2, 3, 4에서도 동일하게 진행될 예정이다.\n\n<!-- PAGE_100 -->\n###### 다만 방문 2, 3의 경우 애플리케이션을 통해 우울장애 심각도 척도\n\n<!-- PAGE_100 -->\n###### (BDI-II) 정보를 수집할 수 있으며, 방문 4는 내원, 애플리케이션,\n\n<!-- PAGE_100 -->\n###### 이메일, 문자, SNS를 이용하여 설문지를 제공한 뒤 회신받는 것으로\n\n<!-- PAGE_100 -->\n###### 방문 1의 설문에서 13점 이하를 기록할 때 연구 대상에서 제외\n\n<!-- PAGE_100 -->\n###### 되게 된다. 방문 3, 4의 설문 점수는 방문 1의 점수와 비교 분석\n\n<!-- PAGE_100 -->\n###### 우울장애 선별 도구(PHQ-9)란 다른 우울장애 평가척도와 유의한\n\n<!-- PAGE_100 -->\n###### 공존 타당도를 나타내고 우울장애를 평가하고 선별하는 척도로서의\n\n<!-- PAGE_100 -->\n###### 신뢰도와 타당도가 입증되었다. PHQ-9의 경우 기존 우울장애 평가\n\n<!-- PAGE_100 -->\n###### 도구보다 문항 수가 적고 작성 시간이 적게 걸려 일차 진료 과정\n\n<!-- PAGE_100 -->\n###### 현재 BDI에 대한 우울 점수에 따라, 경도 우울(10~14점), 중등도\n\n<!-- PAGE_100 -->\n###### 삶의 질, 우울/불안 관련 증상 유무, 직업적/사회적 기능 상태,\n\n<!-- PAGE_100 -->\n###### 등의 항목에 있어서는 자가 보고 설문 혹은 연구자와 대면 인터뷰를\n\n<!-- PAGE_100 -->\n###### 통해 측정할 수 있다. 자가 보고 설문의 경우 우울장애 심각도\n\n<!-- PAGE_100 -->\n###### 척도(BDI-II)와 동등한 방식으로 측정할 수 있다. 연구자와 대면\n\n- - 94 -\n<!-- PAGE_101 -->\n###### 인터뷰 또한 우울장애 심각도 척도(BDI-II)와 유사한 방식으로 하되,\n\n<!-- PAGE_101 -->\n###### 자가 보고 설문 대신 연구자와의 인터뷰를 통해 진행되는 방식으로\n\n<!-- PAGE_101 -->\n###### 사용자 반응 평가에 대해서는 애플리케이션 사용 후 측정이 진행\n\n<!-- PAGE_101 -->\n###### 되어야 하므로 방문 3, 방문 4에 측정을 수행하여야 한다. 여기에는\n\n<!-- PAGE_101 -->\n###### 사용자의 순응도, 만족도, 난이도, 개선점 등이 포함되어야 하며\n\n<!-- PAGE_101 -->\n###### 자가 보고 설문 혹은 연구자와 대면 인터뷰를 통해 측정할 수 있다.\n\n<!-- PAGE_101 -->\n###### 다. 통계분석방법\n\n<!-- PAGE_101 -->\n###### 배정된 대로 분석(Intention-to-treat, ITT) 원칙을 따르며,\n\n<!-- PAGE_101 -->\n###### 무작위배정된 모든 피험자군 중 주요한 선정기준을 위배하거나\n\n<!-- PAGE_101 -->\n###### 무작위배정된 후 우울장애 개선 디지털치료기기를 로그인하여,\n\n<!-- PAGE_101 -->\n###### 한 번이라도 사용한 로그가 존재하지 않거나, 무작위배정 이후\n\n<!-- PAGE_101 -->\n###### 일차 유효성 평가자료가 전혀 없는 경우는 제외한다. 1차/2차\n\n<!-- PAGE_101 -->\n###### 유효성 평가는 모든 분석 대상자군(Full Analysis Set, FAS)를\n\n<!-- PAGE_101 -->\n###### 모든 분석 대상자군(FAS)에 속한 피험자이면서 임상시험 일정\n\n<!-- PAGE_101 -->\n###### 대로 모든 수행을 완료하고, 아래의 주요한 임상시험계획 위반이\n\n<!-- PAGE_101 -->\n###### 없는 피험자로 정의한다. 1차/2차 유효성 평가는 계획서 순응\n\n- - 95 -\n<!-- PAGE_102 -->\n###### 임상시험대상자군(PPS)를 보조분석군으로 분석한다.\n\n<!-- PAGE_102 -->\n###### (1) 임상시험 불순응*으로 판단되는 경우\n\n<!-- PAGE_102 -->\n###### (4) 임상시험 참여 중 심적/신체적 환경 변화로 있는 것으로\n\n<!-- PAGE_102 -->\n###### * 순응도란 어플리케이션 치료 기간 내 총 노출된 모듈 횟수를 통해\n\n<!-- PAGE_102 -->\n###### 평가한다. 총 모듈 횟수 중 75% 미만(예, 총 12주의 경우 9주 미만)\n\n<!-- PAGE_102 -->\n###### 우울장애 개선 디지털치료기기로 한 번이라도 치료를 받은\n\n<!-- PAGE_102 -->\n###### 모든 피험자로 정의한다. 안전성 평가는 안전성 자료를 대상\n\n<!-- PAGE_102 -->\n###### - 치료 전 대비 Post-treatment 후 우울장애 심각도 척도(BDI)\n\n<!-- PAGE_102 -->\n###### : 각 시점에서의 우울장애 심각도 척도(BDI) 총점수와 Post-\n\n<!-- PAGE_102 -->\n###### : Post-treatment 후 변화량의 군간 차이 검정은 기저치를 공\n\n<!-- PAGE_102 -->\n###### 변량으로 한 공분산분석(ANCOVA)을 적용한다. P-value와\n\n<!-- PAGE_102 -->\n###### 함께 양측 95% 신뢰구간을 제시한다. 대조군 대비 시험군의\n\n<!-- PAGE_102 -->\n###### 평균 변화량이 우월한 방향에 있고 P-value가 유의수준\n\n- - 96 -\n<!-- PAGE_103 -->\n###### 0.05에서 작으면 통계적으로 우월하다고 판단한다. 또한,\n\n<!-- PAGE_103 -->\n###### 결과에 대한 임상적 평가를 제시한다.\n\n<!-- PAGE_103 -->\n###### - 치료 전 대비 3개월 후 우울장애 심각도 척도(BDI), 8주 후\n\n<!-- PAGE_103 -->\n###### : 각 유효성 평가변수의 각 시점의 변화량에 대해 기저치, 성,\n\n<!-- PAGE_103 -->\n###### 연령을 포함한 공분산분석을 적용하여 다른 변수를 통제한\n\n<!-- PAGE_103 -->\n###### 후 배정군간 평균 변화량 차이가 있는지 양측 유의수준 0.05\n\n<!-- PAGE_103 -->\n###### : 치료 전 대비 치료 후 각 시점에서 군간 관해율 및 반응율\n\n<!-- PAGE_103 -->\n###### 차이는 카이제곱검정(Chi-square test) 혹은 피셔정확검정\n\n<!-- PAGE_103 -->\n###### (Fisher’s exact test; 전체 셀의 20% 이상에서 기대빈도 5\n\n<!-- PAGE_103 -->\n###### 미만인 경우)을 통해 양측 유의수준 0.05에서 통계적 우월성을\n\n<!-- PAGE_103 -->\n###### : 각 시점에서 군간 답변 차이는 카이제곱검정 혹은 피셔정확\n\n<!-- PAGE_103 -->\n###### : 각 시점에서 군간 응답 빈도와 비율을 제시하고 필요 시 카이\n\n- - 97 -\n<!-- PAGE_104 -->\n###### 제곱검정 혹은 피셔정확검정을 통해 유의수준 0.05에서 통계적\n\n<!-- PAGE_104 -->\n###### 평가를 수행한다.\n\n<!-- PAGE_104 -->\n###### - 모든 분석 대상자군(Full Analysis Set, FAS)에서 중도 탈락 등의\n\n<!-- PAGE_104 -->\n###### 사유로 치료 후 시점에서 발생하는 결측치는 일차/이차 유효성\n\n<!-- PAGE_104 -->\n###### 평가변수에 대해서는 마지막 관측값 선행 대체법(Last Observation\n\n<!-- PAGE_104 -->\n###### Carried Forward, LOCF) 방법으로 대치한다. 그 외 자료는 대치\n\n<!-- PAGE_104 -->\n###### - 1차 유효성 평가 결과가 피험자의 하위집단(성별, 연령별 등)에\n\n<!-- PAGE_104 -->\n###### - 1차 유효성 평가 결과가 기관에 따라 차이가 있는지를 확인하기\n\n<!-- PAGE_104 -->\n###### 위해 기관 및 기관과 그룹 간 상호작용을 공분산 분석 모형에\n\n<!-- PAGE_104 -->\n###### - 대치 처리하지 않고 결측치를 고려한 반복 측정 혼합 모형을\n\n- - 98 -\n<!-- PAGE_105 -->\n###### 9) 안전성 평가\n\n<!-- PAGE_105 -->\n###### - 안전성 평가에서는 수집된 이상 사례의 유형, 임상시험용 의료\n\n<!-- PAGE_105 -->\n###### 기기와의 인과성, 중대성 등을 발생한 환자 수, 발생 빈도 수\n\n<!-- PAGE_105 -->\n###### 및 백분율을 군별로 제시한다. 필요하면 카이제곱검정(Chi-square\n\n<!-- PAGE_105 -->\n###### test) 혹은 피셔정확검정(Fisher’s exact test; 전체 셀의 20%\n\n<!-- PAGE_105 -->\n###### 이상에서 기대빈도 5 미만인 경우)을 통해 발생 환자 비율의\n\n- - 99 -\n<!-- PAGE_106 -->\n##### 15. 부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n<!-- PAGE_106 -->\n###### 가. 피험자 안전성\n\n<!-- PAGE_106 -->\n###### 본 임상시험은 저위험(low-risk) 치료용 의료기기의 임상적 평가\n\n<!-- PAGE_106 -->\n###### 이므로 피험자가 직접적으로 받는 인체의 위해도가 없을 수도 있다.\n\n<!-- PAGE_106 -->\n###### 하지만, 치료 도중 피험자한테 문제(예: 낮 시간 졸음이 과도한 현상 등)가\n\n<!-- PAGE_106 -->\n###### 발생하면 임상시험 담당 연구진에게 연락할 수 있는 긴급 연락망을\n\n<!-- PAGE_106 -->\n###### 제공하고, 디지털 기기(애플리케이션) 사용 관련한 문제(예: 버그 문제,\n\n<!-- PAGE_106 -->\n###### 로그인 실패 등)가 발생하면 회사 측 고객센터로 연락할 수 있는\n\n<!-- PAGE_106 -->\n###### 별도의 연락망을 제공한다. 긴급 연락망과 방문을 통해 이상 반응을\n\n<!-- PAGE_106 -->\n###### 수집한다.\n\n<!-- PAGE_106 -->\n###### 나. 시험자 안전성\n\n<!-- PAGE_106 -->\n###### 해당 임상시험용 의료기기는 소프트웨어에 속하며 비침습적이며 짧은\n\n<!-- PAGE_106 -->\n###### 기간 동안 임상시험에 참여하기 때문에 안전에 대한 위험은 없다고\n\n<!-- PAGE_106 -->\n###### 할 수 있다.\n\n- - 100 -\n<!-- PAGE_107 -->\n###### 다. 이상 사례의 정의\n\n<!-- PAGE_107 -->\n###### 1) 이상 사례(Adverse Event, AE)란 임상시험 중 피험자에게 발생한\n\n<!-- PAGE_107 -->\n###### 모든 의도하지 않은 증후(sign), 증상(symptom) 또는 질병을 말하며,\n\n<!-- PAGE_107 -->\n###### 해당 임상시험용 의료기기와 반드시 인과관계를 가져야 하는 것은\n\n<!-- PAGE_107 -->\n###### 2) 의료기기 이상 반응(Adverse Device Effect, ADE)이란 임상시험용\n\n<!-- PAGE_107 -->\n###### 의료기기로 인하여 발생한 모든 유해하고 의도하지 않은 반응으로서\n\n<!-- PAGE_107 -->\n###### 라. 이상 사례의 평가\n\n<!-- PAGE_107 -->\n###### 이상 사례 발현 시 임상시험용 의료기기와의 관련성 여부는\n\n<!-- PAGE_107 -->\n###### 시험자가 다음 기준에 의하여 평가하며, 시험자의 의견을 기술\n\n<!-- PAGE_107 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적\n\n<!-- PAGE_107 -->\n###### - 이상 반응이 다른 어떤 이유보다 임상시험용 의료기기의 사용\n\n<!-- PAGE_107 -->\n###### - 이상 반응이 임상시험용 의료기기 또는 동일 계열의 의료기기에\n\n<!-- PAGE_107 -->\n###### 대해 이미 알려진 정보와 일관된 양상을 보이는 경우\n\n- - 101 -\n<!-- PAGE_108 -->\n###### ○ 관련성이 많음(Probably related)\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n\n<!-- PAGE_108 -->\n###### - 이상 반응이 다른 원인보다 임상시험용 의료기기의 사용으로\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단으로 이상 반응이 사라지는\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n\n<!-- PAGE_108 -->\n###### - 이상 반응이 다른 가능성이 있는 원인과 같은 수준으로 임상\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단으로(실시된 경우) 이상\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단 결과(실시된 경우)가 음성\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 재사용(실시된 경우) 결과가 음성이거나\n\n- - 102 -\n<!-- PAGE_109 -->\n###### ○ 관련성이 없음(Definitely not related)\n\n<!-- PAGE_109 -->\n###### - 임상시험용 의료기기를 사용하지 않은 경우\n\n<!-- PAGE_109 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현과의 시간적\n\n<!-- PAGE_109 -->\n###### - 정보가 불충분하거나 상충하여 판단할 수 없고 이를 보완\n\n<!-- PAGE_109 -->\n###### 마. 안전성의 평가 기준\n\n<!-- PAGE_109 -->\n###### 본 임상시험에서 이상 반응은 임상시험 시작 전에 관찰되지 않은\n\n<!-- PAGE_109 -->\n###### 증상이 발생하는 모든 바람직하지 않은 의학적ㆍ물리적 소견을 이상\n\n<!-- PAGE_109 -->\n###### 반응으로 분류한다. 예측되는 부작용도 이상 반응으로 분류한다.\n\n<!-- PAGE_109 -->\n###### 바. 이상 사례 보고 방법\n\n<!-- PAGE_109 -->\n###### ○ 시험책임자는 시험담당자 또는 임상의 등에게 임상시험용 의료\n\n<!-- PAGE_109 -->\n###### 기기 사용 후 나타날 수 있는 모든 이상 사례에 대하여 교육을\n\n<!-- PAGE_109 -->\n###### 하고 사용 후 나타나는 모든 현상에 대하여 보고하도록 교육을\n\n<!-- PAGE_109 -->\n###### ※\n\n<!-- PAGE_109 -->\n###### 본 내용은「의료기기법 시행규칙」별표 3“의료기기 임상시험 관리기준” 제8호\n\n- - 103 -\n<!-- PAGE_110 -->\n###### ○ 이외에도 시험자가 중대하다고 간주하거나, 임상시험용 의료\n\n<!-- PAGE_110 -->\n###### 기기와의 사용과 연관 지을 수 있는 유의한 위험, 금기, 부작용,\n\n<!-- PAGE_110 -->\n###### 주의사항을 시사하는 사건 등도 중대한 이상사례/의료기기\n\n<!-- PAGE_110 -->\n###### 이상반응으로 기록하고 사망을 초래하거나 생명을 위협할 때는\n\n<!-- PAGE_110 -->\n###### 의뢰자가 이 사실을 보고받거나 알게 된 날로부터 7일 이내,\n\n<!-- PAGE_110 -->\n###### 이 경우 상세한 정보를 최초 보고일로부터 8일 이내에 추가로\n\n<!-- PAGE_110 -->\n###### 보고 하여야 한다. 그 밖의 중대하거나 예상하지 못한 모든\n\n<!-- PAGE_110 -->\n###### 이상 반응이 나타났을 때 의뢰자가 이 사실을 보고 받거나\n\n- - 104 -\n<!-- PAGE_111 -->\n##### 16. 피험자 동의서 서식\n\n<!-- PAGE_111 -->\n###### 가. 피험자 동의서에 반드시 포함되어야 하는 사항\n\n<!-- PAGE_111 -->\n###### 3) 임상시험용 의료기기에 관한 정보 및 시험군 또는 대조군에\n\n<!-- PAGE_111 -->\n###### 4) 침습적 시술(invasive procedure)을 포함하여 임상시험에서 피험자가\n\n<!-- PAGE_111 -->\n###### 8) 기대되는 이익이 있거나 피험자에게 기대되는 이익이 없을 경우\n\n<!-- PAGE_111 -->\n###### 9) 피험자가 선택할 수 있는 다른 치료방법이나 종류 및 그 치료\n\n- - 105 -\n<!-- PAGE_112 -->\n###### 10) 임상시험과 관련한 손상이 발생하였을 경우 피험자에게 주어질\n\n<!-- PAGE_112 -->\n###### 보상이나 치료방법\n\n<!-- PAGE_112 -->\n###### 11) 피험자가 임상시험에 참여함으로써 받게 될 금전적 보상이 있는\n\n<!-- PAGE_112 -->\n###### 경우 예상 금액 및 이 금액이 임상시험 참여의 정도나 기간에\n\n<!-- PAGE_112 -->\n###### 13) 피험자의 임상시험 참여 여부 결정은 자발적이어야 하며,\n\n<!-- PAGE_112 -->\n###### 피험자가 원래 받을 수 있는 이익에 대한 손실 없이 임상시험의\n\n<!-- PAGE_112 -->\n###### 참여를 거부하거나 임상시험 도중 언제라도 참여를 포기할 수\n\n<!-- PAGE_112 -->\n###### 14) 제8호 항목에 따른 모니터 요원, 제8호 항목에 따른 점검을\n\n<!-- PAGE_112 -->\n###### 실시하는 자, 임상시험심사위원회 및 식품의약품안전처장이 관계\n\n<!-- PAGE_112 -->\n###### 법령에 따라 임상시험의 실시 절차와 자료의 품질을 검증하기\n\n<!-- PAGE_112 -->\n###### 위하여 피험자의 신상에 관한 비밀이 보호되는 범위에서 피험자의\n\n<!-- PAGE_112 -->\n###### 의무기록을 열람할 수 있다는 사실과 피험자 또는 피험자 대리인의\n\n<!-- PAGE_112 -->\n###### 15) 피험자의 신상을 파악할 수 있는 기록은 비밀로 보호될 것이며\n\n<!-- PAGE_112 -->\n###### 임상시험의 결과가 출관될 경우 피험자의 신상은 비밀로 보호\n\n<!-- PAGE_112 -->\n###### 16) 피험자의 임상시험 계속 참여 여부에 영향을 줄 수 있는 새로운\n\n<!-- PAGE_112 -->\n###### 정보를 취득하면 적시에 피험자 또는 피험자의 대리인에게 알릴\n\n<!-- PAGE_112 -->\n###### 17) 임상시험과 피험자의 권익에 관하여 추가적인 정보를 얻고자\n\n- - 106 -\n<!-- PAGE_113 -->\n###### 하거나 임상시험과 관련이 있는 손상이 발생하면 연락해야 하는\n\n<!-- PAGE_113 -->\n###### 사람\n\n<!-- PAGE_113 -->\n###### 18) 임상시험 도중 피험자의 임상시험 참여가 중지되는 경우 및 그\n\n<!-- PAGE_113 -->\n###### 나. 피험자 동의의 일반적 요건\n\n<!-- PAGE_113 -->\n###### 1) 연구자는 연구를 시작하기 전에 임상시험심사위원회(Institutional\n\n<!-- PAGE_113 -->\n###### Review Board, IRB)로부터 피험자에게 제공될 설명서 및 동의서,\n\n<!-- PAGE_113 -->\n###### 2) 연구자는 임상시험심사위원회 승인 직인이 찍힌 동의서 등을\n\n<!-- PAGE_113 -->\n###### 피험자 또는 피험자의 대리인에게 제공해야 하며, 피험자(또는\n\n<!-- PAGE_113 -->\n###### 대리인)와 동의를 받은 책임연구자(또는 책임연구자의 위임을 받은\n\n<!-- PAGE_113 -->\n###### 자)는 동의서 서식에 서명하고, 자필로 해당 날짜를 기재하여야\n\n<!-- PAGE_113 -->\n###### 3) 연구자는 서명된 동의서를 보관해야 하며, 사본을 피험자(또는\n\n<!-- PAGE_113 -->\n###### 4) 동의서를 받는 과정에서 연구자는 피험자 또는 대리인에게 강제나\n\n<!-- PAGE_113 -->\n###### 부당한 영향을 미치지 않아야 하며, 피험자 또는 대리인이 연구의\n\n<!-- PAGE_113 -->\n###### 모든 정보를 이해할 수 있는 용어 및 언어로 작성된 동의서 등을\n\n<!-- PAGE_113 -->\n###### 제공하여 설명하고 질문에 대하여 대답한 후 충분히 생각할\n\n- - 107 -\n<!-- PAGE_114 -->\n###### 5) 피험자 동의서에는 피험자 또는 대리인의 법적 권리를 포기나\n\n<!-- PAGE_114 -->\n###### 제한, 연구자/의뢰자/기관 및 기관장의 과실 책임의 면제를 암시\n\n<!-- PAGE_114 -->\n###### 6) 피험자의 동의에 영향을 줄 수 있는 새로운 연구 관련정보가\n\n<!-- PAGE_114 -->\n###### 수집되면 동의서 서식, 피험자 설명서 및 기타 문서화된 정보는\n\n<!-- PAGE_114 -->\n###### 이에 따라 수정되어야 하며, 사용 전에 반드시 위원회의 승인을\n\n<!-- PAGE_114 -->\n###### 받아야 한다. 피험자의 지속적인 연구 참여 의지에 영향을 줄 경우\n\n<!-- PAGE_114 -->\n###### 연구 책임자는 피험자 또는 대리인에게 즉시 알리고, 이러한\n\n<!-- PAGE_114 -->\n###### 7) 피험자 또는 대리인이 동의서 등을 읽을 수 없는 경우에는 공정한\n\n<!-- PAGE_114 -->\n###### 다. 임상시험 실시 도중 피험자 설명문 등이 변경되었을 때 재동의\n\n<!-- PAGE_114 -->\n###### 임상시험 실시 도중 동의서 서식이 변경되거나, 피험자에게 제공된\n\n<!-- PAGE_114 -->\n###### 문서 정보의 변경이 있는 경우에는 변경일 기준 다음 방문일에 변경\n\n<!-- PAGE_114 -->\n###### 내용을 피험자에게 충분히 설명하고, 시험책임자(또는 시험담당의사)와\n\n<!-- PAGE_114 -->\n###### 피험자는 변경동의서에 서명하고 해당 날짜를 자필로 적어야 한다.\n\n<!-- PAGE_114 -->\n###### 라. 피험자의 대리인이 피험자를 대신하여 임상시험 참여에 동의\n\n<!-- PAGE_114 -->\n###### 피험자의 이해능력, 의사표현능력의 결여 등의 사유로 동의를 받을\n\n<!-- PAGE_114 -->\n###### 수 없는 경우에는 대리인의 동의를 받을 수 있으며, 이와 같은 경우\n\n<!-- PAGE_114 -->\n###### 에도 피험자는 피험자 자신이 이해할 수 있는 정도까지 임상시험에\n\n<!-- PAGE_114 -->\n###### 관한 정보를 제공 받아야하며, 가능하다면 피험자는 동의서 서식에\n\n- - 108 -\n<!-- PAGE_115 -->\n###### 서명하고 자필로 날짜를 기재하여야 한다. 또한, 피험자의 대리인임을\n\n<!-- PAGE_115 -->\n###### 확인할 수 있는 근거자료 등을 확보하고, 피험자 동의 설명서 등에\n\n<!-- PAGE_115 -->\n###### 대리인의 동의 사유를 구체적으로 기술할 것을 권장한다.\n\n- - 109 -\n<!-- PAGE_116 -->\n##### 17. 피해자 보상에 대한 규약\n\n<!-- PAGE_116 -->\n###### 임상시험용 의료기기가 직접적 원인이 되어 피험자에게 손상이\n\n<!-- PAGE_116 -->\n###### 발생하여 응급조치가 필요한 경우 시험책임자가 가입한 보험에 의해\n\n<!-- PAGE_116 -->\n###### 보상한다. 본 임상시험과 관련이 없는 부작용이 발생한 경우에도\n\n<!-- PAGE_116 -->\n###### 해당 과와의 긴밀한 협조를 통하여 신속한 검사와 처치를 시행한다.\n\n<!-- PAGE_116 -->\n###### 예상된 의료기기 이상반응에 대하여 당사자들 간에 미리 합의한\n\n<!-- PAGE_116 -->\n###### 보상액 또는 조치가 있는 경우, 당해 기준에 따라 이를 보상한다.\n\n<!-- PAGE_116 -->\n###### 그 외의 경우에는 신체손상의 정도, 성격, 지속기간, 유사사례 등을\n\n<!-- PAGE_116 -->\n###### 종합적으로 고려하여 당사자들 간에 합의한 보상방법에 따라 이를\n\n<!-- PAGE_116 -->\n###### 보상한다. 당사자들 간에 전항의 합의가 이루어지지 아니한 경우에는,\n\n<!-- PAGE_116 -->\n###### 법원의 판결 및 이에 준하는 결정의 확정내용에 따라 보상한다.\n\n- - 110 -\n<!-- PAGE_117 -->\n##### 18. 임상시험 후 피험자의 진료에 관한 사항\n\n<!-- PAGE_117 -->\n###### 본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 OO병원\n\n<!-- PAGE_117 -->\n###### 에서 진행하던 치료절차가 임상시험 참여 전과 다름없이 진행되며,\n\n<!-- PAGE_117 -->\n###### 이후의 치료비는 피험자가 지불하여야 한다. 다만, 부작용 발생 시\n\n<!-- PAGE_117 -->\n###### 임상시험에 사용된 의료기기와의 인과관계 유무를 확인한 후,\n\n<!-- PAGE_117 -->\n###### 본 임상시험에 사용된 의료기기로 인하여 부작용이 발생한 경우\n\n<!-- PAGE_117 -->\n###### ㈜OOO에서 치료에 관한 부작용이 소실될 때까지 치료비를 지불한다.\n\n- - 111 -\n<!-- PAGE_118 -->\n##### 19. 피험자의 안전보호에 대한 대책\n\n<!-- PAGE_118 -->\n###### 가. 임상시험 실시기관\n\n<!-- PAGE_118 -->\n###### 임상시험 실시기관의 장은 해당 임상시험의 실시에 필요한 임상\n\n<!-- PAGE_118 -->\n###### 시험실, 설비와 전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를\n\n<!-- PAGE_118 -->\n###### 취할 수 있도록 하는 등 해당 임상시험을 적절하게 실시할 수 있도록\n\n<!-- PAGE_118 -->\n###### 하여야 한다.\n\n<!-- PAGE_118 -->\n###### 나. 임상시험심사위원회\n\n<!-- PAGE_118 -->\n###### 1) 임상시험심사위원회는 국내 법규/관례에 따라 구성되어 있어야\n\n<!-- PAGE_118 -->\n###### 한다. 임상시험심사위원회는 피험자의 권리, 안전, 복지를 보호해야\n\n<!-- PAGE_118 -->\n###### 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에는\n\n<!-- PAGE_118 -->\n###### 2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가\n\n<!-- PAGE_118 -->\n###### 동의가 적절하게 얻어지지 않았거나 임상시험이 임상시험계획서에\n\n<!-- PAGE_118 -->\n###### 따라 진행되지 않은 경우 또는 중대한 이상사례/의료기기 이상반응이\n\n<!-- PAGE_118 -->\n###### 나타난 경우에는 임상시험의 일부 또는 전부에 대하여 중지 명령\n\n- - 112 -\n<!-- PAGE_119 -->\n###### 다. 시험자\n\n<!-- PAGE_119 -->\n###### 1) 시험자(Investigator)란 시험책임자, 시험담당자, 임상시험조정자를\n\n<!-- PAGE_119 -->\n###### 말한다. 시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품\n\n<!-- PAGE_119 -->\n###### 의약품안전처장의 승인을 득한 임상시험 계획서를 준수하여\n\n<!-- PAGE_119 -->\n###### 2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미\n\n<!-- PAGE_119 -->\n###### 있는 시험실적 검사치의 이상을 포함하여 임상시험에서 발생한\n\n<!-- PAGE_119 -->\n###### 모든 이상반응에 대해 피험자가 적절한 의학적 처치를 받을 수\n\n<!-- PAGE_119 -->\n###### 있도록 조치하여야 하고, 시험자가 알게 된 피험자의 병발질환에\n\n<!-- PAGE_119 -->\n###### 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려주어야 한다.\n\n<!-- PAGE_119 -->\n###### 3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의\n\n<!-- PAGE_119 -->\n###### 라. 의뢰자\n\n<!-- PAGE_119 -->\n###### 1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로\n\n<!-- PAGE_119 -->\n###### 통상의료기기 임상시험의 경우 의료기기 제조업자(수입자를 포함\n\n<!-- PAGE_119 -->\n###### 2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상\n\n<!-- PAGE_119 -->\n###### 3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상\n\n<!-- PAGE_119 -->\n###### 시험의 종류와 복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의\n\n<!-- PAGE_119 -->\n###### 정도 및 이미 확인된 임상시험 실시상의 문제점 등에 따라 결정\n\n- - 113 -\n<!-- PAGE_120 -->\n###### 마. 모니터링\n\n<!-- PAGE_120 -->\n###### 1) 모니터링(Monitoring)이란 임상시험 진행 과정을 감독하고, 해당\n\n<!-- PAGE_120 -->\n###### 임상시험이 임상시험계획서, 표준작업지침서, 임상시험 실시 기준\n\n<!-- PAGE_120 -->\n###### 및 관련 규정에 따라 실시, 기록되는지 여부를 검토, 확인하는\n\n<!-- PAGE_120 -->\n###### 2) 임상시험에 대한 모니터링은 임상시험모니터요원의 정기적인 임상\n\n<!-- PAGE_120 -->\n###### 시험 실시기관 방문과 전화 등을 통해서 이루어질 것이다. 방문 시\n\n<!-- PAGE_120 -->\n###### 모니터는 환자기록 원본, 임상시험용 의료기기 관리 기록, 자료\n\n<!-- PAGE_120 -->\n###### 3) 또한 임상시험모니터 요원은 임상시험 진행과정을 잘 살피고,\n\n<!-- PAGE_120 -->\n###### 바. 임상시험계획서의 변경\n\n<!-- PAGE_120 -->\n###### 1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장\n\n<!-- PAGE_120 -->\n###### 으로부터 승인받은 후, 시험절차가 광범위해지거나 위험도가\n\n<!-- PAGE_120 -->\n###### 높아지거나 피험자 선정기준에 변화가 있거나 추가적인 안전성\n\n<!-- PAGE_120 -->\n###### 정보로 인해 임사시험계획서를 변경하는 경우에는 임상시험심사\n\n<!-- PAGE_120 -->\n###### 2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정\n\n<!-- PAGE_120 -->\n###### 3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한\n\n<!-- PAGE_120 -->\n###### 경우를 제외하고는, 임상시험심사위원회- 및 식품의약품안전처장의\n\n<!-- PAGE_120 -->\n###### 변경 승인 이전에는 계획서와 다르게 임상시험을 실시하여서는\n\n- - 114 -\n<!-- PAGE_121 -->\n###### 안 된다. 만일 피험자에게 발생한 즉각적 위험요소를 제거하기\n\n<!-- PAGE_121 -->\n###### 위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험\n\n<!-- PAGE_121 -->\n###### 계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에\n\n<!-- PAGE_121 -->\n###### 대하여 임상시험심사위원회(사후검토 승인을 위함), 의뢰자, 식품\n\n<!-- PAGE_121 -->\n###### 의약품안전처장에게 제출하여야 한다. 그리고 임상시험심사위원회\n\n<!-- PAGE_121 -->\n###### 4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이\n\n<!-- PAGE_121 -->\n###### 사. 피험자 동의\n\n<!-- PAGE_121 -->\n###### 1) 피험자 동의(Informed consent)라 함은 피험자가 임상시험 참여\n\n<!-- PAGE_121 -->\n###### 유무를 결정하기 전에 피험자를 위한 설명서를 통해 해당 임상\n\n<!-- PAGE_121 -->\n###### 시험과 관련된 모든 정보를 제공받고, 서명과 서명 날짜가 포함된\n\n<!-- PAGE_121 -->\n###### 문서를 통해 본인이 자발적으로 임상시험에 참여함을 확인하는\n\n<!-- PAGE_121 -->\n###### 2) 피험자 본인 또는 대리인이 동의서 서식, 피험자 설명서 및 기타\n\n<!-- PAGE_121 -->\n###### 문서화된 정보를 읽을 수 없는 경우에는 공정한 입회자가 동의를\n\n<!-- PAGE_121 -->\n###### 3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의\n\n<!-- PAGE_121 -->\n###### 세부 사항에 대해 질문하고 해당 임상시험의 참여 여부를 결정\n\n<!-- PAGE_121 -->\n###### 할 수 있도록 충분한 시간과 기회를 주어야 하며, 모든 임상시험\n\n<!-- PAGE_121 -->\n###### 관련 질문에 대해 피험자 또는 대리인이 만족할 수 있도록 대답\n\n- - 115 -\n<!-- PAGE_122 -->\n###### 아. 피험자 기록의 비밀보장\n\n<!-- PAGE_122 -->\n###### 1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며,\n\n<!-- PAGE_122 -->\n###### 임상시험의 결과가 출관 될 경우에도 피험자의 신원을 비밀상태로\n\n<!-- PAGE_122 -->\n###### 2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의\n\n<!-- PAGE_122 -->\n###### 모니터링과 점검 및 진행사항 관리를 위한 목적으로 피험자의\n\n<!-- PAGE_122 -->\n###### 기록을 열람할 수 있다. 시험자는 본 임상시험 계획서에 서명함\n\n<!-- PAGE_122 -->\n###### 으로써, 국내의 법규와 윤리적 측면에서 임상시험 의뢰자 또는\n\n<!-- PAGE_122 -->\n###### 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을 검증하기\n\n<!-- PAGE_122 -->\n###### 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.\n\n<!-- PAGE_122 -->\n###### 3) 증례기록서 등 임상시험에 관련된 모든 서류에는 피험자 이름이\n\n<!-- PAGE_122 -->\n###### 아닌 피험자 식별코드(일반적으로 피험자 이니셜)로 기록하고\n\n<!-- PAGE_122 -->\n###### 자. 기록의 보존\n\n<!-- PAGE_122 -->\n###### 1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록\n\n<!-- PAGE_122 -->\n###### 하여야 하며 보안을 유지하도록 한다. 제조허가/수입허가 또는\n\n<!-- PAGE_122 -->\n###### 그 변경 허가를 위한 임상시험 관련 자료는 허가일로부터 3년간\n\n<!-- PAGE_122 -->\n###### 보존하도록 하고, 그 밖의 임상시험 관련 자료는 임상시험이 끝난\n\n<!-- PAGE_122 -->\n###### 날부터 3년간 보존하도록 한다. 다만, 식품의약품안전처장이 지시\n\n<!-- PAGE_122 -->\n###### 하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을\n\n- - 116 -\n<!-- PAGE_123 -->\n###### 20. 그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n<!-- PAGE_123 -->\n###### 가. 자료 처리\n\n<!-- PAGE_123 -->\n###### 본 임상시험에 관련된 모니터 및 점검자는 본 임상시험의\n\n<!-- PAGE_123 -->\n###### 모니터링과 점검 및 진행사항 관리를 위한 목적으로 대상자의\n\n<!-- PAGE_123 -->\n###### 임상시험용 의료기기와 연관된 유의한 위험, 금기, 부작용, 주의\n\n<!-- PAGE_123 -->\n###### 사항을 시사하는 사건 등을 포함하며, 발생시간, 정도, 처치, 경과,\n\n<!-- PAGE_123 -->\n###### 임상시험용 의료기기와의 인과관계 등에 대한 정보를 증례기록서에\n\n<!-- PAGE_123 -->\n###### 나. 법규준수\n\n<!-- PAGE_123 -->\n###### 시험자는 서명록에 서명함으로써, 본 임상시험계획서, 의료기기\n\n<!-- PAGE_123 -->\n###### 임상시험 관리기준, 국내의 모든 관련 법규와 임상시험 수행에 관련된\n\n<!-- PAGE_123 -->\n###### 규칙 및 규정에 따라서 효과적이고 성실하게 연구를 수행할 것에\n\n- - 117 -\n<!-- PAGE_124 -->\n###### 동의하게 된다. 임상시험 담당자 및 참여 연구진은 임상시험계획을\n\n<!-- PAGE_124 -->\n###### 정확히 분석, 숙지하도록 하며 시험책임자는 예기치 않은 이상반응\n\n<!-- PAGE_124 -->\n###### 등의 출현에 대한 충분한 대처와 필요에 따른 보고, 시험참여 연구진에\n\n<!-- PAGE_124 -->\n###### 대한 충분한 교육 등 사전조치를 취한다. 임상시험의 진행은 의료기기\n\n<!-- PAGE_124 -->\n###### 임상시험 관리 기준에 합당하게 진행한다.\n\n<!-- PAGE_124 -->\n###### 다. 임상시험 자료의 보관 및 열람\n\n<!-- PAGE_124 -->\n###### 임상시험 자료는 기밀로 보관되고 열람은 본 임상시험의 모니터링과\n\n<!-- PAGE_124 -->\n###### 점검 및 진행 사항 관리를 위한 목적으로 대상자의 기록을 열람할 수\n\n<!-- PAGE_124 -->\n###### 있다.\n\n<!-- PAGE_124 -->\n###### 라. 점검 및 실태조사\n\n<!-- PAGE_124 -->\n###### 임상시험의 중요도, 대상자 수, 임상시험의 종류와 복잡성, 대상자\n\n<!-- PAGE_124 -->\n###### 에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n<!-- PAGE_124 -->\n###### 실시상의 문제점 등에 따라 결정된다.\n\n<!-- PAGE_124 -->\n###### 마. 임상시험용 의료기기의 사용 및 관리\n\n<!-- PAGE_124 -->\n###### 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가\n\n<!-- PAGE_124 -->\n###### 관리한다. 임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급,\n\n<!-- PAGE_124 -->\n###### 저장하며 “임상시험용”이라는 문구가 있어야 한다. 임상시험용 의료\n\n<!-- PAGE_124 -->\n###### 기기 관리자는 임상시험에 사용되는 의료기기에 대해 인수, 재고관리,\n\n<!-- PAGE_124 -->\n###### 반납 등의 업무를 수행하고 관련 기록을 유지하여야 한다.\n\n- - 118 -\n<!-- PAGE_125 -->\n###### 바. 임상시험용 의료기기의 공급과 취급\n\n<!-- PAGE_125 -->\n###### 1) 의뢰자는 임상시험계획서에 대한 심사위원회와 청장의 승인을\n\n<!-- PAGE_125 -->\n###### 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는\n\n<!-- PAGE_125 -->\n###### 2) 의뢰자는 관리자 등이 임상시험용 의료기기를 취급하고 보관하는\n\n<!-- PAGE_125 -->\n###### 방법에 대해 문서화된 절차를 가지고 있어야 하며, 이 절차에는\n\n<!-- PAGE_125 -->\n###### 적절하고 안전한 수, 취급, 보관, 미사용 임상시험용 의료기기의\n\n<!-- PAGE_125 -->\n###### 피험자로부터의 반납 및 의뢰자에 대한 반납 등에 대한 방법이\n\n<!-- PAGE_125 -->\n###### 3) 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관\n\n<!-- PAGE_125 -->\n###### 으로의 공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납\n\n<!-- PAGE_125 -->\n###### 4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상\n\n<!-- PAGE_125 -->\n###### 시험의 종료 또는 사용기간의 만료 등에 의한 임상시험용 의료\n\n- - 119 -\n<!-- PAGE_126 -->\n### Ⅳ\n\n<!-- PAGE_126 -->\n### 참고문헌\n\n- 1. 2020년 국민건강영양조사, 질병관리청, 2020.12\n- 2. 일차 의료용 근거 기반 우울장애 임상진료지침, 대한의학회, 2022\n- 3. 권정혜, & 이재우. (2001). 우울증의 인지행동치료. 인지행동치료, 1, 1-22.\n- 4. 이삼연. (1999). 인지-행동치료의 우울증 사정과 개입전략. 한국가족복지학, 4, 189-218.\n- 5. Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., ... & CANMAT\nDepression Work Group. (2016). Canadian Network for Mood and Anxiety Treatments (CANMAT)\n\n2016 clinical guidelines for the management of adults with major depressive disorder: section 3.\n\n- 6. Gelenberg, A. J., Freeman, M. P., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H.,\n& Van Rhoads, R. S. (2010). American Psychiatric Association practice guidelines for the treatment\n\n- 7. Anderson, I. M., Ferrier, I. N., Baldwin, R. C., Cowen, P. J., Howard, L., Lewis, G., ... & Tylee, A.\n- (2008). Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of\nthe 2000 British Association for Psychopharmacology guidelines. Journal of psychopharmacology,\n\n- 8. Andrews, G., Basu, A., Cuijpers, P., Craske, M. G., McEvoy, P., English, C. L., & Newby, J. M.\n- (2018). Computer therapy for the anxiety and depression disorders is effective, acceptable and\n- 9. Fischer, A., Schröder, J., Vettorazzi, E., Wolf, O. T., Pöttgen, J., Lau, S., ... & Gold, S. M. (2015). An\nonline programme to reduce depression in patients with multiple sclerosis: a randomised controlled\n\n- 10. Berger, T., Hämmerli, K., Gubser, N., Andersson, G., & Caspar, F. (2011). Internet-based treatment\nof depression: a randomized controlled trial comparing guided with unguided self-help. Cognitive\n\n- 11. Klein, J. P., Berger, T., Schröder, J., Späth, C., Meyer, B., Caspar, F., ... & Hohagen, F. (2016).\nEffects of a psychological internet intervention in the treatment of mild to moderate depressive\n\nsymptoms: results of the EVIDENT study, a randomized controlled trial. Psychotherapy and\n\n- 12. Beevers, C. G., Pearson, R., Hoffman, J. S., Foulser, A. A., Shumake, J., & Meyer, B. (2017).\nEffectiveness of an internet intervention (Deprexis) for depression in a united states adult sample:\n\nA parallel-group pragmatic randomized controlled trial. Journal of consulting and clinical psychology,\n\n- 13. Meyer, B., Bierbrodt, J., Schröder, J., Berger, T., Beevers, C. G., Weiss, M., ... & Klein, J. P.\n- (2015). Effects of an Internet intervention (Deprexis) on severe depression symptoms: randomized\n- 14. Krämer, R., & Köhler, S. (2021). Evaluation of the online-based self-help programme “Selfapy” in\npatients with unipolar depression: study protocol for a randomized, blinded parallel group\n\n- 15. Schure, M. B., Lindow, J. C., Greist, J. H., Nakonezny, P. A., Bailey, S. J., Bryan, W. L., & Byerly,\n- - 120 -\nM. J. (2019). Use of a fully automated internet-based cognitive behavior therapy intervention in a\n\ncommunity population of adults with depression symptoms: randomized controlled trial. Journal of\n\n- 16. Deprexis  홈페이지, https://uk.deprexis.com/\n- 17. Selfapy 홈페이지, https://www.selfapy.com/\n- 18. Thrive 홈페이지, https://play.google.com/store/apps/details?id=com.waypointhealth.thrive&hl=ko\n- 19. NOVEGO 홈페이지, https://www.novego.de\n- 20. SparkRx 홈페이지, https://www.sparkrx.com\n- 21. SilverCloud 홈페이지, https://health.colostate.edu/silvercloud/\n- 22. 디지털치료기기 허가·심사 가이드라인 민원인 안내서, 식품의약품안전처 2020.08\n- 23. 의료기기의 사이버 보안 허가·심사 가이드라인 민원인안내서 2022.1. 21\n- 24. 의료기기 소프트웨어 허가·심사 가이드라인, 식품의약품안전처, 2018.06\n- 25. 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인 민원인 안내서 2019. 02.\n- 26. 의료기기 소프트웨어 밸리데이션 가이드라인, 식품의약품안전처, 2007.03\n- 27. 소프트웨어 밸리데이션 규격 안내서, 디지털헬스케어 소프트웨어 시험평가센터, 2018.07\n- 28. 니코틴 사용장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원\n- 29. 알코올 사용장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원\n- 30. 불면증 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원인 안내서,\n- 31. Van Hees, M. L., Rotter, T., Ellermann, T., & Evers, S. M. (2013). The effectiveness of individual\ninterpersonal psychotherapy as a treatment for major depressive disorder in adult outpatients: a\n\n- 32. Andersson, G., Bergström, J., Holländare, F., Carlbring, P. E. R., Kaldo, V., & Ekselius, L. (2005).\nInternet-based self-help for depression: randomised controlled trial. The British Journal of\n\n- 33. Twomey, C., O’Reilly, G., Bültmann, O., & Meyer, B. (2020). Effectiveness of a tailored,\nintegrative Internet intervention (deprexis) for depression: Updated meta-analysis. PLoS One, 15(1),\n\n- 34. Meyer, B., Berger, T., Caspar, F., Beevers, C., Andersson, G., & Weiss, M. (2009). Effectiveness of\na novel integrative online treatment for depression (Deprexis): randomized controlled trial. Journal\n\n- 35. Vernmark, K., Lenndin, J., Bjärehed, J., Carlsson, M., Karlsson, J., Öberg, J., ... & Andersson, G.\n- (2010). Internet administered guided self-help versus individualized e-mail therapy: A randomized\n- 36. Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., & Erbaugh, J. (1961). An inventory for",
  "chunks": [
    {
      "chunk_id": "chunk_001",
      "text": "<!-- PAGE_1 -->\n## 우울장애 개선 디지털치료기기\n\n<!-- PAGE_1 -->\n## 안전성·성능 평가 및 임상시험계획서\n\n<!-- PAGE_1 -->\n## 작성 가이드라인(민원인 안내서)\n\n- 2022. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 0,
        "window_size": 3,
        "char_count": 122,
        "word_count": 24,
        "page_number": 1,
        "window_text": "<!-- PAGE_1 -->\n## 우울장애 개선 디지털치료기기\n\n<!-- PAGE_1 -->\n## 안전성·성능 평가 및 임상시험계획서\n\n<!-- PAGE_1 -->\n## 작성 가이드라인(민원인 안내서)\n\n- 2022.  12.\n 의 료 기 기 심 사 부\n\n<!-- PAGE_3 -->\n#### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n우울장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 소프트웨어 | 6 | 1 | 2 | 2 | Acceptable | 위험 < | 2) 사용 환경 : 병원 내 사용, 병원 외 사용 | 으로서, 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시 | 진행이 피험자의 안전 보호를 위협하여 그 진행을 멈추는 것을 ‘중지’라 하며, 임상 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 개발 계획 | 포함하고 싶은 일, 수행하여야 할 일, 특히 즐거움을 주는 활동 | 반박할 수 있는 증거를 생각해 내는 것이다. ",
        "original_sentence": "<!-- PAGE_1 -->\n## 우울장애 개선 디지털치료기기\n\n<!-- PAGE_1 -->\n## 안전성·성능 평가 및 임상시험계획서\n\n<!-- PAGE_1 -->\n## 작성 가이드라인(민원인 안내서)\n\n- 2022. "
      }
    },
    {
      "chunk_id": "chunk_002",
      "text": "12.\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 1,
        "window_size": 3,
        "char_count": 4,
        "word_count": 1,
        "page_number": 1,
        "window_text": "<!-- PAGE_1 -->\n## 우울장애 개선 디지털치료기기\n\n<!-- PAGE_1 -->\n## 안전성·성능 평가 및 임상시험계획서\n\n<!-- PAGE_1 -->\n## 작성 가이드라인(민원인 안내서)\n\n- 2022.  12.\n 의 료 기 기 심 사 부\n\n<!-- PAGE_3 -->\n#### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n우울장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 소프트웨어 | 6 | 1 | 2 | 2 | Acceptable | 위험 < | 2) 사용 환경 : 병원 내 사용, 병원 외 사용 | 으로서, 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시 | 진행이 피험자의 안전 보호를 위협하여 그 진행을 멈추는 것을 ‘중지’라 하며, 임상 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 개발 계획 | 포함하고 싶은 일, 수행하여야 할 일, 특히 즐거움을 주는 활동 | 반박할 수 있는 증거를 생각해 내는 것이다.  | 환자는 이와 같은 오류나 왜곡을 깨닫게 되고 그들을 수정하려고 | – Part 2-1: Step by step | 개발 활동을 위하여 소프트웨어 | 가상·증강(VR·AR) 기반 소프트웨어를 포함 | 의료기기의 위험관리 | □ 예 | ■ 아니오 | 국외 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 벡 자살 사고 척도 | 생각, 자기에 대한 부정적 생각, 우울 기분, 신체화 증상, 의욕 | “white-box” 방법으로 수행한다. ",
        "original_sentence": "12.\n"
      }
    },
    {
      "chunk_id": "chunk_003",
      "text": "의 료 기 기 심 사 부\n\n<!-- PAGE_3 -->\n#### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n우울장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 2,
        "window_size": 3,
        "char_count": 143,
        "word_count": 31,
        "page_number": 3,
        "window_text": "<!-- PAGE_1 -->\n## 우울장애 개선 디지털치료기기\n\n<!-- PAGE_1 -->\n## 안전성·성능 평가 및 임상시험계획서\n\n<!-- PAGE_1 -->\n## 작성 가이드라인(민원인 안내서)\n\n- 2022.  12.\n 의 료 기 기 심 사 부\n\n<!-- PAGE_3 -->\n#### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n우울장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 소프트웨어 | 6 | 1 | 2 | 2 | Acceptable | 위험 < | 2) 사용 환경 : 병원 내 사용, 병원 외 사용 | 으로서, 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시 | 진행이 피험자의 안전 보호를 위협하여 그 진행을 멈추는 것을 ‘중지’라 하며, 임상 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 개발 계획 | 포함하고 싶은 일, 수행하여야 할 일, 특히 즐거움을 주는 활동 | 반박할 수 있는 증거를 생각해 내는 것이다.  | 환자는 이와 같은 오류나 왜곡을 깨닫게 되고 그들을 수정하려고 | – Part 2-1: Step by step | 개발 활동을 위하여 소프트웨어 | 가상·증강(VR·AR) 기반 소프트웨어를 포함 | 의료기기의 위험관리 | □ 예 | ■ 아니오 | 국외 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 벡 자살 사고 척도 | 생각, 자기에 대한 부정적 생각, 우울 기분, 신체화 증상, 의욕 | “white-box” 방법으로 수행한다.  | 및 유효성 확인’ 자료 등 허가·심사 시 |\n| 6) 사용자 반응 평가(순응도, 만족도, 난이도, 개선점 등) | 제시한다. ",
        "original_sentence": "의 료 기 기 심 사 부\n\n<!-- PAGE_3 -->\n#### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n우울장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_004",
      "text": "**[표 시작]**\n\n| 소프트웨어 | 6 | 1 | 2 | 2 | Acceptable | 위험 < | 2) 사용 환경 : 병원 내 사용, 병원 외 사용 | 으로서, 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시 | 진행이 피험자의 안전 보호를 위협하여 그 진행을 멈추는 것을 ‘중지’라 하며, 임상 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 개발 계획 | 포함하고 싶은 일, 수행하여야 할 일, 특히 즐거움을 주는 활동 | 반박할 수 있는 증거를 생각해 내는 것이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 3,
        "window_size": 3,
        "char_count": 283,
        "word_count": 81,
        "page_number": 9,
        "window_text": "<!-- PAGE_1 -->\n## 우울장애 개선 디지털치료기기\n\n<!-- PAGE_1 -->\n## 안전성·성능 평가 및 임상시험계획서\n\n<!-- PAGE_1 -->\n## 작성 가이드라인(민원인 안내서)\n\n- 2022.  12.\n 의 료 기 기 심 사 부\n\n<!-- PAGE_3 -->\n#### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n우울장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 소프트웨어 | 6 | 1 | 2 | 2 | Acceptable | 위험 < | 2) 사용 환경 : 병원 내 사용, 병원 외 사용 | 으로서, 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시 | 진행이 피험자의 안전 보호를 위협하여 그 진행을 멈추는 것을 ‘중지’라 하며, 임상 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 개발 계획 | 포함하고 싶은 일, 수행하여야 할 일, 특히 즐거움을 주는 활동 | 반박할 수 있는 증거를 생각해 내는 것이다.  | 환자는 이와 같은 오류나 왜곡을 깨닫게 되고 그들을 수정하려고 | – Part 2-1: Step by step | 개발 활동을 위하여 소프트웨어 | 가상·증강(VR·AR) 기반 소프트웨어를 포함 | 의료기기의 위험관리 | □ 예 | ■ 아니오 | 국외 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 벡 자살 사고 척도 | 생각, 자기에 대한 부정적 생각, 우울 기분, 신체화 증상, 의욕 | “white-box” 방법으로 수행한다.  | 및 유효성 확인’ 자료 등 허가·심사 시 |\n| 6) 사용자 반응 평가(순응도, 만족도, 난이도, 개선점 등) | 제시한다.  그 밖에 임상시험 결과의 사용 범위에 따른 성능 평가를 위하여 | 80001-2-1 | software | 데이터 손실 | 장애에 관한 것이다. ",
        "original_sentence": "**[표 시작]**\n\n| 소프트웨어 | 6 | 1 | 2 | 2 | Acceptable | 위험 < | 2) 사용 환경 : 병원 내 사용, 병원 외 사용 | 으로서, 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시 | 진행이 피험자의 안전 보호를 위협하여 그 진행을 멈추는 것을 ‘중지’라 하며, 임상 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 개발 계획 | 포함하고 싶은 일, 수행하여야 할 일, 특히 즐거움을 주는 활동 | 반박할 수 있는 증거를 생각해 내는 것이다. "
      }
    },
    {
      "chunk_id": "chunk_005",
      "text": "| 환자는 이와 같은 오류나 왜곡을 깨닫게 되고 그들을 수정하려고 | – Part 2-1: Step by step | 개발 활동을 위하여 소프트웨어 | 가상·증강(VR·AR) 기반 소프트웨어를 포함 | 의료기기의 위험관리 | □ 예 | ■ 아니오 | 국외 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 벡 자살 사고 척도 | 생각, 자기에 대한 부정적 생각, 우울 기분, 신체화 증상, 의욕 | “white-box” 방법으로 수행한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 4,
        "window_size": 3,
        "char_count": 356,
        "word_count": 104,
        "page_number": 9,
        "window_text": "12.\n 의 료 기 기 심 사 부\n\n<!-- PAGE_3 -->\n#### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n우울장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 소프트웨어 | 6 | 1 | 2 | 2 | Acceptable | 위험 < | 2) 사용 환경 : 병원 내 사용, 병원 외 사용 | 으로서, 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시 | 진행이 피험자의 안전 보호를 위협하여 그 진행을 멈추는 것을 ‘중지’라 하며, 임상 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 개발 계획 | 포함하고 싶은 일, 수행하여야 할 일, 특히 즐거움을 주는 활동 | 반박할 수 있는 증거를 생각해 내는 것이다.  | 환자는 이와 같은 오류나 왜곡을 깨닫게 되고 그들을 수정하려고 | – Part 2-1: Step by step | 개발 활동을 위하여 소프트웨어 | 가상·증강(VR·AR) 기반 소프트웨어를 포함 | 의료기기의 위험관리 | □ 예 | ■ 아니오 | 국외 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 벡 자살 사고 척도 | 생각, 자기에 대한 부정적 생각, 우울 기분, 신체화 증상, 의욕 | “white-box” 방법으로 수행한다.  | 및 유효성 확인’ 자료 등 허가·심사 시 |\n| 6) 사용자 반응 평가(순응도, 만족도, 난이도, 개선점 등) | 제시한다.  그 밖에 임상시험 결과의 사용 범위에 따른 성능 평가를 위하여 | 80001-2-1 | software | 데이터 손실 | 장애에 관한 것이다.  이들 문항 중 10개는 증상이 없는 것 | 사항 | 완료 | 허용가능 | 관리 계획을 수립한다. ",
        "original_sentence": "| 환자는 이와 같은 오류나 왜곡을 깨닫게 되고 그들을 수정하려고 | – Part 2-1: Step by step | 개발 활동을 위하여 소프트웨어 | 가상·증강(VR·AR) 기반 소프트웨어를 포함 | 의료기기의 위험관리 | □ 예 | ■ 아니오 | 국외 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 벡 자살 사고 척도 | 생각, 자기에 대한 부정적 생각, 우울 기분, 신체화 증상, 의욕 | “white-box” 방법으로 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_006",
      "text": "| 및 유효성 확인’ 자료 등 허가·심사 시 |\n| 6) 사용자 반응 평가(순응도, 만족도, 난이도, 개선점 등) | 제시한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 5,
        "window_size": 3,
        "char_count": 72,
        "word_count": 20,
        "page_number": 30,
        "window_text": "의 료 기 기 심 사 부\n\n<!-- PAGE_3 -->\n#### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n우울장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 소프트웨어 | 6 | 1 | 2 | 2 | Acceptable | 위험 < | 2) 사용 환경 : 병원 내 사용, 병원 외 사용 | 으로서, 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시 | 진행이 피험자의 안전 보호를 위협하여 그 진행을 멈추는 것을 ‘중지’라 하며, 임상 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 개발 계획 | 포함하고 싶은 일, 수행하여야 할 일, 특히 즐거움을 주는 활동 | 반박할 수 있는 증거를 생각해 내는 것이다.  | 환자는 이와 같은 오류나 왜곡을 깨닫게 되고 그들을 수정하려고 | – Part 2-1: Step by step | 개발 활동을 위하여 소프트웨어 | 가상·증강(VR·AR) 기반 소프트웨어를 포함 | 의료기기의 위험관리 | □ 예 | ■ 아니오 | 국외 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 벡 자살 사고 척도 | 생각, 자기에 대한 부정적 생각, 우울 기분, 신체화 증상, 의욕 | “white-box” 방법으로 수행한다.  | 및 유효성 확인’ 자료 등 허가·심사 시 |\n| 6) 사용자 반응 평가(순응도, 만족도, 난이도, 개선점 등) | 제시한다.  그 밖에 임상시험 결과의 사용 범위에 따른 성능 평가를 위하여 | 80001-2-1 | software | 데이터 손실 | 장애에 관한 것이다.  이들 문항 중 10개는 증상이 없는 것 | 사항 | 완료 | 허용가능 | 관리 계획을 수립한다.  |\n| 2) 유의수준 | 제조자는 데이터 부인방지(non-repudiation)를 | 제품명(제조업체) | 지침서ㆍ안내서가 있습니까? ",
        "original_sentence": "| 및 유효성 확인’ 자료 등 허가·심사 시 |\n| 6) 사용자 반응 평가(순응도, 만족도, 난이도, 개선점 등) | 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_007",
      "text": "그 밖에 임상시험 결과의 사용 범위에 따른 성능 평가를 위하여 | 80001-2-1 | software | 데이터 손실 | 장애에 관한 것이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 6,
        "window_size": 3,
        "char_count": 81,
        "word_count": 21,
        "page_number": 9,
        "window_text": "**[표 시작]**\n\n| 소프트웨어 | 6 | 1 | 2 | 2 | Acceptable | 위험 < | 2) 사용 환경 : 병원 내 사용, 병원 외 사용 | 으로서, 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시 | 진행이 피험자의 안전 보호를 위협하여 그 진행을 멈추는 것을 ‘중지’라 하며, 임상 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 개발 계획 | 포함하고 싶은 일, 수행하여야 할 일, 특히 즐거움을 주는 활동 | 반박할 수 있는 증거를 생각해 내는 것이다.  | 환자는 이와 같은 오류나 왜곡을 깨닫게 되고 그들을 수정하려고 | – Part 2-1: Step by step | 개발 활동을 위하여 소프트웨어 | 가상·증강(VR·AR) 기반 소프트웨어를 포함 | 의료기기의 위험관리 | □ 예 | ■ 아니오 | 국외 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 벡 자살 사고 척도 | 생각, 자기에 대한 부정적 생각, 우울 기분, 신체화 증상, 의욕 | “white-box” 방법으로 수행한다.  | 및 유효성 확인’ 자료 등 허가·심사 시 |\n| 6) 사용자 반응 평가(순응도, 만족도, 난이도, 개선점 등) | 제시한다.  그 밖에 임상시험 결과의 사용 범위에 따른 성능 평가를 위하여 | 80001-2-1 | software | 데이터 손실 | 장애에 관한 것이다.  이들 문항 중 10개는 증상이 없는 것 | 사항 | 완료 | 허용가능 | 관리 계획을 수립한다.  |\n| 2) 유의수준 | 제조자는 데이터 부인방지(non-repudiation)를 | 제품명(제조업체) | 지침서ㆍ안내서가 있습니까?  | CBTi | 30 | 11.90 | 5.25 | 마지막 시도의 심각성을 평가하지만 점수에는 포함되지 | 지침에 따라 처방전 없이 제공할 수 있다. ",
        "original_sentence": "그 밖에 임상시험 결과의 사용 범위에 따른 성능 평가를 위하여 | 80001-2-1 | software | 데이터 손실 | 장애에 관한 것이다. "
      }
    },
    {
      "chunk_id": "chunk_008",
      "text": "이들 문항 중 10개는 증상이 없는 것 | 사항 | 완료 | 허용가능 | 관리 계획을 수립한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 7,
        "window_size": 3,
        "char_count": 54,
        "word_count": 17,
        "page_number": 3,
        "window_text": "| 환자는 이와 같은 오류나 왜곡을 깨닫게 되고 그들을 수정하려고 | – Part 2-1: Step by step | 개발 활동을 위하여 소프트웨어 | 가상·증강(VR·AR) 기반 소프트웨어를 포함 | 의료기기의 위험관리 | □ 예 | ■ 아니오 | 국외 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 벡 자살 사고 척도 | 생각, 자기에 대한 부정적 생각, 우울 기분, 신체화 증상, 의욕 | “white-box” 방법으로 수행한다.  | 및 유효성 확인’ 자료 등 허가·심사 시 |\n| 6) 사용자 반응 평가(순응도, 만족도, 난이도, 개선점 등) | 제시한다.  그 밖에 임상시험 결과의 사용 범위에 따른 성능 평가를 위하여 | 80001-2-1 | software | 데이터 손실 | 장애에 관한 것이다.  이들 문항 중 10개는 증상이 없는 것 | 사항 | 완료 | 허용가능 | 관리 계획을 수립한다.  |\n| 2) 유의수준 | 제조자는 데이터 부인방지(non-repudiation)를 | 제품명(제조업체) | 지침서ㆍ안내서가 있습니까?  | CBTi | 30 | 11.90 | 5.25 | 마지막 시도의 심각성을 평가하지만 점수에는 포함되지 | 지침에 따라 처방전 없이 제공할 수 있다.  |\n| 19) 피험자의 임상시험 예상 참여 기간 | (Montgomery-˚Asberg | 가이드라인(민원인 안내서)’에 따른다. ",
        "original_sentence": "이들 문항 중 10개는 증상이 없는 것 | 사항 | 완료 | 허용가능 | 관리 계획을 수립한다. "
      }
    },
    {
      "chunk_id": "chunk_009",
      "text": "|\n| 2) 유의수준 | 제조자는 데이터 부인방지(non-repudiation)를 | 제품명(제조업체) | 지침서ㆍ안내서가 있습니까? ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 8,
        "window_size": 3,
        "char_count": 75,
        "word_count": 13,
        "page_number": 9,
        "window_text": "| 및 유효성 확인’ 자료 등 허가·심사 시 |\n| 6) 사용자 반응 평가(순응도, 만족도, 난이도, 개선점 등) | 제시한다.  그 밖에 임상시험 결과의 사용 범위에 따른 성능 평가를 위하여 | 80001-2-1 | software | 데이터 손실 | 장애에 관한 것이다.  이들 문항 중 10개는 증상이 없는 것 | 사항 | 완료 | 허용가능 | 관리 계획을 수립한다.  |\n| 2) 유의수준 | 제조자는 데이터 부인방지(non-repudiation)를 | 제품명(제조업체) | 지침서ㆍ안내서가 있습니까?  | CBTi | 30 | 11.90 | 5.25 | 마지막 시도의 심각성을 평가하지만 점수에는 포함되지 | 지침에 따라 처방전 없이 제공할 수 있다.  |\n| 19) 피험자의 임상시험 예상 참여 기간 | (Montgomery-˚Asberg | 가이드라인(민원인 안내서)’에 따른다.  | 갈음할 수 있다. ",
        "original_sentence": "|\n| 2) 유의수준 | 제조자는 데이터 부인방지(non-repudiation)를 | 제품명(제조업체) | 지침서ㆍ안내서가 있습니까? "
      }
    },
    {
      "chunk_id": "chunk_010",
      "text": "| CBTi | 30 | 11.90 | 5.25 | 마지막 시도의 심각성을 평가하지만 점수에는 포함되지 | 지침에 따라 처방전 없이 제공할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 9,
        "window_size": 3,
        "char_count": 84,
        "word_count": 23,
        "page_number": 9,
        "window_text": "그 밖에 임상시험 결과의 사용 범위에 따른 성능 평가를 위하여 | 80001-2-1 | software | 데이터 손실 | 장애에 관한 것이다.  이들 문항 중 10개는 증상이 없는 것 | 사항 | 완료 | 허용가능 | 관리 계획을 수립한다.  |\n| 2) 유의수준 | 제조자는 데이터 부인방지(non-repudiation)를 | 제품명(제조업체) | 지침서ㆍ안내서가 있습니까?  | CBTi | 30 | 11.90 | 5.25 | 마지막 시도의 심각성을 평가하지만 점수에는 포함되지 | 지침에 따라 처방전 없이 제공할 수 있다.  |\n| 19) 피험자의 임상시험 예상 참여 기간 | (Montgomery-˚Asberg | 가이드라인(민원인 안내서)’에 따른다.  | 갈음할 수 있다.  | 아니다. ",
        "original_sentence": "| CBTi | 30 | 11.90 | 5.25 | 마지막 시도의 심각성을 평가하지만 점수에는 포함되지 | 지침에 따라 처방전 없이 제공할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_011",
      "text": "|\n| 19) 피험자의 임상시험 예상 참여 기간 | (Montgomery-˚Asberg | 가이드라인(민원인 안내서)’에 따른다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 10,
        "window_size": 3,
        "char_count": 73,
        "word_count": 14,
        "page_number": 28,
        "window_text": "이들 문항 중 10개는 증상이 없는 것 | 사항 | 완료 | 허용가능 | 관리 계획을 수립한다.  |\n| 2) 유의수준 | 제조자는 데이터 부인방지(non-repudiation)를 | 제품명(제조업체) | 지침서ㆍ안내서가 있습니까?  | CBTi | 30 | 11.90 | 5.25 | 마지막 시도의 심각성을 평가하지만 점수에는 포함되지 | 지침에 따라 처방전 없이 제공할 수 있다.  |\n| 19) 피험자의 임상시험 예상 참여 기간 | (Montgomery-˚Asberg | 가이드라인(민원인 안내서)’에 따른다.  | 갈음할 수 있다.  | 아니다.  | 임상시험을 실시하여야 한다. ",
        "original_sentence": "|\n| 19) 피험자의 임상시험 예상 참여 기간 | (Montgomery-˚Asberg | 가이드라인(민원인 안내서)’에 따른다. "
      }
    },
    {
      "chunk_id": "chunk_012",
      "text": "| 갈음할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 11,
        "window_size": 3,
        "char_count": 12,
        "word_count": 4,
        "page_number": 11,
        "window_text": "|\n| 2) 유의수준 | 제조자는 데이터 부인방지(non-repudiation)를 | 제품명(제조업체) | 지침서ㆍ안내서가 있습니까?  | CBTi | 30 | 11.90 | 5.25 | 마지막 시도의 심각성을 평가하지만 점수에는 포함되지 | 지침에 따라 처방전 없이 제공할 수 있다.  |\n| 19) 피험자의 임상시험 예상 참여 기간 | (Montgomery-˚Asberg | 가이드라인(민원인 안내서)’에 따른다.  | 갈음할 수 있다.  | 아니다.  | 임상시험을 실시하여야 한다.  | 활동을 말한다. ",
        "original_sentence": "| 갈음할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_013",
      "text": "| 아니다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 12,
        "window_size": 3,
        "char_count": 7,
        "word_count": 2,
        "page_number": 107,
        "window_text": "| CBTi | 30 | 11.90 | 5.25 | 마지막 시도의 심각성을 평가하지만 점수에는 포함되지 | 지침에 따라 처방전 없이 제공할 수 있다.  |\n| 19) 피험자의 임상시험 예상 참여 기간 | (Montgomery-˚Asberg | 가이드라인(민원인 안내서)’에 따른다.  | 갈음할 수 있다.  | 아니다.  | 임상시험을 실시하여야 한다.  | 활동을 말한다.  | 따라 조정될 것이라고 하는 것 | - 이상 반응에 대해 다른 명백한 원인이 있는 경우 | (Integrity)을 고려하여 평가한다. ",
        "original_sentence": "| 아니다. "
      }
    },
    {
      "chunk_id": "chunk_014",
      "text": "| 임상시험을 실시하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 13,
        "window_size": 3,
        "char_count": 18,
        "word_count": 4,
        "page_number": 13,
        "window_text": "|\n| 19) 피험자의 임상시험 예상 참여 기간 | (Montgomery-˚Asberg | 가이드라인(민원인 안내서)’에 따른다.  | 갈음할 수 있다.  | 아니다.  | 임상시험을 실시하여야 한다.  | 활동을 말한다.  | 따라 조정될 것이라고 하는 것 | - 이상 반응에 대해 다른 명백한 원인이 있는 경우 | (Integrity)을 고려하여 평가한다.  | 상황을 발생하지 않으면 안전성 등급은 A등급에 해당한다. ",
        "original_sentence": "| 임상시험을 실시하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_015",
      "text": "| 활동을 말한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 14,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 13,
        "window_text": "| 갈음할 수 있다.  | 아니다.  | 임상시험을 실시하여야 한다.  | 활동을 말한다.  | 따라 조정될 것이라고 하는 것 | - 이상 반응에 대해 다른 명백한 원인이 있는 경우 | (Integrity)을 고려하여 평가한다.  | 상황을 발생하지 않으면 안전성 등급은 A등급에 해당한다.  | (1) 인구학적 정보: 성별, 연령, 직업, 업무 생산성 | 한다. ",
        "original_sentence": "| 활동을 말한다. "
      }
    },
    {
      "chunk_id": "chunk_016",
      "text": "| 따라 조정될 것이라고 하는 것 | - 이상 반응에 대해 다른 명백한 원인이 있는 경우 | (Integrity)을 고려하여 평가한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 15,
        "window_size": 3,
        "char_count": 76,
        "word_count": 20,
        "page_number": 29,
        "window_text": "| 아니다.  | 임상시험을 실시하여야 한다.  | 활동을 말한다.  | 따라 조정될 것이라고 하는 것 | - 이상 반응에 대해 다른 명백한 원인이 있는 경우 | (Integrity)을 고려하여 평가한다.  | 상황을 발생하지 않으면 안전성 등급은 A등급에 해당한다.  | (1) 인구학적 정보: 성별, 연령, 직업, 업무 생산성 | 한다.  | 증상 여부, 직업, 업무 생산성). ",
        "original_sentence": "| 따라 조정될 것이라고 하는 것 | - 이상 반응에 대해 다른 명백한 원인이 있는 경우 | (Integrity)을 고려하여 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_017",
      "text": "| 상황을 발생하지 않으면 안전성 등급은 A등급에 해당한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 16,
        "window_size": 3,
        "char_count": 34,
        "word_count": 8,
        "page_number": 9,
        "window_text": "| 임상시험을 실시하여야 한다.  | 활동을 말한다.  | 따라 조정될 것이라고 하는 것 | - 이상 반응에 대해 다른 명백한 원인이 있는 경우 | (Integrity)을 고려하여 평가한다.  | 상황을 발생하지 않으면 안전성 등급은 A등급에 해당한다.  | (1) 인구학적 정보: 성별, 연령, 직업, 업무 생산성 | 한다.  | 증상 여부, 직업, 업무 생산성).  | 하여 순응도를 조사한다. ",
        "original_sentence": "| 상황을 발생하지 않으면 안전성 등급은 A등급에 해당한다. "
      }
    },
    {
      "chunk_id": "chunk_018",
      "text": "| (1) 인구학적 정보: 성별, 연령, 직업, 업무 생산성 | 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 17,
        "window_size": 3,
        "char_count": 40,
        "word_count": 11,
        "page_number": 13,
        "window_text": "| 활동을 말한다.  | 따라 조정될 것이라고 하는 것 | - 이상 반응에 대해 다른 명백한 원인이 있는 경우 | (Integrity)을 고려하여 평가한다.  | 상황을 발생하지 않으면 안전성 등급은 A등급에 해당한다.  | (1) 인구학적 정보: 성별, 연령, 직업, 업무 생산성 | 한다.  | 증상 여부, 직업, 업무 생산성).  | 하여 순응도를 조사한다.  | 순응도를 조사한다. ",
        "original_sentence": "| (1) 인구학적 정보: 성별, 연령, 직업, 업무 생산성 | 한다. "
      }
    },
    {
      "chunk_id": "chunk_019",
      "text": "| 증상 여부, 직업, 업무 생산성). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 18,
        "window_size": 3,
        "char_count": 22,
        "word_count": 6,
        "page_number": 3,
        "window_text": "| 따라 조정될 것이라고 하는 것 | - 이상 반응에 대해 다른 명백한 원인이 있는 경우 | (Integrity)을 고려하여 평가한다.  | 상황을 발생하지 않으면 안전성 등급은 A등급에 해당한다.  | (1) 인구학적 정보: 성별, 연령, 직업, 업무 생산성 | 한다.  | 증상 여부, 직업, 업무 생산성).  | 하여 순응도를 조사한다.  | 순응도를 조사한다.  | 하도록 한다. ",
        "original_sentence": "| 증상 여부, 직업, 업무 생산성). "
      }
    },
    {
      "chunk_id": "chunk_020",
      "text": "| 하여 순응도를 조사한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 19,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 13,
        "window_text": "| 상황을 발생하지 않으면 안전성 등급은 A등급에 해당한다.  | (1) 인구학적 정보: 성별, 연령, 직업, 업무 생산성 | 한다.  | 증상 여부, 직업, 업무 생산성).  | 하여 순응도를 조사한다.  | 순응도를 조사한다.  | 하도록 한다.  | 시험을 중지해야 한다고 판단한 경우 | - 예를 들어, “내가 아는 모든 사람은 나를 싫어한다”라는 자동적 | 등을 일일이 열거하게 한다. ",
        "original_sentence": "| 하여 순응도를 조사한다. "
      }
    },
    {
      "chunk_id": "chunk_021",
      "text": "| 순응도를 조사한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 20,
        "window_size": 3,
        "char_count": 13,
        "word_count": 3,
        "page_number": 13,
        "window_text": "| (1) 인구학적 정보: 성별, 연령, 직업, 업무 생산성 | 한다.  | 증상 여부, 직업, 업무 생산성).  | 하여 순응도를 조사한다.  | 순응도를 조사한다.  | 하도록 한다.  | 시험을 중지해야 한다고 판단한 경우 | - 예를 들어, “내가 아는 모든 사람은 나를 싫어한다”라는 자동적 | 등을 일일이 열거하게 한다.  | 노력하게 된다. ",
        "original_sentence": "| 순응도를 조사한다. "
      }
    },
    {
      "chunk_id": "chunk_022",
      "text": "| 하도록 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 21,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 13,
        "window_text": "| 증상 여부, 직업, 업무 생산성).  | 하여 순응도를 조사한다.  | 순응도를 조사한다.  | 하도록 한다.  | 시험을 중지해야 한다고 판단한 경우 | - 예를 들어, “내가 아는 모든 사람은 나를 싫어한다”라는 자동적 | 등을 일일이 열거하게 한다.  | 노력하게 된다.  | risk management of medical | 표 9. ",
        "original_sentence": "| 하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_023",
      "text": "| 시험을 중지해야 한다고 판단한 경우 | - 예를 들어, “내가 아는 모든 사람은 나를 싫어한다”라는 자동적 | 등을 일일이 열거하게 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 22,
        "window_size": 3,
        "char_count": 80,
        "word_count": 22,
        "page_number": 29,
        "window_text": "| 하여 순응도를 조사한다.  | 순응도를 조사한다.  | 하도록 한다.  | 시험을 중지해야 한다고 판단한 경우 | - 예를 들어, “내가 아는 모든 사람은 나를 싫어한다”라는 자동적 | 등을 일일이 열거하게 한다.  | 노력하게 된다.  | risk management of medical | 표 9.  소프트웨어 안전성 등급 | 개발 계획을 수립한다. ",
        "original_sentence": "| 시험을 중지해야 한다고 판단한 경우 | - 예를 들어, “내가 아는 모든 사람은 나를 싫어한다”라는 자동적 | 등을 일일이 열거하게 한다. "
      }
    },
    {
      "chunk_id": "chunk_024",
      "text": "| 노력하게 된다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 23,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 20,
        "window_text": "| 순응도를 조사한다.  | 하도록 한다.  | 시험을 중지해야 한다고 판단한 경우 | - 예를 들어, “내가 아는 모든 사람은 나를 싫어한다”라는 자동적 | 등을 일일이 열거하게 한다.  | 노력하게 된다.  | risk management of medical | 표 9.  소프트웨어 안전성 등급 | 개발 계획을 수립한다.  | 이득 | 방법에 대한 국제 규격 |\n| (Beck Suicidal ideation | 3) 공용 네트워크 망 사용여부 : Y | 하기에 충분한 경험이 있는 자가 선정되어야 한다. ",
        "original_sentence": "| 노력하게 된다. "
      }
    },
    {
      "chunk_id": "chunk_025",
      "text": "| risk management of medical | 표 9. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 24,
        "window_size": 3,
        "char_count": 36,
        "word_count": 8,
        "page_number": 38,
        "window_text": "| 하도록 한다.  | 시험을 중지해야 한다고 판단한 경우 | - 예를 들어, “내가 아는 모든 사람은 나를 싫어한다”라는 자동적 | 등을 일일이 열거하게 한다.  | 노력하게 된다.  | risk management of medical | 표 9.  소프트웨어 안전성 등급 | 개발 계획을 수립한다.  | 이득 | 방법에 대한 국제 규격 |\n| (Beck Suicidal ideation | 3) 공용 네트워크 망 사용여부 : Y | 하기에 충분한 경험이 있는 자가 선정되어야 한다.  | 시험 개시에서 완료까지 중지될 수 있는 세부 사항을 ‘중지 기준’에 제시한다. ",
        "original_sentence": "| risk management of medical | 표 9. "
      }
    },
    {
      "chunk_id": "chunk_026",
      "text": "소프트웨어 안전성 등급 | 개발 계획을 수립한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 25,
        "window_size": 3,
        "char_count": 28,
        "word_count": 7,
        "page_number": 9,
        "window_text": "| 시험을 중지해야 한다고 판단한 경우 | - 예를 들어, “내가 아는 모든 사람은 나를 싫어한다”라는 자동적 | 등을 일일이 열거하게 한다.  | 노력하게 된다.  | risk management of medical | 표 9.  소프트웨어 안전성 등급 | 개발 계획을 수립한다.  | 이득 | 방법에 대한 국제 규격 |\n| (Beck Suicidal ideation | 3) 공용 네트워크 망 사용여부 : Y | 하기에 충분한 경험이 있는 자가 선정되어야 한다.  | 시험 개시에서 완료까지 중지될 수 있는 세부 사항을 ‘중지 기준’에 제시한다.  | Scale, KDS ) | 제조자는 새로운 사이버보안 취약성에 대응할 | 상실 총 6 요인이다. ",
        "original_sentence": "소프트웨어 안전성 등급 | 개발 계획을 수립한다. "
      }
    },
    {
      "chunk_id": "chunk_027",
      "text": "| 이득 | 방법에 대한 국제 규격 |\n| (Beck Suicidal ideation | 3) 공용 네트워크 망 사용여부 : Y | 하기에 충분한 경험이 있는 자가 선정되어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 26,
        "window_size": 3,
        "char_count": 102,
        "word_count": 28,
        "page_number": 37,
        "window_text": "| 노력하게 된다.  | risk management of medical | 표 9.  소프트웨어 안전성 등급 | 개발 계획을 수립한다.  | 이득 | 방법에 대한 국제 규격 |\n| (Beck Suicidal ideation | 3) 공용 네트워크 망 사용여부 : Y | 하기에 충분한 경험이 있는 자가 선정되어야 한다.  | 시험 개시에서 완료까지 중지될 수 있는 세부 사항을 ‘중지 기준’에 제시한다.  | Scale, KDS ) | 제조자는 새로운 사이버보안 취약성에 대응할 | 상실 총 6 요인이다.  18세 이상의 일반 성인과 우울장애 | 제출해야 할 첨부 자료에 대하여 제시 | 제품설명 | 소프트웨어 | 1.17 |\n| 제·개정번호 | 승인일자 | 주요 내용 | 이차 유효성 평가변수를 제시하여 각 임상 검사 항목 및 검사 방법에 대한 | 에서 증가하여 심각도 수준(0~6)도 구성되어 있다. ",
        "original_sentence": "| 이득 | 방법에 대한 국제 규격 |\n| (Beck Suicidal ideation | 3) 공용 네트워크 망 사용여부 : Y | 하기에 충분한 경험이 있는 자가 선정되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_028",
      "text": "| 시험 개시에서 완료까지 중지될 수 있는 세부 사항을 ‘중지 기준’에 제시한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 27,
        "window_size": 3,
        "char_count": 46,
        "word_count": 12,
        "page_number": 3,
        "window_text": "| risk management of medical | 표 9.  소프트웨어 안전성 등급 | 개발 계획을 수립한다.  | 이득 | 방법에 대한 국제 규격 |\n| (Beck Suicidal ideation | 3) 공용 네트워크 망 사용여부 : Y | 하기에 충분한 경험이 있는 자가 선정되어야 한다.  | 시험 개시에서 완료까지 중지될 수 있는 세부 사항을 ‘중지 기준’에 제시한다.  | Scale, KDS ) | 제조자는 새로운 사이버보안 취약성에 대응할 | 상실 총 6 요인이다.  18세 이상의 일반 성인과 우울장애 | 제출해야 할 첨부 자료에 대하여 제시 | 제품설명 | 소프트웨어 | 1.17 |\n| 제·개정번호 | 승인일자 | 주요 내용 | 이차 유효성 평가변수를 제시하여 각 임상 검사 항목 및 검사 방법에 대한 | 에서 증가하여 심각도 수준(0~6)도 구성되어 있다.  점수는 | 없음 |\n| 2) 디지털치료기기 치료 기간: 총 8주 | 3) 통계적 검정 방법 | 디지털치료기기 관련 국내외 규격은 <표 6>과 같다. ",
        "original_sentence": "| 시험 개시에서 완료까지 중지될 수 있는 세부 사항을 ‘중지 기준’에 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_029",
      "text": "| Scale, KDS ) | 제조자는 새로운 사이버보안 취약성에 대응할 | 상실 총 6 요인이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 28,
        "window_size": 3,
        "char_count": 56,
        "word_count": 15,
        "page_number": 30,
        "window_text": "소프트웨어 안전성 등급 | 개발 계획을 수립한다.  | 이득 | 방법에 대한 국제 규격 |\n| (Beck Suicidal ideation | 3) 공용 네트워크 망 사용여부 : Y | 하기에 충분한 경험이 있는 자가 선정되어야 한다.  | 시험 개시에서 완료까지 중지될 수 있는 세부 사항을 ‘중지 기준’에 제시한다.  | Scale, KDS ) | 제조자는 새로운 사이버보안 취약성에 대응할 | 상실 총 6 요인이다.  18세 이상의 일반 성인과 우울장애 | 제출해야 할 첨부 자료에 대하여 제시 | 제품설명 | 소프트웨어 | 1.17 |\n| 제·개정번호 | 승인일자 | 주요 내용 | 이차 유효성 평가변수를 제시하여 각 임상 검사 항목 및 검사 방법에 대한 | 에서 증가하여 심각도 수준(0~6)도 구성되어 있다.  점수는 | 없음 |\n| 2) 디지털치료기기 치료 기간: 총 8주 | 3) 통계적 검정 방법 | 디지털치료기기 관련 국내외 규격은 <표 6>과 같다.  | 기술한다. ",
        "original_sentence": "| Scale, KDS ) | 제조자는 새로운 사이버보안 취약성에 대응할 | 상실 총 6 요인이다. "
      }
    },
    {
      "chunk_id": "chunk_030",
      "text": "18세 이상의 일반 성인과 우울장애 | 제출해야 할 첨부 자료에 대하여 제시 | 제품설명 | 소프트웨어 | 1.17 |\n| 제·개정번호 | 승인일자 | 주요 내용 | 이차 유효성 평가변수를 제시하여 각 임상 검사 항목 및 검사 방법에 대한 | 에서 증가하여 심각도 수준(0~6)도 구성되어 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 29,
        "window_size": 3,
        "char_count": 166,
        "word_count": 46,
        "page_number": 28,
        "window_text": "| 이득 | 방법에 대한 국제 규격 |\n| (Beck Suicidal ideation | 3) 공용 네트워크 망 사용여부 : Y | 하기에 충분한 경험이 있는 자가 선정되어야 한다.  | 시험 개시에서 완료까지 중지될 수 있는 세부 사항을 ‘중지 기준’에 제시한다.  | Scale, KDS ) | 제조자는 새로운 사이버보안 취약성에 대응할 | 상실 총 6 요인이다.  18세 이상의 일반 성인과 우울장애 | 제출해야 할 첨부 자료에 대하여 제시 | 제품설명 | 소프트웨어 | 1.17 |\n| 제·개정번호 | 승인일자 | 주요 내용 | 이차 유효성 평가변수를 제시하여 각 임상 검사 항목 및 검사 방법에 대한 | 에서 증가하여 심각도 수준(0~6)도 구성되어 있다.  점수는 | 없음 |\n| 2) 디지털치료기기 치료 기간: 총 8주 | 3) 통계적 검정 방법 | 디지털치료기기 관련 국내외 규격은 <표 6>과 같다.  | 기술한다.  | 보장하기 위한 설계 특성이 필요한지를 결정 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | 제품외형 | 않는다. ",
        "original_sentence": "18세 이상의 일반 성인과 우울장애 | 제출해야 할 첨부 자료에 대하여 제시 | 제품설명 | 소프트웨어 | 1.17 |\n| 제·개정번호 | 승인일자 | 주요 내용 | 이차 유효성 평가변수를 제시하여 각 임상 검사 항목 및 검사 방법에 대한 | 에서 증가하여 심각도 수준(0~6)도 구성되어 있다. "
      }
    },
    {
      "chunk_id": "chunk_031",
      "text": "점수는 | 없음 |\n| 2) 디지털치료기기 치료 기간: 총 8주 | 3) 통계적 검정 방법 | 디지털치료기기 관련 국내외 규격은 <표 6>과 같다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 30,
        "window_size": 3,
        "char_count": 83,
        "word_count": 24,
        "page_number": 9,
        "window_text": "| 시험 개시에서 완료까지 중지될 수 있는 세부 사항을 ‘중지 기준’에 제시한다.  | Scale, KDS ) | 제조자는 새로운 사이버보안 취약성에 대응할 | 상실 총 6 요인이다.  18세 이상의 일반 성인과 우울장애 | 제출해야 할 첨부 자료에 대하여 제시 | 제품설명 | 소프트웨어 | 1.17 |\n| 제·개정번호 | 승인일자 | 주요 내용 | 이차 유효성 평가변수를 제시하여 각 임상 검사 항목 및 검사 방법에 대한 | 에서 증가하여 심각도 수준(0~6)도 구성되어 있다.  점수는 | 없음 |\n| 2) 디지털치료기기 치료 기간: 총 8주 | 3) 통계적 검정 방법 | 디지털치료기기 관련 국내외 규격은 <표 6>과 같다.  | 기술한다.  | 보장하기 위한 설계 특성이 필요한지를 결정 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | 제품외형 | 않는다.  BSS는 현재 자살 욕구를 질문하는 4, 5번 문항에서 | WL | 29 | 4.48 | 7.34 | 소프트웨어 |\n| 1) 임상시험용 의료기기 | 3 | 제품의 주요 기능 선정 시 아래 고려사항을 참고하여 선정한다. ",
        "original_sentence": "점수는 | 없음 |\n| 2) 디지털치료기기 치료 기간: 총 8주 | 3) 통계적 검정 방법 | 디지털치료기기 관련 국내외 규격은 <표 6>과 같다. "
      }
    },
    {
      "chunk_id": "chunk_032",
      "text": "| 기술한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 31,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 13,
        "window_text": "| Scale, KDS ) | 제조자는 새로운 사이버보안 취약성에 대응할 | 상실 총 6 요인이다.  18세 이상의 일반 성인과 우울장애 | 제출해야 할 첨부 자료에 대하여 제시 | 제품설명 | 소프트웨어 | 1.17 |\n| 제·개정번호 | 승인일자 | 주요 내용 | 이차 유효성 평가변수를 제시하여 각 임상 검사 항목 및 검사 방법에 대한 | 에서 증가하여 심각도 수준(0~6)도 구성되어 있다.  점수는 | 없음 |\n| 2) 디지털치료기기 치료 기간: 총 8주 | 3) 통계적 검정 방법 | 디지털치료기기 관련 국내외 규격은 <표 6>과 같다.  | 기술한다.  | 보장하기 위한 설계 특성이 필요한지를 결정 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | 제품외형 | 않는다.  BSS는 현재 자살 욕구를 질문하는 4, 5번 문항에서 | WL | 29 | 4.48 | 7.34 | 소프트웨어 |\n| 1) 임상시험용 의료기기 | 3 | 제품의 주요 기능 선정 시 아래 고려사항을 참고하여 선정한다.  | Depression Rating | 초과하는 자 | - 우울장애 환자와 함께 활동을 채택하고, 채택된 활동을 하기 | 사고를 시험하기 위해서 먼저, 사람이 어떤 사람을 싫어할 때 | IT-networks – Practical |\n| 5 | 에피소드 진단(F32)을 받은 자 | Scale, BSS) | 의료기기 업데이트 방안을 고려하여야 한다. ",
        "original_sentence": "| 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_033",
      "text": "| 보장하기 위한 설계 특성이 필요한지를 결정 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | 제품외형 | 않는다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 32,
        "window_size": 3,
        "char_count": 85,
        "word_count": 22,
        "page_number": 19,
        "window_text": "18세 이상의 일반 성인과 우울장애 | 제출해야 할 첨부 자료에 대하여 제시 | 제품설명 | 소프트웨어 | 1.17 |\n| 제·개정번호 | 승인일자 | 주요 내용 | 이차 유효성 평가변수를 제시하여 각 임상 검사 항목 및 검사 방법에 대한 | 에서 증가하여 심각도 수준(0~6)도 구성되어 있다.  점수는 | 없음 |\n| 2) 디지털치료기기 치료 기간: 총 8주 | 3) 통계적 검정 방법 | 디지털치료기기 관련 국내외 규격은 <표 6>과 같다.  | 기술한다.  | 보장하기 위한 설계 특성이 필요한지를 결정 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | 제품외형 | 않는다.  BSS는 현재 자살 욕구를 질문하는 4, 5번 문항에서 | WL | 29 | 4.48 | 7.34 | 소프트웨어 |\n| 1) 임상시험용 의료기기 | 3 | 제품의 주요 기능 선정 시 아래 고려사항을 참고하여 선정한다.  | Depression Rating | 초과하는 자 | - 우울장애 환자와 함께 활동을 채택하고, 채택된 활동을 하기 | 사고를 시험하기 위해서 먼저, 사람이 어떤 사람을 싫어할 때 | IT-networks – Practical |\n| 5 | 에피소드 진단(F32)을 받은 자 | Scale, BSS) | 의료기기 업데이트 방안을 고려하여야 한다.  | 등급 | 설명 | Psychological | 표 16. ",
        "original_sentence": "| 보장하기 위한 설계 특성이 필요한지를 결정 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | 제품외형 | 않는다. "
      }
    },
    {
      "chunk_id": "chunk_034",
      "text": "BSS는 현재 자살 욕구를 질문하는 4, 5번 문항에서 | WL | 29 | 4.48 | 7.34 | 소프트웨어 |\n| 1) 임상시험용 의료기기 | 3 | 제품의 주요 기능 선정 시 아래 고려사항을 참고하여 선정한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 33,
        "window_size": 3,
        "char_count": 122,
        "word_count": 35,
        "page_number": 9,
        "window_text": "점수는 | 없음 |\n| 2) 디지털치료기기 치료 기간: 총 8주 | 3) 통계적 검정 방법 | 디지털치료기기 관련 국내외 규격은 <표 6>과 같다.  | 기술한다.  | 보장하기 위한 설계 특성이 필요한지를 결정 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | 제품외형 | 않는다.  BSS는 현재 자살 욕구를 질문하는 4, 5번 문항에서 | WL | 29 | 4.48 | 7.34 | 소프트웨어 |\n| 1) 임상시험용 의료기기 | 3 | 제품의 주요 기능 선정 시 아래 고려사항을 참고하여 선정한다.  | Depression Rating | 초과하는 자 | - 우울장애 환자와 함께 활동을 채택하고, 채택된 활동을 하기 | 사고를 시험하기 위해서 먼저, 사람이 어떤 사람을 싫어할 때 | IT-networks – Practical |\n| 5 | 에피소드 진단(F32)을 받은 자 | Scale, BSS) | 의료기기 업데이트 방안을 고려하여야 한다.  | 등급 | 설명 | Psychological | 표 16.  사용자 반응 평가 지표 예시 | 환자에게 적용할 수 있다. ",
        "original_sentence": "BSS는 현재 자살 욕구를 질문하는 4, 5번 문항에서 | WL | 29 | 4.48 | 7.34 | 소프트웨어 |\n| 1) 임상시험용 의료기기 | 3 | 제품의 주요 기능 선정 시 아래 고려사항을 참고하여 선정한다. "
      }
    },
    {
      "chunk_id": "chunk_035",
      "text": "| Depression Rating | 초과하는 자 | - 우울장애 환자와 함께 활동을 채택하고, 채택된 활동을 하기 | 사고를 시험하기 위해서 먼저, 사람이 어떤 사람을 싫어할 때 | IT-networks – Practical |\n| 5 | 에피소드 진단(F32)을 받은 자 | Scale, BSS) | 의료기기 업데이트 방안을 고려하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 34,
        "window_size": 3,
        "char_count": 195,
        "word_count": 47,
        "page_number": 18,
        "window_text": "| 기술한다.  | 보장하기 위한 설계 특성이 필요한지를 결정 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | 제품외형 | 않는다.  BSS는 현재 자살 욕구를 질문하는 4, 5번 문항에서 | WL | 29 | 4.48 | 7.34 | 소프트웨어 |\n| 1) 임상시험용 의료기기 | 3 | 제품의 주요 기능 선정 시 아래 고려사항을 참고하여 선정한다.  | Depression Rating | 초과하는 자 | - 우울장애 환자와 함께 활동을 채택하고, 채택된 활동을 하기 | 사고를 시험하기 위해서 먼저, 사람이 어떤 사람을 싫어할 때 | IT-networks – Practical |\n| 5 | 에피소드 진단(F32)을 받은 자 | Scale, BSS) | 의료기기 업데이트 방안을 고려하여야 한다.  | 등급 | 설명 | Psychological | 표 16.  사용자 반응 평가 지표 예시 | 환자에게 적용할 수 있다.  문항 점수의 총점은 규준에 근거 | 통합계획에 따라 소프트웨어를 | 의료기기 | 허가·심사 | 시 | 사용자의 | 검증 및 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다. ",
        "original_sentence": "| Depression Rating | 초과하는 자 | - 우울장애 환자와 함께 활동을 채택하고, 채택된 활동을 하기 | 사고를 시험하기 위해서 먼저, 사람이 어떤 사람을 싫어할 때 | IT-networks – Practical |\n| 5 | 에피소드 진단(F32)을 받은 자 | Scale, BSS) | 의료기기 업데이트 방안을 고려하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_036",
      "text": "| 등급 | 설명 | Psychological | 표 16. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 35,
        "window_size": 3,
        "char_count": 34,
        "word_count": 9,
        "page_number": 9,
        "window_text": "| 보장하기 위한 설계 특성이 필요한지를 결정 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | 제품외형 | 않는다.  BSS는 현재 자살 욕구를 질문하는 4, 5번 문항에서 | WL | 29 | 4.48 | 7.34 | 소프트웨어 |\n| 1) 임상시험용 의료기기 | 3 | 제품의 주요 기능 선정 시 아래 고려사항을 참고하여 선정한다.  | Depression Rating | 초과하는 자 | - 우울장애 환자와 함께 활동을 채택하고, 채택된 활동을 하기 | 사고를 시험하기 위해서 먼저, 사람이 어떤 사람을 싫어할 때 | IT-networks – Practical |\n| 5 | 에피소드 진단(F32)을 받은 자 | Scale, BSS) | 의료기기 업데이트 방안을 고려하여야 한다.  | 등급 | 설명 | Psychological | 표 16.  사용자 반응 평가 지표 예시 | 환자에게 적용할 수 있다.  문항 점수의 총점은 규준에 근거 | 통합계획에 따라 소프트웨어를 | 의료기기 | 허가·심사 | 시 | 사용자의 | 검증 및 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.  | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 담당 | 2) 사이버보안 요구사항 | 12) 임상시험에 참여함으로써 피험자에게 예상되는 비용 | 20) 임상시험에 참여하는 대략의 피험자 수 | 4) 사용될 통계적 분석 방법(즉, 연구디자인과도 관련) | ‘중지 처리’에는 각 중지 기준에 대한 유효성 평가 통계 처리 시 그 산입 여부와 | ○ 평가 불가능(Unknown) | 위원장이나 간사가 승인한 문서를 의뢰자에게 보내야 한다. ",
        "original_sentence": "| 등급 | 설명 | Psychological | 표 16. "
      }
    },
    {
      "chunk_id": "chunk_037",
      "text": "사용자 반응 평가 지표 예시 | 환자에게 적용할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 36,
        "window_size": 3,
        "char_count": 33,
        "word_count": 10,
        "page_number": 11,
        "window_text": "BSS는 현재 자살 욕구를 질문하는 4, 5번 문항에서 | WL | 29 | 4.48 | 7.34 | 소프트웨어 |\n| 1) 임상시험용 의료기기 | 3 | 제품의 주요 기능 선정 시 아래 고려사항을 참고하여 선정한다.  | Depression Rating | 초과하는 자 | - 우울장애 환자와 함께 활동을 채택하고, 채택된 활동을 하기 | 사고를 시험하기 위해서 먼저, 사람이 어떤 사람을 싫어할 때 | IT-networks – Practical |\n| 5 | 에피소드 진단(F32)을 받은 자 | Scale, BSS) | 의료기기 업데이트 방안을 고려하여야 한다.  | 등급 | 설명 | Psychological | 표 16.  사용자 반응 평가 지표 예시 | 환자에게 적용할 수 있다.  문항 점수의 총점은 규준에 근거 | 통합계획에 따라 소프트웨어를 | 의료기기 | 허가·심사 | 시 | 사용자의 | 검증 및 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.  | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 담당 | 2) 사이버보안 요구사항 | 12) 임상시험에 참여함으로써 피험자에게 예상되는 비용 | 20) 임상시험에 참여하는 대략의 피험자 수 | 4) 사용될 통계적 분석 방법(즉, 연구디자인과도 관련) | ‘중지 처리’에는 각 중지 기준에 대한 유효성 평가 통계 처리 시 그 산입 여부와 | ○ 평가 불가능(Unknown) | 위원장이나 간사가 승인한 문서를 의뢰자에게 보내야 한다.  | 하는 소프트웨어 의료기기(SaMD)이다. ",
        "original_sentence": "사용자 반응 평가 지표 예시 | 환자에게 적용할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_038",
      "text": "문항 점수의 총점은 규준에 근거 | 통합계획에 따라 소프트웨어를 | 의료기기 | 허가·심사 | 시 | 사용자의 | 검증 및 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 37,
        "window_size": 3,
        "char_count": 105,
        "word_count": 30,
        "page_number": 9,
        "window_text": "| Depression Rating | 초과하는 자 | - 우울장애 환자와 함께 활동을 채택하고, 채택된 활동을 하기 | 사고를 시험하기 위해서 먼저, 사람이 어떤 사람을 싫어할 때 | IT-networks – Practical |\n| 5 | 에피소드 진단(F32)을 받은 자 | Scale, BSS) | 의료기기 업데이트 방안을 고려하여야 한다.  | 등급 | 설명 | Psychological | 표 16.  사용자 반응 평가 지표 예시 | 환자에게 적용할 수 있다.  문항 점수의 총점은 규준에 근거 | 통합계획에 따라 소프트웨어를 | 의료기기 | 허가·심사 | 시 | 사용자의 | 검증 및 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.  | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 담당 | 2) 사이버보안 요구사항 | 12) 임상시험에 참여함으로써 피험자에게 예상되는 비용 | 20) 임상시험에 참여하는 대략의 피험자 수 | 4) 사용될 통계적 분석 방법(즉, 연구디자인과도 관련) | ‘중지 처리’에는 각 중지 기준에 대한 유효성 평가 통계 처리 시 그 산입 여부와 | ○ 평가 불가능(Unknown) | 위원장이나 간사가 승인한 문서를 의뢰자에게 보내야 한다.  | 하는 소프트웨어 의료기기(SaMD)이다.  | 인지행동치료의 치료 효과성을 입증된 바 있다. ",
        "original_sentence": "문항 점수의 총점은 규준에 근거 | 통합계획에 따라 소프트웨어를 | 의료기기 | 허가·심사 | 시 | 사용자의 | 검증 및 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다. "
      }
    },
    {
      "chunk_id": "chunk_039",
      "text": "| - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 담당 | 2) 사이버보안 요구사항 | 12) 임상시험에 참여함으로써 피험자에게 예상되는 비용 | 20) 임상시험에 참여하는 대략의 피험자 수 | 4) 사용될 통계적 분석 방법(즉, 연구디자인과도 관련) | ‘중지 처리’에는 각 중지 기준에 대한 유효성 평가 통계 처리 시 그 산입 여부와 | ○ 평가 불가능(Unknown) | 위원장이나 간사가 승인한 문서를 의뢰자에게 보내야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 38,
        "window_size": 3,
        "char_count": 258,
        "word_count": 65,
        "page_number": 3,
        "window_text": "| 등급 | 설명 | Psychological | 표 16.  사용자 반응 평가 지표 예시 | 환자에게 적용할 수 있다.  문항 점수의 총점은 규준에 근거 | 통합계획에 따라 소프트웨어를 | 의료기기 | 허가·심사 | 시 | 사용자의 | 검증 및 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.  | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 담당 | 2) 사이버보안 요구사항 | 12) 임상시험에 참여함으로써 피험자에게 예상되는 비용 | 20) 임상시험에 참여하는 대략의 피험자 수 | 4) 사용될 통계적 분석 방법(즉, 연구디자인과도 관련) | ‘중지 처리’에는 각 중지 기준에 대한 유효성 평가 통계 처리 시 그 산입 여부와 | ○ 평가 불가능(Unknown) | 위원장이나 간사가 승인한 문서를 의뢰자에게 보내야 한다.  | 하는 소프트웨어 의료기기(SaMD)이다.  | 인지행동치료의 치료 효과성을 입증된 바 있다.  | 하여야 한다. ",
        "original_sentence": "| - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 담당 | 2) 사이버보안 요구사항 | 12) 임상시험에 참여함으로써 피험자에게 예상되는 비용 | 20) 임상시험에 참여하는 대략의 피험자 수 | 4) 사용될 통계적 분석 방법(즉, 연구디자인과도 관련) | ‘중지 처리’에는 각 중지 기준에 대한 유효성 평가 통계 처리 시 그 산입 여부와 | ○ 평가 불가능(Unknown) | 위원장이나 간사가 승인한 문서를 의뢰자에게 보내야 한다. "
      }
    },
    {
      "chunk_id": "chunk_040",
      "text": "| 하는 소프트웨어 의료기기(SaMD)이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 39,
        "window_size": 3,
        "char_count": 25,
        "word_count": 4,
        "page_number": 9,
        "window_text": "사용자 반응 평가 지표 예시 | 환자에게 적용할 수 있다.  문항 점수의 총점은 규준에 근거 | 통합계획에 따라 소프트웨어를 | 의료기기 | 허가·심사 | 시 | 사용자의 | 검증 및 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.  | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 담당 | 2) 사이버보안 요구사항 | 12) 임상시험에 참여함으로써 피험자에게 예상되는 비용 | 20) 임상시험에 참여하는 대략의 피험자 수 | 4) 사용될 통계적 분석 방법(즉, 연구디자인과도 관련) | ‘중지 처리’에는 각 중지 기준에 대한 유효성 평가 통계 처리 시 그 산입 여부와 | ○ 평가 불가능(Unknown) | 위원장이나 간사가 승인한 문서를 의뢰자에게 보내야 한다.  | 하는 소프트웨어 의료기기(SaMD)이다.  | 인지행동치료의 치료 효과성을 입증된 바 있다.  | 하여야 한다.  | 하기 위해 시스템 레벨에서의 아키텍쳐를 | (2) 병력조사: 동반 질환 여부 | 비기능 | 순응도를 조사한다. ",
        "original_sentence": "| 하는 소프트웨어 의료기기(SaMD)이다. "
      }
    },
    {
      "chunk_id": "chunk_041",
      "text": "| 인지행동치료의 치료 효과성을 입증된 바 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 40,
        "window_size": 3,
        "char_count": 28,
        "word_count": 7,
        "page_number": 11,
        "window_text": "문항 점수의 총점은 규준에 근거 | 통합계획에 따라 소프트웨어를 | 의료기기 | 허가·심사 | 시 | 사용자의 | 검증 및 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.  | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 담당 | 2) 사이버보안 요구사항 | 12) 임상시험에 참여함으로써 피험자에게 예상되는 비용 | 20) 임상시험에 참여하는 대략의 피험자 수 | 4) 사용될 통계적 분석 방법(즉, 연구디자인과도 관련) | ‘중지 처리’에는 각 중지 기준에 대한 유효성 평가 통계 처리 시 그 산입 여부와 | ○ 평가 불가능(Unknown) | 위원장이나 간사가 승인한 문서를 의뢰자에게 보내야 한다.  | 하는 소프트웨어 의료기기(SaMD)이다.  | 인지행동치료의 치료 효과성을 입증된 바 있다.  | 하여야 한다.  | 하기 위해 시스템 레벨에서의 아키텍쳐를 | (2) 병력조사: 동반 질환 여부 | 비기능 | 순응도를 조사한다.  | 및 3개월 후 우울장애 선별 도구(PHQ-9) 변화량 | 더욱 개연성이 있게 설명되는 경우 | 활동 | 판단되는 경우 | 으로 고려하시기 바랍니다. ",
        "original_sentence": "| 인지행동치료의 치료 효과성을 입증된 바 있다. "
      }
    },
    {
      "chunk_id": "chunk_042",
      "text": "| 하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 41,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 13,
        "window_text": "| - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 담당 | 2) 사이버보안 요구사항 | 12) 임상시험에 참여함으로써 피험자에게 예상되는 비용 | 20) 임상시험에 참여하는 대략의 피험자 수 | 4) 사용될 통계적 분석 방법(즉, 연구디자인과도 관련) | ‘중지 처리’에는 각 중지 기준에 대한 유효성 평가 통계 처리 시 그 산입 여부와 | ○ 평가 불가능(Unknown) | 위원장이나 간사가 승인한 문서를 의뢰자에게 보내야 한다.  | 하는 소프트웨어 의료기기(SaMD)이다.  | 인지행동치료의 치료 효과성을 입증된 바 있다.  | 하여야 한다.  | 하기 위해 시스템 레벨에서의 아키텍쳐를 | (2) 병력조사: 동반 질환 여부 | 비기능 | 순응도를 조사한다.  | 및 3개월 후 우울장애 선별 도구(PHQ-9) 변화량 | 더욱 개연성이 있게 설명되는 경우 | 활동 | 판단되는 경우 | 으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 | 필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다. ",
        "original_sentence": "| 하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_043",
      "text": "| 하기 위해 시스템 레벨에서의 아키텍쳐를 | (2) 병력조사: 동반 질환 여부 | 비기능 | 순응도를 조사한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 42,
        "window_size": 3,
        "char_count": 64,
        "word_count": 17,
        "page_number": 3,
        "window_text": "| 하는 소프트웨어 의료기기(SaMD)이다.  | 인지행동치료의 치료 효과성을 입증된 바 있다.  | 하여야 한다.  | 하기 위해 시스템 레벨에서의 아키텍쳐를 | (2) 병력조사: 동반 질환 여부 | 비기능 | 순응도를 조사한다.  | 및 3개월 후 우울장애 선별 도구(PHQ-9) 변화량 | 더욱 개연성이 있게 설명되는 경우 | 활동 | 판단되는 경우 | 으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 | 필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.  | 최대 60점이 나오고 점수가 높을수록 우울장애가 심각함을 | 적용 |\n| 심리평가 | 기준을 제시한다. ",
        "original_sentence": "| 하기 위해 시스템 레벨에서의 아키텍쳐를 | (2) 병력조사: 동반 질환 여부 | 비기능 | 순응도를 조사한다. "
      }
    },
    {
      "chunk_id": "chunk_044",
      "text": "| 및 3개월 후 우울장애 선별 도구(PHQ-9) 변화량 | 더욱 개연성이 있게 설명되는 경우 | 활동 | 판단되는 경우 | 으로 고려하시기 바랍니다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 43,
        "window_size": 3,
        "char_count": 85,
        "word_count": 23,
        "page_number": 29,
        "window_text": "| 인지행동치료의 치료 효과성을 입증된 바 있다.  | 하여야 한다.  | 하기 위해 시스템 레벨에서의 아키텍쳐를 | (2) 병력조사: 동반 질환 여부 | 비기능 | 순응도를 조사한다.  | 및 3개월 후 우울장애 선별 도구(PHQ-9) 변화량 | 더욱 개연성이 있게 설명되는 경우 | 활동 | 판단되는 경우 | 으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 | 필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.  | 최대 60점이 나오고 점수가 높을수록 우울장애가 심각함을 | 적용 |\n| 심리평가 | 기준을 제시한다.  | Scale, MADRS) | 척도(BDI) 변화량 | 의료기기의 사이버보안 | ‘아니오’로 응답하면 20, 21번 문항을 넘어가도록 되어 있고, | 검증 및 |\n| 손익 분석(cost-benefit analysis) | 위한 구체적인 시간표를 짜서 매일 이것을 실행하게 한다. ",
        "original_sentence": "| 및 3개월 후 우울장애 선별 도구(PHQ-9) 변화량 | 더욱 개연성이 있게 설명되는 경우 | 활동 | 판단되는 경우 | 으로 고려하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_045",
      "text": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 | 필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 44,
        "window_size": 3,
        "char_count": 58,
        "word_count": 14,
        "page_number": 3,
        "window_text": "| 하여야 한다.  | 하기 위해 시스템 레벨에서의 아키텍쳐를 | (2) 병력조사: 동반 질환 여부 | 비기능 | 순응도를 조사한다.  | 및 3개월 후 우울장애 선별 도구(PHQ-9) 변화량 | 더욱 개연성이 있게 설명되는 경우 | 활동 | 판단되는 경우 | 으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 | 필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.  | 최대 60점이 나오고 점수가 높을수록 우울장애가 심각함을 | 적용 |\n| 심리평가 | 기준을 제시한다.  | Scale, MADRS) | 척도(BDI) 변화량 | 의료기기의 사이버보안 | ‘아니오’로 응답하면 20, 21번 문항을 넘어가도록 되어 있고, | 검증 및 |\n| 손익 분석(cost-benefit analysis) | 위한 구체적인 시간표를 짜서 매일 이것을 실행하게 한다.  이러한 | 일반적으로 하는 행동을 생각해볼 수 있다. ",
        "original_sentence": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 | 필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_046",
      "text": "| 최대 60점이 나오고 점수가 높을수록 우울장애가 심각함을 | 적용 |\n| 심리평가 | 기준을 제시한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 45,
        "window_size": 3,
        "char_count": 60,
        "word_count": 16,
        "page_number": 9,
        "window_text": "| 하기 위해 시스템 레벨에서의 아키텍쳐를 | (2) 병력조사: 동반 질환 여부 | 비기능 | 순응도를 조사한다.  | 및 3개월 후 우울장애 선별 도구(PHQ-9) 변화량 | 더욱 개연성이 있게 설명되는 경우 | 활동 | 판단되는 경우 | 으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 | 필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.  | 최대 60점이 나오고 점수가 높을수록 우울장애가 심각함을 | 적용 |\n| 심리평가 | 기준을 제시한다.  | Scale, MADRS) | 척도(BDI) 변화량 | 의료기기의 사이버보안 | ‘아니오’로 응답하면 20, 21번 문항을 넘어가도록 되어 있고, | 검증 및 |\n| 손익 분석(cost-benefit analysis) | 위한 구체적인 시간표를 짜서 매일 이것을 실행하게 한다.  이러한 | 일반적으로 하는 행동을 생각해볼 수 있다.  다음으로 무작위로 | applications and examples | 유효성 | (AB-1234) |\n| ※ 예: 업데이트 시 사용자 개입/ 자동 업 | A등급 | 부상이나 신체적 피해가 발생할 가능성이 없다. ",
        "original_sentence": "| 최대 60점이 나오고 점수가 높을수록 우울장애가 심각함을 | 적용 |\n| 심리평가 | 기준을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_047",
      "text": "| Scale, MADRS) | 척도(BDI) 변화량 | 의료기기의 사이버보안 | ‘아니오’로 응답하면 20, 21번 문항을 넘어가도록 되어 있고, | 검증 및 |\n| 손익 분석(cost-benefit analysis) | 위한 구체적인 시간표를 짜서 매일 이것을 실행하게 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 46,
        "window_size": 3,
        "char_count": 157,
        "word_count": 35,
        "page_number": 38,
        "window_text": "| 및 3개월 후 우울장애 선별 도구(PHQ-9) 변화량 | 더욱 개연성이 있게 설명되는 경우 | 활동 | 판단되는 경우 | 으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 | 필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.  | 최대 60점이 나오고 점수가 높을수록 우울장애가 심각함을 | 적용 |\n| 심리평가 | 기준을 제시한다.  | Scale, MADRS) | 척도(BDI) 변화량 | 의료기기의 사이버보안 | ‘아니오’로 응답하면 20, 21번 문항을 넘어가도록 되어 있고, | 검증 및 |\n| 손익 분석(cost-benefit analysis) | 위한 구체적인 시간표를 짜서 매일 이것을 실행하게 한다.  이러한 | 일반적으로 하는 행동을 생각해볼 수 있다.  다음으로 무작위로 | applications and examples | 유효성 | (AB-1234) |\n| ※ 예: 업데이트 시 사용자 개입/ 자동 업 | A등급 | 부상이나 신체적 피해가 발생할 가능성이 없다.  | 소프트웨어 | assessment | Deprexis | 표 6. ",
        "original_sentence": "| Scale, MADRS) | 척도(BDI) 변화량 | 의료기기의 사이버보안 | ‘아니오’로 응답하면 20, 21번 문항을 넘어가도록 되어 있고, | 검증 및 |\n| 손익 분석(cost-benefit analysis) | 위한 구체적인 시간표를 짜서 매일 이것을 실행하게 한다. "
      }
    },
    {
      "chunk_id": "chunk_048",
      "text": "이러한 | 일반적으로 하는 행동을 생각해볼 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 47,
        "window_size": 3,
        "char_count": 30,
        "word_count": 8,
        "page_number": 11,
        "window_text": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 | 필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.  | 최대 60점이 나오고 점수가 높을수록 우울장애가 심각함을 | 적용 |\n| 심리평가 | 기준을 제시한다.  | Scale, MADRS) | 척도(BDI) 변화량 | 의료기기의 사이버보안 | ‘아니오’로 응답하면 20, 21번 문항을 넘어가도록 되어 있고, | 검증 및 |\n| 손익 분석(cost-benefit analysis) | 위한 구체적인 시간표를 짜서 매일 이것을 실행하게 한다.  이러한 | 일반적으로 하는 행동을 생각해볼 수 있다.  다음으로 무작위로 | applications and examples | 유효성 | (AB-1234) |\n| ※ 예: 업데이트 시 사용자 개입/ 자동 업 | A등급 | 부상이나 신체적 피해가 발생할 가능성이 없다.  | 소프트웨어 | assessment | Deprexis | 표 6.  디지털치료기기 관련 국내/외 규격 | 측정 질문 (0점-10점, 시각아날로그척도 사용) | 나타낸다. ",
        "original_sentence": "이러한 | 일반적으로 하는 행동을 생각해볼 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_049",
      "text": "다음으로 무작위로 | applications and examples | 유효성 | (AB-1234) |\n| ※ 예: 업데이트 시 사용자 개입/ 자동 업 | A등급 | 부상이나 신체적 피해가 발생할 가능성이 없다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 48,
        "window_size": 3,
        "char_count": 119,
        "word_count": 29,
        "page_number": 29,
        "window_text": "| 최대 60점이 나오고 점수가 높을수록 우울장애가 심각함을 | 적용 |\n| 심리평가 | 기준을 제시한다.  | Scale, MADRS) | 척도(BDI) 변화량 | 의료기기의 사이버보안 | ‘아니오’로 응답하면 20, 21번 문항을 넘어가도록 되어 있고, | 검증 및 |\n| 손익 분석(cost-benefit analysis) | 위한 구체적인 시간표를 짜서 매일 이것을 실행하게 한다.  이러한 | 일반적으로 하는 행동을 생각해볼 수 있다.  다음으로 무작위로 | applications and examples | 유효성 | (AB-1234) |\n| ※ 예: 업데이트 시 사용자 개입/ 자동 업 | A등급 | 부상이나 신체적 피해가 발생할 가능성이 없다.  | 소프트웨어 | assessment | Deprexis | 표 6.  디지털치료기기 관련 국내/외 규격 | 측정 질문 (0점-10점, 시각아날로그척도 사용) | 나타낸다.  현재 MADRS에 대한 우울 점수에 따라, 정상(0~7점), | 하여 해석한다. ",
        "original_sentence": "다음으로 무작위로 | applications and examples | 유효성 | (AB-1234) |\n| ※ 예: 업데이트 시 사용자 개입/ 자동 업 | A등급 | 부상이나 신체적 피해가 발생할 가능성이 없다. "
      }
    },
    {
      "chunk_id": "chunk_050",
      "text": "| 소프트웨어 | assessment | Deprexis | 표 6. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 49,
        "window_size": 3,
        "char_count": 39,
        "word_count": 9,
        "page_number": 9,
        "window_text": "| Scale, MADRS) | 척도(BDI) 변화량 | 의료기기의 사이버보안 | ‘아니오’로 응답하면 20, 21번 문항을 넘어가도록 되어 있고, | 검증 및 |\n| 손익 분석(cost-benefit analysis) | 위한 구체적인 시간표를 짜서 매일 이것을 실행하게 한다.  이러한 | 일반적으로 하는 행동을 생각해볼 수 있다.  다음으로 무작위로 | applications and examples | 유효성 | (AB-1234) |\n| ※ 예: 업데이트 시 사용자 개입/ 자동 업 | A등급 | 부상이나 신체적 피해가 발생할 가능성이 없다.  | 소프트웨어 | assessment | Deprexis | 표 6.  디지털치료기기 관련 국내/외 규격 | 측정 질문 (0점-10점, 시각아날로그척도 사용) | 나타낸다.  현재 MADRS에 대한 우울 점수에 따라, 정상(0~7점), | 하여 해석한다.  전체 남자는 T점수 65, 전체 여자는 T점수 | 통합하고 | 통합한 | 소프트웨어 | 건강에 직접적인 영향을 미칠 수 있는 | 되어 있다. ",
        "original_sentence": "| 소프트웨어 | assessment | Deprexis | 표 6. "
      }
    },
    {
      "chunk_id": "chunk_051",
      "text": "디지털치료기기 관련 국내/외 규격 | 측정 질문 (0점-10점, 시각아날로그척도 사용) | 나타낸다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 50,
        "window_size": 3,
        "char_count": 57,
        "word_count": 12,
        "page_number": 28,
        "window_text": "이러한 | 일반적으로 하는 행동을 생각해볼 수 있다.  다음으로 무작위로 | applications and examples | 유효성 | (AB-1234) |\n| ※ 예: 업데이트 시 사용자 개입/ 자동 업 | A등급 | 부상이나 신체적 피해가 발생할 가능성이 없다.  | 소프트웨어 | assessment | Deprexis | 표 6.  디지털치료기기 관련 국내/외 규격 | 측정 질문 (0점-10점, 시각아날로그척도 사용) | 나타낸다.  현재 MADRS에 대한 우울 점수에 따라, 정상(0~7점), | 하여 해석한다.  전체 남자는 T점수 65, 전체 여자는 T점수 | 통합하고 | 통합한 | 소프트웨어 | 건강에 직접적인 영향을 미칠 수 있는 | 되어 있다.  | 적용 |\n| 5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이(및 표준편차) | 가) 시험기기 | - 제품의 사용목적상 필요한 기능(능력) 요구사항 | 평가하여야 한다. ",
        "original_sentence": "디지털치료기기 관련 국내/외 규격 | 측정 질문 (0점-10점, 시각아날로그척도 사용) | 나타낸다. "
      }
    },
    {
      "chunk_id": "chunk_052",
      "text": "현재 MADRS에 대한 우울 점수에 따라, 정상(0~7점), | 하여 해석한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 51,
        "window_size": 3,
        "char_count": 45,
        "word_count": 10,
        "page_number": 13,
        "window_text": "다음으로 무작위로 | applications and examples | 유효성 | (AB-1234) |\n| ※ 예: 업데이트 시 사용자 개입/ 자동 업 | A등급 | 부상이나 신체적 피해가 발생할 가능성이 없다.  | 소프트웨어 | assessment | Deprexis | 표 6.  디지털치료기기 관련 국내/외 규격 | 측정 질문 (0점-10점, 시각아날로그척도 사용) | 나타낸다.  현재 MADRS에 대한 우울 점수에 따라, 정상(0~7점), | 하여 해석한다.  전체 남자는 T점수 65, 전체 여자는 T점수 | 통합하고 | 통합한 | 소프트웨어 | 건강에 직접적인 영향을 미칠 수 있는 | 되어 있다.  | 적용 |\n| 5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이(및 표준편차) | 가) 시험기기 | - 제품의 사용목적상 필요한 기능(능력) 요구사항 | 평가하여야 한다.  | 계획 | 적인 | 유효성 | (AB-1234) |\n| 소프트웨어 | Pharmacological treatments. ",
        "original_sentence": "현재 MADRS에 대한 우울 점수에 따라, 정상(0~7점), | 하여 해석한다. "
      }
    },
    {
      "chunk_id": "chunk_053",
      "text": "전체 남자는 T점수 65, 전체 여자는 T점수 | 통합하고 | 통합한 | 소프트웨어 | 건강에 직접적인 영향을 미칠 수 있는 | 되어 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 52,
        "window_size": 3,
        "char_count": 79,
        "word_count": 23,
        "page_number": 9,
        "window_text": "| 소프트웨어 | assessment | Deprexis | 표 6.  디지털치료기기 관련 국내/외 규격 | 측정 질문 (0점-10점, 시각아날로그척도 사용) | 나타낸다.  현재 MADRS에 대한 우울 점수에 따라, 정상(0~7점), | 하여 해석한다.  전체 남자는 T점수 65, 전체 여자는 T점수 | 통합하고 | 통합한 | 소프트웨어 | 건강에 직접적인 영향을 미칠 수 있는 | 되어 있다.  | 적용 |\n| 5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이(및 표준편차) | 가) 시험기기 | - 제품의 사용목적상 필요한 기능(능력) 요구사항 | 평가하여야 한다.  | 계획 | 적인 | 유효성 | (AB-1234) |\n| 소프트웨어 | Pharmacological treatments.  The Canadian Journal of Psychiatry, 61(9), 540-560. ",
        "original_sentence": "전체 남자는 T점수 65, 전체 여자는 T점수 | 통합하고 | 통합한 | 소프트웨어 | 건강에 직접적인 영향을 미칠 수 있는 | 되어 있다. "
      }
    },
    {
      "chunk_id": "chunk_054",
      "text": "| 적용 |\n| 5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이(및 표준편차) | 가) 시험기기 | - 제품의 사용목적상 필요한 기능(능력) 요구사항 | 평가하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 53,
        "window_size": 3,
        "char_count": 101,
        "word_count": 27,
        "page_number": 7,
        "window_text": "디지털치료기기 관련 국내/외 규격 | 측정 질문 (0점-10점, 시각아날로그척도 사용) | 나타낸다.  현재 MADRS에 대한 우울 점수에 따라, 정상(0~7점), | 하여 해석한다.  전체 남자는 T점수 65, 전체 여자는 T점수 | 통합하고 | 통합한 | 소프트웨어 | 건강에 직접적인 영향을 미칠 수 있는 | 되어 있다.  | 적용 |\n| 5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이(및 표준편차) | 가) 시험기기 | - 제품의 사용목적상 필요한 기능(능력) 요구사항 | 평가하여야 한다.  | 계획 | 적인 | 유효성 | (AB-1234) |\n| 소프트웨어 | Pharmacological treatments.  The Canadian Journal of Psychiatry, 61(9), 540-560.  | 3) 우울장애 심각도 척도(BDI-II)에서 14점 이상 점수를 가진 자 | 6 | 4 | 하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상시험에 | 피험자별 중지 사유를 포함한 관련 임상시험 자료의 처리 방법을 제시한다. ",
        "original_sentence": "| 적용 |\n| 5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이(및 표준편차) | 가) 시험기기 | - 제품의 사용목적상 필요한 기능(능력) 요구사항 | 평가하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_055",
      "text": "| 계획 | 적인 | 유효성 | (AB-1234) |\n| 소프트웨어 | Pharmacological treatments. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 54,
        "window_size": 3,
        "char_count": 68,
        "word_count": 14,
        "page_number": 9,
        "window_text": "현재 MADRS에 대한 우울 점수에 따라, 정상(0~7점), | 하여 해석한다.  전체 남자는 T점수 65, 전체 여자는 T점수 | 통합하고 | 통합한 | 소프트웨어 | 건강에 직접적인 영향을 미칠 수 있는 | 되어 있다.  | 적용 |\n| 5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이(및 표준편차) | 가) 시험기기 | - 제품의 사용목적상 필요한 기능(능력) 요구사항 | 평가하여야 한다.  | 계획 | 적인 | 유효성 | (AB-1234) |\n| 소프트웨어 | Pharmacological treatments.  The Canadian Journal of Psychiatry, 61(9), 540-560.  | 3) 우울장애 심각도 척도(BDI-II)에서 14점 이상 점수를 가진 자 | 6 | 4 | 하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상시험에 | 피험자별 중지 사유를 포함한 관련 임상시험 자료의 처리 방법을 제시한다.  | 범위로 고려할 것을 권고한다. ",
        "original_sentence": "| 계획 | 적인 | 유효성 | (AB-1234) |\n| 소프트웨어 | Pharmacological treatments. "
      }
    },
    {
      "chunk_id": "chunk_056",
      "text": "The Canadian Journal of Psychiatry, 61(9), 540-560. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 55,
        "window_size": 3,
        "char_count": 52,
        "word_count": 7,
        "page_number": 21,
        "window_text": "전체 남자는 T점수 65, 전체 여자는 T점수 | 통합하고 | 통합한 | 소프트웨어 | 건강에 직접적인 영향을 미칠 수 있는 | 되어 있다.  | 적용 |\n| 5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이(및 표준편차) | 가) 시험기기 | - 제품의 사용목적상 필요한 기능(능력) 요구사항 | 평가하여야 한다.  | 계획 | 적인 | 유효성 | (AB-1234) |\n| 소프트웨어 | Pharmacological treatments.  The Canadian Journal of Psychiatry, 61(9), 540-560.  | 3) 우울장애 심각도 척도(BDI-II)에서 14점 이상 점수를 가진 자 | 6 | 4 | 하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상시험에 | 피험자별 중지 사유를 포함한 관련 임상시험 자료의 처리 방법을 제시한다.  | 범위로 고려할 것을 권고한다.  | 허가·심사 가이드라인 | 활동은 즐거움을 주는 활동뿐 아니라 무언가를 수행해야 하는 | ‘예’로 응답하면 6번 이하의 문항에 대해 계속 응답하도록 | 국내 |\n| 안내서-1258-01 | ’22.12.14. ",
        "original_sentence": "The Canadian Journal of Psychiatry, 61(9), 540-560. "
      }
    },
    {
      "chunk_id": "chunk_057",
      "text": "| 3) 우울장애 심각도 척도(BDI-II)에서 14점 이상 점수를 가진 자 | 6 | 4 | 하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상시험에 | 피험자별 중지 사유를 포함한 관련 임상시험 자료의 처리 방법을 제시한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 56,
        "window_size": 3,
        "char_count": 140,
        "word_count": 37,
        "page_number": 28,
        "window_text": "| 적용 |\n| 5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이(및 표준편차) | 가) 시험기기 | - 제품의 사용목적상 필요한 기능(능력) 요구사항 | 평가하여야 한다.  | 계획 | 적인 | 유효성 | (AB-1234) |\n| 소프트웨어 | Pharmacological treatments.  The Canadian Journal of Psychiatry, 61(9), 540-560.  | 3) 우울장애 심각도 척도(BDI-II)에서 14점 이상 점수를 가진 자 | 6 | 4 | 하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상시험에 | 피험자별 중지 사유를 포함한 관련 임상시험 자료의 처리 방법을 제시한다.  | 범위로 고려할 것을 권고한다.  | 허가·심사 가이드라인 | 활동은 즐거움을 주는 활동뿐 아니라 무언가를 수행해야 하는 | ‘예’로 응답하면 6번 이하의 문항에 대해 계속 응답하도록 | 국내 |\n| 안내서-1258-01 | ’22.12.14.  | - 성능 평가방법은 임상시험 기간 동안 일차/이차 유효성 평가변수에 대한 | 3) 방문 3 (치료 기간 종료 1주 후, Post-treatment) | 4) 방문 4 (치료 기간 종료 3개월 후, Follow up) | ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설명하거나 | 명시한다. ",
        "original_sentence": "| 3) 우울장애 심각도 척도(BDI-II)에서 14점 이상 점수를 가진 자 | 6 | 4 | 하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상시험에 | 피험자별 중지 사유를 포함한 관련 임상시험 자료의 처리 방법을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_058",
      "text": "| 범위로 고려할 것을 권고한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 57,
        "window_size": 3,
        "char_count": 19,
        "word_count": 5,
        "page_number": 13,
        "window_text": "| 계획 | 적인 | 유효성 | (AB-1234) |\n| 소프트웨어 | Pharmacological treatments.  The Canadian Journal of Psychiatry, 61(9), 540-560.  | 3) 우울장애 심각도 척도(BDI-II)에서 14점 이상 점수를 가진 자 | 6 | 4 | 하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상시험에 | 피험자별 중지 사유를 포함한 관련 임상시험 자료의 처리 방법을 제시한다.  | 범위로 고려할 것을 권고한다.  | 허가·심사 가이드라인 | 활동은 즐거움을 주는 활동뿐 아니라 무언가를 수행해야 하는 | ‘예’로 응답하면 6번 이하의 문항에 대해 계속 응답하도록 | 국내 |\n| 안내서-1258-01 | ’22.12.14.  | - 성능 평가방법은 임상시험 기간 동안 일차/이차 유효성 평가변수에 대한 | 3) 방문 3 (치료 기간 종료 1주 후, Post-treatment) | 4) 방문 4 (치료 기간 종료 3개월 후, Follow up) | ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설명하거나 | 명시한다.  | ※ “예방, 관리”의 범위는 치료적 개입이 필요한 “환자”를 대상으로 함 | (3) 병용약물: 복용 여부 및 종류 | 데이트 여부, 기기의 안전(safety)과 성능에 | 내용을 기록한다. ",
        "original_sentence": "| 범위로 고려할 것을 권고한다. "
      }
    },
    {
      "chunk_id": "chunk_059",
      "text": "| 허가·심사 가이드라인 | 활동은 즐거움을 주는 활동뿐 아니라 무언가를 수행해야 하는 | ‘예’로 응답하면 6번 이하의 문항에 대해 계속 응답하도록 | 국내 |\n| 안내서-1258-01 | ’22.12.14. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 58,
        "window_size": 3,
        "char_count": 118,
        "word_count": 28,
        "page_number": 18,
        "window_text": "The Canadian Journal of Psychiatry, 61(9), 540-560.  | 3) 우울장애 심각도 척도(BDI-II)에서 14점 이상 점수를 가진 자 | 6 | 4 | 하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상시험에 | 피험자별 중지 사유를 포함한 관련 임상시험 자료의 처리 방법을 제시한다.  | 범위로 고려할 것을 권고한다.  | 허가·심사 가이드라인 | 활동은 즐거움을 주는 활동뿐 아니라 무언가를 수행해야 하는 | ‘예’로 응답하면 6번 이하의 문항에 대해 계속 응답하도록 | 국내 |\n| 안내서-1258-01 | ’22.12.14.  | - 성능 평가방법은 임상시험 기간 동안 일차/이차 유효성 평가변수에 대한 | 3) 방문 3 (치료 기간 종료 1주 후, Post-treatment) | 4) 방문 4 (치료 기간 종료 3개월 후, Follow up) | ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설명하거나 | 명시한다.  | ※ “예방, 관리”의 범위는 치료적 개입이 필요한 “환자”를 대상으로 함 | (3) 병용약물: 복용 여부 및 종류 | 데이트 여부, 기기의 안전(safety)과 성능에 | 내용을 기록한다.  | 수 있다. ",
        "original_sentence": "| 허가·심사 가이드라인 | 활동은 즐거움을 주는 활동뿐 아니라 무언가를 수행해야 하는 | ‘예’로 응답하면 6번 이하의 문항에 대해 계속 응답하도록 | 국내 |\n| 안내서-1258-01 | ’22.12.14. "
      }
    },
    {
      "chunk_id": "chunk_060",
      "text": "| - 성능 평가방법은 임상시험 기간 동안 일차/이차 유효성 평가변수에 대한 | 3) 방문 3 (치료 기간 종료 1주 후, Post-treatment) | 4) 방문 4 (치료 기간 종료 3개월 후, Follow up) | ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설명하거나 | 명시한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 59,
        "window_size": 3,
        "char_count": 187,
        "word_count": 47,
        "page_number": 7,
        "window_text": "| 3) 우울장애 심각도 척도(BDI-II)에서 14점 이상 점수를 가진 자 | 6 | 4 | 하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상시험에 | 피험자별 중지 사유를 포함한 관련 임상시험 자료의 처리 방법을 제시한다.  | 범위로 고려할 것을 권고한다.  | 허가·심사 가이드라인 | 활동은 즐거움을 주는 활동뿐 아니라 무언가를 수행해야 하는 | ‘예’로 응답하면 6번 이하의 문항에 대해 계속 응답하도록 | 국내 |\n| 안내서-1258-01 | ’22.12.14.  | - 성능 평가방법은 임상시험 기간 동안 일차/이차 유효성 평가변수에 대한 | 3) 방문 3 (치료 기간 종료 1주 후, Post-treatment) | 4) 방문 4 (치료 기간 종료 3개월 후, Follow up) | ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설명하거나 | 명시한다.  | ※ “예방, 관리”의 범위는 치료적 개입이 필요한 “환자”를 대상으로 함 | (3) 병용약물: 복용 여부 및 종류 | 데이트 여부, 기기의 안전(safety)과 성능에 | 내용을 기록한다.  | 수 있다.  | 통한 우울장애 치료를 수행한다. ",
        "original_sentence": "| - 성능 평가방법은 임상시험 기간 동안 일차/이차 유효성 평가변수에 대한 | 3) 방문 3 (치료 기간 종료 1주 후, Post-treatment) | 4) 방문 4 (치료 기간 종료 3개월 후, Follow up) | ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설명하거나 | 명시한다. "
      }
    },
    {
      "chunk_id": "chunk_061",
      "text": "| ※ “예방, 관리”의 범위는 치료적 개입이 필요한 “환자”를 대상으로 함 | (3) 병용약물: 복용 여부 및 종류 | 데이트 여부, 기기의 안전(safety)과 성능에 | 내용을 기록한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 60,
        "window_size": 3,
        "char_count": 108,
        "word_count": 27,
        "page_number": 18,
        "window_text": "| 범위로 고려할 것을 권고한다.  | 허가·심사 가이드라인 | 활동은 즐거움을 주는 활동뿐 아니라 무언가를 수행해야 하는 | ‘예’로 응답하면 6번 이하의 문항에 대해 계속 응답하도록 | 국내 |\n| 안내서-1258-01 | ’22.12.14.  | - 성능 평가방법은 임상시험 기간 동안 일차/이차 유효성 평가변수에 대한 | 3) 방문 3 (치료 기간 종료 1주 후, Post-treatment) | 4) 방문 4 (치료 기간 종료 3개월 후, Follow up) | ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설명하거나 | 명시한다.  | ※ “예방, 관리”의 범위는 치료적 개입이 필요한 “환자”를 대상으로 함 | (3) 병용약물: 복용 여부 및 종류 | 데이트 여부, 기기의 안전(safety)과 성능에 | 내용을 기록한다.  | 수 있다.  | 통한 우울장애 치료를 수행한다.  | 되는 경우 | 차이가 있는지 평가한다. ",
        "original_sentence": "| ※ “예방, 관리”의 범위는 치료적 개입이 필요한 “환자”를 대상으로 함 | (3) 병용약물: 복용 여부 및 종류 | 데이트 여부, 기기의 안전(safety)과 성능에 | 내용을 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_062",
      "text": "| 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 61,
        "window_size": 3,
        "char_count": 8,
        "word_count": 3,
        "page_number": 11,
        "window_text": "| 허가·심사 가이드라인 | 활동은 즐거움을 주는 활동뿐 아니라 무언가를 수행해야 하는 | ‘예’로 응답하면 6번 이하의 문항에 대해 계속 응답하도록 | 국내 |\n| 안내서-1258-01 | ’22.12.14.  | - 성능 평가방법은 임상시험 기간 동안 일차/이차 유효성 평가변수에 대한 | 3) 방문 3 (치료 기간 종료 1주 후, Post-treatment) | 4) 방문 4 (치료 기간 종료 3개월 후, Follow up) | ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설명하거나 | 명시한다.  | ※ “예방, 관리”의 범위는 치료적 개입이 필요한 “환자”를 대상으로 함 | (3) 병용약물: 복용 여부 및 종류 | 데이트 여부, 기기의 안전(safety)과 성능에 | 내용을 기록한다.  | 수 있다.  | 통한 우울장애 치료를 수행한다.  | 되는 경우 | 차이가 있는지 평가한다.  | (사유 :                                                                ) | - 비기능적 핵심 신념이 발견되고 비합리성이 밝혀졌음에도 이러한 | 선정된 아는 사람을 만나 그들이 실제로 우울장애 환자에게 | 70으로 우울장애를 분류할 경우, 진단적 효율성은 73.1%이다. ",
        "original_sentence": "| 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_063",
      "text": "| 통한 우울장애 치료를 수행한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 62,
        "window_size": 3,
        "char_count": 20,
        "word_count": 5,
        "page_number": 13,
        "window_text": "| - 성능 평가방법은 임상시험 기간 동안 일차/이차 유효성 평가변수에 대한 | 3) 방문 3 (치료 기간 종료 1주 후, Post-treatment) | 4) 방문 4 (치료 기간 종료 3개월 후, Follow up) | ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설명하거나 | 명시한다.  | ※ “예방, 관리”의 범위는 치료적 개입이 필요한 “환자”를 대상으로 함 | (3) 병용약물: 복용 여부 및 종류 | 데이트 여부, 기기의 안전(safety)과 성능에 | 내용을 기록한다.  | 수 있다.  | 통한 우울장애 치료를 수행한다.  | 되는 경우 | 차이가 있는지 평가한다.  | (사유 :                                                                ) | - 비기능적 핵심 신념이 발견되고 비합리성이 밝혀졌음에도 이러한 | 선정된 아는 사람을 만나 그들이 실제로 우울장애 환자에게 | 70으로 우울장애를 분류할 경우, 진단적 효율성은 73.1%이다.  | 소프트웨어가 어떤(what) 기능을 | 표 12. ",
        "original_sentence": "| 통한 우울장애 치료를 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_064",
      "text": "| 되는 경우 | 차이가 있는지 평가한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 63,
        "window_size": 3,
        "char_count": 24,
        "word_count": 7,
        "page_number": 7,
        "window_text": "| ※ “예방, 관리”의 범위는 치료적 개입이 필요한 “환자”를 대상으로 함 | (3) 병용약물: 복용 여부 및 종류 | 데이트 여부, 기기의 안전(safety)과 성능에 | 내용을 기록한다.  | 수 있다.  | 통한 우울장애 치료를 수행한다.  | 되는 경우 | 차이가 있는지 평가한다.  | (사유 :                                                                ) | - 비기능적 핵심 신념이 발견되고 비합리성이 밝혀졌음에도 이러한 | 선정된 아는 사람을 만나 그들이 실제로 우울장애 환자에게 | 70으로 우울장애를 분류할 경우, 진단적 효율성은 73.1%이다.  | 소프트웨어가 어떤(what) 기능을 | 표 12.  위험통제 예시 | 사이버보안 위협에 적용할 수 있는 | 확인 자료 |\n| 나) 위험평가 | 1 | 나는 디지털치료기기를 통해 우울장애에 대한 이해도가 더 증가하였다. ",
        "original_sentence": "| 되는 경우 | 차이가 있는지 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_065",
      "text": "| (사유 :                                                                ) | - 비기능적 핵심 신념이 발견되고 비합리성이 밝혀졌음에도 이러한 | 선정된 아는 사람을 만나 그들이 실제로 우울장애 환자에게 | 70으로 우울장애를 분류할 경우, 진단적 효율성은 73.1%이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 64,
        "window_size": 3,
        "char_count": 184,
        "word_count": 30,
        "page_number": 113,
        "window_text": "| 수 있다.  | 통한 우울장애 치료를 수행한다.  | 되는 경우 | 차이가 있는지 평가한다.  | (사유 :                                                                ) | - 비기능적 핵심 신념이 발견되고 비합리성이 밝혀졌음에도 이러한 | 선정된 아는 사람을 만나 그들이 실제로 우울장애 환자에게 | 70으로 우울장애를 분류할 경우, 진단적 효율성은 73.1%이다.  | 소프트웨어가 어떤(what) 기능을 | 표 12.  위험통제 예시 | 사이버보안 위협에 적용할 수 있는 | 확인 자료 |\n| 나) 위험평가 | 1 | 나는 디지털치료기기를 통해 우울장애에 대한 이해도가 더 증가하였다.  | (activity | B등급 | 심각하지 않은 부상(경상)이 발생할 가능성이 있다. ",
        "original_sentence": "| (사유 :                                                                ) | - 비기능적 핵심 신념이 발견되고 비합리성이 밝혀졌음에도 이러한 | 선정된 아는 사람을 만나 그들이 실제로 우울장애 환자에게 | 70으로 우울장애를 분류할 경우, 진단적 효율성은 73.1%이다. "
      }
    },
    {
      "chunk_id": "chunk_066",
      "text": "| 소프트웨어가 어떤(what) 기능을 | 표 12. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 65,
        "window_size": 3,
        "char_count": 30,
        "word_count": 7,
        "page_number": 9,
        "window_text": "| 통한 우울장애 치료를 수행한다.  | 되는 경우 | 차이가 있는지 평가한다.  | (사유 :                                                                ) | - 비기능적 핵심 신념이 발견되고 비합리성이 밝혀졌음에도 이러한 | 선정된 아는 사람을 만나 그들이 실제로 우울장애 환자에게 | 70으로 우울장애를 분류할 경우, 진단적 효율성은 73.1%이다.  | 소프트웨어가 어떤(what) 기능을 | 표 12.  위험통제 예시 | 사이버보안 위협에 적용할 수 있는 | 확인 자료 |\n| 나) 위험평가 | 1 | 나는 디지털치료기기를 통해 우울장애에 대한 이해도가 더 증가하였다.  | (activity | B등급 | 심각하지 않은 부상(경상)이 발생할 가능성이 있다.  | 통합 검증 | software | (GAIA) | 경미(8~15점), 중간(16~25점), 심각(26~30점), 매우 심각(31점 | 항목이 | 의도한 | 대로 | 기능을 | 해당 |\n| 1) 대상자군 | ※ 예: 감사 로그 기록 기능 제공 | 핵심 | (민원인 안내서) | 기술을 배우고 그 과정에서 보상을 받는다. ",
        "original_sentence": "| 소프트웨어가 어떤(what) 기능을 | 표 12. "
      }
    },
    {
      "chunk_id": "chunk_067",
      "text": "위험통제 예시 | 사이버보안 위협에 적용할 수 있는 | 확인 자료 |\n| 나) 위험평가 | 1 | 나는 디지털치료기기를 통해 우울장애에 대한 이해도가 더 증가하였다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 66,
        "window_size": 3,
        "char_count": 93,
        "word_count": 26,
        "page_number": 39,
        "window_text": "| 되는 경우 | 차이가 있는지 평가한다.  | (사유 :                                                                ) | - 비기능적 핵심 신념이 발견되고 비합리성이 밝혀졌음에도 이러한 | 선정된 아는 사람을 만나 그들이 실제로 우울장애 환자에게 | 70으로 우울장애를 분류할 경우, 진단적 효율성은 73.1%이다.  | 소프트웨어가 어떤(what) 기능을 | 표 12.  위험통제 예시 | 사이버보안 위협에 적용할 수 있는 | 확인 자료 |\n| 나) 위험평가 | 1 | 나는 디지털치료기기를 통해 우울장애에 대한 이해도가 더 증가하였다.  | (activity | B등급 | 심각하지 않은 부상(경상)이 발생할 가능성이 있다.  | 통합 검증 | software | (GAIA) | 경미(8~15점), 중간(16~25점), 심각(26~30점), 매우 심각(31점 | 항목이 | 의도한 | 대로 | 기능을 | 해당 |\n| 1) 대상자군 | ※ 예: 감사 로그 기록 기능 제공 | 핵심 | (민원인 안내서) | 기술을 배우고 그 과정에서 보상을 받는다.  | 확인 자료 |\n| - ‘탈락’ 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상 | 4) 사이버보안 적용 방법 | 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품의약품안전처 지침서 등의 | 소프트웨어 | 활동도 함께 포함된다. ",
        "original_sentence": "위험통제 예시 | 사이버보안 위협에 적용할 수 있는 | 확인 자료 |\n| 나) 위험평가 | 1 | 나는 디지털치료기기를 통해 우울장애에 대한 이해도가 더 증가하였다. "
      }
    },
    {
      "chunk_id": "chunk_068",
      "text": "| (activity | B등급 | 심각하지 않은 부상(경상)이 발생할 가능성이 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 67,
        "window_size": 3,
        "char_count": 49,
        "word_count": 11,
        "page_number": 9,
        "window_text": "| (사유 :                                                                ) | - 비기능적 핵심 신념이 발견되고 비합리성이 밝혀졌음에도 이러한 | 선정된 아는 사람을 만나 그들이 실제로 우울장애 환자에게 | 70으로 우울장애를 분류할 경우, 진단적 효율성은 73.1%이다.  | 소프트웨어가 어떤(what) 기능을 | 표 12.  위험통제 예시 | 사이버보안 위협에 적용할 수 있는 | 확인 자료 |\n| 나) 위험평가 | 1 | 나는 디지털치료기기를 통해 우울장애에 대한 이해도가 더 증가하였다.  | (activity | B등급 | 심각하지 않은 부상(경상)이 발생할 가능성이 있다.  | 통합 검증 | software | (GAIA) | 경미(8~15점), 중간(16~25점), 심각(26~30점), 매우 심각(31점 | 항목이 | 의도한 | 대로 | 기능을 | 해당 |\n| 1) 대상자군 | ※ 예: 감사 로그 기록 기능 제공 | 핵심 | (민원인 안내서) | 기술을 배우고 그 과정에서 보상을 받는다.  | 확인 자료 |\n| - ‘탈락’ 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상 | 4) 사이버보안 적용 방법 | 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품의약품안전처 지침서 등의 | 소프트웨어 | 활동도 함께 포함된다.  | 되어 있다. ",
        "original_sentence": "| (activity | B등급 | 심각하지 않은 부상(경상)이 발생할 가능성이 있다. "
      }
    },
    {
      "chunk_id": "chunk_069",
      "text": "| 통합 검증 | software | (GAIA) | 경미(8~15점), 중간(16~25점), 심각(26~30점), 매우 심각(31점 | 항목이 | 의도한 | 대로 | 기능을 | 해당 |\n| 1) 대상자군 | ※ 예: 감사 로그 기록 기능 제공 | 핵심 | (민원인 안내서) | 기술을 배우고 그 과정에서 보상을 받는다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 68,
        "window_size": 3,
        "char_count": 180,
        "word_count": 47,
        "page_number": 9,
        "window_text": "| 소프트웨어가 어떤(what) 기능을 | 표 12.  위험통제 예시 | 사이버보안 위협에 적용할 수 있는 | 확인 자료 |\n| 나) 위험평가 | 1 | 나는 디지털치료기기를 통해 우울장애에 대한 이해도가 더 증가하였다.  | (activity | B등급 | 심각하지 않은 부상(경상)이 발생할 가능성이 있다.  | 통합 검증 | software | (GAIA) | 경미(8~15점), 중간(16~25점), 심각(26~30점), 매우 심각(31점 | 항목이 | 의도한 | 대로 | 기능을 | 해당 |\n| 1) 대상자군 | ※ 예: 감사 로그 기록 기능 제공 | 핵심 | (민원인 안내서) | 기술을 배우고 그 과정에서 보상을 받는다.  | 확인 자료 |\n| - ‘탈락’ 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상 | 4) 사이버보안 적용 방법 | 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품의약품안전처 지침서 등의 | 소프트웨어 | 활동도 함께 포함된다.  | 되어 있다.  BSS는 자살 사고 내용 뿐만 아니라 구체적인 | 어떻게(how) 수행할 것인지에 |\n| 관여하는 사람을 말한다. ",
        "original_sentence": "| 통합 검증 | software | (GAIA) | 경미(8~15점), 중간(16~25점), 심각(26~30점), 매우 심각(31점 | 항목이 | 의도한 | 대로 | 기능을 | 해당 |\n| 1) 대상자군 | ※ 예: 감사 로그 기록 기능 제공 | 핵심 | (민원인 안내서) | 기술을 배우고 그 과정에서 보상을 받는다. "
      }
    },
    {
      "chunk_id": "chunk_070",
      "text": "| 확인 자료 |\n| - ‘탈락’ 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상 | 4) 사이버보안 적용 방법 | 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품의약품안전처 지침서 등의 | 소프트웨어 | 활동도 함께 포함된다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 69,
        "window_size": 3,
        "char_count": 150,
        "word_count": 39,
        "page_number": 18,
        "window_text": "위험통제 예시 | 사이버보안 위협에 적용할 수 있는 | 확인 자료 |\n| 나) 위험평가 | 1 | 나는 디지털치료기기를 통해 우울장애에 대한 이해도가 더 증가하였다.  | (activity | B등급 | 심각하지 않은 부상(경상)이 발생할 가능성이 있다.  | 통합 검증 | software | (GAIA) | 경미(8~15점), 중간(16~25점), 심각(26~30점), 매우 심각(31점 | 항목이 | 의도한 | 대로 | 기능을 | 해당 |\n| 1) 대상자군 | ※ 예: 감사 로그 기록 기능 제공 | 핵심 | (민원인 안내서) | 기술을 배우고 그 과정에서 보상을 받는다.  | 확인 자료 |\n| - ‘탈락’ 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상 | 4) 사이버보안 적용 방법 | 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품의약품안전처 지침서 등의 | 소프트웨어 | 활동도 함께 포함된다.  | 되어 있다.  BSS는 자살 사고 내용 뿐만 아니라 구체적인 | 어떻게(how) 수행할 것인지에 |\n| 관여하는 사람을 말한다.  | 되어야 한다. ",
        "original_sentence": "| 확인 자료 |\n| - ‘탈락’ 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상 | 4) 사이버보안 적용 방법 | 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품의약품안전처 지침서 등의 | 소프트웨어 | 활동도 함께 포함된다. "
      }
    },
    {
      "chunk_id": "chunk_071",
      "text": "| 되어 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 70,
        "window_size": 3,
        "char_count": 9,
        "word_count": 3,
        "page_number": 11,
        "window_text": "| (activity | B등급 | 심각하지 않은 부상(경상)이 발생할 가능성이 있다.  | 통합 검증 | software | (GAIA) | 경미(8~15점), 중간(16~25점), 심각(26~30점), 매우 심각(31점 | 항목이 | 의도한 | 대로 | 기능을 | 해당 |\n| 1) 대상자군 | ※ 예: 감사 로그 기록 기능 제공 | 핵심 | (민원인 안내서) | 기술을 배우고 그 과정에서 보상을 받는다.  | 확인 자료 |\n| - ‘탈락’ 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상 | 4) 사이버보안 적용 방법 | 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품의약품안전처 지침서 등의 | 소프트웨어 | 활동도 함께 포함된다.  | 되어 있다.  BSS는 자살 사고 내용 뿐만 아니라 구체적인 | 어떻게(how) 수행할 것인지에 |\n| 관여하는 사람을 말한다.  | 되어야 한다.  | 치료요법을 이미 받는 자 | - 소프트웨어 기반 알람, 경고, 연산 메시지 | 영향을 보장할 수 있는 업데이트 유효성 검증 | C등급 | 심각한 부상 또는 사망이 발생할 가능성이 있다. ",
        "original_sentence": "| 되어 있다. "
      }
    },
    {
      "chunk_id": "chunk_072",
      "text": "BSS는 자살 사고 내용 뿐만 아니라 구체적인 | 어떻게(how) 수행할 것인지에 |\n| 관여하는 사람을 말한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 71,
        "window_size": 3,
        "char_count": 64,
        "word_count": 16,
        "page_number": 18,
        "window_text": "| 통합 검증 | software | (GAIA) | 경미(8~15점), 중간(16~25점), 심각(26~30점), 매우 심각(31점 | 항목이 | 의도한 | 대로 | 기능을 | 해당 |\n| 1) 대상자군 | ※ 예: 감사 로그 기록 기능 제공 | 핵심 | (민원인 안내서) | 기술을 배우고 그 과정에서 보상을 받는다.  | 확인 자료 |\n| - ‘탈락’ 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상 | 4) 사이버보안 적용 방법 | 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품의약품안전처 지침서 등의 | 소프트웨어 | 활동도 함께 포함된다.  | 되어 있다.  BSS는 자살 사고 내용 뿐만 아니라 구체적인 | 어떻게(how) 수행할 것인지에 |\n| 관여하는 사람을 말한다.  | 되어야 한다.  | 치료요법을 이미 받는 자 | - 소프트웨어 기반 알람, 경고, 연산 메시지 | 영향을 보장할 수 있는 업데이트 유효성 검증 | C등급 | 심각한 부상 또는 사망이 발생할 가능성이 있다.  | (출처: Thrive 홈페이지, | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 인사를 하는지 하지 않는지 볼 수 있도록 실험을 구상한다. ",
        "original_sentence": "BSS는 자살 사고 내용 뿐만 아니라 구체적인 | 어떻게(how) 수행할 것인지에 |\n| 관여하는 사람을 말한다. "
      }
    },
    {
      "chunk_id": "chunk_073",
      "text": "| 되어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 72,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 13,
        "window_text": "| 확인 자료 |\n| - ‘탈락’ 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상 | 4) 사이버보안 적용 방법 | 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품의약품안전처 지침서 등의 | 소프트웨어 | 활동도 함께 포함된다.  | 되어 있다.  BSS는 자살 사고 내용 뿐만 아니라 구체적인 | 어떻게(how) 수행할 것인지에 |\n| 관여하는 사람을 말한다.  | 되어야 한다.  | 치료요법을 이미 받는 자 | - 소프트웨어 기반 알람, 경고, 연산 메시지 | 영향을 보장할 수 있는 업데이트 유효성 검증 | C등급 | 심각한 부상 또는 사망이 발생할 가능성이 있다.  | (출처: Thrive 홈페이지, | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 인사를 하는지 하지 않는지 볼 수 있도록 실험을 구상한다.  | 신념이 자기 보호기능을 해왔거나 혹은 그것을 가짐으로써 | 최소한의 권고 사항 등 제시 |\n| - 임상시험 중 관찰 항목을 기술한다. ",
        "original_sentence": "| 되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_074",
      "text": "| 치료요법을 이미 받는 자 | - 소프트웨어 기반 알람, 경고, 연산 메시지 | 영향을 보장할 수 있는 업데이트 유효성 검증 | C등급 | 심각한 부상 또는 사망이 발생할 가능성이 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 73,
        "window_size": 3,
        "char_count": 106,
        "word_count": 31,
        "page_number": 9,
        "window_text": "| 되어 있다.  BSS는 자살 사고 내용 뿐만 아니라 구체적인 | 어떻게(how) 수행할 것인지에 |\n| 관여하는 사람을 말한다.  | 되어야 한다.  | 치료요법을 이미 받는 자 | - 소프트웨어 기반 알람, 경고, 연산 메시지 | 영향을 보장할 수 있는 업데이트 유효성 검증 | C등급 | 심각한 부상 또는 사망이 발생할 가능성이 있다.  | (출처: Thrive 홈페이지, | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 인사를 하는지 하지 않는지 볼 수 있도록 실험을 구상한다.  | 신념이 자기 보호기능을 해왔거나 혹은 그것을 가짐으로써 | 최소한의 권고 사항 등 제시 |\n| - 임상시험 중 관찰 항목을 기술한다.  | 시험군과 대조군간의 비교 분석 방법을 통계적으로 타당하게 제시한다. ",
        "original_sentence": "| 치료요법을 이미 받는 자 | - 소프트웨어 기반 알람, 경고, 연산 메시지 | 영향을 보장할 수 있는 업데이트 유효성 검증 | C등급 | 심각한 부상 또는 사망이 발생할 가능성이 있다. "
      }
    },
    {
      "chunk_id": "chunk_075",
      "text": "| (출처: Thrive 홈페이지, | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 인사를 하는지 하지 않는지 볼 수 있도록 실험을 구상한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 74,
        "window_size": 3,
        "char_count": 77,
        "word_count": 18,
        "page_number": 3,
        "window_text": "BSS는 자살 사고 내용 뿐만 아니라 구체적인 | 어떻게(how) 수행할 것인지에 |\n| 관여하는 사람을 말한다.  | 되어야 한다.  | 치료요법을 이미 받는 자 | - 소프트웨어 기반 알람, 경고, 연산 메시지 | 영향을 보장할 수 있는 업데이트 유효성 검증 | C등급 | 심각한 부상 또는 사망이 발생할 가능성이 있다.  | (출처: Thrive 홈페이지, | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 인사를 하는지 하지 않는지 볼 수 있도록 실험을 구상한다.  | 신념이 자기 보호기능을 해왔거나 혹은 그것을 가짐으로써 | 최소한의 권고 사항 등 제시 |\n| - 임상시험 중 관찰 항목을 기술한다.  | 시험군과 대조군간의 비교 분석 방법을 통계적으로 타당하게 제시한다.  | 2 | 나는 다시 우울장애가 심해지면, 이 디지털치료기기를 사용할 것이다. ",
        "original_sentence": "| (출처: Thrive 홈페이지, | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 인사를 하는지 하지 않는지 볼 수 있도록 실험을 구상한다. "
      }
    },
    {
      "chunk_id": "chunk_076",
      "text": "| 신념이 자기 보호기능을 해왔거나 혹은 그것을 가짐으로써 | 최소한의 권고 사항 등 제시 |\n| - 임상시험 중 관찰 항목을 기술한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 75,
        "window_size": 3,
        "char_count": 77,
        "word_count": 22,
        "page_number": 3,
        "window_text": "| 되어야 한다.  | 치료요법을 이미 받는 자 | - 소프트웨어 기반 알람, 경고, 연산 메시지 | 영향을 보장할 수 있는 업데이트 유효성 검증 | C등급 | 심각한 부상 또는 사망이 발생할 가능성이 있다.  | (출처: Thrive 홈페이지, | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 인사를 하는지 하지 않는지 볼 수 있도록 실험을 구상한다.  | 신념이 자기 보호기능을 해왔거나 혹은 그것을 가짐으로써 | 최소한의 권고 사항 등 제시 |\n| - 임상시험 중 관찰 항목을 기술한다.  | 시험군과 대조군간의 비교 분석 방법을 통계적으로 타당하게 제시한다.  | 2 | 나는 다시 우울장애가 심해지면, 이 디지털치료기기를 사용할 것이다.  | schedul | 사이버보안 요구사항 | 해당기기 | Affective | Application of risk management | 이상)을 나타낸다. ",
        "original_sentence": "| 신념이 자기 보호기능을 해왔거나 혹은 그것을 가짐으로써 | 최소한의 권고 사항 등 제시 |\n| - 임상시험 중 관찰 항목을 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_077",
      "text": "| 시험군과 대조군간의 비교 분석 방법을 통계적으로 타당하게 제시한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 76,
        "window_size": 3,
        "char_count": 40,
        "word_count": 9,
        "page_number": 13,
        "window_text": "| 치료요법을 이미 받는 자 | - 소프트웨어 기반 알람, 경고, 연산 메시지 | 영향을 보장할 수 있는 업데이트 유효성 검증 | C등급 | 심각한 부상 또는 사망이 발생할 가능성이 있다.  | (출처: Thrive 홈페이지, | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 인사를 하는지 하지 않는지 볼 수 있도록 실험을 구상한다.  | 신념이 자기 보호기능을 해왔거나 혹은 그것을 가짐으로써 | 최소한의 권고 사항 등 제시 |\n| - 임상시험 중 관찰 항목을 기술한다.  | 시험군과 대조군간의 비교 분석 방법을 통계적으로 타당하게 제시한다.  | 2 | 나는 다시 우울장애가 심해지면, 이 디지털치료기기를 사용할 것이다.  | schedul | 사이버보안 요구사항 | 해당기기 | Affective | Application of risk management | 이상)을 나타낸다.  | 발휘하는지 확인한다. ",
        "original_sentence": "| 시험군과 대조군간의 비교 분석 방법을 통계적으로 타당하게 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_078",
      "text": "| 2 | 나는 다시 우울장애가 심해지면, 이 디지털치료기기를 사용할 것이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 77,
        "window_size": 3,
        "char_count": 44,
        "word_count": 11,
        "page_number": 9,
        "window_text": "| (출처: Thrive 홈페이지, | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 인사를 하는지 하지 않는지 볼 수 있도록 실험을 구상한다.  | 신념이 자기 보호기능을 해왔거나 혹은 그것을 가짐으로써 | 최소한의 권고 사항 등 제시 |\n| - 임상시험 중 관찰 항목을 기술한다.  | 시험군과 대조군간의 비교 분석 방법을 통계적으로 타당하게 제시한다.  | 2 | 나는 다시 우울장애가 심해지면, 이 디지털치료기기를 사용할 것이다.  | schedul | 사이버보안 요구사항 | 해당기기 | Affective | Application of risk management | 이상)을 나타낸다.  | 발휘하는지 확인한다.  | 잔여위험평가 | 적합성 | □ 예 | ■ 아니오 | 첨부자료 |\n| 1) 탈락 기준 | 2) 탈락 처리 | 되어 유효성에 대한 검증을 위해 사용될 예정이다. ",
        "original_sentence": "| 2 | 나는 다시 우울장애가 심해지면, 이 디지털치료기기를 사용할 것이다. "
      }
    },
    {
      "chunk_id": "chunk_079",
      "text": "| schedul | 사이버보안 요구사항 | 해당기기 | Affective | Application of risk management | 이상)을 나타낸다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 78,
        "window_size": 3,
        "char_count": 88,
        "word_count": 17,
        "page_number": 3,
        "window_text": "| 신념이 자기 보호기능을 해왔거나 혹은 그것을 가짐으로써 | 최소한의 권고 사항 등 제시 |\n| - 임상시험 중 관찰 항목을 기술한다.  | 시험군과 대조군간의 비교 분석 방법을 통계적으로 타당하게 제시한다.  | 2 | 나는 다시 우울장애가 심해지면, 이 디지털치료기기를 사용할 것이다.  | schedul | 사이버보안 요구사항 | 해당기기 | Affective | Application of risk management | 이상)을 나타낸다.  | 발휘하는지 확인한다.  | 잔여위험평가 | 적합성 | □ 예 | ■ 아니오 | 첨부자료 |\n| 1) 탈락 기준 | 2) 탈락 처리 | 되어 유효성에 대한 검증을 위해 사용될 예정이다.  | 이외 기타 치료 관련 변수와 같은 방식으로 측정할 수 있다. ",
        "original_sentence": "| schedul | 사이버보안 요구사항 | 해당기기 | Affective | Application of risk management | 이상)을 나타낸다. "
      }
    },
    {
      "chunk_id": "chunk_080",
      "text": "| 발휘하는지 확인한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 79,
        "window_size": 3,
        "char_count": 14,
        "word_count": 3,
        "page_number": 13,
        "window_text": "| 시험군과 대조군간의 비교 분석 방법을 통계적으로 타당하게 제시한다.  | 2 | 나는 다시 우울장애가 심해지면, 이 디지털치료기기를 사용할 것이다.  | schedul | 사이버보안 요구사항 | 해당기기 | Affective | Application of risk management | 이상)을 나타낸다.  | 발휘하는지 확인한다.  | 잔여위험평가 | 적합성 | □ 예 | ■ 아니오 | 첨부자료 |\n| 1) 탈락 기준 | 2) 탈락 처리 | 되어 유효성에 대한 검증을 위해 사용될 예정이다.  | 이외 기타 치료 관련 변수와 같은 방식으로 측정할 수 있다.  | 라) 피험자 식별코드 부여 | 아) 병용약물 조사 | 바) 병용약물 조사 | 라) 대조군 검사 시험방법 | 가) 치료 후 평가 | 가) 장기 효과 검증 | 반드시 필요한 것은 아니며 행정상 변경이 필요하다. ",
        "original_sentence": "| 발휘하는지 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_081",
      "text": "| 잔여위험평가 | 적합성 | □ 예 | ■ 아니오 | 첨부자료 |\n| 1) 탈락 기준 | 2) 탈락 처리 | 되어 유효성에 대한 검증을 위해 사용될 예정이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 80,
        "window_size": 3,
        "char_count": 90,
        "word_count": 29,
        "page_number": 3,
        "window_text": "| 2 | 나는 다시 우울장애가 심해지면, 이 디지털치료기기를 사용할 것이다.  | schedul | 사이버보안 요구사항 | 해당기기 | Affective | Application of risk management | 이상)을 나타낸다.  | 발휘하는지 확인한다.  | 잔여위험평가 | 적합성 | □ 예 | ■ 아니오 | 첨부자료 |\n| 1) 탈락 기준 | 2) 탈락 처리 | 되어 유효성에 대한 검증을 위해 사용될 예정이다.  | 이외 기타 치료 관련 변수와 같은 방식으로 측정할 수 있다.  | 라) 피험자 식별코드 부여 | 아) 병용약물 조사 | 바) 병용약물 조사 | 라) 대조군 검사 시험방법 | 가) 치료 후 평가 | 가) 장기 효과 검증 | 반드시 필요한 것은 아니며 행정상 변경이 필요하다.  | 필요하면 의료진 연결이 가능하도록 조치한다. ",
        "original_sentence": "| 잔여위험평가 | 적합성 | □ 예 | ■ 아니오 | 첨부자료 |\n| 1) 탈락 기준 | 2) 탈락 처리 | 되어 유효성에 대한 검증을 위해 사용될 예정이다. "
      }
    },
    {
      "chunk_id": "chunk_082",
      "text": "| 이외 기타 치료 관련 변수와 같은 방식으로 측정할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 81,
        "window_size": 3,
        "char_count": 36,
        "word_count": 11,
        "page_number": 11,
        "window_text": "| schedul | 사이버보안 요구사항 | 해당기기 | Affective | Application of risk management | 이상)을 나타낸다.  | 발휘하는지 확인한다.  | 잔여위험평가 | 적합성 | □ 예 | ■ 아니오 | 첨부자료 |\n| 1) 탈락 기준 | 2) 탈락 처리 | 되어 유효성에 대한 검증을 위해 사용될 예정이다.  | 이외 기타 치료 관련 변수와 같은 방식으로 측정할 수 있다.  | 라) 피험자 식별코드 부여 | 아) 병용약물 조사 | 바) 병용약물 조사 | 라) 대조군 검사 시험방법 | 가) 치료 후 평가 | 가) 장기 효과 검증 | 반드시 필요한 것은 아니며 행정상 변경이 필요하다.  | 필요하면 의료진 연결이 가능하도록 조치한다.  | 경우 | 하거나 확인할 수 없는 경우 | 신념 | 그림 2. ",
        "original_sentence": "| 이외 기타 치료 관련 변수와 같은 방식으로 측정할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_083",
      "text": "| 라) 피험자 식별코드 부여 | 아) 병용약물 조사 | 바) 병용약물 조사 | 라) 대조군 검사 시험방법 | 가) 치료 후 평가 | 가) 장기 효과 검증 | 반드시 필요한 것은 아니며 행정상 변경이 필요하다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 82,
        "window_size": 3,
        "char_count": 118,
        "word_count": 36,
        "page_number": 46,
        "window_text": "| 발휘하는지 확인한다.  | 잔여위험평가 | 적합성 | □ 예 | ■ 아니오 | 첨부자료 |\n| 1) 탈락 기준 | 2) 탈락 처리 | 되어 유효성에 대한 검증을 위해 사용될 예정이다.  | 이외 기타 치료 관련 변수와 같은 방식으로 측정할 수 있다.  | 라) 피험자 식별코드 부여 | 아) 병용약물 조사 | 바) 병용약물 조사 | 라) 대조군 검사 시험방법 | 가) 치료 후 평가 | 가) 장기 효과 검증 | 반드시 필요한 것은 아니며 행정상 변경이 필요하다.  | 필요하면 의료진 연결이 가능하도록 조치한다.  | 경우 | 하거나 확인할 수 없는 경우 | 신념 | 그림 2.  데이터 보호 및 보안성 영역 연구의 흐름 | 포함한 정신건강의학과적 증상 등) | 자살 특징(실제 자살 계획)까지도 확인할 수 있는 장점이 | OOO 기능이 구현되도록 입력값을 | 위험/ | 추가 |\n| 식별한 각 위해요인에 대하여 위험관리 계획서에 정의한 위험 | 2 | 관리에 관한 규정 제2조) | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? ",
        "original_sentence": "| 라) 피험자 식별코드 부여 | 아) 병용약물 조사 | 바) 병용약물 조사 | 라) 대조군 검사 시험방법 | 가) 치료 후 평가 | 가) 장기 효과 검증 | 반드시 필요한 것은 아니며 행정상 변경이 필요하다. "
      }
    },
    {
      "chunk_id": "chunk_084",
      "text": "| 필요하면 의료진 연결이 가능하도록 조치한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 83,
        "window_size": 3,
        "char_count": 27,
        "word_count": 6,
        "page_number": 13,
        "window_text": "| 잔여위험평가 | 적합성 | □ 예 | ■ 아니오 | 첨부자료 |\n| 1) 탈락 기준 | 2) 탈락 처리 | 되어 유효성에 대한 검증을 위해 사용될 예정이다.  | 이외 기타 치료 관련 변수와 같은 방식으로 측정할 수 있다.  | 라) 피험자 식별코드 부여 | 아) 병용약물 조사 | 바) 병용약물 조사 | 라) 대조군 검사 시험방법 | 가) 치료 후 평가 | 가) 장기 효과 검증 | 반드시 필요한 것은 아니며 행정상 변경이 필요하다.  | 필요하면 의료진 연결이 가능하도록 조치한다.  | 경우 | 하거나 확인할 수 없는 경우 | 신념 | 그림 2.  데이터 보호 및 보안성 영역 연구의 흐름 | 포함한 정신건강의학과적 증상 등) | 자살 특징(실제 자살 계획)까지도 확인할 수 있는 장점이 | OOO 기능이 구현되도록 입력값을 | 위험/ | 추가 |\n| 식별한 각 위해요인에 대하여 위험관리 계획서에 정의한 위험 | 2 | 관리에 관한 규정 제2조) | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 요구사항 | - 계획된 각각의 활동에서 기대되는 즐거움 혹은 성취 정도를 예측 | - 일련의 실험은 자신의 자동적 사고에 대한 비합리성을 인식하게 | 대하여, 소프트웨어가 수행할 수 | 허용 가능함을 검증한다. ",
        "original_sentence": "| 필요하면 의료진 연결이 가능하도록 조치한다. "
      }
    },
    {
      "chunk_id": "chunk_085",
      "text": "| 경우 | 하거나 확인할 수 없는 경우 | 신념 | 그림 2. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 84,
        "window_size": 3,
        "char_count": 36,
        "word_count": 13,
        "page_number": 9,
        "window_text": "| 이외 기타 치료 관련 변수와 같은 방식으로 측정할 수 있다.  | 라) 피험자 식별코드 부여 | 아) 병용약물 조사 | 바) 병용약물 조사 | 라) 대조군 검사 시험방법 | 가) 치료 후 평가 | 가) 장기 효과 검증 | 반드시 필요한 것은 아니며 행정상 변경이 필요하다.  | 필요하면 의료진 연결이 가능하도록 조치한다.  | 경우 | 하거나 확인할 수 없는 경우 | 신념 | 그림 2.  데이터 보호 및 보안성 영역 연구의 흐름 | 포함한 정신건강의학과적 증상 등) | 자살 특징(실제 자살 계획)까지도 확인할 수 있는 장점이 | OOO 기능이 구현되도록 입력값을 | 위험/ | 추가 |\n| 식별한 각 위해요인에 대하여 위험관리 계획서에 정의한 위험 | 2 | 관리에 관한 규정 제2조) | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 요구사항 | - 계획된 각각의 활동에서 기대되는 즐거움 혹은 성취 정도를 예측 | - 일련의 실험은 자신의 자동적 사고에 대한 비합리성을 인식하게 | 대하여, 소프트웨어가 수행할 수 | 허용 가능함을 검증한다.  | 소프트웨어 |\n| of patients with major depressive disorder. ",
        "original_sentence": "| 경우 | 하거나 확인할 수 없는 경우 | 신념 | 그림 2. "
      }
    },
    {
      "chunk_id": "chunk_086",
      "text": "데이터 보호 및 보안성 영역 연구의 흐름 | 포함한 정신건강의학과적 증상 등) | 자살 특징(실제 자살 계획)까지도 확인할 수 있는 장점이 | OOO 기능이 구현되도록 입력값을 | 위험/ | 추가 |\n| 식별한 각 위해요인에 대하여 위험관리 계획서에 정의한 위험 | 2 | 관리에 관한 규정 제2조) | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 85,
        "window_size": 3,
        "char_count": 211,
        "word_count": 56,
        "page_number": 41,
        "window_text": "| 라) 피험자 식별코드 부여 | 아) 병용약물 조사 | 바) 병용약물 조사 | 라) 대조군 검사 시험방법 | 가) 치료 후 평가 | 가) 장기 효과 검증 | 반드시 필요한 것은 아니며 행정상 변경이 필요하다.  | 필요하면 의료진 연결이 가능하도록 조치한다.  | 경우 | 하거나 확인할 수 없는 경우 | 신념 | 그림 2.  데이터 보호 및 보안성 영역 연구의 흐름 | 포함한 정신건강의학과적 증상 등) | 자살 특징(실제 자살 계획)까지도 확인할 수 있는 장점이 | OOO 기능이 구현되도록 입력값을 | 위험/ | 추가 |\n| 식별한 각 위해요인에 대하여 위험관리 계획서에 정의한 위험 | 2 | 관리에 관한 규정 제2조) | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 요구사항 | - 계획된 각각의 활동에서 기대되는 즐거움 혹은 성취 정도를 예측 | - 일련의 실험은 자신의 자동적 사고에 대한 비합리성을 인식하게 | 대하여, 소프트웨어가 수행할 수 | 허용 가능함을 검증한다.  | 소프트웨어 |\n| of patients with major depressive disorder.  Am J Psychiatry, 167(Suppl 10), 9-118. ",
        "original_sentence": "데이터 보호 및 보안성 영역 연구의 흐름 | 포함한 정신건강의학과적 증상 등) | 자살 특징(실제 자살 계획)까지도 확인할 수 있는 장점이 | OOO 기능이 구현되도록 입력값을 | 위험/ | 추가 |\n| 식별한 각 위해요인에 대하여 위험관리 계획서에 정의한 위험 | 2 | 관리에 관한 규정 제2조) | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_087",
      "text": "| 요구사항 | - 계획된 각각의 활동에서 기대되는 즐거움 혹은 성취 정도를 예측 | - 일련의 실험은 자신의 자동적 사고에 대한 비합리성을 인식하게 | 대하여, 소프트웨어가 수행할 수 | 허용 가능함을 검증한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 86,
        "window_size": 3,
        "char_count": 120,
        "word_count": 32,
        "page_number": 3,
        "window_text": "| 필요하면 의료진 연결이 가능하도록 조치한다.  | 경우 | 하거나 확인할 수 없는 경우 | 신념 | 그림 2.  데이터 보호 및 보안성 영역 연구의 흐름 | 포함한 정신건강의학과적 증상 등) | 자살 특징(실제 자살 계획)까지도 확인할 수 있는 장점이 | OOO 기능이 구현되도록 입력값을 | 위험/ | 추가 |\n| 식별한 각 위해요인에 대하여 위험관리 계획서에 정의한 위험 | 2 | 관리에 관한 규정 제2조) | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 요구사항 | - 계획된 각각의 활동에서 기대되는 즐거움 혹은 성취 정도를 예측 | - 일련의 실험은 자신의 자동적 사고에 대한 비합리성을 인식하게 | 대하여, 소프트웨어가 수행할 수 | 허용 가능함을 검증한다.  | 소프트웨어 |\n| of patients with major depressive disorder.  Am J Psychiatry, 167(Suppl 10), 9-118.  | - 공동연구자는 의학통계 전문가, 의료기기 전문가 등을 말한다. ",
        "original_sentence": "| 요구사항 | - 계획된 각각의 활동에서 기대되는 즐거움 혹은 성취 정도를 예측 | - 일련의 실험은 자신의 자동적 사고에 대한 비합리성을 인식하게 | 대하여, 소프트웨어가 수행할 수 | 허용 가능함을 검증한다. "
      }
    },
    {
      "chunk_id": "chunk_088",
      "text": "| 소프트웨어 |\n| of patients with major depressive disorder. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 87,
        "window_size": 3,
        "char_count": 56,
        "word_count": 10,
        "page_number": 9,
        "window_text": "| 경우 | 하거나 확인할 수 없는 경우 | 신념 | 그림 2.  데이터 보호 및 보안성 영역 연구의 흐름 | 포함한 정신건강의학과적 증상 등) | 자살 특징(실제 자살 계획)까지도 확인할 수 있는 장점이 | OOO 기능이 구현되도록 입력값을 | 위험/ | 추가 |\n| 식별한 각 위해요인에 대하여 위험관리 계획서에 정의한 위험 | 2 | 관리에 관한 규정 제2조) | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 요구사항 | - 계획된 각각의 활동에서 기대되는 즐거움 혹은 성취 정도를 예측 | - 일련의 실험은 자신의 자동적 사고에 대한 비합리성을 인식하게 | 대하여, 소프트웨어가 수행할 수 | 허용 가능함을 검증한다.  | 소프트웨어 |\n| of patients with major depressive disorder.  Am J Psychiatry, 167(Suppl 10), 9-118.  | - 공동연구자는 의학통계 전문가, 의료기기 전문가 등을 말한다.  | 시험이 완료되지 못한 경우를 말하며, 그 분류기준을 ‘탈락 기준’에, 탈락의 사유와 | - 시험군 : 디지털 우울장애 인지행동치료군 | 척도(BDI) 변화량 | https://play.google.com/store/a | 의료기기의 사이버보안 | 위험통제 | 이점이 있을 때 잘못된 신념을 포기하지 않으려 한다. ",
        "original_sentence": "| 소프트웨어 |\n| of patients with major depressive disorder. "
      }
    },
    {
      "chunk_id": "chunk_089",
      "text": "Am J Psychiatry, 167(Suppl 10), 9-118. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 88,
        "window_size": 3,
        "char_count": 39,
        "word_count": 6,
        "page_number": 28,
        "window_text": "데이터 보호 및 보안성 영역 연구의 흐름 | 포함한 정신건강의학과적 증상 등) | 자살 특징(실제 자살 계획)까지도 확인할 수 있는 장점이 | OOO 기능이 구현되도록 입력값을 | 위험/ | 추가 |\n| 식별한 각 위해요인에 대하여 위험관리 계획서에 정의한 위험 | 2 | 관리에 관한 규정 제2조) | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 요구사항 | - 계획된 각각의 활동에서 기대되는 즐거움 혹은 성취 정도를 예측 | - 일련의 실험은 자신의 자동적 사고에 대한 비합리성을 인식하게 | 대하여, 소프트웨어가 수행할 수 | 허용 가능함을 검증한다.  | 소프트웨어 |\n| of patients with major depressive disorder.  Am J Psychiatry, 167(Suppl 10), 9-118.  | - 공동연구자는 의학통계 전문가, 의료기기 전문가 등을 말한다.  | 시험이 완료되지 못한 경우를 말하며, 그 분류기준을 ‘탈락 기준’에, 탈락의 사유와 | - 시험군 : 디지털 우울장애 인지행동치료군 | 척도(BDI) 변화량 | https://play.google.com/store/a | 의료기기의 사이버보안 | 위험통제 | 이점이 있을 때 잘못된 신념을 포기하지 않으려 한다.  | HADS는 병원을 방문한 환자의 불안, 우울 정도와 감정 | 발생 | 의료기기 | 사이버보안 | 적용 | 방법과 | 심 | 위 |\n| 기기 | 1 | 최소 응답시간 | OO초 미만일 것 | 3 | 나는 내 주변의 우울장애 환자에게, 이 디지털치료기기를 추천할 것이다. ",
        "original_sentence": "Am J Psychiatry, 167(Suppl 10), 9-118. "
      }
    },
    {
      "chunk_id": "chunk_090",
      "text": "| - 공동연구자는 의학통계 전문가, 의료기기 전문가 등을 말한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 89,
        "window_size": 3,
        "char_count": 38,
        "word_count": 9,
        "page_number": 13,
        "window_text": "| 요구사항 | - 계획된 각각의 활동에서 기대되는 즐거움 혹은 성취 정도를 예측 | - 일련의 실험은 자신의 자동적 사고에 대한 비합리성을 인식하게 | 대하여, 소프트웨어가 수행할 수 | 허용 가능함을 검증한다.  | 소프트웨어 |\n| of patients with major depressive disorder.  Am J Psychiatry, 167(Suppl 10), 9-118.  | - 공동연구자는 의학통계 전문가, 의료기기 전문가 등을 말한다.  | 시험이 완료되지 못한 경우를 말하며, 그 분류기준을 ‘탈락 기준’에, 탈락의 사유와 | - 시험군 : 디지털 우울장애 인지행동치료군 | 척도(BDI) 변화량 | https://play.google.com/store/a | 의료기기의 사이버보안 | 위험통제 | 이점이 있을 때 잘못된 신념을 포기하지 않으려 한다.  | HADS는 병원을 방문한 환자의 불안, 우울 정도와 감정 | 발생 | 의료기기 | 사이버보안 | 적용 | 방법과 | 심 | 위 |\n| 기기 | 1 | 최소 응답시간 | OO초 미만일 것 | 3 | 나는 내 주변의 우울장애 환자에게, 이 디지털치료기기를 추천할 것이다.  | 제조자는 기기 소프트웨어의 비인가된 변경과 | 변화를 | ing | disorder | for IT-networks incorporating | Medical devices | 진행 상황을 추적할 수 있도록 한다. ",
        "original_sentence": "| - 공동연구자는 의학통계 전문가, 의료기기 전문가 등을 말한다. "
      }
    },
    {
      "chunk_id": "chunk_091",
      "text": "| 시험이 완료되지 못한 경우를 말하며, 그 분류기준을 ‘탈락 기준’에, 탈락의 사유와 | - 시험군 : 디지털 우울장애 인지행동치료군 | 척도(BDI) 변화량 | https://play.google.com/store/a | 의료기기의 사이버보안 | 위험통제 | 이점이 있을 때 잘못된 신념을 포기하지 않으려 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 90,
        "window_size": 3,
        "char_count": 177,
        "word_count": 38,
        "page_number": 39,
        "window_text": "| 소프트웨어 |\n| of patients with major depressive disorder.  Am J Psychiatry, 167(Suppl 10), 9-118.  | - 공동연구자는 의학통계 전문가, 의료기기 전문가 등을 말한다.  | 시험이 완료되지 못한 경우를 말하며, 그 분류기준을 ‘탈락 기준’에, 탈락의 사유와 | - 시험군 : 디지털 우울장애 인지행동치료군 | 척도(BDI) 변화량 | https://play.google.com/store/a | 의료기기의 사이버보안 | 위험통제 | 이점이 있을 때 잘못된 신념을 포기하지 않으려 한다.  | HADS는 병원을 방문한 환자의 불안, 우울 정도와 감정 | 발생 | 의료기기 | 사이버보안 | 적용 | 방법과 | 심 | 위 |\n| 기기 | 1 | 최소 응답시간 | OO초 미만일 것 | 3 | 나는 내 주변의 우울장애 환자에게, 이 디지털치료기기를 추천할 것이다.  | 제조자는 기기 소프트웨어의 비인가된 변경과 | 변화를 | ing | disorder | for IT-networks incorporating | Medical devices | 진행 상황을 추적할 수 있도록 한다.  | 적용여부 | 입력한 후 그에 대한 응답시간을 | 입증 방법 | 또는 |\n| 위험통제 조치 | - 임상시험 후 이상반응 확인에 대해서 기술한다. ",
        "original_sentence": "| 시험이 완료되지 못한 경우를 말하며, 그 분류기준을 ‘탈락 기준’에, 탈락의 사유와 | - 시험군 : 디지털 우울장애 인지행동치료군 | 척도(BDI) 변화량 | https://play.google.com/store/a | 의료기기의 사이버보안 | 위험통제 | 이점이 있을 때 잘못된 신념을 포기하지 않으려 한다. "
      }
    },
    {
      "chunk_id": "chunk_092",
      "text": "| HADS는 병원을 방문한 환자의 불안, 우울 정도와 감정 | 발생 | 의료기기 | 사이버보안 | 적용 | 방법과 | 심 | 위 |\n| 기기 | 1 | 최소 응답시간 | OO초 미만일 것 | 3 | 나는 내 주변의 우울장애 환자에게, 이 디지털치료기기를 추천할 것이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 91,
        "window_size": 3,
        "char_count": 152,
        "word_count": 47,
        "page_number": 38,
        "window_text": "Am J Psychiatry, 167(Suppl 10), 9-118.  | - 공동연구자는 의학통계 전문가, 의료기기 전문가 등을 말한다.  | 시험이 완료되지 못한 경우를 말하며, 그 분류기준을 ‘탈락 기준’에, 탈락의 사유와 | - 시험군 : 디지털 우울장애 인지행동치료군 | 척도(BDI) 변화량 | https://play.google.com/store/a | 의료기기의 사이버보안 | 위험통제 | 이점이 있을 때 잘못된 신념을 포기하지 않으려 한다.  | HADS는 병원을 방문한 환자의 불안, 우울 정도와 감정 | 발생 | 의료기기 | 사이버보안 | 적용 | 방법과 | 심 | 위 |\n| 기기 | 1 | 최소 응답시간 | OO초 미만일 것 | 3 | 나는 내 주변의 우울장애 환자에게, 이 디지털치료기기를 추천할 것이다.  | 제조자는 기기 소프트웨어의 비인가된 변경과 | 변화를 | ing | disorder | for IT-networks incorporating | Medical devices | 진행 상황을 추적할 수 있도록 한다.  | 적용여부 | 입력한 후 그에 대한 응답시간을 | 입증 방법 | 또는 |\n| 위험통제 조치 | - 임상시험 후 이상반응 확인에 대해서 기술한다.  | - 통계 분석 방법에 따른 통계적 유의성에 대한 평가 방법과 기준을 제시한다. ",
        "original_sentence": "| HADS는 병원을 방문한 환자의 불안, 우울 정도와 감정 | 발생 | 의료기기 | 사이버보안 | 적용 | 방법과 | 심 | 위 |\n| 기기 | 1 | 최소 응답시간 | OO초 미만일 것 | 3 | 나는 내 주변의 우울장애 환자에게, 이 디지털치료기기를 추천할 것이다. "
      }
    },
    {
      "chunk_id": "chunk_093",
      "text": "| 제조자는 기기 소프트웨어의 비인가된 변경과 | 변화를 | ing | disorder | for IT-networks incorporating | Medical devices | 진행 상황을 추적할 수 있도록 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 92,
        "window_size": 3,
        "char_count": 122,
        "word_count": 26,
        "page_number": 9,
        "window_text": "| - 공동연구자는 의학통계 전문가, 의료기기 전문가 등을 말한다.  | 시험이 완료되지 못한 경우를 말하며, 그 분류기준을 ‘탈락 기준’에, 탈락의 사유와 | - 시험군 : 디지털 우울장애 인지행동치료군 | 척도(BDI) 변화량 | https://play.google.com/store/a | 의료기기의 사이버보안 | 위험통제 | 이점이 있을 때 잘못된 신념을 포기하지 않으려 한다.  | HADS는 병원을 방문한 환자의 불안, 우울 정도와 감정 | 발생 | 의료기기 | 사이버보안 | 적용 | 방법과 | 심 | 위 |\n| 기기 | 1 | 최소 응답시간 | OO초 미만일 것 | 3 | 나는 내 주변의 우울장애 환자에게, 이 디지털치료기기를 추천할 것이다.  | 제조자는 기기 소프트웨어의 비인가된 변경과 | 변화를 | ing | disorder | for IT-networks incorporating | Medical devices | 진행 상황을 추적할 수 있도록 한다.  | 적용여부 | 입력한 후 그에 대한 응답시간을 | 입증 방법 | 또는 |\n| 위험통제 조치 | - 임상시험 후 이상반응 확인에 대해서 기술한다.  | - 통계 분석 방법에 따른 통계적 유의성에 대한 평가 방법과 기준을 제시한다.  | - 데이터베이스 요구사항 | - 모델명: ○○○ | 으로 노출되면 ‘불순응’으로 판단한다. ",
        "original_sentence": "| 제조자는 기기 소프트웨어의 비인가된 변경과 | 변화를 | ing | disorder | for IT-networks incorporating | Medical devices | 진행 상황을 추적할 수 있도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_094",
      "text": "| 적용여부 | 입력한 후 그에 대한 응답시간을 | 입증 방법 | 또는 |\n| 위험통제 조치 | - 임상시험 후 이상반응 확인에 대해서 기술한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 93,
        "window_size": 3,
        "char_count": 82,
        "word_count": 25,
        "page_number": 3,
        "window_text": "| 시험이 완료되지 못한 경우를 말하며, 그 분류기준을 ‘탈락 기준’에, 탈락의 사유와 | - 시험군 : 디지털 우울장애 인지행동치료군 | 척도(BDI) 변화량 | https://play.google.com/store/a | 의료기기의 사이버보안 | 위험통제 | 이점이 있을 때 잘못된 신념을 포기하지 않으려 한다.  | HADS는 병원을 방문한 환자의 불안, 우울 정도와 감정 | 발생 | 의료기기 | 사이버보안 | 적용 | 방법과 | 심 | 위 |\n| 기기 | 1 | 최소 응답시간 | OO초 미만일 것 | 3 | 나는 내 주변의 우울장애 환자에게, 이 디지털치료기기를 추천할 것이다.  | 제조자는 기기 소프트웨어의 비인가된 변경과 | 변화를 | ing | disorder | for IT-networks incorporating | Medical devices | 진행 상황을 추적할 수 있도록 한다.  | 적용여부 | 입력한 후 그에 대한 응답시간을 | 입증 방법 | 또는 |\n| 위험통제 조치 | - 임상시험 후 이상반응 확인에 대해서 기술한다.  | - 통계 분석 방법에 따른 통계적 유의성에 대한 평가 방법과 기준을 제시한다.  | - 데이터베이스 요구사항 | - 모델명: ○○○ | 으로 노출되면 ‘불순응’으로 판단한다.  | 있다. ",
        "original_sentence": "| 적용여부 | 입력한 후 그에 대한 응답시간을 | 입증 방법 | 또는 |\n| 위험통제 조치 | - 임상시험 후 이상반응 확인에 대해서 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_095",
      "text": "| - 통계 분석 방법에 따른 통계적 유의성에 대한 평가 방법과 기준을 제시한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 94,
        "window_size": 3,
        "char_count": 46,
        "word_count": 13,
        "page_number": 13,
        "window_text": "| HADS는 병원을 방문한 환자의 불안, 우울 정도와 감정 | 발생 | 의료기기 | 사이버보안 | 적용 | 방법과 | 심 | 위 |\n| 기기 | 1 | 최소 응답시간 | OO초 미만일 것 | 3 | 나는 내 주변의 우울장애 환자에게, 이 디지털치료기기를 추천할 것이다.  | 제조자는 기기 소프트웨어의 비인가된 변경과 | 변화를 | ing | disorder | for IT-networks incorporating | Medical devices | 진행 상황을 추적할 수 있도록 한다.  | 적용여부 | 입력한 후 그에 대한 응답시간을 | 입증 방법 | 또는 |\n| 위험통제 조치 | - 임상시험 후 이상반응 확인에 대해서 기술한다.  | - 통계 분석 방법에 따른 통계적 유의성에 대한 평가 방법과 기준을 제시한다.  | - 데이터베이스 요구사항 | - 모델명: ○○○ | 으로 노출되면 ‘불순응’으로 판단한다.  | 있다.  | 결과 | 이득 | 발생 |\n| 2) 국내 가이드라인별 적용 기준 | 1) 시험기기 및 대조기기 정보 | - 이런 경우 그 같은 신념을 유지함으로써 오는 손해와 이익을 | 정의 | 하면 도움이 된다. ",
        "original_sentence": "| - 통계 분석 방법에 따른 통계적 유의성에 대한 평가 방법과 기준을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_096",
      "text": "| - 데이터베이스 요구사항 | - 모델명: ○○○ | 으로 노출되면 ‘불순응’으로 판단한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 95,
        "window_size": 3,
        "char_count": 53,
        "word_count": 13,
        "page_number": 3,
        "window_text": "| 제조자는 기기 소프트웨어의 비인가된 변경과 | 변화를 | ing | disorder | for IT-networks incorporating | Medical devices | 진행 상황을 추적할 수 있도록 한다.  | 적용여부 | 입력한 후 그에 대한 응답시간을 | 입증 방법 | 또는 |\n| 위험통제 조치 | - 임상시험 후 이상반응 확인에 대해서 기술한다.  | - 통계 분석 방법에 따른 통계적 유의성에 대한 평가 방법과 기준을 제시한다.  | - 데이터베이스 요구사항 | - 모델명: ○○○ | 으로 노출되면 ‘불순응’으로 판단한다.  | 있다.  | 결과 | 이득 | 발생 |\n| 2) 국내 가이드라인별 적용 기준 | 1) 시험기기 및 대조기기 정보 | - 이런 경우 그 같은 신념을 유지함으로써 오는 손해와 이익을 | 정의 | 하면 도움이 된다.  이러한 활동에 장애를 예상해보고 그에 대한 | 하고, 더 합리적인 사고로 변화 필요성을 깨닫게 한다. ",
        "original_sentence": "| - 데이터베이스 요구사항 | - 모델명: ○○○ | 으로 노출되면 ‘불순응’으로 판단한다. "
      }
    },
    {
      "chunk_id": "chunk_097",
      "text": "| 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 96,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 11,
        "window_text": "| 적용여부 | 입력한 후 그에 대한 응답시간을 | 입증 방법 | 또는 |\n| 위험통제 조치 | - 임상시험 후 이상반응 확인에 대해서 기술한다.  | - 통계 분석 방법에 따른 통계적 유의성에 대한 평가 방법과 기준을 제시한다.  | - 데이터베이스 요구사항 | - 모델명: ○○○ | 으로 노출되면 ‘불순응’으로 판단한다.  | 있다.  | 결과 | 이득 | 발생 |\n| 2) 국내 가이드라인별 적용 기준 | 1) 시험기기 및 대조기기 정보 | - 이런 경우 그 같은 신념을 유지함으로써 오는 손해와 이익을 | 정의 | 하면 도움이 된다.  이러한 활동에 장애를 예상해보고 그에 대한 | 하고, 더 합리적인 사고로 변화 필요성을 깨닫게 한다.  | 있는 논리적이고 물리적인 표현 | 2 | E06070.01 | 독일 DiGA 디렉터리에 등록되었다. ",
        "original_sentence": "| 있다. "
      }
    },
    {
      "chunk_id": "chunk_098",
      "text": "| 결과 | 이득 | 발생 |\n| 2) 국내 가이드라인별 적용 기준 | 1) 시험기기 및 대조기기 정보 | - 이런 경우 그 같은 신념을 유지함으로써 오는 손해와 이익을 | 정의 | 하면 도움이 된다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 97,
        "window_size": 3,
        "char_count": 113,
        "word_count": 36,
        "page_number": 9,
        "window_text": "| - 통계 분석 방법에 따른 통계적 유의성에 대한 평가 방법과 기준을 제시한다.  | - 데이터베이스 요구사항 | - 모델명: ○○○ | 으로 노출되면 ‘불순응’으로 판단한다.  | 있다.  | 결과 | 이득 | 발생 |\n| 2) 국내 가이드라인별 적용 기준 | 1) 시험기기 및 대조기기 정보 | - 이런 경우 그 같은 신념을 유지함으로써 오는 손해와 이익을 | 정의 | 하면 도움이 된다.  이러한 활동에 장애를 예상해보고 그에 대한 | 하고, 더 합리적인 사고로 변화 필요성을 깨닫게 한다.  | 있는 논리적이고 물리적인 표현 | 2 | E06070.01 | 독일 DiGA 디렉터리에 등록되었다.  | 용하는 소프트웨어 | 의료기기 품질관리 (Quality | 검증 및 |\n| 5 | · 관찰 시기를 표기한다. ",
        "original_sentence": "| 결과 | 이득 | 발생 |\n| 2) 국내 가이드라인별 적용 기준 | 1) 시험기기 및 대조기기 정보 | - 이런 경우 그 같은 신념을 유지함으로써 오는 손해와 이익을 | 정의 | 하면 도움이 된다. "
      }
    },
    {
      "chunk_id": "chunk_099",
      "text": "이러한 활동에 장애를 예상해보고 그에 대한 | 하고, 더 합리적인 사고로 변화 필요성을 깨닫게 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 98,
        "window_size": 3,
        "char_count": 57,
        "word_count": 15,
        "page_number": 18,
        "window_text": "| - 데이터베이스 요구사항 | - 모델명: ○○○ | 으로 노출되면 ‘불순응’으로 판단한다.  | 있다.  | 결과 | 이득 | 발생 |\n| 2) 국내 가이드라인별 적용 기준 | 1) 시험기기 및 대조기기 정보 | - 이런 경우 그 같은 신념을 유지함으로써 오는 손해와 이익을 | 정의 | 하면 도움이 된다.  이러한 활동에 장애를 예상해보고 그에 대한 | 하고, 더 합리적인 사고로 변화 필요성을 깨닫게 한다.  | 있는 논리적이고 물리적인 표현 | 2 | E06070.01 | 독일 DiGA 디렉터리에 등록되었다.  | 용하는 소프트웨어 | 의료기기 품질관리 (Quality | 검증 및 |\n| 5 | · 관찰 시기를 표기한다.  | ○ 의료기기의 오류(결함)로 인한 오진률 발생 가능성 | ○ 관련성이 의심됨(Possibly related) | 고지와 관련된 모든 사항을 문서화해야 한다. ",
        "original_sentence": "이러한 활동에 장애를 예상해보고 그에 대한 | 하고, 더 합리적인 사고로 변화 필요성을 깨닫게 한다. "
      }
    },
    {
      "chunk_id": "chunk_100",
      "text": "| 있는 논리적이고 물리적인 표현 | 2 | E06070.01 | 독일 DiGA 디렉터리에 등록되었다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 99,
        "window_size": 3,
        "char_count": 58,
        "word_count": 14,
        "page_number": 9,
        "window_text": "| 있다.  | 결과 | 이득 | 발생 |\n| 2) 국내 가이드라인별 적용 기준 | 1) 시험기기 및 대조기기 정보 | - 이런 경우 그 같은 신념을 유지함으로써 오는 손해와 이익을 | 정의 | 하면 도움이 된다.  이러한 활동에 장애를 예상해보고 그에 대한 | 하고, 더 합리적인 사고로 변화 필요성을 깨닫게 한다.  | 있는 논리적이고 물리적인 표현 | 2 | E06070.01 | 독일 DiGA 디렉터리에 등록되었다.  | 용하는 소프트웨어 | 의료기기 품질관리 (Quality | 검증 및 |\n| 5 | · 관찰 시기를 표기한다.  | ○ 의료기기의 오류(결함)로 인한 오진률 발생 가능성 | ○ 관련성이 의심됨(Possibly related) | 고지와 관련된 모든 사항을 문서화해야 한다.  | 보관(연구파일) 등을 확인한다. ",
        "original_sentence": "| 있는 논리적이고 물리적인 표현 | 2 | E06070.01 | 독일 DiGA 디렉터리에 등록되었다. "
      }
    },
    {
      "chunk_id": "chunk_101",
      "text": "| 용하는 소프트웨어 | 의료기기 품질관리 (Quality | 검증 및 |\n| 5 | · 관찰 시기를 표기한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 100,
        "window_size": 3,
        "char_count": 63,
        "word_count": 18,
        "page_number": 9,
        "window_text": "| 결과 | 이득 | 발생 |\n| 2) 국내 가이드라인별 적용 기준 | 1) 시험기기 및 대조기기 정보 | - 이런 경우 그 같은 신념을 유지함으로써 오는 손해와 이익을 | 정의 | 하면 도움이 된다.  이러한 활동에 장애를 예상해보고 그에 대한 | 하고, 더 합리적인 사고로 변화 필요성을 깨닫게 한다.  | 있는 논리적이고 물리적인 표현 | 2 | E06070.01 | 독일 DiGA 디렉터리에 등록되었다.  | 용하는 소프트웨어 | 의료기기 품질관리 (Quality | 검증 및 |\n| 5 | · 관찰 시기를 표기한다.  | ○ 의료기기의 오류(결함)로 인한 오진률 발생 가능성 | ○ 관련성이 의심됨(Possibly related) | 고지와 관련된 모든 사항을 문서화해야 한다.  | 보관(연구파일) 등을 확인한다.  | 포함된다. ",
        "original_sentence": "| 용하는 소프트웨어 | 의료기기 품질관리 (Quality | 검증 및 |\n| 5 | · 관찰 시기를 표기한다. "
      }
    },
    {
      "chunk_id": "chunk_102",
      "text": "| ○ 의료기기의 오류(결함)로 인한 오진률 발생 가능성 | ○ 관련성이 의심됨(Possibly related) | 고지와 관련된 모든 사항을 문서화해야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 101,
        "window_size": 3,
        "char_count": 90,
        "word_count": 20,
        "page_number": 38,
        "window_text": "이러한 활동에 장애를 예상해보고 그에 대한 | 하고, 더 합리적인 사고로 변화 필요성을 깨닫게 한다.  | 있는 논리적이고 물리적인 표현 | 2 | E06070.01 | 독일 DiGA 디렉터리에 등록되었다.  | 용하는 소프트웨어 | 의료기기 품질관리 (Quality | 검증 및 |\n| 5 | · 관찰 시기를 표기한다.  | ○ 의료기기의 오류(결함)로 인한 오진률 발생 가능성 | ○ 관련성이 의심됨(Possibly related) | 고지와 관련된 모든 사항을 문서화해야 한다.  | 보관(연구파일) 등을 확인한다.  | 포함된다.  | - 외래 방문마다 병용약물을 수집하여 기록한다. ",
        "original_sentence": "| ○ 의료기기의 오류(결함)로 인한 오진률 발생 가능성 | ○ 관련성이 의심됨(Possibly related) | 고지와 관련된 모든 사항을 문서화해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_103",
      "text": "| 보관(연구파일) 등을 확인한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 102,
        "window_size": 3,
        "char_count": 20,
        "word_count": 4,
        "page_number": 13,
        "window_text": "| 있는 논리적이고 물리적인 표현 | 2 | E06070.01 | 독일 DiGA 디렉터리에 등록되었다.  | 용하는 소프트웨어 | 의료기기 품질관리 (Quality | 검증 및 |\n| 5 | · 관찰 시기를 표기한다.  | ○ 의료기기의 오류(결함)로 인한 오진률 발생 가능성 | ○ 관련성이 의심됨(Possibly related) | 고지와 관련된 모든 사항을 문서화해야 한다.  | 보관(연구파일) 등을 확인한다.  | 포함된다.  | - 외래 방문마다 병용약물을 수집하여 기록한다.  | - 약물 복용력 등을 문진과 과거 진료기록을 통해 조사한다. ",
        "original_sentence": "| 보관(연구파일) 등을 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_104",
      "text": "| 포함된다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 103,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 125,
        "window_text": "| 용하는 소프트웨어 | 의료기기 품질관리 (Quality | 검증 및 |\n| 5 | · 관찰 시기를 표기한다.  | ○ 의료기기의 오류(결함)로 인한 오진률 발생 가능성 | ○ 관련성이 의심됨(Possibly related) | 고지와 관련된 모든 사항을 문서화해야 한다.  | 보관(연구파일) 등을 확인한다.  | 포함된다.  | - 외래 방문마다 병용약물을 수집하여 기록한다.  | - 약물 복용력 등을 문진과 과거 진료기록을 통해 조사한다.  | pps/details?id=com.waypointh | 치료기기 대상이라고 판단할 수 있다. ",
        "original_sentence": "| 포함된다. "
      }
    },
    {
      "chunk_id": "chunk_105",
      "text": "| - 외래 방문마다 병용약물을 수집하여 기록한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 104,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 13,
        "window_text": "| ○ 의료기기의 오류(결함)로 인한 오진률 발생 가능성 | ○ 관련성이 의심됨(Possibly related) | 고지와 관련된 모든 사항을 문서화해야 한다.  | 보관(연구파일) 등을 확인한다.  | 포함된다.  | - 외래 방문마다 병용약물을 수집하여 기록한다.  | - 약물 복용력 등을 문진과 과거 진료기록을 통해 조사한다.  | pps/details?id=com.waypointh | 치료기기 대상이라고 판단할 수 있다.  | 제조자는 업데이트의 수행하기 위해 어떤 | 알게 된 날로부터 15일 이내 보고한다. ",
        "original_sentence": "| - 외래 방문마다 병용약물을 수집하여 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_106",
      "text": "| - 약물 복용력 등을 문진과 과거 진료기록을 통해 조사한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 105,
        "window_size": 3,
        "char_count": 36,
        "word_count": 10,
        "page_number": 13,
        "window_text": "| 보관(연구파일) 등을 확인한다.  | 포함된다.  | - 외래 방문마다 병용약물을 수집하여 기록한다.  | - 약물 복용력 등을 문진과 과거 진료기록을 통해 조사한다.  | pps/details?id=com.waypointh | 치료기기 대상이라고 판단할 수 있다.  | 제조자는 업데이트의 수행하기 위해 어떤 | 알게 된 날로부터 15일 이내 보고한다.  | 부여한다. ",
        "original_sentence": "| - 약물 복용력 등을 문진과 과거 진료기록을 통해 조사한다. "
      }
    },
    {
      "chunk_id": "chunk_107",
      "text": "| pps/details?id=com.waypointh | 치료기기 대상이라고 판단할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 106,
        "window_size": 3,
        "char_count": 54,
        "word_count": 8,
        "page_number": 29,
        "window_text": "| 포함된다.  | - 외래 방문마다 병용약물을 수집하여 기록한다.  | - 약물 복용력 등을 문진과 과거 진료기록을 통해 조사한다.  | pps/details?id=com.waypointh | 치료기기 대상이라고 판단할 수 있다.  | 제조자는 업데이트의 수행하기 위해 어떤 | 알게 된 날로부터 15일 이내 보고한다.  | 부여한다.  | 처리 없이 수집된 자료로 분석한다. ",
        "original_sentence": "| pps/details?id=com.waypointh | 치료기기 대상이라고 판단할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_108",
      "text": "| 제조자는 업데이트의 수행하기 위해 어떤 | 알게 된 날로부터 15일 이내 보고한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 107,
        "window_size": 3,
        "char_count": 49,
        "word_count": 13,
        "page_number": 13,
        "window_text": "| - 외래 방문마다 병용약물을 수집하여 기록한다.  | - 약물 복용력 등을 문진과 과거 진료기록을 통해 조사한다.  | pps/details?id=com.waypointh | 치료기기 대상이라고 판단할 수 있다.  | 제조자는 업데이트의 수행하기 위해 어떤 | 알게 된 날로부터 15일 이내 보고한다.  | 부여한다.  | 처리 없이 수집된 자료로 분석한다.  | 적용방법 및 사례집 | 조치실행 | 상태의 변화를 매우 신속하게 간단하게 평가하고자 고안 | 가능 | 허가신청 시 제출하는 자료의 작성 | 각 | 험 | 소프트웨어 | 국내 |\n| 소프트웨어 | 등록대상 | - 각 임상시험기관의 적절한 임상시험의 수행을 위하여 임상시험기관 및 시험자의 | 관련 임상자료의 처리 방법을 ‘탈락 처리’에 구체적으로 제시한다. ",
        "original_sentence": "| 제조자는 업데이트의 수행하기 위해 어떤 | 알게 된 날로부터 15일 이내 보고한다. "
      }
    },
    {
      "chunk_id": "chunk_109",
      "text": "| 부여한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 108,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 13,
        "window_text": "| - 약물 복용력 등을 문진과 과거 진료기록을 통해 조사한다.  | pps/details?id=com.waypointh | 치료기기 대상이라고 판단할 수 있다.  | 제조자는 업데이트의 수행하기 위해 어떤 | 알게 된 날로부터 15일 이내 보고한다.  | 부여한다.  | 처리 없이 수집된 자료로 분석한다.  | 적용방법 및 사례집 | 조치실행 | 상태의 변화를 매우 신속하게 간단하게 평가하고자 고안 | 가능 | 허가신청 시 제출하는 자료의 작성 | 각 | 험 | 소프트웨어 | 국내 |\n| 소프트웨어 | 등록대상 | - 각 임상시험기관의 적절한 임상시험의 수행을 위하여 임상시험기관 및 시험자의 | 관련 임상자료의 처리 방법을 ‘탈락 처리’에 구체적으로 제시한다.  | 허용 기준을 사용하여 위험 감소가 필요한지 결정한다. ",
        "original_sentence": "| 부여한다. "
      }
    },
    {
      "chunk_id": "chunk_110",
      "text": "| 처리 없이 수집된 자료로 분석한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 109,
        "window_size": 3,
        "char_count": 22,
        "word_count": 6,
        "page_number": 13,
        "window_text": "| pps/details?id=com.waypointh | 치료기기 대상이라고 판단할 수 있다.  | 제조자는 업데이트의 수행하기 위해 어떤 | 알게 된 날로부터 15일 이내 보고한다.  | 부여한다.  | 처리 없이 수집된 자료로 분석한다.  | 적용방법 및 사례집 | 조치실행 | 상태의 변화를 매우 신속하게 간단하게 평가하고자 고안 | 가능 | 허가신청 시 제출하는 자료의 작성 | 각 | 험 | 소프트웨어 | 국내 |\n| 소프트웨어 | 등록대상 | - 각 임상시험기관의 적절한 임상시험의 수행을 위하여 임상시험기관 및 시험자의 | 관련 임상자료의 처리 방법을 ‘탈락 처리’에 구체적으로 제시한다.  | 허용 기준을 사용하여 위험 감소가 필요한지 결정한다.  | 같은 기기의 무결성에 대한 위험을 고려해야 | (출처: SparkRx 홈페이지, | 위한 | 소프트웨어 | therapy | – Quality management | HDRS는 우울장애와 관련된 증상을 총 17문항으로 구성 | medical devices | 측정 | 네트워크로 연결되는 | 적용 | 문서번호 |\n| 임상시험을 복수의 임상시험 기관에서 실시하는 경우에는 기관에 따라 임상시험 | 표 4. ",
        "original_sentence": "| 처리 없이 수집된 자료로 분석한다. "
      }
    },
    {
      "chunk_id": "chunk_111",
      "text": "| 적용방법 및 사례집 | 조치실행 | 상태의 변화를 매우 신속하게 간단하게 평가하고자 고안 | 가능 | 허가신청 시 제출하는 자료의 작성 | 각 | 험 | 소프트웨어 | 국내 |\n| 소프트웨어 | 등록대상 | - 각 임상시험기관의 적절한 임상시험의 수행을 위하여 임상시험기관 및 시험자의 | 관련 임상자료의 처리 방법을 ‘탈락 처리’에 구체적으로 제시한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 110,
        "window_size": 3,
        "char_count": 201,
        "word_count": 55,
        "page_number": 19,
        "window_text": "| 제조자는 업데이트의 수행하기 위해 어떤 | 알게 된 날로부터 15일 이내 보고한다.  | 부여한다.  | 처리 없이 수집된 자료로 분석한다.  | 적용방법 및 사례집 | 조치실행 | 상태의 변화를 매우 신속하게 간단하게 평가하고자 고안 | 가능 | 허가신청 시 제출하는 자료의 작성 | 각 | 험 | 소프트웨어 | 국내 |\n| 소프트웨어 | 등록대상 | - 각 임상시험기관의 적절한 임상시험의 수행을 위하여 임상시험기관 및 시험자의 | 관련 임상자료의 처리 방법을 ‘탈락 처리’에 구체적으로 제시한다.  | 허용 기준을 사용하여 위험 감소가 필요한지 결정한다.  | 같은 기기의 무결성에 대한 위험을 고려해야 | (출처: SparkRx 홈페이지, | 위한 | 소프트웨어 | therapy | – Quality management | HDRS는 우울장애와 관련된 증상을 총 17문항으로 구성 | medical devices | 측정 | 네트워크로 연결되는 | 적용 | 문서번호 |\n| 임상시험을 복수의 임상시험 기관에서 실시하는 경우에는 기관에 따라 임상시험 | 표 4.  진료지침별 우울장애 인지행동치료의 권고등급 및 근거 수준 | - 대조군 : 디지털 우울장애 위약군(sham군) | SNS 등을 통해 수집할 수 있다. ",
        "original_sentence": "| 적용방법 및 사례집 | 조치실행 | 상태의 변화를 매우 신속하게 간단하게 평가하고자 고안 | 가능 | 허가신청 시 제출하는 자료의 작성 | 각 | 험 | 소프트웨어 | 국내 |\n| 소프트웨어 | 등록대상 | - 각 임상시험기관의 적절한 임상시험의 수행을 위하여 임상시험기관 및 시험자의 | 관련 임상자료의 처리 방법을 ‘탈락 처리’에 구체적으로 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_112",
      "text": "| 허용 기준을 사용하여 위험 감소가 필요한지 결정한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 111,
        "window_size": 3,
        "char_count": 32,
        "word_count": 8,
        "page_number": 13,
        "window_text": "| 부여한다.  | 처리 없이 수집된 자료로 분석한다.  | 적용방법 및 사례집 | 조치실행 | 상태의 변화를 매우 신속하게 간단하게 평가하고자 고안 | 가능 | 허가신청 시 제출하는 자료의 작성 | 각 | 험 | 소프트웨어 | 국내 |\n| 소프트웨어 | 등록대상 | - 각 임상시험기관의 적절한 임상시험의 수행을 위하여 임상시험기관 및 시험자의 | 관련 임상자료의 처리 방법을 ‘탈락 처리’에 구체적으로 제시한다.  | 허용 기준을 사용하여 위험 감소가 필요한지 결정한다.  | 같은 기기의 무결성에 대한 위험을 고려해야 | (출처: SparkRx 홈페이지, | 위한 | 소프트웨어 | therapy | – Quality management | HDRS는 우울장애와 관련된 증상을 총 17문항으로 구성 | medical devices | 측정 | 네트워크로 연결되는 | 적용 | 문서번호 |\n| 임상시험을 복수의 임상시험 기관에서 실시하는 경우에는 기관에 따라 임상시험 | 표 4.  진료지침별 우울장애 인지행동치료의 권고등급 및 근거 수준 | - 대조군 : 디지털 우울장애 위약군(sham군) | SNS 등을 통해 수집할 수 있다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? ",
        "original_sentence": "| 허용 기준을 사용하여 위험 감소가 필요한지 결정한다. "
      }
    },
    {
      "chunk_id": "chunk_113",
      "text": "| 같은 기기의 무결성에 대한 위험을 고려해야 | (출처: SparkRx 홈페이지, | 위한 | 소프트웨어 | therapy | – Quality management | HDRS는 우울장애와 관련된 증상을 총 17문항으로 구성 | medical devices | 측정 | 네트워크로 연결되는 | 적용 | 문서번호 |\n| 임상시험을 복수의 임상시험 기관에서 실시하는 경우에는 기관에 따라 임상시험 | 표 4. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 112,
        "window_size": 3,
        "char_count": 228,
        "word_count": 55,
        "page_number": 28,
        "window_text": "| 처리 없이 수집된 자료로 분석한다.  | 적용방법 및 사례집 | 조치실행 | 상태의 변화를 매우 신속하게 간단하게 평가하고자 고안 | 가능 | 허가신청 시 제출하는 자료의 작성 | 각 | 험 | 소프트웨어 | 국내 |\n| 소프트웨어 | 등록대상 | - 각 임상시험기관의 적절한 임상시험의 수행을 위하여 임상시험기관 및 시험자의 | 관련 임상자료의 처리 방법을 ‘탈락 처리’에 구체적으로 제시한다.  | 허용 기준을 사용하여 위험 감소가 필요한지 결정한다.  | 같은 기기의 무결성에 대한 위험을 고려해야 | (출처: SparkRx 홈페이지, | 위한 | 소프트웨어 | therapy | – Quality management | HDRS는 우울장애와 관련된 증상을 총 17문항으로 구성 | medical devices | 측정 | 네트워크로 연결되는 | 적용 | 문서번호 |\n| 임상시험을 복수의 임상시험 기관에서 실시하는 경우에는 기관에 따라 임상시험 | 표 4.  진료지침별 우울장애 인지행동치료의 권고등급 및 근거 수준 | - 대조군 : 디지털 우울장애 위약군(sham군) | SNS 등을 통해 수집할 수 있다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | DAS는 우울장애 관련 구성개념 중 부적응적 사고 유형과 | 동안 프로그램 액세스가 가능하다. ",
        "original_sentence": "| 같은 기기의 무결성에 대한 위험을 고려해야 | (출처: SparkRx 홈페이지, | 위한 | 소프트웨어 | therapy | – Quality management | HDRS는 우울장애와 관련된 증상을 총 17문항으로 구성 | medical devices | 측정 | 네트워크로 연결되는 | 적용 | 문서번호 |\n| 임상시험을 복수의 임상시험 기관에서 실시하는 경우에는 기관에 따라 임상시험 | 표 4. "
      }
    },
    {
      "chunk_id": "chunk_114",
      "text": "진료지침별 우울장애 인지행동치료의 권고등급 및 근거 수준 | - 대조군 : 디지털 우울장애 위약군(sham군) | SNS 등을 통해 수집할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 113,
        "window_size": 3,
        "char_count": 84,
        "word_count": 21,
        "page_number": 9,
        "window_text": "| 적용방법 및 사례집 | 조치실행 | 상태의 변화를 매우 신속하게 간단하게 평가하고자 고안 | 가능 | 허가신청 시 제출하는 자료의 작성 | 각 | 험 | 소프트웨어 | 국내 |\n| 소프트웨어 | 등록대상 | - 각 임상시험기관의 적절한 임상시험의 수행을 위하여 임상시험기관 및 시험자의 | 관련 임상자료의 처리 방법을 ‘탈락 처리’에 구체적으로 제시한다.  | 허용 기준을 사용하여 위험 감소가 필요한지 결정한다.  | 같은 기기의 무결성에 대한 위험을 고려해야 | (출처: SparkRx 홈페이지, | 위한 | 소프트웨어 | therapy | – Quality management | HDRS는 우울장애와 관련된 증상을 총 17문항으로 구성 | medical devices | 측정 | 네트워크로 연결되는 | 적용 | 문서번호 |\n| 임상시험을 복수의 임상시험 기관에서 실시하는 경우에는 기관에 따라 임상시험 | 표 4.  진료지침별 우울장애 인지행동치료의 권고등급 및 근거 수준 | - 대조군 : 디지털 우울장애 위약군(sham군) | SNS 등을 통해 수집할 수 있다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | DAS는 우울장애 관련 구성개념 중 부적응적 사고 유형과 | 동안 프로그램 액세스가 가능하다.  | 분석 | 위험 |\n| 해밀톤 우울장애 척도 | 2) 우울장애 선별 도구(Patient Health Questionnaire-9, PHQ-9) | 1) 근거 자료/문서의 직접 열람 | 인 안내서, 식품의약품안전처, 2021.12 | 1 | ISO 13485 | IEC/TR | ealth.thrive&hl=ko) | (민원인 안내서) | 해결책을 미리 논의해도 좋다. ",
        "original_sentence": "진료지침별 우울장애 인지행동치료의 권고등급 및 근거 수준 | - 대조군 : 디지털 우울장애 위약군(sham군) | SNS 등을 통해 수집할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_115",
      "text": "| □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 114,
        "window_size": 3,
        "char_count": 33,
        "word_count": 8,
        "page_number": 3,
        "window_text": "| 허용 기준을 사용하여 위험 감소가 필요한지 결정한다.  | 같은 기기의 무결성에 대한 위험을 고려해야 | (출처: SparkRx 홈페이지, | 위한 | 소프트웨어 | therapy | – Quality management | HDRS는 우울장애와 관련된 증상을 총 17문항으로 구성 | medical devices | 측정 | 네트워크로 연결되는 | 적용 | 문서번호 |\n| 임상시험을 복수의 임상시험 기관에서 실시하는 경우에는 기관에 따라 임상시험 | 표 4.  진료지침별 우울장애 인지행동치료의 권고등급 및 근거 수준 | - 대조군 : 디지털 우울장애 위약군(sham군) | SNS 등을 통해 수집할 수 있다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | DAS는 우울장애 관련 구성개념 중 부적응적 사고 유형과 | 동안 프로그램 액세스가 가능하다.  | 분석 | 위험 |\n| 해밀톤 우울장애 척도 | 2) 우울장애 선별 도구(Patient Health Questionnaire-9, PHQ-9) | 1) 근거 자료/문서의 직접 열람 | 인 안내서, 식품의약품안전처, 2021.12 | 1 | ISO 13485 | IEC/TR | ealth.thrive&hl=ko) | (민원인 안내서) | 해결책을 미리 논의해도 좋다.  | 하나하나 나열하여 비교해 보도록 하는 방법이 있다. ",
        "original_sentence": "| □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_116",
      "text": "| □ 예 | ■ 아니오 | DAS는 우울장애 관련 구성개념 중 부적응적 사고 유형과 | 동안 프로그램 액세스가 가능하다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 115,
        "window_size": 3,
        "char_count": 69,
        "word_count": 20,
        "page_number": 3,
        "window_text": "| 같은 기기의 무결성에 대한 위험을 고려해야 | (출처: SparkRx 홈페이지, | 위한 | 소프트웨어 | therapy | – Quality management | HDRS는 우울장애와 관련된 증상을 총 17문항으로 구성 | medical devices | 측정 | 네트워크로 연결되는 | 적용 | 문서번호 |\n| 임상시험을 복수의 임상시험 기관에서 실시하는 경우에는 기관에 따라 임상시험 | 표 4.  진료지침별 우울장애 인지행동치료의 권고등급 및 근거 수준 | - 대조군 : 디지털 우울장애 위약군(sham군) | SNS 등을 통해 수집할 수 있다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | DAS는 우울장애 관련 구성개념 중 부적응적 사고 유형과 | 동안 프로그램 액세스가 가능하다.  | 분석 | 위험 |\n| 해밀톤 우울장애 척도 | 2) 우울장애 선별 도구(Patient Health Questionnaire-9, PHQ-9) | 1) 근거 자료/문서의 직접 열람 | 인 안내서, 식품의약품안전처, 2021.12 | 1 | ISO 13485 | IEC/TR | ealth.thrive&hl=ko) | (민원인 안내서) | 해결책을 미리 논의해도 좋다.  | 하나하나 나열하여 비교해 보도록 하는 방법이 있다.  변화된 | 으로 정의한다. ",
        "original_sentence": "| □ 예 | ■ 아니오 | DAS는 우울장애 관련 구성개념 중 부적응적 사고 유형과 | 동안 프로그램 액세스가 가능하다. "
      }
    },
    {
      "chunk_id": "chunk_117",
      "text": "| 분석 | 위험 |\n| 해밀톤 우울장애 척도 | 2) 우울장애 선별 도구(Patient Health Questionnaire-9, PHQ-9) | 1) 근거 자료/문서의 직접 열람 | 인 안내서, 식품의약품안전처, 2021.12 | 1 | ISO 13485 | IEC/TR | ealth.thrive&hl=ko) | (민원인 안내서) | 해결책을 미리 논의해도 좋다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 116,
        "window_size": 3,
        "char_count": 207,
        "word_count": 45,
        "page_number": 9,
        "window_text": "진료지침별 우울장애 인지행동치료의 권고등급 및 근거 수준 | - 대조군 : 디지털 우울장애 위약군(sham군) | SNS 등을 통해 수집할 수 있다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | DAS는 우울장애 관련 구성개념 중 부적응적 사고 유형과 | 동안 프로그램 액세스가 가능하다.  | 분석 | 위험 |\n| 해밀톤 우울장애 척도 | 2) 우울장애 선별 도구(Patient Health Questionnaire-9, PHQ-9) | 1) 근거 자료/문서의 직접 열람 | 인 안내서, 식품의약품안전처, 2021.12 | 1 | ISO 13485 | IEC/TR | ealth.thrive&hl=ko) | (민원인 안내서) | 해결책을 미리 논의해도 좋다.  | 하나하나 나열하여 비교해 보도록 하는 방법이 있다.  변화된 | 으로 정의한다.  | 전체 소프트웨어 시스템이 요구 | 성 | 예시를 제시 | 성 | 도 | Management)에 대한 국제 | 유효성 | (AB-1234) | 국외 |\n| 병원 불안 우울 척도 | 의료기기(SaMD)이다. ",
        "original_sentence": "| 분석 | 위험 |\n| 해밀톤 우울장애 척도 | 2) 우울장애 선별 도구(Patient Health Questionnaire-9, PHQ-9) | 1) 근거 자료/문서의 직접 열람 | 인 안내서, 식품의약품안전처, 2021.12 | 1 | ISO 13485 | IEC/TR | ealth.thrive&hl=ko) | (민원인 안내서) | 해결책을 미리 논의해도 좋다. "
      }
    },
    {
      "chunk_id": "chunk_118",
      "text": "| 하나하나 나열하여 비교해 보도록 하는 방법이 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 117,
        "window_size": 3,
        "char_count": 31,
        "word_count": 8,
        "page_number": 11,
        "window_text": "| □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | DAS는 우울장애 관련 구성개념 중 부적응적 사고 유형과 | 동안 프로그램 액세스가 가능하다.  | 분석 | 위험 |\n| 해밀톤 우울장애 척도 | 2) 우울장애 선별 도구(Patient Health Questionnaire-9, PHQ-9) | 1) 근거 자료/문서의 직접 열람 | 인 안내서, 식품의약품안전처, 2021.12 | 1 | ISO 13485 | IEC/TR | ealth.thrive&hl=ko) | (민원인 안내서) | 해결책을 미리 논의해도 좋다.  | 하나하나 나열하여 비교해 보도록 하는 방법이 있다.  변화된 | 으로 정의한다.  | 전체 소프트웨어 시스템이 요구 | 성 | 예시를 제시 | 성 | 도 | Management)에 대한 국제 | 유효성 | (AB-1234) | 국외 |\n| 병원 불안 우울 척도 | 의료기기(SaMD)이다.  | 여부 | 변화가 있는 자 | 그림 4. ",
        "original_sentence": "| 하나하나 나열하여 비교해 보도록 하는 방법이 있다. "
      }
    },
    {
      "chunk_id": "chunk_119",
      "text": "변화된 | 으로 정의한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 118,
        "window_size": 3,
        "char_count": 15,
        "word_count": 4,
        "page_number": 13,
        "window_text": "| □ 예 | ■ 아니오 | DAS는 우울장애 관련 구성개념 중 부적응적 사고 유형과 | 동안 프로그램 액세스가 가능하다.  | 분석 | 위험 |\n| 해밀톤 우울장애 척도 | 2) 우울장애 선별 도구(Patient Health Questionnaire-9, PHQ-9) | 1) 근거 자료/문서의 직접 열람 | 인 안내서, 식품의약품안전처, 2021.12 | 1 | ISO 13485 | IEC/TR | ealth.thrive&hl=ko) | (민원인 안내서) | 해결책을 미리 논의해도 좋다.  | 하나하나 나열하여 비교해 보도록 하는 방법이 있다.  변화된 | 으로 정의한다.  | 전체 소프트웨어 시스템이 요구 | 성 | 예시를 제시 | 성 | 도 | Management)에 대한 국제 | 유효성 | (AB-1234) | 국외 |\n| 병원 불안 우울 척도 | 의료기기(SaMD)이다.  | 여부 | 변화가 있는 자 | 그림 4.  우울장애 개선 디지털치료기기 임상시험 선행 연구 결과 | - 운영방법 및 유지보수 방법과 관련된 요구사항 | - 제조회사: ㈜○○○ | - 안전성 자료(Safety Set, SS) | 제조자는 의료기기가 다른 기기나 네트워크와 | 한다. ",
        "original_sentence": "변화된 | 으로 정의한다. "
      }
    },
    {
      "chunk_id": "chunk_120",
      "text": "| 전체 소프트웨어 시스템이 요구 | 성 | 예시를 제시 | 성 | 도 | Management)에 대한 국제 | 유효성 | (AB-1234) | 국외 |\n| 병원 불안 우울 척도 | 의료기기(SaMD)이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 119,
        "window_size": 3,
        "char_count": 116,
        "word_count": 32,
        "page_number": 9,
        "window_text": "| 분석 | 위험 |\n| 해밀톤 우울장애 척도 | 2) 우울장애 선별 도구(Patient Health Questionnaire-9, PHQ-9) | 1) 근거 자료/문서의 직접 열람 | 인 안내서, 식품의약품안전처, 2021.12 | 1 | ISO 13485 | IEC/TR | ealth.thrive&hl=ko) | (민원인 안내서) | 해결책을 미리 논의해도 좋다.  | 하나하나 나열하여 비교해 보도록 하는 방법이 있다.  변화된 | 으로 정의한다.  | 전체 소프트웨어 시스템이 요구 | 성 | 예시를 제시 | 성 | 도 | Management)에 대한 국제 | 유효성 | (AB-1234) | 국외 |\n| 병원 불안 우울 척도 | 의료기기(SaMD)이다.  | 여부 | 변화가 있는 자 | 그림 4.  우울장애 개선 디지털치료기기 임상시험 선행 연구 결과 | - 운영방법 및 유지보수 방법과 관련된 요구사항 | - 제조회사: ㈜○○○ | - 안전성 자료(Safety Set, SS) | 제조자는 의료기기가 다른 기기나 네트워크와 | 한다.  | 연결이 필요한지와 코드 서명 및 기타 비슷한 | 하였으며 선별도구로 사용된다. ",
        "original_sentence": "| 전체 소프트웨어 시스템이 요구 | 성 | 예시를 제시 | 성 | 도 | Management)에 대한 국제 | 유효성 | (AB-1234) | 국외 |\n| 병원 불안 우울 척도 | 의료기기(SaMD)이다. "
      }
    },
    {
      "chunk_id": "chunk_121",
      "text": "| 여부 | 변화가 있는 자 | 그림 4. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 120,
        "window_size": 3,
        "char_count": 24,
        "word_count": 9,
        "page_number": 3,
        "window_text": "| 하나하나 나열하여 비교해 보도록 하는 방법이 있다.  변화된 | 으로 정의한다.  | 전체 소프트웨어 시스템이 요구 | 성 | 예시를 제시 | 성 | 도 | Management)에 대한 국제 | 유효성 | (AB-1234) | 국외 |\n| 병원 불안 우울 척도 | 의료기기(SaMD)이다.  | 여부 | 변화가 있는 자 | 그림 4.  우울장애 개선 디지털치료기기 임상시험 선행 연구 결과 | - 운영방법 및 유지보수 방법과 관련된 요구사항 | - 제조회사: ㈜○○○ | - 안전성 자료(Safety Set, SS) | 제조자는 의료기기가 다른 기기나 네트워크와 | 한다.  | 연결이 필요한지와 코드 서명 및 기타 비슷한 | 하였으며 선별도구로 사용된다.  HADS는 불안과 우울을 | 소프트웨어 | 검증 및 |\n| 1) 목표 대상자 수: 총 110명 (군당 55명) | 7 | 7 | 가) 디지털치료기기 허가·심사 가이드라인(민원인 안내서) | 가) 시험기기: 디지털 우울장애 인지행동치료 애플리케이션 | 전략 | https://www.sparkrx.com) | software | 시스템 | systems – Requirements for | – Part 2-2: Guidance for the | 되었다. ",
        "original_sentence": "| 여부 | 변화가 있는 자 | 그림 4. "
      }
    },
    {
      "chunk_id": "chunk_122",
      "text": "우울장애 개선 디지털치료기기 임상시험 선행 연구 결과 | - 운영방법 및 유지보수 방법과 관련된 요구사항 | - 제조회사: ㈜○○○ | - 안전성 자료(Safety Set, SS) | 제조자는 의료기기가 다른 기기나 네트워크와 | 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 121,
        "window_size": 3,
        "char_count": 133,
        "word_count": 33,
        "page_number": 1,
        "window_text": "변화된 | 으로 정의한다.  | 전체 소프트웨어 시스템이 요구 | 성 | 예시를 제시 | 성 | 도 | Management)에 대한 국제 | 유효성 | (AB-1234) | 국외 |\n| 병원 불안 우울 척도 | 의료기기(SaMD)이다.  | 여부 | 변화가 있는 자 | 그림 4.  우울장애 개선 디지털치료기기 임상시험 선행 연구 결과 | - 운영방법 및 유지보수 방법과 관련된 요구사항 | - 제조회사: ㈜○○○ | - 안전성 자료(Safety Set, SS) | 제조자는 의료기기가 다른 기기나 네트워크와 | 한다.  | 연결이 필요한지와 코드 서명 및 기타 비슷한 | 하였으며 선별도구로 사용된다.  HADS는 불안과 우울을 | 소프트웨어 | 검증 및 |\n| 1) 목표 대상자 수: 총 110명 (군당 55명) | 7 | 7 | 가) 디지털치료기기 허가·심사 가이드라인(민원인 안내서) | 가) 시험기기: 디지털 우울장애 인지행동치료 애플리케이션 | 전략 | https://www.sparkrx.com) | software | 시스템 | systems – Requirements for | – Part 2-2: Guidance for the | 되었다.  전체 문항 점수를 합산하며, 11점 이하는 우울하지 | 의료기기의 위험관리 | 국외 |\n| 5) 이상치 처리 | 자) 관찰 및 평가 | 나) 선정/제외 기준 | 의견을 조정하기 위하여 조정위원회를 설치하고 임상시험 조정자를 선정할 수 있다. ",
        "original_sentence": "우울장애 개선 디지털치료기기 임상시험 선행 연구 결과 | - 운영방법 및 유지보수 방법과 관련된 요구사항 | - 제조회사: ㈜○○○ | - 안전성 자료(Safety Set, SS) | 제조자는 의료기기가 다른 기기나 네트워크와 | 한다. "
      }
    },
    {
      "chunk_id": "chunk_123",
      "text": "| 연결이 필요한지와 코드 서명 및 기타 비슷한 | 하였으며 선별도구로 사용된다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 122,
        "window_size": 3,
        "char_count": 46,
        "word_count": 12,
        "page_number": 41,
        "window_text": "| 전체 소프트웨어 시스템이 요구 | 성 | 예시를 제시 | 성 | 도 | Management)에 대한 국제 | 유효성 | (AB-1234) | 국외 |\n| 병원 불안 우울 척도 | 의료기기(SaMD)이다.  | 여부 | 변화가 있는 자 | 그림 4.  우울장애 개선 디지털치료기기 임상시험 선행 연구 결과 | - 운영방법 및 유지보수 방법과 관련된 요구사항 | - 제조회사: ㈜○○○ | - 안전성 자료(Safety Set, SS) | 제조자는 의료기기가 다른 기기나 네트워크와 | 한다.  | 연결이 필요한지와 코드 서명 및 기타 비슷한 | 하였으며 선별도구로 사용된다.  HADS는 불안과 우울을 | 소프트웨어 | 검증 및 |\n| 1) 목표 대상자 수: 총 110명 (군당 55명) | 7 | 7 | 가) 디지털치료기기 허가·심사 가이드라인(민원인 안내서) | 가) 시험기기: 디지털 우울장애 인지행동치료 애플리케이션 | 전략 | https://www.sparkrx.com) | software | 시스템 | systems – Requirements for | – Part 2-2: Guidance for the | 되었다.  전체 문항 점수를 합산하며, 11점 이하는 우울하지 | 의료기기의 위험관리 | 국외 |\n| 5) 이상치 처리 | 자) 관찰 및 평가 | 나) 선정/제외 기준 | 의견을 조정하기 위하여 조정위원회를 설치하고 임상시험 조정자를 선정할 수 있다.  | 탈락시킬 수 있다. ",
        "original_sentence": "| 연결이 필요한지와 코드 서명 및 기타 비슷한 | 하였으며 선별도구로 사용된다. "
      }
    },
    {
      "chunk_id": "chunk_124",
      "text": "HADS는 불안과 우울을 | 소프트웨어 | 검증 및 |\n| 1) 목표 대상자 수: 총 110명 (군당 55명) | 7 | 7 | 가) 디지털치료기기 허가·심사 가이드라인(민원인 안내서) | 가) 시험기기: 디지털 우울장애 인지행동치료 애플리케이션 | 전략 | https://www.sparkrx.com) | software | 시스템 | systems – Requirements for | – Part 2-2: Guidance for the | 되었다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 123,
        "window_size": 3,
        "char_count": 254,
        "word_count": 57,
        "page_number": 7,
        "window_text": "| 여부 | 변화가 있는 자 | 그림 4.  우울장애 개선 디지털치료기기 임상시험 선행 연구 결과 | - 운영방법 및 유지보수 방법과 관련된 요구사항 | - 제조회사: ㈜○○○ | - 안전성 자료(Safety Set, SS) | 제조자는 의료기기가 다른 기기나 네트워크와 | 한다.  | 연결이 필요한지와 코드 서명 및 기타 비슷한 | 하였으며 선별도구로 사용된다.  HADS는 불안과 우울을 | 소프트웨어 | 검증 및 |\n| 1) 목표 대상자 수: 총 110명 (군당 55명) | 7 | 7 | 가) 디지털치료기기 허가·심사 가이드라인(민원인 안내서) | 가) 시험기기: 디지털 우울장애 인지행동치료 애플리케이션 | 전략 | https://www.sparkrx.com) | software | 시스템 | systems – Requirements for | – Part 2-2: Guidance for the | 되었다.  전체 문항 점수를 합산하며, 11점 이하는 우울하지 | 의료기기의 위험관리 | 국외 |\n| 5) 이상치 처리 | 자) 관찰 및 평가 | 나) 선정/제외 기준 | 의견을 조정하기 위하여 조정위원회를 설치하고 임상시험 조정자를 선정할 수 있다.  | 탈락시킬 수 있다.  | 있다는 사실 | 기관명 | 소재지 | 전화 | 팩스 | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 에서 통계적 우월성을 평가한다. ",
        "original_sentence": "HADS는 불안과 우울을 | 소프트웨어 | 검증 및 |\n| 1) 목표 대상자 수: 총 110명 (군당 55명) | 7 | 7 | 가) 디지털치료기기 허가·심사 가이드라인(민원인 안내서) | 가) 시험기기: 디지털 우울장애 인지행동치료 애플리케이션 | 전략 | https://www.sparkrx.com) | software | 시스템 | systems – Requirements for | – Part 2-2: Guidance for the | 되었다. "
      }
    },
    {
      "chunk_id": "chunk_125",
      "text": "전체 문항 점수를 합산하며, 11점 이하는 우울하지 | 의료기기의 위험관리 | 국외 |\n| 5) 이상치 처리 | 자) 관찰 및 평가 | 나) 선정/제외 기준 | 의견을 조정하기 위하여 조정위원회를 설치하고 임상시험 조정자를 선정할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 124,
        "window_size": 3,
        "char_count": 135,
        "word_count": 37,
        "page_number": 28,
        "window_text": "우울장애 개선 디지털치료기기 임상시험 선행 연구 결과 | - 운영방법 및 유지보수 방법과 관련된 요구사항 | - 제조회사: ㈜○○○ | - 안전성 자료(Safety Set, SS) | 제조자는 의료기기가 다른 기기나 네트워크와 | 한다.  | 연결이 필요한지와 코드 서명 및 기타 비슷한 | 하였으며 선별도구로 사용된다.  HADS는 불안과 우울을 | 소프트웨어 | 검증 및 |\n| 1) 목표 대상자 수: 총 110명 (군당 55명) | 7 | 7 | 가) 디지털치료기기 허가·심사 가이드라인(민원인 안내서) | 가) 시험기기: 디지털 우울장애 인지행동치료 애플리케이션 | 전략 | https://www.sparkrx.com) | software | 시스템 | systems – Requirements for | – Part 2-2: Guidance for the | 되었다.  전체 문항 점수를 합산하며, 11점 이하는 우울하지 | 의료기기의 위험관리 | 국외 |\n| 5) 이상치 처리 | 자) 관찰 및 평가 | 나) 선정/제외 기준 | 의견을 조정하기 위하여 조정위원회를 설치하고 임상시험 조정자를 선정할 수 있다.  | 탈락시킬 수 있다.  | 있다는 사실 | 기관명 | 소재지 | 전화 | 팩스 | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 에서 통계적 우월성을 평가한다.  | 애플리케이션을 실행한다. ",
        "original_sentence": "전체 문항 점수를 합산하며, 11점 이하는 우울하지 | 의료기기의 위험관리 | 국외 |\n| 5) 이상치 처리 | 자) 관찰 및 평가 | 나) 선정/제외 기준 | 의견을 조정하기 위하여 조정위원회를 설치하고 임상시험 조정자를 선정할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_126",
      "text": "| 탈락시킬 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 125,
        "window_size": 3,
        "char_count": 13,
        "word_count": 4,
        "page_number": 11,
        "window_text": "| 연결이 필요한지와 코드 서명 및 기타 비슷한 | 하였으며 선별도구로 사용된다.  HADS는 불안과 우울을 | 소프트웨어 | 검증 및 |\n| 1) 목표 대상자 수: 총 110명 (군당 55명) | 7 | 7 | 가) 디지털치료기기 허가·심사 가이드라인(민원인 안내서) | 가) 시험기기: 디지털 우울장애 인지행동치료 애플리케이션 | 전략 | https://www.sparkrx.com) | software | 시스템 | systems – Requirements for | – Part 2-2: Guidance for the | 되었다.  전체 문항 점수를 합산하며, 11점 이하는 우울하지 | 의료기기의 위험관리 | 국외 |\n| 5) 이상치 처리 | 자) 관찰 및 평가 | 나) 선정/제외 기준 | 의견을 조정하기 위하여 조정위원회를 설치하고 임상시험 조정자를 선정할 수 있다.  | 탈락시킬 수 있다.  | 있다는 사실 | 기관명 | 소재지 | 전화 | 팩스 | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 에서 통계적 우월성을 평가한다.  | 애플리케이션을 실행한다.  | 위한 행동 치료를 수행한다. ",
        "original_sentence": "| 탈락시킬 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_127",
      "text": "| 있다는 사실 | 기관명 | 소재지 | 전화 | 팩스 | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 에서 통계적 우월성을 평가한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 126,
        "window_size": 3,
        "char_count": 84,
        "word_count": 24,
        "page_number": 29,
        "window_text": "HADS는 불안과 우울을 | 소프트웨어 | 검증 및 |\n| 1) 목표 대상자 수: 총 110명 (군당 55명) | 7 | 7 | 가) 디지털치료기기 허가·심사 가이드라인(민원인 안내서) | 가) 시험기기: 디지털 우울장애 인지행동치료 애플리케이션 | 전략 | https://www.sparkrx.com) | software | 시스템 | systems – Requirements for | – Part 2-2: Guidance for the | 되었다.  전체 문항 점수를 합산하며, 11점 이하는 우울하지 | 의료기기의 위험관리 | 국외 |\n| 5) 이상치 처리 | 자) 관찰 및 평가 | 나) 선정/제외 기준 | 의견을 조정하기 위하여 조정위원회를 설치하고 임상시험 조정자를 선정할 수 있다.  | 탈락시킬 수 있다.  | 있다는 사실 | 기관명 | 소재지 | 전화 | 팩스 | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 에서 통계적 우월성을 평가한다.  | 애플리케이션을 실행한다.  | 위한 행동 치료를 수행한다.  | 소프트웨어 | 역기능적인지를 평가하기 위해 고안하였다. ",
        "original_sentence": "| 있다는 사실 | 기관명 | 소재지 | 전화 | 팩스 | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 에서 통계적 우월성을 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_128",
      "text": "| 애플리케이션을 실행한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 127,
        "window_size": 3,
        "char_count": 16,
        "word_count": 3,
        "page_number": 13,
        "window_text": "전체 문항 점수를 합산하며, 11점 이하는 우울하지 | 의료기기의 위험관리 | 국외 |\n| 5) 이상치 처리 | 자) 관찰 및 평가 | 나) 선정/제외 기준 | 의견을 조정하기 위하여 조정위원회를 설치하고 임상시험 조정자를 선정할 수 있다.  | 탈락시킬 수 있다.  | 있다는 사실 | 기관명 | 소재지 | 전화 | 팩스 | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 에서 통계적 우월성을 평가한다.  | 애플리케이션을 실행한다.  | 위한 행동 치료를 수행한다.  | 소프트웨어 | 역기능적인지를 평가하기 위해 고안하였다.  원래 DAS는 | 설치될 기기의 메모리 공간을 | 적용 | 규격 | 확인 자료 |\n| 1. ",
        "original_sentence": "| 애플리케이션을 실행한다. "
      }
    },
    {
      "chunk_id": "chunk_129",
      "text": "| 위한 행동 치료를 수행한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 128,
        "window_size": 3,
        "char_count": 18,
        "word_count": 5,
        "page_number": 13,
        "window_text": "| 탈락시킬 수 있다.  | 있다는 사실 | 기관명 | 소재지 | 전화 | 팩스 | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 에서 통계적 우월성을 평가한다.  | 애플리케이션을 실행한다.  | 위한 행동 치료를 수행한다.  | 소프트웨어 | 역기능적인지를 평가하기 위해 고안하였다.  원래 DAS는 | 설치될 기기의 메모리 공간을 | 적용 | 규격 | 확인 자료 |\n| 1.  관련 규정 | (Hospital Anxiety and | (Hamilton Depression | 7) 기타 이차 유효성 평가변수*들의 치료 전 대비 변화량 | 결과에 차이가 있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 | 80001-2-2 | 진료지침* | 권고등급** | 근거 수준 | - 계획된 활동을 통해 실제로 얻은 즐거움 혹은 수행 능력 정도를 | 부정적 단어 정의(operationalizing negative constructs) | 신념에 대해 손해와 이익 분석도 이와 같은 방식으로 행해질 | 측정하는 총 14개의 문항에 대해 4점 척도로 응답하도록 | 사항을 충족하는지 확인한다. ",
        "original_sentence": "| 위한 행동 치료를 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_130",
      "text": "| 소프트웨어 | 역기능적인지를 평가하기 위해 고안하였다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 129,
        "window_size": 3,
        "char_count": 33,
        "word_count": 7,
        "page_number": 9,
        "window_text": "| 있다는 사실 | 기관명 | 소재지 | 전화 | 팩스 | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 에서 통계적 우월성을 평가한다.  | 애플리케이션을 실행한다.  | 위한 행동 치료를 수행한다.  | 소프트웨어 | 역기능적인지를 평가하기 위해 고안하였다.  원래 DAS는 | 설치될 기기의 메모리 공간을 | 적용 | 규격 | 확인 자료 |\n| 1.  관련 규정 | (Hospital Anxiety and | (Hamilton Depression | 7) 기타 이차 유효성 평가변수*들의 치료 전 대비 변화량 | 결과에 차이가 있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 | 80001-2-2 | 진료지침* | 권고등급** | 근거 수준 | - 계획된 활동을 통해 실제로 얻은 즐거움 혹은 수행 능력 정도를 | 부정적 단어 정의(operationalizing negative constructs) | 신념에 대해 손해와 이익 분석도 이와 같은 방식으로 행해질 | 측정하는 총 14개의 문항에 대해 4점 척도로 응답하도록 | 사항을 충족하는지 확인한다.  |\n| 설계 변경을 | 역기능적 태도 척도 | 1) 식품의약품안전처의 임상 계획 승인일로부터 00개월 | 2) 무작위배정 방법 | Off-The-Shelf Software Use in | 어떻게 접속(유·무선 통신 등)하여야 할지를 | 수단을 통한 연결이나 업데이트의 진본성을 | App memory size는 최소 | regulatory purposes | (출처: Twomey et al., 2020.) ",
        "original_sentence": "| 소프트웨어 | 역기능적인지를 평가하기 위해 고안하였다. "
      }
    },
    {
      "chunk_id": "chunk_131",
      "text": "원래 DAS는 | 설치될 기기의 메모리 공간을 | 적용 | 규격 | 확인 자료 |\n| 1. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 130,
        "window_size": 3,
        "char_count": 51,
        "word_count": 17,
        "page_number": 28,
        "window_text": "| 애플리케이션을 실행한다.  | 위한 행동 치료를 수행한다.  | 소프트웨어 | 역기능적인지를 평가하기 위해 고안하였다.  원래 DAS는 | 설치될 기기의 메모리 공간을 | 적용 | 규격 | 확인 자료 |\n| 1.  관련 규정 | (Hospital Anxiety and | (Hamilton Depression | 7) 기타 이차 유효성 평가변수*들의 치료 전 대비 변화량 | 결과에 차이가 있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 | 80001-2-2 | 진료지침* | 권고등급** | 근거 수준 | - 계획된 활동을 통해 실제로 얻은 즐거움 혹은 수행 능력 정도를 | 부정적 단어 정의(operationalizing negative constructs) | 신념에 대해 손해와 이익 분석도 이와 같은 방식으로 행해질 | 측정하는 총 14개의 문항에 대해 4점 척도로 응답하도록 | 사항을 충족하는지 확인한다.  |\n| 설계 변경을 | 역기능적 태도 척도 | 1) 식품의약품안전처의 임상 계획 승인일로부터 00개월 | 2) 무작위배정 방법 | Off-The-Shelf Software Use in | 어떻게 접속(유·무선 통신 등)하여야 할지를 | 수단을 통한 연결이나 업데이트의 진본성을 | App memory size는 최소 | regulatory purposes | (출처: Twomey et al., 2020.)  | 의료기기에서의 | 기성품 | 소프트웨어 | 검증 및 | 유효성 | (AB-1234) |\n| 22(4), 343-396. ",
        "original_sentence": "원래 DAS는 | 설치될 기기의 메모리 공간을 | 적용 | 규격 | 확인 자료 |\n| 1. "
      }
    },
    {
      "chunk_id": "chunk_132",
      "text": "관련 규정 | (Hospital Anxiety and | (Hamilton Depression | 7) 기타 이차 유효성 평가변수*들의 치료 전 대비 변화량 | 결과에 차이가 있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 | 80001-2-2 | 진료지침* | 권고등급** | 근거 수준 | - 계획된 활동을 통해 실제로 얻은 즐거움 혹은 수행 능력 정도를 | 부정적 단어 정의(operationalizing negative constructs) | 신념에 대해 손해와 이익 분석도 이와 같은 방식으로 행해질 | 측정하는 총 14개의 문항에 대해 4점 척도로 응답하도록 | 사항을 충족하는지 확인한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 131,
        "window_size": 3,
        "char_count": 343,
        "word_count": 80,
        "page_number": 81,
        "window_text": "| 위한 행동 치료를 수행한다.  | 소프트웨어 | 역기능적인지를 평가하기 위해 고안하였다.  원래 DAS는 | 설치될 기기의 메모리 공간을 | 적용 | 규격 | 확인 자료 |\n| 1.  관련 규정 | (Hospital Anxiety and | (Hamilton Depression | 7) 기타 이차 유효성 평가변수*들의 치료 전 대비 변화량 | 결과에 차이가 있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 | 80001-2-2 | 진료지침* | 권고등급** | 근거 수준 | - 계획된 활동을 통해 실제로 얻은 즐거움 혹은 수행 능력 정도를 | 부정적 단어 정의(operationalizing negative constructs) | 신념에 대해 손해와 이익 분석도 이와 같은 방식으로 행해질 | 측정하는 총 14개의 문항에 대해 4점 척도로 응답하도록 | 사항을 충족하는지 확인한다.  |\n| 설계 변경을 | 역기능적 태도 척도 | 1) 식품의약품안전처의 임상 계획 승인일로부터 00개월 | 2) 무작위배정 방법 | Off-The-Shelf Software Use in | 어떻게 접속(유·무선 통신 등)하여야 할지를 | 수단을 통한 연결이나 업데이트의 진본성을 | App memory size는 최소 | regulatory purposes | (출처: Twomey et al., 2020.)  | 의료기기에서의 | 기성품 | 소프트웨어 | 검증 및 | 유효성 | (AB-1234) |\n| 22(4), 343-396.  | 1 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 판단할 수 있는 자 | 자동적 | □ 일회성 지시ㆍ명령에 해당하는 내용입니까? ",
        "original_sentence": "관련 규정 | (Hospital Anxiety and | (Hamilton Depression | 7) 기타 이차 유효성 평가변수*들의 치료 전 대비 변화량 | 결과에 차이가 있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 | 80001-2-2 | 진료지침* | 권고등급** | 근거 수준 | - 계획된 활동을 통해 실제로 얻은 즐거움 혹은 수행 능력 정도를 | 부정적 단어 정의(operationalizing negative constructs) | 신념에 대해 손해와 이익 분석도 이와 같은 방식으로 행해질 | 측정하는 총 14개의 문항에 대해 4점 척도로 응답하도록 | 사항을 충족하는지 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_133",
      "text": "|\n| 설계 변경을 | 역기능적 태도 척도 | 1) 식품의약품안전처의 임상 계획 승인일로부터 00개월 | 2) 무작위배정 방법 | Off-The-Shelf Software Use in | 어떻게 접속(유·무선 통신 등)하여야 할지를 | 수단을 통한 연결이나 업데이트의 진본성을 | App memory size는 최소 | regulatory purposes | (출처: Twomey et al., 2020.) ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 132,
        "window_size": 3,
        "char_count": 228,
        "word_count": 50,
        "page_number": 18,
        "window_text": "| 소프트웨어 | 역기능적인지를 평가하기 위해 고안하였다.  원래 DAS는 | 설치될 기기의 메모리 공간을 | 적용 | 규격 | 확인 자료 |\n| 1.  관련 규정 | (Hospital Anxiety and | (Hamilton Depression | 7) 기타 이차 유효성 평가변수*들의 치료 전 대비 변화량 | 결과에 차이가 있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 | 80001-2-2 | 진료지침* | 권고등급** | 근거 수준 | - 계획된 활동을 통해 실제로 얻은 즐거움 혹은 수행 능력 정도를 | 부정적 단어 정의(operationalizing negative constructs) | 신념에 대해 손해와 이익 분석도 이와 같은 방식으로 행해질 | 측정하는 총 14개의 문항에 대해 4점 척도로 응답하도록 | 사항을 충족하는지 확인한다.  |\n| 설계 변경을 | 역기능적 태도 척도 | 1) 식품의약품안전처의 임상 계획 승인일로부터 00개월 | 2) 무작위배정 방법 | Off-The-Shelf Software Use in | 어떻게 접속(유·무선 통신 등)하여야 할지를 | 수단을 통한 연결이나 업데이트의 진본성을 | App memory size는 최소 | regulatory purposes | (출처: Twomey et al., 2020.)  | 의료기기에서의 | 기성품 | 소프트웨어 | 검증 및 | 유효성 | (AB-1234) |\n| 22(4), 343-396.  | 1 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 판단할 수 있는 자 | 자동적 | □ 일회성 지시ㆍ명령에 해당하는 내용입니까?  | □ 예 | ■ 아니오 | 검증 | disclosure and communication | 않음, 11~16점은 경미한 우울, 17~25점은 중등도 우울, 26점 | 방법에 대한 국제 규격 | 사항에 반영한다. ",
        "original_sentence": "|\n| 설계 변경을 | 역기능적 태도 척도 | 1) 식품의약품안전처의 임상 계획 승인일로부터 00개월 | 2) 무작위배정 방법 | Off-The-Shelf Software Use in | 어떻게 접속(유·무선 통신 등)하여야 할지를 | 수단을 통한 연결이나 업데이트의 진본성을 | App memory size는 최소 | regulatory purposes | (출처: Twomey et al., 2020.) "
      }
    },
    {
      "chunk_id": "chunk_134",
      "text": "| 의료기기에서의 | 기성품 | 소프트웨어 | 검증 및 | 유효성 | (AB-1234) |\n| 22(4), 343-396. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 133,
        "window_size": 3,
        "char_count": 69,
        "word_count": 17,
        "page_number": 9,
        "window_text": "원래 DAS는 | 설치될 기기의 메모리 공간을 | 적용 | 규격 | 확인 자료 |\n| 1.  관련 규정 | (Hospital Anxiety and | (Hamilton Depression | 7) 기타 이차 유효성 평가변수*들의 치료 전 대비 변화량 | 결과에 차이가 있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 | 80001-2-2 | 진료지침* | 권고등급** | 근거 수준 | - 계획된 활동을 통해 실제로 얻은 즐거움 혹은 수행 능력 정도를 | 부정적 단어 정의(operationalizing negative constructs) | 신념에 대해 손해와 이익 분석도 이와 같은 방식으로 행해질 | 측정하는 총 14개의 문항에 대해 4점 척도로 응답하도록 | 사항을 충족하는지 확인한다.  |\n| 설계 변경을 | 역기능적 태도 척도 | 1) 식품의약품안전처의 임상 계획 승인일로부터 00개월 | 2) 무작위배정 방법 | Off-The-Shelf Software Use in | 어떻게 접속(유·무선 통신 등)하여야 할지를 | 수단을 통한 연결이나 업데이트의 진본성을 | App memory size는 최소 | regulatory purposes | (출처: Twomey et al., 2020.)  | 의료기기에서의 | 기성품 | 소프트웨어 | 검증 및 | 유효성 | (AB-1234) |\n| 22(4), 343-396.  | 1 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 판단할 수 있는 자 | 자동적 | □ 일회성 지시ㆍ명령에 해당하는 내용입니까?  | □ 예 | ■ 아니오 | 검증 | disclosure and communication | 않음, 11~16점은 경미한 우울, 17~25점은 중등도 우울, 26점 | 방법에 대한 국제 규격 | 사항에 반영한다.  |\n| 2 | 메모리 크기 | 인 안내서, 식품의약품안전처, 2021.12 | 6 | - 원재료: (임상시험용 의료기기의 원재료에 대한 특성 기술) | 검증 자료로 | 기록하게 하는 등 자신의 행동을 스스로 관찰, 기록하도록 | 우울장애와 | 관련 | 있는 | 역기능적인지를 | 평가하기 | 위해 | 확인한다. ",
        "original_sentence": "| 의료기기에서의 | 기성품 | 소프트웨어 | 검증 및 | 유효성 | (AB-1234) |\n| 22(4), 343-396. "
      }
    },
    {
      "chunk_id": "chunk_135",
      "text": "| 1 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 판단할 수 있는 자 | 자동적 | □ 일회성 지시ㆍ명령에 해당하는 내용입니까? ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 134,
        "window_size": 3,
        "char_count": 78,
        "word_count": 25,
        "page_number": 19,
        "window_text": "관련 규정 | (Hospital Anxiety and | (Hamilton Depression | 7) 기타 이차 유효성 평가변수*들의 치료 전 대비 변화량 | 결과에 차이가 있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 | 80001-2-2 | 진료지침* | 권고등급** | 근거 수준 | - 계획된 활동을 통해 실제로 얻은 즐거움 혹은 수행 능력 정도를 | 부정적 단어 정의(operationalizing negative constructs) | 신념에 대해 손해와 이익 분석도 이와 같은 방식으로 행해질 | 측정하는 총 14개의 문항에 대해 4점 척도로 응답하도록 | 사항을 충족하는지 확인한다.  |\n| 설계 변경을 | 역기능적 태도 척도 | 1) 식품의약품안전처의 임상 계획 승인일로부터 00개월 | 2) 무작위배정 방법 | Off-The-Shelf Software Use in | 어떻게 접속(유·무선 통신 등)하여야 할지를 | 수단을 통한 연결이나 업데이트의 진본성을 | App memory size는 최소 | regulatory purposes | (출처: Twomey et al., 2020.)  | 의료기기에서의 | 기성품 | 소프트웨어 | 검증 및 | 유효성 | (AB-1234) |\n| 22(4), 343-396.  | 1 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 판단할 수 있는 자 | 자동적 | □ 일회성 지시ㆍ명령에 해당하는 내용입니까?  | □ 예 | ■ 아니오 | 검증 | disclosure and communication | 않음, 11~16점은 경미한 우울, 17~25점은 중등도 우울, 26점 | 방법에 대한 국제 규격 | 사항에 반영한다.  |\n| 2 | 메모리 크기 | 인 안내서, 식품의약품안전처, 2021.12 | 6 | - 원재료: (임상시험용 의료기기의 원재료에 대한 특성 기술) | 검증 자료로 | 기록하게 하는 등 자신의 행동을 스스로 관찰, 기록하도록 | 우울장애와 | 관련 | 있는 | 역기능적인지를 | 평가하기 | 위해 | 확인한다.  | 적용 | 해당 | 미국 |\n| (1) 「의료기기법」 제2조 (정의) | Rating Scale, HDRS) | Depression Scale, | 회사명 | 대표이사 | 소재지 | 전화 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 제조자는 바이러스, 스파이웨어, 랜섬웨어 등 | 고려하여야 한다. ",
        "original_sentence": "| 1 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 판단할 수 있는 자 | 자동적 | □ 일회성 지시ㆍ명령에 해당하는 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_136",
      "text": "| □ 예 | ■ 아니오 | 검증 | disclosure and communication | 않음, 11~16점은 경미한 우울, 17~25점은 중등도 우울, 26점 | 방법에 대한 국제 규격 | 사항에 반영한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 135,
        "window_size": 3,
        "char_count": 119,
        "word_count": 29,
        "page_number": 3,
        "window_text": "|\n| 설계 변경을 | 역기능적 태도 척도 | 1) 식품의약품안전처의 임상 계획 승인일로부터 00개월 | 2) 무작위배정 방법 | Off-The-Shelf Software Use in | 어떻게 접속(유·무선 통신 등)하여야 할지를 | 수단을 통한 연결이나 업데이트의 진본성을 | App memory size는 최소 | regulatory purposes | (출처: Twomey et al., 2020.)  | 의료기기에서의 | 기성품 | 소프트웨어 | 검증 및 | 유효성 | (AB-1234) |\n| 22(4), 343-396.  | 1 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 판단할 수 있는 자 | 자동적 | □ 일회성 지시ㆍ명령에 해당하는 내용입니까?  | □ 예 | ■ 아니오 | 검증 | disclosure and communication | 않음, 11~16점은 경미한 우울, 17~25점은 중등도 우울, 26점 | 방법에 대한 국제 규격 | 사항에 반영한다.  |\n| 2 | 메모리 크기 | 인 안내서, 식품의약품안전처, 2021.12 | 6 | - 원재료: (임상시험용 의료기기의 원재료에 대한 특성 기술) | 검증 자료로 | 기록하게 하는 등 자신의 행동을 스스로 관찰, 기록하도록 | 우울장애와 | 관련 | 있는 | 역기능적인지를 | 평가하기 | 위해 | 확인한다.  | 적용 | 해당 | 미국 |\n| (1) 「의료기기법」 제2조 (정의) | Rating Scale, HDRS) | Depression Scale, | 회사명 | 대표이사 | 소재지 | 전화 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 제조자는 바이러스, 스파이웨어, 랜섬웨어 등 | 고려하여야 한다.  | - 우울장애 환자의 자동적 사고는 때때로 절대적이고 흑백 논리적 | 수 있다. ",
        "original_sentence": "| □ 예 | ■ 아니오 | 검증 | disclosure and communication | 않음, 11~16점은 경미한 우울, 17~25점은 중등도 우울, 26점 | 방법에 대한 국제 규격 | 사항에 반영한다. "
      }
    },
    {
      "chunk_id": "chunk_137",
      "text": "|\n| 2 | 메모리 크기 | 인 안내서, 식품의약품안전처, 2021.12 | 6 | - 원재료: (임상시험용 의료기기의 원재료에 대한 특성 기술) | 검증 자료로 | 기록하게 하는 등 자신의 행동을 스스로 관찰, 기록하도록 | 우울장애와 | 관련 | 있는 | 역기능적인지를 | 평가하기 | 위해 | 확인한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 136,
        "window_size": 3,
        "char_count": 174,
        "word_count": 48,
        "page_number": 9,
        "window_text": "| 의료기기에서의 | 기성품 | 소프트웨어 | 검증 및 | 유효성 | (AB-1234) |\n| 22(4), 343-396.  | 1 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 판단할 수 있는 자 | 자동적 | □ 일회성 지시ㆍ명령에 해당하는 내용입니까?  | □ 예 | ■ 아니오 | 검증 | disclosure and communication | 않음, 11~16점은 경미한 우울, 17~25점은 중등도 우울, 26점 | 방법에 대한 국제 규격 | 사항에 반영한다.  |\n| 2 | 메모리 크기 | 인 안내서, 식품의약품안전처, 2021.12 | 6 | - 원재료: (임상시험용 의료기기의 원재료에 대한 특성 기술) | 검증 자료로 | 기록하게 하는 등 자신의 행동을 스스로 관찰, 기록하도록 | 우울장애와 | 관련 | 있는 | 역기능적인지를 | 평가하기 | 위해 | 확인한다.  | 적용 | 해당 | 미국 |\n| (1) 「의료기기법」 제2조 (정의) | Rating Scale, HDRS) | Depression Scale, | 회사명 | 대표이사 | 소재지 | 전화 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 제조자는 바이러스, 스파이웨어, 랜섬웨어 등 | 고려하여야 한다.  | - 우울장애 환자의 자동적 사고는 때때로 절대적이고 흑백 논리적 | 수 있다.  | OO MB 이상일 것 | 구성되어 있다. ",
        "original_sentence": "|\n| 2 | 메모리 크기 | 인 안내서, 식품의약품안전처, 2021.12 | 6 | - 원재료: (임상시험용 의료기기의 원재료에 대한 특성 기술) | 검증 자료로 | 기록하게 하는 등 자신의 행동을 스스로 관찰, 기록하도록 | 우울장애와 | 관련 | 있는 | 역기능적인지를 | 평가하기 | 위해 | 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_138",
      "text": "| 적용 | 해당 | 미국 |\n| (1) 「의료기기법」 제2조 (정의) | Rating Scale, HDRS) | Depression Scale, | 회사명 | 대표이사 | 소재지 | 전화 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 제조자는 바이러스, 스파이웨어, 랜섬웨어 등 | 고려하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 137,
        "window_size": 3,
        "char_count": 184,
        "word_count": 45,
        "page_number": 5,
        "window_text": "| 1 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 판단할 수 있는 자 | 자동적 | □ 일회성 지시ㆍ명령에 해당하는 내용입니까?  | □ 예 | ■ 아니오 | 검증 | disclosure and communication | 않음, 11~16점은 경미한 우울, 17~25점은 중등도 우울, 26점 | 방법에 대한 국제 규격 | 사항에 반영한다.  |\n| 2 | 메모리 크기 | 인 안내서, 식품의약품안전처, 2021.12 | 6 | - 원재료: (임상시험용 의료기기의 원재료에 대한 특성 기술) | 검증 자료로 | 기록하게 하는 등 자신의 행동을 스스로 관찰, 기록하도록 | 우울장애와 | 관련 | 있는 | 역기능적인지를 | 평가하기 | 위해 | 확인한다.  | 적용 | 해당 | 미국 |\n| (1) 「의료기기법」 제2조 (정의) | Rating Scale, HDRS) | Depression Scale, | 회사명 | 대표이사 | 소재지 | 전화 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 제조자는 바이러스, 스파이웨어, 랜섬웨어 등 | 고려하여야 한다.  | - 우울장애 환자의 자동적 사고는 때때로 절대적이고 흑백 논리적 | 수 있다.  | OO MB 이상일 것 | 구성되어 있다.  18세에서 65세 성인에게 적용할 수 있다. ",
        "original_sentence": "| 적용 | 해당 | 미국 |\n| (1) 「의료기기법」 제2조 (정의) | Rating Scale, HDRS) | Depression Scale, | 회사명 | 대표이사 | 소재지 | 전화 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 제조자는 바이러스, 스파이웨어, 랜섬웨어 등 | 고려하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_139",
      "text": "| - 우울장애 환자의 자동적 사고는 때때로 절대적이고 흑백 논리적 | 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 138,
        "window_size": 3,
        "char_count": 46,
        "word_count": 13,
        "page_number": 11,
        "window_text": "| □ 예 | ■ 아니오 | 검증 | disclosure and communication | 않음, 11~16점은 경미한 우울, 17~25점은 중등도 우울, 26점 | 방법에 대한 국제 규격 | 사항에 반영한다.  |\n| 2 | 메모리 크기 | 인 안내서, 식품의약품안전처, 2021.12 | 6 | - 원재료: (임상시험용 의료기기의 원재료에 대한 특성 기술) | 검증 자료로 | 기록하게 하는 등 자신의 행동을 스스로 관찰, 기록하도록 | 우울장애와 | 관련 | 있는 | 역기능적인지를 | 평가하기 | 위해 | 확인한다.  | 적용 | 해당 | 미국 |\n| (1) 「의료기기법」 제2조 (정의) | Rating Scale, HDRS) | Depression Scale, | 회사명 | 대표이사 | 소재지 | 전화 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 제조자는 바이러스, 스파이웨어, 랜섬웨어 등 | 고려하여야 한다.  | - 우울장애 환자의 자동적 사고는 때때로 절대적이고 흑백 논리적 | 수 있다.  | OO MB 이상일 것 | 구성되어 있다.  18세에서 65세 성인에게 적용할 수 있다.  | 제공한다. ",
        "original_sentence": "| - 우울장애 환자의 자동적 사고는 때때로 절대적이고 흑백 논리적 | 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_140",
      "text": "| OO MB 이상일 것 | 구성되어 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 139,
        "window_size": 3,
        "char_count": 25,
        "word_count": 8,
        "page_number": 11,
        "window_text": "|\n| 2 | 메모리 크기 | 인 안내서, 식품의약품안전처, 2021.12 | 6 | - 원재료: (임상시험용 의료기기의 원재료에 대한 특성 기술) | 검증 자료로 | 기록하게 하는 등 자신의 행동을 스스로 관찰, 기록하도록 | 우울장애와 | 관련 | 있는 | 역기능적인지를 | 평가하기 | 위해 | 확인한다.  | 적용 | 해당 | 미국 |\n| (1) 「의료기기법」 제2조 (정의) | Rating Scale, HDRS) | Depression Scale, | 회사명 | 대표이사 | 소재지 | 전화 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 제조자는 바이러스, 스파이웨어, 랜섬웨어 등 | 고려하여야 한다.  | - 우울장애 환자의 자동적 사고는 때때로 절대적이고 흑백 논리적 | 수 있다.  | OO MB 이상일 것 | 구성되어 있다.  18세에서 65세 성인에게 적용할 수 있다.  | 제공한다.  | 소프트웨어 | 확인 자료 |\n| 통한 사용자별 | 1) 분석대상군 | (Dysfunctional Attitude | APA 진료지침(2010) | Strong | High (Substantial) | * 기타 이차 유효성 평가지표 예시는 다음과 같다 <표 17>. ",
        "original_sentence": "| OO MB 이상일 것 | 구성되어 있다. "
      }
    },
    {
      "chunk_id": "chunk_141",
      "text": "18세에서 65세 성인에게 적용할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 140,
        "window_size": 3,
        "char_count": 25,
        "word_count": 6,
        "page_number": 11,
        "window_text": "| 적용 | 해당 | 미국 |\n| (1) 「의료기기법」 제2조 (정의) | Rating Scale, HDRS) | Depression Scale, | 회사명 | 대표이사 | 소재지 | 전화 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 제조자는 바이러스, 스파이웨어, 랜섬웨어 등 | 고려하여야 한다.  | - 우울장애 환자의 자동적 사고는 때때로 절대적이고 흑백 논리적 | 수 있다.  | OO MB 이상일 것 | 구성되어 있다.  18세에서 65세 성인에게 적용할 수 있다.  | 제공한다.  | 소프트웨어 | 확인 자료 |\n| 통한 사용자별 | 1) 분석대상군 | (Dysfunctional Attitude | APA 진료지침(2010) | Strong | High (Substantial) | * 기타 이차 유효성 평가지표 예시는 다음과 같다 <표 17>.  | 차이를 보정할 수 있는 경우는 이를 반영하여 분석 결과를 제시해야 한다. ",
        "original_sentence": "18세에서 65세 성인에게 적용할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_142",
      "text": "| 제공한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 141,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 13,
        "window_text": "| - 우울장애 환자의 자동적 사고는 때때로 절대적이고 흑백 논리적 | 수 있다.  | OO MB 이상일 것 | 구성되어 있다.  18세에서 65세 성인에게 적용할 수 있다.  | 제공한다.  | 소프트웨어 | 확인 자료 |\n| 통한 사용자별 | 1) 분석대상군 | (Dysfunctional Attitude | APA 진료지침(2010) | Strong | High (Substantial) | * 기타 이차 유효성 평가지표 예시는 다음과 같다 <표 17>.  | 차이를 보정할 수 있는 경우는 이를 반영하여 분석 결과를 제시해야 한다.  | 기타 문서화된 정보의 사전 서면승인을 받아야 한다. ",
        "original_sentence": "| 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_143",
      "text": "| 소프트웨어 | 확인 자료 |\n| 통한 사용자별 | 1) 분석대상군 | (Dysfunctional Attitude | APA 진료지침(2010) | Strong | High (Substantial) | * 기타 이차 유효성 평가지표 예시는 다음과 같다 <표 17>. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 142,
        "window_size": 3,
        "char_count": 150,
        "word_count": 34,
        "page_number": 9,
        "window_text": "| OO MB 이상일 것 | 구성되어 있다.  18세에서 65세 성인에게 적용할 수 있다.  | 제공한다.  | 소프트웨어 | 확인 자료 |\n| 통한 사용자별 | 1) 분석대상군 | (Dysfunctional Attitude | APA 진료지침(2010) | Strong | High (Substantial) | * 기타 이차 유효성 평가지표 예시는 다음과 같다 <표 17>.  | 차이를 보정할 수 있는 경우는 이를 반영하여 분석 결과를 제시해야 한다.  | 기타 문서화된 정보의 사전 서면승인을 받아야 한다.  | 입회자가 동의를 얻는 전 과정에 참석하여야 한다. ",
        "original_sentence": "| 소프트웨어 | 확인 자료 |\n| 통한 사용자별 | 1) 분석대상군 | (Dysfunctional Attitude | APA 진료지침(2010) | Strong | High (Substantial) | * 기타 이차 유효성 평가지표 예시는 다음과 같다 <표 17>. "
      }
    },
    {
      "chunk_id": "chunk_144",
      "text": "| 차이를 보정할 수 있는 경우는 이를 반영하여 분석 결과를 제시해야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 143,
        "window_size": 3,
        "char_count": 43,
        "word_count": 12,
        "page_number": 7,
        "window_text": "18세에서 65세 성인에게 적용할 수 있다.  | 제공한다.  | 소프트웨어 | 확인 자료 |\n| 통한 사용자별 | 1) 분석대상군 | (Dysfunctional Attitude | APA 진료지침(2010) | Strong | High (Substantial) | * 기타 이차 유효성 평가지표 예시는 다음과 같다 <표 17>.  | 차이를 보정할 수 있는 경우는 이를 반영하여 분석 결과를 제시해야 한다.  | 기타 문서화된 정보의 사전 서면승인을 받아야 한다.  | 입회자가 동의를 얻는 전 과정에 참석하여야 한다.  | 문제가 있을 경우 시험자와 상의한다. ",
        "original_sentence": "| 차이를 보정할 수 있는 경우는 이를 반영하여 분석 결과를 제시해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_145",
      "text": "| 기타 문서화된 정보의 사전 서면승인을 받아야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 144,
        "window_size": 3,
        "char_count": 31,
        "word_count": 8,
        "page_number": 13,
        "window_text": "| 제공한다.  | 소프트웨어 | 확인 자료 |\n| 통한 사용자별 | 1) 분석대상군 | (Dysfunctional Attitude | APA 진료지침(2010) | Strong | High (Substantial) | * 기타 이차 유효성 평가지표 예시는 다음과 같다 <표 17>.  | 차이를 보정할 수 있는 경우는 이를 반영하여 분석 결과를 제시해야 한다.  | 기타 문서화된 정보의 사전 서면승인을 받아야 한다.  | 입회자가 동의를 얻는 전 과정에 참석하여야 한다.  | 문제가 있을 경우 시험자와 상의한다.  | 이러한 정보들은 기밀로 보관되어야 한다. ",
        "original_sentence": "| 기타 문서화된 정보의 사전 서면승인을 받아야 한다. "
      }
    },
    {
      "chunk_id": "chunk_146",
      "text": "| 입회자가 동의를 얻는 전 과정에 참석하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 145,
        "window_size": 3,
        "char_count": 30,
        "word_count": 8,
        "page_number": 13,
        "window_text": "| 소프트웨어 | 확인 자료 |\n| 통한 사용자별 | 1) 분석대상군 | (Dysfunctional Attitude | APA 진료지침(2010) | Strong | High (Substantial) | * 기타 이차 유효성 평가지표 예시는 다음과 같다 <표 17>.  | 차이를 보정할 수 있는 경우는 이를 반영하여 분석 결과를 제시해야 한다.  | 기타 문서화된 정보의 사전 서면승인을 받아야 한다.  | 입회자가 동의를 얻는 전 과정에 참석하여야 한다.  | 문제가 있을 경우 시험자와 상의한다.  | 이러한 정보들은 기밀로 보관되어야 한다.  | - 회원가입 및 초기 우울 증상 평가를 시행한다. ",
        "original_sentence": "| 입회자가 동의를 얻는 전 과정에 참석하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_147",
      "text": "| 문제가 있을 경우 시험자와 상의한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 146,
        "window_size": 3,
        "char_count": 23,
        "word_count": 6,
        "page_number": 13,
        "window_text": "| 차이를 보정할 수 있는 경우는 이를 반영하여 분석 결과를 제시해야 한다.  | 기타 문서화된 정보의 사전 서면승인을 받아야 한다.  | 입회자가 동의를 얻는 전 과정에 참석하여야 한다.  | 문제가 있을 경우 시험자와 상의한다.  | 이러한 정보들은 기밀로 보관되어야 한다.  | - 회원가입 및 초기 우울 증상 평가를 시행한다.  | - 치료 전 대비 8주 후 및 3개월 후 관해율, 반응율 | - 각 변수에 대해 이상치는 별도로 고려하지 않는다. ",
        "original_sentence": "| 문제가 있을 경우 시험자와 상의한다. "
      }
    },
    {
      "chunk_id": "chunk_148",
      "text": "| 이러한 정보들은 기밀로 보관되어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 147,
        "window_size": 3,
        "char_count": 25,
        "word_count": 6,
        "page_number": 13,
        "window_text": "| 기타 문서화된 정보의 사전 서면승인을 받아야 한다.  | 입회자가 동의를 얻는 전 과정에 참석하여야 한다.  | 문제가 있을 경우 시험자와 상의한다.  | 이러한 정보들은 기밀로 보관되어야 한다.  | - 회원가입 및 초기 우울 증상 평가를 시행한다.  | - 치료 전 대비 8주 후 및 3개월 후 관해율, 반응율 | - 각 변수에 대해 이상치는 별도로 고려하지 않는다.  | 고려하여야 한다. ",
        "original_sentence": "| 이러한 정보들은 기밀로 보관되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_149",
      "text": "| - 회원가입 및 초기 우울 증상 평가를 시행한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 148,
        "window_size": 3,
        "char_count": 30,
        "word_count": 9,
        "page_number": 13,
        "window_text": "| 입회자가 동의를 얻는 전 과정에 참석하여야 한다.  | 문제가 있을 경우 시험자와 상의한다.  | 이러한 정보들은 기밀로 보관되어야 한다.  | - 회원가입 및 초기 우울 증상 평가를 시행한다.  | - 치료 전 대비 8주 후 및 3개월 후 관해율, 반응율 | - 각 변수에 대해 이상치는 별도로 고려하지 않는다.  | 고려하여야 한다.  | 기재한다. ",
        "original_sentence": "| - 회원가입 및 초기 우울 증상 평가를 시행한다. "
      }
    },
    {
      "chunk_id": "chunk_150",
      "text": "| - 치료 전 대비 8주 후 및 3개월 후 관해율, 반응율 | - 각 변수에 대해 이상치는 별도로 고려하지 않는다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 149,
        "window_size": 3,
        "char_count": 66,
        "word_count": 21,
        "page_number": 29,
        "window_text": "| 문제가 있을 경우 시험자와 상의한다.  | 이러한 정보들은 기밀로 보관되어야 한다.  | - 회원가입 및 초기 우울 증상 평가를 시행한다.  | - 치료 전 대비 8주 후 및 3개월 후 관해율, 반응율 | - 각 변수에 대해 이상치는 별도로 고려하지 않는다.  | 고려하여야 한다.  | 기재한다.  | Novego: Coping with | 피험자 식별코드를 부여한다. ",
        "original_sentence": "| - 치료 전 대비 8주 후 및 3개월 후 관해율, 반응율 | - 각 변수에 대해 이상치는 별도로 고려하지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_151",
      "text": "| 고려하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 150,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 13,
        "window_text": "| 이러한 정보들은 기밀로 보관되어야 한다.  | - 회원가입 및 초기 우울 증상 평가를 시행한다.  | - 치료 전 대비 8주 후 및 3개월 후 관해율, 반응율 | - 각 변수에 대해 이상치는 별도로 고려하지 않는다.  | 고려하여야 한다.  | 기재한다.  | Novego: Coping with | 피험자 식별코드를 부여한다.  | Medical Devices | (Follow-up, 3개월 후) | 사용에 대한 가이드 | 위험 < | 유효성 | (AB-1234) |\n| 1) 임상시험의 연구목적으로 수행된다는 사실 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 참여하는 사람(피험자)의 선정기준ㆍ제외기준ㆍ인원 및 그 근거 | 사고와 | SilverCloud | of medical device security | 이상은 심한 우울장애로 구분한다. ",
        "original_sentence": "| 고려하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_152",
      "text": "| 기재한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 151,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 13,
        "window_text": "| - 회원가입 및 초기 우울 증상 평가를 시행한다.  | - 치료 전 대비 8주 후 및 3개월 후 관해율, 반응율 | - 각 변수에 대해 이상치는 별도로 고려하지 않는다.  | 고려하여야 한다.  | 기재한다.  | Novego: Coping with | 피험자 식별코드를 부여한다.  | Medical Devices | (Follow-up, 3개월 후) | 사용에 대한 가이드 | 위험 < | 유효성 | (AB-1234) |\n| 1) 임상시험의 연구목적으로 수행된다는 사실 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 참여하는 사람(피험자)의 선정기준ㆍ제외기준ㆍ인원 및 그 근거 | 사고와 | SilverCloud | of medical device security | 이상은 심한 우울장애로 구분한다.  | (ex:설정→애플리케이션→메모리) |\n| 4) 한국어를 읽고 쓰는 데 어려움이 없는 자 | 1) 임상시험용 의료기기와의 인과관계 평가 | 2) 대상자 모집 기간: 00개월 | 접근통제 및 | 한다. ",
        "original_sentence": "| 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_153",
      "text": "| Novego: Coping with | 피험자 식별코드를 부여한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 152,
        "window_size": 3,
        "char_count": 40,
        "word_count": 8,
        "page_number": 13,
        "window_text": "| - 치료 전 대비 8주 후 및 3개월 후 관해율, 반응율 | - 각 변수에 대해 이상치는 별도로 고려하지 않는다.  | 고려하여야 한다.  | 기재한다.  | Novego: Coping with | 피험자 식별코드를 부여한다.  | Medical Devices | (Follow-up, 3개월 후) | 사용에 대한 가이드 | 위험 < | 유효성 | (AB-1234) |\n| 1) 임상시험의 연구목적으로 수행된다는 사실 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 참여하는 사람(피험자)의 선정기준ㆍ제외기준ㆍ인원 및 그 근거 | 사고와 | SilverCloud | of medical device security | 이상은 심한 우울장애로 구분한다.  | (ex:설정→애플리케이션→메모리) |\n| 4) 한국어를 읽고 쓰는 데 어려움이 없는 자 | 1) 임상시험용 의료기기와의 인과관계 평가 | 2) 대상자 모집 기간: 00개월 | 접근통제 및 | 한다.  | 고안된 100개의 문항으로 구성되었다. ",
        "original_sentence": "| Novego: Coping with | 피험자 식별코드를 부여한다. "
      }
    },
    {
      "chunk_id": "chunk_154",
      "text": "| Medical Devices | (Follow-up, 3개월 후) | 사용에 대한 가이드 | 위험 < | 유효성 | (AB-1234) |\n| 1) 임상시험의 연구목적으로 수행된다는 사실 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 참여하는 사람(피험자)의 선정기준ㆍ제외기준ㆍ인원 및 그 근거 | 사고와 | SilverCloud | of medical device security | 이상은 심한 우울장애로 구분한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 153,
        "window_size": 3,
        "char_count": 248,
        "word_count": 56,
        "page_number": 29,
        "window_text": "| 고려하여야 한다.  | 기재한다.  | Novego: Coping with | 피험자 식별코드를 부여한다.  | Medical Devices | (Follow-up, 3개월 후) | 사용에 대한 가이드 | 위험 < | 유효성 | (AB-1234) |\n| 1) 임상시험의 연구목적으로 수행된다는 사실 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 참여하는 사람(피험자)의 선정기준ㆍ제외기준ㆍ인원 및 그 근거 | 사고와 | SilverCloud | of medical device security | 이상은 심한 우울장애로 구분한다.  | (ex:설정→애플리케이션→메모리) |\n| 4) 한국어를 읽고 쓰는 데 어려움이 없는 자 | 1) 임상시험용 의료기기와의 인과관계 평가 | 2) 대상자 모집 기간: 00개월 | 접근통제 및 | 한다.  | 고안된 100개의 문항으로 구성되었다.  그러나 임상적으로 | 층화하여 층내 시험군, 대조군 1:1 배정 | 소프트웨어 요구사항을 소프트 | 1 | 2 | 2 | Acceptable | 사항 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 할 수 있다. ",
        "original_sentence": "| Medical Devices | (Follow-up, 3개월 후) | 사용에 대한 가이드 | 위험 < | 유효성 | (AB-1234) |\n| 1) 임상시험의 연구목적으로 수행된다는 사실 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 참여하는 사람(피험자)의 선정기준ㆍ제외기준ㆍ인원 및 그 근거 | 사고와 | SilverCloud | of medical device security | 이상은 심한 우울장애로 구분한다. "
      }
    },
    {
      "chunk_id": "chunk_155",
      "text": "| (ex:설정→애플리케이션→메모리) |\n| 4) 한국어를 읽고 쓰는 데 어려움이 없는 자 | 1) 임상시험용 의료기기와의 인과관계 평가 | 2) 대상자 모집 기간: 00개월 | 접근통제 및 | 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 154,
        "window_size": 3,
        "char_count": 113,
        "word_count": 29,
        "page_number": 29,
        "window_text": "| 기재한다.  | Novego: Coping with | 피험자 식별코드를 부여한다.  | Medical Devices | (Follow-up, 3개월 후) | 사용에 대한 가이드 | 위험 < | 유효성 | (AB-1234) |\n| 1) 임상시험의 연구목적으로 수행된다는 사실 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 참여하는 사람(피험자)의 선정기준ㆍ제외기준ㆍ인원 및 그 근거 | 사고와 | SilverCloud | of medical device security | 이상은 심한 우울장애로 구분한다.  | (ex:설정→애플리케이션→메모리) |\n| 4) 한국어를 읽고 쓰는 데 어려움이 없는 자 | 1) 임상시험용 의료기기와의 인과관계 평가 | 2) 대상자 모집 기간: 00개월 | 접근통제 및 | 한다.  | 고안된 100개의 문항으로 구성되었다.  그러나 임상적으로 | 층화하여 층내 시험군, 대조군 1:1 배정 | 소프트웨어 요구사항을 소프트 | 1 | 2 | 2 | Acceptable | 사항 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 할 수 있다.  | 고려하지 않는다. ",
        "original_sentence": "| (ex:설정→애플리케이션→메모리) |\n| 4) 한국어를 읽고 쓰는 데 어려움이 없는 자 | 1) 임상시험용 의료기기와의 인과관계 평가 | 2) 대상자 모집 기간: 00개월 | 접근통제 및 | 한다. "
      }
    },
    {
      "chunk_id": "chunk_156",
      "text": "| 고안된 100개의 문항으로 구성되었다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 155,
        "window_size": 3,
        "char_count": 24,
        "word_count": 5,
        "page_number": 21,
        "window_text": "| Novego: Coping with | 피험자 식별코드를 부여한다.  | Medical Devices | (Follow-up, 3개월 후) | 사용에 대한 가이드 | 위험 < | 유효성 | (AB-1234) |\n| 1) 임상시험의 연구목적으로 수행된다는 사실 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 참여하는 사람(피험자)의 선정기준ㆍ제외기준ㆍ인원 및 그 근거 | 사고와 | SilverCloud | of medical device security | 이상은 심한 우울장애로 구분한다.  | (ex:설정→애플리케이션→메모리) |\n| 4) 한국어를 읽고 쓰는 데 어려움이 없는 자 | 1) 임상시험용 의료기기와의 인과관계 평가 | 2) 대상자 모집 기간: 00개월 | 접근통제 및 | 한다.  | 고안된 100개의 문항으로 구성되었다.  그러나 임상적으로 | 층화하여 층내 시험군, 대조군 1:1 배정 | 소프트웨어 요구사항을 소프트 | 1 | 2 | 2 | Acceptable | 사항 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 할 수 있다.  | 고려하지 않는다.  | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 같으면 배제기준에 해당하지 않는다. ",
        "original_sentence": "| 고안된 100개의 문항으로 구성되었다. "
      }
    },
    {
      "chunk_id": "chunk_157",
      "text": "그러나 임상적으로 | 층화하여 층내 시험군, 대조군 1:1 배정 | 소프트웨어 요구사항을 소프트 | 1 | 2 | 2 | Acceptable | 사항 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 156,
        "window_size": 3,
        "char_count": 137,
        "word_count": 39,
        "page_number": 3,
        "window_text": "| Medical Devices | (Follow-up, 3개월 후) | 사용에 대한 가이드 | 위험 < | 유효성 | (AB-1234) |\n| 1) 임상시험의 연구목적으로 수행된다는 사실 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 참여하는 사람(피험자)의 선정기준ㆍ제외기준ㆍ인원 및 그 근거 | 사고와 | SilverCloud | of medical device security | 이상은 심한 우울장애로 구분한다.  | (ex:설정→애플리케이션→메모리) |\n| 4) 한국어를 읽고 쓰는 데 어려움이 없는 자 | 1) 임상시험용 의료기기와의 인과관계 평가 | 2) 대상자 모집 기간: 00개월 | 접근통제 및 | 한다.  | 고안된 100개의 문항으로 구성되었다.  그러나 임상적으로 | 층화하여 층내 시험군, 대조군 1:1 배정 | 소프트웨어 요구사항을 소프트 | 1 | 2 | 2 | Acceptable | 사항 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 할 수 있다.  | 고려하지 않는다.  | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 같으면 배제기준에 해당하지 않는다.  | 기기에서 실행될 수 있는 악성코드를 막기 | HADS) | □ 외국 규정을 단순 번역하거나 설명하는 내용입니까? ",
        "original_sentence": "그러나 임상적으로 | 층화하여 층내 시험군, 대조군 1:1 배정 | 소프트웨어 요구사항을 소프트 | 1 | 2 | 2 | Acceptable | 사항 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_158",
      "text": "| 고려하지 않는다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 157,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 43,
        "window_text": "| (ex:설정→애플리케이션→메모리) |\n| 4) 한국어를 읽고 쓰는 데 어려움이 없는 자 | 1) 임상시험용 의료기기와의 인과관계 평가 | 2) 대상자 모집 기간: 00개월 | 접근통제 및 | 한다.  | 고안된 100개의 문항으로 구성되었다.  그러나 임상적으로 | 층화하여 층내 시험군, 대조군 1:1 배정 | 소프트웨어 요구사항을 소프트 | 1 | 2 | 2 | Acceptable | 사항 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 할 수 있다.  | 고려하지 않는다.  | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 같으면 배제기준에 해당하지 않는다.  | 기기에서 실행될 수 있는 악성코드를 막기 | HADS) | □ 외국 규정을 단순 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | 으로 나타난다. ",
        "original_sentence": "| 고려하지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_159",
      "text": "| ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 같으면 배제기준에 해당하지 않는다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 158,
        "window_size": 3,
        "char_count": 61,
        "word_count": 14,
        "page_number": 29,
        "window_text": "| 고안된 100개의 문항으로 구성되었다.  그러나 임상적으로 | 층화하여 층내 시험군, 대조군 1:1 배정 | 소프트웨어 요구사항을 소프트 | 1 | 2 | 2 | Acceptable | 사항 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 할 수 있다.  | 고려하지 않는다.  | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 같으면 배제기준에 해당하지 않는다.  | 기기에서 실행될 수 있는 악성코드를 막기 | HADS) | □ 외국 규정을 단순 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | 으로 나타난다.  어떤 특정 부정적 단어가 자기 자신에게 어느 | 우울 하위척도를 8점으로 절단할 때 민감도 89.2%, 특이도 | 검증 및 |\n| (2) 「의료기기법」 제3조 (등급분류와 지정) | 접근통제 및 | 식품의약품안전처, 2021.12 | BAP 진료지침(2014) | Strong (A등급) | High (Level I) | Mental Disorders, Fifth Edition, DSM-5) | 웨어 밸리데이션 가이드라인(민원인 안내서)’에 따라 수행한다. ",
        "original_sentence": "| ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 같으면 배제기준에 해당하지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_160",
      "text": "| 기기에서 실행될 수 있는 악성코드를 막기 | HADS) | □ 외국 규정을 단순 번역하거나 설명하는 내용입니까? ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 159,
        "window_size": 3,
        "char_count": 65,
        "word_count": 17,
        "page_number": 45,
        "window_text": "그러나 임상적으로 | 층화하여 층내 시험군, 대조군 1:1 배정 | 소프트웨어 요구사항을 소프트 | 1 | 2 | 2 | Acceptable | 사항 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 할 수 있다.  | 고려하지 않는다.  | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 같으면 배제기준에 해당하지 않는다.  | 기기에서 실행될 수 있는 악성코드를 막기 | HADS) | □ 외국 규정을 단순 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | 으로 나타난다.  어떤 특정 부정적 단어가 자기 자신에게 어느 | 우울 하위척도를 8점으로 절단할 때 민감도 89.2%, 특이도 | 검증 및 |\n| (2) 「의료기기법」 제3조 (등급분류와 지정) | 접근통제 및 | 식품의약품안전처, 2021.12 | BAP 진료지침(2014) | Strong (A등급) | High (Level I) | Mental Disorders, Fifth Edition, DSM-5) | 웨어 밸리데이션 가이드라인(민원인 안내서)’에 따라 수행한다.  | Scale, DAS) | ※ 예: Wi-Fi, 이더넷, 블루투스, USB 등 | * 독립형 소프트웨어 제품은 소프트웨어 명칭, 버전, 운영환경 기재 | Depression | needs, risks and controls | 확인 자료 | 이득 |\n| 소프트 | 왜곡된 | Information for Healthcare | (SilverCloud) | Medical devices | 의료기기 위험관리 | (Risk | 적용 |\n| 6) 하위 분석 | 적합한 통신 개략도와 사이버보안 적용 사항을 기재한다. ",
        "original_sentence": "| 기기에서 실행될 수 있는 악성코드를 막기 | HADS) | □ 외국 규정을 단순 번역하거나 설명하는 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_161",
      "text": "| □ 예 | ■ 아니오 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | 으로 나타난다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 160,
        "window_size": 3,
        "char_count": 59,
        "word_count": 17,
        "page_number": 3,
        "window_text": "| 고려하지 않는다.  | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 같으면 배제기준에 해당하지 않는다.  | 기기에서 실행될 수 있는 악성코드를 막기 | HADS) | □ 외국 규정을 단순 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | 으로 나타난다.  어떤 특정 부정적 단어가 자기 자신에게 어느 | 우울 하위척도를 8점으로 절단할 때 민감도 89.2%, 특이도 | 검증 및 |\n| (2) 「의료기기법」 제3조 (등급분류와 지정) | 접근통제 및 | 식품의약품안전처, 2021.12 | BAP 진료지침(2014) | Strong (A등급) | High (Level I) | Mental Disorders, Fifth Edition, DSM-5) | 웨어 밸리데이션 가이드라인(민원인 안내서)’에 따라 수행한다.  | Scale, DAS) | ※ 예: Wi-Fi, 이더넷, 블루투스, USB 등 | * 독립형 소프트웨어 제품은 소프트웨어 명칭, 버전, 운영환경 기재 | Depression | needs, risks and controls | 확인 자료 | 이득 |\n| 소프트 | 왜곡된 | Information for Healthcare | (SilverCloud) | Medical devices | 의료기기 위험관리 | (Risk | 적용 |\n| 6) 하위 분석 | 적합한 통신 개략도와 사이버보안 적용 사항을 기재한다.  | 문제점을 적극적으로 대응한다. ",
        "original_sentence": "| □ 예 | ■ 아니오 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | 으로 나타난다. "
      }
    },
    {
      "chunk_id": "chunk_162",
      "text": "어떤 특정 부정적 단어가 자기 자신에게 어느 | 우울 하위척도를 8점으로 절단할 때 민감도 89.2%, 특이도 | 검증 및 |\n| (2) 「의료기기법」 제3조 (등급분류와 지정) | 접근통제 및 | 식품의약품안전처, 2021.12 | BAP 진료지침(2014) | Strong (A등급) | High (Level I) | Mental Disorders, Fifth Edition, DSM-5) | 웨어 밸리데이션 가이드라인(민원인 안내서)’에 따라 수행한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 161,
        "window_size": 3,
        "char_count": 257,
        "word_count": 55,
        "page_number": 18,
        "window_text": "| ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 같으면 배제기준에 해당하지 않는다.  | 기기에서 실행될 수 있는 악성코드를 막기 | HADS) | □ 외국 규정을 단순 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | 으로 나타난다.  어떤 특정 부정적 단어가 자기 자신에게 어느 | 우울 하위척도를 8점으로 절단할 때 민감도 89.2%, 특이도 | 검증 및 |\n| (2) 「의료기기법」 제3조 (등급분류와 지정) | 접근통제 및 | 식품의약품안전처, 2021.12 | BAP 진료지침(2014) | Strong (A등급) | High (Level I) | Mental Disorders, Fifth Edition, DSM-5) | 웨어 밸리데이션 가이드라인(민원인 안내서)’에 따라 수행한다.  | Scale, DAS) | ※ 예: Wi-Fi, 이더넷, 블루투스, USB 등 | * 독립형 소프트웨어 제품은 소프트웨어 명칭, 버전, 운영환경 기재 | Depression | needs, risks and controls | 확인 자료 | 이득 |\n| 소프트 | 왜곡된 | Information for Healthcare | (SilverCloud) | Medical devices | 의료기기 위험관리 | (Risk | 적용 |\n| 6) 하위 분석 | 적합한 통신 개략도와 사이버보안 적용 사항을 기재한다.  | 문제점을 적극적으로 대응한다.  | 및 폐기에 관한 기록을 유지하여야 한다. ",
        "original_sentence": "어떤 특정 부정적 단어가 자기 자신에게 어느 | 우울 하위척도를 8점으로 절단할 때 민감도 89.2%, 특이도 | 검증 및 |\n| (2) 「의료기기법」 제3조 (등급분류와 지정) | 접근통제 및 | 식품의약품안전처, 2021.12 | BAP 진료지침(2014) | Strong (A등급) | High (Level I) | Mental Disorders, Fifth Edition, DSM-5) | 웨어 밸리데이션 가이드라인(민원인 안내서)’에 따라 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_163",
      "text": "| Scale, DAS) | ※ 예: Wi-Fi, 이더넷, 블루투스, USB 등 | * 독립형 소프트웨어 제품은 소프트웨어 명칭, 버전, 운영환경 기재 | Depression | needs, risks and controls | 확인 자료 | 이득 |\n| 소프트 | 왜곡된 | Information for Healthcare | (SilverCloud) | Medical devices | 의료기기 위험관리 | (Risk | 적용 |\n| 6) 하위 분석 | 적합한 통신 개략도와 사이버보안 적용 사항을 기재한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 162,
        "window_size": 3,
        "char_count": 287,
        "word_count": 67,
        "page_number": 29,
        "window_text": "| 기기에서 실행될 수 있는 악성코드를 막기 | HADS) | □ 외국 규정을 단순 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | 으로 나타난다.  어떤 특정 부정적 단어가 자기 자신에게 어느 | 우울 하위척도를 8점으로 절단할 때 민감도 89.2%, 특이도 | 검증 및 |\n| (2) 「의료기기법」 제3조 (등급분류와 지정) | 접근통제 및 | 식품의약품안전처, 2021.12 | BAP 진료지침(2014) | Strong (A등급) | High (Level I) | Mental Disorders, Fifth Edition, DSM-5) | 웨어 밸리데이션 가이드라인(민원인 안내서)’에 따라 수행한다.  | Scale, DAS) | ※ 예: Wi-Fi, 이더넷, 블루투스, USB 등 | * 독립형 소프트웨어 제품은 소프트웨어 명칭, 버전, 운영환경 기재 | Depression | needs, risks and controls | 확인 자료 | 이득 |\n| 소프트 | 왜곡된 | Information for Healthcare | (SilverCloud) | Medical devices | 의료기기 위험관리 | (Risk | 적용 |\n| 6) 하위 분석 | 적합한 통신 개략도와 사이버보안 적용 사항을 기재한다.  | 문제점을 적극적으로 대응한다.  | 및 폐기에 관한 기록을 유지하여야 한다.  | - 모든 분석 대상자군(Full Analysis Set, FAS) | 제조자는 비인가 된 개인이 의료기기에 접근 | 내용을 기재한다. ",
        "original_sentence": "| Scale, DAS) | ※ 예: Wi-Fi, 이더넷, 블루투스, USB 등 | * 독립형 소프트웨어 제품은 소프트웨어 명칭, 버전, 운영환경 기재 | Depression | needs, risks and controls | 확인 자료 | 이득 |\n| 소프트 | 왜곡된 | Information for Healthcare | (SilverCloud) | Medical devices | 의료기기 위험관리 | (Risk | 적용 |\n| 6) 하위 분석 | 적합한 통신 개략도와 사이버보안 적용 사항을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_164",
      "text": "| 문제점을 적극적으로 대응한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 163,
        "window_size": 3,
        "char_count": 19,
        "word_count": 4,
        "page_number": 13,
        "window_text": "| □ 예 | ■ 아니오 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | 으로 나타난다.  어떤 특정 부정적 단어가 자기 자신에게 어느 | 우울 하위척도를 8점으로 절단할 때 민감도 89.2%, 특이도 | 검증 및 |\n| (2) 「의료기기법」 제3조 (등급분류와 지정) | 접근통제 및 | 식품의약품안전처, 2021.12 | BAP 진료지침(2014) | Strong (A등급) | High (Level I) | Mental Disorders, Fifth Edition, DSM-5) | 웨어 밸리데이션 가이드라인(민원인 안내서)’에 따라 수행한다.  | Scale, DAS) | ※ 예: Wi-Fi, 이더넷, 블루투스, USB 등 | * 독립형 소프트웨어 제품은 소프트웨어 명칭, 버전, 운영환경 기재 | Depression | needs, risks and controls | 확인 자료 | 이득 |\n| 소프트 | 왜곡된 | Information for Healthcare | (SilverCloud) | Medical devices | 의료기기 위험관리 | (Risk | 적용 |\n| 6) 하위 분석 | 적합한 통신 개략도와 사이버보안 적용 사항을 기재한다.  | 문제점을 적극적으로 대응한다.  | 및 폐기에 관한 기록을 유지하여야 한다.  | - 모든 분석 대상자군(Full Analysis Set, FAS) | 제조자는 비인가 된 개인이 의료기기에 접근 | 내용을 기재한다.  | 위임자가 모든 선정 및 제외 기준을 검토해야 한다. ",
        "original_sentence": "| 문제점을 적극적으로 대응한다. "
      }
    },
    {
      "chunk_id": "chunk_165",
      "text": "| 및 폐기에 관한 기록을 유지하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 164,
        "window_size": 3,
        "char_count": 25,
        "word_count": 7,
        "page_number": 13,
        "window_text": "어떤 특정 부정적 단어가 자기 자신에게 어느 | 우울 하위척도를 8점으로 절단할 때 민감도 89.2%, 특이도 | 검증 및 |\n| (2) 「의료기기법」 제3조 (등급분류와 지정) | 접근통제 및 | 식품의약품안전처, 2021.12 | BAP 진료지침(2014) | Strong (A등급) | High (Level I) | Mental Disorders, Fifth Edition, DSM-5) | 웨어 밸리데이션 가이드라인(민원인 안내서)’에 따라 수행한다.  | Scale, DAS) | ※ 예: Wi-Fi, 이더넷, 블루투스, USB 등 | * 독립형 소프트웨어 제품은 소프트웨어 명칭, 버전, 운영환경 기재 | Depression | needs, risks and controls | 확인 자료 | 이득 |\n| 소프트 | 왜곡된 | Information for Healthcare | (SilverCloud) | Medical devices | 의료기기 위험관리 | (Risk | 적용 |\n| 6) 하위 분석 | 적합한 통신 개략도와 사이버보안 적용 사항을 기재한다.  | 문제점을 적극적으로 대응한다.  | 및 폐기에 관한 기록을 유지하여야 한다.  | - 모든 분석 대상자군(Full Analysis Set, FAS) | 제조자는 비인가 된 개인이 의료기기에 접근 | 내용을 기재한다.  | 위임자가 모든 선정 및 제외 기준을 검토해야 한다.  | 기간, 목적을 확인한다. ",
        "original_sentence": "| 및 폐기에 관한 기록을 유지하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_166",
      "text": "| - 모든 분석 대상자군(Full Analysis Set, FAS) | 제조자는 비인가 된 개인이 의료기기에 접근 | 내용을 기재한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 165,
        "window_size": 3,
        "char_count": 77,
        "word_count": 18,
        "page_number": 29,
        "window_text": "| Scale, DAS) | ※ 예: Wi-Fi, 이더넷, 블루투스, USB 등 | * 독립형 소프트웨어 제품은 소프트웨어 명칭, 버전, 운영환경 기재 | Depression | needs, risks and controls | 확인 자료 | 이득 |\n| 소프트 | 왜곡된 | Information for Healthcare | (SilverCloud) | Medical devices | 의료기기 위험관리 | (Risk | 적용 |\n| 6) 하위 분석 | 적합한 통신 개략도와 사이버보안 적용 사항을 기재한다.  | 문제점을 적극적으로 대응한다.  | 및 폐기에 관한 기록을 유지하여야 한다.  | - 모든 분석 대상자군(Full Analysis Set, FAS) | 제조자는 비인가 된 개인이 의료기기에 접근 | 내용을 기재한다.  | 위임자가 모든 선정 및 제외 기준을 검토해야 한다.  | 기간, 목적을 확인한다.  | 통해 정보를 수집한다. ",
        "original_sentence": "| - 모든 분석 대상자군(Full Analysis Set, FAS) | 제조자는 비인가 된 개인이 의료기기에 접근 | 내용을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_167",
      "text": "| 위임자가 모든 선정 및 제외 기준을 검토해야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 166,
        "window_size": 3,
        "char_count": 31,
        "word_count": 9,
        "page_number": 13,
        "window_text": "| 문제점을 적극적으로 대응한다.  | 및 폐기에 관한 기록을 유지하여야 한다.  | - 모든 분석 대상자군(Full Analysis Set, FAS) | 제조자는 비인가 된 개인이 의료기기에 접근 | 내용을 기재한다.  | 위임자가 모든 선정 및 제외 기준을 검토해야 한다.  | 기간, 목적을 확인한다.  | 통해 정보를 수집한다.  | 애플리케이션, 이메일, 문자, SNS 등을 통해 수집한다. ",
        "original_sentence": "| 위임자가 모든 선정 및 제외 기준을 검토해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_168",
      "text": "| 기간, 목적을 확인한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 167,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 7,
        "window_text": "| 및 폐기에 관한 기록을 유지하여야 한다.  | - 모든 분석 대상자군(Full Analysis Set, FAS) | 제조자는 비인가 된 개인이 의료기기에 접근 | 내용을 기재한다.  | 위임자가 모든 선정 및 제외 기준을 검토해야 한다.  | 기간, 목적을 확인한다.  | 통해 정보를 수집한다.  | 애플리케이션, 이메일, 문자, SNS 등을 통해 수집한다.  | 참여 동의를 철회하는 경우 | 타당한 경우 | 표 17. ",
        "original_sentence": "| 기간, 목적을 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_169",
      "text": "| 통해 정보를 수집한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 168,
        "window_size": 3,
        "char_count": 15,
        "word_count": 4,
        "page_number": 13,
        "window_text": "| - 모든 분석 대상자군(Full Analysis Set, FAS) | 제조자는 비인가 된 개인이 의료기기에 접근 | 내용을 기재한다.  | 위임자가 모든 선정 및 제외 기준을 검토해야 한다.  | 기간, 목적을 확인한다.  | 통해 정보를 수집한다.  | 애플리케이션, 이메일, 문자, SNS 등을 통해 수집한다.  | 참여 동의를 철회하는 경우 | 타당한 경우 | 표 17.  우울장애 이차 유효성 평가 지표 예시 | 인증 기능 | 정도 해당이 되는지 그 정도를 알게 하는 방법으로 이러한 | 손쉽게 활용하기 위해 40문항으로 단축하였으며, 성취지향, | 표 3. ",
        "original_sentence": "| 통해 정보를 수집한다. "
      }
    },
    {
      "chunk_id": "chunk_170",
      "text": "| 애플리케이션, 이메일, 문자, SNS 등을 통해 수집한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 169,
        "window_size": 3,
        "char_count": 35,
        "word_count": 8,
        "page_number": 13,
        "window_text": "| 위임자가 모든 선정 및 제외 기준을 검토해야 한다.  | 기간, 목적을 확인한다.  | 통해 정보를 수집한다.  | 애플리케이션, 이메일, 문자, SNS 등을 통해 수집한다.  | 참여 동의를 철회하는 경우 | 타당한 경우 | 표 17.  우울장애 이차 유효성 평가 지표 예시 | 인증 기능 | 정도 해당이 되는지 그 정도를 알게 하는 방법으로 이러한 | 손쉽게 활용하기 위해 40문항으로 단축하였으며, 성취지향, | 표 3.  항우울제 권고 요약표 | 웨어 구조로 설명하며 소프트 | 없음 | (선택) |\n| practical health care: an updated meta-analysis. ",
        "original_sentence": "| 애플리케이션, 이메일, 문자, SNS 등을 통해 수집한다. "
      }
    },
    {
      "chunk_id": "chunk_171",
      "text": "| 참여 동의를 철회하는 경우 | 타당한 경우 | 표 17. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 170,
        "window_size": 3,
        "char_count": 34,
        "word_count": 11,
        "page_number": 28,
        "window_text": "| 기간, 목적을 확인한다.  | 통해 정보를 수집한다.  | 애플리케이션, 이메일, 문자, SNS 등을 통해 수집한다.  | 참여 동의를 철회하는 경우 | 타당한 경우 | 표 17.  우울장애 이차 유효성 평가 지표 예시 | 인증 기능 | 정도 해당이 되는지 그 정도를 알게 하는 방법으로 이러한 | 손쉽게 활용하기 위해 40문항으로 단축하였으며, 성취지향, | 표 3.  항우울제 권고 요약표 | 웨어 구조로 설명하며 소프트 | 없음 | (선택) |\n| practical health care: an updated meta-analysis.  Journal of anxiety disorders, 55, 70-78. ",
        "original_sentence": "| 참여 동의를 철회하는 경우 | 타당한 경우 | 표 17. "
      }
    },
    {
      "chunk_id": "chunk_172",
      "text": "우울장애 이차 유효성 평가 지표 예시 | 인증 기능 | 정도 해당이 되는지 그 정도를 알게 하는 방법으로 이러한 | 손쉽게 활용하기 위해 40문항으로 단축하였으며, 성취지향, | 표 3. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 171,
        "window_size": 3,
        "char_count": 105,
        "word_count": 29,
        "page_number": 7,
        "window_text": "| 통해 정보를 수집한다.  | 애플리케이션, 이메일, 문자, SNS 등을 통해 수집한다.  | 참여 동의를 철회하는 경우 | 타당한 경우 | 표 17.  우울장애 이차 유효성 평가 지표 예시 | 인증 기능 | 정도 해당이 되는지 그 정도를 알게 하는 방법으로 이러한 | 손쉽게 활용하기 위해 40문항으로 단축하였으며, 성취지향, | 표 3.  항우울제 권고 요약표 | 웨어 구조로 설명하며 소프트 | 없음 | (선택) |\n| practical health care: an updated meta-analysis.  Journal of anxiety disorders, 55, 70-78.  | 행동 | 2) 임상시험의 목적 | 우울장애 개선 디지털치료기기 안전성·성능 평가 및 | 제조자는 | 내·외부의 | 모든 | 입력에 | 대한 | 위해 안티 멀웨어 프로그램과 같은 통제 | 법칙을 깨는 실험(rule-breaking experiments) | 스크리닝 및 | ‘OOOOO’ 경고푸시 알림이 | 82.5%이며, 불안 하위척도를 8점으로 절단할 때 민감도 | 오송보건의료행정타운 | 해당 알림이 발생하는 조건 정하고, | 치료 기간 종료 | 1주 후(8주+1주) | (Post-treatment)3)3)3) | 유효성 | (AB-1234) |\n| CANMAT 진료지침(2016) | Strong (First-line) | High (Level 1) | 개입 | 5) 시험 방법 | 2 | ISO 14971 | 3) 임상시험 수행 기간: 00개월 | 인지 | (IVPNetworks) | – Application of risk | CES-D는 총 20개 문항으로 우울 정서, 긍정적 정서, 신체적 | 치료 시작일 | Management)에 대한 국제 | 성능 시험 | 치료 기간 종료 | 국외 |\n| (3) 「의료기기법」 제10조 (임상시험계획의 승인 등) | 3 | 경고 메시지 | 기록을 열람할 수 있다. ",
        "original_sentence": "우울장애 이차 유효성 평가 지표 예시 | 인증 기능 | 정도 해당이 되는지 그 정도를 알게 하는 방법으로 이러한 | 손쉽게 활용하기 위해 40문항으로 단축하였으며, 성취지향, | 표 3. "
      }
    },
    {
      "chunk_id": "chunk_173",
      "text": "항우울제 권고 요약표 | 웨어 구조로 설명하며 소프트 | 없음 | (선택) |\n| practical health care: an updated meta-analysis. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 172,
        "window_size": 3,
        "char_count": 95,
        "word_count": 20,
        "page_number": 41,
        "window_text": "| 애플리케이션, 이메일, 문자, SNS 등을 통해 수집한다.  | 참여 동의를 철회하는 경우 | 타당한 경우 | 표 17.  우울장애 이차 유효성 평가 지표 예시 | 인증 기능 | 정도 해당이 되는지 그 정도를 알게 하는 방법으로 이러한 | 손쉽게 활용하기 위해 40문항으로 단축하였으며, 성취지향, | 표 3.  항우울제 권고 요약표 | 웨어 구조로 설명하며 소프트 | 없음 | (선택) |\n| practical health care: an updated meta-analysis.  Journal of anxiety disorders, 55, 70-78.  | 행동 | 2) 임상시험의 목적 | 우울장애 개선 디지털치료기기 안전성·성능 평가 및 | 제조자는 | 내·외부의 | 모든 | 입력에 | 대한 | 위해 안티 멀웨어 프로그램과 같은 통제 | 법칙을 깨는 실험(rule-breaking experiments) | 스크리닝 및 | ‘OOOOO’ 경고푸시 알림이 | 82.5%이며, 불안 하위척도를 8점으로 절단할 때 민감도 | 오송보건의료행정타운 | 해당 알림이 발생하는 조건 정하고, | 치료 기간 종료 | 1주 후(8주+1주) | (Post-treatment)3)3)3) | 유효성 | (AB-1234) |\n| CANMAT 진료지침(2016) | Strong (First-line) | High (Level 1) | 개입 | 5) 시험 방법 | 2 | ISO 14971 | 3) 임상시험 수행 기간: 00개월 | 인지 | (IVPNetworks) | – Application of risk | CES-D는 총 20개 문항으로 우울 정서, 긍정적 정서, 신체적 | 치료 시작일 | Management)에 대한 국제 | 성능 시험 | 치료 기간 종료 | 국외 |\n| (3) 「의료기기법」 제10조 (임상시험계획의 승인 등) | 3 | 경고 메시지 | 기록을 열람할 수 있다.  | - 모양 및 구조: (임상시험용 의료기기의 모양 및 구조 기술) | 웨어 | Organizations about FDA’S | 표 15. ",
        "original_sentence": "항우울제 권고 요약표 | 웨어 구조로 설명하며 소프트 | 없음 | (선택) |\n| practical health care: an updated meta-analysis. "
      }
    },
    {
      "chunk_id": "chunk_174",
      "text": "Journal of anxiety disorders, 55, 70-78. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 173,
        "window_size": 3,
        "char_count": 41,
        "word_count": 6,
        "page_number": 9,
        "window_text": "| 참여 동의를 철회하는 경우 | 타당한 경우 | 표 17.  우울장애 이차 유효성 평가 지표 예시 | 인증 기능 | 정도 해당이 되는지 그 정도를 알게 하는 방법으로 이러한 | 손쉽게 활용하기 위해 40문항으로 단축하였으며, 성취지향, | 표 3.  항우울제 권고 요약표 | 웨어 구조로 설명하며 소프트 | 없음 | (선택) |\n| practical health care: an updated meta-analysis.  Journal of anxiety disorders, 55, 70-78.  | 행동 | 2) 임상시험의 목적 | 우울장애 개선 디지털치료기기 안전성·성능 평가 및 | 제조자는 | 내·외부의 | 모든 | 입력에 | 대한 | 위해 안티 멀웨어 프로그램과 같은 통제 | 법칙을 깨는 실험(rule-breaking experiments) | 스크리닝 및 | ‘OOOOO’ 경고푸시 알림이 | 82.5%이며, 불안 하위척도를 8점으로 절단할 때 민감도 | 오송보건의료행정타운 | 해당 알림이 발생하는 조건 정하고, | 치료 기간 종료 | 1주 후(8주+1주) | (Post-treatment)3)3)3) | 유효성 | (AB-1234) |\n| CANMAT 진료지침(2016) | Strong (First-line) | High (Level 1) | 개입 | 5) 시험 방법 | 2 | ISO 14971 | 3) 임상시험 수행 기간: 00개월 | 인지 | (IVPNetworks) | – Application of risk | CES-D는 총 20개 문항으로 우울 정서, 긍정적 정서, 신체적 | 치료 시작일 | Management)에 대한 국제 | 성능 시험 | 치료 기간 종료 | 국외 |\n| (3) 「의료기기법」 제10조 (임상시험계획의 승인 등) | 3 | 경고 메시지 | 기록을 열람할 수 있다.  | - 모양 및 구조: (임상시험용 의료기기의 모양 및 구조 기술) | 웨어 | Organizations about FDA’S | 표 15.  우울장애 이차 유효성 평가 지표 측정도구 예시 | 검사일 | 소프트웨어 |\n| 2) 소프트웨어 개발 및 위험관리 | 역학용 우울 척도 | 으로 분석한다. ",
        "original_sentence": "Journal of anxiety disorders, 55, 70-78. "
      }
    },
    {
      "chunk_id": "chunk_175",
      "text": "| 행동 | 2) 임상시험의 목적 | 우울장애 개선 디지털치료기기 안전성·성능 평가 및 | 제조자는 | 내·외부의 | 모든 | 입력에 | 대한 | 위해 안티 멀웨어 프로그램과 같은 통제 | 법칙을 깨는 실험(rule-breaking experiments) | 스크리닝 및 | ‘OOOOO’ 경고푸시 알림이 | 82.5%이며, 불안 하위척도를 8점으로 절단할 때 민감도 | 오송보건의료행정타운 | 해당 알림이 발생하는 조건 정하고, | 치료 기간 종료 | 1주 후(8주+1주) | (Post-treatment)3)3)3) | 유효성 | (AB-1234) |\n| CANMAT 진료지침(2016) | Strong (First-line) | High (Level 1) | 개입 | 5) 시험 방법 | 2 | ISO 14971 | 3) 임상시험 수행 기간: 00개월 | 인지 | (IVPNetworks) | – Application of risk | CES-D는 총 20개 문항으로 우울 정서, 긍정적 정서, 신체적 | 치료 시작일 | Management)에 대한 국제 | 성능 시험 | 치료 기간 종료 | 국외 |\n| (3) 「의료기기법」 제10조 (임상시험계획의 승인 등) | 3 | 경고 메시지 | 기록을 열람할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 174,
        "window_size": 3,
        "char_count": 627,
        "word_count": 152,
        "page_number": 1,
        "window_text": "우울장애 이차 유효성 평가 지표 예시 | 인증 기능 | 정도 해당이 되는지 그 정도를 알게 하는 방법으로 이러한 | 손쉽게 활용하기 위해 40문항으로 단축하였으며, 성취지향, | 표 3.  항우울제 권고 요약표 | 웨어 구조로 설명하며 소프트 | 없음 | (선택) |\n| practical health care: an updated meta-analysis.  Journal of anxiety disorders, 55, 70-78.  | 행동 | 2) 임상시험의 목적 | 우울장애 개선 디지털치료기기 안전성·성능 평가 및 | 제조자는 | 내·외부의 | 모든 | 입력에 | 대한 | 위해 안티 멀웨어 프로그램과 같은 통제 | 법칙을 깨는 실험(rule-breaking experiments) | 스크리닝 및 | ‘OOOOO’ 경고푸시 알림이 | 82.5%이며, 불안 하위척도를 8점으로 절단할 때 민감도 | 오송보건의료행정타운 | 해당 알림이 발생하는 조건 정하고, | 치료 기간 종료 | 1주 후(8주+1주) | (Post-treatment)3)3)3) | 유효성 | (AB-1234) |\n| CANMAT 진료지침(2016) | Strong (First-line) | High (Level 1) | 개입 | 5) 시험 방법 | 2 | ISO 14971 | 3) 임상시험 수행 기간: 00개월 | 인지 | (IVPNetworks) | – Application of risk | CES-D는 총 20개 문항으로 우울 정서, 긍정적 정서, 신체적 | 치료 시작일 | Management)에 대한 국제 | 성능 시험 | 치료 기간 종료 | 국외 |\n| (3) 「의료기기법」 제10조 (임상시험계획의 승인 등) | 3 | 경고 메시지 | 기록을 열람할 수 있다.  | - 모양 및 구조: (임상시험용 의료기기의 모양 및 구조 기술) | 웨어 | Organizations about FDA’S | 표 15.  우울장애 이차 유효성 평가 지표 측정도구 예시 | 검사일 | 소프트웨어 |\n| 2) 소프트웨어 개발 및 위험관리 | 역학용 우울 척도 | 으로 분석한다.  | 하는 것을 방지하기 위한 통제 수단을 고려 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 종류 | 기전 | 용량(mg) | - 잘못된 신념을 변화시키는 방법으로 환자가 이러한 신념을 깨어 | 구현 확인 | 부정적인 단어를 정확히 정의해보게 할 수 있다. ",
        "original_sentence": "| 행동 | 2) 임상시험의 목적 | 우울장애 개선 디지털치료기기 안전성·성능 평가 및 | 제조자는 | 내·외부의 | 모든 | 입력에 | 대한 | 위해 안티 멀웨어 프로그램과 같은 통제 | 법칙을 깨는 실험(rule-breaking experiments) | 스크리닝 및 | ‘OOOOO’ 경고푸시 알림이 | 82.5%이며, 불안 하위척도를 8점으로 절단할 때 민감도 | 오송보건의료행정타운 | 해당 알림이 발생하는 조건 정하고, | 치료 기간 종료 | 1주 후(8주+1주) | (Post-treatment)3)3)3) | 유효성 | (AB-1234) |\n| CANMAT 진료지침(2016) | Strong (First-line) | High (Level 1) | 개입 | 5) 시험 방법 | 2 | ISO 14971 | 3) 임상시험 수행 기간: 00개월 | 인지 | (IVPNetworks) | – Application of risk | CES-D는 총 20개 문항으로 우울 정서, 긍정적 정서, 신체적 | 치료 시작일 | Management)에 대한 국제 | 성능 시험 | 치료 기간 종료 | 국외 |\n| (3) 「의료기기법」 제10조 (임상시험계획의 승인 등) | 3 | 경고 메시지 | 기록을 열람할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_176",
      "text": "| - 모양 및 구조: (임상시험용 의료기기의 모양 및 구조 기술) | 웨어 | Organizations about FDA’S | 표 15. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 175,
        "window_size": 3,
        "char_count": 79,
        "word_count": 20,
        "page_number": 29,
        "window_text": "항우울제 권고 요약표 | 웨어 구조로 설명하며 소프트 | 없음 | (선택) |\n| practical health care: an updated meta-analysis.  Journal of anxiety disorders, 55, 70-78.  | 행동 | 2) 임상시험의 목적 | 우울장애 개선 디지털치료기기 안전성·성능 평가 및 | 제조자는 | 내·외부의 | 모든 | 입력에 | 대한 | 위해 안티 멀웨어 프로그램과 같은 통제 | 법칙을 깨는 실험(rule-breaking experiments) | 스크리닝 및 | ‘OOOOO’ 경고푸시 알림이 | 82.5%이며, 불안 하위척도를 8점으로 절단할 때 민감도 | 오송보건의료행정타운 | 해당 알림이 발생하는 조건 정하고, | 치료 기간 종료 | 1주 후(8주+1주) | (Post-treatment)3)3)3) | 유효성 | (AB-1234) |\n| CANMAT 진료지침(2016) | Strong (First-line) | High (Level 1) | 개입 | 5) 시험 방법 | 2 | ISO 14971 | 3) 임상시험 수행 기간: 00개월 | 인지 | (IVPNetworks) | – Application of risk | CES-D는 총 20개 문항으로 우울 정서, 긍정적 정서, 신체적 | 치료 시작일 | Management)에 대한 국제 | 성능 시험 | 치료 기간 종료 | 국외 |\n| (3) 「의료기기법」 제10조 (임상시험계획의 승인 등) | 3 | 경고 메시지 | 기록을 열람할 수 있다.  | - 모양 및 구조: (임상시험용 의료기기의 모양 및 구조 기술) | 웨어 | Organizations about FDA’S | 표 15.  우울장애 이차 유효성 평가 지표 측정도구 예시 | 검사일 | 소프트웨어 |\n| 2) 소프트웨어 개발 및 위험관리 | 역학용 우울 척도 | 으로 분석한다.  | 하는 것을 방지하기 위한 통제 수단을 고려 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 종류 | 기전 | 용량(mg) | - 잘못된 신념을 변화시키는 방법으로 환자가 이러한 신념을 깨어 | 구현 확인 | 부정적인 단어를 정확히 정의해보게 할 수 있다.  | 발생할 것 | 대인관계지향 2개 요인으로 구성되었다. ",
        "original_sentence": "| - 모양 및 구조: (임상시험용 의료기기의 모양 및 구조 기술) | 웨어 | Organizations about FDA’S | 표 15. "
      }
    },
    {
      "chunk_id": "chunk_177",
      "text": "우울장애 이차 유효성 평가 지표 측정도구 예시 | 검사일 | 소프트웨어 |\n| 2) 소프트웨어 개발 및 위험관리 | 역학용 우울 척도 | 으로 분석한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 176,
        "window_size": 3,
        "char_count": 86,
        "word_count": 25,
        "page_number": 7,
        "window_text": "Journal of anxiety disorders, 55, 70-78.  | 행동 | 2) 임상시험의 목적 | 우울장애 개선 디지털치료기기 안전성·성능 평가 및 | 제조자는 | 내·외부의 | 모든 | 입력에 | 대한 | 위해 안티 멀웨어 프로그램과 같은 통제 | 법칙을 깨는 실험(rule-breaking experiments) | 스크리닝 및 | ‘OOOOO’ 경고푸시 알림이 | 82.5%이며, 불안 하위척도를 8점으로 절단할 때 민감도 | 오송보건의료행정타운 | 해당 알림이 발생하는 조건 정하고, | 치료 기간 종료 | 1주 후(8주+1주) | (Post-treatment)3)3)3) | 유효성 | (AB-1234) |\n| CANMAT 진료지침(2016) | Strong (First-line) | High (Level 1) | 개입 | 5) 시험 방법 | 2 | ISO 14971 | 3) 임상시험 수행 기간: 00개월 | 인지 | (IVPNetworks) | – Application of risk | CES-D는 총 20개 문항으로 우울 정서, 긍정적 정서, 신체적 | 치료 시작일 | Management)에 대한 국제 | 성능 시험 | 치료 기간 종료 | 국외 |\n| (3) 「의료기기법」 제10조 (임상시험계획의 승인 등) | 3 | 경고 메시지 | 기록을 열람할 수 있다.  | - 모양 및 구조: (임상시험용 의료기기의 모양 및 구조 기술) | 웨어 | Organizations about FDA’S | 표 15.  우울장애 이차 유효성 평가 지표 측정도구 예시 | 검사일 | 소프트웨어 |\n| 2) 소프트웨어 개발 및 위험관리 | 역학용 우울 척도 | 으로 분석한다.  | 하는 것을 방지하기 위한 통제 수단을 고려 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 종류 | 기전 | 용량(mg) | - 잘못된 신념을 변화시키는 방법으로 환자가 이러한 신념을 깨어 | 구현 확인 | 부정적인 단어를 정확히 정의해보게 할 수 있다.  | 발생할 것 | 대인관계지향 2개 요인으로 구성되었다.  | 웨어 항목(item)을 식별하는 아키 | 소프트웨어의 출시 후에 발생 | 실제 제품에 구현시킨다. ",
        "original_sentence": "우울장애 이차 유효성 평가 지표 측정도구 예시 | 검사일 | 소프트웨어 |\n| 2) 소프트웨어 개발 및 위험관리 | 역학용 우울 척도 | 으로 분석한다. "
      }
    },
    {
      "chunk_id": "chunk_178",
      "text": "| 하는 것을 방지하기 위한 통제 수단을 고려 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 종류 | 기전 | 용량(mg) | - 잘못된 신념을 변화시키는 방법으로 환자가 이러한 신념을 깨어 | 구현 확인 | 부정적인 단어를 정확히 정의해보게 할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 177,
        "window_size": 3,
        "char_count": 155,
        "word_count": 46,
        "page_number": 19,
        "window_text": "| 행동 | 2) 임상시험의 목적 | 우울장애 개선 디지털치료기기 안전성·성능 평가 및 | 제조자는 | 내·외부의 | 모든 | 입력에 | 대한 | 위해 안티 멀웨어 프로그램과 같은 통제 | 법칙을 깨는 실험(rule-breaking experiments) | 스크리닝 및 | ‘OOOOO’ 경고푸시 알림이 | 82.5%이며, 불안 하위척도를 8점으로 절단할 때 민감도 | 오송보건의료행정타운 | 해당 알림이 발생하는 조건 정하고, | 치료 기간 종료 | 1주 후(8주+1주) | (Post-treatment)3)3)3) | 유효성 | (AB-1234) |\n| CANMAT 진료지침(2016) | Strong (First-line) | High (Level 1) | 개입 | 5) 시험 방법 | 2 | ISO 14971 | 3) 임상시험 수행 기간: 00개월 | 인지 | (IVPNetworks) | – Application of risk | CES-D는 총 20개 문항으로 우울 정서, 긍정적 정서, 신체적 | 치료 시작일 | Management)에 대한 국제 | 성능 시험 | 치료 기간 종료 | 국외 |\n| (3) 「의료기기법」 제10조 (임상시험계획의 승인 등) | 3 | 경고 메시지 | 기록을 열람할 수 있다.  | - 모양 및 구조: (임상시험용 의료기기의 모양 및 구조 기술) | 웨어 | Organizations about FDA’S | 표 15.  우울장애 이차 유효성 평가 지표 측정도구 예시 | 검사일 | 소프트웨어 |\n| 2) 소프트웨어 개발 및 위험관리 | 역학용 우울 척도 | 으로 분석한다.  | 하는 것을 방지하기 위한 통제 수단을 고려 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 종류 | 기전 | 용량(mg) | - 잘못된 신념을 변화시키는 방법으로 환자가 이러한 신념을 깨어 | 구현 확인 | 부정적인 단어를 정확히 정의해보게 할 수 있다.  | 발생할 것 | 대인관계지향 2개 요인으로 구성되었다.  | 웨어 항목(item)을 식별하는 아키 | 소프트웨어의 출시 후에 발생 | 실제 제품에 구현시킨다.  | □ 예 | ■ 아니오 |\n| 개입 | 행동치료를 처방받아 치료를 수행하는 군(Conal et al., 2020) | 유효성을 확인하는 설계 특성을 고려하여야 | 조치를 고려하여야 한다. ",
        "original_sentence": "| 하는 것을 방지하기 위한 통제 수단을 고려 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 종류 | 기전 | 용량(mg) | - 잘못된 신념을 변화시키는 방법으로 환자가 이러한 신념을 깨어 | 구현 확인 | 부정적인 단어를 정확히 정의해보게 할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_179",
      "text": "| 발생할 것 | 대인관계지향 2개 요인으로 구성되었다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 178,
        "window_size": 3,
        "char_count": 32,
        "word_count": 8,
        "page_number": 8,
        "window_text": "| - 모양 및 구조: (임상시험용 의료기기의 모양 및 구조 기술) | 웨어 | Organizations about FDA’S | 표 15.  우울장애 이차 유효성 평가 지표 측정도구 예시 | 검사일 | 소프트웨어 |\n| 2) 소프트웨어 개발 및 위험관리 | 역학용 우울 척도 | 으로 분석한다.  | 하는 것을 방지하기 위한 통제 수단을 고려 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 종류 | 기전 | 용량(mg) | - 잘못된 신념을 변화시키는 방법으로 환자가 이러한 신념을 깨어 | 구현 확인 | 부정적인 단어를 정확히 정의해보게 할 수 있다.  | 발생할 것 | 대인관계지향 2개 요인으로 구성되었다.  | 웨어 항목(item)을 식별하는 아키 | 소프트웨어의 출시 후에 발생 | 실제 제품에 구현시킨다.  | □ 예 | ■ 아니오 |\n| 개입 | 행동치료를 처방받아 치료를 수행하는 군(Conal et al., 2020) | 유효성을 확인하는 설계 특성을 고려하여야 | 조치를 고려하여야 한다.  | (출처: Deprexis | 홈페이지, | 점진적 | 식품의약품안전처 식품의약품안전평가원 | 78.8%, 특이도 82.5%로 나타났다. ",
        "original_sentence": "| 발생할 것 | 대인관계지향 2개 요인으로 구성되었다. "
      }
    },
    {
      "chunk_id": "chunk_180",
      "text": "| 웨어 항목(item)을 식별하는 아키 | 소프트웨어의 출시 후에 발생 | 실제 제품에 구현시킨다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 179,
        "window_size": 3,
        "char_count": 57,
        "word_count": 14,
        "page_number": 7,
        "window_text": "우울장애 이차 유효성 평가 지표 측정도구 예시 | 검사일 | 소프트웨어 |\n| 2) 소프트웨어 개발 및 위험관리 | 역학용 우울 척도 | 으로 분석한다.  | 하는 것을 방지하기 위한 통제 수단을 고려 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 종류 | 기전 | 용량(mg) | - 잘못된 신념을 변화시키는 방법으로 환자가 이러한 신념을 깨어 | 구현 확인 | 부정적인 단어를 정확히 정의해보게 할 수 있다.  | 발생할 것 | 대인관계지향 2개 요인으로 구성되었다.  | 웨어 항목(item)을 식별하는 아키 | 소프트웨어의 출시 후에 발생 | 실제 제품에 구현시킨다.  | □ 예 | ■ 아니오 |\n| 개입 | 행동치료를 처방받아 치료를 수행하는 군(Conal et al., 2020) | 유효성을 확인하는 설계 특성을 고려하여야 | 조치를 고려하여야 한다.  | (출처: Deprexis | 홈페이지, | 점진적 | 식품의약품안전처 식품의약품안전평가원 | 78.8%, 특이도 82.5%로 나타났다.  | (Baseline) | 측정 지표 | 확인 자료 | 3개월 후 |\n| 전략 | 3) 사이버보안 위험관리 | 다) 인구학적 정보 | - 디지털치료기기에 대한 사용자 반응 평가를 함께 수행한다. ",
        "original_sentence": "| 웨어 항목(item)을 식별하는 아키 | 소프트웨어의 출시 후에 발생 | 실제 제품에 구현시킨다. "
      }
    },
    {
      "chunk_id": "chunk_181",
      "text": "| □ 예 | ■ 아니오 |\n| 개입 | 행동치료를 처방받아 치료를 수행하는 군(Conal et al., 2020) | 유효성을 확인하는 설계 특성을 고려하여야 | 조치를 고려하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 180,
        "window_size": 3,
        "char_count": 106,
        "word_count": 28,
        "page_number": 3,
        "window_text": "| 하는 것을 방지하기 위한 통제 수단을 고려 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 종류 | 기전 | 용량(mg) | - 잘못된 신념을 변화시키는 방법으로 환자가 이러한 신념을 깨어 | 구현 확인 | 부정적인 단어를 정확히 정의해보게 할 수 있다.  | 발생할 것 | 대인관계지향 2개 요인으로 구성되었다.  | 웨어 항목(item)을 식별하는 아키 | 소프트웨어의 출시 후에 발생 | 실제 제품에 구현시킨다.  | □ 예 | ■ 아니오 |\n| 개입 | 행동치료를 처방받아 치료를 수행하는 군(Conal et al., 2020) | 유효성을 확인하는 설계 특성을 고려하여야 | 조치를 고려하여야 한다.  | (출처: Deprexis | 홈페이지, | 점진적 | 식품의약품안전처 식품의약품안전평가원 | 78.8%, 특이도 82.5%로 나타났다.  | (Baseline) | 측정 지표 | 확인 자료 | 3개월 후 |\n| 전략 | 3) 사이버보안 위험관리 | 다) 인구학적 정보 | - 디지털치료기기에 대한 사용자 반응 평가를 함께 수행한다.  | ※ 내원은 필수가 아니며 앱, 이메일, 문자 등을 통해 수집할 수 있다. ",
        "original_sentence": "| □ 예 | ■ 아니오 |\n| 개입 | 행동치료를 처방받아 치료를 수행하는 군(Conal et al., 2020) | 유효성을 확인하는 설계 특성을 고려하여야 | 조치를 고려하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_182",
      "text": "| (출처: Deprexis | 홈페이지, | 점진적 | 식품의약품안전처 식품의약품안전평가원 | 78.8%, 특이도 82.5%로 나타났다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 181,
        "window_size": 3,
        "char_count": 78,
        "word_count": 15,
        "page_number": 18,
        "window_text": "| 발생할 것 | 대인관계지향 2개 요인으로 구성되었다.  | 웨어 항목(item)을 식별하는 아키 | 소프트웨어의 출시 후에 발생 | 실제 제품에 구현시킨다.  | □ 예 | ■ 아니오 |\n| 개입 | 행동치료를 처방받아 치료를 수행하는 군(Conal et al., 2020) | 유효성을 확인하는 설계 특성을 고려하여야 | 조치를 고려하여야 한다.  | (출처: Deprexis | 홈페이지, | 점진적 | 식품의약품안전처 식품의약품안전평가원 | 78.8%, 특이도 82.5%로 나타났다.  | (Baseline) | 측정 지표 | 확인 자료 | 3개월 후 |\n| 전략 | 3) 사이버보안 위험관리 | 다) 인구학적 정보 | - 디지털치료기기에 대한 사용자 반응 평가를 함께 수행한다.  | ※ 내원은 필수가 아니며 앱, 이메일, 문자 등을 통해 수집할 수 있다.  | 개발 | 변화를 | 기반한 정보를 제공한다. ",
        "original_sentence": "| (출처: Deprexis | 홈페이지, | 점진적 | 식품의약품안전처 식품의약품안전평가원 | 78.8%, 특이도 82.5%로 나타났다. "
      }
    },
    {
      "chunk_id": "chunk_183",
      "text": "| (Baseline) | 측정 지표 | 확인 자료 | 3개월 후 |\n| 전략 | 3) 사이버보안 위험관리 | 다) 인구학적 정보 | - 디지털치료기기에 대한 사용자 반응 평가를 함께 수행한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 182,
        "window_size": 3,
        "char_count": 109,
        "word_count": 31,
        "page_number": 18,
        "window_text": "| 웨어 항목(item)을 식별하는 아키 | 소프트웨어의 출시 후에 발생 | 실제 제품에 구현시킨다.  | □ 예 | ■ 아니오 |\n| 개입 | 행동치료를 처방받아 치료를 수행하는 군(Conal et al., 2020) | 유효성을 확인하는 설계 특성을 고려하여야 | 조치를 고려하여야 한다.  | (출처: Deprexis | 홈페이지, | 점진적 | 식품의약품안전처 식품의약품안전평가원 | 78.8%, 특이도 82.5%로 나타났다.  | (Baseline) | 측정 지표 | 확인 자료 | 3개월 후 |\n| 전략 | 3) 사이버보안 위험관리 | 다) 인구학적 정보 | - 디지털치료기기에 대한 사용자 반응 평가를 함께 수행한다.  | ※ 내원은 필수가 아니며 앱, 이메일, 문자 등을 통해 수집할 수 있다.  | 개발 | 변화를 | 기반한 정보를 제공한다.  | 임상시험계획서 작성 가이드라인(민원인 안내서) | 평가한다. ",
        "original_sentence": "| (Baseline) | 측정 지표 | 확인 자료 | 3개월 후 |\n| 전략 | 3) 사이버보안 위험관리 | 다) 인구학적 정보 | - 디지털치료기기에 대한 사용자 반응 평가를 함께 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_184",
      "text": "| ※ 내원은 필수가 아니며 앱, 이메일, 문자 등을 통해 수집할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 183,
        "window_size": 3,
        "char_count": 43,
        "word_count": 13,
        "page_number": 11,
        "window_text": "| □ 예 | ■ 아니오 |\n| 개입 | 행동치료를 처방받아 치료를 수행하는 군(Conal et al., 2020) | 유효성을 확인하는 설계 특성을 고려하여야 | 조치를 고려하여야 한다.  | (출처: Deprexis | 홈페이지, | 점진적 | 식품의약품안전처 식품의약품안전평가원 | 78.8%, 특이도 82.5%로 나타났다.  | (Baseline) | 측정 지표 | 확인 자료 | 3개월 후 |\n| 전략 | 3) 사이버보안 위험관리 | 다) 인구학적 정보 | - 디지털치료기기에 대한 사용자 반응 평가를 함께 수행한다.  | ※ 내원은 필수가 아니며 앱, 이메일, 문자 등을 통해 수집할 수 있다.  | 개발 | 변화를 | 기반한 정보를 제공한다.  | 임상시험계획서 작성 가이드라인(민원인 안내서) | 평가한다.  | management to medical devices | (Screening)1) | 증상 및 둔화된 행동, 대인관계 요인 4개로 구성되었다. ",
        "original_sentence": "| ※ 내원은 필수가 아니며 앱, 이메일, 문자 등을 통해 수집할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_185",
      "text": "| 개발 | 변화를 | 기반한 정보를 제공한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 184,
        "window_size": 3,
        "char_count": 27,
        "word_count": 8,
        "page_number": 13,
        "window_text": "| (출처: Deprexis | 홈페이지, | 점진적 | 식품의약품안전처 식품의약품안전평가원 | 78.8%, 특이도 82.5%로 나타났다.  | (Baseline) | 측정 지표 | 확인 자료 | 3개월 후 |\n| 전략 | 3) 사이버보안 위험관리 | 다) 인구학적 정보 | - 디지털치료기기에 대한 사용자 반응 평가를 함께 수행한다.  | ※ 내원은 필수가 아니며 앱, 이메일, 문자 등을 통해 수집할 수 있다.  | 개발 | 변화를 | 기반한 정보를 제공한다.  | 임상시험계획서 작성 가이드라인(민원인 안내서) | 평가한다.  | management to medical devices | (Screening)1) | 증상 및 둔화된 행동, 대인관계 요인 4개로 구성되었다.  | 규격 | 소프트웨어 |\n| 제1차 약제 | “Guidance for Industry: | - 즐거움을 주는 일이나 수행 능력을 키울 과업을 선택하고 계획 | 네트워크를 | 활용하는 | 의료기기의 | 검증 및 | (Follow up)4) | 4) | 4) |\n| (4) 「의료기기법 시행규칙」 제9조 (기술문서 등의 심사) | CANMAT: Canadian Network for Mood and Anxiety Treatments | systematic review. ",
        "original_sentence": "| 개발 | 변화를 | 기반한 정보를 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_186",
      "text": "| 임상시험계획서 작성 가이드라인(민원인 안내서) | 평가한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 185,
        "window_size": 3,
        "char_count": 36,
        "word_count": 7,
        "page_number": 1,
        "window_text": "| (Baseline) | 측정 지표 | 확인 자료 | 3개월 후 |\n| 전략 | 3) 사이버보안 위험관리 | 다) 인구학적 정보 | - 디지털치료기기에 대한 사용자 반응 평가를 함께 수행한다.  | ※ 내원은 필수가 아니며 앱, 이메일, 문자 등을 통해 수집할 수 있다.  | 개발 | 변화를 | 기반한 정보를 제공한다.  | 임상시험계획서 작성 가이드라인(민원인 안내서) | 평가한다.  | management to medical devices | (Screening)1) | 증상 및 둔화된 행동, 대인관계 요인 4개로 구성되었다.  | 규격 | 소프트웨어 |\n| 제1차 약제 | “Guidance for Industry: | - 즐거움을 주는 일이나 수행 능력을 키울 과업을 선택하고 계획 | 네트워크를 | 활용하는 | 의료기기의 | 검증 및 | (Follow up)4) | 4) | 4) |\n| (4) 「의료기기법 시행규칙」 제9조 (기술문서 등의 심사) | CANMAT: Canadian Network for Mood and Anxiety Treatments | systematic review.  BMC psychiatry, 13(1), 1-10. ",
        "original_sentence": "| 임상시험계획서 작성 가이드라인(민원인 안내서) | 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_187",
      "text": "| management to medical devices | (Screening)1) | 증상 및 둔화된 행동, 대인관계 요인 4개로 구성되었다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 186,
        "window_size": 3,
        "char_count": 82,
        "word_count": 16,
        "page_number": 18,
        "window_text": "| ※ 내원은 필수가 아니며 앱, 이메일, 문자 등을 통해 수집할 수 있다.  | 개발 | 변화를 | 기반한 정보를 제공한다.  | 임상시험계획서 작성 가이드라인(민원인 안내서) | 평가한다.  | management to medical devices | (Screening)1) | 증상 및 둔화된 행동, 대인관계 요인 4개로 구성되었다.  | 규격 | 소프트웨어 |\n| 제1차 약제 | “Guidance for Industry: | - 즐거움을 주는 일이나 수행 능력을 키울 과업을 선택하고 계획 | 네트워크를 | 활용하는 | 의료기기의 | 검증 및 | (Follow up)4) | 4) | 4) |\n| (4) 「의료기기법 시행규칙」 제9조 (기술문서 등의 심사) | CANMAT: Canadian Network for Mood and Anxiety Treatments | systematic review.  BMC psychiatry, 13(1), 1-10.  | 4) 통계처리 및 결과보고서 작성 기간: 00개월 | 가) 스크리닝, 선정·제외 기준 확인 | 애플리케이션을 사용하는 데에 어려움이 없는 자 | (The Center for | 측정도구 | 설명 | 범위 내에서 개발 및 유지가 되어야 한다. ",
        "original_sentence": "| management to medical devices | (Screening)1) | 증상 및 둔화된 행동, 대인관계 요인 4개로 구성되었다. "
      }
    },
    {
      "chunk_id": "chunk_188",
      "text": "| 규격 | 소프트웨어 |\n| 제1차 약제 | “Guidance for Industry: | - 즐거움을 주는 일이나 수행 능력을 키울 과업을 선택하고 계획 | 네트워크를 | 활용하는 | 의료기기의 | 검증 및 | (Follow up)4) | 4) | 4) |\n| (4) 「의료기기법 시행규칙」 제9조 (기술문서 등의 심사) | CANMAT: Canadian Network for Mood and Anxiety Treatments | systematic review. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 187,
        "window_size": 3,
        "char_count": 262,
        "word_count": 60,
        "page_number": 7,
        "window_text": "| 개발 | 변화를 | 기반한 정보를 제공한다.  | 임상시험계획서 작성 가이드라인(민원인 안내서) | 평가한다.  | management to medical devices | (Screening)1) | 증상 및 둔화된 행동, 대인관계 요인 4개로 구성되었다.  | 규격 | 소프트웨어 |\n| 제1차 약제 | “Guidance for Industry: | - 즐거움을 주는 일이나 수행 능력을 키울 과업을 선택하고 계획 | 네트워크를 | 활용하는 | 의료기기의 | 검증 및 | (Follow up)4) | 4) | 4) |\n| (4) 「의료기기법 시행규칙」 제9조 (기술문서 등의 심사) | CANMAT: Canadian Network for Mood and Anxiety Treatments | systematic review.  BMC psychiatry, 13(1), 1-10.  | 4) 통계처리 및 결과보고서 작성 기간: 00개월 | 가) 스크리닝, 선정·제외 기준 확인 | 애플리케이션을 사용하는 데에 어려움이 없는 자 | (The Center for | 측정도구 | 설명 | 범위 내에서 개발 및 유지가 되어야 한다.  | 하여야 한다. ",
        "original_sentence": "| 규격 | 소프트웨어 |\n| 제1차 약제 | “Guidance for Industry: | - 즐거움을 주는 일이나 수행 능력을 키울 과업을 선택하고 계획 | 네트워크를 | 활용하는 | 의료기기의 | 검증 및 | (Follow up)4) | 4) | 4) |\n| (4) 「의료기기법 시행규칙」 제9조 (기술문서 등의 심사) | CANMAT: Canadian Network for Mood and Anxiety Treatments | systematic review. "
      }
    },
    {
      "chunk_id": "chunk_189",
      "text": "BMC psychiatry, 13(1), 1-10. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 188,
        "window_size": 3,
        "char_count": 29,
        "word_count": 4,
        "page_number": 28,
        "window_text": "| 임상시험계획서 작성 가이드라인(민원인 안내서) | 평가한다.  | management to medical devices | (Screening)1) | 증상 및 둔화된 행동, 대인관계 요인 4개로 구성되었다.  | 규격 | 소프트웨어 |\n| 제1차 약제 | “Guidance for Industry: | - 즐거움을 주는 일이나 수행 능력을 키울 과업을 선택하고 계획 | 네트워크를 | 활용하는 | 의료기기의 | 검증 및 | (Follow up)4) | 4) | 4) |\n| (4) 「의료기기법 시행규칙」 제9조 (기술문서 등의 심사) | CANMAT: Canadian Network for Mood and Anxiety Treatments | systematic review.  BMC psychiatry, 13(1), 1-10.  | 4) 통계처리 및 결과보고서 작성 기간: 00개월 | 가) 스크리닝, 선정·제외 기준 확인 | 애플리케이션을 사용하는 데에 어려움이 없는 자 | (The Center for | 측정도구 | 설명 | 범위 내에서 개발 및 유지가 되어야 한다.  | 하여야 한다.  | IWRS)을 통해서 시험군 혹은 대조군으로 1:1 배정한다. ",
        "original_sentence": "BMC psychiatry, 13(1), 1-10. "
      }
    },
    {
      "chunk_id": "chunk_190",
      "text": "| 4) 통계처리 및 결과보고서 작성 기간: 00개월 | 가) 스크리닝, 선정·제외 기준 확인 | 애플리케이션을 사용하는 데에 어려움이 없는 자 | (The Center for | 측정도구 | 설명 | 범위 내에서 개발 및 유지가 되어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 189,
        "window_size": 3,
        "char_count": 137,
        "word_count": 37,
        "page_number": 29,
        "window_text": "| management to medical devices | (Screening)1) | 증상 및 둔화된 행동, 대인관계 요인 4개로 구성되었다.  | 규격 | 소프트웨어 |\n| 제1차 약제 | “Guidance for Industry: | - 즐거움을 주는 일이나 수행 능력을 키울 과업을 선택하고 계획 | 네트워크를 | 활용하는 | 의료기기의 | 검증 및 | (Follow up)4) | 4) | 4) |\n| (4) 「의료기기법 시행규칙」 제9조 (기술문서 등의 심사) | CANMAT: Canadian Network for Mood and Anxiety Treatments | systematic review.  BMC psychiatry, 13(1), 1-10.  | 4) 통계처리 및 결과보고서 작성 기간: 00개월 | 가) 스크리닝, 선정·제외 기준 확인 | 애플리케이션을 사용하는 데에 어려움이 없는 자 | (The Center for | 측정도구 | 설명 | 범위 내에서 개발 및 유지가 되어야 한다.  | 하여야 한다.  | IWRS)을 통해서 시험군 혹은 대조군으로 1:1 배정한다.  | 정리한 자료입니까? ",
        "original_sentence": "| 4) 통계처리 및 결과보고서 작성 기간: 00개월 | 가) 스크리닝, 선정·제외 기준 확인 | 애플리케이션을 사용하는 데에 어려움이 없는 자 | (The Center for | 측정도구 | 설명 | 범위 내에서 개발 및 유지가 되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_191",
      "text": "| 하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 190,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 13,
        "window_text": "| 규격 | 소프트웨어 |\n| 제1차 약제 | “Guidance for Industry: | - 즐거움을 주는 일이나 수행 능력을 키울 과업을 선택하고 계획 | 네트워크를 | 활용하는 | 의료기기의 | 검증 및 | (Follow up)4) | 4) | 4) |\n| (4) 「의료기기법 시행규칙」 제9조 (기술문서 등의 심사) | CANMAT: Canadian Network for Mood and Anxiety Treatments | systematic review.  BMC psychiatry, 13(1), 1-10.  | 4) 통계처리 및 결과보고서 작성 기간: 00개월 | 가) 스크리닝, 선정·제외 기준 확인 | 애플리케이션을 사용하는 데에 어려움이 없는 자 | (The Center for | 측정도구 | 설명 | 범위 내에서 개발 및 유지가 되어야 한다.  | 하여야 한다.  | IWRS)을 통해서 시험군 혹은 대조군으로 1:1 배정한다.  | 정리한 자료입니까?  | 소프트웨어 | - 다음으로 우울장애 환자와 함께 그 개념의 정도를 나타내는 | 버릴 수 있는 실험을 구상하는 방법이다. ",
        "original_sentence": "| 하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_192",
      "text": "| IWRS)을 통해서 시험군 혹은 대조군으로 1:1 배정한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 191,
        "window_size": 3,
        "char_count": 36,
        "word_count": 8,
        "page_number": 13,
        "window_text": "BMC psychiatry, 13(1), 1-10.  | 4) 통계처리 및 결과보고서 작성 기간: 00개월 | 가) 스크리닝, 선정·제외 기준 확인 | 애플리케이션을 사용하는 데에 어려움이 없는 자 | (The Center for | 측정도구 | 설명 | 범위 내에서 개발 및 유지가 되어야 한다.  | 하여야 한다.  | IWRS)을 통해서 시험군 혹은 대조군으로 1:1 배정한다.  | 정리한 자료입니까?  | 소프트웨어 | - 다음으로 우울장애 환자와 함께 그 개념의 정도를 나타내는 | 버릴 수 있는 실험을 구상하는 방법이다.  | SF-36는 신체적 및 정신적 건강 관련 삶의 질에 대한 35개 | 텍처로 | 변환한다. ",
        "original_sentence": "| IWRS)을 통해서 시험군 혹은 대조군으로 1:1 배정한다. "
      }
    },
    {
      "chunk_id": "chunk_193",
      "text": "| 정리한 자료입니까? ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 192,
        "window_size": 3,
        "char_count": 13,
        "word_count": 3,
        "page_number": 3,
        "window_text": "| 4) 통계처리 및 결과보고서 작성 기간: 00개월 | 가) 스크리닝, 선정·제외 기준 확인 | 애플리케이션을 사용하는 데에 어려움이 없는 자 | (The Center for | 측정도구 | 설명 | 범위 내에서 개발 및 유지가 되어야 한다.  | 하여야 한다.  | IWRS)을 통해서 시험군 혹은 대조군으로 1:1 배정한다.  | 정리한 자료입니까?  | 소프트웨어 | - 다음으로 우울장애 환자와 함께 그 개념의 정도를 나타내는 | 버릴 수 있는 실험을 구상하는 방법이다.  | SF-36는 신체적 및 정신적 건강 관련 삶의 질에 대한 35개 | 텍처로 | 변환한다.  | 소프트웨어 | 하는 피드백에 적절히 대응하고 | 맞춤형 피드백과 전략을 제공한다. ",
        "original_sentence": "| 정리한 자료입니까? "
      }
    },
    {
      "chunk_id": "chunk_194",
      "text": "| 소프트웨어 | - 다음으로 우울장애 환자와 함께 그 개념의 정도를 나타내는 | 버릴 수 있는 실험을 구상하는 방법이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 193,
        "window_size": 3,
        "char_count": 69,
        "word_count": 19,
        "page_number": 9,
        "window_text": "| 하여야 한다.  | IWRS)을 통해서 시험군 혹은 대조군으로 1:1 배정한다.  | 정리한 자료입니까?  | 소프트웨어 | - 다음으로 우울장애 환자와 함께 그 개념의 정도를 나타내는 | 버릴 수 있는 실험을 구상하는 방법이다.  | SF-36는 신체적 및 정신적 건강 관련 삶의 질에 대한 35개 | 텍처로 | 변환한다.  | 소프트웨어 | 하는 피드백에 적절히 대응하고 | 맞춤형 피드백과 전략을 제공한다.  |\n| 전략 | 2) 증례기록서의 작성 | 7 | 판단한 자 | 1 | 몽고메리-아스버그 우울장애 척도(Montgomery-As˚ - berg Depression Rating Scale, MADRS) | - 성능: (임상시험용 의료기기의 성능 기술) | 하며, 보안이 취약한 통신(예. ",
        "original_sentence": "| 소프트웨어 | - 다음으로 우울장애 환자와 함께 그 개념의 정도를 나타내는 | 버릴 수 있는 실험을 구상하는 방법이다. "
      }
    },
    {
      "chunk_id": "chunk_195",
      "text": "| SF-36는 신체적 및 정신적 건강 관련 삶의 질에 대한 35개 | 텍처로 | 변환한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 194,
        "window_size": 3,
        "char_count": 52,
        "word_count": 15,
        "page_number": 29,
        "window_text": "| IWRS)을 통해서 시험군 혹은 대조군으로 1:1 배정한다.  | 정리한 자료입니까?  | 소프트웨어 | - 다음으로 우울장애 환자와 함께 그 개념의 정도를 나타내는 | 버릴 수 있는 실험을 구상하는 방법이다.  | SF-36는 신체적 및 정신적 건강 관련 삶의 질에 대한 35개 | 텍처로 | 변환한다.  | 소프트웨어 | 하는 피드백에 적절히 대응하고 | 맞춤형 피드백과 전략을 제공한다.  |\n| 전략 | 2) 증례기록서의 작성 | 7 | 판단한 자 | 1 | 몽고메리-아스버그 우울장애 척도(Montgomery-As˚ - berg Depression Rating Scale, MADRS) | - 성능: (임상시험용 의료기기의 성능 기술) | 하며, 보안이 취약한 통신(예.  가정용 네트 | 과업 | https://uk.deprexis.com/) | 의료기기심사부 첨단의료기기과 | 사이버보안에 대한 정보 가이드라인 | 미국 | 적용 |\n| trial. ",
        "original_sentence": "| SF-36는 신체적 및 정신적 건강 관련 삶의 질에 대한 35개 | 텍처로 | 변환한다. "
      }
    },
    {
      "chunk_id": "chunk_196",
      "text": "| 소프트웨어 | 하는 피드백에 적절히 대응하고 | 맞춤형 피드백과 전략을 제공한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 195,
        "window_size": 3,
        "char_count": 48,
        "word_count": 12,
        "page_number": 9,
        "window_text": "| 정리한 자료입니까?  | 소프트웨어 | - 다음으로 우울장애 환자와 함께 그 개념의 정도를 나타내는 | 버릴 수 있는 실험을 구상하는 방법이다.  | SF-36는 신체적 및 정신적 건강 관련 삶의 질에 대한 35개 | 텍처로 | 변환한다.  | 소프트웨어 | 하는 피드백에 적절히 대응하고 | 맞춤형 피드백과 전략을 제공한다.  |\n| 전략 | 2) 증례기록서의 작성 | 7 | 판단한 자 | 1 | 몽고메리-아스버그 우울장애 척도(Montgomery-As˚ - berg Depression Rating Scale, MADRS) | - 성능: (임상시험용 의료기기의 성능 기술) | 하며, 보안이 취약한 통신(예.  가정용 네트 | 과업 | https://uk.deprexis.com/) | 의료기기심사부 첨단의료기기과 | 사이버보안에 대한 정보 가이드라인 | 미국 | 적용 |\n| trial.  The Lancet Psychiatry, 2(3), 217-223. ",
        "original_sentence": "| 소프트웨어 | 하는 피드백에 적절히 대응하고 | 맞춤형 피드백과 전략을 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_197",
      "text": "|\n| 전략 | 2) 증례기록서의 작성 | 7 | 판단한 자 | 1 | 몽고메리-아스버그 우울장애 척도(Montgomery-As˚ - berg Depression Rating Scale, MADRS) | - 성능: (임상시험용 의료기기의 성능 기술) | 하며, 보안이 취약한 통신(예. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 196,
        "window_size": 3,
        "char_count": 160,
        "word_count": 36,
        "page_number": 9,
        "window_text": "| 소프트웨어 | - 다음으로 우울장애 환자와 함께 그 개념의 정도를 나타내는 | 버릴 수 있는 실험을 구상하는 방법이다.  | SF-36는 신체적 및 정신적 건강 관련 삶의 질에 대한 35개 | 텍처로 | 변환한다.  | 소프트웨어 | 하는 피드백에 적절히 대응하고 | 맞춤형 피드백과 전략을 제공한다.  |\n| 전략 | 2) 증례기록서의 작성 | 7 | 판단한 자 | 1 | 몽고메리-아스버그 우울장애 척도(Montgomery-As˚ - berg Depression Rating Scale, MADRS) | - 성능: (임상시험용 의료기기의 성능 기술) | 하며, 보안이 취약한 통신(예.  가정용 네트 | 과업 | https://uk.deprexis.com/) | 의료기기심사부 첨단의료기기과 | 사이버보안에 대한 정보 가이드라인 | 미국 | 적용 |\n| trial.  The Lancet Psychiatry, 2(3), 217-223.  | 3 | 아고멜라틴(agomelatine) | MT1 and MT2 agonist; 5-HT2 antagonist | 25-50 | 회사명 | 대표이사 | 소재지 | 전화 | 방문일 | 방문1 | 방문2 | 방문3 | 방문4 | 프로 | 제조자는 기기의 사용이 입증된 사용자이거나, | 위한 | 소프트웨어 | CES-D는 18세 이상 65세 이하 성인에게 적용 가능하며, 5, | 네트워크 API를 통해 데이터 | 적용 | 검증 및 |\n| 1) 중지 기준 | 전자파 적합성 인증을 통과한 제품을 사용해야 한다. ",
        "original_sentence": "|\n| 전략 | 2) 증례기록서의 작성 | 7 | 판단한 자 | 1 | 몽고메리-아스버그 우울장애 척도(Montgomery-As˚ - berg Depression Rating Scale, MADRS) | - 성능: (임상시험용 의료기기의 성능 기술) | 하며, 보안이 취약한 통신(예. "
      }
    },
    {
      "chunk_id": "chunk_198",
      "text": "가정용 네트 | 과업 | https://uk.deprexis.com/) | 의료기기심사부 첨단의료기기과 | 사이버보안에 대한 정보 가이드라인 | 미국 | 적용 |\n| trial. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 197,
        "window_size": 3,
        "char_count": 100,
        "word_count": 21,
        "page_number": 18,
        "window_text": "| SF-36는 신체적 및 정신적 건강 관련 삶의 질에 대한 35개 | 텍처로 | 변환한다.  | 소프트웨어 | 하는 피드백에 적절히 대응하고 | 맞춤형 피드백과 전략을 제공한다.  |\n| 전략 | 2) 증례기록서의 작성 | 7 | 판단한 자 | 1 | 몽고메리-아스버그 우울장애 척도(Montgomery-As˚ - berg Depression Rating Scale, MADRS) | - 성능: (임상시험용 의료기기의 성능 기술) | 하며, 보안이 취약한 통신(예.  가정용 네트 | 과업 | https://uk.deprexis.com/) | 의료기기심사부 첨단의료기기과 | 사이버보안에 대한 정보 가이드라인 | 미국 | 적용 |\n| trial.  The Lancet Psychiatry, 2(3), 217-223.  | 3 | 아고멜라틴(agomelatine) | MT1 and MT2 agonist; 5-HT2 antagonist | 25-50 | 회사명 | 대표이사 | 소재지 | 전화 | 방문일 | 방문1 | 방문2 | 방문3 | 방문4 | 프로 | 제조자는 기기의 사용이 입증된 사용자이거나, | 위한 | 소프트웨어 | CES-D는 18세 이상 65세 이하 성인에게 적용 가능하며, 5, | 네트워크 API를 통해 데이터 | 적용 | 검증 및 |\n| 1) 중지 기준 | 전자파 적합성 인증을 통과한 제품을 사용해야 한다.  | 나) 대조기기: 위약 대조군(sham) | 성명 | 소속기관명 | 전공 | 직위 | 전화 | Cybersecurity for Networked | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. ",
        "original_sentence": "가정용 네트 | 과업 | https://uk.deprexis.com/) | 의료기기심사부 첨단의료기기과 | 사이버보안에 대한 정보 가이드라인 | 미국 | 적용 |\n| trial. "
      }
    },
    {
      "chunk_id": "chunk_199",
      "text": "The Lancet Psychiatry, 2(3), 217-223. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 198,
        "window_size": 3,
        "char_count": 38,
        "word_count": 5,
        "page_number": 9,
        "window_text": "| 소프트웨어 | 하는 피드백에 적절히 대응하고 | 맞춤형 피드백과 전략을 제공한다.  |\n| 전략 | 2) 증례기록서의 작성 | 7 | 판단한 자 | 1 | 몽고메리-아스버그 우울장애 척도(Montgomery-As˚ - berg Depression Rating Scale, MADRS) | - 성능: (임상시험용 의료기기의 성능 기술) | 하며, 보안이 취약한 통신(예.  가정용 네트 | 과업 | https://uk.deprexis.com/) | 의료기기심사부 첨단의료기기과 | 사이버보안에 대한 정보 가이드라인 | 미국 | 적용 |\n| trial.  The Lancet Psychiatry, 2(3), 217-223.  | 3 | 아고멜라틴(agomelatine) | MT1 and MT2 agonist; 5-HT2 antagonist | 25-50 | 회사명 | 대표이사 | 소재지 | 전화 | 방문일 | 방문1 | 방문2 | 방문3 | 방문4 | 프로 | 제조자는 기기의 사용이 입증된 사용자이거나, | 위한 | 소프트웨어 | CES-D는 18세 이상 65세 이하 성인에게 적용 가능하며, 5, | 네트워크 API를 통해 데이터 | 적용 | 검증 및 |\n| 1) 중지 기준 | 전자파 적합성 인증을 통과한 제품을 사용해야 한다.  | 나) 대조기기: 위약 대조군(sham) | 성명 | 소속기관명 | 전공 | 직위 | 전화 | Cybersecurity for Networked | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. ",
        "original_sentence": "The Lancet Psychiatry, 2(3), 217-223. "
      }
    },
    {
      "chunk_id": "chunk_200",
      "text": "| 3 | 아고멜라틴(agomelatine) | MT1 and MT2 agonist; 5-HT2 antagonist | 25-50 | 회사명 | 대표이사 | 소재지 | 전화 | 방문일 | 방문1 | 방문2 | 방문3 | 방문4 | 프로 | 제조자는 기기의 사용이 입증된 사용자이거나, | 위한 | 소프트웨어 | CES-D는 18세 이상 65세 이하 성인에게 적용 가능하며, 5, | 네트워크 API를 통해 데이터 | 적용 | 검증 및 |\n| 1) 중지 기준 | 전자파 적합성 인증을 통과한 제품을 사용해야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 199,
        "window_size": 3,
        "char_count": 287,
        "word_count": 76,
        "page_number": 9,
        "window_text": "|\n| 전략 | 2) 증례기록서의 작성 | 7 | 판단한 자 | 1 | 몽고메리-아스버그 우울장애 척도(Montgomery-As˚ - berg Depression Rating Scale, MADRS) | - 성능: (임상시험용 의료기기의 성능 기술) | 하며, 보안이 취약한 통신(예.  가정용 네트 | 과업 | https://uk.deprexis.com/) | 의료기기심사부 첨단의료기기과 | 사이버보안에 대한 정보 가이드라인 | 미국 | 적용 |\n| trial.  The Lancet Psychiatry, 2(3), 217-223.  | 3 | 아고멜라틴(agomelatine) | MT1 and MT2 agonist; 5-HT2 antagonist | 25-50 | 회사명 | 대표이사 | 소재지 | 전화 | 방문일 | 방문1 | 방문2 | 방문3 | 방문4 | 프로 | 제조자는 기기의 사용이 입증된 사용자이거나, | 위한 | 소프트웨어 | CES-D는 18세 이상 65세 이하 성인에게 적용 가능하며, 5, | 네트워크 API를 통해 데이터 | 적용 | 검증 및 |\n| 1) 중지 기준 | 전자파 적합성 인증을 통과한 제품을 사용해야 한다.  | 나) 대조기기: 위약 대조군(sham) | 성명 | 소속기관명 | 전공 | 직위 | 전화 | Cybersecurity for Networked | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 하는 데 있어, 환자의 수행 성공 가능성이 최대화될 수 있도록 | 유효성 | (AB-1234) |\n| 접근 | 2) 방문 2 (치료시작일, Baseline) | Epidemiological Studies | 8 | 나) 이상 반응 확인 | 구분한다. ",
        "original_sentence": "| 3 | 아고멜라틴(agomelatine) | MT1 and MT2 agonist; 5-HT2 antagonist | 25-50 | 회사명 | 대표이사 | 소재지 | 전화 | 방문일 | 방문1 | 방문2 | 방문3 | 방문4 | 프로 | 제조자는 기기의 사용이 입증된 사용자이거나, | 위한 | 소프트웨어 | CES-D는 18세 이상 65세 이하 성인에게 적용 가능하며, 5, | 네트워크 API를 통해 데이터 | 적용 | 검증 및 |\n| 1) 중지 기준 | 전자파 적합성 인증을 통과한 제품을 사용해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_201",
      "text": "| 나) 대조기기: 위약 대조군(sham) | 성명 | 소속기관명 | 전공 | 직위 | 전화 | Cybersecurity for Networked | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 200,
        "window_size": 3,
        "char_count": 137,
        "word_count": 33,
        "page_number": 45,
        "window_text": "가정용 네트 | 과업 | https://uk.deprexis.com/) | 의료기기심사부 첨단의료기기과 | 사이버보안에 대한 정보 가이드라인 | 미국 | 적용 |\n| trial.  The Lancet Psychiatry, 2(3), 217-223.  | 3 | 아고멜라틴(agomelatine) | MT1 and MT2 agonist; 5-HT2 antagonist | 25-50 | 회사명 | 대표이사 | 소재지 | 전화 | 방문일 | 방문1 | 방문2 | 방문3 | 방문4 | 프로 | 제조자는 기기의 사용이 입증된 사용자이거나, | 위한 | 소프트웨어 | CES-D는 18세 이상 65세 이하 성인에게 적용 가능하며, 5, | 네트워크 API를 통해 데이터 | 적용 | 검증 및 |\n| 1) 중지 기준 | 전자파 적합성 인증을 통과한 제품을 사용해야 한다.  | 나) 대조기기: 위약 대조군(sham) | 성명 | 소속기관명 | 전공 | 직위 | 전화 | Cybersecurity for Networked | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 하는 데 있어, 환자의 수행 성공 가능성이 최대화될 수 있도록 | 유효성 | (AB-1234) |\n| 접근 | 2) 방문 2 (치료시작일, Baseline) | Epidemiological Studies | 8 | 나) 이상 반응 확인 | 구분한다.  | 하여야 한다. ",
        "original_sentence": "| 나) 대조기기: 위약 대조군(sham) | 성명 | 소속기관명 | 전공 | 직위 | 전화 | Cybersecurity for Networked | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. "
      }
    },
    {
      "chunk_id": "chunk_202",
      "text": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 201,
        "window_size": 3,
        "char_count": 34,
        "word_count": 7,
        "page_number": 3,
        "window_text": "The Lancet Psychiatry, 2(3), 217-223.  | 3 | 아고멜라틴(agomelatine) | MT1 and MT2 agonist; 5-HT2 antagonist | 25-50 | 회사명 | 대표이사 | 소재지 | 전화 | 방문일 | 방문1 | 방문2 | 방문3 | 방문4 | 프로 | 제조자는 기기의 사용이 입증된 사용자이거나, | 위한 | 소프트웨어 | CES-D는 18세 이상 65세 이하 성인에게 적용 가능하며, 5, | 네트워크 API를 통해 데이터 | 적용 | 검증 및 |\n| 1) 중지 기준 | 전자파 적합성 인증을 통과한 제품을 사용해야 한다.  | 나) 대조기기: 위약 대조군(sham) | 성명 | 소속기관명 | 전공 | 직위 | 전화 | Cybersecurity for Networked | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 하는 데 있어, 환자의 수행 성공 가능성이 최대화될 수 있도록 | 유효성 | (AB-1234) |\n| 접근 | 2) 방문 2 (치료시작일, Baseline) | Epidemiological Studies | 8 | 나) 이상 반응 확인 | 구분한다.  | 하여야 한다.  | (3) 피험자 식별코드는 아래의 방법에 따라 기입한다. ",
        "original_sentence": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. "
      }
    },
    {
      "chunk_id": "chunk_203",
      "text": "| 하는 데 있어, 환자의 수행 성공 가능성이 최대화될 수 있도록 | 유효성 | (AB-1234) |\n| 접근 | 2) 방문 2 (치료시작일, Baseline) | Epidemiological Studies | 8 | 나) 이상 반응 확인 | 구분한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 202,
        "window_size": 3,
        "char_count": 142,
        "word_count": 36,
        "page_number": 18,
        "window_text": "| 3 | 아고멜라틴(agomelatine) | MT1 and MT2 agonist; 5-HT2 antagonist | 25-50 | 회사명 | 대표이사 | 소재지 | 전화 | 방문일 | 방문1 | 방문2 | 방문3 | 방문4 | 프로 | 제조자는 기기의 사용이 입증된 사용자이거나, | 위한 | 소프트웨어 | CES-D는 18세 이상 65세 이하 성인에게 적용 가능하며, 5, | 네트워크 API를 통해 데이터 | 적용 | 검증 및 |\n| 1) 중지 기준 | 전자파 적합성 인증을 통과한 제품을 사용해야 한다.  | 나) 대조기기: 위약 대조군(sham) | 성명 | 소속기관명 | 전공 | 직위 | 전화 | Cybersecurity for Networked | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 하는 데 있어, 환자의 수행 성공 가능성이 최대화될 수 있도록 | 유효성 | (AB-1234) |\n| 접근 | 2) 방문 2 (치료시작일, Baseline) | Epidemiological Studies | 8 | 나) 이상 반응 확인 | 구분한다.  | 하여야 한다.  | (3) 피험자 식별코드는 아래의 방법에 따라 기입한다.  | ※ 예: 물리적 잠금 혹은 포트(port) 접근의 | 자살 고위험군으로 판단되는 경우 | 통화를 하여 탈락의 주요 사유를 파악하도록 한다. ",
        "original_sentence": "| 하는 데 있어, 환자의 수행 성공 가능성이 최대화될 수 있도록 | 유효성 | (AB-1234) |\n| 접근 | 2) 방문 2 (치료시작일, Baseline) | Epidemiological Studies | 8 | 나) 이상 반응 확인 | 구분한다. "
      }
    },
    {
      "chunk_id": "chunk_204",
      "text": "| 하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 203,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 13,
        "window_text": "| 나) 대조기기: 위약 대조군(sham) | 성명 | 소속기관명 | 전공 | 직위 | 전화 | Cybersecurity for Networked | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 하는 데 있어, 환자의 수행 성공 가능성이 최대화될 수 있도록 | 유효성 | (AB-1234) |\n| 접근 | 2) 방문 2 (치료시작일, Baseline) | Epidemiological Studies | 8 | 나) 이상 반응 확인 | 구분한다.  | 하여야 한다.  | (3) 피험자 식별코드는 아래의 방법에 따라 기입한다.  | ※ 예: 물리적 잠금 혹은 포트(port) 접근의 | 자살 고위험군으로 판단되는 경우 | 통화를 하여 탈락의 주요 사유를 파악하도록 한다.  | 따라 차이가 있는지를 확인하기 위해 하위 분석을 제시한다. ",
        "original_sentence": "| 하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_205",
      "text": "| (3) 피험자 식별코드는 아래의 방법에 따라 기입한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 204,
        "window_size": 3,
        "char_count": 33,
        "word_count": 8,
        "page_number": 13,
        "window_text": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 하는 데 있어, 환자의 수행 성공 가능성이 최대화될 수 있도록 | 유효성 | (AB-1234) |\n| 접근 | 2) 방문 2 (치료시작일, Baseline) | Epidemiological Studies | 8 | 나) 이상 반응 확인 | 구분한다.  | 하여야 한다.  | (3) 피험자 식별코드는 아래의 방법에 따라 기입한다.  | ※ 예: 물리적 잠금 혹은 포트(port) 접근의 | 자살 고위험군으로 판단되는 경우 | 통화를 하여 탈락의 주요 사유를 파악하도록 한다.  | 따라 차이가 있는지를 확인하기 위해 하위 분석을 제시한다.  | 시험용 의료기기의 사용에 기인한다고 판단되는 경우 | 그림 3. ",
        "original_sentence": "| (3) 피험자 식별코드는 아래의 방법에 따라 기입한다. "
      }
    },
    {
      "chunk_id": "chunk_206",
      "text": "| ※ 예: 물리적 잠금 혹은 포트(port) 접근의 | 자살 고위험군으로 판단되는 경우 | 통화를 하여 탈락의 주요 사유를 파악하도록 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 205,
        "window_size": 3,
        "char_count": 80,
        "word_count": 21,
        "page_number": 41,
        "window_text": "| 하는 데 있어, 환자의 수행 성공 가능성이 최대화될 수 있도록 | 유효성 | (AB-1234) |\n| 접근 | 2) 방문 2 (치료시작일, Baseline) | Epidemiological Studies | 8 | 나) 이상 반응 확인 | 구분한다.  | 하여야 한다.  | (3) 피험자 식별코드는 아래의 방법에 따라 기입한다.  | ※ 예: 물리적 잠금 혹은 포트(port) 접근의 | 자살 고위험군으로 판단되는 경우 | 통화를 하여 탈락의 주요 사유를 파악하도록 한다.  | 따라 차이가 있는지를 확인하기 위해 하위 분석을 제시한다.  | 시험용 의료기기의 사용에 기인한다고 판단되는 경우 | 그림 3.  소프트웨어의 안전성 평가 관련 연구의 흐름 | 아키텍처 | 등급을 만들고 정의에 자신이 얼마나 부합하는지 정도를 나타 | 데이터베이스 저장했던 정보와 | GDS는 노인 우울장애를 측정하기 위해 간단하고 신속하게 | 문항과 건강 상태 변화에 대한 1개 문항으로 총 36개 | 항목과 소프트웨어 항목 외부의 | 소프트웨어 | 항목의 | 일관성을 | (AB-1234) |\n| (5) 「의료기기법 시행규칙」 제20조 (임상시험계획의 승인 등) | 4 | 데이터베이스 | 라) 전체 잔여위험 허용 가능성 평가 | 부프로피온(bupropion) | NDRI | 150-300 | 무작위배정 될 확률 | 2 | 해밀톤 우울장애 척도(Hamilton Depression Rating Scale, HDRS) | 워크 혹은 기존 기기)만을 지원하는 기기 및 | 기준)를 함께 제시하여야 한다. ",
        "original_sentence": "| ※ 예: 물리적 잠금 혹은 포트(port) 접근의 | 자살 고위험군으로 판단되는 경우 | 통화를 하여 탈락의 주요 사유를 파악하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_207",
      "text": "| 따라 차이가 있는지를 확인하기 위해 하위 분석을 제시한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 206,
        "window_size": 3,
        "char_count": 35,
        "word_count": 9,
        "page_number": 7,
        "window_text": "| 하여야 한다.  | (3) 피험자 식별코드는 아래의 방법에 따라 기입한다.  | ※ 예: 물리적 잠금 혹은 포트(port) 접근의 | 자살 고위험군으로 판단되는 경우 | 통화를 하여 탈락의 주요 사유를 파악하도록 한다.  | 따라 차이가 있는지를 확인하기 위해 하위 분석을 제시한다.  | 시험용 의료기기의 사용에 기인한다고 판단되는 경우 | 그림 3.  소프트웨어의 안전성 평가 관련 연구의 흐름 | 아키텍처 | 등급을 만들고 정의에 자신이 얼마나 부합하는지 정도를 나타 | 데이터베이스 저장했던 정보와 | GDS는 노인 우울장애를 측정하기 위해 간단하고 신속하게 | 문항과 건강 상태 변화에 대한 1개 문항으로 총 36개 | 항목과 소프트웨어 항목 외부의 | 소프트웨어 | 항목의 | 일관성을 | (AB-1234) |\n| (5) 「의료기기법 시행규칙」 제20조 (임상시험계획의 승인 등) | 4 | 데이터베이스 | 라) 전체 잔여위험 허용 가능성 평가 | 부프로피온(bupropion) | NDRI | 150-300 | 무작위배정 될 확률 | 2 | 해밀톤 우울장애 척도(Hamilton Depression Rating Scale, HDRS) | 워크 혹은 기존 기기)만을 지원하는 기기 및 | 기준)를 함께 제시하여야 한다.  | 주기 | PHQ-9은 다른 우울장애 평가척도와 유의한 공존 타당도를 | 베이스로 미리 정해진 데이터를 송신 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 노인 우울 척도 | 한다. ",
        "original_sentence": "| 따라 차이가 있는지를 확인하기 위해 하위 분석을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_208",
      "text": "| 시험용 의료기기의 사용에 기인한다고 판단되는 경우 | 그림 3. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 207,
        "window_size": 3,
        "char_count": 38,
        "word_count": 10,
        "page_number": 29,
        "window_text": "| (3) 피험자 식별코드는 아래의 방법에 따라 기입한다.  | ※ 예: 물리적 잠금 혹은 포트(port) 접근의 | 자살 고위험군으로 판단되는 경우 | 통화를 하여 탈락의 주요 사유를 파악하도록 한다.  | 따라 차이가 있는지를 확인하기 위해 하위 분석을 제시한다.  | 시험용 의료기기의 사용에 기인한다고 판단되는 경우 | 그림 3.  소프트웨어의 안전성 평가 관련 연구의 흐름 | 아키텍처 | 등급을 만들고 정의에 자신이 얼마나 부합하는지 정도를 나타 | 데이터베이스 저장했던 정보와 | GDS는 노인 우울장애를 측정하기 위해 간단하고 신속하게 | 문항과 건강 상태 변화에 대한 1개 문항으로 총 36개 | 항목과 소프트웨어 항목 외부의 | 소프트웨어 | 항목의 | 일관성을 | (AB-1234) |\n| (5) 「의료기기법 시행규칙」 제20조 (임상시험계획의 승인 등) | 4 | 데이터베이스 | 라) 전체 잔여위험 허용 가능성 평가 | 부프로피온(bupropion) | NDRI | 150-300 | 무작위배정 될 확률 | 2 | 해밀톤 우울장애 척도(Hamilton Depression Rating Scale, HDRS) | 워크 혹은 기존 기기)만을 지원하는 기기 및 | 기준)를 함께 제시하여야 한다.  | 주기 | PHQ-9은 다른 우울장애 평가척도와 유의한 공존 타당도를 | 베이스로 미리 정해진 데이터를 송신 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 노인 우울 척도 | 한다.  | 경과일수 | D-28 이내 | DAY1 | - | - | 세스 | 다른 역할의 사용자에게 사용권한을 부여를 | 전략 | 형상 관리 | TEL : 043) 719-3912   FAX : 043) 719-3900 | 10, 15번은 긍정 질문으로 역 채점하여 총점을 산출한다. ",
        "original_sentence": "| 시험용 의료기기의 사용에 기인한다고 판단되는 경우 | 그림 3. "
      }
    },
    {
      "chunk_id": "chunk_209",
      "text": "소프트웨어의 안전성 평가 관련 연구의 흐름 | 아키텍처 | 등급을 만들고 정의에 자신이 얼마나 부합하는지 정도를 나타 | 데이터베이스 저장했던 정보와 | GDS는 노인 우울장애를 측정하기 위해 간단하고 신속하게 | 문항과 건강 상태 변화에 대한 1개 문항으로 총 36개 | 항목과 소프트웨어 항목 외부의 | 소프트웨어 | 항목의 | 일관성을 | (AB-1234) |\n| (5) 「의료기기법 시행규칙」 제20조 (임상시험계획의 승인 등) | 4 | 데이터베이스 | 라) 전체 잔여위험 허용 가능성 평가 | 부프로피온(bupropion) | NDRI | 150-300 | 무작위배정 될 확률 | 2 | 해밀톤 우울장애 척도(Hamilton Depression Rating Scale, HDRS) | 워크 혹은 기존 기기)만을 지원하는 기기 및 | 기준)를 함께 제시하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 208,
        "window_size": 3,
        "char_count": 434,
        "word_count": 105,
        "page_number": 9,
        "window_text": "| ※ 예: 물리적 잠금 혹은 포트(port) 접근의 | 자살 고위험군으로 판단되는 경우 | 통화를 하여 탈락의 주요 사유를 파악하도록 한다.  | 따라 차이가 있는지를 확인하기 위해 하위 분석을 제시한다.  | 시험용 의료기기의 사용에 기인한다고 판단되는 경우 | 그림 3.  소프트웨어의 안전성 평가 관련 연구의 흐름 | 아키텍처 | 등급을 만들고 정의에 자신이 얼마나 부합하는지 정도를 나타 | 데이터베이스 저장했던 정보와 | GDS는 노인 우울장애를 측정하기 위해 간단하고 신속하게 | 문항과 건강 상태 변화에 대한 1개 문항으로 총 36개 | 항목과 소프트웨어 항목 외부의 | 소프트웨어 | 항목의 | 일관성을 | (AB-1234) |\n| (5) 「의료기기법 시행규칙」 제20조 (임상시험계획의 승인 등) | 4 | 데이터베이스 | 라) 전체 잔여위험 허용 가능성 평가 | 부프로피온(bupropion) | NDRI | 150-300 | 무작위배정 될 확률 | 2 | 해밀톤 우울장애 척도(Hamilton Depression Rating Scale, HDRS) | 워크 혹은 기존 기기)만을 지원하는 기기 및 | 기준)를 함께 제시하여야 한다.  | 주기 | PHQ-9은 다른 우울장애 평가척도와 유의한 공존 타당도를 | 베이스로 미리 정해진 데이터를 송신 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 노인 우울 척도 | 한다.  | 경과일수 | D-28 이내 | DAY1 | - | - | 세스 | 다른 역할의 사용자에게 사용권한을 부여를 | 전략 | 형상 관리 | TEL : 043) 719-3912   FAX : 043) 719-3900 | 10, 15번은 긍정 질문으로 역 채점하여 총점을 산출한다.  원래 | 유효성 |\n| 보안 | (출처: Beck, J.S.",
        "original_sentence": "소프트웨어의 안전성 평가 관련 연구의 흐름 | 아키텍처 | 등급을 만들고 정의에 자신이 얼마나 부합하는지 정도를 나타 | 데이터베이스 저장했던 정보와 | GDS는 노인 우울장애를 측정하기 위해 간단하고 신속하게 | 문항과 건강 상태 변화에 대한 1개 문항으로 총 36개 | 항목과 소프트웨어 항목 외부의 | 소프트웨어 | 항목의 | 일관성을 | (AB-1234) |\n| (5) 「의료기기법 시행규칙」 제20조 (임상시험계획의 승인 등) | 4 | 데이터베이스 | 라) 전체 잔여위험 허용 가능성 평가 | 부프로피온(bupropion) | NDRI | 150-300 | 무작위배정 될 확률 | 2 | 해밀톤 우울장애 척도(Hamilton Depression Rating Scale, HDRS) | 워크 혹은 기존 기기)만을 지원하는 기기 및 | 기준)를 함께 제시하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_210",
      "text": "| 주기 | PHQ-9은 다른 우울장애 평가척도와 유의한 공존 타당도를 | 베이스로 미리 정해진 데이터를 송신 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 노인 우울 척도 | 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 209,
        "window_size": 3,
        "char_count": 158,
        "word_count": 44,
        "page_number": 18,
        "window_text": "| 따라 차이가 있는지를 확인하기 위해 하위 분석을 제시한다.  | 시험용 의료기기의 사용에 기인한다고 판단되는 경우 | 그림 3.  소프트웨어의 안전성 평가 관련 연구의 흐름 | 아키텍처 | 등급을 만들고 정의에 자신이 얼마나 부합하는지 정도를 나타 | 데이터베이스 저장했던 정보와 | GDS는 노인 우울장애를 측정하기 위해 간단하고 신속하게 | 문항과 건강 상태 변화에 대한 1개 문항으로 총 36개 | 항목과 소프트웨어 항목 외부의 | 소프트웨어 | 항목의 | 일관성을 | (AB-1234) |\n| (5) 「의료기기법 시행규칙」 제20조 (임상시험계획의 승인 등) | 4 | 데이터베이스 | 라) 전체 잔여위험 허용 가능성 평가 | 부프로피온(bupropion) | NDRI | 150-300 | 무작위배정 될 확률 | 2 | 해밀톤 우울장애 척도(Hamilton Depression Rating Scale, HDRS) | 워크 혹은 기존 기기)만을 지원하는 기기 및 | 기준)를 함께 제시하여야 한다.  | 주기 | PHQ-9은 다른 우울장애 평가척도와 유의한 공존 타당도를 | 베이스로 미리 정해진 데이터를 송신 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 노인 우울 척도 | 한다.  | 경과일수 | D-28 이내 | DAY1 | - | - | 세스 | 다른 역할의 사용자에게 사용권한을 부여를 | 전략 | 형상 관리 | TEL : 043) 719-3912   FAX : 043) 719-3900 | 10, 15번은 긍정 질문으로 역 채점하여 총점을 산출한다.  원래 | 유효성 |\n| 보안 | (출처: Beck, J.S. (1995), 권정혜 & 이재우(2001), 이삼연(1999)) | 에서도 적용하기 쉬워 우울장애를 선별하는데 유용한 도구이다. ",
        "original_sentence": "| 주기 | PHQ-9은 다른 우울장애 평가척도와 유의한 공존 타당도를 | 베이스로 미리 정해진 데이터를 송신 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 노인 우울 척도 | 한다. "
      }
    },
    {
      "chunk_id": "chunk_211",
      "text": "| 경과일수 | D-28 이내 | DAY1 | - | - | 세스 | 다른 역할의 사용자에게 사용권한을 부여를 | 전략 | 형상 관리 | TEL : 043) 719-3912   FAX : 043) 719-3900 | 10, 15번은 긍정 질문으로 역 채점하여 총점을 산출한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 210,
        "window_size": 3,
        "char_count": 155,
        "word_count": 42,
        "page_number": 9,
        "window_text": "| 시험용 의료기기의 사용에 기인한다고 판단되는 경우 | 그림 3.  소프트웨어의 안전성 평가 관련 연구의 흐름 | 아키텍처 | 등급을 만들고 정의에 자신이 얼마나 부합하는지 정도를 나타 | 데이터베이스 저장했던 정보와 | GDS는 노인 우울장애를 측정하기 위해 간단하고 신속하게 | 문항과 건강 상태 변화에 대한 1개 문항으로 총 36개 | 항목과 소프트웨어 항목 외부의 | 소프트웨어 | 항목의 | 일관성을 | (AB-1234) |\n| (5) 「의료기기법 시행규칙」 제20조 (임상시험계획의 승인 등) | 4 | 데이터베이스 | 라) 전체 잔여위험 허용 가능성 평가 | 부프로피온(bupropion) | NDRI | 150-300 | 무작위배정 될 확률 | 2 | 해밀톤 우울장애 척도(Hamilton Depression Rating Scale, HDRS) | 워크 혹은 기존 기기)만을 지원하는 기기 및 | 기준)를 함께 제시하여야 한다.  | 주기 | PHQ-9은 다른 우울장애 평가척도와 유의한 공존 타당도를 | 베이스로 미리 정해진 데이터를 송신 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 노인 우울 척도 | 한다.  | 경과일수 | D-28 이내 | DAY1 | - | - | 세스 | 다른 역할의 사용자에게 사용권한을 부여를 | 전략 | 형상 관리 | TEL : 043) 719-3912   FAX : 043) 719-3900 | 10, 15번은 긍정 질문으로 역 채점하여 총점을 산출한다.  원래 | 유효성 |\n| 보안 | (출처: Beck, J.S. (1995), 권정혜 & 이재우(2001), 이삼연(1999)) | 에서도 적용하기 쉬워 우울장애를 선별하는데 유용한 도구이다.  | 나) 대조기기 | Medical Devices Containing | 하는 계획이 중요하다. ",
        "original_sentence": "| 경과일수 | D-28 이내 | DAY1 | - | - | 세스 | 다른 역할의 사용자에게 사용권한을 부여를 | 전략 | 형상 관리 | TEL : 043) 719-3912   FAX : 043) 719-3900 | 10, 15번은 긍정 질문으로 역 채점하여 총점을 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_212",
      "text": "원래 | 유효성 |\n| 보안 | (출처: Beck, J.S.",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 211,
        "window_size": 3,
        "char_count": 33,
        "word_count": 10,
        "page_number": 45,
        "window_text": "소프트웨어의 안전성 평가 관련 연구의 흐름 | 아키텍처 | 등급을 만들고 정의에 자신이 얼마나 부합하는지 정도를 나타 | 데이터베이스 저장했던 정보와 | GDS는 노인 우울장애를 측정하기 위해 간단하고 신속하게 | 문항과 건강 상태 변화에 대한 1개 문항으로 총 36개 | 항목과 소프트웨어 항목 외부의 | 소프트웨어 | 항목의 | 일관성을 | (AB-1234) |\n| (5) 「의료기기법 시행규칙」 제20조 (임상시험계획의 승인 등) | 4 | 데이터베이스 | 라) 전체 잔여위험 허용 가능성 평가 | 부프로피온(bupropion) | NDRI | 150-300 | 무작위배정 될 확률 | 2 | 해밀톤 우울장애 척도(Hamilton Depression Rating Scale, HDRS) | 워크 혹은 기존 기기)만을 지원하는 기기 및 | 기준)를 함께 제시하여야 한다.  | 주기 | PHQ-9은 다른 우울장애 평가척도와 유의한 공존 타당도를 | 베이스로 미리 정해진 데이터를 송신 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 노인 우울 척도 | 한다.  | 경과일수 | D-28 이내 | DAY1 | - | - | 세스 | 다른 역할의 사용자에게 사용권한을 부여를 | 전략 | 형상 관리 | TEL : 043) 719-3912   FAX : 043) 719-3900 | 10, 15번은 긍정 질문으로 역 채점하여 총점을 산출한다.  원래 | 유효성 |\n| 보안 | (출처: Beck, J.S. (1995), 권정혜 & 이재우(2001), 이삼연(1999)) | 에서도 적용하기 쉬워 우울장애를 선별하는데 유용한 도구이다.  | 나) 대조기기 | Medical Devices Containing | 하는 계획이 중요하다.  | 다시 호출한 정보가 일치 | 문항으로 구성. ",
        "original_sentence": "원래 | 유효성 |\n| 보안 | (출처: Beck, J.S."
      }
    },
    {
      "chunk_id": "chunk_213",
      "text": "(1995), 권정혜 & 이재우(2001), 이삼연(1999)) | 에서도 적용하기 쉬워 우울장애를 선별하는데 유용한 도구이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 212,
        "window_size": 3,
        "char_count": 72,
        "word_count": 13,
        "page_number": 9,
        "window_text": "| 주기 | PHQ-9은 다른 우울장애 평가척도와 유의한 공존 타당도를 | 베이스로 미리 정해진 데이터를 송신 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 노인 우울 척도 | 한다.  | 경과일수 | D-28 이내 | DAY1 | - | - | 세스 | 다른 역할의 사용자에게 사용권한을 부여를 | 전략 | 형상 관리 | TEL : 043) 719-3912   FAX : 043) 719-3900 | 10, 15번은 긍정 질문으로 역 채점하여 총점을 산출한다.  원래 | 유효성 |\n| 보안 | (출처: Beck, J.S. (1995), 권정혜 & 이재우(2001), 이삼연(1999)) | 에서도 적용하기 쉬워 우울장애를 선별하는데 유용한 도구이다.  | 나) 대조기기 | Medical Devices Containing | 하는 계획이 중요하다.  | 다시 호출한 정보가 일치 | 문항으로 구성.  건강 관련 삶의 질은 8개의 하부영역으로 | 유지하면서 설계 변경 및 소프트 | 의료기기 소프트웨어의 | 확인 자료 |\n| 2) 일차 유효성 평가변수 | 시탈로프람(citalopram) | SSRI | 20-40 | (graded | 물리적 제한, 인증이 필요 없는 물리적 케 | 내게 한다. ",
        "original_sentence": "(1995), 권정혜 & 이재우(2001), 이삼연(1999)) | 에서도 적용하기 쉬워 우울장애를 선별하는데 유용한 도구이다. "
      }
    },
    {
      "chunk_id": "chunk_214",
      "text": "| 나) 대조기기 | Medical Devices Containing | 하는 계획이 중요하다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 213,
        "window_size": 3,
        "char_count": 54,
        "word_count": 11,
        "page_number": 18,
        "window_text": "| 경과일수 | D-28 이내 | DAY1 | - | - | 세스 | 다른 역할의 사용자에게 사용권한을 부여를 | 전략 | 형상 관리 | TEL : 043) 719-3912   FAX : 043) 719-3900 | 10, 15번은 긍정 질문으로 역 채점하여 총점을 산출한다.  원래 | 유효성 |\n| 보안 | (출처: Beck, J.S. (1995), 권정혜 & 이재우(2001), 이삼연(1999)) | 에서도 적용하기 쉬워 우울장애를 선별하는데 유용한 도구이다.  | 나) 대조기기 | Medical Devices Containing | 하는 계획이 중요하다.  | 다시 호출한 정보가 일치 | 문항으로 구성.  건강 관련 삶의 질은 8개의 하부영역으로 | 유지하면서 설계 변경 및 소프트 | 의료기기 소프트웨어의 | 확인 자료 |\n| 2) 일차 유효성 평가변수 | 시탈로프람(citalopram) | SSRI | 20-40 | (graded | 물리적 제한, 인증이 필요 없는 물리적 케 | 내게 한다.  환자 자신이 가지고 있는 부정적인 사고에 자신이 | 측정할 수 있도록 고안하였다. ",
        "original_sentence": "| 나) 대조기기 | Medical Devices Containing | 하는 계획이 중요하다. "
      }
    },
    {
      "chunk_id": "chunk_215",
      "text": "| 다시 호출한 정보가 일치 | 문항으로 구성. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 214,
        "window_size": 3,
        "char_count": 27,
        "word_count": 8,
        "page_number": 39,
        "window_text": "원래 | 유효성 |\n| 보안 | (출처: Beck, J.S. (1995), 권정혜 & 이재우(2001), 이삼연(1999)) | 에서도 적용하기 쉬워 우울장애를 선별하는데 유용한 도구이다.  | 나) 대조기기 | Medical Devices Containing | 하는 계획이 중요하다.  | 다시 호출한 정보가 일치 | 문항으로 구성.  건강 관련 삶의 질은 8개의 하부영역으로 | 유지하면서 설계 변경 및 소프트 | 의료기기 소프트웨어의 | 확인 자료 |\n| 2) 일차 유효성 평가변수 | 시탈로프람(citalopram) | SSRI | 20-40 | (graded | 물리적 제한, 인증이 필요 없는 물리적 케 | 내게 한다.  환자 자신이 가지고 있는 부정적인 사고에 자신이 | 측정할 수 있도록 고안하였다.  GDS는 총 30문항에 대해 | 구성요소 간의 연계성과 소프트 | 매주 30분 동안 주 1~2회의 사용을 권장한다. ",
        "original_sentence": "| 다시 호출한 정보가 일치 | 문항으로 구성. "
      }
    },
    {
      "chunk_id": "chunk_216",
      "text": "건강 관련 삶의 질은 8개의 하부영역으로 | 유지하면서 설계 변경 및 소프트 | 의료기기 소프트웨어의 | 확인 자료 |\n| 2) 일차 유효성 평가변수 | 시탈로프람(citalopram) | SSRI | 20-40 | (graded | 물리적 제한, 인증이 필요 없는 물리적 케 | 내게 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 215,
        "window_size": 3,
        "char_count": 164,
        "word_count": 43,
        "page_number": 38,
        "window_text": "(1995), 권정혜 & 이재우(2001), 이삼연(1999)) | 에서도 적용하기 쉬워 우울장애를 선별하는데 유용한 도구이다.  | 나) 대조기기 | Medical Devices Containing | 하는 계획이 중요하다.  | 다시 호출한 정보가 일치 | 문항으로 구성.  건강 관련 삶의 질은 8개의 하부영역으로 | 유지하면서 설계 변경 및 소프트 | 의료기기 소프트웨어의 | 확인 자료 |\n| 2) 일차 유효성 평가변수 | 시탈로프람(citalopram) | SSRI | 20-40 | (graded | 물리적 제한, 인증이 필요 없는 물리적 케 | 내게 한다.  환자 자신이 가지고 있는 부정적인 사고에 자신이 | 측정할 수 있도록 고안하였다.  GDS는 총 30문항에 대해 | 구성요소 간의 연계성과 소프트 | 매주 30분 동안 주 1~2회의 사용을 권장한다.  | 있도록 돕는다. ",
        "original_sentence": "건강 관련 삶의 질은 8개의 하부영역으로 | 유지하면서 설계 변경 및 소프트 | 의료기기 소프트웨어의 | 확인 자료 |\n| 2) 일차 유효성 평가변수 | 시탈로프람(citalopram) | SSRI | 20-40 | (graded | 물리적 제한, 인증이 필요 없는 물리적 케 | 내게 한다. "
      }
    },
    {
      "chunk_id": "chunk_217",
      "text": "환자 자신이 가지고 있는 부정적인 사고에 자신이 | 측정할 수 있도록 고안하였다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 216,
        "window_size": 3,
        "char_count": 46,
        "word_count": 12,
        "page_number": 20,
        "window_text": "| 나) 대조기기 | Medical Devices Containing | 하는 계획이 중요하다.  | 다시 호출한 정보가 일치 | 문항으로 구성.  건강 관련 삶의 질은 8개의 하부영역으로 | 유지하면서 설계 변경 및 소프트 | 의료기기 소프트웨어의 | 확인 자료 |\n| 2) 일차 유효성 평가변수 | 시탈로프람(citalopram) | SSRI | 20-40 | (graded | 물리적 제한, 인증이 필요 없는 물리적 케 | 내게 한다.  환자 자신이 가지고 있는 부정적인 사고에 자신이 | 측정할 수 있도록 고안하였다.  GDS는 총 30문항에 대해 | 구성요소 간의 연계성과 소프트 | 매주 30분 동안 주 1~2회의 사용을 권장한다.  | 있도록 돕는다.  | 구조를 갖추어 설계한다. ",
        "original_sentence": "환자 자신이 가지고 있는 부정적인 사고에 자신이 | 측정할 수 있도록 고안하였다. "
      }
    },
    {
      "chunk_id": "chunk_218",
      "text": "GDS는 총 30문항에 대해 | 구성요소 간의 연계성과 소프트 | 매주 30분 동안 주 1~2회의 사용을 권장한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 217,
        "window_size": 3,
        "char_count": 65,
        "word_count": 17,
        "page_number": 28,
        "window_text": "| 다시 호출한 정보가 일치 | 문항으로 구성.  건강 관련 삶의 질은 8개의 하부영역으로 | 유지하면서 설계 변경 및 소프트 | 의료기기 소프트웨어의 | 확인 자료 |\n| 2) 일차 유효성 평가변수 | 시탈로프람(citalopram) | SSRI | 20-40 | (graded | 물리적 제한, 인증이 필요 없는 물리적 케 | 내게 한다.  환자 자신이 가지고 있는 부정적인 사고에 자신이 | 측정할 수 있도록 고안하였다.  GDS는 총 30문항에 대해 | 구성요소 간의 연계성과 소프트 | 매주 30분 동안 주 1~2회의 사용을 권장한다.  | 있도록 돕는다.  | 구조를 갖추어 설계한다.  |\n| (6) 「의료기기법 시행규칙」 제24조 (임상시험 실시기준 등) | Psychiatry, 187(5), 456-461. ",
        "original_sentence": "GDS는 총 30문항에 대해 | 구성요소 간의 연계성과 소프트 | 매주 30분 동안 주 1~2회의 사용을 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_219",
      "text": "| 있도록 돕는다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 218,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 30,
        "window_text": "건강 관련 삶의 질은 8개의 하부영역으로 | 유지하면서 설계 변경 및 소프트 | 의료기기 소프트웨어의 | 확인 자료 |\n| 2) 일차 유효성 평가변수 | 시탈로프람(citalopram) | SSRI | 20-40 | (graded | 물리적 제한, 인증이 필요 없는 물리적 케 | 내게 한다.  환자 자신이 가지고 있는 부정적인 사고에 자신이 | 측정할 수 있도록 고안하였다.  GDS는 총 30문항에 대해 | 구성요소 간의 연계성과 소프트 | 매주 30분 동안 주 1~2회의 사용을 권장한다.  | 있도록 돕는다.  | 구조를 갖추어 설계한다.  |\n| (6) 「의료기기법 시행규칙」 제24조 (임상시험 실시기준 등) | Psychiatry, 187(5), 456-461.  | 36항 건강수준 척도 | 마) 이상반응 확인 | 나) 이상 반응 확인 | 3 | 역학용 우울 척도(The Center for Epidemioloꠓ | 환경에서 이루어지는 통신도 고려한다. ",
        "original_sentence": "| 있도록 돕는다. "
      }
    },
    {
      "chunk_id": "chunk_220",
      "text": "| 구조를 갖추어 설계한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 219,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 13,
        "window_text": "환자 자신이 가지고 있는 부정적인 사고에 자신이 | 측정할 수 있도록 고안하였다.  GDS는 총 30문항에 대해 | 구성요소 간의 연계성과 소프트 | 매주 30분 동안 주 1~2회의 사용을 권장한다.  | 있도록 돕는다.  | 구조를 갖추어 설계한다.  |\n| (6) 「의료기기법 시행규칙」 제24조 (임상시험 실시기준 등) | Psychiatry, 187(5), 456-461.  | 36항 건강수준 척도 | 마) 이상반응 확인 | 나) 이상 반응 확인 | 3 | 역학용 우울 척도(The Center for Epidemioloꠓ | 환경에서 이루어지는 통신도 고려한다.  | 송수신 | 나타내고 우울장애를 평가하고 선별하는 척도로써 신뢰도와 | gical Studies Depression Scale, CES-D) | 및 저장한 후, 해당 데이터를 다시 | 확인 자료 |\n| 7) 민감도분석 | 3 | IEC 62304 | Medical device software – | (Geriatric Depression | 우울장애 선별 도구 | 디지털치료기기 관련 국내외 가이드라인은 <표 7>과 같다. ",
        "original_sentence": "| 구조를 갖추어 설계한다. "
      }
    },
    {
      "chunk_id": "chunk_221",
      "text": "|\n| (6) 「의료기기법 시행규칙」 제24조 (임상시험 실시기준 등) | Psychiatry, 187(5), 456-461. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 220,
        "window_size": 3,
        "char_count": 71,
        "word_count": 13,
        "page_number": 5,
        "window_text": "GDS는 총 30문항에 대해 | 구성요소 간의 연계성과 소프트 | 매주 30분 동안 주 1~2회의 사용을 권장한다.  | 있도록 돕는다.  | 구조를 갖추어 설계한다.  |\n| (6) 「의료기기법 시행규칙」 제24조 (임상시험 실시기준 등) | Psychiatry, 187(5), 456-461.  | 36항 건강수준 척도 | 마) 이상반응 확인 | 나) 이상 반응 확인 | 3 | 역학용 우울 척도(The Center for Epidemioloꠓ | 환경에서 이루어지는 통신도 고려한다.  | 송수신 | 나타내고 우울장애를 평가하고 선별하는 척도로써 신뢰도와 | gical Studies Depression Scale, CES-D) | 및 저장한 후, 해당 데이터를 다시 | 확인 자료 |\n| 7) 민감도분석 | 3 | IEC 62304 | Medical device software – | (Geriatric Depression | 우울장애 선별 도구 | 디지털치료기기 관련 국내외 가이드라인은 <표 7>과 같다.  | 가) Baseline 유효성 평가 | 데스벤라팍신(desvenlafaxine) | SNRI | 50-100 | 절차를 말한다. ",
        "original_sentence": "|\n| (6) 「의료기기법 시행규칙」 제24조 (임상시험 실시기준 등) | Psychiatry, 187(5), 456-461. "
      }
    },
    {
      "chunk_id": "chunk_222",
      "text": "| 36항 건강수준 척도 | 마) 이상반응 확인 | 나) 이상 반응 확인 | 3 | 역학용 우울 척도(The Center for Epidemioloꠓ | 환경에서 이루어지는 통신도 고려한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 221,
        "window_size": 3,
        "char_count": 107,
        "word_count": 27,
        "page_number": 29,
        "window_text": "| 있도록 돕는다.  | 구조를 갖추어 설계한다.  |\n| (6) 「의료기기법 시행규칙」 제24조 (임상시험 실시기준 등) | Psychiatry, 187(5), 456-461.  | 36항 건강수준 척도 | 마) 이상반응 확인 | 나) 이상 반응 확인 | 3 | 역학용 우울 척도(The Center for Epidemioloꠓ | 환경에서 이루어지는 통신도 고려한다.  | 송수신 | 나타내고 우울장애를 평가하고 선별하는 척도로써 신뢰도와 | gical Studies Depression Scale, CES-D) | 및 저장한 후, 해당 데이터를 다시 | 확인 자료 |\n| 7) 민감도분석 | 3 | IEC 62304 | Medical device software – | (Geriatric Depression | 우울장애 선별 도구 | 디지털치료기기 관련 국내외 가이드라인은 <표 7>과 같다.  | 가) Baseline 유효성 평가 | 데스벤라팍신(desvenlafaxine) | SNRI | 50-100 | 절차를 말한다.  | 기기의 회수체계를 확립하고 이를 문서화하여야 한다. ",
        "original_sentence": "| 36항 건강수준 척도 | 마) 이상반응 확인 | 나) 이상 반응 확인 | 3 | 역학용 우울 척도(The Center for Epidemioloꠓ | 환경에서 이루어지는 통신도 고려한다. "
      }
    },
    {
      "chunk_id": "chunk_223",
      "text": "| 송수신 | 나타내고 우울장애를 평가하고 선별하는 척도로써 신뢰도와 | gical Studies Depression Scale, CES-D) | 및 저장한 후, 해당 데이터를 다시 | 확인 자료 |\n| 7) 민감도분석 | 3 | IEC 62304 | Medical device software – | (Geriatric Depression | 우울장애 선별 도구 | 디지털치료기기 관련 국내외 가이드라인은 <표 7>과 같다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 222,
        "window_size": 3,
        "char_count": 239,
        "word_count": 54,
        "page_number": 45,
        "window_text": "| 구조를 갖추어 설계한다.  |\n| (6) 「의료기기법 시행규칙」 제24조 (임상시험 실시기준 등) | Psychiatry, 187(5), 456-461.  | 36항 건강수준 척도 | 마) 이상반응 확인 | 나) 이상 반응 확인 | 3 | 역학용 우울 척도(The Center for Epidemioloꠓ | 환경에서 이루어지는 통신도 고려한다.  | 송수신 | 나타내고 우울장애를 평가하고 선별하는 척도로써 신뢰도와 | gical Studies Depression Scale, CES-D) | 및 저장한 후, 해당 데이터를 다시 | 확인 자료 |\n| 7) 민감도분석 | 3 | IEC 62304 | Medical device software – | (Geriatric Depression | 우울장애 선별 도구 | 디지털치료기기 관련 국내외 가이드라인은 <표 7>과 같다.  | 가) Baseline 유효성 평가 | 데스벤라팍신(desvenlafaxine) | SNRI | 50-100 | 절차를 말한다.  | 기기의 회수체계를 확립하고 이를 문서화하여야 한다.  | 관찰형태 | 내원 | 내원과 | Off-The-Shelf(OTS) Software” | 허용하거나, 응급상황에서 접근을 허용하는 | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | * 피험자 식별코드: 실시기관 코드 - 등록된 순 | - 수행 가능성 최대화를 위해 과업으로 주는 활동을 수행하기 가장 | CES-D는 16점을 절단 점수로 사용한다. ",
        "original_sentence": "| 송수신 | 나타내고 우울장애를 평가하고 선별하는 척도로써 신뢰도와 | gical Studies Depression Scale, CES-D) | 및 저장한 후, 해당 데이터를 다시 | 확인 자료 |\n| 7) 민감도분석 | 3 | IEC 62304 | Medical device software – | (Geriatric Depression | 우울장애 선별 도구 | 디지털치료기기 관련 국내외 가이드라인은 <표 7>과 같다. "
      }
    },
    {
      "chunk_id": "chunk_224",
      "text": "| 가) Baseline 유효성 평가 | 데스벤라팍신(desvenlafaxine) | SNRI | 50-100 | 절차를 말한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 223,
        "window_size": 3,
        "char_count": 73,
        "word_count": 14,
        "page_number": 21,
        "window_text": "|\n| (6) 「의료기기법 시행규칙」 제24조 (임상시험 실시기준 등) | Psychiatry, 187(5), 456-461.  | 36항 건강수준 척도 | 마) 이상반응 확인 | 나) 이상 반응 확인 | 3 | 역학용 우울 척도(The Center for Epidemioloꠓ | 환경에서 이루어지는 통신도 고려한다.  | 송수신 | 나타내고 우울장애를 평가하고 선별하는 척도로써 신뢰도와 | gical Studies Depression Scale, CES-D) | 및 저장한 후, 해당 데이터를 다시 | 확인 자료 |\n| 7) 민감도분석 | 3 | IEC 62304 | Medical device software – | (Geriatric Depression | 우울장애 선별 도구 | 디지털치료기기 관련 국내외 가이드라인은 <표 7>과 같다.  | 가) Baseline 유효성 평가 | 데스벤라팍신(desvenlafaxine) | SNRI | 50-100 | 절차를 말한다.  | 기기의 회수체계를 확립하고 이를 문서화하여야 한다.  | 관찰형태 | 내원 | 내원과 | Off-The-Shelf(OTS) Software” | 허용하거나, 응급상황에서 접근을 허용하는 | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | * 피험자 식별코드: 실시기관 코드 - 등록된 순 | - 수행 가능성 최대화를 위해 과업으로 주는 활동을 수행하기 가장 | CES-D는 16점을 절단 점수로 사용한다.  | https://www.nifds.go.kr | 개발부터 유지보수를 | 내원과 | 소프트웨어 | □ 예(☞지침서) | ■ 아니오 | 내원 또는 앱, |\n| 통신 | 1) 부작용 | 무작위 확증 임상시험 | 있는 영역(Acceptable)’의 2단계로 구분할 수 있다. ",
        "original_sentence": "| 가) Baseline 유효성 평가 | 데스벤라팍신(desvenlafaxine) | SNRI | 50-100 | 절차를 말한다. "
      }
    },
    {
      "chunk_id": "chunk_225",
      "text": "| 기기의 회수체계를 확립하고 이를 문서화하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 224,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 13,
        "window_text": "| 36항 건강수준 척도 | 마) 이상반응 확인 | 나) 이상 반응 확인 | 3 | 역학용 우울 척도(The Center for Epidemioloꠓ | 환경에서 이루어지는 통신도 고려한다.  | 송수신 | 나타내고 우울장애를 평가하고 선별하는 척도로써 신뢰도와 | gical Studies Depression Scale, CES-D) | 및 저장한 후, 해당 데이터를 다시 | 확인 자료 |\n| 7) 민감도분석 | 3 | IEC 62304 | Medical device software – | (Geriatric Depression | 우울장애 선별 도구 | 디지털치료기기 관련 국내외 가이드라인은 <표 7>과 같다.  | 가) Baseline 유효성 평가 | 데스벤라팍신(desvenlafaxine) | SNRI | 50-100 | 절차를 말한다.  | 기기의 회수체계를 확립하고 이를 문서화하여야 한다.  | 관찰형태 | 내원 | 내원과 | Off-The-Shelf(OTS) Software” | 허용하거나, 응급상황에서 접근을 허용하는 | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | * 피험자 식별코드: 실시기관 코드 - 등록된 순 | - 수행 가능성 최대화를 위해 과업으로 주는 활동을 수행하기 가장 | CES-D는 16점을 절단 점수로 사용한다.  | https://www.nifds.go.kr | 개발부터 유지보수를 | 내원과 | 소프트웨어 | □ 예(☞지침서) | ■ 아니오 | 내원 또는 앱, |\n| 통신 | 1) 부작용 | 무작위 확증 임상시험 | 있는 영역(Acceptable)’의 2단계로 구분할 수 있다.  | 이블의 접근제한 등 | 할 것 | 구성되었고, 이는 신체적 건강 관련 삶의 질과 정신적 건강 | 웨어 형상을 유지한다. ",
        "original_sentence": "| 기기의 회수체계를 확립하고 이를 문서화하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_226",
      "text": "| 관찰형태 | 내원 | 내원과 | Off-The-Shelf(OTS) Software” | 허용하거나, 응급상황에서 접근을 허용하는 | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | * 피험자 식별코드: 실시기관 코드 - 등록된 순 | - 수행 가능성 최대화를 위해 과업으로 주는 활동을 수행하기 가장 | CES-D는 16점을 절단 점수로 사용한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 225,
        "window_size": 3,
        "char_count": 207,
        "word_count": 49,
        "page_number": 29,
        "window_text": "| 송수신 | 나타내고 우울장애를 평가하고 선별하는 척도로써 신뢰도와 | gical Studies Depression Scale, CES-D) | 및 저장한 후, 해당 데이터를 다시 | 확인 자료 |\n| 7) 민감도분석 | 3 | IEC 62304 | Medical device software – | (Geriatric Depression | 우울장애 선별 도구 | 디지털치료기기 관련 국내외 가이드라인은 <표 7>과 같다.  | 가) Baseline 유효성 평가 | 데스벤라팍신(desvenlafaxine) | SNRI | 50-100 | 절차를 말한다.  | 기기의 회수체계를 확립하고 이를 문서화하여야 한다.  | 관찰형태 | 내원 | 내원과 | Off-The-Shelf(OTS) Software” | 허용하거나, 응급상황에서 접근을 허용하는 | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | * 피험자 식별코드: 실시기관 코드 - 등록된 순 | - 수행 가능성 최대화를 위해 과업으로 주는 활동을 수행하기 가장 | CES-D는 16점을 절단 점수로 사용한다.  | https://www.nifds.go.kr | 개발부터 유지보수를 | 내원과 | 소프트웨어 | □ 예(☞지침서) | ■ 아니오 | 내원 또는 앱, |\n| 통신 | 1) 부작용 | 무작위 확증 임상시험 | 있는 영역(Acceptable)’의 2단계로 구분할 수 있다.  | 이블의 접근제한 등 | 할 것 | 구성되었고, 이는 신체적 건강 관련 삶의 질과 정신적 건강 | 웨어 형상을 유지한다.  |\n| behaviour therapy, 40(4), 251-266. ",
        "original_sentence": "| 관찰형태 | 내원 | 내원과 | Off-The-Shelf(OTS) Software” | 허용하거나, 응급상황에서 접근을 허용하는 | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | * 피험자 식별코드: 실시기관 코드 - 등록된 순 | - 수행 가능성 최대화를 위해 과업으로 주는 활동을 수행하기 가장 | CES-D는 16점을 절단 점수로 사용한다. "
      }
    },
    {
      "chunk_id": "chunk_227",
      "text": "| https://www.nifds.go.kr | 개발부터 유지보수를 | 내원과 | 소프트웨어 | □ 예(☞지침서) | ■ 아니오 | 내원 또는 앱, |\n| 통신 | 1) 부작용 | 무작위 확증 임상시험 | 있는 영역(Acceptable)’의 2단계로 구분할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 226,
        "window_size": 3,
        "char_count": 151,
        "word_count": 36,
        "page_number": 37,
        "window_text": "| 가) Baseline 유효성 평가 | 데스벤라팍신(desvenlafaxine) | SNRI | 50-100 | 절차를 말한다.  | 기기의 회수체계를 확립하고 이를 문서화하여야 한다.  | 관찰형태 | 내원 | 내원과 | Off-The-Shelf(OTS) Software” | 허용하거나, 응급상황에서 접근을 허용하는 | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | * 피험자 식별코드: 실시기관 코드 - 등록된 순 | - 수행 가능성 최대화를 위해 과업으로 주는 활동을 수행하기 가장 | CES-D는 16점을 절단 점수로 사용한다.  | https://www.nifds.go.kr | 개발부터 유지보수를 | 내원과 | 소프트웨어 | □ 예(☞지침서) | ■ 아니오 | 내원 또는 앱, |\n| 통신 | 1) 부작용 | 무작위 확증 임상시험 | 있는 영역(Acceptable)’의 2단계로 구분할 수 있다.  | 이블의 접근제한 등 | 할 것 | 구성되었고, 이는 신체적 건강 관련 삶의 질과 정신적 건강 | 웨어 형상을 유지한다.  |\n| behaviour therapy, 40(4), 251-266.  | ○ 관련성이 명백함(Definitely related) | 결정하고 주의사항을 준수하기로 서면 동의한 자 | 소프트 | 제조자는 비인가 접근/변경/반복을 방지하기 | 연구 군을 선별한다. ",
        "original_sentence": "| https://www.nifds.go.kr | 개발부터 유지보수를 | 내원과 | 소프트웨어 | □ 예(☞지침서) | ■ 아니오 | 내원 또는 앱, |\n| 통신 | 1) 부작용 | 무작위 확증 임상시험 | 있는 영역(Acceptable)’의 2단계로 구분할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_228",
      "text": "| 이블의 접근제한 등 | 할 것 | 구성되었고, 이는 신체적 건강 관련 삶의 질과 정신적 건강 | 웨어 형상을 유지한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 227,
        "window_size": 3,
        "char_count": 69,
        "word_count": 21,
        "page_number": 45,
        "window_text": "| 기기의 회수체계를 확립하고 이를 문서화하여야 한다.  | 관찰형태 | 내원 | 내원과 | Off-The-Shelf(OTS) Software” | 허용하거나, 응급상황에서 접근을 허용하는 | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | * 피험자 식별코드: 실시기관 코드 - 등록된 순 | - 수행 가능성 최대화를 위해 과업으로 주는 활동을 수행하기 가장 | CES-D는 16점을 절단 점수로 사용한다.  | https://www.nifds.go.kr | 개발부터 유지보수를 | 내원과 | 소프트웨어 | □ 예(☞지침서) | ■ 아니오 | 내원 또는 앱, |\n| 통신 | 1) 부작용 | 무작위 확증 임상시험 | 있는 영역(Acceptable)’의 2단계로 구분할 수 있다.  | 이블의 접근제한 등 | 할 것 | 구성되었고, 이는 신체적 건강 관련 삶의 질과 정신적 건강 | 웨어 형상을 유지한다.  |\n| behaviour therapy, 40(4), 251-266.  | ○ 관련성이 명백함(Definitely related) | 결정하고 주의사항을 준수하기로 서면 동의한 자 | 소프트 | 제조자는 비인가 접근/변경/반복을 방지하기 | 연구 군을 선별한다.  | task | Selfapy | 해당하지 않는다는 사실을 발견하게 되고 보다 합리적인 사고를 | 타당도가 입증되었다. ",
        "original_sentence": "| 이블의 접근제한 등 | 할 것 | 구성되었고, 이는 신체적 건강 관련 삶의 질과 정신적 건강 | 웨어 형상을 유지한다. "
      }
    },
    {
      "chunk_id": "chunk_229",
      "text": "|\n| behaviour therapy, 40(4), 251-266. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 228,
        "window_size": 3,
        "char_count": 39,
        "word_count": 6,
        "page_number": 9,
        "window_text": "| 관찰형태 | 내원 | 내원과 | Off-The-Shelf(OTS) Software” | 허용하거나, 응급상황에서 접근을 허용하는 | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | * 피험자 식별코드: 실시기관 코드 - 등록된 순 | - 수행 가능성 최대화를 위해 과업으로 주는 활동을 수행하기 가장 | CES-D는 16점을 절단 점수로 사용한다.  | https://www.nifds.go.kr | 개발부터 유지보수를 | 내원과 | 소프트웨어 | □ 예(☞지침서) | ■ 아니오 | 내원 또는 앱, |\n| 통신 | 1) 부작용 | 무작위 확증 임상시험 | 있는 영역(Acceptable)’의 2단계로 구분할 수 있다.  | 이블의 접근제한 등 | 할 것 | 구성되었고, 이는 신체적 건강 관련 삶의 질과 정신적 건강 | 웨어 형상을 유지한다.  |\n| behaviour therapy, 40(4), 251-266.  | ○ 관련성이 명백함(Definitely related) | 결정하고 주의사항을 준수하기로 서면 동의한 자 | 소프트 | 제조자는 비인가 접근/변경/반복을 방지하기 | 연구 군을 선별한다.  | task | Selfapy | 해당하지 않는다는 사실을 발견하게 되고 보다 합리적인 사고를 | 타당도가 입증되었다.  PHQ-9의 경우 기존 우울장애 평가 | ‘예, 아니요’의 단순 형식으로 응답하도록 구성되어 있어 | 웨어 항목 간 연계성을 위한 | 불러오기 한다. ",
        "original_sentence": "|\n| behaviour therapy, 40(4), 251-266. "
      }
    },
    {
      "chunk_id": "chunk_230",
      "text": "| ○ 관련성이 명백함(Definitely related) | 결정하고 주의사항을 준수하기로 서면 동의한 자 | 소프트 | 제조자는 비인가 접근/변경/반복을 방지하기 | 연구 군을 선별한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 229,
        "window_size": 3,
        "char_count": 107,
        "word_count": 23,
        "page_number": 3,
        "window_text": "| https://www.nifds.go.kr | 개발부터 유지보수를 | 내원과 | 소프트웨어 | □ 예(☞지침서) | ■ 아니오 | 내원 또는 앱, |\n| 통신 | 1) 부작용 | 무작위 확증 임상시험 | 있는 영역(Acceptable)’의 2단계로 구분할 수 있다.  | 이블의 접근제한 등 | 할 것 | 구성되었고, 이는 신체적 건강 관련 삶의 질과 정신적 건강 | 웨어 형상을 유지한다.  |\n| behaviour therapy, 40(4), 251-266.  | ○ 관련성이 명백함(Definitely related) | 결정하고 주의사항을 준수하기로 서면 동의한 자 | 소프트 | 제조자는 비인가 접근/변경/반복을 방지하기 | 연구 군을 선별한다.  | task | Selfapy | 해당하지 않는다는 사실을 발견하게 되고 보다 합리적인 사고를 | 타당도가 입증되었다.  PHQ-9의 경우 기존 우울장애 평가 | ‘예, 아니요’의 단순 형식으로 응답하도록 구성되어 있어 | 웨어 항목 간 연계성을 위한 | 불러오기 한다.  | 국외 |\n| (Short Form-36 Health | 4 | 6 | 여부, 적합성 입증방법, 첨부자료 또는 문서번호를 기재한다. ",
        "original_sentence": "| ○ 관련성이 명백함(Definitely related) | 결정하고 주의사항을 준수하기로 서면 동의한 자 | 소프트 | 제조자는 비인가 접근/변경/반복을 방지하기 | 연구 군을 선별한다. "
      }
    },
    {
      "chunk_id": "chunk_231",
      "text": "| task | Selfapy | 해당하지 않는다는 사실을 발견하게 되고 보다 합리적인 사고를 | 타당도가 입증되었다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 230,
        "window_size": 3,
        "char_count": 67,
        "word_count": 16,
        "page_number": 18,
        "window_text": "| 이블의 접근제한 등 | 할 것 | 구성되었고, 이는 신체적 건강 관련 삶의 질과 정신적 건강 | 웨어 형상을 유지한다.  |\n| behaviour therapy, 40(4), 251-266.  | ○ 관련성이 명백함(Definitely related) | 결정하고 주의사항을 준수하기로 서면 동의한 자 | 소프트 | 제조자는 비인가 접근/변경/반복을 방지하기 | 연구 군을 선별한다.  | task | Selfapy | 해당하지 않는다는 사실을 발견하게 되고 보다 합리적인 사고를 | 타당도가 입증되었다.  PHQ-9의 경우 기존 우울장애 평가 | ‘예, 아니요’의 단순 형식으로 응답하도록 구성되어 있어 | 웨어 항목 간 연계성을 위한 | 불러오기 한다.  | 국외 |\n| (Short Form-36 Health | 4 | 6 | 여부, 적합성 입증방법, 첨부자료 또는 문서번호를 기재한다.  | 듀록세틴(duloxetine) | SNRI | 60 | 정확한 피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 한다. ",
        "original_sentence": "| task | Selfapy | 해당하지 않는다는 사실을 발견하게 되고 보다 합리적인 사고를 | 타당도가 입증되었다. "
      }
    },
    {
      "chunk_id": "chunk_232",
      "text": "PHQ-9의 경우 기존 우울장애 평가 | ‘예, 아니요’의 단순 형식으로 응답하도록 구성되어 있어 | 웨어 항목 간 연계성을 위한 | 불러오기 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 231,
        "window_size": 3,
        "char_count": 84,
        "word_count": 22,
        "page_number": 29,
        "window_text": "|\n| behaviour therapy, 40(4), 251-266.  | ○ 관련성이 명백함(Definitely related) | 결정하고 주의사항을 준수하기로 서면 동의한 자 | 소프트 | 제조자는 비인가 접근/변경/반복을 방지하기 | 연구 군을 선별한다.  | task | Selfapy | 해당하지 않는다는 사실을 발견하게 되고 보다 합리적인 사고를 | 타당도가 입증되었다.  PHQ-9의 경우 기존 우울장애 평가 | ‘예, 아니요’의 단순 형식으로 응답하도록 구성되어 있어 | 웨어 항목 간 연계성을 위한 | 불러오기 한다.  | 국외 |\n| (Short Form-36 Health | 4 | 6 | 여부, 적합성 입증방법, 첨부자료 또는 문서번호를 기재한다.  | 듀록세틴(duloxetine) | SNRI | 60 | 정확한 피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 한다.  | 높은 등급이 된다. ",
        "original_sentence": "PHQ-9의 경우 기존 우울장애 평가 | ‘예, 아니요’의 단순 형식으로 응답하도록 구성되어 있어 | 웨어 항목 간 연계성을 위한 | 불러오기 한다. "
      }
    },
    {
      "chunk_id": "chunk_233",
      "text": "| 국외 |\n| (Short Form-36 Health | 4 | 6 | 여부, 적합성 입증방법, 첨부자료 또는 문서번호를 기재한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 232,
        "window_size": 3,
        "char_count": 75,
        "word_count": 19,
        "page_number": 3,
        "window_text": "| ○ 관련성이 명백함(Definitely related) | 결정하고 주의사항을 준수하기로 서면 동의한 자 | 소프트 | 제조자는 비인가 접근/변경/반복을 방지하기 | 연구 군을 선별한다.  | task | Selfapy | 해당하지 않는다는 사실을 발견하게 되고 보다 합리적인 사고를 | 타당도가 입증되었다.  PHQ-9의 경우 기존 우울장애 평가 | ‘예, 아니요’의 단순 형식으로 응답하도록 구성되어 있어 | 웨어 항목 간 연계성을 위한 | 불러오기 한다.  | 국외 |\n| (Short Form-36 Health | 4 | 6 | 여부, 적합성 입증방법, 첨부자료 또는 문서번호를 기재한다.  | 듀록세틴(duloxetine) | SNRI | 60 | 정확한 피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 한다.  | 높은 등급이 된다.  | 4 | 쯍 우울 척도(Zung’s Self-Rating Depression Scale, SDS) | 피험자 수 산출 공식은 아래와 같다. ",
        "original_sentence": "| 국외 |\n| (Short Form-36 Health | 4 | 6 | 여부, 적합성 입증방법, 첨부자료 또는 문서번호를 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_234",
      "text": "| 듀록세틴(duloxetine) | SNRI | 60 | 정확한 피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 233,
        "window_size": 3,
        "char_count": 71,
        "word_count": 16,
        "page_number": 21,
        "window_text": "| task | Selfapy | 해당하지 않는다는 사실을 발견하게 되고 보다 합리적인 사고를 | 타당도가 입증되었다.  PHQ-9의 경우 기존 우울장애 평가 | ‘예, 아니요’의 단순 형식으로 응답하도록 구성되어 있어 | 웨어 항목 간 연계성을 위한 | 불러오기 한다.  | 국외 |\n| (Short Form-36 Health | 4 | 6 | 여부, 적합성 입증방법, 첨부자료 또는 문서번호를 기재한다.  | 듀록세틴(duloxetine) | SNRI | 60 | 정확한 피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 한다.  | 높은 등급이 된다.  | 4 | 쯍 우울 척도(Zung’s Self-Rating Depression Scale, SDS) | 피험자 수 산출 공식은 아래와 같다.  | 기준이나 절차를 제시하는 것입니까? ",
        "original_sentence": "| 듀록세틴(duloxetine) | SNRI | 60 | 정확한 피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_235",
      "text": "| 높은 등급이 된다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 234,
        "window_size": 3,
        "char_count": 13,
        "word_count": 4,
        "page_number": 9,
        "window_text": "PHQ-9의 경우 기존 우울장애 평가 | ‘예, 아니요’의 단순 형식으로 응답하도록 구성되어 있어 | 웨어 항목 간 연계성을 위한 | 불러오기 한다.  | 국외 |\n| (Short Form-36 Health | 4 | 6 | 여부, 적합성 입증방법, 첨부자료 또는 문서번호를 기재한다.  | 듀록세틴(duloxetine) | SNRI | 60 | 정확한 피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 한다.  | 높은 등급이 된다.  | 4 | 쯍 우울 척도(Zung’s Self-Rating Depression Scale, SDS) | 피험자 수 산출 공식은 아래와 같다.  | 기준이나 절차를 제시하는 것입니까?  (공무원용) | 애플리케이션 | 애플리케이션 | 이메일, 문자, SNS |\n| (7) 「의료기기 허가·신고·심사 등에 관한 규정」 | 경우는 별도의 안전성과 성능 시험을 통과한 제품의 사용을 권고한다. ",
        "original_sentence": "| 높은 등급이 된다. "
      }
    },
    {
      "chunk_id": "chunk_236",
      "text": "| 4 | 쯍 우울 척도(Zung’s Self-Rating Depression Scale, SDS) | 피험자 수 산출 공식은 아래와 같다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 235,
        "window_size": 3,
        "char_count": 79,
        "word_count": 17,
        "page_number": 18,
        "window_text": "| 국외 |\n| (Short Form-36 Health | 4 | 6 | 여부, 적합성 입증방법, 첨부자료 또는 문서번호를 기재한다.  | 듀록세틴(duloxetine) | SNRI | 60 | 정확한 피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 한다.  | 높은 등급이 된다.  | 4 | 쯍 우울 척도(Zung’s Self-Rating Depression Scale, SDS) | 피험자 수 산출 공식은 아래와 같다.  | 기준이나 절차를 제시하는 것입니까?  (공무원용) | 애플리케이션 | 애플리케이션 | 이메일, 문자, SNS |\n| (7) 「의료기기 허가·신고·심사 등에 관한 규정」 | 경우는 별도의 안전성과 성능 시험을 통과한 제품의 사용을 권고한다.  | 버전이다. ",
        "original_sentence": "| 4 | 쯍 우울 척도(Zung’s Self-Rating Depression Scale, SDS) | 피험자 수 산출 공식은 아래와 같다. "
      }
    },
    {
      "chunk_id": "chunk_237",
      "text": "| 기준이나 절차를 제시하는 것입니까? ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 236,
        "window_size": 3,
        "char_count": 22,
        "word_count": 5,
        "page_number": 7,
        "window_text": "| 듀록세틴(duloxetine) | SNRI | 60 | 정확한 피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 한다.  | 높은 등급이 된다.  | 4 | 쯍 우울 척도(Zung’s Self-Rating Depression Scale, SDS) | 피험자 수 산출 공식은 아래와 같다.  | 기준이나 절차를 제시하는 것입니까?  (공무원용) | 애플리케이션 | 애플리케이션 | 이메일, 문자, SNS |\n| (7) 「의료기기 허가·신고·심사 등에 관한 규정」 | 경우는 별도의 안전성과 성능 시험을 통과한 제품의 사용을 권고한다.  | 버전이다.  | 웨어의 개발 및 유지를 위한 활동을 수행하여야 한다. ",
        "original_sentence": "| 기준이나 절차를 제시하는 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_238",
      "text": "(공무원용) | 애플리케이션 | 애플리케이션 | 이메일, 문자, SNS |\n| (7) 「의료기기 허가·신고·심사 등에 관한 규정」 | 경우는 별도의 안전성과 성능 시험을 통과한 제품의 사용을 권고한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 237,
        "window_size": 3,
        "char_count": 113,
        "word_count": 27,
        "page_number": 38,
        "window_text": "| 높은 등급이 된다.  | 4 | 쯍 우울 척도(Zung’s Self-Rating Depression Scale, SDS) | 피험자 수 산출 공식은 아래와 같다.  | 기준이나 절차를 제시하는 것입니까?  (공무원용) | 애플리케이션 | 애플리케이션 | 이메일, 문자, SNS |\n| (7) 「의료기기 허가·신고·심사 등에 관한 규정」 | 경우는 별도의 안전성과 성능 시험을 통과한 제품의 사용을 권고한다.  | 버전이다.  | 웨어의 개발 및 유지를 위한 활동을 수행하여야 한다.  | (Patient Health | Scale, GDS) | 사용자 접근통제에 대해 고려하여야 한다. ",
        "original_sentence": "(공무원용) | 애플리케이션 | 애플리케이션 | 이메일, 문자, SNS |\n| (7) 「의료기기 허가·신고·심사 등에 관한 규정」 | 경우는 별도의 안전성과 성능 시험을 통과한 제품의 사용을 권고한다. "
      }
    },
    {
      "chunk_id": "chunk_239",
      "text": "| 버전이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 238,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 10,
        "window_text": "| 4 | 쯍 우울 척도(Zung’s Self-Rating Depression Scale, SDS) | 피험자 수 산출 공식은 아래와 같다.  | 기준이나 절차를 제시하는 것입니까?  (공무원용) | 애플리케이션 | 애플리케이션 | 이메일, 문자, SNS |\n| (7) 「의료기기 허가·신고·심사 등에 관한 규정」 | 경우는 별도의 안전성과 성능 시험을 통과한 제품의 사용을 권고한다.  | 버전이다.  | 웨어의 개발 및 유지를 위한 활동을 수행하여야 한다.  | (Patient Health | Scale, GDS) | 사용자 접근통제에 대해 고려하여야 한다.  | Guidance for the Content of | 쉬운 활동부터 점차 어려운 활동으로 옮겨가는 방법이 있다. ",
        "original_sentence": "| 버전이다. "
      }
    },
    {
      "chunk_id": "chunk_240",
      "text": "| 웨어의 개발 및 유지를 위한 활동을 수행하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 239,
        "window_size": 3,
        "char_count": 32,
        "word_count": 9,
        "page_number": 13,
        "window_text": "| 기준이나 절차를 제시하는 것입니까?  (공무원용) | 애플리케이션 | 애플리케이션 | 이메일, 문자, SNS |\n| (7) 「의료기기 허가·신고·심사 등에 관한 규정」 | 경우는 별도의 안전성과 성능 시험을 통과한 제품의 사용을 권고한다.  | 버전이다.  | 웨어의 개발 및 유지를 위한 활동을 수행하여야 한다.  | (Patient Health | Scale, GDS) | 사용자 접근통제에 대해 고려하여야 한다.  | Guidance for the Content of | 쉬운 활동부터 점차 어려운 활동으로 옮겨가는 방법이 있다.  | Software life cycle processes | 포함하여 전주기에 대한 | 검증 및 |\n| 마) 외래 방문마다 유효성 평가 | 또는 일시 중지시킬 수 있다. ",
        "original_sentence": "| 웨어의 개발 및 유지를 위한 활동을 수행하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_241",
      "text": "| (Patient Health | Scale, GDS) | 사용자 접근통제에 대해 고려하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 240,
        "window_size": 3,
        "char_count": 57,
        "word_count": 12,
        "page_number": 12,
        "window_text": "(공무원용) | 애플리케이션 | 애플리케이션 | 이메일, 문자, SNS |\n| (7) 「의료기기 허가·신고·심사 등에 관한 규정」 | 경우는 별도의 안전성과 성능 시험을 통과한 제품의 사용을 권고한다.  | 버전이다.  | 웨어의 개발 및 유지를 위한 활동을 수행하여야 한다.  | (Patient Health | Scale, GDS) | 사용자 접근통제에 대해 고려하여야 한다.  | Guidance for the Content of | 쉬운 활동부터 점차 어려운 활동으로 옮겨가는 방법이 있다.  | Software life cycle processes | 포함하여 전주기에 대한 | 검증 및 |\n| 마) 외래 방문마다 유효성 평가 | 또는 일시 중지시킬 수 있다.  | 근거를 가진 자살 위험성 평가상 자살 고위험군으로 평가되는 자 | 관련 삶의 질로 구성. ",
        "original_sentence": "| (Patient Health | Scale, GDS) | 사용자 접근통제에 대해 고려하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_242",
      "text": "| Guidance for the Content of | 쉬운 활동부터 점차 어려운 활동으로 옮겨가는 방법이 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 241,
        "window_size": 3,
        "char_count": 65,
        "word_count": 15,
        "page_number": 7,
        "window_text": "| 버전이다.  | 웨어의 개발 및 유지를 위한 활동을 수행하여야 한다.  | (Patient Health | Scale, GDS) | 사용자 접근통제에 대해 고려하여야 한다.  | Guidance for the Content of | 쉬운 활동부터 점차 어려운 활동으로 옮겨가는 방법이 있다.  | Software life cycle processes | 포함하여 전주기에 대한 | 검증 및 |\n| 마) 외래 방문마다 유효성 평가 | 또는 일시 중지시킬 수 있다.  | 근거를 가진 자살 위험성 평가상 자살 고위험군으로 평가되는 자 | 관련 삶의 질로 구성.  점수 산정은 각각의 8개 하위 척도에 | 아키텍처를 개발한다. ",
        "original_sentence": "| Guidance for the Content of | 쉬운 활동부터 점차 어려운 활동으로 옮겨가는 방법이 있다. "
      }
    },
    {
      "chunk_id": "chunk_243",
      "text": "| Software life cycle processes | 포함하여 전주기에 대한 | 검증 및 |\n| 마) 외래 방문마다 유효성 평가 | 또는 일시 중지시킬 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 242,
        "window_size": 3,
        "char_count": 95,
        "word_count": 25,
        "page_number": 18,
        "window_text": "| 웨어의 개발 및 유지를 위한 활동을 수행하여야 한다.  | (Patient Health | Scale, GDS) | 사용자 접근통제에 대해 고려하여야 한다.  | Guidance for the Content of | 쉬운 활동부터 점차 어려운 활동으로 옮겨가는 방법이 있다.  | Software life cycle processes | 포함하여 전주기에 대한 | 검증 및 |\n| 마) 외래 방문마다 유효성 평가 | 또는 일시 중지시킬 수 있다.  | 근거를 가진 자살 위험성 평가상 자살 고위험군으로 평가되는 자 | 관련 삶의 질로 구성.  점수 산정은 각각의 8개 하위 척도에 | 아키텍처를 개발한다.  | 으로 식별한다. ",
        "original_sentence": "| Software life cycle processes | 포함하여 전주기에 대한 | 검증 및 |\n| 마) 외래 방문마다 유효성 평가 | 또는 일시 중지시킬 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_244",
      "text": "| 근거를 가진 자살 위험성 평가상 자살 고위험군으로 평가되는 자 | 관련 삶의 질로 구성. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 243,
        "window_size": 3,
        "char_count": 52,
        "word_count": 15,
        "page_number": 41,
        "window_text": "| (Patient Health | Scale, GDS) | 사용자 접근통제에 대해 고려하여야 한다.  | Guidance for the Content of | 쉬운 활동부터 점차 어려운 활동으로 옮겨가는 방법이 있다.  | Software life cycle processes | 포함하여 전주기에 대한 | 검증 및 |\n| 마) 외래 방문마다 유효성 평가 | 또는 일시 중지시킬 수 있다.  | 근거를 가진 자살 위험성 평가상 자살 고위험군으로 평가되는 자 | 관련 삶의 질로 구성.  점수 산정은 각각의 8개 하위 척도에 | 아키텍처를 개발한다.  | 으로 식별한다.  |\n| 1) 목표 대상자 수 산정의 추정 공식 예시 | 우울(20~28점), 심각한 우울(29~63점)을 나타낸다. ",
        "original_sentence": "| 근거를 가진 자살 위험성 평가상 자살 고위험군으로 평가되는 자 | 관련 삶의 질로 구성. "
      }
    },
    {
      "chunk_id": "chunk_245",
      "text": "점수 산정은 각각의 8개 하위 척도에 | 아키텍처를 개발한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 244,
        "window_size": 3,
        "char_count": 35,
        "word_count": 9,
        "page_number": 13,
        "window_text": "| Guidance for the Content of | 쉬운 활동부터 점차 어려운 활동으로 옮겨가는 방법이 있다.  | Software life cycle processes | 포함하여 전주기에 대한 | 검증 및 |\n| 마) 외래 방문마다 유효성 평가 | 또는 일시 중지시킬 수 있다.  | 근거를 가진 자살 위험성 평가상 자살 고위험군으로 평가되는 자 | 관련 삶의 질로 구성.  점수 산정은 각각의 8개 하위 척도에 | 아키텍처를 개발한다.  | 으로 식별한다.  |\n| 1) 목표 대상자 수 산정의 추정 공식 예시 | 우울(20~28점), 심각한 우울(29~63점)을 나타낸다.  | 에스시탈로프람(escitalopram) | SSRI | 10-20 | 결과가 검증되어야 한다. ",
        "original_sentence": "점수 산정은 각각의 8개 하위 척도에 | 아키텍처를 개발한다. "
      }
    },
    {
      "chunk_id": "chunk_246",
      "text": "| 으로 식별한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 245,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 13,
        "window_text": "| Software life cycle processes | 포함하여 전주기에 대한 | 검증 및 |\n| 마) 외래 방문마다 유효성 평가 | 또는 일시 중지시킬 수 있다.  | 근거를 가진 자살 위험성 평가상 자살 고위험군으로 평가되는 자 | 관련 삶의 질로 구성.  점수 산정은 각각의 8개 하위 척도에 | 아키텍처를 개발한다.  | 으로 식별한다.  |\n| 1) 목표 대상자 수 산정의 추정 공식 예시 | 우울(20~28점), 심각한 우울(29~63점)을 나타낸다.  | 에스시탈로프람(escitalopram) | SSRI | 10-20 | 결과가 검증되어야 한다.  | 한다. ",
        "original_sentence": "| 으로 식별한다. "
      }
    },
    {
      "chunk_id": "chunk_247",
      "text": "|\n| 1) 목표 대상자 수 산정의 추정 공식 예시 | 우울(20~28점), 심각한 우울(29~63점)을 나타낸다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 246,
        "window_size": 3,
        "char_count": 65,
        "word_count": 15,
        "page_number": 7,
        "window_text": "| 근거를 가진 자살 위험성 평가상 자살 고위험군으로 평가되는 자 | 관련 삶의 질로 구성.  점수 산정은 각각의 8개 하위 척도에 | 아키텍처를 개발한다.  | 으로 식별한다.  |\n| 1) 목표 대상자 수 산정의 추정 공식 예시 | 우울(20~28점), 심각한 우울(29~63점)을 나타낸다.  | 에스시탈로프람(escitalopram) | SSRI | 10-20 | 결과가 검증되어야 한다.  | 한다.  | 서명이 이러한 자료의 열람을 허용하게 된다는 사실 | 웨어 | 위한 의료기기의 보안이 보장된(secured) | 평가한다. ",
        "original_sentence": "|\n| 1) 목표 대상자 수 산정의 추정 공식 예시 | 우울(20~28점), 심각한 우울(29~63점)을 나타낸다. "
      }
    },
    {
      "chunk_id": "chunk_248",
      "text": "| 에스시탈로프람(escitalopram) | SSRI | 10-20 | 결과가 검증되어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 247,
        "window_size": 3,
        "char_count": 55,
        "word_count": 10,
        "page_number": 9,
        "window_text": "점수 산정은 각각의 8개 하위 척도에 | 아키텍처를 개발한다.  | 으로 식별한다.  |\n| 1) 목표 대상자 수 산정의 추정 공식 예시 | 우울(20~28점), 심각한 우울(29~63점)을 나타낸다.  | 에스시탈로프람(escitalopram) | SSRI | 10-20 | 결과가 검증되어야 한다.  | 한다.  | 서명이 이러한 자료의 열람을 허용하게 된다는 사실 | 웨어 | 위한 의료기기의 보안이 보장된(secured) | 평가한다.  | assign | 특성에 대한 정보들을 수집한다. ",
        "original_sentence": "| 에스시탈로프람(escitalopram) | SSRI | 10-20 | 결과가 검증되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_249",
      "text": "| 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 248,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 13,
        "window_text": "| 으로 식별한다.  |\n| 1) 목표 대상자 수 산정의 추정 공식 예시 | 우울(20~28점), 심각한 우울(29~63점)을 나타낸다.  | 에스시탈로프람(escitalopram) | SSRI | 10-20 | 결과가 검증되어야 한다.  | 한다.  | 서명이 이러한 자료의 열람을 허용하게 된다는 사실 | 웨어 | 위한 의료기기의 보안이 보장된(secured) | 평가한다.  | assign | 특성에 대한 정보들을 수집한다.  | 반응이 사라지는 경우 | 표 7. ",
        "original_sentence": "| 한다. "
      }
    },
    {
      "chunk_id": "chunk_250",
      "text": "| 서명이 이러한 자료의 열람을 허용하게 된다는 사실 | 웨어 | 위한 의료기기의 보안이 보장된(secured) | 평가한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 249,
        "window_size": 3,
        "char_count": 71,
        "word_count": 17,
        "page_number": 19,
        "window_text": "|\n| 1) 목표 대상자 수 산정의 추정 공식 예시 | 우울(20~28점), 심각한 우울(29~63점)을 나타낸다.  | 에스시탈로프람(escitalopram) | SSRI | 10-20 | 결과가 검증되어야 한다.  | 한다.  | 서명이 이러한 자료의 열람을 허용하게 된다는 사실 | 웨어 | 위한 의료기기의 보안이 보장된(secured) | 평가한다.  | assign | 특성에 대한 정보들을 수집한다.  | 반응이 사라지는 경우 | 표 7.  디지털치료기기 관련 국내외 가이드라인 | 할 수 있게 된다. ",
        "original_sentence": "| 서명이 이러한 자료의 열람을 허용하게 된다는 사실 | 웨어 | 위한 의료기기의 보안이 보장된(secured) | 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_251",
      "text": "| assign | 특성에 대한 정보들을 수집한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 250,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 13,
        "window_text": "| 에스시탈로프람(escitalopram) | SSRI | 10-20 | 결과가 검증되어야 한다.  | 한다.  | 서명이 이러한 자료의 열람을 허용하게 된다는 사실 | 웨어 | 위한 의료기기의 보안이 보장된(secured) | 평가한다.  | assign | 특성에 대한 정보들을 수집한다.  | 반응이 사라지는 경우 | 표 7.  디지털치료기기 관련 국내외 가이드라인 | 할 수 있게 된다.  | 도구보다 문항 수가 적고 작성 시간이 적게 걸려 일차 진료 | 노인에게 시행하기에 적합하다. ",
        "original_sentence": "| assign | 특성에 대한 정보들을 수집한다. "
      }
    },
    {
      "chunk_id": "chunk_252",
      "text": "| 반응이 사라지는 경우 | 표 7. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 251,
        "window_size": 3,
        "char_count": 21,
        "word_count": 7,
        "page_number": 38,
        "window_text": "| 한다.  | 서명이 이러한 자료의 열람을 허용하게 된다는 사실 | 웨어 | 위한 의료기기의 보안이 보장된(secured) | 평가한다.  | assign | 특성에 대한 정보들을 수집한다.  | 반응이 사라지는 경우 | 표 7.  디지털치료기기 관련 국내외 가이드라인 | 할 수 있게 된다.  | 도구보다 문항 수가 적고 작성 시간이 적게 걸려 일차 진료 | 노인에게 시행하기에 적합하다.  | 적용 |\n| 1) 대상 질환 : [F32] Depressive episode - 우울에피소드 | 치료 전 대비 8주 후 우울장애 심각도 척도(BDI) 변화량 | Survey, SF-36 ) | 받게 될 각종 검사나 절차 | 5 | 한국인 우울 척도(Korean Depression Scale, KDS) | 제조자는 의료기기가 필수 성능을 유지하기 | 중 작은 수치에 해당하는 0.65로 정하고자 한다. ",
        "original_sentence": "| 반응이 사라지는 경우 | 표 7. "
      }
    },
    {
      "chunk_id": "chunk_253",
      "text": "디지털치료기기 관련 국내외 가이드라인 | 할 수 있게 된다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 252,
        "window_size": 3,
        "char_count": 34,
        "word_count": 9,
        "page_number": 19,
        "window_text": "| 서명이 이러한 자료의 열람을 허용하게 된다는 사실 | 웨어 | 위한 의료기기의 보안이 보장된(secured) | 평가한다.  | assign | 특성에 대한 정보들을 수집한다.  | 반응이 사라지는 경우 | 표 7.  디지털치료기기 관련 국내외 가이드라인 | 할 수 있게 된다.  | 도구보다 문항 수가 적고 작성 시간이 적게 걸려 일차 진료 | 노인에게 시행하기에 적합하다.  | 적용 |\n| 1) 대상 질환 : [F32] Depressive episode - 우울에피소드 | 치료 전 대비 8주 후 우울장애 심각도 척도(BDI) 변화량 | Survey, SF-36 ) | 받게 될 각종 검사나 절차 | 5 | 한국인 우울 척도(Korean Depression Scale, KDS) | 제조자는 의료기기가 필수 성능을 유지하기 | 중 작은 수치에 해당하는 0.65로 정하고자 한다.  | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 표 11. ",
        "original_sentence": "디지털치료기기 관련 국내외 가이드라인 | 할 수 있게 된다. "
      }
    },
    {
      "chunk_id": "chunk_254",
      "text": "| 도구보다 문항 수가 적고 작성 시간이 적게 걸려 일차 진료 | 노인에게 시행하기에 적합하다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 253,
        "window_size": 3,
        "char_count": 54,
        "word_count": 15,
        "page_number": 7,
        "window_text": "| assign | 특성에 대한 정보들을 수집한다.  | 반응이 사라지는 경우 | 표 7.  디지털치료기기 관련 국내외 가이드라인 | 할 수 있게 된다.  | 도구보다 문항 수가 적고 작성 시간이 적게 걸려 일차 진료 | 노인에게 시행하기에 적합하다.  | 적용 |\n| 1) 대상 질환 : [F32] Depressive episode - 우울에피소드 | 치료 전 대비 8주 후 우울장애 심각도 척도(BDI) 변화량 | Survey, SF-36 ) | 받게 될 각종 검사나 절차 | 5 | 한국인 우울 척도(Korean Depression Scale, KDS) | 제조자는 의료기기가 필수 성능을 유지하기 | 중 작은 수치에 해당하는 0.65로 정하고자 한다.  | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 표 11.  위험평가 예시 | 소프트웨어 |\n| 인증 | 고려하여 적절한 기준을 설정함 | 추가로 동일한 자격증명은 기기와 고객들에게 | Premarket Submissions for | 이용하여 발행된 난수표를 적용한다. ",
        "original_sentence": "| 도구보다 문항 수가 적고 작성 시간이 적게 걸려 일차 진료 | 노인에게 시행하기에 적합하다. "
      }
    },
    {
      "chunk_id": "chunk_255",
      "text": "| 적용 |\n| 1) 대상 질환 : [F32] Depressive episode - 우울에피소드 | 치료 전 대비 8주 후 우울장애 심각도 척도(BDI) 변화량 | Survey, SF-36 ) | 받게 될 각종 검사나 절차 | 5 | 한국인 우울 척도(Korean Depression Scale, KDS) | 제조자는 의료기기가 필수 성능을 유지하기 | 중 작은 수치에 해당하는 0.65로 정하고자 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 254,
        "window_size": 3,
        "char_count": 227,
        "word_count": 56,
        "page_number": 9,
        "window_text": "| 반응이 사라지는 경우 | 표 7.  디지털치료기기 관련 국내외 가이드라인 | 할 수 있게 된다.  | 도구보다 문항 수가 적고 작성 시간이 적게 걸려 일차 진료 | 노인에게 시행하기에 적합하다.  | 적용 |\n| 1) 대상 질환 : [F32] Depressive episode - 우울에피소드 | 치료 전 대비 8주 후 우울장애 심각도 척도(BDI) 변화량 | Survey, SF-36 ) | 받게 될 각종 검사나 절차 | 5 | 한국인 우울 척도(Korean Depression Scale, KDS) | 제조자는 의료기기가 필수 성능을 유지하기 | 중 작은 수치에 해당하는 0.65로 정하고자 한다.  | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 표 11.  위험평가 예시 | 소프트웨어 |\n| 인증 | 고려하여 적절한 기준을 설정함 | 추가로 동일한 자격증명은 기기와 고객들에게 | Premarket Submissions for | 이용하여 발행된 난수표를 적용한다.  | 이를 위해 때때로 과업이 세분화되고 단순화될 필요가 있다. ",
        "original_sentence": "| 적용 |\n| 1) 대상 질환 : [F32] Depressive episode - 우울에피소드 | 치료 전 대비 8주 후 우울장애 심각도 척도(BDI) 변화량 | Survey, SF-36 ) | 받게 될 각종 검사나 절차 | 5 | 한국인 우울 척도(Korean Depression Scale, KDS) | 제조자는 의료기기가 필수 성능을 유지하기 | 중 작은 수치에 해당하는 0.65로 정하고자 한다. "
      }
    },
    {
      "chunk_id": "chunk_256",
      "text": "| □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 표 11. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 255,
        "window_size": 3,
        "char_count": 44,
        "word_count": 13,
        "page_number": 3,
        "window_text": "디지털치료기기 관련 국내외 가이드라인 | 할 수 있게 된다.  | 도구보다 문항 수가 적고 작성 시간이 적게 걸려 일차 진료 | 노인에게 시행하기에 적합하다.  | 적용 |\n| 1) 대상 질환 : [F32] Depressive episode - 우울에피소드 | 치료 전 대비 8주 후 우울장애 심각도 척도(BDI) 변화량 | Survey, SF-36 ) | 받게 될 각종 검사나 절차 | 5 | 한국인 우울 척도(Korean Depression Scale, KDS) | 제조자는 의료기기가 필수 성능을 유지하기 | 중 작은 수치에 해당하는 0.65로 정하고자 한다.  | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 표 11.  위험평가 예시 | 소프트웨어 |\n| 인증 | 고려하여 적절한 기준을 설정함 | 추가로 동일한 자격증명은 기기와 고객들에게 | Premarket Submissions for | 이용하여 발행된 난수표를 적용한다.  | 이를 위해 때때로 과업이 세분화되고 단순화될 필요가 있다.  | 다른 디바이스에서 같은 휴대폰 | SDS는 긍정 문항 10개, 부정 문항 10개 총 20개의 문항에 | 소프트웨어를 | 포함하는 | 의료기기에 | 국제 규격 | 유효성 | (AB-1234) |\n| (8) 「의료기기 임상시험계획 승인에 관한 규정」 | e0228100. ",
        "original_sentence": "| □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 표 11. "
      }
    },
    {
      "chunk_id": "chunk_257",
      "text": "위험평가 예시 | 소프트웨어 |\n| 인증 | 고려하여 적절한 기준을 설정함 | 추가로 동일한 자격증명은 기기와 고객들에게 | Premarket Submissions for | 이용하여 발행된 난수표를 적용한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 256,
        "window_size": 3,
        "char_count": 118,
        "word_count": 27,
        "page_number": 9,
        "window_text": "| 도구보다 문항 수가 적고 작성 시간이 적게 걸려 일차 진료 | 노인에게 시행하기에 적합하다.  | 적용 |\n| 1) 대상 질환 : [F32] Depressive episode - 우울에피소드 | 치료 전 대비 8주 후 우울장애 심각도 척도(BDI) 변화량 | Survey, SF-36 ) | 받게 될 각종 검사나 절차 | 5 | 한국인 우울 척도(Korean Depression Scale, KDS) | 제조자는 의료기기가 필수 성능을 유지하기 | 중 작은 수치에 해당하는 0.65로 정하고자 한다.  | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 표 11.  위험평가 예시 | 소프트웨어 |\n| 인증 | 고려하여 적절한 기준을 설정함 | 추가로 동일한 자격증명은 기기와 고객들에게 | Premarket Submissions for | 이용하여 발행된 난수표를 적용한다.  | 이를 위해 때때로 과업이 세분화되고 단순화될 필요가 있다.  | 다른 디바이스에서 같은 휴대폰 | SDS는 긍정 문항 10개, 부정 문항 10개 총 20개의 문항에 | 소프트웨어를 | 포함하는 | 의료기기에 | 국제 규격 | 유효성 | (AB-1234) |\n| (8) 「의료기기 임상시험계획 승인에 관한 규정」 | e0228100.  | 우울(15~19점), 심각도 우울(20점 이상)을 나타낸다. ",
        "original_sentence": "위험평가 예시 | 소프트웨어 |\n| 인증 | 고려하여 적절한 기준을 설정함 | 추가로 동일한 자격증명은 기기와 고객들에게 | Premarket Submissions for | 이용하여 발행된 난수표를 적용한다. "
      }
    },
    {
      "chunk_id": "chunk_258",
      "text": "| 이를 위해 때때로 과업이 세분화되고 단순화될 필요가 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 257,
        "window_size": 3,
        "char_count": 35,
        "word_count": 9,
        "page_number": 11,
        "window_text": "| 적용 |\n| 1) 대상 질환 : [F32] Depressive episode - 우울에피소드 | 치료 전 대비 8주 후 우울장애 심각도 척도(BDI) 변화량 | Survey, SF-36 ) | 받게 될 각종 검사나 절차 | 5 | 한국인 우울 척도(Korean Depression Scale, KDS) | 제조자는 의료기기가 필수 성능을 유지하기 | 중 작은 수치에 해당하는 0.65로 정하고자 한다.  | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 표 11.  위험평가 예시 | 소프트웨어 |\n| 인증 | 고려하여 적절한 기준을 설정함 | 추가로 동일한 자격증명은 기기와 고객들에게 | Premarket Submissions for | 이용하여 발행된 난수표를 적용한다.  | 이를 위해 때때로 과업이 세분화되고 단순화될 필요가 있다.  | 다른 디바이스에서 같은 휴대폰 | SDS는 긍정 문항 10개, 부정 문항 10개 총 20개의 문항에 | 소프트웨어를 | 포함하는 | 의료기기에 | 국제 규격 | 유효성 | (AB-1234) |\n| (8) 「의료기기 임상시험계획 승인에 관한 규정」 | e0228100.  | 우울(15~19점), 심각도 우울(20점 이상)을 나타낸다.  | 나) 피험자 동의 및 준비 | 플루옥세틴(fluoxetine) | SSRI | 20-60 | 구분 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | (출처 : 일차 의료용 근거 기반 우울장애 임상진료지침(대한의학회, 2022)) | 속하는 세부 항목들을 점수화 한 뒤 합산하여 0점부터 | 추가 12개월 동안 참가자에게 제공한다. ",
        "original_sentence": "| 이를 위해 때때로 과업이 세분화되고 단순화될 필요가 있다. "
      }
    },
    {
      "chunk_id": "chunk_259",
      "text": "| 다른 디바이스에서 같은 휴대폰 | SDS는 긍정 문항 10개, 부정 문항 10개 총 20개의 문항에 | 소프트웨어를 | 포함하는 | 의료기기에 | 국제 규격 | 유효성 | (AB-1234) |\n| (8) 「의료기기 임상시험계획 승인에 관한 규정」 | e0228100. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 258,
        "window_size": 3,
        "char_count": 152,
        "word_count": 39,
        "page_number": 9,
        "window_text": "| □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 표 11.  위험평가 예시 | 소프트웨어 |\n| 인증 | 고려하여 적절한 기준을 설정함 | 추가로 동일한 자격증명은 기기와 고객들에게 | Premarket Submissions for | 이용하여 발행된 난수표를 적용한다.  | 이를 위해 때때로 과업이 세분화되고 단순화될 필요가 있다.  | 다른 디바이스에서 같은 휴대폰 | SDS는 긍정 문항 10개, 부정 문항 10개 총 20개의 문항에 | 소프트웨어를 | 포함하는 | 의료기기에 | 국제 규격 | 유효성 | (AB-1234) |\n| (8) 「의료기기 임상시험계획 승인에 관한 규정」 | e0228100.  | 우울(15~19점), 심각도 우울(20점 이상)을 나타낸다.  | 나) 피험자 동의 및 준비 | 플루옥세틴(fluoxetine) | SSRI | 20-60 | 구분 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | (출처 : 일차 의료용 근거 기반 우울장애 임상진료지침(대한의학회, 2022)) | 속하는 세부 항목들을 점수화 한 뒤 합산하여 0점부터 | 추가 12개월 동안 참가자에게 제공한다.  | ■ 예(☞안내서) | □ 아니오 |\n| 선정/제외기준 확인 | O | O | - | - | 8 | 회사명 | 대표이사 | 소재지 | 전화 | 유지 | 데이터 송·수신 방법을 고려하여야 한다. ",
        "original_sentence": "| 다른 디바이스에서 같은 휴대폰 | SDS는 긍정 문항 10개, 부정 문항 10개 총 20개의 문항에 | 소프트웨어를 | 포함하는 | 의료기기에 | 국제 규격 | 유효성 | (AB-1234) |\n| (8) 「의료기기 임상시험계획 승인에 관한 규정」 | e0228100. "
      }
    },
    {
      "chunk_id": "chunk_260",
      "text": "| 우울(15~19점), 심각도 우울(20점 이상)을 나타낸다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 259,
        "window_size": 3,
        "char_count": 36,
        "word_count": 6,
        "page_number": 9,
        "window_text": "위험평가 예시 | 소프트웨어 |\n| 인증 | 고려하여 적절한 기준을 설정함 | 추가로 동일한 자격증명은 기기와 고객들에게 | Premarket Submissions for | 이용하여 발행된 난수표를 적용한다.  | 이를 위해 때때로 과업이 세분화되고 단순화될 필요가 있다.  | 다른 디바이스에서 같은 휴대폰 | SDS는 긍정 문항 10개, 부정 문항 10개 총 20개의 문항에 | 소프트웨어를 | 포함하는 | 의료기기에 | 국제 규격 | 유효성 | (AB-1234) |\n| (8) 「의료기기 임상시험계획 승인에 관한 규정」 | e0228100.  | 우울(15~19점), 심각도 우울(20점 이상)을 나타낸다.  | 나) 피험자 동의 및 준비 | 플루옥세틴(fluoxetine) | SSRI | 20-60 | 구분 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | (출처 : 일차 의료용 근거 기반 우울장애 임상진료지침(대한의학회, 2022)) | 속하는 세부 항목들을 점수화 한 뒤 합산하여 0점부터 | 추가 12개월 동안 참가자에게 제공한다.  | ■ 예(☞안내서) | □ 아니오 |\n| 선정/제외기준 확인 | O | O | - | - | 8 | 회사명 | 대표이사 | 소재지 | 전화 | 유지 | 데이터 송·수신 방법을 고려하여야 한다.  | ments) | 변화량 | 가능하다. ",
        "original_sentence": "| 우울(15~19점), 심각도 우울(20점 이상)을 나타낸다. "
      }
    },
    {
      "chunk_id": "chunk_261",
      "text": "| 나) 피험자 동의 및 준비 | 플루옥세틴(fluoxetine) | SSRI | 20-60 | 구분 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | (출처 : 일차 의료용 근거 기반 우울장애 임상진료지침(대한의학회, 2022)) | 속하는 세부 항목들을 점수화 한 뒤 합산하여 0점부터 | 추가 12개월 동안 참가자에게 제공한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 260,
        "window_size": 3,
        "char_count": 189,
        "word_count": 49,
        "page_number": 9,
        "window_text": "| 이를 위해 때때로 과업이 세분화되고 단순화될 필요가 있다.  | 다른 디바이스에서 같은 휴대폰 | SDS는 긍정 문항 10개, 부정 문항 10개 총 20개의 문항에 | 소프트웨어를 | 포함하는 | 의료기기에 | 국제 규격 | 유효성 | (AB-1234) |\n| (8) 「의료기기 임상시험계획 승인에 관한 규정」 | e0228100.  | 우울(15~19점), 심각도 우울(20점 이상)을 나타낸다.  | 나) 피험자 동의 및 준비 | 플루옥세틴(fluoxetine) | SSRI | 20-60 | 구분 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | (출처 : 일차 의료용 근거 기반 우울장애 임상진료지침(대한의학회, 2022)) | 속하는 세부 항목들을 점수화 한 뒤 합산하여 0점부터 | 추가 12개월 동안 참가자에게 제공한다.  | ■ 예(☞안내서) | □ 아니오 |\n| 선정/제외기준 확인 | O | O | - | - | 8 | 회사명 | 대표이사 | 소재지 | 전화 | 유지 | 데이터 송·수신 방법을 고려하여야 한다.  | ments) | 변화량 | 가능하다.  | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까? ",
        "original_sentence": "| 나) 피험자 동의 및 준비 | 플루옥세틴(fluoxetine) | SSRI | 20-60 | 구분 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | (출처 : 일차 의료용 근거 기반 우울장애 임상진료지침(대한의학회, 2022)) | 속하는 세부 항목들을 점수화 한 뒤 합산하여 0점부터 | 추가 12개월 동안 참가자에게 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_262",
      "text": "| ■ 예(☞안내서) | □ 아니오 |\n| 선정/제외기준 확인 | O | O | - | - | 8 | 회사명 | 대표이사 | 소재지 | 전화 | 유지 | 데이터 송·수신 방법을 고려하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 261,
        "window_size": 3,
        "char_count": 109,
        "word_count": 36,
        "page_number": 3,
        "window_text": "| 다른 디바이스에서 같은 휴대폰 | SDS는 긍정 문항 10개, 부정 문항 10개 총 20개의 문항에 | 소프트웨어를 | 포함하는 | 의료기기에 | 국제 규격 | 유효성 | (AB-1234) |\n| (8) 「의료기기 임상시험계획 승인에 관한 규정」 | e0228100.  | 우울(15~19점), 심각도 우울(20점 이상)을 나타낸다.  | 나) 피험자 동의 및 준비 | 플루옥세틴(fluoxetine) | SSRI | 20-60 | 구분 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | (출처 : 일차 의료용 근거 기반 우울장애 임상진료지침(대한의학회, 2022)) | 속하는 세부 항목들을 점수화 한 뒤 합산하여 0점부터 | 추가 12개월 동안 참가자에게 제공한다.  | ■ 예(☞안내서) | □ 아니오 |\n| 선정/제외기준 확인 | O | O | - | - | 8 | 회사명 | 대표이사 | 소재지 | 전화 | 유지 | 데이터 송·수신 방법을 고려하여야 한다.  | ments) | 변화량 | 가능하다.  | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까?  (민원인용) | 과정에서도 적용하기 쉬워 우울장애를 선별하는데 유용한 | 소프트웨어 아키텍처를 소프트 | 대한 시판 전 제출에 대한 가이드라인 | 미국 | 소프트웨어 |\n| 그 이유의 타당성을 면밀히 검토하여야 한다. ",
        "original_sentence": "| ■ 예(☞안내서) | □ 아니오 |\n| 선정/제외기준 확인 | O | O | - | - | 8 | 회사명 | 대표이사 | 소재지 | 전화 | 유지 | 데이터 송·수신 방법을 고려하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_263",
      "text": "| ments) | 변화량 | 가능하다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 262,
        "window_size": 3,
        "char_count": 23,
        "word_count": 6,
        "page_number": 18,
        "window_text": "| 우울(15~19점), 심각도 우울(20점 이상)을 나타낸다.  | 나) 피험자 동의 및 준비 | 플루옥세틴(fluoxetine) | SSRI | 20-60 | 구분 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | (출처 : 일차 의료용 근거 기반 우울장애 임상진료지침(대한의학회, 2022)) | 속하는 세부 항목들을 점수화 한 뒤 합산하여 0점부터 | 추가 12개월 동안 참가자에게 제공한다.  | ■ 예(☞안내서) | □ 아니오 |\n| 선정/제외기준 확인 | O | O | - | - | 8 | 회사명 | 대표이사 | 소재지 | 전화 | 유지 | 데이터 송·수신 방법을 고려하여야 한다.  | ments) | 변화량 | 가능하다.  | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까?  (민원인용) | 과정에서도 적용하기 쉬워 우울장애를 선별하는데 유용한 | 소프트웨어 아키텍처를 소프트 | 대한 시판 전 제출에 대한 가이드라인 | 미국 | 소프트웨어 |\n| 그 이유의 타당성을 면밀히 검토하여야 한다.  | 6 | 병원 불안 우울 척도(Hospital Anxiꠓ | - 일차와 이차 유효성 평가 관련된 목록을 작성한다. ",
        "original_sentence": "| ments) | 변화량 | 가능하다. "
      }
    },
    {
      "chunk_id": "chunk_264",
      "text": "| 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까? ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 263,
        "window_size": 3,
        "char_count": 51,
        "word_count": 12,
        "page_number": 3,
        "window_text": "| 나) 피험자 동의 및 준비 | 플루옥세틴(fluoxetine) | SSRI | 20-60 | 구분 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | (출처 : 일차 의료용 근거 기반 우울장애 임상진료지침(대한의학회, 2022)) | 속하는 세부 항목들을 점수화 한 뒤 합산하여 0점부터 | 추가 12개월 동안 참가자에게 제공한다.  | ■ 예(☞안내서) | □ 아니오 |\n| 선정/제외기준 확인 | O | O | - | - | 8 | 회사명 | 대표이사 | 소재지 | 전화 | 유지 | 데이터 송·수신 방법을 고려하여야 한다.  | ments) | 변화량 | 가능하다.  | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까?  (민원인용) | 과정에서도 적용하기 쉬워 우울장애를 선별하는데 유용한 | 소프트웨어 아키텍처를 소프트 | 대한 시판 전 제출에 대한 가이드라인 | 미국 | 소프트웨어 |\n| 그 이유의 타당성을 면밀히 검토하여야 한다.  | 6 | 병원 불안 우울 척도(Hospital Anxiꠓ | - 일차와 이차 유효성 평가 관련된 목록을 작성한다.  | 위해 사이버보안 공격을 탐지, 저항, 대응 | ety and Depression Scale, HADS) | 검증 및 |\n| ○ 관련성이 적음(Probably not related) | 가) 위험분석 | 라) 과거 병력 조사 | 플루복사민(fluvoxamine) | SSRI | 100-300 | 한다)를 말한다. ",
        "original_sentence": "| 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_265",
      "text": "(민원인용) | 과정에서도 적용하기 쉬워 우울장애를 선별하는데 유용한 | 소프트웨어 아키텍처를 소프트 | 대한 시판 전 제출에 대한 가이드라인 | 미국 | 소프트웨어 |\n| 그 이유의 타당성을 면밀히 검토하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 264,
        "window_size": 3,
        "char_count": 122,
        "word_count": 31,
        "page_number": 9,
        "window_text": "| ■ 예(☞안내서) | □ 아니오 |\n| 선정/제외기준 확인 | O | O | - | - | 8 | 회사명 | 대표이사 | 소재지 | 전화 | 유지 | 데이터 송·수신 방법을 고려하여야 한다.  | ments) | 변화량 | 가능하다.  | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까?  (민원인용) | 과정에서도 적용하기 쉬워 우울장애를 선별하는데 유용한 | 소프트웨어 아키텍처를 소프트 | 대한 시판 전 제출에 대한 가이드라인 | 미국 | 소프트웨어 |\n| 그 이유의 타당성을 면밀히 검토하여야 한다.  | 6 | 병원 불안 우울 척도(Hospital Anxiꠓ | - 일차와 이차 유효성 평가 관련된 목록을 작성한다.  | 위해 사이버보안 공격을 탐지, 저항, 대응 | ety and Depression Scale, HADS) | 검증 및 |\n| ○ 관련성이 적음(Probably not related) | 가) 위험분석 | 라) 과거 병력 조사 | 플루복사민(fluvoxamine) | SSRI | 100-300 | 한다)를 말한다.  | - 일차목적 및 가설 | - 삶의 질 | Software Contained in Medical | 공유되지 않아야 한다. ",
        "original_sentence": "(민원인용) | 과정에서도 적용하기 쉬워 우울장애를 선별하는데 유용한 | 소프트웨어 아키텍처를 소프트 | 대한 시판 전 제출에 대한 가이드라인 | 미국 | 소프트웨어 |\n| 그 이유의 타당성을 면밀히 검토하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_266",
      "text": "| 6 | 병원 불안 우울 척도(Hospital Anxiꠓ | - 일차와 이차 유효성 평가 관련된 목록을 작성한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 265,
        "window_size": 3,
        "char_count": 65,
        "word_count": 17,
        "page_number": 7,
        "window_text": "| ments) | 변화량 | 가능하다.  | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까?  (민원인용) | 과정에서도 적용하기 쉬워 우울장애를 선별하는데 유용한 | 소프트웨어 아키텍처를 소프트 | 대한 시판 전 제출에 대한 가이드라인 | 미국 | 소프트웨어 |\n| 그 이유의 타당성을 면밀히 검토하여야 한다.  | 6 | 병원 불안 우울 척도(Hospital Anxiꠓ | - 일차와 이차 유효성 평가 관련된 목록을 작성한다.  | 위해 사이버보안 공격을 탐지, 저항, 대응 | ety and Depression Scale, HADS) | 검증 및 |\n| ○ 관련성이 적음(Probably not related) | 가) 위험분석 | 라) 과거 병력 조사 | 플루복사민(fluvoxamine) | SSRI | 100-300 | 한다)를 말한다.  | - 일차목적 및 가설 | - 삶의 질 | Software Contained in Medical | 공유되지 않아야 한다.  | 번호로 동시에 로그인을 시도 | 대해 4점 척도로 응답하도록 구성되어 있다. ",
        "original_sentence": "| 6 | 병원 불안 우울 척도(Hospital Anxiꠓ | - 일차와 이차 유효성 평가 관련된 목록을 작성한다. "
      }
    },
    {
      "chunk_id": "chunk_267",
      "text": "| 위해 사이버보안 공격을 탐지, 저항, 대응 | ety and Depression Scale, HADS) | 검증 및 |\n| ○ 관련성이 적음(Probably not related) | 가) 위험분석 | 라) 과거 병력 조사 | 플루복사민(fluvoxamine) | SSRI | 100-300 | 한다)를 말한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 266,
        "window_size": 3,
        "char_count": 177,
        "word_count": 40,
        "page_number": 29,
        "window_text": "| 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까?  (민원인용) | 과정에서도 적용하기 쉬워 우울장애를 선별하는데 유용한 | 소프트웨어 아키텍처를 소프트 | 대한 시판 전 제출에 대한 가이드라인 | 미국 | 소프트웨어 |\n| 그 이유의 타당성을 면밀히 검토하여야 한다.  | 6 | 병원 불안 우울 척도(Hospital Anxiꠓ | - 일차와 이차 유효성 평가 관련된 목록을 작성한다.  | 위해 사이버보안 공격을 탐지, 저항, 대응 | ety and Depression Scale, HADS) | 검증 및 |\n| ○ 관련성이 적음(Probably not related) | 가) 위험분석 | 라) 과거 병력 조사 | 플루복사민(fluvoxamine) | SSRI | 100-300 | 한다)를 말한다.  | - 일차목적 및 가설 | - 삶의 질 | Software Contained in Medical | 공유되지 않아야 한다.  | 번호로 동시에 로그인을 시도 | 대해 4점 척도로 응답하도록 구성되어 있다.  일반인을 대상 | 위험분석 | 위험평가 | 한기기에 시험용 정보로 로그인을 | 확인 자료 |\n| * [F32] Depressive episode (우울에피소드)) | 2) 의료기기의 사용 목적 : 환자의 우울 증상을 정량적으로 개선 | 5) 피험자가 준수하여야 할 사항 | 및 | : (치료 8주 후 BDI 점수) – (치료 전 BDI 점수) | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 수는 없으며, 이상 반응 문제가 생길 수 있다. ",
        "original_sentence": "| 위해 사이버보안 공격을 탐지, 저항, 대응 | ety and Depression Scale, HADS) | 검증 및 |\n| ○ 관련성이 적음(Probably not related) | 가) 위험분석 | 라) 과거 병력 조사 | 플루복사민(fluvoxamine) | SSRI | 100-300 | 한다)를 말한다. "
      }
    },
    {
      "chunk_id": "chunk_268",
      "text": "| - 일차목적 및 가설 | - 삶의 질 | Software Contained in Medical | 공유되지 않아야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 267,
        "window_size": 3,
        "char_count": 70,
        "word_count": 18,
        "page_number": 7,
        "window_text": "(민원인용) | 과정에서도 적용하기 쉬워 우울장애를 선별하는데 유용한 | 소프트웨어 아키텍처를 소프트 | 대한 시판 전 제출에 대한 가이드라인 | 미국 | 소프트웨어 |\n| 그 이유의 타당성을 면밀히 검토하여야 한다.  | 6 | 병원 불안 우울 척도(Hospital Anxiꠓ | - 일차와 이차 유효성 평가 관련된 목록을 작성한다.  | 위해 사이버보안 공격을 탐지, 저항, 대응 | ety and Depression Scale, HADS) | 검증 및 |\n| ○ 관련성이 적음(Probably not related) | 가) 위험분석 | 라) 과거 병력 조사 | 플루복사민(fluvoxamine) | SSRI | 100-300 | 한다)를 말한다.  | - 일차목적 및 가설 | - 삶의 질 | Software Contained in Medical | 공유되지 않아야 한다.  | 번호로 동시에 로그인을 시도 | 대해 4점 척도로 응답하도록 구성되어 있다.  일반인을 대상 | 위험분석 | 위험평가 | 한기기에 시험용 정보로 로그인을 | 확인 자료 |\n| * [F32] Depressive episode (우울에피소드)) | 2) 의료기기의 사용 목적 : 환자의 우울 증상을 정량적으로 개선 | 5) 피험자가 준수하여야 할 사항 | 및 | : (치료 8주 후 BDI 점수) – (치료 전 BDI 점수) | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 수는 없으며, 이상 반응 문제가 생길 수 있다.  | 않으면 이에 대한 사유와 근거 등을 제시해야 한다. ",
        "original_sentence": "| - 일차목적 및 가설 | - 삶의 질 | Software Contained in Medical | 공유되지 않아야 한다. "
      }
    },
    {
      "chunk_id": "chunk_269",
      "text": "| 번호로 동시에 로그인을 시도 | 대해 4점 척도로 응답하도록 구성되어 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 268,
        "window_size": 3,
        "char_count": 45,
        "word_count": 12,
        "page_number": 11,
        "window_text": "| 6 | 병원 불안 우울 척도(Hospital Anxiꠓ | - 일차와 이차 유효성 평가 관련된 목록을 작성한다.  | 위해 사이버보안 공격을 탐지, 저항, 대응 | ety and Depression Scale, HADS) | 검증 및 |\n| ○ 관련성이 적음(Probably not related) | 가) 위험분석 | 라) 과거 병력 조사 | 플루복사민(fluvoxamine) | SSRI | 100-300 | 한다)를 말한다.  | - 일차목적 및 가설 | - 삶의 질 | Software Contained in Medical | 공유되지 않아야 한다.  | 번호로 동시에 로그인을 시도 | 대해 4점 척도로 응답하도록 구성되어 있다.  일반인을 대상 | 위험분석 | 위험평가 | 한기기에 시험용 정보로 로그인을 | 확인 자료 |\n| * [F32] Depressive episode (우울에피소드)) | 2) 의료기기의 사용 목적 : 환자의 우울 증상을 정량적으로 개선 | 5) 피험자가 준수하여야 할 사항 | 및 | : (치료 8주 후 BDI 점수) – (치료 전 BDI 점수) | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 수는 없으며, 이상 반응 문제가 생길 수 있다.  | 않으면 이에 대한 사유와 근거 등을 제시해야 한다.  | 중복 로그인 | 귀결 분석(consequential analysis) | HDSQ는 무망감 | 이론(Hopelessness | Theory)에 기초하여, | 100점 사이의 점수로 변환시키는데, 0점은 가장 나쁜 건강 | 적용 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 밀나시프란(milnacipran) | SNRI | 100 | 인구학적 정보 | O | - | - | - | 쯍 우울 척도 | 활동 | · 층: 성별(남/여), 연령(oo세 미만, oo세 이상) | ※ 예: 기기/시스템 간 통신 시 상호인증 | 순서가 타당한 경우 | Medical device software – | 도구이다. ",
        "original_sentence": "| 번호로 동시에 로그인을 시도 | 대해 4점 척도로 응답하도록 구성되어 있다. "
      }
    },
    {
      "chunk_id": "chunk_270",
      "text": "일반인을 대상 | 위험분석 | 위험평가 | 한기기에 시험용 정보로 로그인을 | 확인 자료 |\n| * [F32] Depressive episode (우울에피소드)) | 2) 의료기기의 사용 목적 : 환자의 우울 증상을 정량적으로 개선 | 5) 피험자가 준수하여야 할 사항 | 및 | : (치료 8주 후 BDI 점수) – (치료 전 BDI 점수) | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 수는 없으며, 이상 반응 문제가 생길 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 269,
        "window_size": 3,
        "char_count": 257,
        "word_count": 71,
        "page_number": 39,
        "window_text": "| 위해 사이버보안 공격을 탐지, 저항, 대응 | ety and Depression Scale, HADS) | 검증 및 |\n| ○ 관련성이 적음(Probably not related) | 가) 위험분석 | 라) 과거 병력 조사 | 플루복사민(fluvoxamine) | SSRI | 100-300 | 한다)를 말한다.  | - 일차목적 및 가설 | - 삶의 질 | Software Contained in Medical | 공유되지 않아야 한다.  | 번호로 동시에 로그인을 시도 | 대해 4점 척도로 응답하도록 구성되어 있다.  일반인을 대상 | 위험분석 | 위험평가 | 한기기에 시험용 정보로 로그인을 | 확인 자료 |\n| * [F32] Depressive episode (우울에피소드)) | 2) 의료기기의 사용 목적 : 환자의 우울 증상을 정량적으로 개선 | 5) 피험자가 준수하여야 할 사항 | 및 | : (치료 8주 후 BDI 점수) – (치료 전 BDI 점수) | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 수는 없으며, 이상 반응 문제가 생길 수 있다.  | 않으면 이에 대한 사유와 근거 등을 제시해야 한다.  | 중복 로그인 | 귀결 분석(consequential analysis) | HDSQ는 무망감 | 이론(Hopelessness | Theory)에 기초하여, | 100점 사이의 점수로 변환시키는데, 0점은 가장 나쁜 건강 | 적용 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 밀나시프란(milnacipran) | SNRI | 100 | 인구학적 정보 | O | - | - | - | 쯍 우울 척도 | 활동 | · 층: 성별(남/여), 연령(oo세 미만, oo세 이상) | ※ 예: 기기/시스템 간 통신 시 상호인증 | 순서가 타당한 경우 | Medical device software – | 도구이다.  | 웨어 유닛으로 표현할 수 있을 | 검증 및 |\n| 5 | psychosomatics, 85(4), 218-228. ",
        "original_sentence": "일반인을 대상 | 위험분석 | 위험평가 | 한기기에 시험용 정보로 로그인을 | 확인 자료 |\n| * [F32] Depressive episode (우울에피소드)) | 2) 의료기기의 사용 목적 : 환자의 우울 증상을 정량적으로 개선 | 5) 피험자가 준수하여야 할 사항 | 및 | : (치료 8주 후 BDI 점수) – (치료 전 BDI 점수) | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 수는 없으며, 이상 반응 문제가 생길 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_271",
      "text": "| 않으면 이에 대한 사유와 근거 등을 제시해야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 270,
        "window_size": 3,
        "char_count": 31,
        "word_count": 9,
        "page_number": 13,
        "window_text": "| - 일차목적 및 가설 | - 삶의 질 | Software Contained in Medical | 공유되지 않아야 한다.  | 번호로 동시에 로그인을 시도 | 대해 4점 척도로 응답하도록 구성되어 있다.  일반인을 대상 | 위험분석 | 위험평가 | 한기기에 시험용 정보로 로그인을 | 확인 자료 |\n| * [F32] Depressive episode (우울에피소드)) | 2) 의료기기의 사용 목적 : 환자의 우울 증상을 정량적으로 개선 | 5) 피험자가 준수하여야 할 사항 | 및 | : (치료 8주 후 BDI 점수) – (치료 전 BDI 점수) | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 수는 없으며, 이상 반응 문제가 생길 수 있다.  | 않으면 이에 대한 사유와 근거 등을 제시해야 한다.  | 중복 로그인 | 귀결 분석(consequential analysis) | HDSQ는 무망감 | 이론(Hopelessness | Theory)에 기초하여, | 100점 사이의 점수로 변환시키는데, 0점은 가장 나쁜 건강 | 적용 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 밀나시프란(milnacipran) | SNRI | 100 | 인구학적 정보 | O | - | - | - | 쯍 우울 척도 | 활동 | · 층: 성별(남/여), 연령(oo세 미만, oo세 이상) | ※ 예: 기기/시스템 간 통신 시 상호인증 | 순서가 타당한 경우 | Medical device software – | 도구이다.  | 웨어 유닛으로 표현할 수 있을 | 검증 및 |\n| 5 | psychosomatics, 85(4), 218-228.  | 기록한다. ",
        "original_sentence": "| 않으면 이에 대한 사유와 근거 등을 제시해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_272",
      "text": "| 중복 로그인 | 귀결 분석(consequential analysis) | HDSQ는 무망감 | 이론(Hopelessness | Theory)에 기초하여, | 100점 사이의 점수로 변환시키는데, 0점은 가장 나쁜 건강 | 적용 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 밀나시프란(milnacipran) | SNRI | 100 | 인구학적 정보 | O | - | - | - | 쯍 우울 척도 | 활동 | · 층: 성별(남/여), 연령(oo세 미만, oo세 이상) | ※ 예: 기기/시스템 간 통신 시 상호인증 | 순서가 타당한 경우 | Medical device software – | 도구이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 271,
        "window_size": 3,
        "char_count": 357,
        "word_count": 88,
        "page_number": 19,
        "window_text": "| 번호로 동시에 로그인을 시도 | 대해 4점 척도로 응답하도록 구성되어 있다.  일반인을 대상 | 위험분석 | 위험평가 | 한기기에 시험용 정보로 로그인을 | 확인 자료 |\n| * [F32] Depressive episode (우울에피소드)) | 2) 의료기기의 사용 목적 : 환자의 우울 증상을 정량적으로 개선 | 5) 피험자가 준수하여야 할 사항 | 및 | : (치료 8주 후 BDI 점수) – (치료 전 BDI 점수) | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 수는 없으며, 이상 반응 문제가 생길 수 있다.  | 않으면 이에 대한 사유와 근거 등을 제시해야 한다.  | 중복 로그인 | 귀결 분석(consequential analysis) | HDSQ는 무망감 | 이론(Hopelessness | Theory)에 기초하여, | 100점 사이의 점수로 변환시키는데, 0점은 가장 나쁜 건강 | 적용 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 밀나시프란(milnacipran) | SNRI | 100 | 인구학적 정보 | O | - | - | - | 쯍 우울 척도 | 활동 | · 층: 성별(남/여), 연령(oo세 미만, oo세 이상) | ※ 예: 기기/시스템 간 통신 시 상호인증 | 순서가 타당한 경우 | Medical device software – | 도구이다.  | 웨어 유닛으로 표현할 수 있을 | 검증 및 |\n| 5 | psychosomatics, 85(4), 218-228.  | 기록한다.  | 7 | 노인 우울 척도 (Geriatric Depression Scale, GDS) | 및 복구하도록 허용하는 설계 특성을 고려 | ※ 접근 통제의 예: 비밀번호, 하드웨어 키, | Devices | 했을 때, 기존 로그인되어 | 한 후, 다른 기기에서 같은 정보로 | 유효성 | (AB-1234) |\n| 동시에 의료기기의 전체 수명주기의 위험관리 일부로 수행한다. ",
        "original_sentence": "| 중복 로그인 | 귀결 분석(consequential analysis) | HDSQ는 무망감 | 이론(Hopelessness | Theory)에 기초하여, | 100점 사이의 점수로 변환시키는데, 0점은 가장 나쁜 건강 | 적용 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 밀나시프란(milnacipran) | SNRI | 100 | 인구학적 정보 | O | - | - | - | 쯍 우울 척도 | 활동 | · 층: 성별(남/여), 연령(oo세 미만, oo세 이상) | ※ 예: 기기/시스템 간 통신 시 상호인증 | 순서가 타당한 경우 | Medical device software – | 도구이다. "
      }
    },
    {
      "chunk_id": "chunk_273",
      "text": "| 웨어 유닛으로 표현할 수 있을 | 검증 및 |\n| 5 | psychosomatics, 85(4), 218-228. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 272,
        "window_size": 3,
        "char_count": 66,
        "word_count": 16,
        "page_number": 30,
        "window_text": "일반인을 대상 | 위험분석 | 위험평가 | 한기기에 시험용 정보로 로그인을 | 확인 자료 |\n| * [F32] Depressive episode (우울에피소드)) | 2) 의료기기의 사용 목적 : 환자의 우울 증상을 정량적으로 개선 | 5) 피험자가 준수하여야 할 사항 | 및 | : (치료 8주 후 BDI 점수) – (치료 전 BDI 점수) | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 수는 없으며, 이상 반응 문제가 생길 수 있다.  | 않으면 이에 대한 사유와 근거 등을 제시해야 한다.  | 중복 로그인 | 귀결 분석(consequential analysis) | HDSQ는 무망감 | 이론(Hopelessness | Theory)에 기초하여, | 100점 사이의 점수로 변환시키는데, 0점은 가장 나쁜 건강 | 적용 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 밀나시프란(milnacipran) | SNRI | 100 | 인구학적 정보 | O | - | - | - | 쯍 우울 척도 | 활동 | · 층: 성별(남/여), 연령(oo세 미만, oo세 이상) | ※ 예: 기기/시스템 간 통신 시 상호인증 | 순서가 타당한 경우 | Medical device software – | 도구이다.  | 웨어 유닛으로 표현할 수 있을 | 검증 및 |\n| 5 | psychosomatics, 85(4), 218-228.  | 기록한다.  | 7 | 노인 우울 척도 (Geriatric Depression Scale, GDS) | 및 복구하도록 허용하는 설계 특성을 고려 | ※ 접근 통제의 예: 비밀번호, 하드웨어 키, | Devices | 했을 때, 기존 로그인되어 | 한 후, 다른 기기에서 같은 정보로 | 유효성 | (AB-1234) |\n| 동시에 의료기기의 전체 수명주기의 위험관리 일부로 수행한다.  | 으로 우울장애를 선별하고자 할 때 적용 가능하며, 채점은 | 「의료기기법」 및 「의료기기법시행 | 의료기기 소프트웨어의 | 적용 | 발생 |\n| 멀타자핀(mirtazapine) | α2-Adrenergic agonist; 5-HT2 antagonist | 15-45 | 과거병력 조사 | O | - | - | - | 무망감 질문지 | (출처: SilverCloud 홈페이지, | 질환으로 정의한다. ",
        "original_sentence": "| 웨어 유닛으로 표현할 수 있을 | 검증 및 |\n| 5 | psychosomatics, 85(4), 218-228. "
      }
    },
    {
      "chunk_id": "chunk_274",
      "text": "| 기록한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 273,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 13,
        "window_text": "| 않으면 이에 대한 사유와 근거 등을 제시해야 한다.  | 중복 로그인 | 귀결 분석(consequential analysis) | HDSQ는 무망감 | 이론(Hopelessness | Theory)에 기초하여, | 100점 사이의 점수로 변환시키는데, 0점은 가장 나쁜 건강 | 적용 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 밀나시프란(milnacipran) | SNRI | 100 | 인구학적 정보 | O | - | - | - | 쯍 우울 척도 | 활동 | · 층: 성별(남/여), 연령(oo세 미만, oo세 이상) | ※ 예: 기기/시스템 간 통신 시 상호인증 | 순서가 타당한 경우 | Medical device software – | 도구이다.  | 웨어 유닛으로 표현할 수 있을 | 검증 및 |\n| 5 | psychosomatics, 85(4), 218-228.  | 기록한다.  | 7 | 노인 우울 척도 (Geriatric Depression Scale, GDS) | 및 복구하도록 허용하는 설계 특성을 고려 | ※ 접근 통제의 예: 비밀번호, 하드웨어 키, | Devices | 했을 때, 기존 로그인되어 | 한 후, 다른 기기에서 같은 정보로 | 유효성 | (AB-1234) |\n| 동시에 의료기기의 전체 수명주기의 위험관리 일부로 수행한다.  | 으로 우울장애를 선별하고자 할 때 적용 가능하며, 채점은 | 「의료기기법」 및 「의료기기법시행 | 의료기기 소프트웨어의 | 적용 | 발생 |\n| 멀타자핀(mirtazapine) | α2-Adrenergic agonist; 5-HT2 antagonist | 15-45 | 과거병력 조사 | O | - | - | - | 무망감 질문지 | (출처: SilverCloud 홈페이지, | 질환으로 정의한다.  | (출처: NOVEGO 홈페이지, | 의료기기와의 인과관계에 대하여 증례 기록지에 기록한다. ",
        "original_sentence": "| 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_275",
      "text": "| 7 | 노인 우울 척도 (Geriatric Depression Scale, GDS) | 및 복구하도록 허용하는 설계 특성을 고려 | ※ 접근 통제의 예: 비밀번호, 하드웨어 키, | Devices | 했을 때, 기존 로그인되어 | 한 후, 다른 기기에서 같은 정보로 | 유효성 | (AB-1234) |\n| 동시에 의료기기의 전체 수명주기의 위험관리 일부로 수행한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 274,
        "window_size": 3,
        "char_count": 207,
        "word_count": 52,
        "page_number": 29,
        "window_text": "| 중복 로그인 | 귀결 분석(consequential analysis) | HDSQ는 무망감 | 이론(Hopelessness | Theory)에 기초하여, | 100점 사이의 점수로 변환시키는데, 0점은 가장 나쁜 건강 | 적용 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 밀나시프란(milnacipran) | SNRI | 100 | 인구학적 정보 | O | - | - | - | 쯍 우울 척도 | 활동 | · 층: 성별(남/여), 연령(oo세 미만, oo세 이상) | ※ 예: 기기/시스템 간 통신 시 상호인증 | 순서가 타당한 경우 | Medical device software – | 도구이다.  | 웨어 유닛으로 표현할 수 있을 | 검증 및 |\n| 5 | psychosomatics, 85(4), 218-228.  | 기록한다.  | 7 | 노인 우울 척도 (Geriatric Depression Scale, GDS) | 및 복구하도록 허용하는 설계 특성을 고려 | ※ 접근 통제의 예: 비밀번호, 하드웨어 키, | Devices | 했을 때, 기존 로그인되어 | 한 후, 다른 기기에서 같은 정보로 | 유효성 | (AB-1234) |\n| 동시에 의료기기의 전체 수명주기의 위험관리 일부로 수행한다.  | 으로 우울장애를 선별하고자 할 때 적용 가능하며, 채점은 | 「의료기기법」 및 「의료기기법시행 | 의료기기 소프트웨어의 | 적용 | 발생 |\n| 멀타자핀(mirtazapine) | α2-Adrenergic agonist; 5-HT2 antagonist | 15-45 | 과거병력 조사 | O | - | - | - | 무망감 질문지 | (출처: SilverCloud 홈페이지, | 질환으로 정의한다.  | (출처: NOVEGO 홈페이지, | 의료기기와의 인과관계에 대하여 증례 기록지에 기록한다.  | 것에 무리가 있다고 판단될 때는 임상시험을 중지할 수 있다. ",
        "original_sentence": "| 7 | 노인 우울 척도 (Geriatric Depression Scale, GDS) | 및 복구하도록 허용하는 설계 특성을 고려 | ※ 접근 통제의 예: 비밀번호, 하드웨어 키, | Devices | 했을 때, 기존 로그인되어 | 한 후, 다른 기기에서 같은 정보로 | 유효성 | (AB-1234) |\n| 동시에 의료기기의 전체 수명주기의 위험관리 일부로 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_276",
      "text": "| 으로 우울장애를 선별하고자 할 때 적용 가능하며, 채점은 | 「의료기기법」 및 「의료기기법시행 | 의료기기 소프트웨어의 | 적용 | 발생 |\n| 멀타자핀(mirtazapine) | α2-Adrenergic agonist; 5-HT2 antagonist | 15-45 | 과거병력 조사 | O | - | - | - | 무망감 질문지 | (출처: SilverCloud 홈페이지, | 질환으로 정의한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 275,
        "window_size": 3,
        "char_count": 225,
        "word_count": 51,
        "page_number": 38,
        "window_text": "| 웨어 유닛으로 표현할 수 있을 | 검증 및 |\n| 5 | psychosomatics, 85(4), 218-228.  | 기록한다.  | 7 | 노인 우울 척도 (Geriatric Depression Scale, GDS) | 및 복구하도록 허용하는 설계 특성을 고려 | ※ 접근 통제의 예: 비밀번호, 하드웨어 키, | Devices | 했을 때, 기존 로그인되어 | 한 후, 다른 기기에서 같은 정보로 | 유효성 | (AB-1234) |\n| 동시에 의료기기의 전체 수명주기의 위험관리 일부로 수행한다.  | 으로 우울장애를 선별하고자 할 때 적용 가능하며, 채점은 | 「의료기기법」 및 「의료기기법시행 | 의료기기 소프트웨어의 | 적용 | 발생 |\n| 멀타자핀(mirtazapine) | α2-Adrenergic agonist; 5-HT2 antagonist | 15-45 | 과거병력 조사 | O | - | - | - | 무망감 질문지 | (출처: SilverCloud 홈페이지, | 질환으로 정의한다.  | (출처: NOVEGO 홈페이지, | 의료기기와의 인과관계에 대하여 증례 기록지에 기록한다.  | 것에 무리가 있다고 판단될 때는 임상시험을 중지할 수 있다.  | 방지 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | - 귀결 분석은 감정 저하를 일으키는 잠재된 두려움, 사고, 가정 | 우울장애 관련 요소로서 무망감을 측정하기 위해 고안된 | 상태를 의미하며, 100점은 가장 좋은 건강 상태를 의미이다. ",
        "original_sentence": "| 으로 우울장애를 선별하고자 할 때 적용 가능하며, 채점은 | 「의료기기법」 및 「의료기기법시행 | 의료기기 소프트웨어의 | 적용 | 발생 |\n| 멀타자핀(mirtazapine) | α2-Adrenergic agonist; 5-HT2 antagonist | 15-45 | 과거병력 조사 | O | - | - | - | 무망감 질문지 | (출처: SilverCloud 홈페이지, | 질환으로 정의한다. "
      }
    },
    {
      "chunk_id": "chunk_277",
      "text": "| (출처: NOVEGO 홈페이지, | 의료기기와의 인과관계에 대하여 증례 기록지에 기록한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 276,
        "window_size": 3,
        "char_count": 53,
        "word_count": 11,
        "page_number": 28,
        "window_text": "| 기록한다.  | 7 | 노인 우울 척도 (Geriatric Depression Scale, GDS) | 및 복구하도록 허용하는 설계 특성을 고려 | ※ 접근 통제의 예: 비밀번호, 하드웨어 키, | Devices | 했을 때, 기존 로그인되어 | 한 후, 다른 기기에서 같은 정보로 | 유효성 | (AB-1234) |\n| 동시에 의료기기의 전체 수명주기의 위험관리 일부로 수행한다.  | 으로 우울장애를 선별하고자 할 때 적용 가능하며, 채점은 | 「의료기기법」 및 「의료기기법시행 | 의료기기 소프트웨어의 | 적용 | 발생 |\n| 멀타자핀(mirtazapine) | α2-Adrenergic agonist; 5-HT2 antagonist | 15-45 | 과거병력 조사 | O | - | - | - | 무망감 질문지 | (출처: SilverCloud 홈페이지, | 질환으로 정의한다.  | (출처: NOVEGO 홈페이지, | 의료기기와의 인과관계에 대하여 증례 기록지에 기록한다.  | 것에 무리가 있다고 판단될 때는 임상시험을 중지할 수 있다.  | 방지 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | - 귀결 분석은 감정 저하를 일으키는 잠재된 두려움, 사고, 가정 | 우울장애 관련 요소로서 무망감을 측정하기 위해 고안된 | 상태를 의미하며, 100점은 가장 좋은 건강 상태를 의미이다.  | □ 예 | ■ 아니오 |\n| of medical Internet research, 11(2), e1151. ",
        "original_sentence": "| (출처: NOVEGO 홈페이지, | 의료기기와의 인과관계에 대하여 증례 기록지에 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_278",
      "text": "| 것에 무리가 있다고 판단될 때는 임상시험을 중지할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 277,
        "window_size": 3,
        "char_count": 36,
        "word_count": 10,
        "page_number": 11,
        "window_text": "| 7 | 노인 우울 척도 (Geriatric Depression Scale, GDS) | 및 복구하도록 허용하는 설계 특성을 고려 | ※ 접근 통제의 예: 비밀번호, 하드웨어 키, | Devices | 했을 때, 기존 로그인되어 | 한 후, 다른 기기에서 같은 정보로 | 유효성 | (AB-1234) |\n| 동시에 의료기기의 전체 수명주기의 위험관리 일부로 수행한다.  | 으로 우울장애를 선별하고자 할 때 적용 가능하며, 채점은 | 「의료기기법」 및 「의료기기법시행 | 의료기기 소프트웨어의 | 적용 | 발생 |\n| 멀타자핀(mirtazapine) | α2-Adrenergic agonist; 5-HT2 antagonist | 15-45 | 과거병력 조사 | O | - | - | - | 무망감 질문지 | (출처: SilverCloud 홈페이지, | 질환으로 정의한다.  | (출처: NOVEGO 홈페이지, | 의료기기와의 인과관계에 대하여 증례 기록지에 기록한다.  | 것에 무리가 있다고 판단될 때는 임상시험을 중지할 수 있다.  | 방지 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | - 귀결 분석은 감정 저하를 일으키는 잠재된 두려움, 사고, 가정 | 우울장애 관련 요소로서 무망감을 측정하기 위해 고안된 | 상태를 의미하며, 100점은 가장 좋은 건강 상태를 의미이다.  | □ 예 | ■ 아니오 |\n| of medical Internet research, 11(2), e1151.  | : 일차 유효성 평가변수와 동일한 방법을 적용한다. ",
        "original_sentence": "| 것에 무리가 있다고 판단될 때는 임상시험을 중지할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_279",
      "text": "| 방지 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | - 귀결 분석은 감정 저하를 일으키는 잠재된 두려움, 사고, 가정 | 우울장애 관련 요소로서 무망감을 측정하기 위해 고안된 | 상태를 의미하며, 100점은 가장 좋은 건강 상태를 의미이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 278,
        "window_size": 3,
        "char_count": 146,
        "word_count": 38,
        "page_number": 3,
        "window_text": "| 으로 우울장애를 선별하고자 할 때 적용 가능하며, 채점은 | 「의료기기법」 및 「의료기기법시행 | 의료기기 소프트웨어의 | 적용 | 발생 |\n| 멀타자핀(mirtazapine) | α2-Adrenergic agonist; 5-HT2 antagonist | 15-45 | 과거병력 조사 | O | - | - | - | 무망감 질문지 | (출처: SilverCloud 홈페이지, | 질환으로 정의한다.  | (출처: NOVEGO 홈페이지, | 의료기기와의 인과관계에 대하여 증례 기록지에 기록한다.  | 것에 무리가 있다고 판단될 때는 임상시험을 중지할 수 있다.  | 방지 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | - 귀결 분석은 감정 저하를 일으키는 잠재된 두려움, 사고, 가정 | 우울장애 관련 요소로서 무망감을 측정하기 위해 고안된 | 상태를 의미하며, 100점은 가장 좋은 건강 상태를 의미이다.  | □ 예 | ■ 아니오 |\n| of medical Internet research, 11(2), e1151.  | : 일차 유효성 평가변수와 동일한 방법을 적용한다.  | (Zung’s Self-Rating | 대리인)에게 제공해야 한다. ",
        "original_sentence": "| 방지 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | - 귀결 분석은 감정 저하를 일으키는 잠재된 두려움, 사고, 가정 | 우울장애 관련 요소로서 무망감을 측정하기 위해 고안된 | 상태를 의미하며, 100점은 가장 좋은 건강 상태를 의미이다. "
      }
    },
    {
      "chunk_id": "chunk_280",
      "text": "| □ 예 | ■ 아니오 |\n| of medical Internet research, 11(2), e1151. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 279,
        "window_size": 3,
        "char_count": 62,
        "word_count": 14,
        "page_number": 3,
        "window_text": "| (출처: NOVEGO 홈페이지, | 의료기기와의 인과관계에 대하여 증례 기록지에 기록한다.  | 것에 무리가 있다고 판단될 때는 임상시험을 중지할 수 있다.  | 방지 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | - 귀결 분석은 감정 저하를 일으키는 잠재된 두려움, 사고, 가정 | 우울장애 관련 요소로서 무망감을 측정하기 위해 고안된 | 상태를 의미하며, 100점은 가장 좋은 건강 상태를 의미이다.  | □ 예 | ■ 아니오 |\n| of medical Internet research, 11(2), e1151.  | : 일차 유효성 평가변수와 동일한 방법을 적용한다.  | (Zung’s Self-Rating | 대리인)에게 제공해야 한다.  | 위원회 및 식품의약품안전처장의 승인을 받아야 한다. ",
        "original_sentence": "| □ 예 | ■ 아니오 |\n| of medical Internet research, 11(2), e1151. "
      }
    },
    {
      "chunk_id": "chunk_281",
      "text": "| : 일차 유효성 평가변수와 동일한 방법을 적용한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 280,
        "window_size": 3,
        "char_count": 31,
        "word_count": 8,
        "page_number": 7,
        "window_text": "| 것에 무리가 있다고 판단될 때는 임상시험을 중지할 수 있다.  | 방지 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | - 귀결 분석은 감정 저하를 일으키는 잠재된 두려움, 사고, 가정 | 우울장애 관련 요소로서 무망감을 측정하기 위해 고안된 | 상태를 의미하며, 100점은 가장 좋은 건강 상태를 의미이다.  | □ 예 | ■ 아니오 |\n| of medical Internet research, 11(2), e1151.  | : 일차 유효성 평가변수와 동일한 방법을 적용한다.  | (Zung’s Self-Rating | 대리인)에게 제공해야 한다.  | 위원회 및 식품의약품안전처장의 승인을 받아야 한다.  | 얻는 전 과정에 참석하여야 한다. ",
        "original_sentence": "| : 일차 유효성 평가변수와 동일한 방법을 적용한다. "
      }
    },
    {
      "chunk_id": "chunk_282",
      "text": "| (Zung’s Self-Rating | 대리인)에게 제공해야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 281,
        "window_size": 3,
        "char_count": 40,
        "word_count": 7,
        "page_number": 13,
        "window_text": "| 방지 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | - 귀결 분석은 감정 저하를 일으키는 잠재된 두려움, 사고, 가정 | 우울장애 관련 요소로서 무망감을 측정하기 위해 고안된 | 상태를 의미하며, 100점은 가장 좋은 건강 상태를 의미이다.  | □ 예 | ■ 아니오 |\n| of medical Internet research, 11(2), e1151.  | : 일차 유효성 평가변수와 동일한 방법을 적용한다.  | (Zung’s Self-Rating | 대리인)에게 제공해야 한다.  | 위원회 및 식품의약품안전처장의 승인을 받아야 한다.  | 얻는 전 과정에 참석하여야 한다.  | - 병력 등을 문진과 과거 진료 기록을 통해 조사한다. ",
        "original_sentence": "| (Zung’s Self-Rating | 대리인)에게 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_283",
      "text": "| 위원회 및 식품의약품안전처장의 승인을 받아야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 282,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 13,
        "window_text": "| □ 예 | ■ 아니오 |\n| of medical Internet research, 11(2), e1151.  | : 일차 유효성 평가변수와 동일한 방법을 적용한다.  | (Zung’s Self-Rating | 대리인)에게 제공해야 한다.  | 위원회 및 식품의약품안전처장의 승인을 받아야 한다.  | 얻는 전 과정에 참석하여야 한다.  | - 병력 등을 문진과 과거 진료 기록을 통해 조사한다.  | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 프로 | 교정 및 기저 불안을 줄이는 내용이 포함되어야 한다. ",
        "original_sentence": "| 위원회 및 식품의약품안전처장의 승인을 받아야 한다. "
      }
    },
    {
      "chunk_id": "chunk_284",
      "text": "| 얻는 전 과정에 참석하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 283,
        "window_size": 3,
        "char_count": 21,
        "word_count": 6,
        "page_number": 13,
        "window_text": "| : 일차 유효성 평가변수와 동일한 방법을 적용한다.  | (Zung’s Self-Rating | 대리인)에게 제공해야 한다.  | 위원회 및 식품의약품안전처장의 승인을 받아야 한다.  | 얻는 전 과정에 참석하여야 한다.  | - 병력 등을 문진과 과거 진료 기록을 통해 조사한다.  | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 프로 | 교정 및 기저 불안을 줄이는 내용이 포함되어야 한다.  | IEC/TR | 방법, 암호화 필요 여부, 과거에 전송된 | 내용을 기록한다. ",
        "original_sentence": "| 얻는 전 과정에 참석하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_285",
      "text": "| - 병력 등을 문진과 과거 진료 기록을 통해 조사한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 284,
        "window_size": 3,
        "char_count": 33,
        "word_count": 10,
        "page_number": 13,
        "window_text": "| (Zung’s Self-Rating | 대리인)에게 제공해야 한다.  | 위원회 및 식품의약품안전처장의 승인을 받아야 한다.  | 얻는 전 과정에 참석하여야 한다.  | - 병력 등을 문진과 과거 진료 기록을 통해 조사한다.  | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 프로 | 교정 및 기저 불안을 줄이는 내용이 포함되어야 한다.  | IEC/TR | 방법, 암호화 필요 여부, 과거에 전송된 | 내용을 기록한다.  | 발생 가능한 | Part 1: Guidance on the | 때까지 | 분해하고, | 각 | 유닛에 | DiGA 디렉터리에 등록되었다. ",
        "original_sentence": "| - 병력 등을 문진과 과거 진료 기록을 통해 조사한다. "
      }
    },
    {
      "chunk_id": "chunk_286",
      "text": "| - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 프로 | 교정 및 기저 불안을 줄이는 내용이 포함되어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 285,
        "window_size": 3,
        "char_count": 70,
        "word_count": 19,
        "page_number": 29,
        "window_text": "| 위원회 및 식품의약품안전처장의 승인을 받아야 한다.  | 얻는 전 과정에 참석하여야 한다.  | - 병력 등을 문진과 과거 진료 기록을 통해 조사한다.  | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 프로 | 교정 및 기저 불안을 줄이는 내용이 포함되어야 한다.  | IEC/TR | 방법, 암호화 필요 여부, 과거에 전송된 | 내용을 기록한다.  | 발생 가능한 | Part 1: Guidance on the | 때까지 | 분해하고, | 각 | 유닛에 | DiGA 디렉터리에 등록되었다.  | 유효성 | 심각 | 위험 | (AB-1234) |\n| 3) 임상시험용 의료기기 : 우울장애 개선 디지털치료기기(OOO) | 6) 검증되지 않은 임상시험이라는 사실 | 2) 일반적 주의 | 8 | 무망감 질문지(Hopelessness Depression Symptom Questionnaire, HDSQ) | 기록한다. ",
        "original_sentence": "| - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 프로 | 교정 및 기저 불안을 줄이는 내용이 포함되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_287",
      "text": "| IEC/TR | 방법, 암호화 필요 여부, 과거에 전송된 | 내용을 기록한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 286,
        "window_size": 3,
        "char_count": 46,
        "word_count": 12,
        "page_number": 3,
        "window_text": "| 얻는 전 과정에 참석하여야 한다.  | - 병력 등을 문진과 과거 진료 기록을 통해 조사한다.  | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 프로 | 교정 및 기저 불안을 줄이는 내용이 포함되어야 한다.  | IEC/TR | 방법, 암호화 필요 여부, 과거에 전송된 | 내용을 기록한다.  | 발생 가능한 | Part 1: Guidance on the | 때까지 | 분해하고, | 각 | 유닛에 | DiGA 디렉터리에 등록되었다.  | 유효성 | 심각 | 위험 | (AB-1234) |\n| 3) 임상시험용 의료기기 : 우울장애 개선 디지털치료기기(OOO) | 6) 검증되지 않은 임상시험이라는 사실 | 2) 일반적 주의 | 8 | 무망감 질문지(Hopelessness Depression Symptom Questionnaire, HDSQ) | 기록한다.  | 하여야 한다. ",
        "original_sentence": "| IEC/TR | 방법, 암호화 필요 여부, 과거에 전송된 | 내용을 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_288",
      "text": "| 발생 가능한 | Part 1: Guidance on the | 때까지 | 분해하고, | 각 | 유닛에 | DiGA 디렉터리에 등록되었다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 287,
        "window_size": 3,
        "char_count": 79,
        "word_count": 21,
        "page_number": 28,
        "window_text": "| - 병력 등을 문진과 과거 진료 기록을 통해 조사한다.  | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 프로 | 교정 및 기저 불안을 줄이는 내용이 포함되어야 한다.  | IEC/TR | 방법, 암호화 필요 여부, 과거에 전송된 | 내용을 기록한다.  | 발생 가능한 | Part 1: Guidance on the | 때까지 | 분해하고, | 각 | 유닛에 | DiGA 디렉터리에 등록되었다.  | 유효성 | 심각 | 위험 | (AB-1234) |\n| 3) 임상시험용 의료기기 : 우울장애 개선 디지털치료기기(OOO) | 6) 검증되지 않은 임상시험이라는 사실 | 2) 일반적 주의 | 8 | 무망감 질문지(Hopelessness Depression Symptom Questionnaire, HDSQ) | 기록한다.  | 하여야 한다.  | Deciding When to Submit a | 생체인증 등 | 있던 기기에서는 로그아웃 | 규칙」,「의료기기 | 허가·신고·심사 | 로그인을 시도한다. ",
        "original_sentence": "| 발생 가능한 | Part 1: Guidance on the | 때까지 | 분해하고, | 각 | 유닛에 | DiGA 디렉터리에 등록되었다. "
      }
    },
    {
      "chunk_id": "chunk_289",
      "text": "| 유효성 | 심각 | 위험 | (AB-1234) |\n| 3) 임상시험용 의료기기 : 우울장애 개선 디지털치료기기(OOO) | 6) 검증되지 않은 임상시험이라는 사실 | 2) 일반적 주의 | 8 | 무망감 질문지(Hopelessness Depression Symptom Questionnaire, HDSQ) | 기록한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 288,
        "window_size": 3,
        "char_count": 180,
        "word_count": 38,
        "page_number": 9,
        "window_text": "| - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 프로 | 교정 및 기저 불안을 줄이는 내용이 포함되어야 한다.  | IEC/TR | 방법, 암호화 필요 여부, 과거에 전송된 | 내용을 기록한다.  | 발생 가능한 | Part 1: Guidance on the | 때까지 | 분해하고, | 각 | 유닛에 | DiGA 디렉터리에 등록되었다.  | 유효성 | 심각 | 위험 | (AB-1234) |\n| 3) 임상시험용 의료기기 : 우울장애 개선 디지털치료기기(OOO) | 6) 검증되지 않은 임상시험이라는 사실 | 2) 일반적 주의 | 8 | 무망감 질문지(Hopelessness Depression Symptom Questionnaire, HDSQ) | 기록한다.  | 하여야 한다.  | Deciding When to Submit a | 생체인증 등 | 있던 기기에서는 로그아웃 | 규칙」,「의료기기 | 허가·신고·심사 | 로그인을 시도한다.  | 확인 자료 |\n| 4 | 3) 맹검 방법 | 파록세틴(paroxetine) | SSRI | 20-50 | 사례 | 위해상황 | 위해 | - 어떤 목표를 성공적으로 달성하는 데에서 오는 자기 보상은 점차 | 문항 점수를 합산한다. ",
        "original_sentence": "| 유효성 | 심각 | 위험 | (AB-1234) |\n| 3) 임상시험용 의료기기 : 우울장애 개선 디지털치료기기(OOO) | 6) 검증되지 않은 임상시험이라는 사실 | 2) 일반적 주의 | 8 | 무망감 질문지(Hopelessness Depression Symptom Questionnaire, HDSQ) | 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_290",
      "text": "| 하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 289,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 13,
        "window_text": "| IEC/TR | 방법, 암호화 필요 여부, 과거에 전송된 | 내용을 기록한다.  | 발생 가능한 | Part 1: Guidance on the | 때까지 | 분해하고, | 각 | 유닛에 | DiGA 디렉터리에 등록되었다.  | 유효성 | 심각 | 위험 | (AB-1234) |\n| 3) 임상시험용 의료기기 : 우울장애 개선 디지털치료기기(OOO) | 6) 검증되지 않은 임상시험이라는 사실 | 2) 일반적 주의 | 8 | 무망감 질문지(Hopelessness Depression Symptom Questionnaire, HDSQ) | 기록한다.  | 하여야 한다.  | Deciding When to Submit a | 생체인증 등 | 있던 기기에서는 로그아웃 | 규칙」,「의료기기 | 허가·신고·심사 | 로그인을 시도한다.  | 확인 자료 |\n| 4 | 3) 맹검 방법 | 파록세틴(paroxetine) | SSRI | 20-50 | 사례 | 위해상황 | 위해 | - 어떤 목표를 성공적으로 달성하는 데에서 오는 자기 보상은 점차 | 문항 점수를 합산한다.  SDS에서 50점 이상은 경미, 60점 | 시판 후 소프트웨어에 문제가 | 위험관리 방법에 대한 국제 | 가능 | 도 | 결과 | 국외 |\n| 기타 확인 | 1) 개요 | 3) 기타 이차 유효성 평가변수 | 1 | 디지털치료기기 허가·심사 | (Hopelessness | https://health.colostate.edu/silv | 세스 | 명령어 및 데이터의 비인가 반복에 대한 | https://www.novego.de//) | 민원인을 구속하는 내용이 있습니까? ",
        "original_sentence": "| 하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_291",
      "text": "| Deciding When to Submit a | 생체인증 등 | 있던 기기에서는 로그아웃 | 규칙」,「의료기기 | 허가·신고·심사 | 로그인을 시도한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 290,
        "window_size": 3,
        "char_count": 89,
        "word_count": 20,
        "page_number": 18,
        "window_text": "| 발생 가능한 | Part 1: Guidance on the | 때까지 | 분해하고, | 각 | 유닛에 | DiGA 디렉터리에 등록되었다.  | 유효성 | 심각 | 위험 | (AB-1234) |\n| 3) 임상시험용 의료기기 : 우울장애 개선 디지털치료기기(OOO) | 6) 검증되지 않은 임상시험이라는 사실 | 2) 일반적 주의 | 8 | 무망감 질문지(Hopelessness Depression Symptom Questionnaire, HDSQ) | 기록한다.  | 하여야 한다.  | Deciding When to Submit a | 생체인증 등 | 있던 기기에서는 로그아웃 | 규칙」,「의료기기 | 허가·신고·심사 | 로그인을 시도한다.  | 확인 자료 |\n| 4 | 3) 맹검 방법 | 파록세틴(paroxetine) | SSRI | 20-50 | 사례 | 위해상황 | 위해 | - 어떤 목표를 성공적으로 달성하는 데에서 오는 자기 보상은 점차 | 문항 점수를 합산한다.  SDS에서 50점 이상은 경미, 60점 | 시판 후 소프트웨어에 문제가 | 위험관리 방법에 대한 국제 | 가능 | 도 | 결과 | 국외 |\n| 기타 확인 | 1) 개요 | 3) 기타 이차 유효성 평가변수 | 1 | 디지털치료기기 허가·심사 | (Hopelessness | https://health.colostate.edu/silv | 세스 | 명령어 및 데이터의 비인가 반복에 대한 | https://www.novego.de//) | 민원인을 구속하는 내용이 있습니까?  | 등을 이해하기 위한 유용한 수단이 된다. ",
        "original_sentence": "| Deciding When to Submit a | 생체인증 등 | 있던 기기에서는 로그아웃 | 규칙」,「의료기기 | 허가·신고·심사 | 로그인을 시도한다. "
      }
    },
    {
      "chunk_id": "chunk_292",
      "text": "| 확인 자료 |\n| 4 | 3) 맹검 방법 | 파록세틴(paroxetine) | SSRI | 20-50 | 사례 | 위해상황 | 위해 | - 어떤 목표를 성공적으로 달성하는 데에서 오는 자기 보상은 점차 | 문항 점수를 합산한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 291,
        "window_size": 3,
        "char_count": 130,
        "word_count": 37,
        "page_number": 21,
        "window_text": "| 유효성 | 심각 | 위험 | (AB-1234) |\n| 3) 임상시험용 의료기기 : 우울장애 개선 디지털치료기기(OOO) | 6) 검증되지 않은 임상시험이라는 사실 | 2) 일반적 주의 | 8 | 무망감 질문지(Hopelessness Depression Symptom Questionnaire, HDSQ) | 기록한다.  | 하여야 한다.  | Deciding When to Submit a | 생체인증 등 | 있던 기기에서는 로그아웃 | 규칙」,「의료기기 | 허가·신고·심사 | 로그인을 시도한다.  | 확인 자료 |\n| 4 | 3) 맹검 방법 | 파록세틴(paroxetine) | SSRI | 20-50 | 사례 | 위해상황 | 위해 | - 어떤 목표를 성공적으로 달성하는 데에서 오는 자기 보상은 점차 | 문항 점수를 합산한다.  SDS에서 50점 이상은 경미, 60점 | 시판 후 소프트웨어에 문제가 | 위험관리 방법에 대한 국제 | 가능 | 도 | 결과 | 국외 |\n| 기타 확인 | 1) 개요 | 3) 기타 이차 유효성 평가변수 | 1 | 디지털치료기기 허가·심사 | (Hopelessness | https://health.colostate.edu/silv | 세스 | 명령어 및 데이터의 비인가 반복에 대한 | https://www.novego.de//) | 민원인을 구속하는 내용이 있습니까?  | 등을 이해하기 위한 유용한 수단이 된다.  “만약...라면?”이라는 | 것이다. ",
        "original_sentence": "| 확인 자료 |\n| 4 | 3) 맹검 방법 | 파록세틴(paroxetine) | SSRI | 20-50 | 사례 | 위해상황 | 위해 | - 어떤 목표를 성공적으로 달성하는 데에서 오는 자기 보상은 점차 | 문항 점수를 합산한다. "
      }
    },
    {
      "chunk_id": "chunk_293",
      "text": "SDS에서 50점 이상은 경미, 60점 | 시판 후 소프트웨어에 문제가 | 위험관리 방법에 대한 국제 | 가능 | 도 | 결과 | 국외 |\n| 기타 확인 | 1) 개요 | 3) 기타 이차 유효성 평가변수 | 1 | 디지털치료기기 허가·심사 | (Hopelessness | https://health.colostate.edu/silv | 세스 | 명령어 및 데이터의 비인가 반복에 대한 | https://www.novego.de//) | 민원인을 구속하는 내용이 있습니까? ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 292,
        "window_size": 3,
        "char_count": 264,
        "word_count": 61,
        "page_number": 9,
        "window_text": "| 하여야 한다.  | Deciding When to Submit a | 생체인증 등 | 있던 기기에서는 로그아웃 | 규칙」,「의료기기 | 허가·신고·심사 | 로그인을 시도한다.  | 확인 자료 |\n| 4 | 3) 맹검 방법 | 파록세틴(paroxetine) | SSRI | 20-50 | 사례 | 위해상황 | 위해 | - 어떤 목표를 성공적으로 달성하는 데에서 오는 자기 보상은 점차 | 문항 점수를 합산한다.  SDS에서 50점 이상은 경미, 60점 | 시판 후 소프트웨어에 문제가 | 위험관리 방법에 대한 국제 | 가능 | 도 | 결과 | 국외 |\n| 기타 확인 | 1) 개요 | 3) 기타 이차 유효성 평가변수 | 1 | 디지털치료기기 허가·심사 | (Hopelessness | https://health.colostate.edu/silv | 세스 | 명령어 및 데이터의 비인가 반복에 대한 | https://www.novego.de//) | 민원인을 구속하는 내용이 있습니까?  | 등을 이해하기 위한 유용한 수단이 된다.  “만약...라면?”이라는 | 것이다.  HDSQ는 32문항에 4점 척도로 구성되었으며 하위 | = (건강 문제로 인해 손실된 시간의 비율) + [(1 - 건강 문제로 | 의료기기 내 소프트웨어 변경에 따른 | 확인 자료 |\n| 80002-1 | treatment 후 변화량의 평균과 표준편차를 제시한다. ",
        "original_sentence": "SDS에서 50점 이상은 경미, 60점 | 시판 후 소프트웨어에 문제가 | 위험관리 방법에 대한 국제 | 가능 | 도 | 결과 | 국외 |\n| 기타 확인 | 1) 개요 | 3) 기타 이차 유효성 평가변수 | 1 | 디지털치료기기 허가·심사 | (Hopelessness | https://health.colostate.edu/silv | 세스 | 명령어 및 데이터의 비인가 반복에 대한 | https://www.novego.de//) | 민원인을 구속하는 내용이 있습니까? "
      }
    },
    {
      "chunk_id": "chunk_294",
      "text": "| 등을 이해하기 위한 유용한 수단이 된다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 293,
        "window_size": 3,
        "char_count": 25,
        "word_count": 7,
        "page_number": 19,
        "window_text": "| Deciding When to Submit a | 생체인증 등 | 있던 기기에서는 로그아웃 | 규칙」,「의료기기 | 허가·신고·심사 | 로그인을 시도한다.  | 확인 자료 |\n| 4 | 3) 맹검 방법 | 파록세틴(paroxetine) | SSRI | 20-50 | 사례 | 위해상황 | 위해 | - 어떤 목표를 성공적으로 달성하는 데에서 오는 자기 보상은 점차 | 문항 점수를 합산한다.  SDS에서 50점 이상은 경미, 60점 | 시판 후 소프트웨어에 문제가 | 위험관리 방법에 대한 국제 | 가능 | 도 | 결과 | 국외 |\n| 기타 확인 | 1) 개요 | 3) 기타 이차 유효성 평가변수 | 1 | 디지털치료기기 허가·심사 | (Hopelessness | https://health.colostate.edu/silv | 세스 | 명령어 및 데이터의 비인가 반복에 대한 | https://www.novego.de//) | 민원인을 구속하는 내용이 있습니까?  | 등을 이해하기 위한 유용한 수단이 된다.  “만약...라면?”이라는 | 것이다.  HDSQ는 32문항에 4점 척도로 구성되었으며 하위 | = (건강 문제로 인해 손실된 시간의 비율) + [(1 - 건강 문제로 | 의료기기 내 소프트웨어 변경에 따른 | 확인 자료 |\n| 80002-1 | treatment 후 변화량의 평균과 표준편차를 제시한다.  | application of ISO 14971 to | 되어야 한다. ",
        "original_sentence": "| 등을 이해하기 위한 유용한 수단이 된다. "
      }
    },
    {
      "chunk_id": "chunk_295",
      "text": "“만약...라면?”이라는 | 것이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 294,
        "window_size": 3,
        "char_count": 21,
        "word_count": 3,
        "page_number": 1,
        "window_text": "| 확인 자료 |\n| 4 | 3) 맹검 방법 | 파록세틴(paroxetine) | SSRI | 20-50 | 사례 | 위해상황 | 위해 | - 어떤 목표를 성공적으로 달성하는 데에서 오는 자기 보상은 점차 | 문항 점수를 합산한다.  SDS에서 50점 이상은 경미, 60점 | 시판 후 소프트웨어에 문제가 | 위험관리 방법에 대한 국제 | 가능 | 도 | 결과 | 국외 |\n| 기타 확인 | 1) 개요 | 3) 기타 이차 유효성 평가변수 | 1 | 디지털치료기기 허가·심사 | (Hopelessness | https://health.colostate.edu/silv | 세스 | 명령어 및 데이터의 비인가 반복에 대한 | https://www.novego.de//) | 민원인을 구속하는 내용이 있습니까?  | 등을 이해하기 위한 유용한 수단이 된다.  “만약...라면?”이라는 | 것이다.  HDSQ는 32문항에 4점 척도로 구성되었으며 하위 | = (건강 문제로 인해 손실된 시간의 비율) + [(1 - 건강 문제로 | 의료기기 내 소프트웨어 변경에 따른 | 확인 자료 |\n| 80002-1 | treatment 후 변화량의 평균과 표준편차를 제시한다.  | application of ISO 14971 to | 되어야 한다.  | 대한 | 상세 | 설계를 | 수행한다. ",
        "original_sentence": "“만약...라면?”이라는 | 것이다. "
      }
    },
    {
      "chunk_id": "chunk_296",
      "text": "HDSQ는 32문항에 4점 척도로 구성되었으며 하위 | = (건강 문제로 인해 손실된 시간의 비율) + [(1 - 건강 문제로 | 의료기기 내 소프트웨어 변경에 따른 | 확인 자료 |\n| 80002-1 | treatment 후 변화량의 평균과 표준편차를 제시한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 295,
        "window_size": 3,
        "char_count": 148,
        "word_count": 38,
        "page_number": 9,
        "window_text": "SDS에서 50점 이상은 경미, 60점 | 시판 후 소프트웨어에 문제가 | 위험관리 방법에 대한 국제 | 가능 | 도 | 결과 | 국외 |\n| 기타 확인 | 1) 개요 | 3) 기타 이차 유효성 평가변수 | 1 | 디지털치료기기 허가·심사 | (Hopelessness | https://health.colostate.edu/silv | 세스 | 명령어 및 데이터의 비인가 반복에 대한 | https://www.novego.de//) | 민원인을 구속하는 내용이 있습니까?  | 등을 이해하기 위한 유용한 수단이 된다.  “만약...라면?”이라는 | 것이다.  HDSQ는 32문항에 4점 척도로 구성되었으며 하위 | = (건강 문제로 인해 손실된 시간의 비율) + [(1 - 건강 문제로 | 의료기기 내 소프트웨어 변경에 따른 | 확인 자료 |\n| 80002-1 | treatment 후 변화량의 평균과 표준편차를 제시한다.  | application of ISO 14971 to | 되어야 한다.  | 대한 | 상세 | 설계를 | 수행한다.  | 성 |\n| 2. ",
        "original_sentence": "HDSQ는 32문항에 4점 척도로 구성되었으며 하위 | = (건강 문제로 인해 손실된 시간의 비율) + [(1 - 건강 문제로 | 의료기기 내 소프트웨어 변경에 따른 | 확인 자료 |\n| 80002-1 | treatment 후 변화량의 평균과 표준편차를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_297",
      "text": "| application of ISO 14971 to | 되어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 296,
        "window_size": 3,
        "char_count": 40,
        "word_count": 9,
        "page_number": 13,
        "window_text": "| 등을 이해하기 위한 유용한 수단이 된다.  “만약...라면?”이라는 | 것이다.  HDSQ는 32문항에 4점 척도로 구성되었으며 하위 | = (건강 문제로 인해 손실된 시간의 비율) + [(1 - 건강 문제로 | 의료기기 내 소프트웨어 변경에 따른 | 확인 자료 |\n| 80002-1 | treatment 후 변화량의 평균과 표준편차를 제시한다.  | application of ISO 14971 to | 되어야 한다.  | 대한 | 상세 | 설계를 | 수행한다.  | 성 |\n| 2.  문의처 | 9 | 설트랄린(sertraline) | SSRI | 50-200 | 9 | 벡 자살 사고 척도(Beck Suicidal ideation Scale, BSS) | - 심각한 부작용 발생으로 조기 종료시킬 수 있다. ",
        "original_sentence": "| application of ISO 14971 to | 되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_298",
      "text": "| 대한 | 상세 | 설계를 | 수행한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 297,
        "window_size": 3,
        "char_count": 24,
        "word_count": 8,
        "page_number": 13,
        "window_text": "“만약...라면?”이라는 | 것이다.  HDSQ는 32문항에 4점 척도로 구성되었으며 하위 | = (건강 문제로 인해 손실된 시간의 비율) + [(1 - 건강 문제로 | 의료기기 내 소프트웨어 변경에 따른 | 확인 자료 |\n| 80002-1 | treatment 후 변화량의 평균과 표준편차를 제시한다.  | application of ISO 14971 to | 되어야 한다.  | 대한 | 상세 | 설계를 | 수행한다.  | 성 |\n| 2.  문의처 | 9 | 설트랄린(sertraline) | SSRI | 50-200 | 9 | 벡 자살 사고 척도(Beck Suicidal ideation Scale, BSS) | - 심각한 부작용 발생으로 조기 종료시킬 수 있다.  | 510(k) for a Software Change | 내용을 기록한다. ",
        "original_sentence": "| 대한 | 상세 | 설계를 | 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_299",
      "text": "| 성 |\n| 2. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 298,
        "window_size": 3,
        "char_count": 11,
        "word_count": 5,
        "page_number": 9,
        "window_text": "HDSQ는 32문항에 4점 척도로 구성되었으며 하위 | = (건강 문제로 인해 손실된 시간의 비율) + [(1 - 건강 문제로 | 의료기기 내 소프트웨어 변경에 따른 | 확인 자료 |\n| 80002-1 | treatment 후 변화량의 평균과 표준편차를 제시한다.  | application of ISO 14971 to | 되어야 한다.  | 대한 | 상세 | 설계를 | 수행한다.  | 성 |\n| 2.  문의처 | 9 | 설트랄린(sertraline) | SSRI | 50-200 | 9 | 벡 자살 사고 척도(Beck Suicidal ideation Scale, BSS) | - 심각한 부작용 발생으로 조기 종료시킬 수 있다.  | 510(k) for a Software Change | 내용을 기록한다.  | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | 이상은 중증도, 70점 이상을 고도의 심각성으로 분류할 것을 | 등에 관한 규정」 기반, 디지털치료 | 국내 | 미국 |\n| 사항 | 시험계획서의 절차에 따라 이루어지도록 하여야 한다. ",
        "original_sentence": "| 성 |\n| 2. "
      }
    },
    {
      "chunk_id": "chunk_300",
      "text": "문의처 | 9 | 설트랄린(sertraline) | SSRI | 50-200 | 9 | 벡 자살 사고 척도(Beck Suicidal ideation Scale, BSS) | - 심각한 부작용 발생으로 조기 종료시킬 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 299,
        "window_size": 3,
        "char_count": 126,
        "word_count": 29,
        "page_number": 9,
        "window_text": "| application of ISO 14971 to | 되어야 한다.  | 대한 | 상세 | 설계를 | 수행한다.  | 성 |\n| 2.  문의처 | 9 | 설트랄린(sertraline) | SSRI | 50-200 | 9 | 벡 자살 사고 척도(Beck Suicidal ideation Scale, BSS) | - 심각한 부작용 발생으로 조기 종료시킬 수 있다.  | 510(k) for a Software Change | 내용을 기록한다.  | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | 이상은 중증도, 70점 이상을 고도의 심각성으로 분류할 것을 | 등에 관한 규정」 기반, 디지털치료 | 국내 | 미국 |\n| 사항 | 시험계획서의 절차에 따라 이루어지도록 하여야 한다.  | 될 것이라는 사실 | - 사용자 반응 평가 | - 이상 반응에 대해 보다 가능성 있는 원인이 있는 경우 | 주요분석군으로 분석한다. ",
        "original_sentence": "문의처 | 9 | 설트랄린(sertraline) | SSRI | 50-200 | 9 | 벡 자살 사고 척도(Beck Suicidal ideation Scale, BSS) | - 심각한 부작용 발생으로 조기 종료시킬 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_301",
      "text": "| 510(k) for a Software Change | 내용을 기록한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 300,
        "window_size": 3,
        "char_count": 43,
        "word_count": 9,
        "page_number": 13,
        "window_text": "| 대한 | 상세 | 설계를 | 수행한다.  | 성 |\n| 2.  문의처 | 9 | 설트랄린(sertraline) | SSRI | 50-200 | 9 | 벡 자살 사고 척도(Beck Suicidal ideation Scale, BSS) | - 심각한 부작용 발생으로 조기 종료시킬 수 있다.  | 510(k) for a Software Change | 내용을 기록한다.  | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | 이상은 중증도, 70점 이상을 고도의 심각성으로 분류할 것을 | 등에 관한 규정」 기반, 디지털치료 | 국내 | 미국 |\n| 사항 | 시험계획서의 절차에 따라 이루어지도록 하여야 한다.  | 될 것이라는 사실 | - 사용자 반응 평가 | - 이상 반응에 대해 보다 가능성 있는 원인이 있는 경우 | 주요분석군으로 분석한다.  | Baseline 정보를 수집한다. ",
        "original_sentence": "| 510(k) for a Software Change | 내용을 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_302",
      "text": "| 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | 이상은 중증도, 70점 이상을 고도의 심각성으로 분류할 것을 | 등에 관한 규정」 기반, 디지털치료 | 국내 | 미국 |\n| 사항 | 시험계획서의 절차에 따라 이루어지도록 하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 301,
        "window_size": 3,
        "char_count": 140,
        "word_count": 37,
        "page_number": 9,
        "window_text": "| 성 |\n| 2.  문의처 | 9 | 설트랄린(sertraline) | SSRI | 50-200 | 9 | 벡 자살 사고 척도(Beck Suicidal ideation Scale, BSS) | - 심각한 부작용 발생으로 조기 종료시킬 수 있다.  | 510(k) for a Software Change | 내용을 기록한다.  | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | 이상은 중증도, 70점 이상을 고도의 심각성으로 분류할 것을 | 등에 관한 규정」 기반, 디지털치료 | 국내 | 미국 |\n| 사항 | 시험계획서의 절차에 따라 이루어지도록 하여야 한다.  | 될 것이라는 사실 | - 사용자 반응 평가 | - 이상 반응에 대해 보다 가능성 있는 원인이 있는 경우 | 주요분석군으로 분석한다.  | Baseline 정보를 수집한다.  | 자기 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 활동을 늘리게 하고 그것을 유지케 하는 효과적인 수단이 된다. ",
        "original_sentence": "| 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | 이상은 중증도, 70점 이상을 고도의 심각성으로 분류할 것을 | 등에 관한 규정」 기반, 디지털치료 | 국내 | 미국 |\n| 사항 | 시험계획서의 절차에 따라 이루어지도록 하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_303",
      "text": "| 될 것이라는 사실 | - 사용자 반응 평가 | - 이상 반응에 대해 보다 가능성 있는 원인이 있는 경우 | 주요분석군으로 분석한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 302,
        "window_size": 3,
        "char_count": 76,
        "word_count": 23,
        "page_number": 29,
        "window_text": "문의처 | 9 | 설트랄린(sertraline) | SSRI | 50-200 | 9 | 벡 자살 사고 척도(Beck Suicidal ideation Scale, BSS) | - 심각한 부작용 발생으로 조기 종료시킬 수 있다.  | 510(k) for a Software Change | 내용을 기록한다.  | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | 이상은 중증도, 70점 이상을 고도의 심각성으로 분류할 것을 | 등에 관한 규정」 기반, 디지털치료 | 국내 | 미국 |\n| 사항 | 시험계획서의 절차에 따라 이루어지도록 하여야 한다.  | 될 것이라는 사실 | - 사용자 반응 평가 | - 이상 반응에 대해 보다 가능성 있는 원인이 있는 경우 | 주요분석군으로 분석한다.  | Baseline 정보를 수집한다.  | 자기 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 활동을 늘리게 하고 그것을 유지케 하는 효과적인 수단이 된다.  | 인해 손실된 시간의 비율) × 건강 문제로 인해 일하는 동안 | 발생하거나 개선의 필요성 때문에 | 성 | 규격 | 소프트웨어 |\n| 1) 치료 전 대비 3개월 후 우울장애 심각도 척도(BDI) 변화량 | 7) 피험자에게 미칠 것으로 예상되는 위험이나 불편 | Depression Symptom | 2 | 벤라팍신(venlafaxine) | SNRI | 75-225 | 임상시험에서 배제 | 방지, 사전에 정의된 통신 종료 시점의 | 가이드라인(민원인 안내서) | ercloud/) | 질문을 통해 환자의 잠재된 사고에 이를 수 있도록 유도한다. ",
        "original_sentence": "| 될 것이라는 사실 | - 사용자 반응 평가 | - 이상 반응에 대해 보다 가능성 있는 원인이 있는 경우 | 주요분석군으로 분석한다. "
      }
    },
    {
      "chunk_id": "chunk_304",
      "text": "| Baseline 정보를 수집한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 303,
        "window_size": 3,
        "char_count": 21,
        "word_count": 4,
        "page_number": 13,
        "window_text": "| 510(k) for a Software Change | 내용을 기록한다.  | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | 이상은 중증도, 70점 이상을 고도의 심각성으로 분류할 것을 | 등에 관한 규정」 기반, 디지털치료 | 국내 | 미국 |\n| 사항 | 시험계획서의 절차에 따라 이루어지도록 하여야 한다.  | 될 것이라는 사실 | - 사용자 반응 평가 | - 이상 반응에 대해 보다 가능성 있는 원인이 있는 경우 | 주요분석군으로 분석한다.  | Baseline 정보를 수집한다.  | 자기 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 활동을 늘리게 하고 그것을 유지케 하는 효과적인 수단이 된다.  | 인해 손실된 시간의 비율) × 건강 문제로 인해 일하는 동안 | 발생하거나 개선의 필요성 때문에 | 성 | 규격 | 소프트웨어 |\n| 1) 치료 전 대비 3개월 후 우울장애 심각도 척도(BDI) 변화량 | 7) 피험자에게 미칠 것으로 예상되는 위험이나 불편 | Depression Symptom | 2 | 벤라팍신(venlafaxine) | SNRI | 75-225 | 임상시험에서 배제 | 방지, 사전에 정의된 통신 종료 시점의 | 가이드라인(민원인 안내서) | ercloud/) | 질문을 통해 환자의 잠재된 사고에 이를 수 있도록 유도한다.  | 요인으로 8 요인(동기적 결핍, 대인관계의 의존성, 정신 | 지침 가이드라인 | 것을 권장하고 있다. ",
        "original_sentence": "| Baseline 정보를 수집한다. "
      }
    },
    {
      "chunk_id": "chunk_305",
      "text": "| 자기 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 활동을 늘리게 하고 그것을 유지케 하는 효과적인 수단이 된다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 304,
        "window_size": 3,
        "char_count": 89,
        "word_count": 24,
        "page_number": 18,
        "window_text": "| 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | 이상은 중증도, 70점 이상을 고도의 심각성으로 분류할 것을 | 등에 관한 규정」 기반, 디지털치료 | 국내 | 미국 |\n| 사항 | 시험계획서의 절차에 따라 이루어지도록 하여야 한다.  | 될 것이라는 사실 | - 사용자 반응 평가 | - 이상 반응에 대해 보다 가능성 있는 원인이 있는 경우 | 주요분석군으로 분석한다.  | Baseline 정보를 수집한다.  | 자기 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 활동을 늘리게 하고 그것을 유지케 하는 효과적인 수단이 된다.  | 인해 손실된 시간의 비율) × 건강 문제로 인해 일하는 동안 | 발생하거나 개선의 필요성 때문에 | 성 | 규격 | 소프트웨어 |\n| 1) 치료 전 대비 3개월 후 우울장애 심각도 척도(BDI) 변화량 | 7) 피험자에게 미칠 것으로 예상되는 위험이나 불편 | Depression Symptom | 2 | 벤라팍신(venlafaxine) | SNRI | 75-225 | 임상시험에서 배제 | 방지, 사전에 정의된 통신 종료 시점의 | 가이드라인(민원인 안내서) | ercloud/) | 질문을 통해 환자의 잠재된 사고에 이를 수 있도록 유도한다.  | 요인으로 8 요인(동기적 결핍, 대인관계의 의존성, 정신 | 지침 가이드라인 | 것을 권장하고 있다.  |\n| 9 | 소프트웨어 | 내용을 기재함 | 생산성 손실 점수 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 때문에 가장 개연성이 있게 설명되는 경우 | 오송보건의료행정타운 | medical device software | 또한 소프트웨어 유닛 및 외부 |\n| 85(4), 367. ",
        "original_sentence": "| 자기 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 활동을 늘리게 하고 그것을 유지케 하는 효과적인 수단이 된다. "
      }
    },
    {
      "chunk_id": "chunk_306",
      "text": "| 인해 손실된 시간의 비율) × 건강 문제로 인해 일하는 동안 | 발생하거나 개선의 필요성 때문에 | 성 | 규격 | 소프트웨어 |\n| 1) 치료 전 대비 3개월 후 우울장애 심각도 척도(BDI) 변화량 | 7) 피험자에게 미칠 것으로 예상되는 위험이나 불편 | Depression Symptom | 2 | 벤라팍신(venlafaxine) | SNRI | 75-225 | 임상시험에서 배제 | 방지, 사전에 정의된 통신 종료 시점의 | 가이드라인(민원인 안내서) | ercloud/) | 질문을 통해 환자의 잠재된 사고에 이를 수 있도록 유도한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 305,
        "window_size": 3,
        "char_count": 308,
        "word_count": 78,
        "page_number": 39,
        "window_text": "| 될 것이라는 사실 | - 사용자 반응 평가 | - 이상 반응에 대해 보다 가능성 있는 원인이 있는 경우 | 주요분석군으로 분석한다.  | Baseline 정보를 수집한다.  | 자기 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 활동을 늘리게 하고 그것을 유지케 하는 효과적인 수단이 된다.  | 인해 손실된 시간의 비율) × 건강 문제로 인해 일하는 동안 | 발생하거나 개선의 필요성 때문에 | 성 | 규격 | 소프트웨어 |\n| 1) 치료 전 대비 3개월 후 우울장애 심각도 척도(BDI) 변화량 | 7) 피험자에게 미칠 것으로 예상되는 위험이나 불편 | Depression Symptom | 2 | 벤라팍신(venlafaxine) | SNRI | 75-225 | 임상시험에서 배제 | 방지, 사전에 정의된 통신 종료 시점의 | 가이드라인(민원인 안내서) | ercloud/) | 질문을 통해 환자의 잠재된 사고에 이를 수 있도록 유도한다.  | 요인으로 8 요인(동기적 결핍, 대인관계의 의존성, 정신 | 지침 가이드라인 | 것을 권장하고 있다.  |\n| 9 | 소프트웨어 | 내용을 기재함 | 생산성 손실 점수 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 때문에 가장 개연성이 있게 설명되는 경우 | 오송보건의료행정타운 | medical device software | 또한 소프트웨어 유닛 및 외부 |\n| 85(4), 367.  | 4 | 소프트웨어 | 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다. ",
        "original_sentence": "| 인해 손실된 시간의 비율) × 건강 문제로 인해 일하는 동안 | 발생하거나 개선의 필요성 때문에 | 성 | 규격 | 소프트웨어 |\n| 1) 치료 전 대비 3개월 후 우울장애 심각도 척도(BDI) 변화량 | 7) 피험자에게 미칠 것으로 예상되는 위험이나 불편 | Depression Symptom | 2 | 벤라팍신(venlafaxine) | SNRI | 75-225 | 임상시험에서 배제 | 방지, 사전에 정의된 통신 종료 시점의 | 가이드라인(민원인 안내서) | ercloud/) | 질문을 통해 환자의 잠재된 사고에 이를 수 있도록 유도한다. "
      }
    },
    {
      "chunk_id": "chunk_307",
      "text": "| 요인으로 8 요인(동기적 결핍, 대인관계의 의존성, 정신 | 지침 가이드라인 | 것을 권장하고 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 306,
        "window_size": 3,
        "char_count": 59,
        "word_count": 15,
        "page_number": 39,
        "window_text": "| Baseline 정보를 수집한다.  | 자기 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 활동을 늘리게 하고 그것을 유지케 하는 효과적인 수단이 된다.  | 인해 손실된 시간의 비율) × 건강 문제로 인해 일하는 동안 | 발생하거나 개선의 필요성 때문에 | 성 | 규격 | 소프트웨어 |\n| 1) 치료 전 대비 3개월 후 우울장애 심각도 척도(BDI) 변화량 | 7) 피험자에게 미칠 것으로 예상되는 위험이나 불편 | Depression Symptom | 2 | 벤라팍신(venlafaxine) | SNRI | 75-225 | 임상시험에서 배제 | 방지, 사전에 정의된 통신 종료 시점의 | 가이드라인(민원인 안내서) | ercloud/) | 질문을 통해 환자의 잠재된 사고에 이를 수 있도록 유도한다.  | 요인으로 8 요인(동기적 결핍, 대인관계의 의존성, 정신 | 지침 가이드라인 | 것을 권장하고 있다.  |\n| 9 | 소프트웨어 | 내용을 기재함 | 생산성 손실 점수 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 때문에 가장 개연성이 있게 설명되는 경우 | 오송보건의료행정타운 | medical device software | 또한 소프트웨어 유닛 및 외부 |\n| 85(4), 367.  | 4 | 소프트웨어 | 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.  | 10 | 역기능적 태도 척도(Dysfunctional Attitude Scale, DAS) | to an Existing Device | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다. ",
        "original_sentence": "| 요인으로 8 요인(동기적 결핍, 대인관계의 의존성, 정신 | 지침 가이드라인 | 것을 권장하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_308",
      "text": "|\n| 9 | 소프트웨어 | 내용을 기재함 | 생산성 손실 점수 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 때문에 가장 개연성이 있게 설명되는 경우 | 오송보건의료행정타운 | medical device software | 또한 소프트웨어 유닛 및 외부 |\n| 85(4), 367. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 307,
        "window_size": 3,
        "char_count": 163,
        "word_count": 45,
        "page_number": 9,
        "window_text": "| 자기 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 활동을 늘리게 하고 그것을 유지케 하는 효과적인 수단이 된다.  | 인해 손실된 시간의 비율) × 건강 문제로 인해 일하는 동안 | 발생하거나 개선의 필요성 때문에 | 성 | 규격 | 소프트웨어 |\n| 1) 치료 전 대비 3개월 후 우울장애 심각도 척도(BDI) 변화량 | 7) 피험자에게 미칠 것으로 예상되는 위험이나 불편 | Depression Symptom | 2 | 벤라팍신(venlafaxine) | SNRI | 75-225 | 임상시험에서 배제 | 방지, 사전에 정의된 통신 종료 시점의 | 가이드라인(민원인 안내서) | ercloud/) | 질문을 통해 환자의 잠재된 사고에 이를 수 있도록 유도한다.  | 요인으로 8 요인(동기적 결핍, 대인관계의 의존성, 정신 | 지침 가이드라인 | 것을 권장하고 있다.  |\n| 9 | 소프트웨어 | 내용을 기재함 | 생산성 손실 점수 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 때문에 가장 개연성이 있게 설명되는 경우 | 오송보건의료행정타운 | medical device software | 또한 소프트웨어 유닛 및 외부 |\n| 85(4), 367.  | 4 | 소프트웨어 | 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.  | 10 | 역기능적 태도 척도(Dysfunctional Attitude Scale, DAS) | to an Existing Device | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | 으로 예상하여 30%로 정하고자 한다. ",
        "original_sentence": "|\n| 9 | 소프트웨어 | 내용을 기재함 | 생산성 손실 점수 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 때문에 가장 개연성이 있게 설명되는 경우 | 오송보건의료행정타운 | medical device software | 또한 소프트웨어 유닛 및 외부 |\n| 85(4), 367. "
      }
    },
    {
      "chunk_id": "chunk_309",
      "text": "| 4 | 소프트웨어 | 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 308,
        "window_size": 3,
        "char_count": 46,
        "word_count": 12,
        "page_number": 9,
        "window_text": "| 인해 손실된 시간의 비율) × 건강 문제로 인해 일하는 동안 | 발생하거나 개선의 필요성 때문에 | 성 | 규격 | 소프트웨어 |\n| 1) 치료 전 대비 3개월 후 우울장애 심각도 척도(BDI) 변화량 | 7) 피험자에게 미칠 것으로 예상되는 위험이나 불편 | Depression Symptom | 2 | 벤라팍신(venlafaxine) | SNRI | 75-225 | 임상시험에서 배제 | 방지, 사전에 정의된 통신 종료 시점의 | 가이드라인(민원인 안내서) | ercloud/) | 질문을 통해 환자의 잠재된 사고에 이를 수 있도록 유도한다.  | 요인으로 8 요인(동기적 결핍, 대인관계의 의존성, 정신 | 지침 가이드라인 | 것을 권장하고 있다.  |\n| 9 | 소프트웨어 | 내용을 기재함 | 생산성 손실 점수 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 때문에 가장 개연성이 있게 설명되는 경우 | 오송보건의료행정타운 | medical device software | 또한 소프트웨어 유닛 및 외부 |\n| 85(4), 367.  | 4 | 소프트웨어 | 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.  | 10 | 역기능적 태도 척도(Dysfunctional Attitude Scale, DAS) | to an Existing Device | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | 으로 예상하여 30%로 정하고자 한다.  | 제한하였다. ",
        "original_sentence": "| 4 | 소프트웨어 | 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다. "
      }
    },
    {
      "chunk_id": "chunk_310",
      "text": "| 10 | 역기능적 태도 척도(Dysfunctional Attitude Scale, DAS) | to an Existing Device | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 309,
        "window_size": 3,
        "char_count": 104,
        "word_count": 20,
        "page_number": 28,
        "window_text": "| 요인으로 8 요인(동기적 결핍, 대인관계의 의존성, 정신 | 지침 가이드라인 | 것을 권장하고 있다.  |\n| 9 | 소프트웨어 | 내용을 기재함 | 생산성 손실 점수 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 때문에 가장 개연성이 있게 설명되는 경우 | 오송보건의료행정타운 | medical device software | 또한 소프트웨어 유닛 및 외부 |\n| 85(4), 367.  | 4 | 소프트웨어 | 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.  | 10 | 역기능적 태도 척도(Dysfunctional Attitude Scale, DAS) | to an Existing Device | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | 으로 예상하여 30%로 정하고자 한다.  | 제한하였다.  | 기기에 해당하는 제품의 범위, 판단 |\n| 식품의약품안전처 식품의약품안전평가원 의료기기심사부 첨단의료기기과 | 보티오섹틴(vortioxetine) | Serotonin reuptake inhibitor; 5-HT1A agonist; 5-HT1B | partial agonist; 5-HT1D, 5-HT3A, and 5-HT7 antagonist | 10-20 | 제조자는 주기적인 업데이트의 구현과 배포를 | 대체 수집할 수 있다. ",
        "original_sentence": "| 10 | 역기능적 태도 척도(Dysfunctional Attitude Scale, DAS) | to an Existing Device | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_311",
      "text": "| 으로 예상하여 30%로 정하고자 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 310,
        "window_size": 3,
        "char_count": 24,
        "word_count": 6,
        "page_number": 13,
        "window_text": "|\n| 9 | 소프트웨어 | 내용을 기재함 | 생산성 손실 점수 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 때문에 가장 개연성이 있게 설명되는 경우 | 오송보건의료행정타운 | medical device software | 또한 소프트웨어 유닛 및 외부 |\n| 85(4), 367.  | 4 | 소프트웨어 | 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.  | 10 | 역기능적 태도 척도(Dysfunctional Attitude Scale, DAS) | to an Existing Device | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | 으로 예상하여 30%로 정하고자 한다.  | 제한하였다.  | 기기에 해당하는 제품의 범위, 판단 |\n| 식품의약품안전처 식품의약품안전평가원 의료기기심사부 첨단의료기기과 | 보티오섹틴(vortioxetine) | Serotonin reuptake inhibitor; 5-HT1A agonist; 5-HT1B | partial agonist; 5-HT1D, 5-HT3A, and 5-HT7 antagonist | 10-20 | 제조자는 주기적인 업데이트의 구현과 배포를 | 대체 수집할 수 있다.  | 강화 | - 목표 설정과 수행에 강력한 합리성을 제공하고, 확실하게 정의된 | 발생한 장애(impairment) 비율] | 제품 또는 관련 문서가 수정되는 | 핫라인을 이용할 수 있다. ",
        "original_sentence": "| 으로 예상하여 30%로 정하고자 한다. "
      }
    },
    {
      "chunk_id": "chunk_312",
      "text": "| 제한하였다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 311,
        "window_size": 3,
        "char_count": 9,
        "word_count": 2,
        "page_number": 80,
        "window_text": "| 4 | 소프트웨어 | 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.  | 10 | 역기능적 태도 척도(Dysfunctional Attitude Scale, DAS) | to an Existing Device | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | 으로 예상하여 30%로 정하고자 한다.  | 제한하였다.  | 기기에 해당하는 제품의 범위, 판단 |\n| 식품의약품안전처 식품의약품안전평가원 의료기기심사부 첨단의료기기과 | 보티오섹틴(vortioxetine) | Serotonin reuptake inhibitor; 5-HT1A agonist; 5-HT1B | partial agonist; 5-HT1D, 5-HT3A, and 5-HT7 antagonist | 10-20 | 제조자는 주기적인 업데이트의 구현과 배포를 | 대체 수집할 수 있다.  | 강화 | - 목표 설정과 수행에 강력한 합리성을 제공하고, 확실하게 정의된 | 발생한 장애(impairment) 비율] | 제품 또는 관련 문서가 수정되는 | 핫라인을 이용할 수 있다.  | 검증 및 |\n| 2) 중지 처리 | Questionnaire, HDSQ) | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 적절성 여부 등 | 대체 수집할 수 있다. ",
        "original_sentence": "| 제한하였다. "
      }
    },
    {
      "chunk_id": "chunk_313",
      "text": "| 기기에 해당하는 제품의 범위, 판단 |\n| 식품의약품안전처 식품의약품안전평가원 의료기기심사부 첨단의료기기과 | 보티오섹틴(vortioxetine) | Serotonin reuptake inhibitor; 5-HT1A agonist; 5-HT1B | partial agonist; 5-HT1D, 5-HT3A, and 5-HT7 antagonist | 10-20 | 제조자는 주기적인 업데이트의 구현과 배포를 | 대체 수집할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 312,
        "window_size": 3,
        "char_count": 244,
        "word_count": 42,
        "page_number": 38,
        "window_text": "| 10 | 역기능적 태도 척도(Dysfunctional Attitude Scale, DAS) | to an Existing Device | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | 으로 예상하여 30%로 정하고자 한다.  | 제한하였다.  | 기기에 해당하는 제품의 범위, 판단 |\n| 식품의약품안전처 식품의약품안전평가원 의료기기심사부 첨단의료기기과 | 보티오섹틴(vortioxetine) | Serotonin reuptake inhibitor; 5-HT1A agonist; 5-HT1B | partial agonist; 5-HT1D, 5-HT3A, and 5-HT7 antagonist | 10-20 | 제조자는 주기적인 업데이트의 구현과 배포를 | 대체 수집할 수 있다.  | 강화 | - 목표 설정과 수행에 강력한 합리성을 제공하고, 확실하게 정의된 | 발생한 장애(impairment) 비율] | 제품 또는 관련 문서가 수정되는 | 핫라인을 이용할 수 있다.  | 검증 및 |\n| 2) 중지 처리 | Questionnaire, HDSQ) | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 적절성 여부 등 | 대체 수집할 수 있다.  | 사용자 구분을 | 식품의약품안전처 식품의약품안전평가원 | 운동 지체, 에너지 없음, 냉담/무 쾌락, 불면증, 집중 곤란/ | 구성요인 | 사이의 | 연계성 | 및 | 조작된 환자 | 오진, 잘못 된 | 우울 증상 임의의 시험용 수명 |\n| (Work Productivity and | 내용 등을 기록하여 보관하여야 한다. ",
        "original_sentence": "| 기기에 해당하는 제품의 범위, 판단 |\n| 식품의약품안전처 식품의약품안전평가원 의료기기심사부 첨단의료기기과 | 보티오섹틴(vortioxetine) | Serotonin reuptake inhibitor; 5-HT1A agonist; 5-HT1B | partial agonist; 5-HT1D, 5-HT3A, and 5-HT7 antagonist | 10-20 | 제조자는 주기적인 업데이트의 구현과 배포를 | 대체 수집할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_314",
      "text": "| 강화 | - 목표 설정과 수행에 강력한 합리성을 제공하고, 확실하게 정의된 | 발생한 장애(impairment) 비율] | 제품 또는 관련 문서가 수정되는 | 핫라인을 이용할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 313,
        "window_size": 3,
        "char_count": 106,
        "word_count": 27,
        "page_number": 7,
        "window_text": "| 으로 예상하여 30%로 정하고자 한다.  | 제한하였다.  | 기기에 해당하는 제품의 범위, 판단 |\n| 식품의약품안전처 식품의약품안전평가원 의료기기심사부 첨단의료기기과 | 보티오섹틴(vortioxetine) | Serotonin reuptake inhibitor; 5-HT1A agonist; 5-HT1B | partial agonist; 5-HT1D, 5-HT3A, and 5-HT7 antagonist | 10-20 | 제조자는 주기적인 업데이트의 구현과 배포를 | 대체 수집할 수 있다.  | 강화 | - 목표 설정과 수행에 강력한 합리성을 제공하고, 확실하게 정의된 | 발생한 장애(impairment) 비율] | 제품 또는 관련 문서가 수정되는 | 핫라인을 이용할 수 있다.  | 검증 및 |\n| 2) 중지 처리 | Questionnaire, HDSQ) | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 적절성 여부 등 | 대체 수집할 수 있다.  | 사용자 구분을 | 식품의약품안전처 식품의약품안전평가원 | 운동 지체, 에너지 없음, 냉담/무 쾌락, 불면증, 집중 곤란/ | 구성요인 | 사이의 | 연계성 | 및 | 조작된 환자 | 오진, 잘못 된 | 우울 증상 임의의 시험용 수명 |\n| (Work Productivity and | 내용 등을 기록하여 보관하여야 한다.  | - 계획서 순응 임상시험대상자군(Per-protocol Set, PPS) | 절약할 수 있다.1) | 한다. ",
        "original_sentence": "| 강화 | - 목표 설정과 수행에 강력한 합리성을 제공하고, 확실하게 정의된 | 발생한 장애(impairment) 비율] | 제품 또는 관련 문서가 수정되는 | 핫라인을 이용할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_315",
      "text": "| 검증 및 |\n| 2) 중지 처리 | Questionnaire, HDSQ) | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 적절성 여부 등 | 대체 수집할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 314,
        "window_size": 3,
        "char_count": 105,
        "word_count": 30,
        "page_number": 9,
        "window_text": "| 제한하였다.  | 기기에 해당하는 제품의 범위, 판단 |\n| 식품의약품안전처 식품의약품안전평가원 의료기기심사부 첨단의료기기과 | 보티오섹틴(vortioxetine) | Serotonin reuptake inhibitor; 5-HT1A agonist; 5-HT1B | partial agonist; 5-HT1D, 5-HT3A, and 5-HT7 antagonist | 10-20 | 제조자는 주기적인 업데이트의 구현과 배포를 | 대체 수집할 수 있다.  | 강화 | - 목표 설정과 수행에 강력한 합리성을 제공하고, 확실하게 정의된 | 발생한 장애(impairment) 비율] | 제품 또는 관련 문서가 수정되는 | 핫라인을 이용할 수 있다.  | 검증 및 |\n| 2) 중지 처리 | Questionnaire, HDSQ) | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 적절성 여부 등 | 대체 수집할 수 있다.  | 사용자 구분을 | 식품의약품안전처 식품의약품안전평가원 | 운동 지체, 에너지 없음, 냉담/무 쾌락, 불면증, 집중 곤란/ | 구성요인 | 사이의 | 연계성 | 및 | 조작된 환자 | 오진, 잘못 된 | 우울 증상 임의의 시험용 수명 |\n| (Work Productivity and | 내용 등을 기록하여 보관하여야 한다.  | - 계획서 순응 임상시험대상자군(Per-protocol Set, PPS) | 절약할 수 있다.1) | 한다.  | Postmarket Management of | 적용하여 주요 결과와 차이가 있는지 분석하여 제시한다. ",
        "original_sentence": "| 검증 및 |\n| 2) 중지 처리 | Questionnaire, HDSQ) | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 적절성 여부 등 | 대체 수집할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_316",
      "text": "| 사용자 구분을 | 식품의약품안전처 식품의약품안전평가원 | 운동 지체, 에너지 없음, 냉담/무 쾌락, 불면증, 집중 곤란/ | 구성요인 | 사이의 | 연계성 | 및 | 조작된 환자 | 오진, 잘못 된 | 우울 증상 임의의 시험용 수명 |\n| (Work Productivity and | 내용 등을 기록하여 보관하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 315,
        "window_size": 3,
        "char_count": 182,
        "word_count": 48,
        "page_number": 3,
        "window_text": "| 기기에 해당하는 제품의 범위, 판단 |\n| 식품의약품안전처 식품의약품안전평가원 의료기기심사부 첨단의료기기과 | 보티오섹틴(vortioxetine) | Serotonin reuptake inhibitor; 5-HT1A agonist; 5-HT1B | partial agonist; 5-HT1D, 5-HT3A, and 5-HT7 antagonist | 10-20 | 제조자는 주기적인 업데이트의 구현과 배포를 | 대체 수집할 수 있다.  | 강화 | - 목표 설정과 수행에 강력한 합리성을 제공하고, 확실하게 정의된 | 발생한 장애(impairment) 비율] | 제품 또는 관련 문서가 수정되는 | 핫라인을 이용할 수 있다.  | 검증 및 |\n| 2) 중지 처리 | Questionnaire, HDSQ) | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 적절성 여부 등 | 대체 수집할 수 있다.  | 사용자 구분을 | 식품의약품안전처 식품의약품안전평가원 | 운동 지체, 에너지 없음, 냉담/무 쾌락, 불면증, 집중 곤란/ | 구성요인 | 사이의 | 연계성 | 및 | 조작된 환자 | 오진, 잘못 된 | 우울 증상 임의의 시험용 수명 |\n| (Work Productivity and | 내용 등을 기록하여 보관하여야 한다.  | - 계획서 순응 임상시험대상자군(Per-protocol Set, PPS) | 절약할 수 있다.1) | 한다.  | Postmarket Management of | 적용하여 주요 결과와 차이가 있는지 분석하여 제시한다.  | 문제해결 | 적용 |\n| 5) 임상시험 디자인 : 단일(다)기관, 무작위배정, 전향적 임상시험 | 6 | 우울 증상 | 이상반응 확인 | - | O | O | O | 비 | 11 | 36항 건강수준 척도(Short Form-36 Health Survey, SF-36) | 번호로 연락하고 관리자가 조치할 때까지 대기한다. ",
        "original_sentence": "| 사용자 구분을 | 식품의약품안전처 식품의약품안전평가원 | 운동 지체, 에너지 없음, 냉담/무 쾌락, 불면증, 집중 곤란/ | 구성요인 | 사이의 | 연계성 | 및 | 조작된 환자 | 오진, 잘못 된 | 우울 증상 임의의 시험용 수명 |\n| (Work Productivity and | 내용 등을 기록하여 보관하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_317",
      "text": "| - 계획서 순응 임상시험대상자군(Per-protocol Set, PPS) | 절약할 수 있다.1) | 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 316,
        "window_size": 3,
        "char_count": 63,
        "word_count": 13,
        "page_number": 18,
        "window_text": "| 강화 | - 목표 설정과 수행에 강력한 합리성을 제공하고, 확실하게 정의된 | 발생한 장애(impairment) 비율] | 제품 또는 관련 문서가 수정되는 | 핫라인을 이용할 수 있다.  | 검증 및 |\n| 2) 중지 처리 | Questionnaire, HDSQ) | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 적절성 여부 등 | 대체 수집할 수 있다.  | 사용자 구분을 | 식품의약품안전처 식품의약품안전평가원 | 운동 지체, 에너지 없음, 냉담/무 쾌락, 불면증, 집중 곤란/ | 구성요인 | 사이의 | 연계성 | 및 | 조작된 환자 | 오진, 잘못 된 | 우울 증상 임의의 시험용 수명 |\n| (Work Productivity and | 내용 등을 기록하여 보관하여야 한다.  | - 계획서 순응 임상시험대상자군(Per-protocol Set, PPS) | 절약할 수 있다.1) | 한다.  | Postmarket Management of | 적용하여 주요 결과와 차이가 있는지 분석하여 제시한다.  | 문제해결 | 적용 |\n| 5) 임상시험 디자인 : 단일(다)기관, 무작위배정, 전향적 임상시험 | 6 | 우울 증상 | 이상반응 확인 | - | O | O | O | 비 | 11 | 36항 건강수준 척도(Short Form-36 Health Survey, SF-36) | 번호로 연락하고 관리자가 조치할 때까지 대기한다.  | 상세 설계 | 우울 증상 예상값 대비 결과값 | 기준, 허가·심사 방안 등 제시 |\n| - 사용 중단으로 이상 반응이 없어지는 경우 | and post-production information)로 구분한다. ",
        "original_sentence": "| - 계획서 순응 임상시험대상자군(Per-protocol Set, PPS) | 절약할 수 있다.1) | 한다. "
      }
    },
    {
      "chunk_id": "chunk_318",
      "text": "| Postmarket Management of | 적용하여 주요 결과와 차이가 있는지 분석하여 제시한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 317,
        "window_size": 3,
        "char_count": 60,
        "word_count": 12,
        "page_number": 7,
        "window_text": "| 검증 및 |\n| 2) 중지 처리 | Questionnaire, HDSQ) | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 적절성 여부 등 | 대체 수집할 수 있다.  | 사용자 구분을 | 식품의약품안전처 식품의약품안전평가원 | 운동 지체, 에너지 없음, 냉담/무 쾌락, 불면증, 집중 곤란/ | 구성요인 | 사이의 | 연계성 | 및 | 조작된 환자 | 오진, 잘못 된 | 우울 증상 임의의 시험용 수명 |\n| (Work Productivity and | 내용 등을 기록하여 보관하여야 한다.  | - 계획서 순응 임상시험대상자군(Per-protocol Set, PPS) | 절약할 수 있다.1) | 한다.  | Postmarket Management of | 적용하여 주요 결과와 차이가 있는지 분석하여 제시한다.  | 문제해결 | 적용 |\n| 5) 임상시험 디자인 : 단일(다)기관, 무작위배정, 전향적 임상시험 | 6 | 우울 증상 | 이상반응 확인 | - | O | O | O | 비 | 11 | 36항 건강수준 척도(Short Form-36 Health Survey, SF-36) | 번호로 연락하고 관리자가 조치할 때까지 대기한다.  | 상세 설계 | 우울 증상 예상값 대비 결과값 | 기준, 허가·심사 방안 등 제시 |\n| - 사용 중단으로 이상 반응이 없어지는 경우 | and post-production information)로 구분한다.  | 위한 수행절차를 수립하고 통보하여야 한다. ",
        "original_sentence": "| Postmarket Management of | 적용하여 주요 결과와 차이가 있는지 분석하여 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_319",
      "text": "| 문제해결 | 적용 |\n| 5) 임상시험 디자인 : 단일(다)기관, 무작위배정, 전향적 임상시험 | 6 | 우울 증상 | 이상반응 확인 | - | O | O | O | 비 | 11 | 36항 건강수준 척도(Short Form-36 Health Survey, SF-36) | 번호로 연락하고 관리자가 조치할 때까지 대기한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 318,
        "window_size": 3,
        "char_count": 182,
        "word_count": 49,
        "page_number": 30,
        "window_text": "| 사용자 구분을 | 식품의약품안전처 식품의약품안전평가원 | 운동 지체, 에너지 없음, 냉담/무 쾌락, 불면증, 집중 곤란/ | 구성요인 | 사이의 | 연계성 | 및 | 조작된 환자 | 오진, 잘못 된 | 우울 증상 임의의 시험용 수명 |\n| (Work Productivity and | 내용 등을 기록하여 보관하여야 한다.  | - 계획서 순응 임상시험대상자군(Per-protocol Set, PPS) | 절약할 수 있다.1) | 한다.  | Postmarket Management of | 적용하여 주요 결과와 차이가 있는지 분석하여 제시한다.  | 문제해결 | 적용 |\n| 5) 임상시험 디자인 : 단일(다)기관, 무작위배정, 전향적 임상시험 | 6 | 우울 증상 | 이상반응 확인 | - | O | O | O | 비 | 11 | 36항 건강수준 척도(Short Form-36 Health Survey, SF-36) | 번호로 연락하고 관리자가 조치할 때까지 대기한다.  | 상세 설계 | 우울 증상 예상값 대비 결과값 | 기준, 허가·심사 방안 등 제시 |\n| - 사용 중단으로 이상 반응이 없어지는 경우 | and post-production information)로 구분한다.  | 위한 수행절차를 수립하고 통보하여야 한다.  | (self-re | 수행할 수 있다. ",
        "original_sentence": "| 문제해결 | 적용 |\n| 5) 임상시험 디자인 : 단일(다)기관, 무작위배정, 전향적 임상시험 | 6 | 우울 증상 | 이상반응 확인 | - | O | O | O | 비 | 11 | 36항 건강수준 척도(Short Form-36 Health Survey, SF-36) | 번호로 연락하고 관리자가 조치할 때까지 대기한다. "
      }
    },
    {
      "chunk_id": "chunk_320",
      "text": "| 상세 설계 | 우울 증상 예상값 대비 결과값 | 기준, 허가·심사 방안 등 제시 |\n| - 사용 중단으로 이상 반응이 없어지는 경우 | and post-production information)로 구분한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 319,
        "window_size": 3,
        "char_count": 118,
        "word_count": 29,
        "page_number": 38,
        "window_text": "| - 계획서 순응 임상시험대상자군(Per-protocol Set, PPS) | 절약할 수 있다.1) | 한다.  | Postmarket Management of | 적용하여 주요 결과와 차이가 있는지 분석하여 제시한다.  | 문제해결 | 적용 |\n| 5) 임상시험 디자인 : 단일(다)기관, 무작위배정, 전향적 임상시험 | 6 | 우울 증상 | 이상반응 확인 | - | O | O | O | 비 | 11 | 36항 건강수준 척도(Short Form-36 Health Survey, SF-36) | 번호로 연락하고 관리자가 조치할 때까지 대기한다.  | 상세 설계 | 우울 증상 예상값 대비 결과값 | 기준, 허가·심사 방안 등 제시 |\n| - 사용 중단으로 이상 반응이 없어지는 경우 | and post-production information)로 구분한다.  | 위한 수행절차를 수립하고 통보하여야 한다.  | (self-re | 수행할 수 있다.  | 하지 않고 | 재귀인(reattribution) | 의료기기심사부 첨단의료기기과 | 구체적이고 달성 가능한 목표를 세우도록 고무하며, 환자가 | Application of risk | = 건강 문제로 일을 빠진 시간/(건강 문제로 일을 빠진 시간+ | 상기 사항에 대하여 확인하였음. ",
        "original_sentence": "| 상세 설계 | 우울 증상 예상값 대비 결과값 | 기준, 허가·심사 방안 등 제시 |\n| - 사용 중단으로 이상 반응이 없어지는 경우 | and post-production information)로 구분한다. "
      }
    },
    {
      "chunk_id": "chunk_321",
      "text": "| 위한 수행절차를 수립하고 통보하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 320,
        "window_size": 3,
        "char_count": 26,
        "word_count": 6,
        "page_number": 7,
        "window_text": "| Postmarket Management of | 적용하여 주요 결과와 차이가 있는지 분석하여 제시한다.  | 문제해결 | 적용 |\n| 5) 임상시험 디자인 : 단일(다)기관, 무작위배정, 전향적 임상시험 | 6 | 우울 증상 | 이상반응 확인 | - | O | O | O | 비 | 11 | 36항 건강수준 척도(Short Form-36 Health Survey, SF-36) | 번호로 연락하고 관리자가 조치할 때까지 대기한다.  | 상세 설계 | 우울 증상 예상값 대비 결과값 | 기준, 허가·심사 방안 등 제시 |\n| - 사용 중단으로 이상 반응이 없어지는 경우 | and post-production information)로 구분한다.  | 위한 수행절차를 수립하고 통보하여야 한다.  | (self-re | 수행할 수 있다.  | 하지 않고 | 재귀인(reattribution) | 의료기기심사부 첨단의료기기과 | 구체적이고 달성 가능한 목표를 세우도록 고무하며, 환자가 | Application of risk | = 건강 문제로 일을 빠진 시간/(건강 문제로 일을 빠진 시간+ | 상기 사항에 대하여 확인하였음.  | 경우 문제점과 그 영향 등을 | 결과 | 의료기기 | 사이버보안의 | 시판 | 후 | 치료 수행 | 유효성 | (AB-1234) |\n| 전화 : (043) 719-3912 | 제2차 약제 | 제조자는 안전(safety)과 관련된 데이터가 저장 | 반추, 자살에 관한 생각)이 확인되었다. ",
        "original_sentence": "| 위한 수행절차를 수립하고 통보하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_322",
      "text": "| (self-re | 수행할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 321,
        "window_size": 3,
        "char_count": 23,
        "word_count": 6,
        "page_number": 11,
        "window_text": "| 문제해결 | 적용 |\n| 5) 임상시험 디자인 : 단일(다)기관, 무작위배정, 전향적 임상시험 | 6 | 우울 증상 | 이상반응 확인 | - | O | O | O | 비 | 11 | 36항 건강수준 척도(Short Form-36 Health Survey, SF-36) | 번호로 연락하고 관리자가 조치할 때까지 대기한다.  | 상세 설계 | 우울 증상 예상값 대비 결과값 | 기준, 허가·심사 방안 등 제시 |\n| - 사용 중단으로 이상 반응이 없어지는 경우 | and post-production information)로 구분한다.  | 위한 수행절차를 수립하고 통보하여야 한다.  | (self-re | 수행할 수 있다.  | 하지 않고 | 재귀인(reattribution) | 의료기기심사부 첨단의료기기과 | 구체적이고 달성 가능한 목표를 세우도록 고무하며, 환자가 | Application of risk | = 건강 문제로 일을 빠진 시간/(건강 문제로 일을 빠진 시간+ | 상기 사항에 대하여 확인하였음.  | 경우 문제점과 그 영향 등을 | 결과 | 의료기기 | 사이버보안의 | 시판 | 후 | 치료 수행 | 유효성 | (AB-1234) |\n| 전화 : (043) 719-3912 | 제2차 약제 | 제조자는 안전(safety)과 관련된 데이터가 저장 | 반추, 자살에 관한 생각)이 확인되었다.  | 소프트웨어 유닛 사이의 연계성을 | 개인적인 상황에 맞게 조정하여 제공한다. ",
        "original_sentence": "| (self-re | 수행할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_323",
      "text": "| 하지 않고 | 재귀인(reattribution) | 의료기기심사부 첨단의료기기과 | 구체적이고 달성 가능한 목표를 세우도록 고무하며, 환자가 | Application of risk | = 건강 문제로 일을 빠진 시간/(건강 문제로 일을 빠진 시간+ | 상기 사항에 대하여 확인하였음. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 322,
        "window_size": 3,
        "char_count": 161,
        "word_count": 36,
        "page_number": 19,
        "window_text": "| 상세 설계 | 우울 증상 예상값 대비 결과값 | 기준, 허가·심사 방안 등 제시 |\n| - 사용 중단으로 이상 반응이 없어지는 경우 | and post-production information)로 구분한다.  | 위한 수행절차를 수립하고 통보하여야 한다.  | (self-re | 수행할 수 있다.  | 하지 않고 | 재귀인(reattribution) | 의료기기심사부 첨단의료기기과 | 구체적이고 달성 가능한 목표를 세우도록 고무하며, 환자가 | Application of risk | = 건강 문제로 일을 빠진 시간/(건강 문제로 일을 빠진 시간+ | 상기 사항에 대하여 확인하였음.  | 경우 문제점과 그 영향 등을 | 결과 | 의료기기 | 사이버보안의 | 시판 | 후 | 치료 수행 | 유효성 | (AB-1234) |\n| 전화 : (043) 719-3912 | 제2차 약제 | 제조자는 안전(safety)과 관련된 데이터가 저장 | 반추, 자살에 관한 생각)이 확인되었다.  | 소프트웨어 유닛 사이의 연계성을 | 개인적인 상황에 맞게 조정하여 제공한다.  | 입력정보를 입력했을 때, 산출되는 |\n| 10 | 인가된 | measuring depression. ",
        "original_sentence": "| 하지 않고 | 재귀인(reattribution) | 의료기기심사부 첨단의료기기과 | 구체적이고 달성 가능한 목표를 세우도록 고무하며, 환자가 | Application of risk | = 건강 문제로 일을 빠진 시간/(건강 문제로 일을 빠진 시간+ | 상기 사항에 대하여 확인하였음. "
      }
    },
    {
      "chunk_id": "chunk_324",
      "text": "| 경우 문제점과 그 영향 등을 | 결과 | 의료기기 | 사이버보안의 | 시판 | 후 | 치료 수행 | 유효성 | (AB-1234) |\n| 전화 : (043) 719-3912 | 제2차 약제 | 제조자는 안전(safety)과 관련된 데이터가 저장 | 반추, 자살에 관한 생각)이 확인되었다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 323,
        "window_size": 3,
        "char_count": 163,
        "word_count": 44,
        "page_number": 38,
        "window_text": "| 위한 수행절차를 수립하고 통보하여야 한다.  | (self-re | 수행할 수 있다.  | 하지 않고 | 재귀인(reattribution) | 의료기기심사부 첨단의료기기과 | 구체적이고 달성 가능한 목표를 세우도록 고무하며, 환자가 | Application of risk | = 건강 문제로 일을 빠진 시간/(건강 문제로 일을 빠진 시간+ | 상기 사항에 대하여 확인하였음.  | 경우 문제점과 그 영향 등을 | 결과 | 의료기기 | 사이버보안의 | 시판 | 후 | 치료 수행 | 유효성 | (AB-1234) |\n| 전화 : (043) 719-3912 | 제2차 약제 | 제조자는 안전(safety)과 관련된 데이터가 저장 | 반추, 자살에 관한 생각)이 확인되었다.  | 소프트웨어 유닛 사이의 연계성을 | 개인적인 상황에 맞게 조정하여 제공한다.  | 입력정보를 입력했을 때, 산출되는 |\n| 10 | 인가된 | measuring depression.  Archives of general psychiatry, 4(6), 561-571. ",
        "original_sentence": "| 경우 문제점과 그 영향 등을 | 결과 | 의료기기 | 사이버보안의 | 시판 | 후 | 치료 수행 | 유효성 | (AB-1234) |\n| 전화 : (043) 719-3912 | 제2차 약제 | 제조자는 안전(safety)과 관련된 데이터가 저장 | 반추, 자살에 관한 생각)이 확인되었다. "
      }
    },
    {
      "chunk_id": "chunk_325",
      "text": "| 소프트웨어 유닛 사이의 연계성을 | 개인적인 상황에 맞게 조정하여 제공한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 324,
        "window_size": 3,
        "char_count": 45,
        "word_count": 11,
        "page_number": 9,
        "window_text": "| (self-re | 수행할 수 있다.  | 하지 않고 | 재귀인(reattribution) | 의료기기심사부 첨단의료기기과 | 구체적이고 달성 가능한 목표를 세우도록 고무하며, 환자가 | Application of risk | = 건강 문제로 일을 빠진 시간/(건강 문제로 일을 빠진 시간+ | 상기 사항에 대하여 확인하였음.  | 경우 문제점과 그 영향 등을 | 결과 | 의료기기 | 사이버보안의 | 시판 | 후 | 치료 수행 | 유효성 | (AB-1234) |\n| 전화 : (043) 719-3912 | 제2차 약제 | 제조자는 안전(safety)과 관련된 데이터가 저장 | 반추, 자살에 관한 생각)이 확인되었다.  | 소프트웨어 유닛 사이의 연계성을 | 개인적인 상황에 맞게 조정하여 제공한다.  | 입력정보를 입력했을 때, 산출되는 |\n| 10 | 인가된 | measuring depression.  Archives of general psychiatry, 4(6), 561-571.  | Activity Impairment, | 바) 병용약물 조사 | 다) 병용약물 조사 | 기기로서의 사용 목적을 달성할 수 있음을 증명해야 한다. ",
        "original_sentence": "| 소프트웨어 유닛 사이의 연계성을 | 개인적인 상황에 맞게 조정하여 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_326",
      "text": "| 입력정보를 입력했을 때, 산출되는 |\n| 10 | 인가된 | measuring depression. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 325,
        "window_size": 3,
        "char_count": 58,
        "word_count": 13,
        "page_number": 18,
        "window_text": "| 하지 않고 | 재귀인(reattribution) | 의료기기심사부 첨단의료기기과 | 구체적이고 달성 가능한 목표를 세우도록 고무하며, 환자가 | Application of risk | = 건강 문제로 일을 빠진 시간/(건강 문제로 일을 빠진 시간+ | 상기 사항에 대하여 확인하였음.  | 경우 문제점과 그 영향 등을 | 결과 | 의료기기 | 사이버보안의 | 시판 | 후 | 치료 수행 | 유효성 | (AB-1234) |\n| 전화 : (043) 719-3912 | 제2차 약제 | 제조자는 안전(safety)과 관련된 데이터가 저장 | 반추, 자살에 관한 생각)이 확인되었다.  | 소프트웨어 유닛 사이의 연계성을 | 개인적인 상황에 맞게 조정하여 제공한다.  | 입력정보를 입력했을 때, 산출되는 |\n| 10 | 인가된 | measuring depression.  Archives of general psychiatry, 4(6), 561-571.  | Activity Impairment, | 바) 병용약물 조사 | 다) 병용약물 조사 | 기기로서의 사용 목적을 달성할 수 있음을 증명해야 한다.  | 영향을 줄 것으로 예상하는 약물을 임의로 복용한 경우 | 수집할 수 있다. ",
        "original_sentence": "| 입력정보를 입력했을 때, 산출되는 |\n| 10 | 인가된 | measuring depression. "
      }
    },
    {
      "chunk_id": "chunk_327",
      "text": "Archives of general psychiatry, 4(6), 561-571. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 326,
        "window_size": 3,
        "char_count": 47,
        "word_count": 6,
        "page_number": 28,
        "window_text": "| 경우 문제점과 그 영향 등을 | 결과 | 의료기기 | 사이버보안의 | 시판 | 후 | 치료 수행 | 유효성 | (AB-1234) |\n| 전화 : (043) 719-3912 | 제2차 약제 | 제조자는 안전(safety)과 관련된 데이터가 저장 | 반추, 자살에 관한 생각)이 확인되었다.  | 소프트웨어 유닛 사이의 연계성을 | 개인적인 상황에 맞게 조정하여 제공한다.  | 입력정보를 입력했을 때, 산출되는 |\n| 10 | 인가된 | measuring depression.  Archives of general psychiatry, 4(6), 561-571.  | Activity Impairment, | 바) 병용약물 조사 | 다) 병용약물 조사 | 기기로서의 사용 목적을 달성할 수 있음을 증명해야 한다.  | 영향을 줄 것으로 예상하는 약물을 임의로 복용한 경우 | 수집할 수 있다.  | Cybersecurity in Medical | 의료기기 소프트웨어 | 의료기기 | 소프트웨어 | 밸리데이션에 | 관리에 대한 가이드라인 | 미국 | ALA |\n| 웨어 | ※ 본 장에서 제시한 항목 및 예시는 참고용으로 작성한 것으로 사안에 | 병용약물 조사 | O | O | O | O | 12 | 생산성 손실 점수(Work Productivity and Activity Impairment, WPAI) | 정확도 | 제2판(Beck Depression Inventory, BDI-II)를 이용하도록 한다. ",
        "original_sentence": "Archives of general psychiatry, 4(6), 561-571. "
      }
    },
    {
      "chunk_id": "chunk_328",
      "text": "| Activity Impairment, | 바) 병용약물 조사 | 다) 병용약물 조사 | 기기로서의 사용 목적을 달성할 수 있음을 증명해야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 327,
        "window_size": 3,
        "char_count": 83,
        "word_count": 20,
        "page_number": 82,
        "window_text": "| 소프트웨어 유닛 사이의 연계성을 | 개인적인 상황에 맞게 조정하여 제공한다.  | 입력정보를 입력했을 때, 산출되는 |\n| 10 | 인가된 | measuring depression.  Archives of general psychiatry, 4(6), 561-571.  | Activity Impairment, | 바) 병용약물 조사 | 다) 병용약물 조사 | 기기로서의 사용 목적을 달성할 수 있음을 증명해야 한다.  | 영향을 줄 것으로 예상하는 약물을 임의로 복용한 경우 | 수집할 수 있다.  | Cybersecurity in Medical | 의료기기 소프트웨어 | 의료기기 | 소프트웨어 | 밸리데이션에 | 관리에 대한 가이드라인 | 미국 | ALA |\n| 웨어 | ※ 본 장에서 제시한 항목 및 예시는 참고용으로 작성한 것으로 사안에 | 병용약물 조사 | O | O | O | O | 12 | 생산성 손실 점수(Work Productivity and Activity Impairment, WPAI) | 정확도 | 제2판(Beck Depression Inventory, BDI-II)를 이용하도록 한다.  | 차이는 ± 1% 이내일 것 | 소프트웨어 | 확인 자료 |\n| 1) 사용 전 준비사항 | 8) 중간 분석 | 아미트립틀린(amitriptyline) | TCA | 25-50 | 위해요인에 대해 <표 10>과 같이 기록한다. ",
        "original_sentence": "| Activity Impairment, | 바) 병용약물 조사 | 다) 병용약물 조사 | 기기로서의 사용 목적을 달성할 수 있음을 증명해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_329",
      "text": "| 영향을 줄 것으로 예상하는 약물을 임의로 복용한 경우 | 수집할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 328,
        "window_size": 3,
        "char_count": 44,
        "word_count": 13,
        "page_number": 11,
        "window_text": "| 입력정보를 입력했을 때, 산출되는 |\n| 10 | 인가된 | measuring depression.  Archives of general psychiatry, 4(6), 561-571.  | Activity Impairment, | 바) 병용약물 조사 | 다) 병용약물 조사 | 기기로서의 사용 목적을 달성할 수 있음을 증명해야 한다.  | 영향을 줄 것으로 예상하는 약물을 임의로 복용한 경우 | 수집할 수 있다.  | Cybersecurity in Medical | 의료기기 소프트웨어 | 의료기기 | 소프트웨어 | 밸리데이션에 | 관리에 대한 가이드라인 | 미국 | ALA |\n| 웨어 | ※ 본 장에서 제시한 항목 및 예시는 참고용으로 작성한 것으로 사안에 | 병용약물 조사 | O | O | O | O | 12 | 생산성 손실 점수(Work Productivity and Activity Impairment, WPAI) | 정확도 | 제2판(Beck Depression Inventory, BDI-II)를 이용하도록 한다.  | 차이는 ± 1% 이내일 것 | 소프트웨어 | 확인 자료 |\n| 1) 사용 전 준비사항 | 8) 중간 분석 | 아미트립틀린(amitriptyline) | TCA | 25-50 | 위해요인에 대해 <표 10>과 같이 기록한다.  | 안전성에서‘하’등급의 분류가 불가능하다. ",
        "original_sentence": "| 영향을 줄 것으로 예상하는 약물을 임의로 복용한 경우 | 수집할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_330",
      "text": "| Cybersecurity in Medical | 의료기기 소프트웨어 | 의료기기 | 소프트웨어 | 밸리데이션에 | 관리에 대한 가이드라인 | 미국 | ALA |\n| 웨어 | ※ 본 장에서 제시한 항목 및 예시는 참고용으로 작성한 것으로 사안에 | 병용약물 조사 | O | O | O | O | 12 | 생산성 손실 점수(Work Productivity and Activity Impairment, WPAI) | 정확도 | 제2판(Beck Depression Inventory, BDI-II)를 이용하도록 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 329,
        "window_size": 3,
        "char_count": 288,
        "word_count": 67,
        "page_number": 9,
        "window_text": "Archives of general psychiatry, 4(6), 561-571.  | Activity Impairment, | 바) 병용약물 조사 | 다) 병용약물 조사 | 기기로서의 사용 목적을 달성할 수 있음을 증명해야 한다.  | 영향을 줄 것으로 예상하는 약물을 임의로 복용한 경우 | 수집할 수 있다.  | Cybersecurity in Medical | 의료기기 소프트웨어 | 의료기기 | 소프트웨어 | 밸리데이션에 | 관리에 대한 가이드라인 | 미국 | ALA |\n| 웨어 | ※ 본 장에서 제시한 항목 및 예시는 참고용으로 작성한 것으로 사안에 | 병용약물 조사 | O | O | O | O | 12 | 생산성 손실 점수(Work Productivity and Activity Impairment, WPAI) | 정확도 | 제2판(Beck Depression Inventory, BDI-II)를 이용하도록 한다.  | 차이는 ± 1% 이내일 것 | 소프트웨어 | 확인 자료 |\n| 1) 사용 전 준비사항 | 8) 중간 분석 | 아미트립틀린(amitriptyline) | TCA | 25-50 | 위해요인에 대해 <표 10>과 같이 기록한다.  | 안전성에서‘하’등급의 분류가 불가능하다.  | inforce | 척도(BDI) 정보를 Baseline 지표로 활용할 수 있다. ",
        "original_sentence": "| Cybersecurity in Medical | 의료기기 소프트웨어 | 의료기기 | 소프트웨어 | 밸리데이션에 | 관리에 대한 가이드라인 | 미국 | ALA |\n| 웨어 | ※ 본 장에서 제시한 항목 및 예시는 참고용으로 작성한 것으로 사안에 | 병용약물 조사 | O | O | O | O | 12 | 생산성 손실 점수(Work Productivity and Activity Impairment, WPAI) | 정확도 | 제2판(Beck Depression Inventory, BDI-II)를 이용하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_331",
      "text": "| 차이는 ± 1% 이내일 것 | 소프트웨어 | 확인 자료 |\n| 1) 사용 전 준비사항 | 8) 중간 분석 | 아미트립틀린(amitriptyline) | TCA | 25-50 | 위해요인에 대해 <표 10>과 같이 기록한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 330,
        "window_size": 3,
        "char_count": 127,
        "word_count": 34,
        "page_number": 3,
        "window_text": "| Activity Impairment, | 바) 병용약물 조사 | 다) 병용약물 조사 | 기기로서의 사용 목적을 달성할 수 있음을 증명해야 한다.  | 영향을 줄 것으로 예상하는 약물을 임의로 복용한 경우 | 수집할 수 있다.  | Cybersecurity in Medical | 의료기기 소프트웨어 | 의료기기 | 소프트웨어 | 밸리데이션에 | 관리에 대한 가이드라인 | 미국 | ALA |\n| 웨어 | ※ 본 장에서 제시한 항목 및 예시는 참고용으로 작성한 것으로 사안에 | 병용약물 조사 | O | O | O | O | 12 | 생산성 손실 점수(Work Productivity and Activity Impairment, WPAI) | 정확도 | 제2판(Beck Depression Inventory, BDI-II)를 이용하도록 한다.  | 차이는 ± 1% 이내일 것 | 소프트웨어 | 확인 자료 |\n| 1) 사용 전 준비사항 | 8) 중간 분석 | 아미트립틀린(amitriptyline) | TCA | 25-50 | 위해요인에 대해 <표 10>과 같이 기록한다.  | 안전성에서‘하’등급의 분류가 불가능하다.  | inforce | 척도(BDI) 정보를 Baseline 지표로 활용할 수 있다.  | 이거나 모호한 경우 | 누구나 환자의 | 해당한다. ",
        "original_sentence": "| 차이는 ± 1% 이내일 것 | 소프트웨어 | 확인 자료 |\n| 1) 사용 전 준비사항 | 8) 중간 분석 | 아미트립틀린(amitriptyline) | TCA | 25-50 | 위해요인에 대해 <표 10>과 같이 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_332",
      "text": "| 안전성에서‘하’등급의 분류가 불가능하다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 331,
        "window_size": 3,
        "char_count": 25,
        "word_count": 4,
        "page_number": 9,
        "window_text": "| 영향을 줄 것으로 예상하는 약물을 임의로 복용한 경우 | 수집할 수 있다.  | Cybersecurity in Medical | 의료기기 소프트웨어 | 의료기기 | 소프트웨어 | 밸리데이션에 | 관리에 대한 가이드라인 | 미국 | ALA |\n| 웨어 | ※ 본 장에서 제시한 항목 및 예시는 참고용으로 작성한 것으로 사안에 | 병용약물 조사 | O | O | O | O | 12 | 생산성 손실 점수(Work Productivity and Activity Impairment, WPAI) | 정확도 | 제2판(Beck Depression Inventory, BDI-II)를 이용하도록 한다.  | 차이는 ± 1% 이내일 것 | 소프트웨어 | 확인 자료 |\n| 1) 사용 전 준비사항 | 8) 중간 분석 | 아미트립틀린(amitriptyline) | TCA | 25-50 | 위해요인에 대해 <표 10>과 같이 기록한다.  | 안전성에서‘하’등급의 분류가 불가능하다.  | inforce | 척도(BDI) 정보를 Baseline 지표로 활용할 수 있다.  | 이거나 모호한 경우 | 누구나 환자의 | 해당한다.  | - 부정적인 사건 원인을 더 다양하게 생각해 내도록 도와주어야 | 강화 받을 수 있는 활동을 찾아 선택하게 하고, 목표를 정한 후에 | management for IT-networks | 실제 일한 시간) + [(1 - 건강 문제로 일을 빠진 시간/(건강 | 분석하여 변경해야 한다. ",
        "original_sentence": "| 안전성에서‘하’등급의 분류가 불가능하다. "
      }
    },
    {
      "chunk_id": "chunk_333",
      "text": "| inforce | 척도(BDI) 정보를 Baseline 지표로 활용할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 332,
        "window_size": 3,
        "char_count": 47,
        "word_count": 10,
        "page_number": 11,
        "window_text": "| Cybersecurity in Medical | 의료기기 소프트웨어 | 의료기기 | 소프트웨어 | 밸리데이션에 | 관리에 대한 가이드라인 | 미국 | ALA |\n| 웨어 | ※ 본 장에서 제시한 항목 및 예시는 참고용으로 작성한 것으로 사안에 | 병용약물 조사 | O | O | O | O | 12 | 생산성 손실 점수(Work Productivity and Activity Impairment, WPAI) | 정확도 | 제2판(Beck Depression Inventory, BDI-II)를 이용하도록 한다.  | 차이는 ± 1% 이내일 것 | 소프트웨어 | 확인 자료 |\n| 1) 사용 전 준비사항 | 8) 중간 분석 | 아미트립틀린(amitriptyline) | TCA | 25-50 | 위해요인에 대해 <표 10>과 같이 기록한다.  | 안전성에서‘하’등급의 분류가 불가능하다.  | inforce | 척도(BDI) 정보를 Baseline 지표로 활용할 수 있다.  | 이거나 모호한 경우 | 누구나 환자의 | 해당한다.  | - 부정적인 사건 원인을 더 다양하게 생각해 내도록 도와주어야 | 강화 받을 수 있는 활동을 찾아 선택하게 하고, 목표를 정한 후에 | management for IT-networks | 실제 일한 시간) + [(1 - 건강 문제로 일을 빠진 시간/(건강 | 분석하여 변경해야 한다.  | 데이터로 | 또는 | 네트워크로 연결되는 | 3 | 2 | 6 |\n| 3) 적용상의 주의 | 3) 치료 전 대비 8주 및 3개월 후 관해율* | controlled trial. ",
        "original_sentence": "| inforce | 척도(BDI) 정보를 Baseline 지표로 활용할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_334",
      "text": "| 이거나 모호한 경우 | 누구나 환자의 | 해당한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 333,
        "window_size": 3,
        "char_count": 31,
        "word_count": 9,
        "page_number": 13,
        "window_text": "| 차이는 ± 1% 이내일 것 | 소프트웨어 | 확인 자료 |\n| 1) 사용 전 준비사항 | 8) 중간 분석 | 아미트립틀린(amitriptyline) | TCA | 25-50 | 위해요인에 대해 <표 10>과 같이 기록한다.  | 안전성에서‘하’등급의 분류가 불가능하다.  | inforce | 척도(BDI) 정보를 Baseline 지표로 활용할 수 있다.  | 이거나 모호한 경우 | 누구나 환자의 | 해당한다.  | - 부정적인 사건 원인을 더 다양하게 생각해 내도록 도와주어야 | 강화 받을 수 있는 활동을 찾아 선택하게 하고, 목표를 정한 후에 | management for IT-networks | 실제 일한 시간) + [(1 - 건강 문제로 일을 빠진 시간/(건강 | 분석하여 변경해야 한다.  | 데이터로 | 또는 | 네트워크로 연결되는 | 3 | 2 | 6 |\n| 3) 적용상의 주의 | 3) 치료 전 대비 8주 및 3개월 후 관해율* | controlled trial.  Internet Interventions, 2(1), 48-59. ",
        "original_sentence": "| 이거나 모호한 경우 | 누구나 환자의 | 해당한다. "
      }
    },
    {
      "chunk_id": "chunk_335",
      "text": "| - 부정적인 사건 원인을 더 다양하게 생각해 내도록 도와주어야 | 강화 받을 수 있는 활동을 찾아 선택하게 하고, 목표를 정한 후에 | management for IT-networks | 실제 일한 시간) + [(1 - 건강 문제로 일을 빠진 시간/(건강 | 분석하여 변경해야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 334,
        "window_size": 3,
        "char_count": 161,
        "word_count": 42,
        "page_number": 18,
        "window_text": "| 안전성에서‘하’등급의 분류가 불가능하다.  | inforce | 척도(BDI) 정보를 Baseline 지표로 활용할 수 있다.  | 이거나 모호한 경우 | 누구나 환자의 | 해당한다.  | - 부정적인 사건 원인을 더 다양하게 생각해 내도록 도와주어야 | 강화 받을 수 있는 활동을 찾아 선택하게 하고, 목표를 정한 후에 | management for IT-networks | 실제 일한 시간) + [(1 - 건강 문제로 일을 빠진 시간/(건강 | 분석하여 변경해야 한다.  | 데이터로 | 또는 | 네트워크로 연결되는 | 3 | 2 | 6 |\n| 3) 적용상의 주의 | 3) 치료 전 대비 8주 및 3개월 후 관해율* | controlled trial.  Internet Interventions, 2(1), 48-59.  | 그 사실 | 되거나 기기와 송·수신될 때 암호화와 같은 | 위한 | 상세 | 설계를 | 수행한다. ",
        "original_sentence": "| - 부정적인 사건 원인을 더 다양하게 생각해 내도록 도와주어야 | 강화 받을 수 있는 활동을 찾아 선택하게 하고, 목표를 정한 후에 | management for IT-networks | 실제 일한 시간) + [(1 - 건강 문제로 일을 빠진 시간/(건강 | 분석하여 변경해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_336",
      "text": "| 데이터로 | 또는 | 네트워크로 연결되는 | 3 | 2 | 6 |\n| 3) 적용상의 주의 | 3) 치료 전 대비 8주 및 3개월 후 관해율* | controlled trial. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 335,
        "window_size": 3,
        "char_count": 101,
        "word_count": 31,
        "page_number": 9,
        "window_text": "| inforce | 척도(BDI) 정보를 Baseline 지표로 활용할 수 있다.  | 이거나 모호한 경우 | 누구나 환자의 | 해당한다.  | - 부정적인 사건 원인을 더 다양하게 생각해 내도록 도와주어야 | 강화 받을 수 있는 활동을 찾아 선택하게 하고, 목표를 정한 후에 | management for IT-networks | 실제 일한 시간) + [(1 - 건강 문제로 일을 빠진 시간/(건강 | 분석하여 변경해야 한다.  | 데이터로 | 또는 | 네트워크로 연결되는 | 3 | 2 | 6 |\n| 3) 적용상의 주의 | 3) 치료 전 대비 8주 및 3개월 후 관해율* | controlled trial.  Internet Interventions, 2(1), 48-59.  | 그 사실 | 되거나 기기와 송·수신될 때 암호화와 같은 | 위한 | 상세 | 설계를 | 수행한다.  | 결과값과 예상값을 비교한다. ",
        "original_sentence": "| 데이터로 | 또는 | 네트워크로 연결되는 | 3 | 2 | 6 |\n| 3) 적용상의 주의 | 3) 치료 전 대비 8주 및 3개월 후 관해율* | controlled trial. "
      }
    },
    {
      "chunk_id": "chunk_337",
      "text": "Internet Interventions, 2(1), 48-59. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 336,
        "window_size": 3,
        "char_count": 37,
        "word_count": 4,
        "page_number": 9,
        "window_text": "| 이거나 모호한 경우 | 누구나 환자의 | 해당한다.  | - 부정적인 사건 원인을 더 다양하게 생각해 내도록 도와주어야 | 강화 받을 수 있는 활동을 찾아 선택하게 하고, 목표를 정한 후에 | management for IT-networks | 실제 일한 시간) + [(1 - 건강 문제로 일을 빠진 시간/(건강 | 분석하여 변경해야 한다.  | 데이터로 | 또는 | 네트워크로 연결되는 | 3 | 2 | 6 |\n| 3) 적용상의 주의 | 3) 치료 전 대비 8주 및 3개월 후 관해율* | controlled trial.  Internet Interventions, 2(1), 48-59.  | 그 사실 | 되거나 기기와 송·수신될 때 암호화와 같은 | 위한 | 상세 | 설계를 | 수행한다.  | 결과값과 예상값을 비교한다.  | 실현할 수 있어야 한다. ",
        "original_sentence": "Internet Interventions, 2(1), 48-59. "
      }
    },
    {
      "chunk_id": "chunk_338",
      "text": "| 그 사실 | 되거나 기기와 송·수신될 때 암호화와 같은 | 위한 | 상세 | 설계를 | 수행한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 337,
        "window_size": 3,
        "char_count": 57,
        "word_count": 18,
        "page_number": 19,
        "window_text": "| - 부정적인 사건 원인을 더 다양하게 생각해 내도록 도와주어야 | 강화 받을 수 있는 활동을 찾아 선택하게 하고, 목표를 정한 후에 | management for IT-networks | 실제 일한 시간) + [(1 - 건강 문제로 일을 빠진 시간/(건강 | 분석하여 변경해야 한다.  | 데이터로 | 또는 | 네트워크로 연결되는 | 3 | 2 | 6 |\n| 3) 적용상의 주의 | 3) 치료 전 대비 8주 및 3개월 후 관해율* | controlled trial.  Internet Interventions, 2(1), 48-59.  | 그 사실 | 되거나 기기와 송·수신될 때 암호화와 같은 | 위한 | 상세 | 설계를 | 수행한다.  | 결과값과 예상값을 비교한다.  | 실현할 수 있어야 한다.  |\n| 2 | FAX : (043) 719-3900 | 순응도 조사 | - | O | O | O | 13 | 우울장애 일기를 통한 우울 양상 | - 재사용(재사용이 가능한 경우에만 실시) 결과가 양성인 경우 | WPAI) | IEC | 밸리데이션 가이드라인 | [부패·공익신고 안내] ※ 신고자 및 신고내용은 보호됩니다. ",
        "original_sentence": "| 그 사실 | 되거나 기기와 송·수신될 때 암호화와 같은 | 위한 | 상세 | 설계를 | 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_339",
      "text": "| 결과값과 예상값을 비교한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 338,
        "window_size": 3,
        "char_count": 18,
        "word_count": 4,
        "page_number": 13,
        "window_text": "| 데이터로 | 또는 | 네트워크로 연결되는 | 3 | 2 | 6 |\n| 3) 적용상의 주의 | 3) 치료 전 대비 8주 및 3개월 후 관해율* | controlled trial.  Internet Interventions, 2(1), 48-59.  | 그 사실 | 되거나 기기와 송·수신될 때 암호화와 같은 | 위한 | 상세 | 설계를 | 수행한다.  | 결과값과 예상값을 비교한다.  | 실현할 수 있어야 한다.  |\n| 2 | FAX : (043) 719-3900 | 순응도 조사 | - | O | O | O | 13 | 우울장애 일기를 통한 우울 양상 | - 재사용(재사용이 가능한 경우에만 실시) 결과가 양성인 경우 | WPAI) | IEC | 밸리데이션 가이드라인 | [부패·공익신고 안내] ※ 신고자 및 신고내용은 보호됩니다.  | Devices | 대하여 알기 쉽게 설명하거나 식품 | 소프트웨어 | 국내 | RP |\n| 유지 | 이미프라민 (imipramine) | TCA | 150-300 | 전화: 043-719-3912 |       | 검증 및 |\n| 5 | 다) 병용약물 조사 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. ",
        "original_sentence": "| 결과값과 예상값을 비교한다. "
      }
    },
    {
      "chunk_id": "chunk_340",
      "text": "| 실현할 수 있어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 339,
        "window_size": 3,
        "char_count": 16,
        "word_count": 5,
        "page_number": 13,
        "window_text": "Internet Interventions, 2(1), 48-59.  | 그 사실 | 되거나 기기와 송·수신될 때 암호화와 같은 | 위한 | 상세 | 설계를 | 수행한다.  | 결과값과 예상값을 비교한다.  | 실현할 수 있어야 한다.  |\n| 2 | FAX : (043) 719-3900 | 순응도 조사 | - | O | O | O | 13 | 우울장애 일기를 통한 우울 양상 | - 재사용(재사용이 가능한 경우에만 실시) 결과가 양성인 경우 | WPAI) | IEC | 밸리데이션 가이드라인 | [부패·공익신고 안내] ※ 신고자 및 신고내용은 보호됩니다.  | Devices | 대하여 알기 쉽게 설명하거나 식품 | 소프트웨어 | 국내 | RP |\n| 유지 | 이미프라민 (imipramine) | TCA | 150-300 | 전화: 043-719-3912 |       | 검증 및 |\n| 5 | 다) 병용약물 조사 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. ",
        "original_sentence": "| 실현할 수 있어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_341",
      "text": "|\n| 2 | FAX : (043) 719-3900 | 순응도 조사 | - | O | O | O | 13 | 우울장애 일기를 통한 우울 양상 | - 재사용(재사용이 가능한 경우에만 실시) 결과가 양성인 경우 | WPAI) | IEC | 밸리데이션 가이드라인 | [부패·공익신고 안내] ※ 신고자 및 신고내용은 보호됩니다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 340,
        "window_size": 3,
        "char_count": 180,
        "word_count": 51,
        "page_number": 5,
        "window_text": "| 그 사실 | 되거나 기기와 송·수신될 때 암호화와 같은 | 위한 | 상세 | 설계를 | 수행한다.  | 결과값과 예상값을 비교한다.  | 실현할 수 있어야 한다.  |\n| 2 | FAX : (043) 719-3900 | 순응도 조사 | - | O | O | O | 13 | 우울장애 일기를 통한 우울 양상 | - 재사용(재사용이 가능한 경우에만 실시) 결과가 양성인 경우 | WPAI) | IEC | 밸리데이션 가이드라인 | [부패·공익신고 안내] ※ 신고자 및 신고내용은 보호됩니다.  | Devices | 대하여 알기 쉽게 설명하거나 식품 | 소프트웨어 | 국내 | RP |\n| 유지 | 이미프라민 (imipramine) | TCA | 150-300 | 전화: 043-719-3912 |       | 검증 및 |\n| 5 | 다) 병용약물 조사 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 제조자는 운영 체제(OS) 소프트웨어, 제3자 | ment) | 데이터에 접근 | 즉각적으로 강화를 받을 수 있는 활동에 참여하도록 하고, 변화 | 한다. ",
        "original_sentence": "|\n| 2 | FAX : (043) 719-3900 | 순응도 조사 | - | O | O | O | 13 | 우울장애 일기를 통한 우울 양상 | - 재사용(재사용이 가능한 경우에만 실시) 결과가 양성인 경우 | WPAI) | IEC | 밸리데이션 가이드라인 | [부패·공익신고 안내] ※ 신고자 및 신고내용은 보호됩니다. "
      }
    },
    {
      "chunk_id": "chunk_342",
      "text": "| Devices | 대하여 알기 쉽게 설명하거나 식품 | 소프트웨어 | 국내 | RP |\n| 유지 | 이미프라민 (imipramine) | TCA | 150-300 | 전화: 043-719-3912 |       | 검증 및 |\n| 5 | 다) 병용약물 조사 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 341,
        "window_size": 3,
        "char_count": 198,
        "word_count": 55,
        "page_number": 9,
        "window_text": "| 결과값과 예상값을 비교한다.  | 실현할 수 있어야 한다.  |\n| 2 | FAX : (043) 719-3900 | 순응도 조사 | - | O | O | O | 13 | 우울장애 일기를 통한 우울 양상 | - 재사용(재사용이 가능한 경우에만 실시) 결과가 양성인 경우 | WPAI) | IEC | 밸리데이션 가이드라인 | [부패·공익신고 안내] ※ 신고자 및 신고내용은 보호됩니다.  | Devices | 대하여 알기 쉽게 설명하거나 식품 | 소프트웨어 | 국내 | RP |\n| 유지 | 이미프라민 (imipramine) | TCA | 150-300 | 전화: 043-719-3912 |       | 검증 및 |\n| 5 | 다) 병용약물 조사 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 제조자는 운영 체제(OS) 소프트웨어, 제3자 | ment) | 데이터에 접근 | 즉각적으로 강화를 받을 수 있는 활동에 참여하도록 하고, 변화 | 한다.  불쾌한 사건을 상상하게 하고, 자신이 생각하는 사건이 | incorporating medical devices | 문제로 일을 빠진 시간+실제 일한 시간)] × 건강 문제로 | 2022년  12월  14일 | 전문의 | 치료기회 |   | 의료기기의 위험관리 | 국외 |\n| 등 필요한 조치를 시험책임자에게 하여야 한다. ",
        "original_sentence": "| Devices | 대하여 알기 쉽게 설명하거나 식품 | 소프트웨어 | 국내 | RP |\n| 유지 | 이미프라민 (imipramine) | TCA | 150-300 | 전화: 043-719-3912 |       | 검증 및 |\n| 5 | 다) 병용약물 조사 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. "
      }
    },
    {
      "chunk_id": "chunk_343",
      "text": "| - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 342,
        "window_size": 3,
        "char_count": 37,
        "word_count": 11,
        "page_number": 13,
        "window_text": "| 실현할 수 있어야 한다.  |\n| 2 | FAX : (043) 719-3900 | 순응도 조사 | - | O | O | O | 13 | 우울장애 일기를 통한 우울 양상 | - 재사용(재사용이 가능한 경우에만 실시) 결과가 양성인 경우 | WPAI) | IEC | 밸리데이션 가이드라인 | [부패·공익신고 안내] ※ 신고자 및 신고내용은 보호됩니다.  | Devices | 대하여 알기 쉽게 설명하거나 식품 | 소프트웨어 | 국내 | RP |\n| 유지 | 이미프라민 (imipramine) | TCA | 150-300 | 전화: 043-719-3912 |       | 검증 및 |\n| 5 | 다) 병용약물 조사 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 제조자는 운영 체제(OS) 소프트웨어, 제3자 | ment) | 데이터에 접근 | 즉각적으로 강화를 받을 수 있는 활동에 참여하도록 하고, 변화 | 한다.  불쾌한 사건을 상상하게 하고, 자신이 생각하는 사건이 | incorporating medical devices | 문제로 일을 빠진 시간+실제 일한 시간)] × 건강 문제로 | 2022년  12월  14일 | 전문의 | 치료기회 |   | 의료기기의 위험관리 | 국외 |\n| 등 필요한 조치를 시험책임자에게 하여야 한다.  | 따라 변경될 수 있으며, 제품의 특성에 따라 타당한 근거를 제시할 경우 | Guidance on Cybersecurity for | 일정 수준의 보호가 요구되는지 고려하여야 한다. ",
        "original_sentence": "| - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. "
      }
    },
    {
      "chunk_id": "chunk_344",
      "text": "| 제조자는 운영 체제(OS) 소프트웨어, 제3자 | ment) | 데이터에 접근 | 즉각적으로 강화를 받을 수 있는 활동에 참여하도록 하고, 변화 | 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 343,
        "window_size": 3,
        "char_count": 89,
        "word_count": 23,
        "page_number": 9,
        "window_text": "|\n| 2 | FAX : (043) 719-3900 | 순응도 조사 | - | O | O | O | 13 | 우울장애 일기를 통한 우울 양상 | - 재사용(재사용이 가능한 경우에만 실시) 결과가 양성인 경우 | WPAI) | IEC | 밸리데이션 가이드라인 | [부패·공익신고 안내] ※ 신고자 및 신고내용은 보호됩니다.  | Devices | 대하여 알기 쉽게 설명하거나 식품 | 소프트웨어 | 국내 | RP |\n| 유지 | 이미프라민 (imipramine) | TCA | 150-300 | 전화: 043-719-3912 |       | 검증 및 |\n| 5 | 다) 병용약물 조사 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 제조자는 운영 체제(OS) 소프트웨어, 제3자 | ment) | 데이터에 접근 | 즉각적으로 강화를 받을 수 있는 활동에 참여하도록 하고, 변화 | 한다.  불쾌한 사건을 상상하게 하고, 자신이 생각하는 사건이 | incorporating medical devices | 문제로 일을 빠진 시간+실제 일한 시간)] × 건강 문제로 | 2022년  12월  14일 | 전문의 | 치료기회 |   | 의료기기의 위험관리 | 국외 |\n| 등 필요한 조치를 시험책임자에게 하여야 한다.  | 따라 변경될 수 있으며, 제품의 특성에 따라 타당한 근거를 제시할 경우 | Guidance on Cybersecurity for | 일정 수준의 보호가 요구되는지 고려하여야 한다.  | 그림 1. ",
        "original_sentence": "| 제조자는 운영 체제(OS) 소프트웨어, 제3자 | ment) | 데이터에 접근 | 즉각적으로 강화를 받을 수 있는 활동에 참여하도록 하고, 변화 | 한다. "
      }
    },
    {
      "chunk_id": "chunk_345",
      "text": "불쾌한 사건을 상상하게 하고, 자신이 생각하는 사건이 | incorporating medical devices | 문제로 일을 빠진 시간+실제 일한 시간)] × 건강 문제로 | 2022년  12월  14일 | 전문의 | 치료기회 |   | 의료기기의 위험관리 | 국외 |\n| 등 필요한 조치를 시험책임자에게 하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 344,
        "window_size": 3,
        "char_count": 195,
        "word_count": 45,
        "page_number": 18,
        "window_text": "| Devices | 대하여 알기 쉽게 설명하거나 식품 | 소프트웨어 | 국내 | RP |\n| 유지 | 이미프라민 (imipramine) | TCA | 150-300 | 전화: 043-719-3912 |       | 검증 및 |\n| 5 | 다) 병용약물 조사 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 제조자는 운영 체제(OS) 소프트웨어, 제3자 | ment) | 데이터에 접근 | 즉각적으로 강화를 받을 수 있는 활동에 참여하도록 하고, 변화 | 한다.  불쾌한 사건을 상상하게 하고, 자신이 생각하는 사건이 | incorporating medical devices | 문제로 일을 빠진 시간+실제 일한 시간)] × 건강 문제로 | 2022년  12월  14일 | 전문의 | 치료기회 |   | 의료기기의 위험관리 | 국외 |\n| 등 필요한 조치를 시험책임자에게 하여야 한다.  | 따라 변경될 수 있으며, 제품의 특성에 따라 타당한 근거를 제시할 경우 | Guidance on Cybersecurity for | 일정 수준의 보호가 요구되는지 고려하여야 한다.  | 그림 1.  디지털 치료기기 대상여부 판단 기준 및 절차 | 또는 일시 중지시킬 수 있다. ",
        "original_sentence": "불쾌한 사건을 상상하게 하고, 자신이 생각하는 사건이 | incorporating medical devices | 문제로 일을 빠진 시간+실제 일한 시간)] × 건강 문제로 | 2022년  12월  14일 | 전문의 | 치료기회 |   | 의료기기의 위험관리 | 국외 |\n| 등 필요한 조치를 시험책임자에게 하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_346",
      "text": "| 따라 변경될 수 있으며, 제품의 특성에 따라 타당한 근거를 제시할 경우 | Guidance on Cybersecurity for | 일정 수준의 보호가 요구되는지 고려하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 345,
        "window_size": 3,
        "char_count": 103,
        "word_count": 24,
        "page_number": 39,
        "window_text": "| - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 제조자는 운영 체제(OS) 소프트웨어, 제3자 | ment) | 데이터에 접근 | 즉각적으로 강화를 받을 수 있는 활동에 참여하도록 하고, 변화 | 한다.  불쾌한 사건을 상상하게 하고, 자신이 생각하는 사건이 | incorporating medical devices | 문제로 일을 빠진 시간+실제 일한 시간)] × 건강 문제로 | 2022년  12월  14일 | 전문의 | 치료기회 |   | 의료기기의 위험관리 | 국외 |\n| 등 필요한 조치를 시험책임자에게 하여야 한다.  | 따라 변경될 수 있으며, 제품의 특성에 따라 타당한 근거를 제시할 경우 | Guidance on Cybersecurity for | 일정 수준의 보호가 요구되는지 고려하여야 한다.  | 그림 1.  디지털 치료기기 대상여부 판단 기준 및 절차 | 또는 일시 중지시킬 수 있다.  | ‣ 식약처 홈페이지 “국민소통 > 신고센터 > 부패·공익신고 상담”코너 | 상세 설계를 바탕으로 코딩을 | 적용 |\n| 접근 | 나) 무작위 배정 | 노르트립틸린(nortriptyline) | TCA | 20-40 | 14 | 우울, 불안 관련 증상 유무 | 것이라는 사실 | - 우울/불안 관련 증상 유무 및 직업적/사회적 기능 상태 | - 본 연구는 중간 분석을 수행하지 않는다. ",
        "original_sentence": "| 따라 변경될 수 있으며, 제품의 특성에 따라 타당한 근거를 제시할 경우 | Guidance on Cybersecurity for | 일정 수준의 보호가 요구되는지 고려하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_347",
      "text": "| 그림 1. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 346,
        "window_size": 3,
        "char_count": 8,
        "word_count": 3,
        "page_number": 28,
        "window_text": "| 제조자는 운영 체제(OS) 소프트웨어, 제3자 | ment) | 데이터에 접근 | 즉각적으로 강화를 받을 수 있는 활동에 참여하도록 하고, 변화 | 한다.  불쾌한 사건을 상상하게 하고, 자신이 생각하는 사건이 | incorporating medical devices | 문제로 일을 빠진 시간+실제 일한 시간)] × 건강 문제로 | 2022년  12월  14일 | 전문의 | 치료기회 |   | 의료기기의 위험관리 | 국외 |\n| 등 필요한 조치를 시험책임자에게 하여야 한다.  | 따라 변경될 수 있으며, 제품의 특성에 따라 타당한 근거를 제시할 경우 | Guidance on Cybersecurity for | 일정 수준의 보호가 요구되는지 고려하여야 한다.  | 그림 1.  디지털 치료기기 대상여부 판단 기준 및 절차 | 또는 일시 중지시킬 수 있다.  | ‣ 식약처 홈페이지 “국민소통 > 신고센터 > 부패·공익신고 상담”코너 | 상세 설계를 바탕으로 코딩을 | 적용 |\n| 접근 | 나) 무작위 배정 | 노르트립틸린(nortriptyline) | TCA | 20-40 | 14 | 우울, 불안 관련 증상 유무 | 것이라는 사실 | - 우울/불안 관련 증상 유무 및 직업적/사회적 기능 상태 | - 본 연구는 중간 분석을 수행하지 않는다.  | 80001-1 | (출처: Selfapy 홈페이지, | (민원인 안내서) | 팩스: 043-719-3900 | 의약품안전처의 입장을 기술 | 관련 보고를 시행한다. ",
        "original_sentence": "| 그림 1. "
      }
    },
    {
      "chunk_id": "chunk_348",
      "text": "디지털 치료기기 대상여부 판단 기준 및 절차 | 또는 일시 중지시킬 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 347,
        "window_size": 3,
        "char_count": 44,
        "word_count": 13,
        "page_number": 3,
        "window_text": "불쾌한 사건을 상상하게 하고, 자신이 생각하는 사건이 | incorporating medical devices | 문제로 일을 빠진 시간+실제 일한 시간)] × 건강 문제로 | 2022년  12월  14일 | 전문의 | 치료기회 |   | 의료기기의 위험관리 | 국외 |\n| 등 필요한 조치를 시험책임자에게 하여야 한다.  | 따라 변경될 수 있으며, 제품의 특성에 따라 타당한 근거를 제시할 경우 | Guidance on Cybersecurity for | 일정 수준의 보호가 요구되는지 고려하여야 한다.  | 그림 1.  디지털 치료기기 대상여부 판단 기준 및 절차 | 또는 일시 중지시킬 수 있다.  | ‣ 식약처 홈페이지 “국민소통 > 신고센터 > 부패·공익신고 상담”코너 | 상세 설계를 바탕으로 코딩을 | 적용 |\n| 접근 | 나) 무작위 배정 | 노르트립틸린(nortriptyline) | TCA | 20-40 | 14 | 우울, 불안 관련 증상 유무 | 것이라는 사실 | - 우울/불안 관련 증상 유무 및 직업적/사회적 기능 상태 | - 본 연구는 중간 분석을 수행하지 않는다.  | 80001-1 | (출처: Selfapy 홈페이지, | (민원인 안내서) | 팩스: 043-719-3900 | 의약품안전처의 입장을 기술 | 관련 보고를 시행한다.  | 검증 및 |\n| 보호 | 보수 | 11 | * 관해 정의: 우울장애 심각도 척도(BDI) 13점 이하 | 전문의에 의해 자살 고위험군으로 판단되는 자 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | medical devices | 의료기기 사이버보안에 대한 가이드라인 | 유럽 |   |  |  |  | 유효성 |   | (AB-1234) |\n| 트라조돈(trazodone) | Serotonin reuptake inhibitor; 5-HT2 antagonist | 50-100 | 소프트웨어, 오픈 소스 소프트웨어가 업데이트나 | 하도록 한 경우 | 상황을 관찰 기록함으로써 환자의 자기강화를 도와줄 수 있다. ",
        "original_sentence": "디지털 치료기기 대상여부 판단 기준 및 절차 | 또는 일시 중지시킬 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_349",
      "text": "| ‣ 식약처 홈페이지 “국민소통 > 신고센터 > 부패·공익신고 상담”코너 | 상세 설계를 바탕으로 코딩을 | 적용 |\n| 접근 | 나) 무작위 배정 | 노르트립틸린(nortriptyline) | TCA | 20-40 | 14 | 우울, 불안 관련 증상 유무 | 것이라는 사실 | - 우울/불안 관련 증상 유무 및 직업적/사회적 기능 상태 | - 본 연구는 중간 분석을 수행하지 않는다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 348,
        "window_size": 3,
        "char_count": 217,
        "word_count": 59,
        "page_number": 41,
        "window_text": "| 따라 변경될 수 있으며, 제품의 특성에 따라 타당한 근거를 제시할 경우 | Guidance on Cybersecurity for | 일정 수준의 보호가 요구되는지 고려하여야 한다.  | 그림 1.  디지털 치료기기 대상여부 판단 기준 및 절차 | 또는 일시 중지시킬 수 있다.  | ‣ 식약처 홈페이지 “국민소통 > 신고센터 > 부패·공익신고 상담”코너 | 상세 설계를 바탕으로 코딩을 | 적용 |\n| 접근 | 나) 무작위 배정 | 노르트립틸린(nortriptyline) | TCA | 20-40 | 14 | 우울, 불안 관련 증상 유무 | 것이라는 사실 | - 우울/불안 관련 증상 유무 및 직업적/사회적 기능 상태 | - 본 연구는 중간 분석을 수행하지 않는다.  | 80001-1 | (출처: Selfapy 홈페이지, | (민원인 안내서) | 팩스: 043-719-3900 | 의약품안전처의 입장을 기술 | 관련 보고를 시행한다.  | 검증 및 |\n| 보호 | 보수 | 11 | * 관해 정의: 우울장애 심각도 척도(BDI) 13점 이하 | 전문의에 의해 자살 고위험군으로 판단되는 자 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | medical devices | 의료기기 사이버보안에 대한 가이드라인 | 유럽 |   |  |  |  | 유효성 |   | (AB-1234) |\n| 트라조돈(trazodone) | Serotonin reuptake inhibitor; 5-HT2 antagonist | 50-100 | 소프트웨어, 오픈 소스 소프트웨어가 업데이트나 | 하도록 한 경우 | 상황을 관찰 기록함으로써 환자의 자기강화를 도와줄 수 있다.  | 일어난 이유를 설명하게 한 다음, 보다 합리적이고 현실적인 | 인해 일하는 동안 발생한 작업 능률 점수/10] | – Part 1: Roles, | 진료수행 | 박탈 | 방법에 대한 국제 규격 | 적용 |\n| ※ 예: 비밀번호(passwords)는 암호화된 보안 | https://www.selfapy.com/) | 하며 코드는 정확하고 요구사항에 | 과정은 총 3개월 동안 사용할 수 있다. ",
        "original_sentence": "| ‣ 식약처 홈페이지 “국민소통 > 신고센터 > 부패·공익신고 상담”코너 | 상세 설계를 바탕으로 코딩을 | 적용 |\n| 접근 | 나) 무작위 배정 | 노르트립틸린(nortriptyline) | TCA | 20-40 | 14 | 우울, 불안 관련 증상 유무 | 것이라는 사실 | - 우울/불안 관련 증상 유무 및 직업적/사회적 기능 상태 | - 본 연구는 중간 분석을 수행하지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_350",
      "text": "| 80001-1 | (출처: Selfapy 홈페이지, | (민원인 안내서) | 팩스: 043-719-3900 | 의약품안전처의 입장을 기술 | 관련 보고를 시행한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 349,
        "window_size": 3,
        "char_count": 94,
        "word_count": 20,
        "page_number": 28,
        "window_text": "| 그림 1.  디지털 치료기기 대상여부 판단 기준 및 절차 | 또는 일시 중지시킬 수 있다.  | ‣ 식약처 홈페이지 “국민소통 > 신고센터 > 부패·공익신고 상담”코너 | 상세 설계를 바탕으로 코딩을 | 적용 |\n| 접근 | 나) 무작위 배정 | 노르트립틸린(nortriptyline) | TCA | 20-40 | 14 | 우울, 불안 관련 증상 유무 | 것이라는 사실 | - 우울/불안 관련 증상 유무 및 직업적/사회적 기능 상태 | - 본 연구는 중간 분석을 수행하지 않는다.  | 80001-1 | (출처: Selfapy 홈페이지, | (민원인 안내서) | 팩스: 043-719-3900 | 의약품안전처의 입장을 기술 | 관련 보고를 시행한다.  | 검증 및 |\n| 보호 | 보수 | 11 | * 관해 정의: 우울장애 심각도 척도(BDI) 13점 이하 | 전문의에 의해 자살 고위험군으로 판단되는 자 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | medical devices | 의료기기 사이버보안에 대한 가이드라인 | 유럽 |   |  |  |  | 유효성 |   | (AB-1234) |\n| 트라조돈(trazodone) | Serotonin reuptake inhibitor; 5-HT2 antagonist | 50-100 | 소프트웨어, 오픈 소스 소프트웨어가 업데이트나 | 하도록 한 경우 | 상황을 관찰 기록함으로써 환자의 자기강화를 도와줄 수 있다.  | 일어난 이유를 설명하게 한 다음, 보다 합리적이고 현실적인 | 인해 일하는 동안 발생한 작업 능률 점수/10] | – Part 1: Roles, | 진료수행 | 박탈 | 방법에 대한 국제 규격 | 적용 |\n| ※ 예: 비밀번호(passwords)는 암호화된 보안 | https://www.selfapy.com/) | 하며 코드는 정확하고 요구사항에 | 과정은 총 3개월 동안 사용할 수 있다.  |\n| 세스에 따른다. ",
        "original_sentence": "| 80001-1 | (출처: Selfapy 홈페이지, | (민원인 안내서) | 팩스: 043-719-3900 | 의약품안전처의 입장을 기술 | 관련 보고를 시행한다. "
      }
    },
    {
      "chunk_id": "chunk_351",
      "text": "| 검증 및 |\n| 보호 | 보수 | 11 | * 관해 정의: 우울장애 심각도 척도(BDI) 13점 이하 | 전문의에 의해 자살 고위험군으로 판단되는 자 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | medical devices | 의료기기 사이버보안에 대한 가이드라인 | 유럽 |   |  |  |  | 유효성 |   | (AB-1234) |\n| 트라조돈(trazodone) | Serotonin reuptake inhibitor; 5-HT2 antagonist | 50-100 | 소프트웨어, 오픈 소스 소프트웨어가 업데이트나 | 하도록 한 경우 | 상황을 관찰 기록함으로써 환자의 자기강화를 도와줄 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 350,
        "window_size": 3,
        "char_count": 366,
        "word_count": 92,
        "page_number": 28,
        "window_text": "디지털 치료기기 대상여부 판단 기준 및 절차 | 또는 일시 중지시킬 수 있다.  | ‣ 식약처 홈페이지 “국민소통 > 신고센터 > 부패·공익신고 상담”코너 | 상세 설계를 바탕으로 코딩을 | 적용 |\n| 접근 | 나) 무작위 배정 | 노르트립틸린(nortriptyline) | TCA | 20-40 | 14 | 우울, 불안 관련 증상 유무 | 것이라는 사실 | - 우울/불안 관련 증상 유무 및 직업적/사회적 기능 상태 | - 본 연구는 중간 분석을 수행하지 않는다.  | 80001-1 | (출처: Selfapy 홈페이지, | (민원인 안내서) | 팩스: 043-719-3900 | 의약품안전처의 입장을 기술 | 관련 보고를 시행한다.  | 검증 및 |\n| 보호 | 보수 | 11 | * 관해 정의: 우울장애 심각도 척도(BDI) 13점 이하 | 전문의에 의해 자살 고위험군으로 판단되는 자 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | medical devices | 의료기기 사이버보안에 대한 가이드라인 | 유럽 |   |  |  |  | 유효성 |   | (AB-1234) |\n| 트라조돈(trazodone) | Serotonin reuptake inhibitor; 5-HT2 antagonist | 50-100 | 소프트웨어, 오픈 소스 소프트웨어가 업데이트나 | 하도록 한 경우 | 상황을 관찰 기록함으로써 환자의 자기강화를 도와줄 수 있다.  | 일어난 이유를 설명하게 한 다음, 보다 합리적이고 현실적인 | 인해 일하는 동안 발생한 작업 능률 점수/10] | – Part 1: Roles, | 진료수행 | 박탈 | 방법에 대한 국제 규격 | 적용 |\n| ※ 예: 비밀번호(passwords)는 암호화된 보안 | https://www.selfapy.com/) | 하며 코드는 정확하고 요구사항에 | 과정은 총 3개월 동안 사용할 수 있다.  |\n| 세스에 따른다.  | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 설정 변경이 가능하다. ",
        "original_sentence": "| 검증 및 |\n| 보호 | 보수 | 11 | * 관해 정의: 우울장애 심각도 척도(BDI) 13점 이하 | 전문의에 의해 자살 고위험군으로 판단되는 자 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | medical devices | 의료기기 사이버보안에 대한 가이드라인 | 유럽 |   |  |  |  | 유효성 |   | (AB-1234) |\n| 트라조돈(trazodone) | Serotonin reuptake inhibitor; 5-HT2 antagonist | 50-100 | 소프트웨어, 오픈 소스 소프트웨어가 업데이트나 | 하도록 한 경우 | 상황을 관찰 기록함으로써 환자의 자기강화를 도와줄 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_352",
      "text": "| 일어난 이유를 설명하게 한 다음, 보다 합리적이고 현실적인 | 인해 일하는 동안 발생한 작업 능률 점수/10] | – Part 1: Roles, | 진료수행 | 박탈 | 방법에 대한 국제 규격 | 적용 |\n| ※ 예: 비밀번호(passwords)는 암호화된 보안 | https://www.selfapy.com/) | 하며 코드는 정확하고 요구사항에 | 과정은 총 3개월 동안 사용할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 351,
        "window_size": 3,
        "char_count": 222,
        "word_count": 55,
        "page_number": 19,
        "window_text": "| ‣ 식약처 홈페이지 “국민소통 > 신고센터 > 부패·공익신고 상담”코너 | 상세 설계를 바탕으로 코딩을 | 적용 |\n| 접근 | 나) 무작위 배정 | 노르트립틸린(nortriptyline) | TCA | 20-40 | 14 | 우울, 불안 관련 증상 유무 | 것이라는 사실 | - 우울/불안 관련 증상 유무 및 직업적/사회적 기능 상태 | - 본 연구는 중간 분석을 수행하지 않는다.  | 80001-1 | (출처: Selfapy 홈페이지, | (민원인 안내서) | 팩스: 043-719-3900 | 의약품안전처의 입장을 기술 | 관련 보고를 시행한다.  | 검증 및 |\n| 보호 | 보수 | 11 | * 관해 정의: 우울장애 심각도 척도(BDI) 13점 이하 | 전문의에 의해 자살 고위험군으로 판단되는 자 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | medical devices | 의료기기 사이버보안에 대한 가이드라인 | 유럽 |   |  |  |  | 유효성 |   | (AB-1234) |\n| 트라조돈(trazodone) | Serotonin reuptake inhibitor; 5-HT2 antagonist | 50-100 | 소프트웨어, 오픈 소스 소프트웨어가 업데이트나 | 하도록 한 경우 | 상황을 관찰 기록함으로써 환자의 자기강화를 도와줄 수 있다.  | 일어난 이유를 설명하게 한 다음, 보다 합리적이고 현실적인 | 인해 일하는 동안 발생한 작업 능률 점수/10] | – Part 1: Roles, | 진료수행 | 박탈 | 방법에 대한 국제 규격 | 적용 |\n| ※ 예: 비밀번호(passwords)는 암호화된 보안 | https://www.selfapy.com/) | 하며 코드는 정확하고 요구사항에 | 과정은 총 3개월 동안 사용할 수 있다.  |\n| 세스에 따른다.  | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 설정 변경이 가능하다.  | 15 | 직업적/사회적 기능 상태 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. ",
        "original_sentence": "| 일어난 이유를 설명하게 한 다음, 보다 합리적이고 현실적인 | 인해 일하는 동안 발생한 작업 능률 점수/10] | – Part 1: Roles, | 진료수행 | 박탈 | 방법에 대한 국제 규격 | 적용 |\n| ※ 예: 비밀번호(passwords)는 암호화된 보안 | https://www.selfapy.com/) | 하며 코드는 정확하고 요구사항에 | 과정은 총 3개월 동안 사용할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_353",
      "text": "|\n| 세스에 따른다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 352,
        "window_size": 3,
        "char_count": 13,
        "word_count": 4,
        "page_number": 40,
        "window_text": "| 80001-1 | (출처: Selfapy 홈페이지, | (민원인 안내서) | 팩스: 043-719-3900 | 의약품안전처의 입장을 기술 | 관련 보고를 시행한다.  | 검증 및 |\n| 보호 | 보수 | 11 | * 관해 정의: 우울장애 심각도 척도(BDI) 13점 이하 | 전문의에 의해 자살 고위험군으로 판단되는 자 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | medical devices | 의료기기 사이버보안에 대한 가이드라인 | 유럽 |   |  |  |  | 유효성 |   | (AB-1234) |\n| 트라조돈(trazodone) | Serotonin reuptake inhibitor; 5-HT2 antagonist | 50-100 | 소프트웨어, 오픈 소스 소프트웨어가 업데이트나 | 하도록 한 경우 | 상황을 관찰 기록함으로써 환자의 자기강화를 도와줄 수 있다.  | 일어난 이유를 설명하게 한 다음, 보다 합리적이고 현실적인 | 인해 일하는 동안 발생한 작업 능률 점수/10] | – Part 1: Roles, | 진료수행 | 박탈 | 방법에 대한 국제 규격 | 적용 |\n| ※ 예: 비밀번호(passwords)는 암호화된 보안 | https://www.selfapy.com/) | 하며 코드는 정확하고 요구사항에 | 과정은 총 3개월 동안 사용할 수 있다.  |\n| 세스에 따른다.  | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 설정 변경이 가능하다.  | 15 | 직업적/사회적 기능 상태 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 영향을 줄 수 있는 약물의 사용량이 변경된 경우 | 유효성 | (AB-1234) |\n| dismantling study. ",
        "original_sentence": "|\n| 세스에 따른다. "
      }
    },
    {
      "chunk_id": "chunk_354",
      "text": "| ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 설정 변경이 가능하다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 353,
        "window_size": 3,
        "char_count": 51,
        "word_count": 14,
        "page_number": 29,
        "window_text": "| 검증 및 |\n| 보호 | 보수 | 11 | * 관해 정의: 우울장애 심각도 척도(BDI) 13점 이하 | 전문의에 의해 자살 고위험군으로 판단되는 자 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | medical devices | 의료기기 사이버보안에 대한 가이드라인 | 유럽 |   |  |  |  | 유효성 |   | (AB-1234) |\n| 트라조돈(trazodone) | Serotonin reuptake inhibitor; 5-HT2 antagonist | 50-100 | 소프트웨어, 오픈 소스 소프트웨어가 업데이트나 | 하도록 한 경우 | 상황을 관찰 기록함으로써 환자의 자기강화를 도와줄 수 있다.  | 일어난 이유를 설명하게 한 다음, 보다 합리적이고 현실적인 | 인해 일하는 동안 발생한 작업 능률 점수/10] | – Part 1: Roles, | 진료수행 | 박탈 | 방법에 대한 국제 규격 | 적용 |\n| ※ 예: 비밀번호(passwords)는 암호화된 보안 | https://www.selfapy.com/) | 하며 코드는 정확하고 요구사항에 | 과정은 총 3개월 동안 사용할 수 있다.  |\n| 세스에 따른다.  | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 설정 변경이 가능하다.  | 15 | 직업적/사회적 기능 상태 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 영향을 줄 수 있는 약물의 사용량이 변경된 경우 | 유효성 | (AB-1234) |\n| dismantling study.  Trials, 22(1), 1-10. ",
        "original_sentence": "| ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 설정 변경이 가능하다. "
      }
    },
    {
      "chunk_id": "chunk_355",
      "text": "| 15 | 직업적/사회적 기능 상태 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 354,
        "window_size": 3,
        "char_count": 58,
        "word_count": 17,
        "page_number": 28,
        "window_text": "| 일어난 이유를 설명하게 한 다음, 보다 합리적이고 현실적인 | 인해 일하는 동안 발생한 작업 능률 점수/10] | – Part 1: Roles, | 진료수행 | 박탈 | 방법에 대한 국제 규격 | 적용 |\n| ※ 예: 비밀번호(passwords)는 암호화된 보안 | https://www.selfapy.com/) | 하며 코드는 정확하고 요구사항에 | 과정은 총 3개월 동안 사용할 수 있다.  |\n| 세스에 따른다.  | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 설정 변경이 가능하다.  | 15 | 직업적/사회적 기능 상태 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 영향을 줄 수 있는 약물의 사용량이 변경된 경우 | 유효성 | (AB-1234) |\n| dismantling study.  Trials, 22(1), 1-10.  | 모노클로베미드(monoclobemide) | Reversible inhibitor of MAO-A | 60 | 러목(의료기기이상반응의 보고)에 따른다. ",
        "original_sentence": "| 15 | 직업적/사회적 기능 상태 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. "
      }
    },
    {
      "chunk_id": "chunk_356",
      "text": "| 영향을 줄 수 있는 약물의 사용량이 변경된 경우 | 유효성 | (AB-1234) |\n| dismantling study. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 355,
        "window_size": 3,
        "char_count": 70,
        "word_count": 17,
        "page_number": 9,
        "window_text": "|\n| 세스에 따른다.  | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 설정 변경이 가능하다.  | 15 | 직업적/사회적 기능 상태 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 영향을 줄 수 있는 약물의 사용량이 변경된 경우 | 유효성 | (AB-1234) |\n| dismantling study.  Trials, 22(1), 1-10.  | 모노클로베미드(monoclobemide) | Reversible inhibitor of MAO-A | 60 | 러목(의료기기이상반응의 보고)에 따른다.  | 대상으로 한다. ",
        "original_sentence": "| 영향을 줄 수 있는 약물의 사용량이 변경된 경우 | 유효성 | (AB-1234) |\n| dismantling study. "
      }
    },
    {
      "chunk_id": "chunk_357",
      "text": "Trials, 22(1), 1-10. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 356,
        "window_size": 3,
        "char_count": 21,
        "word_count": 3,
        "page_number": 9,
        "window_text": "| ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 설정 변경이 가능하다.  | 15 | 직업적/사회적 기능 상태 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 영향을 줄 수 있는 약물의 사용량이 변경된 경우 | 유효성 | (AB-1234) |\n| dismantling study.  Trials, 22(1), 1-10.  | 모노클로베미드(monoclobemide) | Reversible inhibitor of MAO-A | 60 | 러목(의료기기이상반응의 보고)에 따른다.  | 대상으로 한다.  | 담당자 | 확  인(부서장) | 확인 자료 | 양 승 하 |\n| 기회를 제공하여 동의를 얻어야 한다. ",
        "original_sentence": "Trials, 22(1), 1-10. "
      }
    },
    {
      "chunk_id": "chunk_358",
      "text": "| 모노클로베미드(monoclobemide) | Reversible inhibitor of MAO-A | 60 | 러목(의료기기이상반응의 보고)에 따른다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 357,
        "window_size": 3,
        "char_count": 87,
        "word_count": 13,
        "page_number": 21,
        "window_text": "| 15 | 직업적/사회적 기능 상태 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 영향을 줄 수 있는 약물의 사용량이 변경된 경우 | 유효성 | (AB-1234) |\n| dismantling study.  Trials, 22(1), 1-10.  | 모노클로베미드(monoclobemide) | Reversible inhibitor of MAO-A | 60 | 러목(의료기기이상반응의 보고)에 따른다.  | 대상으로 한다.  | 담당자 | 확  인(부서장) | 확인 자료 | 양 승 하 |\n| 기회를 제공하여 동의를 얻어야 한다.  | 되어야 한다. ",
        "original_sentence": "| 모노클로베미드(monoclobemide) | Reversible inhibitor of MAO-A | 60 | 러목(의료기기이상반응의 보고)에 따른다. "
      }
    },
    {
      "chunk_id": "chunk_359",
      "text": "| 대상으로 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 358,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 13,
        "window_text": "| 영향을 줄 수 있는 약물의 사용량이 변경된 경우 | 유효성 | (AB-1234) |\n| dismantling study.  Trials, 22(1), 1-10.  | 모노클로베미드(monoclobemide) | Reversible inhibitor of MAO-A | 60 | 러목(의료기기이상반응의 보고)에 따른다.  | 대상으로 한다.  | 담당자 | 확  인(부서장) | 확인 자료 | 양 승 하 |\n| 기회를 제공하여 동의를 얻어야 한다.  | 되어야 한다.  | 해주어야 한다. ",
        "original_sentence": "| 대상으로 한다. "
      }
    },
    {
      "chunk_id": "chunk_360",
      "text": "| 담당자 | 확  인(부서장) | 확인 자료 | 양 승 하 |\n| 기회를 제공하여 동의를 얻어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 359,
        "window_size": 3,
        "char_count": 59,
        "word_count": 19,
        "page_number": 3,
        "window_text": "Trials, 22(1), 1-10.  | 모노클로베미드(monoclobemide) | Reversible inhibitor of MAO-A | 60 | 러목(의료기기이상반응의 보고)에 따른다.  | 대상으로 한다.  | 담당자 | 확  인(부서장) | 확인 자료 | 양 승 하 |\n| 기회를 제공하여 동의를 얻어야 한다.  | 되어야 한다.  | 해주어야 한다.  | 연장할 수 있다. ",
        "original_sentence": "| 담당자 | 확  인(부서장) | 확인 자료 | 양 승 하 |\n| 기회를 제공하여 동의를 얻어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_361",
      "text": "| 되어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 360,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 13,
        "window_text": "| 모노클로베미드(monoclobemide) | Reversible inhibitor of MAO-A | 60 | 러목(의료기기이상반응의 보고)에 따른다.  | 대상으로 한다.  | 담당자 | 확  인(부서장) | 확인 자료 | 양 승 하 |\n| 기회를 제공하여 동의를 얻어야 한다.  | 되어야 한다.  | 해주어야 한다.  | 연장할 수 있다.  | - 시험군 혹은 대조군에 무작위배정을 통해 배치한다. ",
        "original_sentence": "| 되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_362",
      "text": "| 해주어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 361,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 13,
        "window_text": "| 대상으로 한다.  | 담당자 | 확  인(부서장) | 확인 자료 | 양 승 하 |\n| 기회를 제공하여 동의를 얻어야 한다.  | 되어야 한다.  | 해주어야 한다.  | 연장할 수 있다.  | - 시험군 혹은 대조군에 무작위배정을 통해 배치한다.  | 사건들을 조합하여 각 위해요인에 대한 위험을 산정한다. ",
        "original_sentence": "| 해주어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_363",
      "text": "| 연장할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 362,
        "window_size": 3,
        "char_count": 12,
        "word_count": 4,
        "page_number": 11,
        "window_text": "| 담당자 | 확  인(부서장) | 확인 자료 | 양 승 하 |\n| 기회를 제공하여 동의를 얻어야 한다.  | 되어야 한다.  | 해주어야 한다.  | 연장할 수 있다.  | - 시험군 혹은 대조군에 무작위배정을 통해 배치한다.  | 사건들을 조합하여 각 위해요인에 대한 위험을 산정한다.  | 치료기기를 설치한다. ",
        "original_sentence": "| 연장할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_364",
      "text": "| - 시험군 혹은 대조군에 무작위배정을 통해 배치한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 363,
        "window_size": 3,
        "char_count": 32,
        "word_count": 8,
        "page_number": 13,
        "window_text": "| 되어야 한다.  | 해주어야 한다.  | 연장할 수 있다.  | - 시험군 혹은 대조군에 무작위배정을 통해 배치한다.  | 사건들을 조합하여 각 위해요인에 대한 위험을 산정한다.  | 치료기기를 설치한다.  | 통제될 경우에 대해 고려하여야 한다. ",
        "original_sentence": "| - 시험군 혹은 대조군에 무작위배정을 통해 배치한다. "
      }
    },
    {
      "chunk_id": "chunk_365",
      "text": "| 사건들을 조합하여 각 위해요인에 대한 위험을 산정한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 364,
        "window_size": 3,
        "char_count": 33,
        "word_count": 8,
        "page_number": 13,
        "window_text": "| 해주어야 한다.  | 연장할 수 있다.  | - 시험군 혹은 대조군에 무작위배정을 통해 배치한다.  | 사건들을 조합하여 각 위해요인에 대한 위험을 산정한다.  | 치료기기를 설치한다.  | 통제될 경우에 대해 고려하여야 한다.  | 하여야 한다. ",
        "original_sentence": "| 사건들을 조합하여 각 위해요인에 대한 위험을 산정한다. "
      }
    },
    {
      "chunk_id": "chunk_366",
      "text": "| 치료기기를 설치한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 365,
        "window_size": 3,
        "char_count": 14,
        "word_count": 3,
        "page_number": 13,
        "window_text": "| 연장할 수 있다.  | - 시험군 혹은 대조군에 무작위배정을 통해 배치한다.  | 사건들을 조합하여 각 위해요인에 대한 위험을 산정한다.  | 치료기기를 설치한다.  | 통제될 경우에 대해 고려하여야 한다.  | 하여야 한다.  | 및 내용 등을 기재한다. ",
        "original_sentence": "| 치료기기를 설치한다. "
      }
    },
    {
      "chunk_id": "chunk_367",
      "text": "| 통제될 경우에 대해 고려하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 366,
        "window_size": 3,
        "char_count": 23,
        "word_count": 6,
        "page_number": 13,
        "window_text": "| - 시험군 혹은 대조군에 무작위배정을 통해 배치한다.  | 사건들을 조합하여 각 위해요인에 대한 위험을 산정한다.  | 치료기기를 설치한다.  | 통제될 경우에 대해 고려하여야 한다.  | 하여야 한다.  | 및 내용 등을 기재한다.  | 모호한 경우 | 대안적 이유를 생각해 낸다. ",
        "original_sentence": "| 통제될 경우에 대해 고려하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_368",
      "text": "| 하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 367,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 13,
        "window_text": "| 사건들을 조합하여 각 위해요인에 대한 위험을 산정한다.  | 치료기기를 설치한다.  | 통제될 경우에 대해 고려하여야 한다.  | 하여야 한다.  | 및 내용 등을 기재한다.  | 모호한 경우 | 대안적 이유를 생각해 낸다.  | responsibilities, and activities |\n| 방법의 잠재적 위험과 이익 | 요구한 사용 방법을 준수하여야 한다. ",
        "original_sentence": "| 하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_369",
      "text": "| 및 내용 등을 기재한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 368,
        "window_size": 3,
        "char_count": 16,
        "word_count": 5,
        "page_number": 13,
        "window_text": "| 치료기기를 설치한다.  | 통제될 경우에 대해 고려하여야 한다.  | 하여야 한다.  | 및 내용 등을 기재한다.  | 모호한 경우 | 대안적 이유를 생각해 낸다.  | responsibilities, and activities |\n| 방법의 잠재적 위험과 이익 | 요구한 사용 방법을 준수하여야 한다.  | (secure)이 확보된 해쉬(hash)로 저장되어야 함 | 부합한다. ",
        "original_sentence": "| 및 내용 등을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_370",
      "text": "| 모호한 경우 | 대안적 이유를 생각해 낸다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 369,
        "window_size": 3,
        "char_count": 27,
        "word_count": 8,
        "page_number": 19,
        "window_text": "| 통제될 경우에 대해 고려하여야 한다.  | 하여야 한다.  | 및 내용 등을 기재한다.  | 모호한 경우 | 대안적 이유를 생각해 낸다.  | responsibilities, and activities |\n| 방법의 잠재적 위험과 이익 | 요구한 사용 방법을 준수하여야 한다.  | (secure)이 확보된 해쉬(hash)로 저장되어야 함 | 부합한다.  |\n\n**[표 끝]**\n\n지침서ㆍ안내서\n\n이 원 규\n\n<!-- PAGE_4 -->\n#### 제·개정 이력\n\n<!-- PAGE_4 -->\n###### 우울장애 개선 디지털치료기기 안전성·성능 평가 및\n\n<!-- PAGE_4 -->\n###### 임상시험계획서 작성 가이드라인(민원인 안내서)\n\n우울장애 개선 디지털치료기기 안전성·성능\n\n평가 및 임상시험계획서 작성 가이드라인\n\n(민원인 안내서) 제정\n\n이 안내서는 우울장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서\n\n작성에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n",
        "original_sentence": "| 모호한 경우 | 대안적 이유를 생각해 낸다. "
      }
    },
    {
      "chunk_id": "chunk_371",
      "text": "| responsibilities, and activities |\n| 방법의 잠재적 위험과 이익 | 요구한 사용 방법을 준수하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 370,
        "window_size": 3,
        "char_count": 77,
        "word_count": 16,
        "page_number": 37,
        "window_text": "| 하여야 한다.  | 및 내용 등을 기재한다.  | 모호한 경우 | 대안적 이유를 생각해 낸다.  | responsibilities, and activities |\n| 방법의 잠재적 위험과 이익 | 요구한 사용 방법을 준수하여야 한다.  | (secure)이 확보된 해쉬(hash)로 저장되어야 함 | 부합한다.  |\n\n**[표 끝]**\n\n지침서ㆍ안내서\n\n이 원 규\n\n<!-- PAGE_4 -->\n#### 제·개정 이력\n\n<!-- PAGE_4 -->\n###### 우울장애 개선 디지털치료기기 안전성·성능 평가 및\n\n<!-- PAGE_4 -->\n###### 임상시험계획서 작성 가이드라인(민원인 안내서)\n\n우울장애 개선 디지털치료기기 안전성·성능\n\n평가 및 임상시험계획서 작성 가이드라인\n\n(민원인 안내서) 제정\n\n이 안내서는 우울장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서\n\n작성에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이\n\n아님을 알려드립니다. ",
        "original_sentence": "| responsibilities, and activities |\n| 방법의 잠재적 위험과 이익 | 요구한 사용 방법을 준수하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_372",
      "text": "| (secure)이 확보된 해쉬(hash)로 저장되어야 함 | 부합한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 371,
        "window_size": 3,
        "char_count": 42,
        "word_count": 8,
        "page_number": 13,
        "window_text": "| 및 내용 등을 기재한다.  | 모호한 경우 | 대안적 이유를 생각해 낸다.  | responsibilities, and activities |\n| 방법의 잠재적 위험과 이익 | 요구한 사용 방법을 준수하여야 한다.  | (secure)이 확보된 해쉬(hash)로 저장되어야 함 | 부합한다.  |\n\n**[표 끝]**\n\n지침서ㆍ안내서\n\n이 원 규\n\n<!-- PAGE_4 -->\n#### 제·개정 이력\n\n<!-- PAGE_4 -->\n###### 우울장애 개선 디지털치료기기 안전성·성능 평가 및\n\n<!-- PAGE_4 -->\n###### 임상시험계획서 작성 가이드라인(민원인 안내서)\n\n우울장애 개선 디지털치료기기 안전성·성능\n\n평가 및 임상시험계획서 작성 가이드라인\n\n(민원인 안내서) 제정\n\n이 안내서는 우울장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서\n\n작성에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이\n\n아님을 알려드립니다.  또한, 본 안내서는 2022년 12월 현재의 과학적ㆍ기술적 사실\n\n및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정법규 내용 및 구체적인\n\n<!-- PAGE_7 -->\n# 목\n\n<!-- PAGE_7 -->\n# 차\n\n<!-- PAGE_7 -->\n### Ⅰ. ",
        "original_sentence": "| (secure)이 확보된 해쉬(hash)로 저장되어야 함 | 부합한다. "
      }
    },
    {
      "chunk_id": "chunk_373",
      "text": "|\n\n**[표 끝]**\n\n지침서ㆍ안내서\n\n이 원 규\n\n<!-- PAGE_4 -->\n#### 제·개정 이력\n\n<!-- PAGE_4 -->\n###### 우울장애 개선 디지털치료기기 안전성·성능 평가 및\n\n<!-- PAGE_4 -->\n###### 임상시험계획서 작성 가이드라인(민원인 안내서)\n\n우울장애 개선 디지털치료기기 안전성·성능\n\n평가 및 임상시험계획서 작성 가이드라인\n\n(민원인 안내서) 제정\n\n이 안내서는 우울장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서\n\n작성에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 372,
        "window_size": 3,
        "char_count": 312,
        "word_count": 61,
        "page_number": 4,
        "window_text": "| 모호한 경우 | 대안적 이유를 생각해 낸다.  | responsibilities, and activities |\n| 방법의 잠재적 위험과 이익 | 요구한 사용 방법을 준수하여야 한다.  | (secure)이 확보된 해쉬(hash)로 저장되어야 함 | 부합한다.  |\n\n**[표 끝]**\n\n지침서ㆍ안내서\n\n이 원 규\n\n<!-- PAGE_4 -->\n#### 제·개정 이력\n\n<!-- PAGE_4 -->\n###### 우울장애 개선 디지털치료기기 안전성·성능 평가 및\n\n<!-- PAGE_4 -->\n###### 임상시험계획서 작성 가이드라인(민원인 안내서)\n\n우울장애 개선 디지털치료기기 안전성·성능\n\n평가 및 임상시험계획서 작성 가이드라인\n\n(민원인 안내서) 제정\n\n이 안내서는 우울장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서\n\n작성에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이\n\n아님을 알려드립니다.  또한, 본 안내서는 2022년 12월 현재의 과학적ㆍ기술적 사실\n\n및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정법규 내용 및 구체적인\n\n<!-- PAGE_7 -->\n# 목\n\n<!-- PAGE_7 -->\n# 차\n\n<!-- PAGE_7 -->\n### Ⅰ.  개 요 ········································································ 1\n\n<!-- PAGE_7 -->\n##### 1. ",
        "original_sentence": "|\n\n**[표 끝]**\n\n지침서ㆍ안내서\n\n이 원 규\n\n<!-- PAGE_4 -->\n#### 제·개정 이력\n\n<!-- PAGE_4 -->\n###### 우울장애 개선 디지털치료기기 안전성·성능 평가 및\n\n<!-- PAGE_4 -->\n###### 임상시험계획서 작성 가이드라인(민원인 안내서)\n\n우울장애 개선 디지털치료기기 안전성·성능\n\n평가 및 임상시험계획서 작성 가이드라인\n\n(민원인 안내서) 제정\n\n이 안내서는 우울장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서\n\n작성에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_374",
      "text": "본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이\n\n아님을 알려드립니다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 373,
        "window_size": 3,
        "char_count": 103,
        "word_count": 22,
        "page_number": 5,
        "window_text": "| responsibilities, and activities |\n| 방법의 잠재적 위험과 이익 | 요구한 사용 방법을 준수하여야 한다.  | (secure)이 확보된 해쉬(hash)로 저장되어야 함 | 부합한다.  |\n\n**[표 끝]**\n\n지침서ㆍ안내서\n\n이 원 규\n\n<!-- PAGE_4 -->\n#### 제·개정 이력\n\n<!-- PAGE_4 -->\n###### 우울장애 개선 디지털치료기기 안전성·성능 평가 및\n\n<!-- PAGE_4 -->\n###### 임상시험계획서 작성 가이드라인(민원인 안내서)\n\n우울장애 개선 디지털치료기기 안전성·성능\n\n평가 및 임상시험계획서 작성 가이드라인\n\n(민원인 안내서) 제정\n\n이 안내서는 우울장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서\n\n작성에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이\n\n아님을 알려드립니다.  또한, 본 안내서는 2022년 12월 현재의 과학적ㆍ기술적 사실\n\n및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정법규 내용 및 구체적인\n\n<!-- PAGE_7 -->\n# 목\n\n<!-- PAGE_7 -->\n# 차\n\n<!-- PAGE_7 -->\n### Ⅰ.  개 요 ········································································ 1\n\n<!-- PAGE_7 -->\n##### 1.  배경 및 목적 ················································································ 1\n\n<!-- PAGE_7 -->\n##### 2. ",
        "original_sentence": "본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이\n\n아님을 알려드립니다. "
      }
    },
    {
      "chunk_id": "chunk_375",
      "text": "또한, 본 안내서는 2022년 12월 현재의 과학적ㆍ기술적 사실\n\n및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정법규 내용 및 구체적인\n\n<!-- PAGE_7 -->\n# 목\n\n<!-- PAGE_7 -->\n# 차\n\n<!-- PAGE_7 -->\n### Ⅰ. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 374,
        "window_size": 3,
        "char_count": 146,
        "word_count": 34,
        "page_number": 7,
        "window_text": "| (secure)이 확보된 해쉬(hash)로 저장되어야 함 | 부합한다.  |\n\n**[표 끝]**\n\n지침서ㆍ안내서\n\n이 원 규\n\n<!-- PAGE_4 -->\n#### 제·개정 이력\n\n<!-- PAGE_4 -->\n###### 우울장애 개선 디지털치료기기 안전성·성능 평가 및\n\n<!-- PAGE_4 -->\n###### 임상시험계획서 작성 가이드라인(민원인 안내서)\n\n우울장애 개선 디지털치료기기 안전성·성능\n\n평가 및 임상시험계획서 작성 가이드라인\n\n(민원인 안내서) 제정\n\n이 안내서는 우울장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서\n\n작성에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이\n\n아님을 알려드립니다.  또한, 본 안내서는 2022년 12월 현재의 과학적ㆍ기술적 사실\n\n및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정법규 내용 및 구체적인\n\n<!-- PAGE_7 -->\n# 목\n\n<!-- PAGE_7 -->\n# 차\n\n<!-- PAGE_7 -->\n### Ⅰ.  개 요 ········································································ 1\n\n<!-- PAGE_7 -->\n##### 1.  배경 및 목적 ················································································ 1\n\n<!-- PAGE_7 -->\n##### 2.  적용 범위 ······················································································ 1\n\n<!-- PAGE_7 -->\n##### 3. ",
        "original_sentence": "또한, 본 안내서는 2022년 12월 현재의 과학적ㆍ기술적 사실\n\n및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정법규 내용 및 구체적인\n\n<!-- PAGE_7 -->\n# 목\n\n<!-- PAGE_7 -->\n# 차\n\n<!-- PAGE_7 -->\n### Ⅰ. "
      }
    },
    {
      "chunk_id": "chunk_376",
      "text": "개 요 ········································································ 1\n\n<!-- PAGE_7 -->\n##### 1. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 375,
        "window_size": 3,
        "char_count": 105,
        "word_count": 9,
        "page_number": 7,
        "window_text": "|\n\n**[표 끝]**\n\n지침서ㆍ안내서\n\n이 원 규\n\n<!-- PAGE_4 -->\n#### 제·개정 이력\n\n<!-- PAGE_4 -->\n###### 우울장애 개선 디지털치료기기 안전성·성능 평가 및\n\n<!-- PAGE_4 -->\n###### 임상시험계획서 작성 가이드라인(민원인 안내서)\n\n우울장애 개선 디지털치료기기 안전성·성능\n\n평가 및 임상시험계획서 작성 가이드라인\n\n(민원인 안내서) 제정\n\n이 안내서는 우울장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서\n\n작성에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이\n\n아님을 알려드립니다.  또한, 본 안내서는 2022년 12월 현재의 과학적ㆍ기술적 사실\n\n및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정법규 내용 및 구체적인\n\n<!-- PAGE_7 -->\n# 목\n\n<!-- PAGE_7 -->\n# 차\n\n<!-- PAGE_7 -->\n### Ⅰ.  개 요 ········································································ 1\n\n<!-- PAGE_7 -->\n##### 1.  배경 및 목적 ················································································ 1\n\n<!-- PAGE_7 -->\n##### 2.  적용 범위 ······················································································ 1\n\n<!-- PAGE_7 -->\n##### 3.  용어 설명 ······················································································ 3\n\n<!-- PAGE_7 -->\n##### 4. ",
        "original_sentence": "개 요 ········································································ 1\n\n<!-- PAGE_7 -->\n##### 1. "
      }
    },
    {
      "chunk_id": "chunk_377",
      "text": "배경 및 목적 ················································································ 1\n\n<!-- PAGE_7 -->\n##### 2. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 376,
        "window_size": 3,
        "char_count": 117,
        "word_count": 10,
        "page_number": 7,
        "window_text": "본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이\n\n아님을 알려드립니다.  또한, 본 안내서는 2022년 12월 현재의 과학적ㆍ기술적 사실\n\n및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정법규 내용 및 구체적인\n\n<!-- PAGE_7 -->\n# 목\n\n<!-- PAGE_7 -->\n# 차\n\n<!-- PAGE_7 -->\n### Ⅰ.  개 요 ········································································ 1\n\n<!-- PAGE_7 -->\n##### 1.  배경 및 목적 ················································································ 1\n\n<!-- PAGE_7 -->\n##### 2.  적용 범위 ······················································································ 1\n\n<!-- PAGE_7 -->\n##### 3.  용어 설명 ······················································································ 3\n\n<!-- PAGE_7 -->\n##### 4.  현황 ································································································ 4\n\n<!-- PAGE_7 -->\n### Ⅱ. ",
        "original_sentence": "배경 및 목적 ················································································ 1\n\n<!-- PAGE_7 -->\n##### 2. "
      }
    },
    {
      "chunk_id": "chunk_378",
      "text": "적용 범위 ······················································································ 1\n\n<!-- PAGE_7 -->\n##### 3. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 377,
        "window_size": 3,
        "char_count": 121,
        "word_count": 9,
        "page_number": 7,
        "window_text": "또한, 본 안내서는 2022년 12월 현재의 과학적ㆍ기술적 사실\n\n및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정법규 내용 및 구체적인\n\n<!-- PAGE_7 -->\n# 목\n\n<!-- PAGE_7 -->\n# 차\n\n<!-- PAGE_7 -->\n### Ⅰ.  개 요 ········································································ 1\n\n<!-- PAGE_7 -->\n##### 1.  배경 및 목적 ················································································ 1\n\n<!-- PAGE_7 -->\n##### 2.  적용 범위 ······················································································ 1\n\n<!-- PAGE_7 -->\n##### 3.  용어 설명 ······················································································ 3\n\n<!-- PAGE_7 -->\n##### 4.  현황 ································································································ 4\n\n<!-- PAGE_7 -->\n### Ⅱ.  안전성·성능 평가 ·············································· 29\n\n<!-- PAGE_7 -->\n##### 1. ",
        "original_sentence": "적용 범위 ······················································································ 1\n\n<!-- PAGE_7 -->\n##### 3. "
      }
    },
    {
      "chunk_id": "chunk_379",
      "text": "용어 설명 ······················································································ 3\n\n<!-- PAGE_7 -->\n##### 4. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 378,
        "window_size": 3,
        "char_count": 121,
        "word_count": 9,
        "page_number": 7,
        "window_text": "개 요 ········································································ 1\n\n<!-- PAGE_7 -->\n##### 1.  배경 및 목적 ················································································ 1\n\n<!-- PAGE_7 -->\n##### 2.  적용 범위 ······················································································ 1\n\n<!-- PAGE_7 -->\n##### 3.  용어 설명 ······················································································ 3\n\n<!-- PAGE_7 -->\n##### 4.  현황 ································································································ 4\n\n<!-- PAGE_7 -->\n### Ⅱ.  안전성·성능 평가 ·············································· 29\n\n<!-- PAGE_7 -->\n##### 1.  국내외 관련 규격 및 가이드라인 ·········································· 29\n\n<!-- PAGE_7 -->\n##### 2. ",
        "original_sentence": "용어 설명 ······················································································ 3\n\n<!-- PAGE_7 -->\n##### 4. "
      }
    },
    {
      "chunk_id": "chunk_380",
      "text": "현황 ································································································ 4\n\n<!-- PAGE_7 -->\n### Ⅱ. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 379,
        "window_size": 3,
        "char_count": 126,
        "word_count": 8,
        "page_number": 7,
        "window_text": "배경 및 목적 ················································································ 1\n\n<!-- PAGE_7 -->\n##### 2.  적용 범위 ······················································································ 1\n\n<!-- PAGE_7 -->\n##### 3.  용어 설명 ······················································································ 3\n\n<!-- PAGE_7 -->\n##### 4.  현황 ································································································ 4\n\n<!-- PAGE_7 -->\n### Ⅱ.  안전성·성능 평가 ·············································· 29\n\n<!-- PAGE_7 -->\n##### 1.  국내외 관련 규격 및 가이드라인 ·········································· 29\n\n<!-- PAGE_7 -->\n##### 2.  안전성 평가 항목 ······································································ 33\n\n<!-- PAGE_7 -->\n##### 3. ",
        "original_sentence": "현황 ································································································ 4\n\n<!-- PAGE_7 -->\n### Ⅱ. "
      }
    },
    {
      "chunk_id": "chunk_381",
      "text": "안전성·성능 평가 ·············································· 29\n\n<!-- PAGE_7 -->\n##### 1. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 380,
        "window_size": 3,
        "char_count": 86,
        "word_count": 9,
        "page_number": 7,
        "window_text": "적용 범위 ······················································································ 1\n\n<!-- PAGE_7 -->\n##### 3.  용어 설명 ······················································································ 3\n\n<!-- PAGE_7 -->\n##### 4.  현황 ································································································ 4\n\n<!-- PAGE_7 -->\n### Ⅱ.  안전성·성능 평가 ·············································· 29\n\n<!-- PAGE_7 -->\n##### 1.  국내외 관련 규격 및 가이드라인 ·········································· 29\n\n<!-- PAGE_7 -->\n##### 2.  안전성 평가 항목 ······································································ 33\n\n<!-- PAGE_7 -->\n##### 3.  성능 평가 항목 ·········································································· 44\n\n<!-- PAGE_7 -->\n### Ⅲ. ",
        "original_sentence": "안전성·성능 평가 ·············································· 29\n\n<!-- PAGE_7 -->\n##### 1. "
      }
    },
    {
      "chunk_id": "chunk_382",
      "text": "국내외 관련 규격 및 가이드라인 ·········································· 29\n\n<!-- PAGE_7 -->\n##### 2. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 381,
        "window_size": 3,
        "char_count": 90,
        "word_count": 12,
        "page_number": 7,
        "window_text": "용어 설명 ······················································································ 3\n\n<!-- PAGE_7 -->\n##### 4.  현황 ································································································ 4\n\n<!-- PAGE_7 -->\n### Ⅱ.  안전성·성능 평가 ·············································· 29\n\n<!-- PAGE_7 -->\n##### 1.  국내외 관련 규격 및 가이드라인 ·········································· 29\n\n<!-- PAGE_7 -->\n##### 2.  안전성 평가 항목 ······································································ 33\n\n<!-- PAGE_7 -->\n##### 3.  성능 평가 항목 ·········································································· 44\n\n<!-- PAGE_7 -->\n### Ⅲ.  임상시험계획서 작성 시 고려사항 및 예시 ·· 46\n\n<!-- PAGE_7 -->\n### Ⅳ. ",
        "original_sentence": "국내외 관련 규격 및 가이드라인 ·········································· 29\n\n<!-- PAGE_7 -->\n##### 2. "
      }
    },
    {
      "chunk_id": "chunk_383",
      "text": "안전성 평가 항목 ······································································ 33\n\n<!-- PAGE_7 -->\n##### 3. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 382,
        "window_size": 3,
        "char_count": 110,
        "word_count": 10,
        "page_number": 7,
        "window_text": "현황 ································································································ 4\n\n<!-- PAGE_7 -->\n### Ⅱ.  안전성·성능 평가 ·············································· 29\n\n<!-- PAGE_7 -->\n##### 1.  국내외 관련 규격 및 가이드라인 ·········································· 29\n\n<!-- PAGE_7 -->\n##### 2.  안전성 평가 항목 ······································································ 33\n\n<!-- PAGE_7 -->\n##### 3.  성능 평가 항목 ·········································································· 44\n\n<!-- PAGE_7 -->\n### Ⅲ.  임상시험계획서 작성 시 고려사항 및 예시 ·· 46\n\n<!-- PAGE_7 -->\n### Ⅳ.  참고문헌 ······························································ 119\n\n- - 1 -\n<!-- PAGE_8 -->\n### Ⅰ\n\n<!-- PAGE_8 -->\n### 개 요\n\n<!-- PAGE_8 -->\n##### 1. ",
        "original_sentence": "안전성 평가 항목 ······································································ 33\n\n<!-- PAGE_7 -->\n##### 3. "
      }
    },
    {
      "chunk_id": "chunk_384",
      "text": "성능 평가 항목 ·········································································· 44\n\n<!-- PAGE_7 -->\n### Ⅲ. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 383,
        "window_size": 3,
        "char_count": 111,
        "word_count": 10,
        "page_number": 7,
        "window_text": "안전성·성능 평가 ·············································· 29\n\n<!-- PAGE_7 -->\n##### 1.  국내외 관련 규격 및 가이드라인 ·········································· 29\n\n<!-- PAGE_7 -->\n##### 2.  안전성 평가 항목 ······································································ 33\n\n<!-- PAGE_7 -->\n##### 3.  성능 평가 항목 ·········································································· 44\n\n<!-- PAGE_7 -->\n### Ⅲ.  임상시험계획서 작성 시 고려사항 및 예시 ·· 46\n\n<!-- PAGE_7 -->\n### Ⅳ.  참고문헌 ······························································ 119\n\n- - 1 -\n<!-- PAGE_8 -->\n### Ⅰ\n\n<!-- PAGE_8 -->\n### 개 요\n\n<!-- PAGE_8 -->\n##### 1.  배경 및 목적\n\n<!-- PAGE_8 -->\n###### 식품의약품안전처는 정부 지원 과제 중 디지털치료기기에 특화된\n\n<!-- PAGE_8 -->\n###### 과제의 제품 설계부터 제품화에 필요한 안전성·성능 평가 및 임상시험\n\n<!-- PAGE_8 -->\n###### 계획서 작성 방법 제공을 통한 신속 제품화 지원을 하고 있다.\n\n",
        "original_sentence": "성능 평가 항목 ·········································································· 44\n\n<!-- PAGE_7 -->\n### Ⅲ. "
      }
    },
    {
      "chunk_id": "chunk_385",
      "text": "임상시험계획서 작성 시 고려사항 및 예시 ·· 46\n\n<!-- PAGE_7 -->\n### Ⅳ. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 384,
        "window_size": 3,
        "char_count": 53,
        "word_count": 13,
        "page_number": 7,
        "window_text": "국내외 관련 규격 및 가이드라인 ·········································· 29\n\n<!-- PAGE_7 -->\n##### 2.  안전성 평가 항목 ······································································ 33\n\n<!-- PAGE_7 -->\n##### 3.  성능 평가 항목 ·········································································· 44\n\n<!-- PAGE_7 -->\n### Ⅲ.  임상시험계획서 작성 시 고려사항 및 예시 ·· 46\n\n<!-- PAGE_7 -->\n### Ⅳ.  참고문헌 ······························································ 119\n\n- - 1 -\n<!-- PAGE_8 -->\n### Ⅰ\n\n<!-- PAGE_8 -->\n### 개 요\n\n<!-- PAGE_8 -->\n##### 1.  배경 및 목적\n\n<!-- PAGE_8 -->\n###### 식품의약품안전처는 정부 지원 과제 중 디지털치료기기에 특화된\n\n<!-- PAGE_8 -->\n###### 과제의 제품 설계부터 제품화에 필요한 안전성·성능 평가 및 임상시험\n\n<!-- PAGE_8 -->\n###### 계획서 작성 방법 제공을 통한 신속 제품화 지원을 하고 있다.\n\n <!-- PAGE_8 -->\n###### 본 가이드라인은 “우울장애 개선 디지털치료기기”의 안전성 및 성능\n\n<!-- PAGE_8 -->\n###### 평가 방법, 임상시험계획서 작성 시 고려사항 및 예시를 구체적으로\n\n<!-- PAGE_8 -->\n###### 제시하여 신속 제품화를 위한 맞춤형 기술 지원을 목적으로 한다.\n\n",
        "original_sentence": "임상시험계획서 작성 시 고려사항 및 예시 ·· 46\n\n<!-- PAGE_7 -->\n### Ⅳ. "
      }
    },
    {
      "chunk_id": "chunk_386",
      "text": "참고문헌 ······························································ 119\n\n- - 1 -\n<!-- PAGE_8 -->\n### Ⅰ\n\n<!-- PAGE_8 -->\n### 개 요\n\n<!-- PAGE_8 -->\n##### 1. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 385,
        "window_size": 3,
        "char_count": 154,
        "word_count": 23,
        "page_number": 8,
        "window_text": "안전성 평가 항목 ······································································ 33\n\n<!-- PAGE_7 -->\n##### 3.  성능 평가 항목 ·········································································· 44\n\n<!-- PAGE_7 -->\n### Ⅲ.  임상시험계획서 작성 시 고려사항 및 예시 ·· 46\n\n<!-- PAGE_7 -->\n### Ⅳ.  참고문헌 ······························································ 119\n\n- - 1 -\n<!-- PAGE_8 -->\n### Ⅰ\n\n<!-- PAGE_8 -->\n### 개 요\n\n<!-- PAGE_8 -->\n##### 1.  배경 및 목적\n\n<!-- PAGE_8 -->\n###### 식품의약품안전처는 정부 지원 과제 중 디지털치료기기에 특화된\n\n<!-- PAGE_8 -->\n###### 과제의 제품 설계부터 제품화에 필요한 안전성·성능 평가 및 임상시험\n\n<!-- PAGE_8 -->\n###### 계획서 작성 방법 제공을 통한 신속 제품화 지원을 하고 있다.\n\n <!-- PAGE_8 -->\n###### 본 가이드라인은 “우울장애 개선 디지털치료기기”의 안전성 및 성능\n\n<!-- PAGE_8 -->\n###### 평가 방법, 임상시험계획서 작성 시 고려사항 및 예시를 구체적으로\n\n<!-- PAGE_8 -->\n###### 제시하여 신속 제품화를 위한 맞춤형 기술 지원을 목적으로 한다.\n\n <!-- PAGE_8 -->\n##### 2. ",
        "original_sentence": "참고문헌 ······························································ 119\n\n- - 1 -\n<!-- PAGE_8 -->\n### Ⅰ\n\n<!-- PAGE_8 -->\n### 개 요\n\n<!-- PAGE_8 -->\n##### 1. "
      }
    },
    {
      "chunk_id": "chunk_387",
      "text": "배경 및 목적\n\n<!-- PAGE_8 -->\n###### 식품의약품안전처는 정부 지원 과제 중 디지털치료기기에 특화된\n\n<!-- PAGE_8 -->\n###### 과제의 제품 설계부터 제품화에 필요한 안전성·성능 평가 및 임상시험\n\n<!-- PAGE_8 -->\n###### 계획서 작성 방법 제공을 통한 신속 제품화 지원을 하고 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 386,
        "window_size": 3,
        "char_count": 188,
        "word_count": 41,
        "page_number": 8,
        "window_text": "성능 평가 항목 ·········································································· 44\n\n<!-- PAGE_7 -->\n### Ⅲ.  임상시험계획서 작성 시 고려사항 및 예시 ·· 46\n\n<!-- PAGE_7 -->\n### Ⅳ.  참고문헌 ······························································ 119\n\n- - 1 -\n<!-- PAGE_8 -->\n### Ⅰ\n\n<!-- PAGE_8 -->\n### 개 요\n\n<!-- PAGE_8 -->\n##### 1.  배경 및 목적\n\n<!-- PAGE_8 -->\n###### 식품의약품안전처는 정부 지원 과제 중 디지털치료기기에 특화된\n\n<!-- PAGE_8 -->\n###### 과제의 제품 설계부터 제품화에 필요한 안전성·성능 평가 및 임상시험\n\n<!-- PAGE_8 -->\n###### 계획서 작성 방법 제공을 통한 신속 제품화 지원을 하고 있다.\n\n <!-- PAGE_8 -->\n###### 본 가이드라인은 “우울장애 개선 디지털치료기기”의 안전성 및 성능\n\n<!-- PAGE_8 -->\n###### 평가 방법, 임상시험계획서 작성 시 고려사항 및 예시를 구체적으로\n\n<!-- PAGE_8 -->\n###### 제시하여 신속 제품화를 위한 맞춤형 기술 지원을 목적으로 한다.\n\n <!-- PAGE_8 -->\n##### 2.  적용 범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인에서 다루는 우울장애 개선 디지털치료기기는 「의료\n\n<!-- PAGE_8 -->\n###### 기기 품목 및 품목별 등급에 관한 규정(식약처 고시 제2021-83호)」의\n\n<!-- PAGE_8 -->\n###### 품목 분류에 따라 정서장애치료소프트웨어(2등급, E06070.01) 의료기기로\n\n<!-- PAGE_8 -->\n###### 분류된다.\n\n",
        "original_sentence": "배경 및 목적\n\n<!-- PAGE_8 -->\n###### 식품의약품안전처는 정부 지원 과제 중 디지털치료기기에 특화된\n\n<!-- PAGE_8 -->\n###### 과제의 제품 설계부터 제품화에 필요한 안전성·성능 평가 및 임상시험\n\n<!-- PAGE_8 -->\n###### 계획서 작성 방법 제공을 통한 신속 제품화 지원을 하고 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_388",
      "text": "<!-- PAGE_8 -->\n###### 본 가이드라인은 “우울장애 개선 디지털치료기기”의 안전성 및 성능\n\n<!-- PAGE_8 -->\n###### 평가 방법, 임상시험계획서 작성 시 고려사항 및 예시를 구체적으로\n\n<!-- PAGE_8 -->\n###### 제시하여 신속 제품화를 위한 맞춤형 기술 지원을 목적으로 한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 387,
        "window_size": 3,
        "char_count": 182,
        "word_count": 38,
        "page_number": 8,
        "window_text": "임상시험계획서 작성 시 고려사항 및 예시 ·· 46\n\n<!-- PAGE_7 -->\n### Ⅳ.  참고문헌 ······························································ 119\n\n- - 1 -\n<!-- PAGE_8 -->\n### Ⅰ\n\n<!-- PAGE_8 -->\n### 개 요\n\n<!-- PAGE_8 -->\n##### 1.  배경 및 목적\n\n<!-- PAGE_8 -->\n###### 식품의약품안전처는 정부 지원 과제 중 디지털치료기기에 특화된\n\n<!-- PAGE_8 -->\n###### 과제의 제품 설계부터 제품화에 필요한 안전성·성능 평가 및 임상시험\n\n<!-- PAGE_8 -->\n###### 계획서 작성 방법 제공을 통한 신속 제품화 지원을 하고 있다.\n\n <!-- PAGE_8 -->\n###### 본 가이드라인은 “우울장애 개선 디지털치료기기”의 안전성 및 성능\n\n<!-- PAGE_8 -->\n###### 평가 방법, 임상시험계획서 작성 시 고려사항 및 예시를 구체적으로\n\n<!-- PAGE_8 -->\n###### 제시하여 신속 제품화를 위한 맞춤형 기술 지원을 목적으로 한다.\n\n <!-- PAGE_8 -->\n##### 2.  적용 범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인에서 다루는 우울장애 개선 디지털치료기기는 「의료\n\n<!-- PAGE_8 -->\n###### 기기 품목 및 품목별 등급에 관한 규정(식약처 고시 제2021-83호)」의\n\n<!-- PAGE_8 -->\n###### 품목 분류에 따라 정서장애치료소프트웨어(2등급, E06070.01) 의료기기로\n\n<!-- PAGE_8 -->\n###### 분류된다.\n\n <!-- PAGE_8 -->\n###### 단, 추후 우울장애 외 동반된 정신과적 증상에 대한 평가 또는 치료를\n\n<!-- PAGE_8 -->\n###### 동시에 목적으로 한다면 심리평가소프트웨어(2등급, E06050.01) 또는\n\n<!-- PAGE_8 -->\n###### 인지치료소프트웨어(2등급, E06060.02)의 의료기기 분류를 추가하여\n\n<!-- PAGE_8 -->\n###### 조합의료기기로 분류할 수 있다.\n\n",
        "original_sentence": "<!-- PAGE_8 -->\n###### 본 가이드라인은 “우울장애 개선 디지털치료기기”의 안전성 및 성능\n\n<!-- PAGE_8 -->\n###### 평가 방법, 임상시험계획서 작성 시 고려사항 및 예시를 구체적으로\n\n<!-- PAGE_8 -->\n###### 제시하여 신속 제품화를 위한 맞춤형 기술 지원을 목적으로 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_389",
      "text": "<!-- PAGE_8 -->\n##### 2. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 388,
        "window_size": 3,
        "char_count": 25,
        "word_count": 5,
        "page_number": 8,
        "window_text": "참고문헌 ······························································ 119\n\n- - 1 -\n<!-- PAGE_8 -->\n### Ⅰ\n\n<!-- PAGE_8 -->\n### 개 요\n\n<!-- PAGE_8 -->\n##### 1.  배경 및 목적\n\n<!-- PAGE_8 -->\n###### 식품의약품안전처는 정부 지원 과제 중 디지털치료기기에 특화된\n\n<!-- PAGE_8 -->\n###### 과제의 제품 설계부터 제품화에 필요한 안전성·성능 평가 및 임상시험\n\n<!-- PAGE_8 -->\n###### 계획서 작성 방법 제공을 통한 신속 제품화 지원을 하고 있다.\n\n <!-- PAGE_8 -->\n###### 본 가이드라인은 “우울장애 개선 디지털치료기기”의 안전성 및 성능\n\n<!-- PAGE_8 -->\n###### 평가 방법, 임상시험계획서 작성 시 고려사항 및 예시를 구체적으로\n\n<!-- PAGE_8 -->\n###### 제시하여 신속 제품화를 위한 맞춤형 기술 지원을 목적으로 한다.\n\n <!-- PAGE_8 -->\n##### 2.  적용 범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인에서 다루는 우울장애 개선 디지털치료기기는 「의료\n\n<!-- PAGE_8 -->\n###### 기기 품목 및 품목별 등급에 관한 규정(식약처 고시 제2021-83호)」의\n\n<!-- PAGE_8 -->\n###### 품목 분류에 따라 정서장애치료소프트웨어(2등급, E06070.01) 의료기기로\n\n<!-- PAGE_8 -->\n###### 분류된다.\n\n <!-- PAGE_8 -->\n###### 단, 추후 우울장애 외 동반된 정신과적 증상에 대한 평가 또는 치료를\n\n<!-- PAGE_8 -->\n###### 동시에 목적으로 한다면 심리평가소프트웨어(2등급, E06050.01) 또는\n\n<!-- PAGE_8 -->\n###### 인지치료소프트웨어(2등급, E06060.02)의 의료기기 분류를 추가하여\n\n<!-- PAGE_8 -->\n###### 조합의료기기로 분류할 수 있다.\n\n - - 2 -\n품목명\n\n영문명\n\n등급\n\n분류번호\n\n품목정의\n\n**[표 시작]**\n\n| 갖춘 | 의료기관을 | 임상시험기관으로 | 지정하여 | 운영하고 | 있으며, 임상시험기관은 | 임상시험심사위원회 심사 기간 등 충분한 기간을 고려하여 “식품의약품안전처의 임상 계획 | 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시한다. ",
        "original_sentence": "<!-- PAGE_8 -->\n##### 2. "
      }
    },
    {
      "chunk_id": "chunk_390",
      "text": "적용 범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인에서 다루는 우울장애 개선 디지털치료기기는 「의료\n\n<!-- PAGE_8 -->\n###### 기기 품목 및 품목별 등급에 관한 규정(식약처 고시 제2021-83호)」의\n\n<!-- PAGE_8 -->\n###### 품목 분류에 따라 정서장애치료소프트웨어(2등급, E06070.01) 의료기기로\n\n<!-- PAGE_8 -->\n###### 분류된다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 389,
        "window_size": 3,
        "char_count": 230,
        "word_count": 41,
        "page_number": 8,
        "window_text": "배경 및 목적\n\n<!-- PAGE_8 -->\n###### 식품의약품안전처는 정부 지원 과제 중 디지털치료기기에 특화된\n\n<!-- PAGE_8 -->\n###### 과제의 제품 설계부터 제품화에 필요한 안전성·성능 평가 및 임상시험\n\n<!-- PAGE_8 -->\n###### 계획서 작성 방법 제공을 통한 신속 제품화 지원을 하고 있다.\n\n <!-- PAGE_8 -->\n###### 본 가이드라인은 “우울장애 개선 디지털치료기기”의 안전성 및 성능\n\n<!-- PAGE_8 -->\n###### 평가 방법, 임상시험계획서 작성 시 고려사항 및 예시를 구체적으로\n\n<!-- PAGE_8 -->\n###### 제시하여 신속 제품화를 위한 맞춤형 기술 지원을 목적으로 한다.\n\n <!-- PAGE_8 -->\n##### 2.  적용 범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인에서 다루는 우울장애 개선 디지털치료기기는 「의료\n\n<!-- PAGE_8 -->\n###### 기기 품목 및 품목별 등급에 관한 규정(식약처 고시 제2021-83호)」의\n\n<!-- PAGE_8 -->\n###### 품목 분류에 따라 정서장애치료소프트웨어(2등급, E06070.01) 의료기기로\n\n<!-- PAGE_8 -->\n###### 분류된다.\n\n <!-- PAGE_8 -->\n###### 단, 추후 우울장애 외 동반된 정신과적 증상에 대한 평가 또는 치료를\n\n<!-- PAGE_8 -->\n###### 동시에 목적으로 한다면 심리평가소프트웨어(2등급, E06050.01) 또는\n\n<!-- PAGE_8 -->\n###### 인지치료소프트웨어(2등급, E06060.02)의 의료기기 분류를 추가하여\n\n<!-- PAGE_8 -->\n###### 조합의료기기로 분류할 수 있다.\n\n - - 2 -\n품목명\n\n영문명\n\n등급\n\n분류번호\n\n품목정의\n\n**[표 시작]**\n\n| 갖춘 | 의료기관을 | 임상시험기관으로 | 지정하여 | 운영하고 | 있으며, 임상시험기관은 | 임상시험심사위원회 심사 기간 등 충분한 기간을 고려하여 “식품의약품안전처의 임상 계획 | 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시한다.  | (Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험책임자의 이력 | 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각 단계별 조작 순서, 병용 요법 | - 임상시험 전 피험자 선정 과정에서의 확인해야 할 사항, 임상검사, 피험자 동의서 | 1) 만 19세 이상 성인 | 인지치료 | Meyer et al.",
        "original_sentence": "적용 범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인에서 다루는 우울장애 개선 디지털치료기기는 「의료\n\n<!-- PAGE_8 -->\n###### 기기 품목 및 품목별 등급에 관한 규정(식약처 고시 제2021-83호)」의\n\n<!-- PAGE_8 -->\n###### 품목 분류에 따라 정서장애치료소프트웨어(2등급, E06070.01) 의료기기로\n\n<!-- PAGE_8 -->\n###### 분류된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_391",
      "text": "<!-- PAGE_8 -->\n###### 단, 추후 우울장애 외 동반된 정신과적 증상에 대한 평가 또는 치료를\n\n<!-- PAGE_8 -->\n###### 동시에 목적으로 한다면 심리평가소프트웨어(2등급, E06050.01) 또는\n\n<!-- PAGE_8 -->\n###### 인지치료소프트웨어(2등급, E06060.02)의 의료기기 분류를 추가하여\n\n<!-- PAGE_8 -->\n###### 조합의료기기로 분류할 수 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 390,
        "window_size": 3,
        "char_count": 236,
        "word_count": 42,
        "page_number": 8,
        "window_text": "<!-- PAGE_8 -->\n###### 본 가이드라인은 “우울장애 개선 디지털치료기기”의 안전성 및 성능\n\n<!-- PAGE_8 -->\n###### 평가 방법, 임상시험계획서 작성 시 고려사항 및 예시를 구체적으로\n\n<!-- PAGE_8 -->\n###### 제시하여 신속 제품화를 위한 맞춤형 기술 지원을 목적으로 한다.\n\n <!-- PAGE_8 -->\n##### 2.  적용 범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인에서 다루는 우울장애 개선 디지털치료기기는 「의료\n\n<!-- PAGE_8 -->\n###### 기기 품목 및 품목별 등급에 관한 규정(식약처 고시 제2021-83호)」의\n\n<!-- PAGE_8 -->\n###### 품목 분류에 따라 정서장애치료소프트웨어(2등급, E06070.01) 의료기기로\n\n<!-- PAGE_8 -->\n###### 분류된다.\n\n <!-- PAGE_8 -->\n###### 단, 추후 우울장애 외 동반된 정신과적 증상에 대한 평가 또는 치료를\n\n<!-- PAGE_8 -->\n###### 동시에 목적으로 한다면 심리평가소프트웨어(2등급, E06050.01) 또는\n\n<!-- PAGE_8 -->\n###### 인지치료소프트웨어(2등급, E06060.02)의 의료기기 분류를 추가하여\n\n<!-- PAGE_8 -->\n###### 조합의료기기로 분류할 수 있다.\n\n - - 2 -\n품목명\n\n영문명\n\n등급\n\n분류번호\n\n품목정의\n\n**[표 시작]**\n\n| 갖춘 | 의료기관을 | 임상시험기관으로 | 지정하여 | 운영하고 | 있으며, 임상시험기관은 | 임상시험심사위원회 심사 기간 등 충분한 기간을 고려하여 “식품의약품안전처의 임상 계획 | 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시한다.  | (Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험책임자의 이력 | 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각 단계별 조작 순서, 병용 요법 | - 임상시험 전 피험자 선정 과정에서의 확인해야 할 사항, 임상검사, 피험자 동의서 | 1) 만 19세 이상 성인 | 인지치료 | Meyer et al. (2009) | 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능 평가 기준을 | 한국인 우울 | 것을 방지하도록 고려하여야 한다. ",
        "original_sentence": "<!-- PAGE_8 -->\n###### 단, 추후 우울장애 외 동반된 정신과적 증상에 대한 평가 또는 치료를\n\n<!-- PAGE_8 -->\n###### 동시에 목적으로 한다면 심리평가소프트웨어(2등급, E06050.01) 또는\n\n<!-- PAGE_8 -->\n###### 인지치료소프트웨어(2등급, E06060.02)의 의료기기 분류를 추가하여\n\n<!-- PAGE_8 -->\n###### 조합의료기기로 분류할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_392",
      "text": "- - 2 -\n품목명\n\n영문명\n\n등급\n\n분류번호\n\n품목정의\n\n**[표 시작]**\n\n| 갖춘 | 의료기관을 | 임상시험기관으로 | 지정하여 | 운영하고 | 있으며, 임상시험기관은 | 임상시험심사위원회 심사 기간 등 충분한 기간을 고려하여 “식품의약품안전처의 임상 계획 | 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 391,
        "window_size": 3,
        "char_count": 187,
        "word_count": 43,
        "page_number": 7,
        "window_text": "<!-- PAGE_8 -->\n##### 2.  적용 범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인에서 다루는 우울장애 개선 디지털치료기기는 「의료\n\n<!-- PAGE_8 -->\n###### 기기 품목 및 품목별 등급에 관한 규정(식약처 고시 제2021-83호)」의\n\n<!-- PAGE_8 -->\n###### 품목 분류에 따라 정서장애치료소프트웨어(2등급, E06070.01) 의료기기로\n\n<!-- PAGE_8 -->\n###### 분류된다.\n\n <!-- PAGE_8 -->\n###### 단, 추후 우울장애 외 동반된 정신과적 증상에 대한 평가 또는 치료를\n\n<!-- PAGE_8 -->\n###### 동시에 목적으로 한다면 심리평가소프트웨어(2등급, E06050.01) 또는\n\n<!-- PAGE_8 -->\n###### 인지치료소프트웨어(2등급, E06060.02)의 의료기기 분류를 추가하여\n\n<!-- PAGE_8 -->\n###### 조합의료기기로 분류할 수 있다.\n\n - - 2 -\n품목명\n\n영문명\n\n등급\n\n분류번호\n\n품목정의\n\n**[표 시작]**\n\n| 갖춘 | 의료기관을 | 임상시험기관으로 | 지정하여 | 운영하고 | 있으며, 임상시험기관은 | 임상시험심사위원회 심사 기간 등 충분한 기간을 고려하여 “식품의약품안전처의 임상 계획 | 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시한다.  | (Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험책임자의 이력 | 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각 단계별 조작 순서, 병용 요법 | - 임상시험 전 피험자 선정 과정에서의 확인해야 할 사항, 임상검사, 피험자 동의서 | 1) 만 19세 이상 성인 | 인지치료 | Meyer et al. (2009) | 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능 평가 기준을 | 한국인 우울 | 것을 방지하도록 고려하여야 한다.  | - 아이디어를 구상하는 방법은 가정된 자동적 사고를 지지하거나 | 해석함으로써 생길 수 있다. ",
        "original_sentence": "- - 2 -\n품목명\n\n영문명\n\n등급\n\n분류번호\n\n품목정의\n\n**[표 시작]**\n\n| 갖춘 | 의료기관을 | 임상시험기관으로 | 지정하여 | 운영하고 | 있으며, 임상시험기관은 | 임상시험심사위원회 심사 기간 등 충분한 기간을 고려하여 “식품의약품안전처의 임상 계획 | 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_393",
      "text": "| (Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험책임자의 이력 | 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각 단계별 조작 순서, 병용 요법 | - 임상시험 전 피험자 선정 과정에서의 확인해야 할 사항, 임상검사, 피험자 동의서 | 1) 만 19세 이상 성인 | 인지치료 | Meyer et al.",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 392,
        "window_size": 3,
        "char_count": 196,
        "word_count": 51,
        "page_number": 39,
        "window_text": "적용 범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인에서 다루는 우울장애 개선 디지털치료기기는 「의료\n\n<!-- PAGE_8 -->\n###### 기기 품목 및 품목별 등급에 관한 규정(식약처 고시 제2021-83호)」의\n\n<!-- PAGE_8 -->\n###### 품목 분류에 따라 정서장애치료소프트웨어(2등급, E06070.01) 의료기기로\n\n<!-- PAGE_8 -->\n###### 분류된다.\n\n <!-- PAGE_8 -->\n###### 단, 추후 우울장애 외 동반된 정신과적 증상에 대한 평가 또는 치료를\n\n<!-- PAGE_8 -->\n###### 동시에 목적으로 한다면 심리평가소프트웨어(2등급, E06050.01) 또는\n\n<!-- PAGE_8 -->\n###### 인지치료소프트웨어(2등급, E06060.02)의 의료기기 분류를 추가하여\n\n<!-- PAGE_8 -->\n###### 조합의료기기로 분류할 수 있다.\n\n - - 2 -\n품목명\n\n영문명\n\n등급\n\n분류번호\n\n품목정의\n\n**[표 시작]**\n\n| 갖춘 | 의료기관을 | 임상시험기관으로 | 지정하여 | 운영하고 | 있으며, 임상시험기관은 | 임상시험심사위원회 심사 기간 등 충분한 기간을 고려하여 “식품의약품안전처의 임상 계획 | 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시한다.  | (Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험책임자의 이력 | 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각 단계별 조작 순서, 병용 요법 | - 임상시험 전 피험자 선정 과정에서의 확인해야 할 사항, 임상검사, 피험자 동의서 | 1) 만 19세 이상 성인 | 인지치료 | Meyer et al. (2009) | 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능 평가 기준을 | 한국인 우울 | 것을 방지하도록 고려하여야 한다.  | - 아이디어를 구상하는 방법은 가정된 자동적 사고를 지지하거나 | 해석함으로써 생길 수 있다.  이러한 상황을 재점검해봄으로써 | 응답하도록 구성되었으며, 우울 증상은 미래에 대한 부정적 | 인지기능을 개선하는 데 사용하는 소프트웨어 | 0.65 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 등을 제시한다. ",
        "original_sentence": "| (Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험책임자의 이력 | 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각 단계별 조작 순서, 병용 요법 | - 임상시험 전 피험자 선정 과정에서의 확인해야 할 사항, 임상검사, 피험자 동의서 | 1) 만 19세 이상 성인 | 인지치료 | Meyer et al."
      }
    },
    {
      "chunk_id": "chunk_394",
      "text": "(2009) | 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능 평가 기준을 | 한국인 우울 | 것을 방지하도록 고려하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 393,
        "window_size": 3,
        "char_count": 78,
        "word_count": 19,
        "page_number": 7,
        "window_text": "<!-- PAGE_8 -->\n###### 단, 추후 우울장애 외 동반된 정신과적 증상에 대한 평가 또는 치료를\n\n<!-- PAGE_8 -->\n###### 동시에 목적으로 한다면 심리평가소프트웨어(2등급, E06050.01) 또는\n\n<!-- PAGE_8 -->\n###### 인지치료소프트웨어(2등급, E06060.02)의 의료기기 분류를 추가하여\n\n<!-- PAGE_8 -->\n###### 조합의료기기로 분류할 수 있다.\n\n - - 2 -\n품목명\n\n영문명\n\n등급\n\n분류번호\n\n품목정의\n\n**[표 시작]**\n\n| 갖춘 | 의료기관을 | 임상시험기관으로 | 지정하여 | 운영하고 | 있으며, 임상시험기관은 | 임상시험심사위원회 심사 기간 등 충분한 기간을 고려하여 “식품의약품안전처의 임상 계획 | 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시한다.  | (Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험책임자의 이력 | 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각 단계별 조작 순서, 병용 요법 | - 임상시험 전 피험자 선정 과정에서의 확인해야 할 사항, 임상검사, 피험자 동의서 | 1) 만 19세 이상 성인 | 인지치료 | Meyer et al. (2009) | 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능 평가 기준을 | 한국인 우울 | 것을 방지하도록 고려하여야 한다.  | - 아이디어를 구상하는 방법은 가정된 자동적 사고를 지지하거나 | 해석함으로써 생길 수 있다.  이러한 상황을 재점검해봄으로써 | 응답하도록 구성되었으며, 우울 증상은 미래에 대한 부정적 | 인지기능을 개선하는 데 사용하는 소프트웨어 | 0.65 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 등을 제시한다.  | ‘의료기기 임상시험 관리기준’(의료기기법 시행규칙 [별표3])에 의거, 정한 기간 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | 3) 이차 유효성 평가변수: | 4) 결측값 처리 | 1 | 라) 순응도 조사 | 같이 분류한다. ",
        "original_sentence": "(2009) | 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능 평가 기준을 | 한국인 우울 | 것을 방지하도록 고려하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_395",
      "text": "| - 아이디어를 구상하는 방법은 가정된 자동적 사고를 지지하거나 | 해석함으로써 생길 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 394,
        "window_size": 3,
        "char_count": 55,
        "word_count": 14,
        "page_number": 19,
        "window_text": "- - 2 -\n품목명\n\n영문명\n\n등급\n\n분류번호\n\n품목정의\n\n**[표 시작]**\n\n| 갖춘 | 의료기관을 | 임상시험기관으로 | 지정하여 | 운영하고 | 있으며, 임상시험기관은 | 임상시험심사위원회 심사 기간 등 충분한 기간을 고려하여 “식품의약품안전처의 임상 계획 | 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시한다.  | (Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험책임자의 이력 | 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각 단계별 조작 순서, 병용 요법 | - 임상시험 전 피험자 선정 과정에서의 확인해야 할 사항, 임상검사, 피험자 동의서 | 1) 만 19세 이상 성인 | 인지치료 | Meyer et al. (2009) | 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능 평가 기준을 | 한국인 우울 | 것을 방지하도록 고려하여야 한다.  | - 아이디어를 구상하는 방법은 가정된 자동적 사고를 지지하거나 | 해석함으로써 생길 수 있다.  이러한 상황을 재점검해봄으로써 | 응답하도록 구성되었으며, 우울 증상은 미래에 대한 부정적 | 인지기능을 개선하는 데 사용하는 소프트웨어 | 0.65 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 등을 제시한다.  | ‘의료기기 임상시험 관리기준’(의료기기법 시행규칙 [별표3])에 의거, 정한 기간 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | 3) 이차 유효성 평가변수: | 4) 결측값 처리 | 1 | 라) 순응도 조사 | 같이 분류한다.  | 유지한다. ",
        "original_sentence": "| - 아이디어를 구상하는 방법은 가정된 자동적 사고를 지지하거나 | 해석함으로써 생길 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_396",
      "text": "이러한 상황을 재점검해봄으로써 | 응답하도록 구성되었으며, 우울 증상은 미래에 대한 부정적 | 인지기능을 개선하는 데 사용하는 소프트웨어 | 0.65 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 등을 제시한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 395,
        "window_size": 3,
        "char_count": 231,
        "word_count": 68,
        "page_number": 41,
        "window_text": "| (Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험책임자의 이력 | 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각 단계별 조작 순서, 병용 요법 | - 임상시험 전 피험자 선정 과정에서의 확인해야 할 사항, 임상검사, 피험자 동의서 | 1) 만 19세 이상 성인 | 인지치료 | Meyer et al. (2009) | 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능 평가 기준을 | 한국인 우울 | 것을 방지하도록 고려하여야 한다.  | - 아이디어를 구상하는 방법은 가정된 자동적 사고를 지지하거나 | 해석함으로써 생길 수 있다.  이러한 상황을 재점검해봄으로써 | 응답하도록 구성되었으며, 우울 증상은 미래에 대한 부정적 | 인지기능을 개선하는 데 사용하는 소프트웨어 | 0.65 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 등을 제시한다.  | ‘의료기기 임상시험 관리기준’(의료기기법 시행규칙 [별표3])에 의거, 정한 기간 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | 3) 이차 유효성 평가변수: | 4) 결측값 처리 | 1 | 라) 순응도 조사 | 같이 분류한다.  | 유지한다.  | 아니 된다. ",
        "original_sentence": "이러한 상황을 재점검해봄으로써 | 응답하도록 구성되었으며, 우울 증상은 미래에 대한 부정적 | 인지기능을 개선하는 데 사용하는 소프트웨어 | 0.65 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 등을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_397",
      "text": "| ‘의료기기 임상시험 관리기준’(의료기기법 시행규칙 [별표3])에 의거, 정한 기간 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | 3) 이차 유효성 평가변수: | 4) 결측값 처리 | 1 | 라) 순응도 조사 | 같이 분류한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 396,
        "window_size": 3,
        "char_count": 151,
        "word_count": 39,
        "page_number": 29,
        "window_text": "(2009) | 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능 평가 기준을 | 한국인 우울 | 것을 방지하도록 고려하여야 한다.  | - 아이디어를 구상하는 방법은 가정된 자동적 사고를 지지하거나 | 해석함으로써 생길 수 있다.  이러한 상황을 재점검해봄으로써 | 응답하도록 구성되었으며, 우울 증상은 미래에 대한 부정적 | 인지기능을 개선하는 데 사용하는 소프트웨어 | 0.65 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 등을 제시한다.  | ‘의료기기 임상시험 관리기준’(의료기기법 시행규칙 [별표3])에 의거, 정한 기간 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | 3) 이차 유효성 평가변수: | 4) 결측값 처리 | 1 | 라) 순응도 조사 | 같이 분류한다.  | 유지한다.  | 아니 된다.  | 사유 | - 초기 평가에는 최소 다음의 사항이 포함되어야 한다. ",
        "original_sentence": "| ‘의료기기 임상시험 관리기준’(의료기기법 시행규칙 [별표3])에 의거, 정한 기간 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | 3) 이차 유효성 평가변수: | 4) 결측값 처리 | 1 | 라) 순응도 조사 | 같이 분류한다. "
      }
    },
    {
      "chunk_id": "chunk_398",
      "text": "| 유지한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 397,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 13,
        "window_text": "| - 아이디어를 구상하는 방법은 가정된 자동적 사고를 지지하거나 | 해석함으로써 생길 수 있다.  이러한 상황을 재점검해봄으로써 | 응답하도록 구성되었으며, 우울 증상은 미래에 대한 부정적 | 인지기능을 개선하는 데 사용하는 소프트웨어 | 0.65 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 등을 제시한다.  | ‘의료기기 임상시험 관리기준’(의료기기법 시행규칙 [별표3])에 의거, 정한 기간 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | 3) 이차 유효성 평가변수: | 4) 결측값 처리 | 1 | 라) 순응도 조사 | 같이 분류한다.  | 유지한다.  | 아니 된다.  | 사유 | - 초기 평가에는 최소 다음의 사항이 포함되어야 한다.  | 해야 한다. ",
        "original_sentence": "| 유지한다. "
      }
    },
    {
      "chunk_id": "chunk_399",
      "text": "| 아니 된다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 398,
        "window_size": 3,
        "char_count": 9,
        "word_count": 3,
        "page_number": 125,
        "window_text": "이러한 상황을 재점검해봄으로써 | 응답하도록 구성되었으며, 우울 증상은 미래에 대한 부정적 | 인지기능을 개선하는 데 사용하는 소프트웨어 | 0.65 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 등을 제시한다.  | ‘의료기기 임상시험 관리기준’(의료기기법 시행규칙 [별표3])에 의거, 정한 기간 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | 3) 이차 유효성 평가변수: | 4) 결측값 처리 | 1 | 라) 순응도 조사 | 같이 분류한다.  | 유지한다.  | 아니 된다.  | 사유 | - 초기 평가에는 최소 다음의 사항이 포함되어야 한다.  | 해야 한다.  | (3) 정신과적 전문치료를 시작한 것으로 판단되는 경우 | IEC/TR | 체제 버전에서 운영되는 의료기기 소프트웨어 | 점검하고 증례 기록서에 기록한다. ",
        "original_sentence": "| 아니 된다. "
      }
    },
    {
      "chunk_id": "chunk_400",
      "text": "| 사유 | - 초기 평가에는 최소 다음의 사항이 포함되어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 399,
        "window_size": 3,
        "char_count": 38,
        "word_count": 11,
        "page_number": 3,
        "window_text": "| ‘의료기기 임상시험 관리기준’(의료기기법 시행규칙 [별표3])에 의거, 정한 기간 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | 3) 이차 유효성 평가변수: | 4) 결측값 처리 | 1 | 라) 순응도 조사 | 같이 분류한다.  | 유지한다.  | 아니 된다.  | 사유 | - 초기 평가에는 최소 다음의 사항이 포함되어야 한다.  | 해야 한다.  | (3) 정신과적 전문치료를 시작한 것으로 판단되는 경우 | IEC/TR | 체제 버전에서 운영되는 의료기기 소프트웨어 | 점검하고 증례 기록서에 기록한다.  | 타당한 경우 | 순서가 타당하지 않은 경우 | : 군간 예상되는 effect size | 평가지표로 사용할 수 있다. ",
        "original_sentence": "| 사유 | - 초기 평가에는 최소 다음의 사항이 포함되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_401",
      "text": "| 해야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 400,
        "window_size": 3,
        "char_count": 9,
        "word_count": 3,
        "page_number": 13,
        "window_text": "| 유지한다.  | 아니 된다.  | 사유 | - 초기 평가에는 최소 다음의 사항이 포함되어야 한다.  | 해야 한다.  | (3) 정신과적 전문치료를 시작한 것으로 판단되는 경우 | IEC/TR | 체제 버전에서 운영되는 의료기기 소프트웨어 | 점검하고 증례 기록서에 기록한다.  | 타당한 경우 | 순서가 타당하지 않은 경우 | : 군간 예상되는 effect size | 평가지표로 사용할 수 있다.  | 유닛 검증 | therapy | 접근으로 인해 환자 | 느낌의 상실, 비관적 사고, 자살 사고와 같은 특징적인 우울 | 파악할 수 있는 “static test” 및 | 2 | E06060.02 | 보고서’, ‘의료기기 소프트웨어 검증 | 제공하는 우울장애 디지털 프로그램이다. ",
        "original_sentence": "| 해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_402",
      "text": "| (3) 정신과적 전문치료를 시작한 것으로 판단되는 경우 | IEC/TR | 체제 버전에서 운영되는 의료기기 소프트웨어 | 점검하고 증례 기록서에 기록한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 401,
        "window_size": 3,
        "char_count": 89,
        "word_count": 21,
        "page_number": 29,
        "window_text": "| 아니 된다.  | 사유 | - 초기 평가에는 최소 다음의 사항이 포함되어야 한다.  | 해야 한다.  | (3) 정신과적 전문치료를 시작한 것으로 판단되는 경우 | IEC/TR | 체제 버전에서 운영되는 의료기기 소프트웨어 | 점검하고 증례 기록서에 기록한다.  | 타당한 경우 | 순서가 타당하지 않은 경우 | : 군간 예상되는 effect size | 평가지표로 사용할 수 있다.  | 유닛 검증 | therapy | 접근으로 인해 환자 | 느낌의 상실, 비관적 사고, 자살 사고와 같은 특징적인 우울 | 파악할 수 있는 “static test” 및 | 2 | E06060.02 | 보고서’, ‘의료기기 소프트웨어 검증 | 제공하는 우울장애 디지털 프로그램이다.  | 해당 |\n| 1) 연구가설 | 해당 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 대상질환 또는 | (민원인 안내서) | 하게 되어 있다. ",
        "original_sentence": "| (3) 정신과적 전문치료를 시작한 것으로 판단되는 경우 | IEC/TR | 체제 버전에서 운영되는 의료기기 소프트웨어 | 점검하고 증례 기록서에 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_403",
      "text": "| 타당한 경우 | 순서가 타당하지 않은 경우 | : 군간 예상되는 effect size | 평가지표로 사용할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 402,
        "window_size": 3,
        "char_count": 69,
        "word_count": 19,
        "page_number": 73,
        "window_text": "| 사유 | - 초기 평가에는 최소 다음의 사항이 포함되어야 한다.  | 해야 한다.  | (3) 정신과적 전문치료를 시작한 것으로 판단되는 경우 | IEC/TR | 체제 버전에서 운영되는 의료기기 소프트웨어 | 점검하고 증례 기록서에 기록한다.  | 타당한 경우 | 순서가 타당하지 않은 경우 | : 군간 예상되는 effect size | 평가지표로 사용할 수 있다.  | 유닛 검증 | therapy | 접근으로 인해 환자 | 느낌의 상실, 비관적 사고, 자살 사고와 같은 특징적인 우울 | 파악할 수 있는 “static test” 및 | 2 | E06060.02 | 보고서’, ‘의료기기 소프트웨어 검증 | 제공하는 우울장애 디지털 프로그램이다.  | 해당 |\n| 1) 연구가설 | 해당 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 대상질환 또는 | (민원인 안내서) | 하게 되어 있다.  나머지 2개 문항은 이전 자살시도의 횟수와 | WL | 57 | -0.04 | 9.54 |\n| ※ 피험자의 선정·제외 기준, 인원 및 근거 | 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입한다. ",
        "original_sentence": "| 타당한 경우 | 순서가 타당하지 않은 경우 | : 군간 예상되는 effect size | 평가지표로 사용할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_404",
      "text": "| 유닛 검증 | therapy | 접근으로 인해 환자 | 느낌의 상실, 비관적 사고, 자살 사고와 같은 특징적인 우울 | 파악할 수 있는 “static test” 및 | 2 | E06060.02 | 보고서’, ‘의료기기 소프트웨어 검증 | 제공하는 우울장애 디지털 프로그램이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 403,
        "window_size": 3,
        "char_count": 157,
        "word_count": 40,
        "page_number": 9,
        "window_text": "| 해야 한다.  | (3) 정신과적 전문치료를 시작한 것으로 판단되는 경우 | IEC/TR | 체제 버전에서 운영되는 의료기기 소프트웨어 | 점검하고 증례 기록서에 기록한다.  | 타당한 경우 | 순서가 타당하지 않은 경우 | : 군간 예상되는 effect size | 평가지표로 사용할 수 있다.  | 유닛 검증 | therapy | 접근으로 인해 환자 | 느낌의 상실, 비관적 사고, 자살 사고와 같은 특징적인 우울 | 파악할 수 있는 “static test” 및 | 2 | E06060.02 | 보고서’, ‘의료기기 소프트웨어 검증 | 제공하는 우울장애 디지털 프로그램이다.  | 해당 |\n| 1) 연구가설 | 해당 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 대상질환 또는 | (민원인 안내서) | 하게 되어 있다.  나머지 2개 문항은 이전 자살시도의 횟수와 | WL | 57 | -0.04 | 9.54 |\n| ※ 피험자의 선정·제외 기준, 인원 및 근거 | 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입한다.  | 사용자의 접근 | 우울장애 척도 | 또는 치료기회 박탈 | 이상사례 |\n| (Blinding) 전략이 잘 포함되어야 한다. ",
        "original_sentence": "| 유닛 검증 | therapy | 접근으로 인해 환자 | 느낌의 상실, 비관적 사고, 자살 사고와 같은 특징적인 우울 | 파악할 수 있는 “static test” 및 | 2 | E06060.02 | 보고서’, ‘의료기기 소프트웨어 검증 | 제공하는 우울장애 디지털 프로그램이다. "
      }
    },
    {
      "chunk_id": "chunk_405",
      "text": "| 해당 |\n| 1) 연구가설 | 해당 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 대상질환 또는 | (민원인 안내서) | 하게 되어 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 404,
        "window_size": 3,
        "char_count": 85,
        "word_count": 23,
        "page_number": 7,
        "window_text": "| (3) 정신과적 전문치료를 시작한 것으로 판단되는 경우 | IEC/TR | 체제 버전에서 운영되는 의료기기 소프트웨어 | 점검하고 증례 기록서에 기록한다.  | 타당한 경우 | 순서가 타당하지 않은 경우 | : 군간 예상되는 effect size | 평가지표로 사용할 수 있다.  | 유닛 검증 | therapy | 접근으로 인해 환자 | 느낌의 상실, 비관적 사고, 자살 사고와 같은 특징적인 우울 | 파악할 수 있는 “static test” 및 | 2 | E06060.02 | 보고서’, ‘의료기기 소프트웨어 검증 | 제공하는 우울장애 디지털 프로그램이다.  | 해당 |\n| 1) 연구가설 | 해당 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 대상질환 또는 | (민원인 안내서) | 하게 되어 있다.  나머지 2개 문항은 이전 자살시도의 횟수와 | WL | 57 | -0.04 | 9.54 |\n| ※ 피험자의 선정·제외 기준, 인원 및 근거 | 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입한다.  | 사용자의 접근 | 우울장애 척도 | 또는 치료기회 박탈 | 이상사례 |\n| (Blinding) 전략이 잘 포함되어야 한다.  | [의료기기 임상시험기관 지정에 관한 규정(식약처 고시)]에 따라 식약처장으로부터 | 자를 말하며, 임상시험용 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용 | 일반적인 사항, 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 서식, | 하는 원칙과 절차를 수립하여 제시한다. ",
        "original_sentence": "| 해당 |\n| 1) 연구가설 | 해당 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 대상질환 또는 | (민원인 안내서) | 하게 되어 있다. "
      }
    },
    {
      "chunk_id": "chunk_406",
      "text": "나머지 2개 문항은 이전 자살시도의 횟수와 | WL | 57 | -0.04 | 9.54 |\n| ※ 피험자의 선정·제외 기준, 인원 및 근거 | 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 405,
        "window_size": 3,
        "char_count": 113,
        "word_count": 32,
        "page_number": 9,
        "window_text": "| 타당한 경우 | 순서가 타당하지 않은 경우 | : 군간 예상되는 effect size | 평가지표로 사용할 수 있다.  | 유닛 검증 | therapy | 접근으로 인해 환자 | 느낌의 상실, 비관적 사고, 자살 사고와 같은 특징적인 우울 | 파악할 수 있는 “static test” 및 | 2 | E06060.02 | 보고서’, ‘의료기기 소프트웨어 검증 | 제공하는 우울장애 디지털 프로그램이다.  | 해당 |\n| 1) 연구가설 | 해당 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 대상질환 또는 | (민원인 안내서) | 하게 되어 있다.  나머지 2개 문항은 이전 자살시도의 횟수와 | WL | 57 | -0.04 | 9.54 |\n| ※ 피험자의 선정·제외 기준, 인원 및 근거 | 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입한다.  | 사용자의 접근 | 우울장애 척도 | 또는 치료기회 박탈 | 이상사례 |\n| (Blinding) 전략이 잘 포함되어야 한다.  | [의료기기 임상시험기관 지정에 관한 규정(식약처 고시)]에 따라 식약처장으로부터 | 자를 말하며, 임상시험용 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용 | 일반적인 사항, 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 서식, | 하는 원칙과 절차를 수립하여 제시한다.  피해자 보상에 대한 규약에는 보상원칙과 보상이 | 척도(Korean Depression | 등을 기술한다. ",
        "original_sentence": "나머지 2개 문항은 이전 자살시도의 횟수와 | WL | 57 | -0.04 | 9.54 |\n| ※ 피험자의 선정·제외 기준, 인원 및 근거 | 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입한다. "
      }
    },
    {
      "chunk_id": "chunk_407",
      "text": "| 사용자의 접근 | 우울장애 척도 | 또는 치료기회 박탈 | 이상사례 |\n| (Blinding) 전략이 잘 포함되어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 406,
        "window_size": 3,
        "char_count": 71,
        "word_count": 19,
        "page_number": 39,
        "window_text": "| 유닛 검증 | therapy | 접근으로 인해 환자 | 느낌의 상실, 비관적 사고, 자살 사고와 같은 특징적인 우울 | 파악할 수 있는 “static test” 및 | 2 | E06060.02 | 보고서’, ‘의료기기 소프트웨어 검증 | 제공하는 우울장애 디지털 프로그램이다.  | 해당 |\n| 1) 연구가설 | 해당 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 대상질환 또는 | (민원인 안내서) | 하게 되어 있다.  나머지 2개 문항은 이전 자살시도의 횟수와 | WL | 57 | -0.04 | 9.54 |\n| ※ 피험자의 선정·제외 기준, 인원 및 근거 | 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입한다.  | 사용자의 접근 | 우울장애 척도 | 또는 치료기회 박탈 | 이상사례 |\n| (Blinding) 전략이 잘 포함되어야 한다.  | [의료기기 임상시험기관 지정에 관한 규정(식약처 고시)]에 따라 식약처장으로부터 | 자를 말하며, 임상시험용 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용 | 일반적인 사항, 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 서식, | 하는 원칙과 절차를 수립하여 제시한다.  피해자 보상에 대한 규약에는 보상원칙과 보상이 | 척도(Korean Depression | 등을 기술한다.  임상시험을 위한 피험자 동의 및 준비, 치료절차, 관찰 및 평가 절차 등을 |\n| 승인일로부터 OO 개월”로 표시하고 근거자료를 제출한다. ",
        "original_sentence": "| 사용자의 접근 | 우울장애 척도 | 또는 치료기회 박탈 | 이상사례 |\n| (Blinding) 전략이 잘 포함되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_408",
      "text": "| [의료기기 임상시험기관 지정에 관한 규정(식약처 고시)]에 따라 식약처장으로부터 | 자를 말하며, 임상시험용 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용 | 일반적인 사항, 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 서식, | 하는 원칙과 절차를 수립하여 제시한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 407,
        "window_size": 3,
        "char_count": 214,
        "word_count": 49,
        "page_number": 38,
        "window_text": "| 해당 |\n| 1) 연구가설 | 해당 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 대상질환 또는 | (민원인 안내서) | 하게 되어 있다.  나머지 2개 문항은 이전 자살시도의 횟수와 | WL | 57 | -0.04 | 9.54 |\n| ※ 피험자의 선정·제외 기준, 인원 및 근거 | 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입한다.  | 사용자의 접근 | 우울장애 척도 | 또는 치료기회 박탈 | 이상사례 |\n| (Blinding) 전략이 잘 포함되어야 한다.  | [의료기기 임상시험기관 지정에 관한 규정(식약처 고시)]에 따라 식약처장으로부터 | 자를 말하며, 임상시험용 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용 | 일반적인 사항, 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 서식, | 하는 원칙과 절차를 수립하여 제시한다.  피해자 보상에 대한 규약에는 보상원칙과 보상이 | 척도(Korean Depression | 등을 기술한다.  임상시험을 위한 피험자 동의 및 준비, 치료절차, 관찰 및 평가 절차 등을 |\n| 승인일로부터 OO 개월”로 표시하고 근거자료를 제출한다.  | 사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 의료기기의 공급과 | 예시 | 유/무, 피험자 기초정보, 병력조사, 선정 및 제외 기준, 식별코드 부여 등에 대해서 |\n| 내에 가능한 신속한 보고가 되어야 하며, 이상반응 등에 대한 의학적 소견· | 하는 원칙과 절차를 수립하여 제시한다. ",
        "original_sentence": "| [의료기기 임상시험기관 지정에 관한 규정(식약처 고시)]에 따라 식약처장으로부터 | 자를 말하며, 임상시험용 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용 | 일반적인 사항, 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 서식, | 하는 원칙과 절차를 수립하여 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_409",
      "text": "피해자 보상에 대한 규약에는 보상원칙과 보상이 | 척도(Korean Depression | 등을 기술한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 408,
        "window_size": 3,
        "char_count": 60,
        "word_count": 12,
        "page_number": 29,
        "window_text": "나머지 2개 문항은 이전 자살시도의 횟수와 | WL | 57 | -0.04 | 9.54 |\n| ※ 피험자의 선정·제외 기준, 인원 및 근거 | 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입한다.  | 사용자의 접근 | 우울장애 척도 | 또는 치료기회 박탈 | 이상사례 |\n| (Blinding) 전략이 잘 포함되어야 한다.  | [의료기기 임상시험기관 지정에 관한 규정(식약처 고시)]에 따라 식약처장으로부터 | 자를 말하며, 임상시험용 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용 | 일반적인 사항, 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 서식, | 하는 원칙과 절차를 수립하여 제시한다.  피해자 보상에 대한 규약에는 보상원칙과 보상이 | 척도(Korean Depression | 등을 기술한다.  임상시험을 위한 피험자 동의 및 준비, 치료절차, 관찰 및 평가 절차 등을 |\n| 승인일로부터 OO 개월”로 표시하고 근거자료를 제출한다.  | 사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 의료기기의 공급과 | 예시 | 유/무, 피험자 기초정보, 병력조사, 선정 및 제외 기준, 식별코드 부여 등에 대해서 |\n| 내에 가능한 신속한 보고가 되어야 하며, 이상반응 등에 대한 의학적 소견· | 하는 원칙과 절차를 수립하여 제시한다.  |\n**적응증을 포함하도록 한다.",
        "original_sentence": "피해자 보상에 대한 규약에는 보상원칙과 보상이 | 척도(Korean Depression | 등을 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_410",
      "text": "임상시험을 위한 피험자 동의 및 준비, 치료절차, 관찰 및 평가 절차 등을 |\n| 승인일로부터 OO 개월”로 표시하고 근거자료를 제출한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 409,
        "window_size": 3,
        "char_count": 78,
        "word_count": 20,
        "page_number": 7,
        "window_text": "| 사용자의 접근 | 우울장애 척도 | 또는 치료기회 박탈 | 이상사례 |\n| (Blinding) 전략이 잘 포함되어야 한다.  | [의료기기 임상시험기관 지정에 관한 규정(식약처 고시)]에 따라 식약처장으로부터 | 자를 말하며, 임상시험용 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용 | 일반적인 사항, 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 서식, | 하는 원칙과 절차를 수립하여 제시한다.  피해자 보상에 대한 규약에는 보상원칙과 보상이 | 척도(Korean Depression | 등을 기술한다.  임상시험을 위한 피험자 동의 및 준비, 치료절차, 관찰 및 평가 절차 등을 |\n| 승인일로부터 OO 개월”로 표시하고 근거자료를 제출한다.  | 사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 의료기기의 공급과 | 예시 | 유/무, 피험자 기초정보, 병력조사, 선정 및 제외 기준, 식별코드 부여 등에 대해서 |\n| 내에 가능한 신속한 보고가 되어야 하며, 이상반응 등에 대한 의학적 소견· | 하는 원칙과 절차를 수립하여 제시한다.  |\n**적응증을 포함하도록 한다. **\n| 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함한다. ",
        "original_sentence": "임상시험을 위한 피험자 동의 및 준비, 치료절차, 관찰 및 평가 절차 등을 |\n| 승인일로부터 OO 개월”로 표시하고 근거자료를 제출한다. "
      }
    },
    {
      "chunk_id": "chunk_411",
      "text": "| 사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 의료기기의 공급과 | 예시 | 유/무, 피험자 기초정보, 병력조사, 선정 및 제외 기준, 식별코드 부여 등에 대해서 |\n| 내에 가능한 신속한 보고가 되어야 하며, 이상반응 등에 대한 의학적 소견· | 하는 원칙과 절차를 수립하여 제시한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 410,
        "window_size": 3,
        "char_count": 174,
        "word_count": 46,
        "page_number": 3,
        "window_text": "| [의료기기 임상시험기관 지정에 관한 규정(식약처 고시)]에 따라 식약처장으로부터 | 자를 말하며, 임상시험용 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용 | 일반적인 사항, 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 서식, | 하는 원칙과 절차를 수립하여 제시한다.  피해자 보상에 대한 규약에는 보상원칙과 보상이 | 척도(Korean Depression | 등을 기술한다.  임상시험을 위한 피험자 동의 및 준비, 치료절차, 관찰 및 평가 절차 등을 |\n| 승인일로부터 OO 개월”로 표시하고 근거자료를 제출한다.  | 사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 의료기기의 공급과 | 예시 | 유/무, 피험자 기초정보, 병력조사, 선정 및 제외 기준, 식별코드 부여 등에 대해서 |\n| 내에 가능한 신속한 보고가 되어야 하며, 이상반응 등에 대한 의학적 소견· | 하는 원칙과 절차를 수립하여 제시한다.  |\n**적응증을 포함하도록 한다. **\n| 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함한다.  | 연번 | Vernmark et al.",
        "original_sentence": "| 사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 의료기기의 공급과 | 예시 | 유/무, 피험자 기초정보, 병력조사, 선정 및 제외 기준, 식별코드 부여 등에 대해서 |\n| 내에 가능한 신속한 보고가 되어야 하며, 이상반응 등에 대한 의학적 소견· | 하는 원칙과 절차를 수립하여 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_412",
      "text": "|\n**적응증을 포함하도록 한다.",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 411,
        "window_size": 3,
        "char_count": 18,
        "word_count": 4,
        "page_number": 13,
        "window_text": "피해자 보상에 대한 규약에는 보상원칙과 보상이 | 척도(Korean Depression | 등을 기술한다.  임상시험을 위한 피험자 동의 및 준비, 치료절차, 관찰 및 평가 절차 등을 |\n| 승인일로부터 OO 개월”로 표시하고 근거자료를 제출한다.  | 사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 의료기기의 공급과 | 예시 | 유/무, 피험자 기초정보, 병력조사, 선정 및 제외 기준, 식별코드 부여 등에 대해서 |\n| 내에 가능한 신속한 보고가 되어야 하며, 이상반응 등에 대한 의학적 소견· | 하는 원칙과 절차를 수립하여 제시한다.  |\n**적응증을 포함하도록 한다. **\n| 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함한다.  | 연번 | Vernmark et al. (2010) |\n| 의료기기 임상시험기관으로 지정받은 곳이어야 한다. ",
        "original_sentence": "|\n**적응증을 포함하도록 한다."
      }
    },
    {
      "chunk_id": "chunk_413",
      "text": "**\n| 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 412,
        "window_size": 3,
        "char_count": 41,
        "word_count": 11,
        "page_number": 13,
        "window_text": "임상시험을 위한 피험자 동의 및 준비, 치료절차, 관찰 및 평가 절차 등을 |\n| 승인일로부터 OO 개월”로 표시하고 근거자료를 제출한다.  | 사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 의료기기의 공급과 | 예시 | 유/무, 피험자 기초정보, 병력조사, 선정 및 제외 기준, 식별코드 부여 등에 대해서 |\n| 내에 가능한 신속한 보고가 되어야 하며, 이상반응 등에 대한 의학적 소견· | 하는 원칙과 절차를 수립하여 제시한다.  |\n**적응증을 포함하도록 한다. **\n| 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함한다.  | 연번 | Vernmark et al. (2010) |\n| 의료기기 임상시험기관으로 지정받은 곳이어야 한다.  | 할 경우 이를 함께 관리한다. ",
        "original_sentence": "**\n| 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함한다. "
      }
    },
    {
      "chunk_id": "chunk_414",
      "text": "| 연번 | Vernmark et al.",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 413,
        "window_size": 3,
        "char_count": 22,
        "word_count": 6,
        "page_number": 28,
        "window_text": "| 사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 의료기기의 공급과 | 예시 | 유/무, 피험자 기초정보, 병력조사, 선정 및 제외 기준, 식별코드 부여 등에 대해서 |\n| 내에 가능한 신속한 보고가 되어야 하며, 이상반응 등에 대한 의학적 소견· | 하는 원칙과 절차를 수립하여 제시한다.  |\n**적응증을 포함하도록 한다. **\n| 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함한다.  | 연번 | Vernmark et al. (2010) |\n| 의료기기 임상시험기관으로 지정받은 곳이어야 한다.  | 할 경우 이를 함께 관리한다.  임상시험용 의료기기 관리자의 성명, 소속 기관명 및 | 디자인 특성, 원자재 및 성능, 새로운 제조방법 등에 대한 특이성을 함께 기재한다. ",
        "original_sentence": "| 연번 | Vernmark et al."
      }
    },
    {
      "chunk_id": "chunk_415",
      "text": "(2010) |\n| 의료기기 임상시험기관으로 지정받은 곳이어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 414,
        "window_size": 3,
        "char_count": 39,
        "word_count": 8,
        "page_number": 9,
        "window_text": "|\n**적응증을 포함하도록 한다. **\n| 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함한다.  | 연번 | Vernmark et al. (2010) |\n| 의료기기 임상시험기관으로 지정받은 곳이어야 한다.  | 할 경우 이를 함께 관리한다.  임상시험용 의료기기 관리자의 성명, 소속 기관명 및 | 디자인 특성, 원자재 및 성능, 새로운 제조방법 등에 대한 특이성을 함께 기재한다.  | 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 한다. ",
        "original_sentence": "(2010) |\n| 의료기기 임상시험기관으로 지정받은 곳이어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_416",
      "text": "| 할 경우 이를 함께 관리한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 415,
        "window_size": 3,
        "char_count": 19,
        "word_count": 6,
        "page_number": 13,
        "window_text": "**\n| 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함한다.  | 연번 | Vernmark et al. (2010) |\n| 의료기기 임상시험기관으로 지정받은 곳이어야 한다.  | 할 경우 이를 함께 관리한다.  임상시험용 의료기기 관리자의 성명, 소속 기관명 및 | 디자인 특성, 원자재 및 성능, 새로운 제조방법 등에 대한 특이성을 함께 기재한다.  | 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 한다.  | 취급에 관한 사항을 추가로 확보할 수 있다. ",
        "original_sentence": "| 할 경우 이를 함께 관리한다. "
      }
    },
    {
      "chunk_id": "chunk_417",
      "text": "임상시험용 의료기기 관리자의 성명, 소속 기관명 및 | 디자인 특성, 원자재 및 성능, 새로운 제조방법 등에 대한 특이성을 함께 기재한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 416,
        "window_size": 3,
        "char_count": 78,
        "word_count": 20,
        "page_number": 38,
        "window_text": "| 연번 | Vernmark et al. (2010) |\n| 의료기기 임상시험기관으로 지정받은 곳이어야 한다.  | 할 경우 이를 함께 관리한다.  임상시험용 의료기기 관리자의 성명, 소속 기관명 및 | 디자인 특성, 원자재 및 성능, 새로운 제조방법 등에 대한 특이성을 함께 기재한다.  | 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 한다.  | 취급에 관한 사항을 추가로 확보할 수 있다.  | 상세히 시험방법을 기술한다. ",
        "original_sentence": "임상시험용 의료기기 관리자의 성명, 소속 기관명 및 | 디자인 특성, 원자재 및 성능, 새로운 제조방법 등에 대한 특이성을 함께 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_418",
      "text": "| 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 417,
        "window_size": 3,
        "char_count": 45,
        "word_count": 12,
        "page_number": 13,
        "window_text": "(2010) |\n| 의료기기 임상시험기관으로 지정받은 곳이어야 한다.  | 할 경우 이를 함께 관리한다.  임상시험용 의료기기 관리자의 성명, 소속 기관명 및 | 디자인 특성, 원자재 및 성능, 새로운 제조방법 등에 대한 특이성을 함께 기재한다.  | 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 한다.  | 취급에 관한 사항을 추가로 확보할 수 있다.  | 상세히 시험방법을 기술한다.  |\n| 정도와 | 임상시험용 | 의료기기와의 | 인과관계를 | 평가하여 | 증례기록서에 | 기록 |\n**예시**\n**예시**\n| 직명 등 인적사항을 기재한다. ",
        "original_sentence": "| 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 한다. "
      }
    },
    {
      "chunk_id": "chunk_419",
      "text": "| 취급에 관한 사항을 추가로 확보할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 418,
        "window_size": 3,
        "char_count": 27,
        "word_count": 8,
        "page_number": 3,
        "window_text": "| 할 경우 이를 함께 관리한다.  임상시험용 의료기기 관리자의 성명, 소속 기관명 및 | 디자인 특성, 원자재 및 성능, 새로운 제조방법 등에 대한 특이성을 함께 기재한다.  | 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 한다.  | 취급에 관한 사항을 추가로 확보할 수 있다.  | 상세히 시험방법을 기술한다.  |\n| 정도와 | 임상시험용 | 의료기기와의 | 인과관계를 | 평가하여 | 증례기록서에 | 기록 |\n**예시**\n**예시**\n| 직명 등 인적사항을 기재한다.  | 1) BDI 변화량 = Baseline 시점의 BDI 점수 – Post-treatment 시점의 BDI 점수 | 2) Effect size = (시험군의 평균 BDI 변화량 –대조군의 평균 BDI 변화량) / 합동표준편차 | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행규칙 | - 피험자의 방문 일에 따른 관찰 시기별 관찰 항목, 임상 검사 항목과 관찰검사방법을 | 2 | E06050.01 | 의료인이 환자의 심리적 상태를 평가, |\n| 하여야 | 한다. ",
        "original_sentence": "| 취급에 관한 사항을 추가로 확보할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_420",
      "text": "| 상세히 시험방법을 기술한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 419,
        "window_size": 3,
        "char_count": 18,
        "word_count": 4,
        "page_number": 13,
        "window_text": "임상시험용 의료기기 관리자의 성명, 소속 기관명 및 | 디자인 특성, 원자재 및 성능, 새로운 제조방법 등에 대한 특이성을 함께 기재한다.  | 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 한다.  | 취급에 관한 사항을 추가로 확보할 수 있다.  | 상세히 시험방법을 기술한다.  |\n| 정도와 | 임상시험용 | 의료기기와의 | 인과관계를 | 평가하여 | 증례기록서에 | 기록 |\n**예시**\n**예시**\n| 직명 등 인적사항을 기재한다.  | 1) BDI 변화량 = Baseline 시점의 BDI 점수 – Post-treatment 시점의 BDI 점수 | 2) Effect size = (시험군의 평균 BDI 변화량 –대조군의 평균 BDI 변화량) / 합동표준편차 | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행규칙 | - 피험자의 방문 일에 따른 관찰 시기별 관찰 항목, 임상 검사 항목과 관찰검사방법을 | 2 | E06050.01 | 의료인이 환자의 심리적 상태를 평가, |\n| 하여야 | 한다.  따라서 이상반응에 대한 임상시험용 의료기기와의 인과관계에 | 예시 | 예시 |\n**머목(모니터링)에서 정하고 있다.",
        "original_sentence": "| 상세히 시험방법을 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_421",
      "text": "|\n| 정도와 | 임상시험용 | 의료기기와의 | 인과관계를 | 평가하여 | 증례기록서에 | 기록 |\n**예시**\n**예시**\n| 직명 등 인적사항을 기재한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 420,
        "window_size": 3,
        "char_count": 89,
        "word_count": 23,
        "page_number": 38,
        "window_text": "| 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 한다.  | 취급에 관한 사항을 추가로 확보할 수 있다.  | 상세히 시험방법을 기술한다.  |\n| 정도와 | 임상시험용 | 의료기기와의 | 인과관계를 | 평가하여 | 증례기록서에 | 기록 |\n**예시**\n**예시**\n| 직명 등 인적사항을 기재한다.  | 1) BDI 변화량 = Baseline 시점의 BDI 점수 – Post-treatment 시점의 BDI 점수 | 2) Effect size = (시험군의 평균 BDI 변화량 –대조군의 평균 BDI 변화량) / 합동표준편차 | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행규칙 | - 피험자의 방문 일에 따른 관찰 시기별 관찰 항목, 임상 검사 항목과 관찰검사방법을 | 2 | E06050.01 | 의료인이 환자의 심리적 상태를 평가, |\n| 하여야 | 한다.  따라서 이상반응에 대한 임상시험용 의료기기와의 인과관계에 | 예시 | 예시 |\n**머목(모니터링)에서 정하고 있다. **\n| 예시 | 결정하는 데 사용하기 위한 소프트웨어 |\n| [별표 3])에서 정하고 있다. ",
        "original_sentence": "|\n| 정도와 | 임상시험용 | 의료기기와의 | 인과관계를 | 평가하여 | 증례기록서에 | 기록 |\n**예시**\n**예시**\n| 직명 등 인적사항을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_422",
      "text": "| 1) BDI 변화량 = Baseline 시점의 BDI 점수 – Post-treatment 시점의 BDI 점수 | 2) Effect size = (시험군의 평균 BDI 변화량 –대조군의 평균 BDI 변화량) / 합동표준편차 | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행규칙 | - 피험자의 방문 일에 따른 관찰 시기별 관찰 항목, 임상 검사 항목과 관찰검사방법을 | 2 | E06050.01 | 의료인이 환자의 심리적 상태를 평가, |\n| 하여야 | 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 421,
        "window_size": 3,
        "char_count": 275,
        "word_count": 67,
        "page_number": 28,
        "window_text": "| 취급에 관한 사항을 추가로 확보할 수 있다.  | 상세히 시험방법을 기술한다.  |\n| 정도와 | 임상시험용 | 의료기기와의 | 인과관계를 | 평가하여 | 증례기록서에 | 기록 |\n**예시**\n**예시**\n| 직명 등 인적사항을 기재한다.  | 1) BDI 변화량 = Baseline 시점의 BDI 점수 – Post-treatment 시점의 BDI 점수 | 2) Effect size = (시험군의 평균 BDI 변화량 –대조군의 평균 BDI 변화량) / 합동표준편차 | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행규칙 | - 피험자의 방문 일에 따른 관찰 시기별 관찰 항목, 임상 검사 항목과 관찰검사방법을 | 2 | E06050.01 | 의료인이 환자의 심리적 상태를 평가, |\n| 하여야 | 한다.  따라서 이상반응에 대한 임상시험용 의료기기와의 인과관계에 | 예시 | 예시 |\n**머목(모니터링)에서 정하고 있다. **\n| 예시 | 결정하는 데 사용하기 위한 소프트웨어 |\n| [별표 3])에서 정하고 있다.  이에 따른 피험자 동의서 서식을 제시하여야 하며, 피험자 | 예시 |\n| 번호 | 시험 항목 | 시험기준 | 시험 방법 | 대한 평가 기준을 제시하여야 한다. ",
        "original_sentence": "| 1) BDI 변화량 = Baseline 시점의 BDI 점수 – Post-treatment 시점의 BDI 점수 | 2) Effect size = (시험군의 평균 BDI 변화량 –대조군의 평균 BDI 변화량) / 합동표준편차 | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행규칙 | - 피험자의 방문 일에 따른 관찰 시기별 관찰 항목, 임상 검사 항목과 관찰검사방법을 | 2 | E06050.01 | 의료인이 환자의 심리적 상태를 평가, |\n| 하여야 | 한다. "
      }
    },
    {
      "chunk_id": "chunk_423",
      "text": "따라서 이상반응에 대한 임상시험용 의료기기와의 인과관계에 | 예시 | 예시 |\n**머목(모니터링)에서 정하고 있다.",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 422,
        "window_size": 3,
        "char_count": 64,
        "word_count": 14,
        "page_number": 7,
        "window_text": "| 상세히 시험방법을 기술한다.  |\n| 정도와 | 임상시험용 | 의료기기와의 | 인과관계를 | 평가하여 | 증례기록서에 | 기록 |\n**예시**\n**예시**\n| 직명 등 인적사항을 기재한다.  | 1) BDI 변화량 = Baseline 시점의 BDI 점수 – Post-treatment 시점의 BDI 점수 | 2) Effect size = (시험군의 평균 BDI 변화량 –대조군의 평균 BDI 변화량) / 합동표준편차 | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행규칙 | - 피험자의 방문 일에 따른 관찰 시기별 관찰 항목, 임상 검사 항목과 관찰검사방법을 | 2 | E06050.01 | 의료인이 환자의 심리적 상태를 평가, |\n| 하여야 | 한다.  따라서 이상반응에 대한 임상시험용 의료기기와의 인과관계에 | 예시 | 예시 |\n**머목(모니터링)에서 정하고 있다. **\n| 예시 | 결정하는 데 사용하기 위한 소프트웨어 |\n| [별표 3])에서 정하고 있다.  이에 따른 피험자 동의서 서식을 제시하여야 하며, 피험자 | 예시 |\n| 번호 | 시험 항목 | 시험기준 | 시험 방법 | 대한 평가 기준을 제시하여야 한다.  | 예시 |\n**예시**\n| 번호 | 표준 번호 | 규격 명칭 | 주요 내용 | 비고 | 2(Baseline), 방문 3(Post-treatment), 방문 4(Follow-up, 3개월 후) |\n| 설명서에는 동 기준의 제7호 아목의 10)을 포함하여야 한다. ",
        "original_sentence": "따라서 이상반응에 대한 임상시험용 의료기기와의 인과관계에 | 예시 | 예시 |\n**머목(모니터링)에서 정하고 있다."
      }
    },
    {
      "chunk_id": "chunk_424",
      "text": "**\n| 예시 | 결정하는 데 사용하기 위한 소프트웨어 |\n| [별표 3])에서 정하고 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 423,
        "window_size": 3,
        "char_count": 53,
        "word_count": 15,
        "page_number": 9,
        "window_text": "|\n| 정도와 | 임상시험용 | 의료기기와의 | 인과관계를 | 평가하여 | 증례기록서에 | 기록 |\n**예시**\n**예시**\n| 직명 등 인적사항을 기재한다.  | 1) BDI 변화량 = Baseline 시점의 BDI 점수 – Post-treatment 시점의 BDI 점수 | 2) Effect size = (시험군의 평균 BDI 변화량 –대조군의 평균 BDI 변화량) / 합동표준편차 | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행규칙 | - 피험자의 방문 일에 따른 관찰 시기별 관찰 항목, 임상 검사 항목과 관찰검사방법을 | 2 | E06050.01 | 의료인이 환자의 심리적 상태를 평가, |\n| 하여야 | 한다.  따라서 이상반응에 대한 임상시험용 의료기기와의 인과관계에 | 예시 | 예시 |\n**머목(모니터링)에서 정하고 있다. **\n| 예시 | 결정하는 데 사용하기 위한 소프트웨어 |\n| [별표 3])에서 정하고 있다.  이에 따른 피험자 동의서 서식을 제시하여야 하며, 피험자 | 예시 |\n| 번호 | 시험 항목 | 시험기준 | 시험 방법 | 대한 평가 기준을 제시하여야 한다.  | 예시 |\n**예시**\n| 번호 | 표준 번호 | 규격 명칭 | 주요 내용 | 비고 | 2(Baseline), 방문 3(Post-treatment), 방문 4(Follow-up, 3개월 후) |\n| 설명서에는 동 기준의 제7호 아목의 10)을 포함하여야 한다.  | 예시 |\n**예시**\n**(CBT-D)를 기반으로 하였을 경우 다음 사항이 포함되어야 한다.",
        "original_sentence": "**\n| 예시 | 결정하는 데 사용하기 위한 소프트웨어 |\n| [별표 3])에서 정하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_425",
      "text": "이에 따른 피험자 동의서 서식을 제시하여야 하며, 피험자 | 예시 |\n| 번호 | 시험 항목 | 시험기준 | 시험 방법 | 대한 평가 기준을 제시하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 424,
        "window_size": 3,
        "char_count": 89,
        "word_count": 27,
        "page_number": 37,
        "window_text": "| 1) BDI 변화량 = Baseline 시점의 BDI 점수 – Post-treatment 시점의 BDI 점수 | 2) Effect size = (시험군의 평균 BDI 변화량 –대조군의 평균 BDI 변화량) / 합동표준편차 | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행규칙 | - 피험자의 방문 일에 따른 관찰 시기별 관찰 항목, 임상 검사 항목과 관찰검사방법을 | 2 | E06050.01 | 의료인이 환자의 심리적 상태를 평가, |\n| 하여야 | 한다.  따라서 이상반응에 대한 임상시험용 의료기기와의 인과관계에 | 예시 | 예시 |\n**머목(모니터링)에서 정하고 있다. **\n| 예시 | 결정하는 데 사용하기 위한 소프트웨어 |\n| [별표 3])에서 정하고 있다.  이에 따른 피험자 동의서 서식을 제시하여야 하며, 피험자 | 예시 |\n| 번호 | 시험 항목 | 시험기준 | 시험 방법 | 대한 평가 기준을 제시하여야 한다.  | 예시 |\n**예시**\n| 번호 | 표준 번호 | 규격 명칭 | 주요 내용 | 비고 | 2(Baseline), 방문 3(Post-treatment), 방문 4(Follow-up, 3개월 후) |\n| 설명서에는 동 기준의 제7호 아목의 10)을 포함하여야 한다.  | 예시 |\n**예시**\n**(CBT-D)를 기반으로 하였을 경우 다음 사항이 포함되어야 한다. **\n**통제**\n| 정서장애치료 | 예시 |\n| 예시 | 예시 | 예시 |\n| 예시 | 완료 |\n\n**[표 끝]**\n\nCognitive\n\n정서장애(우울장애 등)를 개선하는데 사\n\n가상ㆍ증강(VRㆍAR) 기반 소프트웨어를 포함\n\n<!-- PAGE_9 -->\n###### 표 1. ",
        "original_sentence": "이에 따른 피험자 동의서 서식을 제시하여야 하며, 피험자 | 예시 |\n| 번호 | 시험 항목 | 시험기준 | 시험 방법 | 대한 평가 기준을 제시하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_426",
      "text": "| 예시 |\n**예시**\n| 번호 | 표준 번호 | 규격 명칭 | 주요 내용 | 비고 | 2(Baseline), 방문 3(Post-treatment), 방문 4(Follow-up, 3개월 후) |\n| 설명서에는 동 기준의 제7호 아목의 10)을 포함하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 425,
        "window_size": 3,
        "char_count": 147,
        "word_count": 35,
        "page_number": 3,
        "window_text": "따라서 이상반응에 대한 임상시험용 의료기기와의 인과관계에 | 예시 | 예시 |\n**머목(모니터링)에서 정하고 있다. **\n| 예시 | 결정하는 데 사용하기 위한 소프트웨어 |\n| [별표 3])에서 정하고 있다.  이에 따른 피험자 동의서 서식을 제시하여야 하며, 피험자 | 예시 |\n| 번호 | 시험 항목 | 시험기준 | 시험 방법 | 대한 평가 기준을 제시하여야 한다.  | 예시 |\n**예시**\n| 번호 | 표준 번호 | 규격 명칭 | 주요 내용 | 비고 | 2(Baseline), 방문 3(Post-treatment), 방문 4(Follow-up, 3개월 후) |\n| 설명서에는 동 기준의 제7호 아목의 10)을 포함하여야 한다.  | 예시 |\n**예시**\n**(CBT-D)를 기반으로 하였을 경우 다음 사항이 포함되어야 한다. **\n**통제**\n| 정서장애치료 | 예시 |\n| 예시 | 예시 | 예시 |\n| 예시 | 완료 |\n\n**[표 끝]**\n\nCognitive\n\n정서장애(우울장애 등)를 개선하는데 사\n\n가상ㆍ증강(VRㆍAR) 기반 소프트웨어를 포함\n\n<!-- PAGE_9 -->\n###### 표 1.  우울장애 개선 디지털치료기기 관련 의료기기 품목(식약처 고시 제2021-83호)\n\n<!-- PAGE_9 -->\n###### ※ 본 가이드라인에서 다루는 우울장애 개선 디지털치료기기는 소프트웨어 의료\n\n<!-- PAGE_9 -->\n###### 기기로서, 사용 시 필요한 범용 장비(스마트폰 또는 태블릿 PC 등)는 적용\n\n<!-- PAGE_9 -->\n###### 범위에 포함되지 않으나, 반드시 함께 병용해야 하므로 전기용품 안전 인증과\n\n<!-- PAGE_9 -->\n###### ※ 실생활 습관을 추적 관찰하기 위해 기타 웨어러블 의료기기를 추가로 사용하는\n\n- - 3 -\n<!-- PAGE_10 -->\n##### 3. ",
        "original_sentence": "| 예시 |\n**예시**\n| 번호 | 표준 번호 | 규격 명칭 | 주요 내용 | 비고 | 2(Baseline), 방문 3(Post-treatment), 방문 4(Follow-up, 3개월 후) |\n| 설명서에는 동 기준의 제7호 아목의 10)을 포함하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_427",
      "text": "| 예시 |\n**예시**\n**(CBT-D)를 기반으로 하였을 경우 다음 사항이 포함되어야 한다.",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 426,
        "window_size": 3,
        "char_count": 53,
        "word_count": 12,
        "page_number": 3,
        "window_text": "**\n| 예시 | 결정하는 데 사용하기 위한 소프트웨어 |\n| [별표 3])에서 정하고 있다.  이에 따른 피험자 동의서 서식을 제시하여야 하며, 피험자 | 예시 |\n| 번호 | 시험 항목 | 시험기준 | 시험 방법 | 대한 평가 기준을 제시하여야 한다.  | 예시 |\n**예시**\n| 번호 | 표준 번호 | 규격 명칭 | 주요 내용 | 비고 | 2(Baseline), 방문 3(Post-treatment), 방문 4(Follow-up, 3개월 후) |\n| 설명서에는 동 기준의 제7호 아목의 10)을 포함하여야 한다.  | 예시 |\n**예시**\n**(CBT-D)를 기반으로 하였을 경우 다음 사항이 포함되어야 한다. **\n**통제**\n| 정서장애치료 | 예시 |\n| 예시 | 예시 | 예시 |\n| 예시 | 완료 |\n\n**[표 끝]**\n\nCognitive\n\n정서장애(우울장애 등)를 개선하는데 사\n\n가상ㆍ증강(VRㆍAR) 기반 소프트웨어를 포함\n\n<!-- PAGE_9 -->\n###### 표 1.  우울장애 개선 디지털치료기기 관련 의료기기 품목(식약처 고시 제2021-83호)\n\n<!-- PAGE_9 -->\n###### ※ 본 가이드라인에서 다루는 우울장애 개선 디지털치료기기는 소프트웨어 의료\n\n<!-- PAGE_9 -->\n###### 기기로서, 사용 시 필요한 범용 장비(스마트폰 또는 태블릿 PC 등)는 적용\n\n<!-- PAGE_9 -->\n###### 범위에 포함되지 않으나, 반드시 함께 병용해야 하므로 전기용품 안전 인증과\n\n<!-- PAGE_9 -->\n###### ※ 실생활 습관을 추적 관찰하기 위해 기타 웨어러블 의료기기를 추가로 사용하는\n\n- - 3 -\n<!-- PAGE_10 -->\n##### 3.  용어 설명\n\n<!-- PAGE_10 -->\n###### 가. ",
        "original_sentence": "| 예시 |\n**예시**\n**(CBT-D)를 기반으로 하였을 경우 다음 사항이 포함되어야 한다."
      }
    },
    {
      "chunk_id": "chunk_428",
      "text": "**\n**통제**\n| 정서장애치료 | 예시 |\n| 예시 | 예시 | 예시 |\n| 예시 | 완료 |\n\n**[표 끝]**\n\nCognitive\n\n정서장애(우울장애 등)를 개선하는데 사\n\n가상ㆍ증강(VRㆍAR) 기반 소프트웨어를 포함\n\n<!-- PAGE_9 -->\n###### 표 1. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 427,
        "window_size": 3,
        "char_count": 156,
        "word_count": 36,
        "page_number": 9,
        "window_text": "이에 따른 피험자 동의서 서식을 제시하여야 하며, 피험자 | 예시 |\n| 번호 | 시험 항목 | 시험기준 | 시험 방법 | 대한 평가 기준을 제시하여야 한다.  | 예시 |\n**예시**\n| 번호 | 표준 번호 | 규격 명칭 | 주요 내용 | 비고 | 2(Baseline), 방문 3(Post-treatment), 방문 4(Follow-up, 3개월 후) |\n| 설명서에는 동 기준의 제7호 아목의 10)을 포함하여야 한다.  | 예시 |\n**예시**\n**(CBT-D)를 기반으로 하였을 경우 다음 사항이 포함되어야 한다. **\n**통제**\n| 정서장애치료 | 예시 |\n| 예시 | 예시 | 예시 |\n| 예시 | 완료 |\n\n**[표 끝]**\n\nCognitive\n\n정서장애(우울장애 등)를 개선하는데 사\n\n가상ㆍ증강(VRㆍAR) 기반 소프트웨어를 포함\n\n<!-- PAGE_9 -->\n###### 표 1.  우울장애 개선 디지털치료기기 관련 의료기기 품목(식약처 고시 제2021-83호)\n\n<!-- PAGE_9 -->\n###### ※ 본 가이드라인에서 다루는 우울장애 개선 디지털치료기기는 소프트웨어 의료\n\n<!-- PAGE_9 -->\n###### 기기로서, 사용 시 필요한 범용 장비(스마트폰 또는 태블릿 PC 등)는 적용\n\n<!-- PAGE_9 -->\n###### 범위에 포함되지 않으나, 반드시 함께 병용해야 하므로 전기용품 안전 인증과\n\n<!-- PAGE_9 -->\n###### ※ 실생활 습관을 추적 관찰하기 위해 기타 웨어러블 의료기기를 추가로 사용하는\n\n- - 3 -\n<!-- PAGE_10 -->\n##### 3.  용어 설명\n\n<!-- PAGE_10 -->\n###### 가.  소프트웨어 의료기기(Software as a Medical Device, SaMD)\n\n<!-- PAGE_10 -->\n###### 하드웨어에 종속되지 않고 의료기기의 사용 목적에 부합하는 기능을\n\n<!-- PAGE_10 -->\n###### 가지며 독립적인 형태의 소프트웨어만으로 이루어진 의료기기이다.\n\n",
        "original_sentence": "**\n**통제**\n| 정서장애치료 | 예시 |\n| 예시 | 예시 | 예시 |\n| 예시 | 완료 |\n\n**[표 끝]**\n\nCognitive\n\n정서장애(우울장애 등)를 개선하는데 사\n\n가상ㆍ증강(VRㆍAR) 기반 소프트웨어를 포함\n\n<!-- PAGE_9 -->\n###### 표 1. "
      }
    },
    {
      "chunk_id": "chunk_429",
      "text": "우울장애 개선 디지털치료기기 관련 의료기기 품목(식약처 고시 제2021-83호)\n\n<!-- PAGE_9 -->\n###### ※ 본 가이드라인에서 다루는 우울장애 개선 디지털치료기기는 소프트웨어 의료\n\n<!-- PAGE_9 -->\n###### 기기로서, 사용 시 필요한 범용 장비(스마트폰 또는 태블릿 PC 등)는 적용\n\n<!-- PAGE_9 -->\n###### 범위에 포함되지 않으나, 반드시 함께 병용해야 하므로 전기용품 안전 인증과\n\n<!-- PAGE_9 -->\n###### ※ 실생활 습관을 추적 관찰하기 위해 기타 웨어러블 의료기기를 추가로 사용하는\n\n- - 3 -\n<!-- PAGE_10 -->\n##### 3. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 428,
        "window_size": 3,
        "char_count": 347,
        "word_count": 74,
        "page_number": 9,
        "window_text": "| 예시 |\n**예시**\n| 번호 | 표준 번호 | 규격 명칭 | 주요 내용 | 비고 | 2(Baseline), 방문 3(Post-treatment), 방문 4(Follow-up, 3개월 후) |\n| 설명서에는 동 기준의 제7호 아목의 10)을 포함하여야 한다.  | 예시 |\n**예시**\n**(CBT-D)를 기반으로 하였을 경우 다음 사항이 포함되어야 한다. **\n**통제**\n| 정서장애치료 | 예시 |\n| 예시 | 예시 | 예시 |\n| 예시 | 완료 |\n\n**[표 끝]**\n\nCognitive\n\n정서장애(우울장애 등)를 개선하는데 사\n\n가상ㆍ증강(VRㆍAR) 기반 소프트웨어를 포함\n\n<!-- PAGE_9 -->\n###### 표 1.  우울장애 개선 디지털치료기기 관련 의료기기 품목(식약처 고시 제2021-83호)\n\n<!-- PAGE_9 -->\n###### ※ 본 가이드라인에서 다루는 우울장애 개선 디지털치료기기는 소프트웨어 의료\n\n<!-- PAGE_9 -->\n###### 기기로서, 사용 시 필요한 범용 장비(스마트폰 또는 태블릿 PC 등)는 적용\n\n<!-- PAGE_9 -->\n###### 범위에 포함되지 않으나, 반드시 함께 병용해야 하므로 전기용품 안전 인증과\n\n<!-- PAGE_9 -->\n###### ※ 실생활 습관을 추적 관찰하기 위해 기타 웨어러블 의료기기를 추가로 사용하는\n\n- - 3 -\n<!-- PAGE_10 -->\n##### 3.  용어 설명\n\n<!-- PAGE_10 -->\n###### 가.  소프트웨어 의료기기(Software as a Medical Device, SaMD)\n\n<!-- PAGE_10 -->\n###### 하드웨어에 종속되지 않고 의료기기의 사용 목적에 부합하는 기능을\n\n<!-- PAGE_10 -->\n###### 가지며 독립적인 형태의 소프트웨어만으로 이루어진 의료기기이다.\n\n <!-- PAGE_10 -->\n###### 나. ",
        "original_sentence": "우울장애 개선 디지털치료기기 관련 의료기기 품목(식약처 고시 제2021-83호)\n\n<!-- PAGE_9 -->\n###### ※ 본 가이드라인에서 다루는 우울장애 개선 디지털치료기기는 소프트웨어 의료\n\n<!-- PAGE_9 -->\n###### 기기로서, 사용 시 필요한 범용 장비(스마트폰 또는 태블릿 PC 등)는 적용\n\n<!-- PAGE_9 -->\n###### 범위에 포함되지 않으나, 반드시 함께 병용해야 하므로 전기용품 안전 인증과\n\n<!-- PAGE_9 -->\n###### ※ 실생활 습관을 추적 관찰하기 위해 기타 웨어러블 의료기기를 추가로 사용하는\n\n- - 3 -\n<!-- PAGE_10 -->\n##### 3. "
      }
    },
    {
      "chunk_id": "chunk_430",
      "text": "용어 설명\n\n<!-- PAGE_10 -->\n###### 가. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 429,
        "window_size": 3,
        "char_count": 34,
        "word_count": 7,
        "page_number": 10,
        "window_text": "| 예시 |\n**예시**\n**(CBT-D)를 기반으로 하였을 경우 다음 사항이 포함되어야 한다. **\n**통제**\n| 정서장애치료 | 예시 |\n| 예시 | 예시 | 예시 |\n| 예시 | 완료 |\n\n**[표 끝]**\n\nCognitive\n\n정서장애(우울장애 등)를 개선하는데 사\n\n가상ㆍ증강(VRㆍAR) 기반 소프트웨어를 포함\n\n<!-- PAGE_9 -->\n###### 표 1.  우울장애 개선 디지털치료기기 관련 의료기기 품목(식약처 고시 제2021-83호)\n\n<!-- PAGE_9 -->\n###### ※ 본 가이드라인에서 다루는 우울장애 개선 디지털치료기기는 소프트웨어 의료\n\n<!-- PAGE_9 -->\n###### 기기로서, 사용 시 필요한 범용 장비(스마트폰 또는 태블릿 PC 등)는 적용\n\n<!-- PAGE_9 -->\n###### 범위에 포함되지 않으나, 반드시 함께 병용해야 하므로 전기용품 안전 인증과\n\n<!-- PAGE_9 -->\n###### ※ 실생활 습관을 추적 관찰하기 위해 기타 웨어러블 의료기기를 추가로 사용하는\n\n- - 3 -\n<!-- PAGE_10 -->\n##### 3.  용어 설명\n\n<!-- PAGE_10 -->\n###### 가.  소프트웨어 의료기기(Software as a Medical Device, SaMD)\n\n<!-- PAGE_10 -->\n###### 하드웨어에 종속되지 않고 의료기기의 사용 목적에 부합하는 기능을\n\n<!-- PAGE_10 -->\n###### 가지며 독립적인 형태의 소프트웨어만으로 이루어진 의료기기이다.\n\n <!-- PAGE_10 -->\n###### 나.  디지털치료기기(Digital Therapeutics)\n\n<!-- PAGE_10 -->\n###### 식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인(민원인\n\n<!-- PAGE_10 -->\n###### 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방, 관리, 치료\n\n<!-- PAGE_10 -->\n###### 하기 위해 환자에게 근거 기반의 치료적 개입을 제공하는 소프트웨어\n\n<!-- PAGE_10 -->\n###### 다. ",
        "original_sentence": "용어 설명\n\n<!-- PAGE_10 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_431",
      "text": "소프트웨어 의료기기(Software as a Medical Device, SaMD)\n\n<!-- PAGE_10 -->\n###### 하드웨어에 종속되지 않고 의료기기의 사용 목적에 부합하는 기능을\n\n<!-- PAGE_10 -->\n###### 가지며 독립적인 형태의 소프트웨어만으로 이루어진 의료기기이다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 430,
        "window_size": 3,
        "char_count": 169,
        "word_count": 29,
        "page_number": 10,
        "window_text": "**\n**통제**\n| 정서장애치료 | 예시 |\n| 예시 | 예시 | 예시 |\n| 예시 | 완료 |\n\n**[표 끝]**\n\nCognitive\n\n정서장애(우울장애 등)를 개선하는데 사\n\n가상ㆍ증강(VRㆍAR) 기반 소프트웨어를 포함\n\n<!-- PAGE_9 -->\n###### 표 1.  우울장애 개선 디지털치료기기 관련 의료기기 품목(식약처 고시 제2021-83호)\n\n<!-- PAGE_9 -->\n###### ※ 본 가이드라인에서 다루는 우울장애 개선 디지털치료기기는 소프트웨어 의료\n\n<!-- PAGE_9 -->\n###### 기기로서, 사용 시 필요한 범용 장비(스마트폰 또는 태블릿 PC 등)는 적용\n\n<!-- PAGE_9 -->\n###### 범위에 포함되지 않으나, 반드시 함께 병용해야 하므로 전기용품 안전 인증과\n\n<!-- PAGE_9 -->\n###### ※ 실생활 습관을 추적 관찰하기 위해 기타 웨어러블 의료기기를 추가로 사용하는\n\n- - 3 -\n<!-- PAGE_10 -->\n##### 3.  용어 설명\n\n<!-- PAGE_10 -->\n###### 가.  소프트웨어 의료기기(Software as a Medical Device, SaMD)\n\n<!-- PAGE_10 -->\n###### 하드웨어에 종속되지 않고 의료기기의 사용 목적에 부합하는 기능을\n\n<!-- PAGE_10 -->\n###### 가지며 독립적인 형태의 소프트웨어만으로 이루어진 의료기기이다.\n\n <!-- PAGE_10 -->\n###### 나.  디지털치료기기(Digital Therapeutics)\n\n<!-- PAGE_10 -->\n###### 식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인(민원인\n\n<!-- PAGE_10 -->\n###### 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방, 관리, 치료\n\n<!-- PAGE_10 -->\n###### 하기 위해 환자에게 근거 기반의 치료적 개입을 제공하는 소프트웨어\n\n<!-- PAGE_10 -->\n###### 다.  정신질환의 진단 및 통계 편람(Diagnostic and Statistical Manual of\n\n<!-- PAGE_10 -->\n###### 미국 정신의학협회(American Psychiatric Association, APA)에서 발행한\n\n<!-- PAGE_10 -->\n###### 정신질환의 신뢰할 만한 진단이 가능하도록 고안된 관련 기준들을\n\n<!-- PAGE_10 -->\n###### 통칭하는 정신질환 분류법이다. ",
        "original_sentence": "소프트웨어 의료기기(Software as a Medical Device, SaMD)\n\n<!-- PAGE_10 -->\n###### 하드웨어에 종속되지 않고 의료기기의 사용 목적에 부합하는 기능을\n\n<!-- PAGE_10 -->\n###### 가지며 독립적인 형태의 소프트웨어만으로 이루어진 의료기기이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_432",
      "text": "<!-- PAGE_10 -->\n###### 나. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 431,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 10,
        "window_text": "우울장애 개선 디지털치료기기 관련 의료기기 품목(식약처 고시 제2021-83호)\n\n<!-- PAGE_9 -->\n###### ※ 본 가이드라인에서 다루는 우울장애 개선 디지털치료기기는 소프트웨어 의료\n\n<!-- PAGE_9 -->\n###### 기기로서, 사용 시 필요한 범용 장비(스마트폰 또는 태블릿 PC 등)는 적용\n\n<!-- PAGE_9 -->\n###### 범위에 포함되지 않으나, 반드시 함께 병용해야 하므로 전기용품 안전 인증과\n\n<!-- PAGE_9 -->\n###### ※ 실생활 습관을 추적 관찰하기 위해 기타 웨어러블 의료기기를 추가로 사용하는\n\n- - 3 -\n<!-- PAGE_10 -->\n##### 3.  용어 설명\n\n<!-- PAGE_10 -->\n###### 가.  소프트웨어 의료기기(Software as a Medical Device, SaMD)\n\n<!-- PAGE_10 -->\n###### 하드웨어에 종속되지 않고 의료기기의 사용 목적에 부합하는 기능을\n\n<!-- PAGE_10 -->\n###### 가지며 독립적인 형태의 소프트웨어만으로 이루어진 의료기기이다.\n\n <!-- PAGE_10 -->\n###### 나.  디지털치료기기(Digital Therapeutics)\n\n<!-- PAGE_10 -->\n###### 식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인(민원인\n\n<!-- PAGE_10 -->\n###### 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방, 관리, 치료\n\n<!-- PAGE_10 -->\n###### 하기 위해 환자에게 근거 기반의 치료적 개입을 제공하는 소프트웨어\n\n<!-- PAGE_10 -->\n###### 다.  정신질환의 진단 및 통계 편람(Diagnostic and Statistical Manual of\n\n<!-- PAGE_10 -->\n###### 미국 정신의학협회(American Psychiatric Association, APA)에서 발행한\n\n<!-- PAGE_10 -->\n###### 정신질환의 신뢰할 만한 진단이 가능하도록 고안된 관련 기준들을\n\n<!-- PAGE_10 -->\n###### 통칭하는 정신질환 분류법이다.  DSM-5는 2013년도의 새로운 업데이트\n\n- - 4 -\n<!-- PAGE_11 -->\n##### 4. ",
        "original_sentence": "<!-- PAGE_10 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_433",
      "text": "디지털치료기기(Digital Therapeutics)\n\n<!-- PAGE_10 -->\n###### 식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인(민원인\n\n<!-- PAGE_10 -->\n###### 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방, 관리, 치료\n\n<!-- PAGE_10 -->\n###### 하기 위해 환자에게 근거 기반의 치료적 개입을 제공하는 소프트웨어\n\n<!-- PAGE_10 -->\n###### 다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 432,
        "window_size": 3,
        "char_count": 242,
        "word_count": 41,
        "page_number": 10,
        "window_text": "용어 설명\n\n<!-- PAGE_10 -->\n###### 가.  소프트웨어 의료기기(Software as a Medical Device, SaMD)\n\n<!-- PAGE_10 -->\n###### 하드웨어에 종속되지 않고 의료기기의 사용 목적에 부합하는 기능을\n\n<!-- PAGE_10 -->\n###### 가지며 독립적인 형태의 소프트웨어만으로 이루어진 의료기기이다.\n\n <!-- PAGE_10 -->\n###### 나.  디지털치료기기(Digital Therapeutics)\n\n<!-- PAGE_10 -->\n###### 식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인(민원인\n\n<!-- PAGE_10 -->\n###### 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방, 관리, 치료\n\n<!-- PAGE_10 -->\n###### 하기 위해 환자에게 근거 기반의 치료적 개입을 제공하는 소프트웨어\n\n<!-- PAGE_10 -->\n###### 다.  정신질환의 진단 및 통계 편람(Diagnostic and Statistical Manual of\n\n<!-- PAGE_10 -->\n###### 미국 정신의학협회(American Psychiatric Association, APA)에서 발행한\n\n<!-- PAGE_10 -->\n###### 정신질환의 신뢰할 만한 진단이 가능하도록 고안된 관련 기준들을\n\n<!-- PAGE_10 -->\n###### 통칭하는 정신질환 분류법이다.  DSM-5는 2013년도의 새로운 업데이트\n\n- - 4 -\n<!-- PAGE_11 -->\n##### 4.  현황\n\n<!-- PAGE_11 -->\n###### 가. ",
        "original_sentence": "디지털치료기기(Digital Therapeutics)\n\n<!-- PAGE_10 -->\n###### 식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인(민원인\n\n<!-- PAGE_10 -->\n###### 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방, 관리, 치료\n\n<!-- PAGE_10 -->\n###### 하기 위해 환자에게 근거 기반의 치료적 개입을 제공하는 소프트웨어\n\n<!-- PAGE_10 -->\n###### 다. "
      }
    },
    {
      "chunk_id": "chunk_434",
      "text": "정신질환의 진단 및 통계 편람(Diagnostic and Statistical Manual of\n\n<!-- PAGE_10 -->\n###### 미국 정신의학협회(American Psychiatric Association, APA)에서 발행한\n\n<!-- PAGE_10 -->\n###### 정신질환의 신뢰할 만한 진단이 가능하도록 고안된 관련 기준들을\n\n<!-- PAGE_10 -->\n###### 통칭하는 정신질환 분류법이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 433,
        "window_size": 3,
        "char_count": 236,
        "word_count": 38,
        "page_number": 10,
        "window_text": "소프트웨어 의료기기(Software as a Medical Device, SaMD)\n\n<!-- PAGE_10 -->\n###### 하드웨어에 종속되지 않고 의료기기의 사용 목적에 부합하는 기능을\n\n<!-- PAGE_10 -->\n###### 가지며 독립적인 형태의 소프트웨어만으로 이루어진 의료기기이다.\n\n <!-- PAGE_10 -->\n###### 나.  디지털치료기기(Digital Therapeutics)\n\n<!-- PAGE_10 -->\n###### 식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인(민원인\n\n<!-- PAGE_10 -->\n###### 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방, 관리, 치료\n\n<!-- PAGE_10 -->\n###### 하기 위해 환자에게 근거 기반의 치료적 개입을 제공하는 소프트웨어\n\n<!-- PAGE_10 -->\n###### 다.  정신질환의 진단 및 통계 편람(Diagnostic and Statistical Manual of\n\n<!-- PAGE_10 -->\n###### 미국 정신의학협회(American Psychiatric Association, APA)에서 발행한\n\n<!-- PAGE_10 -->\n###### 정신질환의 신뢰할 만한 진단이 가능하도록 고안된 관련 기준들을\n\n<!-- PAGE_10 -->\n###### 통칭하는 정신질환 분류법이다.  DSM-5는 2013년도의 새로운 업데이트\n\n- - 4 -\n<!-- PAGE_11 -->\n##### 4.  현황\n\n<!-- PAGE_11 -->\n###### 가.  우울장애 인구학적 특성\n\n<!-- PAGE_11 -->\n###### 질병관리청에서 실시한 2020년 국민건강영양조사에 따르면 전국\n\n<!-- PAGE_11 -->\n###### 만 19세 이상 성인을 대상으로 조사한 우울장애 유병률은 5.3%이었다.\n\n",
        "original_sentence": "정신질환의 진단 및 통계 편람(Diagnostic and Statistical Manual of\n\n<!-- PAGE_10 -->\n###### 미국 정신의학협회(American Psychiatric Association, APA)에서 발행한\n\n<!-- PAGE_10 -->\n###### 정신질환의 신뢰할 만한 진단이 가능하도록 고안된 관련 기준들을\n\n<!-- PAGE_10 -->\n###### 통칭하는 정신질환 분류법이다. "
      }
    },
    {
      "chunk_id": "chunk_435",
      "text": "DSM-5는 2013년도의 새로운 업데이트\n\n- - 4 -\n<!-- PAGE_11 -->\n##### 4. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 434,
        "window_size": 3,
        "char_count": 59,
        "word_count": 13,
        "page_number": 11,
        "window_text": "<!-- PAGE_10 -->\n###### 나.  디지털치료기기(Digital Therapeutics)\n\n<!-- PAGE_10 -->\n###### 식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인(민원인\n\n<!-- PAGE_10 -->\n###### 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방, 관리, 치료\n\n<!-- PAGE_10 -->\n###### 하기 위해 환자에게 근거 기반의 치료적 개입을 제공하는 소프트웨어\n\n<!-- PAGE_10 -->\n###### 다.  정신질환의 진단 및 통계 편람(Diagnostic and Statistical Manual of\n\n<!-- PAGE_10 -->\n###### 미국 정신의학협회(American Psychiatric Association, APA)에서 발행한\n\n<!-- PAGE_10 -->\n###### 정신질환의 신뢰할 만한 진단이 가능하도록 고안된 관련 기준들을\n\n<!-- PAGE_10 -->\n###### 통칭하는 정신질환 분류법이다.  DSM-5는 2013년도의 새로운 업데이트\n\n- - 4 -\n<!-- PAGE_11 -->\n##### 4.  현황\n\n<!-- PAGE_11 -->\n###### 가.  우울장애 인구학적 특성\n\n<!-- PAGE_11 -->\n###### 질병관리청에서 실시한 2020년 국민건강영양조사에 따르면 전국\n\n<!-- PAGE_11 -->\n###### 만 19세 이상 성인을 대상으로 조사한 우울장애 유병률은 5.3%이었다.\n\n <!-- PAGE_11 -->\n###### 남성이 4.4%, 여성이 6.2%로 남성보다 여성이 우울장애 유병률이 약\n\n<!-- PAGE_11 -->\n###### 1.4배 더 높다. ",
        "original_sentence": "DSM-5는 2013년도의 새로운 업데이트\n\n- - 4 -\n<!-- PAGE_11 -->\n##### 4. "
      }
    },
    {
      "chunk_id": "chunk_436",
      "text": "현황\n\n<!-- PAGE_11 -->\n###### 가. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 435,
        "window_size": 3,
        "char_count": 31,
        "word_count": 6,
        "page_number": 11,
        "window_text": "디지털치료기기(Digital Therapeutics)\n\n<!-- PAGE_10 -->\n###### 식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인(민원인\n\n<!-- PAGE_10 -->\n###### 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방, 관리, 치료\n\n<!-- PAGE_10 -->\n###### 하기 위해 환자에게 근거 기반의 치료적 개입을 제공하는 소프트웨어\n\n<!-- PAGE_10 -->\n###### 다.  정신질환의 진단 및 통계 편람(Diagnostic and Statistical Manual of\n\n<!-- PAGE_10 -->\n###### 미국 정신의학협회(American Psychiatric Association, APA)에서 발행한\n\n<!-- PAGE_10 -->\n###### 정신질환의 신뢰할 만한 진단이 가능하도록 고안된 관련 기준들을\n\n<!-- PAGE_10 -->\n###### 통칭하는 정신질환 분류법이다.  DSM-5는 2013년도의 새로운 업데이트\n\n- - 4 -\n<!-- PAGE_11 -->\n##### 4.  현황\n\n<!-- PAGE_11 -->\n###### 가.  우울장애 인구학적 특성\n\n<!-- PAGE_11 -->\n###### 질병관리청에서 실시한 2020년 국민건강영양조사에 따르면 전국\n\n<!-- PAGE_11 -->\n###### 만 19세 이상 성인을 대상으로 조사한 우울장애 유병률은 5.3%이었다.\n\n <!-- PAGE_11 -->\n###### 남성이 4.4%, 여성이 6.2%로 남성보다 여성이 우울장애 유병률이 약\n\n<!-- PAGE_11 -->\n###### 1.4배 더 높다.  연령별로 유병률을 살펴보면 전 연령층에서 우울장애가\n\n<!-- PAGE_11 -->\n###### 발병하나, 19~29세에서 유병률이 8.3%로 가장 높고, 30~39세 6.8%,\n\n<!-- PAGE_11 -->\n###### 40~49세 4.9%, 50~59세 2.4%, 60~69세 4.3%, 70세 이상 5.3%로 연령이\n\n<!-- PAGE_11 -->\n###### 증가할수록 유병률이 감소하다가 50대 이후 다시 증가하는 U자형\n\n<!-- PAGE_11 -->\n###### 모양이다. ",
        "original_sentence": "현황\n\n<!-- PAGE_11 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_437",
      "text": "우울장애 인구학적 특성\n\n<!-- PAGE_11 -->\n###### 질병관리청에서 실시한 2020년 국민건강영양조사에 따르면 전국\n\n<!-- PAGE_11 -->\n###### 만 19세 이상 성인을 대상으로 조사한 우울장애 유병률은 5.3%이었다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 436,
        "window_size": 3,
        "char_count": 140,
        "word_count": 26,
        "page_number": 11,
        "window_text": "정신질환의 진단 및 통계 편람(Diagnostic and Statistical Manual of\n\n<!-- PAGE_10 -->\n###### 미국 정신의학협회(American Psychiatric Association, APA)에서 발행한\n\n<!-- PAGE_10 -->\n###### 정신질환의 신뢰할 만한 진단이 가능하도록 고안된 관련 기준들을\n\n<!-- PAGE_10 -->\n###### 통칭하는 정신질환 분류법이다.  DSM-5는 2013년도의 새로운 업데이트\n\n- - 4 -\n<!-- PAGE_11 -->\n##### 4.  현황\n\n<!-- PAGE_11 -->\n###### 가.  우울장애 인구학적 특성\n\n<!-- PAGE_11 -->\n###### 질병관리청에서 실시한 2020년 국민건강영양조사에 따르면 전국\n\n<!-- PAGE_11 -->\n###### 만 19세 이상 성인을 대상으로 조사한 우울장애 유병률은 5.3%이었다.\n\n <!-- PAGE_11 -->\n###### 남성이 4.4%, 여성이 6.2%로 남성보다 여성이 우울장애 유병률이 약\n\n<!-- PAGE_11 -->\n###### 1.4배 더 높다.  연령별로 유병률을 살펴보면 전 연령층에서 우울장애가\n\n<!-- PAGE_11 -->\n###### 발병하나, 19~29세에서 유병률이 8.3%로 가장 높고, 30~39세 6.8%,\n\n<!-- PAGE_11 -->\n###### 40~49세 4.9%, 50~59세 2.4%, 60~69세 4.3%, 70세 이상 5.3%로 연령이\n\n<!-- PAGE_11 -->\n###### 증가할수록 유병률이 감소하다가 50대 이후 다시 증가하는 U자형\n\n<!-- PAGE_11 -->\n###### 모양이다.  성별 기준으로는 남성 30~39세 6.5%, 여성 19~29세에서\n\n<!-- PAGE_11 -->\n###### 11.3%로 가장 우울장애 유병률이 높다. ",
        "original_sentence": "우울장애 인구학적 특성\n\n<!-- PAGE_11 -->\n###### 질병관리청에서 실시한 2020년 국민건강영양조사에 따르면 전국\n\n<!-- PAGE_11 -->\n###### 만 19세 이상 성인을 대상으로 조사한 우울장애 유병률은 5.3%이었다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_438",
      "text": "<!-- PAGE_11 -->\n###### 남성이 4.4%, 여성이 6.2%로 남성보다 여성이 우울장애 유병률이 약\n\n<!-- PAGE_11 -->\n###### 1.4배 더 높다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 437,
        "window_size": 3,
        "char_count": 101,
        "word_count": 20,
        "page_number": 11,
        "window_text": "DSM-5는 2013년도의 새로운 업데이트\n\n- - 4 -\n<!-- PAGE_11 -->\n##### 4.  현황\n\n<!-- PAGE_11 -->\n###### 가.  우울장애 인구학적 특성\n\n<!-- PAGE_11 -->\n###### 질병관리청에서 실시한 2020년 국민건강영양조사에 따르면 전국\n\n<!-- PAGE_11 -->\n###### 만 19세 이상 성인을 대상으로 조사한 우울장애 유병률은 5.3%이었다.\n\n <!-- PAGE_11 -->\n###### 남성이 4.4%, 여성이 6.2%로 남성보다 여성이 우울장애 유병률이 약\n\n<!-- PAGE_11 -->\n###### 1.4배 더 높다.  연령별로 유병률을 살펴보면 전 연령층에서 우울장애가\n\n<!-- PAGE_11 -->\n###### 발병하나, 19~29세에서 유병률이 8.3%로 가장 높고, 30~39세 6.8%,\n\n<!-- PAGE_11 -->\n###### 40~49세 4.9%, 50~59세 2.4%, 60~69세 4.3%, 70세 이상 5.3%로 연령이\n\n<!-- PAGE_11 -->\n###### 증가할수록 유병률이 감소하다가 50대 이후 다시 증가하는 U자형\n\n<!-- PAGE_11 -->\n###### 모양이다.  성별 기준으로는 남성 30~39세 6.5%, 여성 19~29세에서\n\n<!-- PAGE_11 -->\n###### 11.3%로 가장 우울장애 유병률이 높다.  다만 우울장애 의사 진단\n\n<!-- PAGE_11 -->\n###### 경험률은 4.9%이며, 남성이 3.0%, 여성이 6.8%로 여성이 2.3배 높다.\n\n",
        "original_sentence": "<!-- PAGE_11 -->\n###### 남성이 4.4%, 여성이 6.2%로 남성보다 여성이 우울장애 유병률이 약\n\n<!-- PAGE_11 -->\n###### 1.4배 더 높다. "
      }
    },
    {
      "chunk_id": "chunk_439",
      "text": "연령별로 유병률을 살펴보면 전 연령층에서 우울장애가\n\n<!-- PAGE_11 -->\n###### 발병하나, 19~29세에서 유병률이 8.3%로 가장 높고, 30~39세 6.8%,\n\n<!-- PAGE_11 -->\n###### 40~49세 4.9%, 50~59세 2.4%, 60~69세 4.3%, 70세 이상 5.3%로 연령이\n\n<!-- PAGE_11 -->\n###### 증가할수록 유병률이 감소하다가 50대 이후 다시 증가하는 U자형\n\n<!-- PAGE_11 -->\n###### 모양이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 438,
        "window_size": 3,
        "char_count": 273,
        "word_count": 49,
        "page_number": 11,
        "window_text": "현황\n\n<!-- PAGE_11 -->\n###### 가.  우울장애 인구학적 특성\n\n<!-- PAGE_11 -->\n###### 질병관리청에서 실시한 2020년 국민건강영양조사에 따르면 전국\n\n<!-- PAGE_11 -->\n###### 만 19세 이상 성인을 대상으로 조사한 우울장애 유병률은 5.3%이었다.\n\n <!-- PAGE_11 -->\n###### 남성이 4.4%, 여성이 6.2%로 남성보다 여성이 우울장애 유병률이 약\n\n<!-- PAGE_11 -->\n###### 1.4배 더 높다.  연령별로 유병률을 살펴보면 전 연령층에서 우울장애가\n\n<!-- PAGE_11 -->\n###### 발병하나, 19~29세에서 유병률이 8.3%로 가장 높고, 30~39세 6.8%,\n\n<!-- PAGE_11 -->\n###### 40~49세 4.9%, 50~59세 2.4%, 60~69세 4.3%, 70세 이상 5.3%로 연령이\n\n<!-- PAGE_11 -->\n###### 증가할수록 유병률이 감소하다가 50대 이후 다시 증가하는 U자형\n\n<!-- PAGE_11 -->\n###### 모양이다.  성별 기준으로는 남성 30~39세 6.5%, 여성 19~29세에서\n\n<!-- PAGE_11 -->\n###### 11.3%로 가장 우울장애 유병률이 높다.  다만 우울장애 의사 진단\n\n<!-- PAGE_11 -->\n###### 경험률은 4.9%이며, 남성이 3.0%, 여성이 6.8%로 여성이 2.3배 높다.\n\n <!-- PAGE_11 -->\n###### 70세 이상에서 6.6%로 우울장애 의사 진단 경험률이 가장 높으며,\n\n<!-- PAGE_11 -->\n###### 연령별로는 유병률과 마찬가지로 U자형 모양를 띄고 있다. ",
        "original_sentence": "연령별로 유병률을 살펴보면 전 연령층에서 우울장애가\n\n<!-- PAGE_11 -->\n###### 발병하나, 19~29세에서 유병률이 8.3%로 가장 높고, 30~39세 6.8%,\n\n<!-- PAGE_11 -->\n###### 40~49세 4.9%, 50~59세 2.4%, 60~69세 4.3%, 70세 이상 5.3%로 연령이\n\n<!-- PAGE_11 -->\n###### 증가할수록 유병률이 감소하다가 50대 이후 다시 증가하는 U자형\n\n<!-- PAGE_11 -->\n###### 모양이다. "
      }
    },
    {
      "chunk_id": "chunk_440",
      "text": "성별 기준으로는 남성 30~39세 6.5%, 여성 19~29세에서\n\n<!-- PAGE_11 -->\n###### 11.3%로 가장 우울장애 유병률이 높다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 439,
        "window_size": 3,
        "char_count": 86,
        "word_count": 16,
        "page_number": 11,
        "window_text": "우울장애 인구학적 특성\n\n<!-- PAGE_11 -->\n###### 질병관리청에서 실시한 2020년 국민건강영양조사에 따르면 전국\n\n<!-- PAGE_11 -->\n###### 만 19세 이상 성인을 대상으로 조사한 우울장애 유병률은 5.3%이었다.\n\n <!-- PAGE_11 -->\n###### 남성이 4.4%, 여성이 6.2%로 남성보다 여성이 우울장애 유병률이 약\n\n<!-- PAGE_11 -->\n###### 1.4배 더 높다.  연령별로 유병률을 살펴보면 전 연령층에서 우울장애가\n\n<!-- PAGE_11 -->\n###### 발병하나, 19~29세에서 유병률이 8.3%로 가장 높고, 30~39세 6.8%,\n\n<!-- PAGE_11 -->\n###### 40~49세 4.9%, 50~59세 2.4%, 60~69세 4.3%, 70세 이상 5.3%로 연령이\n\n<!-- PAGE_11 -->\n###### 증가할수록 유병률이 감소하다가 50대 이후 다시 증가하는 U자형\n\n<!-- PAGE_11 -->\n###### 모양이다.  성별 기준으로는 남성 30~39세 6.5%, 여성 19~29세에서\n\n<!-- PAGE_11 -->\n###### 11.3%로 가장 우울장애 유병률이 높다.  다만 우울장애 의사 진단\n\n<!-- PAGE_11 -->\n###### 경험률은 4.9%이며, 남성이 3.0%, 여성이 6.8%로 여성이 2.3배 높다.\n\n <!-- PAGE_11 -->\n###### 70세 이상에서 6.6%로 우울장애 의사 진단 경험률이 가장 높으며,\n\n<!-- PAGE_11 -->\n###### 연령별로는 유병률과 마찬가지로 U자형 모양를 띄고 있다.  성별 기준\n\n<!-- PAGE_11 -->\n###### 으로는 남성은 19~29세 4.7%, 여성은 60~69세 8.8%로 우울장애 의사\n\n<!-- PAGE_11 -->\n###### 진단 경험률이 가장 높다. ",
        "original_sentence": "성별 기준으로는 남성 30~39세 6.5%, 여성 19~29세에서\n\n<!-- PAGE_11 -->\n###### 11.3%로 가장 우울장애 유병률이 높다. "
      }
    },
    {
      "chunk_id": "chunk_441",
      "text": "다만 우울장애 의사 진단\n\n<!-- PAGE_11 -->\n###### 경험률은 4.9%이며, 남성이 3.0%, 여성이 6.8%로 여성이 2.3배 높다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 440,
        "window_size": 3,
        "char_count": 86,
        "word_count": 17,
        "page_number": 11,
        "window_text": "<!-- PAGE_11 -->\n###### 남성이 4.4%, 여성이 6.2%로 남성보다 여성이 우울장애 유병률이 약\n\n<!-- PAGE_11 -->\n###### 1.4배 더 높다.  연령별로 유병률을 살펴보면 전 연령층에서 우울장애가\n\n<!-- PAGE_11 -->\n###### 발병하나, 19~29세에서 유병률이 8.3%로 가장 높고, 30~39세 6.8%,\n\n<!-- PAGE_11 -->\n###### 40~49세 4.9%, 50~59세 2.4%, 60~69세 4.3%, 70세 이상 5.3%로 연령이\n\n<!-- PAGE_11 -->\n###### 증가할수록 유병률이 감소하다가 50대 이후 다시 증가하는 U자형\n\n<!-- PAGE_11 -->\n###### 모양이다.  성별 기준으로는 남성 30~39세 6.5%, 여성 19~29세에서\n\n<!-- PAGE_11 -->\n###### 11.3%로 가장 우울장애 유병률이 높다.  다만 우울장애 의사 진단\n\n<!-- PAGE_11 -->\n###### 경험률은 4.9%이며, 남성이 3.0%, 여성이 6.8%로 여성이 2.3배 높다.\n\n <!-- PAGE_11 -->\n###### 70세 이상에서 6.6%로 우울장애 의사 진단 경험률이 가장 높으며,\n\n<!-- PAGE_11 -->\n###### 연령별로는 유병률과 마찬가지로 U자형 모양를 띄고 있다.  성별 기준\n\n<!-- PAGE_11 -->\n###### 으로는 남성은 19~29세 4.7%, 여성은 60~69세 8.8%로 우울장애 의사\n\n<!-- PAGE_11 -->\n###### 진단 경험률이 가장 높다.  2008년 우울장애 의사 진단 경험률이 2.9%에서\n\n<!-- PAGE_11 -->\n###### 2020년 4.9%에 이르기까지 우울장애 의사 진단 경험률이 꾸준하게 증가하고\n\n<!-- PAGE_11 -->\n###### 있으며, 이와 더불어 자살 계획률과 정신 문제 상담 경험률도 증가하고\n\n<!-- PAGE_11 -->\n###### 있다.\n\n",
        "original_sentence": "다만 우울장애 의사 진단\n\n<!-- PAGE_11 -->\n###### 경험률은 4.9%이며, 남성이 3.0%, 여성이 6.8%로 여성이 2.3배 높다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_442",
      "text": "<!-- PAGE_11 -->\n###### 70세 이상에서 6.6%로 우울장애 의사 진단 경험률이 가장 높으며,\n\n<!-- PAGE_11 -->\n###### 연령별로는 유병률과 마찬가지로 U자형 모양를 띄고 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 441,
        "window_size": 3,
        "char_count": 120,
        "word_count": 24,
        "page_number": 11,
        "window_text": "연령별로 유병률을 살펴보면 전 연령층에서 우울장애가\n\n<!-- PAGE_11 -->\n###### 발병하나, 19~29세에서 유병률이 8.3%로 가장 높고, 30~39세 6.8%,\n\n<!-- PAGE_11 -->\n###### 40~49세 4.9%, 50~59세 2.4%, 60~69세 4.3%, 70세 이상 5.3%로 연령이\n\n<!-- PAGE_11 -->\n###### 증가할수록 유병률이 감소하다가 50대 이후 다시 증가하는 U자형\n\n<!-- PAGE_11 -->\n###### 모양이다.  성별 기준으로는 남성 30~39세 6.5%, 여성 19~29세에서\n\n<!-- PAGE_11 -->\n###### 11.3%로 가장 우울장애 유병률이 높다.  다만 우울장애 의사 진단\n\n<!-- PAGE_11 -->\n###### 경험률은 4.9%이며, 남성이 3.0%, 여성이 6.8%로 여성이 2.3배 높다.\n\n <!-- PAGE_11 -->\n###### 70세 이상에서 6.6%로 우울장애 의사 진단 경험률이 가장 높으며,\n\n<!-- PAGE_11 -->\n###### 연령별로는 유병률과 마찬가지로 U자형 모양를 띄고 있다.  성별 기준\n\n<!-- PAGE_11 -->\n###### 으로는 남성은 19~29세 4.7%, 여성은 60~69세 8.8%로 우울장애 의사\n\n<!-- PAGE_11 -->\n###### 진단 경험률이 가장 높다.  2008년 우울장애 의사 진단 경험률이 2.9%에서\n\n<!-- PAGE_11 -->\n###### 2020년 4.9%에 이르기까지 우울장애 의사 진단 경험률이 꾸준하게 증가하고\n\n<!-- PAGE_11 -->\n###### 있으며, 이와 더불어 자살 계획률과 정신 문제 상담 경험률도 증가하고\n\n<!-- PAGE_11 -->\n###### 있다.\n\n <!-- PAGE_11 -->\n###### 우울장애는 다른 정신질환과 동반 위험이 크다. ",
        "original_sentence": "<!-- PAGE_11 -->\n###### 70세 이상에서 6.6%로 우울장애 의사 진단 경험률이 가장 높으며,\n\n<!-- PAGE_11 -->\n###### 연령별로는 유병률과 마찬가지로 U자형 모양를 띄고 있다. "
      }
    },
    {
      "chunk_id": "chunk_443",
      "text": "성별 기준\n\n<!-- PAGE_11 -->\n###### 으로는 남성은 19~29세 4.7%, 여성은 60~69세 8.8%로 우울장애 의사\n\n<!-- PAGE_11 -->\n###### 진단 경험률이 가장 높다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 442,
        "window_size": 3,
        "char_count": 117,
        "word_count": 23,
        "page_number": 11,
        "window_text": "성별 기준으로는 남성 30~39세 6.5%, 여성 19~29세에서\n\n<!-- PAGE_11 -->\n###### 11.3%로 가장 우울장애 유병률이 높다.  다만 우울장애 의사 진단\n\n<!-- PAGE_11 -->\n###### 경험률은 4.9%이며, 남성이 3.0%, 여성이 6.8%로 여성이 2.3배 높다.\n\n <!-- PAGE_11 -->\n###### 70세 이상에서 6.6%로 우울장애 의사 진단 경험률이 가장 높으며,\n\n<!-- PAGE_11 -->\n###### 연령별로는 유병률과 마찬가지로 U자형 모양를 띄고 있다.  성별 기준\n\n<!-- PAGE_11 -->\n###### 으로는 남성은 19~29세 4.7%, 여성은 60~69세 8.8%로 우울장애 의사\n\n<!-- PAGE_11 -->\n###### 진단 경험률이 가장 높다.  2008년 우울장애 의사 진단 경험률이 2.9%에서\n\n<!-- PAGE_11 -->\n###### 2020년 4.9%에 이르기까지 우울장애 의사 진단 경험률이 꾸준하게 증가하고\n\n<!-- PAGE_11 -->\n###### 있으며, 이와 더불어 자살 계획률과 정신 문제 상담 경험률도 증가하고\n\n<!-- PAGE_11 -->\n###### 있다.\n\n <!-- PAGE_11 -->\n###### 우울장애는 다른 정신질환과 동반 위험이 크다.  대표적으로 알코올\n\n<!-- PAGE_11 -->\n###### 중독과 같은 물질 사용 장애(substance use disorder), 공황장애(panic\n\n<!-- PAGE_11 -->\n###### disorder)를 비롯해 불안장애(anxiety disorder), 강박장애(obsessive-\n\n- - 5 -\n<!-- PAGE_12 -->\n###### compulsive disorder), 사회불안장애(social anxiety disorder)등과 동반\n\n<!-- PAGE_12 -->\n###### 이환 위험성이 높다. ",
        "original_sentence": "성별 기준\n\n<!-- PAGE_11 -->\n###### 으로는 남성은 19~29세 4.7%, 여성은 60~69세 8.8%로 우울장애 의사\n\n<!-- PAGE_11 -->\n###### 진단 경험률이 가장 높다. "
      }
    },
    {
      "chunk_id": "chunk_444",
      "text": "2008년 우울장애 의사 진단 경험률이 2.9%에서\n\n<!-- PAGE_11 -->\n###### 2020년 4.9%에 이르기까지 우울장애 의사 진단 경험률이 꾸준하게 증가하고\n\n<!-- PAGE_11 -->\n###### 있으며, 이와 더불어 자살 계획률과 정신 문제 상담 경험률도 증가하고\n\n<!-- PAGE_11 -->\n###### 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 443,
        "window_size": 3,
        "char_count": 192,
        "word_count": 38,
        "page_number": 11,
        "window_text": "다만 우울장애 의사 진단\n\n<!-- PAGE_11 -->\n###### 경험률은 4.9%이며, 남성이 3.0%, 여성이 6.8%로 여성이 2.3배 높다.\n\n <!-- PAGE_11 -->\n###### 70세 이상에서 6.6%로 우울장애 의사 진단 경험률이 가장 높으며,\n\n<!-- PAGE_11 -->\n###### 연령별로는 유병률과 마찬가지로 U자형 모양를 띄고 있다.  성별 기준\n\n<!-- PAGE_11 -->\n###### 으로는 남성은 19~29세 4.7%, 여성은 60~69세 8.8%로 우울장애 의사\n\n<!-- PAGE_11 -->\n###### 진단 경험률이 가장 높다.  2008년 우울장애 의사 진단 경험률이 2.9%에서\n\n<!-- PAGE_11 -->\n###### 2020년 4.9%에 이르기까지 우울장애 의사 진단 경험률이 꾸준하게 증가하고\n\n<!-- PAGE_11 -->\n###### 있으며, 이와 더불어 자살 계획률과 정신 문제 상담 경험률도 증가하고\n\n<!-- PAGE_11 -->\n###### 있다.\n\n <!-- PAGE_11 -->\n###### 우울장애는 다른 정신질환과 동반 위험이 크다.  대표적으로 알코올\n\n<!-- PAGE_11 -->\n###### 중독과 같은 물질 사용 장애(substance use disorder), 공황장애(panic\n\n<!-- PAGE_11 -->\n###### disorder)를 비롯해 불안장애(anxiety disorder), 강박장애(obsessive-\n\n- - 5 -\n<!-- PAGE_12 -->\n###### compulsive disorder), 사회불안장애(social anxiety disorder)등과 동반\n\n<!-- PAGE_12 -->\n###### 이환 위험성이 높다.  이러한 동반 질환은 진단과 치료에 부정적인\n\n<!-- PAGE_12 -->\n###### 영향을 끼치며, 동반 질환도 함께 치료해야 한다.\n\n",
        "original_sentence": "2008년 우울장애 의사 진단 경험률이 2.9%에서\n\n<!-- PAGE_11 -->\n###### 2020년 4.9%에 이르기까지 우울장애 의사 진단 경험률이 꾸준하게 증가하고\n\n<!-- PAGE_11 -->\n###### 있으며, 이와 더불어 자살 계획률과 정신 문제 상담 경험률도 증가하고\n\n<!-- PAGE_11 -->\n###### 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_445",
      "text": "<!-- PAGE_11 -->\n###### 우울장애는 다른 정신질환과 동반 위험이 크다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 444,
        "window_size": 3,
        "char_count": 50,
        "word_count": 10,
        "page_number": 11,
        "window_text": "<!-- PAGE_11 -->\n###### 70세 이상에서 6.6%로 우울장애 의사 진단 경험률이 가장 높으며,\n\n<!-- PAGE_11 -->\n###### 연령별로는 유병률과 마찬가지로 U자형 모양를 띄고 있다.  성별 기준\n\n<!-- PAGE_11 -->\n###### 으로는 남성은 19~29세 4.7%, 여성은 60~69세 8.8%로 우울장애 의사\n\n<!-- PAGE_11 -->\n###### 진단 경험률이 가장 높다.  2008년 우울장애 의사 진단 경험률이 2.9%에서\n\n<!-- PAGE_11 -->\n###### 2020년 4.9%에 이르기까지 우울장애 의사 진단 경험률이 꾸준하게 증가하고\n\n<!-- PAGE_11 -->\n###### 있으며, 이와 더불어 자살 계획률과 정신 문제 상담 경험률도 증가하고\n\n<!-- PAGE_11 -->\n###### 있다.\n\n <!-- PAGE_11 -->\n###### 우울장애는 다른 정신질환과 동반 위험이 크다.  대표적으로 알코올\n\n<!-- PAGE_11 -->\n###### 중독과 같은 물질 사용 장애(substance use disorder), 공황장애(panic\n\n<!-- PAGE_11 -->\n###### disorder)를 비롯해 불안장애(anxiety disorder), 강박장애(obsessive-\n\n- - 5 -\n<!-- PAGE_12 -->\n###### compulsive disorder), 사회불안장애(social anxiety disorder)등과 동반\n\n<!-- PAGE_12 -->\n###### 이환 위험성이 높다.  이러한 동반 질환은 진단과 치료에 부정적인\n\n<!-- PAGE_12 -->\n###### 영향을 끼치며, 동반 질환도 함께 치료해야 한다.\n\n <!-- PAGE_12 -->\n###### 나. ",
        "original_sentence": "<!-- PAGE_11 -->\n###### 우울장애는 다른 정신질환과 동반 위험이 크다. "
      }
    },
    {
      "chunk_id": "chunk_446",
      "text": "대표적으로 알코올\n\n<!-- PAGE_11 -->\n###### 중독과 같은 물질 사용 장애(substance use disorder), 공황장애(panic\n\n<!-- PAGE_11 -->\n###### disorder)를 비롯해 불안장애(anxiety disorder), 강박장애(obsessive-\n\n- - 5 -\n<!-- PAGE_12 -->\n###### compulsive disorder), 사회불안장애(social anxiety disorder)등과 동반\n\n<!-- PAGE_12 -->\n###### 이환 위험성이 높다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 445,
        "window_size": 3,
        "char_count": 296,
        "word_count": 44,
        "page_number": 11,
        "window_text": "성별 기준\n\n<!-- PAGE_11 -->\n###### 으로는 남성은 19~29세 4.7%, 여성은 60~69세 8.8%로 우울장애 의사\n\n<!-- PAGE_11 -->\n###### 진단 경험률이 가장 높다.  2008년 우울장애 의사 진단 경험률이 2.9%에서\n\n<!-- PAGE_11 -->\n###### 2020년 4.9%에 이르기까지 우울장애 의사 진단 경험률이 꾸준하게 증가하고\n\n<!-- PAGE_11 -->\n###### 있으며, 이와 더불어 자살 계획률과 정신 문제 상담 경험률도 증가하고\n\n<!-- PAGE_11 -->\n###### 있다.\n\n <!-- PAGE_11 -->\n###### 우울장애는 다른 정신질환과 동반 위험이 크다.  대표적으로 알코올\n\n<!-- PAGE_11 -->\n###### 중독과 같은 물질 사용 장애(substance use disorder), 공황장애(panic\n\n<!-- PAGE_11 -->\n###### disorder)를 비롯해 불안장애(anxiety disorder), 강박장애(obsessive-\n\n- - 5 -\n<!-- PAGE_12 -->\n###### compulsive disorder), 사회불안장애(social anxiety disorder)등과 동반\n\n<!-- PAGE_12 -->\n###### 이환 위험성이 높다.  이러한 동반 질환은 진단과 치료에 부정적인\n\n<!-- PAGE_12 -->\n###### 영향을 끼치며, 동반 질환도 함께 치료해야 한다.\n\n <!-- PAGE_12 -->\n###### 나.  우울장애 진단 절차/과정\n\n<!-- PAGE_12 -->\n###### DSM-5에서 기분장애(mood disorder)를 양극성 및 관련 장애(bipolar\n\n<!-- PAGE_12 -->\n###### and related disorder)와 우울장애(depressive disorder)로 분류하고 있으며,\n\n<!-- PAGE_12 -->\n###### 우울장애는 주요우울장애(major depressive disorder), 지속성 우울장애\n\n<!-- PAGE_12 -->\n###### (persistent depressive disorder), 월경 전 불쾌감 장애(premenstrual\n\n<!-- PAGE_12 -->\n###### dysphoric\n\n<!-- PAGE_12 -->\n###### disorder)\n\n<!-- PAGE_12 -->\n###### 등으로\n\n<!-- PAGE_12 -->\n###### 구분하고\n\n<!-- PAGE_12 -->\n###### 있다.\n\n",
        "original_sentence": "대표적으로 알코올\n\n<!-- PAGE_11 -->\n###### 중독과 같은 물질 사용 장애(substance use disorder), 공황장애(panic\n\n<!-- PAGE_11 -->\n###### disorder)를 비롯해 불안장애(anxiety disorder), 강박장애(obsessive-\n\n- - 5 -\n<!-- PAGE_12 -->\n###### compulsive disorder), 사회불안장애(social anxiety disorder)등과 동반\n\n<!-- PAGE_12 -->\n###### 이환 위험성이 높다. "
      }
    },
    {
      "chunk_id": "chunk_447",
      "text": "이러한 동반 질환은 진단과 치료에 부정적인\n\n<!-- PAGE_12 -->\n###### 영향을 끼치며, 동반 질환도 함께 치료해야 한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 446,
        "window_size": 3,
        "char_count": 78,
        "word_count": 17,
        "page_number": 12,
        "window_text": "2008년 우울장애 의사 진단 경험률이 2.9%에서\n\n<!-- PAGE_11 -->\n###### 2020년 4.9%에 이르기까지 우울장애 의사 진단 경험률이 꾸준하게 증가하고\n\n<!-- PAGE_11 -->\n###### 있으며, 이와 더불어 자살 계획률과 정신 문제 상담 경험률도 증가하고\n\n<!-- PAGE_11 -->\n###### 있다.\n\n <!-- PAGE_11 -->\n###### 우울장애는 다른 정신질환과 동반 위험이 크다.  대표적으로 알코올\n\n<!-- PAGE_11 -->\n###### 중독과 같은 물질 사용 장애(substance use disorder), 공황장애(panic\n\n<!-- PAGE_11 -->\n###### disorder)를 비롯해 불안장애(anxiety disorder), 강박장애(obsessive-\n\n- - 5 -\n<!-- PAGE_12 -->\n###### compulsive disorder), 사회불안장애(social anxiety disorder)등과 동반\n\n<!-- PAGE_12 -->\n###### 이환 위험성이 높다.  이러한 동반 질환은 진단과 치료에 부정적인\n\n<!-- PAGE_12 -->\n###### 영향을 끼치며, 동반 질환도 함께 치료해야 한다.\n\n <!-- PAGE_12 -->\n###### 나.  우울장애 진단 절차/과정\n\n<!-- PAGE_12 -->\n###### DSM-5에서 기분장애(mood disorder)를 양극성 및 관련 장애(bipolar\n\n<!-- PAGE_12 -->\n###### and related disorder)와 우울장애(depressive disorder)로 분류하고 있으며,\n\n<!-- PAGE_12 -->\n###### 우울장애는 주요우울장애(major depressive disorder), 지속성 우울장애\n\n<!-- PAGE_12 -->\n###### (persistent depressive disorder), 월경 전 불쾌감 장애(premenstrual\n\n<!-- PAGE_12 -->\n###### dysphoric\n\n<!-- PAGE_12 -->\n###### disorder)\n\n<!-- PAGE_12 -->\n###### 등으로\n\n<!-- PAGE_12 -->\n###### 구분하고\n\n<!-- PAGE_12 -->\n###### 있다.\n\n <!-- PAGE_12 -->\n###### Patient\n\n<!-- PAGE_12 -->\n###### Health\n\n<!-- PAGE_12 -->\n###### Questionnaire-9 (PHQ-9)과 같은 우울장애 선별도구로 선별 검사할 수\n\n<!-- PAGE_12 -->\n###### 있으며, 진단은 DSM-5의 진단기준을 적용한다.\n\n",
        "original_sentence": "이러한 동반 질환은 진단과 치료에 부정적인\n\n<!-- PAGE_12 -->\n###### 영향을 끼치며, 동반 질환도 함께 치료해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_448",
      "text": "<!-- PAGE_12 -->\n###### 나. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 447,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 12,
        "window_text": "<!-- PAGE_11 -->\n###### 우울장애는 다른 정신질환과 동반 위험이 크다.  대표적으로 알코올\n\n<!-- PAGE_11 -->\n###### 중독과 같은 물질 사용 장애(substance use disorder), 공황장애(panic\n\n<!-- PAGE_11 -->\n###### disorder)를 비롯해 불안장애(anxiety disorder), 강박장애(obsessive-\n\n- - 5 -\n<!-- PAGE_12 -->\n###### compulsive disorder), 사회불안장애(social anxiety disorder)등과 동반\n\n<!-- PAGE_12 -->\n###### 이환 위험성이 높다.  이러한 동반 질환은 진단과 치료에 부정적인\n\n<!-- PAGE_12 -->\n###### 영향을 끼치며, 동반 질환도 함께 치료해야 한다.\n\n <!-- PAGE_12 -->\n###### 나.  우울장애 진단 절차/과정\n\n<!-- PAGE_12 -->\n###### DSM-5에서 기분장애(mood disorder)를 양극성 및 관련 장애(bipolar\n\n<!-- PAGE_12 -->\n###### and related disorder)와 우울장애(depressive disorder)로 분류하고 있으며,\n\n<!-- PAGE_12 -->\n###### 우울장애는 주요우울장애(major depressive disorder), 지속성 우울장애\n\n<!-- PAGE_12 -->\n###### (persistent depressive disorder), 월경 전 불쾌감 장애(premenstrual\n\n<!-- PAGE_12 -->\n###### dysphoric\n\n<!-- PAGE_12 -->\n###### disorder)\n\n<!-- PAGE_12 -->\n###### 등으로\n\n<!-- PAGE_12 -->\n###### 구분하고\n\n<!-- PAGE_12 -->\n###### 있다.\n\n <!-- PAGE_12 -->\n###### Patient\n\n<!-- PAGE_12 -->\n###### Health\n\n<!-- PAGE_12 -->\n###### Questionnaire-9 (PHQ-9)과 같은 우울장애 선별도구로 선별 검사할 수\n\n<!-- PAGE_12 -->\n###### 있으며, 진단은 DSM-5의 진단기준을 적용한다.\n\n <!-- PAGE_12 -->\n###### 주요우울장애 진단을 위해서는 다음의 증상 중 5가지 이상이 2주일\n\n<!-- PAGE_12 -->\n###### 이상 지속되었는지 확인해야 한다. ",
        "original_sentence": "<!-- PAGE_12 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_449",
      "text": "우울장애 진단 절차/과정\n\n<!-- PAGE_12 -->\n###### DSM-5에서 기분장애(mood disorder)를 양극성 및 관련 장애(bipolar\n\n<!-- PAGE_12 -->\n###### and related disorder)와 우울장애(depressive disorder)로 분류하고 있으며,\n\n<!-- PAGE_12 -->\n###### 우울장애는 주요우울장애(major depressive disorder), 지속성 우울장애\n\n<!-- PAGE_12 -->\n###### (persistent depressive disorder), 월경 전 불쾌감 장애(premenstrual\n\n<!-- PAGE_12 -->\n###### dysphoric\n\n<!-- PAGE_12 -->\n###### disorder)\n\n<!-- PAGE_12 -->\n###### 등으로\n\n<!-- PAGE_12 -->\n###### 구분하고\n\n<!-- PAGE_12 -->\n###### 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 448,
        "window_size": 3,
        "char_count": 491,
        "word_count": 71,
        "page_number": 12,
        "window_text": "대표적으로 알코올\n\n<!-- PAGE_11 -->\n###### 중독과 같은 물질 사용 장애(substance use disorder), 공황장애(panic\n\n<!-- PAGE_11 -->\n###### disorder)를 비롯해 불안장애(anxiety disorder), 강박장애(obsessive-\n\n- - 5 -\n<!-- PAGE_12 -->\n###### compulsive disorder), 사회불안장애(social anxiety disorder)등과 동반\n\n<!-- PAGE_12 -->\n###### 이환 위험성이 높다.  이러한 동반 질환은 진단과 치료에 부정적인\n\n<!-- PAGE_12 -->\n###### 영향을 끼치며, 동반 질환도 함께 치료해야 한다.\n\n <!-- PAGE_12 -->\n###### 나.  우울장애 진단 절차/과정\n\n<!-- PAGE_12 -->\n###### DSM-5에서 기분장애(mood disorder)를 양극성 및 관련 장애(bipolar\n\n<!-- PAGE_12 -->\n###### and related disorder)와 우울장애(depressive disorder)로 분류하고 있으며,\n\n<!-- PAGE_12 -->\n###### 우울장애는 주요우울장애(major depressive disorder), 지속성 우울장애\n\n<!-- PAGE_12 -->\n###### (persistent depressive disorder), 월경 전 불쾌감 장애(premenstrual\n\n<!-- PAGE_12 -->\n###### dysphoric\n\n<!-- PAGE_12 -->\n###### disorder)\n\n<!-- PAGE_12 -->\n###### 등으로\n\n<!-- PAGE_12 -->\n###### 구분하고\n\n<!-- PAGE_12 -->\n###### 있다.\n\n <!-- PAGE_12 -->\n###### Patient\n\n<!-- PAGE_12 -->\n###### Health\n\n<!-- PAGE_12 -->\n###### Questionnaire-9 (PHQ-9)과 같은 우울장애 선별도구로 선별 검사할 수\n\n<!-- PAGE_12 -->\n###### 있으며, 진단은 DSM-5의 진단기준을 적용한다.\n\n <!-- PAGE_12 -->\n###### 주요우울장애 진단을 위해서는 다음의 증상 중 5가지 이상이 2주일\n\n<!-- PAGE_12 -->\n###### 이상 지속되었는지 확인해야 한다.  (1) 주관적 보고나 타인에 의한\n\n<!-- PAGE_12 -->\n###### 관찰로 나타난 거의 매일 또는 거의 하루 내내 우울한 기분, (2) 거의\n\n<!-- PAGE_12 -->\n###### 매일, 하루 대부분 활동에서 현저히 감소한 흥미, (3) 식이요법을 하지\n\n<!-- PAGE_12 -->\n###### 않는 중에 의미 있는 체중 감량과 체중증가 또는 거의 매일의 식욕의\n\n<!-- PAGE_12 -->\n###### 감소 또는 증가, (4) 거의 매일 불면 또는 과수면, (5) 거의 매일 정신\n\n<!-- PAGE_12 -->\n###### 운동 흥분 또는 지체, (6) 거의 매일 피로 또는 에너지 상실, (7) 거의\n\n<!-- PAGE_12 -->\n###### 매일 무가치감 또는 과도하고 부적절한 죄책감을 느낌, (8) 거의 매일\n\n<!-- PAGE_12 -->\n###### 사고와 집중 능력의 감퇴 또는 결정 논란, (9) 반복적인 죽음에 관한\n\n<!-- PAGE_12 -->\n###### 생각 또는 구체적인 계획이 없는 반복적 자살 사고나 자살 시도 또는\n\n<!-- PAGE_12 -->\n###### 자살하려는 구체적 계획 등이 나타나며, 적어도 하나의 증상이 해당해야 한다.\n\n",
        "original_sentence": "우울장애 진단 절차/과정\n\n<!-- PAGE_12 -->\n###### DSM-5에서 기분장애(mood disorder)를 양극성 및 관련 장애(bipolar\n\n<!-- PAGE_12 -->\n###### and related disorder)와 우울장애(depressive disorder)로 분류하고 있으며,\n\n<!-- PAGE_12 -->\n###### 우울장애는 주요우울장애(major depressive disorder), 지속성 우울장애\n\n<!-- PAGE_12 -->\n###### (persistent depressive disorder), 월경 전 불쾌감 장애(premenstrual\n\n<!-- PAGE_12 -->\n###### dysphoric\n\n<!-- PAGE_12 -->\n###### disorder)\n\n<!-- PAGE_12 -->\n###### 등으로\n\n<!-- PAGE_12 -->\n###### 구분하고\n\n<!-- PAGE_12 -->\n###### 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_450",
      "text": "<!-- PAGE_12 -->\n###### Patient\n\n<!-- PAGE_12 -->\n###### Health\n\n<!-- PAGE_12 -->\n###### Questionnaire-9 (PHQ-9)과 같은 우울장애 선별도구로 선별 검사할 수\n\n<!-- PAGE_12 -->\n###### 있으며, 진단은 DSM-5의 진단기준을 적용한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 449,
        "window_size": 3,
        "char_count": 191,
        "word_count": 31,
        "page_number": 12,
        "window_text": "이러한 동반 질환은 진단과 치료에 부정적인\n\n<!-- PAGE_12 -->\n###### 영향을 끼치며, 동반 질환도 함께 치료해야 한다.\n\n <!-- PAGE_12 -->\n###### 나.  우울장애 진단 절차/과정\n\n<!-- PAGE_12 -->\n###### DSM-5에서 기분장애(mood disorder)를 양극성 및 관련 장애(bipolar\n\n<!-- PAGE_12 -->\n###### and related disorder)와 우울장애(depressive disorder)로 분류하고 있으며,\n\n<!-- PAGE_12 -->\n###### 우울장애는 주요우울장애(major depressive disorder), 지속성 우울장애\n\n<!-- PAGE_12 -->\n###### (persistent depressive disorder), 월경 전 불쾌감 장애(premenstrual\n\n<!-- PAGE_12 -->\n###### dysphoric\n\n<!-- PAGE_12 -->\n###### disorder)\n\n<!-- PAGE_12 -->\n###### 등으로\n\n<!-- PAGE_12 -->\n###### 구분하고\n\n<!-- PAGE_12 -->\n###### 있다.\n\n <!-- PAGE_12 -->\n###### Patient\n\n<!-- PAGE_12 -->\n###### Health\n\n<!-- PAGE_12 -->\n###### Questionnaire-9 (PHQ-9)과 같은 우울장애 선별도구로 선별 검사할 수\n\n<!-- PAGE_12 -->\n###### 있으며, 진단은 DSM-5의 진단기준을 적용한다.\n\n <!-- PAGE_12 -->\n###### 주요우울장애 진단을 위해서는 다음의 증상 중 5가지 이상이 2주일\n\n<!-- PAGE_12 -->\n###### 이상 지속되었는지 확인해야 한다.  (1) 주관적 보고나 타인에 의한\n\n<!-- PAGE_12 -->\n###### 관찰로 나타난 거의 매일 또는 거의 하루 내내 우울한 기분, (2) 거의\n\n<!-- PAGE_12 -->\n###### 매일, 하루 대부분 활동에서 현저히 감소한 흥미, (3) 식이요법을 하지\n\n<!-- PAGE_12 -->\n###### 않는 중에 의미 있는 체중 감량과 체중증가 또는 거의 매일의 식욕의\n\n<!-- PAGE_12 -->\n###### 감소 또는 증가, (4) 거의 매일 불면 또는 과수면, (5) 거의 매일 정신\n\n<!-- PAGE_12 -->\n###### 운동 흥분 또는 지체, (6) 거의 매일 피로 또는 에너지 상실, (7) 거의\n\n<!-- PAGE_12 -->\n###### 매일 무가치감 또는 과도하고 부적절한 죄책감을 느낌, (8) 거의 매일\n\n<!-- PAGE_12 -->\n###### 사고와 집중 능력의 감퇴 또는 결정 논란, (9) 반복적인 죽음에 관한\n\n<!-- PAGE_12 -->\n###### 생각 또는 구체적인 계획이 없는 반복적 자살 사고나 자살 시도 또는\n\n<!-- PAGE_12 -->\n###### 자살하려는 구체적 계획 등이 나타나며, 적어도 하나의 증상이 해당해야 한다.\n\n - - 6 -\n<!-- PAGE_13 -->\n###### 이러한 증상이 임상적으로 의미 있는 고통을 일으키거나 사회적, 직업적,\n\n<!-- PAGE_13 -->\n###### 다른 중요한 기능 영역에서 손상을 일으키며, 증상이 물질에 대한 직접적\n\n<!-- PAGE_13 -->\n###### 생리적 효과 또는 일반적 의학적 상태 때문이 아니어야 한다. ",
        "original_sentence": "<!-- PAGE_12 -->\n###### Patient\n\n<!-- PAGE_12 -->\n###### Health\n\n<!-- PAGE_12 -->\n###### Questionnaire-9 (PHQ-9)과 같은 우울장애 선별도구로 선별 검사할 수\n\n<!-- PAGE_12 -->\n###### 있으며, 진단은 DSM-5의 진단기준을 적용한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_451",
      "text": "<!-- PAGE_12 -->\n###### 주요우울장애 진단을 위해서는 다음의 증상 중 5가지 이상이 2주일\n\n<!-- PAGE_12 -->\n###### 이상 지속되었는지 확인해야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 450,
        "window_size": 3,
        "char_count": 105,
        "word_count": 21,
        "page_number": 12,
        "window_text": "<!-- PAGE_12 -->\n###### 나.  우울장애 진단 절차/과정\n\n<!-- PAGE_12 -->\n###### DSM-5에서 기분장애(mood disorder)를 양극성 및 관련 장애(bipolar\n\n<!-- PAGE_12 -->\n###### and related disorder)와 우울장애(depressive disorder)로 분류하고 있으며,\n\n<!-- PAGE_12 -->\n###### 우울장애는 주요우울장애(major depressive disorder), 지속성 우울장애\n\n<!-- PAGE_12 -->\n###### (persistent depressive disorder), 월경 전 불쾌감 장애(premenstrual\n\n<!-- PAGE_12 -->\n###### dysphoric\n\n<!-- PAGE_12 -->\n###### disorder)\n\n<!-- PAGE_12 -->\n###### 등으로\n\n<!-- PAGE_12 -->\n###### 구분하고\n\n<!-- PAGE_12 -->\n###### 있다.\n\n <!-- PAGE_12 -->\n###### Patient\n\n<!-- PAGE_12 -->\n###### Health\n\n<!-- PAGE_12 -->\n###### Questionnaire-9 (PHQ-9)과 같은 우울장애 선별도구로 선별 검사할 수\n\n<!-- PAGE_12 -->\n###### 있으며, 진단은 DSM-5의 진단기준을 적용한다.\n\n <!-- PAGE_12 -->\n###### 주요우울장애 진단을 위해서는 다음의 증상 중 5가지 이상이 2주일\n\n<!-- PAGE_12 -->\n###### 이상 지속되었는지 확인해야 한다.  (1) 주관적 보고나 타인에 의한\n\n<!-- PAGE_12 -->\n###### 관찰로 나타난 거의 매일 또는 거의 하루 내내 우울한 기분, (2) 거의\n\n<!-- PAGE_12 -->\n###### 매일, 하루 대부분 활동에서 현저히 감소한 흥미, (3) 식이요법을 하지\n\n<!-- PAGE_12 -->\n###### 않는 중에 의미 있는 체중 감량과 체중증가 또는 거의 매일의 식욕의\n\n<!-- PAGE_12 -->\n###### 감소 또는 증가, (4) 거의 매일 불면 또는 과수면, (5) 거의 매일 정신\n\n<!-- PAGE_12 -->\n###### 운동 흥분 또는 지체, (6) 거의 매일 피로 또는 에너지 상실, (7) 거의\n\n<!-- PAGE_12 -->\n###### 매일 무가치감 또는 과도하고 부적절한 죄책감을 느낌, (8) 거의 매일\n\n<!-- PAGE_12 -->\n###### 사고와 집중 능력의 감퇴 또는 결정 논란, (9) 반복적인 죽음에 관한\n\n<!-- PAGE_12 -->\n###### 생각 또는 구체적인 계획이 없는 반복적 자살 사고나 자살 시도 또는\n\n<!-- PAGE_12 -->\n###### 자살하려는 구체적 계획 등이 나타나며, 적어도 하나의 증상이 해당해야 한다.\n\n - - 6 -\n<!-- PAGE_13 -->\n###### 이러한 증상이 임상적으로 의미 있는 고통을 일으키거나 사회적, 직업적,\n\n<!-- PAGE_13 -->\n###### 다른 중요한 기능 영역에서 손상을 일으키며, 증상이 물질에 대한 직접적\n\n<!-- PAGE_13 -->\n###### 생리적 효과 또는 일반적 의학적 상태 때문이 아니어야 한다.  환자의\n\n<!-- PAGE_13 -->\n###### 증상이 조현정동장애, 조현병, 조현 형장에, 망상장애, 혹은 기타 정신병적\n\n<!-- PAGE_13 -->\n###### 장애로 잘 설명되지 않아야 하며, 과거 조증 혹은 경조증 삽화가 없어야\n\n<!-- PAGE_13 -->\n###### 한다.\n\n",
        "original_sentence": "<!-- PAGE_12 -->\n###### 주요우울장애 진단을 위해서는 다음의 증상 중 5가지 이상이 2주일\n\n<!-- PAGE_12 -->\n###### 이상 지속되었는지 확인해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_452",
      "text": "(1) 주관적 보고나 타인에 의한\n\n<!-- PAGE_12 -->\n###### 관찰로 나타난 거의 매일 또는 거의 하루 내내 우울한 기분, (2) 거의\n\n<!-- PAGE_12 -->\n###### 매일, 하루 대부분 활동에서 현저히 감소한 흥미, (3) 식이요법을 하지\n\n<!-- PAGE_12 -->\n###### 않는 중에 의미 있는 체중 감량과 체중증가 또는 거의 매일의 식욕의\n\n<!-- PAGE_12 -->\n###### 감소 또는 증가, (4) 거의 매일 불면 또는 과수면, (5) 거의 매일 정신\n\n<!-- PAGE_12 -->\n###### 운동 흥분 또는 지체, (6) 거의 매일 피로 또는 에너지 상실, (7) 거의\n\n<!-- PAGE_12 -->\n###### 매일 무가치감 또는 과도하고 부적절한 죄책감을 느낌, (8) 거의 매일\n\n<!-- PAGE_12 -->\n###### 사고와 집중 능력의 감퇴 또는 결정 논란, (9) 반복적인 죽음에 관한\n\n<!-- PAGE_12 -->\n###### 생각 또는 구체적인 계획이 없는 반복적 자살 사고나 자살 시도 또는\n\n<!-- PAGE_12 -->\n###### 자살하려는 구체적 계획 등이 나타나며, 적어도 하나의 증상이 해당해야 한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 451,
        "window_size": 3,
        "char_count": 614,
        "word_count": 142,
        "page_number": 12,
        "window_text": "우울장애 진단 절차/과정\n\n<!-- PAGE_12 -->\n###### DSM-5에서 기분장애(mood disorder)를 양극성 및 관련 장애(bipolar\n\n<!-- PAGE_12 -->\n###### and related disorder)와 우울장애(depressive disorder)로 분류하고 있으며,\n\n<!-- PAGE_12 -->\n###### 우울장애는 주요우울장애(major depressive disorder), 지속성 우울장애\n\n<!-- PAGE_12 -->\n###### (persistent depressive disorder), 월경 전 불쾌감 장애(premenstrual\n\n<!-- PAGE_12 -->\n###### dysphoric\n\n<!-- PAGE_12 -->\n###### disorder)\n\n<!-- PAGE_12 -->\n###### 등으로\n\n<!-- PAGE_12 -->\n###### 구분하고\n\n<!-- PAGE_12 -->\n###### 있다.\n\n <!-- PAGE_12 -->\n###### Patient\n\n<!-- PAGE_12 -->\n###### Health\n\n<!-- PAGE_12 -->\n###### Questionnaire-9 (PHQ-9)과 같은 우울장애 선별도구로 선별 검사할 수\n\n<!-- PAGE_12 -->\n###### 있으며, 진단은 DSM-5의 진단기준을 적용한다.\n\n <!-- PAGE_12 -->\n###### 주요우울장애 진단을 위해서는 다음의 증상 중 5가지 이상이 2주일\n\n<!-- PAGE_12 -->\n###### 이상 지속되었는지 확인해야 한다.  (1) 주관적 보고나 타인에 의한\n\n<!-- PAGE_12 -->\n###### 관찰로 나타난 거의 매일 또는 거의 하루 내내 우울한 기분, (2) 거의\n\n<!-- PAGE_12 -->\n###### 매일, 하루 대부분 활동에서 현저히 감소한 흥미, (3) 식이요법을 하지\n\n<!-- PAGE_12 -->\n###### 않는 중에 의미 있는 체중 감량과 체중증가 또는 거의 매일의 식욕의\n\n<!-- PAGE_12 -->\n###### 감소 또는 증가, (4) 거의 매일 불면 또는 과수면, (5) 거의 매일 정신\n\n<!-- PAGE_12 -->\n###### 운동 흥분 또는 지체, (6) 거의 매일 피로 또는 에너지 상실, (7) 거의\n\n<!-- PAGE_12 -->\n###### 매일 무가치감 또는 과도하고 부적절한 죄책감을 느낌, (8) 거의 매일\n\n<!-- PAGE_12 -->\n###### 사고와 집중 능력의 감퇴 또는 결정 논란, (9) 반복적인 죽음에 관한\n\n<!-- PAGE_12 -->\n###### 생각 또는 구체적인 계획이 없는 반복적 자살 사고나 자살 시도 또는\n\n<!-- PAGE_12 -->\n###### 자살하려는 구체적 계획 등이 나타나며, 적어도 하나의 증상이 해당해야 한다.\n\n - - 6 -\n<!-- PAGE_13 -->\n###### 이러한 증상이 임상적으로 의미 있는 고통을 일으키거나 사회적, 직업적,\n\n<!-- PAGE_13 -->\n###### 다른 중요한 기능 영역에서 손상을 일으키며, 증상이 물질에 대한 직접적\n\n<!-- PAGE_13 -->\n###### 생리적 효과 또는 일반적 의학적 상태 때문이 아니어야 한다.  환자의\n\n<!-- PAGE_13 -->\n###### 증상이 조현정동장애, 조현병, 조현 형장에, 망상장애, 혹은 기타 정신병적\n\n<!-- PAGE_13 -->\n###### 장애로 잘 설명되지 않아야 하며, 과거 조증 혹은 경조증 삽화가 없어야\n\n<!-- PAGE_13 -->\n###### 한다.\n\n <!-- PAGE_13 -->\n###### 지속성 우울장애는 기분저하증 혹은 감정 부전 장애로도 불리며, 최소\n\n<!-- PAGE_13 -->\n###### 2년 동안 주관적, 객관적으로 거의 종일 우울한 기분이 지속된다. ",
        "original_sentence": "(1) 주관적 보고나 타인에 의한\n\n<!-- PAGE_12 -->\n###### 관찰로 나타난 거의 매일 또는 거의 하루 내내 우울한 기분, (2) 거의\n\n<!-- PAGE_12 -->\n###### 매일, 하루 대부분 활동에서 현저히 감소한 흥미, (3) 식이요법을 하지\n\n<!-- PAGE_12 -->\n###### 않는 중에 의미 있는 체중 감량과 체중증가 또는 거의 매일의 식욕의\n\n<!-- PAGE_12 -->\n###### 감소 또는 증가, (4) 거의 매일 불면 또는 과수면, (5) 거의 매일 정신\n\n<!-- PAGE_12 -->\n###### 운동 흥분 또는 지체, (6) 거의 매일 피로 또는 에너지 상실, (7) 거의\n\n<!-- PAGE_12 -->\n###### 매일 무가치감 또는 과도하고 부적절한 죄책감을 느낌, (8) 거의 매일\n\n<!-- PAGE_12 -->\n###### 사고와 집중 능력의 감퇴 또는 결정 논란, (9) 반복적인 죽음에 관한\n\n<!-- PAGE_12 -->\n###### 생각 또는 구체적인 계획이 없는 반복적 자살 사고나 자살 시도 또는\n\n<!-- PAGE_12 -->\n###### 자살하려는 구체적 계획 등이 나타나며, 적어도 하나의 증상이 해당해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_453",
      "text": "- - 6 -\n<!-- PAGE_13 -->\n###### 이러한 증상이 임상적으로 의미 있는 고통을 일으키거나 사회적, 직업적,\n\n<!-- PAGE_13 -->\n###### 다른 중요한 기능 영역에서 손상을 일으키며, 증상이 물질에 대한 직접적\n\n<!-- PAGE_13 -->\n###### 생리적 효과 또는 일반적 의학적 상태 때문이 아니어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 452,
        "window_size": 3,
        "char_count": 196,
        "word_count": 44,
        "page_number": 13,
        "window_text": "<!-- PAGE_12 -->\n###### Patient\n\n<!-- PAGE_12 -->\n###### Health\n\n<!-- PAGE_12 -->\n###### Questionnaire-9 (PHQ-9)과 같은 우울장애 선별도구로 선별 검사할 수\n\n<!-- PAGE_12 -->\n###### 있으며, 진단은 DSM-5의 진단기준을 적용한다.\n\n <!-- PAGE_12 -->\n###### 주요우울장애 진단을 위해서는 다음의 증상 중 5가지 이상이 2주일\n\n<!-- PAGE_12 -->\n###### 이상 지속되었는지 확인해야 한다.  (1) 주관적 보고나 타인에 의한\n\n<!-- PAGE_12 -->\n###### 관찰로 나타난 거의 매일 또는 거의 하루 내내 우울한 기분, (2) 거의\n\n<!-- PAGE_12 -->\n###### 매일, 하루 대부분 활동에서 현저히 감소한 흥미, (3) 식이요법을 하지\n\n<!-- PAGE_12 -->\n###### 않는 중에 의미 있는 체중 감량과 체중증가 또는 거의 매일의 식욕의\n\n<!-- PAGE_12 -->\n###### 감소 또는 증가, (4) 거의 매일 불면 또는 과수면, (5) 거의 매일 정신\n\n<!-- PAGE_12 -->\n###### 운동 흥분 또는 지체, (6) 거의 매일 피로 또는 에너지 상실, (7) 거의\n\n<!-- PAGE_12 -->\n###### 매일 무가치감 또는 과도하고 부적절한 죄책감을 느낌, (8) 거의 매일\n\n<!-- PAGE_12 -->\n###### 사고와 집중 능력의 감퇴 또는 결정 논란, (9) 반복적인 죽음에 관한\n\n<!-- PAGE_12 -->\n###### 생각 또는 구체적인 계획이 없는 반복적 자살 사고나 자살 시도 또는\n\n<!-- PAGE_12 -->\n###### 자살하려는 구체적 계획 등이 나타나며, 적어도 하나의 증상이 해당해야 한다.\n\n - - 6 -\n<!-- PAGE_13 -->\n###### 이러한 증상이 임상적으로 의미 있는 고통을 일으키거나 사회적, 직업적,\n\n<!-- PAGE_13 -->\n###### 다른 중요한 기능 영역에서 손상을 일으키며, 증상이 물질에 대한 직접적\n\n<!-- PAGE_13 -->\n###### 생리적 효과 또는 일반적 의학적 상태 때문이 아니어야 한다.  환자의\n\n<!-- PAGE_13 -->\n###### 증상이 조현정동장애, 조현병, 조현 형장에, 망상장애, 혹은 기타 정신병적\n\n<!-- PAGE_13 -->\n###### 장애로 잘 설명되지 않아야 하며, 과거 조증 혹은 경조증 삽화가 없어야\n\n<!-- PAGE_13 -->\n###### 한다.\n\n <!-- PAGE_13 -->\n###### 지속성 우울장애는 기분저하증 혹은 감정 부전 장애로도 불리며, 최소\n\n<!-- PAGE_13 -->\n###### 2년 동안 주관적, 객관적으로 거의 종일 우울한 기분이 지속된다.  진단을\n\n<!-- PAGE_13 -->\n###### 위해서는 우울한 기간 다음의 증상 6가지 중 2가지 이상이 존재하는지\n\n<!-- PAGE_13 -->\n###### 확인해야 한다. ",
        "original_sentence": "- - 6 -\n<!-- PAGE_13 -->\n###### 이러한 증상이 임상적으로 의미 있는 고통을 일으키거나 사회적, 직업적,\n\n<!-- PAGE_13 -->\n###### 다른 중요한 기능 영역에서 손상을 일으키며, 증상이 물질에 대한 직접적\n\n<!-- PAGE_13 -->\n###### 생리적 효과 또는 일반적 의학적 상태 때문이 아니어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_454",
      "text": "환자의\n\n<!-- PAGE_13 -->\n###### 증상이 조현정동장애, 조현병, 조현 형장에, 망상장애, 혹은 기타 정신병적\n\n<!-- PAGE_13 -->\n###### 장애로 잘 설명되지 않아야 하며, 과거 조증 혹은 경조증 삽화가 없어야\n\n<!-- PAGE_13 -->\n###### 한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 453,
        "window_size": 3,
        "char_count": 166,
        "word_count": 34,
        "page_number": 13,
        "window_text": "<!-- PAGE_12 -->\n###### 주요우울장애 진단을 위해서는 다음의 증상 중 5가지 이상이 2주일\n\n<!-- PAGE_12 -->\n###### 이상 지속되었는지 확인해야 한다.  (1) 주관적 보고나 타인에 의한\n\n<!-- PAGE_12 -->\n###### 관찰로 나타난 거의 매일 또는 거의 하루 내내 우울한 기분, (2) 거의\n\n<!-- PAGE_12 -->\n###### 매일, 하루 대부분 활동에서 현저히 감소한 흥미, (3) 식이요법을 하지\n\n<!-- PAGE_12 -->\n###### 않는 중에 의미 있는 체중 감량과 체중증가 또는 거의 매일의 식욕의\n\n<!-- PAGE_12 -->\n###### 감소 또는 증가, (4) 거의 매일 불면 또는 과수면, (5) 거의 매일 정신\n\n<!-- PAGE_12 -->\n###### 운동 흥분 또는 지체, (6) 거의 매일 피로 또는 에너지 상실, (7) 거의\n\n<!-- PAGE_12 -->\n###### 매일 무가치감 또는 과도하고 부적절한 죄책감을 느낌, (8) 거의 매일\n\n<!-- PAGE_12 -->\n###### 사고와 집중 능력의 감퇴 또는 결정 논란, (9) 반복적인 죽음에 관한\n\n<!-- PAGE_12 -->\n###### 생각 또는 구체적인 계획이 없는 반복적 자살 사고나 자살 시도 또는\n\n<!-- PAGE_12 -->\n###### 자살하려는 구체적 계획 등이 나타나며, 적어도 하나의 증상이 해당해야 한다.\n\n - - 6 -\n<!-- PAGE_13 -->\n###### 이러한 증상이 임상적으로 의미 있는 고통을 일으키거나 사회적, 직업적,\n\n<!-- PAGE_13 -->\n###### 다른 중요한 기능 영역에서 손상을 일으키며, 증상이 물질에 대한 직접적\n\n<!-- PAGE_13 -->\n###### 생리적 효과 또는 일반적 의학적 상태 때문이 아니어야 한다.  환자의\n\n<!-- PAGE_13 -->\n###### 증상이 조현정동장애, 조현병, 조현 형장에, 망상장애, 혹은 기타 정신병적\n\n<!-- PAGE_13 -->\n###### 장애로 잘 설명되지 않아야 하며, 과거 조증 혹은 경조증 삽화가 없어야\n\n<!-- PAGE_13 -->\n###### 한다.\n\n <!-- PAGE_13 -->\n###### 지속성 우울장애는 기분저하증 혹은 감정 부전 장애로도 불리며, 최소\n\n<!-- PAGE_13 -->\n###### 2년 동안 주관적, 객관적으로 거의 종일 우울한 기분이 지속된다.  진단을\n\n<!-- PAGE_13 -->\n###### 위해서는 우울한 기간 다음의 증상 6가지 중 2가지 이상이 존재하는지\n\n<!-- PAGE_13 -->\n###### 확인해야 한다.  (1) 식욕 저하 혹은 과식, (2) 불면 혹은 과수면, (3) 기력\n\n<!-- PAGE_13 -->\n###### 저하 혹은 피로, (4) 낮은 자존감, (5) 집중 감소 또는 결정 내리기 어려움,\n\n<!-- PAGE_13 -->\n###### (6) 절망감 등의 증상이 이에 해당한다. ",
        "original_sentence": "환자의\n\n<!-- PAGE_13 -->\n###### 증상이 조현정동장애, 조현병, 조현 형장에, 망상장애, 혹은 기타 정신병적\n\n<!-- PAGE_13 -->\n###### 장애로 잘 설명되지 않아야 하며, 과거 조증 혹은 경조증 삽화가 없어야\n\n<!-- PAGE_13 -->\n###### 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_455",
      "text": "<!-- PAGE_13 -->\n###### 지속성 우울장애는 기분저하증 혹은 감정 부전 장애로도 불리며, 최소\n\n<!-- PAGE_13 -->\n###### 2년 동안 주관적, 객관적으로 거의 종일 우울한 기분이 지속된다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 454,
        "window_size": 3,
        "char_count": 124,
        "word_count": 26,
        "page_number": 13,
        "window_text": "(1) 주관적 보고나 타인에 의한\n\n<!-- PAGE_12 -->\n###### 관찰로 나타난 거의 매일 또는 거의 하루 내내 우울한 기분, (2) 거의\n\n<!-- PAGE_12 -->\n###### 매일, 하루 대부분 활동에서 현저히 감소한 흥미, (3) 식이요법을 하지\n\n<!-- PAGE_12 -->\n###### 않는 중에 의미 있는 체중 감량과 체중증가 또는 거의 매일의 식욕의\n\n<!-- PAGE_12 -->\n###### 감소 또는 증가, (4) 거의 매일 불면 또는 과수면, (5) 거의 매일 정신\n\n<!-- PAGE_12 -->\n###### 운동 흥분 또는 지체, (6) 거의 매일 피로 또는 에너지 상실, (7) 거의\n\n<!-- PAGE_12 -->\n###### 매일 무가치감 또는 과도하고 부적절한 죄책감을 느낌, (8) 거의 매일\n\n<!-- PAGE_12 -->\n###### 사고와 집중 능력의 감퇴 또는 결정 논란, (9) 반복적인 죽음에 관한\n\n<!-- PAGE_12 -->\n###### 생각 또는 구체적인 계획이 없는 반복적 자살 사고나 자살 시도 또는\n\n<!-- PAGE_12 -->\n###### 자살하려는 구체적 계획 등이 나타나며, 적어도 하나의 증상이 해당해야 한다.\n\n - - 6 -\n<!-- PAGE_13 -->\n###### 이러한 증상이 임상적으로 의미 있는 고통을 일으키거나 사회적, 직업적,\n\n<!-- PAGE_13 -->\n###### 다른 중요한 기능 영역에서 손상을 일으키며, 증상이 물질에 대한 직접적\n\n<!-- PAGE_13 -->\n###### 생리적 효과 또는 일반적 의학적 상태 때문이 아니어야 한다.  환자의\n\n<!-- PAGE_13 -->\n###### 증상이 조현정동장애, 조현병, 조현 형장에, 망상장애, 혹은 기타 정신병적\n\n<!-- PAGE_13 -->\n###### 장애로 잘 설명되지 않아야 하며, 과거 조증 혹은 경조증 삽화가 없어야\n\n<!-- PAGE_13 -->\n###### 한다.\n\n <!-- PAGE_13 -->\n###### 지속성 우울장애는 기분저하증 혹은 감정 부전 장애로도 불리며, 최소\n\n<!-- PAGE_13 -->\n###### 2년 동안 주관적, 객관적으로 거의 종일 우울한 기분이 지속된다.  진단을\n\n<!-- PAGE_13 -->\n###### 위해서는 우울한 기간 다음의 증상 6가지 중 2가지 이상이 존재하는지\n\n<!-- PAGE_13 -->\n###### 확인해야 한다.  (1) 식욕 저하 혹은 과식, (2) 불면 혹은 과수면, (3) 기력\n\n<!-- PAGE_13 -->\n###### 저하 혹은 피로, (4) 낮은 자존감, (5) 집중 감소 또는 결정 내리기 어려움,\n\n<!-- PAGE_13 -->\n###### (6) 절망감 등의 증상이 이에 해당한다.  조증 삽화, 혼합성 삽화, 또는\n\n<!-- PAGE_13 -->\n###### 경조증 삽화를 만족시킨 적이 없어야 하며 순환성 장애를 만족시킨 적이\n\n<!-- PAGE_13 -->\n###### 없어야 한다. ",
        "original_sentence": "<!-- PAGE_13 -->\n###### 지속성 우울장애는 기분저하증 혹은 감정 부전 장애로도 불리며, 최소\n\n<!-- PAGE_13 -->\n###### 2년 동안 주관적, 객관적으로 거의 종일 우울한 기분이 지속된다. "
      }
    },
    {
      "chunk_id": "chunk_456",
      "text": "진단을\n\n<!-- PAGE_13 -->\n###### 위해서는 우울한 기간 다음의 증상 6가지 중 2가지 이상이 존재하는지\n\n<!-- PAGE_13 -->\n###### 확인해야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 455,
        "window_size": 3,
        "char_count": 102,
        "word_count": 21,
        "page_number": 13,
        "window_text": "- - 6 -\n<!-- PAGE_13 -->\n###### 이러한 증상이 임상적으로 의미 있는 고통을 일으키거나 사회적, 직업적,\n\n<!-- PAGE_13 -->\n###### 다른 중요한 기능 영역에서 손상을 일으키며, 증상이 물질에 대한 직접적\n\n<!-- PAGE_13 -->\n###### 생리적 효과 또는 일반적 의학적 상태 때문이 아니어야 한다.  환자의\n\n<!-- PAGE_13 -->\n###### 증상이 조현정동장애, 조현병, 조현 형장에, 망상장애, 혹은 기타 정신병적\n\n<!-- PAGE_13 -->\n###### 장애로 잘 설명되지 않아야 하며, 과거 조증 혹은 경조증 삽화가 없어야\n\n<!-- PAGE_13 -->\n###### 한다.\n\n <!-- PAGE_13 -->\n###### 지속성 우울장애는 기분저하증 혹은 감정 부전 장애로도 불리며, 최소\n\n<!-- PAGE_13 -->\n###### 2년 동안 주관적, 객관적으로 거의 종일 우울한 기분이 지속된다.  진단을\n\n<!-- PAGE_13 -->\n###### 위해서는 우울한 기간 다음의 증상 6가지 중 2가지 이상이 존재하는지\n\n<!-- PAGE_13 -->\n###### 확인해야 한다.  (1) 식욕 저하 혹은 과식, (2) 불면 혹은 과수면, (3) 기력\n\n<!-- PAGE_13 -->\n###### 저하 혹은 피로, (4) 낮은 자존감, (5) 집중 감소 또는 결정 내리기 어려움,\n\n<!-- PAGE_13 -->\n###### (6) 절망감 등의 증상이 이에 해당한다.  조증 삽화, 혼합성 삽화, 또는\n\n<!-- PAGE_13 -->\n###### 경조증 삽화를 만족시킨 적이 없어야 하며 순환성 장애를 만족시킨 적이\n\n<!-- PAGE_13 -->\n###### 없어야 한다.  만성적인 정신병적 증상의 경과 중에 발생한 것이 아니어야\n\n<!-- PAGE_13 -->\n###### 하며, 물질이나 내과적 상태 때문이 아니어야 한다. ",
        "original_sentence": "진단을\n\n<!-- PAGE_13 -->\n###### 위해서는 우울한 기간 다음의 증상 6가지 중 2가지 이상이 존재하는지\n\n<!-- PAGE_13 -->\n###### 확인해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_457",
      "text": "(1) 식욕 저하 혹은 과식, (2) 불면 혹은 과수면, (3) 기력\n\n<!-- PAGE_13 -->\n###### 저하 혹은 피로, (4) 낮은 자존감, (5) 집중 감소 또는 결정 내리기 어려움,\n\n<!-- PAGE_13 -->\n###### (6) 절망감 등의 증상이 이에 해당한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 456,
        "window_size": 3,
        "char_count": 160,
        "word_count": 38,
        "page_number": 13,
        "window_text": "환자의\n\n<!-- PAGE_13 -->\n###### 증상이 조현정동장애, 조현병, 조현 형장에, 망상장애, 혹은 기타 정신병적\n\n<!-- PAGE_13 -->\n###### 장애로 잘 설명되지 않아야 하며, 과거 조증 혹은 경조증 삽화가 없어야\n\n<!-- PAGE_13 -->\n###### 한다.\n\n <!-- PAGE_13 -->\n###### 지속성 우울장애는 기분저하증 혹은 감정 부전 장애로도 불리며, 최소\n\n<!-- PAGE_13 -->\n###### 2년 동안 주관적, 객관적으로 거의 종일 우울한 기분이 지속된다.  진단을\n\n<!-- PAGE_13 -->\n###### 위해서는 우울한 기간 다음의 증상 6가지 중 2가지 이상이 존재하는지\n\n<!-- PAGE_13 -->\n###### 확인해야 한다.  (1) 식욕 저하 혹은 과식, (2) 불면 혹은 과수면, (3) 기력\n\n<!-- PAGE_13 -->\n###### 저하 혹은 피로, (4) 낮은 자존감, (5) 집중 감소 또는 결정 내리기 어려움,\n\n<!-- PAGE_13 -->\n###### (6) 절망감 등의 증상이 이에 해당한다.  조증 삽화, 혼합성 삽화, 또는\n\n<!-- PAGE_13 -->\n###### 경조증 삽화를 만족시킨 적이 없어야 하며 순환성 장애를 만족시킨 적이\n\n<!-- PAGE_13 -->\n###### 없어야 한다.  만성적인 정신병적 증상의 경과 중에 발생한 것이 아니어야\n\n<!-- PAGE_13 -->\n###### 하며, 물질이나 내과적 상태 때문이 아니어야 한다.  이러한 증상으로\n\n<!-- PAGE_13 -->\n###### 인해 사회적, 직업적, 기타 기능 영역에서 임상적으로 현저한 고통이나\n\n<!-- PAGE_13 -->\n###### 손상을 초래하는지 확인해야 한다.\n\n",
        "original_sentence": "(1) 식욕 저하 혹은 과식, (2) 불면 혹은 과수면, (3) 기력\n\n<!-- PAGE_13 -->\n###### 저하 혹은 피로, (4) 낮은 자존감, (5) 집중 감소 또는 결정 내리기 어려움,\n\n<!-- PAGE_13 -->\n###### (6) 절망감 등의 증상이 이에 해당한다. "
      }
    },
    {
      "chunk_id": "chunk_458",
      "text": "조증 삽화, 혼합성 삽화, 또는\n\n<!-- PAGE_13 -->\n###### 경조증 삽화를 만족시킨 적이 없어야 하며 순환성 장애를 만족시킨 적이\n\n<!-- PAGE_13 -->\n###### 없어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 457,
        "window_size": 3,
        "char_count": 115,
        "word_count": 25,
        "page_number": 13,
        "window_text": "<!-- PAGE_13 -->\n###### 지속성 우울장애는 기분저하증 혹은 감정 부전 장애로도 불리며, 최소\n\n<!-- PAGE_13 -->\n###### 2년 동안 주관적, 객관적으로 거의 종일 우울한 기분이 지속된다.  진단을\n\n<!-- PAGE_13 -->\n###### 위해서는 우울한 기간 다음의 증상 6가지 중 2가지 이상이 존재하는지\n\n<!-- PAGE_13 -->\n###### 확인해야 한다.  (1) 식욕 저하 혹은 과식, (2) 불면 혹은 과수면, (3) 기력\n\n<!-- PAGE_13 -->\n###### 저하 혹은 피로, (4) 낮은 자존감, (5) 집중 감소 또는 결정 내리기 어려움,\n\n<!-- PAGE_13 -->\n###### (6) 절망감 등의 증상이 이에 해당한다.  조증 삽화, 혼합성 삽화, 또는\n\n<!-- PAGE_13 -->\n###### 경조증 삽화를 만족시킨 적이 없어야 하며 순환성 장애를 만족시킨 적이\n\n<!-- PAGE_13 -->\n###### 없어야 한다.  만성적인 정신병적 증상의 경과 중에 발생한 것이 아니어야\n\n<!-- PAGE_13 -->\n###### 하며, 물질이나 내과적 상태 때문이 아니어야 한다.  이러한 증상으로\n\n<!-- PAGE_13 -->\n###### 인해 사회적, 직업적, 기타 기능 영역에서 임상적으로 현저한 고통이나\n\n<!-- PAGE_13 -->\n###### 손상을 초래하는지 확인해야 한다.\n\n <!-- PAGE_13 -->\n###### 우울장애는 특정 양상(specifier)에 따라 분류할 수 있으며 각각의\n\n<!-- PAGE_13 -->\n###### 특성이 달라 약물 선택 등의 치료 방향 결정을 다르게 해야 한다. ",
        "original_sentence": "조증 삽화, 혼합성 삽화, 또는\n\n<!-- PAGE_13 -->\n###### 경조증 삽화를 만족시킨 적이 없어야 하며 순환성 장애를 만족시킨 적이\n\n<!-- PAGE_13 -->\n###### 없어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_459",
      "text": "만성적인 정신병적 증상의 경과 중에 발생한 것이 아니어야\n\n<!-- PAGE_13 -->\n###### 하며, 물질이나 내과적 상태 때문이 아니어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 458,
        "window_size": 3,
        "char_count": 86,
        "word_count": 19,
        "page_number": 13,
        "window_text": "진단을\n\n<!-- PAGE_13 -->\n###### 위해서는 우울한 기간 다음의 증상 6가지 중 2가지 이상이 존재하는지\n\n<!-- PAGE_13 -->\n###### 확인해야 한다.  (1) 식욕 저하 혹은 과식, (2) 불면 혹은 과수면, (3) 기력\n\n<!-- PAGE_13 -->\n###### 저하 혹은 피로, (4) 낮은 자존감, (5) 집중 감소 또는 결정 내리기 어려움,\n\n<!-- PAGE_13 -->\n###### (6) 절망감 등의 증상이 이에 해당한다.  조증 삽화, 혼합성 삽화, 또는\n\n<!-- PAGE_13 -->\n###### 경조증 삽화를 만족시킨 적이 없어야 하며 순환성 장애를 만족시킨 적이\n\n<!-- PAGE_13 -->\n###### 없어야 한다.  만성적인 정신병적 증상의 경과 중에 발생한 것이 아니어야\n\n<!-- PAGE_13 -->\n###### 하며, 물질이나 내과적 상태 때문이 아니어야 한다.  이러한 증상으로\n\n<!-- PAGE_13 -->\n###### 인해 사회적, 직업적, 기타 기능 영역에서 임상적으로 현저한 고통이나\n\n<!-- PAGE_13 -->\n###### 손상을 초래하는지 확인해야 한다.\n\n <!-- PAGE_13 -->\n###### 우울장애는 특정 양상(specifier)에 따라 분류할 수 있으며 각각의\n\n<!-- PAGE_13 -->\n###### 특성이 달라 약물 선택 등의 치료 방향 결정을 다르게 해야 한다.  크게\n\n<!-- PAGE_13 -->\n###### 불안증(anxious distress) 동반, 혼재성 양상(mixed features) 동반, 멜랑\n\n<!-- PAGE_13 -->\n###### 콜리아 양상(melancholic features) 동반, 비전형적 양상(atypical features)\n\n<!-- PAGE_13 -->\n###### 동반, 정신병적 양상(psychotic features) 동반, 긴장증(catatonia) 동반,\n\n<!-- PAGE_13 -->\n###### 주산기 발병(peripartum onset) 동반, 계절성(seasonal patterns) 동반으로\n\n- - 7 -\n<!-- PAGE_14 -->\n###### 진단할 수 있다.\n\n",
        "original_sentence": "만성적인 정신병적 증상의 경과 중에 발생한 것이 아니어야\n\n<!-- PAGE_13 -->\n###### 하며, 물질이나 내과적 상태 때문이 아니어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_460",
      "text": "이러한 증상으로\n\n<!-- PAGE_13 -->\n###### 인해 사회적, 직업적, 기타 기능 영역에서 임상적으로 현저한 고통이나\n\n<!-- PAGE_13 -->\n###### 손상을 초래하는지 확인해야 한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 459,
        "window_size": 3,
        "char_count": 118,
        "word_count": 23,
        "page_number": 13,
        "window_text": "(1) 식욕 저하 혹은 과식, (2) 불면 혹은 과수면, (3) 기력\n\n<!-- PAGE_13 -->\n###### 저하 혹은 피로, (4) 낮은 자존감, (5) 집중 감소 또는 결정 내리기 어려움,\n\n<!-- PAGE_13 -->\n###### (6) 절망감 등의 증상이 이에 해당한다.  조증 삽화, 혼합성 삽화, 또는\n\n<!-- PAGE_13 -->\n###### 경조증 삽화를 만족시킨 적이 없어야 하며 순환성 장애를 만족시킨 적이\n\n<!-- PAGE_13 -->\n###### 없어야 한다.  만성적인 정신병적 증상의 경과 중에 발생한 것이 아니어야\n\n<!-- PAGE_13 -->\n###### 하며, 물질이나 내과적 상태 때문이 아니어야 한다.  이러한 증상으로\n\n<!-- PAGE_13 -->\n###### 인해 사회적, 직업적, 기타 기능 영역에서 임상적으로 현저한 고통이나\n\n<!-- PAGE_13 -->\n###### 손상을 초래하는지 확인해야 한다.\n\n <!-- PAGE_13 -->\n###### 우울장애는 특정 양상(specifier)에 따라 분류할 수 있으며 각각의\n\n<!-- PAGE_13 -->\n###### 특성이 달라 약물 선택 등의 치료 방향 결정을 다르게 해야 한다.  크게\n\n<!-- PAGE_13 -->\n###### 불안증(anxious distress) 동반, 혼재성 양상(mixed features) 동반, 멜랑\n\n<!-- PAGE_13 -->\n###### 콜리아 양상(melancholic features) 동반, 비전형적 양상(atypical features)\n\n<!-- PAGE_13 -->\n###### 동반, 정신병적 양상(psychotic features) 동반, 긴장증(catatonia) 동반,\n\n<!-- PAGE_13 -->\n###### 주산기 발병(peripartum onset) 동반, 계절성(seasonal patterns) 동반으로\n\n- - 7 -\n<!-- PAGE_14 -->\n###### 진단할 수 있다.\n\n <!-- PAGE_14 -->\n###### 우울장애 환자는 기분 증상 외에도 사고 증상, 인지 증상, 정신운동\n\n<!-- PAGE_14 -->\n###### 증상, 신체 증상, 정신병적 증상 등이 다양하게 나타나기 때문에 복잡한\n\n<!-- PAGE_14 -->\n###### 감별이 있을 수 있다. ",
        "original_sentence": "이러한 증상으로\n\n<!-- PAGE_13 -->\n###### 인해 사회적, 직업적, 기타 기능 영역에서 임상적으로 현저한 고통이나\n\n<!-- PAGE_13 -->\n###### 손상을 초래하는지 확인해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_461",
      "text": "<!-- PAGE_13 -->\n###### 우울장애는 특정 양상(specifier)에 따라 분류할 수 있으며 각각의\n\n<!-- PAGE_13 -->\n###### 특성이 달라 약물 선택 등의 치료 방향 결정을 다르게 해야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 460,
        "window_size": 3,
        "char_count": 127,
        "word_count": 27,
        "page_number": 13,
        "window_text": "조증 삽화, 혼합성 삽화, 또는\n\n<!-- PAGE_13 -->\n###### 경조증 삽화를 만족시킨 적이 없어야 하며 순환성 장애를 만족시킨 적이\n\n<!-- PAGE_13 -->\n###### 없어야 한다.  만성적인 정신병적 증상의 경과 중에 발생한 것이 아니어야\n\n<!-- PAGE_13 -->\n###### 하며, 물질이나 내과적 상태 때문이 아니어야 한다.  이러한 증상으로\n\n<!-- PAGE_13 -->\n###### 인해 사회적, 직업적, 기타 기능 영역에서 임상적으로 현저한 고통이나\n\n<!-- PAGE_13 -->\n###### 손상을 초래하는지 확인해야 한다.\n\n <!-- PAGE_13 -->\n###### 우울장애는 특정 양상(specifier)에 따라 분류할 수 있으며 각각의\n\n<!-- PAGE_13 -->\n###### 특성이 달라 약물 선택 등의 치료 방향 결정을 다르게 해야 한다.  크게\n\n<!-- PAGE_13 -->\n###### 불안증(anxious distress) 동반, 혼재성 양상(mixed features) 동반, 멜랑\n\n<!-- PAGE_13 -->\n###### 콜리아 양상(melancholic features) 동반, 비전형적 양상(atypical features)\n\n<!-- PAGE_13 -->\n###### 동반, 정신병적 양상(psychotic features) 동반, 긴장증(catatonia) 동반,\n\n<!-- PAGE_13 -->\n###### 주산기 발병(peripartum onset) 동반, 계절성(seasonal patterns) 동반으로\n\n- - 7 -\n<!-- PAGE_14 -->\n###### 진단할 수 있다.\n\n <!-- PAGE_14 -->\n###### 우울장애 환자는 기분 증상 외에도 사고 증상, 인지 증상, 정신운동\n\n<!-- PAGE_14 -->\n###### 증상, 신체 증상, 정신병적 증상 등이 다양하게 나타나기 때문에 복잡한\n\n<!-- PAGE_14 -->\n###### 감별이 있을 수 있다.  인지 증상의 저하로 인한 가성치매로 인해 치매\n\n<!-- PAGE_14 -->\n###### 환자와 감별해야 하며, 정신병적 증상이 조현병 또는 우울장애 때문인지\n\n<!-- PAGE_14 -->\n###### 감별해야 하며, 환자가 호소하는 여러 가지 신체 증상이 기질적인 문제\n\n<!-- PAGE_14 -->\n###### 때문인지 감별할 필요가 있다.\n\n",
        "original_sentence": "<!-- PAGE_13 -->\n###### 우울장애는 특정 양상(specifier)에 따라 분류할 수 있으며 각각의\n\n<!-- PAGE_13 -->\n###### 특성이 달라 약물 선택 등의 치료 방향 결정을 다르게 해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_462",
      "text": "크게\n\n<!-- PAGE_13 -->\n###### 불안증(anxious distress) 동반, 혼재성 양상(mixed features) 동반, 멜랑\n\n<!-- PAGE_13 -->\n###### 콜리아 양상(melancholic features) 동반, 비전형적 양상(atypical features)\n\n<!-- PAGE_13 -->\n###### 동반, 정신병적 양상(psychotic features) 동반, 긴장증(catatonia) 동반,\n\n<!-- PAGE_13 -->\n###### 주산기 발병(peripartum onset) 동반, 계절성(seasonal patterns) 동반으로\n\n- - 7 -\n<!-- PAGE_14 -->\n###### 진단할 수 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 461,
        "window_size": 3,
        "char_count": 375,
        "word_count": 57,
        "page_number": 13,
        "window_text": "만성적인 정신병적 증상의 경과 중에 발생한 것이 아니어야\n\n<!-- PAGE_13 -->\n###### 하며, 물질이나 내과적 상태 때문이 아니어야 한다.  이러한 증상으로\n\n<!-- PAGE_13 -->\n###### 인해 사회적, 직업적, 기타 기능 영역에서 임상적으로 현저한 고통이나\n\n<!-- PAGE_13 -->\n###### 손상을 초래하는지 확인해야 한다.\n\n <!-- PAGE_13 -->\n###### 우울장애는 특정 양상(specifier)에 따라 분류할 수 있으며 각각의\n\n<!-- PAGE_13 -->\n###### 특성이 달라 약물 선택 등의 치료 방향 결정을 다르게 해야 한다.  크게\n\n<!-- PAGE_13 -->\n###### 불안증(anxious distress) 동반, 혼재성 양상(mixed features) 동반, 멜랑\n\n<!-- PAGE_13 -->\n###### 콜리아 양상(melancholic features) 동반, 비전형적 양상(atypical features)\n\n<!-- PAGE_13 -->\n###### 동반, 정신병적 양상(psychotic features) 동반, 긴장증(catatonia) 동반,\n\n<!-- PAGE_13 -->\n###### 주산기 발병(peripartum onset) 동반, 계절성(seasonal patterns) 동반으로\n\n- - 7 -\n<!-- PAGE_14 -->\n###### 진단할 수 있다.\n\n <!-- PAGE_14 -->\n###### 우울장애 환자는 기분 증상 외에도 사고 증상, 인지 증상, 정신운동\n\n<!-- PAGE_14 -->\n###### 증상, 신체 증상, 정신병적 증상 등이 다양하게 나타나기 때문에 복잡한\n\n<!-- PAGE_14 -->\n###### 감별이 있을 수 있다.  인지 증상의 저하로 인한 가성치매로 인해 치매\n\n<!-- PAGE_14 -->\n###### 환자와 감별해야 하며, 정신병적 증상이 조현병 또는 우울장애 때문인지\n\n<!-- PAGE_14 -->\n###### 감별해야 하며, 환자가 호소하는 여러 가지 신체 증상이 기질적인 문제\n\n<!-- PAGE_14 -->\n###### 때문인지 감별할 필요가 있다.\n\n - - 8 -\n- - 9 -\n<!-- PAGE_16 -->\n###### 다. ",
        "original_sentence": "크게\n\n<!-- PAGE_13 -->\n###### 불안증(anxious distress) 동반, 혼재성 양상(mixed features) 동반, 멜랑\n\n<!-- PAGE_13 -->\n###### 콜리아 양상(melancholic features) 동반, 비전형적 양상(atypical features)\n\n<!-- PAGE_13 -->\n###### 동반, 정신병적 양상(psychotic features) 동반, 긴장증(catatonia) 동반,\n\n<!-- PAGE_13 -->\n###### 주산기 발병(peripartum onset) 동반, 계절성(seasonal patterns) 동반으로\n\n- - 7 -\n<!-- PAGE_14 -->\n###### 진단할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_463",
      "text": "<!-- PAGE_14 -->\n###### 우울장애 환자는 기분 증상 외에도 사고 증상, 인지 증상, 정신운동\n\n<!-- PAGE_14 -->\n###### 증상, 신체 증상, 정신병적 증상 등이 다양하게 나타나기 때문에 복잡한\n\n<!-- PAGE_14 -->\n###### 감별이 있을 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 462,
        "window_size": 3,
        "char_count": 165,
        "word_count": 36,
        "page_number": 14,
        "window_text": "이러한 증상으로\n\n<!-- PAGE_13 -->\n###### 인해 사회적, 직업적, 기타 기능 영역에서 임상적으로 현저한 고통이나\n\n<!-- PAGE_13 -->\n###### 손상을 초래하는지 확인해야 한다.\n\n <!-- PAGE_13 -->\n###### 우울장애는 특정 양상(specifier)에 따라 분류할 수 있으며 각각의\n\n<!-- PAGE_13 -->\n###### 특성이 달라 약물 선택 등의 치료 방향 결정을 다르게 해야 한다.  크게\n\n<!-- PAGE_13 -->\n###### 불안증(anxious distress) 동반, 혼재성 양상(mixed features) 동반, 멜랑\n\n<!-- PAGE_13 -->\n###### 콜리아 양상(melancholic features) 동반, 비전형적 양상(atypical features)\n\n<!-- PAGE_13 -->\n###### 동반, 정신병적 양상(psychotic features) 동반, 긴장증(catatonia) 동반,\n\n<!-- PAGE_13 -->\n###### 주산기 발병(peripartum onset) 동반, 계절성(seasonal patterns) 동반으로\n\n- - 7 -\n<!-- PAGE_14 -->\n###### 진단할 수 있다.\n\n <!-- PAGE_14 -->\n###### 우울장애 환자는 기분 증상 외에도 사고 증상, 인지 증상, 정신운동\n\n<!-- PAGE_14 -->\n###### 증상, 신체 증상, 정신병적 증상 등이 다양하게 나타나기 때문에 복잡한\n\n<!-- PAGE_14 -->\n###### 감별이 있을 수 있다.  인지 증상의 저하로 인한 가성치매로 인해 치매\n\n<!-- PAGE_14 -->\n###### 환자와 감별해야 하며, 정신병적 증상이 조현병 또는 우울장애 때문인지\n\n<!-- PAGE_14 -->\n###### 감별해야 하며, 환자가 호소하는 여러 가지 신체 증상이 기질적인 문제\n\n<!-- PAGE_14 -->\n###### 때문인지 감별할 필요가 있다.\n\n - - 8 -\n- - 9 -\n<!-- PAGE_16 -->\n###### 다.  우울장애 비약물 치료\n\n<!-- PAGE_16 -->\n###### 우울장애 비약물 치료에는 인지행동치료(Cognitive Behavioral Therapy,\n\n<!-- PAGE_16 -->\n###### CBT), 대인관계 정신치료(Interpersonal Therapy, ITP), 마음 챙김 인지\n\n<!-- PAGE_16 -->\n###### 치료(Mindfulness-Based Cognitive therapy, MBCT) 등이 증상을 경감\n\n<!-- PAGE_16 -->\n###### 시키는데 효과적인 방법이며, 경증 또는 중등도 우울장애에서는 비약물\n\n<!-- PAGE_16 -->\n###### 치료를 우선하여 고려할 수 있다. ",
        "original_sentence": "<!-- PAGE_14 -->\n###### 우울장애 환자는 기분 증상 외에도 사고 증상, 인지 증상, 정신운동\n\n<!-- PAGE_14 -->\n###### 증상, 신체 증상, 정신병적 증상 등이 다양하게 나타나기 때문에 복잡한\n\n<!-- PAGE_14 -->\n###### 감별이 있을 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_464",
      "text": "인지 증상의 저하로 인한 가성치매로 인해 치매\n\n<!-- PAGE_14 -->\n###### 환자와 감별해야 하며, 정신병적 증상이 조현병 또는 우울장애 때문인지\n\n<!-- PAGE_14 -->\n###### 감별해야 하며, 환자가 호소하는 여러 가지 신체 증상이 기질적인 문제\n\n<!-- PAGE_14 -->\n###### 때문인지 감별할 필요가 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 463,
        "window_size": 3,
        "char_count": 197,
        "word_count": 42,
        "page_number": 14,
        "window_text": "<!-- PAGE_13 -->\n###### 우울장애는 특정 양상(specifier)에 따라 분류할 수 있으며 각각의\n\n<!-- PAGE_13 -->\n###### 특성이 달라 약물 선택 등의 치료 방향 결정을 다르게 해야 한다.  크게\n\n<!-- PAGE_13 -->\n###### 불안증(anxious distress) 동반, 혼재성 양상(mixed features) 동반, 멜랑\n\n<!-- PAGE_13 -->\n###### 콜리아 양상(melancholic features) 동반, 비전형적 양상(atypical features)\n\n<!-- PAGE_13 -->\n###### 동반, 정신병적 양상(psychotic features) 동반, 긴장증(catatonia) 동반,\n\n<!-- PAGE_13 -->\n###### 주산기 발병(peripartum onset) 동반, 계절성(seasonal patterns) 동반으로\n\n- - 7 -\n<!-- PAGE_14 -->\n###### 진단할 수 있다.\n\n <!-- PAGE_14 -->\n###### 우울장애 환자는 기분 증상 외에도 사고 증상, 인지 증상, 정신운동\n\n<!-- PAGE_14 -->\n###### 증상, 신체 증상, 정신병적 증상 등이 다양하게 나타나기 때문에 복잡한\n\n<!-- PAGE_14 -->\n###### 감별이 있을 수 있다.  인지 증상의 저하로 인한 가성치매로 인해 치매\n\n<!-- PAGE_14 -->\n###### 환자와 감별해야 하며, 정신병적 증상이 조현병 또는 우울장애 때문인지\n\n<!-- PAGE_14 -->\n###### 감별해야 하며, 환자가 호소하는 여러 가지 신체 증상이 기질적인 문제\n\n<!-- PAGE_14 -->\n###### 때문인지 감별할 필요가 있다.\n\n - - 8 -\n- - 9 -\n<!-- PAGE_16 -->\n###### 다.  우울장애 비약물 치료\n\n<!-- PAGE_16 -->\n###### 우울장애 비약물 치료에는 인지행동치료(Cognitive Behavioral Therapy,\n\n<!-- PAGE_16 -->\n###### CBT), 대인관계 정신치료(Interpersonal Therapy, ITP), 마음 챙김 인지\n\n<!-- PAGE_16 -->\n###### 치료(Mindfulness-Based Cognitive therapy, MBCT) 등이 증상을 경감\n\n<!-- PAGE_16 -->\n###### 시키는데 효과적인 방법이며, 경증 또는 중등도 우울장애에서는 비약물\n\n<!-- PAGE_16 -->\n###### 치료를 우선하여 고려할 수 있다.  비약물 치료 중 대표적으로 인지행동\n\n<!-- PAGE_16 -->\n###### 치료(CBT)가 권고되고 있으며, 임상에서 개인치료 또는 집단치료\n\n<!-- PAGE_16 -->\n###### 형식으로 활발하게 사용되고 있다.\n\n",
        "original_sentence": "인지 증상의 저하로 인한 가성치매로 인해 치매\n\n<!-- PAGE_14 -->\n###### 환자와 감별해야 하며, 정신병적 증상이 조현병 또는 우울장애 때문인지\n\n<!-- PAGE_14 -->\n###### 감별해야 하며, 환자가 호소하는 여러 가지 신체 증상이 기질적인 문제\n\n<!-- PAGE_14 -->\n###### 때문인지 감별할 필요가 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_465",
      "text": "- - 8 -\n- - 9 -\n<!-- PAGE_16 -->\n###### 다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 464,
        "window_size": 3,
        "char_count": 43,
        "word_count": 13,
        "page_number": 16,
        "window_text": "크게\n\n<!-- PAGE_13 -->\n###### 불안증(anxious distress) 동반, 혼재성 양상(mixed features) 동반, 멜랑\n\n<!-- PAGE_13 -->\n###### 콜리아 양상(melancholic features) 동반, 비전형적 양상(atypical features)\n\n<!-- PAGE_13 -->\n###### 동반, 정신병적 양상(psychotic features) 동반, 긴장증(catatonia) 동반,\n\n<!-- PAGE_13 -->\n###### 주산기 발병(peripartum onset) 동반, 계절성(seasonal patterns) 동반으로\n\n- - 7 -\n<!-- PAGE_14 -->\n###### 진단할 수 있다.\n\n <!-- PAGE_14 -->\n###### 우울장애 환자는 기분 증상 외에도 사고 증상, 인지 증상, 정신운동\n\n<!-- PAGE_14 -->\n###### 증상, 신체 증상, 정신병적 증상 등이 다양하게 나타나기 때문에 복잡한\n\n<!-- PAGE_14 -->\n###### 감별이 있을 수 있다.  인지 증상의 저하로 인한 가성치매로 인해 치매\n\n<!-- PAGE_14 -->\n###### 환자와 감별해야 하며, 정신병적 증상이 조현병 또는 우울장애 때문인지\n\n<!-- PAGE_14 -->\n###### 감별해야 하며, 환자가 호소하는 여러 가지 신체 증상이 기질적인 문제\n\n<!-- PAGE_14 -->\n###### 때문인지 감별할 필요가 있다.\n\n - - 8 -\n- - 9 -\n<!-- PAGE_16 -->\n###### 다.  우울장애 비약물 치료\n\n<!-- PAGE_16 -->\n###### 우울장애 비약물 치료에는 인지행동치료(Cognitive Behavioral Therapy,\n\n<!-- PAGE_16 -->\n###### CBT), 대인관계 정신치료(Interpersonal Therapy, ITP), 마음 챙김 인지\n\n<!-- PAGE_16 -->\n###### 치료(Mindfulness-Based Cognitive therapy, MBCT) 등이 증상을 경감\n\n<!-- PAGE_16 -->\n###### 시키는데 효과적인 방법이며, 경증 또는 중등도 우울장애에서는 비약물\n\n<!-- PAGE_16 -->\n###### 치료를 우선하여 고려할 수 있다.  비약물 치료 중 대표적으로 인지행동\n\n<!-- PAGE_16 -->\n###### 치료(CBT)가 권고되고 있으며, 임상에서 개인치료 또는 집단치료\n\n<!-- PAGE_16 -->\n###### 형식으로 활발하게 사용되고 있다.\n\n <!-- PAGE_16 -->\n###### 우울장애 인지행동치료(Cognitive Behavioral Therapy for Depression,\n\n<!-- PAGE_16 -->\n###### CBT-D)는 단기적으로는 약물치료와 그 효과가 유사하며 장기적인\n\n<!-- PAGE_16 -->\n###### 효과는 약물치료보다 우수한 것으로 밝혀져 있으며, 이러한 효과\n\n<!-- PAGE_16 -->\n###### 입증을 통해 일차 치료로 권장되고 있다(Churchill et al., 2013, Van\n\n<!-- PAGE_16 -->\n###### Hees et al., 2013). ",
        "original_sentence": "- - 8 -\n- - 9 -\n<!-- PAGE_16 -->\n###### 다. "
      }
    },
    {
      "chunk_id": "chunk_466",
      "text": "우울장애 비약물 치료\n\n<!-- PAGE_16 -->\n###### 우울장애 비약물 치료에는 인지행동치료(Cognitive Behavioral Therapy,\n\n<!-- PAGE_16 -->\n###### CBT), 대인관계 정신치료(Interpersonal Therapy, ITP), 마음 챙김 인지\n\n<!-- PAGE_16 -->\n###### 치료(Mindfulness-Based Cognitive therapy, MBCT) 등이 증상을 경감\n\n<!-- PAGE_16 -->\n###### 시키는데 효과적인 방법이며, 경증 또는 중등도 우울장애에서는 비약물\n\n<!-- PAGE_16 -->\n###### 치료를 우선하여 고려할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 465,
        "window_size": 3,
        "char_count": 355,
        "word_count": 57,
        "page_number": 16,
        "window_text": "<!-- PAGE_14 -->\n###### 우울장애 환자는 기분 증상 외에도 사고 증상, 인지 증상, 정신운동\n\n<!-- PAGE_14 -->\n###### 증상, 신체 증상, 정신병적 증상 등이 다양하게 나타나기 때문에 복잡한\n\n<!-- PAGE_14 -->\n###### 감별이 있을 수 있다.  인지 증상의 저하로 인한 가성치매로 인해 치매\n\n<!-- PAGE_14 -->\n###### 환자와 감별해야 하며, 정신병적 증상이 조현병 또는 우울장애 때문인지\n\n<!-- PAGE_14 -->\n###### 감별해야 하며, 환자가 호소하는 여러 가지 신체 증상이 기질적인 문제\n\n<!-- PAGE_14 -->\n###### 때문인지 감별할 필요가 있다.\n\n - - 8 -\n- - 9 -\n<!-- PAGE_16 -->\n###### 다.  우울장애 비약물 치료\n\n<!-- PAGE_16 -->\n###### 우울장애 비약물 치료에는 인지행동치료(Cognitive Behavioral Therapy,\n\n<!-- PAGE_16 -->\n###### CBT), 대인관계 정신치료(Interpersonal Therapy, ITP), 마음 챙김 인지\n\n<!-- PAGE_16 -->\n###### 치료(Mindfulness-Based Cognitive therapy, MBCT) 등이 증상을 경감\n\n<!-- PAGE_16 -->\n###### 시키는데 효과적인 방법이며, 경증 또는 중등도 우울장애에서는 비약물\n\n<!-- PAGE_16 -->\n###### 치료를 우선하여 고려할 수 있다.  비약물 치료 중 대표적으로 인지행동\n\n<!-- PAGE_16 -->\n###### 치료(CBT)가 권고되고 있으며, 임상에서 개인치료 또는 집단치료\n\n<!-- PAGE_16 -->\n###### 형식으로 활발하게 사용되고 있다.\n\n <!-- PAGE_16 -->\n###### 우울장애 인지행동치료(Cognitive Behavioral Therapy for Depression,\n\n<!-- PAGE_16 -->\n###### CBT-D)는 단기적으로는 약물치료와 그 효과가 유사하며 장기적인\n\n<!-- PAGE_16 -->\n###### 효과는 약물치료보다 우수한 것으로 밝혀져 있으며, 이러한 효과\n\n<!-- PAGE_16 -->\n###### 입증을 통해 일차 치료로 권장되고 있다(Churchill et al., 2013, Van\n\n<!-- PAGE_16 -->\n###### Hees et al., 2013).  선행 연구에 의하면, 약물치료나 비약물 치료를\n\n<!-- PAGE_16 -->\n###### 단독으로 사용하기보다는 병용하면 우울장애에 대한 치료 효과가\n\n<!-- PAGE_16 -->\n###### 더 우수한 것으로 나타났다(Cuijpers et al., 2013, Kriston et al., 2014).\n\n",
        "original_sentence": "우울장애 비약물 치료\n\n<!-- PAGE_16 -->\n###### 우울장애 비약물 치료에는 인지행동치료(Cognitive Behavioral Therapy,\n\n<!-- PAGE_16 -->\n###### CBT), 대인관계 정신치료(Interpersonal Therapy, ITP), 마음 챙김 인지\n\n<!-- PAGE_16 -->\n###### 치료(Mindfulness-Based Cognitive therapy, MBCT) 등이 증상을 경감\n\n<!-- PAGE_16 -->\n###### 시키는데 효과적인 방법이며, 경증 또는 중등도 우울장애에서는 비약물\n\n<!-- PAGE_16 -->\n###### 치료를 우선하여 고려할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_467",
      "text": "비약물 치료 중 대표적으로 인지행동\n\n<!-- PAGE_16 -->\n###### 치료(CBT)가 권고되고 있으며, 임상에서 개인치료 또는 집단치료\n\n<!-- PAGE_16 -->\n###### 형식으로 활발하게 사용되고 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 466,
        "window_size": 3,
        "char_count": 127,
        "word_count": 24,
        "page_number": 16,
        "window_text": "인지 증상의 저하로 인한 가성치매로 인해 치매\n\n<!-- PAGE_14 -->\n###### 환자와 감별해야 하며, 정신병적 증상이 조현병 또는 우울장애 때문인지\n\n<!-- PAGE_14 -->\n###### 감별해야 하며, 환자가 호소하는 여러 가지 신체 증상이 기질적인 문제\n\n<!-- PAGE_14 -->\n###### 때문인지 감별할 필요가 있다.\n\n - - 8 -\n- - 9 -\n<!-- PAGE_16 -->\n###### 다.  우울장애 비약물 치료\n\n<!-- PAGE_16 -->\n###### 우울장애 비약물 치료에는 인지행동치료(Cognitive Behavioral Therapy,\n\n<!-- PAGE_16 -->\n###### CBT), 대인관계 정신치료(Interpersonal Therapy, ITP), 마음 챙김 인지\n\n<!-- PAGE_16 -->\n###### 치료(Mindfulness-Based Cognitive therapy, MBCT) 등이 증상을 경감\n\n<!-- PAGE_16 -->\n###### 시키는데 효과적인 방법이며, 경증 또는 중등도 우울장애에서는 비약물\n\n<!-- PAGE_16 -->\n###### 치료를 우선하여 고려할 수 있다.  비약물 치료 중 대표적으로 인지행동\n\n<!-- PAGE_16 -->\n###### 치료(CBT)가 권고되고 있으며, 임상에서 개인치료 또는 집단치료\n\n<!-- PAGE_16 -->\n###### 형식으로 활발하게 사용되고 있다.\n\n <!-- PAGE_16 -->\n###### 우울장애 인지행동치료(Cognitive Behavioral Therapy for Depression,\n\n<!-- PAGE_16 -->\n###### CBT-D)는 단기적으로는 약물치료와 그 효과가 유사하며 장기적인\n\n<!-- PAGE_16 -->\n###### 효과는 약물치료보다 우수한 것으로 밝혀져 있으며, 이러한 효과\n\n<!-- PAGE_16 -->\n###### 입증을 통해 일차 치료로 권장되고 있다(Churchill et al., 2013, Van\n\n<!-- PAGE_16 -->\n###### Hees et al., 2013).  선행 연구에 의하면, 약물치료나 비약물 치료를\n\n<!-- PAGE_16 -->\n###### 단독으로 사용하기보다는 병용하면 우울장애에 대한 치료 효과가\n\n<!-- PAGE_16 -->\n###### 더 우수한 것으로 나타났다(Cuijpers et al., 2013, Kriston et al., 2014).\n\n <!-- PAGE_16 -->\n###### 우울장애 인지행동치료는 우울장애 환자의 역기능 사고로 인해\n\n<!-- PAGE_16 -->\n###### 발생하고 유지된다는 이론 근거를 기반으로 하며, 이러한 역기능 사고를\n\n<!-- PAGE_16 -->\n###### 발견하고 수정하는 것을 치료 목표로 한다. ",
        "original_sentence": "비약물 치료 중 대표적으로 인지행동\n\n<!-- PAGE_16 -->\n###### 치료(CBT)가 권고되고 있으며, 임상에서 개인치료 또는 집단치료\n\n<!-- PAGE_16 -->\n###### 형식으로 활발하게 사용되고 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_468",
      "text": "<!-- PAGE_16 -->\n###### 우울장애 인지행동치료(Cognitive Behavioral Therapy for Depression,\n\n<!-- PAGE_16 -->\n###### CBT-D)는 단기적으로는 약물치료와 그 효과가 유사하며 장기적인\n\n<!-- PAGE_16 -->\n###### 효과는 약물치료보다 우수한 것으로 밝혀져 있으며, 이러한 효과\n\n<!-- PAGE_16 -->\n###### 입증을 통해 일차 치료로 권장되고 있다(Churchill et al., 2013, Van\n\n<!-- PAGE_16 -->\n###### Hees et al., 2013). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 467,
        "window_size": 3,
        "char_count": 323,
        "word_count": 55,
        "page_number": 16,
        "window_text": "- - 8 -\n- - 9 -\n<!-- PAGE_16 -->\n###### 다.  우울장애 비약물 치료\n\n<!-- PAGE_16 -->\n###### 우울장애 비약물 치료에는 인지행동치료(Cognitive Behavioral Therapy,\n\n<!-- PAGE_16 -->\n###### CBT), 대인관계 정신치료(Interpersonal Therapy, ITP), 마음 챙김 인지\n\n<!-- PAGE_16 -->\n###### 치료(Mindfulness-Based Cognitive therapy, MBCT) 등이 증상을 경감\n\n<!-- PAGE_16 -->\n###### 시키는데 효과적인 방법이며, 경증 또는 중등도 우울장애에서는 비약물\n\n<!-- PAGE_16 -->\n###### 치료를 우선하여 고려할 수 있다.  비약물 치료 중 대표적으로 인지행동\n\n<!-- PAGE_16 -->\n###### 치료(CBT)가 권고되고 있으며, 임상에서 개인치료 또는 집단치료\n\n<!-- PAGE_16 -->\n###### 형식으로 활발하게 사용되고 있다.\n\n <!-- PAGE_16 -->\n###### 우울장애 인지행동치료(Cognitive Behavioral Therapy for Depression,\n\n<!-- PAGE_16 -->\n###### CBT-D)는 단기적으로는 약물치료와 그 효과가 유사하며 장기적인\n\n<!-- PAGE_16 -->\n###### 효과는 약물치료보다 우수한 것으로 밝혀져 있으며, 이러한 효과\n\n<!-- PAGE_16 -->\n###### 입증을 통해 일차 치료로 권장되고 있다(Churchill et al., 2013, Van\n\n<!-- PAGE_16 -->\n###### Hees et al., 2013).  선행 연구에 의하면, 약물치료나 비약물 치료를\n\n<!-- PAGE_16 -->\n###### 단독으로 사용하기보다는 병용하면 우울장애에 대한 치료 효과가\n\n<!-- PAGE_16 -->\n###### 더 우수한 것으로 나타났다(Cuijpers et al., 2013, Kriston et al., 2014).\n\n <!-- PAGE_16 -->\n###### 우울장애 인지행동치료는 우울장애 환자의 역기능 사고로 인해\n\n<!-- PAGE_16 -->\n###### 발생하고 유지된다는 이론 근거를 기반으로 하며, 이러한 역기능 사고를\n\n<!-- PAGE_16 -->\n###### 발견하고 수정하는 것을 치료 목표로 한다.  우울장애 환자의 자기, 환경,\n\n<!-- PAGE_16 -->\n###### 미래에 대한 비합리적인 믿음과 왜곡된 태도가 우울한 영향을 영속\n\n<!-- PAGE_16 -->\n###### 시키고 기능을 훼손한다고 가정한다. ",
        "original_sentence": "<!-- PAGE_16 -->\n###### 우울장애 인지행동치료(Cognitive Behavioral Therapy for Depression,\n\n<!-- PAGE_16 -->\n###### CBT-D)는 단기적으로는 약물치료와 그 효과가 유사하며 장기적인\n\n<!-- PAGE_16 -->\n###### 효과는 약물치료보다 우수한 것으로 밝혀져 있으며, 이러한 효과\n\n<!-- PAGE_16 -->\n###### 입증을 통해 일차 치료로 권장되고 있다(Churchill et al., 2013, Van\n\n<!-- PAGE_16 -->\n###### Hees et al., 2013). "
      }
    },
    {
      "chunk_id": "chunk_469",
      "text": "선행 연구에 의하면, 약물치료나 비약물 치료를\n\n<!-- PAGE_16 -->\n###### 단독으로 사용하기보다는 병용하면 우울장애에 대한 치료 효과가\n\n<!-- PAGE_16 -->\n###### 더 우수한 것으로 나타났다(Cuijpers et al., 2013, Kriston et al., 2014).\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 468,
        "window_size": 3,
        "char_count": 172,
        "word_count": 32,
        "page_number": 16,
        "window_text": "우울장애 비약물 치료\n\n<!-- PAGE_16 -->\n###### 우울장애 비약물 치료에는 인지행동치료(Cognitive Behavioral Therapy,\n\n<!-- PAGE_16 -->\n###### CBT), 대인관계 정신치료(Interpersonal Therapy, ITP), 마음 챙김 인지\n\n<!-- PAGE_16 -->\n###### 치료(Mindfulness-Based Cognitive therapy, MBCT) 등이 증상을 경감\n\n<!-- PAGE_16 -->\n###### 시키는데 효과적인 방법이며, 경증 또는 중등도 우울장애에서는 비약물\n\n<!-- PAGE_16 -->\n###### 치료를 우선하여 고려할 수 있다.  비약물 치료 중 대표적으로 인지행동\n\n<!-- PAGE_16 -->\n###### 치료(CBT)가 권고되고 있으며, 임상에서 개인치료 또는 집단치료\n\n<!-- PAGE_16 -->\n###### 형식으로 활발하게 사용되고 있다.\n\n <!-- PAGE_16 -->\n###### 우울장애 인지행동치료(Cognitive Behavioral Therapy for Depression,\n\n<!-- PAGE_16 -->\n###### CBT-D)는 단기적으로는 약물치료와 그 효과가 유사하며 장기적인\n\n<!-- PAGE_16 -->\n###### 효과는 약물치료보다 우수한 것으로 밝혀져 있으며, 이러한 효과\n\n<!-- PAGE_16 -->\n###### 입증을 통해 일차 치료로 권장되고 있다(Churchill et al., 2013, Van\n\n<!-- PAGE_16 -->\n###### Hees et al., 2013).  선행 연구에 의하면, 약물치료나 비약물 치료를\n\n<!-- PAGE_16 -->\n###### 단독으로 사용하기보다는 병용하면 우울장애에 대한 치료 효과가\n\n<!-- PAGE_16 -->\n###### 더 우수한 것으로 나타났다(Cuijpers et al., 2013, Kriston et al., 2014).\n\n <!-- PAGE_16 -->\n###### 우울장애 인지행동치료는 우울장애 환자의 역기능 사고로 인해\n\n<!-- PAGE_16 -->\n###### 발생하고 유지된다는 이론 근거를 기반으로 하며, 이러한 역기능 사고를\n\n<!-- PAGE_16 -->\n###### 발견하고 수정하는 것을 치료 목표로 한다.  우울장애 환자의 자기, 환경,\n\n<!-- PAGE_16 -->\n###### 미래에 대한 비합리적인 믿음과 왜곡된 태도가 우울한 영향을 영속\n\n<!-- PAGE_16 -->\n###### 시키고 기능을 훼손한다고 가정한다.  우울장애 인지행동치료는 환자의\n\n<!-- PAGE_16 -->\n###### 신념과 태도를 도전하고 뒤집으며 실생활에서 부적응 선입견과 행동을\n\n<!-- PAGE_16 -->\n###### 환자가 바꾸도록 유도함으로써 우울장애 증상을 줄이고자 한다.\n\n",
        "original_sentence": "선행 연구에 의하면, 약물치료나 비약물 치료를\n\n<!-- PAGE_16 -->\n###### 단독으로 사용하기보다는 병용하면 우울장애에 대한 치료 효과가\n\n<!-- PAGE_16 -->\n###### 더 우수한 것으로 나타났다(Cuijpers et al., 2013, Kriston et al., 2014).\n\n"
      }
    },
    {
      "chunk_id": "chunk_470",
      "text": "<!-- PAGE_16 -->\n###### 우울장애 인지행동치료는 우울장애 환자의 역기능 사고로 인해\n\n<!-- PAGE_16 -->\n###### 발생하고 유지된다는 이론 근거를 기반으로 하며, 이러한 역기능 사고를\n\n<!-- PAGE_16 -->\n###### 발견하고 수정하는 것을 치료 목표로 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 469,
        "window_size": 3,
        "char_count": 170,
        "word_count": 34,
        "page_number": 16,
        "window_text": "비약물 치료 중 대표적으로 인지행동\n\n<!-- PAGE_16 -->\n###### 치료(CBT)가 권고되고 있으며, 임상에서 개인치료 또는 집단치료\n\n<!-- PAGE_16 -->\n###### 형식으로 활발하게 사용되고 있다.\n\n <!-- PAGE_16 -->\n###### 우울장애 인지행동치료(Cognitive Behavioral Therapy for Depression,\n\n<!-- PAGE_16 -->\n###### CBT-D)는 단기적으로는 약물치료와 그 효과가 유사하며 장기적인\n\n<!-- PAGE_16 -->\n###### 효과는 약물치료보다 우수한 것으로 밝혀져 있으며, 이러한 효과\n\n<!-- PAGE_16 -->\n###### 입증을 통해 일차 치료로 권장되고 있다(Churchill et al., 2013, Van\n\n<!-- PAGE_16 -->\n###### Hees et al., 2013).  선행 연구에 의하면, 약물치료나 비약물 치료를\n\n<!-- PAGE_16 -->\n###### 단독으로 사용하기보다는 병용하면 우울장애에 대한 치료 효과가\n\n<!-- PAGE_16 -->\n###### 더 우수한 것으로 나타났다(Cuijpers et al., 2013, Kriston et al., 2014).\n\n <!-- PAGE_16 -->\n###### 우울장애 인지행동치료는 우울장애 환자의 역기능 사고로 인해\n\n<!-- PAGE_16 -->\n###### 발생하고 유지된다는 이론 근거를 기반으로 하며, 이러한 역기능 사고를\n\n<!-- PAGE_16 -->\n###### 발견하고 수정하는 것을 치료 목표로 한다.  우울장애 환자의 자기, 환경,\n\n<!-- PAGE_16 -->\n###### 미래에 대한 비합리적인 믿음과 왜곡된 태도가 우울한 영향을 영속\n\n<!-- PAGE_16 -->\n###### 시키고 기능을 훼손한다고 가정한다.  우울장애 인지행동치료는 환자의\n\n<!-- PAGE_16 -->\n###### 신념과 태도를 도전하고 뒤집으며 실생활에서 부적응 선입견과 행동을\n\n<!-- PAGE_16 -->\n###### 환자가 바꾸도록 유도함으로써 우울장애 증상을 줄이고자 한다.\n\n <!-- PAGE_16 -->\n###### 우울장애와 관련된 역기능 사고는 두 가지 수준으로 구분이 되는데,\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 하나는 자동 사고이며, 다른 하나는 핵심 신념이다. ",
        "original_sentence": "<!-- PAGE_16 -->\n###### 우울장애 인지행동치료는 우울장애 환자의 역기능 사고로 인해\n\n<!-- PAGE_16 -->\n###### 발생하고 유지된다는 이론 근거를 기반으로 하며, 이러한 역기능 사고를\n\n<!-- PAGE_16 -->\n###### 발견하고 수정하는 것을 치료 목표로 한다. "
      }
    },
    {
      "chunk_id": "chunk_471",
      "text": "우울장애 환자의 자기, 환경,\n\n<!-- PAGE_16 -->\n###### 미래에 대한 비합리적인 믿음과 왜곡된 태도가 우울한 영향을 영속\n\n<!-- PAGE_16 -->\n###### 시키고 기능을 훼손한다고 가정한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 470,
        "window_size": 3,
        "char_count": 123,
        "word_count": 25,
        "page_number": 16,
        "window_text": "<!-- PAGE_16 -->\n###### 우울장애 인지행동치료(Cognitive Behavioral Therapy for Depression,\n\n<!-- PAGE_16 -->\n###### CBT-D)는 단기적으로는 약물치료와 그 효과가 유사하며 장기적인\n\n<!-- PAGE_16 -->\n###### 효과는 약물치료보다 우수한 것으로 밝혀져 있으며, 이러한 효과\n\n<!-- PAGE_16 -->\n###### 입증을 통해 일차 치료로 권장되고 있다(Churchill et al., 2013, Van\n\n<!-- PAGE_16 -->\n###### Hees et al., 2013).  선행 연구에 의하면, 약물치료나 비약물 치료를\n\n<!-- PAGE_16 -->\n###### 단독으로 사용하기보다는 병용하면 우울장애에 대한 치료 효과가\n\n<!-- PAGE_16 -->\n###### 더 우수한 것으로 나타났다(Cuijpers et al., 2013, Kriston et al., 2014).\n\n <!-- PAGE_16 -->\n###### 우울장애 인지행동치료는 우울장애 환자의 역기능 사고로 인해\n\n<!-- PAGE_16 -->\n###### 발생하고 유지된다는 이론 근거를 기반으로 하며, 이러한 역기능 사고를\n\n<!-- PAGE_16 -->\n###### 발견하고 수정하는 것을 치료 목표로 한다.  우울장애 환자의 자기, 환경,\n\n<!-- PAGE_16 -->\n###### 미래에 대한 비합리적인 믿음과 왜곡된 태도가 우울한 영향을 영속\n\n<!-- PAGE_16 -->\n###### 시키고 기능을 훼손한다고 가정한다.  우울장애 인지행동치료는 환자의\n\n<!-- PAGE_16 -->\n###### 신념과 태도를 도전하고 뒤집으며 실생활에서 부적응 선입견과 행동을\n\n<!-- PAGE_16 -->\n###### 환자가 바꾸도록 유도함으로써 우울장애 증상을 줄이고자 한다.\n\n <!-- PAGE_16 -->\n###### 우울장애와 관련된 역기능 사고는 두 가지 수준으로 구분이 되는데,\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 하나는 자동 사고이며, 다른 하나는 핵심 신념이다.  자동 사고는 특정\n\n<!-- PAGE_17 -->\n###### 상황과 관련하여 자동으로 떠오르는 생각으로, 주의를 약간 기울이면\n\n<!-- PAGE_17 -->\n###### 쉽게 의식화할 수 있다. ",
        "original_sentence": "우울장애 환자의 자기, 환경,\n\n<!-- PAGE_16 -->\n###### 미래에 대한 비합리적인 믿음과 왜곡된 태도가 우울한 영향을 영속\n\n<!-- PAGE_16 -->\n###### 시키고 기능을 훼손한다고 가정한다. "
      }
    },
    {
      "chunk_id": "chunk_472",
      "text": "우울장애 인지행동치료는 환자의\n\n<!-- PAGE_16 -->\n###### 신념과 태도를 도전하고 뒤집으며 실생활에서 부적응 선입견과 행동을\n\n<!-- PAGE_16 -->\n###### 환자가 바꾸도록 유도함으로써 우울장애 증상을 줄이고자 한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 471,
        "window_size": 3,
        "char_count": 139,
        "word_count": 26,
        "page_number": 16,
        "window_text": "선행 연구에 의하면, 약물치료나 비약물 치료를\n\n<!-- PAGE_16 -->\n###### 단독으로 사용하기보다는 병용하면 우울장애에 대한 치료 효과가\n\n<!-- PAGE_16 -->\n###### 더 우수한 것으로 나타났다(Cuijpers et al., 2013, Kriston et al., 2014).\n\n <!-- PAGE_16 -->\n###### 우울장애 인지행동치료는 우울장애 환자의 역기능 사고로 인해\n\n<!-- PAGE_16 -->\n###### 발생하고 유지된다는 이론 근거를 기반으로 하며, 이러한 역기능 사고를\n\n<!-- PAGE_16 -->\n###### 발견하고 수정하는 것을 치료 목표로 한다.  우울장애 환자의 자기, 환경,\n\n<!-- PAGE_16 -->\n###### 미래에 대한 비합리적인 믿음과 왜곡된 태도가 우울한 영향을 영속\n\n<!-- PAGE_16 -->\n###### 시키고 기능을 훼손한다고 가정한다.  우울장애 인지행동치료는 환자의\n\n<!-- PAGE_16 -->\n###### 신념과 태도를 도전하고 뒤집으며 실생활에서 부적응 선입견과 행동을\n\n<!-- PAGE_16 -->\n###### 환자가 바꾸도록 유도함으로써 우울장애 증상을 줄이고자 한다.\n\n <!-- PAGE_16 -->\n###### 우울장애와 관련된 역기능 사고는 두 가지 수준으로 구분이 되는데,\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 하나는 자동 사고이며, 다른 하나는 핵심 신념이다.  자동 사고는 특정\n\n<!-- PAGE_17 -->\n###### 상황과 관련하여 자동으로 떠오르는 생각으로, 주의를 약간 기울이면\n\n<!-- PAGE_17 -->\n###### 쉽게 의식화할 수 있다.  반면 핵심 신념은 자동 사고보다는 추상화되어\n\n<!-- PAGE_17 -->\n###### 있으며, 일상생활 경험을 조직화한다. ",
        "original_sentence": "우울장애 인지행동치료는 환자의\n\n<!-- PAGE_16 -->\n###### 신념과 태도를 도전하고 뒤집으며 실생활에서 부적응 선입견과 행동을\n\n<!-- PAGE_16 -->\n###### 환자가 바꾸도록 유도함으로써 우울장애 증상을 줄이고자 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_473",
      "text": "<!-- PAGE_16 -->\n###### 우울장애와 관련된 역기능 사고는 두 가지 수준으로 구분이 되는데,\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 하나는 자동 사고이며, 다른 하나는 핵심 신념이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 472,
        "window_size": 3,
        "char_count": 124,
        "word_count": 28,
        "page_number": 16,
        "window_text": "<!-- PAGE_16 -->\n###### 우울장애 인지행동치료는 우울장애 환자의 역기능 사고로 인해\n\n<!-- PAGE_16 -->\n###### 발생하고 유지된다는 이론 근거를 기반으로 하며, 이러한 역기능 사고를\n\n<!-- PAGE_16 -->\n###### 발견하고 수정하는 것을 치료 목표로 한다.  우울장애 환자의 자기, 환경,\n\n<!-- PAGE_16 -->\n###### 미래에 대한 비합리적인 믿음과 왜곡된 태도가 우울한 영향을 영속\n\n<!-- PAGE_16 -->\n###### 시키고 기능을 훼손한다고 가정한다.  우울장애 인지행동치료는 환자의\n\n<!-- PAGE_16 -->\n###### 신념과 태도를 도전하고 뒤집으며 실생활에서 부적응 선입견과 행동을\n\n<!-- PAGE_16 -->\n###### 환자가 바꾸도록 유도함으로써 우울장애 증상을 줄이고자 한다.\n\n <!-- PAGE_16 -->\n###### 우울장애와 관련된 역기능 사고는 두 가지 수준으로 구분이 되는데,\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 하나는 자동 사고이며, 다른 하나는 핵심 신념이다.  자동 사고는 특정\n\n<!-- PAGE_17 -->\n###### 상황과 관련하여 자동으로 떠오르는 생각으로, 주의를 약간 기울이면\n\n<!-- PAGE_17 -->\n###### 쉽게 의식화할 수 있다.  반면 핵심 신념은 자동 사고보다는 추상화되어\n\n<!-- PAGE_17 -->\n###### 있으며, 일상생활 경험을 조직화한다.  우울장애 인지행동치료는 우울한\n\n<!-- PAGE_17 -->\n###### 기분에 대한 자동 사고를 수정하고 궁극적으로는 핵심 신념 변화를\n\n<!-- PAGE_17 -->\n###### 통해 우울장애 재발을 막고자 한다.\n\n",
        "original_sentence": "<!-- PAGE_16 -->\n###### 우울장애와 관련된 역기능 사고는 두 가지 수준으로 구분이 되는데,\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 하나는 자동 사고이며, 다른 하나는 핵심 신념이다. "
      }
    },
    {
      "chunk_id": "chunk_474",
      "text": "자동 사고는 특정\n\n<!-- PAGE_17 -->\n###### 상황과 관련하여 자동으로 떠오르는 생각으로, 주의를 약간 기울이면\n\n<!-- PAGE_17 -->\n###### 쉽게 의식화할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 473,
        "window_size": 3,
        "char_count": 111,
        "word_count": 23,
        "page_number": 17,
        "window_text": "우울장애 환자의 자기, 환경,\n\n<!-- PAGE_16 -->\n###### 미래에 대한 비합리적인 믿음과 왜곡된 태도가 우울한 영향을 영속\n\n<!-- PAGE_16 -->\n###### 시키고 기능을 훼손한다고 가정한다.  우울장애 인지행동치료는 환자의\n\n<!-- PAGE_16 -->\n###### 신념과 태도를 도전하고 뒤집으며 실생활에서 부적응 선입견과 행동을\n\n<!-- PAGE_16 -->\n###### 환자가 바꾸도록 유도함으로써 우울장애 증상을 줄이고자 한다.\n\n <!-- PAGE_16 -->\n###### 우울장애와 관련된 역기능 사고는 두 가지 수준으로 구분이 되는데,\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 하나는 자동 사고이며, 다른 하나는 핵심 신념이다.  자동 사고는 특정\n\n<!-- PAGE_17 -->\n###### 상황과 관련하여 자동으로 떠오르는 생각으로, 주의를 약간 기울이면\n\n<!-- PAGE_17 -->\n###### 쉽게 의식화할 수 있다.  반면 핵심 신념은 자동 사고보다는 추상화되어\n\n<!-- PAGE_17 -->\n###### 있으며, 일상생활 경험을 조직화한다.  우울장애 인지행동치료는 우울한\n\n<!-- PAGE_17 -->\n###### 기분에 대한 자동 사고를 수정하고 궁극적으로는 핵심 신념 변화를\n\n<!-- PAGE_17 -->\n###### 통해 우울장애 재발을 막고자 한다.\n\n <!-- PAGE_17 -->\n###### 우울장애 인지행동치료는 행동 기법과 인지 기법으로 구분할 수\n\n<!-- PAGE_17 -->\n###### 있다. ",
        "original_sentence": "자동 사고는 특정\n\n<!-- PAGE_17 -->\n###### 상황과 관련하여 자동으로 떠오르는 생각으로, 주의를 약간 기울이면\n\n<!-- PAGE_17 -->\n###### 쉽게 의식화할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_475",
      "text": "반면 핵심 신념은 자동 사고보다는 추상화되어\n\n<!-- PAGE_17 -->\n###### 있으며, 일상생활 경험을 조직화한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 474,
        "window_size": 3,
        "char_count": 71,
        "word_count": 14,
        "page_number": 17,
        "window_text": "우울장애 인지행동치료는 환자의\n\n<!-- PAGE_16 -->\n###### 신념과 태도를 도전하고 뒤집으며 실생활에서 부적응 선입견과 행동을\n\n<!-- PAGE_16 -->\n###### 환자가 바꾸도록 유도함으로써 우울장애 증상을 줄이고자 한다.\n\n <!-- PAGE_16 -->\n###### 우울장애와 관련된 역기능 사고는 두 가지 수준으로 구분이 되는데,\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 하나는 자동 사고이며, 다른 하나는 핵심 신념이다.  자동 사고는 특정\n\n<!-- PAGE_17 -->\n###### 상황과 관련하여 자동으로 떠오르는 생각으로, 주의를 약간 기울이면\n\n<!-- PAGE_17 -->\n###### 쉽게 의식화할 수 있다.  반면 핵심 신념은 자동 사고보다는 추상화되어\n\n<!-- PAGE_17 -->\n###### 있으며, 일상생활 경험을 조직화한다.  우울장애 인지행동치료는 우울한\n\n<!-- PAGE_17 -->\n###### 기분에 대한 자동 사고를 수정하고 궁극적으로는 핵심 신념 변화를\n\n<!-- PAGE_17 -->\n###### 통해 우울장애 재발을 막고자 한다.\n\n <!-- PAGE_17 -->\n###### 우울장애 인지행동치료는 행동 기법과 인지 기법으로 구분할 수\n\n<!-- PAGE_17 -->\n###### 있다.  우울장애 환자는 일상생활과 관련된 기능이 많이 떨어져 있을\n\n<!-- PAGE_17 -->\n###### 수 있으므로 행동 기법을 먼저 적용하는 것이 도움이 된다. ",
        "original_sentence": "반면 핵심 신념은 자동 사고보다는 추상화되어\n\n<!-- PAGE_17 -->\n###### 있으며, 일상생활 경험을 조직화한다. "
      }
    },
    {
      "chunk_id": "chunk_476",
      "text": "우울장애 인지행동치료는 우울한\n\n<!-- PAGE_17 -->\n###### 기분에 대한 자동 사고를 수정하고 궁극적으로는 핵심 신념 변화를\n\n<!-- PAGE_17 -->\n###### 통해 우울장애 재발을 막고자 한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 475,
        "window_size": 3,
        "char_count": 124,
        "word_count": 25,
        "page_number": 17,
        "window_text": "<!-- PAGE_16 -->\n###### 우울장애와 관련된 역기능 사고는 두 가지 수준으로 구분이 되는데,\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 하나는 자동 사고이며, 다른 하나는 핵심 신념이다.  자동 사고는 특정\n\n<!-- PAGE_17 -->\n###### 상황과 관련하여 자동으로 떠오르는 생각으로, 주의를 약간 기울이면\n\n<!-- PAGE_17 -->\n###### 쉽게 의식화할 수 있다.  반면 핵심 신념은 자동 사고보다는 추상화되어\n\n<!-- PAGE_17 -->\n###### 있으며, 일상생활 경험을 조직화한다.  우울장애 인지행동치료는 우울한\n\n<!-- PAGE_17 -->\n###### 기분에 대한 자동 사고를 수정하고 궁극적으로는 핵심 신념 변화를\n\n<!-- PAGE_17 -->\n###### 통해 우울장애 재발을 막고자 한다.\n\n <!-- PAGE_17 -->\n###### 우울장애 인지행동치료는 행동 기법과 인지 기법으로 구분할 수\n\n<!-- PAGE_17 -->\n###### 있다.  우울장애 환자는 일상생활과 관련된 기능이 많이 떨어져 있을\n\n<!-- PAGE_17 -->\n###### 수 있으므로 행동 기법을 먼저 적용하는 것이 도움이 된다.  행동 기법은\n\n<!-- PAGE_17 -->\n###### ① 활동 계획(activity scheduling), ② 점진적 과업 주기(graded task\n\n<!-- PAGE_17 -->\n###### assignments), ③ 자기강화(self-reinforcement) 등이 있으며, 이를 통해\n\n<!-- PAGE_17 -->\n###### 우울장애 환자의 자기효능감을 향상하는 데 도움을 줄 수 있다.\n\n",
        "original_sentence": "우울장애 인지행동치료는 우울한\n\n<!-- PAGE_17 -->\n###### 기분에 대한 자동 사고를 수정하고 궁극적으로는 핵심 신념 변화를\n\n<!-- PAGE_17 -->\n###### 통해 우울장애 재발을 막고자 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_477",
      "text": "<!-- PAGE_17 -->\n###### 우울장애 인지행동치료는 행동 기법과 인지 기법으로 구분할 수\n\n<!-- PAGE_17 -->\n###### 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 476,
        "window_size": 3,
        "char_count": 87,
        "word_count": 17,
        "page_number": 17,
        "window_text": "자동 사고는 특정\n\n<!-- PAGE_17 -->\n###### 상황과 관련하여 자동으로 떠오르는 생각으로, 주의를 약간 기울이면\n\n<!-- PAGE_17 -->\n###### 쉽게 의식화할 수 있다.  반면 핵심 신념은 자동 사고보다는 추상화되어\n\n<!-- PAGE_17 -->\n###### 있으며, 일상생활 경험을 조직화한다.  우울장애 인지행동치료는 우울한\n\n<!-- PAGE_17 -->\n###### 기분에 대한 자동 사고를 수정하고 궁극적으로는 핵심 신념 변화를\n\n<!-- PAGE_17 -->\n###### 통해 우울장애 재발을 막고자 한다.\n\n <!-- PAGE_17 -->\n###### 우울장애 인지행동치료는 행동 기법과 인지 기법으로 구분할 수\n\n<!-- PAGE_17 -->\n###### 있다.  우울장애 환자는 일상생활과 관련된 기능이 많이 떨어져 있을\n\n<!-- PAGE_17 -->\n###### 수 있으므로 행동 기법을 먼저 적용하는 것이 도움이 된다.  행동 기법은\n\n<!-- PAGE_17 -->\n###### ① 활동 계획(activity scheduling), ② 점진적 과업 주기(graded task\n\n<!-- PAGE_17 -->\n###### assignments), ③ 자기강화(self-reinforcement) 등이 있으며, 이를 통해\n\n<!-- PAGE_17 -->\n###### 우울장애 환자의 자기효능감을 향상하는 데 도움을 줄 수 있다.\n\n <!-- PAGE_17 -->\n###### 인지행동치료 인지 기법으로는 ① 자동 사고 파악하기, ② 인지\n\n<!-- PAGE_17 -->\n###### 오류 찾기 등이 있다. ",
        "original_sentence": "<!-- PAGE_17 -->\n###### 우울장애 인지행동치료는 행동 기법과 인지 기법으로 구분할 수\n\n<!-- PAGE_17 -->\n###### 있다. "
      }
    },
    {
      "chunk_id": "chunk_478",
      "text": "우울장애 환자는 일상생활과 관련된 기능이 많이 떨어져 있을\n\n<!-- PAGE_17 -->\n###### 수 있으므로 행동 기법을 먼저 적용하는 것이 도움이 된다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 477,
        "window_size": 3,
        "char_count": 91,
        "word_count": 21,
        "page_number": 17,
        "window_text": "반면 핵심 신념은 자동 사고보다는 추상화되어\n\n<!-- PAGE_17 -->\n###### 있으며, 일상생활 경험을 조직화한다.  우울장애 인지행동치료는 우울한\n\n<!-- PAGE_17 -->\n###### 기분에 대한 자동 사고를 수정하고 궁극적으로는 핵심 신념 변화를\n\n<!-- PAGE_17 -->\n###### 통해 우울장애 재발을 막고자 한다.\n\n <!-- PAGE_17 -->\n###### 우울장애 인지행동치료는 행동 기법과 인지 기법으로 구분할 수\n\n<!-- PAGE_17 -->\n###### 있다.  우울장애 환자는 일상생활과 관련된 기능이 많이 떨어져 있을\n\n<!-- PAGE_17 -->\n###### 수 있으므로 행동 기법을 먼저 적용하는 것이 도움이 된다.  행동 기법은\n\n<!-- PAGE_17 -->\n###### ① 활동 계획(activity scheduling), ② 점진적 과업 주기(graded task\n\n<!-- PAGE_17 -->\n###### assignments), ③ 자기강화(self-reinforcement) 등이 있으며, 이를 통해\n\n<!-- PAGE_17 -->\n###### 우울장애 환자의 자기효능감을 향상하는 데 도움을 줄 수 있다.\n\n <!-- PAGE_17 -->\n###### 인지행동치료 인지 기법으로는 ① 자동 사고 파악하기, ② 인지\n\n<!-- PAGE_17 -->\n###### 오류 찾기 등이 있다.  우울한 기분과 관련성이 높은 자동 사고를 확인\n\n<!-- PAGE_17 -->\n###### 하기 위해서는 자동 사고가 무엇인지 알려주고, 우울감을 심하게 느낀\n\n<!-- PAGE_17 -->\n###### 상황을 이야기해봄으로써 자동 사고를 파악한다. ",
        "original_sentence": "우울장애 환자는 일상생활과 관련된 기능이 많이 떨어져 있을\n\n<!-- PAGE_17 -->\n###### 수 있으므로 행동 기법을 먼저 적용하는 것이 도움이 된다. "
      }
    },
    {
      "chunk_id": "chunk_479",
      "text": "행동 기법은\n\n<!-- PAGE_17 -->\n###### ① 활동 계획(activity scheduling), ② 점진적 과업 주기(graded task\n\n<!-- PAGE_17 -->\n###### assignments), ③ 자기강화(self-reinforcement) 등이 있으며, 이를 통해\n\n<!-- PAGE_17 -->\n###### 우울장애 환자의 자기효능감을 향상하는 데 도움을 줄 수 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 478,
        "window_size": 3,
        "char_count": 227,
        "word_count": 39,
        "page_number": 17,
        "window_text": "우울장애 인지행동치료는 우울한\n\n<!-- PAGE_17 -->\n###### 기분에 대한 자동 사고를 수정하고 궁극적으로는 핵심 신념 변화를\n\n<!-- PAGE_17 -->\n###### 통해 우울장애 재발을 막고자 한다.\n\n <!-- PAGE_17 -->\n###### 우울장애 인지행동치료는 행동 기법과 인지 기법으로 구분할 수\n\n<!-- PAGE_17 -->\n###### 있다.  우울장애 환자는 일상생활과 관련된 기능이 많이 떨어져 있을\n\n<!-- PAGE_17 -->\n###### 수 있으므로 행동 기법을 먼저 적용하는 것이 도움이 된다.  행동 기법은\n\n<!-- PAGE_17 -->\n###### ① 활동 계획(activity scheduling), ② 점진적 과업 주기(graded task\n\n<!-- PAGE_17 -->\n###### assignments), ③ 자기강화(self-reinforcement) 등이 있으며, 이를 통해\n\n<!-- PAGE_17 -->\n###### 우울장애 환자의 자기효능감을 향상하는 데 도움을 줄 수 있다.\n\n <!-- PAGE_17 -->\n###### 인지행동치료 인지 기법으로는 ① 자동 사고 파악하기, ② 인지\n\n<!-- PAGE_17 -->\n###### 오류 찾기 등이 있다.  우울한 기분과 관련성이 높은 자동 사고를 확인\n\n<!-- PAGE_17 -->\n###### 하기 위해서는 자동 사고가 무엇인지 알려주고, 우울감을 심하게 느낀\n\n<!-- PAGE_17 -->\n###### 상황을 이야기해봄으로써 자동 사고를 파악한다.  우울장애 환자에게는\n\n<!-- PAGE_17 -->\n###### ① 흑백논리(all-or-nothing thinking), ② 과잉 일반화(overgeneralization),\n\n<!-- PAGE_17 -->\n###### ③ 평가절하 사고(disqualifying the positive), ④ 성급한 결론(jumping\n\n<!-- PAGE_17 -->\n###### to conclusions), ⑤ 사고 확대와 추론(magnification or minimization)\n\n<!-- PAGE_17 -->\n###### 등과 같은 인지 오류가 자주 발생한다. ",
        "original_sentence": "행동 기법은\n\n<!-- PAGE_17 -->\n###### ① 활동 계획(activity scheduling), ② 점진적 과업 주기(graded task\n\n<!-- PAGE_17 -->\n###### assignments), ③ 자기강화(self-reinforcement) 등이 있으며, 이를 통해\n\n<!-- PAGE_17 -->\n###### 우울장애 환자의 자기효능감을 향상하는 데 도움을 줄 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_480",
      "text": "<!-- PAGE_17 -->\n###### 인지행동치료 인지 기법으로는 ① 자동 사고 파악하기, ② 인지\n\n<!-- PAGE_17 -->\n###### 오류 찾기 등이 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 479,
        "window_size": 3,
        "char_count": 97,
        "word_count": 21,
        "page_number": 17,
        "window_text": "<!-- PAGE_17 -->\n###### 우울장애 인지행동치료는 행동 기법과 인지 기법으로 구분할 수\n\n<!-- PAGE_17 -->\n###### 있다.  우울장애 환자는 일상생활과 관련된 기능이 많이 떨어져 있을\n\n<!-- PAGE_17 -->\n###### 수 있으므로 행동 기법을 먼저 적용하는 것이 도움이 된다.  행동 기법은\n\n<!-- PAGE_17 -->\n###### ① 활동 계획(activity scheduling), ② 점진적 과업 주기(graded task\n\n<!-- PAGE_17 -->\n###### assignments), ③ 자기강화(self-reinforcement) 등이 있으며, 이를 통해\n\n<!-- PAGE_17 -->\n###### 우울장애 환자의 자기효능감을 향상하는 데 도움을 줄 수 있다.\n\n <!-- PAGE_17 -->\n###### 인지행동치료 인지 기법으로는 ① 자동 사고 파악하기, ② 인지\n\n<!-- PAGE_17 -->\n###### 오류 찾기 등이 있다.  우울한 기분과 관련성이 높은 자동 사고를 확인\n\n<!-- PAGE_17 -->\n###### 하기 위해서는 자동 사고가 무엇인지 알려주고, 우울감을 심하게 느낀\n\n<!-- PAGE_17 -->\n###### 상황을 이야기해봄으로써 자동 사고를 파악한다.  우울장애 환자에게는\n\n<!-- PAGE_17 -->\n###### ① 흑백논리(all-or-nothing thinking), ② 과잉 일반화(overgeneralization),\n\n<!-- PAGE_17 -->\n###### ③ 평가절하 사고(disqualifying the positive), ④ 성급한 결론(jumping\n\n<!-- PAGE_17 -->\n###### to conclusions), ⑤ 사고 확대와 추론(magnification or minimization)\n\n<!-- PAGE_17 -->\n###### 등과 같은 인지 오류가 자주 발생한다.  따라서 자동 사고에 나타난\n\n<!-- PAGE_17 -->\n###### 인지 오류를 검토하게 함으로써 자동 사고를 변화시킬 수 있다.\n\n",
        "original_sentence": "<!-- PAGE_17 -->\n###### 인지행동치료 인지 기법으로는 ① 자동 사고 파악하기, ② 인지\n\n<!-- PAGE_17 -->\n###### 오류 찾기 등이 있다. "
      }
    },
    {
      "chunk_id": "chunk_481",
      "text": "우울한 기분과 관련성이 높은 자동 사고를 확인\n\n<!-- PAGE_17 -->\n###### 하기 위해서는 자동 사고가 무엇인지 알려주고, 우울감을 심하게 느낀\n\n<!-- PAGE_17 -->\n###### 상황을 이야기해봄으로써 자동 사고를 파악한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 480,
        "window_size": 3,
        "char_count": 140,
        "word_count": 29,
        "page_number": 17,
        "window_text": "우울장애 환자는 일상생활과 관련된 기능이 많이 떨어져 있을\n\n<!-- PAGE_17 -->\n###### 수 있으므로 행동 기법을 먼저 적용하는 것이 도움이 된다.  행동 기법은\n\n<!-- PAGE_17 -->\n###### ① 활동 계획(activity scheduling), ② 점진적 과업 주기(graded task\n\n<!-- PAGE_17 -->\n###### assignments), ③ 자기강화(self-reinforcement) 등이 있으며, 이를 통해\n\n<!-- PAGE_17 -->\n###### 우울장애 환자의 자기효능감을 향상하는 데 도움을 줄 수 있다.\n\n <!-- PAGE_17 -->\n###### 인지행동치료 인지 기법으로는 ① 자동 사고 파악하기, ② 인지\n\n<!-- PAGE_17 -->\n###### 오류 찾기 등이 있다.  우울한 기분과 관련성이 높은 자동 사고를 확인\n\n<!-- PAGE_17 -->\n###### 하기 위해서는 자동 사고가 무엇인지 알려주고, 우울감을 심하게 느낀\n\n<!-- PAGE_17 -->\n###### 상황을 이야기해봄으로써 자동 사고를 파악한다.  우울장애 환자에게는\n\n<!-- PAGE_17 -->\n###### ① 흑백논리(all-or-nothing thinking), ② 과잉 일반화(overgeneralization),\n\n<!-- PAGE_17 -->\n###### ③ 평가절하 사고(disqualifying the positive), ④ 성급한 결론(jumping\n\n<!-- PAGE_17 -->\n###### to conclusions), ⑤ 사고 확대와 추론(magnification or minimization)\n\n<!-- PAGE_17 -->\n###### 등과 같은 인지 오류가 자주 발생한다.  따라서 자동 사고에 나타난\n\n<!-- PAGE_17 -->\n###### 인지 오류를 검토하게 함으로써 자동 사고를 변화시킬 수 있다.\n\n - - 11 -\n구분\n\n제목\n\n내용\n\n- - 먼저 우울장애 환자의 현재 활동 정도와 그에 따른 감정 상태를\n측정한다. ",
        "original_sentence": "우울한 기분과 관련성이 높은 자동 사고를 확인\n\n<!-- PAGE_17 -->\n###### 하기 위해서는 자동 사고가 무엇인지 알려주고, 우울감을 심하게 느낀\n\n<!-- PAGE_17 -->\n###### 상황을 이야기해봄으로써 자동 사고를 파악한다. "
      }
    },
    {
      "chunk_id": "chunk_482",
      "text": "우울장애 환자에게는\n\n<!-- PAGE_17 -->\n###### ① 흑백논리(all-or-nothing thinking), ② 과잉 일반화(overgeneralization),\n\n<!-- PAGE_17 -->\n###### ③ 평가절하 사고(disqualifying the positive), ④ 성급한 결론(jumping\n\n<!-- PAGE_17 -->\n###### to conclusions), ⑤ 사고 확대와 추론(magnification or minimization)\n\n<!-- PAGE_17 -->\n###### 등과 같은 인지 오류가 자주 발생한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 481,
        "window_size": 3,
        "char_count": 312,
        "word_count": 46,
        "page_number": 17,
        "window_text": "행동 기법은\n\n<!-- PAGE_17 -->\n###### ① 활동 계획(activity scheduling), ② 점진적 과업 주기(graded task\n\n<!-- PAGE_17 -->\n###### assignments), ③ 자기강화(self-reinforcement) 등이 있으며, 이를 통해\n\n<!-- PAGE_17 -->\n###### 우울장애 환자의 자기효능감을 향상하는 데 도움을 줄 수 있다.\n\n <!-- PAGE_17 -->\n###### 인지행동치료 인지 기법으로는 ① 자동 사고 파악하기, ② 인지\n\n<!-- PAGE_17 -->\n###### 오류 찾기 등이 있다.  우울한 기분과 관련성이 높은 자동 사고를 확인\n\n<!-- PAGE_17 -->\n###### 하기 위해서는 자동 사고가 무엇인지 알려주고, 우울감을 심하게 느낀\n\n<!-- PAGE_17 -->\n###### 상황을 이야기해봄으로써 자동 사고를 파악한다.  우울장애 환자에게는\n\n<!-- PAGE_17 -->\n###### ① 흑백논리(all-or-nothing thinking), ② 과잉 일반화(overgeneralization),\n\n<!-- PAGE_17 -->\n###### ③ 평가절하 사고(disqualifying the positive), ④ 성급한 결론(jumping\n\n<!-- PAGE_17 -->\n###### to conclusions), ⑤ 사고 확대와 추론(magnification or minimization)\n\n<!-- PAGE_17 -->\n###### 등과 같은 인지 오류가 자주 발생한다.  따라서 자동 사고에 나타난\n\n<!-- PAGE_17 -->\n###### 인지 오류를 검토하게 함으로써 자동 사고를 변화시킬 수 있다.\n\n - - 11 -\n구분\n\n제목\n\n내용\n\n- - 먼저 우울장애 환자의 현재 활동 정도와 그에 따른 감정 상태를\n측정한다.  다음 단계로, 우울장애 환자가 자신의 활동 계획에\n\n<!-- PAGE_18 -->\n###### 표 2. ",
        "original_sentence": "우울장애 환자에게는\n\n<!-- PAGE_17 -->\n###### ① 흑백논리(all-or-nothing thinking), ② 과잉 일반화(overgeneralization),\n\n<!-- PAGE_17 -->\n###### ③ 평가절하 사고(disqualifying the positive), ④ 성급한 결론(jumping\n\n<!-- PAGE_17 -->\n###### to conclusions), ⑤ 사고 확대와 추론(magnification or minimization)\n\n<!-- PAGE_17 -->\n###### 등과 같은 인지 오류가 자주 발생한다. "
      }
    },
    {
      "chunk_id": "chunk_483",
      "text": "따라서 자동 사고에 나타난\n\n<!-- PAGE_17 -->\n###### 인지 오류를 검토하게 함으로써 자동 사고를 변화시킬 수 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 482,
        "window_size": 3,
        "char_count": 76,
        "word_count": 17,
        "page_number": 17,
        "window_text": "<!-- PAGE_17 -->\n###### 인지행동치료 인지 기법으로는 ① 자동 사고 파악하기, ② 인지\n\n<!-- PAGE_17 -->\n###### 오류 찾기 등이 있다.  우울한 기분과 관련성이 높은 자동 사고를 확인\n\n<!-- PAGE_17 -->\n###### 하기 위해서는 자동 사고가 무엇인지 알려주고, 우울감을 심하게 느낀\n\n<!-- PAGE_17 -->\n###### 상황을 이야기해봄으로써 자동 사고를 파악한다.  우울장애 환자에게는\n\n<!-- PAGE_17 -->\n###### ① 흑백논리(all-or-nothing thinking), ② 과잉 일반화(overgeneralization),\n\n<!-- PAGE_17 -->\n###### ③ 평가절하 사고(disqualifying the positive), ④ 성급한 결론(jumping\n\n<!-- PAGE_17 -->\n###### to conclusions), ⑤ 사고 확대와 추론(magnification or minimization)\n\n<!-- PAGE_17 -->\n###### 등과 같은 인지 오류가 자주 발생한다.  따라서 자동 사고에 나타난\n\n<!-- PAGE_17 -->\n###### 인지 오류를 검토하게 함으로써 자동 사고를 변화시킬 수 있다.\n\n - - 11 -\n구분\n\n제목\n\n내용\n\n- - 먼저 우울장애 환자의 현재 활동 정도와 그에 따른 감정 상태를\n측정한다.  다음 단계로, 우울장애 환자가 자신의 활동 계획에\n\n<!-- PAGE_18 -->\n###### 표 2.  우울장애 인지행동치료 구성\n\n- - 12 -\n구분\n\n제목\n\n내용\n\n**[표 시작]**\n\n| 인지적 | 예시 |\n| --- | --- |\n**예시**\n**인증 기능 구현**\n\n**[표 끝]**\n\n시험 구상(designing experiments)\n\n- - 우울장애 환자가 자신의 자동적 사고를 실증적 검증이 가능한\n과학적인 가정으로 간주하도록 고무한다.\n\n",
        "original_sentence": "따라서 자동 사고에 나타난\n\n<!-- PAGE_17 -->\n###### 인지 오류를 검토하게 함으로써 자동 사고를 변화시킬 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_484",
      "text": "- - 11 -\n구분\n\n제목\n\n내용\n\n- - 먼저 우울장애 환자의 현재 활동 정도와 그에 따른 감정 상태를\n측정한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 483,
        "window_size": 3,
        "char_count": 66,
        "word_count": 20,
        "page_number": 3,
        "window_text": "우울한 기분과 관련성이 높은 자동 사고를 확인\n\n<!-- PAGE_17 -->\n###### 하기 위해서는 자동 사고가 무엇인지 알려주고, 우울감을 심하게 느낀\n\n<!-- PAGE_17 -->\n###### 상황을 이야기해봄으로써 자동 사고를 파악한다.  우울장애 환자에게는\n\n<!-- PAGE_17 -->\n###### ① 흑백논리(all-or-nothing thinking), ② 과잉 일반화(overgeneralization),\n\n<!-- PAGE_17 -->\n###### ③ 평가절하 사고(disqualifying the positive), ④ 성급한 결론(jumping\n\n<!-- PAGE_17 -->\n###### to conclusions), ⑤ 사고 확대와 추론(magnification or minimization)\n\n<!-- PAGE_17 -->\n###### 등과 같은 인지 오류가 자주 발생한다.  따라서 자동 사고에 나타난\n\n<!-- PAGE_17 -->\n###### 인지 오류를 검토하게 함으로써 자동 사고를 변화시킬 수 있다.\n\n - - 11 -\n구분\n\n제목\n\n내용\n\n- - 먼저 우울장애 환자의 현재 활동 정도와 그에 따른 감정 상태를\n측정한다.  다음 단계로, 우울장애 환자가 자신의 활동 계획에\n\n<!-- PAGE_18 -->\n###### 표 2.  우울장애 인지행동치료 구성\n\n- - 12 -\n구분\n\n제목\n\n내용\n\n**[표 시작]**\n\n| 인지적 | 예시 |\n| --- | --- |\n**예시**\n**인증 기능 구현**\n\n**[표 끝]**\n\n시험 구상(designing experiments)\n\n- - 우울장애 환자가 자신의 자동적 사고를 실증적 검증이 가능한\n과학적인 가정으로 간주하도록 고무한다.\n\n - - 13 -\n구분\n\n제목\n\n내용\n\n과거력 조사(historical exploration)\n\n- - 비기능적 신념은 때때로 고통스러운 과거 경험을 왜곡되게\n- - 14 -\n<!-- PAGE_21 -->\n###### 라. ",
        "original_sentence": "- - 11 -\n구분\n\n제목\n\n내용\n\n- - 먼저 우울장애 환자의 현재 활동 정도와 그에 따른 감정 상태를\n측정한다. "
      }
    },
    {
      "chunk_id": "chunk_485",
      "text": "다음 단계로, 우울장애 환자가 자신의 활동 계획에\n\n<!-- PAGE_18 -->\n###### 표 2. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 484,
        "window_size": 3,
        "char_count": 58,
        "word_count": 13,
        "page_number": 18,
        "window_text": "우울장애 환자에게는\n\n<!-- PAGE_17 -->\n###### ① 흑백논리(all-or-nothing thinking), ② 과잉 일반화(overgeneralization),\n\n<!-- PAGE_17 -->\n###### ③ 평가절하 사고(disqualifying the positive), ④ 성급한 결론(jumping\n\n<!-- PAGE_17 -->\n###### to conclusions), ⑤ 사고 확대와 추론(magnification or minimization)\n\n<!-- PAGE_17 -->\n###### 등과 같은 인지 오류가 자주 발생한다.  따라서 자동 사고에 나타난\n\n<!-- PAGE_17 -->\n###### 인지 오류를 검토하게 함으로써 자동 사고를 변화시킬 수 있다.\n\n - - 11 -\n구분\n\n제목\n\n내용\n\n- - 먼저 우울장애 환자의 현재 활동 정도와 그에 따른 감정 상태를\n측정한다.  다음 단계로, 우울장애 환자가 자신의 활동 계획에\n\n<!-- PAGE_18 -->\n###### 표 2.  우울장애 인지행동치료 구성\n\n- - 12 -\n구분\n\n제목\n\n내용\n\n**[표 시작]**\n\n| 인지적 | 예시 |\n| --- | --- |\n**예시**\n**인증 기능 구현**\n\n**[표 끝]**\n\n시험 구상(designing experiments)\n\n- - 우울장애 환자가 자신의 자동적 사고를 실증적 검증이 가능한\n과학적인 가정으로 간주하도록 고무한다.\n\n - - 13 -\n구분\n\n제목\n\n내용\n\n과거력 조사(historical exploration)\n\n- - 비기능적 신념은 때때로 고통스러운 과거 경험을 왜곡되게\n- - 14 -\n<!-- PAGE_21 -->\n###### 라.  우울장애 약물치료\n\n<!-- PAGE_21 -->\n###### 우울장애 인지행동치료를 적용하기가 어렵거나, 적용하더라도 효과가\n\n<!-- PAGE_21 -->\n###### 없으면 약물적 치료를 통해 우울장애를 개선할 수 있다. ",
        "original_sentence": "다음 단계로, 우울장애 환자가 자신의 활동 계획에\n\n<!-- PAGE_18 -->\n###### 표 2. "
      }
    },
    {
      "chunk_id": "chunk_486",
      "text": "우울장애 인지행동치료 구성\n\n- - 12 -\n구분\n\n제목\n\n내용\n\n**[표 시작]**\n\n| 인지적 | 예시 |\n| --- | --- |\n**예시**\n**인증 기능 구현**\n\n**[표 끝]**\n\n시험 구상(designing experiments)\n\n- - 우울장애 환자가 자신의 자동적 사고를 실증적 검증이 가능한\n과학적인 가정으로 간주하도록 고무한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 485,
        "window_size": 3,
        "char_count": 198,
        "word_count": 45,
        "page_number": 3,
        "window_text": "따라서 자동 사고에 나타난\n\n<!-- PAGE_17 -->\n###### 인지 오류를 검토하게 함으로써 자동 사고를 변화시킬 수 있다.\n\n - - 11 -\n구분\n\n제목\n\n내용\n\n- - 먼저 우울장애 환자의 현재 활동 정도와 그에 따른 감정 상태를\n측정한다.  다음 단계로, 우울장애 환자가 자신의 활동 계획에\n\n<!-- PAGE_18 -->\n###### 표 2.  우울장애 인지행동치료 구성\n\n- - 12 -\n구분\n\n제목\n\n내용\n\n**[표 시작]**\n\n| 인지적 | 예시 |\n| --- | --- |\n**예시**\n**인증 기능 구현**\n\n**[표 끝]**\n\n시험 구상(designing experiments)\n\n- - 우울장애 환자가 자신의 자동적 사고를 실증적 검증이 가능한\n과학적인 가정으로 간주하도록 고무한다.\n\n - - 13 -\n구분\n\n제목\n\n내용\n\n과거력 조사(historical exploration)\n\n- - 비기능적 신념은 때때로 고통스러운 과거 경험을 왜곡되게\n- - 14 -\n<!-- PAGE_21 -->\n###### 라.  우울장애 약물치료\n\n<!-- PAGE_21 -->\n###### 우울장애 인지행동치료를 적용하기가 어렵거나, 적용하더라도 효과가\n\n<!-- PAGE_21 -->\n###### 없으면 약물적 치료를 통해 우울장애를 개선할 수 있다.  <표 3>은 일차\n\n<!-- PAGE_21 -->\n###### 의료용 근거 기반 우울장애 임상진료지침(대한의학회, 2022)의 항우울제\n\n<!-- PAGE_21 -->\n###### 권고 요약표를 정리하였다. ",
        "original_sentence": "우울장애 인지행동치료 구성\n\n- - 12 -\n구분\n\n제목\n\n내용\n\n**[표 시작]**\n\n| 인지적 | 예시 |\n| --- | --- |\n**예시**\n**인증 기능 구현**\n\n**[표 끝]**\n\n시험 구상(designing experiments)\n\n- - 우울장애 환자가 자신의 자동적 사고를 실증적 검증이 가능한\n과학적인 가정으로 간주하도록 고무한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_487",
      "text": "- - 13 -\n구분\n\n제목\n\n내용\n\n과거력 조사(historical exploration)\n\n- - 비기능적 신념은 때때로 고통스러운 과거 경험을 왜곡되게\n- - 14 -\n<!-- PAGE_21 -->\n###### 라. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 486,
        "window_size": 3,
        "char_count": 124,
        "word_count": 28,
        "page_number": 21,
        "window_text": "- - 11 -\n구분\n\n제목\n\n내용\n\n- - 먼저 우울장애 환자의 현재 활동 정도와 그에 따른 감정 상태를\n측정한다.  다음 단계로, 우울장애 환자가 자신의 활동 계획에\n\n<!-- PAGE_18 -->\n###### 표 2.  우울장애 인지행동치료 구성\n\n- - 12 -\n구분\n\n제목\n\n내용\n\n**[표 시작]**\n\n| 인지적 | 예시 |\n| --- | --- |\n**예시**\n**인증 기능 구현**\n\n**[표 끝]**\n\n시험 구상(designing experiments)\n\n- - 우울장애 환자가 자신의 자동적 사고를 실증적 검증이 가능한\n과학적인 가정으로 간주하도록 고무한다.\n\n - - 13 -\n구분\n\n제목\n\n내용\n\n과거력 조사(historical exploration)\n\n- - 비기능적 신념은 때때로 고통스러운 과거 경험을 왜곡되게\n- - 14 -\n<!-- PAGE_21 -->\n###### 라.  우울장애 약물치료\n\n<!-- PAGE_21 -->\n###### 우울장애 인지행동치료를 적용하기가 어렵거나, 적용하더라도 효과가\n\n<!-- PAGE_21 -->\n###### 없으면 약물적 치료를 통해 우울장애를 개선할 수 있다.  <표 3>은 일차\n\n<!-- PAGE_21 -->\n###### 의료용 근거 기반 우울장애 임상진료지침(대한의학회, 2022)의 항우울제\n\n<!-- PAGE_21 -->\n###### 권고 요약표를 정리하였다.  우울장애 약물치료는 임상 양상, 공존 질환,\n\n<!-- PAGE_21 -->\n###### 이전 약물치료 병력, 부작용, 약물 상호작용, 환자 기호 등을 종합하여\n\n<!-- PAGE_21 -->\n###### 상황에 맞게 각 임상의가 적절하게 판단하여 사용하여야 한다. ",
        "original_sentence": "- - 13 -\n구분\n\n제목\n\n내용\n\n과거력 조사(historical exploration)\n\n- - 비기능적 신념은 때때로 고통스러운 과거 경험을 왜곡되게\n- - 14 -\n<!-- PAGE_21 -->\n###### 라. "
      }
    },
    {
      "chunk_id": "chunk_488",
      "text": "우울장애 약물치료\n\n<!-- PAGE_21 -->\n###### 우울장애 인지행동치료를 적용하기가 어렵거나, 적용하더라도 효과가\n\n<!-- PAGE_21 -->\n###### 없으면 약물적 치료를 통해 우울장애를 개선할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 487,
        "window_size": 3,
        "char_count": 127,
        "word_count": 24,
        "page_number": 21,
        "window_text": "다음 단계로, 우울장애 환자가 자신의 활동 계획에\n\n<!-- PAGE_18 -->\n###### 표 2.  우울장애 인지행동치료 구성\n\n- - 12 -\n구분\n\n제목\n\n내용\n\n**[표 시작]**\n\n| 인지적 | 예시 |\n| --- | --- |\n**예시**\n**인증 기능 구현**\n\n**[표 끝]**\n\n시험 구상(designing experiments)\n\n- - 우울장애 환자가 자신의 자동적 사고를 실증적 검증이 가능한\n과학적인 가정으로 간주하도록 고무한다.\n\n - - 13 -\n구분\n\n제목\n\n내용\n\n과거력 조사(historical exploration)\n\n- - 비기능적 신념은 때때로 고통스러운 과거 경험을 왜곡되게\n- - 14 -\n<!-- PAGE_21 -->\n###### 라.  우울장애 약물치료\n\n<!-- PAGE_21 -->\n###### 우울장애 인지행동치료를 적용하기가 어렵거나, 적용하더라도 효과가\n\n<!-- PAGE_21 -->\n###### 없으면 약물적 치료를 통해 우울장애를 개선할 수 있다.  <표 3>은 일차\n\n<!-- PAGE_21 -->\n###### 의료용 근거 기반 우울장애 임상진료지침(대한의학회, 2022)의 항우울제\n\n<!-- PAGE_21 -->\n###### 권고 요약표를 정리하였다.  우울장애 약물치료는 임상 양상, 공존 질환,\n\n<!-- PAGE_21 -->\n###### 이전 약물치료 병력, 부작용, 약물 상호작용, 환자 기호 등을 종합하여\n\n<!-- PAGE_21 -->\n###### 상황에 맞게 각 임상의가 적절하게 판단하여 사용하여야 한다.  단, 이\n\n<!-- PAGE_21 -->\n###### 부분은 본 의료기기의 주요부문이 아니므로 더 서술하지 않되, 환자의\n\n<!-- PAGE_21 -->\n###### 적절한 치료를 위해 우울 증상을 파악하고 개선한다는 점에서, 약물\n\n<!-- PAGE_21 -->\n###### 복용력을 고려하는 디지털치료기기라면 환자의 상태를 파악하기를\n\n<!-- PAGE_21 -->\n###### 권고한다.\n\n",
        "original_sentence": "우울장애 약물치료\n\n<!-- PAGE_21 -->\n###### 우울장애 인지행동치료를 적용하기가 어렵거나, 적용하더라도 효과가\n\n<!-- PAGE_21 -->\n###### 없으면 약물적 치료를 통해 우울장애를 개선할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_489",
      "text": "<표 3>은 일차\n\n<!-- PAGE_21 -->\n###### 의료용 근거 기반 우울장애 임상진료지침(대한의학회, 2022)의 항우울제\n\n<!-- PAGE_21 -->\n###### 권고 요약표를 정리하였다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 488,
        "window_size": 3,
        "char_count": 116,
        "word_count": 21,
        "page_number": 21,
        "window_text": "우울장애 인지행동치료 구성\n\n- - 12 -\n구분\n\n제목\n\n내용\n\n**[표 시작]**\n\n| 인지적 | 예시 |\n| --- | --- |\n**예시**\n**인증 기능 구현**\n\n**[표 끝]**\n\n시험 구상(designing experiments)\n\n- - 우울장애 환자가 자신의 자동적 사고를 실증적 검증이 가능한\n과학적인 가정으로 간주하도록 고무한다.\n\n - - 13 -\n구분\n\n제목\n\n내용\n\n과거력 조사(historical exploration)\n\n- - 비기능적 신념은 때때로 고통스러운 과거 경험을 왜곡되게\n- - 14 -\n<!-- PAGE_21 -->\n###### 라.  우울장애 약물치료\n\n<!-- PAGE_21 -->\n###### 우울장애 인지행동치료를 적용하기가 어렵거나, 적용하더라도 효과가\n\n<!-- PAGE_21 -->\n###### 없으면 약물적 치료를 통해 우울장애를 개선할 수 있다.  <표 3>은 일차\n\n<!-- PAGE_21 -->\n###### 의료용 근거 기반 우울장애 임상진료지침(대한의학회, 2022)의 항우울제\n\n<!-- PAGE_21 -->\n###### 권고 요약표를 정리하였다.  우울장애 약물치료는 임상 양상, 공존 질환,\n\n<!-- PAGE_21 -->\n###### 이전 약물치료 병력, 부작용, 약물 상호작용, 환자 기호 등을 종합하여\n\n<!-- PAGE_21 -->\n###### 상황에 맞게 각 임상의가 적절하게 판단하여 사용하여야 한다.  단, 이\n\n<!-- PAGE_21 -->\n###### 부분은 본 의료기기의 주요부문이 아니므로 더 서술하지 않되, 환자의\n\n<!-- PAGE_21 -->\n###### 적절한 치료를 위해 우울 증상을 파악하고 개선한다는 점에서, 약물\n\n<!-- PAGE_21 -->\n###### 복용력을 고려하는 디지털치료기기라면 환자의 상태를 파악하기를\n\n<!-- PAGE_21 -->\n###### 권고한다.\n\n (출처: 대한의학회(2022), 일차 의료용 근거기반 우울장애 임상진료지침)\n\n- - 15 -\n<!-- PAGE_22 -->\n###### 마. ",
        "original_sentence": "<표 3>은 일차\n\n<!-- PAGE_21 -->\n###### 의료용 근거 기반 우울장애 임상진료지침(대한의학회, 2022)의 항우울제\n\n<!-- PAGE_21 -->\n###### 권고 요약표를 정리하였다. "
      }
    },
    {
      "chunk_id": "chunk_490",
      "text": "우울장애 약물치료는 임상 양상, 공존 질환,\n\n<!-- PAGE_21 -->\n###### 이전 약물치료 병력, 부작용, 약물 상호작용, 환자 기호 등을 종합하여\n\n<!-- PAGE_21 -->\n###### 상황에 맞게 각 임상의가 적절하게 판단하여 사용하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 489,
        "window_size": 3,
        "char_count": 149,
        "word_count": 32,
        "page_number": 21,
        "window_text": "- - 13 -\n구분\n\n제목\n\n내용\n\n과거력 조사(historical exploration)\n\n- - 비기능적 신념은 때때로 고통스러운 과거 경험을 왜곡되게\n- - 14 -\n<!-- PAGE_21 -->\n###### 라.  우울장애 약물치료\n\n<!-- PAGE_21 -->\n###### 우울장애 인지행동치료를 적용하기가 어렵거나, 적용하더라도 효과가\n\n<!-- PAGE_21 -->\n###### 없으면 약물적 치료를 통해 우울장애를 개선할 수 있다.  <표 3>은 일차\n\n<!-- PAGE_21 -->\n###### 의료용 근거 기반 우울장애 임상진료지침(대한의학회, 2022)의 항우울제\n\n<!-- PAGE_21 -->\n###### 권고 요약표를 정리하였다.  우울장애 약물치료는 임상 양상, 공존 질환,\n\n<!-- PAGE_21 -->\n###### 이전 약물치료 병력, 부작용, 약물 상호작용, 환자 기호 등을 종합하여\n\n<!-- PAGE_21 -->\n###### 상황에 맞게 각 임상의가 적절하게 판단하여 사용하여야 한다.  단, 이\n\n<!-- PAGE_21 -->\n###### 부분은 본 의료기기의 주요부문이 아니므로 더 서술하지 않되, 환자의\n\n<!-- PAGE_21 -->\n###### 적절한 치료를 위해 우울 증상을 파악하고 개선한다는 점에서, 약물\n\n<!-- PAGE_21 -->\n###### 복용력을 고려하는 디지털치료기기라면 환자의 상태를 파악하기를\n\n<!-- PAGE_21 -->\n###### 권고한다.\n\n (출처: 대한의학회(2022), 일차 의료용 근거기반 우울장애 임상진료지침)\n\n- - 15 -\n<!-- PAGE_22 -->\n###### 마.  우울장애 비약물 치료의 임상 권고 사항\n\n<!-- PAGE_22 -->\n###### 미국정신의학회(APA), 캐나다 기분·불안 치료 네트워크(Canadian\n\n<!-- PAGE_22 -->\n###### Network for Mood and Anxiety Treatments, CANMAT), 영국정신의학회\n\n<!-- PAGE_22 -->\n###### (British Association for Psychopharmacology, BAP) 등은 우울장애 치료를\n\n<!-- PAGE_22 -->\n###### 위해 인지행동치료(CBT)를 먼저 권고한다. ",
        "original_sentence": "우울장애 약물치료는 임상 양상, 공존 질환,\n\n<!-- PAGE_21 -->\n###### 이전 약물치료 병력, 부작용, 약물 상호작용, 환자 기호 등을 종합하여\n\n<!-- PAGE_21 -->\n###### 상황에 맞게 각 임상의가 적절하게 판단하여 사용하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_491",
      "text": "단, 이\n\n<!-- PAGE_21 -->\n###### 부분은 본 의료기기의 주요부문이 아니므로 더 서술하지 않되, 환자의\n\n<!-- PAGE_21 -->\n###### 적절한 치료를 위해 우울 증상을 파악하고 개선한다는 점에서, 약물\n\n<!-- PAGE_21 -->\n###### 복용력을 고려하는 디지털치료기기라면 환자의 상태를 파악하기를\n\n<!-- PAGE_21 -->\n###### 권고한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 490,
        "window_size": 3,
        "char_count": 221,
        "word_count": 43,
        "page_number": 21,
        "window_text": "우울장애 약물치료\n\n<!-- PAGE_21 -->\n###### 우울장애 인지행동치료를 적용하기가 어렵거나, 적용하더라도 효과가\n\n<!-- PAGE_21 -->\n###### 없으면 약물적 치료를 통해 우울장애를 개선할 수 있다.  <표 3>은 일차\n\n<!-- PAGE_21 -->\n###### 의료용 근거 기반 우울장애 임상진료지침(대한의학회, 2022)의 항우울제\n\n<!-- PAGE_21 -->\n###### 권고 요약표를 정리하였다.  우울장애 약물치료는 임상 양상, 공존 질환,\n\n<!-- PAGE_21 -->\n###### 이전 약물치료 병력, 부작용, 약물 상호작용, 환자 기호 등을 종합하여\n\n<!-- PAGE_21 -->\n###### 상황에 맞게 각 임상의가 적절하게 판단하여 사용하여야 한다.  단, 이\n\n<!-- PAGE_21 -->\n###### 부분은 본 의료기기의 주요부문이 아니므로 더 서술하지 않되, 환자의\n\n<!-- PAGE_21 -->\n###### 적절한 치료를 위해 우울 증상을 파악하고 개선한다는 점에서, 약물\n\n<!-- PAGE_21 -->\n###### 복용력을 고려하는 디지털치료기기라면 환자의 상태를 파악하기를\n\n<!-- PAGE_21 -->\n###### 권고한다.\n\n (출처: 대한의학회(2022), 일차 의료용 근거기반 우울장애 임상진료지침)\n\n- - 15 -\n<!-- PAGE_22 -->\n###### 마.  우울장애 비약물 치료의 임상 권고 사항\n\n<!-- PAGE_22 -->\n###### 미국정신의학회(APA), 캐나다 기분·불안 치료 네트워크(Canadian\n\n<!-- PAGE_22 -->\n###### Network for Mood and Anxiety Treatments, CANMAT), 영국정신의학회\n\n<!-- PAGE_22 -->\n###### (British Association for Psychopharmacology, BAP) 등은 우울장애 치료를\n\n<!-- PAGE_22 -->\n###### 위해 인지행동치료(CBT)를 먼저 권고한다.  또한 대한의학회 ‘일차 의료용\n\n<!-- PAGE_22 -->\n###### 근거 기반 우울장애 임상진료지침(2022)’에서도 경증 혹은 중등도 수준\n\n<!-- PAGE_22 -->\n###### 우울장애에서는 인지행동치료 등 정신사회 치료를 먼저 고려하도록\n\n<!-- PAGE_22 -->\n###### 권장하고 있다.\n\n",
        "original_sentence": "단, 이\n\n<!-- PAGE_21 -->\n###### 부분은 본 의료기기의 주요부문이 아니므로 더 서술하지 않되, 환자의\n\n<!-- PAGE_21 -->\n###### 적절한 치료를 위해 우울 증상을 파악하고 개선한다는 점에서, 약물\n\n<!-- PAGE_21 -->\n###### 복용력을 고려하는 디지털치료기기라면 환자의 상태를 파악하기를\n\n<!-- PAGE_21 -->\n###### 권고한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_492",
      "text": "(출처: 대한의학회(2022), 일차 의료용 근거기반 우울장애 임상진료지침)\n\n- - 15 -\n<!-- PAGE_22 -->\n###### 마. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 491,
        "window_size": 3,
        "char_count": 80,
        "word_count": 16,
        "page_number": 22,
        "window_text": "<표 3>은 일차\n\n<!-- PAGE_21 -->\n###### 의료용 근거 기반 우울장애 임상진료지침(대한의학회, 2022)의 항우울제\n\n<!-- PAGE_21 -->\n###### 권고 요약표를 정리하였다.  우울장애 약물치료는 임상 양상, 공존 질환,\n\n<!-- PAGE_21 -->\n###### 이전 약물치료 병력, 부작용, 약물 상호작용, 환자 기호 등을 종합하여\n\n<!-- PAGE_21 -->\n###### 상황에 맞게 각 임상의가 적절하게 판단하여 사용하여야 한다.  단, 이\n\n<!-- PAGE_21 -->\n###### 부분은 본 의료기기의 주요부문이 아니므로 더 서술하지 않되, 환자의\n\n<!-- PAGE_21 -->\n###### 적절한 치료를 위해 우울 증상을 파악하고 개선한다는 점에서, 약물\n\n<!-- PAGE_21 -->\n###### 복용력을 고려하는 디지털치료기기라면 환자의 상태를 파악하기를\n\n<!-- PAGE_21 -->\n###### 권고한다.\n\n (출처: 대한의학회(2022), 일차 의료용 근거기반 우울장애 임상진료지침)\n\n- - 15 -\n<!-- PAGE_22 -->\n###### 마.  우울장애 비약물 치료의 임상 권고 사항\n\n<!-- PAGE_22 -->\n###### 미국정신의학회(APA), 캐나다 기분·불안 치료 네트워크(Canadian\n\n<!-- PAGE_22 -->\n###### Network for Mood and Anxiety Treatments, CANMAT), 영국정신의학회\n\n<!-- PAGE_22 -->\n###### (British Association for Psychopharmacology, BAP) 등은 우울장애 치료를\n\n<!-- PAGE_22 -->\n###### 위해 인지행동치료(CBT)를 먼저 권고한다.  또한 대한의학회 ‘일차 의료용\n\n<!-- PAGE_22 -->\n###### 근거 기반 우울장애 임상진료지침(2022)’에서도 경증 혹은 중등도 수준\n\n<!-- PAGE_22 -->\n###### 우울장애에서는 인지행동치료 등 정신사회 치료를 먼저 고려하도록\n\n<!-- PAGE_22 -->\n###### 권장하고 있다.\n\n * APA: American Psychiatric Association, BAP: British Association for Psychopharmacology,\n\n** 진료지침별 권고 등급의 수준이 상이하여 재분류함\n\n<!-- PAGE_22 -->\n###### 미국정신의학협회(APA) 진료지침(2010)은 대수롭지 않거나 중등도\n\n<!-- PAGE_22 -->\n###### 수준 우울장애이면 초기 치료로 인지행동치료를 제안한다(권고등급,\n\n<!-- PAGE_22 -->\n###### Strong). ",
        "original_sentence": "(출처: 대한의학회(2022), 일차 의료용 근거기반 우울장애 임상진료지침)\n\n- - 15 -\n<!-- PAGE_22 -->\n###### 마. "
      }
    },
    {
      "chunk_id": "chunk_493",
      "text": "우울장애 비약물 치료의 임상 권고 사항\n\n<!-- PAGE_22 -->\n###### 미국정신의학회(APA), 캐나다 기분·불안 치료 네트워크(Canadian\n\n<!-- PAGE_22 -->\n###### Network for Mood and Anxiety Treatments, CANMAT), 영국정신의학회\n\n<!-- PAGE_22 -->\n###### (British Association for Psychopharmacology, BAP) 등은 우울장애 치료를\n\n<!-- PAGE_22 -->\n###### 위해 인지행동치료(CBT)를 먼저 권고한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 492,
        "window_size": 3,
        "char_count": 308,
        "word_count": 47,
        "page_number": 22,
        "window_text": "우울장애 약물치료는 임상 양상, 공존 질환,\n\n<!-- PAGE_21 -->\n###### 이전 약물치료 병력, 부작용, 약물 상호작용, 환자 기호 등을 종합하여\n\n<!-- PAGE_21 -->\n###### 상황에 맞게 각 임상의가 적절하게 판단하여 사용하여야 한다.  단, 이\n\n<!-- PAGE_21 -->\n###### 부분은 본 의료기기의 주요부문이 아니므로 더 서술하지 않되, 환자의\n\n<!-- PAGE_21 -->\n###### 적절한 치료를 위해 우울 증상을 파악하고 개선한다는 점에서, 약물\n\n<!-- PAGE_21 -->\n###### 복용력을 고려하는 디지털치료기기라면 환자의 상태를 파악하기를\n\n<!-- PAGE_21 -->\n###### 권고한다.\n\n (출처: 대한의학회(2022), 일차 의료용 근거기반 우울장애 임상진료지침)\n\n- - 15 -\n<!-- PAGE_22 -->\n###### 마.  우울장애 비약물 치료의 임상 권고 사항\n\n<!-- PAGE_22 -->\n###### 미국정신의학회(APA), 캐나다 기분·불안 치료 네트워크(Canadian\n\n<!-- PAGE_22 -->\n###### Network for Mood and Anxiety Treatments, CANMAT), 영국정신의학회\n\n<!-- PAGE_22 -->\n###### (British Association for Psychopharmacology, BAP) 등은 우울장애 치료를\n\n<!-- PAGE_22 -->\n###### 위해 인지행동치료(CBT)를 먼저 권고한다.  또한 대한의학회 ‘일차 의료용\n\n<!-- PAGE_22 -->\n###### 근거 기반 우울장애 임상진료지침(2022)’에서도 경증 혹은 중등도 수준\n\n<!-- PAGE_22 -->\n###### 우울장애에서는 인지행동치료 등 정신사회 치료를 먼저 고려하도록\n\n<!-- PAGE_22 -->\n###### 권장하고 있다.\n\n * APA: American Psychiatric Association, BAP: British Association for Psychopharmacology,\n\n** 진료지침별 권고 등급의 수준이 상이하여 재분류함\n\n<!-- PAGE_22 -->\n###### 미국정신의학협회(APA) 진료지침(2010)은 대수롭지 않거나 중등도\n\n<!-- PAGE_22 -->\n###### 수준 우울장애이면 초기 치료로 인지행동치료를 제안한다(권고등급,\n\n<!-- PAGE_22 -->\n###### Strong).  캐나다 기분·불안 치료 네트워크(CANMAT) 진료지침(2016)은\n\n<!-- PAGE_22 -->\n###### 급성기 치료(Acute Treatment) 및 유지 치료(Maintenance Treatment)에\n\n<!-- PAGE_22 -->\n###### 대해 인지행동치료가 효과가 있으며, 근거 수준이 높다고 제안한다(권고\n\n<!-- PAGE_22 -->\n###### 등급, Strong [First-line]). ",
        "original_sentence": "우울장애 비약물 치료의 임상 권고 사항\n\n<!-- PAGE_22 -->\n###### 미국정신의학회(APA), 캐나다 기분·불안 치료 네트워크(Canadian\n\n<!-- PAGE_22 -->\n###### Network for Mood and Anxiety Treatments, CANMAT), 영국정신의학회\n\n<!-- PAGE_22 -->\n###### (British Association for Psychopharmacology, BAP) 등은 우울장애 치료를\n\n<!-- PAGE_22 -->\n###### 위해 인지행동치료(CBT)를 먼저 권고한다. "
      }
    },
    {
      "chunk_id": "chunk_494",
      "text": "또한 대한의학회 ‘일차 의료용\n\n<!-- PAGE_22 -->\n###### 근거 기반 우울장애 임상진료지침(2022)’에서도 경증 혹은 중등도 수준\n\n<!-- PAGE_22 -->\n###### 우울장애에서는 인지행동치료 등 정신사회 치료를 먼저 고려하도록\n\n<!-- PAGE_22 -->\n###### 권장하고 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 493,
        "window_size": 3,
        "char_count": 178,
        "word_count": 33,
        "page_number": 22,
        "window_text": "단, 이\n\n<!-- PAGE_21 -->\n###### 부분은 본 의료기기의 주요부문이 아니므로 더 서술하지 않되, 환자의\n\n<!-- PAGE_21 -->\n###### 적절한 치료를 위해 우울 증상을 파악하고 개선한다는 점에서, 약물\n\n<!-- PAGE_21 -->\n###### 복용력을 고려하는 디지털치료기기라면 환자의 상태를 파악하기를\n\n<!-- PAGE_21 -->\n###### 권고한다.\n\n (출처: 대한의학회(2022), 일차 의료용 근거기반 우울장애 임상진료지침)\n\n- - 15 -\n<!-- PAGE_22 -->\n###### 마.  우울장애 비약물 치료의 임상 권고 사항\n\n<!-- PAGE_22 -->\n###### 미국정신의학회(APA), 캐나다 기분·불안 치료 네트워크(Canadian\n\n<!-- PAGE_22 -->\n###### Network for Mood and Anxiety Treatments, CANMAT), 영국정신의학회\n\n<!-- PAGE_22 -->\n###### (British Association for Psychopharmacology, BAP) 등은 우울장애 치료를\n\n<!-- PAGE_22 -->\n###### 위해 인지행동치료(CBT)를 먼저 권고한다.  또한 대한의학회 ‘일차 의료용\n\n<!-- PAGE_22 -->\n###### 근거 기반 우울장애 임상진료지침(2022)’에서도 경증 혹은 중등도 수준\n\n<!-- PAGE_22 -->\n###### 우울장애에서는 인지행동치료 등 정신사회 치료를 먼저 고려하도록\n\n<!-- PAGE_22 -->\n###### 권장하고 있다.\n\n * APA: American Psychiatric Association, BAP: British Association for Psychopharmacology,\n\n** 진료지침별 권고 등급의 수준이 상이하여 재분류함\n\n<!-- PAGE_22 -->\n###### 미국정신의학협회(APA) 진료지침(2010)은 대수롭지 않거나 중등도\n\n<!-- PAGE_22 -->\n###### 수준 우울장애이면 초기 치료로 인지행동치료를 제안한다(권고등급,\n\n<!-- PAGE_22 -->\n###### Strong).  캐나다 기분·불안 치료 네트워크(CANMAT) 진료지침(2016)은\n\n<!-- PAGE_22 -->\n###### 급성기 치료(Acute Treatment) 및 유지 치료(Maintenance Treatment)에\n\n<!-- PAGE_22 -->\n###### 대해 인지행동치료가 효과가 있으며, 근거 수준이 높다고 제안한다(권고\n\n<!-- PAGE_22 -->\n###### 등급, Strong [First-line]).  전화를 활용한 인지행동치료, 인터넷이나\n\n<!-- PAGE_22 -->\n###### 컴퓨터를 활용한 급성기 치료(Acute Treatment)는 권고등급을 Strong\n\n<!-- PAGE_22 -->\n###### [Second-line]으로 제안한다. ",
        "original_sentence": "또한 대한의학회 ‘일차 의료용\n\n<!-- PAGE_22 -->\n###### 근거 기반 우울장애 임상진료지침(2022)’에서도 경증 혹은 중등도 수준\n\n<!-- PAGE_22 -->\n###### 우울장애에서는 인지행동치료 등 정신사회 치료를 먼저 고려하도록\n\n<!-- PAGE_22 -->\n###### 권장하고 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_495",
      "text": "* APA: American Psychiatric Association, BAP: British Association for Psychopharmacology,\n\n** 진료지침별 권고 등급의 수준이 상이하여 재분류함\n\n<!-- PAGE_22 -->\n###### 미국정신의학협회(APA) 진료지침(2010)은 대수롭지 않거나 중등도\n\n<!-- PAGE_22 -->\n###### 수준 우울장애이면 초기 치료로 인지행동치료를 제안한다(권고등급,\n\n<!-- PAGE_22 -->\n###### Strong). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 494,
        "window_size": 3,
        "char_count": 280,
        "word_count": 41,
        "page_number": 22,
        "window_text": "(출처: 대한의학회(2022), 일차 의료용 근거기반 우울장애 임상진료지침)\n\n- - 15 -\n<!-- PAGE_22 -->\n###### 마.  우울장애 비약물 치료의 임상 권고 사항\n\n<!-- PAGE_22 -->\n###### 미국정신의학회(APA), 캐나다 기분·불안 치료 네트워크(Canadian\n\n<!-- PAGE_22 -->\n###### Network for Mood and Anxiety Treatments, CANMAT), 영국정신의학회\n\n<!-- PAGE_22 -->\n###### (British Association for Psychopharmacology, BAP) 등은 우울장애 치료를\n\n<!-- PAGE_22 -->\n###### 위해 인지행동치료(CBT)를 먼저 권고한다.  또한 대한의학회 ‘일차 의료용\n\n<!-- PAGE_22 -->\n###### 근거 기반 우울장애 임상진료지침(2022)’에서도 경증 혹은 중등도 수준\n\n<!-- PAGE_22 -->\n###### 우울장애에서는 인지행동치료 등 정신사회 치료를 먼저 고려하도록\n\n<!-- PAGE_22 -->\n###### 권장하고 있다.\n\n * APA: American Psychiatric Association, BAP: British Association for Psychopharmacology,\n\n** 진료지침별 권고 등급의 수준이 상이하여 재분류함\n\n<!-- PAGE_22 -->\n###### 미국정신의학협회(APA) 진료지침(2010)은 대수롭지 않거나 중등도\n\n<!-- PAGE_22 -->\n###### 수준 우울장애이면 초기 치료로 인지행동치료를 제안한다(권고등급,\n\n<!-- PAGE_22 -->\n###### Strong).  캐나다 기분·불안 치료 네트워크(CANMAT) 진료지침(2016)은\n\n<!-- PAGE_22 -->\n###### 급성기 치료(Acute Treatment) 및 유지 치료(Maintenance Treatment)에\n\n<!-- PAGE_22 -->\n###### 대해 인지행동치료가 효과가 있으며, 근거 수준이 높다고 제안한다(권고\n\n<!-- PAGE_22 -->\n###### 등급, Strong [First-line]).  전화를 활용한 인지행동치료, 인터넷이나\n\n<!-- PAGE_22 -->\n###### 컴퓨터를 활용한 급성기 치료(Acute Treatment)는 권고등급을 Strong\n\n<!-- PAGE_22 -->\n###### [Second-line]으로 제안한다.  마음챙김 기반 인지치료(Mindfulness-based\n\n<!-- PAGE_22 -->\n###### cognitive therapy, MBCT)은 유지 치료(Maintenance Treatment) 단계에서\n\n- - 16 -\n<!-- PAGE_23 -->\n###### 활용하도록 권고한다(권고등급, Strong [First-line]).\n\n",
        "original_sentence": "* APA: American Psychiatric Association, BAP: British Association for Psychopharmacology,\n\n** 진료지침별 권고 등급의 수준이 상이하여 재분류함\n\n<!-- PAGE_22 -->\n###### 미국정신의학협회(APA) 진료지침(2010)은 대수롭지 않거나 중등도\n\n<!-- PAGE_22 -->\n###### 수준 우울장애이면 초기 치료로 인지행동치료를 제안한다(권고등급,\n\n<!-- PAGE_22 -->\n###### Strong). "
      }
    },
    {
      "chunk_id": "chunk_496",
      "text": "캐나다 기분·불안 치료 네트워크(CANMAT) 진료지침(2016)은\n\n<!-- PAGE_22 -->\n###### 급성기 치료(Acute Treatment) 및 유지 치료(Maintenance Treatment)에\n\n<!-- PAGE_22 -->\n###### 대해 인지행동치료가 효과가 있으며, 근거 수준이 높다고 제안한다(권고\n\n<!-- PAGE_22 -->\n###### 등급, Strong [First-line]). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 495,
        "window_size": 3,
        "char_count": 234,
        "word_count": 35,
        "page_number": 22,
        "window_text": "우울장애 비약물 치료의 임상 권고 사항\n\n<!-- PAGE_22 -->\n###### 미국정신의학회(APA), 캐나다 기분·불안 치료 네트워크(Canadian\n\n<!-- PAGE_22 -->\n###### Network for Mood and Anxiety Treatments, CANMAT), 영국정신의학회\n\n<!-- PAGE_22 -->\n###### (British Association for Psychopharmacology, BAP) 등은 우울장애 치료를\n\n<!-- PAGE_22 -->\n###### 위해 인지행동치료(CBT)를 먼저 권고한다.  또한 대한의학회 ‘일차 의료용\n\n<!-- PAGE_22 -->\n###### 근거 기반 우울장애 임상진료지침(2022)’에서도 경증 혹은 중등도 수준\n\n<!-- PAGE_22 -->\n###### 우울장애에서는 인지행동치료 등 정신사회 치료를 먼저 고려하도록\n\n<!-- PAGE_22 -->\n###### 권장하고 있다.\n\n * APA: American Psychiatric Association, BAP: British Association for Psychopharmacology,\n\n** 진료지침별 권고 등급의 수준이 상이하여 재분류함\n\n<!-- PAGE_22 -->\n###### 미국정신의학협회(APA) 진료지침(2010)은 대수롭지 않거나 중등도\n\n<!-- PAGE_22 -->\n###### 수준 우울장애이면 초기 치료로 인지행동치료를 제안한다(권고등급,\n\n<!-- PAGE_22 -->\n###### Strong).  캐나다 기분·불안 치료 네트워크(CANMAT) 진료지침(2016)은\n\n<!-- PAGE_22 -->\n###### 급성기 치료(Acute Treatment) 및 유지 치료(Maintenance Treatment)에\n\n<!-- PAGE_22 -->\n###### 대해 인지행동치료가 효과가 있으며, 근거 수준이 높다고 제안한다(권고\n\n<!-- PAGE_22 -->\n###### 등급, Strong [First-line]).  전화를 활용한 인지행동치료, 인터넷이나\n\n<!-- PAGE_22 -->\n###### 컴퓨터를 활용한 급성기 치료(Acute Treatment)는 권고등급을 Strong\n\n<!-- PAGE_22 -->\n###### [Second-line]으로 제안한다.  마음챙김 기반 인지치료(Mindfulness-based\n\n<!-- PAGE_22 -->\n###### cognitive therapy, MBCT)은 유지 치료(Maintenance Treatment) 단계에서\n\n- - 16 -\n<!-- PAGE_23 -->\n###### 활용하도록 권고한다(권고등급, Strong [First-line]).\n\n <!-- PAGE_23 -->\n###### 영국정신의학회(BAP) 진료지침은 경증(mild)에서 중등도(moderate)\n\n<!-- PAGE_23 -->\n###### 우울장애를 위한 급성 치료는 인지행동치료(CBT), 대인관계 정신치료\n\n<!-- PAGE_23 -->\n###### (Interpersonal psychotherapy, IPT), 행동 활성화(Behavioural activation,\n\n<!-- PAGE_23 -->\n###### BA)가 항우울제 대안이라고 제안하며(권고등급 Strong [A]), 재발성 우울\n\n<!-- PAGE_23 -->\n###### 장애에 대해서 단독 요법으로 심리치료 할 때는 인지행동 치료를\n\n<!-- PAGE_23 -->\n###### 권고한다(권고등급 B). ",
        "original_sentence": "캐나다 기분·불안 치료 네트워크(CANMAT) 진료지침(2016)은\n\n<!-- PAGE_22 -->\n###### 급성기 치료(Acute Treatment) 및 유지 치료(Maintenance Treatment)에\n\n<!-- PAGE_22 -->\n###### 대해 인지행동치료가 효과가 있으며, 근거 수준이 높다고 제안한다(권고\n\n<!-- PAGE_22 -->\n###### 등급, Strong [First-line]). "
      }
    },
    {
      "chunk_id": "chunk_497",
      "text": "전화를 활용한 인지행동치료, 인터넷이나\n\n<!-- PAGE_22 -->\n###### 컴퓨터를 활용한 급성기 치료(Acute Treatment)는 권고등급을 Strong\n\n<!-- PAGE_22 -->\n###### [Second-line]으로 제안한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 496,
        "window_size": 3,
        "char_count": 141,
        "word_count": 21,
        "page_number": 22,
        "window_text": "또한 대한의학회 ‘일차 의료용\n\n<!-- PAGE_22 -->\n###### 근거 기반 우울장애 임상진료지침(2022)’에서도 경증 혹은 중등도 수준\n\n<!-- PAGE_22 -->\n###### 우울장애에서는 인지행동치료 등 정신사회 치료를 먼저 고려하도록\n\n<!-- PAGE_22 -->\n###### 권장하고 있다.\n\n * APA: American Psychiatric Association, BAP: British Association for Psychopharmacology,\n\n** 진료지침별 권고 등급의 수준이 상이하여 재분류함\n\n<!-- PAGE_22 -->\n###### 미국정신의학협회(APA) 진료지침(2010)은 대수롭지 않거나 중등도\n\n<!-- PAGE_22 -->\n###### 수준 우울장애이면 초기 치료로 인지행동치료를 제안한다(권고등급,\n\n<!-- PAGE_22 -->\n###### Strong).  캐나다 기분·불안 치료 네트워크(CANMAT) 진료지침(2016)은\n\n<!-- PAGE_22 -->\n###### 급성기 치료(Acute Treatment) 및 유지 치료(Maintenance Treatment)에\n\n<!-- PAGE_22 -->\n###### 대해 인지행동치료가 효과가 있으며, 근거 수준이 높다고 제안한다(권고\n\n<!-- PAGE_22 -->\n###### 등급, Strong [First-line]).  전화를 활용한 인지행동치료, 인터넷이나\n\n<!-- PAGE_22 -->\n###### 컴퓨터를 활용한 급성기 치료(Acute Treatment)는 권고등급을 Strong\n\n<!-- PAGE_22 -->\n###### [Second-line]으로 제안한다.  마음챙김 기반 인지치료(Mindfulness-based\n\n<!-- PAGE_22 -->\n###### cognitive therapy, MBCT)은 유지 치료(Maintenance Treatment) 단계에서\n\n- - 16 -\n<!-- PAGE_23 -->\n###### 활용하도록 권고한다(권고등급, Strong [First-line]).\n\n <!-- PAGE_23 -->\n###### 영국정신의학회(BAP) 진료지침은 경증(mild)에서 중등도(moderate)\n\n<!-- PAGE_23 -->\n###### 우울장애를 위한 급성 치료는 인지행동치료(CBT), 대인관계 정신치료\n\n<!-- PAGE_23 -->\n###### (Interpersonal psychotherapy, IPT), 행동 활성화(Behavioural activation,\n\n<!-- PAGE_23 -->\n###### BA)가 항우울제 대안이라고 제안하며(권고등급 Strong [A]), 재발성 우울\n\n<!-- PAGE_23 -->\n###### 장애에 대해서 단독 요법으로 심리치료 할 때는 인지행동 치료를\n\n<!-- PAGE_23 -->\n###### 권고한다(권고등급 B).  심각한 우울장애는 비약물 치료 단독보다\n\n<!-- PAGE_23 -->\n###### 항우울제 치료에 추가로 활용하기를 권장한다. ",
        "original_sentence": "전화를 활용한 인지행동치료, 인터넷이나\n\n<!-- PAGE_22 -->\n###### 컴퓨터를 활용한 급성기 치료(Acute Treatment)는 권고등급을 Strong\n\n<!-- PAGE_22 -->\n###### [Second-line]으로 제안한다. "
      }
    },
    {
      "chunk_id": "chunk_498",
      "text": "마음챙김 기반 인지치료(Mindfulness-based\n\n<!-- PAGE_22 -->\n###### cognitive therapy, MBCT)은 유지 치료(Maintenance Treatment) 단계에서\n\n- - 16 -\n<!-- PAGE_23 -->\n###### 활용하도록 권고한다(권고등급, Strong [First-line]).\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 497,
        "window_size": 3,
        "char_count": 190,
        "word_count": 26,
        "page_number": 22,
        "window_text": "* APA: American Psychiatric Association, BAP: British Association for Psychopharmacology,\n\n** 진료지침별 권고 등급의 수준이 상이하여 재분류함\n\n<!-- PAGE_22 -->\n###### 미국정신의학협회(APA) 진료지침(2010)은 대수롭지 않거나 중등도\n\n<!-- PAGE_22 -->\n###### 수준 우울장애이면 초기 치료로 인지행동치료를 제안한다(권고등급,\n\n<!-- PAGE_22 -->\n###### Strong).  캐나다 기분·불안 치료 네트워크(CANMAT) 진료지침(2016)은\n\n<!-- PAGE_22 -->\n###### 급성기 치료(Acute Treatment) 및 유지 치료(Maintenance Treatment)에\n\n<!-- PAGE_22 -->\n###### 대해 인지행동치료가 효과가 있으며, 근거 수준이 높다고 제안한다(권고\n\n<!-- PAGE_22 -->\n###### 등급, Strong [First-line]).  전화를 활용한 인지행동치료, 인터넷이나\n\n<!-- PAGE_22 -->\n###### 컴퓨터를 활용한 급성기 치료(Acute Treatment)는 권고등급을 Strong\n\n<!-- PAGE_22 -->\n###### [Second-line]으로 제안한다.  마음챙김 기반 인지치료(Mindfulness-based\n\n<!-- PAGE_22 -->\n###### cognitive therapy, MBCT)은 유지 치료(Maintenance Treatment) 단계에서\n\n- - 16 -\n<!-- PAGE_23 -->\n###### 활용하도록 권고한다(권고등급, Strong [First-line]).\n\n <!-- PAGE_23 -->\n###### 영국정신의학회(BAP) 진료지침은 경증(mild)에서 중등도(moderate)\n\n<!-- PAGE_23 -->\n###### 우울장애를 위한 급성 치료는 인지행동치료(CBT), 대인관계 정신치료\n\n<!-- PAGE_23 -->\n###### (Interpersonal psychotherapy, IPT), 행동 활성화(Behavioural activation,\n\n<!-- PAGE_23 -->\n###### BA)가 항우울제 대안이라고 제안하며(권고등급 Strong [A]), 재발성 우울\n\n<!-- PAGE_23 -->\n###### 장애에 대해서 단독 요법으로 심리치료 할 때는 인지행동 치료를\n\n<!-- PAGE_23 -->\n###### 권고한다(권고등급 B).  심각한 우울장애는 비약물 치료 단독보다\n\n<!-- PAGE_23 -->\n###### 항우울제 치료에 추가로 활용하기를 권장한다.  다만, 우울장애 인지\n\n<!-- PAGE_23 -->\n###### 행동치료는 시간과 비용에 제약이 있고, 약물치료보다 효과가 늦기\n\n<!-- PAGE_23 -->\n###### 때문에 모든 환자에게 같게 적용하는 데 제한이 있을 수 있다.\n\n",
        "original_sentence": "마음챙김 기반 인지치료(Mindfulness-based\n\n<!-- PAGE_22 -->\n###### cognitive therapy, MBCT)은 유지 치료(Maintenance Treatment) 단계에서\n\n- - 16 -\n<!-- PAGE_23 -->\n###### 활용하도록 권고한다(권고등급, Strong [First-line]).\n\n"
      }
    },
    {
      "chunk_id": "chunk_499",
      "text": "<!-- PAGE_23 -->\n###### 영국정신의학회(BAP) 진료지침은 경증(mild)에서 중등도(moderate)\n\n<!-- PAGE_23 -->\n###### 우울장애를 위한 급성 치료는 인지행동치료(CBT), 대인관계 정신치료\n\n<!-- PAGE_23 -->\n###### (Interpersonal psychotherapy, IPT), 행동 활성화(Behavioural activation,\n\n<!-- PAGE_23 -->\n###### BA)가 항우울제 대안이라고 제안하며(권고등급 Strong [A]), 재발성 우울\n\n<!-- PAGE_23 -->\n###### 장애에 대해서 단독 요법으로 심리치료 할 때는 인지행동 치료를\n\n<!-- PAGE_23 -->\n###### 권고한다(권고등급 B). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 498,
        "window_size": 3,
        "char_count": 394,
        "word_count": 60,
        "page_number": 23,
        "window_text": "캐나다 기분·불안 치료 네트워크(CANMAT) 진료지침(2016)은\n\n<!-- PAGE_22 -->\n###### 급성기 치료(Acute Treatment) 및 유지 치료(Maintenance Treatment)에\n\n<!-- PAGE_22 -->\n###### 대해 인지행동치료가 효과가 있으며, 근거 수준이 높다고 제안한다(권고\n\n<!-- PAGE_22 -->\n###### 등급, Strong [First-line]).  전화를 활용한 인지행동치료, 인터넷이나\n\n<!-- PAGE_22 -->\n###### 컴퓨터를 활용한 급성기 치료(Acute Treatment)는 권고등급을 Strong\n\n<!-- PAGE_22 -->\n###### [Second-line]으로 제안한다.  마음챙김 기반 인지치료(Mindfulness-based\n\n<!-- PAGE_22 -->\n###### cognitive therapy, MBCT)은 유지 치료(Maintenance Treatment) 단계에서\n\n- - 16 -\n<!-- PAGE_23 -->\n###### 활용하도록 권고한다(권고등급, Strong [First-line]).\n\n <!-- PAGE_23 -->\n###### 영국정신의학회(BAP) 진료지침은 경증(mild)에서 중등도(moderate)\n\n<!-- PAGE_23 -->\n###### 우울장애를 위한 급성 치료는 인지행동치료(CBT), 대인관계 정신치료\n\n<!-- PAGE_23 -->\n###### (Interpersonal psychotherapy, IPT), 행동 활성화(Behavioural activation,\n\n<!-- PAGE_23 -->\n###### BA)가 항우울제 대안이라고 제안하며(권고등급 Strong [A]), 재발성 우울\n\n<!-- PAGE_23 -->\n###### 장애에 대해서 단독 요법으로 심리치료 할 때는 인지행동 치료를\n\n<!-- PAGE_23 -->\n###### 권고한다(권고등급 B).  심각한 우울장애는 비약물 치료 단독보다\n\n<!-- PAGE_23 -->\n###### 항우울제 치료에 추가로 활용하기를 권장한다.  다만, 우울장애 인지\n\n<!-- PAGE_23 -->\n###### 행동치료는 시간과 비용에 제약이 있고, 약물치료보다 효과가 늦기\n\n<!-- PAGE_23 -->\n###### 때문에 모든 환자에게 같게 적용하는 데 제한이 있을 수 있다.\n\n <!-- PAGE_23 -->\n###### 바. ",
        "original_sentence": "<!-- PAGE_23 -->\n###### 영국정신의학회(BAP) 진료지침은 경증(mild)에서 중등도(moderate)\n\n<!-- PAGE_23 -->\n###### 우울장애를 위한 급성 치료는 인지행동치료(CBT), 대인관계 정신치료\n\n<!-- PAGE_23 -->\n###### (Interpersonal psychotherapy, IPT), 행동 활성화(Behavioural activation,\n\n<!-- PAGE_23 -->\n###### BA)가 항우울제 대안이라고 제안하며(권고등급 Strong [A]), 재발성 우울\n\n<!-- PAGE_23 -->\n###### 장애에 대해서 단독 요법으로 심리치료 할 때는 인지행동 치료를\n\n<!-- PAGE_23 -->\n###### 권고한다(권고등급 B). "
      }
    },
    {
      "chunk_id": "chunk_500",
      "text": "심각한 우울장애는 비약물 치료 단독보다\n\n<!-- PAGE_23 -->\n###### 항우울제 치료에 추가로 활용하기를 권장한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 499,
        "window_size": 3,
        "char_count": 72,
        "word_count": 14,
        "page_number": 23,
        "window_text": "전화를 활용한 인지행동치료, 인터넷이나\n\n<!-- PAGE_22 -->\n###### 컴퓨터를 활용한 급성기 치료(Acute Treatment)는 권고등급을 Strong\n\n<!-- PAGE_22 -->\n###### [Second-line]으로 제안한다.  마음챙김 기반 인지치료(Mindfulness-based\n\n<!-- PAGE_22 -->\n###### cognitive therapy, MBCT)은 유지 치료(Maintenance Treatment) 단계에서\n\n- - 16 -\n<!-- PAGE_23 -->\n###### 활용하도록 권고한다(권고등급, Strong [First-line]).\n\n <!-- PAGE_23 -->\n###### 영국정신의학회(BAP) 진료지침은 경증(mild)에서 중등도(moderate)\n\n<!-- PAGE_23 -->\n###### 우울장애를 위한 급성 치료는 인지행동치료(CBT), 대인관계 정신치료\n\n<!-- PAGE_23 -->\n###### (Interpersonal psychotherapy, IPT), 행동 활성화(Behavioural activation,\n\n<!-- PAGE_23 -->\n###### BA)가 항우울제 대안이라고 제안하며(권고등급 Strong [A]), 재발성 우울\n\n<!-- PAGE_23 -->\n###### 장애에 대해서 단독 요법으로 심리치료 할 때는 인지행동 치료를\n\n<!-- PAGE_23 -->\n###### 권고한다(권고등급 B).  심각한 우울장애는 비약물 치료 단독보다\n\n<!-- PAGE_23 -->\n###### 항우울제 치료에 추가로 활용하기를 권장한다.  다만, 우울장애 인지\n\n<!-- PAGE_23 -->\n###### 행동치료는 시간과 비용에 제약이 있고, 약물치료보다 효과가 늦기\n\n<!-- PAGE_23 -->\n###### 때문에 모든 환자에게 같게 적용하는 데 제한이 있을 수 있다.\n\n <!-- PAGE_23 -->\n###### 바.  디지털 기반 우울장애 치료 관련 선행연구\n\n<!-- PAGE_23 -->\n###### 디지털 기반 우울장애 인지행동치료는 웹 또는 모바일 앱 등을 이용\n\n<!-- PAGE_23 -->\n###### 하여 병원에 내원하지 않고도 인지행동치료를 시행 받게 되어 치료\n\n<!-- PAGE_23 -->\n###### 접근성 개선을 기대하게 한다. ",
        "original_sentence": "심각한 우울장애는 비약물 치료 단독보다\n\n<!-- PAGE_23 -->\n###### 항우울제 치료에 추가로 활용하기를 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_501",
      "text": "다만, 우울장애 인지\n\n<!-- PAGE_23 -->\n###### 행동치료는 시간과 비용에 제약이 있고, 약물치료보다 효과가 늦기\n\n<!-- PAGE_23 -->\n###### 때문에 모든 환자에게 같게 적용하는 데 제한이 있을 수 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 500,
        "window_size": 3,
        "char_count": 134,
        "word_count": 29,
        "page_number": 23,
        "window_text": "마음챙김 기반 인지치료(Mindfulness-based\n\n<!-- PAGE_22 -->\n###### cognitive therapy, MBCT)은 유지 치료(Maintenance Treatment) 단계에서\n\n- - 16 -\n<!-- PAGE_23 -->\n###### 활용하도록 권고한다(권고등급, Strong [First-line]).\n\n <!-- PAGE_23 -->\n###### 영국정신의학회(BAP) 진료지침은 경증(mild)에서 중등도(moderate)\n\n<!-- PAGE_23 -->\n###### 우울장애를 위한 급성 치료는 인지행동치료(CBT), 대인관계 정신치료\n\n<!-- PAGE_23 -->\n###### (Interpersonal psychotherapy, IPT), 행동 활성화(Behavioural activation,\n\n<!-- PAGE_23 -->\n###### BA)가 항우울제 대안이라고 제안하며(권고등급 Strong [A]), 재발성 우울\n\n<!-- PAGE_23 -->\n###### 장애에 대해서 단독 요법으로 심리치료 할 때는 인지행동 치료를\n\n<!-- PAGE_23 -->\n###### 권고한다(권고등급 B).  심각한 우울장애는 비약물 치료 단독보다\n\n<!-- PAGE_23 -->\n###### 항우울제 치료에 추가로 활용하기를 권장한다.  다만, 우울장애 인지\n\n<!-- PAGE_23 -->\n###### 행동치료는 시간과 비용에 제약이 있고, 약물치료보다 효과가 늦기\n\n<!-- PAGE_23 -->\n###### 때문에 모든 환자에게 같게 적용하는 데 제한이 있을 수 있다.\n\n <!-- PAGE_23 -->\n###### 바.  디지털 기반 우울장애 치료 관련 선행연구\n\n<!-- PAGE_23 -->\n###### 디지털 기반 우울장애 인지행동치료는 웹 또는 모바일 앱 등을 이용\n\n<!-- PAGE_23 -->\n###### 하여 병원에 내원하지 않고도 인지행동치료를 시행 받게 되어 치료\n\n<!-- PAGE_23 -->\n###### 접근성 개선을 기대하게 한다.  또한 디지털 기반 치료로, 환자가 대부분\n\n<!-- PAGE_23 -->\n###### 프로그램을 수행하고 피드백을 받을 수 있으므로 치료자 관점에서 비용\n\n<!-- PAGE_23 -->\n###### 대비 효용성도 증가한다. ",
        "original_sentence": "다만, 우울장애 인지\n\n<!-- PAGE_23 -->\n###### 행동치료는 시간과 비용에 제약이 있고, 약물치료보다 효과가 늦기\n\n<!-- PAGE_23 -->\n###### 때문에 모든 환자에게 같게 적용하는 데 제한이 있을 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_502",
      "text": "<!-- PAGE_23 -->\n###### 바. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 501,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 23,
        "window_text": "<!-- PAGE_23 -->\n###### 영국정신의학회(BAP) 진료지침은 경증(mild)에서 중등도(moderate)\n\n<!-- PAGE_23 -->\n###### 우울장애를 위한 급성 치료는 인지행동치료(CBT), 대인관계 정신치료\n\n<!-- PAGE_23 -->\n###### (Interpersonal psychotherapy, IPT), 행동 활성화(Behavioural activation,\n\n<!-- PAGE_23 -->\n###### BA)가 항우울제 대안이라고 제안하며(권고등급 Strong [A]), 재발성 우울\n\n<!-- PAGE_23 -->\n###### 장애에 대해서 단독 요법으로 심리치료 할 때는 인지행동 치료를\n\n<!-- PAGE_23 -->\n###### 권고한다(권고등급 B).  심각한 우울장애는 비약물 치료 단독보다\n\n<!-- PAGE_23 -->\n###### 항우울제 치료에 추가로 활용하기를 권장한다.  다만, 우울장애 인지\n\n<!-- PAGE_23 -->\n###### 행동치료는 시간과 비용에 제약이 있고, 약물치료보다 효과가 늦기\n\n<!-- PAGE_23 -->\n###### 때문에 모든 환자에게 같게 적용하는 데 제한이 있을 수 있다.\n\n <!-- PAGE_23 -->\n###### 바.  디지털 기반 우울장애 치료 관련 선행연구\n\n<!-- PAGE_23 -->\n###### 디지털 기반 우울장애 인지행동치료는 웹 또는 모바일 앱 등을 이용\n\n<!-- PAGE_23 -->\n###### 하여 병원에 내원하지 않고도 인지행동치료를 시행 받게 되어 치료\n\n<!-- PAGE_23 -->\n###### 접근성 개선을 기대하게 한다.  또한 디지털 기반 치료로, 환자가 대부분\n\n<!-- PAGE_23 -->\n###### 프로그램을 수행하고 피드백을 받을 수 있으므로 치료자 관점에서 비용\n\n<!-- PAGE_23 -->\n###### 대비 효용성도 증가한다.  따라서, 환자가 병원에 매주 내원해야 시행이\n\n<!-- PAGE_23 -->\n###### 가능한 전통적인 치료 공간 접근성과 시간 자원 여부에 따른 치료\n\n<!-- PAGE_23 -->\n###### 제약을 개선할 수 있다(Andrews, 2018).\n\n",
        "original_sentence": "<!-- PAGE_23 -->\n###### 바. "
      }
    },
    {
      "chunk_id": "chunk_503",
      "text": "디지털 기반 우울장애 치료 관련 선행연구\n\n<!-- PAGE_23 -->\n###### 디지털 기반 우울장애 인지행동치료는 웹 또는 모바일 앱 등을 이용\n\n<!-- PAGE_23 -->\n###### 하여 병원에 내원하지 않고도 인지행동치료를 시행 받게 되어 치료\n\n<!-- PAGE_23 -->\n###### 접근성 개선을 기대하게 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 502,
        "window_size": 3,
        "char_count": 188,
        "word_count": 41,
        "page_number": 23,
        "window_text": "심각한 우울장애는 비약물 치료 단독보다\n\n<!-- PAGE_23 -->\n###### 항우울제 치료에 추가로 활용하기를 권장한다.  다만, 우울장애 인지\n\n<!-- PAGE_23 -->\n###### 행동치료는 시간과 비용에 제약이 있고, 약물치료보다 효과가 늦기\n\n<!-- PAGE_23 -->\n###### 때문에 모든 환자에게 같게 적용하는 데 제한이 있을 수 있다.\n\n <!-- PAGE_23 -->\n###### 바.  디지털 기반 우울장애 치료 관련 선행연구\n\n<!-- PAGE_23 -->\n###### 디지털 기반 우울장애 인지행동치료는 웹 또는 모바일 앱 등을 이용\n\n<!-- PAGE_23 -->\n###### 하여 병원에 내원하지 않고도 인지행동치료를 시행 받게 되어 치료\n\n<!-- PAGE_23 -->\n###### 접근성 개선을 기대하게 한다.  또한 디지털 기반 치료로, 환자가 대부분\n\n<!-- PAGE_23 -->\n###### 프로그램을 수행하고 피드백을 받을 수 있으므로 치료자 관점에서 비용\n\n<!-- PAGE_23 -->\n###### 대비 효용성도 증가한다.  따라서, 환자가 병원에 매주 내원해야 시행이\n\n<!-- PAGE_23 -->\n###### 가능한 전통적인 치료 공간 접근성과 시간 자원 여부에 따른 치료\n\n<!-- PAGE_23 -->\n###### 제약을 개선할 수 있다(Andrews, 2018).\n\n <!-- PAGE_23 -->\n###### 먼저, 독일에서 개발한 Deprexis를 활용하여 우울장애 디지털 치료\n\n<!-- PAGE_23 -->\n###### 기기 효과성을 검증한 많은 연구가 진행되었다(Fischer et al., 2015,\n\n<!-- PAGE_23 -->\n###### Berger et al., 2011, Klein et al., 2016, Beevers et al., 2017, Moritz et\n\n<!-- PAGE_23 -->\n###### al., 2015). ",
        "original_sentence": "디지털 기반 우울장애 치료 관련 선행연구\n\n<!-- PAGE_23 -->\n###### 디지털 기반 우울장애 인지행동치료는 웹 또는 모바일 앱 등을 이용\n\n<!-- PAGE_23 -->\n###### 하여 병원에 내원하지 않고도 인지행동치료를 시행 받게 되어 치료\n\n<!-- PAGE_23 -->\n###### 접근성 개선을 기대하게 한다. "
      }
    },
    {
      "chunk_id": "chunk_504",
      "text": "또한 디지털 기반 치료로, 환자가 대부분\n\n<!-- PAGE_23 -->\n###### 프로그램을 수행하고 피드백을 받을 수 있으므로 치료자 관점에서 비용\n\n<!-- PAGE_23 -->\n###### 대비 효용성도 증가한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 503,
        "window_size": 3,
        "char_count": 125,
        "word_count": 26,
        "page_number": 23,
        "window_text": "다만, 우울장애 인지\n\n<!-- PAGE_23 -->\n###### 행동치료는 시간과 비용에 제약이 있고, 약물치료보다 효과가 늦기\n\n<!-- PAGE_23 -->\n###### 때문에 모든 환자에게 같게 적용하는 데 제한이 있을 수 있다.\n\n <!-- PAGE_23 -->\n###### 바.  디지털 기반 우울장애 치료 관련 선행연구\n\n<!-- PAGE_23 -->\n###### 디지털 기반 우울장애 인지행동치료는 웹 또는 모바일 앱 등을 이용\n\n<!-- PAGE_23 -->\n###### 하여 병원에 내원하지 않고도 인지행동치료를 시행 받게 되어 치료\n\n<!-- PAGE_23 -->\n###### 접근성 개선을 기대하게 한다.  또한 디지털 기반 치료로, 환자가 대부분\n\n<!-- PAGE_23 -->\n###### 프로그램을 수행하고 피드백을 받을 수 있으므로 치료자 관점에서 비용\n\n<!-- PAGE_23 -->\n###### 대비 효용성도 증가한다.  따라서, 환자가 병원에 매주 내원해야 시행이\n\n<!-- PAGE_23 -->\n###### 가능한 전통적인 치료 공간 접근성과 시간 자원 여부에 따른 치료\n\n<!-- PAGE_23 -->\n###### 제약을 개선할 수 있다(Andrews, 2018).\n\n <!-- PAGE_23 -->\n###### 먼저, 독일에서 개발한 Deprexis를 활용하여 우울장애 디지털 치료\n\n<!-- PAGE_23 -->\n###### 기기 효과성을 검증한 많은 연구가 진행되었다(Fischer et al., 2015,\n\n<!-- PAGE_23 -->\n###### Berger et al., 2011, Klein et al., 2016, Beevers et al., 2017, Moritz et\n\n<!-- PAGE_23 -->\n###### al., 2015).  Deprexis의 효과성 검증을 위해 Beck Depression Inventory\n\n- - 17 -\n<!-- PAGE_24 -->\n###### (BDI-II) 척도 13점 이상이고 연령은 18세 이상인 우울장애 환자 98명을\n\n<!-- PAGE_24 -->\n###### 대상으로 무작위배정 임상시험을 진행하였다(Berger et al., 2018).\n\n",
        "original_sentence": "또한 디지털 기반 치료로, 환자가 대부분\n\n<!-- PAGE_23 -->\n###### 프로그램을 수행하고 피드백을 받을 수 있으므로 치료자 관점에서 비용\n\n<!-- PAGE_23 -->\n###### 대비 효용성도 증가한다. "
      }
    },
    {
      "chunk_id": "chunk_505",
      "text": "따라서, 환자가 병원에 매주 내원해야 시행이\n\n<!-- PAGE_23 -->\n###### 가능한 전통적인 치료 공간 접근성과 시간 자원 여부에 따른 치료\n\n<!-- PAGE_23 -->\n###### 제약을 개선할 수 있다(Andrews, 2018).\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 504,
        "window_size": 3,
        "char_count": 141,
        "word_count": 29,
        "page_number": 23,
        "window_text": "<!-- PAGE_23 -->\n###### 바.  디지털 기반 우울장애 치료 관련 선행연구\n\n<!-- PAGE_23 -->\n###### 디지털 기반 우울장애 인지행동치료는 웹 또는 모바일 앱 등을 이용\n\n<!-- PAGE_23 -->\n###### 하여 병원에 내원하지 않고도 인지행동치료를 시행 받게 되어 치료\n\n<!-- PAGE_23 -->\n###### 접근성 개선을 기대하게 한다.  또한 디지털 기반 치료로, 환자가 대부분\n\n<!-- PAGE_23 -->\n###### 프로그램을 수행하고 피드백을 받을 수 있으므로 치료자 관점에서 비용\n\n<!-- PAGE_23 -->\n###### 대비 효용성도 증가한다.  따라서, 환자가 병원에 매주 내원해야 시행이\n\n<!-- PAGE_23 -->\n###### 가능한 전통적인 치료 공간 접근성과 시간 자원 여부에 따른 치료\n\n<!-- PAGE_23 -->\n###### 제약을 개선할 수 있다(Andrews, 2018).\n\n <!-- PAGE_23 -->\n###### 먼저, 독일에서 개발한 Deprexis를 활용하여 우울장애 디지털 치료\n\n<!-- PAGE_23 -->\n###### 기기 효과성을 검증한 많은 연구가 진행되었다(Fischer et al., 2015,\n\n<!-- PAGE_23 -->\n###### Berger et al., 2011, Klein et al., 2016, Beevers et al., 2017, Moritz et\n\n<!-- PAGE_23 -->\n###### al., 2015).  Deprexis의 효과성 검증을 위해 Beck Depression Inventory\n\n- - 17 -\n<!-- PAGE_24 -->\n###### (BDI-II) 척도 13점 이상이고 연령은 18세 이상인 우울장애 환자 98명을\n\n<!-- PAGE_24 -->\n###### 대상으로 무작위배정 임상시험을 진행하였다(Berger et al., 2018).\n\n <!-- PAGE_24 -->\n###### 실험군(51명)은 기존 심리상담과 함께 웹 기반 우울장애 프로그램인\n\n<!-- PAGE_24 -->\n###### Deprexis를 사용하였고, 대조군(47명)은 심리상담만을 진행하였다.\n\n",
        "original_sentence": "따라서, 환자가 병원에 매주 내원해야 시행이\n\n<!-- PAGE_23 -->\n###### 가능한 전통적인 치료 공간 접근성과 시간 자원 여부에 따른 치료\n\n<!-- PAGE_23 -->\n###### 제약을 개선할 수 있다(Andrews, 2018).\n\n"
      }
    },
    {
      "chunk_id": "chunk_506",
      "text": "<!-- PAGE_23 -->\n###### 먼저, 독일에서 개발한 Deprexis를 활용하여 우울장애 디지털 치료\n\n<!-- PAGE_23 -->\n###### 기기 효과성을 검증한 많은 연구가 진행되었다(Fischer et al., 2015,\n\n<!-- PAGE_23 -->\n###### Berger et al., 2011, Klein et al., 2016, Beevers et al., 2017, Moritz et\n\n<!-- PAGE_23 -->\n###### al., 2015). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 505,
        "window_size": 3,
        "char_count": 271,
        "word_count": 49,
        "page_number": 23,
        "window_text": "디지털 기반 우울장애 치료 관련 선행연구\n\n<!-- PAGE_23 -->\n###### 디지털 기반 우울장애 인지행동치료는 웹 또는 모바일 앱 등을 이용\n\n<!-- PAGE_23 -->\n###### 하여 병원에 내원하지 않고도 인지행동치료를 시행 받게 되어 치료\n\n<!-- PAGE_23 -->\n###### 접근성 개선을 기대하게 한다.  또한 디지털 기반 치료로, 환자가 대부분\n\n<!-- PAGE_23 -->\n###### 프로그램을 수행하고 피드백을 받을 수 있으므로 치료자 관점에서 비용\n\n<!-- PAGE_23 -->\n###### 대비 효용성도 증가한다.  따라서, 환자가 병원에 매주 내원해야 시행이\n\n<!-- PAGE_23 -->\n###### 가능한 전통적인 치료 공간 접근성과 시간 자원 여부에 따른 치료\n\n<!-- PAGE_23 -->\n###### 제약을 개선할 수 있다(Andrews, 2018).\n\n <!-- PAGE_23 -->\n###### 먼저, 독일에서 개발한 Deprexis를 활용하여 우울장애 디지털 치료\n\n<!-- PAGE_23 -->\n###### 기기 효과성을 검증한 많은 연구가 진행되었다(Fischer et al., 2015,\n\n<!-- PAGE_23 -->\n###### Berger et al., 2011, Klein et al., 2016, Beevers et al., 2017, Moritz et\n\n<!-- PAGE_23 -->\n###### al., 2015).  Deprexis의 효과성 검증을 위해 Beck Depression Inventory\n\n- - 17 -\n<!-- PAGE_24 -->\n###### (BDI-II) 척도 13점 이상이고 연령은 18세 이상인 우울장애 환자 98명을\n\n<!-- PAGE_24 -->\n###### 대상으로 무작위배정 임상시험을 진행하였다(Berger et al., 2018).\n\n <!-- PAGE_24 -->\n###### 실험군(51명)은 기존 심리상담과 함께 웹 기반 우울장애 프로그램인\n\n<!-- PAGE_24 -->\n###### Deprexis를 사용하였고, 대조군(47명)은 심리상담만을 진행하였다.\n\n <!-- PAGE_24 -->\n###### Deprexis는 주로 인지행동 심리치료를 기반으로 하는 정신교육 정보와\n\n<!-- PAGE_24 -->\n###### 운동 정보 등을 제공하는 10개 콘텐츠 모듈을 제공하여 환자가 사용\n\n<!-- PAGE_24 -->\n###### 할 수 있도록 했다.\n\n",
        "original_sentence": "<!-- PAGE_23 -->\n###### 먼저, 독일에서 개발한 Deprexis를 활용하여 우울장애 디지털 치료\n\n<!-- PAGE_23 -->\n###### 기기 효과성을 검증한 많은 연구가 진행되었다(Fischer et al., 2015,\n\n<!-- PAGE_23 -->\n###### Berger et al., 2011, Klein et al., 2016, Beevers et al., 2017, Moritz et\n\n<!-- PAGE_23 -->\n###### al., 2015). "
      }
    },
    {
      "chunk_id": "chunk_507",
      "text": "Deprexis의 효과성 검증을 위해 Beck Depression Inventory\n\n- - 17 -\n<!-- PAGE_24 -->\n###### (BDI-II) 척도 13점 이상이고 연령은 18세 이상인 우울장애 환자 98명을\n\n<!-- PAGE_24 -->\n###### 대상으로 무작위배정 임상시험을 진행하였다(Berger et al., 2018).\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 506,
        "window_size": 3,
        "char_count": 198,
        "word_count": 36,
        "page_number": 24,
        "window_text": "또한 디지털 기반 치료로, 환자가 대부분\n\n<!-- PAGE_23 -->\n###### 프로그램을 수행하고 피드백을 받을 수 있으므로 치료자 관점에서 비용\n\n<!-- PAGE_23 -->\n###### 대비 효용성도 증가한다.  따라서, 환자가 병원에 매주 내원해야 시행이\n\n<!-- PAGE_23 -->\n###### 가능한 전통적인 치료 공간 접근성과 시간 자원 여부에 따른 치료\n\n<!-- PAGE_23 -->\n###### 제약을 개선할 수 있다(Andrews, 2018).\n\n <!-- PAGE_23 -->\n###### 먼저, 독일에서 개발한 Deprexis를 활용하여 우울장애 디지털 치료\n\n<!-- PAGE_23 -->\n###### 기기 효과성을 검증한 많은 연구가 진행되었다(Fischer et al., 2015,\n\n<!-- PAGE_23 -->\n###### Berger et al., 2011, Klein et al., 2016, Beevers et al., 2017, Moritz et\n\n<!-- PAGE_23 -->\n###### al., 2015).  Deprexis의 효과성 검증을 위해 Beck Depression Inventory\n\n- - 17 -\n<!-- PAGE_24 -->\n###### (BDI-II) 척도 13점 이상이고 연령은 18세 이상인 우울장애 환자 98명을\n\n<!-- PAGE_24 -->\n###### 대상으로 무작위배정 임상시험을 진행하였다(Berger et al., 2018).\n\n <!-- PAGE_24 -->\n###### 실험군(51명)은 기존 심리상담과 함께 웹 기반 우울장애 프로그램인\n\n<!-- PAGE_24 -->\n###### Deprexis를 사용하였고, 대조군(47명)은 심리상담만을 진행하였다.\n\n <!-- PAGE_24 -->\n###### Deprexis는 주로 인지행동 심리치료를 기반으로 하는 정신교육 정보와\n\n<!-- PAGE_24 -->\n###### 운동 정보 등을 제공하는 10개 콘텐츠 모듈을 제공하여 환자가 사용\n\n<!-- PAGE_24 -->\n###### 할 수 있도록 했다.\n\n <!-- PAGE_24 -->\n###### 해당 연구에서 일차 유효성 평가지표는 BDI-II를 사용하였으며, 이차\n\n<!-- PAGE_24 -->\n###### 유효성 지표로는 불안 증상을 측정하기 위한 Generalized Anxiety\n\n<!-- PAGE_24 -->\n###### Disorder Scale(GAD-7), 신체 증상을 측정하기 위한 Patient Health\n\n<!-- PAGE_24 -->\n###### Questionnaire(PHQ-15), 삶의 질을 확인하기 위한 Short-Form Health\n\n<!-- PAGE_24 -->\n###### Survey(SF-12)을 사용하였다. ",
        "original_sentence": "Deprexis의 효과성 검증을 위해 Beck Depression Inventory\n\n- - 17 -\n<!-- PAGE_24 -->\n###### (BDI-II) 척도 13점 이상이고 연령은 18세 이상인 우울장애 환자 98명을\n\n<!-- PAGE_24 -->\n###### 대상으로 무작위배정 임상시험을 진행하였다(Berger et al., 2018).\n\n"
      }
    },
    {
      "chunk_id": "chunk_508",
      "text": "<!-- PAGE_24 -->\n###### 실험군(51명)은 기존 심리상담과 함께 웹 기반 우울장애 프로그램인\n\n<!-- PAGE_24 -->\n###### Deprexis를 사용하였고, 대조군(47명)은 심리상담만을 진행하였다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 507,
        "window_size": 3,
        "char_count": 129,
        "word_count": 21,
        "page_number": 24,
        "window_text": "따라서, 환자가 병원에 매주 내원해야 시행이\n\n<!-- PAGE_23 -->\n###### 가능한 전통적인 치료 공간 접근성과 시간 자원 여부에 따른 치료\n\n<!-- PAGE_23 -->\n###### 제약을 개선할 수 있다(Andrews, 2018).\n\n <!-- PAGE_23 -->\n###### 먼저, 독일에서 개발한 Deprexis를 활용하여 우울장애 디지털 치료\n\n<!-- PAGE_23 -->\n###### 기기 효과성을 검증한 많은 연구가 진행되었다(Fischer et al., 2015,\n\n<!-- PAGE_23 -->\n###### Berger et al., 2011, Klein et al., 2016, Beevers et al., 2017, Moritz et\n\n<!-- PAGE_23 -->\n###### al., 2015).  Deprexis의 효과성 검증을 위해 Beck Depression Inventory\n\n- - 17 -\n<!-- PAGE_24 -->\n###### (BDI-II) 척도 13점 이상이고 연령은 18세 이상인 우울장애 환자 98명을\n\n<!-- PAGE_24 -->\n###### 대상으로 무작위배정 임상시험을 진행하였다(Berger et al., 2018).\n\n <!-- PAGE_24 -->\n###### 실험군(51명)은 기존 심리상담과 함께 웹 기반 우울장애 프로그램인\n\n<!-- PAGE_24 -->\n###### Deprexis를 사용하였고, 대조군(47명)은 심리상담만을 진행하였다.\n\n <!-- PAGE_24 -->\n###### Deprexis는 주로 인지행동 심리치료를 기반으로 하는 정신교육 정보와\n\n<!-- PAGE_24 -->\n###### 운동 정보 등을 제공하는 10개 콘텐츠 모듈을 제공하여 환자가 사용\n\n<!-- PAGE_24 -->\n###### 할 수 있도록 했다.\n\n <!-- PAGE_24 -->\n###### 해당 연구에서 일차 유효성 평가지표는 BDI-II를 사용하였으며, 이차\n\n<!-- PAGE_24 -->\n###### 유효성 지표로는 불안 증상을 측정하기 위한 Generalized Anxiety\n\n<!-- PAGE_24 -->\n###### Disorder Scale(GAD-7), 신체 증상을 측정하기 위한 Patient Health\n\n<!-- PAGE_24 -->\n###### Questionnaire(PHQ-15), 삶의 질을 확인하기 위한 Short-Form Health\n\n<!-- PAGE_24 -->\n###### Survey(SF-12)을 사용하였다.  웹 기반 프로그램을 함께 사용한 치료가\n\n<!-- PAGE_24 -->\n###### 심리치료 단독 수행보다 우울장애를 개선하는 효과가 더 있었고\n\n<!-- PAGE_24 -->\n###### (Cohen’s d=0.51), 이차 유효성 변수도 개선하는 효과가 있었다\n\n<!-- PAGE_24 -->\n###### (SF-12 physical subscale Cohen’s d=0.07, SF-12 mental health\n\n<!-- PAGE_24 -->\n###### Cohen’s d=0.55).\n\n",
        "original_sentence": "<!-- PAGE_24 -->\n###### 실험군(51명)은 기존 심리상담과 함께 웹 기반 우울장애 프로그램인\n\n<!-- PAGE_24 -->\n###### Deprexis를 사용하였고, 대조군(47명)은 심리상담만을 진행하였다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_509",
      "text": "<!-- PAGE_24 -->\n###### Deprexis는 주로 인지행동 심리치료를 기반으로 하는 정신교육 정보와\n\n<!-- PAGE_24 -->\n###### 운동 정보 등을 제공하는 10개 콘텐츠 모듈을 제공하여 환자가 사용\n\n<!-- PAGE_24 -->\n###### 할 수 있도록 했다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 508,
        "window_size": 3,
        "char_count": 166,
        "word_count": 34,
        "page_number": 24,
        "window_text": "<!-- PAGE_23 -->\n###### 먼저, 독일에서 개발한 Deprexis를 활용하여 우울장애 디지털 치료\n\n<!-- PAGE_23 -->\n###### 기기 효과성을 검증한 많은 연구가 진행되었다(Fischer et al., 2015,\n\n<!-- PAGE_23 -->\n###### Berger et al., 2011, Klein et al., 2016, Beevers et al., 2017, Moritz et\n\n<!-- PAGE_23 -->\n###### al., 2015).  Deprexis의 효과성 검증을 위해 Beck Depression Inventory\n\n- - 17 -\n<!-- PAGE_24 -->\n###### (BDI-II) 척도 13점 이상이고 연령은 18세 이상인 우울장애 환자 98명을\n\n<!-- PAGE_24 -->\n###### 대상으로 무작위배정 임상시험을 진행하였다(Berger et al., 2018).\n\n <!-- PAGE_24 -->\n###### 실험군(51명)은 기존 심리상담과 함께 웹 기반 우울장애 프로그램인\n\n<!-- PAGE_24 -->\n###### Deprexis를 사용하였고, 대조군(47명)은 심리상담만을 진행하였다.\n\n <!-- PAGE_24 -->\n###### Deprexis는 주로 인지행동 심리치료를 기반으로 하는 정신교육 정보와\n\n<!-- PAGE_24 -->\n###### 운동 정보 등을 제공하는 10개 콘텐츠 모듈을 제공하여 환자가 사용\n\n<!-- PAGE_24 -->\n###### 할 수 있도록 했다.\n\n <!-- PAGE_24 -->\n###### 해당 연구에서 일차 유효성 평가지표는 BDI-II를 사용하였으며, 이차\n\n<!-- PAGE_24 -->\n###### 유효성 지표로는 불안 증상을 측정하기 위한 Generalized Anxiety\n\n<!-- PAGE_24 -->\n###### Disorder Scale(GAD-7), 신체 증상을 측정하기 위한 Patient Health\n\n<!-- PAGE_24 -->\n###### Questionnaire(PHQ-15), 삶의 질을 확인하기 위한 Short-Form Health\n\n<!-- PAGE_24 -->\n###### Survey(SF-12)을 사용하였다.  웹 기반 프로그램을 함께 사용한 치료가\n\n<!-- PAGE_24 -->\n###### 심리치료 단독 수행보다 우울장애를 개선하는 효과가 더 있었고\n\n<!-- PAGE_24 -->\n###### (Cohen’s d=0.51), 이차 유효성 변수도 개선하는 효과가 있었다\n\n<!-- PAGE_24 -->\n###### (SF-12 physical subscale Cohen’s d=0.07, SF-12 mental health\n\n<!-- PAGE_24 -->\n###### Cohen’s d=0.55).\n\n <!-- PAGE_24 -->\n###### 18세 이상인 경증에서 중등도 수준 우울 증상(PHQ-9 5점~14점)이\n\n<!-- PAGE_24 -->\n###### 있는 총 1,013명을 대상으로 Deprexis 효과성을 검증하는 다기관 무작위\n\n<!-- PAGE_24 -->\n###### 배정 임상시험도 진행되었다(Klein et al., 2016). ",
        "original_sentence": "<!-- PAGE_24 -->\n###### Deprexis는 주로 인지행동 심리치료를 기반으로 하는 정신교육 정보와\n\n<!-- PAGE_24 -->\n###### 운동 정보 등을 제공하는 10개 콘텐츠 모듈을 제공하여 환자가 사용\n\n<!-- PAGE_24 -->\n###### 할 수 있도록 했다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_510",
      "text": "<!-- PAGE_24 -->\n###### 해당 연구에서 일차 유효성 평가지표는 BDI-II를 사용하였으며, 이차\n\n<!-- PAGE_24 -->\n###### 유효성 지표로는 불안 증상을 측정하기 위한 Generalized Anxiety\n\n<!-- PAGE_24 -->\n###### Disorder Scale(GAD-7), 신체 증상을 측정하기 위한 Patient Health\n\n<!-- PAGE_24 -->\n###### Questionnaire(PHQ-15), 삶의 질을 확인하기 위한 Short-Form Health\n\n<!-- PAGE_24 -->\n###### Survey(SF-12)을 사용하였다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 509,
        "window_size": 3,
        "char_count": 338,
        "word_count": 53,
        "page_number": 24,
        "window_text": "Deprexis의 효과성 검증을 위해 Beck Depression Inventory\n\n- - 17 -\n<!-- PAGE_24 -->\n###### (BDI-II) 척도 13점 이상이고 연령은 18세 이상인 우울장애 환자 98명을\n\n<!-- PAGE_24 -->\n###### 대상으로 무작위배정 임상시험을 진행하였다(Berger et al., 2018).\n\n <!-- PAGE_24 -->\n###### 실험군(51명)은 기존 심리상담과 함께 웹 기반 우울장애 프로그램인\n\n<!-- PAGE_24 -->\n###### Deprexis를 사용하였고, 대조군(47명)은 심리상담만을 진행하였다.\n\n <!-- PAGE_24 -->\n###### Deprexis는 주로 인지행동 심리치료를 기반으로 하는 정신교육 정보와\n\n<!-- PAGE_24 -->\n###### 운동 정보 등을 제공하는 10개 콘텐츠 모듈을 제공하여 환자가 사용\n\n<!-- PAGE_24 -->\n###### 할 수 있도록 했다.\n\n <!-- PAGE_24 -->\n###### 해당 연구에서 일차 유효성 평가지표는 BDI-II를 사용하였으며, 이차\n\n<!-- PAGE_24 -->\n###### 유효성 지표로는 불안 증상을 측정하기 위한 Generalized Anxiety\n\n<!-- PAGE_24 -->\n###### Disorder Scale(GAD-7), 신체 증상을 측정하기 위한 Patient Health\n\n<!-- PAGE_24 -->\n###### Questionnaire(PHQ-15), 삶의 질을 확인하기 위한 Short-Form Health\n\n<!-- PAGE_24 -->\n###### Survey(SF-12)을 사용하였다.  웹 기반 프로그램을 함께 사용한 치료가\n\n<!-- PAGE_24 -->\n###### 심리치료 단독 수행보다 우울장애를 개선하는 효과가 더 있었고\n\n<!-- PAGE_24 -->\n###### (Cohen’s d=0.51), 이차 유효성 변수도 개선하는 효과가 있었다\n\n<!-- PAGE_24 -->\n###### (SF-12 physical subscale Cohen’s d=0.07, SF-12 mental health\n\n<!-- PAGE_24 -->\n###### Cohen’s d=0.55).\n\n <!-- PAGE_24 -->\n###### 18세 이상인 경증에서 중등도 수준 우울 증상(PHQ-9 5점~14점)이\n\n<!-- PAGE_24 -->\n###### 있는 총 1,013명을 대상으로 Deprexis 효과성을 검증하는 다기관 무작위\n\n<!-- PAGE_24 -->\n###### 배정 임상시험도 진행되었다(Klein et al., 2016).  대조군(504명)은 일반적인\n\n<!-- PAGE_24 -->\n###### 의료 서비스를 받았고, 실험군(509명)은 Deprexis 프로그램에 대한\n\n<!-- PAGE_24 -->\n###### 권한을 받아서 사용하였다. ",
        "original_sentence": "<!-- PAGE_24 -->\n###### 해당 연구에서 일차 유효성 평가지표는 BDI-II를 사용하였으며, 이차\n\n<!-- PAGE_24 -->\n###### 유효성 지표로는 불안 증상을 측정하기 위한 Generalized Anxiety\n\n<!-- PAGE_24 -->\n###### Disorder Scale(GAD-7), 신체 증상을 측정하기 위한 Patient Health\n\n<!-- PAGE_24 -->\n###### Questionnaire(PHQ-15), 삶의 질을 확인하기 위한 Short-Form Health\n\n<!-- PAGE_24 -->\n###### Survey(SF-12)을 사용하였다. "
      }
    },
    {
      "chunk_id": "chunk_511",
      "text": "웹 기반 프로그램을 함께 사용한 치료가\n\n<!-- PAGE_24 -->\n###### 심리치료 단독 수행보다 우울장애를 개선하는 효과가 더 있었고\n\n<!-- PAGE_24 -->\n###### (Cohen’s d=0.51), 이차 유효성 변수도 개선하는 효과가 있었다\n\n<!-- PAGE_24 -->\n###### (SF-12 physical subscale Cohen’s d=0.07, SF-12 mental health\n\n<!-- PAGE_24 -->\n###### Cohen’s d=0.55).\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 510,
        "window_size": 3,
        "char_count": 277,
        "word_count": 48,
        "page_number": 24,
        "window_text": "<!-- PAGE_24 -->\n###### 실험군(51명)은 기존 심리상담과 함께 웹 기반 우울장애 프로그램인\n\n<!-- PAGE_24 -->\n###### Deprexis를 사용하였고, 대조군(47명)은 심리상담만을 진행하였다.\n\n <!-- PAGE_24 -->\n###### Deprexis는 주로 인지행동 심리치료를 기반으로 하는 정신교육 정보와\n\n<!-- PAGE_24 -->\n###### 운동 정보 등을 제공하는 10개 콘텐츠 모듈을 제공하여 환자가 사용\n\n<!-- PAGE_24 -->\n###### 할 수 있도록 했다.\n\n <!-- PAGE_24 -->\n###### 해당 연구에서 일차 유효성 평가지표는 BDI-II를 사용하였으며, 이차\n\n<!-- PAGE_24 -->\n###### 유효성 지표로는 불안 증상을 측정하기 위한 Generalized Anxiety\n\n<!-- PAGE_24 -->\n###### Disorder Scale(GAD-7), 신체 증상을 측정하기 위한 Patient Health\n\n<!-- PAGE_24 -->\n###### Questionnaire(PHQ-15), 삶의 질을 확인하기 위한 Short-Form Health\n\n<!-- PAGE_24 -->\n###### Survey(SF-12)을 사용하였다.  웹 기반 프로그램을 함께 사용한 치료가\n\n<!-- PAGE_24 -->\n###### 심리치료 단독 수행보다 우울장애를 개선하는 효과가 더 있었고\n\n<!-- PAGE_24 -->\n###### (Cohen’s d=0.51), 이차 유효성 변수도 개선하는 효과가 있었다\n\n<!-- PAGE_24 -->\n###### (SF-12 physical subscale Cohen’s d=0.07, SF-12 mental health\n\n<!-- PAGE_24 -->\n###### Cohen’s d=0.55).\n\n <!-- PAGE_24 -->\n###### 18세 이상인 경증에서 중등도 수준 우울 증상(PHQ-9 5점~14점)이\n\n<!-- PAGE_24 -->\n###### 있는 총 1,013명을 대상으로 Deprexis 효과성을 검증하는 다기관 무작위\n\n<!-- PAGE_24 -->\n###### 배정 임상시험도 진행되었다(Klein et al., 2016).  대조군(504명)은 일반적인\n\n<!-- PAGE_24 -->\n###### 의료 서비스를 받았고, 실험군(509명)은 Deprexis 프로그램에 대한\n\n<!-- PAGE_24 -->\n###### 권한을 받아서 사용하였다.  프로그램은 CBT 기반 12주 프로그램이고,\n\n<!-- PAGE_24 -->\n###### 인지 재구성, 행동 활성화, 수용 및 마음챙김 등과 같은 내용을 포함\n\n<!-- PAGE_24 -->\n###### 하는 10개 모듈로 구성되어 있다.\n\n",
        "original_sentence": "웹 기반 프로그램을 함께 사용한 치료가\n\n<!-- PAGE_24 -->\n###### 심리치료 단독 수행보다 우울장애를 개선하는 효과가 더 있었고\n\n<!-- PAGE_24 -->\n###### (Cohen’s d=0.51), 이차 유효성 변수도 개선하는 효과가 있었다\n\n<!-- PAGE_24 -->\n###### (SF-12 physical subscale Cohen’s d=0.07, SF-12 mental health\n\n<!-- PAGE_24 -->\n###### Cohen’s d=0.55).\n\n"
      }
    },
    {
      "chunk_id": "chunk_512",
      "text": "<!-- PAGE_24 -->\n###### 18세 이상인 경증에서 중등도 수준 우울 증상(PHQ-9 5점~14점)이\n\n<!-- PAGE_24 -->\n###### 있는 총 1,013명을 대상으로 Deprexis 효과성을 검증하는 다기관 무작위\n\n<!-- PAGE_24 -->\n###### 배정 임상시험도 진행되었다(Klein et al., 2016). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 511,
        "window_size": 3,
        "char_count": 196,
        "word_count": 35,
        "page_number": 24,
        "window_text": "<!-- PAGE_24 -->\n###### Deprexis는 주로 인지행동 심리치료를 기반으로 하는 정신교육 정보와\n\n<!-- PAGE_24 -->\n###### 운동 정보 등을 제공하는 10개 콘텐츠 모듈을 제공하여 환자가 사용\n\n<!-- PAGE_24 -->\n###### 할 수 있도록 했다.\n\n <!-- PAGE_24 -->\n###### 해당 연구에서 일차 유효성 평가지표는 BDI-II를 사용하였으며, 이차\n\n<!-- PAGE_24 -->\n###### 유효성 지표로는 불안 증상을 측정하기 위한 Generalized Anxiety\n\n<!-- PAGE_24 -->\n###### Disorder Scale(GAD-7), 신체 증상을 측정하기 위한 Patient Health\n\n<!-- PAGE_24 -->\n###### Questionnaire(PHQ-15), 삶의 질을 확인하기 위한 Short-Form Health\n\n<!-- PAGE_24 -->\n###### Survey(SF-12)을 사용하였다.  웹 기반 프로그램을 함께 사용한 치료가\n\n<!-- PAGE_24 -->\n###### 심리치료 단독 수행보다 우울장애를 개선하는 효과가 더 있었고\n\n<!-- PAGE_24 -->\n###### (Cohen’s d=0.51), 이차 유효성 변수도 개선하는 효과가 있었다\n\n<!-- PAGE_24 -->\n###### (SF-12 physical subscale Cohen’s d=0.07, SF-12 mental health\n\n<!-- PAGE_24 -->\n###### Cohen’s d=0.55).\n\n <!-- PAGE_24 -->\n###### 18세 이상인 경증에서 중등도 수준 우울 증상(PHQ-9 5점~14점)이\n\n<!-- PAGE_24 -->\n###### 있는 총 1,013명을 대상으로 Deprexis 효과성을 검증하는 다기관 무작위\n\n<!-- PAGE_24 -->\n###### 배정 임상시험도 진행되었다(Klein et al., 2016).  대조군(504명)은 일반적인\n\n<!-- PAGE_24 -->\n###### 의료 서비스를 받았고, 실험군(509명)은 Deprexis 프로그램에 대한\n\n<!-- PAGE_24 -->\n###### 권한을 받아서 사용하였다.  프로그램은 CBT 기반 12주 프로그램이고,\n\n<!-- PAGE_24 -->\n###### 인지 재구성, 행동 활성화, 수용 및 마음챙김 등과 같은 내용을 포함\n\n<!-- PAGE_24 -->\n###### 하는 10개 모듈로 구성되어 있다.\n\n - - 18 -\n<!-- PAGE_25 -->\n###### 연구에서는 PHQ-9를 일차 유효성 평가지표로 사용하였으며, 5점이\n\n<!-- PAGE_25 -->\n###### 감소 되었을 때 임상적으로 중요한 개선이 있다고 정의하였다. ",
        "original_sentence": "<!-- PAGE_24 -->\n###### 18세 이상인 경증에서 중등도 수준 우울 증상(PHQ-9 5점~14점)이\n\n<!-- PAGE_24 -->\n###### 있는 총 1,013명을 대상으로 Deprexis 효과성을 검증하는 다기관 무작위\n\n<!-- PAGE_24 -->\n###### 배정 임상시험도 진행되었다(Klein et al., 2016). "
      }
    },
    {
      "chunk_id": "chunk_513",
      "text": "대조군(504명)은 일반적인\n\n<!-- PAGE_24 -->\n###### 의료 서비스를 받았고, 실험군(509명)은 Deprexis 프로그램에 대한\n\n<!-- PAGE_24 -->\n###### 권한을 받아서 사용하였다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 512,
        "window_size": 3,
        "char_count": 123,
        "word_count": 20,
        "page_number": 24,
        "window_text": "<!-- PAGE_24 -->\n###### 해당 연구에서 일차 유효성 평가지표는 BDI-II를 사용하였으며, 이차\n\n<!-- PAGE_24 -->\n###### 유효성 지표로는 불안 증상을 측정하기 위한 Generalized Anxiety\n\n<!-- PAGE_24 -->\n###### Disorder Scale(GAD-7), 신체 증상을 측정하기 위한 Patient Health\n\n<!-- PAGE_24 -->\n###### Questionnaire(PHQ-15), 삶의 질을 확인하기 위한 Short-Form Health\n\n<!-- PAGE_24 -->\n###### Survey(SF-12)을 사용하였다.  웹 기반 프로그램을 함께 사용한 치료가\n\n<!-- PAGE_24 -->\n###### 심리치료 단독 수행보다 우울장애를 개선하는 효과가 더 있었고\n\n<!-- PAGE_24 -->\n###### (Cohen’s d=0.51), 이차 유효성 변수도 개선하는 효과가 있었다\n\n<!-- PAGE_24 -->\n###### (SF-12 physical subscale Cohen’s d=0.07, SF-12 mental health\n\n<!-- PAGE_24 -->\n###### Cohen’s d=0.55).\n\n <!-- PAGE_24 -->\n###### 18세 이상인 경증에서 중등도 수준 우울 증상(PHQ-9 5점~14점)이\n\n<!-- PAGE_24 -->\n###### 있는 총 1,013명을 대상으로 Deprexis 효과성을 검증하는 다기관 무작위\n\n<!-- PAGE_24 -->\n###### 배정 임상시험도 진행되었다(Klein et al., 2016).  대조군(504명)은 일반적인\n\n<!-- PAGE_24 -->\n###### 의료 서비스를 받았고, 실험군(509명)은 Deprexis 프로그램에 대한\n\n<!-- PAGE_24 -->\n###### 권한을 받아서 사용하였다.  프로그램은 CBT 기반 12주 프로그램이고,\n\n<!-- PAGE_24 -->\n###### 인지 재구성, 행동 활성화, 수용 및 마음챙김 등과 같은 내용을 포함\n\n<!-- PAGE_24 -->\n###### 하는 10개 모듈로 구성되어 있다.\n\n - - 18 -\n<!-- PAGE_25 -->\n###### 연구에서는 PHQ-9를 일차 유효성 평가지표로 사용하였으며, 5점이\n\n<!-- PAGE_25 -->\n###### 감소 되었을 때 임상적으로 중요한 개선이 있다고 정의하였다.  이차 유\n\n<!-- PAGE_25 -->\n###### 효성 평가지표는 Hamilton Depression Rating Scale(HDRS-24), Quick\n\n<!-- PAGE_25 -->\n###### Inventory of Depressive Symptomatology(QIDS-C16)가 사용되었다. ",
        "original_sentence": "대조군(504명)은 일반적인\n\n<!-- PAGE_24 -->\n###### 의료 서비스를 받았고, 실험군(509명)은 Deprexis 프로그램에 대한\n\n<!-- PAGE_24 -->\n###### 권한을 받아서 사용하였다. "
      }
    },
    {
      "chunk_id": "chunk_514",
      "text": "프로그램은 CBT 기반 12주 프로그램이고,\n\n<!-- PAGE_24 -->\n###### 인지 재구성, 행동 활성화, 수용 및 마음챙김 등과 같은 내용을 포함\n\n<!-- PAGE_24 -->\n###### 하는 10개 모듈로 구성되어 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 513,
        "window_size": 3,
        "char_count": 135,
        "word_count": 29,
        "page_number": 24,
        "window_text": "웹 기반 프로그램을 함께 사용한 치료가\n\n<!-- PAGE_24 -->\n###### 심리치료 단독 수행보다 우울장애를 개선하는 효과가 더 있었고\n\n<!-- PAGE_24 -->\n###### (Cohen’s d=0.51), 이차 유효성 변수도 개선하는 효과가 있었다\n\n<!-- PAGE_24 -->\n###### (SF-12 physical subscale Cohen’s d=0.07, SF-12 mental health\n\n<!-- PAGE_24 -->\n###### Cohen’s d=0.55).\n\n <!-- PAGE_24 -->\n###### 18세 이상인 경증에서 중등도 수준 우울 증상(PHQ-9 5점~14점)이\n\n<!-- PAGE_24 -->\n###### 있는 총 1,013명을 대상으로 Deprexis 효과성을 검증하는 다기관 무작위\n\n<!-- PAGE_24 -->\n###### 배정 임상시험도 진행되었다(Klein et al., 2016).  대조군(504명)은 일반적인\n\n<!-- PAGE_24 -->\n###### 의료 서비스를 받았고, 실험군(509명)은 Deprexis 프로그램에 대한\n\n<!-- PAGE_24 -->\n###### 권한을 받아서 사용하였다.  프로그램은 CBT 기반 12주 프로그램이고,\n\n<!-- PAGE_24 -->\n###### 인지 재구성, 행동 활성화, 수용 및 마음챙김 등과 같은 내용을 포함\n\n<!-- PAGE_24 -->\n###### 하는 10개 모듈로 구성되어 있다.\n\n - - 18 -\n<!-- PAGE_25 -->\n###### 연구에서는 PHQ-9를 일차 유효성 평가지표로 사용하였으며, 5점이\n\n<!-- PAGE_25 -->\n###### 감소 되었을 때 임상적으로 중요한 개선이 있다고 정의하였다.  이차 유\n\n<!-- PAGE_25 -->\n###### 효성 평가지표는 Hamilton Depression Rating Scale(HDRS-24), Quick\n\n<!-- PAGE_25 -->\n###### Inventory of Depressive Symptomatology(QIDS-C16)가 사용되었다.  지표는\n\n<!-- PAGE_25 -->\n###### 연구 시작 시(Baseline), 3개월(평가 후) 및 6개월(추적)에 측정하였다.\n\n",
        "original_sentence": "프로그램은 CBT 기반 12주 프로그램이고,\n\n<!-- PAGE_24 -->\n###### 인지 재구성, 행동 활성화, 수용 및 마음챙김 등과 같은 내용을 포함\n\n<!-- PAGE_24 -->\n###### 하는 10개 모듈로 구성되어 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_515",
      "text": "- - 18 -\n<!-- PAGE_25 -->\n###### 연구에서는 PHQ-9를 일차 유효성 평가지표로 사용하였으며, 5점이\n\n<!-- PAGE_25 -->\n###### 감소 되었을 때 임상적으로 중요한 개선이 있다고 정의하였다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 514,
        "window_size": 3,
        "char_count": 130,
        "word_count": 27,
        "page_number": 25,
        "window_text": "<!-- PAGE_24 -->\n###### 18세 이상인 경증에서 중등도 수준 우울 증상(PHQ-9 5점~14점)이\n\n<!-- PAGE_24 -->\n###### 있는 총 1,013명을 대상으로 Deprexis 효과성을 검증하는 다기관 무작위\n\n<!-- PAGE_24 -->\n###### 배정 임상시험도 진행되었다(Klein et al., 2016).  대조군(504명)은 일반적인\n\n<!-- PAGE_24 -->\n###### 의료 서비스를 받았고, 실험군(509명)은 Deprexis 프로그램에 대한\n\n<!-- PAGE_24 -->\n###### 권한을 받아서 사용하였다.  프로그램은 CBT 기반 12주 프로그램이고,\n\n<!-- PAGE_24 -->\n###### 인지 재구성, 행동 활성화, 수용 및 마음챙김 등과 같은 내용을 포함\n\n<!-- PAGE_24 -->\n###### 하는 10개 모듈로 구성되어 있다.\n\n - - 18 -\n<!-- PAGE_25 -->\n###### 연구에서는 PHQ-9를 일차 유효성 평가지표로 사용하였으며, 5점이\n\n<!-- PAGE_25 -->\n###### 감소 되었을 때 임상적으로 중요한 개선이 있다고 정의하였다.  이차 유\n\n<!-- PAGE_25 -->\n###### 효성 평가지표는 Hamilton Depression Rating Scale(HDRS-24), Quick\n\n<!-- PAGE_25 -->\n###### Inventory of Depressive Symptomatology(QIDS-C16)가 사용되었다.  지표는\n\n<!-- PAGE_25 -->\n###### 연구 시작 시(Baseline), 3개월(평가 후) 및 6개월(추적)에 측정하였다.\n\n <!-- PAGE_25 -->\n###### 3개월 후 측정된 결과에 의하면, 점수는 두 집단 모두에서 감소하\n\n<!-- PAGE_25 -->\n###### 였는데, PHQ-9 변화는 집단 간에 유의하게 달랐다(t=6.12, p<0.001).\n\n",
        "original_sentence": "- - 18 -\n<!-- PAGE_25 -->\n###### 연구에서는 PHQ-9를 일차 유효성 평가지표로 사용하였으며, 5점이\n\n<!-- PAGE_25 -->\n###### 감소 되었을 때 임상적으로 중요한 개선이 있다고 정의하였다. "
      }
    },
    {
      "chunk_id": "chunk_516",
      "text": "이차 유\n\n<!-- PAGE_25 -->\n###### 효성 평가지표는 Hamilton Depression Rating Scale(HDRS-24), Quick\n\n<!-- PAGE_25 -->\n###### Inventory of Depressive Symptomatology(QIDS-C16)가 사용되었다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 515,
        "window_size": 3,
        "char_count": 170,
        "word_count": 22,
        "page_number": 25,
        "window_text": "대조군(504명)은 일반적인\n\n<!-- PAGE_24 -->\n###### 의료 서비스를 받았고, 실험군(509명)은 Deprexis 프로그램에 대한\n\n<!-- PAGE_24 -->\n###### 권한을 받아서 사용하였다.  프로그램은 CBT 기반 12주 프로그램이고,\n\n<!-- PAGE_24 -->\n###### 인지 재구성, 행동 활성화, 수용 및 마음챙김 등과 같은 내용을 포함\n\n<!-- PAGE_24 -->\n###### 하는 10개 모듈로 구성되어 있다.\n\n - - 18 -\n<!-- PAGE_25 -->\n###### 연구에서는 PHQ-9를 일차 유효성 평가지표로 사용하였으며, 5점이\n\n<!-- PAGE_25 -->\n###### 감소 되었을 때 임상적으로 중요한 개선이 있다고 정의하였다.  이차 유\n\n<!-- PAGE_25 -->\n###### 효성 평가지표는 Hamilton Depression Rating Scale(HDRS-24), Quick\n\n<!-- PAGE_25 -->\n###### Inventory of Depressive Symptomatology(QIDS-C16)가 사용되었다.  지표는\n\n<!-- PAGE_25 -->\n###### 연구 시작 시(Baseline), 3개월(평가 후) 및 6개월(추적)에 측정하였다.\n\n <!-- PAGE_25 -->\n###### 3개월 후 측정된 결과에 의하면, 점수는 두 집단 모두에서 감소하\n\n<!-- PAGE_25 -->\n###### 였는데, PHQ-9 변화는 집단 간에 유의하게 달랐다(t=6.12, p<0.001).\n\n <!-- PAGE_25 -->\n###### PHQ-9 점수는 대조군보다 평균 1.57점(95% confidence intervals [CI]:\n\n<!-- PAGE_25 -->\n###### 1.07-2.07) 포인트 더 많이 감소했다. ",
        "original_sentence": "이차 유\n\n<!-- PAGE_25 -->\n###### 효성 평가지표는 Hamilton Depression Rating Scale(HDRS-24), Quick\n\n<!-- PAGE_25 -->\n###### Inventory of Depressive Symptomatology(QIDS-C16)가 사용되었다. "
      }
    },
    {
      "chunk_id": "chunk_517",
      "text": "지표는\n\n<!-- PAGE_25 -->\n###### 연구 시작 시(Baseline), 3개월(평가 후) 및 6개월(추적)에 측정하였다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 516,
        "window_size": 3,
        "char_count": 77,
        "word_count": 13,
        "page_number": 25,
        "window_text": "프로그램은 CBT 기반 12주 프로그램이고,\n\n<!-- PAGE_24 -->\n###### 인지 재구성, 행동 활성화, 수용 및 마음챙김 등과 같은 내용을 포함\n\n<!-- PAGE_24 -->\n###### 하는 10개 모듈로 구성되어 있다.\n\n - - 18 -\n<!-- PAGE_25 -->\n###### 연구에서는 PHQ-9를 일차 유효성 평가지표로 사용하였으며, 5점이\n\n<!-- PAGE_25 -->\n###### 감소 되었을 때 임상적으로 중요한 개선이 있다고 정의하였다.  이차 유\n\n<!-- PAGE_25 -->\n###### 효성 평가지표는 Hamilton Depression Rating Scale(HDRS-24), Quick\n\n<!-- PAGE_25 -->\n###### Inventory of Depressive Symptomatology(QIDS-C16)가 사용되었다.  지표는\n\n<!-- PAGE_25 -->\n###### 연구 시작 시(Baseline), 3개월(평가 후) 및 6개월(추적)에 측정하였다.\n\n <!-- PAGE_25 -->\n###### 3개월 후 측정된 결과에 의하면, 점수는 두 집단 모두에서 감소하\n\n<!-- PAGE_25 -->\n###### 였는데, PHQ-9 변화는 집단 간에 유의하게 달랐다(t=6.12, p<0.001).\n\n <!-- PAGE_25 -->\n###### PHQ-9 점수는 대조군보다 평균 1.57점(95% confidence intervals [CI]:\n\n<!-- PAGE_25 -->\n###### 1.07-2.07) 포인트 더 많이 감소했다.  3개월 후 집단 간 효과 크기는\n\n<!-- PAGE_25 -->\n###### 0.39(95% CI: 0.13-0.64)였으며, 6개월 후도 효과 크기는 0.32(95% CI:\n\n<!-- PAGE_25 -->\n###### 0.06-0.69)로 안정적이었다. ",
        "original_sentence": "지표는\n\n<!-- PAGE_25 -->\n###### 연구 시작 시(Baseline), 3개월(평가 후) 및 6개월(추적)에 측정하였다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_518",
      "text": "<!-- PAGE_25 -->\n###### 3개월 후 측정된 결과에 의하면, 점수는 두 집단 모두에서 감소하\n\n<!-- PAGE_25 -->\n###### 였는데, PHQ-9 변화는 집단 간에 유의하게 달랐다(t=6.12, p<0.001).\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 517,
        "window_size": 3,
        "char_count": 135,
        "word_count": 26,
        "page_number": 25,
        "window_text": "- - 18 -\n<!-- PAGE_25 -->\n###### 연구에서는 PHQ-9를 일차 유효성 평가지표로 사용하였으며, 5점이\n\n<!-- PAGE_25 -->\n###### 감소 되었을 때 임상적으로 중요한 개선이 있다고 정의하였다.  이차 유\n\n<!-- PAGE_25 -->\n###### 효성 평가지표는 Hamilton Depression Rating Scale(HDRS-24), Quick\n\n<!-- PAGE_25 -->\n###### Inventory of Depressive Symptomatology(QIDS-C16)가 사용되었다.  지표는\n\n<!-- PAGE_25 -->\n###### 연구 시작 시(Baseline), 3개월(평가 후) 및 6개월(추적)에 측정하였다.\n\n <!-- PAGE_25 -->\n###### 3개월 후 측정된 결과에 의하면, 점수는 두 집단 모두에서 감소하\n\n<!-- PAGE_25 -->\n###### 였는데, PHQ-9 변화는 집단 간에 유의하게 달랐다(t=6.12, p<0.001).\n\n <!-- PAGE_25 -->\n###### PHQ-9 점수는 대조군보다 평균 1.57점(95% confidence intervals [CI]:\n\n<!-- PAGE_25 -->\n###### 1.07-2.07) 포인트 더 많이 감소했다.  3개월 후 집단 간 효과 크기는\n\n<!-- PAGE_25 -->\n###### 0.39(95% CI: 0.13-0.64)였으며, 6개월 후도 효과 크기는 0.32(95% CI:\n\n<!-- PAGE_25 -->\n###### 0.06-0.69)로 안정적이었다.  임상적으로 중요한 PHQ-9 변화를 경험한\n\n<!-- PAGE_25 -->\n###### 참가자 비율도 실험군이 대조군에 비해 높았다(35.6 vs. ",
        "original_sentence": "<!-- PAGE_25 -->\n###### 3개월 후 측정된 결과에 의하면, 점수는 두 집단 모두에서 감소하\n\n<!-- PAGE_25 -->\n###### 였는데, PHQ-9 변화는 집단 간에 유의하게 달랐다(t=6.12, p<0.001).\n\n"
      }
    },
    {
      "chunk_id": "chunk_519",
      "text": "<!-- PAGE_25 -->\n###### PHQ-9 점수는 대조군보다 평균 1.57점(95% confidence intervals [CI]:\n\n<!-- PAGE_25 -->\n###### 1.07-2.07) 포인트 더 많이 감소했다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 518,
        "window_size": 3,
        "char_count": 131,
        "word_count": 21,
        "page_number": 25,
        "window_text": "이차 유\n\n<!-- PAGE_25 -->\n###### 효성 평가지표는 Hamilton Depression Rating Scale(HDRS-24), Quick\n\n<!-- PAGE_25 -->\n###### Inventory of Depressive Symptomatology(QIDS-C16)가 사용되었다.  지표는\n\n<!-- PAGE_25 -->\n###### 연구 시작 시(Baseline), 3개월(평가 후) 및 6개월(추적)에 측정하였다.\n\n <!-- PAGE_25 -->\n###### 3개월 후 측정된 결과에 의하면, 점수는 두 집단 모두에서 감소하\n\n<!-- PAGE_25 -->\n###### 였는데, PHQ-9 변화는 집단 간에 유의하게 달랐다(t=6.12, p<0.001).\n\n <!-- PAGE_25 -->\n###### PHQ-9 점수는 대조군보다 평균 1.57점(95% confidence intervals [CI]:\n\n<!-- PAGE_25 -->\n###### 1.07-2.07) 포인트 더 많이 감소했다.  3개월 후 집단 간 효과 크기는\n\n<!-- PAGE_25 -->\n###### 0.39(95% CI: 0.13-0.64)였으며, 6개월 후도 효과 크기는 0.32(95% CI:\n\n<!-- PAGE_25 -->\n###### 0.06-0.69)로 안정적이었다.  임상적으로 중요한 PHQ-9 변화를 경험한\n\n<!-- PAGE_25 -->\n###### 참가자 비율도 실험군이 대조군에 비해 높았다(35.6 vs.  20.2%).\n\n",
        "original_sentence": "<!-- PAGE_25 -->\n###### PHQ-9 점수는 대조군보다 평균 1.57점(95% confidence intervals [CI]:\n\n<!-- PAGE_25 -->\n###### 1.07-2.07) 포인트 더 많이 감소했다. "
      }
    },
    {
      "chunk_id": "chunk_520",
      "text": "3개월 후 집단 간 효과 크기는\n\n<!-- PAGE_25 -->\n###### 0.39(95% CI: 0.13-0.64)였으며, 6개월 후도 효과 크기는 0.32(95% CI:\n\n<!-- PAGE_25 -->\n###### 0.06-0.69)로 안정적이었다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 519,
        "window_size": 3,
        "char_count": 143,
        "word_count": 25,
        "page_number": 25,
        "window_text": "지표는\n\n<!-- PAGE_25 -->\n###### 연구 시작 시(Baseline), 3개월(평가 후) 및 6개월(추적)에 측정하였다.\n\n <!-- PAGE_25 -->\n###### 3개월 후 측정된 결과에 의하면, 점수는 두 집단 모두에서 감소하\n\n<!-- PAGE_25 -->\n###### 였는데, PHQ-9 변화는 집단 간에 유의하게 달랐다(t=6.12, p<0.001).\n\n <!-- PAGE_25 -->\n###### PHQ-9 점수는 대조군보다 평균 1.57점(95% confidence intervals [CI]:\n\n<!-- PAGE_25 -->\n###### 1.07-2.07) 포인트 더 많이 감소했다.  3개월 후 집단 간 효과 크기는\n\n<!-- PAGE_25 -->\n###### 0.39(95% CI: 0.13-0.64)였으며, 6개월 후도 효과 크기는 0.32(95% CI:\n\n<!-- PAGE_25 -->\n###### 0.06-0.69)로 안정적이었다.  임상적으로 중요한 PHQ-9 변화를 경험한\n\n<!-- PAGE_25 -->\n###### 참가자 비율도 실험군이 대조군에 비해 높았다(35.6 vs.  20.2%).\n\n <!-- PAGE_25 -->\n###### 다른 선행 연구에서는 단극성 우울장애에 대해 Selfapy라는 웹 기반\n\n<!-- PAGE_25 -->\n###### 중재 효과성을 평가하는 무작위배정 임상시험을 실시하였다 (Krämer\n\n<!-- PAGE_25 -->\n###### et al., 2021). ",
        "original_sentence": "3개월 후 집단 간 효과 크기는\n\n<!-- PAGE_25 -->\n###### 0.39(95% CI: 0.13-0.64)였으며, 6개월 후도 효과 크기는 0.32(95% CI:\n\n<!-- PAGE_25 -->\n###### 0.06-0.69)로 안정적이었다. "
      }
    },
    {
      "chunk_id": "chunk_521",
      "text": "임상적으로 중요한 PHQ-9 변화를 경험한\n\n<!-- PAGE_25 -->\n###### 참가자 비율도 실험군이 대조군에 비해 높았다(35.6 vs. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 520,
        "window_size": 3,
        "char_count": 83,
        "word_count": 16,
        "page_number": 25,
        "window_text": "<!-- PAGE_25 -->\n###### 3개월 후 측정된 결과에 의하면, 점수는 두 집단 모두에서 감소하\n\n<!-- PAGE_25 -->\n###### 였는데, PHQ-9 변화는 집단 간에 유의하게 달랐다(t=6.12, p<0.001).\n\n <!-- PAGE_25 -->\n###### PHQ-9 점수는 대조군보다 평균 1.57점(95% confidence intervals [CI]:\n\n<!-- PAGE_25 -->\n###### 1.07-2.07) 포인트 더 많이 감소했다.  3개월 후 집단 간 효과 크기는\n\n<!-- PAGE_25 -->\n###### 0.39(95% CI: 0.13-0.64)였으며, 6개월 후도 효과 크기는 0.32(95% CI:\n\n<!-- PAGE_25 -->\n###### 0.06-0.69)로 안정적이었다.  임상적으로 중요한 PHQ-9 변화를 경험한\n\n<!-- PAGE_25 -->\n###### 참가자 비율도 실험군이 대조군에 비해 높았다(35.6 vs.  20.2%).\n\n <!-- PAGE_25 -->\n###### 다른 선행 연구에서는 단극성 우울장애에 대해 Selfapy라는 웹 기반\n\n<!-- PAGE_25 -->\n###### 중재 효과성을 평가하는 무작위배정 임상시험을 실시하였다 (Krämer\n\n<!-- PAGE_25 -->\n###### et al., 2021).  특히 심리치료사 가이드 여부에 따른 효과성도 확인\n\n<!-- PAGE_25 -->\n###### 하고자 세 그룹으로 구분하여 실험을 진행하였다. ",
        "original_sentence": "임상적으로 중요한 PHQ-9 변화를 경험한\n\n<!-- PAGE_25 -->\n###### 참가자 비율도 실험군이 대조군에 비해 높았다(35.6 vs. "
      }
    },
    {
      "chunk_id": "chunk_522",
      "text": "20.2%).\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 521,
        "window_size": 3,
        "char_count": 9,
        "word_count": 1,
        "page_number": 9,
        "window_text": "<!-- PAGE_25 -->\n###### PHQ-9 점수는 대조군보다 평균 1.57점(95% confidence intervals [CI]:\n\n<!-- PAGE_25 -->\n###### 1.07-2.07) 포인트 더 많이 감소했다.  3개월 후 집단 간 효과 크기는\n\n<!-- PAGE_25 -->\n###### 0.39(95% CI: 0.13-0.64)였으며, 6개월 후도 효과 크기는 0.32(95% CI:\n\n<!-- PAGE_25 -->\n###### 0.06-0.69)로 안정적이었다.  임상적으로 중요한 PHQ-9 변화를 경험한\n\n<!-- PAGE_25 -->\n###### 참가자 비율도 실험군이 대조군에 비해 높았다(35.6 vs.  20.2%).\n\n <!-- PAGE_25 -->\n###### 다른 선행 연구에서는 단극성 우울장애에 대해 Selfapy라는 웹 기반\n\n<!-- PAGE_25 -->\n###### 중재 효과성을 평가하는 무작위배정 임상시험을 실시하였다 (Krämer\n\n<!-- PAGE_25 -->\n###### et al., 2021).  특히 심리치료사 가이드 여부에 따른 효과성도 확인\n\n<!-- PAGE_25 -->\n###### 하고자 세 그룹으로 구분하여 실험을 진행하였다.  18~65세이며 BDI-II가\n\n<!-- PAGE_25 -->\n###### 13점 이상인 우울장애가 있는 환자(401명)를 모집하였으며, 가이드 그룹\n\n<!-- PAGE_25 -->\n###### (151명), 가이드가 없는 그룹(150명), 대조군(100명)으로 무작위 할당\n\n<!-- PAGE_25 -->\n###### 하였다. ",
        "original_sentence": "20.2%).\n\n"
      }
    },
    {
      "chunk_id": "chunk_523",
      "text": "<!-- PAGE_25 -->\n###### 다른 선행 연구에서는 단극성 우울장애에 대해 Selfapy라는 웹 기반\n\n<!-- PAGE_25 -->\n###### 중재 효과성을 평가하는 무작위배정 임상시험을 실시하였다 (Krämer\n\n<!-- PAGE_25 -->\n###### et al., 2021). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 522,
        "window_size": 3,
        "char_count": 168,
        "word_count": 31,
        "page_number": 25,
        "window_text": "3개월 후 집단 간 효과 크기는\n\n<!-- PAGE_25 -->\n###### 0.39(95% CI: 0.13-0.64)였으며, 6개월 후도 효과 크기는 0.32(95% CI:\n\n<!-- PAGE_25 -->\n###### 0.06-0.69)로 안정적이었다.  임상적으로 중요한 PHQ-9 변화를 경험한\n\n<!-- PAGE_25 -->\n###### 참가자 비율도 실험군이 대조군에 비해 높았다(35.6 vs.  20.2%).\n\n <!-- PAGE_25 -->\n###### 다른 선행 연구에서는 단극성 우울장애에 대해 Selfapy라는 웹 기반\n\n<!-- PAGE_25 -->\n###### 중재 효과성을 평가하는 무작위배정 임상시험을 실시하였다 (Krämer\n\n<!-- PAGE_25 -->\n###### et al., 2021).  특히 심리치료사 가이드 여부에 따른 효과성도 확인\n\n<!-- PAGE_25 -->\n###### 하고자 세 그룹으로 구분하여 실험을 진행하였다.  18~65세이며 BDI-II가\n\n<!-- PAGE_25 -->\n###### 13점 이상인 우울장애가 있는 환자(401명)를 모집하였으며, 가이드 그룹\n\n<!-- PAGE_25 -->\n###### (151명), 가이드가 없는 그룹(150명), 대조군(100명)으로 무작위 할당\n\n<!-- PAGE_25 -->\n###### 하였다.  가이드 그룹은 매주 25분 동안 전화로 개인 지도를 받았고,\n\n<!-- PAGE_25 -->\n###### 가이드가 없는 그룹은 Selfapy만 사용하였다. ",
        "original_sentence": "<!-- PAGE_25 -->\n###### 다른 선행 연구에서는 단극성 우울장애에 대해 Selfapy라는 웹 기반\n\n<!-- PAGE_25 -->\n###### 중재 효과성을 평가하는 무작위배정 임상시험을 실시하였다 (Krämer\n\n<!-- PAGE_25 -->\n###### et al., 2021). "
      }
    },
    {
      "chunk_id": "chunk_524",
      "text": "특히 심리치료사 가이드 여부에 따른 효과성도 확인\n\n<!-- PAGE_25 -->\n###### 하고자 세 그룹으로 구분하여 실험을 진행하였다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 523,
        "window_size": 3,
        "char_count": 80,
        "word_count": 17,
        "page_number": 25,
        "window_text": "임상적으로 중요한 PHQ-9 변화를 경험한\n\n<!-- PAGE_25 -->\n###### 참가자 비율도 실험군이 대조군에 비해 높았다(35.6 vs.  20.2%).\n\n <!-- PAGE_25 -->\n###### 다른 선행 연구에서는 단극성 우울장애에 대해 Selfapy라는 웹 기반\n\n<!-- PAGE_25 -->\n###### 중재 효과성을 평가하는 무작위배정 임상시험을 실시하였다 (Krämer\n\n<!-- PAGE_25 -->\n###### et al., 2021).  특히 심리치료사 가이드 여부에 따른 효과성도 확인\n\n<!-- PAGE_25 -->\n###### 하고자 세 그룹으로 구분하여 실험을 진행하였다.  18~65세이며 BDI-II가\n\n<!-- PAGE_25 -->\n###### 13점 이상인 우울장애가 있는 환자(401명)를 모집하였으며, 가이드 그룹\n\n<!-- PAGE_25 -->\n###### (151명), 가이드가 없는 그룹(150명), 대조군(100명)으로 무작위 할당\n\n<!-- PAGE_25 -->\n###### 하였다.  가이드 그룹은 매주 25분 동안 전화로 개인 지도를 받았고,\n\n<!-- PAGE_25 -->\n###### 가이드가 없는 그룹은 Selfapy만 사용하였다.  대조군은 이메일을 통해\n\n<!-- PAGE_25 -->\n###### 표준화된 마음챙김 훈련을 받았다.\n\n",
        "original_sentence": "특히 심리치료사 가이드 여부에 따른 효과성도 확인\n\n<!-- PAGE_25 -->\n###### 하고자 세 그룹으로 구분하여 실험을 진행하였다. "
      }
    },
    {
      "chunk_id": "chunk_525",
      "text": "18~65세이며 BDI-II가\n\n<!-- PAGE_25 -->\n###### 13점 이상인 우울장애가 있는 환자(401명)를 모집하였으며, 가이드 그룹\n\n<!-- PAGE_25 -->\n###### (151명), 가이드가 없는 그룹(150명), 대조군(100명)으로 무작위 할당\n\n<!-- PAGE_25 -->\n###### 하였다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 524,
        "window_size": 3,
        "char_count": 184,
        "word_count": 30,
        "page_number": 25,
        "window_text": "20.2%).\n\n <!-- PAGE_25 -->\n###### 다른 선행 연구에서는 단극성 우울장애에 대해 Selfapy라는 웹 기반\n\n<!-- PAGE_25 -->\n###### 중재 효과성을 평가하는 무작위배정 임상시험을 실시하였다 (Krämer\n\n<!-- PAGE_25 -->\n###### et al., 2021).  특히 심리치료사 가이드 여부에 따른 효과성도 확인\n\n<!-- PAGE_25 -->\n###### 하고자 세 그룹으로 구분하여 실험을 진행하였다.  18~65세이며 BDI-II가\n\n<!-- PAGE_25 -->\n###### 13점 이상인 우울장애가 있는 환자(401명)를 모집하였으며, 가이드 그룹\n\n<!-- PAGE_25 -->\n###### (151명), 가이드가 없는 그룹(150명), 대조군(100명)으로 무작위 할당\n\n<!-- PAGE_25 -->\n###### 하였다.  가이드 그룹은 매주 25분 동안 전화로 개인 지도를 받았고,\n\n<!-- PAGE_25 -->\n###### 가이드가 없는 그룹은 Selfapy만 사용하였다.  대조군은 이메일을 통해\n\n<!-- PAGE_25 -->\n###### 표준화된 마음챙김 훈련을 받았다.\n\n <!-- PAGE_25 -->\n###### 프로그램은 인지행동치료 등을 근거로 하고 있으며, 6개 핵심 중재\n\n<!-- PAGE_25 -->\n###### 모듈과 6개 추가적인 심층 모듈로 구성되어 12주 동안 제공되었다.\n\n",
        "original_sentence": "18~65세이며 BDI-II가\n\n<!-- PAGE_25 -->\n###### 13점 이상인 우울장애가 있는 환자(401명)를 모집하였으며, 가이드 그룹\n\n<!-- PAGE_25 -->\n###### (151명), 가이드가 없는 그룹(150명), 대조군(100명)으로 무작위 할당\n\n<!-- PAGE_25 -->\n###### 하였다. "
      }
    },
    {
      "chunk_id": "chunk_526",
      "text": "가이드 그룹은 매주 25분 동안 전화로 개인 지도를 받았고,\n\n<!-- PAGE_25 -->\n###### 가이드가 없는 그룹은 Selfapy만 사용하였다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 525,
        "window_size": 3,
        "char_count": 87,
        "word_count": 18,
        "page_number": 25,
        "window_text": "<!-- PAGE_25 -->\n###### 다른 선행 연구에서는 단극성 우울장애에 대해 Selfapy라는 웹 기반\n\n<!-- PAGE_25 -->\n###### 중재 효과성을 평가하는 무작위배정 임상시험을 실시하였다 (Krämer\n\n<!-- PAGE_25 -->\n###### et al., 2021).  특히 심리치료사 가이드 여부에 따른 효과성도 확인\n\n<!-- PAGE_25 -->\n###### 하고자 세 그룹으로 구분하여 실험을 진행하였다.  18~65세이며 BDI-II가\n\n<!-- PAGE_25 -->\n###### 13점 이상인 우울장애가 있는 환자(401명)를 모집하였으며, 가이드 그룹\n\n<!-- PAGE_25 -->\n###### (151명), 가이드가 없는 그룹(150명), 대조군(100명)으로 무작위 할당\n\n<!-- PAGE_25 -->\n###### 하였다.  가이드 그룹은 매주 25분 동안 전화로 개인 지도를 받았고,\n\n<!-- PAGE_25 -->\n###### 가이드가 없는 그룹은 Selfapy만 사용하였다.  대조군은 이메일을 통해\n\n<!-- PAGE_25 -->\n###### 표준화된 마음챙김 훈련을 받았다.\n\n <!-- PAGE_25 -->\n###### 프로그램은 인지행동치료 등을 근거로 하고 있으며, 6개 핵심 중재\n\n<!-- PAGE_25 -->\n###### 모듈과 6개 추가적인 심층 모듈로 구성되어 12주 동안 제공되었다.\n\n - - 19 -\n<!-- PAGE_26 -->\n###### 일차 유효성 평가지표는 BDI-II를 사용하여 우울 증상에 대해 측정\n\n<!-- PAGE_26 -->\n###### 하였으며, QIDS-SR-16, HRSD-24가 이차 유효성 평가지표로 사용되었다.\n\n",
        "original_sentence": "가이드 그룹은 매주 25분 동안 전화로 개인 지도를 받았고,\n\n<!-- PAGE_25 -->\n###### 가이드가 없는 그룹은 Selfapy만 사용하였다. "
      }
    },
    {
      "chunk_id": "chunk_527",
      "text": "대조군은 이메일을 통해\n\n<!-- PAGE_25 -->\n###### 표준화된 마음챙김 훈련을 받았다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 526,
        "window_size": 3,
        "char_count": 58,
        "word_count": 11,
        "page_number": 25,
        "window_text": "특히 심리치료사 가이드 여부에 따른 효과성도 확인\n\n<!-- PAGE_25 -->\n###### 하고자 세 그룹으로 구분하여 실험을 진행하였다.  18~65세이며 BDI-II가\n\n<!-- PAGE_25 -->\n###### 13점 이상인 우울장애가 있는 환자(401명)를 모집하였으며, 가이드 그룹\n\n<!-- PAGE_25 -->\n###### (151명), 가이드가 없는 그룹(150명), 대조군(100명)으로 무작위 할당\n\n<!-- PAGE_25 -->\n###### 하였다.  가이드 그룹은 매주 25분 동안 전화로 개인 지도를 받았고,\n\n<!-- PAGE_25 -->\n###### 가이드가 없는 그룹은 Selfapy만 사용하였다.  대조군은 이메일을 통해\n\n<!-- PAGE_25 -->\n###### 표준화된 마음챙김 훈련을 받았다.\n\n <!-- PAGE_25 -->\n###### 프로그램은 인지행동치료 등을 근거로 하고 있으며, 6개 핵심 중재\n\n<!-- PAGE_25 -->\n###### 모듈과 6개 추가적인 심층 모듈로 구성되어 12주 동안 제공되었다.\n\n - - 19 -\n<!-- PAGE_26 -->\n###### 일차 유효성 평가지표는 BDI-II를 사용하여 우울 증상에 대해 측정\n\n<!-- PAGE_26 -->\n###### 하였으며, QIDS-SR-16, HRSD-24가 이차 유효성 평가지표로 사용되었다.\n\n <!-- PAGE_26 -->\n###### 연구 시작 시(Baseline), 중재 중(6주), 중재 종료(12주), 추적 관찰(6개월) 시\n\n<!-- PAGE_26 -->\n###### 우울 증상을 평가했다.\n\n",
        "original_sentence": "대조군은 이메일을 통해\n\n<!-- PAGE_25 -->\n###### 표준화된 마음챙김 훈련을 받았다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_528",
      "text": "<!-- PAGE_25 -->\n###### 프로그램은 인지행동치료 등을 근거로 하고 있으며, 6개 핵심 중재\n\n<!-- PAGE_25 -->\n###### 모듈과 6개 추가적인 심층 모듈로 구성되어 12주 동안 제공되었다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 527,
        "window_size": 3,
        "char_count": 125,
        "word_count": 26,
        "page_number": 25,
        "window_text": "18~65세이며 BDI-II가\n\n<!-- PAGE_25 -->\n###### 13점 이상인 우울장애가 있는 환자(401명)를 모집하였으며, 가이드 그룹\n\n<!-- PAGE_25 -->\n###### (151명), 가이드가 없는 그룹(150명), 대조군(100명)으로 무작위 할당\n\n<!-- PAGE_25 -->\n###### 하였다.  가이드 그룹은 매주 25분 동안 전화로 개인 지도를 받았고,\n\n<!-- PAGE_25 -->\n###### 가이드가 없는 그룹은 Selfapy만 사용하였다.  대조군은 이메일을 통해\n\n<!-- PAGE_25 -->\n###### 표준화된 마음챙김 훈련을 받았다.\n\n <!-- PAGE_25 -->\n###### 프로그램은 인지행동치료 등을 근거로 하고 있으며, 6개 핵심 중재\n\n<!-- PAGE_25 -->\n###### 모듈과 6개 추가적인 심층 모듈로 구성되어 12주 동안 제공되었다.\n\n - - 19 -\n<!-- PAGE_26 -->\n###### 일차 유효성 평가지표는 BDI-II를 사용하여 우울 증상에 대해 측정\n\n<!-- PAGE_26 -->\n###### 하였으며, QIDS-SR-16, HRSD-24가 이차 유효성 평가지표로 사용되었다.\n\n <!-- PAGE_26 -->\n###### 연구 시작 시(Baseline), 중재 중(6주), 중재 종료(12주), 추적 관찰(6개월) 시\n\n<!-- PAGE_26 -->\n###### 우울 증상을 평가했다.\n\n BDI-II 변화는 중재 후 그룹 간에 유의한 차이가 있었다(F2,398\n\n<!-- PAGE_26 -->\n###### =37.20, P<.001). ",
        "original_sentence": "<!-- PAGE_25 -->\n###### 프로그램은 인지행동치료 등을 근거로 하고 있으며, 6개 핵심 중재\n\n<!-- PAGE_25 -->\n###### 모듈과 6개 추가적인 심층 모듈로 구성되어 12주 동안 제공되었다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_529",
      "text": "- - 19 -\n<!-- PAGE_26 -->\n###### 일차 유효성 평가지표는 BDI-II를 사용하여 우울 증상에 대해 측정\n\n<!-- PAGE_26 -->\n###### 하였으며, QIDS-SR-16, HRSD-24가 이차 유효성 평가지표로 사용되었다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 528,
        "window_size": 3,
        "char_count": 145,
        "word_count": 28,
        "page_number": 26,
        "window_text": "가이드 그룹은 매주 25분 동안 전화로 개인 지도를 받았고,\n\n<!-- PAGE_25 -->\n###### 가이드가 없는 그룹은 Selfapy만 사용하였다.  대조군은 이메일을 통해\n\n<!-- PAGE_25 -->\n###### 표준화된 마음챙김 훈련을 받았다.\n\n <!-- PAGE_25 -->\n###### 프로그램은 인지행동치료 등을 근거로 하고 있으며, 6개 핵심 중재\n\n<!-- PAGE_25 -->\n###### 모듈과 6개 추가적인 심층 모듈로 구성되어 12주 동안 제공되었다.\n\n - - 19 -\n<!-- PAGE_26 -->\n###### 일차 유효성 평가지표는 BDI-II를 사용하여 우울 증상에 대해 측정\n\n<!-- PAGE_26 -->\n###### 하였으며, QIDS-SR-16, HRSD-24가 이차 유효성 평가지표로 사용되었다.\n\n <!-- PAGE_26 -->\n###### 연구 시작 시(Baseline), 중재 중(6주), 중재 종료(12주), 추적 관찰(6개월) 시\n\n<!-- PAGE_26 -->\n###### 우울 증상을 평가했다.\n\n BDI-II 변화는 중재 후 그룹 간에 유의한 차이가 있었다(F2,398\n\n<!-- PAGE_26 -->\n###### =37.20, P<.001).  가이드 또는 가이드가 없는 그룹에서 BDI-II 점수\n\n<!-- PAGE_26 -->\n###### 감소는 그룹 간 효과 크기가 대조군보다 더 컸다(guided vs control:\n\n<!-- PAGE_26 -->\n###### d=1.63, 95% CI 1.37-1.93; unguided vs control: d=1.47, 95% CI\n\n<!-- PAGE_26 -->\n###### 1.22-1.73). ",
        "original_sentence": "- - 19 -\n<!-- PAGE_26 -->\n###### 일차 유효성 평가지표는 BDI-II를 사용하여 우울 증상에 대해 측정\n\n<!-- PAGE_26 -->\n###### 하였으며, QIDS-SR-16, HRSD-24가 이차 유효성 평가지표로 사용되었다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_530",
      "text": "<!-- PAGE_26 -->\n###### 연구 시작 시(Baseline), 중재 중(6주), 중재 종료(12주), 추적 관찰(6개월) 시\n\n<!-- PAGE_26 -->\n###### 우울 증상을 평가했다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 529,
        "window_size": 3,
        "char_count": 117,
        "word_count": 21,
        "page_number": 26,
        "window_text": "대조군은 이메일을 통해\n\n<!-- PAGE_25 -->\n###### 표준화된 마음챙김 훈련을 받았다.\n\n <!-- PAGE_25 -->\n###### 프로그램은 인지행동치료 등을 근거로 하고 있으며, 6개 핵심 중재\n\n<!-- PAGE_25 -->\n###### 모듈과 6개 추가적인 심층 모듈로 구성되어 12주 동안 제공되었다.\n\n - - 19 -\n<!-- PAGE_26 -->\n###### 일차 유효성 평가지표는 BDI-II를 사용하여 우울 증상에 대해 측정\n\n<!-- PAGE_26 -->\n###### 하였으며, QIDS-SR-16, HRSD-24가 이차 유효성 평가지표로 사용되었다.\n\n <!-- PAGE_26 -->\n###### 연구 시작 시(Baseline), 중재 중(6주), 중재 종료(12주), 추적 관찰(6개월) 시\n\n<!-- PAGE_26 -->\n###### 우울 증상을 평가했다.\n\n BDI-II 변화는 중재 후 그룹 간에 유의한 차이가 있었다(F2,398\n\n<!-- PAGE_26 -->\n###### =37.20, P<.001).  가이드 또는 가이드가 없는 그룹에서 BDI-II 점수\n\n<!-- PAGE_26 -->\n###### 감소는 그룹 간 효과 크기가 대조군보다 더 컸다(guided vs control:\n\n<!-- PAGE_26 -->\n###### d=1.63, 95% CI 1.37-1.93; unguided vs control: d=1.47, 95% CI\n\n<!-- PAGE_26 -->\n###### 1.22-1.73).  반면, 가이드 또는 가이드가 없는 그룹 간 유의미한 차이가\n\n<!-- PAGE_26 -->\n###### 발견되지는 않았다. ",
        "original_sentence": "<!-- PAGE_26 -->\n###### 연구 시작 시(Baseline), 중재 중(6주), 중재 종료(12주), 추적 관찰(6개월) 시\n\n<!-- PAGE_26 -->\n###### 우울 증상을 평가했다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_531",
      "text": "BDI-II 변화는 중재 후 그룹 간에 유의한 차이가 있었다(F2,398\n\n<!-- PAGE_26 -->\n###### =37.20, P<.001). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 530,
        "window_size": 3,
        "char_count": 83,
        "word_count": 15,
        "page_number": 26,
        "window_text": "<!-- PAGE_25 -->\n###### 프로그램은 인지행동치료 등을 근거로 하고 있으며, 6개 핵심 중재\n\n<!-- PAGE_25 -->\n###### 모듈과 6개 추가적인 심층 모듈로 구성되어 12주 동안 제공되었다.\n\n - - 19 -\n<!-- PAGE_26 -->\n###### 일차 유효성 평가지표는 BDI-II를 사용하여 우울 증상에 대해 측정\n\n<!-- PAGE_26 -->\n###### 하였으며, QIDS-SR-16, HRSD-24가 이차 유효성 평가지표로 사용되었다.\n\n <!-- PAGE_26 -->\n###### 연구 시작 시(Baseline), 중재 중(6주), 중재 종료(12주), 추적 관찰(6개월) 시\n\n<!-- PAGE_26 -->\n###### 우울 증상을 평가했다.\n\n BDI-II 변화는 중재 후 그룹 간에 유의한 차이가 있었다(F2,398\n\n<!-- PAGE_26 -->\n###### =37.20, P<.001).  가이드 또는 가이드가 없는 그룹에서 BDI-II 점수\n\n<!-- PAGE_26 -->\n###### 감소는 그룹 간 효과 크기가 대조군보다 더 컸다(guided vs control:\n\n<!-- PAGE_26 -->\n###### d=1.63, 95% CI 1.37-1.93; unguided vs control: d=1.47, 95% CI\n\n<!-- PAGE_26 -->\n###### 1.22-1.73).  반면, 가이드 또는 가이드가 없는 그룹 간 유의미한 차이가\n\n<!-- PAGE_26 -->\n###### 발견되지는 않았다.  추적 관찰(6개월)에서 치료 효과는 두 중재 그룹\n\n<!-- PAGE_26 -->\n###### 모두에서\n\n<!-- PAGE_26 -->\n###### 유지되었습니다(guided:\n\n<!-- PAGE_26 -->\n###### F1,194=0.62,\n\n<!-- PAGE_26 -->\n###### P>.999;\n\n<!-- PAGE_26 -->\n###### unguided:\n\n<!-- PAGE_26 -->\n###### F1,176=0.13, P>.999).\n\n",
        "original_sentence": "BDI-II 변화는 중재 후 그룹 간에 유의한 차이가 있었다(F2,398\n\n<!-- PAGE_26 -->\n###### =37.20, P<.001). "
      }
    },
    {
      "chunk_id": "chunk_532",
      "text": "가이드 또는 가이드가 없는 그룹에서 BDI-II 점수\n\n<!-- PAGE_26 -->\n###### 감소는 그룹 간 효과 크기가 대조군보다 더 컸다(guided vs control:\n\n<!-- PAGE_26 -->\n###### d=1.63, 95% CI 1.37-1.93; unguided vs control: d=1.47, 95% CI\n\n<!-- PAGE_26 -->\n###### 1.22-1.73). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 531,
        "window_size": 3,
        "char_count": 225,
        "word_count": 40,
        "page_number": 26,
        "window_text": "- - 19 -\n<!-- PAGE_26 -->\n###### 일차 유효성 평가지표는 BDI-II를 사용하여 우울 증상에 대해 측정\n\n<!-- PAGE_26 -->\n###### 하였으며, QIDS-SR-16, HRSD-24가 이차 유효성 평가지표로 사용되었다.\n\n <!-- PAGE_26 -->\n###### 연구 시작 시(Baseline), 중재 중(6주), 중재 종료(12주), 추적 관찰(6개월) 시\n\n<!-- PAGE_26 -->\n###### 우울 증상을 평가했다.\n\n BDI-II 변화는 중재 후 그룹 간에 유의한 차이가 있었다(F2,398\n\n<!-- PAGE_26 -->\n###### =37.20, P<.001).  가이드 또는 가이드가 없는 그룹에서 BDI-II 점수\n\n<!-- PAGE_26 -->\n###### 감소는 그룹 간 효과 크기가 대조군보다 더 컸다(guided vs control:\n\n<!-- PAGE_26 -->\n###### d=1.63, 95% CI 1.37-1.93; unguided vs control: d=1.47, 95% CI\n\n<!-- PAGE_26 -->\n###### 1.22-1.73).  반면, 가이드 또는 가이드가 없는 그룹 간 유의미한 차이가\n\n<!-- PAGE_26 -->\n###### 발견되지는 않았다.  추적 관찰(6개월)에서 치료 효과는 두 중재 그룹\n\n<!-- PAGE_26 -->\n###### 모두에서\n\n<!-- PAGE_26 -->\n###### 유지되었습니다(guided:\n\n<!-- PAGE_26 -->\n###### F1,194=0.62,\n\n<!-- PAGE_26 -->\n###### P>.999;\n\n<!-- PAGE_26 -->\n###### unguided:\n\n<!-- PAGE_26 -->\n###### F1,176=0.13, P>.999).\n\n <!-- PAGE_26 -->\n###### 또 다른 선행 연구에서는 인터넷 기반 우울장애 인지행동치료\n\n<!-- PAGE_26 -->\n###### 프로그램인 Thrive 효과성을 검증하는 무작위배정 임상시험을 실시\n\n<!-- PAGE_26 -->\n###### 하였다(Schure et al., 2019). ",
        "original_sentence": "가이드 또는 가이드가 없는 그룹에서 BDI-II 점수\n\n<!-- PAGE_26 -->\n###### 감소는 그룹 간 효과 크기가 대조군보다 더 컸다(guided vs control:\n\n<!-- PAGE_26 -->\n###### d=1.63, 95% CI 1.37-1.93; unguided vs control: d=1.47, 95% CI\n\n<!-- PAGE_26 -->\n###### 1.22-1.73). "
      }
    },
    {
      "chunk_id": "chunk_533",
      "text": "반면, 가이드 또는 가이드가 없는 그룹 간 유의미한 차이가\n\n<!-- PAGE_26 -->\n###### 발견되지는 않았다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 532,
        "window_size": 3,
        "char_count": 69,
        "word_count": 15,
        "page_number": 26,
        "window_text": "<!-- PAGE_26 -->\n###### 연구 시작 시(Baseline), 중재 중(6주), 중재 종료(12주), 추적 관찰(6개월) 시\n\n<!-- PAGE_26 -->\n###### 우울 증상을 평가했다.\n\n BDI-II 변화는 중재 후 그룹 간에 유의한 차이가 있었다(F2,398\n\n<!-- PAGE_26 -->\n###### =37.20, P<.001).  가이드 또는 가이드가 없는 그룹에서 BDI-II 점수\n\n<!-- PAGE_26 -->\n###### 감소는 그룹 간 효과 크기가 대조군보다 더 컸다(guided vs control:\n\n<!-- PAGE_26 -->\n###### d=1.63, 95% CI 1.37-1.93; unguided vs control: d=1.47, 95% CI\n\n<!-- PAGE_26 -->\n###### 1.22-1.73).  반면, 가이드 또는 가이드가 없는 그룹 간 유의미한 차이가\n\n<!-- PAGE_26 -->\n###### 발견되지는 않았다.  추적 관찰(6개월)에서 치료 효과는 두 중재 그룹\n\n<!-- PAGE_26 -->\n###### 모두에서\n\n<!-- PAGE_26 -->\n###### 유지되었습니다(guided:\n\n<!-- PAGE_26 -->\n###### F1,194=0.62,\n\n<!-- PAGE_26 -->\n###### P>.999;\n\n<!-- PAGE_26 -->\n###### unguided:\n\n<!-- PAGE_26 -->\n###### F1,176=0.13, P>.999).\n\n <!-- PAGE_26 -->\n###### 또 다른 선행 연구에서는 인터넷 기반 우울장애 인지행동치료\n\n<!-- PAGE_26 -->\n###### 프로그램인 Thrive 효과성을 검증하는 무작위배정 임상시험을 실시\n\n<!-- PAGE_26 -->\n###### 하였다(Schure et al., 2019).  우울 증상(PHQ-9 5점 이상)이 있는 18세 이상\n\n<!-- PAGE_26 -->\n###### 성인 343명을 모집하고, Trive를 활용한 실험군(181명)과 대조군(162명)\n\n<!-- PAGE_26 -->\n###### 으로 무작위 할당하였다. ",
        "original_sentence": "반면, 가이드 또는 가이드가 없는 그룹 간 유의미한 차이가\n\n<!-- PAGE_26 -->\n###### 발견되지는 않았다. "
      }
    },
    {
      "chunk_id": "chunk_534",
      "text": "추적 관찰(6개월)에서 치료 효과는 두 중재 그룹\n\n<!-- PAGE_26 -->\n###### 모두에서\n\n<!-- PAGE_26 -->\n###### 유지되었습니다(guided:\n\n<!-- PAGE_26 -->\n###### F1,194=0.62,\n\n<!-- PAGE_26 -->\n###### P>.999;\n\n<!-- PAGE_26 -->\n###### unguided:\n\n<!-- PAGE_26 -->\n###### F1,176=0.13, P>.999).\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 533,
        "window_size": 3,
        "char_count": 253,
        "word_count": 38,
        "page_number": 26,
        "window_text": "BDI-II 변화는 중재 후 그룹 간에 유의한 차이가 있었다(F2,398\n\n<!-- PAGE_26 -->\n###### =37.20, P<.001).  가이드 또는 가이드가 없는 그룹에서 BDI-II 점수\n\n<!-- PAGE_26 -->\n###### 감소는 그룹 간 효과 크기가 대조군보다 더 컸다(guided vs control:\n\n<!-- PAGE_26 -->\n###### d=1.63, 95% CI 1.37-1.93; unguided vs control: d=1.47, 95% CI\n\n<!-- PAGE_26 -->\n###### 1.22-1.73).  반면, 가이드 또는 가이드가 없는 그룹 간 유의미한 차이가\n\n<!-- PAGE_26 -->\n###### 발견되지는 않았다.  추적 관찰(6개월)에서 치료 효과는 두 중재 그룹\n\n<!-- PAGE_26 -->\n###### 모두에서\n\n<!-- PAGE_26 -->\n###### 유지되었습니다(guided:\n\n<!-- PAGE_26 -->\n###### F1,194=0.62,\n\n<!-- PAGE_26 -->\n###### P>.999;\n\n<!-- PAGE_26 -->\n###### unguided:\n\n<!-- PAGE_26 -->\n###### F1,176=0.13, P>.999).\n\n <!-- PAGE_26 -->\n###### 또 다른 선행 연구에서는 인터넷 기반 우울장애 인지행동치료\n\n<!-- PAGE_26 -->\n###### 프로그램인 Thrive 효과성을 검증하는 무작위배정 임상시험을 실시\n\n<!-- PAGE_26 -->\n###### 하였다(Schure et al., 2019).  우울 증상(PHQ-9 5점 이상)이 있는 18세 이상\n\n<!-- PAGE_26 -->\n###### 성인 343명을 모집하고, Trive를 활용한 실험군(181명)과 대조군(162명)\n\n<!-- PAGE_26 -->\n###### 으로 무작위 할당하였다.  실험군은 완전 자동화된 프로그램인 Thrive를\n\n<!-- PAGE_26 -->\n###### 웹 브라우저 및 모바일 앱을 사용하였다. ",
        "original_sentence": "추적 관찰(6개월)에서 치료 효과는 두 중재 그룹\n\n<!-- PAGE_26 -->\n###### 모두에서\n\n<!-- PAGE_26 -->\n###### 유지되었습니다(guided:\n\n<!-- PAGE_26 -->\n###### F1,194=0.62,\n\n<!-- PAGE_26 -->\n###### P>.999;\n\n<!-- PAGE_26 -->\n###### unguided:\n\n<!-- PAGE_26 -->\n###### F1,176=0.13, P>.999).\n\n"
      }
    },
    {
      "chunk_id": "chunk_535",
      "text": "<!-- PAGE_26 -->\n###### 또 다른 선행 연구에서는 인터넷 기반 우울장애 인지행동치료\n\n<!-- PAGE_26 -->\n###### 프로그램인 Thrive 효과성을 검증하는 무작위배정 임상시험을 실시\n\n<!-- PAGE_26 -->\n###### 하였다(Schure et al., 2019). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 534,
        "window_size": 3,
        "char_count": 171,
        "word_count": 31,
        "page_number": 26,
        "window_text": "가이드 또는 가이드가 없는 그룹에서 BDI-II 점수\n\n<!-- PAGE_26 -->\n###### 감소는 그룹 간 효과 크기가 대조군보다 더 컸다(guided vs control:\n\n<!-- PAGE_26 -->\n###### d=1.63, 95% CI 1.37-1.93; unguided vs control: d=1.47, 95% CI\n\n<!-- PAGE_26 -->\n###### 1.22-1.73).  반면, 가이드 또는 가이드가 없는 그룹 간 유의미한 차이가\n\n<!-- PAGE_26 -->\n###### 발견되지는 않았다.  추적 관찰(6개월)에서 치료 효과는 두 중재 그룹\n\n<!-- PAGE_26 -->\n###### 모두에서\n\n<!-- PAGE_26 -->\n###### 유지되었습니다(guided:\n\n<!-- PAGE_26 -->\n###### F1,194=0.62,\n\n<!-- PAGE_26 -->\n###### P>.999;\n\n<!-- PAGE_26 -->\n###### unguided:\n\n<!-- PAGE_26 -->\n###### F1,176=0.13, P>.999).\n\n <!-- PAGE_26 -->\n###### 또 다른 선행 연구에서는 인터넷 기반 우울장애 인지행동치료\n\n<!-- PAGE_26 -->\n###### 프로그램인 Thrive 효과성을 검증하는 무작위배정 임상시험을 실시\n\n<!-- PAGE_26 -->\n###### 하였다(Schure et al., 2019).  우울 증상(PHQ-9 5점 이상)이 있는 18세 이상\n\n<!-- PAGE_26 -->\n###### 성인 343명을 모집하고, Trive를 활용한 실험군(181명)과 대조군(162명)\n\n<!-- PAGE_26 -->\n###### 으로 무작위 할당하였다.  실험군은 완전 자동화된 프로그램인 Thrive를\n\n<!-- PAGE_26 -->\n###### 웹 브라우저 및 모바일 앱을 사용하였다.  콘텐츠는 비디오를 통해 전달\n\n<!-- PAGE_26 -->\n###### 되며, 행동 활성화, 인지 재구조화, 사회 기술 훈련에 중점을 둔 세\n\n<!-- PAGE_26 -->\n###### 가지 대화형 모듈을 제공하였다. ",
        "original_sentence": "<!-- PAGE_26 -->\n###### 또 다른 선행 연구에서는 인터넷 기반 우울장애 인지행동치료\n\n<!-- PAGE_26 -->\n###### 프로그램인 Thrive 효과성을 검증하는 무작위배정 임상시험을 실시\n\n<!-- PAGE_26 -->\n###### 하였다(Schure et al., 2019). "
      }
    },
    {
      "chunk_id": "chunk_536",
      "text": "우울 증상(PHQ-9 5점 이상)이 있는 18세 이상\n\n<!-- PAGE_26 -->\n###### 성인 343명을 모집하고, Trive를 활용한 실험군(181명)과 대조군(162명)\n\n<!-- PAGE_26 -->\n###### 으로 무작위 할당하였다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 535,
        "window_size": 3,
        "char_count": 141,
        "word_count": 25,
        "page_number": 26,
        "window_text": "반면, 가이드 또는 가이드가 없는 그룹 간 유의미한 차이가\n\n<!-- PAGE_26 -->\n###### 발견되지는 않았다.  추적 관찰(6개월)에서 치료 효과는 두 중재 그룹\n\n<!-- PAGE_26 -->\n###### 모두에서\n\n<!-- PAGE_26 -->\n###### 유지되었습니다(guided:\n\n<!-- PAGE_26 -->\n###### F1,194=0.62,\n\n<!-- PAGE_26 -->\n###### P>.999;\n\n<!-- PAGE_26 -->\n###### unguided:\n\n<!-- PAGE_26 -->\n###### F1,176=0.13, P>.999).\n\n <!-- PAGE_26 -->\n###### 또 다른 선행 연구에서는 인터넷 기반 우울장애 인지행동치료\n\n<!-- PAGE_26 -->\n###### 프로그램인 Thrive 효과성을 검증하는 무작위배정 임상시험을 실시\n\n<!-- PAGE_26 -->\n###### 하였다(Schure et al., 2019).  우울 증상(PHQ-9 5점 이상)이 있는 18세 이상\n\n<!-- PAGE_26 -->\n###### 성인 343명을 모집하고, Trive를 활용한 실험군(181명)과 대조군(162명)\n\n<!-- PAGE_26 -->\n###### 으로 무작위 할당하였다.  실험군은 완전 자동화된 프로그램인 Thrive를\n\n<!-- PAGE_26 -->\n###### 웹 브라우저 및 모바일 앱을 사용하였다.  콘텐츠는 비디오를 통해 전달\n\n<!-- PAGE_26 -->\n###### 되며, 행동 활성화, 인지 재구조화, 사회 기술 훈련에 중점을 둔 세\n\n<!-- PAGE_26 -->\n###### 가지 대화형 모듈을 제공하였다.  사용자 입력 및 사용자 패턴을 기반\n\n<!-- PAGE_26 -->\n###### 으로 알고리즘을 사용하여 개인에 맞게 피드백을 제공했다. ",
        "original_sentence": "우울 증상(PHQ-9 5점 이상)이 있는 18세 이상\n\n<!-- PAGE_26 -->\n###### 성인 343명을 모집하고, Trive를 활용한 실험군(181명)과 대조군(162명)\n\n<!-- PAGE_26 -->\n###### 으로 무작위 할당하였다. "
      }
    },
    {
      "chunk_id": "chunk_537",
      "text": "실험군은 완전 자동화된 프로그램인 Thrive를\n\n<!-- PAGE_26 -->\n###### 웹 브라우저 및 모바일 앱을 사용하였다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 536,
        "window_size": 3,
        "char_count": 75,
        "word_count": 15,
        "page_number": 26,
        "window_text": "추적 관찰(6개월)에서 치료 효과는 두 중재 그룹\n\n<!-- PAGE_26 -->\n###### 모두에서\n\n<!-- PAGE_26 -->\n###### 유지되었습니다(guided:\n\n<!-- PAGE_26 -->\n###### F1,194=0.62,\n\n<!-- PAGE_26 -->\n###### P>.999;\n\n<!-- PAGE_26 -->\n###### unguided:\n\n<!-- PAGE_26 -->\n###### F1,176=0.13, P>.999).\n\n <!-- PAGE_26 -->\n###### 또 다른 선행 연구에서는 인터넷 기반 우울장애 인지행동치료\n\n<!-- PAGE_26 -->\n###### 프로그램인 Thrive 효과성을 검증하는 무작위배정 임상시험을 실시\n\n<!-- PAGE_26 -->\n###### 하였다(Schure et al., 2019).  우울 증상(PHQ-9 5점 이상)이 있는 18세 이상\n\n<!-- PAGE_26 -->\n###### 성인 343명을 모집하고, Trive를 활용한 실험군(181명)과 대조군(162명)\n\n<!-- PAGE_26 -->\n###### 으로 무작위 할당하였다.  실험군은 완전 자동화된 프로그램인 Thrive를\n\n<!-- PAGE_26 -->\n###### 웹 브라우저 및 모바일 앱을 사용하였다.  콘텐츠는 비디오를 통해 전달\n\n<!-- PAGE_26 -->\n###### 되며, 행동 활성화, 인지 재구조화, 사회 기술 훈련에 중점을 둔 세\n\n<!-- PAGE_26 -->\n###### 가지 대화형 모듈을 제공하였다.  사용자 입력 및 사용자 패턴을 기반\n\n<!-- PAGE_26 -->\n###### 으로 알고리즘을 사용하여 개인에 맞게 피드백을 제공했다.  대조군은\n\n<!-- PAGE_26 -->\n###### 일반 우울장애 정보에 대한 링크를 받았다.\n\n",
        "original_sentence": "실험군은 완전 자동화된 프로그램인 Thrive를\n\n<!-- PAGE_26 -->\n###### 웹 브라우저 및 모바일 앱을 사용하였다. "
      }
    },
    {
      "chunk_id": "chunk_538",
      "text": "콘텐츠는 비디오를 통해 전달\n\n<!-- PAGE_26 -->\n###### 되며, 행동 활성화, 인지 재구조화, 사회 기술 훈련에 중점을 둔 세\n\n<!-- PAGE_26 -->\n###### 가지 대화형 모듈을 제공하였다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 537,
        "window_size": 3,
        "char_count": 123,
        "word_count": 27,
        "page_number": 26,
        "window_text": "<!-- PAGE_26 -->\n###### 또 다른 선행 연구에서는 인터넷 기반 우울장애 인지행동치료\n\n<!-- PAGE_26 -->\n###### 프로그램인 Thrive 효과성을 검증하는 무작위배정 임상시험을 실시\n\n<!-- PAGE_26 -->\n###### 하였다(Schure et al., 2019).  우울 증상(PHQ-9 5점 이상)이 있는 18세 이상\n\n<!-- PAGE_26 -->\n###### 성인 343명을 모집하고, Trive를 활용한 실험군(181명)과 대조군(162명)\n\n<!-- PAGE_26 -->\n###### 으로 무작위 할당하였다.  실험군은 완전 자동화된 프로그램인 Thrive를\n\n<!-- PAGE_26 -->\n###### 웹 브라우저 및 모바일 앱을 사용하였다.  콘텐츠는 비디오를 통해 전달\n\n<!-- PAGE_26 -->\n###### 되며, 행동 활성화, 인지 재구조화, 사회 기술 훈련에 중점을 둔 세\n\n<!-- PAGE_26 -->\n###### 가지 대화형 모듈을 제공하였다.  사용자 입력 및 사용자 패턴을 기반\n\n<!-- PAGE_26 -->\n###### 으로 알고리즘을 사용하여 개인에 맞게 피드백을 제공했다.  대조군은\n\n<!-- PAGE_26 -->\n###### 일반 우울장애 정보에 대한 링크를 받았다.\n\n - - 20 -\n<!-- PAGE_27 -->\n###### 일차 유효성 변수는 환자가 직접 보고한 PHQ-9 점수였으며, 불안\n\n<!-- PAGE_27 -->\n###### 증상 심각성(GAD-7), 일상 기능(Work and Social Adjustment Scale,\n\n<!-- PAGE_27 -->\n###### WSAS), 회복력(Conner-Davidson Resilience Scale, CD-RISC-10), 자살에\n\n<!-- PAGE_27 -->\n###### 관한 생각 등이 이차 유효성 변수로 활용되었다. ",
        "original_sentence": "콘텐츠는 비디오를 통해 전달\n\n<!-- PAGE_26 -->\n###### 되며, 행동 활성화, 인지 재구조화, 사회 기술 훈련에 중점을 둔 세\n\n<!-- PAGE_26 -->\n###### 가지 대화형 모듈을 제공하였다. "
      }
    },
    {
      "chunk_id": "chunk_539",
      "text": "사용자 입력 및 사용자 패턴을 기반\n\n<!-- PAGE_26 -->\n###### 으로 알고리즘을 사용하여 개인에 맞게 피드백을 제공했다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 538,
        "window_size": 3,
        "char_count": 77,
        "word_count": 17,
        "page_number": 26,
        "window_text": "우울 증상(PHQ-9 5점 이상)이 있는 18세 이상\n\n<!-- PAGE_26 -->\n###### 성인 343명을 모집하고, Trive를 활용한 실험군(181명)과 대조군(162명)\n\n<!-- PAGE_26 -->\n###### 으로 무작위 할당하였다.  실험군은 완전 자동화된 프로그램인 Thrive를\n\n<!-- PAGE_26 -->\n###### 웹 브라우저 및 모바일 앱을 사용하였다.  콘텐츠는 비디오를 통해 전달\n\n<!-- PAGE_26 -->\n###### 되며, 행동 활성화, 인지 재구조화, 사회 기술 훈련에 중점을 둔 세\n\n<!-- PAGE_26 -->\n###### 가지 대화형 모듈을 제공하였다.  사용자 입력 및 사용자 패턴을 기반\n\n<!-- PAGE_26 -->\n###### 으로 알고리즘을 사용하여 개인에 맞게 피드백을 제공했다.  대조군은\n\n<!-- PAGE_26 -->\n###### 일반 우울장애 정보에 대한 링크를 받았다.\n\n - - 20 -\n<!-- PAGE_27 -->\n###### 일차 유효성 변수는 환자가 직접 보고한 PHQ-9 점수였으며, 불안\n\n<!-- PAGE_27 -->\n###### 증상 심각성(GAD-7), 일상 기능(Work and Social Adjustment Scale,\n\n<!-- PAGE_27 -->\n###### WSAS), 회복력(Conner-Davidson Resilience Scale, CD-RISC-10), 자살에\n\n<!-- PAGE_27 -->\n###### 관한 생각 등이 이차 유효성 변수로 활용되었다.  평가지표는 연구 시작 시\n\n<!-- PAGE_27 -->\n###### (Baseline), 4주 및 8주에 측정하였다.\n\n",
        "original_sentence": "사용자 입력 및 사용자 패턴을 기반\n\n<!-- PAGE_26 -->\n###### 으로 알고리즘을 사용하여 개인에 맞게 피드백을 제공했다. "
      }
    },
    {
      "chunk_id": "chunk_540",
      "text": "대조군은\n\n<!-- PAGE_26 -->\n###### 일반 우울장애 정보에 대한 링크를 받았다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 539,
        "window_size": 3,
        "char_count": 55,
        "word_count": 11,
        "page_number": 26,
        "window_text": "실험군은 완전 자동화된 프로그램인 Thrive를\n\n<!-- PAGE_26 -->\n###### 웹 브라우저 및 모바일 앱을 사용하였다.  콘텐츠는 비디오를 통해 전달\n\n<!-- PAGE_26 -->\n###### 되며, 행동 활성화, 인지 재구조화, 사회 기술 훈련에 중점을 둔 세\n\n<!-- PAGE_26 -->\n###### 가지 대화형 모듈을 제공하였다.  사용자 입력 및 사용자 패턴을 기반\n\n<!-- PAGE_26 -->\n###### 으로 알고리즘을 사용하여 개인에 맞게 피드백을 제공했다.  대조군은\n\n<!-- PAGE_26 -->\n###### 일반 우울장애 정보에 대한 링크를 받았다.\n\n - - 20 -\n<!-- PAGE_27 -->\n###### 일차 유효성 변수는 환자가 직접 보고한 PHQ-9 점수였으며, 불안\n\n<!-- PAGE_27 -->\n###### 증상 심각성(GAD-7), 일상 기능(Work and Social Adjustment Scale,\n\n<!-- PAGE_27 -->\n###### WSAS), 회복력(Conner-Davidson Resilience Scale, CD-RISC-10), 자살에\n\n<!-- PAGE_27 -->\n###### 관한 생각 등이 이차 유효성 변수로 활용되었다.  평가지표는 연구 시작 시\n\n<!-- PAGE_27 -->\n###### (Baseline), 4주 및 8주에 측정하였다.\n\n <!-- PAGE_27 -->\n###### 실험군은 대조군보다 우울장애 증상 중증도가 유의하게 낮았고\n\n<!-- PAGE_27 -->\n###### (F1,248=28.67, P<.001), 치료 효과 크기(d=0.63)를 확인하였다. ",
        "original_sentence": "대조군은\n\n<!-- PAGE_26 -->\n###### 일반 우울장애 정보에 대한 링크를 받았다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_541",
      "text": "- - 20 -\n<!-- PAGE_27 -->\n###### 일차 유효성 변수는 환자가 직접 보고한 PHQ-9 점수였으며, 불안\n\n<!-- PAGE_27 -->\n###### 증상 심각성(GAD-7), 일상 기능(Work and Social Adjustment Scale,\n\n<!-- PAGE_27 -->\n###### WSAS), 회복력(Conner-Davidson Resilience Scale, CD-RISC-10), 자살에\n\n<!-- PAGE_27 -->\n###### 관한 생각 등이 이차 유효성 변수로 활용되었다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 540,
        "window_size": 3,
        "char_count": 290,
        "word_count": 50,
        "page_number": 27,
        "window_text": "콘텐츠는 비디오를 통해 전달\n\n<!-- PAGE_26 -->\n###### 되며, 행동 활성화, 인지 재구조화, 사회 기술 훈련에 중점을 둔 세\n\n<!-- PAGE_26 -->\n###### 가지 대화형 모듈을 제공하였다.  사용자 입력 및 사용자 패턴을 기반\n\n<!-- PAGE_26 -->\n###### 으로 알고리즘을 사용하여 개인에 맞게 피드백을 제공했다.  대조군은\n\n<!-- PAGE_26 -->\n###### 일반 우울장애 정보에 대한 링크를 받았다.\n\n - - 20 -\n<!-- PAGE_27 -->\n###### 일차 유효성 변수는 환자가 직접 보고한 PHQ-9 점수였으며, 불안\n\n<!-- PAGE_27 -->\n###### 증상 심각성(GAD-7), 일상 기능(Work and Social Adjustment Scale,\n\n<!-- PAGE_27 -->\n###### WSAS), 회복력(Conner-Davidson Resilience Scale, CD-RISC-10), 자살에\n\n<!-- PAGE_27 -->\n###### 관한 생각 등이 이차 유효성 변수로 활용되었다.  평가지표는 연구 시작 시\n\n<!-- PAGE_27 -->\n###### (Baseline), 4주 및 8주에 측정하였다.\n\n <!-- PAGE_27 -->\n###### 실험군은 대조군보다 우울장애 증상 중증도가 유의하게 낮았고\n\n<!-- PAGE_27 -->\n###### (F1,248=28.67, P<.001), 치료 효과 크기(d=0.63)를 확인하였다.  그룹 평균\n\n<!-- PAGE_27 -->\n###### 패턴은 실험군 우울장애 심각도(8주 개입 후)가 대조군 그룹보다 유의\n\n<!-- PAGE_27 -->\n###### 하게 낮았다(7.702 [Standard Error, SE 0.336] vs 10.224 [SE 0.328],\n\n<!-- PAGE_27 -->\n###### adjusted P<.001; d=0.63).\n\n",
        "original_sentence": "- - 20 -\n<!-- PAGE_27 -->\n###### 일차 유효성 변수는 환자가 직접 보고한 PHQ-9 점수였으며, 불안\n\n<!-- PAGE_27 -->\n###### 증상 심각성(GAD-7), 일상 기능(Work and Social Adjustment Scale,\n\n<!-- PAGE_27 -->\n###### WSAS), 회복력(Conner-Davidson Resilience Scale, CD-RISC-10), 자살에\n\n<!-- PAGE_27 -->\n###### 관한 생각 등이 이차 유효성 변수로 활용되었다. "
      }
    },
    {
      "chunk_id": "chunk_542",
      "text": "평가지표는 연구 시작 시\n\n<!-- PAGE_27 -->\n###### (Baseline), 4주 및 8주에 측정하였다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 541,
        "window_size": 3,
        "char_count": 68,
        "word_count": 13,
        "page_number": 27,
        "window_text": "사용자 입력 및 사용자 패턴을 기반\n\n<!-- PAGE_26 -->\n###### 으로 알고리즘을 사용하여 개인에 맞게 피드백을 제공했다.  대조군은\n\n<!-- PAGE_26 -->\n###### 일반 우울장애 정보에 대한 링크를 받았다.\n\n - - 20 -\n<!-- PAGE_27 -->\n###### 일차 유효성 변수는 환자가 직접 보고한 PHQ-9 점수였으며, 불안\n\n<!-- PAGE_27 -->\n###### 증상 심각성(GAD-7), 일상 기능(Work and Social Adjustment Scale,\n\n<!-- PAGE_27 -->\n###### WSAS), 회복력(Conner-Davidson Resilience Scale, CD-RISC-10), 자살에\n\n<!-- PAGE_27 -->\n###### 관한 생각 등이 이차 유효성 변수로 활용되었다.  평가지표는 연구 시작 시\n\n<!-- PAGE_27 -->\n###### (Baseline), 4주 및 8주에 측정하였다.\n\n <!-- PAGE_27 -->\n###### 실험군은 대조군보다 우울장애 증상 중증도가 유의하게 낮았고\n\n<!-- PAGE_27 -->\n###### (F1,248=28.67, P<.001), 치료 효과 크기(d=0.63)를 확인하였다.  그룹 평균\n\n<!-- PAGE_27 -->\n###### 패턴은 실험군 우울장애 심각도(8주 개입 후)가 대조군 그룹보다 유의\n\n<!-- PAGE_27 -->\n###### 하게 낮았다(7.702 [Standard Error, SE 0.336] vs 10.224 [SE 0.328],\n\n<!-- PAGE_27 -->\n###### adjusted P<.001; d=0.63).\n\n - - 21 -\n<!-- PAGE_28 -->\n###### 사. ",
        "original_sentence": "평가지표는 연구 시작 시\n\n<!-- PAGE_27 -->\n###### (Baseline), 4주 및 8주에 측정하였다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_543",
      "text": "<!-- PAGE_27 -->\n###### 실험군은 대조군보다 우울장애 증상 중증도가 유의하게 낮았고\n\n<!-- PAGE_27 -->\n###### (F1,248=28.67, P<.001), 치료 효과 크기(d=0.63)를 확인하였다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 542,
        "window_size": 3,
        "char_count": 131,
        "word_count": 21,
        "page_number": 27,
        "window_text": "대조군은\n\n<!-- PAGE_26 -->\n###### 일반 우울장애 정보에 대한 링크를 받았다.\n\n - - 20 -\n<!-- PAGE_27 -->\n###### 일차 유효성 변수는 환자가 직접 보고한 PHQ-9 점수였으며, 불안\n\n<!-- PAGE_27 -->\n###### 증상 심각성(GAD-7), 일상 기능(Work and Social Adjustment Scale,\n\n<!-- PAGE_27 -->\n###### WSAS), 회복력(Conner-Davidson Resilience Scale, CD-RISC-10), 자살에\n\n<!-- PAGE_27 -->\n###### 관한 생각 등이 이차 유효성 변수로 활용되었다.  평가지표는 연구 시작 시\n\n<!-- PAGE_27 -->\n###### (Baseline), 4주 및 8주에 측정하였다.\n\n <!-- PAGE_27 -->\n###### 실험군은 대조군보다 우울장애 증상 중증도가 유의하게 낮았고\n\n<!-- PAGE_27 -->\n###### (F1,248=28.67, P<.001), 치료 효과 크기(d=0.63)를 확인하였다.  그룹 평균\n\n<!-- PAGE_27 -->\n###### 패턴은 실험군 우울장애 심각도(8주 개입 후)가 대조군 그룹보다 유의\n\n<!-- PAGE_27 -->\n###### 하게 낮았다(7.702 [Standard Error, SE 0.336] vs 10.224 [SE 0.328],\n\n<!-- PAGE_27 -->\n###### adjusted P<.001; d=0.63).\n\n - - 21 -\n<!-- PAGE_28 -->\n###### 사.  우울장애 개선 디지털치료기기의 국외 사례\n\n<!-- PAGE_28 -->\n###### 현재 국외에서 우울장애 개선 디지털치료기기로서, 허가된 제품 및\n\n<!-- PAGE_28 -->\n###### 인지행동치료(CBT)를 이용한 제품은 다음과 같다 <표 5>.\n\n",
        "original_sentence": "<!-- PAGE_27 -->\n###### 실험군은 대조군보다 우울장애 증상 중증도가 유의하게 낮았고\n\n<!-- PAGE_27 -->\n###### (F1,248=28.67, P<.001), 치료 효과 크기(d=0.63)를 확인하였다. "
      }
    },
    {
      "chunk_id": "chunk_544",
      "text": "그룹 평균\n\n<!-- PAGE_27 -->\n###### 패턴은 실험군 우울장애 심각도(8주 개입 후)가 대조군 그룹보다 유의\n\n<!-- PAGE_27 -->\n###### 하게 낮았다(7.702 [Standard Error, SE 0.336] vs 10.224 [SE 0.328],\n\n<!-- PAGE_27 -->\n###### adjusted P<.001; d=0.63).\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 543,
        "window_size": 3,
        "char_count": 209,
        "word_count": 36,
        "page_number": 27,
        "window_text": "- - 20 -\n<!-- PAGE_27 -->\n###### 일차 유효성 변수는 환자가 직접 보고한 PHQ-9 점수였으며, 불안\n\n<!-- PAGE_27 -->\n###### 증상 심각성(GAD-7), 일상 기능(Work and Social Adjustment Scale,\n\n<!-- PAGE_27 -->\n###### WSAS), 회복력(Conner-Davidson Resilience Scale, CD-RISC-10), 자살에\n\n<!-- PAGE_27 -->\n###### 관한 생각 등이 이차 유효성 변수로 활용되었다.  평가지표는 연구 시작 시\n\n<!-- PAGE_27 -->\n###### (Baseline), 4주 및 8주에 측정하였다.\n\n <!-- PAGE_27 -->\n###### 실험군은 대조군보다 우울장애 증상 중증도가 유의하게 낮았고\n\n<!-- PAGE_27 -->\n###### (F1,248=28.67, P<.001), 치료 효과 크기(d=0.63)를 확인하였다.  그룹 평균\n\n<!-- PAGE_27 -->\n###### 패턴은 실험군 우울장애 심각도(8주 개입 후)가 대조군 그룹보다 유의\n\n<!-- PAGE_27 -->\n###### 하게 낮았다(7.702 [Standard Error, SE 0.336] vs 10.224 [SE 0.328],\n\n<!-- PAGE_27 -->\n###### adjusted P<.001; d=0.63).\n\n - - 21 -\n<!-- PAGE_28 -->\n###### 사.  우울장애 개선 디지털치료기기의 국외 사례\n\n<!-- PAGE_28 -->\n###### 현재 국외에서 우울장애 개선 디지털치료기기로서, 허가된 제품 및\n\n<!-- PAGE_28 -->\n###### 인지행동치료(CBT)를 이용한 제품은 다음과 같다 <표 5>.\n\n **[표 시작]**\n\n**기술을 기반으로 하는 세 가지 CBT 모듈이**\n**- 우울장애를 이해하는 데 도움이 되는 상호작용**\n| 대상이 되는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄격한 피험자의 선정 | 시험보고서 |\n**포함되어있고, 각 모듈은 10개의 강의로 구성**\n**시험보고서**\n**- Deprexis는 18세 이상인 우울장애 및 우울한**\n| 기준과 제외 기준을 제시하여야 한다. ",
        "original_sentence": "그룹 평균\n\n<!-- PAGE_27 -->\n###### 패턴은 실험군 우울장애 심각도(8주 개입 후)가 대조군 그룹보다 유의\n\n<!-- PAGE_27 -->\n###### 하게 낮았다(7.702 [Standard Error, SE 0.336] vs 10.224 [SE 0.328],\n\n<!-- PAGE_27 -->\n###### adjusted P<.001; d=0.63).\n\n"
      }
    },
    {
      "chunk_id": "chunk_545",
      "text": "- - 21 -\n<!-- PAGE_28 -->\n###### 사. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 544,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 28,
        "window_text": "평가지표는 연구 시작 시\n\n<!-- PAGE_27 -->\n###### (Baseline), 4주 및 8주에 측정하였다.\n\n <!-- PAGE_27 -->\n###### 실험군은 대조군보다 우울장애 증상 중증도가 유의하게 낮았고\n\n<!-- PAGE_27 -->\n###### (F1,248=28.67, P<.001), 치료 효과 크기(d=0.63)를 확인하였다.  그룹 평균\n\n<!-- PAGE_27 -->\n###### 패턴은 실험군 우울장애 심각도(8주 개입 후)가 대조군 그룹보다 유의\n\n<!-- PAGE_27 -->\n###### 하게 낮았다(7.702 [Standard Error, SE 0.336] vs 10.224 [SE 0.328],\n\n<!-- PAGE_27 -->\n###### adjusted P<.001; d=0.63).\n\n - - 21 -\n<!-- PAGE_28 -->\n###### 사.  우울장애 개선 디지털치료기기의 국외 사례\n\n<!-- PAGE_28 -->\n###### 현재 국외에서 우울장애 개선 디지털치료기기로서, 허가된 제품 및\n\n<!-- PAGE_28 -->\n###### 인지행동치료(CBT)를 이용한 제품은 다음과 같다 <표 5>.\n\n **[표 시작]**\n\n**기술을 기반으로 하는 세 가지 CBT 모듈이**\n**- 우울장애를 이해하는 데 도움이 되는 상호작용**\n| 대상이 되는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄격한 피험자의 선정 | 시험보고서 |\n**포함되어있고, 각 모듈은 10개의 강의로 구성**\n**시험보고서**\n**- Deprexis는 18세 이상인 우울장애 및 우울한**\n| 기준과 제외 기준을 제시하여야 한다.  이 때 임상시험 참여와 연관된 이익을 기대 | 기분 추적을 포함하여 증상을 관리하는 대처 |\n**기분이 있는 환자를 위한 치료를 지원하는**\n**하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 불이익을 우려하여 자발적인**\n**대화형 온라인 기반 자조 프로그램으로 인지**\n**우울장애 평가를 사용하여 사용자와 임상의가**\n**행동치료(CBT)를 기반으로 하며, 21년 2월 20일에**\n**참여 결정에 영향을 받을 소지가 있는 등 취약한 환경에 있는 피험자 (Vulnerable**\n| 매주 | 1레벨을 | 완료하도록 | 권장하지만 | 7주 |\n**시험보고서**\n**Subjects)는 선정대상에서 제외한다. ",
        "original_sentence": "- - 21 -\n<!-- PAGE_28 -->\n###### 사. "
      }
    },
    {
      "chunk_id": "chunk_546",
      "text": "우울장애 개선 디지털치료기기의 국외 사례\n\n<!-- PAGE_28 -->\n###### 현재 국외에서 우울장애 개선 디지털치료기기로서, 허가된 제품 및\n\n<!-- PAGE_28 -->\n###### 인지행동치료(CBT)를 이용한 제품은 다음과 같다 <표 5>.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 545,
        "window_size": 3,
        "char_count": 145,
        "word_count": 28,
        "page_number": 28,
        "window_text": "<!-- PAGE_27 -->\n###### 실험군은 대조군보다 우울장애 증상 중증도가 유의하게 낮았고\n\n<!-- PAGE_27 -->\n###### (F1,248=28.67, P<.001), 치료 효과 크기(d=0.63)를 확인하였다.  그룹 평균\n\n<!-- PAGE_27 -->\n###### 패턴은 실험군 우울장애 심각도(8주 개입 후)가 대조군 그룹보다 유의\n\n<!-- PAGE_27 -->\n###### 하게 낮았다(7.702 [Standard Error, SE 0.336] vs 10.224 [SE 0.328],\n\n<!-- PAGE_27 -->\n###### adjusted P<.001; d=0.63).\n\n - - 21 -\n<!-- PAGE_28 -->\n###### 사.  우울장애 개선 디지털치료기기의 국외 사례\n\n<!-- PAGE_28 -->\n###### 현재 국외에서 우울장애 개선 디지털치료기기로서, 허가된 제품 및\n\n<!-- PAGE_28 -->\n###### 인지행동치료(CBT)를 이용한 제품은 다음과 같다 <표 5>.\n\n **[표 시작]**\n\n**기술을 기반으로 하는 세 가지 CBT 모듈이**\n**- 우울장애를 이해하는 데 도움이 되는 상호작용**\n| 대상이 되는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄격한 피험자의 선정 | 시험보고서 |\n**포함되어있고, 각 모듈은 10개의 강의로 구성**\n**시험보고서**\n**- Deprexis는 18세 이상인 우울장애 및 우울한**\n| 기준과 제외 기준을 제시하여야 한다.  이 때 임상시험 참여와 연관된 이익을 기대 | 기분 추적을 포함하여 증상을 관리하는 대처 |\n**기분이 있는 환자를 위한 치료를 지원하는**\n**하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 불이익을 우려하여 자발적인**\n**대화형 온라인 기반 자조 프로그램으로 인지**\n**우울장애 평가를 사용하여 사용자와 임상의가**\n**행동치료(CBT)를 기반으로 하며, 21년 2월 20일에**\n**참여 결정에 영향을 받을 소지가 있는 등 취약한 환경에 있는 피험자 (Vulnerable**\n| 매주 | 1레벨을 | 완료하도록 | 권장하지만 | 7주 |\n**시험보고서**\n**Subjects)는 선정대상에서 제외한다.  또한, 시험군과 대조군을 포함한 피험자 수는 해당**\n**- 인지행동치료 기반 행동의 활성화, 인지 재구**\n**시험보고서**\n**의료기기의 특성, 임상시험 디자인, 근거를 통한 시험에서 기대하는 연구결과의 사전**\n**조화, 이완, 수용과 마음챙김 등의 프로그램을**\n**시험보고서**\n**예측, 통계적 유의성, 검정 방법, 탈락률 등을 반영하여 통계학 적으로 타당하게 제시**\n| - Novego의 우울장애 프로그램은 전신 치료 및 | 완료 |\n| 되어야 하며, 임상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 한다. ",
        "original_sentence": "우울장애 개선 디지털치료기기의 국외 사례\n\n<!-- PAGE_28 -->\n###### 현재 국외에서 우울장애 개선 디지털치료기기로서, 허가된 제품 및\n\n<!-- PAGE_28 -->\n###### 인지행동치료(CBT)를 이용한 제품은 다음과 같다 <표 5>.\n\n"
      }
    },
    {
      "chunk_id": "chunk_547",
      "text": "**[표 시작]**\n\n**기술을 기반으로 하는 세 가지 CBT 모듈이**\n**- 우울장애를 이해하는 데 도움이 되는 상호작용**\n| 대상이 되는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄격한 피험자의 선정 | 시험보고서 |\n**포함되어있고, 각 모듈은 10개의 강의로 구성**\n**시험보고서**\n**- Deprexis는 18세 이상인 우울장애 및 우울한**\n| 기준과 제외 기준을 제시하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 546,
        "window_size": 3,
        "char_count": 227,
        "word_count": 50,
        "page_number": 29,
        "window_text": "그룹 평균\n\n<!-- PAGE_27 -->\n###### 패턴은 실험군 우울장애 심각도(8주 개입 후)가 대조군 그룹보다 유의\n\n<!-- PAGE_27 -->\n###### 하게 낮았다(7.702 [Standard Error, SE 0.336] vs 10.224 [SE 0.328],\n\n<!-- PAGE_27 -->\n###### adjusted P<.001; d=0.63).\n\n - - 21 -\n<!-- PAGE_28 -->\n###### 사.  우울장애 개선 디지털치료기기의 국외 사례\n\n<!-- PAGE_28 -->\n###### 현재 국외에서 우울장애 개선 디지털치료기기로서, 허가된 제품 및\n\n<!-- PAGE_28 -->\n###### 인지행동치료(CBT)를 이용한 제품은 다음과 같다 <표 5>.\n\n **[표 시작]**\n\n**기술을 기반으로 하는 세 가지 CBT 모듈이**\n**- 우울장애를 이해하는 데 도움이 되는 상호작용**\n| 대상이 되는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄격한 피험자의 선정 | 시험보고서 |\n**포함되어있고, 각 모듈은 10개의 강의로 구성**\n**시험보고서**\n**- Deprexis는 18세 이상인 우울장애 및 우울한**\n| 기준과 제외 기준을 제시하여야 한다.  이 때 임상시험 참여와 연관된 이익을 기대 | 기분 추적을 포함하여 증상을 관리하는 대처 |\n**기분이 있는 환자를 위한 치료를 지원하는**\n**하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 불이익을 우려하여 자발적인**\n**대화형 온라인 기반 자조 프로그램으로 인지**\n**우울장애 평가를 사용하여 사용자와 임상의가**\n**행동치료(CBT)를 기반으로 하며, 21년 2월 20일에**\n**참여 결정에 영향을 받을 소지가 있는 등 취약한 환경에 있는 피험자 (Vulnerable**\n| 매주 | 1레벨을 | 완료하도록 | 권장하지만 | 7주 |\n**시험보고서**\n**Subjects)는 선정대상에서 제외한다.  또한, 시험군과 대조군을 포함한 피험자 수는 해당**\n**- 인지행동치료 기반 행동의 활성화, 인지 재구**\n**시험보고서**\n**의료기기의 특성, 임상시험 디자인, 근거를 통한 시험에서 기대하는 연구결과의 사전**\n**조화, 이완, 수용과 마음챙김 등의 프로그램을**\n**시험보고서**\n**예측, 통계적 유의성, 검정 방법, 탈락률 등을 반영하여 통계학 적으로 타당하게 제시**\n| - Novego의 우울장애 프로그램은 전신 치료 및 | 완료 |\n| 되어야 하며, 임상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 한다.  | - Deprexis는 인공 지능을 사용하여 사용자와 | - SilverCloud의 우울장애 프로그램은 경증에서 | 시험보고서 |\n| 상호 작용하고 질문에 대한 응답을 분석하여 | 마음챙김 훈련의 일부 및 입증된 인지행동치료 | 중증도의 우울장애를 겪는 개인에게 인지행동 |\n| 우울장애 증상을 관리하는 데 도움이 되는 | 방법을 제공하며, 심리적으로 스트레스가 많은 |\n**시험보고서**\n| 자기 기분과 유발 요인을 잘 이해하고 가르치기 | 시험보고서 |\n| - 임상연구에서 피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 수가 보장 | - 디지털치료기기에 대한 장기 사용자 반응 평가를 함께 수행한다. ",
        "original_sentence": "**[표 시작]**\n\n**기술을 기반으로 하는 세 가지 CBT 모듈이**\n**- 우울장애를 이해하는 데 도움이 되는 상호작용**\n| 대상이 되는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄격한 피험자의 선정 | 시험보고서 |\n**포함되어있고, 각 모듈은 10개의 강의로 구성**\n**시험보고서**\n**- Deprexis는 18세 이상인 우울장애 및 우울한**\n| 기준과 제외 기준을 제시하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_548",
      "text": "이 때 임상시험 참여와 연관된 이익을 기대 | 기분 추적을 포함하여 증상을 관리하는 대처 |\n**기분이 있는 환자를 위한 치료를 지원하는**\n**하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 불이익을 우려하여 자발적인**\n**대화형 온라인 기반 자조 프로그램으로 인지**\n**우울장애 평가를 사용하여 사용자와 임상의가**\n**행동치료(CBT)를 기반으로 하며, 21년 2월 20일에**\n**참여 결정에 영향을 받을 소지가 있는 등 취약한 환경에 있는 피험자 (Vulnerable**\n| 매주 | 1레벨을 | 완료하도록 | 권장하지만 | 7주 |\n**시험보고서**\n**Subjects)는 선정대상에서 제외한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 547,
        "window_size": 3,
        "char_count": 347,
        "word_count": 76,
        "page_number": 30,
        "window_text": "- - 21 -\n<!-- PAGE_28 -->\n###### 사.  우울장애 개선 디지털치료기기의 국외 사례\n\n<!-- PAGE_28 -->\n###### 현재 국외에서 우울장애 개선 디지털치료기기로서, 허가된 제품 및\n\n<!-- PAGE_28 -->\n###### 인지행동치료(CBT)를 이용한 제품은 다음과 같다 <표 5>.\n\n **[표 시작]**\n\n**기술을 기반으로 하는 세 가지 CBT 모듈이**\n**- 우울장애를 이해하는 데 도움이 되는 상호작용**\n| 대상이 되는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄격한 피험자의 선정 | 시험보고서 |\n**포함되어있고, 각 모듈은 10개의 강의로 구성**\n**시험보고서**\n**- Deprexis는 18세 이상인 우울장애 및 우울한**\n| 기준과 제외 기준을 제시하여야 한다.  이 때 임상시험 참여와 연관된 이익을 기대 | 기분 추적을 포함하여 증상을 관리하는 대처 |\n**기분이 있는 환자를 위한 치료를 지원하는**\n**하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 불이익을 우려하여 자발적인**\n**대화형 온라인 기반 자조 프로그램으로 인지**\n**우울장애 평가를 사용하여 사용자와 임상의가**\n**행동치료(CBT)를 기반으로 하며, 21년 2월 20일에**\n**참여 결정에 영향을 받을 소지가 있는 등 취약한 환경에 있는 피험자 (Vulnerable**\n| 매주 | 1레벨을 | 완료하도록 | 권장하지만 | 7주 |\n**시험보고서**\n**Subjects)는 선정대상에서 제외한다.  또한, 시험군과 대조군을 포함한 피험자 수는 해당**\n**- 인지행동치료 기반 행동의 활성화, 인지 재구**\n**시험보고서**\n**의료기기의 특성, 임상시험 디자인, 근거를 통한 시험에서 기대하는 연구결과의 사전**\n**조화, 이완, 수용과 마음챙김 등의 프로그램을**\n**시험보고서**\n**예측, 통계적 유의성, 검정 방법, 탈락률 등을 반영하여 통계학 적으로 타당하게 제시**\n| - Novego의 우울장애 프로그램은 전신 치료 및 | 완료 |\n| 되어야 하며, 임상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 한다.  | - Deprexis는 인공 지능을 사용하여 사용자와 | - SilverCloud의 우울장애 프로그램은 경증에서 | 시험보고서 |\n| 상호 작용하고 질문에 대한 응답을 분석하여 | 마음챙김 훈련의 일부 및 입증된 인지행동치료 | 중증도의 우울장애를 겪는 개인에게 인지행동 |\n| 우울장애 증상을 관리하는 데 도움이 되는 | 방법을 제공하며, 심리적으로 스트레스가 많은 |\n**시험보고서**\n| 자기 기분과 유발 요인을 잘 이해하고 가르치기 | 시험보고서 |\n| - 임상연구에서 피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 수가 보장 | - 디지털치료기기에 대한 장기 사용자 반응 평가를 함께 수행한다.  | 으로 인한 질병의 증상을 완화하거나 예방하기 |\n**위한 유연한 사고방식과 전략을 개발할 수**\n**위해 고안된 온라인 자조 프로그램을 제공한다.",
        "original_sentence": "이 때 임상시험 참여와 연관된 이익을 기대 | 기분 추적을 포함하여 증상을 관리하는 대처 |\n**기분이 있는 환자를 위한 치료를 지원하는**\n**하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 불이익을 우려하여 자발적인**\n**대화형 온라인 기반 자조 프로그램으로 인지**\n**우울장애 평가를 사용하여 사용자와 임상의가**\n**행동치료(CBT)를 기반으로 하며, 21년 2월 20일에**\n**참여 결정에 영향을 받을 소지가 있는 등 취약한 환경에 있는 피험자 (Vulnerable**\n| 매주 | 1레벨을 | 완료하도록 | 권장하지만 | 7주 |\n**시험보고서**\n**Subjects)는 선정대상에서 제외한다. "
      }
    },
    {
      "chunk_id": "chunk_549",
      "text": "또한, 시험군과 대조군을 포함한 피험자 수는 해당**\n**- 인지행동치료 기반 행동의 활성화, 인지 재구**\n**시험보고서**\n**의료기기의 특성, 임상시험 디자인, 근거를 통한 시험에서 기대하는 연구결과의 사전**\n**조화, 이완, 수용과 마음챙김 등의 프로그램을**\n**시험보고서**\n**예측, 통계적 유의성, 검정 방법, 탈락률 등을 반영하여 통계학 적으로 타당하게 제시**\n| - Novego의 우울장애 프로그램은 전신 치료 및 | 완료 |\n| 되어야 하며, 임상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 548,
        "window_size": 3,
        "char_count": 301,
        "word_count": 68,
        "page_number": 18,
        "window_text": "우울장애 개선 디지털치료기기의 국외 사례\n\n<!-- PAGE_28 -->\n###### 현재 국외에서 우울장애 개선 디지털치료기기로서, 허가된 제품 및\n\n<!-- PAGE_28 -->\n###### 인지행동치료(CBT)를 이용한 제품은 다음과 같다 <표 5>.\n\n **[표 시작]**\n\n**기술을 기반으로 하는 세 가지 CBT 모듈이**\n**- 우울장애를 이해하는 데 도움이 되는 상호작용**\n| 대상이 되는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄격한 피험자의 선정 | 시험보고서 |\n**포함되어있고, 각 모듈은 10개의 강의로 구성**\n**시험보고서**\n**- Deprexis는 18세 이상인 우울장애 및 우울한**\n| 기준과 제외 기준을 제시하여야 한다.  이 때 임상시험 참여와 연관된 이익을 기대 | 기분 추적을 포함하여 증상을 관리하는 대처 |\n**기분이 있는 환자를 위한 치료를 지원하는**\n**하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 불이익을 우려하여 자발적인**\n**대화형 온라인 기반 자조 프로그램으로 인지**\n**우울장애 평가를 사용하여 사용자와 임상의가**\n**행동치료(CBT)를 기반으로 하며, 21년 2월 20일에**\n**참여 결정에 영향을 받을 소지가 있는 등 취약한 환경에 있는 피험자 (Vulnerable**\n| 매주 | 1레벨을 | 완료하도록 | 권장하지만 | 7주 |\n**시험보고서**\n**Subjects)는 선정대상에서 제외한다.  또한, 시험군과 대조군을 포함한 피험자 수는 해당**\n**- 인지행동치료 기반 행동의 활성화, 인지 재구**\n**시험보고서**\n**의료기기의 특성, 임상시험 디자인, 근거를 통한 시험에서 기대하는 연구결과의 사전**\n**조화, 이완, 수용과 마음챙김 등의 프로그램을**\n**시험보고서**\n**예측, 통계적 유의성, 검정 방법, 탈락률 등을 반영하여 통계학 적으로 타당하게 제시**\n| - Novego의 우울장애 프로그램은 전신 치료 및 | 완료 |\n| 되어야 하며, 임상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 한다.  | - Deprexis는 인공 지능을 사용하여 사용자와 | - SilverCloud의 우울장애 프로그램은 경증에서 | 시험보고서 |\n| 상호 작용하고 질문에 대한 응답을 분석하여 | 마음챙김 훈련의 일부 및 입증된 인지행동치료 | 중증도의 우울장애를 겪는 개인에게 인지행동 |\n| 우울장애 증상을 관리하는 데 도움이 되는 | 방법을 제공하며, 심리적으로 스트레스가 많은 |\n**시험보고서**\n| 자기 기분과 유발 요인을 잘 이해하고 가르치기 | 시험보고서 |\n| - 임상연구에서 피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 수가 보장 | - 디지털치료기기에 대한 장기 사용자 반응 평가를 함께 수행한다.  | 으로 인한 질병의 증상을 완화하거나 예방하기 |\n**위한 유연한 사고방식과 전략을 개발할 수**\n**위해 고안된 온라인 자조 프로그램을 제공한다. **\n**되어야 하며, 일반적으로 1차 유효성 평가변수를 기준으로 정해지고, 연구 계획서상에**\n**(예) 우울 일기기능과 기록 알림 기능만 탑재된 애플리케이션 등**\n**- 21년 10월 10일 독일 DiGA 디렉터리에 포함**\n| - | 영국의 | 임상의가 | 환자를 | 의뢰하면 | 무료로 |\n**시험보고서**\n**되었으며, 12주의 정규 프로그램 기간 이후**\n| 1) 이상 사례 교육 | (Selfapy GmbH) | - Selfapy는 근거 기반 이론과 인지 행동 치료 |\n**가입 후 서포터가 배정되어 목표를 설정한다.",
        "original_sentence": "또한, 시험군과 대조군을 포함한 피험자 수는 해당**\n**- 인지행동치료 기반 행동의 활성화, 인지 재구**\n**시험보고서**\n**의료기기의 특성, 임상시험 디자인, 근거를 통한 시험에서 기대하는 연구결과의 사전**\n**조화, 이완, 수용과 마음챙김 등의 프로그램을**\n**시험보고서**\n**예측, 통계적 유의성, 검정 방법, 탈락률 등을 반영하여 통계학 적으로 타당하게 제시**\n| - Novego의 우울장애 프로그램은 전신 치료 및 | 완료 |\n| 되어야 하며, 임상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_550",
      "text": "| - Deprexis는 인공 지능을 사용하여 사용자와 | - SilverCloud의 우울장애 프로그램은 경증에서 | 시험보고서 |\n| 상호 작용하고 질문에 대한 응답을 분석하여 | 마음챙김 훈련의 일부 및 입증된 인지행동치료 | 중증도의 우울장애를 겪는 개인에게 인지행동 |\n| 우울장애 증상을 관리하는 데 도움이 되는 | 방법을 제공하며, 심리적으로 스트레스가 많은 |\n**시험보고서**\n| 자기 기분과 유발 요인을 잘 이해하고 가르치기 | 시험보고서 |\n| - 임상연구에서 피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 수가 보장 | - 디지털치료기기에 대한 장기 사용자 반응 평가를 함께 수행한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 549,
        "window_size": 3,
        "char_count": 345,
        "word_count": 87,
        "page_number": 28,
        "window_text": "**[표 시작]**\n\n**기술을 기반으로 하는 세 가지 CBT 모듈이**\n**- 우울장애를 이해하는 데 도움이 되는 상호작용**\n| 대상이 되는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄격한 피험자의 선정 | 시험보고서 |\n**포함되어있고, 각 모듈은 10개의 강의로 구성**\n**시험보고서**\n**- Deprexis는 18세 이상인 우울장애 및 우울한**\n| 기준과 제외 기준을 제시하여야 한다.  이 때 임상시험 참여와 연관된 이익을 기대 | 기분 추적을 포함하여 증상을 관리하는 대처 |\n**기분이 있는 환자를 위한 치료를 지원하는**\n**하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 불이익을 우려하여 자발적인**\n**대화형 온라인 기반 자조 프로그램으로 인지**\n**우울장애 평가를 사용하여 사용자와 임상의가**\n**행동치료(CBT)를 기반으로 하며, 21년 2월 20일에**\n**참여 결정에 영향을 받을 소지가 있는 등 취약한 환경에 있는 피험자 (Vulnerable**\n| 매주 | 1레벨을 | 완료하도록 | 권장하지만 | 7주 |\n**시험보고서**\n**Subjects)는 선정대상에서 제외한다.  또한, 시험군과 대조군을 포함한 피험자 수는 해당**\n**- 인지행동치료 기반 행동의 활성화, 인지 재구**\n**시험보고서**\n**의료기기의 특성, 임상시험 디자인, 근거를 통한 시험에서 기대하는 연구결과의 사전**\n**조화, 이완, 수용과 마음챙김 등의 프로그램을**\n**시험보고서**\n**예측, 통계적 유의성, 검정 방법, 탈락률 등을 반영하여 통계학 적으로 타당하게 제시**\n| - Novego의 우울장애 프로그램은 전신 치료 및 | 완료 |\n| 되어야 하며, 임상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 한다.  | - Deprexis는 인공 지능을 사용하여 사용자와 | - SilverCloud의 우울장애 프로그램은 경증에서 | 시험보고서 |\n| 상호 작용하고 질문에 대한 응답을 분석하여 | 마음챙김 훈련의 일부 및 입증된 인지행동치료 | 중증도의 우울장애를 겪는 개인에게 인지행동 |\n| 우울장애 증상을 관리하는 데 도움이 되는 | 방법을 제공하며, 심리적으로 스트레스가 많은 |\n**시험보고서**\n| 자기 기분과 유발 요인을 잘 이해하고 가르치기 | 시험보고서 |\n| - 임상연구에서 피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 수가 보장 | - 디지털치료기기에 대한 장기 사용자 반응 평가를 함께 수행한다.  | 으로 인한 질병의 증상을 완화하거나 예방하기 |\n**위한 유연한 사고방식과 전략을 개발할 수**\n**위해 고안된 온라인 자조 프로그램을 제공한다. **\n**되어야 하며, 일반적으로 1차 유효성 평가변수를 기준으로 정해지고, 연구 계획서상에**\n**(예) 우울 일기기능과 기록 알림 기능만 탑재된 애플리케이션 등**\n**- 21년 10월 10일 독일 DiGA 디렉터리에 포함**\n| - | 영국의 | 임상의가 | 환자를 | 의뢰하면 | 무료로 |\n**시험보고서**\n**되었으며, 12주의 정규 프로그램 기간 이후**\n| 1) 이상 사례 교육 | (Selfapy GmbH) | - Selfapy는 근거 기반 이론과 인지 행동 치료 |\n**가입 후 서포터가 배정되어 목표를 설정한다. **\n**기술을 기반으로 우울장애 환자에게 개별 온라인**\n**시험보고서**\n| 번호 | 가이드라인 명칭 | 주요 내용 | 비고 |\n| - 참가자는 내용과 운동에 대해 질문이 있는 | - | 임상적으로 | 입증된 | 디지털 | 인지행동치료를 |\n| 과정을 | 제공하며, | 20년 | 6월 | 12일에 | 독일 | 시험보고서 |\n**경우 일주일에 한 번 메시지로 Novego 심리**\n**(1) 일차 유효성 평가지표: 한국판 우울장애 심각도 척도 제2판(BDI-II)**\n**포함하여 기관에 따른 군간 차이가 있는지 분석하여 제시한다.",
        "original_sentence": "| - Deprexis는 인공 지능을 사용하여 사용자와 | - SilverCloud의 우울장애 프로그램은 경증에서 | 시험보고서 |\n| 상호 작용하고 질문에 대한 응답을 분석하여 | 마음챙김 훈련의 일부 및 입증된 인지행동치료 | 중증도의 우울장애를 겪는 개인에게 인지행동 |\n| 우울장애 증상을 관리하는 데 도움이 되는 | 방법을 제공하며, 심리적으로 스트레스가 많은 |\n**시험보고서**\n| 자기 기분과 유발 요인을 잘 이해하고 가르치기 | 시험보고서 |\n| - 임상연구에서 피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 수가 보장 | - 디지털치료기기에 대한 장기 사용자 반응 평가를 함께 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_551",
      "text": "| 으로 인한 질병의 증상을 완화하거나 예방하기 |\n**위한 유연한 사고방식과 전략을 개발할 수**\n**위해 고안된 온라인 자조 프로그램을 제공한다.",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 550,
        "window_size": 3,
        "char_count": 83,
        "word_count": 20,
        "page_number": 18,
        "window_text": "이 때 임상시험 참여와 연관된 이익을 기대 | 기분 추적을 포함하여 증상을 관리하는 대처 |\n**기분이 있는 환자를 위한 치료를 지원하는**\n**하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 불이익을 우려하여 자발적인**\n**대화형 온라인 기반 자조 프로그램으로 인지**\n**우울장애 평가를 사용하여 사용자와 임상의가**\n**행동치료(CBT)를 기반으로 하며, 21년 2월 20일에**\n**참여 결정에 영향을 받을 소지가 있는 등 취약한 환경에 있는 피험자 (Vulnerable**\n| 매주 | 1레벨을 | 완료하도록 | 권장하지만 | 7주 |\n**시험보고서**\n**Subjects)는 선정대상에서 제외한다.  또한, 시험군과 대조군을 포함한 피험자 수는 해당**\n**- 인지행동치료 기반 행동의 활성화, 인지 재구**\n**시험보고서**\n**의료기기의 특성, 임상시험 디자인, 근거를 통한 시험에서 기대하는 연구결과의 사전**\n**조화, 이완, 수용과 마음챙김 등의 프로그램을**\n**시험보고서**\n**예측, 통계적 유의성, 검정 방법, 탈락률 등을 반영하여 통계학 적으로 타당하게 제시**\n| - Novego의 우울장애 프로그램은 전신 치료 및 | 완료 |\n| 되어야 하며, 임상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 한다.  | - Deprexis는 인공 지능을 사용하여 사용자와 | - SilverCloud의 우울장애 프로그램은 경증에서 | 시험보고서 |\n| 상호 작용하고 질문에 대한 응답을 분석하여 | 마음챙김 훈련의 일부 및 입증된 인지행동치료 | 중증도의 우울장애를 겪는 개인에게 인지행동 |\n| 우울장애 증상을 관리하는 데 도움이 되는 | 방법을 제공하며, 심리적으로 스트레스가 많은 |\n**시험보고서**\n| 자기 기분과 유발 요인을 잘 이해하고 가르치기 | 시험보고서 |\n| - 임상연구에서 피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 수가 보장 | - 디지털치료기기에 대한 장기 사용자 반응 평가를 함께 수행한다.  | 으로 인한 질병의 증상을 완화하거나 예방하기 |\n**위한 유연한 사고방식과 전략을 개발할 수**\n**위해 고안된 온라인 자조 프로그램을 제공한다. **\n**되어야 하며, 일반적으로 1차 유효성 평가변수를 기준으로 정해지고, 연구 계획서상에**\n**(예) 우울 일기기능과 기록 알림 기능만 탑재된 애플리케이션 등**\n**- 21년 10월 10일 독일 DiGA 디렉터리에 포함**\n| - | 영국의 | 임상의가 | 환자를 | 의뢰하면 | 무료로 |\n**시험보고서**\n**되었으며, 12주의 정규 프로그램 기간 이후**\n| 1) 이상 사례 교육 | (Selfapy GmbH) | - Selfapy는 근거 기반 이론과 인지 행동 치료 |\n**가입 후 서포터가 배정되어 목표를 설정한다. **\n**기술을 기반으로 우울장애 환자에게 개별 온라인**\n**시험보고서**\n| 번호 | 가이드라인 명칭 | 주요 내용 | 비고 |\n| - 참가자는 내용과 운동에 대해 질문이 있는 | - | 임상적으로 | 입증된 | 디지털 | 인지행동치료를 |\n| 과정을 | 제공하며, | 20년 | 6월 | 12일에 | 독일 | 시험보고서 |\n**경우 일주일에 한 번 메시지로 Novego 심리**\n**(1) 일차 유효성 평가지표: 한국판 우울장애 심각도 척도 제2판(BDI-II)**\n**포함하여 기관에 따른 군간 차이가 있는지 분석하여 제시한다. **\n| 위해요인 | 학자 팀에 직접 연락할 수 있고, 심각한 위기 |\n| - 부정적인 생각 다루기, 긍정적인 일상 구조 | 하루에 15분, 일주일에 3~4번 정도 사용하는 |\n**또는 담당자가 임상시험 수행이 불가능한 것으로 판단한 경우**\n**상황의 경우 프로그램과 함께 24시간 위기**\n**만들기, 이완 기술, 수면 문제 및 재발 방지**\n| trial of two versions of CBT for major depression. ",
        "original_sentence": "| 으로 인한 질병의 증상을 완화하거나 예방하기 |\n**위한 유연한 사고방식과 전략을 개발할 수**\n**위해 고안된 온라인 자조 프로그램을 제공한다."
      }
    },
    {
      "chunk_id": "chunk_552",
      "text": "**\n**되어야 하며, 일반적으로 1차 유효성 평가변수를 기준으로 정해지고, 연구 계획서상에**\n**(예) 우울 일기기능과 기록 알림 기능만 탑재된 애플리케이션 등**\n**- 21년 10월 10일 독일 DiGA 디렉터리에 포함**\n| - | 영국의 | 임상의가 | 환자를 | 의뢰하면 | 무료로 |\n**시험보고서**\n**되었으며, 12주의 정규 프로그램 기간 이후**\n| 1) 이상 사례 교육 | (Selfapy GmbH) | - Selfapy는 근거 기반 이론과 인지 행동 치료 |\n**가입 후 서포터가 배정되어 목표를 설정한다.",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 551,
        "window_size": 3,
        "char_count": 297,
        "word_count": 72,
        "page_number": 7,
        "window_text": "또한, 시험군과 대조군을 포함한 피험자 수는 해당**\n**- 인지행동치료 기반 행동의 활성화, 인지 재구**\n**시험보고서**\n**의료기기의 특성, 임상시험 디자인, 근거를 통한 시험에서 기대하는 연구결과의 사전**\n**조화, 이완, 수용과 마음챙김 등의 프로그램을**\n**시험보고서**\n**예측, 통계적 유의성, 검정 방법, 탈락률 등을 반영하여 통계학 적으로 타당하게 제시**\n| - Novego의 우울장애 프로그램은 전신 치료 및 | 완료 |\n| 되어야 하며, 임상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 한다.  | - Deprexis는 인공 지능을 사용하여 사용자와 | - SilverCloud의 우울장애 프로그램은 경증에서 | 시험보고서 |\n| 상호 작용하고 질문에 대한 응답을 분석하여 | 마음챙김 훈련의 일부 및 입증된 인지행동치료 | 중증도의 우울장애를 겪는 개인에게 인지행동 |\n| 우울장애 증상을 관리하는 데 도움이 되는 | 방법을 제공하며, 심리적으로 스트레스가 많은 |\n**시험보고서**\n| 자기 기분과 유발 요인을 잘 이해하고 가르치기 | 시험보고서 |\n| - 임상연구에서 피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 수가 보장 | - 디지털치료기기에 대한 장기 사용자 반응 평가를 함께 수행한다.  | 으로 인한 질병의 증상을 완화하거나 예방하기 |\n**위한 유연한 사고방식과 전략을 개발할 수**\n**위해 고안된 온라인 자조 프로그램을 제공한다. **\n**되어야 하며, 일반적으로 1차 유효성 평가변수를 기준으로 정해지고, 연구 계획서상에**\n**(예) 우울 일기기능과 기록 알림 기능만 탑재된 애플리케이션 등**\n**- 21년 10월 10일 독일 DiGA 디렉터리에 포함**\n| - | 영국의 | 임상의가 | 환자를 | 의뢰하면 | 무료로 |\n**시험보고서**\n**되었으며, 12주의 정규 프로그램 기간 이후**\n| 1) 이상 사례 교육 | (Selfapy GmbH) | - Selfapy는 근거 기반 이론과 인지 행동 치료 |\n**가입 후 서포터가 배정되어 목표를 설정한다. **\n**기술을 기반으로 우울장애 환자에게 개별 온라인**\n**시험보고서**\n| 번호 | 가이드라인 명칭 | 주요 내용 | 비고 |\n| - 참가자는 내용과 운동에 대해 질문이 있는 | - | 임상적으로 | 입증된 | 디지털 | 인지행동치료를 |\n| 과정을 | 제공하며, | 20년 | 6월 | 12일에 | 독일 | 시험보고서 |\n**경우 일주일에 한 번 메시지로 Novego 심리**\n**(1) 일차 유효성 평가지표: 한국판 우울장애 심각도 척도 제2판(BDI-II)**\n**포함하여 기관에 따른 군간 차이가 있는지 분석하여 제시한다. **\n| 위해요인 | 학자 팀에 직접 연락할 수 있고, 심각한 위기 |\n| - 부정적인 생각 다루기, 긍정적인 일상 구조 | 하루에 15분, 일주일에 3~4번 정도 사용하는 |\n**또는 담당자가 임상시험 수행이 불가능한 것으로 판단한 경우**\n**상황의 경우 프로그램과 함께 24시간 위기**\n**만들기, 이완 기술, 수면 문제 및 재발 방지**\n| trial of two versions of CBT for major depression.  Behaviour research and therapy, 48(5), 368-376. ",
        "original_sentence": "**\n**되어야 하며, 일반적으로 1차 유효성 평가변수를 기준으로 정해지고, 연구 계획서상에**\n**(예) 우울 일기기능과 기록 알림 기능만 탑재된 애플리케이션 등**\n**- 21년 10월 10일 독일 DiGA 디렉터리에 포함**\n| - | 영국의 | 임상의가 | 환자를 | 의뢰하면 | 무료로 |\n**시험보고서**\n**되었으며, 12주의 정규 프로그램 기간 이후**\n| 1) 이상 사례 교육 | (Selfapy GmbH) | - Selfapy는 근거 기반 이론과 인지 행동 치료 |\n**가입 후 서포터가 배정되어 목표를 설정한다."
      }
    },
    {
      "chunk_id": "chunk_553",
      "text": "**\n**기술을 기반으로 우울장애 환자에게 개별 온라인**\n**시험보고서**\n| 번호 | 가이드라인 명칭 | 주요 내용 | 비고 |\n| - 참가자는 내용과 운동에 대해 질문이 있는 | - | 임상적으로 | 입증된 | 디지털 | 인지행동치료를 |\n| 과정을 | 제공하며, | 20년 | 6월 | 12일에 | 독일 | 시험보고서 |\n**경우 일주일에 한 번 메시지로 Novego 심리**\n**(1) 일차 유효성 평가지표: 한국판 우울장애 심각도 척도 제2판(BDI-II)**\n**포함하여 기관에 따른 군간 차이가 있는지 분석하여 제시한다.",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 552,
        "window_size": 3,
        "char_count": 299,
        "word_count": 77,
        "page_number": 28,
        "window_text": "| - Deprexis는 인공 지능을 사용하여 사용자와 | - SilverCloud의 우울장애 프로그램은 경증에서 | 시험보고서 |\n| 상호 작용하고 질문에 대한 응답을 분석하여 | 마음챙김 훈련의 일부 및 입증된 인지행동치료 | 중증도의 우울장애를 겪는 개인에게 인지행동 |\n| 우울장애 증상을 관리하는 데 도움이 되는 | 방법을 제공하며, 심리적으로 스트레스가 많은 |\n**시험보고서**\n| 자기 기분과 유발 요인을 잘 이해하고 가르치기 | 시험보고서 |\n| - 임상연구에서 피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 수가 보장 | - 디지털치료기기에 대한 장기 사용자 반응 평가를 함께 수행한다.  | 으로 인한 질병의 증상을 완화하거나 예방하기 |\n**위한 유연한 사고방식과 전략을 개발할 수**\n**위해 고안된 온라인 자조 프로그램을 제공한다. **\n**되어야 하며, 일반적으로 1차 유효성 평가변수를 기준으로 정해지고, 연구 계획서상에**\n**(예) 우울 일기기능과 기록 알림 기능만 탑재된 애플리케이션 등**\n**- 21년 10월 10일 독일 DiGA 디렉터리에 포함**\n| - | 영국의 | 임상의가 | 환자를 | 의뢰하면 | 무료로 |\n**시험보고서**\n**되었으며, 12주의 정규 프로그램 기간 이후**\n| 1) 이상 사례 교육 | (Selfapy GmbH) | - Selfapy는 근거 기반 이론과 인지 행동 치료 |\n**가입 후 서포터가 배정되어 목표를 설정한다. **\n**기술을 기반으로 우울장애 환자에게 개별 온라인**\n**시험보고서**\n| 번호 | 가이드라인 명칭 | 주요 내용 | 비고 |\n| - 참가자는 내용과 운동에 대해 질문이 있는 | - | 임상적으로 | 입증된 | 디지털 | 인지행동치료를 |\n| 과정을 | 제공하며, | 20년 | 6월 | 12일에 | 독일 | 시험보고서 |\n**경우 일주일에 한 번 메시지로 Novego 심리**\n**(1) 일차 유효성 평가지표: 한국판 우울장애 심각도 척도 제2판(BDI-II)**\n**포함하여 기관에 따른 군간 차이가 있는지 분석하여 제시한다. **\n| 위해요인 | 학자 팀에 직접 연락할 수 있고, 심각한 위기 |\n| - 부정적인 생각 다루기, 긍정적인 일상 구조 | 하루에 15분, 일주일에 3~4번 정도 사용하는 |\n**또는 담당자가 임상시험 수행이 불가능한 것으로 판단한 경우**\n**상황의 경우 프로그램과 함께 24시간 위기**\n**만들기, 이완 기술, 수면 문제 및 재발 방지**\n| trial of two versions of CBT for major depression.  Behaviour research and therapy, 48(5), 368-376.  | 시험보고서 |\n**1) 양극성 장애 또는 조현병과 같은 심각한 정신질환을 앓고 있는 자**\n| 1) 중대한 이상사례·의료기기 이상반응 보고 | 검정을 통해 양측 유의수준 0.05에서 통계적 우월성을 평가한다. ",
        "original_sentence": "**\n**기술을 기반으로 우울장애 환자에게 개별 온라인**\n**시험보고서**\n| 번호 | 가이드라인 명칭 | 주요 내용 | 비고 |\n| - 참가자는 내용과 운동에 대해 질문이 있는 | - | 임상적으로 | 입증된 | 디지털 | 인지행동치료를 |\n| 과정을 | 제공하며, | 20년 | 6월 | 12일에 | 독일 | 시험보고서 |\n**경우 일주일에 한 번 메시지로 Novego 심리**\n**(1) 일차 유효성 평가지표: 한국판 우울장애 심각도 척도 제2판(BDI-II)**\n**포함하여 기관에 따른 군간 차이가 있는지 분석하여 제시한다."
      }
    },
    {
      "chunk_id": "chunk_554",
      "text": "**\n| 위해요인 | 학자 팀에 직접 연락할 수 있고, 심각한 위기 |\n| - 부정적인 생각 다루기, 긍정적인 일상 구조 | 하루에 15분, 일주일에 3~4번 정도 사용하는 |\n**또는 담당자가 임상시험 수행이 불가능한 것으로 판단한 경우**\n**상황의 경우 프로그램과 함께 24시간 위기**\n**만들기, 이완 기술, 수면 문제 및 재발 방지**\n| trial of two versions of CBT for major depression. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 553,
        "window_size": 3,
        "char_count": 247,
        "word_count": 61,
        "page_number": 20,
        "window_text": "| 으로 인한 질병의 증상을 완화하거나 예방하기 |\n**위한 유연한 사고방식과 전략을 개발할 수**\n**위해 고안된 온라인 자조 프로그램을 제공한다. **\n**되어야 하며, 일반적으로 1차 유효성 평가변수를 기준으로 정해지고, 연구 계획서상에**\n**(예) 우울 일기기능과 기록 알림 기능만 탑재된 애플리케이션 등**\n**- 21년 10월 10일 독일 DiGA 디렉터리에 포함**\n| - | 영국의 | 임상의가 | 환자를 | 의뢰하면 | 무료로 |\n**시험보고서**\n**되었으며, 12주의 정규 프로그램 기간 이후**\n| 1) 이상 사례 교육 | (Selfapy GmbH) | - Selfapy는 근거 기반 이론과 인지 행동 치료 |\n**가입 후 서포터가 배정되어 목표를 설정한다. **\n**기술을 기반으로 우울장애 환자에게 개별 온라인**\n**시험보고서**\n| 번호 | 가이드라인 명칭 | 주요 내용 | 비고 |\n| - 참가자는 내용과 운동에 대해 질문이 있는 | - | 임상적으로 | 입증된 | 디지털 | 인지행동치료를 |\n| 과정을 | 제공하며, | 20년 | 6월 | 12일에 | 독일 | 시험보고서 |\n**경우 일주일에 한 번 메시지로 Novego 심리**\n**(1) 일차 유효성 평가지표: 한국판 우울장애 심각도 척도 제2판(BDI-II)**\n**포함하여 기관에 따른 군간 차이가 있는지 분석하여 제시한다. **\n| 위해요인 | 학자 팀에 직접 연락할 수 있고, 심각한 위기 |\n| - 부정적인 생각 다루기, 긍정적인 일상 구조 | 하루에 15분, 일주일에 3~4번 정도 사용하는 |\n**또는 담당자가 임상시험 수행이 불가능한 것으로 판단한 경우**\n**상황의 경우 프로그램과 함께 24시간 위기**\n**만들기, 이완 기술, 수면 문제 및 재발 방지**\n| trial of two versions of CBT for major depression.  Behaviour research and therapy, 48(5), 368-376.  | 시험보고서 |\n**1) 양극성 장애 또는 조현병과 같은 심각한 정신질환을 앓고 있는 자**\n| 1) 중대한 이상사례·의료기기 이상반응 보고 | 검정을 통해 양측 유의수준 0.05에서 통계적 우월성을 평가한다.  |\n**- 최소 30분 동안 지속되는 1~2회 세션으로 매주**\n**사용자의**\n**시험보고서**\n**시험보고서**\n\n**[표 끝]**\n\n- - 최초 등록 후 90일 동안 사용을 할 수 있으며,\n전략과 같은 주제에 대한 프로그램을 제공하며,\n\n최소 1개의 수업을 완료하는 것을 권장하며,\n\n<!-- PAGE_28 -->\n###### 표 5. ",
        "original_sentence": "**\n| 위해요인 | 학자 팀에 직접 연락할 수 있고, 심각한 위기 |\n| - 부정적인 생각 다루기, 긍정적인 일상 구조 | 하루에 15분, 일주일에 3~4번 정도 사용하는 |\n**또는 담당자가 임상시험 수행이 불가능한 것으로 판단한 경우**\n**상황의 경우 프로그램과 함께 24시간 위기**\n**만들기, 이완 기술, 수면 문제 및 재발 방지**\n| trial of two versions of CBT for major depression. "
      }
    },
    {
      "chunk_id": "chunk_555",
      "text": "Behaviour research and therapy, 48(5), 368-376. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 554,
        "window_size": 3,
        "char_count": 48,
        "word_count": 6,
        "page_number": 9,
        "window_text": "**\n**되어야 하며, 일반적으로 1차 유효성 평가변수를 기준으로 정해지고, 연구 계획서상에**\n**(예) 우울 일기기능과 기록 알림 기능만 탑재된 애플리케이션 등**\n**- 21년 10월 10일 독일 DiGA 디렉터리에 포함**\n| - | 영국의 | 임상의가 | 환자를 | 의뢰하면 | 무료로 |\n**시험보고서**\n**되었으며, 12주의 정규 프로그램 기간 이후**\n| 1) 이상 사례 교육 | (Selfapy GmbH) | - Selfapy는 근거 기반 이론과 인지 행동 치료 |\n**가입 후 서포터가 배정되어 목표를 설정한다. **\n**기술을 기반으로 우울장애 환자에게 개별 온라인**\n**시험보고서**\n| 번호 | 가이드라인 명칭 | 주요 내용 | 비고 |\n| - 참가자는 내용과 운동에 대해 질문이 있는 | - | 임상적으로 | 입증된 | 디지털 | 인지행동치료를 |\n| 과정을 | 제공하며, | 20년 | 6월 | 12일에 | 독일 | 시험보고서 |\n**경우 일주일에 한 번 메시지로 Novego 심리**\n**(1) 일차 유효성 평가지표: 한국판 우울장애 심각도 척도 제2판(BDI-II)**\n**포함하여 기관에 따른 군간 차이가 있는지 분석하여 제시한다. **\n| 위해요인 | 학자 팀에 직접 연락할 수 있고, 심각한 위기 |\n| - 부정적인 생각 다루기, 긍정적인 일상 구조 | 하루에 15분, 일주일에 3~4번 정도 사용하는 |\n**또는 담당자가 임상시험 수행이 불가능한 것으로 판단한 경우**\n**상황의 경우 프로그램과 함께 24시간 위기**\n**만들기, 이완 기술, 수면 문제 및 재발 방지**\n| trial of two versions of CBT for major depression.  Behaviour research and therapy, 48(5), 368-376.  | 시험보고서 |\n**1) 양극성 장애 또는 조현병과 같은 심각한 정신질환을 앓고 있는 자**\n| 1) 중대한 이상사례·의료기기 이상반응 보고 | 검정을 통해 양측 유의수준 0.05에서 통계적 우월성을 평가한다.  |\n**- 최소 30분 동안 지속되는 1~2회 세션으로 매주**\n**사용자의**\n**시험보고서**\n**시험보고서**\n\n**[표 끝]**\n\n- - 최초 등록 후 90일 동안 사용을 할 수 있으며,\n전략과 같은 주제에 대한 프로그램을 제공하며,\n\n최소 1개의 수업을 완료하는 것을 권장하며,\n\n<!-- PAGE_28 -->\n###### 표 5.  국외 우울장애 개선 디지털치료기기 허가 제품 및 관련 제품의 개발 동향(2022. ",
        "original_sentence": "Behaviour research and therapy, 48(5), 368-376. "
      }
    },
    {
      "chunk_id": "chunk_556",
      "text": "| 시험보고서 |\n**1) 양극성 장애 또는 조현병과 같은 심각한 정신질환을 앓고 있는 자**\n| 1) 중대한 이상사례·의료기기 이상반응 보고 | 검정을 통해 양측 유의수준 0.05에서 통계적 우월성을 평가한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 555,
        "window_size": 3,
        "char_count": 119,
        "word_count": 29,
        "page_number": 28,
        "window_text": "**\n**기술을 기반으로 우울장애 환자에게 개별 온라인**\n**시험보고서**\n| 번호 | 가이드라인 명칭 | 주요 내용 | 비고 |\n| - 참가자는 내용과 운동에 대해 질문이 있는 | - | 임상적으로 | 입증된 | 디지털 | 인지행동치료를 |\n| 과정을 | 제공하며, | 20년 | 6월 | 12일에 | 독일 | 시험보고서 |\n**경우 일주일에 한 번 메시지로 Novego 심리**\n**(1) 일차 유효성 평가지표: 한국판 우울장애 심각도 척도 제2판(BDI-II)**\n**포함하여 기관에 따른 군간 차이가 있는지 분석하여 제시한다. **\n| 위해요인 | 학자 팀에 직접 연락할 수 있고, 심각한 위기 |\n| - 부정적인 생각 다루기, 긍정적인 일상 구조 | 하루에 15분, 일주일에 3~4번 정도 사용하는 |\n**또는 담당자가 임상시험 수행이 불가능한 것으로 판단한 경우**\n**상황의 경우 프로그램과 함께 24시간 위기**\n**만들기, 이완 기술, 수면 문제 및 재발 방지**\n| trial of two versions of CBT for major depression.  Behaviour research and therapy, 48(5), 368-376.  | 시험보고서 |\n**1) 양극성 장애 또는 조현병과 같은 심각한 정신질환을 앓고 있는 자**\n| 1) 중대한 이상사례·의료기기 이상반응 보고 | 검정을 통해 양측 유의수준 0.05에서 통계적 우월성을 평가한다.  |\n**- 최소 30분 동안 지속되는 1~2회 세션으로 매주**\n**사용자의**\n**시험보고서**\n**시험보고서**\n\n**[표 끝]**\n\n- - 최초 등록 후 90일 동안 사용을 할 수 있으며,\n전략과 같은 주제에 대한 프로그램을 제공하며,\n\n최소 1개의 수업을 완료하는 것을 권장하며,\n\n<!-- PAGE_28 -->\n###### 표 5.  국외 우울장애 개선 디지털치료기기 허가 제품 및 관련 제품의 개발 동향(2022.  11. ",
        "original_sentence": "| 시험보고서 |\n**1) 양극성 장애 또는 조현병과 같은 심각한 정신질환을 앓고 있는 자**\n| 1) 중대한 이상사례·의료기기 이상반응 보고 | 검정을 통해 양측 유의수준 0.05에서 통계적 우월성을 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_557",
      "text": "|\n**- 최소 30분 동안 지속되는 1~2회 세션으로 매주**\n**사용자의**\n**시험보고서**\n**시험보고서**\n\n**[표 끝]**\n\n- - 최초 등록 후 90일 동안 사용을 할 수 있으며,\n전략과 같은 주제에 대한 프로그램을 제공하며,\n\n최소 1개의 수업을 완료하는 것을 권장하며,\n\n<!-- PAGE_28 -->\n###### 표 5. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 556,
        "window_size": 3,
        "char_count": 191,
        "word_count": 43,
        "page_number": 28,
        "window_text": "**\n| 위해요인 | 학자 팀에 직접 연락할 수 있고, 심각한 위기 |\n| - 부정적인 생각 다루기, 긍정적인 일상 구조 | 하루에 15분, 일주일에 3~4번 정도 사용하는 |\n**또는 담당자가 임상시험 수행이 불가능한 것으로 판단한 경우**\n**상황의 경우 프로그램과 함께 24시간 위기**\n**만들기, 이완 기술, 수면 문제 및 재발 방지**\n| trial of two versions of CBT for major depression.  Behaviour research and therapy, 48(5), 368-376.  | 시험보고서 |\n**1) 양극성 장애 또는 조현병과 같은 심각한 정신질환을 앓고 있는 자**\n| 1) 중대한 이상사례·의료기기 이상반응 보고 | 검정을 통해 양측 유의수준 0.05에서 통계적 우월성을 평가한다.  |\n**- 최소 30분 동안 지속되는 1~2회 세션으로 매주**\n**사용자의**\n**시험보고서**\n**시험보고서**\n\n**[표 끝]**\n\n- - 최초 등록 후 90일 동안 사용을 할 수 있으며,\n전략과 같은 주제에 대한 프로그램을 제공하며,\n\n최소 1개의 수업을 완료하는 것을 권장하며,\n\n<!-- PAGE_28 -->\n###### 표 5.  국외 우울장애 개선 디지털치료기기 허가 제품 및 관련 제품의 개발 동향(2022.  11.  기준)\n\n- - 22 -\nThrive\n\n(Waypoint)\n\n- -\nThrive는\n\n인지행동치료(CBT)의\n\n모범\n\n사례를\n\n바탕으로 구조화된 디지털 커리큘럼을 통해\n\n- - 행동 활성화, 인지 재구성 및 사회적 기술 훈련\n- - Thrive는 PHQ-9(Patient Health Questionnaire)\n생활 상황(예: 우울장애, 불안, 소진, 스트레스)\n\n- - 23 -\nSparkRx\n\n(Limbix)\n\n- - SparkRx는 13세에서 22세 사이의 우울장애\n환자에게\n\n인지행동치료를\n\n제공하는\n\n디지털\n\n치료제이며,\n\n미국\n\nFDA에\n\n아직\n\n승인되지는\n\n않았지만, COVID-19로 인해 정신 장애를 치료\n\n하는 디지털 건강 장치에 대한 FDA 비상\n\n프로그램을 수행하며, 활동 일정, 마음챙김,\n\n- - 프로그램은 5가지 레벨로 구성되어 있으며,\n치료 기반의 서비스가 제공되도록 설계되었으며,\n\n플랫폼에 접근할 수 있는 권한을 주어지며,\n\n**[표 시작]**\n\n**사용하며 전체 과정은 8주 동안 지원이 되며,**\n\n**[표 끝]**\n\n- - 24 -\n<!-- PAGE_31 -->\n###### 아. ",
        "original_sentence": "|\n**- 최소 30분 동안 지속되는 1~2회 세션으로 매주**\n**사용자의**\n**시험보고서**\n**시험보고서**\n\n**[표 끝]**\n\n- - 최초 등록 후 90일 동안 사용을 할 수 있으며,\n전략과 같은 주제에 대한 프로그램을 제공하며,\n\n최소 1개의 수업을 완료하는 것을 권장하며,\n\n<!-- PAGE_28 -->\n###### 표 5. "
      }
    },
    {
      "chunk_id": "chunk_558",
      "text": "국외 우울장애 개선 디지털치료기기 허가 제품 및 관련 제품의 개발 동향(2022. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 557,
        "window_size": 3,
        "char_count": 46,
        "word_count": 11,
        "page_number": 1,
        "window_text": "Behaviour research and therapy, 48(5), 368-376.  | 시험보고서 |\n**1) 양극성 장애 또는 조현병과 같은 심각한 정신질환을 앓고 있는 자**\n| 1) 중대한 이상사례·의료기기 이상반응 보고 | 검정을 통해 양측 유의수준 0.05에서 통계적 우월성을 평가한다.  |\n**- 최소 30분 동안 지속되는 1~2회 세션으로 매주**\n**사용자의**\n**시험보고서**\n**시험보고서**\n\n**[표 끝]**\n\n- - 최초 등록 후 90일 동안 사용을 할 수 있으며,\n전략과 같은 주제에 대한 프로그램을 제공하며,\n\n최소 1개의 수업을 완료하는 것을 권장하며,\n\n<!-- PAGE_28 -->\n###### 표 5.  국외 우울장애 개선 디지털치료기기 허가 제품 및 관련 제품의 개발 동향(2022.  11.  기준)\n\n- - 22 -\nThrive\n\n(Waypoint)\n\n- -\nThrive는\n\n인지행동치료(CBT)의\n\n모범\n\n사례를\n\n바탕으로 구조화된 디지털 커리큘럼을 통해\n\n- - 행동 활성화, 인지 재구성 및 사회적 기술 훈련\n- - Thrive는 PHQ-9(Patient Health Questionnaire)\n생활 상황(예: 우울장애, 불안, 소진, 스트레스)\n\n- - 23 -\nSparkRx\n\n(Limbix)\n\n- - SparkRx는 13세에서 22세 사이의 우울장애\n환자에게\n\n인지행동치료를\n\n제공하는\n\n디지털\n\n치료제이며,\n\n미국\n\nFDA에\n\n아직\n\n승인되지는\n\n않았지만, COVID-19로 인해 정신 장애를 치료\n\n하는 디지털 건강 장치에 대한 FDA 비상\n\n프로그램을 수행하며, 활동 일정, 마음챙김,\n\n- - 프로그램은 5가지 레벨로 구성되어 있으며,\n치료 기반의 서비스가 제공되도록 설계되었으며,\n\n플랫폼에 접근할 수 있는 권한을 주어지며,\n\n**[표 시작]**\n\n**사용하며 전체 과정은 8주 동안 지원이 되며,**\n\n**[표 끝]**\n\n- - 24 -\n<!-- PAGE_31 -->\n###### 아.  디지털치료기기의 정의와 국내 가이드라인별 적용 기준\n\n<!-- PAGE_31 -->\n###### 1) 디지털치료기기 정의\n\n<!-- PAGE_31 -->\n###### 식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인\n\n<!-- PAGE_31 -->\n###### (민원인 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방,\n\n<!-- PAGE_31 -->\n###### 관리, 치료하기 위해 환자에게 근거 기반의 치료적 개입을 제공\n\n<!-- PAGE_31 -->\n###### 디지털치료기기는 「의료기기법」 제2조에 따른 사용 목적에\n\n<!-- PAGE_31 -->\n###### 해당해야 하며, <그림 1>과 같이 소프트웨어 의료기기로써 범용\n\n<!-- PAGE_31 -->\n###### 하드웨어에 설치되고, 질병을 예방, 관리 또는 치료하기 위한\n\n<!-- PAGE_31 -->\n###### 목적으로 환자에게 적용되어야 한다. ",
        "original_sentence": "국외 우울장애 개선 디지털치료기기 허가 제품 및 관련 제품의 개발 동향(2022. "
      }
    },
    {
      "chunk_id": "chunk_559",
      "text": "11. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 558,
        "window_size": 3,
        "char_count": 4,
        "word_count": 1,
        "page_number": 11,
        "window_text": "| 시험보고서 |\n**1) 양극성 장애 또는 조현병과 같은 심각한 정신질환을 앓고 있는 자**\n| 1) 중대한 이상사례·의료기기 이상반응 보고 | 검정을 통해 양측 유의수준 0.05에서 통계적 우월성을 평가한다.  |\n**- 최소 30분 동안 지속되는 1~2회 세션으로 매주**\n**사용자의**\n**시험보고서**\n**시험보고서**\n\n**[표 끝]**\n\n- - 최초 등록 후 90일 동안 사용을 할 수 있으며,\n전략과 같은 주제에 대한 프로그램을 제공하며,\n\n최소 1개의 수업을 완료하는 것을 권장하며,\n\n<!-- PAGE_28 -->\n###### 표 5.  국외 우울장애 개선 디지털치료기기 허가 제품 및 관련 제품의 개발 동향(2022.  11.  기준)\n\n- - 22 -\nThrive\n\n(Waypoint)\n\n- -\nThrive는\n\n인지행동치료(CBT)의\n\n모범\n\n사례를\n\n바탕으로 구조화된 디지털 커리큘럼을 통해\n\n- - 행동 활성화, 인지 재구성 및 사회적 기술 훈련\n- - Thrive는 PHQ-9(Patient Health Questionnaire)\n생활 상황(예: 우울장애, 불안, 소진, 스트레스)\n\n- - 23 -\nSparkRx\n\n(Limbix)\n\n- - SparkRx는 13세에서 22세 사이의 우울장애\n환자에게\n\n인지행동치료를\n\n제공하는\n\n디지털\n\n치료제이며,\n\n미국\n\nFDA에\n\n아직\n\n승인되지는\n\n않았지만, COVID-19로 인해 정신 장애를 치료\n\n하는 디지털 건강 장치에 대한 FDA 비상\n\n프로그램을 수행하며, 활동 일정, 마음챙김,\n\n- - 프로그램은 5가지 레벨로 구성되어 있으며,\n치료 기반의 서비스가 제공되도록 설계되었으며,\n\n플랫폼에 접근할 수 있는 권한을 주어지며,\n\n**[표 시작]**\n\n**사용하며 전체 과정은 8주 동안 지원이 되며,**\n\n**[표 끝]**\n\n- - 24 -\n<!-- PAGE_31 -->\n###### 아.  디지털치료기기의 정의와 국내 가이드라인별 적용 기준\n\n<!-- PAGE_31 -->\n###### 1) 디지털치료기기 정의\n\n<!-- PAGE_31 -->\n###### 식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인\n\n<!-- PAGE_31 -->\n###### (민원인 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방,\n\n<!-- PAGE_31 -->\n###### 관리, 치료하기 위해 환자에게 근거 기반의 치료적 개입을 제공\n\n<!-- PAGE_31 -->\n###### 디지털치료기기는 「의료기기법」 제2조에 따른 사용 목적에\n\n<!-- PAGE_31 -->\n###### 해당해야 하며, <그림 1>과 같이 소프트웨어 의료기기로써 범용\n\n<!-- PAGE_31 -->\n###### 하드웨어에 설치되고, 질병을 예방, 관리 또는 치료하기 위한\n\n<!-- PAGE_31 -->\n###### 목적으로 환자에게 적용되어야 한다.  또한, 치료 작용기전의\n\n<!-- PAGE_31 -->\n###### 과학적(임상적) 근거에 해당하는 자료가 있어야 한다. ",
        "original_sentence": "11. "
      }
    },
    {
      "chunk_id": "chunk_560",
      "text": "기준)\n\n- - 22 -\nThrive\n\n(Waypoint)\n\n- -\nThrive는\n\n인지행동치료(CBT)의\n\n모범\n\n사례를\n\n바탕으로 구조화된 디지털 커리큘럼을 통해\n\n- - 행동 활성화, 인지 재구성 및 사회적 기술 훈련\n- - Thrive는 PHQ-9(Patient Health Questionnaire)\n생활 상황(예: 우울장애, 불안, 소진, 스트레스)\n\n- - 23 -\nSparkRx\n\n(Limbix)\n\n- - SparkRx는 13세에서 22세 사이의 우울장애\n환자에게\n\n인지행동치료를\n\n제공하는\n\n디지털\n\n치료제이며,\n\n미국\n\nFDA에\n\n아직\n\n승인되지는\n\n않았지만, COVID-19로 인해 정신 장애를 치료\n\n하는 디지털 건강 장치에 대한 FDA 비상\n\n프로그램을 수행하며, 활동 일정, 마음챙김,\n\n- - 프로그램은 5가지 레벨로 구성되어 있으며,\n치료 기반의 서비스가 제공되도록 설계되었으며,\n\n플랫폼에 접근할 수 있는 권한을 주어지며,\n\n**[표 시작]**\n\n**사용하며 전체 과정은 8주 동안 지원이 되며,**\n\n**[표 끝]**\n\n- - 24 -\n<!-- PAGE_31 -->\n###### 아. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 559,
        "window_size": 3,
        "char_count": 569,
        "word_count": 118,
        "page_number": 31,
        "window_text": "|\n**- 최소 30분 동안 지속되는 1~2회 세션으로 매주**\n**사용자의**\n**시험보고서**\n**시험보고서**\n\n**[표 끝]**\n\n- - 최초 등록 후 90일 동안 사용을 할 수 있으며,\n전략과 같은 주제에 대한 프로그램을 제공하며,\n\n최소 1개의 수업을 완료하는 것을 권장하며,\n\n<!-- PAGE_28 -->\n###### 표 5.  국외 우울장애 개선 디지털치료기기 허가 제품 및 관련 제품의 개발 동향(2022.  11.  기준)\n\n- - 22 -\nThrive\n\n(Waypoint)\n\n- -\nThrive는\n\n인지행동치료(CBT)의\n\n모범\n\n사례를\n\n바탕으로 구조화된 디지털 커리큘럼을 통해\n\n- - 행동 활성화, 인지 재구성 및 사회적 기술 훈련\n- - Thrive는 PHQ-9(Patient Health Questionnaire)\n생활 상황(예: 우울장애, 불안, 소진, 스트레스)\n\n- - 23 -\nSparkRx\n\n(Limbix)\n\n- - SparkRx는 13세에서 22세 사이의 우울장애\n환자에게\n\n인지행동치료를\n\n제공하는\n\n디지털\n\n치료제이며,\n\n미국\n\nFDA에\n\n아직\n\n승인되지는\n\n않았지만, COVID-19로 인해 정신 장애를 치료\n\n하는 디지털 건강 장치에 대한 FDA 비상\n\n프로그램을 수행하며, 활동 일정, 마음챙김,\n\n- - 프로그램은 5가지 레벨로 구성되어 있으며,\n치료 기반의 서비스가 제공되도록 설계되었으며,\n\n플랫폼에 접근할 수 있는 권한을 주어지며,\n\n**[표 시작]**\n\n**사용하며 전체 과정은 8주 동안 지원이 되며,**\n\n**[표 끝]**\n\n- - 24 -\n<!-- PAGE_31 -->\n###### 아.  디지털치료기기의 정의와 국내 가이드라인별 적용 기준\n\n<!-- PAGE_31 -->\n###### 1) 디지털치료기기 정의\n\n<!-- PAGE_31 -->\n###### 식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인\n\n<!-- PAGE_31 -->\n###### (민원인 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방,\n\n<!-- PAGE_31 -->\n###### 관리, 치료하기 위해 환자에게 근거 기반의 치료적 개입을 제공\n\n<!-- PAGE_31 -->\n###### 디지털치료기기는 「의료기기법」 제2조에 따른 사용 목적에\n\n<!-- PAGE_31 -->\n###### 해당해야 하며, <그림 1>과 같이 소프트웨어 의료기기로써 범용\n\n<!-- PAGE_31 -->\n###### 하드웨어에 설치되고, 질병을 예방, 관리 또는 치료하기 위한\n\n<!-- PAGE_31 -->\n###### 목적으로 환자에게 적용되어야 한다.  또한, 치료 작용기전의\n\n<!-- PAGE_31 -->\n###### 과학적(임상적) 근거에 해당하는 자료가 있어야 한다.  여기서\n\n<!-- PAGE_31 -->\n###### 질병이란 국제질병분류코드(International Classification of Disease,\n\n<!-- PAGE_31 -->\n###### ICD)에 기반한 한국표준질병사인분류에 독립적으로 분류 가능한\n\n<!-- PAGE_31 -->\n###### 디지털 우울장애 인지행동치료(CBT)는 우울장애 인지행동치료\n\n<!-- PAGE_31 -->\n###### 기반의 콘텐츠를 범용 스마트폰이나 태블릿 PC에 설치되어\n\n<!-- PAGE_31 -->\n###### 제공하므로 소프트웨어 의료기기에 해당한다. ",
        "original_sentence": "기준)\n\n- - 22 -\nThrive\n\n(Waypoint)\n\n- -\nThrive는\n\n인지행동치료(CBT)의\n\n모범\n\n사례를\n\n바탕으로 구조화된 디지털 커리큘럼을 통해\n\n- - 행동 활성화, 인지 재구성 및 사회적 기술 훈련\n- - Thrive는 PHQ-9(Patient Health Questionnaire)\n생활 상황(예: 우울장애, 불안, 소진, 스트레스)\n\n- - 23 -\nSparkRx\n\n(Limbix)\n\n- - SparkRx는 13세에서 22세 사이의 우울장애\n환자에게\n\n인지행동치료를\n\n제공하는\n\n디지털\n\n치료제이며,\n\n미국\n\nFDA에\n\n아직\n\n승인되지는\n\n않았지만, COVID-19로 인해 정신 장애를 치료\n\n하는 디지털 건강 장치에 대한 FDA 비상\n\n프로그램을 수행하며, 활동 일정, 마음챙김,\n\n- - 프로그램은 5가지 레벨로 구성되어 있으며,\n치료 기반의 서비스가 제공되도록 설계되었으며,\n\n플랫폼에 접근할 수 있는 권한을 주어지며,\n\n**[표 시작]**\n\n**사용하며 전체 과정은 8주 동안 지원이 되며,**\n\n**[표 끝]**\n\n- - 24 -\n<!-- PAGE_31 -->\n###### 아. "
      }
    },
    {
      "chunk_id": "chunk_561",
      "text": "디지털치료기기의 정의와 국내 가이드라인별 적용 기준\n\n<!-- PAGE_31 -->\n###### 1) 디지털치료기기 정의\n\n<!-- PAGE_31 -->\n###### 식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인\n\n<!-- PAGE_31 -->\n###### (민원인 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방,\n\n<!-- PAGE_31 -->\n###### 관리, 치료하기 위해 환자에게 근거 기반의 치료적 개입을 제공\n\n<!-- PAGE_31 -->\n###### 디지털치료기기는 「의료기기법」 제2조에 따른 사용 목적에\n\n<!-- PAGE_31 -->\n###### 해당해야 하며, <그림 1>과 같이 소프트웨어 의료기기로써 범용\n\n<!-- PAGE_31 -->\n###### 하드웨어에 설치되고, 질병을 예방, 관리 또는 치료하기 위한\n\n<!-- PAGE_31 -->\n###### 목적으로 환자에게 적용되어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 560,
        "window_size": 3,
        "char_count": 466,
        "word_count": 88,
        "page_number": 31,
        "window_text": "국외 우울장애 개선 디지털치료기기 허가 제품 및 관련 제품의 개발 동향(2022.  11.  기준)\n\n- - 22 -\nThrive\n\n(Waypoint)\n\n- -\nThrive는\n\n인지행동치료(CBT)의\n\n모범\n\n사례를\n\n바탕으로 구조화된 디지털 커리큘럼을 통해\n\n- - 행동 활성화, 인지 재구성 및 사회적 기술 훈련\n- - Thrive는 PHQ-9(Patient Health Questionnaire)\n생활 상황(예: 우울장애, 불안, 소진, 스트레스)\n\n- - 23 -\nSparkRx\n\n(Limbix)\n\n- - SparkRx는 13세에서 22세 사이의 우울장애\n환자에게\n\n인지행동치료를\n\n제공하는\n\n디지털\n\n치료제이며,\n\n미국\n\nFDA에\n\n아직\n\n승인되지는\n\n않았지만, COVID-19로 인해 정신 장애를 치료\n\n하는 디지털 건강 장치에 대한 FDA 비상\n\n프로그램을 수행하며, 활동 일정, 마음챙김,\n\n- - 프로그램은 5가지 레벨로 구성되어 있으며,\n치료 기반의 서비스가 제공되도록 설계되었으며,\n\n플랫폼에 접근할 수 있는 권한을 주어지며,\n\n**[표 시작]**\n\n**사용하며 전체 과정은 8주 동안 지원이 되며,**\n\n**[표 끝]**\n\n- - 24 -\n<!-- PAGE_31 -->\n###### 아.  디지털치료기기의 정의와 국내 가이드라인별 적용 기준\n\n<!-- PAGE_31 -->\n###### 1) 디지털치료기기 정의\n\n<!-- PAGE_31 -->\n###### 식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인\n\n<!-- PAGE_31 -->\n###### (민원인 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방,\n\n<!-- PAGE_31 -->\n###### 관리, 치료하기 위해 환자에게 근거 기반의 치료적 개입을 제공\n\n<!-- PAGE_31 -->\n###### 디지털치료기기는 「의료기기법」 제2조에 따른 사용 목적에\n\n<!-- PAGE_31 -->\n###### 해당해야 하며, <그림 1>과 같이 소프트웨어 의료기기로써 범용\n\n<!-- PAGE_31 -->\n###### 하드웨어에 설치되고, 질병을 예방, 관리 또는 치료하기 위한\n\n<!-- PAGE_31 -->\n###### 목적으로 환자에게 적용되어야 한다.  또한, 치료 작용기전의\n\n<!-- PAGE_31 -->\n###### 과학적(임상적) 근거에 해당하는 자료가 있어야 한다.  여기서\n\n<!-- PAGE_31 -->\n###### 질병이란 국제질병분류코드(International Classification of Disease,\n\n<!-- PAGE_31 -->\n###### ICD)에 기반한 한국표준질병사인분류에 독립적으로 분류 가능한\n\n<!-- PAGE_31 -->\n###### 디지털 우울장애 인지행동치료(CBT)는 우울장애 인지행동치료\n\n<!-- PAGE_31 -->\n###### 기반의 콘텐츠를 범용 스마트폰이나 태블릿 PC에 설치되어\n\n<!-- PAGE_31 -->\n###### 제공하므로 소프트웨어 의료기기에 해당한다.  또한 한국표준\n\n<!-- PAGE_31 -->\n###### 질병사인분류에 따라 우울장애를 의사에게 진단받은 환자들을\n\n- - 25 -\n<!-- PAGE_32 -->\n###### 미국, 영국, 캐나다 등 많은 학회에서 개발한 임상진료지침을\n\n<!-- PAGE_32 -->\n###### 비롯하여, 국내 대한의학회의 한국형 우울장애 치료지침서에\n\n<!-- PAGE_32 -->\n###### 따르면, 우울장애의 비약물치료로써 인지행동치료(CBT)를 시행\n\n<!-- PAGE_32 -->\n###### 하기를 권고하고 있다. ",
        "original_sentence": "디지털치료기기의 정의와 국내 가이드라인별 적용 기준\n\n<!-- PAGE_31 -->\n###### 1) 디지털치료기기 정의\n\n<!-- PAGE_31 -->\n###### 식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인\n\n<!-- PAGE_31 -->\n###### (민원인 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방,\n\n<!-- PAGE_31 -->\n###### 관리, 치료하기 위해 환자에게 근거 기반의 치료적 개입을 제공\n\n<!-- PAGE_31 -->\n###### 디지털치료기기는 「의료기기법」 제2조에 따른 사용 목적에\n\n<!-- PAGE_31 -->\n###### 해당해야 하며, <그림 1>과 같이 소프트웨어 의료기기로써 범용\n\n<!-- PAGE_31 -->\n###### 하드웨어에 설치되고, 질병을 예방, 관리 또는 치료하기 위한\n\n<!-- PAGE_31 -->\n###### 목적으로 환자에게 적용되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_562",
      "text": "또한, 치료 작용기전의\n\n<!-- PAGE_31 -->\n###### 과학적(임상적) 근거에 해당하는 자료가 있어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 561,
        "window_size": 3,
        "char_count": 68,
        "word_count": 13,
        "page_number": 31,
        "window_text": "11.  기준)\n\n- - 22 -\nThrive\n\n(Waypoint)\n\n- -\nThrive는\n\n인지행동치료(CBT)의\n\n모범\n\n사례를\n\n바탕으로 구조화된 디지털 커리큘럼을 통해\n\n- - 행동 활성화, 인지 재구성 및 사회적 기술 훈련\n- - Thrive는 PHQ-9(Patient Health Questionnaire)\n생활 상황(예: 우울장애, 불안, 소진, 스트레스)\n\n- - 23 -\nSparkRx\n\n(Limbix)\n\n- - SparkRx는 13세에서 22세 사이의 우울장애\n환자에게\n\n인지행동치료를\n\n제공하는\n\n디지털\n\n치료제이며,\n\n미국\n\nFDA에\n\n아직\n\n승인되지는\n\n않았지만, COVID-19로 인해 정신 장애를 치료\n\n하는 디지털 건강 장치에 대한 FDA 비상\n\n프로그램을 수행하며, 활동 일정, 마음챙김,\n\n- - 프로그램은 5가지 레벨로 구성되어 있으며,\n치료 기반의 서비스가 제공되도록 설계되었으며,\n\n플랫폼에 접근할 수 있는 권한을 주어지며,\n\n**[표 시작]**\n\n**사용하며 전체 과정은 8주 동안 지원이 되며,**\n\n**[표 끝]**\n\n- - 24 -\n<!-- PAGE_31 -->\n###### 아.  디지털치료기기의 정의와 국내 가이드라인별 적용 기준\n\n<!-- PAGE_31 -->\n###### 1) 디지털치료기기 정의\n\n<!-- PAGE_31 -->\n###### 식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인\n\n<!-- PAGE_31 -->\n###### (민원인 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방,\n\n<!-- PAGE_31 -->\n###### 관리, 치료하기 위해 환자에게 근거 기반의 치료적 개입을 제공\n\n<!-- PAGE_31 -->\n###### 디지털치료기기는 「의료기기법」 제2조에 따른 사용 목적에\n\n<!-- PAGE_31 -->\n###### 해당해야 하며, <그림 1>과 같이 소프트웨어 의료기기로써 범용\n\n<!-- PAGE_31 -->\n###### 하드웨어에 설치되고, 질병을 예방, 관리 또는 치료하기 위한\n\n<!-- PAGE_31 -->\n###### 목적으로 환자에게 적용되어야 한다.  또한, 치료 작용기전의\n\n<!-- PAGE_31 -->\n###### 과학적(임상적) 근거에 해당하는 자료가 있어야 한다.  여기서\n\n<!-- PAGE_31 -->\n###### 질병이란 국제질병분류코드(International Classification of Disease,\n\n<!-- PAGE_31 -->\n###### ICD)에 기반한 한국표준질병사인분류에 독립적으로 분류 가능한\n\n<!-- PAGE_31 -->\n###### 디지털 우울장애 인지행동치료(CBT)는 우울장애 인지행동치료\n\n<!-- PAGE_31 -->\n###### 기반의 콘텐츠를 범용 스마트폰이나 태블릿 PC에 설치되어\n\n<!-- PAGE_31 -->\n###### 제공하므로 소프트웨어 의료기기에 해당한다.  또한 한국표준\n\n<!-- PAGE_31 -->\n###### 질병사인분류에 따라 우울장애를 의사에게 진단받은 환자들을\n\n- - 25 -\n<!-- PAGE_32 -->\n###### 미국, 영국, 캐나다 등 많은 학회에서 개발한 임상진료지침을\n\n<!-- PAGE_32 -->\n###### 비롯하여, 국내 대한의학회의 한국형 우울장애 치료지침서에\n\n<!-- PAGE_32 -->\n###### 따르면, 우울장애의 비약물치료로써 인지행동치료(CBT)를 시행\n\n<!-- PAGE_32 -->\n###### 하기를 권고하고 있다.  또한 다수의 동료검토 선행연구\n\n<!-- PAGE_32 -->\n###### (Peer-reviewed Journal)에서 임상시험을 통해 디지털 우울장애\n\n<!-- PAGE_32 -->\n###### 위와 같이 디지털 우울장애 인지행동치료(Digital CBT)는 디지털\n\n<!-- PAGE_32 -->\n###### 치료기기 대상 여부 판단기준 및 절차를 충족하므로 디지털\n\n[출처: 식품의약품안전처(2020.08), 디지털치료기기 허가·심사 가이드라인(민원인 안내서)]\n\n- - 26 -\n<!-- PAGE_33 -->\n###### 나) 의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)\n\n<!-- PAGE_33 -->\n###### 디지털치료기기는 식품의약품안전처‘의료기기의 사이버보안\n\n<!-- PAGE_33 -->\n###### 허가·심사 가이드라인(민원인 안내서)’에 근거하여 보안성\n\n<!-- PAGE_33 -->\n###### 영역은 가용성(Availability), 기밀성(Confidentiality), 무결성\n\n<!-- PAGE_33 -->\n###### 가용성은 데이터가 승인된 사용자에게 즉시 제공되어야 하며,\n\n<!-- PAGE_33 -->\n###### 필요한 때에 필요한 곳에서 필요한 형태로 존재되어야 함을\n\n<!-- PAGE_33 -->\n###### 의미한다. ",
        "original_sentence": "또한, 치료 작용기전의\n\n<!-- PAGE_31 -->\n###### 과학적(임상적) 근거에 해당하는 자료가 있어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_563",
      "text": "여기서\n\n<!-- PAGE_31 -->\n###### 질병이란 국제질병분류코드(International Classification of Disease,\n\n<!-- PAGE_31 -->\n###### ICD)에 기반한 한국표준질병사인분류에 독립적으로 분류 가능한\n\n<!-- PAGE_31 -->\n###### 디지털 우울장애 인지행동치료(CBT)는 우울장애 인지행동치료\n\n<!-- PAGE_31 -->\n###### 기반의 콘텐츠를 범용 스마트폰이나 태블릿 PC에 설치되어\n\n<!-- PAGE_31 -->\n###### 제공하므로 소프트웨어 의료기기에 해당한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 562,
        "window_size": 3,
        "char_count": 309,
        "word_count": 48,
        "page_number": 31,
        "window_text": "기준)\n\n- - 22 -\nThrive\n\n(Waypoint)\n\n- -\nThrive는\n\n인지행동치료(CBT)의\n\n모범\n\n사례를\n\n바탕으로 구조화된 디지털 커리큘럼을 통해\n\n- - 행동 활성화, 인지 재구성 및 사회적 기술 훈련\n- - Thrive는 PHQ-9(Patient Health Questionnaire)\n생활 상황(예: 우울장애, 불안, 소진, 스트레스)\n\n- - 23 -\nSparkRx\n\n(Limbix)\n\n- - SparkRx는 13세에서 22세 사이의 우울장애\n환자에게\n\n인지행동치료를\n\n제공하는\n\n디지털\n\n치료제이며,\n\n미국\n\nFDA에\n\n아직\n\n승인되지는\n\n않았지만, COVID-19로 인해 정신 장애를 치료\n\n하는 디지털 건강 장치에 대한 FDA 비상\n\n프로그램을 수행하며, 활동 일정, 마음챙김,\n\n- - 프로그램은 5가지 레벨로 구성되어 있으며,\n치료 기반의 서비스가 제공되도록 설계되었으며,\n\n플랫폼에 접근할 수 있는 권한을 주어지며,\n\n**[표 시작]**\n\n**사용하며 전체 과정은 8주 동안 지원이 되며,**\n\n**[표 끝]**\n\n- - 24 -\n<!-- PAGE_31 -->\n###### 아.  디지털치료기기의 정의와 국내 가이드라인별 적용 기준\n\n<!-- PAGE_31 -->\n###### 1) 디지털치료기기 정의\n\n<!-- PAGE_31 -->\n###### 식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인\n\n<!-- PAGE_31 -->\n###### (민원인 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방,\n\n<!-- PAGE_31 -->\n###### 관리, 치료하기 위해 환자에게 근거 기반의 치료적 개입을 제공\n\n<!-- PAGE_31 -->\n###### 디지털치료기기는 「의료기기법」 제2조에 따른 사용 목적에\n\n<!-- PAGE_31 -->\n###### 해당해야 하며, <그림 1>과 같이 소프트웨어 의료기기로써 범용\n\n<!-- PAGE_31 -->\n###### 하드웨어에 설치되고, 질병을 예방, 관리 또는 치료하기 위한\n\n<!-- PAGE_31 -->\n###### 목적으로 환자에게 적용되어야 한다.  또한, 치료 작용기전의\n\n<!-- PAGE_31 -->\n###### 과학적(임상적) 근거에 해당하는 자료가 있어야 한다.  여기서\n\n<!-- PAGE_31 -->\n###### 질병이란 국제질병분류코드(International Classification of Disease,\n\n<!-- PAGE_31 -->\n###### ICD)에 기반한 한국표준질병사인분류에 독립적으로 분류 가능한\n\n<!-- PAGE_31 -->\n###### 디지털 우울장애 인지행동치료(CBT)는 우울장애 인지행동치료\n\n<!-- PAGE_31 -->\n###### 기반의 콘텐츠를 범용 스마트폰이나 태블릿 PC에 설치되어\n\n<!-- PAGE_31 -->\n###### 제공하므로 소프트웨어 의료기기에 해당한다.  또한 한국표준\n\n<!-- PAGE_31 -->\n###### 질병사인분류에 따라 우울장애를 의사에게 진단받은 환자들을\n\n- - 25 -\n<!-- PAGE_32 -->\n###### 미국, 영국, 캐나다 등 많은 학회에서 개발한 임상진료지침을\n\n<!-- PAGE_32 -->\n###### 비롯하여, 국내 대한의학회의 한국형 우울장애 치료지침서에\n\n<!-- PAGE_32 -->\n###### 따르면, 우울장애의 비약물치료로써 인지행동치료(CBT)를 시행\n\n<!-- PAGE_32 -->\n###### 하기를 권고하고 있다.  또한 다수의 동료검토 선행연구\n\n<!-- PAGE_32 -->\n###### (Peer-reviewed Journal)에서 임상시험을 통해 디지털 우울장애\n\n<!-- PAGE_32 -->\n###### 위와 같이 디지털 우울장애 인지행동치료(Digital CBT)는 디지털\n\n<!-- PAGE_32 -->\n###### 치료기기 대상 여부 판단기준 및 절차를 충족하므로 디지털\n\n[출처: 식품의약품안전처(2020.08), 디지털치료기기 허가·심사 가이드라인(민원인 안내서)]\n\n- - 26 -\n<!-- PAGE_33 -->\n###### 나) 의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)\n\n<!-- PAGE_33 -->\n###### 디지털치료기기는 식품의약품안전처‘의료기기의 사이버보안\n\n<!-- PAGE_33 -->\n###### 허가·심사 가이드라인(민원인 안내서)’에 근거하여 보안성\n\n<!-- PAGE_33 -->\n###### 영역은 가용성(Availability), 기밀성(Confidentiality), 무결성\n\n<!-- PAGE_33 -->\n###### 가용성은 데이터가 승인된 사용자에게 즉시 제공되어야 하며,\n\n<!-- PAGE_33 -->\n###### 필요한 때에 필요한 곳에서 필요한 형태로 존재되어야 함을\n\n<!-- PAGE_33 -->\n###### 의미한다.  기밀성은 데이터가 허가되지 않은 사람에게 공개\n\n<!-- PAGE_33 -->\n###### 되거나, 허가되지 않은 용도로 사용되지 않아야 함을 의미하며,\n\n<!-- PAGE_33 -->\n###### 무결성은 데이터가 허가되지 않은 방법으로 변환되거나 파괴\n\n<!-- PAGE_33 -->\n###### 되지 않아야 함을 의미한다. ",
        "original_sentence": "여기서\n\n<!-- PAGE_31 -->\n###### 질병이란 국제질병분류코드(International Classification of Disease,\n\n<!-- PAGE_31 -->\n###### ICD)에 기반한 한국표준질병사인분류에 독립적으로 분류 가능한\n\n<!-- PAGE_31 -->\n###### 디지털 우울장애 인지행동치료(CBT)는 우울장애 인지행동치료\n\n<!-- PAGE_31 -->\n###### 기반의 콘텐츠를 범용 스마트폰이나 태블릿 PC에 설치되어\n\n<!-- PAGE_31 -->\n###### 제공하므로 소프트웨어 의료기기에 해당한다. "
      }
    },
    {
      "chunk_id": "chunk_564",
      "text": "또한 한국표준\n\n<!-- PAGE_31 -->\n###### 질병사인분류에 따라 우울장애를 의사에게 진단받은 환자들을\n\n- - 25 -\n<!-- PAGE_32 -->\n###### 미국, 영국, 캐나다 등 많은 학회에서 개발한 임상진료지침을\n\n<!-- PAGE_32 -->\n###### 비롯하여, 국내 대한의학회의 한국형 우울장애 치료지침서에\n\n<!-- PAGE_32 -->\n###### 따르면, 우울장애의 비약물치료로써 인지행동치료(CBT)를 시행\n\n<!-- PAGE_32 -->\n###### 하기를 권고하고 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 563,
        "window_size": 3,
        "char_count": 288,
        "word_count": 54,
        "page_number": 31,
        "window_text": "디지털치료기기의 정의와 국내 가이드라인별 적용 기준\n\n<!-- PAGE_31 -->\n###### 1) 디지털치료기기 정의\n\n<!-- PAGE_31 -->\n###### 식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인\n\n<!-- PAGE_31 -->\n###### (민원인 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방,\n\n<!-- PAGE_31 -->\n###### 관리, 치료하기 위해 환자에게 근거 기반의 치료적 개입을 제공\n\n<!-- PAGE_31 -->\n###### 디지털치료기기는 「의료기기법」 제2조에 따른 사용 목적에\n\n<!-- PAGE_31 -->\n###### 해당해야 하며, <그림 1>과 같이 소프트웨어 의료기기로써 범용\n\n<!-- PAGE_31 -->\n###### 하드웨어에 설치되고, 질병을 예방, 관리 또는 치료하기 위한\n\n<!-- PAGE_31 -->\n###### 목적으로 환자에게 적용되어야 한다.  또한, 치료 작용기전의\n\n<!-- PAGE_31 -->\n###### 과학적(임상적) 근거에 해당하는 자료가 있어야 한다.  여기서\n\n<!-- PAGE_31 -->\n###### 질병이란 국제질병분류코드(International Classification of Disease,\n\n<!-- PAGE_31 -->\n###### ICD)에 기반한 한국표준질병사인분류에 독립적으로 분류 가능한\n\n<!-- PAGE_31 -->\n###### 디지털 우울장애 인지행동치료(CBT)는 우울장애 인지행동치료\n\n<!-- PAGE_31 -->\n###### 기반의 콘텐츠를 범용 스마트폰이나 태블릿 PC에 설치되어\n\n<!-- PAGE_31 -->\n###### 제공하므로 소프트웨어 의료기기에 해당한다.  또한 한국표준\n\n<!-- PAGE_31 -->\n###### 질병사인분류에 따라 우울장애를 의사에게 진단받은 환자들을\n\n- - 25 -\n<!-- PAGE_32 -->\n###### 미국, 영국, 캐나다 등 많은 학회에서 개발한 임상진료지침을\n\n<!-- PAGE_32 -->\n###### 비롯하여, 국내 대한의학회의 한국형 우울장애 치료지침서에\n\n<!-- PAGE_32 -->\n###### 따르면, 우울장애의 비약물치료로써 인지행동치료(CBT)를 시행\n\n<!-- PAGE_32 -->\n###### 하기를 권고하고 있다.  또한 다수의 동료검토 선행연구\n\n<!-- PAGE_32 -->\n###### (Peer-reviewed Journal)에서 임상시험을 통해 디지털 우울장애\n\n<!-- PAGE_32 -->\n###### 위와 같이 디지털 우울장애 인지행동치료(Digital CBT)는 디지털\n\n<!-- PAGE_32 -->\n###### 치료기기 대상 여부 판단기준 및 절차를 충족하므로 디지털\n\n[출처: 식품의약품안전처(2020.08), 디지털치료기기 허가·심사 가이드라인(민원인 안내서)]\n\n- - 26 -\n<!-- PAGE_33 -->\n###### 나) 의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)\n\n<!-- PAGE_33 -->\n###### 디지털치료기기는 식품의약품안전처‘의료기기의 사이버보안\n\n<!-- PAGE_33 -->\n###### 허가·심사 가이드라인(민원인 안내서)’에 근거하여 보안성\n\n<!-- PAGE_33 -->\n###### 영역은 가용성(Availability), 기밀성(Confidentiality), 무결성\n\n<!-- PAGE_33 -->\n###### 가용성은 데이터가 승인된 사용자에게 즉시 제공되어야 하며,\n\n<!-- PAGE_33 -->\n###### 필요한 때에 필요한 곳에서 필요한 형태로 존재되어야 함을\n\n<!-- PAGE_33 -->\n###### 의미한다.  기밀성은 데이터가 허가되지 않은 사람에게 공개\n\n<!-- PAGE_33 -->\n###### 되거나, 허가되지 않은 용도로 사용되지 않아야 함을 의미하며,\n\n<!-- PAGE_33 -->\n###### 무결성은 데이터가 허가되지 않은 방법으로 변환되거나 파괴\n\n<!-- PAGE_33 -->\n###### 되지 않아야 함을 의미한다.  유·무선 통신이 가능하거나 통신\n\n<!-- PAGE_33 -->\n###### 경로가 존재하는 의료기기는 정보의 위변조, 오작동 또는 의료\n\n<!-- PAGE_33 -->\n###### 기기에 승인되지 않은 접근 등을 방지하기 위한 대책을 마련\n\n<!-- PAGE_33 -->\n###### 사이버보안 침해로 인한 위해도는 의료기기의 잠재적 결함\n\n<!-- PAGE_33 -->\n###### 으로 인해 사용자에게 발생할 수 있는 위해(harm)의 정도, 의료\n\n<!-- PAGE_33 -->\n###### 기기의 통신방법 및 사용환경을 종합적으로 고려하여 ‘상’,\n\n<!-- PAGE_33 -->\n###### ‘중’, ‘하’로 결정되고, 그에 따른 사이버보안 요구사항을\n\n<!-- PAGE_33 -->\n###### 적용한다. ",
        "original_sentence": "또한 한국표준\n\n<!-- PAGE_31 -->\n###### 질병사인분류에 따라 우울장애를 의사에게 진단받은 환자들을\n\n- - 25 -\n<!-- PAGE_32 -->\n###### 미국, 영국, 캐나다 등 많은 학회에서 개발한 임상진료지침을\n\n<!-- PAGE_32 -->\n###### 비롯하여, 국내 대한의학회의 한국형 우울장애 치료지침서에\n\n<!-- PAGE_32 -->\n###### 따르면, 우울장애의 비약물치료로써 인지행동치료(CBT)를 시행\n\n<!-- PAGE_32 -->\n###### 하기를 권고하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_565",
      "text": "또한 다수의 동료검토 선행연구\n\n<!-- PAGE_32 -->\n###### (Peer-reviewed Journal)에서 임상시험을 통해 디지털 우울장애\n\n<!-- PAGE_32 -->\n###### 위와 같이 디지털 우울장애 인지행동치료(Digital CBT)는 디지털\n\n<!-- PAGE_32 -->\n###### 치료기기 대상 여부 판단기준 및 절차를 충족하므로 디지털\n\n[출처: 식품의약품안전처(2020.08), 디지털치료기기 허가·심사 가이드라인(민원인 안내서)]\n\n- - 26 -\n<!-- PAGE_33 -->\n###### 나) 의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)\n\n<!-- PAGE_33 -->\n###### 디지털치료기기는 식품의약품안전처‘의료기기의 사이버보안\n\n<!-- PAGE_33 -->\n###### 허가·심사 가이드라인(민원인 안내서)’에 근거하여 보안성\n\n<!-- PAGE_33 -->\n###### 영역은 가용성(Availability), 기밀성(Confidentiality), 무결성\n\n<!-- PAGE_33 -->\n###### 가용성은 데이터가 승인된 사용자에게 즉시 제공되어야 하며,\n\n<!-- PAGE_33 -->\n###### 필요한 때에 필요한 곳에서 필요한 형태로 존재되어야 함을\n\n<!-- PAGE_33 -->\n###### 의미한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 564,
        "window_size": 3,
        "char_count": 665,
        "word_count": 109,
        "page_number": 32,
        "window_text": "또한, 치료 작용기전의\n\n<!-- PAGE_31 -->\n###### 과학적(임상적) 근거에 해당하는 자료가 있어야 한다.  여기서\n\n<!-- PAGE_31 -->\n###### 질병이란 국제질병분류코드(International Classification of Disease,\n\n<!-- PAGE_31 -->\n###### ICD)에 기반한 한국표준질병사인분류에 독립적으로 분류 가능한\n\n<!-- PAGE_31 -->\n###### 디지털 우울장애 인지행동치료(CBT)는 우울장애 인지행동치료\n\n<!-- PAGE_31 -->\n###### 기반의 콘텐츠를 범용 스마트폰이나 태블릿 PC에 설치되어\n\n<!-- PAGE_31 -->\n###### 제공하므로 소프트웨어 의료기기에 해당한다.  또한 한국표준\n\n<!-- PAGE_31 -->\n###### 질병사인분류에 따라 우울장애를 의사에게 진단받은 환자들을\n\n- - 25 -\n<!-- PAGE_32 -->\n###### 미국, 영국, 캐나다 등 많은 학회에서 개발한 임상진료지침을\n\n<!-- PAGE_32 -->\n###### 비롯하여, 국내 대한의학회의 한국형 우울장애 치료지침서에\n\n<!-- PAGE_32 -->\n###### 따르면, 우울장애의 비약물치료로써 인지행동치료(CBT)를 시행\n\n<!-- PAGE_32 -->\n###### 하기를 권고하고 있다.  또한 다수의 동료검토 선행연구\n\n<!-- PAGE_32 -->\n###### (Peer-reviewed Journal)에서 임상시험을 통해 디지털 우울장애\n\n<!-- PAGE_32 -->\n###### 위와 같이 디지털 우울장애 인지행동치료(Digital CBT)는 디지털\n\n<!-- PAGE_32 -->\n###### 치료기기 대상 여부 판단기준 및 절차를 충족하므로 디지털\n\n[출처: 식품의약품안전처(2020.08), 디지털치료기기 허가·심사 가이드라인(민원인 안내서)]\n\n- - 26 -\n<!-- PAGE_33 -->\n###### 나) 의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)\n\n<!-- PAGE_33 -->\n###### 디지털치료기기는 식품의약품안전처‘의료기기의 사이버보안\n\n<!-- PAGE_33 -->\n###### 허가·심사 가이드라인(민원인 안내서)’에 근거하여 보안성\n\n<!-- PAGE_33 -->\n###### 영역은 가용성(Availability), 기밀성(Confidentiality), 무결성\n\n<!-- PAGE_33 -->\n###### 가용성은 데이터가 승인된 사용자에게 즉시 제공되어야 하며,\n\n<!-- PAGE_33 -->\n###### 필요한 때에 필요한 곳에서 필요한 형태로 존재되어야 함을\n\n<!-- PAGE_33 -->\n###### 의미한다.  기밀성은 데이터가 허가되지 않은 사람에게 공개\n\n<!-- PAGE_33 -->\n###### 되거나, 허가되지 않은 용도로 사용되지 않아야 함을 의미하며,\n\n<!-- PAGE_33 -->\n###### 무결성은 데이터가 허가되지 않은 방법으로 변환되거나 파괴\n\n<!-- PAGE_33 -->\n###### 되지 않아야 함을 의미한다.  유·무선 통신이 가능하거나 통신\n\n<!-- PAGE_33 -->\n###### 경로가 존재하는 의료기기는 정보의 위변조, 오작동 또는 의료\n\n<!-- PAGE_33 -->\n###### 기기에 승인되지 않은 접근 등을 방지하기 위한 대책을 마련\n\n<!-- PAGE_33 -->\n###### 사이버보안 침해로 인한 위해도는 의료기기의 잠재적 결함\n\n<!-- PAGE_33 -->\n###### 으로 인해 사용자에게 발생할 수 있는 위해(harm)의 정도, 의료\n\n<!-- PAGE_33 -->\n###### 기기의 통신방법 및 사용환경을 종합적으로 고려하여 ‘상’,\n\n<!-- PAGE_33 -->\n###### ‘중’, ‘하’로 결정되고, 그에 따른 사이버보안 요구사항을\n\n<!-- PAGE_33 -->\n###### 적용한다.  일반적으로 디지털 치료기기는 ‘치료’를 목적으로\n\n<!-- PAGE_33 -->\n###### 하는 2등급 이상의 의료기기로 품목 분류되므로 사이버보안\n\n- - 27 -\n<!-- PAGE_34 -->\n###### 다) 의료기기의 소프트웨어 허가·심사 가이드라인(민원인 안내서)\n\n<!-- PAGE_34 -->\n###### 소프트웨어 의료기기도 일반 의료기기와 마찬가지로 제조 및\n\n<!-- PAGE_34 -->\n###### 품질관리체계의 기준과 위험관리 프로세스가 조화를 이루는\n\n<!-- PAGE_34 -->\n###### 식품의약품안전처‘의료기기 소프트웨어 허가·심사 가이드라인\n\n<!-- PAGE_34 -->\n###### (민원인 안내서)’를 기준으로 디지털치료기기의 위험성 관리\n\n<!-- PAGE_34 -->\n###### 프로세스는 의료기기에서 발생하는 위험분석(risk analysis), 위험\n\n<!-- PAGE_34 -->\n###### 평가(risk evaluation), 위험통제(risk control), 잔여 위험 허용평가\n\n<!-- PAGE_34 -->\n###### (evaluation of overall residual risk acceptability), 위험관리 보고서\n\n<!-- PAGE_34 -->\n###### (risk management report), 생산 및 생산 후 정보(production\n\n<!-- PAGE_34 -->\n###### 의료기기 소프트웨어 안전성 등급은 고장 또는 잠재적 결함으로\n\n<!-- PAGE_34 -->\n###### 인해 환자나 사용자에게 미치는 위해의 영향에 따라 분류한다.\n\n",
        "original_sentence": "또한 다수의 동료검토 선행연구\n\n<!-- PAGE_32 -->\n###### (Peer-reviewed Journal)에서 임상시험을 통해 디지털 우울장애\n\n<!-- PAGE_32 -->\n###### 위와 같이 디지털 우울장애 인지행동치료(Digital CBT)는 디지털\n\n<!-- PAGE_32 -->\n###### 치료기기 대상 여부 판단기준 및 절차를 충족하므로 디지털\n\n[출처: 식품의약품안전처(2020.08), 디지털치료기기 허가·심사 가이드라인(민원인 안내서)]\n\n- - 26 -\n<!-- PAGE_33 -->\n###### 나) 의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)\n\n<!-- PAGE_33 -->\n###### 디지털치료기기는 식품의약품안전처‘의료기기의 사이버보안\n\n<!-- PAGE_33 -->\n###### 허가·심사 가이드라인(민원인 안내서)’에 근거하여 보안성\n\n<!-- PAGE_33 -->\n###### 영역은 가용성(Availability), 기밀성(Confidentiality), 무결성\n\n<!-- PAGE_33 -->\n###### 가용성은 데이터가 승인된 사용자에게 즉시 제공되어야 하며,\n\n<!-- PAGE_33 -->\n###### 필요한 때에 필요한 곳에서 필요한 형태로 존재되어야 함을\n\n<!-- PAGE_33 -->\n###### 의미한다. "
      }
    },
    {
      "chunk_id": "chunk_566",
      "text": "기밀성은 데이터가 허가되지 않은 사람에게 공개\n\n<!-- PAGE_33 -->\n###### 되거나, 허가되지 않은 용도로 사용되지 않아야 함을 의미하며,\n\n<!-- PAGE_33 -->\n###### 무결성은 데이터가 허가되지 않은 방법으로 변환되거나 파괴\n\n<!-- PAGE_33 -->\n###### 되지 않아야 함을 의미한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 565,
        "window_size": 3,
        "char_count": 184,
        "word_count": 37,
        "page_number": 33,
        "window_text": "여기서\n\n<!-- PAGE_31 -->\n###### 질병이란 국제질병분류코드(International Classification of Disease,\n\n<!-- PAGE_31 -->\n###### ICD)에 기반한 한국표준질병사인분류에 독립적으로 분류 가능한\n\n<!-- PAGE_31 -->\n###### 디지털 우울장애 인지행동치료(CBT)는 우울장애 인지행동치료\n\n<!-- PAGE_31 -->\n###### 기반의 콘텐츠를 범용 스마트폰이나 태블릿 PC에 설치되어\n\n<!-- PAGE_31 -->\n###### 제공하므로 소프트웨어 의료기기에 해당한다.  또한 한국표준\n\n<!-- PAGE_31 -->\n###### 질병사인분류에 따라 우울장애를 의사에게 진단받은 환자들을\n\n- - 25 -\n<!-- PAGE_32 -->\n###### 미국, 영국, 캐나다 등 많은 학회에서 개발한 임상진료지침을\n\n<!-- PAGE_32 -->\n###### 비롯하여, 국내 대한의학회의 한국형 우울장애 치료지침서에\n\n<!-- PAGE_32 -->\n###### 따르면, 우울장애의 비약물치료로써 인지행동치료(CBT)를 시행\n\n<!-- PAGE_32 -->\n###### 하기를 권고하고 있다.  또한 다수의 동료검토 선행연구\n\n<!-- PAGE_32 -->\n###### (Peer-reviewed Journal)에서 임상시험을 통해 디지털 우울장애\n\n<!-- PAGE_32 -->\n###### 위와 같이 디지털 우울장애 인지행동치료(Digital CBT)는 디지털\n\n<!-- PAGE_32 -->\n###### 치료기기 대상 여부 판단기준 및 절차를 충족하므로 디지털\n\n[출처: 식품의약품안전처(2020.08), 디지털치료기기 허가·심사 가이드라인(민원인 안내서)]\n\n- - 26 -\n<!-- PAGE_33 -->\n###### 나) 의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)\n\n<!-- PAGE_33 -->\n###### 디지털치료기기는 식품의약품안전처‘의료기기의 사이버보안\n\n<!-- PAGE_33 -->\n###### 허가·심사 가이드라인(민원인 안내서)’에 근거하여 보안성\n\n<!-- PAGE_33 -->\n###### 영역은 가용성(Availability), 기밀성(Confidentiality), 무결성\n\n<!-- PAGE_33 -->\n###### 가용성은 데이터가 승인된 사용자에게 즉시 제공되어야 하며,\n\n<!-- PAGE_33 -->\n###### 필요한 때에 필요한 곳에서 필요한 형태로 존재되어야 함을\n\n<!-- PAGE_33 -->\n###### 의미한다.  기밀성은 데이터가 허가되지 않은 사람에게 공개\n\n<!-- PAGE_33 -->\n###### 되거나, 허가되지 않은 용도로 사용되지 않아야 함을 의미하며,\n\n<!-- PAGE_33 -->\n###### 무결성은 데이터가 허가되지 않은 방법으로 변환되거나 파괴\n\n<!-- PAGE_33 -->\n###### 되지 않아야 함을 의미한다.  유·무선 통신이 가능하거나 통신\n\n<!-- PAGE_33 -->\n###### 경로가 존재하는 의료기기는 정보의 위변조, 오작동 또는 의료\n\n<!-- PAGE_33 -->\n###### 기기에 승인되지 않은 접근 등을 방지하기 위한 대책을 마련\n\n<!-- PAGE_33 -->\n###### 사이버보안 침해로 인한 위해도는 의료기기의 잠재적 결함\n\n<!-- PAGE_33 -->\n###### 으로 인해 사용자에게 발생할 수 있는 위해(harm)의 정도, 의료\n\n<!-- PAGE_33 -->\n###### 기기의 통신방법 및 사용환경을 종합적으로 고려하여 ‘상’,\n\n<!-- PAGE_33 -->\n###### ‘중’, ‘하’로 결정되고, 그에 따른 사이버보안 요구사항을\n\n<!-- PAGE_33 -->\n###### 적용한다.  일반적으로 디지털 치료기기는 ‘치료’를 목적으로\n\n<!-- PAGE_33 -->\n###### 하는 2등급 이상의 의료기기로 품목 분류되므로 사이버보안\n\n- - 27 -\n<!-- PAGE_34 -->\n###### 다) 의료기기의 소프트웨어 허가·심사 가이드라인(민원인 안내서)\n\n<!-- PAGE_34 -->\n###### 소프트웨어 의료기기도 일반 의료기기와 마찬가지로 제조 및\n\n<!-- PAGE_34 -->\n###### 품질관리체계의 기준과 위험관리 프로세스가 조화를 이루는\n\n<!-- PAGE_34 -->\n###### 식품의약품안전처‘의료기기 소프트웨어 허가·심사 가이드라인\n\n<!-- PAGE_34 -->\n###### (민원인 안내서)’를 기준으로 디지털치료기기의 위험성 관리\n\n<!-- PAGE_34 -->\n###### 프로세스는 의료기기에서 발생하는 위험분석(risk analysis), 위험\n\n<!-- PAGE_34 -->\n###### 평가(risk evaluation), 위험통제(risk control), 잔여 위험 허용평가\n\n<!-- PAGE_34 -->\n###### (evaluation of overall residual risk acceptability), 위험관리 보고서\n\n<!-- PAGE_34 -->\n###### (risk management report), 생산 및 생산 후 정보(production\n\n<!-- PAGE_34 -->\n###### 의료기기 소프트웨어 안전성 등급은 고장 또는 잠재적 결함으로\n\n<!-- PAGE_34 -->\n###### 인해 환자나 사용자에게 미치는 위해의 영향에 따라 분류한다.\n\n <!-- PAGE_34 -->\n###### 의료기기 소프트웨어 사용으로 건강상의 상해 또는 손상이 없는\n\n- - 28 -\n<!-- PAGE_35 -->\n###### 경우 A등급, 심각하지 않은 상해의 가능성 있으면 B등급, 심각한\n\n<!-- PAGE_35 -->\n###### 상해 또는 사망의 가능성이 있는 경우 C등급으로 구분한다.\n\n",
        "original_sentence": "기밀성은 데이터가 허가되지 않은 사람에게 공개\n\n<!-- PAGE_33 -->\n###### 되거나, 허가되지 않은 용도로 사용되지 않아야 함을 의미하며,\n\n<!-- PAGE_33 -->\n###### 무결성은 데이터가 허가되지 않은 방법으로 변환되거나 파괴\n\n<!-- PAGE_33 -->\n###### 되지 않아야 함을 의미한다. "
      }
    },
    {
      "chunk_id": "chunk_567",
      "text": "유·무선 통신이 가능하거나 통신\n\n<!-- PAGE_33 -->\n###### 경로가 존재하는 의료기기는 정보의 위변조, 오작동 또는 의료\n\n<!-- PAGE_33 -->\n###### 기기에 승인되지 않은 접근 등을 방지하기 위한 대책을 마련\n\n<!-- PAGE_33 -->\n###### 사이버보안 침해로 인한 위해도는 의료기기의 잠재적 결함\n\n<!-- PAGE_33 -->\n###### 으로 인해 사용자에게 발생할 수 있는 위해(harm)의 정도, 의료\n\n<!-- PAGE_33 -->\n###### 기기의 통신방법 및 사용환경을 종합적으로 고려하여 ‘상’,\n\n<!-- PAGE_33 -->\n###### ‘중’, ‘하’로 결정되고, 그에 따른 사이버보안 요구사항을\n\n<!-- PAGE_33 -->\n###### 적용한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 566,
        "window_size": 3,
        "char_count": 402,
        "word_count": 80,
        "page_number": 33,
        "window_text": "또한 한국표준\n\n<!-- PAGE_31 -->\n###### 질병사인분류에 따라 우울장애를 의사에게 진단받은 환자들을\n\n- - 25 -\n<!-- PAGE_32 -->\n###### 미국, 영국, 캐나다 등 많은 학회에서 개발한 임상진료지침을\n\n<!-- PAGE_32 -->\n###### 비롯하여, 국내 대한의학회의 한국형 우울장애 치료지침서에\n\n<!-- PAGE_32 -->\n###### 따르면, 우울장애의 비약물치료로써 인지행동치료(CBT)를 시행\n\n<!-- PAGE_32 -->\n###### 하기를 권고하고 있다.  또한 다수의 동료검토 선행연구\n\n<!-- PAGE_32 -->\n###### (Peer-reviewed Journal)에서 임상시험을 통해 디지털 우울장애\n\n<!-- PAGE_32 -->\n###### 위와 같이 디지털 우울장애 인지행동치료(Digital CBT)는 디지털\n\n<!-- PAGE_32 -->\n###### 치료기기 대상 여부 판단기준 및 절차를 충족하므로 디지털\n\n[출처: 식품의약품안전처(2020.08), 디지털치료기기 허가·심사 가이드라인(민원인 안내서)]\n\n- - 26 -\n<!-- PAGE_33 -->\n###### 나) 의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)\n\n<!-- PAGE_33 -->\n###### 디지털치료기기는 식품의약품안전처‘의료기기의 사이버보안\n\n<!-- PAGE_33 -->\n###### 허가·심사 가이드라인(민원인 안내서)’에 근거하여 보안성\n\n<!-- PAGE_33 -->\n###### 영역은 가용성(Availability), 기밀성(Confidentiality), 무결성\n\n<!-- PAGE_33 -->\n###### 가용성은 데이터가 승인된 사용자에게 즉시 제공되어야 하며,\n\n<!-- PAGE_33 -->\n###### 필요한 때에 필요한 곳에서 필요한 형태로 존재되어야 함을\n\n<!-- PAGE_33 -->\n###### 의미한다.  기밀성은 데이터가 허가되지 않은 사람에게 공개\n\n<!-- PAGE_33 -->\n###### 되거나, 허가되지 않은 용도로 사용되지 않아야 함을 의미하며,\n\n<!-- PAGE_33 -->\n###### 무결성은 데이터가 허가되지 않은 방법으로 변환되거나 파괴\n\n<!-- PAGE_33 -->\n###### 되지 않아야 함을 의미한다.  유·무선 통신이 가능하거나 통신\n\n<!-- PAGE_33 -->\n###### 경로가 존재하는 의료기기는 정보의 위변조, 오작동 또는 의료\n\n<!-- PAGE_33 -->\n###### 기기에 승인되지 않은 접근 등을 방지하기 위한 대책을 마련\n\n<!-- PAGE_33 -->\n###### 사이버보안 침해로 인한 위해도는 의료기기의 잠재적 결함\n\n<!-- PAGE_33 -->\n###### 으로 인해 사용자에게 발생할 수 있는 위해(harm)의 정도, 의료\n\n<!-- PAGE_33 -->\n###### 기기의 통신방법 및 사용환경을 종합적으로 고려하여 ‘상’,\n\n<!-- PAGE_33 -->\n###### ‘중’, ‘하’로 결정되고, 그에 따른 사이버보안 요구사항을\n\n<!-- PAGE_33 -->\n###### 적용한다.  일반적으로 디지털 치료기기는 ‘치료’를 목적으로\n\n<!-- PAGE_33 -->\n###### 하는 2등급 이상의 의료기기로 품목 분류되므로 사이버보안\n\n- - 27 -\n<!-- PAGE_34 -->\n###### 다) 의료기기의 소프트웨어 허가·심사 가이드라인(민원인 안내서)\n\n<!-- PAGE_34 -->\n###### 소프트웨어 의료기기도 일반 의료기기와 마찬가지로 제조 및\n\n<!-- PAGE_34 -->\n###### 품질관리체계의 기준과 위험관리 프로세스가 조화를 이루는\n\n<!-- PAGE_34 -->\n###### 식품의약품안전처‘의료기기 소프트웨어 허가·심사 가이드라인\n\n<!-- PAGE_34 -->\n###### (민원인 안내서)’를 기준으로 디지털치료기기의 위험성 관리\n\n<!-- PAGE_34 -->\n###### 프로세스는 의료기기에서 발생하는 위험분석(risk analysis), 위험\n\n<!-- PAGE_34 -->\n###### 평가(risk evaluation), 위험통제(risk control), 잔여 위험 허용평가\n\n<!-- PAGE_34 -->\n###### (evaluation of overall residual risk acceptability), 위험관리 보고서\n\n<!-- PAGE_34 -->\n###### (risk management report), 생산 및 생산 후 정보(production\n\n<!-- PAGE_34 -->\n###### 의료기기 소프트웨어 안전성 등급은 고장 또는 잠재적 결함으로\n\n<!-- PAGE_34 -->\n###### 인해 환자나 사용자에게 미치는 위해의 영향에 따라 분류한다.\n\n <!-- PAGE_34 -->\n###### 의료기기 소프트웨어 사용으로 건강상의 상해 또는 손상이 없는\n\n- - 28 -\n<!-- PAGE_35 -->\n###### 경우 A등급, 심각하지 않은 상해의 가능성 있으면 B등급, 심각한\n\n<!-- PAGE_35 -->\n###### 상해 또는 사망의 가능성이 있는 경우 C등급으로 구분한다.\n\n <!-- PAGE_35 -->\n###### 의료기기 소프트웨어는 안전성 등급이 결정될 때까지 초기에는\n\n<!-- PAGE_35 -->\n###### C등급 요구사항이 적용되며, 소프트웨어 시스템의 실패가 위험한\n\n<!-- PAGE_35 -->\n###### 라) 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인(민원인 안내서)\n\n<!-- PAGE_35 -->\n###### 디지털치료기기는 실사용증거(Real World Evidence, RWE)를\n\n<!-- PAGE_35 -->\n###### 사용하여 의료기기의 사전 및 사후와 관련된 안전성 및 유효성\n\n<!-- PAGE_35 -->\n###### 입증 근거로 제시할 수 있으며, 이에 따른 기간 및 비용을\n\n<!-- PAGE_35 -->\n###### 실사용증거 수집은 데이터의 타당성 및 신뢰성 확보를 위해\n\n1) 실사용데이터(RWD)는 기존의 중재적 방법에 의한 임상시험으로부터 수집되지 않은 다양한 유형의 의료데이터에 대한 포괄적인\n\n용어이다. ",
        "original_sentence": "유·무선 통신이 가능하거나 통신\n\n<!-- PAGE_33 -->\n###### 경로가 존재하는 의료기기는 정보의 위변조, 오작동 또는 의료\n\n<!-- PAGE_33 -->\n###### 기기에 승인되지 않은 접근 등을 방지하기 위한 대책을 마련\n\n<!-- PAGE_33 -->\n###### 사이버보안 침해로 인한 위해도는 의료기기의 잠재적 결함\n\n<!-- PAGE_33 -->\n###### 으로 인해 사용자에게 발생할 수 있는 위해(harm)의 정도, 의료\n\n<!-- PAGE_33 -->\n###### 기기의 통신방법 및 사용환경을 종합적으로 고려하여 ‘상’,\n\n<!-- PAGE_33 -->\n###### ‘중’, ‘하’로 결정되고, 그에 따른 사이버보안 요구사항을\n\n<!-- PAGE_33 -->\n###### 적용한다. "
      }
    },
    {
      "chunk_id": "chunk_568",
      "text": "일반적으로 디지털 치료기기는 ‘치료’를 목적으로\n\n<!-- PAGE_33 -->\n###### 하는 2등급 이상의 의료기기로 품목 분류되므로 사이버보안\n\n- - 27 -\n<!-- PAGE_34 -->\n###### 다) 의료기기의 소프트웨어 허가·심사 가이드라인(민원인 안내서)\n\n<!-- PAGE_34 -->\n###### 소프트웨어 의료기기도 일반 의료기기와 마찬가지로 제조 및\n\n<!-- PAGE_34 -->\n###### 품질관리체계의 기준과 위험관리 프로세스가 조화를 이루는\n\n<!-- PAGE_34 -->\n###### 식품의약품안전처‘의료기기 소프트웨어 허가·심사 가이드라인\n\n<!-- PAGE_34 -->\n###### (민원인 안내서)’를 기준으로 디지털치료기기의 위험성 관리\n\n<!-- PAGE_34 -->\n###### 프로세스는 의료기기에서 발생하는 위험분석(risk analysis), 위험\n\n<!-- PAGE_34 -->\n###### 평가(risk evaluation), 위험통제(risk control), 잔여 위험 허용평가\n\n<!-- PAGE_34 -->\n###### (evaluation of overall residual risk acceptability), 위험관리 보고서\n\n<!-- PAGE_34 -->\n###### (risk management report), 생산 및 생산 후 정보(production\n\n<!-- PAGE_34 -->\n###### 의료기기 소프트웨어 안전성 등급은 고장 또는 잠재적 결함으로\n\n<!-- PAGE_34 -->\n###### 인해 환자나 사용자에게 미치는 위해의 영향에 따라 분류한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 567,
        "window_size": 3,
        "char_count": 807,
        "word_count": 138,
        "page_number": 33,
        "window_text": "또한 다수의 동료검토 선행연구\n\n<!-- PAGE_32 -->\n###### (Peer-reviewed Journal)에서 임상시험을 통해 디지털 우울장애\n\n<!-- PAGE_32 -->\n###### 위와 같이 디지털 우울장애 인지행동치료(Digital CBT)는 디지털\n\n<!-- PAGE_32 -->\n###### 치료기기 대상 여부 판단기준 및 절차를 충족하므로 디지털\n\n[출처: 식품의약품안전처(2020.08), 디지털치료기기 허가·심사 가이드라인(민원인 안내서)]\n\n- - 26 -\n<!-- PAGE_33 -->\n###### 나) 의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)\n\n<!-- PAGE_33 -->\n###### 디지털치료기기는 식품의약품안전처‘의료기기의 사이버보안\n\n<!-- PAGE_33 -->\n###### 허가·심사 가이드라인(민원인 안내서)’에 근거하여 보안성\n\n<!-- PAGE_33 -->\n###### 영역은 가용성(Availability), 기밀성(Confidentiality), 무결성\n\n<!-- PAGE_33 -->\n###### 가용성은 데이터가 승인된 사용자에게 즉시 제공되어야 하며,\n\n<!-- PAGE_33 -->\n###### 필요한 때에 필요한 곳에서 필요한 형태로 존재되어야 함을\n\n<!-- PAGE_33 -->\n###### 의미한다.  기밀성은 데이터가 허가되지 않은 사람에게 공개\n\n<!-- PAGE_33 -->\n###### 되거나, 허가되지 않은 용도로 사용되지 않아야 함을 의미하며,\n\n<!-- PAGE_33 -->\n###### 무결성은 데이터가 허가되지 않은 방법으로 변환되거나 파괴\n\n<!-- PAGE_33 -->\n###### 되지 않아야 함을 의미한다.  유·무선 통신이 가능하거나 통신\n\n<!-- PAGE_33 -->\n###### 경로가 존재하는 의료기기는 정보의 위변조, 오작동 또는 의료\n\n<!-- PAGE_33 -->\n###### 기기에 승인되지 않은 접근 등을 방지하기 위한 대책을 마련\n\n<!-- PAGE_33 -->\n###### 사이버보안 침해로 인한 위해도는 의료기기의 잠재적 결함\n\n<!-- PAGE_33 -->\n###### 으로 인해 사용자에게 발생할 수 있는 위해(harm)의 정도, 의료\n\n<!-- PAGE_33 -->\n###### 기기의 통신방법 및 사용환경을 종합적으로 고려하여 ‘상’,\n\n<!-- PAGE_33 -->\n###### ‘중’, ‘하’로 결정되고, 그에 따른 사이버보안 요구사항을\n\n<!-- PAGE_33 -->\n###### 적용한다.  일반적으로 디지털 치료기기는 ‘치료’를 목적으로\n\n<!-- PAGE_33 -->\n###### 하는 2등급 이상의 의료기기로 품목 분류되므로 사이버보안\n\n- - 27 -\n<!-- PAGE_34 -->\n###### 다) 의료기기의 소프트웨어 허가·심사 가이드라인(민원인 안내서)\n\n<!-- PAGE_34 -->\n###### 소프트웨어 의료기기도 일반 의료기기와 마찬가지로 제조 및\n\n<!-- PAGE_34 -->\n###### 품질관리체계의 기준과 위험관리 프로세스가 조화를 이루는\n\n<!-- PAGE_34 -->\n###### 식품의약품안전처‘의료기기 소프트웨어 허가·심사 가이드라인\n\n<!-- PAGE_34 -->\n###### (민원인 안내서)’를 기준으로 디지털치료기기의 위험성 관리\n\n<!-- PAGE_34 -->\n###### 프로세스는 의료기기에서 발생하는 위험분석(risk analysis), 위험\n\n<!-- PAGE_34 -->\n###### 평가(risk evaluation), 위험통제(risk control), 잔여 위험 허용평가\n\n<!-- PAGE_34 -->\n###### (evaluation of overall residual risk acceptability), 위험관리 보고서\n\n<!-- PAGE_34 -->\n###### (risk management report), 생산 및 생산 후 정보(production\n\n<!-- PAGE_34 -->\n###### 의료기기 소프트웨어 안전성 등급은 고장 또는 잠재적 결함으로\n\n<!-- PAGE_34 -->\n###### 인해 환자나 사용자에게 미치는 위해의 영향에 따라 분류한다.\n\n <!-- PAGE_34 -->\n###### 의료기기 소프트웨어 사용으로 건강상의 상해 또는 손상이 없는\n\n- - 28 -\n<!-- PAGE_35 -->\n###### 경우 A등급, 심각하지 않은 상해의 가능성 있으면 B등급, 심각한\n\n<!-- PAGE_35 -->\n###### 상해 또는 사망의 가능성이 있는 경우 C등급으로 구분한다.\n\n <!-- PAGE_35 -->\n###### 의료기기 소프트웨어는 안전성 등급이 결정될 때까지 초기에는\n\n<!-- PAGE_35 -->\n###### C등급 요구사항이 적용되며, 소프트웨어 시스템의 실패가 위험한\n\n<!-- PAGE_35 -->\n###### 라) 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인(민원인 안내서)\n\n<!-- PAGE_35 -->\n###### 디지털치료기기는 실사용증거(Real World Evidence, RWE)를\n\n<!-- PAGE_35 -->\n###### 사용하여 의료기기의 사전 및 사후와 관련된 안전성 및 유효성\n\n<!-- PAGE_35 -->\n###### 입증 근거로 제시할 수 있으며, 이에 따른 기간 및 비용을\n\n<!-- PAGE_35 -->\n###### 실사용증거 수집은 데이터의 타당성 및 신뢰성 확보를 위해\n\n1) 실사용데이터(RWD)는 기존의 중재적 방법에 의한 임상시험으로부터 수집되지 않은 다양한 유형의 의료데이터에 대한 포괄적인\n\n용어이다.  실사용증거(RWE)는 RWD를 분석하여 파생된 증거로써, RWD 분석을 통해 얻은 의료기기의 사용 결과나 잠재적 이익\n\n또는 위험성에 관한 임상적 근거를 말한다. ",
        "original_sentence": "일반적으로 디지털 치료기기는 ‘치료’를 목적으로\n\n<!-- PAGE_33 -->\n###### 하는 2등급 이상의 의료기기로 품목 분류되므로 사이버보안\n\n- - 27 -\n<!-- PAGE_34 -->\n###### 다) 의료기기의 소프트웨어 허가·심사 가이드라인(민원인 안내서)\n\n<!-- PAGE_34 -->\n###### 소프트웨어 의료기기도 일반 의료기기와 마찬가지로 제조 및\n\n<!-- PAGE_34 -->\n###### 품질관리체계의 기준과 위험관리 프로세스가 조화를 이루는\n\n<!-- PAGE_34 -->\n###### 식품의약품안전처‘의료기기 소프트웨어 허가·심사 가이드라인\n\n<!-- PAGE_34 -->\n###### (민원인 안내서)’를 기준으로 디지털치료기기의 위험성 관리\n\n<!-- PAGE_34 -->\n###### 프로세스는 의료기기에서 발생하는 위험분석(risk analysis), 위험\n\n<!-- PAGE_34 -->\n###### 평가(risk evaluation), 위험통제(risk control), 잔여 위험 허용평가\n\n<!-- PAGE_34 -->\n###### (evaluation of overall residual risk acceptability), 위험관리 보고서\n\n<!-- PAGE_34 -->\n###### (risk management report), 생산 및 생산 후 정보(production\n\n<!-- PAGE_34 -->\n###### 의료기기 소프트웨어 안전성 등급은 고장 또는 잠재적 결함으로\n\n<!-- PAGE_34 -->\n###### 인해 환자나 사용자에게 미치는 위해의 영향에 따라 분류한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_569",
      "text": "<!-- PAGE_34 -->\n###### 의료기기 소프트웨어 사용으로 건강상의 상해 또는 손상이 없는\n\n- - 28 -\n<!-- PAGE_35 -->\n###### 경우 A등급, 심각하지 않은 상해의 가능성 있으면 B등급, 심각한\n\n<!-- PAGE_35 -->\n###### 상해 또는 사망의 가능성이 있는 경우 C등급으로 구분한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 568,
        "window_size": 3,
        "char_count": 188,
        "word_count": 41,
        "page_number": 34,
        "window_text": "기밀성은 데이터가 허가되지 않은 사람에게 공개\n\n<!-- PAGE_33 -->\n###### 되거나, 허가되지 않은 용도로 사용되지 않아야 함을 의미하며,\n\n<!-- PAGE_33 -->\n###### 무결성은 데이터가 허가되지 않은 방법으로 변환되거나 파괴\n\n<!-- PAGE_33 -->\n###### 되지 않아야 함을 의미한다.  유·무선 통신이 가능하거나 통신\n\n<!-- PAGE_33 -->\n###### 경로가 존재하는 의료기기는 정보의 위변조, 오작동 또는 의료\n\n<!-- PAGE_33 -->\n###### 기기에 승인되지 않은 접근 등을 방지하기 위한 대책을 마련\n\n<!-- PAGE_33 -->\n###### 사이버보안 침해로 인한 위해도는 의료기기의 잠재적 결함\n\n<!-- PAGE_33 -->\n###### 으로 인해 사용자에게 발생할 수 있는 위해(harm)의 정도, 의료\n\n<!-- PAGE_33 -->\n###### 기기의 통신방법 및 사용환경을 종합적으로 고려하여 ‘상’,\n\n<!-- PAGE_33 -->\n###### ‘중’, ‘하’로 결정되고, 그에 따른 사이버보안 요구사항을\n\n<!-- PAGE_33 -->\n###### 적용한다.  일반적으로 디지털 치료기기는 ‘치료’를 목적으로\n\n<!-- PAGE_33 -->\n###### 하는 2등급 이상의 의료기기로 품목 분류되므로 사이버보안\n\n- - 27 -\n<!-- PAGE_34 -->\n###### 다) 의료기기의 소프트웨어 허가·심사 가이드라인(민원인 안내서)\n\n<!-- PAGE_34 -->\n###### 소프트웨어 의료기기도 일반 의료기기와 마찬가지로 제조 및\n\n<!-- PAGE_34 -->\n###### 품질관리체계의 기준과 위험관리 프로세스가 조화를 이루는\n\n<!-- PAGE_34 -->\n###### 식품의약품안전처‘의료기기 소프트웨어 허가·심사 가이드라인\n\n<!-- PAGE_34 -->\n###### (민원인 안내서)’를 기준으로 디지털치료기기의 위험성 관리\n\n<!-- PAGE_34 -->\n###### 프로세스는 의료기기에서 발생하는 위험분석(risk analysis), 위험\n\n<!-- PAGE_34 -->\n###### 평가(risk evaluation), 위험통제(risk control), 잔여 위험 허용평가\n\n<!-- PAGE_34 -->\n###### (evaluation of overall residual risk acceptability), 위험관리 보고서\n\n<!-- PAGE_34 -->\n###### (risk management report), 생산 및 생산 후 정보(production\n\n<!-- PAGE_34 -->\n###### 의료기기 소프트웨어 안전성 등급은 고장 또는 잠재적 결함으로\n\n<!-- PAGE_34 -->\n###### 인해 환자나 사용자에게 미치는 위해의 영향에 따라 분류한다.\n\n <!-- PAGE_34 -->\n###### 의료기기 소프트웨어 사용으로 건강상의 상해 또는 손상이 없는\n\n- - 28 -\n<!-- PAGE_35 -->\n###### 경우 A등급, 심각하지 않은 상해의 가능성 있으면 B등급, 심각한\n\n<!-- PAGE_35 -->\n###### 상해 또는 사망의 가능성이 있는 경우 C등급으로 구분한다.\n\n <!-- PAGE_35 -->\n###### 의료기기 소프트웨어는 안전성 등급이 결정될 때까지 초기에는\n\n<!-- PAGE_35 -->\n###### C등급 요구사항이 적용되며, 소프트웨어 시스템의 실패가 위험한\n\n<!-- PAGE_35 -->\n###### 라) 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인(민원인 안내서)\n\n<!-- PAGE_35 -->\n###### 디지털치료기기는 실사용증거(Real World Evidence, RWE)를\n\n<!-- PAGE_35 -->\n###### 사용하여 의료기기의 사전 및 사후와 관련된 안전성 및 유효성\n\n<!-- PAGE_35 -->\n###### 입증 근거로 제시할 수 있으며, 이에 따른 기간 및 비용을\n\n<!-- PAGE_35 -->\n###### 실사용증거 수집은 데이터의 타당성 및 신뢰성 확보를 위해\n\n1) 실사용데이터(RWD)는 기존의 중재적 방법에 의한 임상시험으로부터 수집되지 않은 다양한 유형의 의료데이터에 대한 포괄적인\n\n용어이다.  실사용증거(RWE)는 RWD를 분석하여 파생된 증거로써, RWD 분석을 통해 얻은 의료기기의 사용 결과나 잠재적 이익\n\n또는 위험성에 관한 임상적 근거를 말한다.  또한, 임상 문헌을 분석하여 파생된 새로운 증거도 포함한다.\n\n",
        "original_sentence": "<!-- PAGE_34 -->\n###### 의료기기 소프트웨어 사용으로 건강상의 상해 또는 손상이 없는\n\n- - 28 -\n<!-- PAGE_35 -->\n###### 경우 A등급, 심각하지 않은 상해의 가능성 있으면 B등급, 심각한\n\n<!-- PAGE_35 -->\n###### 상해 또는 사망의 가능성이 있는 경우 C등급으로 구분한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_570",
      "text": "<!-- PAGE_35 -->\n###### 의료기기 소프트웨어는 안전성 등급이 결정될 때까지 초기에는\n\n<!-- PAGE_35 -->\n###### C등급 요구사항이 적용되며, 소프트웨어 시스템의 실패가 위험한\n\n<!-- PAGE_35 -->\n###### 라) 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인(민원인 안내서)\n\n<!-- PAGE_35 -->\n###### 디지털치료기기는 실사용증거(Real World Evidence, RWE)를\n\n<!-- PAGE_35 -->\n###### 사용하여 의료기기의 사전 및 사후와 관련된 안전성 및 유효성\n\n<!-- PAGE_35 -->\n###### 입증 근거로 제시할 수 있으며, 이에 따른 기간 및 비용을\n\n<!-- PAGE_35 -->\n###### 실사용증거 수집은 데이터의 타당성 및 신뢰성 확보를 위해\n\n1) 실사용데이터(RWD)는 기존의 중재적 방법에 의한 임상시험으로부터 수집되지 않은 다양한 유형의 의료데이터에 대한 포괄적인\n\n용어이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 569,
        "window_size": 3,
        "char_count": 504,
        "word_count": 96,
        "page_number": 35,
        "window_text": "유·무선 통신이 가능하거나 통신\n\n<!-- PAGE_33 -->\n###### 경로가 존재하는 의료기기는 정보의 위변조, 오작동 또는 의료\n\n<!-- PAGE_33 -->\n###### 기기에 승인되지 않은 접근 등을 방지하기 위한 대책을 마련\n\n<!-- PAGE_33 -->\n###### 사이버보안 침해로 인한 위해도는 의료기기의 잠재적 결함\n\n<!-- PAGE_33 -->\n###### 으로 인해 사용자에게 발생할 수 있는 위해(harm)의 정도, 의료\n\n<!-- PAGE_33 -->\n###### 기기의 통신방법 및 사용환경을 종합적으로 고려하여 ‘상’,\n\n<!-- PAGE_33 -->\n###### ‘중’, ‘하’로 결정되고, 그에 따른 사이버보안 요구사항을\n\n<!-- PAGE_33 -->\n###### 적용한다.  일반적으로 디지털 치료기기는 ‘치료’를 목적으로\n\n<!-- PAGE_33 -->\n###### 하는 2등급 이상의 의료기기로 품목 분류되므로 사이버보안\n\n- - 27 -\n<!-- PAGE_34 -->\n###### 다) 의료기기의 소프트웨어 허가·심사 가이드라인(민원인 안내서)\n\n<!-- PAGE_34 -->\n###### 소프트웨어 의료기기도 일반 의료기기와 마찬가지로 제조 및\n\n<!-- PAGE_34 -->\n###### 품질관리체계의 기준과 위험관리 프로세스가 조화를 이루는\n\n<!-- PAGE_34 -->\n###### 식품의약품안전처‘의료기기 소프트웨어 허가·심사 가이드라인\n\n<!-- PAGE_34 -->\n###### (민원인 안내서)’를 기준으로 디지털치료기기의 위험성 관리\n\n<!-- PAGE_34 -->\n###### 프로세스는 의료기기에서 발생하는 위험분석(risk analysis), 위험\n\n<!-- PAGE_34 -->\n###### 평가(risk evaluation), 위험통제(risk control), 잔여 위험 허용평가\n\n<!-- PAGE_34 -->\n###### (evaluation of overall residual risk acceptability), 위험관리 보고서\n\n<!-- PAGE_34 -->\n###### (risk management report), 생산 및 생산 후 정보(production\n\n<!-- PAGE_34 -->\n###### 의료기기 소프트웨어 안전성 등급은 고장 또는 잠재적 결함으로\n\n<!-- PAGE_34 -->\n###### 인해 환자나 사용자에게 미치는 위해의 영향에 따라 분류한다.\n\n <!-- PAGE_34 -->\n###### 의료기기 소프트웨어 사용으로 건강상의 상해 또는 손상이 없는\n\n- - 28 -\n<!-- PAGE_35 -->\n###### 경우 A등급, 심각하지 않은 상해의 가능성 있으면 B등급, 심각한\n\n<!-- PAGE_35 -->\n###### 상해 또는 사망의 가능성이 있는 경우 C등급으로 구분한다.\n\n <!-- PAGE_35 -->\n###### 의료기기 소프트웨어는 안전성 등급이 결정될 때까지 초기에는\n\n<!-- PAGE_35 -->\n###### C등급 요구사항이 적용되며, 소프트웨어 시스템의 실패가 위험한\n\n<!-- PAGE_35 -->\n###### 라) 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인(민원인 안내서)\n\n<!-- PAGE_35 -->\n###### 디지털치료기기는 실사용증거(Real World Evidence, RWE)를\n\n<!-- PAGE_35 -->\n###### 사용하여 의료기기의 사전 및 사후와 관련된 안전성 및 유효성\n\n<!-- PAGE_35 -->\n###### 입증 근거로 제시할 수 있으며, 이에 따른 기간 및 비용을\n\n<!-- PAGE_35 -->\n###### 실사용증거 수집은 데이터의 타당성 및 신뢰성 확보를 위해\n\n1) 실사용데이터(RWD)는 기존의 중재적 방법에 의한 임상시험으로부터 수집되지 않은 다양한 유형의 의료데이터에 대한 포괄적인\n\n용어이다.  실사용증거(RWE)는 RWD를 분석하여 파생된 증거로써, RWD 분석을 통해 얻은 의료기기의 사용 결과나 잠재적 이익\n\n또는 위험성에 관한 임상적 근거를 말한다.  또한, 임상 문헌을 분석하여 파생된 새로운 증거도 포함한다.\n\n - - 29 -\n<!-- PAGE_36 -->\n###### 품질, 수집 및 분석 방법, 수집한 인력의 역량을 입증할 수 있는\n\n<!-- PAGE_36 -->\n###### 객관적인 사항이 반드시 포함되어야 한다. ",
        "original_sentence": "<!-- PAGE_35 -->\n###### 의료기기 소프트웨어는 안전성 등급이 결정될 때까지 초기에는\n\n<!-- PAGE_35 -->\n###### C등급 요구사항이 적용되며, 소프트웨어 시스템의 실패가 위험한\n\n<!-- PAGE_35 -->\n###### 라) 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인(민원인 안내서)\n\n<!-- PAGE_35 -->\n###### 디지털치료기기는 실사용증거(Real World Evidence, RWE)를\n\n<!-- PAGE_35 -->\n###### 사용하여 의료기기의 사전 및 사후와 관련된 안전성 및 유효성\n\n<!-- PAGE_35 -->\n###### 입증 근거로 제시할 수 있으며, 이에 따른 기간 및 비용을\n\n<!-- PAGE_35 -->\n###### 실사용증거 수집은 데이터의 타당성 및 신뢰성 확보를 위해\n\n1) 실사용데이터(RWD)는 기존의 중재적 방법에 의한 임상시험으로부터 수집되지 않은 다양한 유형의 의료데이터에 대한 포괄적인\n\n용어이다. "
      }
    },
    {
      "chunk_id": "chunk_571",
      "text": "실사용증거(RWE)는 RWD를 분석하여 파생된 증거로써, RWD 분석을 통해 얻은 의료기기의 사용 결과나 잠재적 이익\n\n또는 위험성에 관한 임상적 근거를 말한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 570,
        "window_size": 3,
        "char_count": 91,
        "word_count": 20,
        "page_number": 35,
        "window_text": "일반적으로 디지털 치료기기는 ‘치료’를 목적으로\n\n<!-- PAGE_33 -->\n###### 하는 2등급 이상의 의료기기로 품목 분류되므로 사이버보안\n\n- - 27 -\n<!-- PAGE_34 -->\n###### 다) 의료기기의 소프트웨어 허가·심사 가이드라인(민원인 안내서)\n\n<!-- PAGE_34 -->\n###### 소프트웨어 의료기기도 일반 의료기기와 마찬가지로 제조 및\n\n<!-- PAGE_34 -->\n###### 품질관리체계의 기준과 위험관리 프로세스가 조화를 이루는\n\n<!-- PAGE_34 -->\n###### 식품의약품안전처‘의료기기 소프트웨어 허가·심사 가이드라인\n\n<!-- PAGE_34 -->\n###### (민원인 안내서)’를 기준으로 디지털치료기기의 위험성 관리\n\n<!-- PAGE_34 -->\n###### 프로세스는 의료기기에서 발생하는 위험분석(risk analysis), 위험\n\n<!-- PAGE_34 -->\n###### 평가(risk evaluation), 위험통제(risk control), 잔여 위험 허용평가\n\n<!-- PAGE_34 -->\n###### (evaluation of overall residual risk acceptability), 위험관리 보고서\n\n<!-- PAGE_34 -->\n###### (risk management report), 생산 및 생산 후 정보(production\n\n<!-- PAGE_34 -->\n###### 의료기기 소프트웨어 안전성 등급은 고장 또는 잠재적 결함으로\n\n<!-- PAGE_34 -->\n###### 인해 환자나 사용자에게 미치는 위해의 영향에 따라 분류한다.\n\n <!-- PAGE_34 -->\n###### 의료기기 소프트웨어 사용으로 건강상의 상해 또는 손상이 없는\n\n- - 28 -\n<!-- PAGE_35 -->\n###### 경우 A등급, 심각하지 않은 상해의 가능성 있으면 B등급, 심각한\n\n<!-- PAGE_35 -->\n###### 상해 또는 사망의 가능성이 있는 경우 C등급으로 구분한다.\n\n <!-- PAGE_35 -->\n###### 의료기기 소프트웨어는 안전성 등급이 결정될 때까지 초기에는\n\n<!-- PAGE_35 -->\n###### C등급 요구사항이 적용되며, 소프트웨어 시스템의 실패가 위험한\n\n<!-- PAGE_35 -->\n###### 라) 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인(민원인 안내서)\n\n<!-- PAGE_35 -->\n###### 디지털치료기기는 실사용증거(Real World Evidence, RWE)를\n\n<!-- PAGE_35 -->\n###### 사용하여 의료기기의 사전 및 사후와 관련된 안전성 및 유효성\n\n<!-- PAGE_35 -->\n###### 입증 근거로 제시할 수 있으며, 이에 따른 기간 및 비용을\n\n<!-- PAGE_35 -->\n###### 실사용증거 수집은 데이터의 타당성 및 신뢰성 확보를 위해\n\n1) 실사용데이터(RWD)는 기존의 중재적 방법에 의한 임상시험으로부터 수집되지 않은 다양한 유형의 의료데이터에 대한 포괄적인\n\n용어이다.  실사용증거(RWE)는 RWD를 분석하여 파생된 증거로써, RWD 분석을 통해 얻은 의료기기의 사용 결과나 잠재적 이익\n\n또는 위험성에 관한 임상적 근거를 말한다.  또한, 임상 문헌을 분석하여 파생된 새로운 증거도 포함한다.\n\n - - 29 -\n<!-- PAGE_36 -->\n###### 품질, 수집 및 분석 방법, 수집한 인력의 역량을 입증할 수 있는\n\n<!-- PAGE_36 -->\n###### 객관적인 사항이 반드시 포함되어야 한다.  또한 실사용증거는\n\n<!-- PAGE_36 -->\n###### 적용 목적, 수집 및 분석 정보, 분석 결과에 대한 사항을 제시\n\n- - 30 -\n<!-- PAGE_37 -->\n### Ⅱ\n\n<!-- PAGE_37 -->\n### 안전성·성능 평가\n\n<!-- PAGE_37 -->\n##### 1. ",
        "original_sentence": "실사용증거(RWE)는 RWD를 분석하여 파생된 증거로써, RWD 분석을 통해 얻은 의료기기의 사용 결과나 잠재적 이익\n\n또는 위험성에 관한 임상적 근거를 말한다. "
      }
    },
    {
      "chunk_id": "chunk_572",
      "text": "또한, 임상 문헌을 분석하여 파생된 새로운 증거도 포함한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 571,
        "window_size": 3,
        "char_count": 35,
        "word_count": 8,
        "page_number": 13,
        "window_text": "<!-- PAGE_34 -->\n###### 의료기기 소프트웨어 사용으로 건강상의 상해 또는 손상이 없는\n\n- - 28 -\n<!-- PAGE_35 -->\n###### 경우 A등급, 심각하지 않은 상해의 가능성 있으면 B등급, 심각한\n\n<!-- PAGE_35 -->\n###### 상해 또는 사망의 가능성이 있는 경우 C등급으로 구분한다.\n\n <!-- PAGE_35 -->\n###### 의료기기 소프트웨어는 안전성 등급이 결정될 때까지 초기에는\n\n<!-- PAGE_35 -->\n###### C등급 요구사항이 적용되며, 소프트웨어 시스템의 실패가 위험한\n\n<!-- PAGE_35 -->\n###### 라) 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인(민원인 안내서)\n\n<!-- PAGE_35 -->\n###### 디지털치료기기는 실사용증거(Real World Evidence, RWE)를\n\n<!-- PAGE_35 -->\n###### 사용하여 의료기기의 사전 및 사후와 관련된 안전성 및 유효성\n\n<!-- PAGE_35 -->\n###### 입증 근거로 제시할 수 있으며, 이에 따른 기간 및 비용을\n\n<!-- PAGE_35 -->\n###### 실사용증거 수집은 데이터의 타당성 및 신뢰성 확보를 위해\n\n1) 실사용데이터(RWD)는 기존의 중재적 방법에 의한 임상시험으로부터 수집되지 않은 다양한 유형의 의료데이터에 대한 포괄적인\n\n용어이다.  실사용증거(RWE)는 RWD를 분석하여 파생된 증거로써, RWD 분석을 통해 얻은 의료기기의 사용 결과나 잠재적 이익\n\n또는 위험성에 관한 임상적 근거를 말한다.  또한, 임상 문헌을 분석하여 파생된 새로운 증거도 포함한다.\n\n - - 29 -\n<!-- PAGE_36 -->\n###### 품질, 수집 및 분석 방법, 수집한 인력의 역량을 입증할 수 있는\n\n<!-- PAGE_36 -->\n###### 객관적인 사항이 반드시 포함되어야 한다.  또한 실사용증거는\n\n<!-- PAGE_36 -->\n###### 적용 목적, 수집 및 분석 정보, 분석 결과에 대한 사항을 제시\n\n- - 30 -\n<!-- PAGE_37 -->\n### Ⅱ\n\n<!-- PAGE_37 -->\n### 안전성·성능 평가\n\n<!-- PAGE_37 -->\n##### 1.  국내외 관련 규격 및 가이드라인\n\n<!-- PAGE_37 -->\n###### 가. ",
        "original_sentence": "또한, 임상 문헌을 분석하여 파생된 새로운 증거도 포함한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_573",
      "text": "- - 29 -\n<!-- PAGE_36 -->\n###### 품질, 수집 및 분석 방법, 수집한 인력의 역량을 입증할 수 있는\n\n<!-- PAGE_36 -->\n###### 객관적인 사항이 반드시 포함되어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 572,
        "window_size": 3,
        "char_count": 118,
        "word_count": 28,
        "page_number": 36,
        "window_text": "<!-- PAGE_35 -->\n###### 의료기기 소프트웨어는 안전성 등급이 결정될 때까지 초기에는\n\n<!-- PAGE_35 -->\n###### C등급 요구사항이 적용되며, 소프트웨어 시스템의 실패가 위험한\n\n<!-- PAGE_35 -->\n###### 라) 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인(민원인 안내서)\n\n<!-- PAGE_35 -->\n###### 디지털치료기기는 실사용증거(Real World Evidence, RWE)를\n\n<!-- PAGE_35 -->\n###### 사용하여 의료기기의 사전 및 사후와 관련된 안전성 및 유효성\n\n<!-- PAGE_35 -->\n###### 입증 근거로 제시할 수 있으며, 이에 따른 기간 및 비용을\n\n<!-- PAGE_35 -->\n###### 실사용증거 수집은 데이터의 타당성 및 신뢰성 확보를 위해\n\n1) 실사용데이터(RWD)는 기존의 중재적 방법에 의한 임상시험으로부터 수집되지 않은 다양한 유형의 의료데이터에 대한 포괄적인\n\n용어이다.  실사용증거(RWE)는 RWD를 분석하여 파생된 증거로써, RWD 분석을 통해 얻은 의료기기의 사용 결과나 잠재적 이익\n\n또는 위험성에 관한 임상적 근거를 말한다.  또한, 임상 문헌을 분석하여 파생된 새로운 증거도 포함한다.\n\n - - 29 -\n<!-- PAGE_36 -->\n###### 품질, 수집 및 분석 방법, 수집한 인력의 역량을 입증할 수 있는\n\n<!-- PAGE_36 -->\n###### 객관적인 사항이 반드시 포함되어야 한다.  또한 실사용증거는\n\n<!-- PAGE_36 -->\n###### 적용 목적, 수집 및 분석 정보, 분석 결과에 대한 사항을 제시\n\n- - 30 -\n<!-- PAGE_37 -->\n### Ⅱ\n\n<!-- PAGE_37 -->\n### 안전성·성능 평가\n\n<!-- PAGE_37 -->\n##### 1.  국내외 관련 규격 및 가이드라인\n\n<!-- PAGE_37 -->\n###### 가.  국내외 규격\n\n- - 31 -\n<!-- PAGE_38 -->\n###### 나. ",
        "original_sentence": "- - 29 -\n<!-- PAGE_36 -->\n###### 품질, 수집 및 분석 방법, 수집한 인력의 역량을 입증할 수 있는\n\n<!-- PAGE_36 -->\n###### 객관적인 사항이 반드시 포함되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_574",
      "text": "또한 실사용증거는\n\n<!-- PAGE_36 -->\n###### 적용 목적, 수집 및 분석 정보, 분석 결과에 대한 사항을 제시\n\n- - 30 -\n<!-- PAGE_37 -->\n### Ⅱ\n\n<!-- PAGE_37 -->\n### 안전성·성능 평가\n\n<!-- PAGE_37 -->\n##### 1. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 573,
        "window_size": 3,
        "char_count": 163,
        "word_count": 37,
        "page_number": 36,
        "window_text": "실사용증거(RWE)는 RWD를 분석하여 파생된 증거로써, RWD 분석을 통해 얻은 의료기기의 사용 결과나 잠재적 이익\n\n또는 위험성에 관한 임상적 근거를 말한다.  또한, 임상 문헌을 분석하여 파생된 새로운 증거도 포함한다.\n\n - - 29 -\n<!-- PAGE_36 -->\n###### 품질, 수집 및 분석 방법, 수집한 인력의 역량을 입증할 수 있는\n\n<!-- PAGE_36 -->\n###### 객관적인 사항이 반드시 포함되어야 한다.  또한 실사용증거는\n\n<!-- PAGE_36 -->\n###### 적용 목적, 수집 및 분석 정보, 분석 결과에 대한 사항을 제시\n\n- - 30 -\n<!-- PAGE_37 -->\n### Ⅱ\n\n<!-- PAGE_37 -->\n### 안전성·성능 평가\n\n<!-- PAGE_37 -->\n##### 1.  국내외 관련 규격 및 가이드라인\n\n<!-- PAGE_37 -->\n###### 가.  국내외 규격\n\n- - 31 -\n<!-- PAGE_38 -->\n###### 나.  국내외 가이드라인\n\n번호\n\n표준 번호\n\n규격 명칭\n\n주요 내용\n\n비고\n\nApplication of risk\n\nmanagement for IT-networks\n\n**[표 시작]**\n\n| incorporating medical devices | 네트워크로 연결되는 |\n| --- | --- |\n\n**[표 끝]**\n\n- - 32 -\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n**[표 시작]**\n\n| 5 | 3 | 몽고메리-아스버그 | 정신질환 또는 정신과 입원 이력이 있는 자 | 비 인가된 | 허가심사 가이드라인 | 소프트웨어 | 및 소프트웨어 안전에 적합한 | 오진, 잘못된 치료 수행 | 국내·외 | 국내 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n\n**[표 끝]**\n\n의료기기 소프트웨어\n\n의료기기 소프트웨어의 기술문서 작성\n\n방법에\n\n대하여\n\n상세히\n\n기술하고\n\n‘의료기기\n\n소프트웨어\n\n적합성\n\n확인\n\n- - 33 -\n<!-- PAGE_40 -->\n##### 2. ",
        "original_sentence": "또한 실사용증거는\n\n<!-- PAGE_36 -->\n###### 적용 목적, 수집 및 분석 정보, 분석 결과에 대한 사항을 제시\n\n- - 30 -\n<!-- PAGE_37 -->\n### Ⅱ\n\n<!-- PAGE_37 -->\n### 안전성·성능 평가\n\n<!-- PAGE_37 -->\n##### 1. "
      }
    },
    {
      "chunk_id": "chunk_575",
      "text": "국내외 관련 규격 및 가이드라인\n\n<!-- PAGE_37 -->\n###### 가. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 574,
        "window_size": 3,
        "char_count": 46,
        "word_count": 10,
        "page_number": 37,
        "window_text": "또한, 임상 문헌을 분석하여 파생된 새로운 증거도 포함한다.\n\n - - 29 -\n<!-- PAGE_36 -->\n###### 품질, 수집 및 분석 방법, 수집한 인력의 역량을 입증할 수 있는\n\n<!-- PAGE_36 -->\n###### 객관적인 사항이 반드시 포함되어야 한다.  또한 실사용증거는\n\n<!-- PAGE_36 -->\n###### 적용 목적, 수집 및 분석 정보, 분석 결과에 대한 사항을 제시\n\n- - 30 -\n<!-- PAGE_37 -->\n### Ⅱ\n\n<!-- PAGE_37 -->\n### 안전성·성능 평가\n\n<!-- PAGE_37 -->\n##### 1.  국내외 관련 규격 및 가이드라인\n\n<!-- PAGE_37 -->\n###### 가.  국내외 규격\n\n- - 31 -\n<!-- PAGE_38 -->\n###### 나.  국내외 가이드라인\n\n번호\n\n표준 번호\n\n규격 명칭\n\n주요 내용\n\n비고\n\nApplication of risk\n\nmanagement for IT-networks\n\n**[표 시작]**\n\n| incorporating medical devices | 네트워크로 연결되는 |\n| --- | --- |\n\n**[표 끝]**\n\n- - 32 -\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n**[표 시작]**\n\n| 5 | 3 | 몽고메리-아스버그 | 정신질환 또는 정신과 입원 이력이 있는 자 | 비 인가된 | 허가심사 가이드라인 | 소프트웨어 | 및 소프트웨어 안전에 적합한 | 오진, 잘못된 치료 수행 | 국내·외 | 국내 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n\n**[표 끝]**\n\n의료기기 소프트웨어\n\n의료기기 소프트웨어의 기술문서 작성\n\n방법에\n\n대하여\n\n상세히\n\n기술하고\n\n‘의료기기\n\n소프트웨어\n\n적합성\n\n확인\n\n- - 33 -\n<!-- PAGE_40 -->\n##### 2.  안전성 평가 항목\n\n<!-- PAGE_40 -->\n###### 가. ",
        "original_sentence": "국내외 관련 규격 및 가이드라인\n\n<!-- PAGE_37 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_576",
      "text": "국내외 규격\n\n- - 31 -\n<!-- PAGE_38 -->\n###### 나. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 575,
        "window_size": 3,
        "char_count": 44,
        "word_count": 11,
        "page_number": 38,
        "window_text": "- - 29 -\n<!-- PAGE_36 -->\n###### 품질, 수집 및 분석 방법, 수집한 인력의 역량을 입증할 수 있는\n\n<!-- PAGE_36 -->\n###### 객관적인 사항이 반드시 포함되어야 한다.  또한 실사용증거는\n\n<!-- PAGE_36 -->\n###### 적용 목적, 수집 및 분석 정보, 분석 결과에 대한 사항을 제시\n\n- - 30 -\n<!-- PAGE_37 -->\n### Ⅱ\n\n<!-- PAGE_37 -->\n### 안전성·성능 평가\n\n<!-- PAGE_37 -->\n##### 1.  국내외 관련 규격 및 가이드라인\n\n<!-- PAGE_37 -->\n###### 가.  국내외 규격\n\n- - 31 -\n<!-- PAGE_38 -->\n###### 나.  국내외 가이드라인\n\n번호\n\n표준 번호\n\n규격 명칭\n\n주요 내용\n\n비고\n\nApplication of risk\n\nmanagement for IT-networks\n\n**[표 시작]**\n\n| incorporating medical devices | 네트워크로 연결되는 |\n| --- | --- |\n\n**[표 끝]**\n\n- - 32 -\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n**[표 시작]**\n\n| 5 | 3 | 몽고메리-아스버그 | 정신질환 또는 정신과 입원 이력이 있는 자 | 비 인가된 | 허가심사 가이드라인 | 소프트웨어 | 및 소프트웨어 안전에 적합한 | 오진, 잘못된 치료 수행 | 국내·외 | 국내 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n\n**[표 끝]**\n\n의료기기 소프트웨어\n\n의료기기 소프트웨어의 기술문서 작성\n\n방법에\n\n대하여\n\n상세히\n\n기술하고\n\n‘의료기기\n\n소프트웨어\n\n적합성\n\n확인\n\n- - 33 -\n<!-- PAGE_40 -->\n##### 2.  안전성 평가 항목\n\n<!-- PAGE_40 -->\n###### 가.  소프트웨어 검증 및 유효성 확인\n\n<!-- PAGE_40 -->\n###### 1) 개요\n\n<!-- PAGE_40 -->\n###### 의료기기에 포함되는 소프트웨어 또는 의료기기 자체가 소프트\n\n<!-- PAGE_40 -->\n###### 웨어면 ‘의료기기 제조 및 품질관리 기준’ 및 ‘의료기기 위험\n\n<!-- PAGE_40 -->\n###### 관리 시스템’과 조화를 이루는 범위에서 개발, 유지되고 사용\n\n<!-- PAGE_40 -->\n###### 소프트웨어 검증 및 유효성 확인은 의료기기로서의 소프트웨어의\n\n<!-- PAGE_40 -->\n###### 신뢰도를 높이고 환자 또는 사용자에 대한 위험을 낮추기 위한\n\n<!-- PAGE_40 -->\n###### 활동으로, 국제 표준 IEC 62304, ISO 14971 및 ‘의료기기 소프트\n\n<!-- PAGE_40 -->\n###### 의료기기 제조업체는 ‘의료기기 제조 및 품질관리 기준’에\n\n<!-- PAGE_40 -->\n###### 규정된 바와 같이 수립된 품질시스템에서 관련 절차에 따라 소프트\n\n<!-- PAGE_40 -->\n###### 의료기기 소프트웨어의 위험관리는 소프트웨어 개발 활동의 일부이며,\n\n<!-- PAGE_40 -->\n###### 제조자는 소프트웨어 위험관리를 통해 의료기기에 포함된 소프트\n\n<!-- PAGE_40 -->\n###### 웨어 사용에 따른 허용 불가능한 위험이 발생하지 않고, 의료\n\n<!-- PAGE_40 -->\n###### 소프트웨어 개발 및 위험관리는 <표 8>와 같이 IEC 62304 프로\n\n- - 34 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n개발 소프트웨어의 범위, 규모\n\n소프트웨어의 개발 계획을\n\n**[표 시작]**\n\n| 수립하면서 | 동시에 | 위험 |\n| --- | --- | --- |\n| : 성별, 연령, 항우울제 복용 여부, 우울 증상에 대한 기초 평가 | 소프트웨어 요구사항에서 |\n| 정의한 | 위험통제 | 조치가 |\n**소프트웨어의 정상 상태 및**\n**실제 제품에 올바르게 반영**\n| 고장 | 상태에서의 | 잠재적 |\n**되었으며, 위험이 효과적**\n**결함을 고려하여 위험을 분석**\n**으로 통제되어 잔여 위험이**\n**하고, 해당 위험을 통제하기**\n**임상시험용 의료기기와의 인과관계를 부정할 수 없는 경우를 말한다.",
        "original_sentence": "국내외 규격\n\n- - 31 -\n<!-- PAGE_38 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_577",
      "text": "국내외 가이드라인\n\n번호\n\n표준 번호\n\n규격 명칭\n\n주요 내용\n\n비고\n\nApplication of risk\n\nmanagement for IT-networks\n\n**[표 시작]**\n\n| incorporating medical devices | 네트워크로 연결되는 |\n| --- | --- |\n\n**[표 끝]**\n\n- - 32 -\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n**[표 시작]**\n\n| 5 | 3 | 몽고메리-아스버그 | 정신질환 또는 정신과 입원 이력이 있는 자 | 비 인가된 | 허가심사 가이드라인 | 소프트웨어 | 및 소프트웨어 안전에 적합한 | 오진, 잘못된 치료 수행 | 국내·외 | 국내 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n\n**[표 끝]**\n\n의료기기 소프트웨어\n\n의료기기 소프트웨어의 기술문서 작성\n\n방법에\n\n대하여\n\n상세히\n\n기술하고\n\n‘의료기기\n\n소프트웨어\n\n적합성\n\n확인\n\n- - 33 -\n<!-- PAGE_40 -->\n##### 2. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 576,
        "window_size": 3,
        "char_count": 535,
        "word_count": 130,
        "page_number": 40,
        "window_text": "또한 실사용증거는\n\n<!-- PAGE_36 -->\n###### 적용 목적, 수집 및 분석 정보, 분석 결과에 대한 사항을 제시\n\n- - 30 -\n<!-- PAGE_37 -->\n### Ⅱ\n\n<!-- PAGE_37 -->\n### 안전성·성능 평가\n\n<!-- PAGE_37 -->\n##### 1.  국내외 관련 규격 및 가이드라인\n\n<!-- PAGE_37 -->\n###### 가.  국내외 규격\n\n- - 31 -\n<!-- PAGE_38 -->\n###### 나.  국내외 가이드라인\n\n번호\n\n표준 번호\n\n규격 명칭\n\n주요 내용\n\n비고\n\nApplication of risk\n\nmanagement for IT-networks\n\n**[표 시작]**\n\n| incorporating medical devices | 네트워크로 연결되는 |\n| --- | --- |\n\n**[표 끝]**\n\n- - 32 -\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n**[표 시작]**\n\n| 5 | 3 | 몽고메리-아스버그 | 정신질환 또는 정신과 입원 이력이 있는 자 | 비 인가된 | 허가심사 가이드라인 | 소프트웨어 | 및 소프트웨어 안전에 적합한 | 오진, 잘못된 치료 수행 | 국내·외 | 국내 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n\n**[표 끝]**\n\n의료기기 소프트웨어\n\n의료기기 소프트웨어의 기술문서 작성\n\n방법에\n\n대하여\n\n상세히\n\n기술하고\n\n‘의료기기\n\n소프트웨어\n\n적합성\n\n확인\n\n- - 33 -\n<!-- PAGE_40 -->\n##### 2.  안전성 평가 항목\n\n<!-- PAGE_40 -->\n###### 가.  소프트웨어 검증 및 유효성 확인\n\n<!-- PAGE_40 -->\n###### 1) 개요\n\n<!-- PAGE_40 -->\n###### 의료기기에 포함되는 소프트웨어 또는 의료기기 자체가 소프트\n\n<!-- PAGE_40 -->\n###### 웨어면 ‘의료기기 제조 및 품질관리 기준’ 및 ‘의료기기 위험\n\n<!-- PAGE_40 -->\n###### 관리 시스템’과 조화를 이루는 범위에서 개발, 유지되고 사용\n\n<!-- PAGE_40 -->\n###### 소프트웨어 검증 및 유효성 확인은 의료기기로서의 소프트웨어의\n\n<!-- PAGE_40 -->\n###### 신뢰도를 높이고 환자 또는 사용자에 대한 위험을 낮추기 위한\n\n<!-- PAGE_40 -->\n###### 활동으로, 국제 표준 IEC 62304, ISO 14971 및 ‘의료기기 소프트\n\n<!-- PAGE_40 -->\n###### 의료기기 제조업체는 ‘의료기기 제조 및 품질관리 기준’에\n\n<!-- PAGE_40 -->\n###### 규정된 바와 같이 수립된 품질시스템에서 관련 절차에 따라 소프트\n\n<!-- PAGE_40 -->\n###### 의료기기 소프트웨어의 위험관리는 소프트웨어 개발 활동의 일부이며,\n\n<!-- PAGE_40 -->\n###### 제조자는 소프트웨어 위험관리를 통해 의료기기에 포함된 소프트\n\n<!-- PAGE_40 -->\n###### 웨어 사용에 따른 허용 불가능한 위험이 발생하지 않고, 의료\n\n<!-- PAGE_40 -->\n###### 소프트웨어 개발 및 위험관리는 <표 8>와 같이 IEC 62304 프로\n\n- - 34 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n개발 소프트웨어의 범위, 규모\n\n소프트웨어의 개발 계획을\n\n**[표 시작]**\n\n| 수립하면서 | 동시에 | 위험 |\n| --- | --- | --- |\n| : 성별, 연령, 항우울제 복용 여부, 우울 증상에 대한 기초 평가 | 소프트웨어 요구사항에서 |\n| 정의한 | 위험통제 | 조치가 |\n**소프트웨어의 정상 상태 및**\n**실제 제품에 올바르게 반영**\n| 고장 | 상태에서의 | 잠재적 |\n**되었으며, 위험이 효과적**\n**결함을 고려하여 위험을 분석**\n**으로 통제되어 잔여 위험이**\n**하고, 해당 위험을 통제하기**\n**임상시험용 의료기기와의 인과관계를 부정할 수 없는 경우를 말한다. **\n**위한 조치를 결정한다. ",
        "original_sentence": "국내외 가이드라인\n\n번호\n\n표준 번호\n\n규격 명칭\n\n주요 내용\n\n비고\n\nApplication of risk\n\nmanagement for IT-networks\n\n**[표 시작]**\n\n| incorporating medical devices | 네트워크로 연결되는 |\n| --- | --- |\n\n**[표 끝]**\n\n- - 32 -\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n**[표 시작]**\n\n| 5 | 3 | 몽고메리-아스버그 | 정신질환 또는 정신과 입원 이력이 있는 자 | 비 인가된 | 허가심사 가이드라인 | 소프트웨어 | 및 소프트웨어 안전에 적합한 | 오진, 잘못된 치료 수행 | 국내·외 | 국내 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n\n**[표 끝]**\n\n의료기기 소프트웨어\n\n의료기기 소프트웨어의 기술문서 작성\n\n방법에\n\n대하여\n\n상세히\n\n기술하고\n\n‘의료기기\n\n소프트웨어\n\n적합성\n\n확인\n\n- - 33 -\n<!-- PAGE_40 -->\n##### 2. "
      }
    },
    {
      "chunk_id": "chunk_578",
      "text": "안전성 평가 항목\n\n<!-- PAGE_40 -->\n###### 가. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 577,
        "window_size": 3,
        "char_count": 38,
        "word_count": 8,
        "page_number": 40,
        "window_text": "국내외 관련 규격 및 가이드라인\n\n<!-- PAGE_37 -->\n###### 가.  국내외 규격\n\n- - 31 -\n<!-- PAGE_38 -->\n###### 나.  국내외 가이드라인\n\n번호\n\n표준 번호\n\n규격 명칭\n\n주요 내용\n\n비고\n\nApplication of risk\n\nmanagement for IT-networks\n\n**[표 시작]**\n\n| incorporating medical devices | 네트워크로 연결되는 |\n| --- | --- |\n\n**[표 끝]**\n\n- - 32 -\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n**[표 시작]**\n\n| 5 | 3 | 몽고메리-아스버그 | 정신질환 또는 정신과 입원 이력이 있는 자 | 비 인가된 | 허가심사 가이드라인 | 소프트웨어 | 및 소프트웨어 안전에 적합한 | 오진, 잘못된 치료 수행 | 국내·외 | 국내 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n\n**[표 끝]**\n\n의료기기 소프트웨어\n\n의료기기 소프트웨어의 기술문서 작성\n\n방법에\n\n대하여\n\n상세히\n\n기술하고\n\n‘의료기기\n\n소프트웨어\n\n적합성\n\n확인\n\n- - 33 -\n<!-- PAGE_40 -->\n##### 2.  안전성 평가 항목\n\n<!-- PAGE_40 -->\n###### 가.  소프트웨어 검증 및 유효성 확인\n\n<!-- PAGE_40 -->\n###### 1) 개요\n\n<!-- PAGE_40 -->\n###### 의료기기에 포함되는 소프트웨어 또는 의료기기 자체가 소프트\n\n<!-- PAGE_40 -->\n###### 웨어면 ‘의료기기 제조 및 품질관리 기준’ 및 ‘의료기기 위험\n\n<!-- PAGE_40 -->\n###### 관리 시스템’과 조화를 이루는 범위에서 개발, 유지되고 사용\n\n<!-- PAGE_40 -->\n###### 소프트웨어 검증 및 유효성 확인은 의료기기로서의 소프트웨어의\n\n<!-- PAGE_40 -->\n###### 신뢰도를 높이고 환자 또는 사용자에 대한 위험을 낮추기 위한\n\n<!-- PAGE_40 -->\n###### 활동으로, 국제 표준 IEC 62304, ISO 14971 및 ‘의료기기 소프트\n\n<!-- PAGE_40 -->\n###### 의료기기 제조업체는 ‘의료기기 제조 및 품질관리 기준’에\n\n<!-- PAGE_40 -->\n###### 규정된 바와 같이 수립된 품질시스템에서 관련 절차에 따라 소프트\n\n<!-- PAGE_40 -->\n###### 의료기기 소프트웨어의 위험관리는 소프트웨어 개발 활동의 일부이며,\n\n<!-- PAGE_40 -->\n###### 제조자는 소프트웨어 위험관리를 통해 의료기기에 포함된 소프트\n\n<!-- PAGE_40 -->\n###### 웨어 사용에 따른 허용 불가능한 위험이 발생하지 않고, 의료\n\n<!-- PAGE_40 -->\n###### 소프트웨어 개발 및 위험관리는 <표 8>와 같이 IEC 62304 프로\n\n- - 34 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n개발 소프트웨어의 범위, 규모\n\n소프트웨어의 개발 계획을\n\n**[표 시작]**\n\n| 수립하면서 | 동시에 | 위험 |\n| --- | --- | --- |\n| : 성별, 연령, 항우울제 복용 여부, 우울 증상에 대한 기초 평가 | 소프트웨어 요구사항에서 |\n| 정의한 | 위험통제 | 조치가 |\n**소프트웨어의 정상 상태 및**\n**실제 제품에 올바르게 반영**\n| 고장 | 상태에서의 | 잠재적 |\n**되었으며, 위험이 효과적**\n**결함을 고려하여 위험을 분석**\n**으로 통제되어 잔여 위험이**\n**하고, 해당 위험을 통제하기**\n**임상시험용 의료기기와의 인과관계를 부정할 수 없는 경우를 말한다. **\n**위한 조치를 결정한다.  이 중**\n**소프트웨어 설계에 해당하는**\n**통제 조치를 소프트웨어 요구**\n**새로운 위험의 발생 또는**\n| 소프트웨어 | 요구사항에 | 기존에 식별한 위험 평가의 |\n| 반영한 위험 통제 조치가 | 변경이 필요한 경우, 소프트 |\n| 실현될 수 있도록 안전한 | 웨어 형상의 변경이 위해 |\n**요인이 될 수 있는 경우**\n**위험관리 프로세스의 입력**\n**시판 후 발견된 문제점을**\n| 분석하고 | 안전과 | 관련된 |\n| 소프트웨어 위험 통제 조치를 | 항목은 위험관리 프로세스의 |\n| 제품에 구현한다. ",
        "original_sentence": "안전성 평가 항목\n\n<!-- PAGE_40 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_579",
      "text": "소프트웨어 검증 및 유효성 확인\n\n<!-- PAGE_40 -->\n###### 1) 개요\n\n<!-- PAGE_40 -->\n###### 의료기기에 포함되는 소프트웨어 또는 의료기기 자체가 소프트\n\n<!-- PAGE_40 -->\n###### 웨어면 ‘의료기기 제조 및 품질관리 기준’ 및 ‘의료기기 위험\n\n<!-- PAGE_40 -->\n###### 관리 시스템’과 조화를 이루는 범위에서 개발, 유지되고 사용\n\n<!-- PAGE_40 -->\n###### 소프트웨어 검증 및 유효성 확인은 의료기기로서의 소프트웨어의\n\n<!-- PAGE_40 -->\n###### 신뢰도를 높이고 환자 또는 사용자에 대한 위험을 낮추기 위한\n\n<!-- PAGE_40 -->\n###### 활동으로, 국제 표준 IEC 62304, ISO 14971 및 ‘의료기기 소프트\n\n<!-- PAGE_40 -->\n###### 의료기기 제조업체는 ‘의료기기 제조 및 품질관리 기준’에\n\n<!-- PAGE_40 -->\n###### 규정된 바와 같이 수립된 품질시스템에서 관련 절차에 따라 소프트\n\n<!-- PAGE_40 -->\n###### 의료기기 소프트웨어의 위험관리는 소프트웨어 개발 활동의 일부이며,\n\n<!-- PAGE_40 -->\n###### 제조자는 소프트웨어 위험관리를 통해 의료기기에 포함된 소프트\n\n<!-- PAGE_40 -->\n###### 웨어 사용에 따른 허용 불가능한 위험이 발생하지 않고, 의료\n\n<!-- PAGE_40 -->\n###### 소프트웨어 개발 및 위험관리는 <표 8>와 같이 IEC 62304 프로\n\n- - 34 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n개발 소프트웨어의 범위, 규모\n\n소프트웨어의 개발 계획을\n\n**[표 시작]**\n\n| 수립하면서 | 동시에 | 위험 |\n| --- | --- | --- |\n| : 성별, 연령, 항우울제 복용 여부, 우울 증상에 대한 기초 평가 | 소프트웨어 요구사항에서 |\n| 정의한 | 위험통제 | 조치가 |\n**소프트웨어의 정상 상태 및**\n**실제 제품에 올바르게 반영**\n| 고장 | 상태에서의 | 잠재적 |\n**되었으며, 위험이 효과적**\n**결함을 고려하여 위험을 분석**\n**으로 통제되어 잔여 위험이**\n**하고, 해당 위험을 통제하기**\n**임상시험용 의료기기와의 인과관계를 부정할 수 없는 경우를 말한다.",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 578,
        "window_size": 3,
        "char_count": 1168,
        "word_count": 254,
        "page_number": 40,
        "window_text": "국내외 규격\n\n- - 31 -\n<!-- PAGE_38 -->\n###### 나.  국내외 가이드라인\n\n번호\n\n표준 번호\n\n규격 명칭\n\n주요 내용\n\n비고\n\nApplication of risk\n\nmanagement for IT-networks\n\n**[표 시작]**\n\n| incorporating medical devices | 네트워크로 연결되는 |\n| --- | --- |\n\n**[표 끝]**\n\n- - 32 -\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n**[표 시작]**\n\n| 5 | 3 | 몽고메리-아스버그 | 정신질환 또는 정신과 입원 이력이 있는 자 | 비 인가된 | 허가심사 가이드라인 | 소프트웨어 | 및 소프트웨어 안전에 적합한 | 오진, 잘못된 치료 수행 | 국내·외 | 국내 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n\n**[표 끝]**\n\n의료기기 소프트웨어\n\n의료기기 소프트웨어의 기술문서 작성\n\n방법에\n\n대하여\n\n상세히\n\n기술하고\n\n‘의료기기\n\n소프트웨어\n\n적합성\n\n확인\n\n- - 33 -\n<!-- PAGE_40 -->\n##### 2.  안전성 평가 항목\n\n<!-- PAGE_40 -->\n###### 가.  소프트웨어 검증 및 유효성 확인\n\n<!-- PAGE_40 -->\n###### 1) 개요\n\n<!-- PAGE_40 -->\n###### 의료기기에 포함되는 소프트웨어 또는 의료기기 자체가 소프트\n\n<!-- PAGE_40 -->\n###### 웨어면 ‘의료기기 제조 및 품질관리 기준’ 및 ‘의료기기 위험\n\n<!-- PAGE_40 -->\n###### 관리 시스템’과 조화를 이루는 범위에서 개발, 유지되고 사용\n\n<!-- PAGE_40 -->\n###### 소프트웨어 검증 및 유효성 확인은 의료기기로서의 소프트웨어의\n\n<!-- PAGE_40 -->\n###### 신뢰도를 높이고 환자 또는 사용자에 대한 위험을 낮추기 위한\n\n<!-- PAGE_40 -->\n###### 활동으로, 국제 표준 IEC 62304, ISO 14971 및 ‘의료기기 소프트\n\n<!-- PAGE_40 -->\n###### 의료기기 제조업체는 ‘의료기기 제조 및 품질관리 기준’에\n\n<!-- PAGE_40 -->\n###### 규정된 바와 같이 수립된 품질시스템에서 관련 절차에 따라 소프트\n\n<!-- PAGE_40 -->\n###### 의료기기 소프트웨어의 위험관리는 소프트웨어 개발 활동의 일부이며,\n\n<!-- PAGE_40 -->\n###### 제조자는 소프트웨어 위험관리를 통해 의료기기에 포함된 소프트\n\n<!-- PAGE_40 -->\n###### 웨어 사용에 따른 허용 불가능한 위험이 발생하지 않고, 의료\n\n<!-- PAGE_40 -->\n###### 소프트웨어 개발 및 위험관리는 <표 8>와 같이 IEC 62304 프로\n\n- - 34 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n개발 소프트웨어의 범위, 규모\n\n소프트웨어의 개발 계획을\n\n**[표 시작]**\n\n| 수립하면서 | 동시에 | 위험 |\n| --- | --- | --- |\n| : 성별, 연령, 항우울제 복용 여부, 우울 증상에 대한 기초 평가 | 소프트웨어 요구사항에서 |\n| 정의한 | 위험통제 | 조치가 |\n**소프트웨어의 정상 상태 및**\n**실제 제품에 올바르게 반영**\n| 고장 | 상태에서의 | 잠재적 |\n**되었으며, 위험이 효과적**\n**결함을 고려하여 위험을 분석**\n**으로 통제되어 잔여 위험이**\n**하고, 해당 위험을 통제하기**\n**임상시험용 의료기기와의 인과관계를 부정할 수 없는 경우를 말한다. **\n**위한 조치를 결정한다.  이 중**\n**소프트웨어 설계에 해당하는**\n**통제 조치를 소프트웨어 요구**\n**새로운 위험의 발생 또는**\n| 소프트웨어 | 요구사항에 | 기존에 식별한 위험 평가의 |\n| 반영한 위험 통제 조치가 | 변경이 필요한 경우, 소프트 |\n| 실현될 수 있도록 안전한 | 웨어 형상의 변경이 위해 |\n**요인이 될 수 있는 경우**\n**위험관리 프로세스의 입력**\n**시판 후 발견된 문제점을**\n| 분석하고 | 안전과 | 관련된 |\n| 소프트웨어 위험 통제 조치를 | 항목은 위험관리 프로세스의 |\n| 제품에 구현한다.  이때 코드는 | 입력으로 식별한다. ",
        "original_sentence": "소프트웨어 검증 및 유효성 확인\n\n<!-- PAGE_40 -->\n###### 1) 개요\n\n<!-- PAGE_40 -->\n###### 의료기기에 포함되는 소프트웨어 또는 의료기기 자체가 소프트\n\n<!-- PAGE_40 -->\n###### 웨어면 ‘의료기기 제조 및 품질관리 기준’ 및 ‘의료기기 위험\n\n<!-- PAGE_40 -->\n###### 관리 시스템’과 조화를 이루는 범위에서 개발, 유지되고 사용\n\n<!-- PAGE_40 -->\n###### 소프트웨어 검증 및 유효성 확인은 의료기기로서의 소프트웨어의\n\n<!-- PAGE_40 -->\n###### 신뢰도를 높이고 환자 또는 사용자에 대한 위험을 낮추기 위한\n\n<!-- PAGE_40 -->\n###### 활동으로, 국제 표준 IEC 62304, ISO 14971 및 ‘의료기기 소프트\n\n<!-- PAGE_40 -->\n###### 의료기기 제조업체는 ‘의료기기 제조 및 품질관리 기준’에\n\n<!-- PAGE_40 -->\n###### 규정된 바와 같이 수립된 품질시스템에서 관련 절차에 따라 소프트\n\n<!-- PAGE_40 -->\n###### 의료기기 소프트웨어의 위험관리는 소프트웨어 개발 활동의 일부이며,\n\n<!-- PAGE_40 -->\n###### 제조자는 소프트웨어 위험관리를 통해 의료기기에 포함된 소프트\n\n<!-- PAGE_40 -->\n###### 웨어 사용에 따른 허용 불가능한 위험이 발생하지 않고, 의료\n\n<!-- PAGE_40 -->\n###### 소프트웨어 개발 및 위험관리는 <표 8>와 같이 IEC 62304 프로\n\n- - 34 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n개발 소프트웨어의 범위, 규모\n\n소프트웨어의 개발 계획을\n\n**[표 시작]**\n\n| 수립하면서 | 동시에 | 위험 |\n| --- | --- | --- |\n| : 성별, 연령, 항우울제 복용 여부, 우울 증상에 대한 기초 평가 | 소프트웨어 요구사항에서 |\n| 정의한 | 위험통제 | 조치가 |\n**소프트웨어의 정상 상태 및**\n**실제 제품에 올바르게 반영**\n| 고장 | 상태에서의 | 잠재적 |\n**되었으며, 위험이 효과적**\n**결함을 고려하여 위험을 분석**\n**으로 통제되어 잔여 위험이**\n**하고, 해당 위험을 통제하기**\n**임상시험용 의료기기와의 인과관계를 부정할 수 없는 경우를 말한다."
      }
    },
    {
      "chunk_id": "chunk_580",
      "text": "**\n**위한 조치를 결정한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 579,
        "window_size": 3,
        "char_count": 18,
        "word_count": 4,
        "page_number": 13,
        "window_text": "국내외 가이드라인\n\n번호\n\n표준 번호\n\n규격 명칭\n\n주요 내용\n\n비고\n\nApplication of risk\n\nmanagement for IT-networks\n\n**[표 시작]**\n\n| incorporating medical devices | 네트워크로 연결되는 |\n| --- | --- |\n\n**[표 끝]**\n\n- - 32 -\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n**[표 시작]**\n\n| 5 | 3 | 몽고메리-아스버그 | 정신질환 또는 정신과 입원 이력이 있는 자 | 비 인가된 | 허가심사 가이드라인 | 소프트웨어 | 및 소프트웨어 안전에 적합한 | 오진, 잘못된 치료 수행 | 국내·외 | 국내 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n\n**[표 끝]**\n\n의료기기 소프트웨어\n\n의료기기 소프트웨어의 기술문서 작성\n\n방법에\n\n대하여\n\n상세히\n\n기술하고\n\n‘의료기기\n\n소프트웨어\n\n적합성\n\n확인\n\n- - 33 -\n<!-- PAGE_40 -->\n##### 2.  안전성 평가 항목\n\n<!-- PAGE_40 -->\n###### 가.  소프트웨어 검증 및 유효성 확인\n\n<!-- PAGE_40 -->\n###### 1) 개요\n\n<!-- PAGE_40 -->\n###### 의료기기에 포함되는 소프트웨어 또는 의료기기 자체가 소프트\n\n<!-- PAGE_40 -->\n###### 웨어면 ‘의료기기 제조 및 품질관리 기준’ 및 ‘의료기기 위험\n\n<!-- PAGE_40 -->\n###### 관리 시스템’과 조화를 이루는 범위에서 개발, 유지되고 사용\n\n<!-- PAGE_40 -->\n###### 소프트웨어 검증 및 유효성 확인은 의료기기로서의 소프트웨어의\n\n<!-- PAGE_40 -->\n###### 신뢰도를 높이고 환자 또는 사용자에 대한 위험을 낮추기 위한\n\n<!-- PAGE_40 -->\n###### 활동으로, 국제 표준 IEC 62304, ISO 14971 및 ‘의료기기 소프트\n\n<!-- PAGE_40 -->\n###### 의료기기 제조업체는 ‘의료기기 제조 및 품질관리 기준’에\n\n<!-- PAGE_40 -->\n###### 규정된 바와 같이 수립된 품질시스템에서 관련 절차에 따라 소프트\n\n<!-- PAGE_40 -->\n###### 의료기기 소프트웨어의 위험관리는 소프트웨어 개발 활동의 일부이며,\n\n<!-- PAGE_40 -->\n###### 제조자는 소프트웨어 위험관리를 통해 의료기기에 포함된 소프트\n\n<!-- PAGE_40 -->\n###### 웨어 사용에 따른 허용 불가능한 위험이 발생하지 않고, 의료\n\n<!-- PAGE_40 -->\n###### 소프트웨어 개발 및 위험관리는 <표 8>와 같이 IEC 62304 프로\n\n- - 34 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n개발 소프트웨어의 범위, 규모\n\n소프트웨어의 개발 계획을\n\n**[표 시작]**\n\n| 수립하면서 | 동시에 | 위험 |\n| --- | --- | --- |\n| : 성별, 연령, 항우울제 복용 여부, 우울 증상에 대한 기초 평가 | 소프트웨어 요구사항에서 |\n| 정의한 | 위험통제 | 조치가 |\n**소프트웨어의 정상 상태 및**\n**실제 제품에 올바르게 반영**\n| 고장 | 상태에서의 | 잠재적 |\n**되었으며, 위험이 효과적**\n**결함을 고려하여 위험을 분석**\n**으로 통제되어 잔여 위험이**\n**하고, 해당 위험을 통제하기**\n**임상시험용 의료기기와의 인과관계를 부정할 수 없는 경우를 말한다. **\n**위한 조치를 결정한다.  이 중**\n**소프트웨어 설계에 해당하는**\n**통제 조치를 소프트웨어 요구**\n**새로운 위험의 발생 또는**\n| 소프트웨어 | 요구사항에 | 기존에 식별한 위험 평가의 |\n| 반영한 위험 통제 조치가 | 변경이 필요한 경우, 소프트 |\n| 실현될 수 있도록 안전한 | 웨어 형상의 변경이 위해 |\n**요인이 될 수 있는 경우**\n**위험관리 프로세스의 입력**\n**시판 후 발견된 문제점을**\n| 분석하고 | 안전과 | 관련된 |\n| 소프트웨어 위험 통제 조치를 | 항목은 위험관리 프로세스의 |\n| 제품에 구현한다.  이때 코드는 | 입력으로 식별한다.  문제 |\n**위험관리 프로세스에서 식별한**\n**해결 및 설계 변경은 위험**\n| 안전 | 요구사항을 | 정확하게 |\n\n**[표 끝]**\n\n<!-- PAGE_41 -->\n###### 표 8. ",
        "original_sentence": "**\n**위한 조치를 결정한다. "
      }
    },
    {
      "chunk_id": "chunk_581",
      "text": "이 중**\n**소프트웨어 설계에 해당하는**\n**통제 조치를 소프트웨어 요구**\n**새로운 위험의 발생 또는**\n| 소프트웨어 | 요구사항에 | 기존에 식별한 위험 평가의 |\n| 반영한 위험 통제 조치가 | 변경이 필요한 경우, 소프트 |\n| 실현될 수 있도록 안전한 | 웨어 형상의 변경이 위해 |\n**요인이 될 수 있는 경우**\n**위험관리 프로세스의 입력**\n**시판 후 발견된 문제점을**\n| 분석하고 | 안전과 | 관련된 |\n| 소프트웨어 위험 통제 조치를 | 항목은 위험관리 프로세스의 |\n| 제품에 구현한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 580,
        "window_size": 3,
        "char_count": 292,
        "word_count": 77,
        "page_number": 9,
        "window_text": "안전성 평가 항목\n\n<!-- PAGE_40 -->\n###### 가.  소프트웨어 검증 및 유효성 확인\n\n<!-- PAGE_40 -->\n###### 1) 개요\n\n<!-- PAGE_40 -->\n###### 의료기기에 포함되는 소프트웨어 또는 의료기기 자체가 소프트\n\n<!-- PAGE_40 -->\n###### 웨어면 ‘의료기기 제조 및 품질관리 기준’ 및 ‘의료기기 위험\n\n<!-- PAGE_40 -->\n###### 관리 시스템’과 조화를 이루는 범위에서 개발, 유지되고 사용\n\n<!-- PAGE_40 -->\n###### 소프트웨어 검증 및 유효성 확인은 의료기기로서의 소프트웨어의\n\n<!-- PAGE_40 -->\n###### 신뢰도를 높이고 환자 또는 사용자에 대한 위험을 낮추기 위한\n\n<!-- PAGE_40 -->\n###### 활동으로, 국제 표준 IEC 62304, ISO 14971 및 ‘의료기기 소프트\n\n<!-- PAGE_40 -->\n###### 의료기기 제조업체는 ‘의료기기 제조 및 품질관리 기준’에\n\n<!-- PAGE_40 -->\n###### 규정된 바와 같이 수립된 품질시스템에서 관련 절차에 따라 소프트\n\n<!-- PAGE_40 -->\n###### 의료기기 소프트웨어의 위험관리는 소프트웨어 개발 활동의 일부이며,\n\n<!-- PAGE_40 -->\n###### 제조자는 소프트웨어 위험관리를 통해 의료기기에 포함된 소프트\n\n<!-- PAGE_40 -->\n###### 웨어 사용에 따른 허용 불가능한 위험이 발생하지 않고, 의료\n\n<!-- PAGE_40 -->\n###### 소프트웨어 개발 및 위험관리는 <표 8>와 같이 IEC 62304 프로\n\n- - 34 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n개발 소프트웨어의 범위, 규모\n\n소프트웨어의 개발 계획을\n\n**[표 시작]**\n\n| 수립하면서 | 동시에 | 위험 |\n| --- | --- | --- |\n| : 성별, 연령, 항우울제 복용 여부, 우울 증상에 대한 기초 평가 | 소프트웨어 요구사항에서 |\n| 정의한 | 위험통제 | 조치가 |\n**소프트웨어의 정상 상태 및**\n**실제 제품에 올바르게 반영**\n| 고장 | 상태에서의 | 잠재적 |\n**되었으며, 위험이 효과적**\n**결함을 고려하여 위험을 분석**\n**으로 통제되어 잔여 위험이**\n**하고, 해당 위험을 통제하기**\n**임상시험용 의료기기와의 인과관계를 부정할 수 없는 경우를 말한다. **\n**위한 조치를 결정한다.  이 중**\n**소프트웨어 설계에 해당하는**\n**통제 조치를 소프트웨어 요구**\n**새로운 위험의 발생 또는**\n| 소프트웨어 | 요구사항에 | 기존에 식별한 위험 평가의 |\n| 반영한 위험 통제 조치가 | 변경이 필요한 경우, 소프트 |\n| 실현될 수 있도록 안전한 | 웨어 형상의 변경이 위해 |\n**요인이 될 수 있는 경우**\n**위험관리 프로세스의 입력**\n**시판 후 발견된 문제점을**\n| 분석하고 | 안전과 | 관련된 |\n| 소프트웨어 위험 통제 조치를 | 항목은 위험관리 프로세스의 |\n| 제품에 구현한다.  이때 코드는 | 입력으로 식별한다.  문제 |\n**위험관리 프로세스에서 식별한**\n**해결 및 설계 변경은 위험**\n| 안전 | 요구사항을 | 정확하게 |\n\n**[표 끝]**\n\n<!-- PAGE_41 -->\n###### 표 8.  소프트웨어 개발 및 위험관리\n\n- - 35 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n**[표 시작]**\n\n| 임상시험 의뢰자는 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 | 소프트웨어 | 비 인가된 사용자의 | 내적 긴장감, 수면저하, 식욕 저하, 집중의 어려움, 나태(권태), | 것으로 코드 실행 전에 오류를 | 위험 | (허용 가능/불가) |\n| --- | --- | --- | --- | --- | --- | --- |\n| 임상시험용 ‘우울장애 개선 디지털치료기기’의 안전성과 유효성을 증명하고자 | 1) 사용되는 통신 기술 : 유선 통신(LAN), 무선통신(Wi-fi, 블루투스) | 동등함을 보이는 연구시험이다. ",
        "original_sentence": "이 중**\n**소프트웨어 설계에 해당하는**\n**통제 조치를 소프트웨어 요구**\n**새로운 위험의 발생 또는**\n| 소프트웨어 | 요구사항에 | 기존에 식별한 위험 평가의 |\n| 반영한 위험 통제 조치가 | 변경이 필요한 경우, 소프트 |\n| 실현될 수 있도록 안전한 | 웨어 형상의 변경이 위해 |\n**요인이 될 수 있는 경우**\n**위험관리 프로세스의 입력**\n**시판 후 발견된 문제점을**\n| 분석하고 | 안전과 | 관련된 |\n| 소프트웨어 위험 통제 조치를 | 항목은 위험관리 프로세스의 |\n| 제품에 구현한다. "
      }
    },
    {
      "chunk_id": "chunk_582",
      "text": "이때 코드는 | 입력으로 식별한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 581,
        "window_size": 3,
        "char_count": 20,
        "word_count": 5,
        "page_number": 13,
        "window_text": "소프트웨어 검증 및 유효성 확인\n\n<!-- PAGE_40 -->\n###### 1) 개요\n\n<!-- PAGE_40 -->\n###### 의료기기에 포함되는 소프트웨어 또는 의료기기 자체가 소프트\n\n<!-- PAGE_40 -->\n###### 웨어면 ‘의료기기 제조 및 품질관리 기준’ 및 ‘의료기기 위험\n\n<!-- PAGE_40 -->\n###### 관리 시스템’과 조화를 이루는 범위에서 개발, 유지되고 사용\n\n<!-- PAGE_40 -->\n###### 소프트웨어 검증 및 유효성 확인은 의료기기로서의 소프트웨어의\n\n<!-- PAGE_40 -->\n###### 신뢰도를 높이고 환자 또는 사용자에 대한 위험을 낮추기 위한\n\n<!-- PAGE_40 -->\n###### 활동으로, 국제 표준 IEC 62304, ISO 14971 및 ‘의료기기 소프트\n\n<!-- PAGE_40 -->\n###### 의료기기 제조업체는 ‘의료기기 제조 및 품질관리 기준’에\n\n<!-- PAGE_40 -->\n###### 규정된 바와 같이 수립된 품질시스템에서 관련 절차에 따라 소프트\n\n<!-- PAGE_40 -->\n###### 의료기기 소프트웨어의 위험관리는 소프트웨어 개발 활동의 일부이며,\n\n<!-- PAGE_40 -->\n###### 제조자는 소프트웨어 위험관리를 통해 의료기기에 포함된 소프트\n\n<!-- PAGE_40 -->\n###### 웨어 사용에 따른 허용 불가능한 위험이 발생하지 않고, 의료\n\n<!-- PAGE_40 -->\n###### 소프트웨어 개발 및 위험관리는 <표 8>와 같이 IEC 62304 프로\n\n- - 34 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n개발 소프트웨어의 범위, 규모\n\n소프트웨어의 개발 계획을\n\n**[표 시작]**\n\n| 수립하면서 | 동시에 | 위험 |\n| --- | --- | --- |\n| : 성별, 연령, 항우울제 복용 여부, 우울 증상에 대한 기초 평가 | 소프트웨어 요구사항에서 |\n| 정의한 | 위험통제 | 조치가 |\n**소프트웨어의 정상 상태 및**\n**실제 제품에 올바르게 반영**\n| 고장 | 상태에서의 | 잠재적 |\n**되었으며, 위험이 효과적**\n**결함을 고려하여 위험을 분석**\n**으로 통제되어 잔여 위험이**\n**하고, 해당 위험을 통제하기**\n**임상시험용 의료기기와의 인과관계를 부정할 수 없는 경우를 말한다. **\n**위한 조치를 결정한다.  이 중**\n**소프트웨어 설계에 해당하는**\n**통제 조치를 소프트웨어 요구**\n**새로운 위험의 발생 또는**\n| 소프트웨어 | 요구사항에 | 기존에 식별한 위험 평가의 |\n| 반영한 위험 통제 조치가 | 변경이 필요한 경우, 소프트 |\n| 실현될 수 있도록 안전한 | 웨어 형상의 변경이 위해 |\n**요인이 될 수 있는 경우**\n**위험관리 프로세스의 입력**\n**시판 후 발견된 문제점을**\n| 분석하고 | 안전과 | 관련된 |\n| 소프트웨어 위험 통제 조치를 | 항목은 위험관리 프로세스의 |\n| 제품에 구현한다.  이때 코드는 | 입력으로 식별한다.  문제 |\n**위험관리 프로세스에서 식별한**\n**해결 및 설계 변경은 위험**\n| 안전 | 요구사항을 | 정확하게 |\n\n**[표 끝]**\n\n<!-- PAGE_41 -->\n###### 표 8.  소프트웨어 개발 및 위험관리\n\n- - 35 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n**[표 시작]**\n\n| 임상시험 의뢰자는 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 | 소프트웨어 | 비 인가된 사용자의 | 내적 긴장감, 수면저하, 식욕 저하, 집중의 어려움, 나태(권태), | 것으로 코드 실행 전에 오류를 | 위험 | (허용 가능/불가) |\n| --- | --- | --- | --- | --- | --- | --- |\n| 임상시험용 ‘우울장애 개선 디지털치료기기’의 안전성과 유효성을 증명하고자 | 1) 사용되는 통신 기술 : 유선 통신(LAN), 무선통신(Wi-fi, 블루투스) | 동등함을 보이는 연구시험이다.  | CBTi | 159 | 6.85 | 10.99 | 확인 자료 |\n| 임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료 방법 등을 제공 | 자살 소망, 자살 태도, 자살 계획에 대해 0~2점으로 응답 | 확인 자료 |\n\n**[표 끝]**\n\n각 유닛에 대한 코드를 검증하는\n\n통제 조치가 될 수 있다.\n\n",
        "original_sentence": "이때 코드는 | 입력으로 식별한다. "
      }
    },
    {
      "chunk_id": "chunk_583",
      "text": "문제 |\n**위험관리 프로세스에서 식별한**\n**해결 및 설계 변경은 위험**\n| 안전 | 요구사항을 | 정확하게 |\n\n**[표 끝]**\n\n<!-- PAGE_41 -->\n###### 표 8. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 582,
        "window_size": 3,
        "char_count": 107,
        "word_count": 25,
        "page_number": 41,
        "window_text": "**\n**위한 조치를 결정한다.  이 중**\n**소프트웨어 설계에 해당하는**\n**통제 조치를 소프트웨어 요구**\n**새로운 위험의 발생 또는**\n| 소프트웨어 | 요구사항에 | 기존에 식별한 위험 평가의 |\n| 반영한 위험 통제 조치가 | 변경이 필요한 경우, 소프트 |\n| 실현될 수 있도록 안전한 | 웨어 형상의 변경이 위해 |\n**요인이 될 수 있는 경우**\n**위험관리 프로세스의 입력**\n**시판 후 발견된 문제점을**\n| 분석하고 | 안전과 | 관련된 |\n| 소프트웨어 위험 통제 조치를 | 항목은 위험관리 프로세스의 |\n| 제품에 구현한다.  이때 코드는 | 입력으로 식별한다.  문제 |\n**위험관리 프로세스에서 식별한**\n**해결 및 설계 변경은 위험**\n| 안전 | 요구사항을 | 정확하게 |\n\n**[표 끝]**\n\n<!-- PAGE_41 -->\n###### 표 8.  소프트웨어 개발 및 위험관리\n\n- - 35 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n**[표 시작]**\n\n| 임상시험 의뢰자는 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 | 소프트웨어 | 비 인가된 사용자의 | 내적 긴장감, 수면저하, 식욕 저하, 집중의 어려움, 나태(권태), | 것으로 코드 실행 전에 오류를 | 위험 | (허용 가능/불가) |\n| --- | --- | --- | --- | --- | --- | --- |\n| 임상시험용 ‘우울장애 개선 디지털치료기기’의 안전성과 유효성을 증명하고자 | 1) 사용되는 통신 기술 : 유선 통신(LAN), 무선통신(Wi-fi, 블루투스) | 동등함을 보이는 연구시험이다.  | CBTi | 159 | 6.85 | 10.99 | 확인 자료 |\n| 임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료 방법 등을 제공 | 자살 소망, 자살 태도, 자살 계획에 대해 0~2점으로 응답 | 확인 자료 |\n\n**[표 끝]**\n\n각 유닛에 대한 코드를 검증하는\n\n통제 조치가 될 수 있다.\n\n 필요시 규제 당국에 안전성\n\n- - 36 -\n<!-- PAGE_43 -->\n###### 3) 소프트웨어 안전성 등급\n\n<!-- PAGE_43 -->\n###### 의료기기 소프트웨어의 고장 또는 잠재적 결함으로 인해 환자나\n\n<!-- PAGE_43 -->\n###### 사용자에게 미치는 위해의 영향에 따라 안전성 등급을 <표 9>과\n\n<!-- PAGE_43 -->\n###### 소프트웨어 안전성 등급은 위험통제 후 잔여 위험의 심각도를\n\n<!-- PAGE_43 -->\n###### 토대로 분류할 수 있다. ",
        "original_sentence": "문제 |\n**위험관리 프로세스에서 식별한**\n**해결 및 설계 변경은 위험**\n| 안전 | 요구사항을 | 정확하게 |\n\n**[표 끝]**\n\n<!-- PAGE_41 -->\n###### 표 8. "
      }
    },
    {
      "chunk_id": "chunk_584",
      "text": "소프트웨어 개발 및 위험관리\n\n- - 35 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n**[표 시작]**\n\n| 임상시험 의뢰자는 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 | 소프트웨어 | 비 인가된 사용자의 | 내적 긴장감, 수면저하, 식욕 저하, 집중의 어려움, 나태(권태), | 것으로 코드 실행 전에 오류를 | 위험 | (허용 가능/불가) |\n| --- | --- | --- | --- | --- | --- | --- |\n| 임상시험용 ‘우울장애 개선 디지털치료기기’의 안전성과 유효성을 증명하고자 | 1) 사용되는 통신 기술 : 유선 통신(LAN), 무선통신(Wi-fi, 블루투스) | 동등함을 보이는 연구시험이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 583,
        "window_size": 3,
        "char_count": 382,
        "word_count": 94,
        "page_number": 9,
        "window_text": "이 중**\n**소프트웨어 설계에 해당하는**\n**통제 조치를 소프트웨어 요구**\n**새로운 위험의 발생 또는**\n| 소프트웨어 | 요구사항에 | 기존에 식별한 위험 평가의 |\n| 반영한 위험 통제 조치가 | 변경이 필요한 경우, 소프트 |\n| 실현될 수 있도록 안전한 | 웨어 형상의 변경이 위해 |\n**요인이 될 수 있는 경우**\n**위험관리 프로세스의 입력**\n**시판 후 발견된 문제점을**\n| 분석하고 | 안전과 | 관련된 |\n| 소프트웨어 위험 통제 조치를 | 항목은 위험관리 프로세스의 |\n| 제품에 구현한다.  이때 코드는 | 입력으로 식별한다.  문제 |\n**위험관리 프로세스에서 식별한**\n**해결 및 설계 변경은 위험**\n| 안전 | 요구사항을 | 정확하게 |\n\n**[표 끝]**\n\n<!-- PAGE_41 -->\n###### 표 8.  소프트웨어 개발 및 위험관리\n\n- - 35 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n**[표 시작]**\n\n| 임상시험 의뢰자는 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 | 소프트웨어 | 비 인가된 사용자의 | 내적 긴장감, 수면저하, 식욕 저하, 집중의 어려움, 나태(권태), | 것으로 코드 실행 전에 오류를 | 위험 | (허용 가능/불가) |\n| --- | --- | --- | --- | --- | --- | --- |\n| 임상시험용 ‘우울장애 개선 디지털치료기기’의 안전성과 유효성을 증명하고자 | 1) 사용되는 통신 기술 : 유선 통신(LAN), 무선통신(Wi-fi, 블루투스) | 동등함을 보이는 연구시험이다.  | CBTi | 159 | 6.85 | 10.99 | 확인 자료 |\n| 임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료 방법 등을 제공 | 자살 소망, 자살 태도, 자살 계획에 대해 0~2점으로 응답 | 확인 자료 |\n\n**[표 끝]**\n\n각 유닛에 대한 코드를 검증하는\n\n통제 조치가 될 수 있다.\n\n 필요시 규제 당국에 안전성\n\n- - 36 -\n<!-- PAGE_43 -->\n###### 3) 소프트웨어 안전성 등급\n\n<!-- PAGE_43 -->\n###### 의료기기 소프트웨어의 고장 또는 잠재적 결함으로 인해 환자나\n\n<!-- PAGE_43 -->\n###### 사용자에게 미치는 위해의 영향에 따라 안전성 등급을 <표 9>과\n\n<!-- PAGE_43 -->\n###### 소프트웨어 안전성 등급은 위험통제 후 잔여 위험의 심각도를\n\n<!-- PAGE_43 -->\n###### 토대로 분류할 수 있다.  이때, 발생 가능성은 안전성 등급 결정 시\n\n<!-- PAGE_43 -->\n###### 소프트웨어가 여러 개의 독립적인 모듈이 모여서 구성된 경우\n\n<!-- PAGE_43 -->\n###### 각 모듈에 대해 별도로 안전성 등급을 부여할 수 있다. ",
        "original_sentence": "소프트웨어 개발 및 위험관리\n\n- - 35 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n**[표 시작]**\n\n| 임상시험 의뢰자는 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 | 소프트웨어 | 비 인가된 사용자의 | 내적 긴장감, 수면저하, 식욕 저하, 집중의 어려움, 나태(권태), | 것으로 코드 실행 전에 오류를 | 위험 | (허용 가능/불가) |\n| --- | --- | --- | --- | --- | --- | --- |\n| 임상시험용 ‘우울장애 개선 디지털치료기기’의 안전성과 유효성을 증명하고자 | 1) 사용되는 통신 기술 : 유선 통신(LAN), 무선통신(Wi-fi, 블루투스) | 동등함을 보이는 연구시험이다. "
      }
    },
    {
      "chunk_id": "chunk_585",
      "text": "| CBTi | 159 | 6.85 | 10.99 | 확인 자료 |\n| 임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료 방법 등을 제공 | 자살 소망, 자살 태도, 자살 계획에 대해 0~2점으로 응답 | 확인 자료 |\n\n**[표 끝]**\n\n각 유닛에 대한 코드를 검증하는\n\n통제 조치가 될 수 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 584,
        "window_size": 3,
        "char_count": 178,
        "word_count": 51,
        "page_number": 28,
        "window_text": "이때 코드는 | 입력으로 식별한다.  문제 |\n**위험관리 프로세스에서 식별한**\n**해결 및 설계 변경은 위험**\n| 안전 | 요구사항을 | 정확하게 |\n\n**[표 끝]**\n\n<!-- PAGE_41 -->\n###### 표 8.  소프트웨어 개발 및 위험관리\n\n- - 35 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n**[표 시작]**\n\n| 임상시험 의뢰자는 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 | 소프트웨어 | 비 인가된 사용자의 | 내적 긴장감, 수면저하, 식욕 저하, 집중의 어려움, 나태(권태), | 것으로 코드 실행 전에 오류를 | 위험 | (허용 가능/불가) |\n| --- | --- | --- | --- | --- | --- | --- |\n| 임상시험용 ‘우울장애 개선 디지털치료기기’의 안전성과 유효성을 증명하고자 | 1) 사용되는 통신 기술 : 유선 통신(LAN), 무선통신(Wi-fi, 블루투스) | 동등함을 보이는 연구시험이다.  | CBTi | 159 | 6.85 | 10.99 | 확인 자료 |\n| 임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료 방법 등을 제공 | 자살 소망, 자살 태도, 자살 계획에 대해 0~2점으로 응답 | 확인 자료 |\n\n**[표 끝]**\n\n각 유닛에 대한 코드를 검증하는\n\n통제 조치가 될 수 있다.\n\n 필요시 규제 당국에 안전성\n\n- - 36 -\n<!-- PAGE_43 -->\n###### 3) 소프트웨어 안전성 등급\n\n<!-- PAGE_43 -->\n###### 의료기기 소프트웨어의 고장 또는 잠재적 결함으로 인해 환자나\n\n<!-- PAGE_43 -->\n###### 사용자에게 미치는 위해의 영향에 따라 안전성 등급을 <표 9>과\n\n<!-- PAGE_43 -->\n###### 소프트웨어 안전성 등급은 위험통제 후 잔여 위험의 심각도를\n\n<!-- PAGE_43 -->\n###### 토대로 분류할 수 있다.  이때, 발생 가능성은 안전성 등급 결정 시\n\n<!-- PAGE_43 -->\n###### 소프트웨어가 여러 개의 독립적인 모듈이 모여서 구성된 경우\n\n<!-- PAGE_43 -->\n###### 각 모듈에 대해 별도로 안전성 등급을 부여할 수 있다.  이때 전체\n\n<!-- PAGE_43 -->\n###### 소프트웨어의 안전성 등급은 개별 모듈의 안전성 등급 중 가장\n\n<!-- PAGE_43 -->\n###### 나. ",
        "original_sentence": "| CBTi | 159 | 6.85 | 10.99 | 확인 자료 |\n| 임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료 방법 등을 제공 | 자살 소망, 자살 태도, 자살 계획에 대해 0~2점으로 응답 | 확인 자료 |\n\n**[표 끝]**\n\n각 유닛에 대한 코드를 검증하는\n\n통제 조치가 될 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_586",
      "text": "필요시 규제 당국에 안전성\n\n- - 36 -\n<!-- PAGE_43 -->\n###### 3) 소프트웨어 안전성 등급\n\n<!-- PAGE_43 -->\n###### 의료기기 소프트웨어의 고장 또는 잠재적 결함으로 인해 환자나\n\n<!-- PAGE_43 -->\n###### 사용자에게 미치는 위해의 영향에 따라 안전성 등급을 <표 9>과\n\n<!-- PAGE_43 -->\n###### 소프트웨어 안전성 등급은 위험통제 후 잔여 위험의 심각도를\n\n<!-- PAGE_43 -->\n###### 토대로 분류할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 585,
        "window_size": 3,
        "char_count": 282,
        "word_count": 61,
        "page_number": 43,
        "window_text": "문제 |\n**위험관리 프로세스에서 식별한**\n**해결 및 설계 변경은 위험**\n| 안전 | 요구사항을 | 정확하게 |\n\n**[표 끝]**\n\n<!-- PAGE_41 -->\n###### 표 8.  소프트웨어 개발 및 위험관리\n\n- - 35 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n**[표 시작]**\n\n| 임상시험 의뢰자는 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 | 소프트웨어 | 비 인가된 사용자의 | 내적 긴장감, 수면저하, 식욕 저하, 집중의 어려움, 나태(권태), | 것으로 코드 실행 전에 오류를 | 위험 | (허용 가능/불가) |\n| --- | --- | --- | --- | --- | --- | --- |\n| 임상시험용 ‘우울장애 개선 디지털치료기기’의 안전성과 유효성을 증명하고자 | 1) 사용되는 통신 기술 : 유선 통신(LAN), 무선통신(Wi-fi, 블루투스) | 동등함을 보이는 연구시험이다.  | CBTi | 159 | 6.85 | 10.99 | 확인 자료 |\n| 임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료 방법 등을 제공 | 자살 소망, 자살 태도, 자살 계획에 대해 0~2점으로 응답 | 확인 자료 |\n\n**[표 끝]**\n\n각 유닛에 대한 코드를 검증하는\n\n통제 조치가 될 수 있다.\n\n 필요시 규제 당국에 안전성\n\n- - 36 -\n<!-- PAGE_43 -->\n###### 3) 소프트웨어 안전성 등급\n\n<!-- PAGE_43 -->\n###### 의료기기 소프트웨어의 고장 또는 잠재적 결함으로 인해 환자나\n\n<!-- PAGE_43 -->\n###### 사용자에게 미치는 위해의 영향에 따라 안전성 등급을 <표 9>과\n\n<!-- PAGE_43 -->\n###### 소프트웨어 안전성 등급은 위험통제 후 잔여 위험의 심각도를\n\n<!-- PAGE_43 -->\n###### 토대로 분류할 수 있다.  이때, 발생 가능성은 안전성 등급 결정 시\n\n<!-- PAGE_43 -->\n###### 소프트웨어가 여러 개의 독립적인 모듈이 모여서 구성된 경우\n\n<!-- PAGE_43 -->\n###### 각 모듈에 대해 별도로 안전성 등급을 부여할 수 있다.  이때 전체\n\n<!-- PAGE_43 -->\n###### 소프트웨어의 안전성 등급은 개별 모듈의 안전성 등급 중 가장\n\n<!-- PAGE_43 -->\n###### 나.  의료기기의 사이버 보안\n\n<!-- PAGE_43 -->\n###### 유·무선 통신이 가능하거나 통신 경로가 존재하는 제품의 경우\n\n<!-- PAGE_43 -->\n###### 사이버보안에 대한 요구사항을 준수해야 한다. ",
        "original_sentence": "필요시 규제 당국에 안전성\n\n- - 36 -\n<!-- PAGE_43 -->\n###### 3) 소프트웨어 안전성 등급\n\n<!-- PAGE_43 -->\n###### 의료기기 소프트웨어의 고장 또는 잠재적 결함으로 인해 환자나\n\n<!-- PAGE_43 -->\n###### 사용자에게 미치는 위해의 영향에 따라 안전성 등급을 <표 9>과\n\n<!-- PAGE_43 -->\n###### 소프트웨어 안전성 등급은 위험통제 후 잔여 위험의 심각도를\n\n<!-- PAGE_43 -->\n###### 토대로 분류할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_587",
      "text": "이때, 발생 가능성은 안전성 등급 결정 시\n\n<!-- PAGE_43 -->\n###### 소프트웨어가 여러 개의 독립적인 모듈이 모여서 구성된 경우\n\n<!-- PAGE_43 -->\n###### 각 모듈에 대해 별도로 안전성 등급을 부여할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 586,
        "window_size": 3,
        "char_count": 138,
        "word_count": 32,
        "page_number": 43,
        "window_text": "소프트웨어 개발 및 위험관리\n\n- - 35 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n**[표 시작]**\n\n| 임상시험 의뢰자는 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 | 소프트웨어 | 비 인가된 사용자의 | 내적 긴장감, 수면저하, 식욕 저하, 집중의 어려움, 나태(권태), | 것으로 코드 실행 전에 오류를 | 위험 | (허용 가능/불가) |\n| --- | --- | --- | --- | --- | --- | --- |\n| 임상시험용 ‘우울장애 개선 디지털치료기기’의 안전성과 유효성을 증명하고자 | 1) 사용되는 통신 기술 : 유선 통신(LAN), 무선통신(Wi-fi, 블루투스) | 동등함을 보이는 연구시험이다.  | CBTi | 159 | 6.85 | 10.99 | 확인 자료 |\n| 임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료 방법 등을 제공 | 자살 소망, 자살 태도, 자살 계획에 대해 0~2점으로 응답 | 확인 자료 |\n\n**[표 끝]**\n\n각 유닛에 대한 코드를 검증하는\n\n통제 조치가 될 수 있다.\n\n 필요시 규제 당국에 안전성\n\n- - 36 -\n<!-- PAGE_43 -->\n###### 3) 소프트웨어 안전성 등급\n\n<!-- PAGE_43 -->\n###### 의료기기 소프트웨어의 고장 또는 잠재적 결함으로 인해 환자나\n\n<!-- PAGE_43 -->\n###### 사용자에게 미치는 위해의 영향에 따라 안전성 등급을 <표 9>과\n\n<!-- PAGE_43 -->\n###### 소프트웨어 안전성 등급은 위험통제 후 잔여 위험의 심각도를\n\n<!-- PAGE_43 -->\n###### 토대로 분류할 수 있다.  이때, 발생 가능성은 안전성 등급 결정 시\n\n<!-- PAGE_43 -->\n###### 소프트웨어가 여러 개의 독립적인 모듈이 모여서 구성된 경우\n\n<!-- PAGE_43 -->\n###### 각 모듈에 대해 별도로 안전성 등급을 부여할 수 있다.  이때 전체\n\n<!-- PAGE_43 -->\n###### 소프트웨어의 안전성 등급은 개별 모듈의 안전성 등급 중 가장\n\n<!-- PAGE_43 -->\n###### 나.  의료기기의 사이버 보안\n\n<!-- PAGE_43 -->\n###### 유·무선 통신이 가능하거나 통신 경로가 존재하는 제품의 경우\n\n<!-- PAGE_43 -->\n###### 사이버보안에 대한 요구사항을 준수해야 한다.  제조자는 이를 확인\n\n<!-- PAGE_43 -->\n###### 할 수 있도록 ‘의료기기 사이버보안 요구사항 체크리스트’와\n\n<!-- PAGE_43 -->\n###### 요구사항을 실제로 검증한 자료를 제출하여야 한다. ",
        "original_sentence": "이때, 발생 가능성은 안전성 등급 결정 시\n\n<!-- PAGE_43 -->\n###### 소프트웨어가 여러 개의 독립적인 모듈이 모여서 구성된 경우\n\n<!-- PAGE_43 -->\n###### 각 모듈에 대해 별도로 안전성 등급을 부여할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_588",
      "text": "이때 전체\n\n<!-- PAGE_43 -->\n###### 소프트웨어의 안전성 등급은 개별 모듈의 안전성 등급 중 가장\n\n<!-- PAGE_43 -->\n###### 나. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 587,
        "window_size": 3,
        "char_count": 93,
        "word_count": 20,
        "page_number": 43,
        "window_text": "| CBTi | 159 | 6.85 | 10.99 | 확인 자료 |\n| 임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료 방법 등을 제공 | 자살 소망, 자살 태도, 자살 계획에 대해 0~2점으로 응답 | 확인 자료 |\n\n**[표 끝]**\n\n각 유닛에 대한 코드를 검증하는\n\n통제 조치가 될 수 있다.\n\n 필요시 규제 당국에 안전성\n\n- - 36 -\n<!-- PAGE_43 -->\n###### 3) 소프트웨어 안전성 등급\n\n<!-- PAGE_43 -->\n###### 의료기기 소프트웨어의 고장 또는 잠재적 결함으로 인해 환자나\n\n<!-- PAGE_43 -->\n###### 사용자에게 미치는 위해의 영향에 따라 안전성 등급을 <표 9>과\n\n<!-- PAGE_43 -->\n###### 소프트웨어 안전성 등급은 위험통제 후 잔여 위험의 심각도를\n\n<!-- PAGE_43 -->\n###### 토대로 분류할 수 있다.  이때, 발생 가능성은 안전성 등급 결정 시\n\n<!-- PAGE_43 -->\n###### 소프트웨어가 여러 개의 독립적인 모듈이 모여서 구성된 경우\n\n<!-- PAGE_43 -->\n###### 각 모듈에 대해 별도로 안전성 등급을 부여할 수 있다.  이때 전체\n\n<!-- PAGE_43 -->\n###### 소프트웨어의 안전성 등급은 개별 모듈의 안전성 등급 중 가장\n\n<!-- PAGE_43 -->\n###### 나.  의료기기의 사이버 보안\n\n<!-- PAGE_43 -->\n###### 유·무선 통신이 가능하거나 통신 경로가 존재하는 제품의 경우\n\n<!-- PAGE_43 -->\n###### 사이버보안에 대한 요구사항을 준수해야 한다.  제조자는 이를 확인\n\n<!-- PAGE_43 -->\n###### 할 수 있도록 ‘의료기기 사이버보안 요구사항 체크리스트’와\n\n<!-- PAGE_43 -->\n###### 요구사항을 실제로 검증한 자료를 제출하여야 한다.  다만, 제조사의\n\n- - 37 -\n<!-- PAGE_44 -->\n###### 위험분석을 통해 요구사항 일부를 제외하거나 수정하여 적용할 때는\n\n<!-- PAGE_44 -->\n###### 시험규격 및 그 설정 근거를 제출하여야 하며 해당 자료로\n\n<!-- PAGE_44 -->\n###### ‘사이버보안 위험관리문서’를 제출할 수 있다.\n\n",
        "original_sentence": "이때 전체\n\n<!-- PAGE_43 -->\n###### 소프트웨어의 안전성 등급은 개별 모듈의 안전성 등급 중 가장\n\n<!-- PAGE_43 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_589",
      "text": "의료기기의 사이버 보안\n\n<!-- PAGE_43 -->\n###### 유·무선 통신이 가능하거나 통신 경로가 존재하는 제품의 경우\n\n<!-- PAGE_43 -->\n###### 사이버보안에 대한 요구사항을 준수해야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 588,
        "window_size": 3,
        "char_count": 122,
        "word_count": 24,
        "page_number": 43,
        "window_text": "필요시 규제 당국에 안전성\n\n- - 36 -\n<!-- PAGE_43 -->\n###### 3) 소프트웨어 안전성 등급\n\n<!-- PAGE_43 -->\n###### 의료기기 소프트웨어의 고장 또는 잠재적 결함으로 인해 환자나\n\n<!-- PAGE_43 -->\n###### 사용자에게 미치는 위해의 영향에 따라 안전성 등급을 <표 9>과\n\n<!-- PAGE_43 -->\n###### 소프트웨어 안전성 등급은 위험통제 후 잔여 위험의 심각도를\n\n<!-- PAGE_43 -->\n###### 토대로 분류할 수 있다.  이때, 발생 가능성은 안전성 등급 결정 시\n\n<!-- PAGE_43 -->\n###### 소프트웨어가 여러 개의 독립적인 모듈이 모여서 구성된 경우\n\n<!-- PAGE_43 -->\n###### 각 모듈에 대해 별도로 안전성 등급을 부여할 수 있다.  이때 전체\n\n<!-- PAGE_43 -->\n###### 소프트웨어의 안전성 등급은 개별 모듈의 안전성 등급 중 가장\n\n<!-- PAGE_43 -->\n###### 나.  의료기기의 사이버 보안\n\n<!-- PAGE_43 -->\n###### 유·무선 통신이 가능하거나 통신 경로가 존재하는 제품의 경우\n\n<!-- PAGE_43 -->\n###### 사이버보안에 대한 요구사항을 준수해야 한다.  제조자는 이를 확인\n\n<!-- PAGE_43 -->\n###### 할 수 있도록 ‘의료기기 사이버보안 요구사항 체크리스트’와\n\n<!-- PAGE_43 -->\n###### 요구사항을 실제로 검증한 자료를 제출하여야 한다.  다만, 제조사의\n\n- - 37 -\n<!-- PAGE_44 -->\n###### 위험분석을 통해 요구사항 일부를 제외하거나 수정하여 적용할 때는\n\n<!-- PAGE_44 -->\n###### 시험규격 및 그 설정 근거를 제출하여야 하며 해당 자료로\n\n<!-- PAGE_44 -->\n###### ‘사이버보안 위험관리문서’를 제출할 수 있다.\n\n <!-- PAGE_44 -->\n###### 사이버보안 요구사항은 ‘의료기기의 사이버보안 허가·심사\n\n<!-- PAGE_44 -->\n###### ‘의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)’\n\n<!-- PAGE_44 -->\n###### 에는 보안통신, 데이터 보호, 기기 무결성, 사용자 인증, 소프트웨어\n\n<!-- PAGE_44 -->\n###### 유지보수, 물리적 접근, 신뢰성 및 가용성 등에 대한 요구사항을 제시\n\n<!-- PAGE_44 -->\n###### 하고 있다. ",
        "original_sentence": "의료기기의 사이버 보안\n\n<!-- PAGE_43 -->\n###### 유·무선 통신이 가능하거나 통신 경로가 존재하는 제품의 경우\n\n<!-- PAGE_43 -->\n###### 사이버보안에 대한 요구사항을 준수해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_590",
      "text": "제조자는 이를 확인\n\n<!-- PAGE_43 -->\n###### 할 수 있도록 ‘의료기기 사이버보안 요구사항 체크리스트’와\n\n<!-- PAGE_43 -->\n###### 요구사항을 실제로 검증한 자료를 제출하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 589,
        "window_size": 3,
        "char_count": 122,
        "word_count": 24,
        "page_number": 43,
        "window_text": "이때, 발생 가능성은 안전성 등급 결정 시\n\n<!-- PAGE_43 -->\n###### 소프트웨어가 여러 개의 독립적인 모듈이 모여서 구성된 경우\n\n<!-- PAGE_43 -->\n###### 각 모듈에 대해 별도로 안전성 등급을 부여할 수 있다.  이때 전체\n\n<!-- PAGE_43 -->\n###### 소프트웨어의 안전성 등급은 개별 모듈의 안전성 등급 중 가장\n\n<!-- PAGE_43 -->\n###### 나.  의료기기의 사이버 보안\n\n<!-- PAGE_43 -->\n###### 유·무선 통신이 가능하거나 통신 경로가 존재하는 제품의 경우\n\n<!-- PAGE_43 -->\n###### 사이버보안에 대한 요구사항을 준수해야 한다.  제조자는 이를 확인\n\n<!-- PAGE_43 -->\n###### 할 수 있도록 ‘의료기기 사이버보안 요구사항 체크리스트’와\n\n<!-- PAGE_43 -->\n###### 요구사항을 실제로 검증한 자료를 제출하여야 한다.  다만, 제조사의\n\n- - 37 -\n<!-- PAGE_44 -->\n###### 위험분석을 통해 요구사항 일부를 제외하거나 수정하여 적용할 때는\n\n<!-- PAGE_44 -->\n###### 시험규격 및 그 설정 근거를 제출하여야 하며 해당 자료로\n\n<!-- PAGE_44 -->\n###### ‘사이버보안 위험관리문서’를 제출할 수 있다.\n\n <!-- PAGE_44 -->\n###### 사이버보안 요구사항은 ‘의료기기의 사이버보안 허가·심사\n\n<!-- PAGE_44 -->\n###### ‘의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)’\n\n<!-- PAGE_44 -->\n###### 에는 보안통신, 데이터 보호, 기기 무결성, 사용자 인증, 소프트웨어\n\n<!-- PAGE_44 -->\n###### 유지보수, 물리적 접근, 신뢰성 및 가용성 등에 대한 요구사항을 제시\n\n<!-- PAGE_44 -->\n###### 하고 있다.  본 요구사항은 제품의 사이버보안 안전성 등급 및\n\n<!-- PAGE_44 -->\n###### 제품의 특성에 따라 적용한다. ",
        "original_sentence": "제조자는 이를 확인\n\n<!-- PAGE_43 -->\n###### 할 수 있도록 ‘의료기기 사이버보안 요구사항 체크리스트’와\n\n<!-- PAGE_43 -->\n###### 요구사항을 실제로 검증한 자료를 제출하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_591",
      "text": "다만, 제조사의\n\n- - 37 -\n<!-- PAGE_44 -->\n###### 위험분석을 통해 요구사항 일부를 제외하거나 수정하여 적용할 때는\n\n<!-- PAGE_44 -->\n###### 시험규격 및 그 설정 근거를 제출하여야 하며 해당 자료로\n\n<!-- PAGE_44 -->\n###### ‘사이버보안 위험관리문서’를 제출할 수 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 590,
        "window_size": 3,
        "char_count": 188,
        "word_count": 40,
        "page_number": 44,
        "window_text": "이때 전체\n\n<!-- PAGE_43 -->\n###### 소프트웨어의 안전성 등급은 개별 모듈의 안전성 등급 중 가장\n\n<!-- PAGE_43 -->\n###### 나.  의료기기의 사이버 보안\n\n<!-- PAGE_43 -->\n###### 유·무선 통신이 가능하거나 통신 경로가 존재하는 제품의 경우\n\n<!-- PAGE_43 -->\n###### 사이버보안에 대한 요구사항을 준수해야 한다.  제조자는 이를 확인\n\n<!-- PAGE_43 -->\n###### 할 수 있도록 ‘의료기기 사이버보안 요구사항 체크리스트’와\n\n<!-- PAGE_43 -->\n###### 요구사항을 실제로 검증한 자료를 제출하여야 한다.  다만, 제조사의\n\n- - 37 -\n<!-- PAGE_44 -->\n###### 위험분석을 통해 요구사항 일부를 제외하거나 수정하여 적용할 때는\n\n<!-- PAGE_44 -->\n###### 시험규격 및 그 설정 근거를 제출하여야 하며 해당 자료로\n\n<!-- PAGE_44 -->\n###### ‘사이버보안 위험관리문서’를 제출할 수 있다.\n\n <!-- PAGE_44 -->\n###### 사이버보안 요구사항은 ‘의료기기의 사이버보안 허가·심사\n\n<!-- PAGE_44 -->\n###### ‘의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)’\n\n<!-- PAGE_44 -->\n###### 에는 보안통신, 데이터 보호, 기기 무결성, 사용자 인증, 소프트웨어\n\n<!-- PAGE_44 -->\n###### 유지보수, 물리적 접근, 신뢰성 및 가용성 등에 대한 요구사항을 제시\n\n<!-- PAGE_44 -->\n###### 하고 있다.  본 요구사항은 제품의 사이버보안 안전성 등급 및\n\n<!-- PAGE_44 -->\n###### 제품의 특성에 따라 적용한다.  해당 가이드라인에 따라 제품에\n\n<!-- PAGE_44 -->\n###### 소프트웨어 위험관리에는 사이버보안에 대한 위험관리 항목이\n\n<!-- PAGE_44 -->\n###### 포함되어야 하며, 소프트웨어 위험관리와 동일한 방식으로 위험관리\n\n<!-- PAGE_44 -->\n###### ‘위해요인 식별’에서는 관련 자료(규격, 가이드라인, 국내외\n\n<!-- PAGE_44 -->\n###### 이상 사례 등)에 근거하여 의료기기의 정상 및 고장상태에서\n\n<!-- PAGE_44 -->\n###### 이미 알고 있거나 예측 가능한 의료기기 사이버보안 측면의\n\n<!-- PAGE_44 -->\n###### ‘위험산정’에서는 위해상황을 초래할 수 있는 예측 가능한\n\n- - 38 -\n위해요인\n\n구체적인 예시\n\n사용자 또는 환자에게\n\n발생 가능한 손상\n\n관련자료\n\n<!-- PAGE_45 -->\n###### 표 10. ",
        "original_sentence": "다만, 제조사의\n\n- - 37 -\n<!-- PAGE_44 -->\n###### 위험분석을 통해 요구사항 일부를 제외하거나 수정하여 적용할 때는\n\n<!-- PAGE_44 -->\n###### 시험규격 및 그 설정 근거를 제출하여야 하며 해당 자료로\n\n<!-- PAGE_44 -->\n###### ‘사이버보안 위험관리문서’를 제출할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_592",
      "text": "<!-- PAGE_44 -->\n###### 사이버보안 요구사항은 ‘의료기기의 사이버보안 허가·심사\n\n<!-- PAGE_44 -->\n###### ‘의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)’\n\n<!-- PAGE_44 -->\n###### 에는 보안통신, 데이터 보호, 기기 무결성, 사용자 인증, 소프트웨어\n\n<!-- PAGE_44 -->\n###### 유지보수, 물리적 접근, 신뢰성 및 가용성 등에 대한 요구사항을 제시\n\n<!-- PAGE_44 -->\n###### 하고 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 591,
        "window_size": 3,
        "char_count": 275,
        "word_count": 51,
        "page_number": 44,
        "window_text": "의료기기의 사이버 보안\n\n<!-- PAGE_43 -->\n###### 유·무선 통신이 가능하거나 통신 경로가 존재하는 제품의 경우\n\n<!-- PAGE_43 -->\n###### 사이버보안에 대한 요구사항을 준수해야 한다.  제조자는 이를 확인\n\n<!-- PAGE_43 -->\n###### 할 수 있도록 ‘의료기기 사이버보안 요구사항 체크리스트’와\n\n<!-- PAGE_43 -->\n###### 요구사항을 실제로 검증한 자료를 제출하여야 한다.  다만, 제조사의\n\n- - 37 -\n<!-- PAGE_44 -->\n###### 위험분석을 통해 요구사항 일부를 제외하거나 수정하여 적용할 때는\n\n<!-- PAGE_44 -->\n###### 시험규격 및 그 설정 근거를 제출하여야 하며 해당 자료로\n\n<!-- PAGE_44 -->\n###### ‘사이버보안 위험관리문서’를 제출할 수 있다.\n\n <!-- PAGE_44 -->\n###### 사이버보안 요구사항은 ‘의료기기의 사이버보안 허가·심사\n\n<!-- PAGE_44 -->\n###### ‘의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)’\n\n<!-- PAGE_44 -->\n###### 에는 보안통신, 데이터 보호, 기기 무결성, 사용자 인증, 소프트웨어\n\n<!-- PAGE_44 -->\n###### 유지보수, 물리적 접근, 신뢰성 및 가용성 등에 대한 요구사항을 제시\n\n<!-- PAGE_44 -->\n###### 하고 있다.  본 요구사항은 제품의 사이버보안 안전성 등급 및\n\n<!-- PAGE_44 -->\n###### 제품의 특성에 따라 적용한다.  해당 가이드라인에 따라 제품에\n\n<!-- PAGE_44 -->\n###### 소프트웨어 위험관리에는 사이버보안에 대한 위험관리 항목이\n\n<!-- PAGE_44 -->\n###### 포함되어야 하며, 소프트웨어 위험관리와 동일한 방식으로 위험관리\n\n<!-- PAGE_44 -->\n###### ‘위해요인 식별’에서는 관련 자료(규격, 가이드라인, 국내외\n\n<!-- PAGE_44 -->\n###### 이상 사례 등)에 근거하여 의료기기의 정상 및 고장상태에서\n\n<!-- PAGE_44 -->\n###### 이미 알고 있거나 예측 가능한 의료기기 사이버보안 측면의\n\n<!-- PAGE_44 -->\n###### ‘위험산정’에서는 위해상황을 초래할 수 있는 예측 가능한\n\n- - 38 -\n위해요인\n\n구체적인 예시\n\n사용자 또는 환자에게\n\n발생 가능한 손상\n\n관련자료\n\n<!-- PAGE_45 -->\n###### 표 10.  위해요인 식별 예시\n\n<!-- PAGE_45 -->\n###### 식별한 모든 위험에 대하여 위험의 평가 결과를 ‘위험을\n\n<!-- PAGE_45 -->\n###### 허용할 수 없는 영역(unacceptable)’과‘합리적으로 실현할\n\n<!-- PAGE_45 -->\n###### 수 있는 가장 낮은 영역(As Low As Reasonably Practicable,\n\n<!-- PAGE_45 -->\n###### ALARP)’, ‘허용할 수 있는 영역(acceptable)’의 3단계 또는\n\n<!-- PAGE_45 -->\n###### ‘위험을 허용할 수 없는 영역(unacceptable)’과 ‘허용할 수\n\n- - 39 -\n<!-- PAGE_46 -->\n###### 다) 위험통제\n\n<!-- PAGE_46 -->\n###### 제조자는 위험평가 결과 중 ‘위험을 허용할 수 없는 영역\n\n<!-- PAGE_46 -->\n###### (unacceptable)’과‘합리적으로 실현할 수 있는 가장 낮은 영역\n\n<!-- PAGE_46 -->\n###### (ALARP)’을 허용 가능한 수준까지 감소시키기 위하여 위험\n\n<!-- PAGE_46 -->\n###### 통제 조치를 식별하고, <표 12>와 같이 위험통제 활동을 수행\n\n<!-- PAGE_46 -->\n###### 모든 위험통제 조치를 하고 검증한 뒤 위험관리 계획에서 정\n\n<!-- PAGE_46 -->\n###### 의한 위험허용 기준을 사용하여 해당 의료기기에서 식별한 전체\n\n<!-- PAGE_46 -->\n###### 잔여위험이 허용 가능한지 아닌지를 결정하고 <표 13>과 같이\n\n- - 40 -\n잔여위험평가\n\n**[표 시작]**\n\n| medical Internet research, 21(11), e14754. ",
        "original_sentence": "<!-- PAGE_44 -->\n###### 사이버보안 요구사항은 ‘의료기기의 사이버보안 허가·심사\n\n<!-- PAGE_44 -->\n###### ‘의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)’\n\n<!-- PAGE_44 -->\n###### 에는 보안통신, 데이터 보호, 기기 무결성, 사용자 인증, 소프트웨어\n\n<!-- PAGE_44 -->\n###### 유지보수, 물리적 접근, 신뢰성 및 가용성 등에 대한 요구사항을 제시\n\n<!-- PAGE_44 -->\n###### 하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_593",
      "text": "본 요구사항은 제품의 사이버보안 안전성 등급 및\n\n<!-- PAGE_44 -->\n###### 제품의 특성에 따라 적용한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 592,
        "window_size": 3,
        "char_count": 69,
        "word_count": 15,
        "page_number": 44,
        "window_text": "제조자는 이를 확인\n\n<!-- PAGE_43 -->\n###### 할 수 있도록 ‘의료기기 사이버보안 요구사항 체크리스트’와\n\n<!-- PAGE_43 -->\n###### 요구사항을 실제로 검증한 자료를 제출하여야 한다.  다만, 제조사의\n\n- - 37 -\n<!-- PAGE_44 -->\n###### 위험분석을 통해 요구사항 일부를 제외하거나 수정하여 적용할 때는\n\n<!-- PAGE_44 -->\n###### 시험규격 및 그 설정 근거를 제출하여야 하며 해당 자료로\n\n<!-- PAGE_44 -->\n###### ‘사이버보안 위험관리문서’를 제출할 수 있다.\n\n <!-- PAGE_44 -->\n###### 사이버보안 요구사항은 ‘의료기기의 사이버보안 허가·심사\n\n<!-- PAGE_44 -->\n###### ‘의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)’\n\n<!-- PAGE_44 -->\n###### 에는 보안통신, 데이터 보호, 기기 무결성, 사용자 인증, 소프트웨어\n\n<!-- PAGE_44 -->\n###### 유지보수, 물리적 접근, 신뢰성 및 가용성 등에 대한 요구사항을 제시\n\n<!-- PAGE_44 -->\n###### 하고 있다.  본 요구사항은 제품의 사이버보안 안전성 등급 및\n\n<!-- PAGE_44 -->\n###### 제품의 특성에 따라 적용한다.  해당 가이드라인에 따라 제품에\n\n<!-- PAGE_44 -->\n###### 소프트웨어 위험관리에는 사이버보안에 대한 위험관리 항목이\n\n<!-- PAGE_44 -->\n###### 포함되어야 하며, 소프트웨어 위험관리와 동일한 방식으로 위험관리\n\n<!-- PAGE_44 -->\n###### ‘위해요인 식별’에서는 관련 자료(규격, 가이드라인, 국내외\n\n<!-- PAGE_44 -->\n###### 이상 사례 등)에 근거하여 의료기기의 정상 및 고장상태에서\n\n<!-- PAGE_44 -->\n###### 이미 알고 있거나 예측 가능한 의료기기 사이버보안 측면의\n\n<!-- PAGE_44 -->\n###### ‘위험산정’에서는 위해상황을 초래할 수 있는 예측 가능한\n\n- - 38 -\n위해요인\n\n구체적인 예시\n\n사용자 또는 환자에게\n\n발생 가능한 손상\n\n관련자료\n\n<!-- PAGE_45 -->\n###### 표 10.  위해요인 식별 예시\n\n<!-- PAGE_45 -->\n###### 식별한 모든 위험에 대하여 위험의 평가 결과를 ‘위험을\n\n<!-- PAGE_45 -->\n###### 허용할 수 없는 영역(unacceptable)’과‘합리적으로 실현할\n\n<!-- PAGE_45 -->\n###### 수 있는 가장 낮은 영역(As Low As Reasonably Practicable,\n\n<!-- PAGE_45 -->\n###### ALARP)’, ‘허용할 수 있는 영역(acceptable)’의 3단계 또는\n\n<!-- PAGE_45 -->\n###### ‘위험을 허용할 수 없는 영역(unacceptable)’과 ‘허용할 수\n\n- - 39 -\n<!-- PAGE_46 -->\n###### 다) 위험통제\n\n<!-- PAGE_46 -->\n###### 제조자는 위험평가 결과 중 ‘위험을 허용할 수 없는 영역\n\n<!-- PAGE_46 -->\n###### (unacceptable)’과‘합리적으로 실현할 수 있는 가장 낮은 영역\n\n<!-- PAGE_46 -->\n###### (ALARP)’을 허용 가능한 수준까지 감소시키기 위하여 위험\n\n<!-- PAGE_46 -->\n###### 통제 조치를 식별하고, <표 12>와 같이 위험통제 활동을 수행\n\n<!-- PAGE_46 -->\n###### 모든 위험통제 조치를 하고 검증한 뒤 위험관리 계획에서 정\n\n<!-- PAGE_46 -->\n###### 의한 위험허용 기준을 사용하여 해당 의료기기에서 식별한 전체\n\n<!-- PAGE_46 -->\n###### 잔여위험이 허용 가능한지 아닌지를 결정하고 <표 13>과 같이\n\n- - 40 -\n잔여위험평가\n\n**[표 시작]**\n\n| medical Internet research, 21(11), e14754.  | 추가 | 전체 잔여위험 허용 |\n| --- | --- | --- |\n| 임상시험 디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고 | MADRS는 우울장애를 측정하는 문항 총 10개로 구성되어 | 검증 및 |\n| 발생 | 결과 | 위험/이득 | 자살 사고를 평가하기 위해 고안된 자기보고 질문지이다. ",
        "original_sentence": "본 요구사항은 제품의 사이버보안 안전성 등급 및\n\n<!-- PAGE_44 -->\n###### 제품의 특성에 따라 적용한다. "
      }
    },
    {
      "chunk_id": "chunk_594",
      "text": "해당 가이드라인에 따라 제품에\n\n<!-- PAGE_44 -->\n###### 소프트웨어 위험관리에는 사이버보안에 대한 위험관리 항목이\n\n<!-- PAGE_44 -->\n###### 포함되어야 하며, 소프트웨어 위험관리와 동일한 방식으로 위험관리\n\n<!-- PAGE_44 -->\n###### ‘위해요인 식별’에서는 관련 자료(규격, 가이드라인, 국내외\n\n<!-- PAGE_44 -->\n###### 이상 사례 등)에 근거하여 의료기기의 정상 및 고장상태에서\n\n<!-- PAGE_44 -->\n###### 이미 알고 있거나 예측 가능한 의료기기 사이버보안 측면의\n\n<!-- PAGE_44 -->\n###### ‘위험산정’에서는 위해상황을 초래할 수 있는 예측 가능한\n\n- - 38 -\n위해요인\n\n구체적인 예시\n\n사용자 또는 환자에게\n\n발생 가능한 손상\n\n관련자료\n\n<!-- PAGE_45 -->\n###### 표 10. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 593,
        "window_size": 3,
        "char_count": 451,
        "word_count": 90,
        "page_number": 44,
        "window_text": "다만, 제조사의\n\n- - 37 -\n<!-- PAGE_44 -->\n###### 위험분석을 통해 요구사항 일부를 제외하거나 수정하여 적용할 때는\n\n<!-- PAGE_44 -->\n###### 시험규격 및 그 설정 근거를 제출하여야 하며 해당 자료로\n\n<!-- PAGE_44 -->\n###### ‘사이버보안 위험관리문서’를 제출할 수 있다.\n\n <!-- PAGE_44 -->\n###### 사이버보안 요구사항은 ‘의료기기의 사이버보안 허가·심사\n\n<!-- PAGE_44 -->\n###### ‘의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)’\n\n<!-- PAGE_44 -->\n###### 에는 보안통신, 데이터 보호, 기기 무결성, 사용자 인증, 소프트웨어\n\n<!-- PAGE_44 -->\n###### 유지보수, 물리적 접근, 신뢰성 및 가용성 등에 대한 요구사항을 제시\n\n<!-- PAGE_44 -->\n###### 하고 있다.  본 요구사항은 제품의 사이버보안 안전성 등급 및\n\n<!-- PAGE_44 -->\n###### 제품의 특성에 따라 적용한다.  해당 가이드라인에 따라 제품에\n\n<!-- PAGE_44 -->\n###### 소프트웨어 위험관리에는 사이버보안에 대한 위험관리 항목이\n\n<!-- PAGE_44 -->\n###### 포함되어야 하며, 소프트웨어 위험관리와 동일한 방식으로 위험관리\n\n<!-- PAGE_44 -->\n###### ‘위해요인 식별’에서는 관련 자료(규격, 가이드라인, 국내외\n\n<!-- PAGE_44 -->\n###### 이상 사례 등)에 근거하여 의료기기의 정상 및 고장상태에서\n\n<!-- PAGE_44 -->\n###### 이미 알고 있거나 예측 가능한 의료기기 사이버보안 측면의\n\n<!-- PAGE_44 -->\n###### ‘위험산정’에서는 위해상황을 초래할 수 있는 예측 가능한\n\n- - 38 -\n위해요인\n\n구체적인 예시\n\n사용자 또는 환자에게\n\n발생 가능한 손상\n\n관련자료\n\n<!-- PAGE_45 -->\n###### 표 10.  위해요인 식별 예시\n\n<!-- PAGE_45 -->\n###### 식별한 모든 위험에 대하여 위험의 평가 결과를 ‘위험을\n\n<!-- PAGE_45 -->\n###### 허용할 수 없는 영역(unacceptable)’과‘합리적으로 실현할\n\n<!-- PAGE_45 -->\n###### 수 있는 가장 낮은 영역(As Low As Reasonably Practicable,\n\n<!-- PAGE_45 -->\n###### ALARP)’, ‘허용할 수 있는 영역(acceptable)’의 3단계 또는\n\n<!-- PAGE_45 -->\n###### ‘위험을 허용할 수 없는 영역(unacceptable)’과 ‘허용할 수\n\n- - 39 -\n<!-- PAGE_46 -->\n###### 다) 위험통제\n\n<!-- PAGE_46 -->\n###### 제조자는 위험평가 결과 중 ‘위험을 허용할 수 없는 영역\n\n<!-- PAGE_46 -->\n###### (unacceptable)’과‘합리적으로 실현할 수 있는 가장 낮은 영역\n\n<!-- PAGE_46 -->\n###### (ALARP)’을 허용 가능한 수준까지 감소시키기 위하여 위험\n\n<!-- PAGE_46 -->\n###### 통제 조치를 식별하고, <표 12>와 같이 위험통제 활동을 수행\n\n<!-- PAGE_46 -->\n###### 모든 위험통제 조치를 하고 검증한 뒤 위험관리 계획에서 정\n\n<!-- PAGE_46 -->\n###### 의한 위험허용 기준을 사용하여 해당 의료기기에서 식별한 전체\n\n<!-- PAGE_46 -->\n###### 잔여위험이 허용 가능한지 아닌지를 결정하고 <표 13>과 같이\n\n- - 40 -\n잔여위험평가\n\n**[표 시작]**\n\n| medical Internet research, 21(11), e14754.  | 추가 | 전체 잔여위험 허용 |\n| --- | --- | --- |\n| 임상시험 디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고 | MADRS는 우울장애를 측정하는 문항 총 10개로 구성되어 | 검증 및 |\n| 발생 | 결과 | 위험/이득 | 자살 사고를 평가하기 위해 고안된 자기보고 질문지이다.  | 통제 | 검증 및 |\n| 선행연구 | 군 | N | BDI 변화량1) | 시퀀싱(sequencing) 필드의 메시지를 보호 | 적용 |\n| < 의료기기 사이버보안 특성 기재 > | 심각 | 대응 계획을 수립하여야 한다. ",
        "original_sentence": "해당 가이드라인에 따라 제품에\n\n<!-- PAGE_44 -->\n###### 소프트웨어 위험관리에는 사이버보안에 대한 위험관리 항목이\n\n<!-- PAGE_44 -->\n###### 포함되어야 하며, 소프트웨어 위험관리와 동일한 방식으로 위험관리\n\n<!-- PAGE_44 -->\n###### ‘위해요인 식별’에서는 관련 자료(규격, 가이드라인, 국내외\n\n<!-- PAGE_44 -->\n###### 이상 사례 등)에 근거하여 의료기기의 정상 및 고장상태에서\n\n<!-- PAGE_44 -->\n###### 이미 알고 있거나 예측 가능한 의료기기 사이버보안 측면의\n\n<!-- PAGE_44 -->\n###### ‘위험산정’에서는 위해상황을 초래할 수 있는 예측 가능한\n\n- - 38 -\n위해요인\n\n구체적인 예시\n\n사용자 또는 환자에게\n\n발생 가능한 손상\n\n관련자료\n\n<!-- PAGE_45 -->\n###### 표 10. "
      }
    },
    {
      "chunk_id": "chunk_595",
      "text": "위해요인 식별 예시\n\n<!-- PAGE_45 -->\n###### 식별한 모든 위험에 대하여 위험의 평가 결과를 ‘위험을\n\n<!-- PAGE_45 -->\n###### 허용할 수 없는 영역(unacceptable)’과‘합리적으로 실현할\n\n<!-- PAGE_45 -->\n###### 수 있는 가장 낮은 영역(As Low As Reasonably Practicable,\n\n<!-- PAGE_45 -->\n###### ALARP)’, ‘허용할 수 있는 영역(acceptable)’의 3단계 또는\n\n<!-- PAGE_45 -->\n###### ‘위험을 허용할 수 없는 영역(unacceptable)’과 ‘허용할 수\n\n- - 39 -\n<!-- PAGE_46 -->\n###### 다) 위험통제\n\n<!-- PAGE_46 -->\n###### 제조자는 위험평가 결과 중 ‘위험을 허용할 수 없는 영역\n\n<!-- PAGE_46 -->\n###### (unacceptable)’과‘합리적으로 실현할 수 있는 가장 낮은 영역\n\n<!-- PAGE_46 -->\n###### (ALARP)’을 허용 가능한 수준까지 감소시키기 위하여 위험\n\n<!-- PAGE_46 -->\n###### 통제 조치를 식별하고, <표 12>와 같이 위험통제 활동을 수행\n\n<!-- PAGE_46 -->\n###### 모든 위험통제 조치를 하고 검증한 뒤 위험관리 계획에서 정\n\n<!-- PAGE_46 -->\n###### 의한 위험허용 기준을 사용하여 해당 의료기기에서 식별한 전체\n\n<!-- PAGE_46 -->\n###### 잔여위험이 허용 가능한지 아닌지를 결정하고 <표 13>과 같이\n\n- - 40 -\n잔여위험평가\n\n**[표 시작]**\n\n| medical Internet research, 21(11), e14754. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 594,
        "window_size": 3,
        "char_count": 874,
        "word_count": 167,
        "page_number": 45,
        "window_text": "<!-- PAGE_44 -->\n###### 사이버보안 요구사항은 ‘의료기기의 사이버보안 허가·심사\n\n<!-- PAGE_44 -->\n###### ‘의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)’\n\n<!-- PAGE_44 -->\n###### 에는 보안통신, 데이터 보호, 기기 무결성, 사용자 인증, 소프트웨어\n\n<!-- PAGE_44 -->\n###### 유지보수, 물리적 접근, 신뢰성 및 가용성 등에 대한 요구사항을 제시\n\n<!-- PAGE_44 -->\n###### 하고 있다.  본 요구사항은 제품의 사이버보안 안전성 등급 및\n\n<!-- PAGE_44 -->\n###### 제품의 특성에 따라 적용한다.  해당 가이드라인에 따라 제품에\n\n<!-- PAGE_44 -->\n###### 소프트웨어 위험관리에는 사이버보안에 대한 위험관리 항목이\n\n<!-- PAGE_44 -->\n###### 포함되어야 하며, 소프트웨어 위험관리와 동일한 방식으로 위험관리\n\n<!-- PAGE_44 -->\n###### ‘위해요인 식별’에서는 관련 자료(규격, 가이드라인, 국내외\n\n<!-- PAGE_44 -->\n###### 이상 사례 등)에 근거하여 의료기기의 정상 및 고장상태에서\n\n<!-- PAGE_44 -->\n###### 이미 알고 있거나 예측 가능한 의료기기 사이버보안 측면의\n\n<!-- PAGE_44 -->\n###### ‘위험산정’에서는 위해상황을 초래할 수 있는 예측 가능한\n\n- - 38 -\n위해요인\n\n구체적인 예시\n\n사용자 또는 환자에게\n\n발생 가능한 손상\n\n관련자료\n\n<!-- PAGE_45 -->\n###### 표 10.  위해요인 식별 예시\n\n<!-- PAGE_45 -->\n###### 식별한 모든 위험에 대하여 위험의 평가 결과를 ‘위험을\n\n<!-- PAGE_45 -->\n###### 허용할 수 없는 영역(unacceptable)’과‘합리적으로 실현할\n\n<!-- PAGE_45 -->\n###### 수 있는 가장 낮은 영역(As Low As Reasonably Practicable,\n\n<!-- PAGE_45 -->\n###### ALARP)’, ‘허용할 수 있는 영역(acceptable)’의 3단계 또는\n\n<!-- PAGE_45 -->\n###### ‘위험을 허용할 수 없는 영역(unacceptable)’과 ‘허용할 수\n\n- - 39 -\n<!-- PAGE_46 -->\n###### 다) 위험통제\n\n<!-- PAGE_46 -->\n###### 제조자는 위험평가 결과 중 ‘위험을 허용할 수 없는 영역\n\n<!-- PAGE_46 -->\n###### (unacceptable)’과‘합리적으로 실현할 수 있는 가장 낮은 영역\n\n<!-- PAGE_46 -->\n###### (ALARP)’을 허용 가능한 수준까지 감소시키기 위하여 위험\n\n<!-- PAGE_46 -->\n###### 통제 조치를 식별하고, <표 12>와 같이 위험통제 활동을 수행\n\n<!-- PAGE_46 -->\n###### 모든 위험통제 조치를 하고 검증한 뒤 위험관리 계획에서 정\n\n<!-- PAGE_46 -->\n###### 의한 위험허용 기준을 사용하여 해당 의료기기에서 식별한 전체\n\n<!-- PAGE_46 -->\n###### 잔여위험이 허용 가능한지 아닌지를 결정하고 <표 13>과 같이\n\n- - 40 -\n잔여위험평가\n\n**[표 시작]**\n\n| medical Internet research, 21(11), e14754.  | 추가 | 전체 잔여위험 허용 |\n| --- | --- | --- |\n| 임상시험 디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고 | MADRS는 우울장애를 측정하는 문항 총 10개로 구성되어 | 검증 및 |\n| 발생 | 결과 | 위험/이득 | 자살 사고를 평가하기 위해 고안된 자기보고 질문지이다.  | 통제 | 검증 및 |\n| 선행연구 | 군 | N | BDI 변화량1) | 시퀀싱(sequencing) 필드의 메시지를 보호 | 적용 |\n| < 의료기기 사이버보안 특성 기재 > | 심각 | 대응 계획을 수립하여야 한다.  | 위험 | 있다. ",
        "original_sentence": "위해요인 식별 예시\n\n<!-- PAGE_45 -->\n###### 식별한 모든 위험에 대하여 위험의 평가 결과를 ‘위험을\n\n<!-- PAGE_45 -->\n###### 허용할 수 없는 영역(unacceptable)’과‘합리적으로 실현할\n\n<!-- PAGE_45 -->\n###### 수 있는 가장 낮은 영역(As Low As Reasonably Practicable,\n\n<!-- PAGE_45 -->\n###### ALARP)’, ‘허용할 수 있는 영역(acceptable)’의 3단계 또는\n\n<!-- PAGE_45 -->\n###### ‘위험을 허용할 수 없는 영역(unacceptable)’과 ‘허용할 수\n\n- - 39 -\n<!-- PAGE_46 -->\n###### 다) 위험통제\n\n<!-- PAGE_46 -->\n###### 제조자는 위험평가 결과 중 ‘위험을 허용할 수 없는 영역\n\n<!-- PAGE_46 -->\n###### (unacceptable)’과‘합리적으로 실현할 수 있는 가장 낮은 영역\n\n<!-- PAGE_46 -->\n###### (ALARP)’을 허용 가능한 수준까지 감소시키기 위하여 위험\n\n<!-- PAGE_46 -->\n###### 통제 조치를 식별하고, <표 12>와 같이 위험통제 활동을 수행\n\n<!-- PAGE_46 -->\n###### 모든 위험통제 조치를 하고 검증한 뒤 위험관리 계획에서 정\n\n<!-- PAGE_46 -->\n###### 의한 위험허용 기준을 사용하여 해당 의료기기에서 식별한 전체\n\n<!-- PAGE_46 -->\n###### 잔여위험이 허용 가능한지 아닌지를 결정하고 <표 13>과 같이\n\n- - 40 -\n잔여위험평가\n\n**[표 시작]**\n\n| medical Internet research, 21(11), e14754. "
      }
    },
    {
      "chunk_id": "chunk_596",
      "text": "| 추가 | 전체 잔여위험 허용 |\n| --- | --- | --- |\n| 임상시험 디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고 | MADRS는 우울장애를 측정하는 문항 총 10개로 구성되어 | 검증 및 |\n| 발생 | 결과 | 위험/이득 | 자살 사고를 평가하기 위해 고안된 자기보고 질문지이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 595,
        "window_size": 3,
        "char_count": 179,
        "word_count": 50,
        "page_number": 29,
        "window_text": "본 요구사항은 제품의 사이버보안 안전성 등급 및\n\n<!-- PAGE_44 -->\n###### 제품의 특성에 따라 적용한다.  해당 가이드라인에 따라 제품에\n\n<!-- PAGE_44 -->\n###### 소프트웨어 위험관리에는 사이버보안에 대한 위험관리 항목이\n\n<!-- PAGE_44 -->\n###### 포함되어야 하며, 소프트웨어 위험관리와 동일한 방식으로 위험관리\n\n<!-- PAGE_44 -->\n###### ‘위해요인 식별’에서는 관련 자료(규격, 가이드라인, 국내외\n\n<!-- PAGE_44 -->\n###### 이상 사례 등)에 근거하여 의료기기의 정상 및 고장상태에서\n\n<!-- PAGE_44 -->\n###### 이미 알고 있거나 예측 가능한 의료기기 사이버보안 측면의\n\n<!-- PAGE_44 -->\n###### ‘위험산정’에서는 위해상황을 초래할 수 있는 예측 가능한\n\n- - 38 -\n위해요인\n\n구체적인 예시\n\n사용자 또는 환자에게\n\n발생 가능한 손상\n\n관련자료\n\n<!-- PAGE_45 -->\n###### 표 10.  위해요인 식별 예시\n\n<!-- PAGE_45 -->\n###### 식별한 모든 위험에 대하여 위험의 평가 결과를 ‘위험을\n\n<!-- PAGE_45 -->\n###### 허용할 수 없는 영역(unacceptable)’과‘합리적으로 실현할\n\n<!-- PAGE_45 -->\n###### 수 있는 가장 낮은 영역(As Low As Reasonably Practicable,\n\n<!-- PAGE_45 -->\n###### ALARP)’, ‘허용할 수 있는 영역(acceptable)’의 3단계 또는\n\n<!-- PAGE_45 -->\n###### ‘위험을 허용할 수 없는 영역(unacceptable)’과 ‘허용할 수\n\n- - 39 -\n<!-- PAGE_46 -->\n###### 다) 위험통제\n\n<!-- PAGE_46 -->\n###### 제조자는 위험평가 결과 중 ‘위험을 허용할 수 없는 영역\n\n<!-- PAGE_46 -->\n###### (unacceptable)’과‘합리적으로 실현할 수 있는 가장 낮은 영역\n\n<!-- PAGE_46 -->\n###### (ALARP)’을 허용 가능한 수준까지 감소시키기 위하여 위험\n\n<!-- PAGE_46 -->\n###### 통제 조치를 식별하고, <표 12>와 같이 위험통제 활동을 수행\n\n<!-- PAGE_46 -->\n###### 모든 위험통제 조치를 하고 검증한 뒤 위험관리 계획에서 정\n\n<!-- PAGE_46 -->\n###### 의한 위험허용 기준을 사용하여 해당 의료기기에서 식별한 전체\n\n<!-- PAGE_46 -->\n###### 잔여위험이 허용 가능한지 아닌지를 결정하고 <표 13>과 같이\n\n- - 40 -\n잔여위험평가\n\n**[표 시작]**\n\n| medical Internet research, 21(11), e14754.  | 추가 | 전체 잔여위험 허용 |\n| --- | --- | --- |\n| 임상시험 디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고 | MADRS는 우울장애를 측정하는 문항 총 10개로 구성되어 | 검증 및 |\n| 발생 | 결과 | 위험/이득 | 자살 사고를 평가하기 위해 고안된 자기보고 질문지이다.  | 통제 | 검증 및 |\n| 선행연구 | 군 | N | BDI 변화량1) | 시퀀싱(sequencing) 필드의 메시지를 보호 | 적용 |\n| < 의료기기 사이버보안 특성 기재 > | 심각 | 대응 계획을 수립하여야 한다.  | 위험 | 있다.  문항은 겉으로 드러나는 슬픔, 스스로 보고하는 슬픔, | 대한 내용분석을 통해 문항을 구성하였다는 것에 의미가 | 발생 | 적용 | 가능성 평가 |\n| - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함한다. ",
        "original_sentence": "| 추가 | 전체 잔여위험 허용 |\n| --- | --- | --- |\n| 임상시험 디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고 | MADRS는 우울장애를 측정하는 문항 총 10개로 구성되어 | 검증 및 |\n| 발생 | 결과 | 위험/이득 | 자살 사고를 평가하기 위해 고안된 자기보고 질문지이다. "
      }
    },
    {
      "chunk_id": "chunk_597",
      "text": "| 통제 | 검증 및 |\n| 선행연구 | 군 | N | BDI 변화량1) | 시퀀싱(sequencing) 필드의 메시지를 보호 | 적용 |\n| < 의료기기 사이버보안 특성 기재 > | 심각 | 대응 계획을 수립하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 596,
        "window_size": 3,
        "char_count": 125,
        "word_count": 37,
        "page_number": 28,
        "window_text": "해당 가이드라인에 따라 제품에\n\n<!-- PAGE_44 -->\n###### 소프트웨어 위험관리에는 사이버보안에 대한 위험관리 항목이\n\n<!-- PAGE_44 -->\n###### 포함되어야 하며, 소프트웨어 위험관리와 동일한 방식으로 위험관리\n\n<!-- PAGE_44 -->\n###### ‘위해요인 식별’에서는 관련 자료(규격, 가이드라인, 국내외\n\n<!-- PAGE_44 -->\n###### 이상 사례 등)에 근거하여 의료기기의 정상 및 고장상태에서\n\n<!-- PAGE_44 -->\n###### 이미 알고 있거나 예측 가능한 의료기기 사이버보안 측면의\n\n<!-- PAGE_44 -->\n###### ‘위험산정’에서는 위해상황을 초래할 수 있는 예측 가능한\n\n- - 38 -\n위해요인\n\n구체적인 예시\n\n사용자 또는 환자에게\n\n발생 가능한 손상\n\n관련자료\n\n<!-- PAGE_45 -->\n###### 표 10.  위해요인 식별 예시\n\n<!-- PAGE_45 -->\n###### 식별한 모든 위험에 대하여 위험의 평가 결과를 ‘위험을\n\n<!-- PAGE_45 -->\n###### 허용할 수 없는 영역(unacceptable)’과‘합리적으로 실현할\n\n<!-- PAGE_45 -->\n###### 수 있는 가장 낮은 영역(As Low As Reasonably Practicable,\n\n<!-- PAGE_45 -->\n###### ALARP)’, ‘허용할 수 있는 영역(acceptable)’의 3단계 또는\n\n<!-- PAGE_45 -->\n###### ‘위험을 허용할 수 없는 영역(unacceptable)’과 ‘허용할 수\n\n- - 39 -\n<!-- PAGE_46 -->\n###### 다) 위험통제\n\n<!-- PAGE_46 -->\n###### 제조자는 위험평가 결과 중 ‘위험을 허용할 수 없는 영역\n\n<!-- PAGE_46 -->\n###### (unacceptable)’과‘합리적으로 실현할 수 있는 가장 낮은 영역\n\n<!-- PAGE_46 -->\n###### (ALARP)’을 허용 가능한 수준까지 감소시키기 위하여 위험\n\n<!-- PAGE_46 -->\n###### 통제 조치를 식별하고, <표 12>와 같이 위험통제 활동을 수행\n\n<!-- PAGE_46 -->\n###### 모든 위험통제 조치를 하고 검증한 뒤 위험관리 계획에서 정\n\n<!-- PAGE_46 -->\n###### 의한 위험허용 기준을 사용하여 해당 의료기기에서 식별한 전체\n\n<!-- PAGE_46 -->\n###### 잔여위험이 허용 가능한지 아닌지를 결정하고 <표 13>과 같이\n\n- - 40 -\n잔여위험평가\n\n**[표 시작]**\n\n| medical Internet research, 21(11), e14754.  | 추가 | 전체 잔여위험 허용 |\n| --- | --- | --- |\n| 임상시험 디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고 | MADRS는 우울장애를 측정하는 문항 총 10개로 구성되어 | 검증 및 |\n| 발생 | 결과 | 위험/이득 | 자살 사고를 평가하기 위해 고안된 자기보고 질문지이다.  | 통제 | 검증 및 |\n| 선행연구 | 군 | N | BDI 변화량1) | 시퀀싱(sequencing) 필드의 메시지를 보호 | 적용 |\n| < 의료기기 사이버보안 특성 기재 > | 심각 | 대응 계획을 수립하여야 한다.  | 위험 | 있다.  문항은 겉으로 드러나는 슬픔, 스스로 보고하는 슬픔, | 대한 내용분석을 통해 문항을 구성하였다는 것에 의미가 | 발생 | 적용 | 가능성 평가 |\n| - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함한다.  | : 선정기준 모두를 만족하는 자 | 비율이 50% 이상이면 반응(호전)이 있는 것으로 평가 | 유효성 |\n| 가능 | - 임상시험 전, 중, 후에 관찰해야 할 항목들을 나열한다. ",
        "original_sentence": "| 통제 | 검증 및 |\n| 선행연구 | 군 | N | BDI 변화량1) | 시퀀싱(sequencing) 필드의 메시지를 보호 | 적용 |\n| < 의료기기 사이버보안 특성 기재 > | 심각 | 대응 계획을 수립하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_598",
      "text": "| 위험 | 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 597,
        "window_size": 3,
        "char_count": 11,
        "word_count": 4,
        "page_number": 11,
        "window_text": "위해요인 식별 예시\n\n<!-- PAGE_45 -->\n###### 식별한 모든 위험에 대하여 위험의 평가 결과를 ‘위험을\n\n<!-- PAGE_45 -->\n###### 허용할 수 없는 영역(unacceptable)’과‘합리적으로 실현할\n\n<!-- PAGE_45 -->\n###### 수 있는 가장 낮은 영역(As Low As Reasonably Practicable,\n\n<!-- PAGE_45 -->\n###### ALARP)’, ‘허용할 수 있는 영역(acceptable)’의 3단계 또는\n\n<!-- PAGE_45 -->\n###### ‘위험을 허용할 수 없는 영역(unacceptable)’과 ‘허용할 수\n\n- - 39 -\n<!-- PAGE_46 -->\n###### 다) 위험통제\n\n<!-- PAGE_46 -->\n###### 제조자는 위험평가 결과 중 ‘위험을 허용할 수 없는 영역\n\n<!-- PAGE_46 -->\n###### (unacceptable)’과‘합리적으로 실현할 수 있는 가장 낮은 영역\n\n<!-- PAGE_46 -->\n###### (ALARP)’을 허용 가능한 수준까지 감소시키기 위하여 위험\n\n<!-- PAGE_46 -->\n###### 통제 조치를 식별하고, <표 12>와 같이 위험통제 활동을 수행\n\n<!-- PAGE_46 -->\n###### 모든 위험통제 조치를 하고 검증한 뒤 위험관리 계획에서 정\n\n<!-- PAGE_46 -->\n###### 의한 위험허용 기준을 사용하여 해당 의료기기에서 식별한 전체\n\n<!-- PAGE_46 -->\n###### 잔여위험이 허용 가능한지 아닌지를 결정하고 <표 13>과 같이\n\n- - 40 -\n잔여위험평가\n\n**[표 시작]**\n\n| medical Internet research, 21(11), e14754.  | 추가 | 전체 잔여위험 허용 |\n| --- | --- | --- |\n| 임상시험 디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고 | MADRS는 우울장애를 측정하는 문항 총 10개로 구성되어 | 검증 및 |\n| 발생 | 결과 | 위험/이득 | 자살 사고를 평가하기 위해 고안된 자기보고 질문지이다.  | 통제 | 검증 및 |\n| 선행연구 | 군 | N | BDI 변화량1) | 시퀀싱(sequencing) 필드의 메시지를 보호 | 적용 |\n| < 의료기기 사이버보안 특성 기재 > | 심각 | 대응 계획을 수립하여야 한다.  | 위험 | 있다.  문항은 겉으로 드러나는 슬픔, 스스로 보고하는 슬픔, | 대한 내용분석을 통해 문항을 구성하였다는 것에 의미가 | 발생 | 적용 | 가능성 평가 |\n| - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함한다.  | : 선정기준 모두를 만족하는 자 | 비율이 50% 이상이면 반응(호전)이 있는 것으로 평가 | 유효성 |\n| 가능 | - 임상시험 전, 중, 후에 관찰해야 할 항목들을 나열한다.  | 식약처장은 [의료법]에 따른 의료기관 중 임상시험에 필요한 시설, 인력 및 기구를 | 임상시험용 의료기기 관리자는 임상시험기관에서 임상시험용 해당 의료기기를 | 측정할 수 있다. ",
        "original_sentence": "| 위험 | 있다. "
      }
    },
    {
      "chunk_id": "chunk_599",
      "text": "문항은 겉으로 드러나는 슬픔, 스스로 보고하는 슬픔, | 대한 내용분석을 통해 문항을 구성하였다는 것에 의미가 | 발생 | 적용 | 가능성 평가 |\n| - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 598,
        "window_size": 3,
        "char_count": 121,
        "word_count": 30,
        "page_number": 18,
        "window_text": "| 추가 | 전체 잔여위험 허용 |\n| --- | --- | --- |\n| 임상시험 디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고 | MADRS는 우울장애를 측정하는 문항 총 10개로 구성되어 | 검증 및 |\n| 발생 | 결과 | 위험/이득 | 자살 사고를 평가하기 위해 고안된 자기보고 질문지이다.  | 통제 | 검증 및 |\n| 선행연구 | 군 | N | BDI 변화량1) | 시퀀싱(sequencing) 필드의 메시지를 보호 | 적용 |\n| < 의료기기 사이버보안 특성 기재 > | 심각 | 대응 계획을 수립하여야 한다.  | 위험 | 있다.  문항은 겉으로 드러나는 슬픔, 스스로 보고하는 슬픔, | 대한 내용분석을 통해 문항을 구성하였다는 것에 의미가 | 발생 | 적용 | 가능성 평가 |\n| - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함한다.  | : 선정기준 모두를 만족하는 자 | 비율이 50% 이상이면 반응(호전)이 있는 것으로 평가 | 유효성 |\n| 가능 | - 임상시험 전, 중, 후에 관찰해야 할 항목들을 나열한다.  | 식약처장은 [의료법]에 따른 의료기관 중 임상시험에 필요한 시설, 인력 및 기구를 | 임상시험용 의료기기 관리자는 임상시험기관에서 임상시험용 해당 의료기기를 | 측정할 수 있다.  | 나) 회원가입 및 초기 우울장애 평가를 시행한다. ",
        "original_sentence": "문항은 겉으로 드러나는 슬픔, 스스로 보고하는 슬픔, | 대한 내용분석을 통해 문항을 구성하였다는 것에 의미가 | 발생 | 적용 | 가능성 평가 |\n| - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함한다. "
      }
    },
    {
      "chunk_id": "chunk_600",
      "text": "| : 선정기준 모두를 만족하는 자 | 비율이 50% 이상이면 반응(호전)이 있는 것으로 평가 | 유효성 |\n| 가능 | - 임상시험 전, 중, 후에 관찰해야 할 항목들을 나열한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 599,
        "window_size": 3,
        "char_count": 102,
        "word_count": 29,
        "page_number": 30,
        "window_text": "| 통제 | 검증 및 |\n| 선행연구 | 군 | N | BDI 변화량1) | 시퀀싱(sequencing) 필드의 메시지를 보호 | 적용 |\n| < 의료기기 사이버보안 특성 기재 > | 심각 | 대응 계획을 수립하여야 한다.  | 위험 | 있다.  문항은 겉으로 드러나는 슬픔, 스스로 보고하는 슬픔, | 대한 내용분석을 통해 문항을 구성하였다는 것에 의미가 | 발생 | 적용 | 가능성 평가 |\n| - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함한다.  | : 선정기준 모두를 만족하는 자 | 비율이 50% 이상이면 반응(호전)이 있는 것으로 평가 | 유효성 |\n| 가능 | - 임상시험 전, 중, 후에 관찰해야 할 항목들을 나열한다.  | 식약처장은 [의료법]에 따른 의료기관 중 임상시험에 필요한 시설, 인력 및 기구를 | 임상시험용 의료기기 관리자는 임상시험기관에서 임상시험용 해당 의료기기를 | 측정할 수 있다.  | 나) 회원가입 및 초기 우울장애 평가를 시행한다.  | 사) 이상반응 조사 | 가) 임상시험 설명 및 동의 | 마) 우울장애 심각도 척도(BDI-II) 조사 | 사) 순응도 조사 | 라) 순응도 조사 | 하는 내용이 포함되어서는 안된다. ",
        "original_sentence": "| : 선정기준 모두를 만족하는 자 | 비율이 50% 이상이면 반응(호전)이 있는 것으로 평가 | 유효성 |\n| 가능 | - 임상시험 전, 중, 후에 관찰해야 할 항목들을 나열한다. "
      }
    },
    {
      "chunk_id": "chunk_601",
      "text": "| 식약처장은 [의료법]에 따른 의료기관 중 임상시험에 필요한 시설, 인력 및 기구를 | 임상시험용 의료기기 관리자는 임상시험기관에서 임상시험용 해당 의료기기를 | 측정할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 600,
        "window_size": 3,
        "char_count": 102,
        "word_count": 24,
        "page_number": 39,
        "window_text": "| 위험 | 있다.  문항은 겉으로 드러나는 슬픔, 스스로 보고하는 슬픔, | 대한 내용분석을 통해 문항을 구성하였다는 것에 의미가 | 발생 | 적용 | 가능성 평가 |\n| - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함한다.  | : 선정기준 모두를 만족하는 자 | 비율이 50% 이상이면 반응(호전)이 있는 것으로 평가 | 유효성 |\n| 가능 | - 임상시험 전, 중, 후에 관찰해야 할 항목들을 나열한다.  | 식약처장은 [의료법]에 따른 의료기관 중 임상시험에 필요한 시설, 인력 및 기구를 | 임상시험용 의료기기 관리자는 임상시험기관에서 임상시험용 해당 의료기기를 | 측정할 수 있다.  | 나) 회원가입 및 초기 우울장애 평가를 시행한다.  | 사) 이상반응 조사 | 가) 임상시험 설명 및 동의 | 마) 우울장애 심각도 척도(BDI-II) 조사 | 사) 순응도 조사 | 라) 순응도 조사 | 하는 내용이 포함되어서는 안된다.  | - 피험자가 제때 방문을 안 하며 연락이 안 되는 경우 | (2) 우울장애 관련한 약물을 복용한 경우 | 기간, 목적을 확인한다. ",
        "original_sentence": "| 식약처장은 [의료법]에 따른 의료기관 중 임상시험에 필요한 시설, 인력 및 기구를 | 임상시험용 의료기기 관리자는 임상시험기관에서 임상시험용 해당 의료기기를 | 측정할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_602",
      "text": "| 나) 회원가입 및 초기 우울장애 평가를 시행한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 601,
        "window_size": 3,
        "char_count": 30,
        "word_count": 8,
        "page_number": 13,
        "window_text": "문항은 겉으로 드러나는 슬픔, 스스로 보고하는 슬픔, | 대한 내용분석을 통해 문항을 구성하였다는 것에 의미가 | 발생 | 적용 | 가능성 평가 |\n| - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함한다.  | : 선정기준 모두를 만족하는 자 | 비율이 50% 이상이면 반응(호전)이 있는 것으로 평가 | 유효성 |\n| 가능 | - 임상시험 전, 중, 후에 관찰해야 할 항목들을 나열한다.  | 식약처장은 [의료법]에 따른 의료기관 중 임상시험에 필요한 시설, 인력 및 기구를 | 임상시험용 의료기기 관리자는 임상시험기관에서 임상시험용 해당 의료기기를 | 측정할 수 있다.  | 나) 회원가입 및 초기 우울장애 평가를 시행한다.  | 사) 이상반응 조사 | 가) 임상시험 설명 및 동의 | 마) 우울장애 심각도 척도(BDI-II) 조사 | 사) 순응도 조사 | 라) 순응도 조사 | 하는 내용이 포함되어서는 안된다.  | - 피험자가 제때 방문을 안 하며 연락이 안 되는 경우 | (2) 우울장애 관련한 약물을 복용한 경우 | 기간, 목적을 확인한다.  | : 제2종 오류 0.20 | BSS는 총 21개 문항으로 구성되어 있으며 이 중 19개 문항은 |      |     ≠ | 분석 | Mean | SD | 완료 | 유효성 |\n| 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 | 하거나 암호화의 키 관련 자료가 손상되는 | 있는 국내 제작 척도이다. ",
        "original_sentence": "| 나) 회원가입 및 초기 우울장애 평가를 시행한다. "
      }
    },
    {
      "chunk_id": "chunk_603",
      "text": "| 사) 이상반응 조사 | 가) 임상시험 설명 및 동의 | 마) 우울장애 심각도 척도(BDI-II) 조사 | 사) 순응도 조사 | 라) 순응도 조사 | 하는 내용이 포함되어서는 안된다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 602,
        "window_size": 3,
        "char_count": 104,
        "word_count": 29,
        "page_number": 39,
        "window_text": "| : 선정기준 모두를 만족하는 자 | 비율이 50% 이상이면 반응(호전)이 있는 것으로 평가 | 유효성 |\n| 가능 | - 임상시험 전, 중, 후에 관찰해야 할 항목들을 나열한다.  | 식약처장은 [의료법]에 따른 의료기관 중 임상시험에 필요한 시설, 인력 및 기구를 | 임상시험용 의료기기 관리자는 임상시험기관에서 임상시험용 해당 의료기기를 | 측정할 수 있다.  | 나) 회원가입 및 초기 우울장애 평가를 시행한다.  | 사) 이상반응 조사 | 가) 임상시험 설명 및 동의 | 마) 우울장애 심각도 척도(BDI-II) 조사 | 사) 순응도 조사 | 라) 순응도 조사 | 하는 내용이 포함되어서는 안된다.  | - 피험자가 제때 방문을 안 하며 연락이 안 되는 경우 | (2) 우울장애 관련한 약물을 복용한 경우 | 기간, 목적을 확인한다.  | : 제2종 오류 0.20 | BSS는 총 21개 문항으로 구성되어 있으며 이 중 19개 문항은 |      |     ≠ | 분석 | Mean | SD | 완료 | 유효성 |\n| 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 | 하거나 암호화의 키 관련 자료가 손상되는 | 있는 국내 제작 척도이다.  총 30문항에 대해 5점 척도로 |\n| 성 | ※ 예: 보안이 보장되지 않은(unsecure) 운영 | 도 |\n**성**\n\n**[표 끝]**\n\n<!-- PAGE_47 -->\n###### 표 13. ",
        "original_sentence": "| 사) 이상반응 조사 | 가) 임상시험 설명 및 동의 | 마) 우울장애 심각도 척도(BDI-II) 조사 | 사) 순응도 조사 | 라) 순응도 조사 | 하는 내용이 포함되어서는 안된다. "
      }
    },
    {
      "chunk_id": "chunk_604",
      "text": "| - 피험자가 제때 방문을 안 하며 연락이 안 되는 경우 | (2) 우울장애 관련한 약물을 복용한 경우 | 기간, 목적을 확인한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 603,
        "window_size": 3,
        "char_count": 75,
        "word_count": 22,
        "page_number": 9,
        "window_text": "| 식약처장은 [의료법]에 따른 의료기관 중 임상시험에 필요한 시설, 인력 및 기구를 | 임상시험용 의료기기 관리자는 임상시험기관에서 임상시험용 해당 의료기기를 | 측정할 수 있다.  | 나) 회원가입 및 초기 우울장애 평가를 시행한다.  | 사) 이상반응 조사 | 가) 임상시험 설명 및 동의 | 마) 우울장애 심각도 척도(BDI-II) 조사 | 사) 순응도 조사 | 라) 순응도 조사 | 하는 내용이 포함되어서는 안된다.  | - 피험자가 제때 방문을 안 하며 연락이 안 되는 경우 | (2) 우울장애 관련한 약물을 복용한 경우 | 기간, 목적을 확인한다.  | : 제2종 오류 0.20 | BSS는 총 21개 문항으로 구성되어 있으며 이 중 19개 문항은 |      |     ≠ | 분석 | Mean | SD | 완료 | 유효성 |\n| 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 | 하거나 암호화의 키 관련 자료가 손상되는 | 있는 국내 제작 척도이다.  총 30문항에 대해 5점 척도로 |\n| 성 | ※ 예: 보안이 보장되지 않은(unsecure) 운영 | 도 |\n**성**\n\n**[표 끝]**\n\n<!-- PAGE_47 -->\n###### 표 13.  전체 잔여위험 허용 가능성 평가 예시\n\n<!-- PAGE_47 -->\n###### ‘의료기기 사이버보안 요구사항 체크리스트’는 의료기기 사이버\n\n<!-- PAGE_47 -->\n###### 보안 요구사항에 대한 적합성 여부를 확인할 수 있는 자료로 제조자는\n\n<!-- PAGE_47 -->\n###### 체크리스트의 질의 사항을 확인하여 요구사항의 적용여부 등을 확인\n\n<!-- PAGE_47 -->\n###### 사용되는 통신기술(유·무선 통신 방식 등), 사용환경(병원 내/외\n\n<!-- PAGE_47 -->\n###### 사용, 공용 네트워크망 사용 등) 등 통신 특성을 확인할 수 있는\n\n<!-- PAGE_47 -->\n###### 사항을 기재한다. ",
        "original_sentence": "| - 피험자가 제때 방문을 안 하며 연락이 안 되는 경우 | (2) 우울장애 관련한 약물을 복용한 경우 | 기간, 목적을 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_605",
      "text": "| : 제2종 오류 0.20 | BSS는 총 21개 문항으로 구성되어 있으며 이 중 19개 문항은 |      |     ≠ | 분석 | Mean | SD | 완료 | 유효성 |\n| 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 | 하거나 암호화의 키 관련 자료가 손상되는 | 있는 국내 제작 척도이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 604,
        "window_size": 3,
        "char_count": 202,
        "word_count": 63,
        "page_number": 9,
        "window_text": "| 나) 회원가입 및 초기 우울장애 평가를 시행한다.  | 사) 이상반응 조사 | 가) 임상시험 설명 및 동의 | 마) 우울장애 심각도 척도(BDI-II) 조사 | 사) 순응도 조사 | 라) 순응도 조사 | 하는 내용이 포함되어서는 안된다.  | - 피험자가 제때 방문을 안 하며 연락이 안 되는 경우 | (2) 우울장애 관련한 약물을 복용한 경우 | 기간, 목적을 확인한다.  | : 제2종 오류 0.20 | BSS는 총 21개 문항으로 구성되어 있으며 이 중 19개 문항은 |      |     ≠ | 분석 | Mean | SD | 완료 | 유효성 |\n| 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 | 하거나 암호화의 키 관련 자료가 손상되는 | 있는 국내 제작 척도이다.  총 30문항에 대해 5점 척도로 |\n| 성 | ※ 예: 보안이 보장되지 않은(unsecure) 운영 | 도 |\n**성**\n\n**[표 끝]**\n\n<!-- PAGE_47 -->\n###### 표 13.  전체 잔여위험 허용 가능성 평가 예시\n\n<!-- PAGE_47 -->\n###### ‘의료기기 사이버보안 요구사항 체크리스트’는 의료기기 사이버\n\n<!-- PAGE_47 -->\n###### 보안 요구사항에 대한 적합성 여부를 확인할 수 있는 자료로 제조자는\n\n<!-- PAGE_47 -->\n###### 체크리스트의 질의 사항을 확인하여 요구사항의 적용여부 등을 확인\n\n<!-- PAGE_47 -->\n###### 사용되는 통신기술(유·무선 통신 방식 등), 사용환경(병원 내/외\n\n<!-- PAGE_47 -->\n###### 사용, 공용 네트워크망 사용 등) 등 통신 특성을 확인할 수 있는\n\n<!-- PAGE_47 -->\n###### 사항을 기재한다.  이를 기반으로 체크리스트에 따라 요구사항 적용\n\n- - 41 -\n<!-- PAGE_48 -->\n###### <예시> - 의료기기 사이버보안 요구사항 체크리스트\n\n**[표 시작]**\n\n**예시**\n**무결성**\n**예시**\n**예시**\n**※ 피험자 수: 시험대상수 산출시 일반적인 고려사항**\n**물리적**\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 |\n**예시**\n**Depression Scale, CES-D)**\n| 발 | 행 | 일 2022년 12월 14일 |\n**사용자**\n| 발 | 행 | 인 | 서경원 |\n| 연구 참여 동의서 취득 | O | - | - | - |\n**Questionnaire-9, PHQ-9)**\n**신뢰성**\n**편 집 위 원 장 이정림**\n| 편 | 집 | 위 | 원 | 이원규, 박종호, 양승하, 한영민, 김건소, 채형래 |\n**가용성**\n| 임상시험 의료기기 적용 | O | O | O | O | Depression Scale, SDS) |\n| 평가지표 Baseline 수집 | (O) | O | - | - |\n| 평가지표 수집 및 분석2) | 2)2) | O | O | O | O |\n| 소프트 | 예시 |\n| 문 | 의 | 처 |\n**데이터**\n\n**[표 끝]**\n\n- - 42 -\n제조자는 기밀성에 대한 위험통제 수단이\n\n요구될 때, 통신 프로토콜의 컨트롤(control)/\n\n소프트웨어\n\n**[표 시작]**\n\n**시험보고서**\n**시험보고서**\n**할 수 있다. ",
        "original_sentence": "| : 제2종 오류 0.20 | BSS는 총 21개 문항으로 구성되어 있으며 이 중 19개 문항은 |      |     ≠ | 분석 | Mean | SD | 완료 | 유효성 |\n| 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 | 하거나 암호화의 키 관련 자료가 손상되는 | 있는 국내 제작 척도이다. "
      }
    },
    {
      "chunk_id": "chunk_606",
      "text": "총 30문항에 대해 5점 척도로 |\n| 성 | ※ 예: 보안이 보장되지 않은(unsecure) 운영 | 도 |\n**성**\n\n**[표 끝]**\n\n<!-- PAGE_47 -->\n###### 표 13. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 605,
        "window_size": 3,
        "char_count": 110,
        "word_count": 27,
        "page_number": 47,
        "window_text": "| 사) 이상반응 조사 | 가) 임상시험 설명 및 동의 | 마) 우울장애 심각도 척도(BDI-II) 조사 | 사) 순응도 조사 | 라) 순응도 조사 | 하는 내용이 포함되어서는 안된다.  | - 피험자가 제때 방문을 안 하며 연락이 안 되는 경우 | (2) 우울장애 관련한 약물을 복용한 경우 | 기간, 목적을 확인한다.  | : 제2종 오류 0.20 | BSS는 총 21개 문항으로 구성되어 있으며 이 중 19개 문항은 |      |     ≠ | 분석 | Mean | SD | 완료 | 유효성 |\n| 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 | 하거나 암호화의 키 관련 자료가 손상되는 | 있는 국내 제작 척도이다.  총 30문항에 대해 5점 척도로 |\n| 성 | ※ 예: 보안이 보장되지 않은(unsecure) 운영 | 도 |\n**성**\n\n**[표 끝]**\n\n<!-- PAGE_47 -->\n###### 표 13.  전체 잔여위험 허용 가능성 평가 예시\n\n<!-- PAGE_47 -->\n###### ‘의료기기 사이버보안 요구사항 체크리스트’는 의료기기 사이버\n\n<!-- PAGE_47 -->\n###### 보안 요구사항에 대한 적합성 여부를 확인할 수 있는 자료로 제조자는\n\n<!-- PAGE_47 -->\n###### 체크리스트의 질의 사항을 확인하여 요구사항의 적용여부 등을 확인\n\n<!-- PAGE_47 -->\n###### 사용되는 통신기술(유·무선 통신 방식 등), 사용환경(병원 내/외\n\n<!-- PAGE_47 -->\n###### 사용, 공용 네트워크망 사용 등) 등 통신 특성을 확인할 수 있는\n\n<!-- PAGE_47 -->\n###### 사항을 기재한다.  이를 기반으로 체크리스트에 따라 요구사항 적용\n\n- - 41 -\n<!-- PAGE_48 -->\n###### <예시> - 의료기기 사이버보안 요구사항 체크리스트\n\n**[표 시작]**\n\n**예시**\n**무결성**\n**예시**\n**예시**\n**※ 피험자 수: 시험대상수 산출시 일반적인 고려사항**\n**물리적**\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 |\n**예시**\n**Depression Scale, CES-D)**\n| 발 | 행 | 일 2022년 12월 14일 |\n**사용자**\n| 발 | 행 | 인 | 서경원 |\n| 연구 참여 동의서 취득 | O | - | - | - |\n**Questionnaire-9, PHQ-9)**\n**신뢰성**\n**편 집 위 원 장 이정림**\n| 편 | 집 | 위 | 원 | 이원규, 박종호, 양승하, 한영민, 김건소, 채형래 |\n**가용성**\n| 임상시험 의료기기 적용 | O | O | O | O | Depression Scale, SDS) |\n| 평가지표 Baseline 수집 | (O) | O | - | - |\n| 평가지표 수집 및 분석2) | 2)2) | O | O | O | O |\n| 소프트 | 예시 |\n| 문 | 의 | 처 |\n**데이터**\n\n**[표 끝]**\n\n- - 42 -\n제조자는 기밀성에 대한 위험통제 수단이\n\n요구될 때, 통신 프로토콜의 컨트롤(control)/\n\n소프트웨어\n\n**[표 시작]**\n\n**시험보고서**\n**시험보고서**\n**할 수 있다.  본 예시는 대표적인 예를 작성한 것으로 실제 시험규격에 대해 작성**\n**Effect size2)**\n| 가이드라인’을 참고하여 임상시험 피험자 수 산출 방식을 적용한다. ",
        "original_sentence": "총 30문항에 대해 5점 척도로 |\n| 성 | ※ 예: 보안이 보장되지 않은(unsecure) 운영 | 도 |\n**성**\n\n**[표 끝]**\n\n<!-- PAGE_47 -->\n###### 표 13. "
      }
    },
    {
      "chunk_id": "chunk_607",
      "text": "전체 잔여위험 허용 가능성 평가 예시\n\n<!-- PAGE_47 -->\n###### ‘의료기기 사이버보안 요구사항 체크리스트’는 의료기기 사이버\n\n<!-- PAGE_47 -->\n###### 보안 요구사항에 대한 적합성 여부를 확인할 수 있는 자료로 제조자는\n\n<!-- PAGE_47 -->\n###### 체크리스트의 질의 사항을 확인하여 요구사항의 적용여부 등을 확인\n\n<!-- PAGE_47 -->\n###### 사용되는 통신기술(유·무선 통신 방식 등), 사용환경(병원 내/외\n\n<!-- PAGE_47 -->\n###### 사용, 공용 네트워크망 사용 등) 등 통신 특성을 확인할 수 있는\n\n<!-- PAGE_47 -->\n###### 사항을 기재한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 606,
        "window_size": 3,
        "char_count": 363,
        "word_count": 74,
        "page_number": 47,
        "window_text": "| - 피험자가 제때 방문을 안 하며 연락이 안 되는 경우 | (2) 우울장애 관련한 약물을 복용한 경우 | 기간, 목적을 확인한다.  | : 제2종 오류 0.20 | BSS는 총 21개 문항으로 구성되어 있으며 이 중 19개 문항은 |      |     ≠ | 분석 | Mean | SD | 완료 | 유효성 |\n| 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 | 하거나 암호화의 키 관련 자료가 손상되는 | 있는 국내 제작 척도이다.  총 30문항에 대해 5점 척도로 |\n| 성 | ※ 예: 보안이 보장되지 않은(unsecure) 운영 | 도 |\n**성**\n\n**[표 끝]**\n\n<!-- PAGE_47 -->\n###### 표 13.  전체 잔여위험 허용 가능성 평가 예시\n\n<!-- PAGE_47 -->\n###### ‘의료기기 사이버보안 요구사항 체크리스트’는 의료기기 사이버\n\n<!-- PAGE_47 -->\n###### 보안 요구사항에 대한 적합성 여부를 확인할 수 있는 자료로 제조자는\n\n<!-- PAGE_47 -->\n###### 체크리스트의 질의 사항을 확인하여 요구사항의 적용여부 등을 확인\n\n<!-- PAGE_47 -->\n###### 사용되는 통신기술(유·무선 통신 방식 등), 사용환경(병원 내/외\n\n<!-- PAGE_47 -->\n###### 사용, 공용 네트워크망 사용 등) 등 통신 특성을 확인할 수 있는\n\n<!-- PAGE_47 -->\n###### 사항을 기재한다.  이를 기반으로 체크리스트에 따라 요구사항 적용\n\n- - 41 -\n<!-- PAGE_48 -->\n###### <예시> - 의료기기 사이버보안 요구사항 체크리스트\n\n**[표 시작]**\n\n**예시**\n**무결성**\n**예시**\n**예시**\n**※ 피험자 수: 시험대상수 산출시 일반적인 고려사항**\n**물리적**\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 |\n**예시**\n**Depression Scale, CES-D)**\n| 발 | 행 | 일 2022년 12월 14일 |\n**사용자**\n| 발 | 행 | 인 | 서경원 |\n| 연구 참여 동의서 취득 | O | - | - | - |\n**Questionnaire-9, PHQ-9)**\n**신뢰성**\n**편 집 위 원 장 이정림**\n| 편 | 집 | 위 | 원 | 이원규, 박종호, 양승하, 한영민, 김건소, 채형래 |\n**가용성**\n| 임상시험 의료기기 적용 | O | O | O | O | Depression Scale, SDS) |\n| 평가지표 Baseline 수집 | (O) | O | - | - |\n| 평가지표 수집 및 분석2) | 2)2) | O | O | O | O |\n| 소프트 | 예시 |\n| 문 | 의 | 처 |\n**데이터**\n\n**[표 끝]**\n\n- - 42 -\n제조자는 기밀성에 대한 위험통제 수단이\n\n요구될 때, 통신 프로토콜의 컨트롤(control)/\n\n소프트웨어\n\n**[표 시작]**\n\n**시험보고서**\n**시험보고서**\n**할 수 있다.  본 예시는 대표적인 예를 작성한 것으로 실제 시험규격에 대해 작성**\n**Effect size2)**\n| 가이드라인’을 참고하여 임상시험 피험자 수 산출 방식을 적용한다.  피험자 수를 결정 | (AB-1234) |\n| 그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있다. ",
        "original_sentence": "전체 잔여위험 허용 가능성 평가 예시\n\n<!-- PAGE_47 -->\n###### ‘의료기기 사이버보안 요구사항 체크리스트’는 의료기기 사이버\n\n<!-- PAGE_47 -->\n###### 보안 요구사항에 대한 적합성 여부를 확인할 수 있는 자료로 제조자는\n\n<!-- PAGE_47 -->\n###### 체크리스트의 질의 사항을 확인하여 요구사항의 적용여부 등을 확인\n\n<!-- PAGE_47 -->\n###### 사용되는 통신기술(유·무선 통신 방식 등), 사용환경(병원 내/외\n\n<!-- PAGE_47 -->\n###### 사용, 공용 네트워크망 사용 등) 등 통신 특성을 확인할 수 있는\n\n<!-- PAGE_47 -->\n###### 사항을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_608",
      "text": "이를 기반으로 체크리스트에 따라 요구사항 적용\n\n- - 41 -\n<!-- PAGE_48 -->\n###### <예시> - 의료기기 사이버보안 요구사항 체크리스트\n\n**[표 시작]**\n\n**예시**\n**무결성**\n**예시**\n**예시**\n**※ 피험자 수: 시험대상수 산출시 일반적인 고려사항**\n**물리적**\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 |\n**예시**\n**Depression Scale, CES-D)**\n| 발 | 행 | 일 2022년 12월 14일 |\n**사용자**\n| 발 | 행 | 인 | 서경원 |\n| 연구 참여 동의서 취득 | O | - | - | - |\n**Questionnaire-9, PHQ-9)**\n**신뢰성**\n**편 집 위 원 장 이정림**\n| 편 | 집 | 위 | 원 | 이원규, 박종호, 양승하, 한영민, 김건소, 채형래 |\n**가용성**\n| 임상시험 의료기기 적용 | O | O | O | O | Depression Scale, SDS) |\n| 평가지표 Baseline 수집 | (O) | O | - | - |\n| 평가지표 수집 및 분석2) | 2)2) | O | O | O | O |\n| 소프트 | 예시 |\n| 문 | 의 | 처 |\n**데이터**\n\n**[표 끝]**\n\n- - 42 -\n제조자는 기밀성에 대한 위험통제 수단이\n\n요구될 때, 통신 프로토콜의 컨트롤(control)/\n\n소프트웨어\n\n**[표 시작]**\n\n**시험보고서**\n**시험보고서**\n**할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 607,
        "window_size": 3,
        "char_count": 740,
        "word_count": 190,
        "page_number": 48,
        "window_text": "| : 제2종 오류 0.20 | BSS는 총 21개 문항으로 구성되어 있으며 이 중 19개 문항은 |      |     ≠ | 분석 | Mean | SD | 완료 | 유효성 |\n| 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 | 하거나 암호화의 키 관련 자료가 손상되는 | 있는 국내 제작 척도이다.  총 30문항에 대해 5점 척도로 |\n| 성 | ※ 예: 보안이 보장되지 않은(unsecure) 운영 | 도 |\n**성**\n\n**[표 끝]**\n\n<!-- PAGE_47 -->\n###### 표 13.  전체 잔여위험 허용 가능성 평가 예시\n\n<!-- PAGE_47 -->\n###### ‘의료기기 사이버보안 요구사항 체크리스트’는 의료기기 사이버\n\n<!-- PAGE_47 -->\n###### 보안 요구사항에 대한 적합성 여부를 확인할 수 있는 자료로 제조자는\n\n<!-- PAGE_47 -->\n###### 체크리스트의 질의 사항을 확인하여 요구사항의 적용여부 등을 확인\n\n<!-- PAGE_47 -->\n###### 사용되는 통신기술(유·무선 통신 방식 등), 사용환경(병원 내/외\n\n<!-- PAGE_47 -->\n###### 사용, 공용 네트워크망 사용 등) 등 통신 특성을 확인할 수 있는\n\n<!-- PAGE_47 -->\n###### 사항을 기재한다.  이를 기반으로 체크리스트에 따라 요구사항 적용\n\n- - 41 -\n<!-- PAGE_48 -->\n###### <예시> - 의료기기 사이버보안 요구사항 체크리스트\n\n**[표 시작]**\n\n**예시**\n**무결성**\n**예시**\n**예시**\n**※ 피험자 수: 시험대상수 산출시 일반적인 고려사항**\n**물리적**\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 |\n**예시**\n**Depression Scale, CES-D)**\n| 발 | 행 | 일 2022년 12월 14일 |\n**사용자**\n| 발 | 행 | 인 | 서경원 |\n| 연구 참여 동의서 취득 | O | - | - | - |\n**Questionnaire-9, PHQ-9)**\n**신뢰성**\n**편 집 위 원 장 이정림**\n| 편 | 집 | 위 | 원 | 이원규, 박종호, 양승하, 한영민, 김건소, 채형래 |\n**가용성**\n| 임상시험 의료기기 적용 | O | O | O | O | Depression Scale, SDS) |\n| 평가지표 Baseline 수집 | (O) | O | - | - |\n| 평가지표 수집 및 분석2) | 2)2) | O | O | O | O |\n| 소프트 | 예시 |\n| 문 | 의 | 처 |\n**데이터**\n\n**[표 끝]**\n\n- - 42 -\n제조자는 기밀성에 대한 위험통제 수단이\n\n요구될 때, 통신 프로토콜의 컨트롤(control)/\n\n소프트웨어\n\n**[표 시작]**\n\n**시험보고서**\n**시험보고서**\n**할 수 있다.  본 예시는 대표적인 예를 작성한 것으로 실제 시험규격에 대해 작성**\n**Effect size2)**\n| 가이드라인’을 참고하여 임상시험 피험자 수 산출 방식을 적용한다.  피험자 수를 결정 | (AB-1234) |\n| 그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있다.  피험자 배정과 | 구조, 성능 등을 구체적으로 기재하도록 한다. ",
        "original_sentence": "이를 기반으로 체크리스트에 따라 요구사항 적용\n\n- - 41 -\n<!-- PAGE_48 -->\n###### <예시> - 의료기기 사이버보안 요구사항 체크리스트\n\n**[표 시작]**\n\n**예시**\n**무결성**\n**예시**\n**예시**\n**※ 피험자 수: 시험대상수 산출시 일반적인 고려사항**\n**물리적**\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 |\n**예시**\n**Depression Scale, CES-D)**\n| 발 | 행 | 일 2022년 12월 14일 |\n**사용자**\n| 발 | 행 | 인 | 서경원 |\n| 연구 참여 동의서 취득 | O | - | - | - |\n**Questionnaire-9, PHQ-9)**\n**신뢰성**\n**편 집 위 원 장 이정림**\n| 편 | 집 | 위 | 원 | 이원규, 박종호, 양승하, 한영민, 김건소, 채형래 |\n**가용성**\n| 임상시험 의료기기 적용 | O | O | O | O | Depression Scale, SDS) |\n| 평가지표 Baseline 수집 | (O) | O | - | - |\n| 평가지표 수집 및 분석2) | 2)2) | O | O | O | O |\n| 소프트 | 예시 |\n| 문 | 의 | 처 |\n**데이터**\n\n**[표 끝]**\n\n- - 42 -\n제조자는 기밀성에 대한 위험통제 수단이\n\n요구될 때, 통신 프로토콜의 컨트롤(control)/\n\n소프트웨어\n\n**[표 시작]**\n\n**시험보고서**\n**시험보고서**\n**할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_609",
      "text": "본 예시는 대표적인 예를 작성한 것으로 실제 시험규격에 대해 작성**\n**Effect size2)**\n| 가이드라인’을 참고하여 임상시험 피험자 수 산출 방식을 적용한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 608,
        "window_size": 3,
        "char_count": 96,
        "word_count": 21,
        "page_number": 20,
        "window_text": "총 30문항에 대해 5점 척도로 |\n| 성 | ※ 예: 보안이 보장되지 않은(unsecure) 운영 | 도 |\n**성**\n\n**[표 끝]**\n\n<!-- PAGE_47 -->\n###### 표 13.  전체 잔여위험 허용 가능성 평가 예시\n\n<!-- PAGE_47 -->\n###### ‘의료기기 사이버보안 요구사항 체크리스트’는 의료기기 사이버\n\n<!-- PAGE_47 -->\n###### 보안 요구사항에 대한 적합성 여부를 확인할 수 있는 자료로 제조자는\n\n<!-- PAGE_47 -->\n###### 체크리스트의 질의 사항을 확인하여 요구사항의 적용여부 등을 확인\n\n<!-- PAGE_47 -->\n###### 사용되는 통신기술(유·무선 통신 방식 등), 사용환경(병원 내/외\n\n<!-- PAGE_47 -->\n###### 사용, 공용 네트워크망 사용 등) 등 통신 특성을 확인할 수 있는\n\n<!-- PAGE_47 -->\n###### 사항을 기재한다.  이를 기반으로 체크리스트에 따라 요구사항 적용\n\n- - 41 -\n<!-- PAGE_48 -->\n###### <예시> - 의료기기 사이버보안 요구사항 체크리스트\n\n**[표 시작]**\n\n**예시**\n**무결성**\n**예시**\n**예시**\n**※ 피험자 수: 시험대상수 산출시 일반적인 고려사항**\n**물리적**\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 |\n**예시**\n**Depression Scale, CES-D)**\n| 발 | 행 | 일 2022년 12월 14일 |\n**사용자**\n| 발 | 행 | 인 | 서경원 |\n| 연구 참여 동의서 취득 | O | - | - | - |\n**Questionnaire-9, PHQ-9)**\n**신뢰성**\n**편 집 위 원 장 이정림**\n| 편 | 집 | 위 | 원 | 이원규, 박종호, 양승하, 한영민, 김건소, 채형래 |\n**가용성**\n| 임상시험 의료기기 적용 | O | O | O | O | Depression Scale, SDS) |\n| 평가지표 Baseline 수집 | (O) | O | - | - |\n| 평가지표 수집 및 분석2) | 2)2) | O | O | O | O |\n| 소프트 | 예시 |\n| 문 | 의 | 처 |\n**데이터**\n\n**[표 끝]**\n\n- - 42 -\n제조자는 기밀성에 대한 위험통제 수단이\n\n요구될 때, 통신 프로토콜의 컨트롤(control)/\n\n소프트웨어\n\n**[표 시작]**\n\n**시험보고서**\n**시험보고서**\n**할 수 있다.  본 예시는 대표적인 예를 작성한 것으로 실제 시험규격에 대해 작성**\n**Effect size2)**\n| 가이드라인’을 참고하여 임상시험 피험자 수 산출 방식을 적용한다.  피험자 수를 결정 | (AB-1234) |\n| 그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있다.  피험자 배정과 | 구조, 성능 등을 구체적으로 기재하도록 한다.  | - 해당 의료기기의 임상시험에 따른 유효성 평가는 사용된 모든 의료기기를 | 피험자의 모집 기간, 임상 관찰 및 시험 수행 기간, 통계 처리 기간, 결과보고서 작성 기간, | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 및 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례기록서 | 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | 시험책임자는 의료기기법 시행규칙 제24조 제1항 제4호의 규정에 따라 임상 | 임상시험 방법은 해당 의료기기에 대한 모양, 구조 및 사용 전 준비사항/피험자에 대한 | (AB-1234) |\n| 시에는 해당 제품의 특성 및 주요 기능을 고려하여 작성하여야 한다. ",
        "original_sentence": "본 예시는 대표적인 예를 작성한 것으로 실제 시험규격에 대해 작성**\n**Effect size2)**\n| 가이드라인’을 참고하여 임상시험 피험자 수 산출 방식을 적용한다. "
      }
    },
    {
      "chunk_id": "chunk_610",
      "text": "피험자 수를 결정 | (AB-1234) |\n| 그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 609,
        "window_size": 3,
        "char_count": 62,
        "word_count": 17,
        "page_number": 7,
        "window_text": "전체 잔여위험 허용 가능성 평가 예시\n\n<!-- PAGE_47 -->\n###### ‘의료기기 사이버보안 요구사항 체크리스트’는 의료기기 사이버\n\n<!-- PAGE_47 -->\n###### 보안 요구사항에 대한 적합성 여부를 확인할 수 있는 자료로 제조자는\n\n<!-- PAGE_47 -->\n###### 체크리스트의 질의 사항을 확인하여 요구사항의 적용여부 등을 확인\n\n<!-- PAGE_47 -->\n###### 사용되는 통신기술(유·무선 통신 방식 등), 사용환경(병원 내/외\n\n<!-- PAGE_47 -->\n###### 사용, 공용 네트워크망 사용 등) 등 통신 특성을 확인할 수 있는\n\n<!-- PAGE_47 -->\n###### 사항을 기재한다.  이를 기반으로 체크리스트에 따라 요구사항 적용\n\n- - 41 -\n<!-- PAGE_48 -->\n###### <예시> - 의료기기 사이버보안 요구사항 체크리스트\n\n**[표 시작]**\n\n**예시**\n**무결성**\n**예시**\n**예시**\n**※ 피험자 수: 시험대상수 산출시 일반적인 고려사항**\n**물리적**\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 |\n**예시**\n**Depression Scale, CES-D)**\n| 발 | 행 | 일 2022년 12월 14일 |\n**사용자**\n| 발 | 행 | 인 | 서경원 |\n| 연구 참여 동의서 취득 | O | - | - | - |\n**Questionnaire-9, PHQ-9)**\n**신뢰성**\n**편 집 위 원 장 이정림**\n| 편 | 집 | 위 | 원 | 이원규, 박종호, 양승하, 한영민, 김건소, 채형래 |\n**가용성**\n| 임상시험 의료기기 적용 | O | O | O | O | Depression Scale, SDS) |\n| 평가지표 Baseline 수집 | (O) | O | - | - |\n| 평가지표 수집 및 분석2) | 2)2) | O | O | O | O |\n| 소프트 | 예시 |\n| 문 | 의 | 처 |\n**데이터**\n\n**[표 끝]**\n\n- - 42 -\n제조자는 기밀성에 대한 위험통제 수단이\n\n요구될 때, 통신 프로토콜의 컨트롤(control)/\n\n소프트웨어\n\n**[표 시작]**\n\n**시험보고서**\n**시험보고서**\n**할 수 있다.  본 예시는 대표적인 예를 작성한 것으로 실제 시험규격에 대해 작성**\n**Effect size2)**\n| 가이드라인’을 참고하여 임상시험 피험자 수 산출 방식을 적용한다.  피험자 수를 결정 | (AB-1234) |\n| 그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있다.  피험자 배정과 | 구조, 성능 등을 구체적으로 기재하도록 한다.  | - 해당 의료기기의 임상시험에 따른 유효성 평가는 사용된 모든 의료기기를 | 피험자의 모집 기간, 임상 관찰 및 시험 수행 기간, 통계 처리 기간, 결과보고서 작성 기간, | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 및 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례기록서 | 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | 시험책임자는 의료기기법 시행규칙 제24조 제1항 제4호의 규정에 따라 임상 | 임상시험 방법은 해당 의료기기에 대한 모양, 구조 및 사용 전 준비사항/피험자에 대한 | (AB-1234) |\n| 시에는 해당 제품의 특성 및 주요 기능을 고려하여 작성하여야 한다.  | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상반응 등에 대하여 임상 | 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생 시 |\n| 하기 위해서는 사전 정보가 필요한데, 여기에 포함되어야 할 필수 정보로는 다음이 있다. ",
        "original_sentence": "피험자 수를 결정 | (AB-1234) |\n| 그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_611",
      "text": "피험자 배정과 | 구조, 성능 등을 구체적으로 기재하도록 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 610,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 13,
        "window_text": "이를 기반으로 체크리스트에 따라 요구사항 적용\n\n- - 41 -\n<!-- PAGE_48 -->\n###### <예시> - 의료기기 사이버보안 요구사항 체크리스트\n\n**[표 시작]**\n\n**예시**\n**무결성**\n**예시**\n**예시**\n**※ 피험자 수: 시험대상수 산출시 일반적인 고려사항**\n**물리적**\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 |\n**예시**\n**Depression Scale, CES-D)**\n| 발 | 행 | 일 2022년 12월 14일 |\n**사용자**\n| 발 | 행 | 인 | 서경원 |\n| 연구 참여 동의서 취득 | O | - | - | - |\n**Questionnaire-9, PHQ-9)**\n**신뢰성**\n**편 집 위 원 장 이정림**\n| 편 | 집 | 위 | 원 | 이원규, 박종호, 양승하, 한영민, 김건소, 채형래 |\n**가용성**\n| 임상시험 의료기기 적용 | O | O | O | O | Depression Scale, SDS) |\n| 평가지표 Baseline 수집 | (O) | O | - | - |\n| 평가지표 수집 및 분석2) | 2)2) | O | O | O | O |\n| 소프트 | 예시 |\n| 문 | 의 | 처 |\n**데이터**\n\n**[표 끝]**\n\n- - 42 -\n제조자는 기밀성에 대한 위험통제 수단이\n\n요구될 때, 통신 프로토콜의 컨트롤(control)/\n\n소프트웨어\n\n**[표 시작]**\n\n**시험보고서**\n**시험보고서**\n**할 수 있다.  본 예시는 대표적인 예를 작성한 것으로 실제 시험규격에 대해 작성**\n**Effect size2)**\n| 가이드라인’을 참고하여 임상시험 피험자 수 산출 방식을 적용한다.  피험자 수를 결정 | (AB-1234) |\n| 그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있다.  피험자 배정과 | 구조, 성능 등을 구체적으로 기재하도록 한다.  | - 해당 의료기기의 임상시험에 따른 유효성 평가는 사용된 모든 의료기기를 | 피험자의 모집 기간, 임상 관찰 및 시험 수행 기간, 통계 처리 기간, 결과보고서 작성 기간, | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 및 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례기록서 | 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | 시험책임자는 의료기기법 시행규칙 제24조 제1항 제4호의 규정에 따라 임상 | 임상시험 방법은 해당 의료기기에 대한 모양, 구조 및 사용 전 준비사항/피험자에 대한 | (AB-1234) |\n| 시에는 해당 제품의 특성 및 주요 기능을 고려하여 작성하여야 한다.  | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상반응 등에 대하여 임상 | 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생 시 |\n| 하기 위해서는 사전 정보가 필요한데, 여기에 포함되어야 할 필수 정보로는 다음이 있다.  | - 부작용, 이상반응 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상 시험의 |\n| 보관, 관리하는 임상의, 의료기사 또는 간호사 등으로 임상시험기관의 장이 지정한 | 시험을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화할 때, 헬싱키 선언에 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람 |\n| 처리 할당에 있어 편향(Bias)을 줄이기 위해 무작위배정(Randomization)과 눈가림 | 기술하는 것을 말하며, 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 |\n**해당 의료기기의 제조업자 또는 수입업자가 해당된다. ",
        "original_sentence": "피험자 배정과 | 구조, 성능 등을 구체적으로 기재하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_612",
      "text": "| - 해당 의료기기의 임상시험에 따른 유효성 평가는 사용된 모든 의료기기를 | 피험자의 모집 기간, 임상 관찰 및 시험 수행 기간, 통계 처리 기간, 결과보고서 작성 기간, | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 및 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례기록서 | 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | 시험책임자는 의료기기법 시행규칙 제24조 제1항 제4호의 규정에 따라 임상 | 임상시험 방법은 해당 의료기기에 대한 모양, 구조 및 사용 전 준비사항/피험자에 대한 | (AB-1234) |\n| 시에는 해당 제품의 특성 및 주요 기능을 고려하여 작성하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 611,
        "window_size": 3,
        "char_count": 384,
        "word_count": 95,
        "page_number": 29,
        "window_text": "본 예시는 대표적인 예를 작성한 것으로 실제 시험규격에 대해 작성**\n**Effect size2)**\n| 가이드라인’을 참고하여 임상시험 피험자 수 산출 방식을 적용한다.  피험자 수를 결정 | (AB-1234) |\n| 그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있다.  피험자 배정과 | 구조, 성능 등을 구체적으로 기재하도록 한다.  | - 해당 의료기기의 임상시험에 따른 유효성 평가는 사용된 모든 의료기기를 | 피험자의 모집 기간, 임상 관찰 및 시험 수행 기간, 통계 처리 기간, 결과보고서 작성 기간, | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 및 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례기록서 | 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | 시험책임자는 의료기기법 시행규칙 제24조 제1항 제4호의 규정에 따라 임상 | 임상시험 방법은 해당 의료기기에 대한 모양, 구조 및 사용 전 준비사항/피험자에 대한 | (AB-1234) |\n| 시에는 해당 제품의 특성 및 주요 기능을 고려하여 작성하여야 한다.  | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상반응 등에 대하여 임상 | 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생 시 |\n| 하기 위해서는 사전 정보가 필요한데, 여기에 포함되어야 할 필수 정보로는 다음이 있다.  | - 부작용, 이상반응 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상 시험의 |\n| 보관, 관리하는 임상의, 의료기사 또는 간호사 등으로 임상시험기관의 장이 지정한 | 시험을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화할 때, 헬싱키 선언에 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람 |\n| 처리 할당에 있어 편향(Bias)을 줄이기 위해 무작위배정(Randomization)과 눈가림 | 기술하는 것을 말하며, 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 |\n**해당 의료기기의 제조업자 또는 수입업자가 해당된다.  의뢰자는 임상시험 모니터**\n| 요원을 지정하여야 한다. ",
        "original_sentence": "| - 해당 의료기기의 임상시험에 따른 유효성 평가는 사용된 모든 의료기기를 | 피험자의 모집 기간, 임상 관찰 및 시험 수행 기간, 통계 처리 기간, 결과보고서 작성 기간, | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 및 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례기록서 | 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | 시험책임자는 의료기기법 시행규칙 제24조 제1항 제4호의 규정에 따라 임상 | 임상시험 방법은 해당 의료기기에 대한 모양, 구조 및 사용 전 준비사항/피험자에 대한 | (AB-1234) |\n| 시에는 해당 제품의 특성 및 주요 기능을 고려하여 작성하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_613",
      "text": "| 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상반응 등에 대하여 임상 | 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생 시 |\n| 하기 위해서는 사전 정보가 필요한데, 여기에 포함되어야 할 필수 정보로는 다음이 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 612,
        "window_size": 3,
        "char_count": 143,
        "word_count": 33,
        "page_number": 39,
        "window_text": "피험자 수를 결정 | (AB-1234) |\n| 그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있다.  피험자 배정과 | 구조, 성능 등을 구체적으로 기재하도록 한다.  | - 해당 의료기기의 임상시험에 따른 유효성 평가는 사용된 모든 의료기기를 | 피험자의 모집 기간, 임상 관찰 및 시험 수행 기간, 통계 처리 기간, 결과보고서 작성 기간, | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 및 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례기록서 | 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | 시험책임자는 의료기기법 시행규칙 제24조 제1항 제4호의 규정에 따라 임상 | 임상시험 방법은 해당 의료기기에 대한 모양, 구조 및 사용 전 준비사항/피험자에 대한 | (AB-1234) |\n| 시에는 해당 제품의 특성 및 주요 기능을 고려하여 작성하여야 한다.  | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상반응 등에 대하여 임상 | 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생 시 |\n| 하기 위해서는 사전 정보가 필요한데, 여기에 포함되어야 할 필수 정보로는 다음이 있다.  | - 부작용, 이상반응 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상 시험의 |\n| 보관, 관리하는 임상의, 의료기사 또는 간호사 등으로 임상시험기관의 장이 지정한 | 시험을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화할 때, 헬싱키 선언에 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람 |\n| 처리 할당에 있어 편향(Bias)을 줄이기 위해 무작위배정(Randomization)과 눈가림 | 기술하는 것을 말하며, 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 |\n**해당 의료기기의 제조업자 또는 수입업자가 해당된다.  의뢰자는 임상시험 모니터**\n| 요원을 지정하여야 한다.  임상시험 모니터요원의 선정, 자격기준, 수행임무 등에 | - 피험자(Subject)란 임상시험에 참여하는 임상시험용 또는 대조시험용 의료기기의 적용 |\n**대한 사항은 「의료기기법 시행규칙」별표3 “의료기기의 임상시험 관리기준” 제8호**\n\n**[표 끝]**\n\n확인 자료\n\n- - 43 -\n또한 제조자는 외부의 통제에 의한 소프트\n\n웨어의 업데이트나 운영환경 만료에 대한\n\n소프트웨어\n\n- - 44 -\n<!-- PAGE_51 -->\n##### 3. ",
        "original_sentence": "| 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상반응 등에 대하여 임상 | 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생 시 |\n| 하기 위해서는 사전 정보가 필요한데, 여기에 포함되어야 할 필수 정보로는 다음이 있다. "
      }
    },
    {
      "chunk_id": "chunk_614",
      "text": "| - 부작용, 이상반응 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상 시험의 |\n| 보관, 관리하는 임상의, 의료기사 또는 간호사 등으로 임상시험기관의 장이 지정한 | 시험을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화할 때, 헬싱키 선언에 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람 |\n| 처리 할당에 있어 편향(Bias)을 줄이기 위해 무작위배정(Randomization)과 눈가림 | 기술하는 것을 말하며, 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 |\n**해당 의료기기의 제조업자 또는 수입업자가 해당된다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 613,
        "window_size": 3,
        "char_count": 326,
        "word_count": 76,
        "page_number": 12,
        "window_text": "피험자 배정과 | 구조, 성능 등을 구체적으로 기재하도록 한다.  | - 해당 의료기기의 임상시험에 따른 유효성 평가는 사용된 모든 의료기기를 | 피험자의 모집 기간, 임상 관찰 및 시험 수행 기간, 통계 처리 기간, 결과보고서 작성 기간, | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 및 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례기록서 | 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | 시험책임자는 의료기기법 시행규칙 제24조 제1항 제4호의 규정에 따라 임상 | 임상시험 방법은 해당 의료기기에 대한 모양, 구조 및 사용 전 준비사항/피험자에 대한 | (AB-1234) |\n| 시에는 해당 제품의 특성 및 주요 기능을 고려하여 작성하여야 한다.  | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상반응 등에 대하여 임상 | 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생 시 |\n| 하기 위해서는 사전 정보가 필요한데, 여기에 포함되어야 할 필수 정보로는 다음이 있다.  | - 부작용, 이상반응 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상 시험의 |\n| 보관, 관리하는 임상의, 의료기사 또는 간호사 등으로 임상시험기관의 장이 지정한 | 시험을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화할 때, 헬싱키 선언에 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람 |\n| 처리 할당에 있어 편향(Bias)을 줄이기 위해 무작위배정(Randomization)과 눈가림 | 기술하는 것을 말하며, 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 |\n**해당 의료기기의 제조업자 또는 수입업자가 해당된다.  의뢰자는 임상시험 모니터**\n| 요원을 지정하여야 한다.  임상시험 모니터요원의 선정, 자격기준, 수행임무 등에 | - 피험자(Subject)란 임상시험에 참여하는 임상시험용 또는 대조시험용 의료기기의 적용 |\n**대한 사항은 「의료기기법 시행규칙」별표3 “의료기기의 임상시험 관리기준” 제8호**\n\n**[표 끝]**\n\n확인 자료\n\n- - 43 -\n또한 제조자는 외부의 통제에 의한 소프트\n\n웨어의 업데이트나 운영환경 만료에 대한\n\n소프트웨어\n\n- - 44 -\n<!-- PAGE_51 -->\n##### 3.  성능 평가 항목\n\n<!-- PAGE_51 -->\n###### 우울장애 개선 디지털치료기기의 성능 평가 항목은 제품의 주요\n\n<!-- PAGE_51 -->\n###### 기능을 근거로 설정하며, 시험 기준 및 시험 방법은 제품의 특성을\n\n<!-- PAGE_51 -->\n###### 고려하여 가능한 정량적이고 구체적으로 작성한다.\n\n",
        "original_sentence": "| - 부작용, 이상반응 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상 시험의 |\n| 보관, 관리하는 임상의, 의료기사 또는 간호사 등으로 임상시험기관의 장이 지정한 | 시험을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화할 때, 헬싱키 선언에 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람 |\n| 처리 할당에 있어 편향(Bias)을 줄이기 위해 무작위배정(Randomization)과 눈가림 | 기술하는 것을 말하며, 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 |\n**해당 의료기기의 제조업자 또는 수입업자가 해당된다. "
      }
    },
    {
      "chunk_id": "chunk_615",
      "text": "의뢰자는 임상시험 모니터**\n| 요원을 지정하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 614,
        "window_size": 3,
        "char_count": 32,
        "word_count": 7,
        "page_number": 13,
        "window_text": "| - 해당 의료기기의 임상시험에 따른 유효성 평가는 사용된 모든 의료기기를 | 피험자의 모집 기간, 임상 관찰 및 시험 수행 기간, 통계 처리 기간, 결과보고서 작성 기간, | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 및 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례기록서 | 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | 시험책임자는 의료기기법 시행규칙 제24조 제1항 제4호의 규정에 따라 임상 | 임상시험 방법은 해당 의료기기에 대한 모양, 구조 및 사용 전 준비사항/피험자에 대한 | (AB-1234) |\n| 시에는 해당 제품의 특성 및 주요 기능을 고려하여 작성하여야 한다.  | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상반응 등에 대하여 임상 | 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생 시 |\n| 하기 위해서는 사전 정보가 필요한데, 여기에 포함되어야 할 필수 정보로는 다음이 있다.  | - 부작용, 이상반응 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상 시험의 |\n| 보관, 관리하는 임상의, 의료기사 또는 간호사 등으로 임상시험기관의 장이 지정한 | 시험을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화할 때, 헬싱키 선언에 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람 |\n| 처리 할당에 있어 편향(Bias)을 줄이기 위해 무작위배정(Randomization)과 눈가림 | 기술하는 것을 말하며, 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 |\n**해당 의료기기의 제조업자 또는 수입업자가 해당된다.  의뢰자는 임상시험 모니터**\n| 요원을 지정하여야 한다.  임상시험 모니터요원의 선정, 자격기준, 수행임무 등에 | - 피험자(Subject)란 임상시험에 참여하는 임상시험용 또는 대조시험용 의료기기의 적용 |\n**대한 사항은 「의료기기법 시행규칙」별표3 “의료기기의 임상시험 관리기준” 제8호**\n\n**[표 끝]**\n\n확인 자료\n\n- - 43 -\n또한 제조자는 외부의 통제에 의한 소프트\n\n웨어의 업데이트나 운영환경 만료에 대한\n\n소프트웨어\n\n- - 44 -\n<!-- PAGE_51 -->\n##### 3.  성능 평가 항목\n\n<!-- PAGE_51 -->\n###### 우울장애 개선 디지털치료기기의 성능 평가 항목은 제품의 주요\n\n<!-- PAGE_51 -->\n###### 기능을 근거로 설정하며, 시험 기준 및 시험 방법은 제품의 특성을\n\n<!-- PAGE_51 -->\n###### 고려하여 가능한 정량적이고 구체적으로 작성한다.\n\n - - 45 -\n본 예시는 이해를 돕기 위하여 작성된 것으로 실제 신청하려는 제품의 내용과 상이\n\n<!-- PAGE_52 -->\n###### 예시)\n\n- - 46 -\n<!-- PAGE_53 -->\n### Ⅲ\n\n<!-- PAGE_53 -->\n### 임상시험계획서 작성 시 고려사항 및 예시\n\n<!-- PAGE_53 -->\n###### 「의료기기법 시행규칙」제20조(임상시험계획의 승인 등) 제2항에 따라\n\n<!-- PAGE_53 -->\n###### 임상시험계획서에 포함되어야 할 사항은 다음과 같다.\n\n",
        "original_sentence": "의뢰자는 임상시험 모니터**\n| 요원을 지정하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_616",
      "text": "임상시험 모니터요원의 선정, 자격기준, 수행임무 등에 | - 피험자(Subject)란 임상시험에 참여하는 임상시험용 또는 대조시험용 의료기기의 적용 |\n**대한 사항은 「의료기기법 시행규칙」별표3 “의료기기의 임상시험 관리기준” 제8호**\n\n**[표 끝]**\n\n확인 자료\n\n- - 43 -\n또한 제조자는 외부의 통제에 의한 소프트\n\n웨어의 업데이트나 운영환경 만료에 대한\n\n소프트웨어\n\n- - 44 -\n<!-- PAGE_51 -->\n##### 3. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 615,
        "window_size": 3,
        "char_count": 251,
        "word_count": 54,
        "page_number": 51,
        "window_text": "| 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상반응 등에 대하여 임상 | 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생 시 |\n| 하기 위해서는 사전 정보가 필요한데, 여기에 포함되어야 할 필수 정보로는 다음이 있다.  | - 부작용, 이상반응 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상 시험의 |\n| 보관, 관리하는 임상의, 의료기사 또는 간호사 등으로 임상시험기관의 장이 지정한 | 시험을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화할 때, 헬싱키 선언에 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람 |\n| 처리 할당에 있어 편향(Bias)을 줄이기 위해 무작위배정(Randomization)과 눈가림 | 기술하는 것을 말하며, 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 |\n**해당 의료기기의 제조업자 또는 수입업자가 해당된다.  의뢰자는 임상시험 모니터**\n| 요원을 지정하여야 한다.  임상시험 모니터요원의 선정, 자격기준, 수행임무 등에 | - 피험자(Subject)란 임상시험에 참여하는 임상시험용 또는 대조시험용 의료기기의 적용 |\n**대한 사항은 「의료기기법 시행규칙」별표3 “의료기기의 임상시험 관리기준” 제8호**\n\n**[표 끝]**\n\n확인 자료\n\n- - 43 -\n또한 제조자는 외부의 통제에 의한 소프트\n\n웨어의 업데이트나 운영환경 만료에 대한\n\n소프트웨어\n\n- - 44 -\n<!-- PAGE_51 -->\n##### 3.  성능 평가 항목\n\n<!-- PAGE_51 -->\n###### 우울장애 개선 디지털치료기기의 성능 평가 항목은 제품의 주요\n\n<!-- PAGE_51 -->\n###### 기능을 근거로 설정하며, 시험 기준 및 시험 방법은 제품의 특성을\n\n<!-- PAGE_51 -->\n###### 고려하여 가능한 정량적이고 구체적으로 작성한다.\n\n - - 45 -\n본 예시는 이해를 돕기 위하여 작성된 것으로 실제 신청하려는 제품의 내용과 상이\n\n<!-- PAGE_52 -->\n###### 예시)\n\n- - 46 -\n<!-- PAGE_53 -->\n### Ⅲ\n\n<!-- PAGE_53 -->\n### 임상시험계획서 작성 시 고려사항 및 예시\n\n<!-- PAGE_53 -->\n###### 「의료기기법 시행규칙」제20조(임상시험계획의 승인 등) 제2항에 따라\n\n<!-- PAGE_53 -->\n###### 임상시험계획서에 포함되어야 할 사항은 다음과 같다.\n\n <!-- PAGE_53 -->\n###### 1. ",
        "original_sentence": "임상시험 모니터요원의 선정, 자격기준, 수행임무 등에 | - 피험자(Subject)란 임상시험에 참여하는 임상시험용 또는 대조시험용 의료기기의 적용 |\n**대한 사항은 「의료기기법 시행규칙」별표3 “의료기기의 임상시험 관리기준” 제8호**\n\n**[표 끝]**\n\n확인 자료\n\n- - 43 -\n또한 제조자는 외부의 통제에 의한 소프트\n\n웨어의 업데이트나 운영환경 만료에 대한\n\n소프트웨어\n\n- - 44 -\n<!-- PAGE_51 -->\n##### 3. "
      }
    },
    {
      "chunk_id": "chunk_617",
      "text": "성능 평가 항목\n\n<!-- PAGE_51 -->\n###### 우울장애 개선 디지털치료기기의 성능 평가 항목은 제품의 주요\n\n<!-- PAGE_51 -->\n###### 기능을 근거로 설정하며, 시험 기준 및 시험 방법은 제품의 특성을\n\n<!-- PAGE_51 -->\n###### 고려하여 가능한 정량적이고 구체적으로 작성한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 616,
        "window_size": 3,
        "char_count": 183,
        "word_count": 38,
        "page_number": 51,
        "window_text": "| - 부작용, 이상반응 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상 시험의 |\n| 보관, 관리하는 임상의, 의료기사 또는 간호사 등으로 임상시험기관의 장이 지정한 | 시험을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화할 때, 헬싱키 선언에 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람 |\n| 처리 할당에 있어 편향(Bias)을 줄이기 위해 무작위배정(Randomization)과 눈가림 | 기술하는 것을 말하며, 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 |\n**해당 의료기기의 제조업자 또는 수입업자가 해당된다.  의뢰자는 임상시험 모니터**\n| 요원을 지정하여야 한다.  임상시험 모니터요원의 선정, 자격기준, 수행임무 등에 | - 피험자(Subject)란 임상시험에 참여하는 임상시험용 또는 대조시험용 의료기기의 적용 |\n**대한 사항은 「의료기기법 시행규칙」별표3 “의료기기의 임상시험 관리기준” 제8호**\n\n**[표 끝]**\n\n확인 자료\n\n- - 43 -\n또한 제조자는 외부의 통제에 의한 소프트\n\n웨어의 업데이트나 운영환경 만료에 대한\n\n소프트웨어\n\n- - 44 -\n<!-- PAGE_51 -->\n##### 3.  성능 평가 항목\n\n<!-- PAGE_51 -->\n###### 우울장애 개선 디지털치료기기의 성능 평가 항목은 제품의 주요\n\n<!-- PAGE_51 -->\n###### 기능을 근거로 설정하며, 시험 기준 및 시험 방법은 제품의 특성을\n\n<!-- PAGE_51 -->\n###### 고려하여 가능한 정량적이고 구체적으로 작성한다.\n\n - - 45 -\n본 예시는 이해를 돕기 위하여 작성된 것으로 실제 신청하려는 제품의 내용과 상이\n\n<!-- PAGE_52 -->\n###### 예시)\n\n- - 46 -\n<!-- PAGE_53 -->\n### Ⅲ\n\n<!-- PAGE_53 -->\n### 임상시험계획서 작성 시 고려사항 및 예시\n\n<!-- PAGE_53 -->\n###### 「의료기기법 시행규칙」제20조(임상시험계획의 승인 등) 제2항에 따라\n\n<!-- PAGE_53 -->\n###### 임상시험계획서에 포함되어야 할 사항은 다음과 같다.\n\n <!-- PAGE_53 -->\n###### 1.  임상시험의 제목\n\n<!-- PAGE_53 -->\n###### 2. ",
        "original_sentence": "성능 평가 항목\n\n<!-- PAGE_51 -->\n###### 우울장애 개선 디지털치료기기의 성능 평가 항목은 제품의 주요\n\n<!-- PAGE_51 -->\n###### 기능을 근거로 설정하며, 시험 기준 및 시험 방법은 제품의 특성을\n\n<!-- PAGE_51 -->\n###### 고려하여 가능한 정량적이고 구체적으로 작성한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_618",
      "text": "- - 45 -\n본 예시는 이해를 돕기 위하여 작성된 것으로 실제 신청하려는 제품의 내용과 상이\n\n<!-- PAGE_52 -->\n###### 예시)\n\n- - 46 -\n<!-- PAGE_53 -->\n### Ⅲ\n\n<!-- PAGE_53 -->\n### 임상시험계획서 작성 시 고려사항 및 예시\n\n<!-- PAGE_53 -->\n###### 「의료기기법 시행규칙」제20조(임상시험계획의 승인 등) 제2항에 따라\n\n<!-- PAGE_53 -->\n###### 임상시험계획서에 포함되어야 할 사항은 다음과 같다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 617,
        "window_size": 3,
        "char_count": 280,
        "word_count": 60,
        "page_number": 52,
        "window_text": "의뢰자는 임상시험 모니터**\n| 요원을 지정하여야 한다.  임상시험 모니터요원의 선정, 자격기준, 수행임무 등에 | - 피험자(Subject)란 임상시험에 참여하는 임상시험용 또는 대조시험용 의료기기의 적용 |\n**대한 사항은 「의료기기법 시행규칙」별표3 “의료기기의 임상시험 관리기준” 제8호**\n\n**[표 끝]**\n\n확인 자료\n\n- - 43 -\n또한 제조자는 외부의 통제에 의한 소프트\n\n웨어의 업데이트나 운영환경 만료에 대한\n\n소프트웨어\n\n- - 44 -\n<!-- PAGE_51 -->\n##### 3.  성능 평가 항목\n\n<!-- PAGE_51 -->\n###### 우울장애 개선 디지털치료기기의 성능 평가 항목은 제품의 주요\n\n<!-- PAGE_51 -->\n###### 기능을 근거로 설정하며, 시험 기준 및 시험 방법은 제품의 특성을\n\n<!-- PAGE_51 -->\n###### 고려하여 가능한 정량적이고 구체적으로 작성한다.\n\n - - 45 -\n본 예시는 이해를 돕기 위하여 작성된 것으로 실제 신청하려는 제품의 내용과 상이\n\n<!-- PAGE_52 -->\n###### 예시)\n\n- - 46 -\n<!-- PAGE_53 -->\n### Ⅲ\n\n<!-- PAGE_53 -->\n### 임상시험계획서 작성 시 고려사항 및 예시\n\n<!-- PAGE_53 -->\n###### 「의료기기법 시행규칙」제20조(임상시험계획의 승인 등) 제2항에 따라\n\n<!-- PAGE_53 -->\n###### 임상시험계획서에 포함되어야 할 사항은 다음과 같다.\n\n <!-- PAGE_53 -->\n###### 1.  임상시험의 제목\n\n<!-- PAGE_53 -->\n###### 2.  임상시험기관의 명칭 및 소재지\n\n<!-- PAGE_53 -->\n###### 3. ",
        "original_sentence": "- - 45 -\n본 예시는 이해를 돕기 위하여 작성된 것으로 실제 신청하려는 제품의 내용과 상이\n\n<!-- PAGE_52 -->\n###### 예시)\n\n- - 46 -\n<!-- PAGE_53 -->\n### Ⅲ\n\n<!-- PAGE_53 -->\n### 임상시험계획서 작성 시 고려사항 및 예시\n\n<!-- PAGE_53 -->\n###### 「의료기기법 시행규칙」제20조(임상시험계획의 승인 등) 제2항에 따라\n\n<!-- PAGE_53 -->\n###### 임상시험계획서에 포함되어야 할 사항은 다음과 같다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_619",
      "text": "<!-- PAGE_53 -->\n###### 1. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 618,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 53,
        "window_text": "임상시험 모니터요원의 선정, 자격기준, 수행임무 등에 | - 피험자(Subject)란 임상시험에 참여하는 임상시험용 또는 대조시험용 의료기기의 적용 |\n**대한 사항은 「의료기기법 시행규칙」별표3 “의료기기의 임상시험 관리기준” 제8호**\n\n**[표 끝]**\n\n확인 자료\n\n- - 43 -\n또한 제조자는 외부의 통제에 의한 소프트\n\n웨어의 업데이트나 운영환경 만료에 대한\n\n소프트웨어\n\n- - 44 -\n<!-- PAGE_51 -->\n##### 3.  성능 평가 항목\n\n<!-- PAGE_51 -->\n###### 우울장애 개선 디지털치료기기의 성능 평가 항목은 제품의 주요\n\n<!-- PAGE_51 -->\n###### 기능을 근거로 설정하며, 시험 기준 및 시험 방법은 제품의 특성을\n\n<!-- PAGE_51 -->\n###### 고려하여 가능한 정량적이고 구체적으로 작성한다.\n\n - - 45 -\n본 예시는 이해를 돕기 위하여 작성된 것으로 실제 신청하려는 제품의 내용과 상이\n\n<!-- PAGE_52 -->\n###### 예시)\n\n- - 46 -\n<!-- PAGE_53 -->\n### Ⅲ\n\n<!-- PAGE_53 -->\n### 임상시험계획서 작성 시 고려사항 및 예시\n\n<!-- PAGE_53 -->\n###### 「의료기기법 시행규칙」제20조(임상시험계획의 승인 등) 제2항에 따라\n\n<!-- PAGE_53 -->\n###### 임상시험계획서에 포함되어야 할 사항은 다음과 같다.\n\n <!-- PAGE_53 -->\n###### 1.  임상시험의 제목\n\n<!-- PAGE_53 -->\n###### 2.  임상시험기관의 명칭 및 소재지\n\n<!-- PAGE_53 -->\n###### 3.  임상시험의 책임자ㆍ담당자 및 공동연구자의 성명 및 직명\n\n<!-- PAGE_53 -->\n###### 4. ",
        "original_sentence": "<!-- PAGE_53 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_620",
      "text": "임상시험의 제목\n\n<!-- PAGE_53 -->\n###### 2. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 619,
        "window_size": 3,
        "char_count": 37,
        "word_count": 7,
        "page_number": 53,
        "window_text": "성능 평가 항목\n\n<!-- PAGE_51 -->\n###### 우울장애 개선 디지털치료기기의 성능 평가 항목은 제품의 주요\n\n<!-- PAGE_51 -->\n###### 기능을 근거로 설정하며, 시험 기준 및 시험 방법은 제품의 특성을\n\n<!-- PAGE_51 -->\n###### 고려하여 가능한 정량적이고 구체적으로 작성한다.\n\n - - 45 -\n본 예시는 이해를 돕기 위하여 작성된 것으로 실제 신청하려는 제품의 내용과 상이\n\n<!-- PAGE_52 -->\n###### 예시)\n\n- - 46 -\n<!-- PAGE_53 -->\n### Ⅲ\n\n<!-- PAGE_53 -->\n### 임상시험계획서 작성 시 고려사항 및 예시\n\n<!-- PAGE_53 -->\n###### 「의료기기법 시행규칙」제20조(임상시험계획의 승인 등) 제2항에 따라\n\n<!-- PAGE_53 -->\n###### 임상시험계획서에 포함되어야 할 사항은 다음과 같다.\n\n <!-- PAGE_53 -->\n###### 1.  임상시험의 제목\n\n<!-- PAGE_53 -->\n###### 2.  임상시험기관의 명칭 및 소재지\n\n<!-- PAGE_53 -->\n###### 3.  임상시험의 책임자ㆍ담당자 및 공동연구자의 성명 및 직명\n\n<!-- PAGE_53 -->\n###### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n<!-- PAGE_53 -->\n###### 5. ",
        "original_sentence": "임상시험의 제목\n\n<!-- PAGE_53 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_621",
      "text": "임상시험기관의 명칭 및 소재지\n\n<!-- PAGE_53 -->\n###### 3. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 620,
        "window_size": 3,
        "char_count": 45,
        "word_count": 9,
        "page_number": 53,
        "window_text": "- - 45 -\n본 예시는 이해를 돕기 위하여 작성된 것으로 실제 신청하려는 제품의 내용과 상이\n\n<!-- PAGE_52 -->\n###### 예시)\n\n- - 46 -\n<!-- PAGE_53 -->\n### Ⅲ\n\n<!-- PAGE_53 -->\n### 임상시험계획서 작성 시 고려사항 및 예시\n\n<!-- PAGE_53 -->\n###### 「의료기기법 시행규칙」제20조(임상시험계획의 승인 등) 제2항에 따라\n\n<!-- PAGE_53 -->\n###### 임상시험계획서에 포함되어야 할 사항은 다음과 같다.\n\n <!-- PAGE_53 -->\n###### 1.  임상시험의 제목\n\n<!-- PAGE_53 -->\n###### 2.  임상시험기관의 명칭 및 소재지\n\n<!-- PAGE_53 -->\n###### 3.  임상시험의 책임자ㆍ담당자 및 공동연구자의 성명 및 직명\n\n<!-- PAGE_53 -->\n###### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n<!-- PAGE_53 -->\n###### 5.  임상시험을 하려는 자의 성명 및 주소\n\n<!-- PAGE_53 -->\n###### 6. ",
        "original_sentence": "임상시험기관의 명칭 및 소재지\n\n<!-- PAGE_53 -->\n###### 3. "
      }
    },
    {
      "chunk_id": "chunk_622",
      "text": "임상시험의 책임자ㆍ담당자 및 공동연구자의 성명 및 직명\n\n<!-- PAGE_53 -->\n###### 4. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 621,
        "window_size": 3,
        "char_count": 59,
        "word_count": 12,
        "page_number": 53,
        "window_text": "<!-- PAGE_53 -->\n###### 1.  임상시험의 제목\n\n<!-- PAGE_53 -->\n###### 2.  임상시험기관의 명칭 및 소재지\n\n<!-- PAGE_53 -->\n###### 3.  임상시험의 책임자ㆍ담당자 및 공동연구자의 성명 및 직명\n\n<!-- PAGE_53 -->\n###### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n<!-- PAGE_53 -->\n###### 5.  임상시험을 하려는 자의 성명 및 주소\n\n<!-- PAGE_53 -->\n###### 6.  임상시험의 목적 및 배경\n\n<!-- PAGE_53 -->\n###### 7. ",
        "original_sentence": "임상시험의 책임자ㆍ담당자 및 공동연구자의 성명 및 직명\n\n<!-- PAGE_53 -->\n###### 4. "
      }
    },
    {
      "chunk_id": "chunk_623",
      "text": "임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n<!-- PAGE_53 -->\n###### 5. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 622,
        "window_size": 3,
        "char_count": 58,
        "word_count": 12,
        "page_number": 53,
        "window_text": "임상시험의 제목\n\n<!-- PAGE_53 -->\n###### 2.  임상시험기관의 명칭 및 소재지\n\n<!-- PAGE_53 -->\n###### 3.  임상시험의 책임자ㆍ담당자 및 공동연구자의 성명 및 직명\n\n<!-- PAGE_53 -->\n###### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n<!-- PAGE_53 -->\n###### 5.  임상시험을 하려는 자의 성명 및 주소\n\n<!-- PAGE_53 -->\n###### 6.  임상시험의 목적 및 배경\n\n<!-- PAGE_53 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다)\n\n<!-- PAGE_53 -->\n###### 8. ",
        "original_sentence": "임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n<!-- PAGE_53 -->\n###### 5. "
      }
    },
    {
      "chunk_id": "chunk_624",
      "text": "임상시험을 하려는 자의 성명 및 주소\n\n<!-- PAGE_53 -->\n###### 6. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 623,
        "window_size": 3,
        "char_count": 49,
        "word_count": 11,
        "page_number": 53,
        "window_text": "임상시험기관의 명칭 및 소재지\n\n<!-- PAGE_53 -->\n###### 3.  임상시험의 책임자ㆍ담당자 및 공동연구자의 성명 및 직명\n\n<!-- PAGE_53 -->\n###### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n<!-- PAGE_53 -->\n###### 5.  임상시험을 하려는 자의 성명 및 주소\n\n<!-- PAGE_53 -->\n###### 6.  임상시험의 목적 및 배경\n\n<!-- PAGE_53 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다)\n\n<!-- PAGE_53 -->\n###### 8.  임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되어 임상시험에\n\n<!-- PAGE_53 -->\n###### 9. ",
        "original_sentence": "임상시험을 하려는 자의 성명 및 주소\n\n<!-- PAGE_53 -->\n###### 6. "
      }
    },
    {
      "chunk_id": "chunk_625",
      "text": "임상시험의 목적 및 배경\n\n<!-- PAGE_53 -->\n###### 7. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 624,
        "window_size": 3,
        "char_count": 42,
        "word_count": 9,
        "page_number": 53,
        "window_text": "임상시험의 책임자ㆍ담당자 및 공동연구자의 성명 및 직명\n\n<!-- PAGE_53 -->\n###### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n<!-- PAGE_53 -->\n###### 5.  임상시험을 하려는 자의 성명 및 주소\n\n<!-- PAGE_53 -->\n###### 6.  임상시험의 목적 및 배경\n\n<!-- PAGE_53 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다)\n\n<!-- PAGE_53 -->\n###### 8.  임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되어 임상시험에\n\n<!-- PAGE_53 -->\n###### 9.  임상시험기간\n\n<!-- PAGE_53 -->\n###### 10. ",
        "original_sentence": "임상시험의 목적 및 배경\n\n<!-- PAGE_53 -->\n###### 7. "
      }
    },
    {
      "chunk_id": "chunk_626",
      "text": "임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다)\n\n<!-- PAGE_53 -->\n###### 8. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 625,
        "window_size": 3,
        "char_count": 68,
        "word_count": 12,
        "page_number": 53,
        "window_text": "임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n<!-- PAGE_53 -->\n###### 5.  임상시험을 하려는 자의 성명 및 주소\n\n<!-- PAGE_53 -->\n###### 6.  임상시험의 목적 및 배경\n\n<!-- PAGE_53 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다)\n\n<!-- PAGE_53 -->\n###### 8.  임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되어 임상시험에\n\n<!-- PAGE_53 -->\n###### 9.  임상시험기간\n\n<!-- PAGE_53 -->\n###### 10.  임상시험방법(사용량ㆍ사용방법ㆍ사용기간ㆍ병용요법 등을 포함한다)\n\n<!-- PAGE_53 -->\n###### 11. ",
        "original_sentence": "임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다)\n\n<!-- PAGE_53 -->\n###### 8. "
      }
    },
    {
      "chunk_id": "chunk_627",
      "text": "임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되어 임상시험에\n\n<!-- PAGE_53 -->\n###### 9. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 626,
        "window_size": 3,
        "char_count": 67,
        "word_count": 13,
        "page_number": 53,
        "window_text": "임상시험을 하려는 자의 성명 및 주소\n\n<!-- PAGE_53 -->\n###### 6.  임상시험의 목적 및 배경\n\n<!-- PAGE_53 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다)\n\n<!-- PAGE_53 -->\n###### 8.  임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되어 임상시험에\n\n<!-- PAGE_53 -->\n###### 9.  임상시험기간\n\n<!-- PAGE_53 -->\n###### 10.  임상시험방법(사용량ㆍ사용방법ㆍ사용기간ㆍ병용요법 등을 포함한다)\n\n<!-- PAGE_53 -->\n###### 11.  관찰항목ㆍ임상검사항목 및 관찰검사방법\n\n<!-- PAGE_53 -->\n###### 12. ",
        "original_sentence": "임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되어 임상시험에\n\n<!-- PAGE_53 -->\n###### 9. "
      }
    },
    {
      "chunk_id": "chunk_628",
      "text": "임상시험기간\n\n<!-- PAGE_53 -->\n###### 10. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 627,
        "window_size": 3,
        "char_count": 36,
        "word_count": 6,
        "page_number": 53,
        "window_text": "임상시험의 목적 및 배경\n\n<!-- PAGE_53 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다)\n\n<!-- PAGE_53 -->\n###### 8.  임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되어 임상시험에\n\n<!-- PAGE_53 -->\n###### 9.  임상시험기간\n\n<!-- PAGE_53 -->\n###### 10.  임상시험방법(사용량ㆍ사용방법ㆍ사용기간ㆍ병용요법 등을 포함한다)\n\n<!-- PAGE_53 -->\n###### 11.  관찰항목ㆍ임상검사항목 및 관찰검사방법\n\n<!-- PAGE_53 -->\n###### 12.  예측되는 부작용 및 사용 시 주의사항\n\n<!-- PAGE_53 -->\n###### 13. ",
        "original_sentence": "임상시험기간\n\n<!-- PAGE_53 -->\n###### 10. "
      }
    },
    {
      "chunk_id": "chunk_629",
      "text": "임상시험방법(사용량ㆍ사용방법ㆍ사용기간ㆍ병용요법 등을 포함한다)\n\n<!-- PAGE_53 -->\n###### 11. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 628,
        "window_size": 3,
        "char_count": 64,
        "word_count": 8,
        "page_number": 53,
        "window_text": "임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다)\n\n<!-- PAGE_53 -->\n###### 8.  임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되어 임상시험에\n\n<!-- PAGE_53 -->\n###### 9.  임상시험기간\n\n<!-- PAGE_53 -->\n###### 10.  임상시험방법(사용량ㆍ사용방법ㆍ사용기간ㆍ병용요법 등을 포함한다)\n\n<!-- PAGE_53 -->\n###### 11.  관찰항목ㆍ임상검사항목 및 관찰검사방법\n\n<!-- PAGE_53 -->\n###### 12.  예측되는 부작용 및 사용 시 주의사항\n\n<!-- PAGE_53 -->\n###### 13.  중지ㆍ탈락 기준\n\n<!-- PAGE_53 -->\n###### 14. ",
        "original_sentence": "임상시험방법(사용량ㆍ사용방법ㆍ사용기간ㆍ병용요법 등을 포함한다)\n\n<!-- PAGE_53 -->\n###### 11. "
      }
    },
    {
      "chunk_id": "chunk_630",
      "text": "관찰항목ㆍ임상검사항목 및 관찰검사방법\n\n<!-- PAGE_53 -->\n###### 12. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 629,
        "window_size": 3,
        "char_count": 50,
        "word_count": 8,
        "page_number": 53,
        "window_text": "임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되어 임상시험에\n\n<!-- PAGE_53 -->\n###### 9.  임상시험기간\n\n<!-- PAGE_53 -->\n###### 10.  임상시험방법(사용량ㆍ사용방법ㆍ사용기간ㆍ병용요법 등을 포함한다)\n\n<!-- PAGE_53 -->\n###### 11.  관찰항목ㆍ임상검사항목 및 관찰검사방법\n\n<!-- PAGE_53 -->\n###### 12.  예측되는 부작용 및 사용 시 주의사항\n\n<!-- PAGE_53 -->\n###### 13.  중지ㆍ탈락 기준\n\n<!-- PAGE_53 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 따른다)\n\n<!-- PAGE_53 -->\n###### 15. ",
        "original_sentence": "관찰항목ㆍ임상검사항목 및 관찰검사방법\n\n<!-- PAGE_53 -->\n###### 12. "
      }
    },
    {
      "chunk_id": "chunk_631",
      "text": "예측되는 부작용 및 사용 시 주의사항\n\n<!-- PAGE_53 -->\n###### 13. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 630,
        "window_size": 3,
        "char_count": 50,
        "word_count": 11,
        "page_number": 53,
        "window_text": "임상시험기간\n\n<!-- PAGE_53 -->\n###### 10.  임상시험방법(사용량ㆍ사용방법ㆍ사용기간ㆍ병용요법 등을 포함한다)\n\n<!-- PAGE_53 -->\n###### 11.  관찰항목ㆍ임상검사항목 및 관찰검사방법\n\n<!-- PAGE_53 -->\n###### 12.  예측되는 부작용 및 사용 시 주의사항\n\n<!-- PAGE_53 -->\n###### 13.  중지ㆍ탈락 기준\n\n<!-- PAGE_53 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 따른다)\n\n<!-- PAGE_53 -->\n###### 15.  부작용을 포함한 안전성의 평가기준ㆍ평가방법 및 보고방법\n\n<!-- PAGE_53 -->\n###### 16. ",
        "original_sentence": "예측되는 부작용 및 사용 시 주의사항\n\n<!-- PAGE_53 -->\n###### 13. "
      }
    },
    {
      "chunk_id": "chunk_632",
      "text": "중지ㆍ탈락 기준\n\n<!-- PAGE_53 -->\n###### 14. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 631,
        "window_size": 3,
        "char_count": 38,
        "word_count": 7,
        "page_number": 53,
        "window_text": "임상시험방법(사용량ㆍ사용방법ㆍ사용기간ㆍ병용요법 등을 포함한다)\n\n<!-- PAGE_53 -->\n###### 11.  관찰항목ㆍ임상검사항목 및 관찰검사방법\n\n<!-- PAGE_53 -->\n###### 12.  예측되는 부작용 및 사용 시 주의사항\n\n<!-- PAGE_53 -->\n###### 13.  중지ㆍ탈락 기준\n\n<!-- PAGE_53 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 따른다)\n\n<!-- PAGE_53 -->\n###### 15.  부작용을 포함한 안전성의 평가기준ㆍ평가방법 및 보고방법\n\n<!-- PAGE_53 -->\n###### 16.  피험자동의서 서식\n\n<!-- PAGE_53 -->\n###### 17. ",
        "original_sentence": "중지ㆍ탈락 기준\n\n<!-- PAGE_53 -->\n###### 14. "
      }
    },
    {
      "chunk_id": "chunk_633",
      "text": "유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 따른다)\n\n<!-- PAGE_53 -->\n###### 15. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 632,
        "window_size": 3,
        "char_count": 65,
        "word_count": 11,
        "page_number": 53,
        "window_text": "관찰항목ㆍ임상검사항목 및 관찰검사방법\n\n<!-- PAGE_53 -->\n###### 12.  예측되는 부작용 및 사용 시 주의사항\n\n<!-- PAGE_53 -->\n###### 13.  중지ㆍ탈락 기준\n\n<!-- PAGE_53 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 따른다)\n\n<!-- PAGE_53 -->\n###### 15.  부작용을 포함한 안전성의 평가기준ㆍ평가방법 및 보고방법\n\n<!-- PAGE_53 -->\n###### 16.  피험자동의서 서식\n\n<!-- PAGE_53 -->\n###### 17.  피해자 보상에 대한 규약\n\n<!-- PAGE_53 -->\n###### 18. ",
        "original_sentence": "유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 따른다)\n\n<!-- PAGE_53 -->\n###### 15. "
      }
    },
    {
      "chunk_id": "chunk_634",
      "text": "부작용을 포함한 안전성의 평가기준ㆍ평가방법 및 보고방법\n\n<!-- PAGE_53 -->\n###### 16. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 633,
        "window_size": 3,
        "char_count": 60,
        "word_count": 11,
        "page_number": 53,
        "window_text": "예측되는 부작용 및 사용 시 주의사항\n\n<!-- PAGE_53 -->\n###### 13.  중지ㆍ탈락 기준\n\n<!-- PAGE_53 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 따른다)\n\n<!-- PAGE_53 -->\n###### 15.  부작용을 포함한 안전성의 평가기준ㆍ평가방법 및 보고방법\n\n<!-- PAGE_53 -->\n###### 16.  피험자동의서 서식\n\n<!-- PAGE_53 -->\n###### 17.  피해자 보상에 대한 규약\n\n<!-- PAGE_53 -->\n###### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n<!-- PAGE_53 -->\n###### 19. ",
        "original_sentence": "부작용을 포함한 안전성의 평가기준ㆍ평가방법 및 보고방법\n\n<!-- PAGE_53 -->\n###### 16. "
      }
    },
    {
      "chunk_id": "chunk_635",
      "text": "피험자동의서 서식\n\n<!-- PAGE_53 -->\n###### 17. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 634,
        "window_size": 3,
        "char_count": 39,
        "word_count": 7,
        "page_number": 53,
        "window_text": "중지ㆍ탈락 기준\n\n<!-- PAGE_53 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 따른다)\n\n<!-- PAGE_53 -->\n###### 15.  부작용을 포함한 안전성의 평가기준ㆍ평가방법 및 보고방법\n\n<!-- PAGE_53 -->\n###### 16.  피험자동의서 서식\n\n<!-- PAGE_53 -->\n###### 17.  피해자 보상에 대한 규약\n\n<!-- PAGE_53 -->\n###### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n<!-- PAGE_53 -->\n###### 19.  피험자의 안전보호에 관한 대책\n\n<!-- PAGE_53 -->\n###### 20. ",
        "original_sentence": "피험자동의서 서식\n\n<!-- PAGE_53 -->\n###### 17. "
      }
    },
    {
      "chunk_id": "chunk_636",
      "text": "피해자 보상에 대한 규약\n\n<!-- PAGE_53 -->\n###### 18. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 635,
        "window_size": 3,
        "char_count": 43,
        "word_count": 9,
        "page_number": 53,
        "window_text": "유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 따른다)\n\n<!-- PAGE_53 -->\n###### 15.  부작용을 포함한 안전성의 평가기준ㆍ평가방법 및 보고방법\n\n<!-- PAGE_53 -->\n###### 16.  피험자동의서 서식\n\n<!-- PAGE_53 -->\n###### 17.  피해자 보상에 대한 규약\n\n<!-- PAGE_53 -->\n###### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n<!-- PAGE_53 -->\n###### 19.  피험자의 안전보호에 관한 대책\n\n<!-- PAGE_53 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 실시하기 위하여 필요한 사항\n\n- - 47 -\n<!-- PAGE_54 -->\n##### 1. ",
        "original_sentence": "피해자 보상에 대한 규약\n\n<!-- PAGE_53 -->\n###### 18. "
      }
    },
    {
      "chunk_id": "chunk_637",
      "text": "임상시험 후 피험자의 진료에 관한 사항\n\n<!-- PAGE_53 -->\n###### 19. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 636,
        "window_size": 3,
        "char_count": 51,
        "word_count": 11,
        "page_number": 53,
        "window_text": "부작용을 포함한 안전성의 평가기준ㆍ평가방법 및 보고방법\n\n<!-- PAGE_53 -->\n###### 16.  피험자동의서 서식\n\n<!-- PAGE_53 -->\n###### 17.  피해자 보상에 대한 규약\n\n<!-- PAGE_53 -->\n###### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n<!-- PAGE_53 -->\n###### 19.  피험자의 안전보호에 관한 대책\n\n<!-- PAGE_53 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 실시하기 위하여 필요한 사항\n\n- - 47 -\n<!-- PAGE_54 -->\n##### 1.  임상시험의 제목\n\n<!-- PAGE_54 -->\n###### 우울장애 진단환자의 우울 증상을 개선하기 위해서 사용되는\n\n<!-- PAGE_54 -->\n###### OOO 디지털치료기기의 안전성 및 유효성을 평가하기 위한 전향적\n\n<!-- PAGE_54 -->\n###### 4) 임상시험 평가 내용 : 우울장애 심각도 척도(Depressive Severity Index)\n\n- - 48 -\n<!-- PAGE_55 -->\n##### 2. ",
        "original_sentence": "임상시험 후 피험자의 진료에 관한 사항\n\n<!-- PAGE_53 -->\n###### 19. "
      }
    },
    {
      "chunk_id": "chunk_638",
      "text": "피험자의 안전보호에 관한 대책\n\n<!-- PAGE_53 -->\n###### 20. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 637,
        "window_size": 3,
        "char_count": 46,
        "word_count": 9,
        "page_number": 53,
        "window_text": "피험자동의서 서식\n\n<!-- PAGE_53 -->\n###### 17.  피해자 보상에 대한 규약\n\n<!-- PAGE_53 -->\n###### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n<!-- PAGE_53 -->\n###### 19.  피험자의 안전보호에 관한 대책\n\n<!-- PAGE_53 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 실시하기 위하여 필요한 사항\n\n- - 47 -\n<!-- PAGE_54 -->\n##### 1.  임상시험의 제목\n\n<!-- PAGE_54 -->\n###### 우울장애 진단환자의 우울 증상을 개선하기 위해서 사용되는\n\n<!-- PAGE_54 -->\n###### OOO 디지털치료기기의 안전성 및 유효성을 평가하기 위한 전향적\n\n<!-- PAGE_54 -->\n###### 4) 임상시험 평가 내용 : 우울장애 심각도 척도(Depressive Severity Index)\n\n- - 48 -\n<!-- PAGE_55 -->\n##### 2.  임상시험기관의 명칭 및 소재지\n\n<!-- PAGE_55 -->\n###### 임상시험기관\n\n- - 49 -\n<!-- PAGE_56 -->\n##### 3. ",
        "original_sentence": "피험자의 안전보호에 관한 대책\n\n<!-- PAGE_53 -->\n###### 20. "
      }
    },
    {
      "chunk_id": "chunk_639",
      "text": "그 밖에 임상시험을 안전하고 과학적으로 실시하기 위하여 필요한 사항\n\n- - 47 -\n<!-- PAGE_54 -->\n##### 1. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 638,
        "window_size": 3,
        "char_count": 74,
        "word_count": 18,
        "page_number": 54,
        "window_text": "피해자 보상에 대한 규약\n\n<!-- PAGE_53 -->\n###### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n<!-- PAGE_53 -->\n###### 19.  피험자의 안전보호에 관한 대책\n\n<!-- PAGE_53 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 실시하기 위하여 필요한 사항\n\n- - 47 -\n<!-- PAGE_54 -->\n##### 1.  임상시험의 제목\n\n<!-- PAGE_54 -->\n###### 우울장애 진단환자의 우울 증상을 개선하기 위해서 사용되는\n\n<!-- PAGE_54 -->\n###### OOO 디지털치료기기의 안전성 및 유효성을 평가하기 위한 전향적\n\n<!-- PAGE_54 -->\n###### 4) 임상시험 평가 내용 : 우울장애 심각도 척도(Depressive Severity Index)\n\n- - 48 -\n<!-- PAGE_55 -->\n##### 2.  임상시험기관의 명칭 및 소재지\n\n<!-- PAGE_55 -->\n###### 임상시험기관\n\n- - 49 -\n<!-- PAGE_56 -->\n##### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n<!-- PAGE_56 -->\n###### 가. ",
        "original_sentence": "그 밖에 임상시험을 안전하고 과학적으로 실시하기 위하여 필요한 사항\n\n- - 47 -\n<!-- PAGE_54 -->\n##### 1. "
      }
    },
    {
      "chunk_id": "chunk_640",
      "text": "임상시험의 제목\n\n<!-- PAGE_54 -->\n###### 우울장애 진단환자의 우울 증상을 개선하기 위해서 사용되는\n\n<!-- PAGE_54 -->\n###### OOO 디지털치료기기의 안전성 및 유효성을 평가하기 위한 전향적\n\n<!-- PAGE_54 -->\n###### 4) 임상시험 평가 내용 : 우울장애 심각도 척도(Depressive Severity Index)\n\n- - 48 -\n<!-- PAGE_55 -->\n##### 2. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 639,
        "window_size": 3,
        "char_count": 243,
        "word_count": 48,
        "page_number": 54,
        "window_text": "임상시험 후 피험자의 진료에 관한 사항\n\n<!-- PAGE_53 -->\n###### 19.  피험자의 안전보호에 관한 대책\n\n<!-- PAGE_53 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 실시하기 위하여 필요한 사항\n\n- - 47 -\n<!-- PAGE_54 -->\n##### 1.  임상시험의 제목\n\n<!-- PAGE_54 -->\n###### 우울장애 진단환자의 우울 증상을 개선하기 위해서 사용되는\n\n<!-- PAGE_54 -->\n###### OOO 디지털치료기기의 안전성 및 유효성을 평가하기 위한 전향적\n\n<!-- PAGE_54 -->\n###### 4) 임상시험 평가 내용 : 우울장애 심각도 척도(Depressive Severity Index)\n\n- - 48 -\n<!-- PAGE_55 -->\n##### 2.  임상시험기관의 명칭 및 소재지\n\n<!-- PAGE_55 -->\n###### 임상시험기관\n\n- - 49 -\n<!-- PAGE_56 -->\n##### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n<!-- PAGE_56 -->\n###### 가.  시험책임자\n\n<!-- PAGE_56 -->\n###### 나. ",
        "original_sentence": "임상시험의 제목\n\n<!-- PAGE_54 -->\n###### 우울장애 진단환자의 우울 증상을 개선하기 위해서 사용되는\n\n<!-- PAGE_54 -->\n###### OOO 디지털치료기기의 안전성 및 유효성을 평가하기 위한 전향적\n\n<!-- PAGE_54 -->\n###### 4) 임상시험 평가 내용 : 우울장애 심각도 척도(Depressive Severity Index)\n\n- - 48 -\n<!-- PAGE_55 -->\n##### 2. "
      }
    },
    {
      "chunk_id": "chunk_641",
      "text": "임상시험기관의 명칭 및 소재지\n\n<!-- PAGE_55 -->\n###### 임상시험기관\n\n- - 49 -\n<!-- PAGE_56 -->\n##### 3. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 640,
        "window_size": 3,
        "char_count": 85,
        "word_count": 18,
        "page_number": 55,
        "window_text": "피험자의 안전보호에 관한 대책\n\n<!-- PAGE_53 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 실시하기 위하여 필요한 사항\n\n- - 47 -\n<!-- PAGE_54 -->\n##### 1.  임상시험의 제목\n\n<!-- PAGE_54 -->\n###### 우울장애 진단환자의 우울 증상을 개선하기 위해서 사용되는\n\n<!-- PAGE_54 -->\n###### OOO 디지털치료기기의 안전성 및 유효성을 평가하기 위한 전향적\n\n<!-- PAGE_54 -->\n###### 4) 임상시험 평가 내용 : 우울장애 심각도 척도(Depressive Severity Index)\n\n- - 48 -\n<!-- PAGE_55 -->\n##### 2.  임상시험기관의 명칭 및 소재지\n\n<!-- PAGE_55 -->\n###### 임상시험기관\n\n- - 49 -\n<!-- PAGE_56 -->\n##### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n<!-- PAGE_56 -->\n###### 가.  시험책임자\n\n<!-- PAGE_56 -->\n###### 나.  시험담당자\n\n<!-- PAGE_56 -->\n###### 다. ",
        "original_sentence": "임상시험기관의 명칭 및 소재지\n\n<!-- PAGE_55 -->\n###### 임상시험기관\n\n- - 49 -\n<!-- PAGE_56 -->\n##### 3. "
      }
    },
    {
      "chunk_id": "chunk_642",
      "text": "임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n<!-- PAGE_56 -->\n###### 가. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 641,
        "window_size": 3,
        "char_count": 58,
        "word_count": 12,
        "page_number": 56,
        "window_text": "그 밖에 임상시험을 안전하고 과학적으로 실시하기 위하여 필요한 사항\n\n- - 47 -\n<!-- PAGE_54 -->\n##### 1.  임상시험의 제목\n\n<!-- PAGE_54 -->\n###### 우울장애 진단환자의 우울 증상을 개선하기 위해서 사용되는\n\n<!-- PAGE_54 -->\n###### OOO 디지털치료기기의 안전성 및 유효성을 평가하기 위한 전향적\n\n<!-- PAGE_54 -->\n###### 4) 임상시험 평가 내용 : 우울장애 심각도 척도(Depressive Severity Index)\n\n- - 48 -\n<!-- PAGE_55 -->\n##### 2.  임상시험기관의 명칭 및 소재지\n\n<!-- PAGE_55 -->\n###### 임상시험기관\n\n- - 49 -\n<!-- PAGE_56 -->\n##### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n<!-- PAGE_56 -->\n###### 가.  시험책임자\n\n<!-- PAGE_56 -->\n###### 나.  시험담당자\n\n<!-- PAGE_56 -->\n###### 다.  공동연구자\n\n<!-- PAGE_56 -->\n###### 라. ",
        "original_sentence": "임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n<!-- PAGE_56 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_643",
      "text": "시험책임자\n\n<!-- PAGE_56 -->\n###### 나. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 642,
        "window_size": 3,
        "char_count": 34,
        "word_count": 6,
        "page_number": 56,
        "window_text": "임상시험의 제목\n\n<!-- PAGE_54 -->\n###### 우울장애 진단환자의 우울 증상을 개선하기 위해서 사용되는\n\n<!-- PAGE_54 -->\n###### OOO 디지털치료기기의 안전성 및 유효성을 평가하기 위한 전향적\n\n<!-- PAGE_54 -->\n###### 4) 임상시험 평가 내용 : 우울장애 심각도 척도(Depressive Severity Index)\n\n- - 48 -\n<!-- PAGE_55 -->\n##### 2.  임상시험기관의 명칭 및 소재지\n\n<!-- PAGE_55 -->\n###### 임상시험기관\n\n- - 49 -\n<!-- PAGE_56 -->\n##### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n<!-- PAGE_56 -->\n###### 가.  시험책임자\n\n<!-- PAGE_56 -->\n###### 나.  시험담당자\n\n<!-- PAGE_56 -->\n###### 다.  공동연구자\n\n<!-- PAGE_56 -->\n###### 라.  임상시험 조정자\n\n- - 50 -\n<!-- PAGE_57 -->\n##### 4. ",
        "original_sentence": "시험책임자\n\n<!-- PAGE_56 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_644",
      "text": "시험담당자\n\n<!-- PAGE_56 -->\n###### 다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 643,
        "window_size": 3,
        "char_count": 34,
        "word_count": 6,
        "page_number": 56,
        "window_text": "임상시험기관의 명칭 및 소재지\n\n<!-- PAGE_55 -->\n###### 임상시험기관\n\n- - 49 -\n<!-- PAGE_56 -->\n##### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n<!-- PAGE_56 -->\n###### 가.  시험책임자\n\n<!-- PAGE_56 -->\n###### 나.  시험담당자\n\n<!-- PAGE_56 -->\n###### 다.  공동연구자\n\n<!-- PAGE_56 -->\n###### 라.  임상시험 조정자\n\n- - 50 -\n<!-- PAGE_57 -->\n##### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n<!-- PAGE_57 -->\n###### 의료기기 관리자\n\n- - 51 -\n<!-- PAGE_58 -->\n##### 5. ",
        "original_sentence": "시험담당자\n\n<!-- PAGE_56 -->\n###### 다. "
      }
    },
    {
      "chunk_id": "chunk_645",
      "text": "공동연구자\n\n<!-- PAGE_56 -->\n###### 라. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 644,
        "window_size": 3,
        "char_count": 34,
        "word_count": 6,
        "page_number": 56,
        "window_text": "임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n<!-- PAGE_56 -->\n###### 가.  시험책임자\n\n<!-- PAGE_56 -->\n###### 나.  시험담당자\n\n<!-- PAGE_56 -->\n###### 다.  공동연구자\n\n<!-- PAGE_56 -->\n###### 라.  임상시험 조정자\n\n- - 50 -\n<!-- PAGE_57 -->\n##### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n<!-- PAGE_57 -->\n###### 의료기기 관리자\n\n- - 51 -\n<!-- PAGE_58 -->\n##### 5.  임상시험을 하려는 자의 성명 및 주소\n\n<!-- PAGE_58 -->\n###### 가. ",
        "original_sentence": "공동연구자\n\n<!-- PAGE_56 -->\n###### 라. "
      }
    },
    {
      "chunk_id": "chunk_646",
      "text": "임상시험 조정자\n\n- - 50 -\n<!-- PAGE_57 -->\n##### 4. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 645,
        "window_size": 3,
        "char_count": 45,
        "word_count": 11,
        "page_number": 57,
        "window_text": "시험책임자\n\n<!-- PAGE_56 -->\n###### 나.  시험담당자\n\n<!-- PAGE_56 -->\n###### 다.  공동연구자\n\n<!-- PAGE_56 -->\n###### 라.  임상시험 조정자\n\n- - 50 -\n<!-- PAGE_57 -->\n##### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n<!-- PAGE_57 -->\n###### 의료기기 관리자\n\n- - 51 -\n<!-- PAGE_58 -->\n##### 5.  임상시험을 하려는 자의 성명 및 주소\n\n<!-- PAGE_58 -->\n###### 가.  의뢰자\n\n<!-- PAGE_58 -->\n###### 나. ",
        "original_sentence": "임상시험 조정자\n\n- - 50 -\n<!-- PAGE_57 -->\n##### 4. "
      }
    },
    {
      "chunk_id": "chunk_647",
      "text": "임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n<!-- PAGE_57 -->\n###### 의료기기 관리자\n\n- - 51 -\n<!-- PAGE_58 -->\n##### 5. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 646,
        "window_size": 3,
        "char_count": 100,
        "word_count": 22,
        "page_number": 57,
        "window_text": "시험담당자\n\n<!-- PAGE_56 -->\n###### 다.  공동연구자\n\n<!-- PAGE_56 -->\n###### 라.  임상시험 조정자\n\n- - 50 -\n<!-- PAGE_57 -->\n##### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n<!-- PAGE_57 -->\n###### 의료기기 관리자\n\n- - 51 -\n<!-- PAGE_58 -->\n##### 5.  임상시험을 하려는 자의 성명 및 주소\n\n<!-- PAGE_58 -->\n###### 가.  의뢰자\n\n<!-- PAGE_58 -->\n###### 나.  모니터요원\n\n<!-- PAGE_58 -->\n###### 다. ",
        "original_sentence": "임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n<!-- PAGE_57 -->\n###### 의료기기 관리자\n\n- - 51 -\n<!-- PAGE_58 -->\n##### 5. "
      }
    },
    {
      "chunk_id": "chunk_648",
      "text": "임상시험을 하려는 자의 성명 및 주소\n\n<!-- PAGE_58 -->\n###### 가. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 647,
        "window_size": 3,
        "char_count": 49,
        "word_count": 11,
        "page_number": 58,
        "window_text": "공동연구자\n\n<!-- PAGE_56 -->\n###### 라.  임상시험 조정자\n\n- - 50 -\n<!-- PAGE_57 -->\n##### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n<!-- PAGE_57 -->\n###### 의료기기 관리자\n\n- - 51 -\n<!-- PAGE_58 -->\n##### 5.  임상시험을 하려는 자의 성명 및 주소\n\n<!-- PAGE_58 -->\n###### 가.  의뢰자\n\n<!-- PAGE_58 -->\n###### 나.  모니터요원\n\n<!-- PAGE_58 -->\n###### 다.  임상시험 수탁업체\n\n<!-- PAGE_58 -->\n###### ※ 임상시험 수탁기관(Contact Research Organization, CRO)이 있는 경우 해당\n\n- - 52 -\n<!-- PAGE_59 -->\n##### 6. ",
        "original_sentence": "임상시험을 하려는 자의 성명 및 주소\n\n<!-- PAGE_58 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_649",
      "text": "의뢰자\n\n<!-- PAGE_58 -->\n###### 나. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 648,
        "window_size": 3,
        "char_count": 32,
        "word_count": 6,
        "page_number": 58,
        "window_text": "임상시험 조정자\n\n- - 50 -\n<!-- PAGE_57 -->\n##### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n<!-- PAGE_57 -->\n###### 의료기기 관리자\n\n- - 51 -\n<!-- PAGE_58 -->\n##### 5.  임상시험을 하려는 자의 성명 및 주소\n\n<!-- PAGE_58 -->\n###### 가.  의뢰자\n\n<!-- PAGE_58 -->\n###### 나.  모니터요원\n\n<!-- PAGE_58 -->\n###### 다.  임상시험 수탁업체\n\n<!-- PAGE_58 -->\n###### ※ 임상시험 수탁기관(Contact Research Organization, CRO)이 있는 경우 해당\n\n- - 52 -\n<!-- PAGE_59 -->\n##### 6.  임상시험의 목적 및 배경\n\n<!-- PAGE_59 -->\n###### 가. ",
        "original_sentence": "의뢰자\n\n<!-- PAGE_58 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_650",
      "text": "모니터요원\n\n<!-- PAGE_58 -->\n###### 다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 649,
        "window_size": 3,
        "char_count": 34,
        "word_count": 6,
        "page_number": 58,
        "window_text": "임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n<!-- PAGE_57 -->\n###### 의료기기 관리자\n\n- - 51 -\n<!-- PAGE_58 -->\n##### 5.  임상시험을 하려는 자의 성명 및 주소\n\n<!-- PAGE_58 -->\n###### 가.  의뢰자\n\n<!-- PAGE_58 -->\n###### 나.  모니터요원\n\n<!-- PAGE_58 -->\n###### 다.  임상시험 수탁업체\n\n<!-- PAGE_58 -->\n###### ※ 임상시험 수탁기관(Contact Research Organization, CRO)이 있는 경우 해당\n\n- - 52 -\n<!-- PAGE_59 -->\n##### 6.  임상시험의 목적 및 배경\n\n<!-- PAGE_59 -->\n###### 가.  임상시험의 목적\n\n<!-- PAGE_59 -->\n###### [목적]\n\n<!-- PAGE_59 -->\n###### 1) 임상시험용 디지털치료기기의 우울장애 치료에 대한 안전성 평가\n\n<!-- PAGE_59 -->\n###### 2) 임상시험용 디지털치료기기의 우울장애 치료에 대한 유효성 평가\n\n<!-- PAGE_59 -->\n###### 최근 우울장애로 치료받는 환자의 숫자가 급격히 증가하는 추세로\n\n<!-- PAGE_59 -->\n###### 우울장애를 치료하는 방법들 또한 많은 주목을 받고 있다(우울장애\n\n<!-- PAGE_59 -->\n###### 임상진료지침, 2022, ICSI, 2016). ",
        "original_sentence": "모니터요원\n\n<!-- PAGE_58 -->\n###### 다. "
      }
    },
    {
      "chunk_id": "chunk_651",
      "text": "임상시험 수탁업체\n\n<!-- PAGE_58 -->\n###### ※ 임상시험 수탁기관(Contact Research Organization, CRO)이 있는 경우 해당\n\n- - 52 -\n<!-- PAGE_59 -->\n##### 6. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 650,
        "window_size": 3,
        "char_count": 129,
        "word_count": 24,
        "page_number": 58,
        "window_text": "임상시험을 하려는 자의 성명 및 주소\n\n<!-- PAGE_58 -->\n###### 가.  의뢰자\n\n<!-- PAGE_58 -->\n###### 나.  모니터요원\n\n<!-- PAGE_58 -->\n###### 다.  임상시험 수탁업체\n\n<!-- PAGE_58 -->\n###### ※ 임상시험 수탁기관(Contact Research Organization, CRO)이 있는 경우 해당\n\n- - 52 -\n<!-- PAGE_59 -->\n##### 6.  임상시험의 목적 및 배경\n\n<!-- PAGE_59 -->\n###### 가.  임상시험의 목적\n\n<!-- PAGE_59 -->\n###### [목적]\n\n<!-- PAGE_59 -->\n###### 1) 임상시험용 디지털치료기기의 우울장애 치료에 대한 안전성 평가\n\n<!-- PAGE_59 -->\n###### 2) 임상시험용 디지털치료기기의 우울장애 치료에 대한 유효성 평가\n\n<!-- PAGE_59 -->\n###### 최근 우울장애로 치료받는 환자의 숫자가 급격히 증가하는 추세로\n\n<!-- PAGE_59 -->\n###### 우울장애를 치료하는 방법들 또한 많은 주목을 받고 있다(우울장애\n\n<!-- PAGE_59 -->\n###### 임상진료지침, 2022, ICSI, 2016).  임상에서 우울장애 환자들에게 주로\n\n<!-- PAGE_59 -->\n###### 사용되는 치료는 약물치료이다. ",
        "original_sentence": "임상시험 수탁업체\n\n<!-- PAGE_58 -->\n###### ※ 임상시험 수탁기관(Contact Research Organization, CRO)이 있는 경우 해당\n\n- - 52 -\n<!-- PAGE_59 -->\n##### 6. "
      }
    },
    {
      "chunk_id": "chunk_652",
      "text": "임상시험의 목적 및 배경\n\n<!-- PAGE_59 -->\n###### 가. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 651,
        "window_size": 3,
        "char_count": 42,
        "word_count": 9,
        "page_number": 59,
        "window_text": "의뢰자\n\n<!-- PAGE_58 -->\n###### 나.  모니터요원\n\n<!-- PAGE_58 -->\n###### 다.  임상시험 수탁업체\n\n<!-- PAGE_58 -->\n###### ※ 임상시험 수탁기관(Contact Research Organization, CRO)이 있는 경우 해당\n\n- - 52 -\n<!-- PAGE_59 -->\n##### 6.  임상시험의 목적 및 배경\n\n<!-- PAGE_59 -->\n###### 가.  임상시험의 목적\n\n<!-- PAGE_59 -->\n###### [목적]\n\n<!-- PAGE_59 -->\n###### 1) 임상시험용 디지털치료기기의 우울장애 치료에 대한 안전성 평가\n\n<!-- PAGE_59 -->\n###### 2) 임상시험용 디지털치료기기의 우울장애 치료에 대한 유효성 평가\n\n<!-- PAGE_59 -->\n###### 최근 우울장애로 치료받는 환자의 숫자가 급격히 증가하는 추세로\n\n<!-- PAGE_59 -->\n###### 우울장애를 치료하는 방법들 또한 많은 주목을 받고 있다(우울장애\n\n<!-- PAGE_59 -->\n###### 임상진료지침, 2022, ICSI, 2016).  임상에서 우울장애 환자들에게 주로\n\n<!-- PAGE_59 -->\n###### 사용되는 치료는 약물치료이다.  약물치료는 우울장애의 단기 치료에\n\n<!-- PAGE_59 -->\n###### 있어서 유용성이 확립되어 있으나 성기능장애, 졸림(진정 작용), 체중증가,\n\n<!-- PAGE_59 -->\n###### 수면장애(불면), 소화기장애(오심, 구토) 등의 부작용의 위험성이 있다.\n\n",
        "original_sentence": "임상시험의 목적 및 배경\n\n<!-- PAGE_59 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_653",
      "text": "임상시험의 목적\n\n<!-- PAGE_59 -->\n###### [목적]\n\n<!-- PAGE_59 -->\n###### 1) 임상시험용 디지털치료기기의 우울장애 치료에 대한 안전성 평가\n\n<!-- PAGE_59 -->\n###### 2) 임상시험용 디지털치료기기의 우울장애 치료에 대한 유효성 평가\n\n<!-- PAGE_59 -->\n###### 최근 우울장애로 치료받는 환자의 숫자가 급격히 증가하는 추세로\n\n<!-- PAGE_59 -->\n###### 우울장애를 치료하는 방법들 또한 많은 주목을 받고 있다(우울장애\n\n<!-- PAGE_59 -->\n###### 임상진료지침, 2022, ICSI, 2016). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 652,
        "window_size": 3,
        "char_count": 336,
        "word_count": 63,
        "page_number": 59,
        "window_text": "모니터요원\n\n<!-- PAGE_58 -->\n###### 다.  임상시험 수탁업체\n\n<!-- PAGE_58 -->\n###### ※ 임상시험 수탁기관(Contact Research Organization, CRO)이 있는 경우 해당\n\n- - 52 -\n<!-- PAGE_59 -->\n##### 6.  임상시험의 목적 및 배경\n\n<!-- PAGE_59 -->\n###### 가.  임상시험의 목적\n\n<!-- PAGE_59 -->\n###### [목적]\n\n<!-- PAGE_59 -->\n###### 1) 임상시험용 디지털치료기기의 우울장애 치료에 대한 안전성 평가\n\n<!-- PAGE_59 -->\n###### 2) 임상시험용 디지털치료기기의 우울장애 치료에 대한 유효성 평가\n\n<!-- PAGE_59 -->\n###### 최근 우울장애로 치료받는 환자의 숫자가 급격히 증가하는 추세로\n\n<!-- PAGE_59 -->\n###### 우울장애를 치료하는 방법들 또한 많은 주목을 받고 있다(우울장애\n\n<!-- PAGE_59 -->\n###### 임상진료지침, 2022, ICSI, 2016).  임상에서 우울장애 환자들에게 주로\n\n<!-- PAGE_59 -->\n###### 사용되는 치료는 약물치료이다.  약물치료는 우울장애의 단기 치료에\n\n<!-- PAGE_59 -->\n###### 있어서 유용성이 확립되어 있으나 성기능장애, 졸림(진정 작용), 체중증가,\n\n<!-- PAGE_59 -->\n###### 수면장애(불면), 소화기장애(오심, 구토) 등의 부작용의 위험성이 있다.\n\n <!-- PAGE_59 -->\n###### 이러한 약물치료의 단점들을 보완해줄 수 있는 치료는 우울장애\n\n<!-- PAGE_59 -->\n###### 인지행동치료(CBT-D)이다. ",
        "original_sentence": "임상시험의 목적\n\n<!-- PAGE_59 -->\n###### [목적]\n\n<!-- PAGE_59 -->\n###### 1) 임상시험용 디지털치료기기의 우울장애 치료에 대한 안전성 평가\n\n<!-- PAGE_59 -->\n###### 2) 임상시험용 디지털치료기기의 우울장애 치료에 대한 유효성 평가\n\n<!-- PAGE_59 -->\n###### 최근 우울장애로 치료받는 환자의 숫자가 급격히 증가하는 추세로\n\n<!-- PAGE_59 -->\n###### 우울장애를 치료하는 방법들 또한 많은 주목을 받고 있다(우울장애\n\n<!-- PAGE_59 -->\n###### 임상진료지침, 2022, ICSI, 2016). "
      }
    },
    {
      "chunk_id": "chunk_654",
      "text": "임상에서 우울장애 환자들에게 주로\n\n<!-- PAGE_59 -->\n###### 사용되는 치료는 약물치료이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 653,
        "window_size": 3,
        "char_count": 61,
        "word_count": 11,
        "page_number": 59,
        "window_text": "임상시험 수탁업체\n\n<!-- PAGE_58 -->\n###### ※ 임상시험 수탁기관(Contact Research Organization, CRO)이 있는 경우 해당\n\n- - 52 -\n<!-- PAGE_59 -->\n##### 6.  임상시험의 목적 및 배경\n\n<!-- PAGE_59 -->\n###### 가.  임상시험의 목적\n\n<!-- PAGE_59 -->\n###### [목적]\n\n<!-- PAGE_59 -->\n###### 1) 임상시험용 디지털치료기기의 우울장애 치료에 대한 안전성 평가\n\n<!-- PAGE_59 -->\n###### 2) 임상시험용 디지털치료기기의 우울장애 치료에 대한 유효성 평가\n\n<!-- PAGE_59 -->\n###### 최근 우울장애로 치료받는 환자의 숫자가 급격히 증가하는 추세로\n\n<!-- PAGE_59 -->\n###### 우울장애를 치료하는 방법들 또한 많은 주목을 받고 있다(우울장애\n\n<!-- PAGE_59 -->\n###### 임상진료지침, 2022, ICSI, 2016).  임상에서 우울장애 환자들에게 주로\n\n<!-- PAGE_59 -->\n###### 사용되는 치료는 약물치료이다.  약물치료는 우울장애의 단기 치료에\n\n<!-- PAGE_59 -->\n###### 있어서 유용성이 확립되어 있으나 성기능장애, 졸림(진정 작용), 체중증가,\n\n<!-- PAGE_59 -->\n###### 수면장애(불면), 소화기장애(오심, 구토) 등의 부작용의 위험성이 있다.\n\n <!-- PAGE_59 -->\n###### 이러한 약물치료의 단점들을 보완해줄 수 있는 치료는 우울장애\n\n<!-- PAGE_59 -->\n###### 인지행동치료(CBT-D)이다.  우울장애 인지행동치료(CBT-D)는 단기적으로는\n\n<!-- PAGE_59 -->\n###### 약물치료와 그 효과가 유사하며 장기적인 효과는 약물치료보다 우수한\n\n<!-- PAGE_59 -->\n###### 것으로 밝혀져 있으며, 이러한 효과의 입증을 통해 우울증의 일차\n\n- - 53 -\n<!-- PAGE_60 -->\n###### 치료로 권장되고 있다(Van Hees et al., 2013).\n\n",
        "original_sentence": "임상에서 우울장애 환자들에게 주로\n\n<!-- PAGE_59 -->\n###### 사용되는 치료는 약물치료이다. "
      }
    },
    {
      "chunk_id": "chunk_655",
      "text": "약물치료는 우울장애의 단기 치료에\n\n<!-- PAGE_59 -->\n###### 있어서 유용성이 확립되어 있으나 성기능장애, 졸림(진정 작용), 체중증가,\n\n<!-- PAGE_59 -->\n###### 수면장애(불면), 소화기장애(오심, 구토) 등의 부작용의 위험성이 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 654,
        "window_size": 3,
        "char_count": 153,
        "word_count": 27,
        "page_number": 59,
        "window_text": "임상시험의 목적 및 배경\n\n<!-- PAGE_59 -->\n###### 가.  임상시험의 목적\n\n<!-- PAGE_59 -->\n###### [목적]\n\n<!-- PAGE_59 -->\n###### 1) 임상시험용 디지털치료기기의 우울장애 치료에 대한 안전성 평가\n\n<!-- PAGE_59 -->\n###### 2) 임상시험용 디지털치료기기의 우울장애 치료에 대한 유효성 평가\n\n<!-- PAGE_59 -->\n###### 최근 우울장애로 치료받는 환자의 숫자가 급격히 증가하는 추세로\n\n<!-- PAGE_59 -->\n###### 우울장애를 치료하는 방법들 또한 많은 주목을 받고 있다(우울장애\n\n<!-- PAGE_59 -->\n###### 임상진료지침, 2022, ICSI, 2016).  임상에서 우울장애 환자들에게 주로\n\n<!-- PAGE_59 -->\n###### 사용되는 치료는 약물치료이다.  약물치료는 우울장애의 단기 치료에\n\n<!-- PAGE_59 -->\n###### 있어서 유용성이 확립되어 있으나 성기능장애, 졸림(진정 작용), 체중증가,\n\n<!-- PAGE_59 -->\n###### 수면장애(불면), 소화기장애(오심, 구토) 등의 부작용의 위험성이 있다.\n\n <!-- PAGE_59 -->\n###### 이러한 약물치료의 단점들을 보완해줄 수 있는 치료는 우울장애\n\n<!-- PAGE_59 -->\n###### 인지행동치료(CBT-D)이다.  우울장애 인지행동치료(CBT-D)는 단기적으로는\n\n<!-- PAGE_59 -->\n###### 약물치료와 그 효과가 유사하며 장기적인 효과는 약물치료보다 우수한\n\n<!-- PAGE_59 -->\n###### 것으로 밝혀져 있으며, 이러한 효과의 입증을 통해 우울증의 일차\n\n- - 53 -\n<!-- PAGE_60 -->\n###### 치료로 권장되고 있다(Van Hees et al., 2013).\n\n <!-- PAGE_60 -->\n###### 하지만 실제 임상에서 우울장애 인지행동치료(CBT-D)가 처방되는\n\n<!-- PAGE_60 -->\n###### 비율은 약물치료보다 현저히 낮다. ",
        "original_sentence": "약물치료는 우울장애의 단기 치료에\n\n<!-- PAGE_59 -->\n###### 있어서 유용성이 확립되어 있으나 성기능장애, 졸림(진정 작용), 체중증가,\n\n<!-- PAGE_59 -->\n###### 수면장애(불면), 소화기장애(오심, 구토) 등의 부작용의 위험성이 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_656",
      "text": "<!-- PAGE_59 -->\n###### 이러한 약물치료의 단점들을 보완해줄 수 있는 치료는 우울장애\n\n<!-- PAGE_59 -->\n###### 인지행동치료(CBT-D)이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 655,
        "window_size": 3,
        "char_count": 100,
        "word_count": 17,
        "page_number": 59,
        "window_text": "임상시험의 목적\n\n<!-- PAGE_59 -->\n###### [목적]\n\n<!-- PAGE_59 -->\n###### 1) 임상시험용 디지털치료기기의 우울장애 치료에 대한 안전성 평가\n\n<!-- PAGE_59 -->\n###### 2) 임상시험용 디지털치료기기의 우울장애 치료에 대한 유효성 평가\n\n<!-- PAGE_59 -->\n###### 최근 우울장애로 치료받는 환자의 숫자가 급격히 증가하는 추세로\n\n<!-- PAGE_59 -->\n###### 우울장애를 치료하는 방법들 또한 많은 주목을 받고 있다(우울장애\n\n<!-- PAGE_59 -->\n###### 임상진료지침, 2022, ICSI, 2016).  임상에서 우울장애 환자들에게 주로\n\n<!-- PAGE_59 -->\n###### 사용되는 치료는 약물치료이다.  약물치료는 우울장애의 단기 치료에\n\n<!-- PAGE_59 -->\n###### 있어서 유용성이 확립되어 있으나 성기능장애, 졸림(진정 작용), 체중증가,\n\n<!-- PAGE_59 -->\n###### 수면장애(불면), 소화기장애(오심, 구토) 등의 부작용의 위험성이 있다.\n\n <!-- PAGE_59 -->\n###### 이러한 약물치료의 단점들을 보완해줄 수 있는 치료는 우울장애\n\n<!-- PAGE_59 -->\n###### 인지행동치료(CBT-D)이다.  우울장애 인지행동치료(CBT-D)는 단기적으로는\n\n<!-- PAGE_59 -->\n###### 약물치료와 그 효과가 유사하며 장기적인 효과는 약물치료보다 우수한\n\n<!-- PAGE_59 -->\n###### 것으로 밝혀져 있으며, 이러한 효과의 입증을 통해 우울증의 일차\n\n- - 53 -\n<!-- PAGE_60 -->\n###### 치료로 권장되고 있다(Van Hees et al., 2013).\n\n <!-- PAGE_60 -->\n###### 하지만 실제 임상에서 우울장애 인지행동치료(CBT-D)가 처방되는\n\n<!-- PAGE_60 -->\n###### 비율은 약물치료보다 현저히 낮다.  우울장애 인지행동치료(CBT-D)가 약물\n\n<!-- PAGE_60 -->\n###### 치료에 비해 많은 장점이 있음에도 널리 시행되지 않는 이유는 첫째,\n\n<!-- PAGE_60 -->\n###### 우울장애 인지행동치료(CBT-D)를 위해 환자들이 병원에 매주 내원\n\n<!-- PAGE_60 -->\n###### 하여야 하므로 병원에의 공간적 접근성, 치료를 위해 확보할 수 있는\n\n<!-- PAGE_60 -->\n###### 시간 자원 여부에 따른 치료적 제약이 생기기 때문이다. ",
        "original_sentence": "<!-- PAGE_59 -->\n###### 이러한 약물치료의 단점들을 보완해줄 수 있는 치료는 우울장애\n\n<!-- PAGE_59 -->\n###### 인지행동치료(CBT-D)이다. "
      }
    },
    {
      "chunk_id": "chunk_657",
      "text": "우울장애 인지행동치료(CBT-D)는 단기적으로는\n\n<!-- PAGE_59 -->\n###### 약물치료와 그 효과가 유사하며 장기적인 효과는 약물치료보다 우수한\n\n<!-- PAGE_59 -->\n###### 것으로 밝혀져 있으며, 이러한 효과의 입증을 통해 우울증의 일차\n\n- - 53 -\n<!-- PAGE_60 -->\n###### 치료로 권장되고 있다(Van Hees et al., 2013).\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 656,
        "window_size": 3,
        "char_count": 221,
        "word_count": 43,
        "page_number": 59,
        "window_text": "임상에서 우울장애 환자들에게 주로\n\n<!-- PAGE_59 -->\n###### 사용되는 치료는 약물치료이다.  약물치료는 우울장애의 단기 치료에\n\n<!-- PAGE_59 -->\n###### 있어서 유용성이 확립되어 있으나 성기능장애, 졸림(진정 작용), 체중증가,\n\n<!-- PAGE_59 -->\n###### 수면장애(불면), 소화기장애(오심, 구토) 등의 부작용의 위험성이 있다.\n\n <!-- PAGE_59 -->\n###### 이러한 약물치료의 단점들을 보완해줄 수 있는 치료는 우울장애\n\n<!-- PAGE_59 -->\n###### 인지행동치료(CBT-D)이다.  우울장애 인지행동치료(CBT-D)는 단기적으로는\n\n<!-- PAGE_59 -->\n###### 약물치료와 그 효과가 유사하며 장기적인 효과는 약물치료보다 우수한\n\n<!-- PAGE_59 -->\n###### 것으로 밝혀져 있으며, 이러한 효과의 입증을 통해 우울증의 일차\n\n- - 53 -\n<!-- PAGE_60 -->\n###### 치료로 권장되고 있다(Van Hees et al., 2013).\n\n <!-- PAGE_60 -->\n###### 하지만 실제 임상에서 우울장애 인지행동치료(CBT-D)가 처방되는\n\n<!-- PAGE_60 -->\n###### 비율은 약물치료보다 현저히 낮다.  우울장애 인지행동치료(CBT-D)가 약물\n\n<!-- PAGE_60 -->\n###### 치료에 비해 많은 장점이 있음에도 널리 시행되지 않는 이유는 첫째,\n\n<!-- PAGE_60 -->\n###### 우울장애 인지행동치료(CBT-D)를 위해 환자들이 병원에 매주 내원\n\n<!-- PAGE_60 -->\n###### 하여야 하므로 병원에의 공간적 접근성, 치료를 위해 확보할 수 있는\n\n<!-- PAGE_60 -->\n###### 시간 자원 여부에 따른 치료적 제약이 생기기 때문이다.  둘째, 특히\n\n<!-- PAGE_60 -->\n###### 고령 환자이거나, 기타 내과 질환으로 인해 이동이 힘든 환자들의\n\n<!-- PAGE_60 -->\n###### 경우, 혹은 직장인이라 매주 시간을 내기 어려운 환자들의 경우 본인\n\n<!-- PAGE_60 -->\n###### 들이 원하더라도 우울장애 인지행동치료(CBT-D)를 받기 어려운 것이\n\n<!-- PAGE_60 -->\n###### 현실이다. ",
        "original_sentence": "우울장애 인지행동치료(CBT-D)는 단기적으로는\n\n<!-- PAGE_59 -->\n###### 약물치료와 그 효과가 유사하며 장기적인 효과는 약물치료보다 우수한\n\n<!-- PAGE_59 -->\n###### 것으로 밝혀져 있으며, 이러한 효과의 입증을 통해 우울증의 일차\n\n- - 53 -\n<!-- PAGE_60 -->\n###### 치료로 권장되고 있다(Van Hees et al., 2013).\n\n"
      }
    },
    {
      "chunk_id": "chunk_658",
      "text": "<!-- PAGE_60 -->\n###### 하지만 실제 임상에서 우울장애 인지행동치료(CBT-D)가 처방되는\n\n<!-- PAGE_60 -->\n###### 비율은 약물치료보다 현저히 낮다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 657,
        "window_size": 3,
        "char_count": 105,
        "word_count": 18,
        "page_number": 60,
        "window_text": "약물치료는 우울장애의 단기 치료에\n\n<!-- PAGE_59 -->\n###### 있어서 유용성이 확립되어 있으나 성기능장애, 졸림(진정 작용), 체중증가,\n\n<!-- PAGE_59 -->\n###### 수면장애(불면), 소화기장애(오심, 구토) 등의 부작용의 위험성이 있다.\n\n <!-- PAGE_59 -->\n###### 이러한 약물치료의 단점들을 보완해줄 수 있는 치료는 우울장애\n\n<!-- PAGE_59 -->\n###### 인지행동치료(CBT-D)이다.  우울장애 인지행동치료(CBT-D)는 단기적으로는\n\n<!-- PAGE_59 -->\n###### 약물치료와 그 효과가 유사하며 장기적인 효과는 약물치료보다 우수한\n\n<!-- PAGE_59 -->\n###### 것으로 밝혀져 있으며, 이러한 효과의 입증을 통해 우울증의 일차\n\n- - 53 -\n<!-- PAGE_60 -->\n###### 치료로 권장되고 있다(Van Hees et al., 2013).\n\n <!-- PAGE_60 -->\n###### 하지만 실제 임상에서 우울장애 인지행동치료(CBT-D)가 처방되는\n\n<!-- PAGE_60 -->\n###### 비율은 약물치료보다 현저히 낮다.  우울장애 인지행동치료(CBT-D)가 약물\n\n<!-- PAGE_60 -->\n###### 치료에 비해 많은 장점이 있음에도 널리 시행되지 않는 이유는 첫째,\n\n<!-- PAGE_60 -->\n###### 우울장애 인지행동치료(CBT-D)를 위해 환자들이 병원에 매주 내원\n\n<!-- PAGE_60 -->\n###### 하여야 하므로 병원에의 공간적 접근성, 치료를 위해 확보할 수 있는\n\n<!-- PAGE_60 -->\n###### 시간 자원 여부에 따른 치료적 제약이 생기기 때문이다.  둘째, 특히\n\n<!-- PAGE_60 -->\n###### 고령 환자이거나, 기타 내과 질환으로 인해 이동이 힘든 환자들의\n\n<!-- PAGE_60 -->\n###### 경우, 혹은 직장인이라 매주 시간을 내기 어려운 환자들의 경우 본인\n\n<!-- PAGE_60 -->\n###### 들이 원하더라도 우울장애 인지행동치료(CBT-D)를 받기 어려운 것이\n\n<!-- PAGE_60 -->\n###### 현실이다.  셋째, 치료진 관점에서 약물치료와 비교해 우울장애 인지행동\n\n<!-- PAGE_60 -->\n###### 치료(CBT-D)를 시행하는 것이 시간 대비 효용성이 높지 않으므로 선호도가\n\n<!-- PAGE_60 -->\n###### 떨어지는 경향이 있다.\n\n",
        "original_sentence": "<!-- PAGE_60 -->\n###### 하지만 실제 임상에서 우울장애 인지행동치료(CBT-D)가 처방되는\n\n<!-- PAGE_60 -->\n###### 비율은 약물치료보다 현저히 낮다. "
      }
    },
    {
      "chunk_id": "chunk_659",
      "text": "우울장애 인지행동치료(CBT-D)가 약물\n\n<!-- PAGE_60 -->\n###### 치료에 비해 많은 장점이 있음에도 널리 시행되지 않는 이유는 첫째,\n\n<!-- PAGE_60 -->\n###### 우울장애 인지행동치료(CBT-D)를 위해 환자들이 병원에 매주 내원\n\n<!-- PAGE_60 -->\n###### 하여야 하므로 병원에의 공간적 접근성, 치료를 위해 확보할 수 있는\n\n<!-- PAGE_60 -->\n###### 시간 자원 여부에 따른 치료적 제약이 생기기 때문이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 658,
        "window_size": 3,
        "char_count": 268,
        "word_count": 54,
        "page_number": 60,
        "window_text": "<!-- PAGE_59 -->\n###### 이러한 약물치료의 단점들을 보완해줄 수 있는 치료는 우울장애\n\n<!-- PAGE_59 -->\n###### 인지행동치료(CBT-D)이다.  우울장애 인지행동치료(CBT-D)는 단기적으로는\n\n<!-- PAGE_59 -->\n###### 약물치료와 그 효과가 유사하며 장기적인 효과는 약물치료보다 우수한\n\n<!-- PAGE_59 -->\n###### 것으로 밝혀져 있으며, 이러한 효과의 입증을 통해 우울증의 일차\n\n- - 53 -\n<!-- PAGE_60 -->\n###### 치료로 권장되고 있다(Van Hees et al., 2013).\n\n <!-- PAGE_60 -->\n###### 하지만 실제 임상에서 우울장애 인지행동치료(CBT-D)가 처방되는\n\n<!-- PAGE_60 -->\n###### 비율은 약물치료보다 현저히 낮다.  우울장애 인지행동치료(CBT-D)가 약물\n\n<!-- PAGE_60 -->\n###### 치료에 비해 많은 장점이 있음에도 널리 시행되지 않는 이유는 첫째,\n\n<!-- PAGE_60 -->\n###### 우울장애 인지행동치료(CBT-D)를 위해 환자들이 병원에 매주 내원\n\n<!-- PAGE_60 -->\n###### 하여야 하므로 병원에의 공간적 접근성, 치료를 위해 확보할 수 있는\n\n<!-- PAGE_60 -->\n###### 시간 자원 여부에 따른 치료적 제약이 생기기 때문이다.  둘째, 특히\n\n<!-- PAGE_60 -->\n###### 고령 환자이거나, 기타 내과 질환으로 인해 이동이 힘든 환자들의\n\n<!-- PAGE_60 -->\n###### 경우, 혹은 직장인이라 매주 시간을 내기 어려운 환자들의 경우 본인\n\n<!-- PAGE_60 -->\n###### 들이 원하더라도 우울장애 인지행동치료(CBT-D)를 받기 어려운 것이\n\n<!-- PAGE_60 -->\n###### 현실이다.  셋째, 치료진 관점에서 약물치료와 비교해 우울장애 인지행동\n\n<!-- PAGE_60 -->\n###### 치료(CBT-D)를 시행하는 것이 시간 대비 효용성이 높지 않으므로 선호도가\n\n<!-- PAGE_60 -->\n###### 떨어지는 경향이 있다.\n\n <!-- PAGE_60 -->\n###### 이러한 단점들을 보완하기 위해 디지털로 수행하는 우울장애 인지\n\n<!-- PAGE_60 -->\n###### 행동치료(Digital CBT-D)가 개발되고 있다. ",
        "original_sentence": "우울장애 인지행동치료(CBT-D)가 약물\n\n<!-- PAGE_60 -->\n###### 치료에 비해 많은 장점이 있음에도 널리 시행되지 않는 이유는 첫째,\n\n<!-- PAGE_60 -->\n###### 우울장애 인지행동치료(CBT-D)를 위해 환자들이 병원에 매주 내원\n\n<!-- PAGE_60 -->\n###### 하여야 하므로 병원에의 공간적 접근성, 치료를 위해 확보할 수 있는\n\n<!-- PAGE_60 -->\n###### 시간 자원 여부에 따른 치료적 제약이 생기기 때문이다. "
      }
    },
    {
      "chunk_id": "chunk_660",
      "text": "둘째, 특히\n\n<!-- PAGE_60 -->\n###### 고령 환자이거나, 기타 내과 질환으로 인해 이동이 힘든 환자들의\n\n<!-- PAGE_60 -->\n###### 경우, 혹은 직장인이라 매주 시간을 내기 어려운 환자들의 경우 본인\n\n<!-- PAGE_60 -->\n###### 들이 원하더라도 우울장애 인지행동치료(CBT-D)를 받기 어려운 것이\n\n<!-- PAGE_60 -->\n###### 현실이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 659,
        "window_size": 3,
        "char_count": 226,
        "word_count": 45,
        "page_number": 60,
        "window_text": "우울장애 인지행동치료(CBT-D)는 단기적으로는\n\n<!-- PAGE_59 -->\n###### 약물치료와 그 효과가 유사하며 장기적인 효과는 약물치료보다 우수한\n\n<!-- PAGE_59 -->\n###### 것으로 밝혀져 있으며, 이러한 효과의 입증을 통해 우울증의 일차\n\n- - 53 -\n<!-- PAGE_60 -->\n###### 치료로 권장되고 있다(Van Hees et al., 2013).\n\n <!-- PAGE_60 -->\n###### 하지만 실제 임상에서 우울장애 인지행동치료(CBT-D)가 처방되는\n\n<!-- PAGE_60 -->\n###### 비율은 약물치료보다 현저히 낮다.  우울장애 인지행동치료(CBT-D)가 약물\n\n<!-- PAGE_60 -->\n###### 치료에 비해 많은 장점이 있음에도 널리 시행되지 않는 이유는 첫째,\n\n<!-- PAGE_60 -->\n###### 우울장애 인지행동치료(CBT-D)를 위해 환자들이 병원에 매주 내원\n\n<!-- PAGE_60 -->\n###### 하여야 하므로 병원에의 공간적 접근성, 치료를 위해 확보할 수 있는\n\n<!-- PAGE_60 -->\n###### 시간 자원 여부에 따른 치료적 제약이 생기기 때문이다.  둘째, 특히\n\n<!-- PAGE_60 -->\n###### 고령 환자이거나, 기타 내과 질환으로 인해 이동이 힘든 환자들의\n\n<!-- PAGE_60 -->\n###### 경우, 혹은 직장인이라 매주 시간을 내기 어려운 환자들의 경우 본인\n\n<!-- PAGE_60 -->\n###### 들이 원하더라도 우울장애 인지행동치료(CBT-D)를 받기 어려운 것이\n\n<!-- PAGE_60 -->\n###### 현실이다.  셋째, 치료진 관점에서 약물치료와 비교해 우울장애 인지행동\n\n<!-- PAGE_60 -->\n###### 치료(CBT-D)를 시행하는 것이 시간 대비 효용성이 높지 않으므로 선호도가\n\n<!-- PAGE_60 -->\n###### 떨어지는 경향이 있다.\n\n <!-- PAGE_60 -->\n###### 이러한 단점들을 보완하기 위해 디지털로 수행하는 우울장애 인지\n\n<!-- PAGE_60 -->\n###### 행동치료(Digital CBT-D)가 개발되고 있다.  디지털 우울장애 인지행동\n\n<!-- PAGE_60 -->\n###### 치료(Digital CBT-D)의 개념은 2005년에 처음으로 등장하였으며, 인터넷을\n\n<!-- PAGE_60 -->\n###### 이용하여 병원에 내원하지 않고도 우울장애 인지행동치료(CBT-D)를\n\n<!-- PAGE_60 -->\n###### 시행 받을 수 있도록 하는 것이다(Andersson et al. ",
        "original_sentence": "둘째, 특히\n\n<!-- PAGE_60 -->\n###### 고령 환자이거나, 기타 내과 질환으로 인해 이동이 힘든 환자들의\n\n<!-- PAGE_60 -->\n###### 경우, 혹은 직장인이라 매주 시간을 내기 어려운 환자들의 경우 본인\n\n<!-- PAGE_60 -->\n###### 들이 원하더라도 우울장애 인지행동치료(CBT-D)를 받기 어려운 것이\n\n<!-- PAGE_60 -->\n###### 현실이다. "
      }
    },
    {
      "chunk_id": "chunk_661",
      "text": "셋째, 치료진 관점에서 약물치료와 비교해 우울장애 인지행동\n\n<!-- PAGE_60 -->\n###### 치료(CBT-D)를 시행하는 것이 시간 대비 효용성이 높지 않으므로 선호도가\n\n<!-- PAGE_60 -->\n###### 떨어지는 경향이 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 660,
        "window_size": 3,
        "char_count": 140,
        "word_count": 27,
        "page_number": 60,
        "window_text": "<!-- PAGE_60 -->\n###### 하지만 실제 임상에서 우울장애 인지행동치료(CBT-D)가 처방되는\n\n<!-- PAGE_60 -->\n###### 비율은 약물치료보다 현저히 낮다.  우울장애 인지행동치료(CBT-D)가 약물\n\n<!-- PAGE_60 -->\n###### 치료에 비해 많은 장점이 있음에도 널리 시행되지 않는 이유는 첫째,\n\n<!-- PAGE_60 -->\n###### 우울장애 인지행동치료(CBT-D)를 위해 환자들이 병원에 매주 내원\n\n<!-- PAGE_60 -->\n###### 하여야 하므로 병원에의 공간적 접근성, 치료를 위해 확보할 수 있는\n\n<!-- PAGE_60 -->\n###### 시간 자원 여부에 따른 치료적 제약이 생기기 때문이다.  둘째, 특히\n\n<!-- PAGE_60 -->\n###### 고령 환자이거나, 기타 내과 질환으로 인해 이동이 힘든 환자들의\n\n<!-- PAGE_60 -->\n###### 경우, 혹은 직장인이라 매주 시간을 내기 어려운 환자들의 경우 본인\n\n<!-- PAGE_60 -->\n###### 들이 원하더라도 우울장애 인지행동치료(CBT-D)를 받기 어려운 것이\n\n<!-- PAGE_60 -->\n###### 현실이다.  셋째, 치료진 관점에서 약물치료와 비교해 우울장애 인지행동\n\n<!-- PAGE_60 -->\n###### 치료(CBT-D)를 시행하는 것이 시간 대비 효용성이 높지 않으므로 선호도가\n\n<!-- PAGE_60 -->\n###### 떨어지는 경향이 있다.\n\n <!-- PAGE_60 -->\n###### 이러한 단점들을 보완하기 위해 디지털로 수행하는 우울장애 인지\n\n<!-- PAGE_60 -->\n###### 행동치료(Digital CBT-D)가 개발되고 있다.  디지털 우울장애 인지행동\n\n<!-- PAGE_60 -->\n###### 치료(Digital CBT-D)의 개념은 2005년에 처음으로 등장하였으며, 인터넷을\n\n<!-- PAGE_60 -->\n###### 이용하여 병원에 내원하지 않고도 우울장애 인지행동치료(CBT-D)를\n\n<!-- PAGE_60 -->\n###### 시행 받을 수 있도록 하는 것이다(Andersson et al.  2005). ",
        "original_sentence": "셋째, 치료진 관점에서 약물치료와 비교해 우울장애 인지행동\n\n<!-- PAGE_60 -->\n###### 치료(CBT-D)를 시행하는 것이 시간 대비 효용성이 높지 않으므로 선호도가\n\n<!-- PAGE_60 -->\n###### 떨어지는 경향이 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_662",
      "text": "<!-- PAGE_60 -->\n###### 이러한 단점들을 보완하기 위해 디지털로 수행하는 우울장애 인지\n\n<!-- PAGE_60 -->\n###### 행동치료(Digital CBT-D)가 개발되고 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 661,
        "window_size": 3,
        "char_count": 114,
        "word_count": 20,
        "page_number": 60,
        "window_text": "우울장애 인지행동치료(CBT-D)가 약물\n\n<!-- PAGE_60 -->\n###### 치료에 비해 많은 장점이 있음에도 널리 시행되지 않는 이유는 첫째,\n\n<!-- PAGE_60 -->\n###### 우울장애 인지행동치료(CBT-D)를 위해 환자들이 병원에 매주 내원\n\n<!-- PAGE_60 -->\n###### 하여야 하므로 병원에의 공간적 접근성, 치료를 위해 확보할 수 있는\n\n<!-- PAGE_60 -->\n###### 시간 자원 여부에 따른 치료적 제약이 생기기 때문이다.  둘째, 특히\n\n<!-- PAGE_60 -->\n###### 고령 환자이거나, 기타 내과 질환으로 인해 이동이 힘든 환자들의\n\n<!-- PAGE_60 -->\n###### 경우, 혹은 직장인이라 매주 시간을 내기 어려운 환자들의 경우 본인\n\n<!-- PAGE_60 -->\n###### 들이 원하더라도 우울장애 인지행동치료(CBT-D)를 받기 어려운 것이\n\n<!-- PAGE_60 -->\n###### 현실이다.  셋째, 치료진 관점에서 약물치료와 비교해 우울장애 인지행동\n\n<!-- PAGE_60 -->\n###### 치료(CBT-D)를 시행하는 것이 시간 대비 효용성이 높지 않으므로 선호도가\n\n<!-- PAGE_60 -->\n###### 떨어지는 경향이 있다.\n\n <!-- PAGE_60 -->\n###### 이러한 단점들을 보완하기 위해 디지털로 수행하는 우울장애 인지\n\n<!-- PAGE_60 -->\n###### 행동치료(Digital CBT-D)가 개발되고 있다.  디지털 우울장애 인지행동\n\n<!-- PAGE_60 -->\n###### 치료(Digital CBT-D)의 개념은 2005년에 처음으로 등장하였으며, 인터넷을\n\n<!-- PAGE_60 -->\n###### 이용하여 병원에 내원하지 않고도 우울장애 인지행동치료(CBT-D)를\n\n<!-- PAGE_60 -->\n###### 시행 받을 수 있도록 하는 것이다(Andersson et al.  2005).  이를 통해\n\n<!-- PAGE_60 -->\n###### 환자들이 직접 집에서 컴퓨터, 혹은 스마트폰을 이용하여 치료를 시행\n\n<!-- PAGE_60 -->\n###### 받을 수 있으므로 시·공간의 제약에서 자유롭게 될 것이며, 치료 대\n\n<!-- PAGE_60 -->\n###### 부분을 환자가 프로그램을 통해 수행하고 피드백을 받을 수 있으므로\n\n<!-- PAGE_60 -->\n###### 치료자 입장에서 비용 대비 효용성 또한 증가하게 될 것으로 기대된다.\n\n",
        "original_sentence": "<!-- PAGE_60 -->\n###### 이러한 단점들을 보완하기 위해 디지털로 수행하는 우울장애 인지\n\n<!-- PAGE_60 -->\n###### 행동치료(Digital CBT-D)가 개발되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_663",
      "text": "디지털 우울장애 인지행동\n\n<!-- PAGE_60 -->\n###### 치료(Digital CBT-D)의 개념은 2005년에 처음으로 등장하였으며, 인터넷을\n\n<!-- PAGE_60 -->\n###### 이용하여 병원에 내원하지 않고도 우울장애 인지행동치료(CBT-D)를\n\n<!-- PAGE_60 -->\n###### 시행 받을 수 있도록 하는 것이다(Andersson et al. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 662,
        "window_size": 3,
        "char_count": 211,
        "word_count": 36,
        "page_number": 60,
        "window_text": "둘째, 특히\n\n<!-- PAGE_60 -->\n###### 고령 환자이거나, 기타 내과 질환으로 인해 이동이 힘든 환자들의\n\n<!-- PAGE_60 -->\n###### 경우, 혹은 직장인이라 매주 시간을 내기 어려운 환자들의 경우 본인\n\n<!-- PAGE_60 -->\n###### 들이 원하더라도 우울장애 인지행동치료(CBT-D)를 받기 어려운 것이\n\n<!-- PAGE_60 -->\n###### 현실이다.  셋째, 치료진 관점에서 약물치료와 비교해 우울장애 인지행동\n\n<!-- PAGE_60 -->\n###### 치료(CBT-D)를 시행하는 것이 시간 대비 효용성이 높지 않으므로 선호도가\n\n<!-- PAGE_60 -->\n###### 떨어지는 경향이 있다.\n\n <!-- PAGE_60 -->\n###### 이러한 단점들을 보완하기 위해 디지털로 수행하는 우울장애 인지\n\n<!-- PAGE_60 -->\n###### 행동치료(Digital CBT-D)가 개발되고 있다.  디지털 우울장애 인지행동\n\n<!-- PAGE_60 -->\n###### 치료(Digital CBT-D)의 개념은 2005년에 처음으로 등장하였으며, 인터넷을\n\n<!-- PAGE_60 -->\n###### 이용하여 병원에 내원하지 않고도 우울장애 인지행동치료(CBT-D)를\n\n<!-- PAGE_60 -->\n###### 시행 받을 수 있도록 하는 것이다(Andersson et al.  2005).  이를 통해\n\n<!-- PAGE_60 -->\n###### 환자들이 직접 집에서 컴퓨터, 혹은 스마트폰을 이용하여 치료를 시행\n\n<!-- PAGE_60 -->\n###### 받을 수 있으므로 시·공간의 제약에서 자유롭게 될 것이며, 치료 대\n\n<!-- PAGE_60 -->\n###### 부분을 환자가 프로그램을 통해 수행하고 피드백을 받을 수 있으므로\n\n<!-- PAGE_60 -->\n###### 치료자 입장에서 비용 대비 효용성 또한 증가하게 될 것으로 기대된다.\n\n <!-- PAGE_60 -->\n###### 디지털 우울장애 인지행동치료(Digital CBT-D)가 등장한지도 약 15년이\n\n- - 54 -\n<!-- PAGE_61 -->\n###### 되어 치료 효과에 관한 여러 연구 결과들이 발표되고 있다. ",
        "original_sentence": "디지털 우울장애 인지행동\n\n<!-- PAGE_60 -->\n###### 치료(Digital CBT-D)의 개념은 2005년에 처음으로 등장하였으며, 인터넷을\n\n<!-- PAGE_60 -->\n###### 이용하여 병원에 내원하지 않고도 우울장애 인지행동치료(CBT-D)를\n\n<!-- PAGE_60 -->\n###### 시행 받을 수 있도록 하는 것이다(Andersson et al. "
      }
    },
    {
      "chunk_id": "chunk_664",
      "text": "2005). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 663,
        "window_size": 3,
        "char_count": 7,
        "word_count": 1,
        "page_number": 9,
        "window_text": "셋째, 치료진 관점에서 약물치료와 비교해 우울장애 인지행동\n\n<!-- PAGE_60 -->\n###### 치료(CBT-D)를 시행하는 것이 시간 대비 효용성이 높지 않으므로 선호도가\n\n<!-- PAGE_60 -->\n###### 떨어지는 경향이 있다.\n\n <!-- PAGE_60 -->\n###### 이러한 단점들을 보완하기 위해 디지털로 수행하는 우울장애 인지\n\n<!-- PAGE_60 -->\n###### 행동치료(Digital CBT-D)가 개발되고 있다.  디지털 우울장애 인지행동\n\n<!-- PAGE_60 -->\n###### 치료(Digital CBT-D)의 개념은 2005년에 처음으로 등장하였으며, 인터넷을\n\n<!-- PAGE_60 -->\n###### 이용하여 병원에 내원하지 않고도 우울장애 인지행동치료(CBT-D)를\n\n<!-- PAGE_60 -->\n###### 시행 받을 수 있도록 하는 것이다(Andersson et al.  2005).  이를 통해\n\n<!-- PAGE_60 -->\n###### 환자들이 직접 집에서 컴퓨터, 혹은 스마트폰을 이용하여 치료를 시행\n\n<!-- PAGE_60 -->\n###### 받을 수 있으므로 시·공간의 제약에서 자유롭게 될 것이며, 치료 대\n\n<!-- PAGE_60 -->\n###### 부분을 환자가 프로그램을 통해 수행하고 피드백을 받을 수 있으므로\n\n<!-- PAGE_60 -->\n###### 치료자 입장에서 비용 대비 효용성 또한 증가하게 될 것으로 기대된다.\n\n <!-- PAGE_60 -->\n###### 디지털 우울장애 인지행동치료(Digital CBT-D)가 등장한지도 약 15년이\n\n- - 54 -\n<!-- PAGE_61 -->\n###### 되어 치료 효과에 관한 여러 연구 결과들이 발표되고 있다.  특히, 최근\n\n<!-- PAGE_61 -->\n###### 연구들은 단순히 우울장애 인지행동치료(CBT-D)를 디지털 환경으로\n\n<!-- PAGE_61 -->\n###### 옮기는 것에서 발전하여, 애플리케이션을 통하여 환자에게 바로\n\n<!-- PAGE_61 -->\n###### 피드백을 제공함으로써 의사나 치료자가 직접적인 가이드를 주지\n\n<!-- PAGE_61 -->\n###### 않더라도 치료 효과를 볼 수 있게 하는 “디지털치료기기(Digital\n\n<!-- PAGE_61 -->\n###### Therapeutics, DTx)”의 개념을 추구하고 있다.\n\n",
        "original_sentence": "2005). "
      }
    },
    {
      "chunk_id": "chunk_665",
      "text": "이를 통해\n\n<!-- PAGE_60 -->\n###### 환자들이 직접 집에서 컴퓨터, 혹은 스마트폰을 이용하여 치료를 시행\n\n<!-- PAGE_60 -->\n###### 받을 수 있으므로 시·공간의 제약에서 자유롭게 될 것이며, 치료 대\n\n<!-- PAGE_60 -->\n###### 부분을 환자가 프로그램을 통해 수행하고 피드백을 받을 수 있으므로\n\n<!-- PAGE_60 -->\n###### 치료자 입장에서 비용 대비 효용성 또한 증가하게 될 것으로 기대된다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 664,
        "window_size": 3,
        "char_count": 259,
        "word_count": 56,
        "page_number": 60,
        "window_text": "<!-- PAGE_60 -->\n###### 이러한 단점들을 보완하기 위해 디지털로 수행하는 우울장애 인지\n\n<!-- PAGE_60 -->\n###### 행동치료(Digital CBT-D)가 개발되고 있다.  디지털 우울장애 인지행동\n\n<!-- PAGE_60 -->\n###### 치료(Digital CBT-D)의 개념은 2005년에 처음으로 등장하였으며, 인터넷을\n\n<!-- PAGE_60 -->\n###### 이용하여 병원에 내원하지 않고도 우울장애 인지행동치료(CBT-D)를\n\n<!-- PAGE_60 -->\n###### 시행 받을 수 있도록 하는 것이다(Andersson et al.  2005).  이를 통해\n\n<!-- PAGE_60 -->\n###### 환자들이 직접 집에서 컴퓨터, 혹은 스마트폰을 이용하여 치료를 시행\n\n<!-- PAGE_60 -->\n###### 받을 수 있으므로 시·공간의 제약에서 자유롭게 될 것이며, 치료 대\n\n<!-- PAGE_60 -->\n###### 부분을 환자가 프로그램을 통해 수행하고 피드백을 받을 수 있으므로\n\n<!-- PAGE_60 -->\n###### 치료자 입장에서 비용 대비 효용성 또한 증가하게 될 것으로 기대된다.\n\n <!-- PAGE_60 -->\n###### 디지털 우울장애 인지행동치료(Digital CBT-D)가 등장한지도 약 15년이\n\n- - 54 -\n<!-- PAGE_61 -->\n###### 되어 치료 효과에 관한 여러 연구 결과들이 발표되고 있다.  특히, 최근\n\n<!-- PAGE_61 -->\n###### 연구들은 단순히 우울장애 인지행동치료(CBT-D)를 디지털 환경으로\n\n<!-- PAGE_61 -->\n###### 옮기는 것에서 발전하여, 애플리케이션을 통하여 환자에게 바로\n\n<!-- PAGE_61 -->\n###### 피드백을 제공함으로써 의사나 치료자가 직접적인 가이드를 주지\n\n<!-- PAGE_61 -->\n###### 않더라도 치료 효과를 볼 수 있게 하는 “디지털치료기기(Digital\n\n<!-- PAGE_61 -->\n###### Therapeutics, DTx)”의 개념을 추구하고 있다.\n\n <!-- PAGE_61 -->\n###### 본 임상 시험을 통해 우울장애가 있는 환자들을 대상으로 개발된 우울\n\n<!-- PAGE_61 -->\n###### 장애 개선 디지털치료기기의 작용기전에 대한 안전성(Safety)과 유효성\n\n<!-- PAGE_61 -->\n###### (effectiveness)을 검증하고자 한다.\n\n",
        "original_sentence": "이를 통해\n\n<!-- PAGE_60 -->\n###### 환자들이 직접 집에서 컴퓨터, 혹은 스마트폰을 이용하여 치료를 시행\n\n<!-- PAGE_60 -->\n###### 받을 수 있으므로 시·공간의 제약에서 자유롭게 될 것이며, 치료 대\n\n<!-- PAGE_60 -->\n###### 부분을 환자가 프로그램을 통해 수행하고 피드백을 받을 수 있으므로\n\n<!-- PAGE_60 -->\n###### 치료자 입장에서 비용 대비 효용성 또한 증가하게 될 것으로 기대된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_666",
      "text": "<!-- PAGE_60 -->\n###### 디지털 우울장애 인지행동치료(Digital CBT-D)가 등장한지도 약 15년이\n\n- - 54 -\n<!-- PAGE_61 -->\n###### 되어 치료 효과에 관한 여러 연구 결과들이 발표되고 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 665,
        "window_size": 3,
        "char_count": 136,
        "word_count": 28,
        "page_number": 60,
        "window_text": "디지털 우울장애 인지행동\n\n<!-- PAGE_60 -->\n###### 치료(Digital CBT-D)의 개념은 2005년에 처음으로 등장하였으며, 인터넷을\n\n<!-- PAGE_60 -->\n###### 이용하여 병원에 내원하지 않고도 우울장애 인지행동치료(CBT-D)를\n\n<!-- PAGE_60 -->\n###### 시행 받을 수 있도록 하는 것이다(Andersson et al.  2005).  이를 통해\n\n<!-- PAGE_60 -->\n###### 환자들이 직접 집에서 컴퓨터, 혹은 스마트폰을 이용하여 치료를 시행\n\n<!-- PAGE_60 -->\n###### 받을 수 있으므로 시·공간의 제약에서 자유롭게 될 것이며, 치료 대\n\n<!-- PAGE_60 -->\n###### 부분을 환자가 프로그램을 통해 수행하고 피드백을 받을 수 있으므로\n\n<!-- PAGE_60 -->\n###### 치료자 입장에서 비용 대비 효용성 또한 증가하게 될 것으로 기대된다.\n\n <!-- PAGE_60 -->\n###### 디지털 우울장애 인지행동치료(Digital CBT-D)가 등장한지도 약 15년이\n\n- - 54 -\n<!-- PAGE_61 -->\n###### 되어 치료 효과에 관한 여러 연구 결과들이 발표되고 있다.  특히, 최근\n\n<!-- PAGE_61 -->\n###### 연구들은 단순히 우울장애 인지행동치료(CBT-D)를 디지털 환경으로\n\n<!-- PAGE_61 -->\n###### 옮기는 것에서 발전하여, 애플리케이션을 통하여 환자에게 바로\n\n<!-- PAGE_61 -->\n###### 피드백을 제공함으로써 의사나 치료자가 직접적인 가이드를 주지\n\n<!-- PAGE_61 -->\n###### 않더라도 치료 효과를 볼 수 있게 하는 “디지털치료기기(Digital\n\n<!-- PAGE_61 -->\n###### Therapeutics, DTx)”의 개념을 추구하고 있다.\n\n <!-- PAGE_61 -->\n###### 본 임상 시험을 통해 우울장애가 있는 환자들을 대상으로 개발된 우울\n\n<!-- PAGE_61 -->\n###### 장애 개선 디지털치료기기의 작용기전에 대한 안전성(Safety)과 유효성\n\n<!-- PAGE_61 -->\n###### (effectiveness)을 검증하고자 한다.\n\n - - 55 -\n<!-- PAGE_62 -->\n###### 나. ",
        "original_sentence": "<!-- PAGE_60 -->\n###### 디지털 우울장애 인지행동치료(Digital CBT-D)가 등장한지도 약 15년이\n\n- - 54 -\n<!-- PAGE_61 -->\n###### 되어 치료 효과에 관한 여러 연구 결과들이 발표되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_667",
      "text": "특히, 최근\n\n<!-- PAGE_61 -->\n###### 연구들은 단순히 우울장애 인지행동치료(CBT-D)를 디지털 환경으로\n\n<!-- PAGE_61 -->\n###### 옮기는 것에서 발전하여, 애플리케이션을 통하여 환자에게 바로\n\n<!-- PAGE_61 -->\n###### 피드백을 제공함으로써 의사나 치료자가 직접적인 가이드를 주지\n\n<!-- PAGE_61 -->\n###### 않더라도 치료 효과를 볼 수 있게 하는 “디지털치료기기(Digital\n\n<!-- PAGE_61 -->\n###### Therapeutics, DTx)”의 개념을 추구하고 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 666,
        "window_size": 3,
        "char_count": 312,
        "word_count": 55,
        "page_number": 61,
        "window_text": "2005).  이를 통해\n\n<!-- PAGE_60 -->\n###### 환자들이 직접 집에서 컴퓨터, 혹은 스마트폰을 이용하여 치료를 시행\n\n<!-- PAGE_60 -->\n###### 받을 수 있으므로 시·공간의 제약에서 자유롭게 될 것이며, 치료 대\n\n<!-- PAGE_60 -->\n###### 부분을 환자가 프로그램을 통해 수행하고 피드백을 받을 수 있으므로\n\n<!-- PAGE_60 -->\n###### 치료자 입장에서 비용 대비 효용성 또한 증가하게 될 것으로 기대된다.\n\n <!-- PAGE_60 -->\n###### 디지털 우울장애 인지행동치료(Digital CBT-D)가 등장한지도 약 15년이\n\n- - 54 -\n<!-- PAGE_61 -->\n###### 되어 치료 효과에 관한 여러 연구 결과들이 발표되고 있다.  특히, 최근\n\n<!-- PAGE_61 -->\n###### 연구들은 단순히 우울장애 인지행동치료(CBT-D)를 디지털 환경으로\n\n<!-- PAGE_61 -->\n###### 옮기는 것에서 발전하여, 애플리케이션을 통하여 환자에게 바로\n\n<!-- PAGE_61 -->\n###### 피드백을 제공함으로써 의사나 치료자가 직접적인 가이드를 주지\n\n<!-- PAGE_61 -->\n###### 않더라도 치료 효과를 볼 수 있게 하는 “디지털치료기기(Digital\n\n<!-- PAGE_61 -->\n###### Therapeutics, DTx)”의 개념을 추구하고 있다.\n\n <!-- PAGE_61 -->\n###### 본 임상 시험을 통해 우울장애가 있는 환자들을 대상으로 개발된 우울\n\n<!-- PAGE_61 -->\n###### 장애 개선 디지털치료기기의 작용기전에 대한 안전성(Safety)과 유효성\n\n<!-- PAGE_61 -->\n###### (effectiveness)을 검증하고자 한다.\n\n - - 55 -\n<!-- PAGE_62 -->\n###### 나.  임상시험의 배경\n\n<!-- PAGE_62 -->\n###### 디지털치료기기란 질병이나 장애를 예방, 관리, 치료하기 위해 환자\n\n<!-- PAGE_62 -->\n###### 에게 근거 기반의 치료적 중재(evidence-based therapeutic intervention)를\n\n<!-- PAGE_62 -->\n###### 제공하는 고도화된 소프트웨어 의료기기를 가리킨다.\n\n",
        "original_sentence": "특히, 최근\n\n<!-- PAGE_61 -->\n###### 연구들은 단순히 우울장애 인지행동치료(CBT-D)를 디지털 환경으로\n\n<!-- PAGE_61 -->\n###### 옮기는 것에서 발전하여, 애플리케이션을 통하여 환자에게 바로\n\n<!-- PAGE_61 -->\n###### 피드백을 제공함으로써 의사나 치료자가 직접적인 가이드를 주지\n\n<!-- PAGE_61 -->\n###### 않더라도 치료 효과를 볼 수 있게 하는 “디지털치료기기(Digital\n\n<!-- PAGE_61 -->\n###### Therapeutics, DTx)”의 개념을 추구하고 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_668",
      "text": "<!-- PAGE_61 -->\n###### 본 임상 시험을 통해 우울장애가 있는 환자들을 대상으로 개발된 우울\n\n<!-- PAGE_61 -->\n###### 장애 개선 디지털치료기기의 작용기전에 대한 안전성(Safety)과 유효성\n\n<!-- PAGE_61 -->\n###### (effectiveness)을 검증하고자 한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 667,
        "window_size": 3,
        "char_count": 181,
        "word_count": 32,
        "page_number": 61,
        "window_text": "이를 통해\n\n<!-- PAGE_60 -->\n###### 환자들이 직접 집에서 컴퓨터, 혹은 스마트폰을 이용하여 치료를 시행\n\n<!-- PAGE_60 -->\n###### 받을 수 있으므로 시·공간의 제약에서 자유롭게 될 것이며, 치료 대\n\n<!-- PAGE_60 -->\n###### 부분을 환자가 프로그램을 통해 수행하고 피드백을 받을 수 있으므로\n\n<!-- PAGE_60 -->\n###### 치료자 입장에서 비용 대비 효용성 또한 증가하게 될 것으로 기대된다.\n\n <!-- PAGE_60 -->\n###### 디지털 우울장애 인지행동치료(Digital CBT-D)가 등장한지도 약 15년이\n\n- - 54 -\n<!-- PAGE_61 -->\n###### 되어 치료 효과에 관한 여러 연구 결과들이 발표되고 있다.  특히, 최근\n\n<!-- PAGE_61 -->\n###### 연구들은 단순히 우울장애 인지행동치료(CBT-D)를 디지털 환경으로\n\n<!-- PAGE_61 -->\n###### 옮기는 것에서 발전하여, 애플리케이션을 통하여 환자에게 바로\n\n<!-- PAGE_61 -->\n###### 피드백을 제공함으로써 의사나 치료자가 직접적인 가이드를 주지\n\n<!-- PAGE_61 -->\n###### 않더라도 치료 효과를 볼 수 있게 하는 “디지털치료기기(Digital\n\n<!-- PAGE_61 -->\n###### Therapeutics, DTx)”의 개념을 추구하고 있다.\n\n <!-- PAGE_61 -->\n###### 본 임상 시험을 통해 우울장애가 있는 환자들을 대상으로 개발된 우울\n\n<!-- PAGE_61 -->\n###### 장애 개선 디지털치료기기의 작용기전에 대한 안전성(Safety)과 유효성\n\n<!-- PAGE_61 -->\n###### (effectiveness)을 검증하고자 한다.\n\n - - 55 -\n<!-- PAGE_62 -->\n###### 나.  임상시험의 배경\n\n<!-- PAGE_62 -->\n###### 디지털치료기기란 질병이나 장애를 예방, 관리, 치료하기 위해 환자\n\n<!-- PAGE_62 -->\n###### 에게 근거 기반의 치료적 중재(evidence-based therapeutic intervention)를\n\n<!-- PAGE_62 -->\n###### 제공하는 고도화된 소프트웨어 의료기기를 가리킨다.\n\n <!-- PAGE_62 -->\n###### 독일 GAIA 社에서 제공하는 Deprexis™는 CE 승인을 받은 우울장애\n\n<!-- PAGE_62 -->\n###### 개선 디지털치료기기로서, 실제 임상에서 사용되고 있다. ",
        "original_sentence": "<!-- PAGE_61 -->\n###### 본 임상 시험을 통해 우울장애가 있는 환자들을 대상으로 개발된 우울\n\n<!-- PAGE_61 -->\n###### 장애 개선 디지털치료기기의 작용기전에 대한 안전성(Safety)과 유효성\n\n<!-- PAGE_61 -->\n###### (effectiveness)을 검증하고자 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_669",
      "text": "- - 55 -\n<!-- PAGE_62 -->\n###### 나. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 668,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 62,
        "window_text": "<!-- PAGE_60 -->\n###### 디지털 우울장애 인지행동치료(Digital CBT-D)가 등장한지도 약 15년이\n\n- - 54 -\n<!-- PAGE_61 -->\n###### 되어 치료 효과에 관한 여러 연구 결과들이 발표되고 있다.  특히, 최근\n\n<!-- PAGE_61 -->\n###### 연구들은 단순히 우울장애 인지행동치료(CBT-D)를 디지털 환경으로\n\n<!-- PAGE_61 -->\n###### 옮기는 것에서 발전하여, 애플리케이션을 통하여 환자에게 바로\n\n<!-- PAGE_61 -->\n###### 피드백을 제공함으로써 의사나 치료자가 직접적인 가이드를 주지\n\n<!-- PAGE_61 -->\n###### 않더라도 치료 효과를 볼 수 있게 하는 “디지털치료기기(Digital\n\n<!-- PAGE_61 -->\n###### Therapeutics, DTx)”의 개념을 추구하고 있다.\n\n <!-- PAGE_61 -->\n###### 본 임상 시험을 통해 우울장애가 있는 환자들을 대상으로 개발된 우울\n\n<!-- PAGE_61 -->\n###### 장애 개선 디지털치료기기의 작용기전에 대한 안전성(Safety)과 유효성\n\n<!-- PAGE_61 -->\n###### (effectiveness)을 검증하고자 한다.\n\n - - 55 -\n<!-- PAGE_62 -->\n###### 나.  임상시험의 배경\n\n<!-- PAGE_62 -->\n###### 디지털치료기기란 질병이나 장애를 예방, 관리, 치료하기 위해 환자\n\n<!-- PAGE_62 -->\n###### 에게 근거 기반의 치료적 중재(evidence-based therapeutic intervention)를\n\n<!-- PAGE_62 -->\n###### 제공하는 고도화된 소프트웨어 의료기기를 가리킨다.\n\n <!-- PAGE_62 -->\n###### 독일 GAIA 社에서 제공하는 Deprexis™는 CE 승인을 받은 우울장애\n\n<!-- PAGE_62 -->\n###### 개선 디지털치료기기로서, 실제 임상에서 사용되고 있다.  Deprexis™는\n\n<!-- PAGE_62 -->\n###### 여러 무작위배정 임상시험을 통해 그 효용성 또한 입증된 바 있으며,\n\n<!-- PAGE_62 -->\n###### 우울과 관련된 변수들을 포함하여 신체적 건강, 심리적 웰빙 및 우울\n\n<!-- PAGE_62 -->\n###### 관련 지표 또한 호전되었다는 것이 밝혀진 바 있다(Twomey et al., 2020.).\n\n",
        "original_sentence": "- - 55 -\n<!-- PAGE_62 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_670",
      "text": "임상시험의 배경\n\n<!-- PAGE_62 -->\n###### 디지털치료기기란 질병이나 장애를 예방, 관리, 치료하기 위해 환자\n\n<!-- PAGE_62 -->\n###### 에게 근거 기반의 치료적 중재(evidence-based therapeutic intervention)를\n\n<!-- PAGE_62 -->\n###### 제공하는 고도화된 소프트웨어 의료기기를 가리킨다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 669,
        "window_size": 3,
        "char_count": 209,
        "word_count": 34,
        "page_number": 62,
        "window_text": "특히, 최근\n\n<!-- PAGE_61 -->\n###### 연구들은 단순히 우울장애 인지행동치료(CBT-D)를 디지털 환경으로\n\n<!-- PAGE_61 -->\n###### 옮기는 것에서 발전하여, 애플리케이션을 통하여 환자에게 바로\n\n<!-- PAGE_61 -->\n###### 피드백을 제공함으로써 의사나 치료자가 직접적인 가이드를 주지\n\n<!-- PAGE_61 -->\n###### 않더라도 치료 효과를 볼 수 있게 하는 “디지털치료기기(Digital\n\n<!-- PAGE_61 -->\n###### Therapeutics, DTx)”의 개념을 추구하고 있다.\n\n <!-- PAGE_61 -->\n###### 본 임상 시험을 통해 우울장애가 있는 환자들을 대상으로 개발된 우울\n\n<!-- PAGE_61 -->\n###### 장애 개선 디지털치료기기의 작용기전에 대한 안전성(Safety)과 유효성\n\n<!-- PAGE_61 -->\n###### (effectiveness)을 검증하고자 한다.\n\n - - 55 -\n<!-- PAGE_62 -->\n###### 나.  임상시험의 배경\n\n<!-- PAGE_62 -->\n###### 디지털치료기기란 질병이나 장애를 예방, 관리, 치료하기 위해 환자\n\n<!-- PAGE_62 -->\n###### 에게 근거 기반의 치료적 중재(evidence-based therapeutic intervention)를\n\n<!-- PAGE_62 -->\n###### 제공하는 고도화된 소프트웨어 의료기기를 가리킨다.\n\n <!-- PAGE_62 -->\n###### 독일 GAIA 社에서 제공하는 Deprexis™는 CE 승인을 받은 우울장애\n\n<!-- PAGE_62 -->\n###### 개선 디지털치료기기로서, 실제 임상에서 사용되고 있다.  Deprexis™는\n\n<!-- PAGE_62 -->\n###### 여러 무작위배정 임상시험을 통해 그 효용성 또한 입증된 바 있으며,\n\n<!-- PAGE_62 -->\n###### 우울과 관련된 변수들을 포함하여 신체적 건강, 심리적 웰빙 및 우울\n\n<!-- PAGE_62 -->\n###### 관련 지표 또한 호전되었다는 것이 밝혀진 바 있다(Twomey et al., 2020.).\n\n <!-- PAGE_62 -->\n###### 12개의 Deprexis RCT(총 피험자=2,901명)에 대한 메타분석은 우울\n\n<!-- PAGE_62 -->\n###### 장애 감소에 대한 Deprexis™의 효과를 확인하였다(g = 0.51, 95% CI:\n\n<!-- PAGE_62 -->\n###### 0.40–0.62, I2 = 26%). ",
        "original_sentence": "임상시험의 배경\n\n<!-- PAGE_62 -->\n###### 디지털치료기기란 질병이나 장애를 예방, 관리, 치료하기 위해 환자\n\n<!-- PAGE_62 -->\n###### 에게 근거 기반의 치료적 중재(evidence-based therapeutic intervention)를\n\n<!-- PAGE_62 -->\n###### 제공하는 고도화된 소프트웨어 의료기기를 가리킨다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_671",
      "text": "<!-- PAGE_62 -->\n###### 독일 GAIA 社에서 제공하는 Deprexis™는 CE 승인을 받은 우울장애\n\n<!-- PAGE_62 -->\n###### 개선 디지털치료기기로서, 실제 임상에서 사용되고 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 670,
        "window_size": 3,
        "char_count": 123,
        "word_count": 23,
        "page_number": 62,
        "window_text": "<!-- PAGE_61 -->\n###### 본 임상 시험을 통해 우울장애가 있는 환자들을 대상으로 개발된 우울\n\n<!-- PAGE_61 -->\n###### 장애 개선 디지털치료기기의 작용기전에 대한 안전성(Safety)과 유효성\n\n<!-- PAGE_61 -->\n###### (effectiveness)을 검증하고자 한다.\n\n - - 55 -\n<!-- PAGE_62 -->\n###### 나.  임상시험의 배경\n\n<!-- PAGE_62 -->\n###### 디지털치료기기란 질병이나 장애를 예방, 관리, 치료하기 위해 환자\n\n<!-- PAGE_62 -->\n###### 에게 근거 기반의 치료적 중재(evidence-based therapeutic intervention)를\n\n<!-- PAGE_62 -->\n###### 제공하는 고도화된 소프트웨어 의료기기를 가리킨다.\n\n <!-- PAGE_62 -->\n###### 독일 GAIA 社에서 제공하는 Deprexis™는 CE 승인을 받은 우울장애\n\n<!-- PAGE_62 -->\n###### 개선 디지털치료기기로서, 실제 임상에서 사용되고 있다.  Deprexis™는\n\n<!-- PAGE_62 -->\n###### 여러 무작위배정 임상시험을 통해 그 효용성 또한 입증된 바 있으며,\n\n<!-- PAGE_62 -->\n###### 우울과 관련된 변수들을 포함하여 신체적 건강, 심리적 웰빙 및 우울\n\n<!-- PAGE_62 -->\n###### 관련 지표 또한 호전되었다는 것이 밝혀진 바 있다(Twomey et al., 2020.).\n\n <!-- PAGE_62 -->\n###### 12개의 Deprexis RCT(총 피험자=2,901명)에 대한 메타분석은 우울\n\n<!-- PAGE_62 -->\n###### 장애 감소에 대한 Deprexis™의 효과를 확인하였다(g = 0.51, 95% CI:\n\n<!-- PAGE_62 -->\n###### 0.40–0.62, I2 = 26%).  임상 연구의 질, 선별 및 무작위배정 절차를\n\n<!-- PAGE_62 -->\n###### 고려할 때 결과는 유사하였다. ",
        "original_sentence": "<!-- PAGE_62 -->\n###### 독일 GAIA 社에서 제공하는 Deprexis™는 CE 승인을 받은 우울장애\n\n<!-- PAGE_62 -->\n###### 개선 디지털치료기기로서, 실제 임상에서 사용되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_672",
      "text": "Deprexis™는\n\n<!-- PAGE_62 -->\n###### 여러 무작위배정 임상시험을 통해 그 효용성 또한 입증된 바 있으며,\n\n<!-- PAGE_62 -->\n###### 우울과 관련된 변수들을 포함하여 신체적 건강, 심리적 웰빙 및 우울\n\n<!-- PAGE_62 -->\n###### 관련 지표 또한 호전되었다는 것이 밝혀진 바 있다(Twomey et al., 2020.).\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 671,
        "window_size": 3,
        "char_count": 214,
        "word_count": 44,
        "page_number": 62,
        "window_text": "- - 55 -\n<!-- PAGE_62 -->\n###### 나.  임상시험의 배경\n\n<!-- PAGE_62 -->\n###### 디지털치료기기란 질병이나 장애를 예방, 관리, 치료하기 위해 환자\n\n<!-- PAGE_62 -->\n###### 에게 근거 기반의 치료적 중재(evidence-based therapeutic intervention)를\n\n<!-- PAGE_62 -->\n###### 제공하는 고도화된 소프트웨어 의료기기를 가리킨다.\n\n <!-- PAGE_62 -->\n###### 독일 GAIA 社에서 제공하는 Deprexis™는 CE 승인을 받은 우울장애\n\n<!-- PAGE_62 -->\n###### 개선 디지털치료기기로서, 실제 임상에서 사용되고 있다.  Deprexis™는\n\n<!-- PAGE_62 -->\n###### 여러 무작위배정 임상시험을 통해 그 효용성 또한 입증된 바 있으며,\n\n<!-- PAGE_62 -->\n###### 우울과 관련된 변수들을 포함하여 신체적 건강, 심리적 웰빙 및 우울\n\n<!-- PAGE_62 -->\n###### 관련 지표 또한 호전되었다는 것이 밝혀진 바 있다(Twomey et al., 2020.).\n\n <!-- PAGE_62 -->\n###### 12개의 Deprexis RCT(총 피험자=2,901명)에 대한 메타분석은 우울\n\n<!-- PAGE_62 -->\n###### 장애 감소에 대한 Deprexis™의 효과를 확인하였다(g = 0.51, 95% CI:\n\n<!-- PAGE_62 -->\n###### 0.40–0.62, I2 = 26%).  임상 연구의 질, 선별 및 무작위배정 절차를\n\n<!-- PAGE_62 -->\n###### 고려할 때 결과는 유사하였다.  임상 연구의 지도, 개발자 참여, 환경\n\n<!-- PAGE_62 -->\n###### (지역사회 대 임상) 및 초기 증상 심각도는 효과 크기에 통계적으로\n\n<!-- PAGE_62 -->\n###### 유의한 영향을 미치지 않았으며 출판 편향의 증거도 없었다. ",
        "original_sentence": "Deprexis™는\n\n<!-- PAGE_62 -->\n###### 여러 무작위배정 임상시험을 통해 그 효용성 또한 입증된 바 있으며,\n\n<!-- PAGE_62 -->\n###### 우울과 관련된 변수들을 포함하여 신체적 건강, 심리적 웰빙 및 우울\n\n<!-- PAGE_62 -->\n###### 관련 지표 또한 호전되었다는 것이 밝혀진 바 있다(Twomey et al., 2020.).\n\n"
      }
    },
    {
      "chunk_id": "chunk_673",
      "text": "<!-- PAGE_62 -->\n###### 12개의 Deprexis RCT(총 피험자=2,901명)에 대한 메타분석은 우울\n\n<!-- PAGE_62 -->\n###### 장애 감소에 대한 Deprexis™의 효과를 확인하였다(g = 0.51, 95% CI:\n\n<!-- PAGE_62 -->\n###### 0.40–0.62, I2 = 26%). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 672,
        "window_size": 3,
        "char_count": 190,
        "word_count": 33,
        "page_number": 62,
        "window_text": "임상시험의 배경\n\n<!-- PAGE_62 -->\n###### 디지털치료기기란 질병이나 장애를 예방, 관리, 치료하기 위해 환자\n\n<!-- PAGE_62 -->\n###### 에게 근거 기반의 치료적 중재(evidence-based therapeutic intervention)를\n\n<!-- PAGE_62 -->\n###### 제공하는 고도화된 소프트웨어 의료기기를 가리킨다.\n\n <!-- PAGE_62 -->\n###### 독일 GAIA 社에서 제공하는 Deprexis™는 CE 승인을 받은 우울장애\n\n<!-- PAGE_62 -->\n###### 개선 디지털치료기기로서, 실제 임상에서 사용되고 있다.  Deprexis™는\n\n<!-- PAGE_62 -->\n###### 여러 무작위배정 임상시험을 통해 그 효용성 또한 입증된 바 있으며,\n\n<!-- PAGE_62 -->\n###### 우울과 관련된 변수들을 포함하여 신체적 건강, 심리적 웰빙 및 우울\n\n<!-- PAGE_62 -->\n###### 관련 지표 또한 호전되었다는 것이 밝혀진 바 있다(Twomey et al., 2020.).\n\n <!-- PAGE_62 -->\n###### 12개의 Deprexis RCT(총 피험자=2,901명)에 대한 메타분석은 우울\n\n<!-- PAGE_62 -->\n###### 장애 감소에 대한 Deprexis™의 효과를 확인하였다(g = 0.51, 95% CI:\n\n<!-- PAGE_62 -->\n###### 0.40–0.62, I2 = 26%).  임상 연구의 질, 선별 및 무작위배정 절차를\n\n<!-- PAGE_62 -->\n###### 고려할 때 결과는 유사하였다.  임상 연구의 지도, 개발자 참여, 환경\n\n<!-- PAGE_62 -->\n###### (지역사회 대 임상) 및 초기 증상 심각도는 효과 크기에 통계적으로\n\n<!-- PAGE_62 -->\n###### 유의한 영향을 미치지 않았으며 출판 편향의 증거도 없었다.  따라서\n\n<!-- PAGE_62 -->\n###### 이러한 결과는 Deprexis가 8-12주에 걸쳐 임상적으로 관련된 우울\n\n<!-- PAGE_62 -->\n###### 증상의 개선할 수 있음을 확인하였다, 아래의 <그림 4>는 우울장애\n\n<!-- PAGE_62 -->\n###### 개선 디지털치료기기와 관련하여 수행한 임상시험의 선행 연구의\n\n<!-- PAGE_62 -->\n###### 메타분석 결과이다.\n\n",
        "original_sentence": "<!-- PAGE_62 -->\n###### 12개의 Deprexis RCT(총 피험자=2,901명)에 대한 메타분석은 우울\n\n<!-- PAGE_62 -->\n###### 장애 감소에 대한 Deprexis™의 효과를 확인하였다(g = 0.51, 95% CI:\n\n<!-- PAGE_62 -->\n###### 0.40–0.62, I2 = 26%). "
      }
    },
    {
      "chunk_id": "chunk_674",
      "text": "임상 연구의 질, 선별 및 무작위배정 절차를\n\n<!-- PAGE_62 -->\n###### 고려할 때 결과는 유사하였다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 673,
        "window_size": 3,
        "char_count": 67,
        "word_count": 15,
        "page_number": 62,
        "window_text": "<!-- PAGE_62 -->\n###### 독일 GAIA 社에서 제공하는 Deprexis™는 CE 승인을 받은 우울장애\n\n<!-- PAGE_62 -->\n###### 개선 디지털치료기기로서, 실제 임상에서 사용되고 있다.  Deprexis™는\n\n<!-- PAGE_62 -->\n###### 여러 무작위배정 임상시험을 통해 그 효용성 또한 입증된 바 있으며,\n\n<!-- PAGE_62 -->\n###### 우울과 관련된 변수들을 포함하여 신체적 건강, 심리적 웰빙 및 우울\n\n<!-- PAGE_62 -->\n###### 관련 지표 또한 호전되었다는 것이 밝혀진 바 있다(Twomey et al., 2020.).\n\n <!-- PAGE_62 -->\n###### 12개의 Deprexis RCT(총 피험자=2,901명)에 대한 메타분석은 우울\n\n<!-- PAGE_62 -->\n###### 장애 감소에 대한 Deprexis™의 효과를 확인하였다(g = 0.51, 95% CI:\n\n<!-- PAGE_62 -->\n###### 0.40–0.62, I2 = 26%).  임상 연구의 질, 선별 및 무작위배정 절차를\n\n<!-- PAGE_62 -->\n###### 고려할 때 결과는 유사하였다.  임상 연구의 지도, 개발자 참여, 환경\n\n<!-- PAGE_62 -->\n###### (지역사회 대 임상) 및 초기 증상 심각도는 효과 크기에 통계적으로\n\n<!-- PAGE_62 -->\n###### 유의한 영향을 미치지 않았으며 출판 편향의 증거도 없었다.  따라서\n\n<!-- PAGE_62 -->\n###### 이러한 결과는 Deprexis가 8-12주에 걸쳐 임상적으로 관련된 우울\n\n<!-- PAGE_62 -->\n###### 증상의 개선할 수 있음을 확인하였다, 아래의 <그림 4>는 우울장애\n\n<!-- PAGE_62 -->\n###### 개선 디지털치료기기와 관련하여 수행한 임상시험의 선행 연구의\n\n<!-- PAGE_62 -->\n###### 메타분석 결과이다.\n\n <!-- PAGE_62 -->\n###### 이러한 디지털치료기기는 기존의 우울장애 개선을 위한 웰니스\n\n<!-- PAGE_62 -->\n###### 프로그램과 다음과 같은 차이점을 가진다. ",
        "original_sentence": "임상 연구의 질, 선별 및 무작위배정 절차를\n\n<!-- PAGE_62 -->\n###### 고려할 때 결과는 유사하였다. "
      }
    },
    {
      "chunk_id": "chunk_675",
      "text": "임상 연구의 지도, 개발자 참여, 환경\n\n<!-- PAGE_62 -->\n###### (지역사회 대 임상) 및 초기 증상 심각도는 효과 크기에 통계적으로\n\n<!-- PAGE_62 -->\n###### 유의한 영향을 미치지 않았으며 출판 편향의 증거도 없었다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 674,
        "window_size": 3,
        "char_count": 143,
        "word_count": 32,
        "page_number": 62,
        "window_text": "Deprexis™는\n\n<!-- PAGE_62 -->\n###### 여러 무작위배정 임상시험을 통해 그 효용성 또한 입증된 바 있으며,\n\n<!-- PAGE_62 -->\n###### 우울과 관련된 변수들을 포함하여 신체적 건강, 심리적 웰빙 및 우울\n\n<!-- PAGE_62 -->\n###### 관련 지표 또한 호전되었다는 것이 밝혀진 바 있다(Twomey et al., 2020.).\n\n <!-- PAGE_62 -->\n###### 12개의 Deprexis RCT(총 피험자=2,901명)에 대한 메타분석은 우울\n\n<!-- PAGE_62 -->\n###### 장애 감소에 대한 Deprexis™의 효과를 확인하였다(g = 0.51, 95% CI:\n\n<!-- PAGE_62 -->\n###### 0.40–0.62, I2 = 26%).  임상 연구의 질, 선별 및 무작위배정 절차를\n\n<!-- PAGE_62 -->\n###### 고려할 때 결과는 유사하였다.  임상 연구의 지도, 개발자 참여, 환경\n\n<!-- PAGE_62 -->\n###### (지역사회 대 임상) 및 초기 증상 심각도는 효과 크기에 통계적으로\n\n<!-- PAGE_62 -->\n###### 유의한 영향을 미치지 않았으며 출판 편향의 증거도 없었다.  따라서\n\n<!-- PAGE_62 -->\n###### 이러한 결과는 Deprexis가 8-12주에 걸쳐 임상적으로 관련된 우울\n\n<!-- PAGE_62 -->\n###### 증상의 개선할 수 있음을 확인하였다, 아래의 <그림 4>는 우울장애\n\n<!-- PAGE_62 -->\n###### 개선 디지털치료기기와 관련하여 수행한 임상시험의 선행 연구의\n\n<!-- PAGE_62 -->\n###### 메타분석 결과이다.\n\n <!-- PAGE_62 -->\n###### 이러한 디지털치료기기는 기존의 우울장애 개선을 위한 웰니스\n\n<!-- PAGE_62 -->\n###### 프로그램과 다음과 같은 차이점을 가진다.  첫째, 일방적인 콘텐츠\n\n<!-- PAGE_62 -->\n###### 제공을 넘어 쌍방향적인 피드백을 제공한다. ",
        "original_sentence": "임상 연구의 지도, 개발자 참여, 환경\n\n<!-- PAGE_62 -->\n###### (지역사회 대 임상) 및 초기 증상 심각도는 효과 크기에 통계적으로\n\n<!-- PAGE_62 -->\n###### 유의한 영향을 미치지 않았으며 출판 편향의 증거도 없었다. "
      }
    },
    {
      "chunk_id": "chunk_676",
      "text": "따라서\n\n<!-- PAGE_62 -->\n###### 이러한 결과는 Deprexis가 8-12주에 걸쳐 임상적으로 관련된 우울\n\n<!-- PAGE_62 -->\n###### 증상의 개선할 수 있음을 확인하였다, 아래의 <그림 4>는 우울장애\n\n<!-- PAGE_62 -->\n###### 개선 디지털치료기기와 관련하여 수행한 임상시험의 선행 연구의\n\n<!-- PAGE_62 -->\n###### 메타분석 결과이다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 675,
        "window_size": 3,
        "char_count": 229,
        "word_count": 43,
        "page_number": 62,
        "window_text": "<!-- PAGE_62 -->\n###### 12개의 Deprexis RCT(총 피험자=2,901명)에 대한 메타분석은 우울\n\n<!-- PAGE_62 -->\n###### 장애 감소에 대한 Deprexis™의 효과를 확인하였다(g = 0.51, 95% CI:\n\n<!-- PAGE_62 -->\n###### 0.40–0.62, I2 = 26%).  임상 연구의 질, 선별 및 무작위배정 절차를\n\n<!-- PAGE_62 -->\n###### 고려할 때 결과는 유사하였다.  임상 연구의 지도, 개발자 참여, 환경\n\n<!-- PAGE_62 -->\n###### (지역사회 대 임상) 및 초기 증상 심각도는 효과 크기에 통계적으로\n\n<!-- PAGE_62 -->\n###### 유의한 영향을 미치지 않았으며 출판 편향의 증거도 없었다.  따라서\n\n<!-- PAGE_62 -->\n###### 이러한 결과는 Deprexis가 8-12주에 걸쳐 임상적으로 관련된 우울\n\n<!-- PAGE_62 -->\n###### 증상의 개선할 수 있음을 확인하였다, 아래의 <그림 4>는 우울장애\n\n<!-- PAGE_62 -->\n###### 개선 디지털치료기기와 관련하여 수행한 임상시험의 선행 연구의\n\n<!-- PAGE_62 -->\n###### 메타분석 결과이다.\n\n <!-- PAGE_62 -->\n###### 이러한 디지털치료기기는 기존의 우울장애 개선을 위한 웰니스\n\n<!-- PAGE_62 -->\n###### 프로그램과 다음과 같은 차이점을 가진다.  첫째, 일방적인 콘텐츠\n\n<!-- PAGE_62 -->\n###### 제공을 넘어 쌍방향적인 피드백을 제공한다.  피험자의 우울과 관련된\n\n<!-- PAGE_62 -->\n###### 변수를 지속해서 수집하고, 이에 대해 다음 목표를 제시함으로써 치료\n\n- - 56 -\n<!-- PAGE_63 -->\n###### 효과를 극대화한다. ",
        "original_sentence": "따라서\n\n<!-- PAGE_62 -->\n###### 이러한 결과는 Deprexis가 8-12주에 걸쳐 임상적으로 관련된 우울\n\n<!-- PAGE_62 -->\n###### 증상의 개선할 수 있음을 확인하였다, 아래의 <그림 4>는 우울장애\n\n<!-- PAGE_62 -->\n###### 개선 디지털치료기기와 관련하여 수행한 임상시험의 선행 연구의\n\n<!-- PAGE_62 -->\n###### 메타분석 결과이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_677",
      "text": "<!-- PAGE_62 -->\n###### 이러한 디지털치료기기는 기존의 우울장애 개선을 위한 웰니스\n\n<!-- PAGE_62 -->\n###### 프로그램과 다음과 같은 차이점을 가진다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 676,
        "window_size": 3,
        "char_count": 105,
        "word_count": 20,
        "page_number": 62,
        "window_text": "임상 연구의 질, 선별 및 무작위배정 절차를\n\n<!-- PAGE_62 -->\n###### 고려할 때 결과는 유사하였다.  임상 연구의 지도, 개발자 참여, 환경\n\n<!-- PAGE_62 -->\n###### (지역사회 대 임상) 및 초기 증상 심각도는 효과 크기에 통계적으로\n\n<!-- PAGE_62 -->\n###### 유의한 영향을 미치지 않았으며 출판 편향의 증거도 없었다.  따라서\n\n<!-- PAGE_62 -->\n###### 이러한 결과는 Deprexis가 8-12주에 걸쳐 임상적으로 관련된 우울\n\n<!-- PAGE_62 -->\n###### 증상의 개선할 수 있음을 확인하였다, 아래의 <그림 4>는 우울장애\n\n<!-- PAGE_62 -->\n###### 개선 디지털치료기기와 관련하여 수행한 임상시험의 선행 연구의\n\n<!-- PAGE_62 -->\n###### 메타분석 결과이다.\n\n <!-- PAGE_62 -->\n###### 이러한 디지털치료기기는 기존의 우울장애 개선을 위한 웰니스\n\n<!-- PAGE_62 -->\n###### 프로그램과 다음과 같은 차이점을 가진다.  첫째, 일방적인 콘텐츠\n\n<!-- PAGE_62 -->\n###### 제공을 넘어 쌍방향적인 피드백을 제공한다.  피험자의 우울과 관련된\n\n<!-- PAGE_62 -->\n###### 변수를 지속해서 수집하고, 이에 대해 다음 목표를 제시함으로써 치료\n\n- - 56 -\n<!-- PAGE_63 -->\n###### 효과를 극대화한다.  이 과정에서 피험자는 단순히 콘텐츠를 소비하는\n\n<!-- PAGE_63 -->\n###### 것을 넘어서, 스스로 콘텐츠에 참여하고 있다는 느낌을 받을 수 있다.\n\n",
        "original_sentence": "<!-- PAGE_62 -->\n###### 이러한 디지털치료기기는 기존의 우울장애 개선을 위한 웰니스\n\n<!-- PAGE_62 -->\n###### 프로그램과 다음과 같은 차이점을 가진다. "
      }
    },
    {
      "chunk_id": "chunk_678",
      "text": "첫째, 일방적인 콘텐츠\n\n<!-- PAGE_62 -->\n###### 제공을 넘어 쌍방향적인 피드백을 제공한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 677,
        "window_size": 3,
        "char_count": 62,
        "word_count": 12,
        "page_number": 62,
        "window_text": "임상 연구의 지도, 개발자 참여, 환경\n\n<!-- PAGE_62 -->\n###### (지역사회 대 임상) 및 초기 증상 심각도는 효과 크기에 통계적으로\n\n<!-- PAGE_62 -->\n###### 유의한 영향을 미치지 않았으며 출판 편향의 증거도 없었다.  따라서\n\n<!-- PAGE_62 -->\n###### 이러한 결과는 Deprexis가 8-12주에 걸쳐 임상적으로 관련된 우울\n\n<!-- PAGE_62 -->\n###### 증상의 개선할 수 있음을 확인하였다, 아래의 <그림 4>는 우울장애\n\n<!-- PAGE_62 -->\n###### 개선 디지털치료기기와 관련하여 수행한 임상시험의 선행 연구의\n\n<!-- PAGE_62 -->\n###### 메타분석 결과이다.\n\n <!-- PAGE_62 -->\n###### 이러한 디지털치료기기는 기존의 우울장애 개선을 위한 웰니스\n\n<!-- PAGE_62 -->\n###### 프로그램과 다음과 같은 차이점을 가진다.  첫째, 일방적인 콘텐츠\n\n<!-- PAGE_62 -->\n###### 제공을 넘어 쌍방향적인 피드백을 제공한다.  피험자의 우울과 관련된\n\n<!-- PAGE_62 -->\n###### 변수를 지속해서 수집하고, 이에 대해 다음 목표를 제시함으로써 치료\n\n- - 56 -\n<!-- PAGE_63 -->\n###### 효과를 극대화한다.  이 과정에서 피험자는 단순히 콘텐츠를 소비하는\n\n<!-- PAGE_63 -->\n###### 것을 넘어서, 스스로 콘텐츠에 참여하고 있다는 느낌을 받을 수 있다.\n\n <!-- PAGE_63 -->\n###### 둘째, 피험자 맞춤형 콘텐츠 제공이 가능하다. ",
        "original_sentence": "첫째, 일방적인 콘텐츠\n\n<!-- PAGE_62 -->\n###### 제공을 넘어 쌍방향적인 피드백을 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_679",
      "text": "피험자의 우울과 관련된\n\n<!-- PAGE_62 -->\n###### 변수를 지속해서 수집하고, 이에 대해 다음 목표를 제시함으로써 치료\n\n- - 56 -\n<!-- PAGE_63 -->\n###### 효과를 극대화한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 678,
        "window_size": 3,
        "char_count": 121,
        "word_count": 26,
        "page_number": 62,
        "window_text": "따라서\n\n<!-- PAGE_62 -->\n###### 이러한 결과는 Deprexis가 8-12주에 걸쳐 임상적으로 관련된 우울\n\n<!-- PAGE_62 -->\n###### 증상의 개선할 수 있음을 확인하였다, 아래의 <그림 4>는 우울장애\n\n<!-- PAGE_62 -->\n###### 개선 디지털치료기기와 관련하여 수행한 임상시험의 선행 연구의\n\n<!-- PAGE_62 -->\n###### 메타분석 결과이다.\n\n <!-- PAGE_62 -->\n###### 이러한 디지털치료기기는 기존의 우울장애 개선을 위한 웰니스\n\n<!-- PAGE_62 -->\n###### 프로그램과 다음과 같은 차이점을 가진다.  첫째, 일방적인 콘텐츠\n\n<!-- PAGE_62 -->\n###### 제공을 넘어 쌍방향적인 피드백을 제공한다.  피험자의 우울과 관련된\n\n<!-- PAGE_62 -->\n###### 변수를 지속해서 수집하고, 이에 대해 다음 목표를 제시함으로써 치료\n\n- - 56 -\n<!-- PAGE_63 -->\n###### 효과를 극대화한다.  이 과정에서 피험자는 단순히 콘텐츠를 소비하는\n\n<!-- PAGE_63 -->\n###### 것을 넘어서, 스스로 콘텐츠에 참여하고 있다는 느낌을 받을 수 있다.\n\n <!-- PAGE_63 -->\n###### 둘째, 피험자 맞춤형 콘텐츠 제공이 가능하다.  모든 콘텐츠를 같은\n\n<!-- PAGE_63 -->\n###### 비율로 제공하는 것에 그치지 않고 피험자의 정보를 수집함으로써 취\n\n<!-- PAGE_63 -->\n###### 약한 부분에 대한 집중적인 맞춤형 콘텐츠 제공을 하는 것이 가능하다.\n\n",
        "original_sentence": "피험자의 우울과 관련된\n\n<!-- PAGE_62 -->\n###### 변수를 지속해서 수집하고, 이에 대해 다음 목표를 제시함으로써 치료\n\n- - 56 -\n<!-- PAGE_63 -->\n###### 효과를 극대화한다. "
      }
    },
    {
      "chunk_id": "chunk_680",
      "text": "이 과정에서 피험자는 단순히 콘텐츠를 소비하는\n\n<!-- PAGE_63 -->\n###### 것을 넘어서, 스스로 콘텐츠에 참여하고 있다는 느낌을 받을 수 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 679,
        "window_size": 3,
        "char_count": 91,
        "word_count": 20,
        "page_number": 63,
        "window_text": "<!-- PAGE_62 -->\n###### 이러한 디지털치료기기는 기존의 우울장애 개선을 위한 웰니스\n\n<!-- PAGE_62 -->\n###### 프로그램과 다음과 같은 차이점을 가진다.  첫째, 일방적인 콘텐츠\n\n<!-- PAGE_62 -->\n###### 제공을 넘어 쌍방향적인 피드백을 제공한다.  피험자의 우울과 관련된\n\n<!-- PAGE_62 -->\n###### 변수를 지속해서 수집하고, 이에 대해 다음 목표를 제시함으로써 치료\n\n- - 56 -\n<!-- PAGE_63 -->\n###### 효과를 극대화한다.  이 과정에서 피험자는 단순히 콘텐츠를 소비하는\n\n<!-- PAGE_63 -->\n###### 것을 넘어서, 스스로 콘텐츠에 참여하고 있다는 느낌을 받을 수 있다.\n\n <!-- PAGE_63 -->\n###### 둘째, 피험자 맞춤형 콘텐츠 제공이 가능하다.  모든 콘텐츠를 같은\n\n<!-- PAGE_63 -->\n###### 비율로 제공하는 것에 그치지 않고 피험자의 정보를 수집함으로써 취\n\n<!-- PAGE_63 -->\n###### 약한 부분에 대한 집중적인 맞춤형 콘텐츠 제공을 하는 것이 가능하다.\n\n <!-- PAGE_63 -->\n###### 셋째, 일정 시간 동안의 꾸준한 사용을 독려하며 치료 효과에 대한\n\n<!-- PAGE_63 -->\n###### 모니터링이 가능하다. ",
        "original_sentence": "이 과정에서 피험자는 단순히 콘텐츠를 소비하는\n\n<!-- PAGE_63 -->\n###### 것을 넘어서, 스스로 콘텐츠에 참여하고 있다는 느낌을 받을 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_681",
      "text": "<!-- PAGE_63 -->\n###### 둘째, 피험자 맞춤형 콘텐츠 제공이 가능하다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 680,
        "window_size": 3,
        "char_count": 50,
        "word_count": 10,
        "page_number": 63,
        "window_text": "첫째, 일방적인 콘텐츠\n\n<!-- PAGE_62 -->\n###### 제공을 넘어 쌍방향적인 피드백을 제공한다.  피험자의 우울과 관련된\n\n<!-- PAGE_62 -->\n###### 변수를 지속해서 수집하고, 이에 대해 다음 목표를 제시함으로써 치료\n\n- - 56 -\n<!-- PAGE_63 -->\n###### 효과를 극대화한다.  이 과정에서 피험자는 단순히 콘텐츠를 소비하는\n\n<!-- PAGE_63 -->\n###### 것을 넘어서, 스스로 콘텐츠에 참여하고 있다는 느낌을 받을 수 있다.\n\n <!-- PAGE_63 -->\n###### 둘째, 피험자 맞춤형 콘텐츠 제공이 가능하다.  모든 콘텐츠를 같은\n\n<!-- PAGE_63 -->\n###### 비율로 제공하는 것에 그치지 않고 피험자의 정보를 수집함으로써 취\n\n<!-- PAGE_63 -->\n###### 약한 부분에 대한 집중적인 맞춤형 콘텐츠 제공을 하는 것이 가능하다.\n\n <!-- PAGE_63 -->\n###### 셋째, 일정 시간 동안의 꾸준한 사용을 독려하며 치료 효과에 대한\n\n<!-- PAGE_63 -->\n###### 모니터링이 가능하다.  일반적으로 디지털치료기기는 모든 콘텐츠를\n\n<!-- PAGE_63 -->\n###### 한 번에 제공하지 않고 일정 기간 순차적인 콘텐츠 제공을 함으로써\n\n<!-- PAGE_63 -->\n###### 사용기간을 조정한다. ",
        "original_sentence": "<!-- PAGE_63 -->\n###### 둘째, 피험자 맞춤형 콘텐츠 제공이 가능하다. "
      }
    },
    {
      "chunk_id": "chunk_682",
      "text": "모든 콘텐츠를 같은\n\n<!-- PAGE_63 -->\n###### 비율로 제공하는 것에 그치지 않고 피험자의 정보를 수집함으로써 취\n\n<!-- PAGE_63 -->\n###### 약한 부분에 대한 집중적인 맞춤형 콘텐츠 제공을 하는 것이 가능하다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 681,
        "window_size": 3,
        "char_count": 138,
        "word_count": 30,
        "page_number": 63,
        "window_text": "피험자의 우울과 관련된\n\n<!-- PAGE_62 -->\n###### 변수를 지속해서 수집하고, 이에 대해 다음 목표를 제시함으로써 치료\n\n- - 56 -\n<!-- PAGE_63 -->\n###### 효과를 극대화한다.  이 과정에서 피험자는 단순히 콘텐츠를 소비하는\n\n<!-- PAGE_63 -->\n###### 것을 넘어서, 스스로 콘텐츠에 참여하고 있다는 느낌을 받을 수 있다.\n\n <!-- PAGE_63 -->\n###### 둘째, 피험자 맞춤형 콘텐츠 제공이 가능하다.  모든 콘텐츠를 같은\n\n<!-- PAGE_63 -->\n###### 비율로 제공하는 것에 그치지 않고 피험자의 정보를 수집함으로써 취\n\n<!-- PAGE_63 -->\n###### 약한 부분에 대한 집중적인 맞춤형 콘텐츠 제공을 하는 것이 가능하다.\n\n <!-- PAGE_63 -->\n###### 셋째, 일정 시간 동안의 꾸준한 사용을 독려하며 치료 효과에 대한\n\n<!-- PAGE_63 -->\n###### 모니터링이 가능하다.  일반적으로 디지털치료기기는 모든 콘텐츠를\n\n<!-- PAGE_63 -->\n###### 한 번에 제공하지 않고 일정 기간 순차적인 콘텐츠 제공을 함으로써\n\n<!-- PAGE_63 -->\n###### 사용기간을 조정한다.  이에 따라 피험자들은 치료 기간 중 자신의 우울\n\n<!-- PAGE_63 -->\n###### 장애 증상이 어떻게 변화하는지 실제 체감하고, 또한 디지털치료기기를\n\n<!-- PAGE_63 -->\n###### 통한 모니터링을 받을 수 있어 치료 동기 부여에 긍정적으로 작용할\n\n<!-- PAGE_63 -->\n###### 수 있다.\n\n",
        "original_sentence": "모든 콘텐츠를 같은\n\n<!-- PAGE_63 -->\n###### 비율로 제공하는 것에 그치지 않고 피험자의 정보를 수집함으로써 취\n\n<!-- PAGE_63 -->\n###### 약한 부분에 대한 집중적인 맞춤형 콘텐츠 제공을 하는 것이 가능하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_683",
      "text": "<!-- PAGE_63 -->\n###### 셋째, 일정 시간 동안의 꾸준한 사용을 독려하며 치료 효과에 대한\n\n<!-- PAGE_63 -->\n###### 모니터링이 가능하다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 682,
        "window_size": 3,
        "char_count": 98,
        "word_count": 20,
        "page_number": 63,
        "window_text": "이 과정에서 피험자는 단순히 콘텐츠를 소비하는\n\n<!-- PAGE_63 -->\n###### 것을 넘어서, 스스로 콘텐츠에 참여하고 있다는 느낌을 받을 수 있다.\n\n <!-- PAGE_63 -->\n###### 둘째, 피험자 맞춤형 콘텐츠 제공이 가능하다.  모든 콘텐츠를 같은\n\n<!-- PAGE_63 -->\n###### 비율로 제공하는 것에 그치지 않고 피험자의 정보를 수집함으로써 취\n\n<!-- PAGE_63 -->\n###### 약한 부분에 대한 집중적인 맞춤형 콘텐츠 제공을 하는 것이 가능하다.\n\n <!-- PAGE_63 -->\n###### 셋째, 일정 시간 동안의 꾸준한 사용을 독려하며 치료 효과에 대한\n\n<!-- PAGE_63 -->\n###### 모니터링이 가능하다.  일반적으로 디지털치료기기는 모든 콘텐츠를\n\n<!-- PAGE_63 -->\n###### 한 번에 제공하지 않고 일정 기간 순차적인 콘텐츠 제공을 함으로써\n\n<!-- PAGE_63 -->\n###### 사용기간을 조정한다.  이에 따라 피험자들은 치료 기간 중 자신의 우울\n\n<!-- PAGE_63 -->\n###### 장애 증상이 어떻게 변화하는지 실제 체감하고, 또한 디지털치료기기를\n\n<!-- PAGE_63 -->\n###### 통한 모니터링을 받을 수 있어 치료 동기 부여에 긍정적으로 작용할\n\n<!-- PAGE_63 -->\n###### 수 있다.\n\n - - 57 -\n<!-- PAGE_64 -->\n###### 본 연구에서는 국내에서 개발된 디지털 우울장애 인지행동치료\n\n<!-- PAGE_64 -->\n###### 애플리케이션을 무작위배정 임상시험을 통해 효과성과 안전성 검증을\n\n<!-- PAGE_64 -->\n###### 함으로써 해당 애플리케이션을 실제 국내 임상에서 활용할 수 있는지\n\n<!-- PAGE_64 -->\n###### 확인을 할 수 있겠으며 국내 우울장애 환자들에게 새로운 치료의\n\n<!-- PAGE_64 -->\n###### 선택지를 열어주고자 한다.\n\n",
        "original_sentence": "<!-- PAGE_63 -->\n###### 셋째, 일정 시간 동안의 꾸준한 사용을 독려하며 치료 효과에 대한\n\n<!-- PAGE_63 -->\n###### 모니터링이 가능하다. "
      }
    },
    {
      "chunk_id": "chunk_684",
      "text": "일반적으로 디지털치료기기는 모든 콘텐츠를\n\n<!-- PAGE_63 -->\n###### 한 번에 제공하지 않고 일정 기간 순차적인 콘텐츠 제공을 함으로써\n\n<!-- PAGE_63 -->\n###### 사용기간을 조정한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 683,
        "window_size": 3,
        "char_count": 122,
        "word_count": 24,
        "page_number": 63,
        "window_text": "<!-- PAGE_63 -->\n###### 둘째, 피험자 맞춤형 콘텐츠 제공이 가능하다.  모든 콘텐츠를 같은\n\n<!-- PAGE_63 -->\n###### 비율로 제공하는 것에 그치지 않고 피험자의 정보를 수집함으로써 취\n\n<!-- PAGE_63 -->\n###### 약한 부분에 대한 집중적인 맞춤형 콘텐츠 제공을 하는 것이 가능하다.\n\n <!-- PAGE_63 -->\n###### 셋째, 일정 시간 동안의 꾸준한 사용을 독려하며 치료 효과에 대한\n\n<!-- PAGE_63 -->\n###### 모니터링이 가능하다.  일반적으로 디지털치료기기는 모든 콘텐츠를\n\n<!-- PAGE_63 -->\n###### 한 번에 제공하지 않고 일정 기간 순차적인 콘텐츠 제공을 함으로써\n\n<!-- PAGE_63 -->\n###### 사용기간을 조정한다.  이에 따라 피험자들은 치료 기간 중 자신의 우울\n\n<!-- PAGE_63 -->\n###### 장애 증상이 어떻게 변화하는지 실제 체감하고, 또한 디지털치료기기를\n\n<!-- PAGE_63 -->\n###### 통한 모니터링을 받을 수 있어 치료 동기 부여에 긍정적으로 작용할\n\n<!-- PAGE_63 -->\n###### 수 있다.\n\n - - 57 -\n<!-- PAGE_64 -->\n###### 본 연구에서는 국내에서 개발된 디지털 우울장애 인지행동치료\n\n<!-- PAGE_64 -->\n###### 애플리케이션을 무작위배정 임상시험을 통해 효과성과 안전성 검증을\n\n<!-- PAGE_64 -->\n###### 함으로써 해당 애플리케이션을 실제 국내 임상에서 활용할 수 있는지\n\n<!-- PAGE_64 -->\n###### 확인을 할 수 있겠으며 국내 우울장애 환자들에게 새로운 치료의\n\n<!-- PAGE_64 -->\n###### 선택지를 열어주고자 한다.\n\n - - 58 -\n<!-- PAGE_65 -->\n###### 7. ",
        "original_sentence": "일반적으로 디지털치료기기는 모든 콘텐츠를\n\n<!-- PAGE_63 -->\n###### 한 번에 제공하지 않고 일정 기간 순차적인 콘텐츠 제공을 함으로써\n\n<!-- PAGE_63 -->\n###### 사용기간을 조정한다. "
      }
    },
    {
      "chunk_id": "chunk_685",
      "text": "이에 따라 피험자들은 치료 기간 중 자신의 우울\n\n<!-- PAGE_63 -->\n###### 장애 증상이 어떻게 변화하는지 실제 체감하고, 또한 디지털치료기기를\n\n<!-- PAGE_63 -->\n###### 통한 모니터링을 받을 수 있어 치료 동기 부여에 긍정적으로 작용할\n\n<!-- PAGE_63 -->\n###### 수 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 684,
        "window_size": 3,
        "char_count": 184,
        "word_count": 40,
        "page_number": 63,
        "window_text": "모든 콘텐츠를 같은\n\n<!-- PAGE_63 -->\n###### 비율로 제공하는 것에 그치지 않고 피험자의 정보를 수집함으로써 취\n\n<!-- PAGE_63 -->\n###### 약한 부분에 대한 집중적인 맞춤형 콘텐츠 제공을 하는 것이 가능하다.\n\n <!-- PAGE_63 -->\n###### 셋째, 일정 시간 동안의 꾸준한 사용을 독려하며 치료 효과에 대한\n\n<!-- PAGE_63 -->\n###### 모니터링이 가능하다.  일반적으로 디지털치료기기는 모든 콘텐츠를\n\n<!-- PAGE_63 -->\n###### 한 번에 제공하지 않고 일정 기간 순차적인 콘텐츠 제공을 함으로써\n\n<!-- PAGE_63 -->\n###### 사용기간을 조정한다.  이에 따라 피험자들은 치료 기간 중 자신의 우울\n\n<!-- PAGE_63 -->\n###### 장애 증상이 어떻게 변화하는지 실제 체감하고, 또한 디지털치료기기를\n\n<!-- PAGE_63 -->\n###### 통한 모니터링을 받을 수 있어 치료 동기 부여에 긍정적으로 작용할\n\n<!-- PAGE_63 -->\n###### 수 있다.\n\n - - 57 -\n<!-- PAGE_64 -->\n###### 본 연구에서는 국내에서 개발된 디지털 우울장애 인지행동치료\n\n<!-- PAGE_64 -->\n###### 애플리케이션을 무작위배정 임상시험을 통해 효과성과 안전성 검증을\n\n<!-- PAGE_64 -->\n###### 함으로써 해당 애플리케이션을 실제 국내 임상에서 활용할 수 있는지\n\n<!-- PAGE_64 -->\n###### 확인을 할 수 있겠으며 국내 우울장애 환자들에게 새로운 치료의\n\n<!-- PAGE_64 -->\n###### 선택지를 열어주고자 한다.\n\n - - 58 -\n<!-- PAGE_65 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증 포함)\n\n<!-- PAGE_65 -->\n###### 가. ",
        "original_sentence": "이에 따라 피험자들은 치료 기간 중 자신의 우울\n\n<!-- PAGE_63 -->\n###### 장애 증상이 어떻게 변화하는지 실제 체감하고, 또한 디지털치료기기를\n\n<!-- PAGE_63 -->\n###### 통한 모니터링을 받을 수 있어 치료 동기 부여에 긍정적으로 작용할\n\n<!-- PAGE_63 -->\n###### 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_686",
      "text": "- - 57 -\n<!-- PAGE_64 -->\n###### 본 연구에서는 국내에서 개발된 디지털 우울장애 인지행동치료\n\n<!-- PAGE_64 -->\n###### 애플리케이션을 무작위배정 임상시험을 통해 효과성과 안전성 검증을\n\n<!-- PAGE_64 -->\n###### 함으로써 해당 애플리케이션을 실제 국내 임상에서 활용할 수 있는지\n\n<!-- PAGE_64 -->\n###### 확인을 할 수 있겠으며 국내 우울장애 환자들에게 새로운 치료의\n\n<!-- PAGE_64 -->\n###### 선택지를 열어주고자 한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 685,
        "window_size": 3,
        "char_count": 290,
        "word_count": 59,
        "page_number": 64,
        "window_text": "<!-- PAGE_63 -->\n###### 셋째, 일정 시간 동안의 꾸준한 사용을 독려하며 치료 효과에 대한\n\n<!-- PAGE_63 -->\n###### 모니터링이 가능하다.  일반적으로 디지털치료기기는 모든 콘텐츠를\n\n<!-- PAGE_63 -->\n###### 한 번에 제공하지 않고 일정 기간 순차적인 콘텐츠 제공을 함으로써\n\n<!-- PAGE_63 -->\n###### 사용기간을 조정한다.  이에 따라 피험자들은 치료 기간 중 자신의 우울\n\n<!-- PAGE_63 -->\n###### 장애 증상이 어떻게 변화하는지 실제 체감하고, 또한 디지털치료기기를\n\n<!-- PAGE_63 -->\n###### 통한 모니터링을 받을 수 있어 치료 동기 부여에 긍정적으로 작용할\n\n<!-- PAGE_63 -->\n###### 수 있다.\n\n - - 57 -\n<!-- PAGE_64 -->\n###### 본 연구에서는 국내에서 개발된 디지털 우울장애 인지행동치료\n\n<!-- PAGE_64 -->\n###### 애플리케이션을 무작위배정 임상시험을 통해 효과성과 안전성 검증을\n\n<!-- PAGE_64 -->\n###### 함으로써 해당 애플리케이션을 실제 국내 임상에서 활용할 수 있는지\n\n<!-- PAGE_64 -->\n###### 확인을 할 수 있겠으며 국내 우울장애 환자들에게 새로운 치료의\n\n<!-- PAGE_64 -->\n###### 선택지를 열어주고자 한다.\n\n - - 58 -\n<!-- PAGE_65 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증 포함)\n\n<!-- PAGE_65 -->\n###### 가.  임상시험용 의료기기 사용 목적\n\n<!-- PAGE_65 -->\n###### [사용목적]\n\n<!-- PAGE_65 -->\n###### 모바일 애플리케이션 형태의 우울장애 인지행동치료 기반 콘텐츠를\n\n<!-- PAGE_65 -->\n###### 범용 장비(스마트폰 또는 태블릿 PC)를 통해 제공하는 소프트웨어 의료\n\n<!-- PAGE_65 -->\n###### 기기이다. ",
        "original_sentence": "- - 57 -\n<!-- PAGE_64 -->\n###### 본 연구에서는 국내에서 개발된 디지털 우울장애 인지행동치료\n\n<!-- PAGE_64 -->\n###### 애플리케이션을 무작위배정 임상시험을 통해 효과성과 안전성 검증을\n\n<!-- PAGE_64 -->\n###### 함으로써 해당 애플리케이션을 실제 국내 임상에서 활용할 수 있는지\n\n<!-- PAGE_64 -->\n###### 확인을 할 수 있겠으며 국내 우울장애 환자들에게 새로운 치료의\n\n<!-- PAGE_64 -->\n###### 선택지를 열어주고자 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_687",
      "text": "- - 58 -\n<!-- PAGE_65 -->\n###### 7. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 686,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 65,
        "window_text": "일반적으로 디지털치료기기는 모든 콘텐츠를\n\n<!-- PAGE_63 -->\n###### 한 번에 제공하지 않고 일정 기간 순차적인 콘텐츠 제공을 함으로써\n\n<!-- PAGE_63 -->\n###### 사용기간을 조정한다.  이에 따라 피험자들은 치료 기간 중 자신의 우울\n\n<!-- PAGE_63 -->\n###### 장애 증상이 어떻게 변화하는지 실제 체감하고, 또한 디지털치료기기를\n\n<!-- PAGE_63 -->\n###### 통한 모니터링을 받을 수 있어 치료 동기 부여에 긍정적으로 작용할\n\n<!-- PAGE_63 -->\n###### 수 있다.\n\n - - 57 -\n<!-- PAGE_64 -->\n###### 본 연구에서는 국내에서 개발된 디지털 우울장애 인지행동치료\n\n<!-- PAGE_64 -->\n###### 애플리케이션을 무작위배정 임상시험을 통해 효과성과 안전성 검증을\n\n<!-- PAGE_64 -->\n###### 함으로써 해당 애플리케이션을 실제 국내 임상에서 활용할 수 있는지\n\n<!-- PAGE_64 -->\n###### 확인을 할 수 있겠으며 국내 우울장애 환자들에게 새로운 치료의\n\n<!-- PAGE_64 -->\n###### 선택지를 열어주고자 한다.\n\n - - 58 -\n<!-- PAGE_65 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증 포함)\n\n<!-- PAGE_65 -->\n###### 가.  임상시험용 의료기기 사용 목적\n\n<!-- PAGE_65 -->\n###### [사용목적]\n\n<!-- PAGE_65 -->\n###### 모바일 애플리케이션 형태의 우울장애 인지행동치료 기반 콘텐츠를\n\n<!-- PAGE_65 -->\n###### 범용 장비(스마트폰 또는 태블릿 PC)를 통해 제공하는 소프트웨어 의료\n\n<!-- PAGE_65 -->\n###### 기기이다.  임상시험용 기기는 우울장애 인지행동치료(CBT-D)를 제공하여\n\n<!-- PAGE_65 -->\n###### 대조군(우울장애 일기 작성 권고 및 간단한 우울장애 교육 제공) 대비\n\n<!-- PAGE_65 -->\n###### 우울장애 증상을 개선하는 것을 목표로 한다.\n\n",
        "original_sentence": "- - 58 -\n<!-- PAGE_65 -->\n###### 7. "
      }
    },
    {
      "chunk_id": "chunk_688",
      "text": "임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증 포함)\n\n<!-- PAGE_65 -->\n###### 가. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 687,
        "window_size": 3,
        "char_count": 65,
        "word_count": 12,
        "page_number": 65,
        "window_text": "이에 따라 피험자들은 치료 기간 중 자신의 우울\n\n<!-- PAGE_63 -->\n###### 장애 증상이 어떻게 변화하는지 실제 체감하고, 또한 디지털치료기기를\n\n<!-- PAGE_63 -->\n###### 통한 모니터링을 받을 수 있어 치료 동기 부여에 긍정적으로 작용할\n\n<!-- PAGE_63 -->\n###### 수 있다.\n\n - - 57 -\n<!-- PAGE_64 -->\n###### 본 연구에서는 국내에서 개발된 디지털 우울장애 인지행동치료\n\n<!-- PAGE_64 -->\n###### 애플리케이션을 무작위배정 임상시험을 통해 효과성과 안전성 검증을\n\n<!-- PAGE_64 -->\n###### 함으로써 해당 애플리케이션을 실제 국내 임상에서 활용할 수 있는지\n\n<!-- PAGE_64 -->\n###### 확인을 할 수 있겠으며 국내 우울장애 환자들에게 새로운 치료의\n\n<!-- PAGE_64 -->\n###### 선택지를 열어주고자 한다.\n\n - - 58 -\n<!-- PAGE_65 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증 포함)\n\n<!-- PAGE_65 -->\n###### 가.  임상시험용 의료기기 사용 목적\n\n<!-- PAGE_65 -->\n###### [사용목적]\n\n<!-- PAGE_65 -->\n###### 모바일 애플리케이션 형태의 우울장애 인지행동치료 기반 콘텐츠를\n\n<!-- PAGE_65 -->\n###### 범용 장비(스마트폰 또는 태블릿 PC)를 통해 제공하는 소프트웨어 의료\n\n<!-- PAGE_65 -->\n###### 기기이다.  임상시험용 기기는 우울장애 인지행동치료(CBT-D)를 제공하여\n\n<!-- PAGE_65 -->\n###### 대조군(우울장애 일기 작성 권고 및 간단한 우울장애 교육 제공) 대비\n\n<!-- PAGE_65 -->\n###### 우울장애 증상을 개선하는 것을 목표로 한다.\n\n <!-- PAGE_65 -->\n###### 본 의료기기는 의사에게 우울장애* 진단을 받은 환자들을 대상으로 하며,\n\n<!-- PAGE_65 -->\n###### 추후 추가적인 적응증 확대는 가능하나 우울장애에 대한 의사 진단을\n\n<!-- PAGE_65 -->\n###### 기반으로 한다.\n\n",
        "original_sentence": "임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증 포함)\n\n<!-- PAGE_65 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_689",
      "text": "임상시험용 의료기기 사용 목적\n\n<!-- PAGE_65 -->\n###### [사용목적]\n\n<!-- PAGE_65 -->\n###### 모바일 애플리케이션 형태의 우울장애 인지행동치료 기반 콘텐츠를\n\n<!-- PAGE_65 -->\n###### 범용 장비(스마트폰 또는 태블릿 PC)를 통해 제공하는 소프트웨어 의료\n\n<!-- PAGE_65 -->\n###### 기기이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 688,
        "window_size": 3,
        "char_count": 205,
        "word_count": 38,
        "page_number": 65,
        "window_text": "- - 57 -\n<!-- PAGE_64 -->\n###### 본 연구에서는 국내에서 개발된 디지털 우울장애 인지행동치료\n\n<!-- PAGE_64 -->\n###### 애플리케이션을 무작위배정 임상시험을 통해 효과성과 안전성 검증을\n\n<!-- PAGE_64 -->\n###### 함으로써 해당 애플리케이션을 실제 국내 임상에서 활용할 수 있는지\n\n<!-- PAGE_64 -->\n###### 확인을 할 수 있겠으며 국내 우울장애 환자들에게 새로운 치료의\n\n<!-- PAGE_64 -->\n###### 선택지를 열어주고자 한다.\n\n - - 58 -\n<!-- PAGE_65 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증 포함)\n\n<!-- PAGE_65 -->\n###### 가.  임상시험용 의료기기 사용 목적\n\n<!-- PAGE_65 -->\n###### [사용목적]\n\n<!-- PAGE_65 -->\n###### 모바일 애플리케이션 형태의 우울장애 인지행동치료 기반 콘텐츠를\n\n<!-- PAGE_65 -->\n###### 범용 장비(스마트폰 또는 태블릿 PC)를 통해 제공하는 소프트웨어 의료\n\n<!-- PAGE_65 -->\n###### 기기이다.  임상시험용 기기는 우울장애 인지행동치료(CBT-D)를 제공하여\n\n<!-- PAGE_65 -->\n###### 대조군(우울장애 일기 작성 권고 및 간단한 우울장애 교육 제공) 대비\n\n<!-- PAGE_65 -->\n###### 우울장애 증상을 개선하는 것을 목표로 한다.\n\n <!-- PAGE_65 -->\n###### 본 의료기기는 의사에게 우울장애* 진단을 받은 환자들을 대상으로 하며,\n\n<!-- PAGE_65 -->\n###### 추후 추가적인 적응증 확대는 가능하나 우울장애에 대한 의사 진단을\n\n<!-- PAGE_65 -->\n###### 기반으로 한다.\n\n - - 59 -\n<!-- PAGE_66 -->\n###### 나. ",
        "original_sentence": "임상시험용 의료기기 사용 목적\n\n<!-- PAGE_65 -->\n###### [사용목적]\n\n<!-- PAGE_65 -->\n###### 모바일 애플리케이션 형태의 우울장애 인지행동치료 기반 콘텐츠를\n\n<!-- PAGE_65 -->\n###### 범용 장비(스마트폰 또는 태블릿 PC)를 통해 제공하는 소프트웨어 의료\n\n<!-- PAGE_65 -->\n###### 기기이다. "
      }
    },
    {
      "chunk_id": "chunk_690",
      "text": "임상시험용 기기는 우울장애 인지행동치료(CBT-D)를 제공하여\n\n<!-- PAGE_65 -->\n###### 대조군(우울장애 일기 작성 권고 및 간단한 우울장애 교육 제공) 대비\n\n<!-- PAGE_65 -->\n###### 우울장애 증상을 개선하는 것을 목표로 한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 689,
        "window_size": 3,
        "char_count": 150,
        "word_count": 29,
        "page_number": 65,
        "window_text": "- - 58 -\n<!-- PAGE_65 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증 포함)\n\n<!-- PAGE_65 -->\n###### 가.  임상시험용 의료기기 사용 목적\n\n<!-- PAGE_65 -->\n###### [사용목적]\n\n<!-- PAGE_65 -->\n###### 모바일 애플리케이션 형태의 우울장애 인지행동치료 기반 콘텐츠를\n\n<!-- PAGE_65 -->\n###### 범용 장비(스마트폰 또는 태블릿 PC)를 통해 제공하는 소프트웨어 의료\n\n<!-- PAGE_65 -->\n###### 기기이다.  임상시험용 기기는 우울장애 인지행동치료(CBT-D)를 제공하여\n\n<!-- PAGE_65 -->\n###### 대조군(우울장애 일기 작성 권고 및 간단한 우울장애 교육 제공) 대비\n\n<!-- PAGE_65 -->\n###### 우울장애 증상을 개선하는 것을 목표로 한다.\n\n <!-- PAGE_65 -->\n###### 본 의료기기는 의사에게 우울장애* 진단을 받은 환자들을 대상으로 하며,\n\n<!-- PAGE_65 -->\n###### 추후 추가적인 적응증 확대는 가능하나 우울장애에 대한 의사 진단을\n\n<!-- PAGE_65 -->\n###### 기반으로 한다.\n\n - - 59 -\n<!-- PAGE_66 -->\n###### 나.  임상시험용 의료기기 정보\n\n해당 임상시험용 의료기기 및 대조시험용 의료기기의 품목명, 제조회사, 원재료, 모양,\n\n<!-- PAGE_66 -->\n###### - 품목명(품목분류번호, 등급): 정서장애치료소프트웨어(E06070.01, 2등급)\n\n<!-- PAGE_66 -->\n###### ※ 대조 시험용 의료기기의 구체적인 정보를 ‘가)’를 참고하여 작성한다. ",
        "original_sentence": "임상시험용 기기는 우울장애 인지행동치료(CBT-D)를 제공하여\n\n<!-- PAGE_65 -->\n###### 대조군(우울장애 일기 작성 권고 및 간단한 우울장애 교육 제공) 대비\n\n<!-- PAGE_65 -->\n###### 우울장애 증상을 개선하는 것을 목표로 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_691",
      "text": "<!-- PAGE_65 -->\n###### 본 의료기기는 의사에게 우울장애* 진단을 받은 환자들을 대상으로 하며,\n\n<!-- PAGE_65 -->\n###### 추후 추가적인 적응증 확대는 가능하나 우울장애에 대한 의사 진단을\n\n<!-- PAGE_65 -->\n###### 기반으로 한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 690,
        "window_size": 3,
        "char_count": 161,
        "word_count": 32,
        "page_number": 65,
        "window_text": "임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증 포함)\n\n<!-- PAGE_65 -->\n###### 가.  임상시험용 의료기기 사용 목적\n\n<!-- PAGE_65 -->\n###### [사용목적]\n\n<!-- PAGE_65 -->\n###### 모바일 애플리케이션 형태의 우울장애 인지행동치료 기반 콘텐츠를\n\n<!-- PAGE_65 -->\n###### 범용 장비(스마트폰 또는 태블릿 PC)를 통해 제공하는 소프트웨어 의료\n\n<!-- PAGE_65 -->\n###### 기기이다.  임상시험용 기기는 우울장애 인지행동치료(CBT-D)를 제공하여\n\n<!-- PAGE_65 -->\n###### 대조군(우울장애 일기 작성 권고 및 간단한 우울장애 교육 제공) 대비\n\n<!-- PAGE_65 -->\n###### 우울장애 증상을 개선하는 것을 목표로 한다.\n\n <!-- PAGE_65 -->\n###### 본 의료기기는 의사에게 우울장애* 진단을 받은 환자들을 대상으로 하며,\n\n<!-- PAGE_65 -->\n###### 추후 추가적인 적응증 확대는 가능하나 우울장애에 대한 의사 진단을\n\n<!-- PAGE_65 -->\n###### 기반으로 한다.\n\n - - 59 -\n<!-- PAGE_66 -->\n###### 나.  임상시험용 의료기기 정보\n\n해당 임상시험용 의료기기 및 대조시험용 의료기기의 품목명, 제조회사, 원재료, 모양,\n\n<!-- PAGE_66 -->\n###### - 품목명(품목분류번호, 등급): 정서장애치료소프트웨어(E06070.01, 2등급)\n\n<!-- PAGE_66 -->\n###### ※ 대조 시험용 의료기기의 구체적인 정보를 ‘가)’를 참고하여 작성한다.  대조\n\n<!-- PAGE_66 -->\n###### 시험용 의료기기가 설정되지 않았을 경우 생략할 수 있으며, 설정하지\n\n<!-- PAGE_66 -->\n###### 다. ",
        "original_sentence": "<!-- PAGE_65 -->\n###### 본 의료기기는 의사에게 우울장애* 진단을 받은 환자들을 대상으로 하며,\n\n<!-- PAGE_65 -->\n###### 추후 추가적인 적응증 확대는 가능하나 우울장애에 대한 의사 진단을\n\n<!-- PAGE_65 -->\n###### 기반으로 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_692",
      "text": "- - 59 -\n<!-- PAGE_66 -->\n###### 나. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 691,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 66,
        "window_text": "임상시험용 의료기기 사용 목적\n\n<!-- PAGE_65 -->\n###### [사용목적]\n\n<!-- PAGE_65 -->\n###### 모바일 애플리케이션 형태의 우울장애 인지행동치료 기반 콘텐츠를\n\n<!-- PAGE_65 -->\n###### 범용 장비(스마트폰 또는 태블릿 PC)를 통해 제공하는 소프트웨어 의료\n\n<!-- PAGE_65 -->\n###### 기기이다.  임상시험용 기기는 우울장애 인지행동치료(CBT-D)를 제공하여\n\n<!-- PAGE_65 -->\n###### 대조군(우울장애 일기 작성 권고 및 간단한 우울장애 교육 제공) 대비\n\n<!-- PAGE_65 -->\n###### 우울장애 증상을 개선하는 것을 목표로 한다.\n\n <!-- PAGE_65 -->\n###### 본 의료기기는 의사에게 우울장애* 진단을 받은 환자들을 대상으로 하며,\n\n<!-- PAGE_65 -->\n###### 추후 추가적인 적응증 확대는 가능하나 우울장애에 대한 의사 진단을\n\n<!-- PAGE_65 -->\n###### 기반으로 한다.\n\n - - 59 -\n<!-- PAGE_66 -->\n###### 나.  임상시험용 의료기기 정보\n\n해당 임상시험용 의료기기 및 대조시험용 의료기기의 품목명, 제조회사, 원재료, 모양,\n\n<!-- PAGE_66 -->\n###### - 품목명(품목분류번호, 등급): 정서장애치료소프트웨어(E06070.01, 2등급)\n\n<!-- PAGE_66 -->\n###### ※ 대조 시험용 의료기기의 구체적인 정보를 ‘가)’를 참고하여 작성한다.  대조\n\n<!-- PAGE_66 -->\n###### 시험용 의료기기가 설정되지 않았을 경우 생략할 수 있으며, 설정하지\n\n<!-- PAGE_66 -->\n###### 다.  임상시험용 의료기기 사용 방법\n\n<!-- PAGE_66 -->\n###### - 치료에 앞서 범용장비(스마트폰, 태블릿, PC 등)에 OOO 디지털\n\n- - 60 -\n<!-- PAGE_67 -->\n###### 2) 사용 방법\n\n<!-- PAGE_67 -->\n###### 가) OOO 디지털치료기기를 실행한다.\n\n",
        "original_sentence": "- - 59 -\n<!-- PAGE_66 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_693",
      "text": "임상시험용 의료기기 정보\n\n해당 임상시험용 의료기기 및 대조시험용 의료기기의 품목명, 제조회사, 원재료, 모양,\n\n<!-- PAGE_66 -->\n###### - 품목명(품목분류번호, 등급): 정서장애치료소프트웨어(E06070.01, 2등급)\n\n<!-- PAGE_66 -->\n###### ※ 대조 시험용 의료기기의 구체적인 정보를 ‘가)’를 참고하여 작성한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 692,
        "window_size": 3,
        "char_count": 201,
        "word_count": 35,
        "page_number": 66,
        "window_text": "임상시험용 기기는 우울장애 인지행동치료(CBT-D)를 제공하여\n\n<!-- PAGE_65 -->\n###### 대조군(우울장애 일기 작성 권고 및 간단한 우울장애 교육 제공) 대비\n\n<!-- PAGE_65 -->\n###### 우울장애 증상을 개선하는 것을 목표로 한다.\n\n <!-- PAGE_65 -->\n###### 본 의료기기는 의사에게 우울장애* 진단을 받은 환자들을 대상으로 하며,\n\n<!-- PAGE_65 -->\n###### 추후 추가적인 적응증 확대는 가능하나 우울장애에 대한 의사 진단을\n\n<!-- PAGE_65 -->\n###### 기반으로 한다.\n\n - - 59 -\n<!-- PAGE_66 -->\n###### 나.  임상시험용 의료기기 정보\n\n해당 임상시험용 의료기기 및 대조시험용 의료기기의 품목명, 제조회사, 원재료, 모양,\n\n<!-- PAGE_66 -->\n###### - 품목명(품목분류번호, 등급): 정서장애치료소프트웨어(E06070.01, 2등급)\n\n<!-- PAGE_66 -->\n###### ※ 대조 시험용 의료기기의 구체적인 정보를 ‘가)’를 참고하여 작성한다.  대조\n\n<!-- PAGE_66 -->\n###### 시험용 의료기기가 설정되지 않았을 경우 생략할 수 있으며, 설정하지\n\n<!-- PAGE_66 -->\n###### 다.  임상시험용 의료기기 사용 방법\n\n<!-- PAGE_66 -->\n###### - 치료에 앞서 범용장비(스마트폰, 태블릿, PC 등)에 OOO 디지털\n\n- - 60 -\n<!-- PAGE_67 -->\n###### 2) 사용 방법\n\n<!-- PAGE_67 -->\n###### 가) OOO 디지털치료기기를 실행한다.\n\n <!-- PAGE_67 -->\n###### 다) 디지털치료기기를 통한 우울과 관련된 행동의 교정을 수행한다.\n\n",
        "original_sentence": "임상시험용 의료기기 정보\n\n해당 임상시험용 의료기기 및 대조시험용 의료기기의 품목명, 제조회사, 원재료, 모양,\n\n<!-- PAGE_66 -->\n###### - 품목명(품목분류번호, 등급): 정서장애치료소프트웨어(E06070.01, 2등급)\n\n<!-- PAGE_66 -->\n###### ※ 대조 시험용 의료기기의 구체적인 정보를 ‘가)’를 참고하여 작성한다. "
      }
    },
    {
      "chunk_id": "chunk_694",
      "text": "대조\n\n<!-- PAGE_66 -->\n###### 시험용 의료기기가 설정되지 않았을 경우 생략할 수 있으며, 설정하지\n\n<!-- PAGE_66 -->\n###### 다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 693,
        "window_size": 3,
        "char_count": 94,
        "word_count": 19,
        "page_number": 66,
        "window_text": "<!-- PAGE_65 -->\n###### 본 의료기기는 의사에게 우울장애* 진단을 받은 환자들을 대상으로 하며,\n\n<!-- PAGE_65 -->\n###### 추후 추가적인 적응증 확대는 가능하나 우울장애에 대한 의사 진단을\n\n<!-- PAGE_65 -->\n###### 기반으로 한다.\n\n - - 59 -\n<!-- PAGE_66 -->\n###### 나.  임상시험용 의료기기 정보\n\n해당 임상시험용 의료기기 및 대조시험용 의료기기의 품목명, 제조회사, 원재료, 모양,\n\n<!-- PAGE_66 -->\n###### - 품목명(품목분류번호, 등급): 정서장애치료소프트웨어(E06070.01, 2등급)\n\n<!-- PAGE_66 -->\n###### ※ 대조 시험용 의료기기의 구체적인 정보를 ‘가)’를 참고하여 작성한다.  대조\n\n<!-- PAGE_66 -->\n###### 시험용 의료기기가 설정되지 않았을 경우 생략할 수 있으며, 설정하지\n\n<!-- PAGE_66 -->\n###### 다.  임상시험용 의료기기 사용 방법\n\n<!-- PAGE_66 -->\n###### - 치료에 앞서 범용장비(스마트폰, 태블릿, PC 등)에 OOO 디지털\n\n- - 60 -\n<!-- PAGE_67 -->\n###### 2) 사용 방법\n\n<!-- PAGE_67 -->\n###### 가) OOO 디지털치료기기를 실행한다.\n\n <!-- PAGE_67 -->\n###### 다) 디지털치료기기를 통한 우울과 관련된 행동의 교정을 수행한다.\n\n <!-- PAGE_67 -->\n###### 이 내용은 과학적 근거에 기반하여야 하며, 우울장애 인지행동치료\n\n<!-- PAGE_67 -->\n###### (1) 자극 조절법: 우울장애와 각성 자극이 연관된 상태를 해소하기\n\n<!-- PAGE_67 -->\n###### (2) 우울 일기 및 동등한 수준으로 우울에 대한 평가가 가능한 도구:\n\n<!-- PAGE_67 -->\n###### 우울장애에 대한 평가 및 피드백을 할 수 있게 하려면\n\n<!-- PAGE_67 -->\n###### 우울에 대한 평가를 해야 하며, 우울장애 인지행동치료를\n\n<!-- PAGE_67 -->\n###### 기반으로 하였을 경우 일반적으로 우울장애 일기가 사용된다.\n\n",
        "original_sentence": "대조\n\n<!-- PAGE_66 -->\n###### 시험용 의료기기가 설정되지 않았을 경우 생략할 수 있으며, 설정하지\n\n<!-- PAGE_66 -->\n###### 다. "
      }
    },
    {
      "chunk_id": "chunk_695",
      "text": "임상시험용 의료기기 사용 방법\n\n<!-- PAGE_66 -->\n###### - 치료에 앞서 범용장비(스마트폰, 태블릿, PC 등)에 OOO 디지털\n\n- - 60 -\n<!-- PAGE_67 -->\n###### 2) 사용 방법\n\n<!-- PAGE_67 -->\n###### 가) OOO 디지털치료기기를 실행한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 694,
        "window_size": 3,
        "char_count": 173,
        "word_count": 36,
        "page_number": 66,
        "window_text": "- - 59 -\n<!-- PAGE_66 -->\n###### 나.  임상시험용 의료기기 정보\n\n해당 임상시험용 의료기기 및 대조시험용 의료기기의 품목명, 제조회사, 원재료, 모양,\n\n<!-- PAGE_66 -->\n###### - 품목명(품목분류번호, 등급): 정서장애치료소프트웨어(E06070.01, 2등급)\n\n<!-- PAGE_66 -->\n###### ※ 대조 시험용 의료기기의 구체적인 정보를 ‘가)’를 참고하여 작성한다.  대조\n\n<!-- PAGE_66 -->\n###### 시험용 의료기기가 설정되지 않았을 경우 생략할 수 있으며, 설정하지\n\n<!-- PAGE_66 -->\n###### 다.  임상시험용 의료기기 사용 방법\n\n<!-- PAGE_66 -->\n###### - 치료에 앞서 범용장비(스마트폰, 태블릿, PC 등)에 OOO 디지털\n\n- - 60 -\n<!-- PAGE_67 -->\n###### 2) 사용 방법\n\n<!-- PAGE_67 -->\n###### 가) OOO 디지털치료기기를 실행한다.\n\n <!-- PAGE_67 -->\n###### 다) 디지털치료기기를 통한 우울과 관련된 행동의 교정을 수행한다.\n\n <!-- PAGE_67 -->\n###### 이 내용은 과학적 근거에 기반하여야 하며, 우울장애 인지행동치료\n\n<!-- PAGE_67 -->\n###### (1) 자극 조절법: 우울장애와 각성 자극이 연관된 상태를 해소하기\n\n<!-- PAGE_67 -->\n###### (2) 우울 일기 및 동등한 수준으로 우울에 대한 평가가 가능한 도구:\n\n<!-- PAGE_67 -->\n###### 우울장애에 대한 평가 및 피드백을 할 수 있게 하려면\n\n<!-- PAGE_67 -->\n###### 우울에 대한 평가를 해야 하며, 우울장애 인지행동치료를\n\n<!-- PAGE_67 -->\n###### 기반으로 하였을 경우 일반적으로 우울장애 일기가 사용된다.\n\n <!-- PAGE_67 -->\n###### 라) 디지털치료기기를 통한 우울과 관련된 인지의 교정을 수행한다.\n\n",
        "original_sentence": "임상시험용 의료기기 사용 방법\n\n<!-- PAGE_66 -->\n###### - 치료에 앞서 범용장비(스마트폰, 태블릿, PC 등)에 OOO 디지털\n\n- - 60 -\n<!-- PAGE_67 -->\n###### 2) 사용 방법\n\n<!-- PAGE_67 -->\n###### 가) OOO 디지털치료기기를 실행한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_696",
      "text": "<!-- PAGE_67 -->\n###### 다) 디지털치료기기를 통한 우울과 관련된 행동의 교정을 수행한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 695,
        "window_size": 3,
        "char_count": 62,
        "word_count": 12,
        "page_number": 67,
        "window_text": "임상시험용 의료기기 정보\n\n해당 임상시험용 의료기기 및 대조시험용 의료기기의 품목명, 제조회사, 원재료, 모양,\n\n<!-- PAGE_66 -->\n###### - 품목명(품목분류번호, 등급): 정서장애치료소프트웨어(E06070.01, 2등급)\n\n<!-- PAGE_66 -->\n###### ※ 대조 시험용 의료기기의 구체적인 정보를 ‘가)’를 참고하여 작성한다.  대조\n\n<!-- PAGE_66 -->\n###### 시험용 의료기기가 설정되지 않았을 경우 생략할 수 있으며, 설정하지\n\n<!-- PAGE_66 -->\n###### 다.  임상시험용 의료기기 사용 방법\n\n<!-- PAGE_66 -->\n###### - 치료에 앞서 범용장비(스마트폰, 태블릿, PC 등)에 OOO 디지털\n\n- - 60 -\n<!-- PAGE_67 -->\n###### 2) 사용 방법\n\n<!-- PAGE_67 -->\n###### 가) OOO 디지털치료기기를 실행한다.\n\n <!-- PAGE_67 -->\n###### 다) 디지털치료기기를 통한 우울과 관련된 행동의 교정을 수행한다.\n\n <!-- PAGE_67 -->\n###### 이 내용은 과학적 근거에 기반하여야 하며, 우울장애 인지행동치료\n\n<!-- PAGE_67 -->\n###### (1) 자극 조절법: 우울장애와 각성 자극이 연관된 상태를 해소하기\n\n<!-- PAGE_67 -->\n###### (2) 우울 일기 및 동등한 수준으로 우울에 대한 평가가 가능한 도구:\n\n<!-- PAGE_67 -->\n###### 우울장애에 대한 평가 및 피드백을 할 수 있게 하려면\n\n<!-- PAGE_67 -->\n###### 우울에 대한 평가를 해야 하며, 우울장애 인지행동치료를\n\n<!-- PAGE_67 -->\n###### 기반으로 하였을 경우 일반적으로 우울장애 일기가 사용된다.\n\n <!-- PAGE_67 -->\n###### 라) 디지털치료기기를 통한 우울과 관련된 인지의 교정을 수행한다.\n\n <!-- PAGE_67 -->\n###### 이 내용은 과학적 근거에 기반하여야 하며, 우울장애 인지행동\n\n<!-- PAGE_67 -->\n###### 치료를 기반으로 하였을 경우 우울과 관련된 왜곡된 인지의\n\n<!-- PAGE_67 -->\n###### 마) 상술한 치료의 경우 환자의 순응도를 높이기 위한 전략이 포함\n\n<!-- PAGE_67 -->\n###### 되어야 하며(콘텐츠 제공 방식의 다양화, 알림 제공, 보상 방안\n\n<!-- PAGE_67 -->\n###### 등을 포함) 환자가 입력한 정보에 따른 피드백이 제공되어야\n\n<!-- PAGE_67 -->\n###### 하고 환자가 스스로 입력한 정보를 모니터링할 수 있도록\n\n- - 61 -\n<!-- PAGE_68 -->\n##### 8. ",
        "original_sentence": "<!-- PAGE_67 -->\n###### 다) 디지털치료기기를 통한 우울과 관련된 행동의 교정을 수행한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_697",
      "text": "<!-- PAGE_67 -->\n###### 이 내용은 과학적 근거에 기반하여야 하며, 우울장애 인지행동치료\n\n<!-- PAGE_67 -->\n###### (1) 자극 조절법: 우울장애와 각성 자극이 연관된 상태를 해소하기\n\n<!-- PAGE_67 -->\n###### (2) 우울 일기 및 동등한 수준으로 우울에 대한 평가가 가능한 도구:\n\n<!-- PAGE_67 -->\n###### 우울장애에 대한 평가 및 피드백을 할 수 있게 하려면\n\n<!-- PAGE_67 -->\n###### 우울에 대한 평가를 해야 하며, 우울장애 인지행동치료를\n\n<!-- PAGE_67 -->\n###### 기반으로 하였을 경우 일반적으로 우울장애 일기가 사용된다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 696,
        "window_size": 3,
        "char_count": 358,
        "word_count": 75,
        "page_number": 67,
        "window_text": "대조\n\n<!-- PAGE_66 -->\n###### 시험용 의료기기가 설정되지 않았을 경우 생략할 수 있으며, 설정하지\n\n<!-- PAGE_66 -->\n###### 다.  임상시험용 의료기기 사용 방법\n\n<!-- PAGE_66 -->\n###### - 치료에 앞서 범용장비(스마트폰, 태블릿, PC 등)에 OOO 디지털\n\n- - 60 -\n<!-- PAGE_67 -->\n###### 2) 사용 방법\n\n<!-- PAGE_67 -->\n###### 가) OOO 디지털치료기기를 실행한다.\n\n <!-- PAGE_67 -->\n###### 다) 디지털치료기기를 통한 우울과 관련된 행동의 교정을 수행한다.\n\n <!-- PAGE_67 -->\n###### 이 내용은 과학적 근거에 기반하여야 하며, 우울장애 인지행동치료\n\n<!-- PAGE_67 -->\n###### (1) 자극 조절법: 우울장애와 각성 자극이 연관된 상태를 해소하기\n\n<!-- PAGE_67 -->\n###### (2) 우울 일기 및 동등한 수준으로 우울에 대한 평가가 가능한 도구:\n\n<!-- PAGE_67 -->\n###### 우울장애에 대한 평가 및 피드백을 할 수 있게 하려면\n\n<!-- PAGE_67 -->\n###### 우울에 대한 평가를 해야 하며, 우울장애 인지행동치료를\n\n<!-- PAGE_67 -->\n###### 기반으로 하였을 경우 일반적으로 우울장애 일기가 사용된다.\n\n <!-- PAGE_67 -->\n###### 라) 디지털치료기기를 통한 우울과 관련된 인지의 교정을 수행한다.\n\n <!-- PAGE_67 -->\n###### 이 내용은 과학적 근거에 기반하여야 하며, 우울장애 인지행동\n\n<!-- PAGE_67 -->\n###### 치료를 기반으로 하였을 경우 우울과 관련된 왜곡된 인지의\n\n<!-- PAGE_67 -->\n###### 마) 상술한 치료의 경우 환자의 순응도를 높이기 위한 전략이 포함\n\n<!-- PAGE_67 -->\n###### 되어야 하며(콘텐츠 제공 방식의 다양화, 알림 제공, 보상 방안\n\n<!-- PAGE_67 -->\n###### 등을 포함) 환자가 입력한 정보에 따른 피드백이 제공되어야\n\n<!-- PAGE_67 -->\n###### 하고 환자가 스스로 입력한 정보를 모니터링할 수 있도록\n\n- - 61 -\n<!-- PAGE_68 -->\n##### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n- - 62 -\n<!-- PAGE_69 -->\n###### 예시\n\n<!-- PAGE_69 -->\n###### 가. ",
        "original_sentence": "<!-- PAGE_67 -->\n###### 이 내용은 과학적 근거에 기반하여야 하며, 우울장애 인지행동치료\n\n<!-- PAGE_67 -->\n###### (1) 자극 조절법: 우울장애와 각성 자극이 연관된 상태를 해소하기\n\n<!-- PAGE_67 -->\n###### (2) 우울 일기 및 동등한 수준으로 우울에 대한 평가가 가능한 도구:\n\n<!-- PAGE_67 -->\n###### 우울장애에 대한 평가 및 피드백을 할 수 있게 하려면\n\n<!-- PAGE_67 -->\n###### 우울에 대한 평가를 해야 하며, 우울장애 인지행동치료를\n\n<!-- PAGE_67 -->\n###### 기반으로 하였을 경우 일반적으로 우울장애 일기가 사용된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_698",
      "text": "<!-- PAGE_67 -->\n###### 라) 디지털치료기기를 통한 우울과 관련된 인지의 교정을 수행한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 697,
        "window_size": 3,
        "char_count": 62,
        "word_count": 12,
        "page_number": 67,
        "window_text": "임상시험용 의료기기 사용 방법\n\n<!-- PAGE_66 -->\n###### - 치료에 앞서 범용장비(스마트폰, 태블릿, PC 등)에 OOO 디지털\n\n- - 60 -\n<!-- PAGE_67 -->\n###### 2) 사용 방법\n\n<!-- PAGE_67 -->\n###### 가) OOO 디지털치료기기를 실행한다.\n\n <!-- PAGE_67 -->\n###### 다) 디지털치료기기를 통한 우울과 관련된 행동의 교정을 수행한다.\n\n <!-- PAGE_67 -->\n###### 이 내용은 과학적 근거에 기반하여야 하며, 우울장애 인지행동치료\n\n<!-- PAGE_67 -->\n###### (1) 자극 조절법: 우울장애와 각성 자극이 연관된 상태를 해소하기\n\n<!-- PAGE_67 -->\n###### (2) 우울 일기 및 동등한 수준으로 우울에 대한 평가가 가능한 도구:\n\n<!-- PAGE_67 -->\n###### 우울장애에 대한 평가 및 피드백을 할 수 있게 하려면\n\n<!-- PAGE_67 -->\n###### 우울에 대한 평가를 해야 하며, 우울장애 인지행동치료를\n\n<!-- PAGE_67 -->\n###### 기반으로 하였을 경우 일반적으로 우울장애 일기가 사용된다.\n\n <!-- PAGE_67 -->\n###### 라) 디지털치료기기를 통한 우울과 관련된 인지의 교정을 수행한다.\n\n <!-- PAGE_67 -->\n###### 이 내용은 과학적 근거에 기반하여야 하며, 우울장애 인지행동\n\n<!-- PAGE_67 -->\n###### 치료를 기반으로 하였을 경우 우울과 관련된 왜곡된 인지의\n\n<!-- PAGE_67 -->\n###### 마) 상술한 치료의 경우 환자의 순응도를 높이기 위한 전략이 포함\n\n<!-- PAGE_67 -->\n###### 되어야 하며(콘텐츠 제공 방식의 다양화, 알림 제공, 보상 방안\n\n<!-- PAGE_67 -->\n###### 등을 포함) 환자가 입력한 정보에 따른 피드백이 제공되어야\n\n<!-- PAGE_67 -->\n###### 하고 환자가 스스로 입력한 정보를 모니터링할 수 있도록\n\n- - 61 -\n<!-- PAGE_68 -->\n##### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n- - 62 -\n<!-- PAGE_69 -->\n###### 예시\n\n<!-- PAGE_69 -->\n###### 가.  피험자 선정기준\n\n<!-- PAGE_69 -->\n###### 2) DSM-5의 주요우울장애 진단기준을 만족하거나 ICD-10의 우울\n\n<!-- PAGE_69 -->\n###### ※ BDI-II에서 14점 이상의 점수를 가져 mild depression 이상 수준의 임상적\n\n<!-- PAGE_69 -->\n###### 우울이 있다고 판단할 수 있는 자, 혹은 이외 유사한, 과학적 근거를 가진\n\n<!-- PAGE_69 -->\n###### 우울 척도 검사상 mild depression 이상 수준의 임상적 우울이 있다고\n\n<!-- PAGE_69 -->\n###### 5) 범용 장비(스마트폰 또는 태블릿 PC 등)를 이용하여 모바일\n\n<!-- PAGE_69 -->\n###### 6) 본 임상시험에 대해 충분한 설명을 듣고 이해한 후, 스스로 참여를\n\n<!-- PAGE_69 -->\n###### 나. ",
        "original_sentence": "<!-- PAGE_67 -->\n###### 라) 디지털치료기기를 통한 우울과 관련된 인지의 교정을 수행한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_699",
      "text": "<!-- PAGE_67 -->\n###### 이 내용은 과학적 근거에 기반하여야 하며, 우울장애 인지행동\n\n<!-- PAGE_67 -->\n###### 치료를 기반으로 하였을 경우 우울과 관련된 왜곡된 인지의\n\n<!-- PAGE_67 -->\n###### 마) 상술한 치료의 경우 환자의 순응도를 높이기 위한 전략이 포함\n\n<!-- PAGE_67 -->\n###### 되어야 하며(콘텐츠 제공 방식의 다양화, 알림 제공, 보상 방안\n\n<!-- PAGE_67 -->\n###### 등을 포함) 환자가 입력한 정보에 따른 피드백이 제공되어야\n\n<!-- PAGE_67 -->\n###### 하고 환자가 스스로 입력한 정보를 모니터링할 수 있도록\n\n- - 61 -\n<!-- PAGE_68 -->\n##### 8. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 698,
        "window_size": 3,
        "char_count": 388,
        "word_count": 84,
        "page_number": 67,
        "window_text": "<!-- PAGE_67 -->\n###### 다) 디지털치료기기를 통한 우울과 관련된 행동의 교정을 수행한다.\n\n <!-- PAGE_67 -->\n###### 이 내용은 과학적 근거에 기반하여야 하며, 우울장애 인지행동치료\n\n<!-- PAGE_67 -->\n###### (1) 자극 조절법: 우울장애와 각성 자극이 연관된 상태를 해소하기\n\n<!-- PAGE_67 -->\n###### (2) 우울 일기 및 동등한 수준으로 우울에 대한 평가가 가능한 도구:\n\n<!-- PAGE_67 -->\n###### 우울장애에 대한 평가 및 피드백을 할 수 있게 하려면\n\n<!-- PAGE_67 -->\n###### 우울에 대한 평가를 해야 하며, 우울장애 인지행동치료를\n\n<!-- PAGE_67 -->\n###### 기반으로 하였을 경우 일반적으로 우울장애 일기가 사용된다.\n\n <!-- PAGE_67 -->\n###### 라) 디지털치료기기를 통한 우울과 관련된 인지의 교정을 수행한다.\n\n <!-- PAGE_67 -->\n###### 이 내용은 과학적 근거에 기반하여야 하며, 우울장애 인지행동\n\n<!-- PAGE_67 -->\n###### 치료를 기반으로 하였을 경우 우울과 관련된 왜곡된 인지의\n\n<!-- PAGE_67 -->\n###### 마) 상술한 치료의 경우 환자의 순응도를 높이기 위한 전략이 포함\n\n<!-- PAGE_67 -->\n###### 되어야 하며(콘텐츠 제공 방식의 다양화, 알림 제공, 보상 방안\n\n<!-- PAGE_67 -->\n###### 등을 포함) 환자가 입력한 정보에 따른 피드백이 제공되어야\n\n<!-- PAGE_67 -->\n###### 하고 환자가 스스로 입력한 정보를 모니터링할 수 있도록\n\n- - 61 -\n<!-- PAGE_68 -->\n##### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n- - 62 -\n<!-- PAGE_69 -->\n###### 예시\n\n<!-- PAGE_69 -->\n###### 가.  피험자 선정기준\n\n<!-- PAGE_69 -->\n###### 2) DSM-5의 주요우울장애 진단기준을 만족하거나 ICD-10의 우울\n\n<!-- PAGE_69 -->\n###### ※ BDI-II에서 14점 이상의 점수를 가져 mild depression 이상 수준의 임상적\n\n<!-- PAGE_69 -->\n###### 우울이 있다고 판단할 수 있는 자, 혹은 이외 유사한, 과학적 근거를 가진\n\n<!-- PAGE_69 -->\n###### 우울 척도 검사상 mild depression 이상 수준의 임상적 우울이 있다고\n\n<!-- PAGE_69 -->\n###### 5) 범용 장비(스마트폰 또는 태블릿 PC 등)를 이용하여 모바일\n\n<!-- PAGE_69 -->\n###### 6) 본 임상시험에 대해 충분한 설명을 듣고 이해한 후, 스스로 참여를\n\n<!-- PAGE_69 -->\n###### 나.  피험자 제외기준\n\n<!-- PAGE_69 -->\n###### : 제외기준 중 어느 하나라도 해당하는 항목이 있는 경우 본\n\n<!-- PAGE_69 -->\n###### 2) 스크리닝 시점 3개월 이내에 자살 시도를 한 바 있으며, 정신과\n\n<!-- PAGE_69 -->\n###### ※ 콜롬비아 자살 위험성 스케일(Columbia Suicide Severity Rating Scale,\n\n- - 63 -\n<!-- PAGE_70 -->\n###### C-SSRS) 혹은 이와 유사한 과학적 근거를 가진 자살 위험성 평가상 자\n\n<!-- PAGE_70 -->\n###### 살 고위험군으로 평가되는 자\n\n<!-- PAGE_70 -->\n###### 3) 스크리닝 시점 1년 동안 제대로 치료받지 못한 간질, 심각한\n\n<!-- PAGE_70 -->\n###### 4) 스크리닝 이전 1주일 이내에 평균 알코올 섭취량이 1일 20g을\n\n<!-- PAGE_70 -->\n###### 5) 스크리닝 시점 3개월 이내에 우울장애에 대한 다른 비약물적인\n\n<!-- PAGE_70 -->\n###### 6) 최근 1개월 이내 사용하는 신경정신과 관련 약물의 종류 및 용량에\n\n<!-- PAGE_70 -->\n###### ※ 최근 1개월 이내 (필요시 처방을 포함하여) 복용 약물의 종류 및 용량이\n\n<!-- PAGE_70 -->\n###### 7) 기타 사유로 인하여 시험자가 임상시험 참여에 부적합하다고\n\n<!-- PAGE_70 -->\n###### ※ 피험자 선정기준 및 제외기준은 의료기기의 특성, 내용 구성 등을\n\n- - 64 -\n<!-- PAGE_71 -->\n###### 다. ",
        "original_sentence": "<!-- PAGE_67 -->\n###### 이 내용은 과학적 근거에 기반하여야 하며, 우울장애 인지행동\n\n<!-- PAGE_67 -->\n###### 치료를 기반으로 하였을 경우 우울과 관련된 왜곡된 인지의\n\n<!-- PAGE_67 -->\n###### 마) 상술한 치료의 경우 환자의 순응도를 높이기 위한 전략이 포함\n\n<!-- PAGE_67 -->\n###### 되어야 하며(콘텐츠 제공 방식의 다양화, 알림 제공, 보상 방안\n\n<!-- PAGE_67 -->\n###### 등을 포함) 환자가 입력한 정보에 따른 피드백이 제공되어야\n\n<!-- PAGE_67 -->\n###### 하고 환자가 스스로 입력한 정보를 모니터링할 수 있도록\n\n- - 61 -\n<!-- PAGE_68 -->\n##### 8. "
      }
    },
    {
      "chunk_id": "chunk_700",
      "text": "피험자의 선정기준·제외기준·인원 및 그 근거\n\n- - 62 -\n<!-- PAGE_69 -->\n###### 예시\n\n<!-- PAGE_69 -->\n###### 가. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 699,
        "window_size": 3,
        "char_count": 90,
        "word_count": 19,
        "page_number": 69,
        "window_text": "<!-- PAGE_67 -->\n###### 이 내용은 과학적 근거에 기반하여야 하며, 우울장애 인지행동치료\n\n<!-- PAGE_67 -->\n###### (1) 자극 조절법: 우울장애와 각성 자극이 연관된 상태를 해소하기\n\n<!-- PAGE_67 -->\n###### (2) 우울 일기 및 동등한 수준으로 우울에 대한 평가가 가능한 도구:\n\n<!-- PAGE_67 -->\n###### 우울장애에 대한 평가 및 피드백을 할 수 있게 하려면\n\n<!-- PAGE_67 -->\n###### 우울에 대한 평가를 해야 하며, 우울장애 인지행동치료를\n\n<!-- PAGE_67 -->\n###### 기반으로 하였을 경우 일반적으로 우울장애 일기가 사용된다.\n\n <!-- PAGE_67 -->\n###### 라) 디지털치료기기를 통한 우울과 관련된 인지의 교정을 수행한다.\n\n <!-- PAGE_67 -->\n###### 이 내용은 과학적 근거에 기반하여야 하며, 우울장애 인지행동\n\n<!-- PAGE_67 -->\n###### 치료를 기반으로 하였을 경우 우울과 관련된 왜곡된 인지의\n\n<!-- PAGE_67 -->\n###### 마) 상술한 치료의 경우 환자의 순응도를 높이기 위한 전략이 포함\n\n<!-- PAGE_67 -->\n###### 되어야 하며(콘텐츠 제공 방식의 다양화, 알림 제공, 보상 방안\n\n<!-- PAGE_67 -->\n###### 등을 포함) 환자가 입력한 정보에 따른 피드백이 제공되어야\n\n<!-- PAGE_67 -->\n###### 하고 환자가 스스로 입력한 정보를 모니터링할 수 있도록\n\n- - 61 -\n<!-- PAGE_68 -->\n##### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n- - 62 -\n<!-- PAGE_69 -->\n###### 예시\n\n<!-- PAGE_69 -->\n###### 가.  피험자 선정기준\n\n<!-- PAGE_69 -->\n###### 2) DSM-5의 주요우울장애 진단기준을 만족하거나 ICD-10의 우울\n\n<!-- PAGE_69 -->\n###### ※ BDI-II에서 14점 이상의 점수를 가져 mild depression 이상 수준의 임상적\n\n<!-- PAGE_69 -->\n###### 우울이 있다고 판단할 수 있는 자, 혹은 이외 유사한, 과학적 근거를 가진\n\n<!-- PAGE_69 -->\n###### 우울 척도 검사상 mild depression 이상 수준의 임상적 우울이 있다고\n\n<!-- PAGE_69 -->\n###### 5) 범용 장비(스마트폰 또는 태블릿 PC 등)를 이용하여 모바일\n\n<!-- PAGE_69 -->\n###### 6) 본 임상시험에 대해 충분한 설명을 듣고 이해한 후, 스스로 참여를\n\n<!-- PAGE_69 -->\n###### 나.  피험자 제외기준\n\n<!-- PAGE_69 -->\n###### : 제외기준 중 어느 하나라도 해당하는 항목이 있는 경우 본\n\n<!-- PAGE_69 -->\n###### 2) 스크리닝 시점 3개월 이내에 자살 시도를 한 바 있으며, 정신과\n\n<!-- PAGE_69 -->\n###### ※ 콜롬비아 자살 위험성 스케일(Columbia Suicide Severity Rating Scale,\n\n- - 63 -\n<!-- PAGE_70 -->\n###### C-SSRS) 혹은 이와 유사한 과학적 근거를 가진 자살 위험성 평가상 자\n\n<!-- PAGE_70 -->\n###### 살 고위험군으로 평가되는 자\n\n<!-- PAGE_70 -->\n###### 3) 스크리닝 시점 1년 동안 제대로 치료받지 못한 간질, 심각한\n\n<!-- PAGE_70 -->\n###### 4) 스크리닝 이전 1주일 이내에 평균 알코올 섭취량이 1일 20g을\n\n<!-- PAGE_70 -->\n###### 5) 스크리닝 시점 3개월 이내에 우울장애에 대한 다른 비약물적인\n\n<!-- PAGE_70 -->\n###### 6) 최근 1개월 이내 사용하는 신경정신과 관련 약물의 종류 및 용량에\n\n<!-- PAGE_70 -->\n###### ※ 최근 1개월 이내 (필요시 처방을 포함하여) 복용 약물의 종류 및 용량이\n\n<!-- PAGE_70 -->\n###### 7) 기타 사유로 인하여 시험자가 임상시험 참여에 부적합하다고\n\n<!-- PAGE_70 -->\n###### ※ 피험자 선정기준 및 제외기준은 의료기기의 특성, 내용 구성 등을\n\n- - 64 -\n<!-- PAGE_71 -->\n###### 다.  목표대상자 수 및 그 근거\n\n피험자 수는 임상시험 방법에 따라 식약처의 ‘의료기기 임상시험 관련 통계기법\n\n<!-- PAGE_71 -->\n###### ※ 본 가이드라인에 작성된 산출 방법은 공개된 선행연구 결과를 기반으로\n\n<!-- PAGE_71 -->\n###### 작성된 예시이며, 목표 대상자 수는 개발 제품 특성과 탐색 임상시험 등\n\n<!-- PAGE_71 -->\n###### 제품별 선행연구 결과에 따라 다르므로, 개발 제품의 선행연구 결과\n\n<!-- PAGE_71 -->\n###### 및 참고문헌을 기준으로 산출한다. ",
        "original_sentence": "피험자의 선정기준·제외기준·인원 및 그 근거\n\n- - 62 -\n<!-- PAGE_69 -->\n###### 예시\n\n<!-- PAGE_69 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_701",
      "text": "피험자 선정기준\n\n<!-- PAGE_69 -->\n###### 2) DSM-5의 주요우울장애 진단기준을 만족하거나 ICD-10의 우울\n\n<!-- PAGE_69 -->\n###### ※ BDI-II에서 14점 이상의 점수를 가져 mild depression 이상 수준의 임상적\n\n<!-- PAGE_69 -->\n###### 우울이 있다고 판단할 수 있는 자, 혹은 이외 유사한, 과학적 근거를 가진\n\n<!-- PAGE_69 -->\n###### 우울 척도 검사상 mild depression 이상 수준의 임상적 우울이 있다고\n\n<!-- PAGE_69 -->\n###### 5) 범용 장비(스마트폰 또는 태블릿 PC 등)를 이용하여 모바일\n\n<!-- PAGE_69 -->\n###### 6) 본 임상시험에 대해 충분한 설명을 듣고 이해한 후, 스스로 참여를\n\n<!-- PAGE_69 -->\n###### 나. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 700,
        "window_size": 3,
        "char_count": 444,
        "word_count": 91,
        "page_number": 69,
        "window_text": "<!-- PAGE_67 -->\n###### 라) 디지털치료기기를 통한 우울과 관련된 인지의 교정을 수행한다.\n\n <!-- PAGE_67 -->\n###### 이 내용은 과학적 근거에 기반하여야 하며, 우울장애 인지행동\n\n<!-- PAGE_67 -->\n###### 치료를 기반으로 하였을 경우 우울과 관련된 왜곡된 인지의\n\n<!-- PAGE_67 -->\n###### 마) 상술한 치료의 경우 환자의 순응도를 높이기 위한 전략이 포함\n\n<!-- PAGE_67 -->\n###### 되어야 하며(콘텐츠 제공 방식의 다양화, 알림 제공, 보상 방안\n\n<!-- PAGE_67 -->\n###### 등을 포함) 환자가 입력한 정보에 따른 피드백이 제공되어야\n\n<!-- PAGE_67 -->\n###### 하고 환자가 스스로 입력한 정보를 모니터링할 수 있도록\n\n- - 61 -\n<!-- PAGE_68 -->\n##### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n- - 62 -\n<!-- PAGE_69 -->\n###### 예시\n\n<!-- PAGE_69 -->\n###### 가.  피험자 선정기준\n\n<!-- PAGE_69 -->\n###### 2) DSM-5의 주요우울장애 진단기준을 만족하거나 ICD-10의 우울\n\n<!-- PAGE_69 -->\n###### ※ BDI-II에서 14점 이상의 점수를 가져 mild depression 이상 수준의 임상적\n\n<!-- PAGE_69 -->\n###### 우울이 있다고 판단할 수 있는 자, 혹은 이외 유사한, 과학적 근거를 가진\n\n<!-- PAGE_69 -->\n###### 우울 척도 검사상 mild depression 이상 수준의 임상적 우울이 있다고\n\n<!-- PAGE_69 -->\n###### 5) 범용 장비(스마트폰 또는 태블릿 PC 등)를 이용하여 모바일\n\n<!-- PAGE_69 -->\n###### 6) 본 임상시험에 대해 충분한 설명을 듣고 이해한 후, 스스로 참여를\n\n<!-- PAGE_69 -->\n###### 나.  피험자 제외기준\n\n<!-- PAGE_69 -->\n###### : 제외기준 중 어느 하나라도 해당하는 항목이 있는 경우 본\n\n<!-- PAGE_69 -->\n###### 2) 스크리닝 시점 3개월 이내에 자살 시도를 한 바 있으며, 정신과\n\n<!-- PAGE_69 -->\n###### ※ 콜롬비아 자살 위험성 스케일(Columbia Suicide Severity Rating Scale,\n\n- - 63 -\n<!-- PAGE_70 -->\n###### C-SSRS) 혹은 이와 유사한 과학적 근거를 가진 자살 위험성 평가상 자\n\n<!-- PAGE_70 -->\n###### 살 고위험군으로 평가되는 자\n\n<!-- PAGE_70 -->\n###### 3) 스크리닝 시점 1년 동안 제대로 치료받지 못한 간질, 심각한\n\n<!-- PAGE_70 -->\n###### 4) 스크리닝 이전 1주일 이내에 평균 알코올 섭취량이 1일 20g을\n\n<!-- PAGE_70 -->\n###### 5) 스크리닝 시점 3개월 이내에 우울장애에 대한 다른 비약물적인\n\n<!-- PAGE_70 -->\n###### 6) 최근 1개월 이내 사용하는 신경정신과 관련 약물의 종류 및 용량에\n\n<!-- PAGE_70 -->\n###### ※ 최근 1개월 이내 (필요시 처방을 포함하여) 복용 약물의 종류 및 용량이\n\n<!-- PAGE_70 -->\n###### 7) 기타 사유로 인하여 시험자가 임상시험 참여에 부적합하다고\n\n<!-- PAGE_70 -->\n###### ※ 피험자 선정기준 및 제외기준은 의료기기의 특성, 내용 구성 등을\n\n- - 64 -\n<!-- PAGE_71 -->\n###### 다.  목표대상자 수 및 그 근거\n\n피험자 수는 임상시험 방법에 따라 식약처의 ‘의료기기 임상시험 관련 통계기법\n\n<!-- PAGE_71 -->\n###### ※ 본 가이드라인에 작성된 산출 방법은 공개된 선행연구 결과를 기반으로\n\n<!-- PAGE_71 -->\n###### 작성된 예시이며, 목표 대상자 수는 개발 제품 특성과 탐색 임상시험 등\n\n<!-- PAGE_71 -->\n###### 제품별 선행연구 결과에 따라 다르므로, 개발 제품의 선행연구 결과\n\n<!-- PAGE_71 -->\n###### 및 참고문헌을 기준으로 산출한다.  이때, 그 근거(가설, 변수, 성공\n\n<!-- PAGE_71 -->\n###### 본 시험의 일차목적: 우울장애 진단환자의 우울장애 심각도\n\n<!-- PAGE_71 -->\n###### 척도(BDI) 변화량이 대조군과 비교해 시험군에서 치료 전과\n\n<!-- PAGE_71 -->\n###### 비교하여 우월하게 개선되는 것을 확증하는 것이다. ",
        "original_sentence": "피험자 선정기준\n\n<!-- PAGE_69 -->\n###### 2) DSM-5의 주요우울장애 진단기준을 만족하거나 ICD-10의 우울\n\n<!-- PAGE_69 -->\n###### ※ BDI-II에서 14점 이상의 점수를 가져 mild depression 이상 수준의 임상적\n\n<!-- PAGE_69 -->\n###### 우울이 있다고 판단할 수 있는 자, 혹은 이외 유사한, 과학적 근거를 가진\n\n<!-- PAGE_69 -->\n###### 우울 척도 검사상 mild depression 이상 수준의 임상적 우울이 있다고\n\n<!-- PAGE_69 -->\n###### 5) 범용 장비(스마트폰 또는 태블릿 PC 등)를 이용하여 모바일\n\n<!-- PAGE_69 -->\n###### 6) 본 임상시험에 대해 충분한 설명을 듣고 이해한 후, 스스로 참여를\n\n<!-- PAGE_69 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_702",
      "text": "피험자 제외기준\n\n<!-- PAGE_69 -->\n###### : 제외기준 중 어느 하나라도 해당하는 항목이 있는 경우 본\n\n<!-- PAGE_69 -->\n###### 2) 스크리닝 시점 3개월 이내에 자살 시도를 한 바 있으며, 정신과\n\n<!-- PAGE_69 -->\n###### ※ 콜롬비아 자살 위험성 스케일(Columbia Suicide Severity Rating Scale,\n\n- - 63 -\n<!-- PAGE_70 -->\n###### C-SSRS) 혹은 이와 유사한 과학적 근거를 가진 자살 위험성 평가상 자\n\n<!-- PAGE_70 -->\n###### 살 고위험군으로 평가되는 자\n\n<!-- PAGE_70 -->\n###### 3) 스크리닝 시점 1년 동안 제대로 치료받지 못한 간질, 심각한\n\n<!-- PAGE_70 -->\n###### 4) 스크리닝 이전 1주일 이내에 평균 알코올 섭취량이 1일 20g을\n\n<!-- PAGE_70 -->\n###### 5) 스크리닝 시점 3개월 이내에 우울장애에 대한 다른 비약물적인\n\n<!-- PAGE_70 -->\n###### 6) 최근 1개월 이내 사용하는 신경정신과 관련 약물의 종류 및 용량에\n\n<!-- PAGE_70 -->\n###### ※ 최근 1개월 이내 (필요시 처방을 포함하여) 복용 약물의 종류 및 용량이\n\n<!-- PAGE_70 -->\n###### 7) 기타 사유로 인하여 시험자가 임상시험 참여에 부적합하다고\n\n<!-- PAGE_70 -->\n###### ※ 피험자 선정기준 및 제외기준은 의료기기의 특성, 내용 구성 등을\n\n- - 64 -\n<!-- PAGE_71 -->\n###### 다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 701,
        "window_size": 3,
        "char_count": 813,
        "word_count": 178,
        "page_number": 69,
        "window_text": "<!-- PAGE_67 -->\n###### 이 내용은 과학적 근거에 기반하여야 하며, 우울장애 인지행동\n\n<!-- PAGE_67 -->\n###### 치료를 기반으로 하였을 경우 우울과 관련된 왜곡된 인지의\n\n<!-- PAGE_67 -->\n###### 마) 상술한 치료의 경우 환자의 순응도를 높이기 위한 전략이 포함\n\n<!-- PAGE_67 -->\n###### 되어야 하며(콘텐츠 제공 방식의 다양화, 알림 제공, 보상 방안\n\n<!-- PAGE_67 -->\n###### 등을 포함) 환자가 입력한 정보에 따른 피드백이 제공되어야\n\n<!-- PAGE_67 -->\n###### 하고 환자가 스스로 입력한 정보를 모니터링할 수 있도록\n\n- - 61 -\n<!-- PAGE_68 -->\n##### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n- - 62 -\n<!-- PAGE_69 -->\n###### 예시\n\n<!-- PAGE_69 -->\n###### 가.  피험자 선정기준\n\n<!-- PAGE_69 -->\n###### 2) DSM-5의 주요우울장애 진단기준을 만족하거나 ICD-10의 우울\n\n<!-- PAGE_69 -->\n###### ※ BDI-II에서 14점 이상의 점수를 가져 mild depression 이상 수준의 임상적\n\n<!-- PAGE_69 -->\n###### 우울이 있다고 판단할 수 있는 자, 혹은 이외 유사한, 과학적 근거를 가진\n\n<!-- PAGE_69 -->\n###### 우울 척도 검사상 mild depression 이상 수준의 임상적 우울이 있다고\n\n<!-- PAGE_69 -->\n###### 5) 범용 장비(스마트폰 또는 태블릿 PC 등)를 이용하여 모바일\n\n<!-- PAGE_69 -->\n###### 6) 본 임상시험에 대해 충분한 설명을 듣고 이해한 후, 스스로 참여를\n\n<!-- PAGE_69 -->\n###### 나.  피험자 제외기준\n\n<!-- PAGE_69 -->\n###### : 제외기준 중 어느 하나라도 해당하는 항목이 있는 경우 본\n\n<!-- PAGE_69 -->\n###### 2) 스크리닝 시점 3개월 이내에 자살 시도를 한 바 있으며, 정신과\n\n<!-- PAGE_69 -->\n###### ※ 콜롬비아 자살 위험성 스케일(Columbia Suicide Severity Rating Scale,\n\n- - 63 -\n<!-- PAGE_70 -->\n###### C-SSRS) 혹은 이와 유사한 과학적 근거를 가진 자살 위험성 평가상 자\n\n<!-- PAGE_70 -->\n###### 살 고위험군으로 평가되는 자\n\n<!-- PAGE_70 -->\n###### 3) 스크리닝 시점 1년 동안 제대로 치료받지 못한 간질, 심각한\n\n<!-- PAGE_70 -->\n###### 4) 스크리닝 이전 1주일 이내에 평균 알코올 섭취량이 1일 20g을\n\n<!-- PAGE_70 -->\n###### 5) 스크리닝 시점 3개월 이내에 우울장애에 대한 다른 비약물적인\n\n<!-- PAGE_70 -->\n###### 6) 최근 1개월 이내 사용하는 신경정신과 관련 약물의 종류 및 용량에\n\n<!-- PAGE_70 -->\n###### ※ 최근 1개월 이내 (필요시 처방을 포함하여) 복용 약물의 종류 및 용량이\n\n<!-- PAGE_70 -->\n###### 7) 기타 사유로 인하여 시험자가 임상시험 참여에 부적합하다고\n\n<!-- PAGE_70 -->\n###### ※ 피험자 선정기준 및 제외기준은 의료기기의 특성, 내용 구성 등을\n\n- - 64 -\n<!-- PAGE_71 -->\n###### 다.  목표대상자 수 및 그 근거\n\n피험자 수는 임상시험 방법에 따라 식약처의 ‘의료기기 임상시험 관련 통계기법\n\n<!-- PAGE_71 -->\n###### ※ 본 가이드라인에 작성된 산출 방법은 공개된 선행연구 결과를 기반으로\n\n<!-- PAGE_71 -->\n###### 작성된 예시이며, 목표 대상자 수는 개발 제품 특성과 탐색 임상시험 등\n\n<!-- PAGE_71 -->\n###### 제품별 선행연구 결과에 따라 다르므로, 개발 제품의 선행연구 결과\n\n<!-- PAGE_71 -->\n###### 및 참고문헌을 기준으로 산출한다.  이때, 그 근거(가설, 변수, 성공\n\n<!-- PAGE_71 -->\n###### 본 시험의 일차목적: 우울장애 진단환자의 우울장애 심각도\n\n<!-- PAGE_71 -->\n###### 척도(BDI) 변화량이 대조군과 비교해 시험군에서 치료 전과\n\n<!-- PAGE_71 -->\n###### 비교하여 우월하게 개선되는 것을 확증하는 것이다.  변화량은\n\n<!-- PAGE_71 -->\n###### 치료 시작 전 평가지표 Baseline 조사에서 수집한 정보와 대비\n\n<!-- PAGE_71 -->\n###### 하여 치료 종료 후(Post-treatment) 수집한 정보와의 차이를\n\n<!-- PAGE_71 -->\n###### 의미하며, 이에 대한 가설은 아래와 같다. ",
        "original_sentence": "피험자 제외기준\n\n<!-- PAGE_69 -->\n###### : 제외기준 중 어느 하나라도 해당하는 항목이 있는 경우 본\n\n<!-- PAGE_69 -->\n###### 2) 스크리닝 시점 3개월 이내에 자살 시도를 한 바 있으며, 정신과\n\n<!-- PAGE_69 -->\n###### ※ 콜롬비아 자살 위험성 스케일(Columbia Suicide Severity Rating Scale,\n\n- - 63 -\n<!-- PAGE_70 -->\n###### C-SSRS) 혹은 이와 유사한 과학적 근거를 가진 자살 위험성 평가상 자\n\n<!-- PAGE_70 -->\n###### 살 고위험군으로 평가되는 자\n\n<!-- PAGE_70 -->\n###### 3) 스크리닝 시점 1년 동안 제대로 치료받지 못한 간질, 심각한\n\n<!-- PAGE_70 -->\n###### 4) 스크리닝 이전 1주일 이내에 평균 알코올 섭취량이 1일 20g을\n\n<!-- PAGE_70 -->\n###### 5) 스크리닝 시점 3개월 이내에 우울장애에 대한 다른 비약물적인\n\n<!-- PAGE_70 -->\n###### 6) 최근 1개월 이내 사용하는 신경정신과 관련 약물의 종류 및 용량에\n\n<!-- PAGE_70 -->\n###### ※ 최근 1개월 이내 (필요시 처방을 포함하여) 복용 약물의 종류 및 용량이\n\n<!-- PAGE_70 -->\n###### 7) 기타 사유로 인하여 시험자가 임상시험 참여에 부적합하다고\n\n<!-- PAGE_70 -->\n###### ※ 피험자 선정기준 및 제외기준은 의료기기의 특성, 내용 구성 등을\n\n- - 64 -\n<!-- PAGE_71 -->\n###### 다. "
      }
    },
    {
      "chunk_id": "chunk_703",
      "text": "목표대상자 수 및 그 근거\n\n피험자 수는 임상시험 방법에 따라 식약처의 ‘의료기기 임상시험 관련 통계기법\n\n<!-- PAGE_71 -->\n###### ※ 본 가이드라인에 작성된 산출 방법은 공개된 선행연구 결과를 기반으로\n\n<!-- PAGE_71 -->\n###### 작성된 예시이며, 목표 대상자 수는 개발 제품 특성과 탐색 임상시험 등\n\n<!-- PAGE_71 -->\n###### 제품별 선행연구 결과에 따라 다르므로, 개발 제품의 선행연구 결과\n\n<!-- PAGE_71 -->\n###### 및 참고문헌을 기준으로 산출한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 702,
        "window_size": 3,
        "char_count": 295,
        "word_count": 65,
        "page_number": 71,
        "window_text": "피험자의 선정기준·제외기준·인원 및 그 근거\n\n- - 62 -\n<!-- PAGE_69 -->\n###### 예시\n\n<!-- PAGE_69 -->\n###### 가.  피험자 선정기준\n\n<!-- PAGE_69 -->\n###### 2) DSM-5의 주요우울장애 진단기준을 만족하거나 ICD-10의 우울\n\n<!-- PAGE_69 -->\n###### ※ BDI-II에서 14점 이상의 점수를 가져 mild depression 이상 수준의 임상적\n\n<!-- PAGE_69 -->\n###### 우울이 있다고 판단할 수 있는 자, 혹은 이외 유사한, 과학적 근거를 가진\n\n<!-- PAGE_69 -->\n###### 우울 척도 검사상 mild depression 이상 수준의 임상적 우울이 있다고\n\n<!-- PAGE_69 -->\n###### 5) 범용 장비(스마트폰 또는 태블릿 PC 등)를 이용하여 모바일\n\n<!-- PAGE_69 -->\n###### 6) 본 임상시험에 대해 충분한 설명을 듣고 이해한 후, 스스로 참여를\n\n<!-- PAGE_69 -->\n###### 나.  피험자 제외기준\n\n<!-- PAGE_69 -->\n###### : 제외기준 중 어느 하나라도 해당하는 항목이 있는 경우 본\n\n<!-- PAGE_69 -->\n###### 2) 스크리닝 시점 3개월 이내에 자살 시도를 한 바 있으며, 정신과\n\n<!-- PAGE_69 -->\n###### ※ 콜롬비아 자살 위험성 스케일(Columbia Suicide Severity Rating Scale,\n\n- - 63 -\n<!-- PAGE_70 -->\n###### C-SSRS) 혹은 이와 유사한 과학적 근거를 가진 자살 위험성 평가상 자\n\n<!-- PAGE_70 -->\n###### 살 고위험군으로 평가되는 자\n\n<!-- PAGE_70 -->\n###### 3) 스크리닝 시점 1년 동안 제대로 치료받지 못한 간질, 심각한\n\n<!-- PAGE_70 -->\n###### 4) 스크리닝 이전 1주일 이내에 평균 알코올 섭취량이 1일 20g을\n\n<!-- PAGE_70 -->\n###### 5) 스크리닝 시점 3개월 이내에 우울장애에 대한 다른 비약물적인\n\n<!-- PAGE_70 -->\n###### 6) 최근 1개월 이내 사용하는 신경정신과 관련 약물의 종류 및 용량에\n\n<!-- PAGE_70 -->\n###### ※ 최근 1개월 이내 (필요시 처방을 포함하여) 복용 약물의 종류 및 용량이\n\n<!-- PAGE_70 -->\n###### 7) 기타 사유로 인하여 시험자가 임상시험 참여에 부적합하다고\n\n<!-- PAGE_70 -->\n###### ※ 피험자 선정기준 및 제외기준은 의료기기의 특성, 내용 구성 등을\n\n- - 64 -\n<!-- PAGE_71 -->\n###### 다.  목표대상자 수 및 그 근거\n\n피험자 수는 임상시험 방법에 따라 식약처의 ‘의료기기 임상시험 관련 통계기법\n\n<!-- PAGE_71 -->\n###### ※ 본 가이드라인에 작성된 산출 방법은 공개된 선행연구 결과를 기반으로\n\n<!-- PAGE_71 -->\n###### 작성된 예시이며, 목표 대상자 수는 개발 제품 특성과 탐색 임상시험 등\n\n<!-- PAGE_71 -->\n###### 제품별 선행연구 결과에 따라 다르므로, 개발 제품의 선행연구 결과\n\n<!-- PAGE_71 -->\n###### 및 참고문헌을 기준으로 산출한다.  이때, 그 근거(가설, 변수, 성공\n\n<!-- PAGE_71 -->\n###### 본 시험의 일차목적: 우울장애 진단환자의 우울장애 심각도\n\n<!-- PAGE_71 -->\n###### 척도(BDI) 변화량이 대조군과 비교해 시험군에서 치료 전과\n\n<!-- PAGE_71 -->\n###### 비교하여 우월하게 개선되는 것을 확증하는 것이다.  변화량은\n\n<!-- PAGE_71 -->\n###### 치료 시작 전 평가지표 Baseline 조사에서 수집한 정보와 대비\n\n<!-- PAGE_71 -->\n###### 하여 치료 종료 후(Post-treatment) 수집한 정보와의 차이를\n\n<!-- PAGE_71 -->\n###### 의미하며, 이에 대한 가설은 아래와 같다.  이 가설의 평균 차이\n\n- - 65 -\n<!-- PAGE_72 -->\n###### 검정에서 통계학적으로 유의하면 임상시험 성공으로 평가한다.\n\n",
        "original_sentence": "목표대상자 수 및 그 근거\n\n피험자 수는 임상시험 방법에 따라 식약처의 ‘의료기기 임상시험 관련 통계기법\n\n<!-- PAGE_71 -->\n###### ※ 본 가이드라인에 작성된 산출 방법은 공개된 선행연구 결과를 기반으로\n\n<!-- PAGE_71 -->\n###### 작성된 예시이며, 목표 대상자 수는 개발 제품 특성과 탐색 임상시험 등\n\n<!-- PAGE_71 -->\n###### 제품별 선행연구 결과에 따라 다르므로, 개발 제품의 선행연구 결과\n\n<!-- PAGE_71 -->\n###### 및 참고문헌을 기준으로 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_704",
      "text": "이때, 그 근거(가설, 변수, 성공\n\n<!-- PAGE_71 -->\n###### 본 시험의 일차목적: 우울장애 진단환자의 우울장애 심각도\n\n<!-- PAGE_71 -->\n###### 척도(BDI) 변화량이 대조군과 비교해 시험군에서 치료 전과\n\n<!-- PAGE_71 -->\n###### 비교하여 우월하게 개선되는 것을 확증하는 것이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 703,
        "window_size": 3,
        "char_count": 189,
        "word_count": 37,
        "page_number": 71,
        "window_text": "피험자 선정기준\n\n<!-- PAGE_69 -->\n###### 2) DSM-5의 주요우울장애 진단기준을 만족하거나 ICD-10의 우울\n\n<!-- PAGE_69 -->\n###### ※ BDI-II에서 14점 이상의 점수를 가져 mild depression 이상 수준의 임상적\n\n<!-- PAGE_69 -->\n###### 우울이 있다고 판단할 수 있는 자, 혹은 이외 유사한, 과학적 근거를 가진\n\n<!-- PAGE_69 -->\n###### 우울 척도 검사상 mild depression 이상 수준의 임상적 우울이 있다고\n\n<!-- PAGE_69 -->\n###### 5) 범용 장비(스마트폰 또는 태블릿 PC 등)를 이용하여 모바일\n\n<!-- PAGE_69 -->\n###### 6) 본 임상시험에 대해 충분한 설명을 듣고 이해한 후, 스스로 참여를\n\n<!-- PAGE_69 -->\n###### 나.  피험자 제외기준\n\n<!-- PAGE_69 -->\n###### : 제외기준 중 어느 하나라도 해당하는 항목이 있는 경우 본\n\n<!-- PAGE_69 -->\n###### 2) 스크리닝 시점 3개월 이내에 자살 시도를 한 바 있으며, 정신과\n\n<!-- PAGE_69 -->\n###### ※ 콜롬비아 자살 위험성 스케일(Columbia Suicide Severity Rating Scale,\n\n- - 63 -\n<!-- PAGE_70 -->\n###### C-SSRS) 혹은 이와 유사한 과학적 근거를 가진 자살 위험성 평가상 자\n\n<!-- PAGE_70 -->\n###### 살 고위험군으로 평가되는 자\n\n<!-- PAGE_70 -->\n###### 3) 스크리닝 시점 1년 동안 제대로 치료받지 못한 간질, 심각한\n\n<!-- PAGE_70 -->\n###### 4) 스크리닝 이전 1주일 이내에 평균 알코올 섭취량이 1일 20g을\n\n<!-- PAGE_70 -->\n###### 5) 스크리닝 시점 3개월 이내에 우울장애에 대한 다른 비약물적인\n\n<!-- PAGE_70 -->\n###### 6) 최근 1개월 이내 사용하는 신경정신과 관련 약물의 종류 및 용량에\n\n<!-- PAGE_70 -->\n###### ※ 최근 1개월 이내 (필요시 처방을 포함하여) 복용 약물의 종류 및 용량이\n\n<!-- PAGE_70 -->\n###### 7) 기타 사유로 인하여 시험자가 임상시험 참여에 부적합하다고\n\n<!-- PAGE_70 -->\n###### ※ 피험자 선정기준 및 제외기준은 의료기기의 특성, 내용 구성 등을\n\n- - 64 -\n<!-- PAGE_71 -->\n###### 다.  목표대상자 수 및 그 근거\n\n피험자 수는 임상시험 방법에 따라 식약처의 ‘의료기기 임상시험 관련 통계기법\n\n<!-- PAGE_71 -->\n###### ※ 본 가이드라인에 작성된 산출 방법은 공개된 선행연구 결과를 기반으로\n\n<!-- PAGE_71 -->\n###### 작성된 예시이며, 목표 대상자 수는 개발 제품 특성과 탐색 임상시험 등\n\n<!-- PAGE_71 -->\n###### 제품별 선행연구 결과에 따라 다르므로, 개발 제품의 선행연구 결과\n\n<!-- PAGE_71 -->\n###### 및 참고문헌을 기준으로 산출한다.  이때, 그 근거(가설, 변수, 성공\n\n<!-- PAGE_71 -->\n###### 본 시험의 일차목적: 우울장애 진단환자의 우울장애 심각도\n\n<!-- PAGE_71 -->\n###### 척도(BDI) 변화량이 대조군과 비교해 시험군에서 치료 전과\n\n<!-- PAGE_71 -->\n###### 비교하여 우월하게 개선되는 것을 확증하는 것이다.  변화량은\n\n<!-- PAGE_71 -->\n###### 치료 시작 전 평가지표 Baseline 조사에서 수집한 정보와 대비\n\n<!-- PAGE_71 -->\n###### 하여 치료 종료 후(Post-treatment) 수집한 정보와의 차이를\n\n<!-- PAGE_71 -->\n###### 의미하며, 이에 대한 가설은 아래와 같다.  이 가설의 평균 차이\n\n- - 65 -\n<!-- PAGE_72 -->\n###### 검정에서 통계학적으로 유의하면 임상시험 성공으로 평가한다.\n\n <!-- PAGE_72 -->\n###### : 시험군의 치료 전 대비 post-treatment 후 평균 우울장애 심각도\n\n<!-- PAGE_72 -->\n###### : 대조군의 치료 전 대비 post-treatment 후 평균 우울장애 심각도\n\n<!-- PAGE_72 -->\n###### 19세 이상 우울장애 환자를 대상으로 한 국외 인터넷 기반\n\n<!-- PAGE_72 -->\n###### 우울장애 인지행동치료(Web-based CBT-D) 선행 연구를 검토한\n\n<!-- PAGE_72 -->\n###### 결과, 대조군 대비 인터넷 기반 우울장애 인지행동치료\n\n<!-- PAGE_72 -->\n###### (Web-based CBT-D)의 치료 전 대비 Post-treatment 후 우울장애\n\n<!-- PAGE_72 -->\n###### 심각도 척도(BDI)의 effect size는 0.65, 1.17로 조사되었다. ",
        "original_sentence": "이때, 그 근거(가설, 변수, 성공\n\n<!-- PAGE_71 -->\n###### 본 시험의 일차목적: 우울장애 진단환자의 우울장애 심각도\n\n<!-- PAGE_71 -->\n###### 척도(BDI) 변화량이 대조군과 비교해 시험군에서 치료 전과\n\n<!-- PAGE_71 -->\n###### 비교하여 우월하게 개선되는 것을 확증하는 것이다. "
      }
    },
    {
      "chunk_id": "chunk_705",
      "text": "변화량은\n\n<!-- PAGE_71 -->\n###### 치료 시작 전 평가지표 Baseline 조사에서 수집한 정보와 대비\n\n<!-- PAGE_71 -->\n###### 하여 치료 종료 후(Post-treatment) 수집한 정보와의 차이를\n\n<!-- PAGE_71 -->\n###### 의미하며, 이에 대한 가설은 아래와 같다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 704,
        "window_size": 3,
        "char_count": 182,
        "word_count": 35,
        "page_number": 71,
        "window_text": "피험자 제외기준\n\n<!-- PAGE_69 -->\n###### : 제외기준 중 어느 하나라도 해당하는 항목이 있는 경우 본\n\n<!-- PAGE_69 -->\n###### 2) 스크리닝 시점 3개월 이내에 자살 시도를 한 바 있으며, 정신과\n\n<!-- PAGE_69 -->\n###### ※ 콜롬비아 자살 위험성 스케일(Columbia Suicide Severity Rating Scale,\n\n- - 63 -\n<!-- PAGE_70 -->\n###### C-SSRS) 혹은 이와 유사한 과학적 근거를 가진 자살 위험성 평가상 자\n\n<!-- PAGE_70 -->\n###### 살 고위험군으로 평가되는 자\n\n<!-- PAGE_70 -->\n###### 3) 스크리닝 시점 1년 동안 제대로 치료받지 못한 간질, 심각한\n\n<!-- PAGE_70 -->\n###### 4) 스크리닝 이전 1주일 이내에 평균 알코올 섭취량이 1일 20g을\n\n<!-- PAGE_70 -->\n###### 5) 스크리닝 시점 3개월 이내에 우울장애에 대한 다른 비약물적인\n\n<!-- PAGE_70 -->\n###### 6) 최근 1개월 이내 사용하는 신경정신과 관련 약물의 종류 및 용량에\n\n<!-- PAGE_70 -->\n###### ※ 최근 1개월 이내 (필요시 처방을 포함하여) 복용 약물의 종류 및 용량이\n\n<!-- PAGE_70 -->\n###### 7) 기타 사유로 인하여 시험자가 임상시험 참여에 부적합하다고\n\n<!-- PAGE_70 -->\n###### ※ 피험자 선정기준 및 제외기준은 의료기기의 특성, 내용 구성 등을\n\n- - 64 -\n<!-- PAGE_71 -->\n###### 다.  목표대상자 수 및 그 근거\n\n피험자 수는 임상시험 방법에 따라 식약처의 ‘의료기기 임상시험 관련 통계기법\n\n<!-- PAGE_71 -->\n###### ※ 본 가이드라인에 작성된 산출 방법은 공개된 선행연구 결과를 기반으로\n\n<!-- PAGE_71 -->\n###### 작성된 예시이며, 목표 대상자 수는 개발 제품 특성과 탐색 임상시험 등\n\n<!-- PAGE_71 -->\n###### 제품별 선행연구 결과에 따라 다르므로, 개발 제품의 선행연구 결과\n\n<!-- PAGE_71 -->\n###### 및 참고문헌을 기준으로 산출한다.  이때, 그 근거(가설, 변수, 성공\n\n<!-- PAGE_71 -->\n###### 본 시험의 일차목적: 우울장애 진단환자의 우울장애 심각도\n\n<!-- PAGE_71 -->\n###### 척도(BDI) 변화량이 대조군과 비교해 시험군에서 치료 전과\n\n<!-- PAGE_71 -->\n###### 비교하여 우월하게 개선되는 것을 확증하는 것이다.  변화량은\n\n<!-- PAGE_71 -->\n###### 치료 시작 전 평가지표 Baseline 조사에서 수집한 정보와 대비\n\n<!-- PAGE_71 -->\n###### 하여 치료 종료 후(Post-treatment) 수집한 정보와의 차이를\n\n<!-- PAGE_71 -->\n###### 의미하며, 이에 대한 가설은 아래와 같다.  이 가설의 평균 차이\n\n- - 65 -\n<!-- PAGE_72 -->\n###### 검정에서 통계학적으로 유의하면 임상시험 성공으로 평가한다.\n\n <!-- PAGE_72 -->\n###### : 시험군의 치료 전 대비 post-treatment 후 평균 우울장애 심각도\n\n<!-- PAGE_72 -->\n###### : 대조군의 치료 전 대비 post-treatment 후 평균 우울장애 심각도\n\n<!-- PAGE_72 -->\n###### 19세 이상 우울장애 환자를 대상으로 한 국외 인터넷 기반\n\n<!-- PAGE_72 -->\n###### 우울장애 인지행동치료(Web-based CBT-D) 선행 연구를 검토한\n\n<!-- PAGE_72 -->\n###### 결과, 대조군 대비 인터넷 기반 우울장애 인지행동치료\n\n<!-- PAGE_72 -->\n###### (Web-based CBT-D)의 치료 전 대비 Post-treatment 후 우울장애\n\n<!-- PAGE_72 -->\n###### 심각도 척도(BDI)의 effect size는 0.65, 1.17로 조사되었다.  이에\n\n<!-- PAGE_72 -->\n###### 본 연구에서의 예상되는 effect size는 보수적으로 조사된 결과\n\n- - 66 -\n<!-- PAGE_73 -->\n###### 표 14. ",
        "original_sentence": "변화량은\n\n<!-- PAGE_71 -->\n###### 치료 시작 전 평가지표 Baseline 조사에서 수집한 정보와 대비\n\n<!-- PAGE_71 -->\n###### 하여 치료 종료 후(Post-treatment) 수집한 정보와의 차이를\n\n<!-- PAGE_71 -->\n###### 의미하며, 이에 대한 가설은 아래와 같다. "
      }
    },
    {
      "chunk_id": "chunk_706",
      "text": "이 가설의 평균 차이\n\n- - 65 -\n<!-- PAGE_72 -->\n###### 검정에서 통계학적으로 유의하면 임상시험 성공으로 평가한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 705,
        "window_size": 3,
        "char_count": 80,
        "word_count": 18,
        "page_number": 72,
        "window_text": "목표대상자 수 및 그 근거\n\n피험자 수는 임상시험 방법에 따라 식약처의 ‘의료기기 임상시험 관련 통계기법\n\n<!-- PAGE_71 -->\n###### ※ 본 가이드라인에 작성된 산출 방법은 공개된 선행연구 결과를 기반으로\n\n<!-- PAGE_71 -->\n###### 작성된 예시이며, 목표 대상자 수는 개발 제품 특성과 탐색 임상시험 등\n\n<!-- PAGE_71 -->\n###### 제품별 선행연구 결과에 따라 다르므로, 개발 제품의 선행연구 결과\n\n<!-- PAGE_71 -->\n###### 및 참고문헌을 기준으로 산출한다.  이때, 그 근거(가설, 변수, 성공\n\n<!-- PAGE_71 -->\n###### 본 시험의 일차목적: 우울장애 진단환자의 우울장애 심각도\n\n<!-- PAGE_71 -->\n###### 척도(BDI) 변화량이 대조군과 비교해 시험군에서 치료 전과\n\n<!-- PAGE_71 -->\n###### 비교하여 우월하게 개선되는 것을 확증하는 것이다.  변화량은\n\n<!-- PAGE_71 -->\n###### 치료 시작 전 평가지표 Baseline 조사에서 수집한 정보와 대비\n\n<!-- PAGE_71 -->\n###### 하여 치료 종료 후(Post-treatment) 수집한 정보와의 차이를\n\n<!-- PAGE_71 -->\n###### 의미하며, 이에 대한 가설은 아래와 같다.  이 가설의 평균 차이\n\n- - 65 -\n<!-- PAGE_72 -->\n###### 검정에서 통계학적으로 유의하면 임상시험 성공으로 평가한다.\n\n <!-- PAGE_72 -->\n###### : 시험군의 치료 전 대비 post-treatment 후 평균 우울장애 심각도\n\n<!-- PAGE_72 -->\n###### : 대조군의 치료 전 대비 post-treatment 후 평균 우울장애 심각도\n\n<!-- PAGE_72 -->\n###### 19세 이상 우울장애 환자를 대상으로 한 국외 인터넷 기반\n\n<!-- PAGE_72 -->\n###### 우울장애 인지행동치료(Web-based CBT-D) 선행 연구를 검토한\n\n<!-- PAGE_72 -->\n###### 결과, 대조군 대비 인터넷 기반 우울장애 인지행동치료\n\n<!-- PAGE_72 -->\n###### (Web-based CBT-D)의 치료 전 대비 Post-treatment 후 우울장애\n\n<!-- PAGE_72 -->\n###### 심각도 척도(BDI)의 effect size는 0.65, 1.17로 조사되었다.  이에\n\n<!-- PAGE_72 -->\n###### 본 연구에서의 예상되는 effect size는 보수적으로 조사된 결과\n\n- - 66 -\n<!-- PAGE_73 -->\n###### 표 14.  치료 전 대비 Post-treatment 후 우울장애 심각도 척도(BDI) 변화량\n\n<!-- PAGE_73 -->\n###### 비교결과\n\n<!-- PAGE_73 -->\n###### 본 연구에서는 가설의 평균 변화량 차이 검정에 대해 최소\n\n<!-- PAGE_73 -->\n###### 필요한 피험자 수를 산출하기 위해 effect size는 0.65를 가정\n\n<!-- PAGE_73 -->\n###### 하였고, 양측 유의수준 5%, 검정력 80%를 만족하는 데 필요한\n\n<!-- PAGE_73 -->\n###### 피험자 수(군당 1:1 배정)를 산출한 결과, 한 군당 38명이었다.\n\n",
        "original_sentence": "이 가설의 평균 차이\n\n- - 65 -\n<!-- PAGE_72 -->\n###### 검정에서 통계학적으로 유의하면 임상시험 성공으로 평가한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_707",
      "text": "<!-- PAGE_72 -->\n###### : 시험군의 치료 전 대비 post-treatment 후 평균 우울장애 심각도\n\n<!-- PAGE_72 -->\n###### : 대조군의 치료 전 대비 post-treatment 후 평균 우울장애 심각도\n\n<!-- PAGE_72 -->\n###### 19세 이상 우울장애 환자를 대상으로 한 국외 인터넷 기반\n\n<!-- PAGE_72 -->\n###### 우울장애 인지행동치료(Web-based CBT-D) 선행 연구를 검토한\n\n<!-- PAGE_72 -->\n###### 결과, 대조군 대비 인터넷 기반 우울장애 인지행동치료\n\n<!-- PAGE_72 -->\n###### (Web-based CBT-D)의 치료 전 대비 Post-treatment 후 우울장애\n\n<!-- PAGE_72 -->\n###### 심각도 척도(BDI)의 effect size는 0.65, 1.17로 조사되었다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 706,
        "window_size": 3,
        "char_count": 463,
        "word_count": 85,
        "page_number": 72,
        "window_text": "이때, 그 근거(가설, 변수, 성공\n\n<!-- PAGE_71 -->\n###### 본 시험의 일차목적: 우울장애 진단환자의 우울장애 심각도\n\n<!-- PAGE_71 -->\n###### 척도(BDI) 변화량이 대조군과 비교해 시험군에서 치료 전과\n\n<!-- PAGE_71 -->\n###### 비교하여 우월하게 개선되는 것을 확증하는 것이다.  변화량은\n\n<!-- PAGE_71 -->\n###### 치료 시작 전 평가지표 Baseline 조사에서 수집한 정보와 대비\n\n<!-- PAGE_71 -->\n###### 하여 치료 종료 후(Post-treatment) 수집한 정보와의 차이를\n\n<!-- PAGE_71 -->\n###### 의미하며, 이에 대한 가설은 아래와 같다.  이 가설의 평균 차이\n\n- - 65 -\n<!-- PAGE_72 -->\n###### 검정에서 통계학적으로 유의하면 임상시험 성공으로 평가한다.\n\n <!-- PAGE_72 -->\n###### : 시험군의 치료 전 대비 post-treatment 후 평균 우울장애 심각도\n\n<!-- PAGE_72 -->\n###### : 대조군의 치료 전 대비 post-treatment 후 평균 우울장애 심각도\n\n<!-- PAGE_72 -->\n###### 19세 이상 우울장애 환자를 대상으로 한 국외 인터넷 기반\n\n<!-- PAGE_72 -->\n###### 우울장애 인지행동치료(Web-based CBT-D) 선행 연구를 검토한\n\n<!-- PAGE_72 -->\n###### 결과, 대조군 대비 인터넷 기반 우울장애 인지행동치료\n\n<!-- PAGE_72 -->\n###### (Web-based CBT-D)의 치료 전 대비 Post-treatment 후 우울장애\n\n<!-- PAGE_72 -->\n###### 심각도 척도(BDI)의 effect size는 0.65, 1.17로 조사되었다.  이에\n\n<!-- PAGE_72 -->\n###### 본 연구에서의 예상되는 effect size는 보수적으로 조사된 결과\n\n- - 66 -\n<!-- PAGE_73 -->\n###### 표 14.  치료 전 대비 Post-treatment 후 우울장애 심각도 척도(BDI) 변화량\n\n<!-- PAGE_73 -->\n###### 비교결과\n\n<!-- PAGE_73 -->\n###### 본 연구에서는 가설의 평균 변화량 차이 검정에 대해 최소\n\n<!-- PAGE_73 -->\n###### 필요한 피험자 수를 산출하기 위해 effect size는 0.65를 가정\n\n<!-- PAGE_73 -->\n###### 하였고, 양측 유의수준 5%, 검정력 80%를 만족하는 데 필요한\n\n<!-- PAGE_73 -->\n###### 피험자 수(군당 1:1 배정)를 산출한 결과, 한 군당 38명이었다.\n\n <!-- PAGE_73 -->\n###### 이에 중도 탈락을 30%를 고려하여 목표 피험자 수는 총 110명\n\n<!-- PAGE_73 -->\n###### (군당 55명)으로 결정하였다. ",
        "original_sentence": "<!-- PAGE_72 -->\n###### : 시험군의 치료 전 대비 post-treatment 후 평균 우울장애 심각도\n\n<!-- PAGE_72 -->\n###### : 대조군의 치료 전 대비 post-treatment 후 평균 우울장애 심각도\n\n<!-- PAGE_72 -->\n###### 19세 이상 우울장애 환자를 대상으로 한 국외 인터넷 기반\n\n<!-- PAGE_72 -->\n###### 우울장애 인지행동치료(Web-based CBT-D) 선행 연구를 검토한\n\n<!-- PAGE_72 -->\n###### 결과, 대조군 대비 인터넷 기반 우울장애 인지행동치료\n\n<!-- PAGE_72 -->\n###### (Web-based CBT-D)의 치료 전 대비 Post-treatment 후 우울장애\n\n<!-- PAGE_72 -->\n###### 심각도 척도(BDI)의 effect size는 0.65, 1.17로 조사되었다. "
      }
    },
    {
      "chunk_id": "chunk_708",
      "text": "이에\n\n<!-- PAGE_72 -->\n###### 본 연구에서의 예상되는 effect size는 보수적으로 조사된 결과\n\n- - 66 -\n<!-- PAGE_73 -->\n###### 표 14. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 707,
        "window_size": 3,
        "char_count": 107,
        "word_count": 23,
        "page_number": 72,
        "window_text": "변화량은\n\n<!-- PAGE_71 -->\n###### 치료 시작 전 평가지표 Baseline 조사에서 수집한 정보와 대비\n\n<!-- PAGE_71 -->\n###### 하여 치료 종료 후(Post-treatment) 수집한 정보와의 차이를\n\n<!-- PAGE_71 -->\n###### 의미하며, 이에 대한 가설은 아래와 같다.  이 가설의 평균 차이\n\n- - 65 -\n<!-- PAGE_72 -->\n###### 검정에서 통계학적으로 유의하면 임상시험 성공으로 평가한다.\n\n <!-- PAGE_72 -->\n###### : 시험군의 치료 전 대비 post-treatment 후 평균 우울장애 심각도\n\n<!-- PAGE_72 -->\n###### : 대조군의 치료 전 대비 post-treatment 후 평균 우울장애 심각도\n\n<!-- PAGE_72 -->\n###### 19세 이상 우울장애 환자를 대상으로 한 국외 인터넷 기반\n\n<!-- PAGE_72 -->\n###### 우울장애 인지행동치료(Web-based CBT-D) 선행 연구를 검토한\n\n<!-- PAGE_72 -->\n###### 결과, 대조군 대비 인터넷 기반 우울장애 인지행동치료\n\n<!-- PAGE_72 -->\n###### (Web-based CBT-D)의 치료 전 대비 Post-treatment 후 우울장애\n\n<!-- PAGE_72 -->\n###### 심각도 척도(BDI)의 effect size는 0.65, 1.17로 조사되었다.  이에\n\n<!-- PAGE_72 -->\n###### 본 연구에서의 예상되는 effect size는 보수적으로 조사된 결과\n\n- - 66 -\n<!-- PAGE_73 -->\n###### 표 14.  치료 전 대비 Post-treatment 후 우울장애 심각도 척도(BDI) 변화량\n\n<!-- PAGE_73 -->\n###### 비교결과\n\n<!-- PAGE_73 -->\n###### 본 연구에서는 가설의 평균 변화량 차이 검정에 대해 최소\n\n<!-- PAGE_73 -->\n###### 필요한 피험자 수를 산출하기 위해 effect size는 0.65를 가정\n\n<!-- PAGE_73 -->\n###### 하였고, 양측 유의수준 5%, 검정력 80%를 만족하는 데 필요한\n\n<!-- PAGE_73 -->\n###### 피험자 수(군당 1:1 배정)를 산출한 결과, 한 군당 38명이었다.\n\n <!-- PAGE_73 -->\n###### 이에 중도 탈락을 30%를 고려하여 목표 피험자 수는 총 110명\n\n<!-- PAGE_73 -->\n###### (군당 55명)으로 결정하였다.  두 군의 평균 차이 검정에 대한\n\n<!-- PAGE_73 -->\n###### · 기존 CBTi 연구에서는 병원 방문 없이 온라인 수집으로만\n\n<!-- PAGE_73 -->\n###### 한 경우 40% 정도의 중도 탈락을 보였다. ",
        "original_sentence": "이에\n\n<!-- PAGE_72 -->\n###### 본 연구에서의 예상되는 effect size는 보수적으로 조사된 결과\n\n- - 66 -\n<!-- PAGE_73 -->\n###### 표 14. "
      }
    },
    {
      "chunk_id": "chunk_709",
      "text": "치료 전 대비 Post-treatment 후 우울장애 심각도 척도(BDI) 변화량\n\n<!-- PAGE_73 -->\n###### 비교결과\n\n<!-- PAGE_73 -->\n###### 본 연구에서는 가설의 평균 변화량 차이 검정에 대해 최소\n\n<!-- PAGE_73 -->\n###### 필요한 피험자 수를 산출하기 위해 effect size는 0.65를 가정\n\n<!-- PAGE_73 -->\n###### 하였고, 양측 유의수준 5%, 검정력 80%를 만족하는 데 필요한\n\n<!-- PAGE_73 -->\n###### 피험자 수(군당 1:1 배정)를 산출한 결과, 한 군당 38명이었다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 708,
        "window_size": 3,
        "char_count": 326,
        "word_count": 66,
        "page_number": 73,
        "window_text": "이 가설의 평균 차이\n\n- - 65 -\n<!-- PAGE_72 -->\n###### 검정에서 통계학적으로 유의하면 임상시험 성공으로 평가한다.\n\n <!-- PAGE_72 -->\n###### : 시험군의 치료 전 대비 post-treatment 후 평균 우울장애 심각도\n\n<!-- PAGE_72 -->\n###### : 대조군의 치료 전 대비 post-treatment 후 평균 우울장애 심각도\n\n<!-- PAGE_72 -->\n###### 19세 이상 우울장애 환자를 대상으로 한 국외 인터넷 기반\n\n<!-- PAGE_72 -->\n###### 우울장애 인지행동치료(Web-based CBT-D) 선행 연구를 검토한\n\n<!-- PAGE_72 -->\n###### 결과, 대조군 대비 인터넷 기반 우울장애 인지행동치료\n\n<!-- PAGE_72 -->\n###### (Web-based CBT-D)의 치료 전 대비 Post-treatment 후 우울장애\n\n<!-- PAGE_72 -->\n###### 심각도 척도(BDI)의 effect size는 0.65, 1.17로 조사되었다.  이에\n\n<!-- PAGE_72 -->\n###### 본 연구에서의 예상되는 effect size는 보수적으로 조사된 결과\n\n- - 66 -\n<!-- PAGE_73 -->\n###### 표 14.  치료 전 대비 Post-treatment 후 우울장애 심각도 척도(BDI) 변화량\n\n<!-- PAGE_73 -->\n###### 비교결과\n\n<!-- PAGE_73 -->\n###### 본 연구에서는 가설의 평균 변화량 차이 검정에 대해 최소\n\n<!-- PAGE_73 -->\n###### 필요한 피험자 수를 산출하기 위해 effect size는 0.65를 가정\n\n<!-- PAGE_73 -->\n###### 하였고, 양측 유의수준 5%, 검정력 80%를 만족하는 데 필요한\n\n<!-- PAGE_73 -->\n###### 피험자 수(군당 1:1 배정)를 산출한 결과, 한 군당 38명이었다.\n\n <!-- PAGE_73 -->\n###### 이에 중도 탈락을 30%를 고려하여 목표 피험자 수는 총 110명\n\n<!-- PAGE_73 -->\n###### (군당 55명)으로 결정하였다.  두 군의 평균 차이 검정에 대한\n\n<!-- PAGE_73 -->\n###### · 기존 CBTi 연구에서는 병원 방문 없이 온라인 수집으로만\n\n<!-- PAGE_73 -->\n###### 한 경우 40% 정도의 중도 탈락을 보였다.  그러나, 본\n\n<!-- PAGE_73 -->\n###### 연구에서는 병원 방문으로 이보다는 더 적게 탈락할 것\n\n- - 67 -\n<!-- PAGE_74 -->\n###### : 한 군당 필요한 피험자 수\n\n<!-- PAGE_74 -->\n###### : 제1종 오류 0.05 (유의수준)\n\n<!-- PAGE_74 -->\n###### ※ 본 임상시험의 경우 임상시험 설계 시 중도 탈락율은 약 10∼30%\n\n- - 68 -\n<!-- PAGE_75 -->\n###### 피험자의 모집 기간, 임상 관찰 및 수행 기간, 통계분석 기간, 결과\n\n<!-- PAGE_75 -->\n###### 보고서 작성 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을\n\n<!-- PAGE_75 -->\n###### 고려하도록 한다.\n\n",
        "original_sentence": "치료 전 대비 Post-treatment 후 우울장애 심각도 척도(BDI) 변화량\n\n<!-- PAGE_73 -->\n###### 비교결과\n\n<!-- PAGE_73 -->\n###### 본 연구에서는 가설의 평균 변화량 차이 검정에 대해 최소\n\n<!-- PAGE_73 -->\n###### 필요한 피험자 수를 산출하기 위해 effect size는 0.65를 가정\n\n<!-- PAGE_73 -->\n###### 하였고, 양측 유의수준 5%, 검정력 80%를 만족하는 데 필요한\n\n<!-- PAGE_73 -->\n###### 피험자 수(군당 1:1 배정)를 산출한 결과, 한 군당 38명이었다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_710",
      "text": "<!-- PAGE_73 -->\n###### 이에 중도 탈락을 30%를 고려하여 목표 피험자 수는 총 110명\n\n<!-- PAGE_73 -->\n###### (군당 55명)으로 결정하였다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 709,
        "window_size": 3,
        "char_count": 104,
        "word_count": 21,
        "page_number": 73,
        "window_text": "<!-- PAGE_72 -->\n###### : 시험군의 치료 전 대비 post-treatment 후 평균 우울장애 심각도\n\n<!-- PAGE_72 -->\n###### : 대조군의 치료 전 대비 post-treatment 후 평균 우울장애 심각도\n\n<!-- PAGE_72 -->\n###### 19세 이상 우울장애 환자를 대상으로 한 국외 인터넷 기반\n\n<!-- PAGE_72 -->\n###### 우울장애 인지행동치료(Web-based CBT-D) 선행 연구를 검토한\n\n<!-- PAGE_72 -->\n###### 결과, 대조군 대비 인터넷 기반 우울장애 인지행동치료\n\n<!-- PAGE_72 -->\n###### (Web-based CBT-D)의 치료 전 대비 Post-treatment 후 우울장애\n\n<!-- PAGE_72 -->\n###### 심각도 척도(BDI)의 effect size는 0.65, 1.17로 조사되었다.  이에\n\n<!-- PAGE_72 -->\n###### 본 연구에서의 예상되는 effect size는 보수적으로 조사된 결과\n\n- - 66 -\n<!-- PAGE_73 -->\n###### 표 14.  치료 전 대비 Post-treatment 후 우울장애 심각도 척도(BDI) 변화량\n\n<!-- PAGE_73 -->\n###### 비교결과\n\n<!-- PAGE_73 -->\n###### 본 연구에서는 가설의 평균 변화량 차이 검정에 대해 최소\n\n<!-- PAGE_73 -->\n###### 필요한 피험자 수를 산출하기 위해 effect size는 0.65를 가정\n\n<!-- PAGE_73 -->\n###### 하였고, 양측 유의수준 5%, 검정력 80%를 만족하는 데 필요한\n\n<!-- PAGE_73 -->\n###### 피험자 수(군당 1:1 배정)를 산출한 결과, 한 군당 38명이었다.\n\n <!-- PAGE_73 -->\n###### 이에 중도 탈락을 30%를 고려하여 목표 피험자 수는 총 110명\n\n<!-- PAGE_73 -->\n###### (군당 55명)으로 결정하였다.  두 군의 평균 차이 검정에 대한\n\n<!-- PAGE_73 -->\n###### · 기존 CBTi 연구에서는 병원 방문 없이 온라인 수집으로만\n\n<!-- PAGE_73 -->\n###### 한 경우 40% 정도의 중도 탈락을 보였다.  그러나, 본\n\n<!-- PAGE_73 -->\n###### 연구에서는 병원 방문으로 이보다는 더 적게 탈락할 것\n\n- - 67 -\n<!-- PAGE_74 -->\n###### : 한 군당 필요한 피험자 수\n\n<!-- PAGE_74 -->\n###### : 제1종 오류 0.05 (유의수준)\n\n<!-- PAGE_74 -->\n###### ※ 본 임상시험의 경우 임상시험 설계 시 중도 탈락율은 약 10∼30%\n\n- - 68 -\n<!-- PAGE_75 -->\n###### 피험자의 모집 기간, 임상 관찰 및 수행 기간, 통계분석 기간, 결과\n\n<!-- PAGE_75 -->\n###### 보고서 작성 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을\n\n<!-- PAGE_75 -->\n###### 고려하도록 한다.\n\n <!-- PAGE_75 -->\n##### 9. ",
        "original_sentence": "<!-- PAGE_73 -->\n###### 이에 중도 탈락을 30%를 고려하여 목표 피험자 수는 총 110명\n\n<!-- PAGE_73 -->\n###### (군당 55명)으로 결정하였다. "
      }
    },
    {
      "chunk_id": "chunk_711",
      "text": "두 군의 평균 차이 검정에 대한\n\n<!-- PAGE_73 -->\n###### · 기존 CBTi 연구에서는 병원 방문 없이 온라인 수집으로만\n\n<!-- PAGE_73 -->\n###### 한 경우 40% 정도의 중도 탈락을 보였다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 710,
        "window_size": 3,
        "char_count": 128,
        "word_count": 30,
        "page_number": 73,
        "window_text": "이에\n\n<!-- PAGE_72 -->\n###### 본 연구에서의 예상되는 effect size는 보수적으로 조사된 결과\n\n- - 66 -\n<!-- PAGE_73 -->\n###### 표 14.  치료 전 대비 Post-treatment 후 우울장애 심각도 척도(BDI) 변화량\n\n<!-- PAGE_73 -->\n###### 비교결과\n\n<!-- PAGE_73 -->\n###### 본 연구에서는 가설의 평균 변화량 차이 검정에 대해 최소\n\n<!-- PAGE_73 -->\n###### 필요한 피험자 수를 산출하기 위해 effect size는 0.65를 가정\n\n<!-- PAGE_73 -->\n###### 하였고, 양측 유의수준 5%, 검정력 80%를 만족하는 데 필요한\n\n<!-- PAGE_73 -->\n###### 피험자 수(군당 1:1 배정)를 산출한 결과, 한 군당 38명이었다.\n\n <!-- PAGE_73 -->\n###### 이에 중도 탈락을 30%를 고려하여 목표 피험자 수는 총 110명\n\n<!-- PAGE_73 -->\n###### (군당 55명)으로 결정하였다.  두 군의 평균 차이 검정에 대한\n\n<!-- PAGE_73 -->\n###### · 기존 CBTi 연구에서는 병원 방문 없이 온라인 수집으로만\n\n<!-- PAGE_73 -->\n###### 한 경우 40% 정도의 중도 탈락을 보였다.  그러나, 본\n\n<!-- PAGE_73 -->\n###### 연구에서는 병원 방문으로 이보다는 더 적게 탈락할 것\n\n- - 67 -\n<!-- PAGE_74 -->\n###### : 한 군당 필요한 피험자 수\n\n<!-- PAGE_74 -->\n###### : 제1종 오류 0.05 (유의수준)\n\n<!-- PAGE_74 -->\n###### ※ 본 임상시험의 경우 임상시험 설계 시 중도 탈락율은 약 10∼30%\n\n- - 68 -\n<!-- PAGE_75 -->\n###### 피험자의 모집 기간, 임상 관찰 및 수행 기간, 통계분석 기간, 결과\n\n<!-- PAGE_75 -->\n###### 보고서 작성 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을\n\n<!-- PAGE_75 -->\n###### 고려하도록 한다.\n\n <!-- PAGE_75 -->\n##### 9.  임상시험기간\n\n- - 69 -\n<!-- PAGE_76 -->\n###### 가. ",
        "original_sentence": "두 군의 평균 차이 검정에 대한\n\n<!-- PAGE_73 -->\n###### · 기존 CBTi 연구에서는 병원 방문 없이 온라인 수집으로만\n\n<!-- PAGE_73 -->\n###### 한 경우 40% 정도의 중도 탈락을 보였다. "
      }
    },
    {
      "chunk_id": "chunk_712",
      "text": "그러나, 본\n\n<!-- PAGE_73 -->\n###### 연구에서는 병원 방문으로 이보다는 더 적게 탈락할 것\n\n- - 67 -\n<!-- PAGE_74 -->\n###### : 한 군당 필요한 피험자 수\n\n<!-- PAGE_74 -->\n###### : 제1종 오류 0.05 (유의수준)\n\n<!-- PAGE_74 -->\n###### ※ 본 임상시험의 경우 임상시험 설계 시 중도 탈락율은 약 10∼30%\n\n- - 68 -\n<!-- PAGE_75 -->\n###### 피험자의 모집 기간, 임상 관찰 및 수행 기간, 통계분석 기간, 결과\n\n<!-- PAGE_75 -->\n###### 보고서 작성 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을\n\n<!-- PAGE_75 -->\n###### 고려하도록 한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 711,
        "window_size": 3,
        "char_count": 397,
        "word_count": 90,
        "page_number": 73,
        "window_text": "치료 전 대비 Post-treatment 후 우울장애 심각도 척도(BDI) 변화량\n\n<!-- PAGE_73 -->\n###### 비교결과\n\n<!-- PAGE_73 -->\n###### 본 연구에서는 가설의 평균 변화량 차이 검정에 대해 최소\n\n<!-- PAGE_73 -->\n###### 필요한 피험자 수를 산출하기 위해 effect size는 0.65를 가정\n\n<!-- PAGE_73 -->\n###### 하였고, 양측 유의수준 5%, 검정력 80%를 만족하는 데 필요한\n\n<!-- PAGE_73 -->\n###### 피험자 수(군당 1:1 배정)를 산출한 결과, 한 군당 38명이었다.\n\n <!-- PAGE_73 -->\n###### 이에 중도 탈락을 30%를 고려하여 목표 피험자 수는 총 110명\n\n<!-- PAGE_73 -->\n###### (군당 55명)으로 결정하였다.  두 군의 평균 차이 검정에 대한\n\n<!-- PAGE_73 -->\n###### · 기존 CBTi 연구에서는 병원 방문 없이 온라인 수집으로만\n\n<!-- PAGE_73 -->\n###### 한 경우 40% 정도의 중도 탈락을 보였다.  그러나, 본\n\n<!-- PAGE_73 -->\n###### 연구에서는 병원 방문으로 이보다는 더 적게 탈락할 것\n\n- - 67 -\n<!-- PAGE_74 -->\n###### : 한 군당 필요한 피험자 수\n\n<!-- PAGE_74 -->\n###### : 제1종 오류 0.05 (유의수준)\n\n<!-- PAGE_74 -->\n###### ※ 본 임상시험의 경우 임상시험 설계 시 중도 탈락율은 약 10∼30%\n\n- - 68 -\n<!-- PAGE_75 -->\n###### 피험자의 모집 기간, 임상 관찰 및 수행 기간, 통계분석 기간, 결과\n\n<!-- PAGE_75 -->\n###### 보고서 작성 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을\n\n<!-- PAGE_75 -->\n###### 고려하도록 한다.\n\n <!-- PAGE_75 -->\n##### 9.  임상시험기간\n\n- - 69 -\n<!-- PAGE_76 -->\n###### 가.  시험방법\n\n<!-- PAGE_76 -->\n###### (예) 무작위배정 이후, 8주 동안 치료 기간이 종결된 직후에 방문\n\n<!-- PAGE_76 -->\n###### (Post-treatment)하여 임상 평가를 받고, 디지털 우울장애 인지\n\n<!-- PAGE_76 -->\n###### ※ 단, 본 연구에서는 연구설계에 따라 비처치대조군(wait-list)*의 적용도\n\n<!-- PAGE_76 -->\n###### * 비처치대조군: 치료 기간 동안 아무런 처치를 받지 않고 대기하는 군\n\n<!-- PAGE_76 -->\n###### 이다. ",
        "original_sentence": "그러나, 본\n\n<!-- PAGE_73 -->\n###### 연구에서는 병원 방문으로 이보다는 더 적게 탈락할 것\n\n- - 67 -\n<!-- PAGE_74 -->\n###### : 한 군당 필요한 피험자 수\n\n<!-- PAGE_74 -->\n###### : 제1종 오류 0.05 (유의수준)\n\n<!-- PAGE_74 -->\n###### ※ 본 임상시험의 경우 임상시험 설계 시 중도 탈락율은 약 10∼30%\n\n- - 68 -\n<!-- PAGE_75 -->\n###### 피험자의 모집 기간, 임상 관찰 및 수행 기간, 통계분석 기간, 결과\n\n<!-- PAGE_75 -->\n###### 보고서 작성 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을\n\n<!-- PAGE_75 -->\n###### 고려하도록 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_713",
      "text": "<!-- PAGE_75 -->\n##### 9. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 712,
        "window_size": 3,
        "char_count": 26,
        "word_count": 5,
        "page_number": 75,
        "window_text": "<!-- PAGE_73 -->\n###### 이에 중도 탈락을 30%를 고려하여 목표 피험자 수는 총 110명\n\n<!-- PAGE_73 -->\n###### (군당 55명)으로 결정하였다.  두 군의 평균 차이 검정에 대한\n\n<!-- PAGE_73 -->\n###### · 기존 CBTi 연구에서는 병원 방문 없이 온라인 수집으로만\n\n<!-- PAGE_73 -->\n###### 한 경우 40% 정도의 중도 탈락을 보였다.  그러나, 본\n\n<!-- PAGE_73 -->\n###### 연구에서는 병원 방문으로 이보다는 더 적게 탈락할 것\n\n- - 67 -\n<!-- PAGE_74 -->\n###### : 한 군당 필요한 피험자 수\n\n<!-- PAGE_74 -->\n###### : 제1종 오류 0.05 (유의수준)\n\n<!-- PAGE_74 -->\n###### ※ 본 임상시험의 경우 임상시험 설계 시 중도 탈락율은 약 10∼30%\n\n- - 68 -\n<!-- PAGE_75 -->\n###### 피험자의 모집 기간, 임상 관찰 및 수행 기간, 통계분석 기간, 결과\n\n<!-- PAGE_75 -->\n###### 보고서 작성 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을\n\n<!-- PAGE_75 -->\n###### 고려하도록 한다.\n\n <!-- PAGE_75 -->\n##### 9.  임상시험기간\n\n- - 69 -\n<!-- PAGE_76 -->\n###### 가.  시험방법\n\n<!-- PAGE_76 -->\n###### (예) 무작위배정 이후, 8주 동안 치료 기간이 종결된 직후에 방문\n\n<!-- PAGE_76 -->\n###### (Post-treatment)하여 임상 평가를 받고, 디지털 우울장애 인지\n\n<!-- PAGE_76 -->\n###### ※ 단, 본 연구에서는 연구설계에 따라 비처치대조군(wait-list)*의 적용도\n\n<!-- PAGE_76 -->\n###### * 비처치대조군: 치료 기간 동안 아무런 처치를 받지 않고 대기하는 군\n\n<!-- PAGE_76 -->\n###### 이다.  다만, 맹검을 유지하는 수준의 최소한 치료가 제공되어야 하며,\n\n<!-- PAGE_76 -->\n###### 이에는 과학적인 근거가 있어야 한다. ",
        "original_sentence": "<!-- PAGE_75 -->\n##### 9. "
      }
    },
    {
      "chunk_id": "chunk_714",
      "text": "임상시험기간\n\n- - 69 -\n<!-- PAGE_76 -->\n###### 가. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 713,
        "window_size": 3,
        "char_count": 44,
        "word_count": 10,
        "page_number": 76,
        "window_text": "두 군의 평균 차이 검정에 대한\n\n<!-- PAGE_73 -->\n###### · 기존 CBTi 연구에서는 병원 방문 없이 온라인 수집으로만\n\n<!-- PAGE_73 -->\n###### 한 경우 40% 정도의 중도 탈락을 보였다.  그러나, 본\n\n<!-- PAGE_73 -->\n###### 연구에서는 병원 방문으로 이보다는 더 적게 탈락할 것\n\n- - 67 -\n<!-- PAGE_74 -->\n###### : 한 군당 필요한 피험자 수\n\n<!-- PAGE_74 -->\n###### : 제1종 오류 0.05 (유의수준)\n\n<!-- PAGE_74 -->\n###### ※ 본 임상시험의 경우 임상시험 설계 시 중도 탈락율은 약 10∼30%\n\n- - 68 -\n<!-- PAGE_75 -->\n###### 피험자의 모집 기간, 임상 관찰 및 수행 기간, 통계분석 기간, 결과\n\n<!-- PAGE_75 -->\n###### 보고서 작성 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을\n\n<!-- PAGE_75 -->\n###### 고려하도록 한다.\n\n <!-- PAGE_75 -->\n##### 9.  임상시험기간\n\n- - 69 -\n<!-- PAGE_76 -->\n###### 가.  시험방법\n\n<!-- PAGE_76 -->\n###### (예) 무작위배정 이후, 8주 동안 치료 기간이 종결된 직후에 방문\n\n<!-- PAGE_76 -->\n###### (Post-treatment)하여 임상 평가를 받고, 디지털 우울장애 인지\n\n<!-- PAGE_76 -->\n###### ※ 단, 본 연구에서는 연구설계에 따라 비처치대조군(wait-list)*의 적용도\n\n<!-- PAGE_76 -->\n###### * 비처치대조군: 치료 기간 동안 아무런 처치를 받지 않고 대기하는 군\n\n<!-- PAGE_76 -->\n###### 이다.  다만, 맹검을 유지하는 수준의 최소한 치료가 제공되어야 하며,\n\n<!-- PAGE_76 -->\n###### 이에는 과학적인 근거가 있어야 한다.  우울장애 인지행동치료를 기반으로 한\n\n<!-- PAGE_76 -->\n###### 디지털치료기기의 경우 서면 형태로 된 우울장애 교육 자료 등이 이에\n\n<!-- PAGE_76 -->\n###### ※ 우울장애 개선 디지털치료기기 허가제품이 출시된 이후에는 기허가\n\n<!-- PAGE_76 -->\n###### 제품과 비교시험 하는 동등성 검정 혹은 비열등성 검정 등을 시행하여\n\n<!-- PAGE_76 -->\n###### 10. ",
        "original_sentence": "임상시험기간\n\n- - 69 -\n<!-- PAGE_76 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_715",
      "text": "시험방법\n\n<!-- PAGE_76 -->\n###### (예) 무작위배정 이후, 8주 동안 치료 기간이 종결된 직후에 방문\n\n<!-- PAGE_76 -->\n###### (Post-treatment)하여 임상 평가를 받고, 디지털 우울장애 인지\n\n<!-- PAGE_76 -->\n###### ※ 단, 본 연구에서는 연구설계에 따라 비처치대조군(wait-list)*의 적용도\n\n<!-- PAGE_76 -->\n###### * 비처치대조군: 치료 기간 동안 아무런 처치를 받지 않고 대기하는 군\n\n<!-- PAGE_76 -->\n###### 이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 714,
        "window_size": 3,
        "char_count": 300,
        "word_count": 58,
        "page_number": 76,
        "window_text": "그러나, 본\n\n<!-- PAGE_73 -->\n###### 연구에서는 병원 방문으로 이보다는 더 적게 탈락할 것\n\n- - 67 -\n<!-- PAGE_74 -->\n###### : 한 군당 필요한 피험자 수\n\n<!-- PAGE_74 -->\n###### : 제1종 오류 0.05 (유의수준)\n\n<!-- PAGE_74 -->\n###### ※ 본 임상시험의 경우 임상시험 설계 시 중도 탈락율은 약 10∼30%\n\n- - 68 -\n<!-- PAGE_75 -->\n###### 피험자의 모집 기간, 임상 관찰 및 수행 기간, 통계분석 기간, 결과\n\n<!-- PAGE_75 -->\n###### 보고서 작성 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을\n\n<!-- PAGE_75 -->\n###### 고려하도록 한다.\n\n <!-- PAGE_75 -->\n##### 9.  임상시험기간\n\n- - 69 -\n<!-- PAGE_76 -->\n###### 가.  시험방법\n\n<!-- PAGE_76 -->\n###### (예) 무작위배정 이후, 8주 동안 치료 기간이 종결된 직후에 방문\n\n<!-- PAGE_76 -->\n###### (Post-treatment)하여 임상 평가를 받고, 디지털 우울장애 인지\n\n<!-- PAGE_76 -->\n###### ※ 단, 본 연구에서는 연구설계에 따라 비처치대조군(wait-list)*의 적용도\n\n<!-- PAGE_76 -->\n###### * 비처치대조군: 치료 기간 동안 아무런 처치를 받지 않고 대기하는 군\n\n<!-- PAGE_76 -->\n###### 이다.  다만, 맹검을 유지하는 수준의 최소한 치료가 제공되어야 하며,\n\n<!-- PAGE_76 -->\n###### 이에는 과학적인 근거가 있어야 한다.  우울장애 인지행동치료를 기반으로 한\n\n<!-- PAGE_76 -->\n###### 디지털치료기기의 경우 서면 형태로 된 우울장애 교육 자료 등이 이에\n\n<!-- PAGE_76 -->\n###### ※ 우울장애 개선 디지털치료기기 허가제품이 출시된 이후에는 기허가\n\n<!-- PAGE_76 -->\n###### 제품과 비교시험 하는 동등성 검정 혹은 비열등성 검정 등을 시행하여\n\n<!-- PAGE_76 -->\n###### 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n- - 70 -\n<!-- PAGE_77 -->\n###### 해당 성능을 증명할 수 있다.\n\n",
        "original_sentence": "시험방법\n\n<!-- PAGE_76 -->\n###### (예) 무작위배정 이후, 8주 동안 치료 기간이 종결된 직후에 방문\n\n<!-- PAGE_76 -->\n###### (Post-treatment)하여 임상 평가를 받고, 디지털 우울장애 인지\n\n<!-- PAGE_76 -->\n###### ※ 단, 본 연구에서는 연구설계에 따라 비처치대조군(wait-list)*의 적용도\n\n<!-- PAGE_76 -->\n###### * 비처치대조군: 치료 기간 동안 아무런 처치를 받지 않고 대기하는 군\n\n<!-- PAGE_76 -->\n###### 이다. "
      }
    },
    {
      "chunk_id": "chunk_716",
      "text": "다만, 맹검을 유지하는 수준의 최소한 치료가 제공되어야 하며,\n\n<!-- PAGE_76 -->\n###### 이에는 과학적인 근거가 있어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 715,
        "window_size": 3,
        "char_count": 81,
        "word_count": 17,
        "page_number": 76,
        "window_text": "<!-- PAGE_75 -->\n##### 9.  임상시험기간\n\n- - 69 -\n<!-- PAGE_76 -->\n###### 가.  시험방법\n\n<!-- PAGE_76 -->\n###### (예) 무작위배정 이후, 8주 동안 치료 기간이 종결된 직후에 방문\n\n<!-- PAGE_76 -->\n###### (Post-treatment)하여 임상 평가를 받고, 디지털 우울장애 인지\n\n<!-- PAGE_76 -->\n###### ※ 단, 본 연구에서는 연구설계에 따라 비처치대조군(wait-list)*의 적용도\n\n<!-- PAGE_76 -->\n###### * 비처치대조군: 치료 기간 동안 아무런 처치를 받지 않고 대기하는 군\n\n<!-- PAGE_76 -->\n###### 이다.  다만, 맹검을 유지하는 수준의 최소한 치료가 제공되어야 하며,\n\n<!-- PAGE_76 -->\n###### 이에는 과학적인 근거가 있어야 한다.  우울장애 인지행동치료를 기반으로 한\n\n<!-- PAGE_76 -->\n###### 디지털치료기기의 경우 서면 형태로 된 우울장애 교육 자료 등이 이에\n\n<!-- PAGE_76 -->\n###### ※ 우울장애 개선 디지털치료기기 허가제품이 출시된 이후에는 기허가\n\n<!-- PAGE_76 -->\n###### 제품과 비교시험 하는 동등성 검정 혹은 비열등성 검정 등을 시행하여\n\n<!-- PAGE_76 -->\n###### 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n- - 70 -\n<!-- PAGE_77 -->\n###### 해당 성능을 증명할 수 있다.\n\n <!-- PAGE_77 -->\n###### * 비열등성/동등성 시험(Non-inferiority, equivalence trial): 비교 연구에 있어\n\n<!-- PAGE_77 -->\n###### 대조기기와 비교해 시험기기의 성능이 열등하지 않음을 보이거나,\n\n<!-- PAGE_77 -->\n###### 3) 총 4회의 외래 방문을 통한 조사: 방문 1(Screening), 방문\n\n<!-- PAGE_77 -->\n###### ※ 방문 4(Follow-up, 3개월 후)는 필요시 애플리케이션, 이메일, 문자,\n\n<!-- PAGE_77 -->\n###### 4) 층화무작위배정: 기관별 성별(남/여), 연령(oo세 미만, oo세 이상)을\n\n<!-- PAGE_77 -->\n###### - 기관별로 내원한 환자 중 선정, 제외 기준에 따라 적합한\n\n<!-- PAGE_77 -->\n###### - 본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한\n\n<!-- PAGE_77 -->\n###### 내용을 피험자 본인 또는 대리인에게 설명하고, 피험자 또는\n\n<!-- PAGE_77 -->\n###### 대리인이 내용을 잘 이해한 것을 확인한 다음, 자유의사에 따른\n\n<!-- PAGE_77 -->\n###### 임상시험 참가의 동의를 문서로 받는다. ",
        "original_sentence": "다만, 맹검을 유지하는 수준의 최소한 치료가 제공되어야 하며,\n\n<!-- PAGE_76 -->\n###### 이에는 과학적인 근거가 있어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_717",
      "text": "우울장애 인지행동치료를 기반으로 한\n\n<!-- PAGE_76 -->\n###### 디지털치료기기의 경우 서면 형태로 된 우울장애 교육 자료 등이 이에\n\n<!-- PAGE_76 -->\n###### ※ 우울장애 개선 디지털치료기기 허가제품이 출시된 이후에는 기허가\n\n<!-- PAGE_76 -->\n###### 제품과 비교시험 하는 동등성 검정 혹은 비열등성 검정 등을 시행하여\n\n<!-- PAGE_76 -->\n###### 10. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 716,
        "window_size": 3,
        "char_count": 237,
        "word_count": 49,
        "page_number": 76,
        "window_text": "임상시험기간\n\n- - 69 -\n<!-- PAGE_76 -->\n###### 가.  시험방법\n\n<!-- PAGE_76 -->\n###### (예) 무작위배정 이후, 8주 동안 치료 기간이 종결된 직후에 방문\n\n<!-- PAGE_76 -->\n###### (Post-treatment)하여 임상 평가를 받고, 디지털 우울장애 인지\n\n<!-- PAGE_76 -->\n###### ※ 단, 본 연구에서는 연구설계에 따라 비처치대조군(wait-list)*의 적용도\n\n<!-- PAGE_76 -->\n###### * 비처치대조군: 치료 기간 동안 아무런 처치를 받지 않고 대기하는 군\n\n<!-- PAGE_76 -->\n###### 이다.  다만, 맹검을 유지하는 수준의 최소한 치료가 제공되어야 하며,\n\n<!-- PAGE_76 -->\n###### 이에는 과학적인 근거가 있어야 한다.  우울장애 인지행동치료를 기반으로 한\n\n<!-- PAGE_76 -->\n###### 디지털치료기기의 경우 서면 형태로 된 우울장애 교육 자료 등이 이에\n\n<!-- PAGE_76 -->\n###### ※ 우울장애 개선 디지털치료기기 허가제품이 출시된 이후에는 기허가\n\n<!-- PAGE_76 -->\n###### 제품과 비교시험 하는 동등성 검정 혹은 비열등성 검정 등을 시행하여\n\n<!-- PAGE_76 -->\n###### 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n- - 70 -\n<!-- PAGE_77 -->\n###### 해당 성능을 증명할 수 있다.\n\n <!-- PAGE_77 -->\n###### * 비열등성/동등성 시험(Non-inferiority, equivalence trial): 비교 연구에 있어\n\n<!-- PAGE_77 -->\n###### 대조기기와 비교해 시험기기의 성능이 열등하지 않음을 보이거나,\n\n<!-- PAGE_77 -->\n###### 3) 총 4회의 외래 방문을 통한 조사: 방문 1(Screening), 방문\n\n<!-- PAGE_77 -->\n###### ※ 방문 4(Follow-up, 3개월 후)는 필요시 애플리케이션, 이메일, 문자,\n\n<!-- PAGE_77 -->\n###### 4) 층화무작위배정: 기관별 성별(남/여), 연령(oo세 미만, oo세 이상)을\n\n<!-- PAGE_77 -->\n###### - 기관별로 내원한 환자 중 선정, 제외 기준에 따라 적합한\n\n<!-- PAGE_77 -->\n###### - 본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한\n\n<!-- PAGE_77 -->\n###### 내용을 피험자 본인 또는 대리인에게 설명하고, 피험자 또는\n\n<!-- PAGE_77 -->\n###### 대리인이 내용을 잘 이해한 것을 확인한 다음, 자유의사에 따른\n\n<!-- PAGE_77 -->\n###### 임상시험 참가의 동의를 문서로 받는다.  또한 동의에 서명한\n\n<!-- PAGE_77 -->\n###### 연월일을 기록하며, 동의서 사본을 환자에게 제공하여 환자가\n\n<!-- PAGE_77 -->\n###### 지속해서 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n",
        "original_sentence": "우울장애 인지행동치료를 기반으로 한\n\n<!-- PAGE_76 -->\n###### 디지털치료기기의 경우 서면 형태로 된 우울장애 교육 자료 등이 이에\n\n<!-- PAGE_76 -->\n###### ※ 우울장애 개선 디지털치료기기 허가제품이 출시된 이후에는 기허가\n\n<!-- PAGE_76 -->\n###### 제품과 비교시험 하는 동등성 검정 혹은 비열등성 검정 등을 시행하여\n\n<!-- PAGE_76 -->\n###### 10. "
      }
    },
    {
      "chunk_id": "chunk_718",
      "text": "임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n- - 70 -\n<!-- PAGE_77 -->\n###### 해당 성능을 증명할 수 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 717,
        "window_size": 3,
        "char_count": 84,
        "word_count": 16,
        "page_number": 77,
        "window_text": "시험방법\n\n<!-- PAGE_76 -->\n###### (예) 무작위배정 이후, 8주 동안 치료 기간이 종결된 직후에 방문\n\n<!-- PAGE_76 -->\n###### (Post-treatment)하여 임상 평가를 받고, 디지털 우울장애 인지\n\n<!-- PAGE_76 -->\n###### ※ 단, 본 연구에서는 연구설계에 따라 비처치대조군(wait-list)*의 적용도\n\n<!-- PAGE_76 -->\n###### * 비처치대조군: 치료 기간 동안 아무런 처치를 받지 않고 대기하는 군\n\n<!-- PAGE_76 -->\n###### 이다.  다만, 맹검을 유지하는 수준의 최소한 치료가 제공되어야 하며,\n\n<!-- PAGE_76 -->\n###### 이에는 과학적인 근거가 있어야 한다.  우울장애 인지행동치료를 기반으로 한\n\n<!-- PAGE_76 -->\n###### 디지털치료기기의 경우 서면 형태로 된 우울장애 교육 자료 등이 이에\n\n<!-- PAGE_76 -->\n###### ※ 우울장애 개선 디지털치료기기 허가제품이 출시된 이후에는 기허가\n\n<!-- PAGE_76 -->\n###### 제품과 비교시험 하는 동등성 검정 혹은 비열등성 검정 등을 시행하여\n\n<!-- PAGE_76 -->\n###### 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n- - 70 -\n<!-- PAGE_77 -->\n###### 해당 성능을 증명할 수 있다.\n\n <!-- PAGE_77 -->\n###### * 비열등성/동등성 시험(Non-inferiority, equivalence trial): 비교 연구에 있어\n\n<!-- PAGE_77 -->\n###### 대조기기와 비교해 시험기기의 성능이 열등하지 않음을 보이거나,\n\n<!-- PAGE_77 -->\n###### 3) 총 4회의 외래 방문을 통한 조사: 방문 1(Screening), 방문\n\n<!-- PAGE_77 -->\n###### ※ 방문 4(Follow-up, 3개월 후)는 필요시 애플리케이션, 이메일, 문자,\n\n<!-- PAGE_77 -->\n###### 4) 층화무작위배정: 기관별 성별(남/여), 연령(oo세 미만, oo세 이상)을\n\n<!-- PAGE_77 -->\n###### - 기관별로 내원한 환자 중 선정, 제외 기준에 따라 적합한\n\n<!-- PAGE_77 -->\n###### - 본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한\n\n<!-- PAGE_77 -->\n###### 내용을 피험자 본인 또는 대리인에게 설명하고, 피험자 또는\n\n<!-- PAGE_77 -->\n###### 대리인이 내용을 잘 이해한 것을 확인한 다음, 자유의사에 따른\n\n<!-- PAGE_77 -->\n###### 임상시험 참가의 동의를 문서로 받는다.  또한 동의에 서명한\n\n<!-- PAGE_77 -->\n###### 연월일을 기록하며, 동의서 사본을 환자에게 제공하여 환자가\n\n<!-- PAGE_77 -->\n###### 지속해서 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n - - 71 -\n<!-- PAGE_78 -->\n###### 다) 인구학적 조사, 병력조사 요법\n\n<!-- PAGE_78 -->\n###### - 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력\n\n<!-- PAGE_78 -->\n###### 등에 대하여 차트 확인 및 애플리케이션 내 질문 등을 통하여\n\n<!-- PAGE_78 -->\n###### (1) 피험자에게 서명하고 동의를 받은 후 동의 취득 순서에 따라\n\n<!-- PAGE_78 -->\n###### 스크리닝 번호를 부여하며 피험자가 참여를 종료할 때까지\n\n<!-- PAGE_78 -->\n###### (2) 피험자 적합성 평가: 피험자 선정 및 제외 기준에 적합한지\n\n<!-- PAGE_78 -->\n###### · 일차 유효성 평가지표로는 우울장애의 증상 개선을 확인\n\n<!-- PAGE_78 -->\n###### 하고자 하는 연구에서 널리 사용되고 있는 우울장애 심각도 척도\n\n<!-- PAGE_78 -->\n###### · 필요하면 과학적인 근거를 가진 기타 우울에 대한 주관적 보고\n\n<!-- PAGE_78 -->\n###### 척도로 대체할 수 있다(e.g. ",
        "original_sentence": "임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n- - 70 -\n<!-- PAGE_77 -->\n###### 해당 성능을 증명할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_719",
      "text": "<!-- PAGE_77 -->\n###### * 비열등성/동등성 시험(Non-inferiority, equivalence trial): 비교 연구에 있어\n\n<!-- PAGE_77 -->\n###### 대조기기와 비교해 시험기기의 성능이 열등하지 않음을 보이거나,\n\n<!-- PAGE_77 -->\n###### 3) 총 4회의 외래 방문을 통한 조사: 방문 1(Screening), 방문\n\n<!-- PAGE_77 -->\n###### ※ 방문 4(Follow-up, 3개월 후)는 필요시 애플리케이션, 이메일, 문자,\n\n<!-- PAGE_77 -->\n###### 4) 층화무작위배정: 기관별 성별(남/여), 연령(oo세 미만, oo세 이상)을\n\n<!-- PAGE_77 -->\n###### - 기관별로 내원한 환자 중 선정, 제외 기준에 따라 적합한\n\n<!-- PAGE_77 -->\n###### - 본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한\n\n<!-- PAGE_77 -->\n###### 내용을 피험자 본인 또는 대리인에게 설명하고, 피험자 또는\n\n<!-- PAGE_77 -->\n###### 대리인이 내용을 잘 이해한 것을 확인한 다음, 자유의사에 따른\n\n<!-- PAGE_77 -->\n###### 임상시험 참가의 동의를 문서로 받는다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 718,
        "window_size": 3,
        "char_count": 638,
        "word_count": 122,
        "page_number": 77,
        "window_text": "다만, 맹검을 유지하는 수준의 최소한 치료가 제공되어야 하며,\n\n<!-- PAGE_76 -->\n###### 이에는 과학적인 근거가 있어야 한다.  우울장애 인지행동치료를 기반으로 한\n\n<!-- PAGE_76 -->\n###### 디지털치료기기의 경우 서면 형태로 된 우울장애 교육 자료 등이 이에\n\n<!-- PAGE_76 -->\n###### ※ 우울장애 개선 디지털치료기기 허가제품이 출시된 이후에는 기허가\n\n<!-- PAGE_76 -->\n###### 제품과 비교시험 하는 동등성 검정 혹은 비열등성 검정 등을 시행하여\n\n<!-- PAGE_76 -->\n###### 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n- - 70 -\n<!-- PAGE_77 -->\n###### 해당 성능을 증명할 수 있다.\n\n <!-- PAGE_77 -->\n###### * 비열등성/동등성 시험(Non-inferiority, equivalence trial): 비교 연구에 있어\n\n<!-- PAGE_77 -->\n###### 대조기기와 비교해 시험기기의 성능이 열등하지 않음을 보이거나,\n\n<!-- PAGE_77 -->\n###### 3) 총 4회의 외래 방문을 통한 조사: 방문 1(Screening), 방문\n\n<!-- PAGE_77 -->\n###### ※ 방문 4(Follow-up, 3개월 후)는 필요시 애플리케이션, 이메일, 문자,\n\n<!-- PAGE_77 -->\n###### 4) 층화무작위배정: 기관별 성별(남/여), 연령(oo세 미만, oo세 이상)을\n\n<!-- PAGE_77 -->\n###### - 기관별로 내원한 환자 중 선정, 제외 기준에 따라 적합한\n\n<!-- PAGE_77 -->\n###### - 본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한\n\n<!-- PAGE_77 -->\n###### 내용을 피험자 본인 또는 대리인에게 설명하고, 피험자 또는\n\n<!-- PAGE_77 -->\n###### 대리인이 내용을 잘 이해한 것을 확인한 다음, 자유의사에 따른\n\n<!-- PAGE_77 -->\n###### 임상시험 참가의 동의를 문서로 받는다.  또한 동의에 서명한\n\n<!-- PAGE_77 -->\n###### 연월일을 기록하며, 동의서 사본을 환자에게 제공하여 환자가\n\n<!-- PAGE_77 -->\n###### 지속해서 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n - - 71 -\n<!-- PAGE_78 -->\n###### 다) 인구학적 조사, 병력조사 요법\n\n<!-- PAGE_78 -->\n###### - 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력\n\n<!-- PAGE_78 -->\n###### 등에 대하여 차트 확인 및 애플리케이션 내 질문 등을 통하여\n\n<!-- PAGE_78 -->\n###### (1) 피험자에게 서명하고 동의를 받은 후 동의 취득 순서에 따라\n\n<!-- PAGE_78 -->\n###### 스크리닝 번호를 부여하며 피험자가 참여를 종료할 때까지\n\n<!-- PAGE_78 -->\n###### (2) 피험자 적합성 평가: 피험자 선정 및 제외 기준에 적합한지\n\n<!-- PAGE_78 -->\n###### · 일차 유효성 평가지표로는 우울장애의 증상 개선을 확인\n\n<!-- PAGE_78 -->\n###### 하고자 하는 연구에서 널리 사용되고 있는 우울장애 심각도 척도\n\n<!-- PAGE_78 -->\n###### · 필요하면 과학적인 근거를 가진 기타 우울에 대한 주관적 보고\n\n<!-- PAGE_78 -->\n###### 척도로 대체할 수 있다(e.g.  Patient Health Questionnaire-9, PHQ-9).\n\n",
        "original_sentence": "<!-- PAGE_77 -->\n###### * 비열등성/동등성 시험(Non-inferiority, equivalence trial): 비교 연구에 있어\n\n<!-- PAGE_77 -->\n###### 대조기기와 비교해 시험기기의 성능이 열등하지 않음을 보이거나,\n\n<!-- PAGE_77 -->\n###### 3) 총 4회의 외래 방문을 통한 조사: 방문 1(Screening), 방문\n\n<!-- PAGE_77 -->\n###### ※ 방문 4(Follow-up, 3개월 후)는 필요시 애플리케이션, 이메일, 문자,\n\n<!-- PAGE_77 -->\n###### 4) 층화무작위배정: 기관별 성별(남/여), 연령(oo세 미만, oo세 이상)을\n\n<!-- PAGE_77 -->\n###### - 기관별로 내원한 환자 중 선정, 제외 기준에 따라 적합한\n\n<!-- PAGE_77 -->\n###### - 본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한\n\n<!-- PAGE_77 -->\n###### 내용을 피험자 본인 또는 대리인에게 설명하고, 피험자 또는\n\n<!-- PAGE_77 -->\n###### 대리인이 내용을 잘 이해한 것을 확인한 다음, 자유의사에 따른\n\n<!-- PAGE_77 -->\n###### 임상시험 참가의 동의를 문서로 받는다. "
      }
    },
    {
      "chunk_id": "chunk_720",
      "text": "또한 동의에 서명한\n\n<!-- PAGE_77 -->\n###### 연월일을 기록하며, 동의서 사본을 환자에게 제공하여 환자가\n\n<!-- PAGE_77 -->\n###### 지속해서 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 719,
        "window_size": 3,
        "char_count": 130,
        "word_count": 27,
        "page_number": 77,
        "window_text": "우울장애 인지행동치료를 기반으로 한\n\n<!-- PAGE_76 -->\n###### 디지털치료기기의 경우 서면 형태로 된 우울장애 교육 자료 등이 이에\n\n<!-- PAGE_76 -->\n###### ※ 우울장애 개선 디지털치료기기 허가제품이 출시된 이후에는 기허가\n\n<!-- PAGE_76 -->\n###### 제품과 비교시험 하는 동등성 검정 혹은 비열등성 검정 등을 시행하여\n\n<!-- PAGE_76 -->\n###### 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n- - 70 -\n<!-- PAGE_77 -->\n###### 해당 성능을 증명할 수 있다.\n\n <!-- PAGE_77 -->\n###### * 비열등성/동등성 시험(Non-inferiority, equivalence trial): 비교 연구에 있어\n\n<!-- PAGE_77 -->\n###### 대조기기와 비교해 시험기기의 성능이 열등하지 않음을 보이거나,\n\n<!-- PAGE_77 -->\n###### 3) 총 4회의 외래 방문을 통한 조사: 방문 1(Screening), 방문\n\n<!-- PAGE_77 -->\n###### ※ 방문 4(Follow-up, 3개월 후)는 필요시 애플리케이션, 이메일, 문자,\n\n<!-- PAGE_77 -->\n###### 4) 층화무작위배정: 기관별 성별(남/여), 연령(oo세 미만, oo세 이상)을\n\n<!-- PAGE_77 -->\n###### - 기관별로 내원한 환자 중 선정, 제외 기준에 따라 적합한\n\n<!-- PAGE_77 -->\n###### - 본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한\n\n<!-- PAGE_77 -->\n###### 내용을 피험자 본인 또는 대리인에게 설명하고, 피험자 또는\n\n<!-- PAGE_77 -->\n###### 대리인이 내용을 잘 이해한 것을 확인한 다음, 자유의사에 따른\n\n<!-- PAGE_77 -->\n###### 임상시험 참가의 동의를 문서로 받는다.  또한 동의에 서명한\n\n<!-- PAGE_77 -->\n###### 연월일을 기록하며, 동의서 사본을 환자에게 제공하여 환자가\n\n<!-- PAGE_77 -->\n###### 지속해서 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n - - 71 -\n<!-- PAGE_78 -->\n###### 다) 인구학적 조사, 병력조사 요법\n\n<!-- PAGE_78 -->\n###### - 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력\n\n<!-- PAGE_78 -->\n###### 등에 대하여 차트 확인 및 애플리케이션 내 질문 등을 통하여\n\n<!-- PAGE_78 -->\n###### (1) 피험자에게 서명하고 동의를 받은 후 동의 취득 순서에 따라\n\n<!-- PAGE_78 -->\n###### 스크리닝 번호를 부여하며 피험자가 참여를 종료할 때까지\n\n<!-- PAGE_78 -->\n###### (2) 피험자 적합성 평가: 피험자 선정 및 제외 기준에 적합한지\n\n<!-- PAGE_78 -->\n###### · 일차 유효성 평가지표로는 우울장애의 증상 개선을 확인\n\n<!-- PAGE_78 -->\n###### 하고자 하는 연구에서 널리 사용되고 있는 우울장애 심각도 척도\n\n<!-- PAGE_78 -->\n###### · 필요하면 과학적인 근거를 가진 기타 우울에 대한 주관적 보고\n\n<!-- PAGE_78 -->\n###### 척도로 대체할 수 있다(e.g.  Patient Health Questionnaire-9, PHQ-9).\n\n - - 72 -\n<!-- PAGE_79 -->\n###### (2) 이차 유효성 평가지표\n\n<!-- PAGE_79 -->\n###### · 일차 유효성 평가지표를 통해 유효성을 검증하는 것이\n\n<!-- PAGE_79 -->\n###### 기본적인 원칙이지만, 이외 필요하면 변수를 이차 유효성\n\n<!-- PAGE_79 -->\n###### · 과학적인 근거를 가진 변수이되, 기존 우울 증상 개선 시\n\n<!-- PAGE_79 -->\n###### 함께 개선될 수 있다고 여겨진 영역에 한정한다(우울장애\n\n<!-- PAGE_79 -->\n###### 개선, 삶의 질, 직업적 혹은 사회적 기능, 우울과 불안을\n\n<!-- PAGE_79 -->\n###### - 방문 2(Baseline), 방문 3(Post-treatment,), 방문 4\n\n- - 73 -\n측정도구\n\n설명\n\n- - 74 -\n측정도구\n\n설명\n\nKDS는 한국인 우울장애 환자들이 호소하는 증상과 생활사건에\n\n- - 75 -\n측정도구\n\n설명\n\nBSS는 우울장애 관련 구성개념의 하나로, 자살 위험의 지침인\n\n(출처: 우울장애 임상지료지침, 2022, H.J. ",
        "original_sentence": "또한 동의에 서명한\n\n<!-- PAGE_77 -->\n###### 연월일을 기록하며, 동의서 사본을 환자에게 제공하여 환자가\n\n<!-- PAGE_77 -->\n###### 지속해서 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_721",
      "text": "- - 71 -\n<!-- PAGE_78 -->\n###### 다) 인구학적 조사, 병력조사 요법\n\n<!-- PAGE_78 -->\n###### - 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력\n\n<!-- PAGE_78 -->\n###### 등에 대하여 차트 확인 및 애플리케이션 내 질문 등을 통하여\n\n<!-- PAGE_78 -->\n###### (1) 피험자에게 서명하고 동의를 받은 후 동의 취득 순서에 따라\n\n<!-- PAGE_78 -->\n###### 스크리닝 번호를 부여하며 피험자가 참여를 종료할 때까지\n\n<!-- PAGE_78 -->\n###### (2) 피험자 적합성 평가: 피험자 선정 및 제외 기준에 적합한지\n\n<!-- PAGE_78 -->\n###### · 일차 유효성 평가지표로는 우울장애의 증상 개선을 확인\n\n<!-- PAGE_78 -->\n###### 하고자 하는 연구에서 널리 사용되고 있는 우울장애 심각도 척도\n\n<!-- PAGE_78 -->\n###### · 필요하면 과학적인 근거를 가진 기타 우울에 대한 주관적 보고\n\n<!-- PAGE_78 -->\n###### 척도로 대체할 수 있다(e.g. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 720,
        "window_size": 3,
        "char_count": 572,
        "word_count": 126,
        "page_number": 78,
        "window_text": "임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n- - 70 -\n<!-- PAGE_77 -->\n###### 해당 성능을 증명할 수 있다.\n\n <!-- PAGE_77 -->\n###### * 비열등성/동등성 시험(Non-inferiority, equivalence trial): 비교 연구에 있어\n\n<!-- PAGE_77 -->\n###### 대조기기와 비교해 시험기기의 성능이 열등하지 않음을 보이거나,\n\n<!-- PAGE_77 -->\n###### 3) 총 4회의 외래 방문을 통한 조사: 방문 1(Screening), 방문\n\n<!-- PAGE_77 -->\n###### ※ 방문 4(Follow-up, 3개월 후)는 필요시 애플리케이션, 이메일, 문자,\n\n<!-- PAGE_77 -->\n###### 4) 층화무작위배정: 기관별 성별(남/여), 연령(oo세 미만, oo세 이상)을\n\n<!-- PAGE_77 -->\n###### - 기관별로 내원한 환자 중 선정, 제외 기준에 따라 적합한\n\n<!-- PAGE_77 -->\n###### - 본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한\n\n<!-- PAGE_77 -->\n###### 내용을 피험자 본인 또는 대리인에게 설명하고, 피험자 또는\n\n<!-- PAGE_77 -->\n###### 대리인이 내용을 잘 이해한 것을 확인한 다음, 자유의사에 따른\n\n<!-- PAGE_77 -->\n###### 임상시험 참가의 동의를 문서로 받는다.  또한 동의에 서명한\n\n<!-- PAGE_77 -->\n###### 연월일을 기록하며, 동의서 사본을 환자에게 제공하여 환자가\n\n<!-- PAGE_77 -->\n###### 지속해서 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n - - 71 -\n<!-- PAGE_78 -->\n###### 다) 인구학적 조사, 병력조사 요법\n\n<!-- PAGE_78 -->\n###### - 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력\n\n<!-- PAGE_78 -->\n###### 등에 대하여 차트 확인 및 애플리케이션 내 질문 등을 통하여\n\n<!-- PAGE_78 -->\n###### (1) 피험자에게 서명하고 동의를 받은 후 동의 취득 순서에 따라\n\n<!-- PAGE_78 -->\n###### 스크리닝 번호를 부여하며 피험자가 참여를 종료할 때까지\n\n<!-- PAGE_78 -->\n###### (2) 피험자 적합성 평가: 피험자 선정 및 제외 기준에 적합한지\n\n<!-- PAGE_78 -->\n###### · 일차 유효성 평가지표로는 우울장애의 증상 개선을 확인\n\n<!-- PAGE_78 -->\n###### 하고자 하는 연구에서 널리 사용되고 있는 우울장애 심각도 척도\n\n<!-- PAGE_78 -->\n###### · 필요하면 과학적인 근거를 가진 기타 우울에 대한 주관적 보고\n\n<!-- PAGE_78 -->\n###### 척도로 대체할 수 있다(e.g.  Patient Health Questionnaire-9, PHQ-9).\n\n - - 72 -\n<!-- PAGE_79 -->\n###### (2) 이차 유효성 평가지표\n\n<!-- PAGE_79 -->\n###### · 일차 유효성 평가지표를 통해 유효성을 검증하는 것이\n\n<!-- PAGE_79 -->\n###### 기본적인 원칙이지만, 이외 필요하면 변수를 이차 유효성\n\n<!-- PAGE_79 -->\n###### · 과학적인 근거를 가진 변수이되, 기존 우울 증상 개선 시\n\n<!-- PAGE_79 -->\n###### 함께 개선될 수 있다고 여겨진 영역에 한정한다(우울장애\n\n<!-- PAGE_79 -->\n###### 개선, 삶의 질, 직업적 혹은 사회적 기능, 우울과 불안을\n\n<!-- PAGE_79 -->\n###### - 방문 2(Baseline), 방문 3(Post-treatment,), 방문 4\n\n- - 73 -\n측정도구\n\n설명\n\n- - 74 -\n측정도구\n\n설명\n\nKDS는 한국인 우울장애 환자들이 호소하는 증상과 생활사건에\n\n- - 75 -\n측정도구\n\n설명\n\nBSS는 우울장애 관련 구성개념의 하나로, 자살 위험의 지침인\n\n(출처: 우울장애 임상지료지침, 2022, H.J.  Cho et al., 2007, VA/DoD, 2016\n\n- - 76 -\n<!-- PAGE_83 -->\n###### 바) 순응도 조사\n\n<!-- PAGE_83 -->\n###### - 치료기간 동안 어플리케이션 사용 시간 및 활용 여부를 수집한다.\n\n",
        "original_sentence": "- - 71 -\n<!-- PAGE_78 -->\n###### 다) 인구학적 조사, 병력조사 요법\n\n<!-- PAGE_78 -->\n###### - 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력\n\n<!-- PAGE_78 -->\n###### 등에 대하여 차트 확인 및 애플리케이션 내 질문 등을 통하여\n\n<!-- PAGE_78 -->\n###### (1) 피험자에게 서명하고 동의를 받은 후 동의 취득 순서에 따라\n\n<!-- PAGE_78 -->\n###### 스크리닝 번호를 부여하며 피험자가 참여를 종료할 때까지\n\n<!-- PAGE_78 -->\n###### (2) 피험자 적합성 평가: 피험자 선정 및 제외 기준에 적합한지\n\n<!-- PAGE_78 -->\n###### · 일차 유효성 평가지표로는 우울장애의 증상 개선을 확인\n\n<!-- PAGE_78 -->\n###### 하고자 하는 연구에서 널리 사용되고 있는 우울장애 심각도 척도\n\n<!-- PAGE_78 -->\n###### · 필요하면 과학적인 근거를 가진 기타 우울에 대한 주관적 보고\n\n<!-- PAGE_78 -->\n###### 척도로 대체할 수 있다(e.g. "
      }
    },
    {
      "chunk_id": "chunk_722",
      "text": "Patient Health Questionnaire-9, PHQ-9).\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 721,
        "window_size": 3,
        "char_count": 41,
        "word_count": 4,
        "page_number": 12,
        "window_text": "<!-- PAGE_77 -->\n###### * 비열등성/동등성 시험(Non-inferiority, equivalence trial): 비교 연구에 있어\n\n<!-- PAGE_77 -->\n###### 대조기기와 비교해 시험기기의 성능이 열등하지 않음을 보이거나,\n\n<!-- PAGE_77 -->\n###### 3) 총 4회의 외래 방문을 통한 조사: 방문 1(Screening), 방문\n\n<!-- PAGE_77 -->\n###### ※ 방문 4(Follow-up, 3개월 후)는 필요시 애플리케이션, 이메일, 문자,\n\n<!-- PAGE_77 -->\n###### 4) 층화무작위배정: 기관별 성별(남/여), 연령(oo세 미만, oo세 이상)을\n\n<!-- PAGE_77 -->\n###### - 기관별로 내원한 환자 중 선정, 제외 기준에 따라 적합한\n\n<!-- PAGE_77 -->\n###### - 본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한\n\n<!-- PAGE_77 -->\n###### 내용을 피험자 본인 또는 대리인에게 설명하고, 피험자 또는\n\n<!-- PAGE_77 -->\n###### 대리인이 내용을 잘 이해한 것을 확인한 다음, 자유의사에 따른\n\n<!-- PAGE_77 -->\n###### 임상시험 참가의 동의를 문서로 받는다.  또한 동의에 서명한\n\n<!-- PAGE_77 -->\n###### 연월일을 기록하며, 동의서 사본을 환자에게 제공하여 환자가\n\n<!-- PAGE_77 -->\n###### 지속해서 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n - - 71 -\n<!-- PAGE_78 -->\n###### 다) 인구학적 조사, 병력조사 요법\n\n<!-- PAGE_78 -->\n###### - 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력\n\n<!-- PAGE_78 -->\n###### 등에 대하여 차트 확인 및 애플리케이션 내 질문 등을 통하여\n\n<!-- PAGE_78 -->\n###### (1) 피험자에게 서명하고 동의를 받은 후 동의 취득 순서에 따라\n\n<!-- PAGE_78 -->\n###### 스크리닝 번호를 부여하며 피험자가 참여를 종료할 때까지\n\n<!-- PAGE_78 -->\n###### (2) 피험자 적합성 평가: 피험자 선정 및 제외 기준에 적합한지\n\n<!-- PAGE_78 -->\n###### · 일차 유효성 평가지표로는 우울장애의 증상 개선을 확인\n\n<!-- PAGE_78 -->\n###### 하고자 하는 연구에서 널리 사용되고 있는 우울장애 심각도 척도\n\n<!-- PAGE_78 -->\n###### · 필요하면 과학적인 근거를 가진 기타 우울에 대한 주관적 보고\n\n<!-- PAGE_78 -->\n###### 척도로 대체할 수 있다(e.g.  Patient Health Questionnaire-9, PHQ-9).\n\n - - 72 -\n<!-- PAGE_79 -->\n###### (2) 이차 유효성 평가지표\n\n<!-- PAGE_79 -->\n###### · 일차 유효성 평가지표를 통해 유효성을 검증하는 것이\n\n<!-- PAGE_79 -->\n###### 기본적인 원칙이지만, 이외 필요하면 변수를 이차 유효성\n\n<!-- PAGE_79 -->\n###### · 과학적인 근거를 가진 변수이되, 기존 우울 증상 개선 시\n\n<!-- PAGE_79 -->\n###### 함께 개선될 수 있다고 여겨진 영역에 한정한다(우울장애\n\n<!-- PAGE_79 -->\n###### 개선, 삶의 질, 직업적 혹은 사회적 기능, 우울과 불안을\n\n<!-- PAGE_79 -->\n###### - 방문 2(Baseline), 방문 3(Post-treatment,), 방문 4\n\n- - 73 -\n측정도구\n\n설명\n\n- - 74 -\n측정도구\n\n설명\n\nKDS는 한국인 우울장애 환자들이 호소하는 증상과 생활사건에\n\n- - 75 -\n측정도구\n\n설명\n\nBSS는 우울장애 관련 구성개념의 하나로, 자살 위험의 지침인\n\n(출처: 우울장애 임상지료지침, 2022, H.J.  Cho et al., 2007, VA/DoD, 2016\n\n- - 76 -\n<!-- PAGE_83 -->\n###### 바) 순응도 조사\n\n<!-- PAGE_83 -->\n###### - 치료기간 동안 어플리케이션 사용 시간 및 활용 여부를 수집한다.\n\n <!-- PAGE_83 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_83 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_83 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_83 -->\n###### - 각 관찰 항목에 대한 평가 도구 및 평가 방법에 대한 자세한\n\n- - 77 -\n<!-- PAGE_84 -->\n###### 나. ",
        "original_sentence": "Patient Health Questionnaire-9, PHQ-9).\n\n"
      }
    },
    {
      "chunk_id": "chunk_723",
      "text": "- - 72 -\n<!-- PAGE_79 -->\n###### (2) 이차 유효성 평가지표\n\n<!-- PAGE_79 -->\n###### · 일차 유효성 평가지표를 통해 유효성을 검증하는 것이\n\n<!-- PAGE_79 -->\n###### 기본적인 원칙이지만, 이외 필요하면 변수를 이차 유효성\n\n<!-- PAGE_79 -->\n###### · 과학적인 근거를 가진 변수이되, 기존 우울 증상 개선 시\n\n<!-- PAGE_79 -->\n###### 함께 개선될 수 있다고 여겨진 영역에 한정한다(우울장애\n\n<!-- PAGE_79 -->\n###### 개선, 삶의 질, 직업적 혹은 사회적 기능, 우울과 불안을\n\n<!-- PAGE_79 -->\n###### - 방문 2(Baseline), 방문 3(Post-treatment,), 방문 4\n\n- - 73 -\n측정도구\n\n설명\n\n- - 74 -\n측정도구\n\n설명\n\nKDS는 한국인 우울장애 환자들이 호소하는 증상과 생활사건에\n\n- - 75 -\n측정도구\n\n설명\n\nBSS는 우울장애 관련 구성개념의 하나로, 자살 위험의 지침인\n\n(출처: 우울장애 임상지료지침, 2022, H.J. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 722,
        "window_size": 3,
        "char_count": 563,
        "word_count": 122,
        "page_number": 79,
        "window_text": "또한 동의에 서명한\n\n<!-- PAGE_77 -->\n###### 연월일을 기록하며, 동의서 사본을 환자에게 제공하여 환자가\n\n<!-- PAGE_77 -->\n###### 지속해서 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n - - 71 -\n<!-- PAGE_78 -->\n###### 다) 인구학적 조사, 병력조사 요법\n\n<!-- PAGE_78 -->\n###### - 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력\n\n<!-- PAGE_78 -->\n###### 등에 대하여 차트 확인 및 애플리케이션 내 질문 등을 통하여\n\n<!-- PAGE_78 -->\n###### (1) 피험자에게 서명하고 동의를 받은 후 동의 취득 순서에 따라\n\n<!-- PAGE_78 -->\n###### 스크리닝 번호를 부여하며 피험자가 참여를 종료할 때까지\n\n<!-- PAGE_78 -->\n###### (2) 피험자 적합성 평가: 피험자 선정 및 제외 기준에 적합한지\n\n<!-- PAGE_78 -->\n###### · 일차 유효성 평가지표로는 우울장애의 증상 개선을 확인\n\n<!-- PAGE_78 -->\n###### 하고자 하는 연구에서 널리 사용되고 있는 우울장애 심각도 척도\n\n<!-- PAGE_78 -->\n###### · 필요하면 과학적인 근거를 가진 기타 우울에 대한 주관적 보고\n\n<!-- PAGE_78 -->\n###### 척도로 대체할 수 있다(e.g.  Patient Health Questionnaire-9, PHQ-9).\n\n - - 72 -\n<!-- PAGE_79 -->\n###### (2) 이차 유효성 평가지표\n\n<!-- PAGE_79 -->\n###### · 일차 유효성 평가지표를 통해 유효성을 검증하는 것이\n\n<!-- PAGE_79 -->\n###### 기본적인 원칙이지만, 이외 필요하면 변수를 이차 유효성\n\n<!-- PAGE_79 -->\n###### · 과학적인 근거를 가진 변수이되, 기존 우울 증상 개선 시\n\n<!-- PAGE_79 -->\n###### 함께 개선될 수 있다고 여겨진 영역에 한정한다(우울장애\n\n<!-- PAGE_79 -->\n###### 개선, 삶의 질, 직업적 혹은 사회적 기능, 우울과 불안을\n\n<!-- PAGE_79 -->\n###### - 방문 2(Baseline), 방문 3(Post-treatment,), 방문 4\n\n- - 73 -\n측정도구\n\n설명\n\n- - 74 -\n측정도구\n\n설명\n\nKDS는 한국인 우울장애 환자들이 호소하는 증상과 생활사건에\n\n- - 75 -\n측정도구\n\n설명\n\nBSS는 우울장애 관련 구성개념의 하나로, 자살 위험의 지침인\n\n(출처: 우울장애 임상지료지침, 2022, H.J.  Cho et al., 2007, VA/DoD, 2016\n\n- - 76 -\n<!-- PAGE_83 -->\n###### 바) 순응도 조사\n\n<!-- PAGE_83 -->\n###### - 치료기간 동안 어플리케이션 사용 시간 및 활용 여부를 수집한다.\n\n <!-- PAGE_83 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_83 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_83 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_83 -->\n###### - 각 관찰 항목에 대한 평가 도구 및 평가 방법에 대한 자세한\n\n- - 77 -\n<!-- PAGE_84 -->\n###### 나.  설계 방법\n\n<!-- PAGE_84 -->\n###### - 연구자는 선정·제외 기준을 합격한 피험자의 순서대로 배정일에\n\n<!-- PAGE_84 -->\n###### 쌍방향 웹반응시스템(Interactive Web Response System,\n\n<!-- PAGE_84 -->\n###### - 본 연구와 독립된 통계학자가 SAS 통계 패키지를 가지고 층화\n\n<!-- PAGE_84 -->\n###### 순열화 블록 무작위배정법(stratified permuted block randomization)을\n\n<!-- PAGE_84 -->\n###### - 연구의 특성상 단일 맹검을 지향하되, 필요시 비맹검 임상시험을\n\n<!-- PAGE_84 -->\n###### - 단일맹검인 경우, 임상시험 도중 응급상황 발생 등으로 인하여\n\n<!-- PAGE_84 -->\n###### 피험자의 눈가림을 해제할 수 있다. ",
        "original_sentence": "- - 72 -\n<!-- PAGE_79 -->\n###### (2) 이차 유효성 평가지표\n\n<!-- PAGE_79 -->\n###### · 일차 유효성 평가지표를 통해 유효성을 검증하는 것이\n\n<!-- PAGE_79 -->\n###### 기본적인 원칙이지만, 이외 필요하면 변수를 이차 유효성\n\n<!-- PAGE_79 -->\n###### · 과학적인 근거를 가진 변수이되, 기존 우울 증상 개선 시\n\n<!-- PAGE_79 -->\n###### 함께 개선될 수 있다고 여겨진 영역에 한정한다(우울장애\n\n<!-- PAGE_79 -->\n###### 개선, 삶의 질, 직업적 혹은 사회적 기능, 우울과 불안을\n\n<!-- PAGE_79 -->\n###### - 방문 2(Baseline), 방문 3(Post-treatment,), 방문 4\n\n- - 73 -\n측정도구\n\n설명\n\n- - 74 -\n측정도구\n\n설명\n\nKDS는 한국인 우울장애 환자들이 호소하는 증상과 생활사건에\n\n- - 75 -\n측정도구\n\n설명\n\nBSS는 우울장애 관련 구성개념의 하나로, 자살 위험의 지침인\n\n(출처: 우울장애 임상지료지침, 2022, H.J. "
      }
    },
    {
      "chunk_id": "chunk_724",
      "text": "Cho et al., 2007, VA/DoD, 2016\n\n- - 76 -\n<!-- PAGE_83 -->\n###### 바) 순응도 조사\n\n<!-- PAGE_83 -->\n###### - 치료기간 동안 어플리케이션 사용 시간 및 활용 여부를 수집한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 723,
        "window_size": 3,
        "char_count": 139,
        "word_count": 31,
        "page_number": 83,
        "window_text": "- - 71 -\n<!-- PAGE_78 -->\n###### 다) 인구학적 조사, 병력조사 요법\n\n<!-- PAGE_78 -->\n###### - 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력\n\n<!-- PAGE_78 -->\n###### 등에 대하여 차트 확인 및 애플리케이션 내 질문 등을 통하여\n\n<!-- PAGE_78 -->\n###### (1) 피험자에게 서명하고 동의를 받은 후 동의 취득 순서에 따라\n\n<!-- PAGE_78 -->\n###### 스크리닝 번호를 부여하며 피험자가 참여를 종료할 때까지\n\n<!-- PAGE_78 -->\n###### (2) 피험자 적합성 평가: 피험자 선정 및 제외 기준에 적합한지\n\n<!-- PAGE_78 -->\n###### · 일차 유효성 평가지표로는 우울장애의 증상 개선을 확인\n\n<!-- PAGE_78 -->\n###### 하고자 하는 연구에서 널리 사용되고 있는 우울장애 심각도 척도\n\n<!-- PAGE_78 -->\n###### · 필요하면 과학적인 근거를 가진 기타 우울에 대한 주관적 보고\n\n<!-- PAGE_78 -->\n###### 척도로 대체할 수 있다(e.g.  Patient Health Questionnaire-9, PHQ-9).\n\n - - 72 -\n<!-- PAGE_79 -->\n###### (2) 이차 유효성 평가지표\n\n<!-- PAGE_79 -->\n###### · 일차 유효성 평가지표를 통해 유효성을 검증하는 것이\n\n<!-- PAGE_79 -->\n###### 기본적인 원칙이지만, 이외 필요하면 변수를 이차 유효성\n\n<!-- PAGE_79 -->\n###### · 과학적인 근거를 가진 변수이되, 기존 우울 증상 개선 시\n\n<!-- PAGE_79 -->\n###### 함께 개선될 수 있다고 여겨진 영역에 한정한다(우울장애\n\n<!-- PAGE_79 -->\n###### 개선, 삶의 질, 직업적 혹은 사회적 기능, 우울과 불안을\n\n<!-- PAGE_79 -->\n###### - 방문 2(Baseline), 방문 3(Post-treatment,), 방문 4\n\n- - 73 -\n측정도구\n\n설명\n\n- - 74 -\n측정도구\n\n설명\n\nKDS는 한국인 우울장애 환자들이 호소하는 증상과 생활사건에\n\n- - 75 -\n측정도구\n\n설명\n\nBSS는 우울장애 관련 구성개념의 하나로, 자살 위험의 지침인\n\n(출처: 우울장애 임상지료지침, 2022, H.J.  Cho et al., 2007, VA/DoD, 2016\n\n- - 76 -\n<!-- PAGE_83 -->\n###### 바) 순응도 조사\n\n<!-- PAGE_83 -->\n###### - 치료기간 동안 어플리케이션 사용 시간 및 활용 여부를 수집한다.\n\n <!-- PAGE_83 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_83 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_83 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_83 -->\n###### - 각 관찰 항목에 대한 평가 도구 및 평가 방법에 대한 자세한\n\n- - 77 -\n<!-- PAGE_84 -->\n###### 나.  설계 방법\n\n<!-- PAGE_84 -->\n###### - 연구자는 선정·제외 기준을 합격한 피험자의 순서대로 배정일에\n\n<!-- PAGE_84 -->\n###### 쌍방향 웹반응시스템(Interactive Web Response System,\n\n<!-- PAGE_84 -->\n###### - 본 연구와 독립된 통계학자가 SAS 통계 패키지를 가지고 층화\n\n<!-- PAGE_84 -->\n###### 순열화 블록 무작위배정법(stratified permuted block randomization)을\n\n<!-- PAGE_84 -->\n###### - 연구의 특성상 단일 맹검을 지향하되, 필요시 비맹검 임상시험을\n\n<!-- PAGE_84 -->\n###### - 단일맹검인 경우, 임상시험 도중 응급상황 발생 등으로 인하여\n\n<!-- PAGE_84 -->\n###### 피험자의 눈가림을 해제할 수 있다.  이 경우, 사유와 해제일,\n\n<!-- PAGE_84 -->\n###### 열람자, 해제 후 조치사항 등에 대한 문서를 기록·보관한다.\n\n",
        "original_sentence": "Cho et al., 2007, VA/DoD, 2016\n\n- - 76 -\n<!-- PAGE_83 -->\n###### 바) 순응도 조사\n\n<!-- PAGE_83 -->\n###### - 치료기간 동안 어플리케이션 사용 시간 및 활용 여부를 수집한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_725",
      "text": "<!-- PAGE_83 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_83 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_83 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_83 -->\n###### - 각 관찰 항목에 대한 평가 도구 및 평가 방법에 대한 자세한\n\n- - 77 -\n<!-- PAGE_84 -->\n###### 나. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 724,
        "window_size": 3,
        "char_count": 273,
        "word_count": 61,
        "page_number": 83,
        "window_text": "Patient Health Questionnaire-9, PHQ-9).\n\n - - 72 -\n<!-- PAGE_79 -->\n###### (2) 이차 유효성 평가지표\n\n<!-- PAGE_79 -->\n###### · 일차 유효성 평가지표를 통해 유효성을 검증하는 것이\n\n<!-- PAGE_79 -->\n###### 기본적인 원칙이지만, 이외 필요하면 변수를 이차 유효성\n\n<!-- PAGE_79 -->\n###### · 과학적인 근거를 가진 변수이되, 기존 우울 증상 개선 시\n\n<!-- PAGE_79 -->\n###### 함께 개선될 수 있다고 여겨진 영역에 한정한다(우울장애\n\n<!-- PAGE_79 -->\n###### 개선, 삶의 질, 직업적 혹은 사회적 기능, 우울과 불안을\n\n<!-- PAGE_79 -->\n###### - 방문 2(Baseline), 방문 3(Post-treatment,), 방문 4\n\n- - 73 -\n측정도구\n\n설명\n\n- - 74 -\n측정도구\n\n설명\n\nKDS는 한국인 우울장애 환자들이 호소하는 증상과 생활사건에\n\n- - 75 -\n측정도구\n\n설명\n\nBSS는 우울장애 관련 구성개념의 하나로, 자살 위험의 지침인\n\n(출처: 우울장애 임상지료지침, 2022, H.J.  Cho et al., 2007, VA/DoD, 2016\n\n- - 76 -\n<!-- PAGE_83 -->\n###### 바) 순응도 조사\n\n<!-- PAGE_83 -->\n###### - 치료기간 동안 어플리케이션 사용 시간 및 활용 여부를 수집한다.\n\n <!-- PAGE_83 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_83 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_83 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_83 -->\n###### - 각 관찰 항목에 대한 평가 도구 및 평가 방법에 대한 자세한\n\n- - 77 -\n<!-- PAGE_84 -->\n###### 나.  설계 방법\n\n<!-- PAGE_84 -->\n###### - 연구자는 선정·제외 기준을 합격한 피험자의 순서대로 배정일에\n\n<!-- PAGE_84 -->\n###### 쌍방향 웹반응시스템(Interactive Web Response System,\n\n<!-- PAGE_84 -->\n###### - 본 연구와 독립된 통계학자가 SAS 통계 패키지를 가지고 층화\n\n<!-- PAGE_84 -->\n###### 순열화 블록 무작위배정법(stratified permuted block randomization)을\n\n<!-- PAGE_84 -->\n###### - 연구의 특성상 단일 맹검을 지향하되, 필요시 비맹검 임상시험을\n\n<!-- PAGE_84 -->\n###### - 단일맹검인 경우, 임상시험 도중 응급상황 발생 등으로 인하여\n\n<!-- PAGE_84 -->\n###### 피험자의 눈가림을 해제할 수 있다.  이 경우, 사유와 해제일,\n\n<!-- PAGE_84 -->\n###### 열람자, 해제 후 조치사항 등에 대한 문서를 기록·보관한다.\n\n - - 78 -\n<!-- PAGE_85 -->\n##### 11. ",
        "original_sentence": "<!-- PAGE_83 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_83 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_83 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_83 -->\n###### - 각 관찰 항목에 대한 평가 도구 및 평가 방법에 대한 자세한\n\n- - 77 -\n<!-- PAGE_84 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_726",
      "text": "설계 방법\n\n<!-- PAGE_84 -->\n###### - 연구자는 선정·제외 기준을 합격한 피험자의 순서대로 배정일에\n\n<!-- PAGE_84 -->\n###### 쌍방향 웹반응시스템(Interactive Web Response System,\n\n<!-- PAGE_84 -->\n###### - 본 연구와 독립된 통계학자가 SAS 통계 패키지를 가지고 층화\n\n<!-- PAGE_84 -->\n###### 순열화 블록 무작위배정법(stratified permuted block randomization)을\n\n<!-- PAGE_84 -->\n###### - 연구의 특성상 단일 맹검을 지향하되, 필요시 비맹검 임상시험을\n\n<!-- PAGE_84 -->\n###### - 단일맹검인 경우, 임상시험 도중 응급상황 발생 등으로 인하여\n\n<!-- PAGE_84 -->\n###### 피험자의 눈가림을 해제할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 725,
        "window_size": 3,
        "char_count": 447,
        "word_count": 82,
        "page_number": 84,
        "window_text": "- - 72 -\n<!-- PAGE_79 -->\n###### (2) 이차 유효성 평가지표\n\n<!-- PAGE_79 -->\n###### · 일차 유효성 평가지표를 통해 유효성을 검증하는 것이\n\n<!-- PAGE_79 -->\n###### 기본적인 원칙이지만, 이외 필요하면 변수를 이차 유효성\n\n<!-- PAGE_79 -->\n###### · 과학적인 근거를 가진 변수이되, 기존 우울 증상 개선 시\n\n<!-- PAGE_79 -->\n###### 함께 개선될 수 있다고 여겨진 영역에 한정한다(우울장애\n\n<!-- PAGE_79 -->\n###### 개선, 삶의 질, 직업적 혹은 사회적 기능, 우울과 불안을\n\n<!-- PAGE_79 -->\n###### - 방문 2(Baseline), 방문 3(Post-treatment,), 방문 4\n\n- - 73 -\n측정도구\n\n설명\n\n- - 74 -\n측정도구\n\n설명\n\nKDS는 한국인 우울장애 환자들이 호소하는 증상과 생활사건에\n\n- - 75 -\n측정도구\n\n설명\n\nBSS는 우울장애 관련 구성개념의 하나로, 자살 위험의 지침인\n\n(출처: 우울장애 임상지료지침, 2022, H.J.  Cho et al., 2007, VA/DoD, 2016\n\n- - 76 -\n<!-- PAGE_83 -->\n###### 바) 순응도 조사\n\n<!-- PAGE_83 -->\n###### - 치료기간 동안 어플리케이션 사용 시간 및 활용 여부를 수집한다.\n\n <!-- PAGE_83 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_83 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_83 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_83 -->\n###### - 각 관찰 항목에 대한 평가 도구 및 평가 방법에 대한 자세한\n\n- - 77 -\n<!-- PAGE_84 -->\n###### 나.  설계 방법\n\n<!-- PAGE_84 -->\n###### - 연구자는 선정·제외 기준을 합격한 피험자의 순서대로 배정일에\n\n<!-- PAGE_84 -->\n###### 쌍방향 웹반응시스템(Interactive Web Response System,\n\n<!-- PAGE_84 -->\n###### - 본 연구와 독립된 통계학자가 SAS 통계 패키지를 가지고 층화\n\n<!-- PAGE_84 -->\n###### 순열화 블록 무작위배정법(stratified permuted block randomization)을\n\n<!-- PAGE_84 -->\n###### - 연구의 특성상 단일 맹검을 지향하되, 필요시 비맹검 임상시험을\n\n<!-- PAGE_84 -->\n###### - 단일맹검인 경우, 임상시험 도중 응급상황 발생 등으로 인하여\n\n<!-- PAGE_84 -->\n###### 피험자의 눈가림을 해제할 수 있다.  이 경우, 사유와 해제일,\n\n<!-- PAGE_84 -->\n###### 열람자, 해제 후 조치사항 등에 대한 문서를 기록·보관한다.\n\n - - 78 -\n<!-- PAGE_85 -->\n##### 11.  관찰항목·임상검사항목 및 관찰검사방법\n\n<!-- PAGE_85 -->\n###### 임상시험 일정표\n\n1) 스크리닝 및 검사일은 치료 시작일 전 28일 이내에 시작한다.\n\n",
        "original_sentence": "설계 방법\n\n<!-- PAGE_84 -->\n###### - 연구자는 선정·제외 기준을 합격한 피험자의 순서대로 배정일에\n\n<!-- PAGE_84 -->\n###### 쌍방향 웹반응시스템(Interactive Web Response System,\n\n<!-- PAGE_84 -->\n###### - 본 연구와 독립된 통계학자가 SAS 통계 패키지를 가지고 층화\n\n<!-- PAGE_84 -->\n###### 순열화 블록 무작위배정법(stratified permuted block randomization)을\n\n<!-- PAGE_84 -->\n###### - 연구의 특성상 단일 맹검을 지향하되, 필요시 비맹검 임상시험을\n\n<!-- PAGE_84 -->\n###### - 단일맹검인 경우, 임상시험 도중 응급상황 발생 등으로 인하여\n\n<!-- PAGE_84 -->\n###### 피험자의 눈가림을 해제할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_727",
      "text": "이 경우, 사유와 해제일,\n\n<!-- PAGE_84 -->\n###### 열람자, 해제 후 조치사항 등에 대한 문서를 기록·보관한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 726,
        "window_size": 3,
        "char_count": 75,
        "word_count": 16,
        "page_number": 84,
        "window_text": "Cho et al., 2007, VA/DoD, 2016\n\n- - 76 -\n<!-- PAGE_83 -->\n###### 바) 순응도 조사\n\n<!-- PAGE_83 -->\n###### - 치료기간 동안 어플리케이션 사용 시간 및 활용 여부를 수집한다.\n\n <!-- PAGE_83 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_83 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_83 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_83 -->\n###### - 각 관찰 항목에 대한 평가 도구 및 평가 방법에 대한 자세한\n\n- - 77 -\n<!-- PAGE_84 -->\n###### 나.  설계 방법\n\n<!-- PAGE_84 -->\n###### - 연구자는 선정·제외 기준을 합격한 피험자의 순서대로 배정일에\n\n<!-- PAGE_84 -->\n###### 쌍방향 웹반응시스템(Interactive Web Response System,\n\n<!-- PAGE_84 -->\n###### - 본 연구와 독립된 통계학자가 SAS 통계 패키지를 가지고 층화\n\n<!-- PAGE_84 -->\n###### 순열화 블록 무작위배정법(stratified permuted block randomization)을\n\n<!-- PAGE_84 -->\n###### - 연구의 특성상 단일 맹검을 지향하되, 필요시 비맹검 임상시험을\n\n<!-- PAGE_84 -->\n###### - 단일맹검인 경우, 임상시험 도중 응급상황 발생 등으로 인하여\n\n<!-- PAGE_84 -->\n###### 피험자의 눈가림을 해제할 수 있다.  이 경우, 사유와 해제일,\n\n<!-- PAGE_84 -->\n###### 열람자, 해제 후 조치사항 등에 대한 문서를 기록·보관한다.\n\n - - 78 -\n<!-- PAGE_85 -->\n##### 11.  관찰항목·임상검사항목 및 관찰검사방법\n\n<!-- PAGE_85 -->\n###### 임상시험 일정표\n\n1) 스크리닝 및 검사일은 치료 시작일 전 28일 이내에 시작한다.\n\n 2) 수집하는 지표에 따라 수집이 다를 경우 나누어 표현한다. ",
        "original_sentence": "이 경우, 사유와 해제일,\n\n<!-- PAGE_84 -->\n###### 열람자, 해제 후 조치사항 등에 대한 문서를 기록·보관한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_728",
      "text": "- - 78 -\n<!-- PAGE_85 -->\n##### 11. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 727,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 85,
        "window_text": "<!-- PAGE_83 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_83 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_83 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_83 -->\n###### - 각 관찰 항목에 대한 평가 도구 및 평가 방법에 대한 자세한\n\n- - 77 -\n<!-- PAGE_84 -->\n###### 나.  설계 방법\n\n<!-- PAGE_84 -->\n###### - 연구자는 선정·제외 기준을 합격한 피험자의 순서대로 배정일에\n\n<!-- PAGE_84 -->\n###### 쌍방향 웹반응시스템(Interactive Web Response System,\n\n<!-- PAGE_84 -->\n###### - 본 연구와 독립된 통계학자가 SAS 통계 패키지를 가지고 층화\n\n<!-- PAGE_84 -->\n###### 순열화 블록 무작위배정법(stratified permuted block randomization)을\n\n<!-- PAGE_84 -->\n###### - 연구의 특성상 단일 맹검을 지향하되, 필요시 비맹검 임상시험을\n\n<!-- PAGE_84 -->\n###### - 단일맹검인 경우, 임상시험 도중 응급상황 발생 등으로 인하여\n\n<!-- PAGE_84 -->\n###### 피험자의 눈가림을 해제할 수 있다.  이 경우, 사유와 해제일,\n\n<!-- PAGE_84 -->\n###### 열람자, 해제 후 조치사항 등에 대한 문서를 기록·보관한다.\n\n - - 78 -\n<!-- PAGE_85 -->\n##### 11.  관찰항목·임상검사항목 및 관찰검사방법\n\n<!-- PAGE_85 -->\n###### 임상시험 일정표\n\n1) 스크리닝 및 검사일은 치료 시작일 전 28일 이내에 시작한다.\n\n 2) 수집하는 지표에 따라 수집이 다를 경우 나누어 표현한다.  (예: BDI는 스크리닝에도 수집함)\n\n3) 우울장애 개선 디지털치료기기 제품의 치료 기간에 따라 전체 치료 기간은 변경될 수 있다.\n\n",
        "original_sentence": "- - 78 -\n<!-- PAGE_85 -->\n##### 11. "
      }
    },
    {
      "chunk_id": "chunk_729",
      "text": "관찰항목·임상검사항목 및 관찰검사방법\n\n<!-- PAGE_85 -->\n###### 임상시험 일정표\n\n1) 스크리닝 및 검사일은 치료 시작일 전 28일 이내에 시작한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 728,
        "window_size": 3,
        "char_count": 95,
        "word_count": 19,
        "page_number": 85,
        "window_text": "설계 방법\n\n<!-- PAGE_84 -->\n###### - 연구자는 선정·제외 기준을 합격한 피험자의 순서대로 배정일에\n\n<!-- PAGE_84 -->\n###### 쌍방향 웹반응시스템(Interactive Web Response System,\n\n<!-- PAGE_84 -->\n###### - 본 연구와 독립된 통계학자가 SAS 통계 패키지를 가지고 층화\n\n<!-- PAGE_84 -->\n###### 순열화 블록 무작위배정법(stratified permuted block randomization)을\n\n<!-- PAGE_84 -->\n###### - 연구의 특성상 단일 맹검을 지향하되, 필요시 비맹검 임상시험을\n\n<!-- PAGE_84 -->\n###### - 단일맹검인 경우, 임상시험 도중 응급상황 발생 등으로 인하여\n\n<!-- PAGE_84 -->\n###### 피험자의 눈가림을 해제할 수 있다.  이 경우, 사유와 해제일,\n\n<!-- PAGE_84 -->\n###### 열람자, 해제 후 조치사항 등에 대한 문서를 기록·보관한다.\n\n - - 78 -\n<!-- PAGE_85 -->\n##### 11.  관찰항목·임상검사항목 및 관찰검사방법\n\n<!-- PAGE_85 -->\n###### 임상시험 일정표\n\n1) 스크리닝 및 검사일은 치료 시작일 전 28일 이내에 시작한다.\n\n 2) 수집하는 지표에 따라 수집이 다를 경우 나누어 표현한다.  (예: BDI는 스크리닝에도 수집함)\n\n3) 우울장애 개선 디지털치료기기 제품의 치료 기간에 따라 전체 치료 기간은 변경될 수 있다.\n\n 4) 임상시험 설계에 따른 선택사항이므로 치료 기간 종료 후 추적 관찰 기간은 변경될 수 있다.\n\n",
        "original_sentence": "관찰항목·임상검사항목 및 관찰검사방법\n\n<!-- PAGE_85 -->\n###### 임상시험 일정표\n\n1) 스크리닝 및 검사일은 치료 시작일 전 28일 이내에 시작한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_730",
      "text": "2) 수집하는 지표에 따라 수집이 다를 경우 나누어 표현한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 729,
        "window_size": 3,
        "char_count": 35,
        "word_count": 9,
        "page_number": 9,
        "window_text": "이 경우, 사유와 해제일,\n\n<!-- PAGE_84 -->\n###### 열람자, 해제 후 조치사항 등에 대한 문서를 기록·보관한다.\n\n - - 78 -\n<!-- PAGE_85 -->\n##### 11.  관찰항목·임상검사항목 및 관찰검사방법\n\n<!-- PAGE_85 -->\n###### 임상시험 일정표\n\n1) 스크리닝 및 검사일은 치료 시작일 전 28일 이내에 시작한다.\n\n 2) 수집하는 지표에 따라 수집이 다를 경우 나누어 표현한다.  (예: BDI는 스크리닝에도 수집함)\n\n3) 우울장애 개선 디지털치료기기 제품의 치료 기간에 따라 전체 치료 기간은 변경될 수 있다.\n\n 4) 임상시험 설계에 따른 선택사항이므로 치료 기간 종료 후 추적 관찰 기간은 변경될 수 있다.\n\n - - 79 -\n<!-- PAGE_86 -->\n###### 가. ",
        "original_sentence": "2) 수집하는 지표에 따라 수집이 다를 경우 나누어 표현한다. "
      }
    },
    {
      "chunk_id": "chunk_731",
      "text": "(예: BDI는 스크리닝에도 수집함)\n\n3) 우울장애 개선 디지털치료기기 제품의 치료 기간에 따라 전체 치료 기간은 변경될 수 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 730,
        "window_size": 3,
        "char_count": 76,
        "word_count": 18,
        "page_number": 1,
        "window_text": "- - 78 -\n<!-- PAGE_85 -->\n##### 11.  관찰항목·임상검사항목 및 관찰검사방법\n\n<!-- PAGE_85 -->\n###### 임상시험 일정표\n\n1) 스크리닝 및 검사일은 치료 시작일 전 28일 이내에 시작한다.\n\n 2) 수집하는 지표에 따라 수집이 다를 경우 나누어 표현한다.  (예: BDI는 스크리닝에도 수집함)\n\n3) 우울장애 개선 디지털치료기기 제품의 치료 기간에 따라 전체 치료 기간은 변경될 수 있다.\n\n 4) 임상시험 설계에 따른 선택사항이므로 치료 기간 종료 후 추적 관찰 기간은 변경될 수 있다.\n\n - - 79 -\n<!-- PAGE_86 -->\n###### 가.  임상시험 절차\n\n<!-- PAGE_86 -->\n###### 1) 방문 1 (스크리닝 및 검사일, Screening)\n\n<!-- PAGE_86 -->\n###### - 임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여\n\n<!-- PAGE_86 -->\n###### 대상자 또는 법정대리인에게 상세히 설명한다. ",
        "original_sentence": "(예: BDI는 스크리닝에도 수집함)\n\n3) 우울장애 개선 디지털치료기기 제품의 치료 기간에 따라 전체 치료 기간은 변경될 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_732",
      "text": "4) 임상시험 설계에 따른 선택사항이므로 치료 기간 종료 후 추적 관찰 기간은 변경될 수 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 731,
        "window_size": 3,
        "char_count": 55,
        "word_count": 15,
        "page_number": 3,
        "window_text": "관찰항목·임상검사항목 및 관찰검사방법\n\n<!-- PAGE_85 -->\n###### 임상시험 일정표\n\n1) 스크리닝 및 검사일은 치료 시작일 전 28일 이내에 시작한다.\n\n 2) 수집하는 지표에 따라 수집이 다를 경우 나누어 표현한다.  (예: BDI는 스크리닝에도 수집함)\n\n3) 우울장애 개선 디지털치료기기 제품의 치료 기간에 따라 전체 치료 기간은 변경될 수 있다.\n\n 4) 임상시험 설계에 따른 선택사항이므로 치료 기간 종료 후 추적 관찰 기간은 변경될 수 있다.\n\n - - 79 -\n<!-- PAGE_86 -->\n###### 가.  임상시험 절차\n\n<!-- PAGE_86 -->\n###### 1) 방문 1 (스크리닝 및 검사일, Screening)\n\n<!-- PAGE_86 -->\n###### - 임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여\n\n<!-- PAGE_86 -->\n###### 대상자 또는 법정대리인에게 상세히 설명한다.  서명 일자를\n\n<!-- PAGE_86 -->\n###### 정확히 기재하여야 하며, 작성된 동의서 원본은 시험자가 보관\n\n<!-- PAGE_86 -->\n###### 하고 사본은 시험대상자 또는 법정대리인에게 내준다. ",
        "original_sentence": "4) 임상시험 설계에 따른 선택사항이므로 치료 기간 종료 후 추적 관찰 기간은 변경될 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_733",
      "text": "- - 79 -\n<!-- PAGE_86 -->\n###### 가. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 732,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 86,
        "window_text": "2) 수집하는 지표에 따라 수집이 다를 경우 나누어 표현한다.  (예: BDI는 스크리닝에도 수집함)\n\n3) 우울장애 개선 디지털치료기기 제품의 치료 기간에 따라 전체 치료 기간은 변경될 수 있다.\n\n 4) 임상시험 설계에 따른 선택사항이므로 치료 기간 종료 후 추적 관찰 기간은 변경될 수 있다.\n\n - - 79 -\n<!-- PAGE_86 -->\n###### 가.  임상시험 절차\n\n<!-- PAGE_86 -->\n###### 1) 방문 1 (스크리닝 및 검사일, Screening)\n\n<!-- PAGE_86 -->\n###### - 임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여\n\n<!-- PAGE_86 -->\n###### 대상자 또는 법정대리인에게 상세히 설명한다.  서명 일자를\n\n<!-- PAGE_86 -->\n###### 정확히 기재하여야 하며, 작성된 동의서 원본은 시험자가 보관\n\n<!-- PAGE_86 -->\n###### 하고 사본은 시험대상자 또는 법정대리인에게 내준다.  대상자\n\n<!-- PAGE_86 -->\n###### 에게 동의를 받은 후 동의 취득 순서에 따라 스크리닝 번호를\n\n<!-- PAGE_86 -->\n###### - 대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그\n\n<!-- PAGE_86 -->\n###### - 인구학적 정보로 대상자 이니셜, 만 나이, 성별, 직업, 그리고\n\n<!-- PAGE_86 -->\n###### 업무 생산성을 조사하며 기초 문진에 필요한 환자들의 의학적\n\n<!-- PAGE_86 -->\n###### - 병력조사에 포함되어야 하는 내용은 다음과 같다. ",
        "original_sentence": "- - 79 -\n<!-- PAGE_86 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_734",
      "text": "임상시험 절차\n\n<!-- PAGE_86 -->\n###### 1) 방문 1 (스크리닝 및 검사일, Screening)\n\n<!-- PAGE_86 -->\n###### - 임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여\n\n<!-- PAGE_86 -->\n###### 대상자 또는 법정대리인에게 상세히 설명한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 733,
        "window_size": 3,
        "char_count": 176,
        "word_count": 35,
        "page_number": 86,
        "window_text": "(예: BDI는 스크리닝에도 수집함)\n\n3) 우울장애 개선 디지털치료기기 제품의 치료 기간에 따라 전체 치료 기간은 변경될 수 있다.\n\n 4) 임상시험 설계에 따른 선택사항이므로 치료 기간 종료 후 추적 관찰 기간은 변경될 수 있다.\n\n - - 79 -\n<!-- PAGE_86 -->\n###### 가.  임상시험 절차\n\n<!-- PAGE_86 -->\n###### 1) 방문 1 (스크리닝 및 검사일, Screening)\n\n<!-- PAGE_86 -->\n###### - 임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여\n\n<!-- PAGE_86 -->\n###### 대상자 또는 법정대리인에게 상세히 설명한다.  서명 일자를\n\n<!-- PAGE_86 -->\n###### 정확히 기재하여야 하며, 작성된 동의서 원본은 시험자가 보관\n\n<!-- PAGE_86 -->\n###### 하고 사본은 시험대상자 또는 법정대리인에게 내준다.  대상자\n\n<!-- PAGE_86 -->\n###### 에게 동의를 받은 후 동의 취득 순서에 따라 스크리닝 번호를\n\n<!-- PAGE_86 -->\n###### - 대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그\n\n<!-- PAGE_86 -->\n###### - 인구학적 정보로 대상자 이니셜, 만 나이, 성별, 직업, 그리고\n\n<!-- PAGE_86 -->\n###### 업무 생산성을 조사하며 기초 문진에 필요한 환자들의 의학적\n\n<!-- PAGE_86 -->\n###### - 병력조사에 포함되어야 하는 내용은 다음과 같다.  치매, 인지\n\n<!-- PAGE_86 -->\n###### 기능 장애, 정신증, 양극성 장애 및 현재 주요 우울 삽화\n\n<!-- PAGE_86 -->\n###### (current major depressive episode) 등 스크리닝 확인해야 할\n\n<!-- PAGE_86 -->\n###### 질병군 등의 과거력 및 현 병력, 발생 시기, 치료와 진행여부\n\n- - 80 -\n<!-- PAGE_87 -->\n###### - 동의서 취득일 기준으로 최근 5년 이내 과거 및 현재 병력을\n\n<!-- PAGE_87 -->\n###### 조사한다.\n\n",
        "original_sentence": "임상시험 절차\n\n<!-- PAGE_86 -->\n###### 1) 방문 1 (스크리닝 및 검사일, Screening)\n\n<!-- PAGE_86 -->\n###### - 임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여\n\n<!-- PAGE_86 -->\n###### 대상자 또는 법정대리인에게 상세히 설명한다. "
      }
    },
    {
      "chunk_id": "chunk_735",
      "text": "서명 일자를\n\n<!-- PAGE_86 -->\n###### 정확히 기재하여야 하며, 작성된 동의서 원본은 시험자가 보관\n\n<!-- PAGE_86 -->\n###### 하고 사본은 시험대상자 또는 법정대리인에게 내준다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 734,
        "window_size": 3,
        "char_count": 120,
        "word_count": 24,
        "page_number": 86,
        "window_text": "4) 임상시험 설계에 따른 선택사항이므로 치료 기간 종료 후 추적 관찰 기간은 변경될 수 있다.\n\n - - 79 -\n<!-- PAGE_86 -->\n###### 가.  임상시험 절차\n\n<!-- PAGE_86 -->\n###### 1) 방문 1 (스크리닝 및 검사일, Screening)\n\n<!-- PAGE_86 -->\n###### - 임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여\n\n<!-- PAGE_86 -->\n###### 대상자 또는 법정대리인에게 상세히 설명한다.  서명 일자를\n\n<!-- PAGE_86 -->\n###### 정확히 기재하여야 하며, 작성된 동의서 원본은 시험자가 보관\n\n<!-- PAGE_86 -->\n###### 하고 사본은 시험대상자 또는 법정대리인에게 내준다.  대상자\n\n<!-- PAGE_86 -->\n###### 에게 동의를 받은 후 동의 취득 순서에 따라 스크리닝 번호를\n\n<!-- PAGE_86 -->\n###### - 대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그\n\n<!-- PAGE_86 -->\n###### - 인구학적 정보로 대상자 이니셜, 만 나이, 성별, 직업, 그리고\n\n<!-- PAGE_86 -->\n###### 업무 생산성을 조사하며 기초 문진에 필요한 환자들의 의학적\n\n<!-- PAGE_86 -->\n###### - 병력조사에 포함되어야 하는 내용은 다음과 같다.  치매, 인지\n\n<!-- PAGE_86 -->\n###### 기능 장애, 정신증, 양극성 장애 및 현재 주요 우울 삽화\n\n<!-- PAGE_86 -->\n###### (current major depressive episode) 등 스크리닝 확인해야 할\n\n<!-- PAGE_86 -->\n###### 질병군 등의 과거력 및 현 병력, 발생 시기, 치료와 진행여부\n\n- - 80 -\n<!-- PAGE_87 -->\n###### - 동의서 취득일 기준으로 최근 5년 이내 과거 및 현재 병력을\n\n<!-- PAGE_87 -->\n###### 조사한다.\n\n <!-- PAGE_87 -->\n###### - 피험자 선정을 위한 한국판 우울장애 심각도 척도 정보를 수집\n\n<!-- PAGE_87 -->\n###### - 필요시 본 단계에서 수집한 정보를 Baseline 지표로 활용할\n\n<!-- PAGE_87 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n<!-- PAGE_87 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_87 -->\n###### - 일차 유효성 평가지표, 이차 임상 변수를 평가하기 위해 우울장애\n\n<!-- PAGE_87 -->\n###### 심각도 척도(BDI) 및 해당하는 자가 보고를 작성하도록 하여\n\n<!-- PAGE_87 -->\n###### 지참하게 하거나, 애플리케이션 등을 통해 평가지표에 대한\n\n<!-- PAGE_87 -->\n###### - 필요에 따라 방문 1(스크리닝 단계)에서 측정한 우울장애 심각도\n\n- - 81 -\n<!-- PAGE_88 -->\n###### 다) 임상시험 의료기기 시험방법\n\n<!-- PAGE_88 -->\n###### - OOO 애플리케이션을 실행한다.\n\n",
        "original_sentence": "서명 일자를\n\n<!-- PAGE_86 -->\n###### 정확히 기재하여야 하며, 작성된 동의서 원본은 시험자가 보관\n\n<!-- PAGE_86 -->\n###### 하고 사본은 시험대상자 또는 법정대리인에게 내준다. "
      }
    },
    {
      "chunk_id": "chunk_736",
      "text": "대상자\n\n<!-- PAGE_86 -->\n###### 에게 동의를 받은 후 동의 취득 순서에 따라 스크리닝 번호를\n\n<!-- PAGE_86 -->\n###### - 대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그\n\n<!-- PAGE_86 -->\n###### - 인구학적 정보로 대상자 이니셜, 만 나이, 성별, 직업, 그리고\n\n<!-- PAGE_86 -->\n###### 업무 생산성을 조사하며 기초 문진에 필요한 환자들의 의학적\n\n<!-- PAGE_86 -->\n###### - 병력조사에 포함되어야 하는 내용은 다음과 같다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 735,
        "window_size": 3,
        "char_count": 298,
        "word_count": 66,
        "page_number": 86,
        "window_text": "- - 79 -\n<!-- PAGE_86 -->\n###### 가.  임상시험 절차\n\n<!-- PAGE_86 -->\n###### 1) 방문 1 (스크리닝 및 검사일, Screening)\n\n<!-- PAGE_86 -->\n###### - 임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여\n\n<!-- PAGE_86 -->\n###### 대상자 또는 법정대리인에게 상세히 설명한다.  서명 일자를\n\n<!-- PAGE_86 -->\n###### 정확히 기재하여야 하며, 작성된 동의서 원본은 시험자가 보관\n\n<!-- PAGE_86 -->\n###### 하고 사본은 시험대상자 또는 법정대리인에게 내준다.  대상자\n\n<!-- PAGE_86 -->\n###### 에게 동의를 받은 후 동의 취득 순서에 따라 스크리닝 번호를\n\n<!-- PAGE_86 -->\n###### - 대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그\n\n<!-- PAGE_86 -->\n###### - 인구학적 정보로 대상자 이니셜, 만 나이, 성별, 직업, 그리고\n\n<!-- PAGE_86 -->\n###### 업무 생산성을 조사하며 기초 문진에 필요한 환자들의 의학적\n\n<!-- PAGE_86 -->\n###### - 병력조사에 포함되어야 하는 내용은 다음과 같다.  치매, 인지\n\n<!-- PAGE_86 -->\n###### 기능 장애, 정신증, 양극성 장애 및 현재 주요 우울 삽화\n\n<!-- PAGE_86 -->\n###### (current major depressive episode) 등 스크리닝 확인해야 할\n\n<!-- PAGE_86 -->\n###### 질병군 등의 과거력 및 현 병력, 발생 시기, 치료와 진행여부\n\n- - 80 -\n<!-- PAGE_87 -->\n###### - 동의서 취득일 기준으로 최근 5년 이내 과거 및 현재 병력을\n\n<!-- PAGE_87 -->\n###### 조사한다.\n\n <!-- PAGE_87 -->\n###### - 피험자 선정을 위한 한국판 우울장애 심각도 척도 정보를 수집\n\n<!-- PAGE_87 -->\n###### - 필요시 본 단계에서 수집한 정보를 Baseline 지표로 활용할\n\n<!-- PAGE_87 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n<!-- PAGE_87 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_87 -->\n###### - 일차 유효성 평가지표, 이차 임상 변수를 평가하기 위해 우울장애\n\n<!-- PAGE_87 -->\n###### 심각도 척도(BDI) 및 해당하는 자가 보고를 작성하도록 하여\n\n<!-- PAGE_87 -->\n###### 지참하게 하거나, 애플리케이션 등을 통해 평가지표에 대한\n\n<!-- PAGE_87 -->\n###### - 필요에 따라 방문 1(스크리닝 단계)에서 측정한 우울장애 심각도\n\n- - 81 -\n<!-- PAGE_88 -->\n###### 다) 임상시험 의료기기 시험방법\n\n<!-- PAGE_88 -->\n###### - OOO 애플리케이션을 실행한다.\n\n <!-- PAGE_88 -->\n###### - 회원가입 및 초기 증상 평가를 시행한다(7가지 기본 입력 정보:\n\n<!-- PAGE_88 -->\n###### 성별, 나이, 우울장애 증상의 정도, 우울장애 증상의 양상, 동반\n\n<!-- PAGE_88 -->\n###### - 정해진 기간에 상술 된 방식으로 디지털치료기기 콘텐츠를\n\n<!-- PAGE_88 -->\n###### - 우울장애 교육/우울장애 일기(예: Sham, 대면교육, 교육책자 등)\n\n<!-- PAGE_88 -->\n###### - 정해진 기간에 환자에게 해가 되지 않는 내용으로 과학적 근거에\n\n<!-- PAGE_88 -->\n###### ※ 실험 설계에 따라 대조군에 Sham을 적용하지 않고 wait-list로 대체할 수 있다.\n\n",
        "original_sentence": "대상자\n\n<!-- PAGE_86 -->\n###### 에게 동의를 받은 후 동의 취득 순서에 따라 스크리닝 번호를\n\n<!-- PAGE_86 -->\n###### - 대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그\n\n<!-- PAGE_86 -->\n###### - 인구학적 정보로 대상자 이니셜, 만 나이, 성별, 직업, 그리고\n\n<!-- PAGE_86 -->\n###### 업무 생산성을 조사하며 기초 문진에 필요한 환자들의 의학적\n\n<!-- PAGE_86 -->\n###### - 병력조사에 포함되어야 하는 내용은 다음과 같다. "
      }
    },
    {
      "chunk_id": "chunk_737",
      "text": "치매, 인지\n\n<!-- PAGE_86 -->\n###### 기능 장애, 정신증, 양극성 장애 및 현재 주요 우울 삽화\n\n<!-- PAGE_86 -->\n###### (current major depressive episode) 등 스크리닝 확인해야 할\n\n<!-- PAGE_86 -->\n###### 질병군 등의 과거력 및 현 병력, 발생 시기, 치료와 진행여부\n\n- - 80 -\n<!-- PAGE_87 -->\n###### - 동의서 취득일 기준으로 최근 5년 이내 과거 및 현재 병력을\n\n<!-- PAGE_87 -->\n###### 조사한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 736,
        "window_size": 3,
        "char_count": 301,
        "word_count": 66,
        "page_number": 86,
        "window_text": "임상시험 절차\n\n<!-- PAGE_86 -->\n###### 1) 방문 1 (스크리닝 및 검사일, Screening)\n\n<!-- PAGE_86 -->\n###### - 임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여\n\n<!-- PAGE_86 -->\n###### 대상자 또는 법정대리인에게 상세히 설명한다.  서명 일자를\n\n<!-- PAGE_86 -->\n###### 정확히 기재하여야 하며, 작성된 동의서 원본은 시험자가 보관\n\n<!-- PAGE_86 -->\n###### 하고 사본은 시험대상자 또는 법정대리인에게 내준다.  대상자\n\n<!-- PAGE_86 -->\n###### 에게 동의를 받은 후 동의 취득 순서에 따라 스크리닝 번호를\n\n<!-- PAGE_86 -->\n###### - 대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그\n\n<!-- PAGE_86 -->\n###### - 인구학적 정보로 대상자 이니셜, 만 나이, 성별, 직업, 그리고\n\n<!-- PAGE_86 -->\n###### 업무 생산성을 조사하며 기초 문진에 필요한 환자들의 의학적\n\n<!-- PAGE_86 -->\n###### - 병력조사에 포함되어야 하는 내용은 다음과 같다.  치매, 인지\n\n<!-- PAGE_86 -->\n###### 기능 장애, 정신증, 양극성 장애 및 현재 주요 우울 삽화\n\n<!-- PAGE_86 -->\n###### (current major depressive episode) 등 스크리닝 확인해야 할\n\n<!-- PAGE_86 -->\n###### 질병군 등의 과거력 및 현 병력, 발생 시기, 치료와 진행여부\n\n- - 80 -\n<!-- PAGE_87 -->\n###### - 동의서 취득일 기준으로 최근 5년 이내 과거 및 현재 병력을\n\n<!-- PAGE_87 -->\n###### 조사한다.\n\n <!-- PAGE_87 -->\n###### - 피험자 선정을 위한 한국판 우울장애 심각도 척도 정보를 수집\n\n<!-- PAGE_87 -->\n###### - 필요시 본 단계에서 수집한 정보를 Baseline 지표로 활용할\n\n<!-- PAGE_87 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n<!-- PAGE_87 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_87 -->\n###### - 일차 유효성 평가지표, 이차 임상 변수를 평가하기 위해 우울장애\n\n<!-- PAGE_87 -->\n###### 심각도 척도(BDI) 및 해당하는 자가 보고를 작성하도록 하여\n\n<!-- PAGE_87 -->\n###### 지참하게 하거나, 애플리케이션 등을 통해 평가지표에 대한\n\n<!-- PAGE_87 -->\n###### - 필요에 따라 방문 1(스크리닝 단계)에서 측정한 우울장애 심각도\n\n- - 81 -\n<!-- PAGE_88 -->\n###### 다) 임상시험 의료기기 시험방법\n\n<!-- PAGE_88 -->\n###### - OOO 애플리케이션을 실행한다.\n\n <!-- PAGE_88 -->\n###### - 회원가입 및 초기 증상 평가를 시행한다(7가지 기본 입력 정보:\n\n<!-- PAGE_88 -->\n###### 성별, 나이, 우울장애 증상의 정도, 우울장애 증상의 양상, 동반\n\n<!-- PAGE_88 -->\n###### - 정해진 기간에 상술 된 방식으로 디지털치료기기 콘텐츠를\n\n<!-- PAGE_88 -->\n###### - 우울장애 교육/우울장애 일기(예: Sham, 대면교육, 교육책자 등)\n\n<!-- PAGE_88 -->\n###### - 정해진 기간에 환자에게 해가 되지 않는 내용으로 과학적 근거에\n\n<!-- PAGE_88 -->\n###### ※ 실험 설계에 따라 대조군에 Sham을 적용하지 않고 wait-list로 대체할 수 있다.\n\n <!-- PAGE_88 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_88 -->\n###### 이상 반응 여부를 방문일에 진찰을 통해 관찰하고, 임상시험용\n\n<!-- PAGE_88 -->\n###### ※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n<!-- PAGE_88 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n- - 82 -\n<!-- PAGE_89 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_89 -->\n###### 기간, 목적을 확인한다.\n\n",
        "original_sentence": "치매, 인지\n\n<!-- PAGE_86 -->\n###### 기능 장애, 정신증, 양극성 장애 및 현재 주요 우울 삽화\n\n<!-- PAGE_86 -->\n###### (current major depressive episode) 등 스크리닝 확인해야 할\n\n<!-- PAGE_86 -->\n###### 질병군 등의 과거력 및 현 병력, 발생 시기, 치료와 진행여부\n\n- - 80 -\n<!-- PAGE_87 -->\n###### - 동의서 취득일 기준으로 최근 5년 이내 과거 및 현재 병력을\n\n<!-- PAGE_87 -->\n###### 조사한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_738",
      "text": "<!-- PAGE_87 -->\n###### - 피험자 선정을 위한 한국판 우울장애 심각도 척도 정보를 수집\n\n<!-- PAGE_87 -->\n###### - 필요시 본 단계에서 수집한 정보를 Baseline 지표로 활용할\n\n<!-- PAGE_87 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n<!-- PAGE_87 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_87 -->\n###### - 일차 유효성 평가지표, 이차 임상 변수를 평가하기 위해 우울장애\n\n<!-- PAGE_87 -->\n###### 심각도 척도(BDI) 및 해당하는 자가 보고를 작성하도록 하여\n\n<!-- PAGE_87 -->\n###### 지참하게 하거나, 애플리케이션 등을 통해 평가지표에 대한\n\n<!-- PAGE_87 -->\n###### - 필요에 따라 방문 1(스크리닝 단계)에서 측정한 우울장애 심각도\n\n- - 81 -\n<!-- PAGE_88 -->\n###### 다) 임상시험 의료기기 시험방법\n\n<!-- PAGE_88 -->\n###### - OOO 애플리케이션을 실행한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 737,
        "window_size": 3,
        "char_count": 585,
        "word_count": 123,
        "page_number": 87,
        "window_text": "서명 일자를\n\n<!-- PAGE_86 -->\n###### 정확히 기재하여야 하며, 작성된 동의서 원본은 시험자가 보관\n\n<!-- PAGE_86 -->\n###### 하고 사본은 시험대상자 또는 법정대리인에게 내준다.  대상자\n\n<!-- PAGE_86 -->\n###### 에게 동의를 받은 후 동의 취득 순서에 따라 스크리닝 번호를\n\n<!-- PAGE_86 -->\n###### - 대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그\n\n<!-- PAGE_86 -->\n###### - 인구학적 정보로 대상자 이니셜, 만 나이, 성별, 직업, 그리고\n\n<!-- PAGE_86 -->\n###### 업무 생산성을 조사하며 기초 문진에 필요한 환자들의 의학적\n\n<!-- PAGE_86 -->\n###### - 병력조사에 포함되어야 하는 내용은 다음과 같다.  치매, 인지\n\n<!-- PAGE_86 -->\n###### 기능 장애, 정신증, 양극성 장애 및 현재 주요 우울 삽화\n\n<!-- PAGE_86 -->\n###### (current major depressive episode) 등 스크리닝 확인해야 할\n\n<!-- PAGE_86 -->\n###### 질병군 등의 과거력 및 현 병력, 발생 시기, 치료와 진행여부\n\n- - 80 -\n<!-- PAGE_87 -->\n###### - 동의서 취득일 기준으로 최근 5년 이내 과거 및 현재 병력을\n\n<!-- PAGE_87 -->\n###### 조사한다.\n\n <!-- PAGE_87 -->\n###### - 피험자 선정을 위한 한국판 우울장애 심각도 척도 정보를 수집\n\n<!-- PAGE_87 -->\n###### - 필요시 본 단계에서 수집한 정보를 Baseline 지표로 활용할\n\n<!-- PAGE_87 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n<!-- PAGE_87 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_87 -->\n###### - 일차 유효성 평가지표, 이차 임상 변수를 평가하기 위해 우울장애\n\n<!-- PAGE_87 -->\n###### 심각도 척도(BDI) 및 해당하는 자가 보고를 작성하도록 하여\n\n<!-- PAGE_87 -->\n###### 지참하게 하거나, 애플리케이션 등을 통해 평가지표에 대한\n\n<!-- PAGE_87 -->\n###### - 필요에 따라 방문 1(스크리닝 단계)에서 측정한 우울장애 심각도\n\n- - 81 -\n<!-- PAGE_88 -->\n###### 다) 임상시험 의료기기 시험방법\n\n<!-- PAGE_88 -->\n###### - OOO 애플리케이션을 실행한다.\n\n <!-- PAGE_88 -->\n###### - 회원가입 및 초기 증상 평가를 시행한다(7가지 기본 입력 정보:\n\n<!-- PAGE_88 -->\n###### 성별, 나이, 우울장애 증상의 정도, 우울장애 증상의 양상, 동반\n\n<!-- PAGE_88 -->\n###### - 정해진 기간에 상술 된 방식으로 디지털치료기기 콘텐츠를\n\n<!-- PAGE_88 -->\n###### - 우울장애 교육/우울장애 일기(예: Sham, 대면교육, 교육책자 등)\n\n<!-- PAGE_88 -->\n###### - 정해진 기간에 환자에게 해가 되지 않는 내용으로 과학적 근거에\n\n<!-- PAGE_88 -->\n###### ※ 실험 설계에 따라 대조군에 Sham을 적용하지 않고 wait-list로 대체할 수 있다.\n\n <!-- PAGE_88 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_88 -->\n###### 이상 반응 여부를 방문일에 진찰을 통해 관찰하고, 임상시험용\n\n<!-- PAGE_88 -->\n###### ※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n<!-- PAGE_88 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n- - 82 -\n<!-- PAGE_89 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_89 -->\n###### 기간, 목적을 확인한다.\n\n <!-- PAGE_89 -->\n###### - 치료기간 동안 어플리케이션 사용도 및 컨텐츠 이용도를 수집\n\n<!-- PAGE_89 -->\n###### - 치료 후 평가 및 일차 유효성 평가지표, 이차 유효성 평가지표의\n\n<!-- PAGE_89 -->\n###### 변화를 검증하기 위해 우울장애 심각도 척도 및 해당하는 자가\n\n<!-- PAGE_89 -->\n###### 보고를 작성하도록 하여 지참하게 하거나, 애플리케이션을\n\n<!-- PAGE_89 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_89 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_89 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_89 -->\n###### ※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n<!-- PAGE_89 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n- - 83 -\n<!-- PAGE_90 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_90 -->\n###### 기간, 목적을 확인한다.\n\n",
        "original_sentence": "<!-- PAGE_87 -->\n###### - 피험자 선정을 위한 한국판 우울장애 심각도 척도 정보를 수집\n\n<!-- PAGE_87 -->\n###### - 필요시 본 단계에서 수집한 정보를 Baseline 지표로 활용할\n\n<!-- PAGE_87 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n<!-- PAGE_87 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_87 -->\n###### - 일차 유효성 평가지표, 이차 임상 변수를 평가하기 위해 우울장애\n\n<!-- PAGE_87 -->\n###### 심각도 척도(BDI) 및 해당하는 자가 보고를 작성하도록 하여\n\n<!-- PAGE_87 -->\n###### 지참하게 하거나, 애플리케이션 등을 통해 평가지표에 대한\n\n<!-- PAGE_87 -->\n###### - 필요에 따라 방문 1(스크리닝 단계)에서 측정한 우울장애 심각도\n\n- - 81 -\n<!-- PAGE_88 -->\n###### 다) 임상시험 의료기기 시험방법\n\n<!-- PAGE_88 -->\n###### - OOO 애플리케이션을 실행한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_739",
      "text": "<!-- PAGE_88 -->\n###### - 회원가입 및 초기 증상 평가를 시행한다(7가지 기본 입력 정보:\n\n<!-- PAGE_88 -->\n###### 성별, 나이, 우울장애 증상의 정도, 우울장애 증상의 양상, 동반\n\n<!-- PAGE_88 -->\n###### - 정해진 기간에 상술 된 방식으로 디지털치료기기 콘텐츠를\n\n<!-- PAGE_88 -->\n###### - 우울장애 교육/우울장애 일기(예: Sham, 대면교육, 교육책자 등)\n\n<!-- PAGE_88 -->\n###### - 정해진 기간에 환자에게 해가 되지 않는 내용으로 과학적 근거에\n\n<!-- PAGE_88 -->\n###### ※ 실험 설계에 따라 대조군에 Sham을 적용하지 않고 wait-list로 대체할 수 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 738,
        "window_size": 3,
        "char_count": 388,
        "word_count": 81,
        "page_number": 88,
        "window_text": "대상자\n\n<!-- PAGE_86 -->\n###### 에게 동의를 받은 후 동의 취득 순서에 따라 스크리닝 번호를\n\n<!-- PAGE_86 -->\n###### - 대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그\n\n<!-- PAGE_86 -->\n###### - 인구학적 정보로 대상자 이니셜, 만 나이, 성별, 직업, 그리고\n\n<!-- PAGE_86 -->\n###### 업무 생산성을 조사하며 기초 문진에 필요한 환자들의 의학적\n\n<!-- PAGE_86 -->\n###### - 병력조사에 포함되어야 하는 내용은 다음과 같다.  치매, 인지\n\n<!-- PAGE_86 -->\n###### 기능 장애, 정신증, 양극성 장애 및 현재 주요 우울 삽화\n\n<!-- PAGE_86 -->\n###### (current major depressive episode) 등 스크리닝 확인해야 할\n\n<!-- PAGE_86 -->\n###### 질병군 등의 과거력 및 현 병력, 발생 시기, 치료와 진행여부\n\n- - 80 -\n<!-- PAGE_87 -->\n###### - 동의서 취득일 기준으로 최근 5년 이내 과거 및 현재 병력을\n\n<!-- PAGE_87 -->\n###### 조사한다.\n\n <!-- PAGE_87 -->\n###### - 피험자 선정을 위한 한국판 우울장애 심각도 척도 정보를 수집\n\n<!-- PAGE_87 -->\n###### - 필요시 본 단계에서 수집한 정보를 Baseline 지표로 활용할\n\n<!-- PAGE_87 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n<!-- PAGE_87 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_87 -->\n###### - 일차 유효성 평가지표, 이차 임상 변수를 평가하기 위해 우울장애\n\n<!-- PAGE_87 -->\n###### 심각도 척도(BDI) 및 해당하는 자가 보고를 작성하도록 하여\n\n<!-- PAGE_87 -->\n###### 지참하게 하거나, 애플리케이션 등을 통해 평가지표에 대한\n\n<!-- PAGE_87 -->\n###### - 필요에 따라 방문 1(스크리닝 단계)에서 측정한 우울장애 심각도\n\n- - 81 -\n<!-- PAGE_88 -->\n###### 다) 임상시험 의료기기 시험방법\n\n<!-- PAGE_88 -->\n###### - OOO 애플리케이션을 실행한다.\n\n <!-- PAGE_88 -->\n###### - 회원가입 및 초기 증상 평가를 시행한다(7가지 기본 입력 정보:\n\n<!-- PAGE_88 -->\n###### 성별, 나이, 우울장애 증상의 정도, 우울장애 증상의 양상, 동반\n\n<!-- PAGE_88 -->\n###### - 정해진 기간에 상술 된 방식으로 디지털치료기기 콘텐츠를\n\n<!-- PAGE_88 -->\n###### - 우울장애 교육/우울장애 일기(예: Sham, 대면교육, 교육책자 등)\n\n<!-- PAGE_88 -->\n###### - 정해진 기간에 환자에게 해가 되지 않는 내용으로 과학적 근거에\n\n<!-- PAGE_88 -->\n###### ※ 실험 설계에 따라 대조군에 Sham을 적용하지 않고 wait-list로 대체할 수 있다.\n\n <!-- PAGE_88 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_88 -->\n###### 이상 반응 여부를 방문일에 진찰을 통해 관찰하고, 임상시험용\n\n<!-- PAGE_88 -->\n###### ※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n<!-- PAGE_88 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n- - 82 -\n<!-- PAGE_89 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_89 -->\n###### 기간, 목적을 확인한다.\n\n <!-- PAGE_89 -->\n###### - 치료기간 동안 어플리케이션 사용도 및 컨텐츠 이용도를 수집\n\n<!-- PAGE_89 -->\n###### - 치료 후 평가 및 일차 유효성 평가지표, 이차 유효성 평가지표의\n\n<!-- PAGE_89 -->\n###### 변화를 검증하기 위해 우울장애 심각도 척도 및 해당하는 자가\n\n<!-- PAGE_89 -->\n###### 보고를 작성하도록 하여 지참하게 하거나, 애플리케이션을\n\n<!-- PAGE_89 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_89 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_89 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_89 -->\n###### ※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n<!-- PAGE_89 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n- - 83 -\n<!-- PAGE_90 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_90 -->\n###### 기간, 목적을 확인한다.\n\n <!-- PAGE_90 -->\n###### - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n\n<!-- PAGE_90 -->\n###### - 장기 효과 확인을 위한 일차 유효성 평가지표, 이차 유효성\n\n<!-- PAGE_90 -->\n###### 평가지표의 변화를 검증하기 위해 우울장애 심각도 척도 및\n\n<!-- PAGE_90 -->\n###### 해당하는 자가 보고를 작성하도록 하여 지참하게 하거나,\n\n<!-- PAGE_90 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_90 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_90 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_90 -->\n###### ※ 단, 이상반응 여부는 필요시 온라인(앱, 이메일, 문자, SNS 등)으로 대체\n\n- - 84 -\n<!-- PAGE_91 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n<!-- PAGE_91 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_91 -->\n###### - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n\n- - 85 -\n<!-- PAGE_92 -->\n##### 12. ",
        "original_sentence": "<!-- PAGE_88 -->\n###### - 회원가입 및 초기 증상 평가를 시행한다(7가지 기본 입력 정보:\n\n<!-- PAGE_88 -->\n###### 성별, 나이, 우울장애 증상의 정도, 우울장애 증상의 양상, 동반\n\n<!-- PAGE_88 -->\n###### - 정해진 기간에 상술 된 방식으로 디지털치료기기 콘텐츠를\n\n<!-- PAGE_88 -->\n###### - 우울장애 교육/우울장애 일기(예: Sham, 대면교육, 교육책자 등)\n\n<!-- PAGE_88 -->\n###### - 정해진 기간에 환자에게 해가 되지 않는 내용으로 과학적 근거에\n\n<!-- PAGE_88 -->\n###### ※ 실험 설계에 따라 대조군에 Sham을 적용하지 않고 wait-list로 대체할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_740",
      "text": "<!-- PAGE_88 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_88 -->\n###### 이상 반응 여부를 방문일에 진찰을 통해 관찰하고, 임상시험용\n\n<!-- PAGE_88 -->\n###### ※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n<!-- PAGE_88 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n- - 82 -\n<!-- PAGE_89 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_89 -->\n###### 기간, 목적을 확인한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 739,
        "window_size": 3,
        "char_count": 356,
        "word_count": 76,
        "page_number": 88,
        "window_text": "치매, 인지\n\n<!-- PAGE_86 -->\n###### 기능 장애, 정신증, 양극성 장애 및 현재 주요 우울 삽화\n\n<!-- PAGE_86 -->\n###### (current major depressive episode) 등 스크리닝 확인해야 할\n\n<!-- PAGE_86 -->\n###### 질병군 등의 과거력 및 현 병력, 발생 시기, 치료와 진행여부\n\n- - 80 -\n<!-- PAGE_87 -->\n###### - 동의서 취득일 기준으로 최근 5년 이내 과거 및 현재 병력을\n\n<!-- PAGE_87 -->\n###### 조사한다.\n\n <!-- PAGE_87 -->\n###### - 피험자 선정을 위한 한국판 우울장애 심각도 척도 정보를 수집\n\n<!-- PAGE_87 -->\n###### - 필요시 본 단계에서 수집한 정보를 Baseline 지표로 활용할\n\n<!-- PAGE_87 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n<!-- PAGE_87 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_87 -->\n###### - 일차 유효성 평가지표, 이차 임상 변수를 평가하기 위해 우울장애\n\n<!-- PAGE_87 -->\n###### 심각도 척도(BDI) 및 해당하는 자가 보고를 작성하도록 하여\n\n<!-- PAGE_87 -->\n###### 지참하게 하거나, 애플리케이션 등을 통해 평가지표에 대한\n\n<!-- PAGE_87 -->\n###### - 필요에 따라 방문 1(스크리닝 단계)에서 측정한 우울장애 심각도\n\n- - 81 -\n<!-- PAGE_88 -->\n###### 다) 임상시험 의료기기 시험방법\n\n<!-- PAGE_88 -->\n###### - OOO 애플리케이션을 실행한다.\n\n <!-- PAGE_88 -->\n###### - 회원가입 및 초기 증상 평가를 시행한다(7가지 기본 입력 정보:\n\n<!-- PAGE_88 -->\n###### 성별, 나이, 우울장애 증상의 정도, 우울장애 증상의 양상, 동반\n\n<!-- PAGE_88 -->\n###### - 정해진 기간에 상술 된 방식으로 디지털치료기기 콘텐츠를\n\n<!-- PAGE_88 -->\n###### - 우울장애 교육/우울장애 일기(예: Sham, 대면교육, 교육책자 등)\n\n<!-- PAGE_88 -->\n###### - 정해진 기간에 환자에게 해가 되지 않는 내용으로 과학적 근거에\n\n<!-- PAGE_88 -->\n###### ※ 실험 설계에 따라 대조군에 Sham을 적용하지 않고 wait-list로 대체할 수 있다.\n\n <!-- PAGE_88 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_88 -->\n###### 이상 반응 여부를 방문일에 진찰을 통해 관찰하고, 임상시험용\n\n<!-- PAGE_88 -->\n###### ※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n<!-- PAGE_88 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n- - 82 -\n<!-- PAGE_89 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_89 -->\n###### 기간, 목적을 확인한다.\n\n <!-- PAGE_89 -->\n###### - 치료기간 동안 어플리케이션 사용도 및 컨텐츠 이용도를 수집\n\n<!-- PAGE_89 -->\n###### - 치료 후 평가 및 일차 유효성 평가지표, 이차 유효성 평가지표의\n\n<!-- PAGE_89 -->\n###### 변화를 검증하기 위해 우울장애 심각도 척도 및 해당하는 자가\n\n<!-- PAGE_89 -->\n###### 보고를 작성하도록 하여 지참하게 하거나, 애플리케이션을\n\n<!-- PAGE_89 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_89 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_89 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_89 -->\n###### ※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n<!-- PAGE_89 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n- - 83 -\n<!-- PAGE_90 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_90 -->\n###### 기간, 목적을 확인한다.\n\n <!-- PAGE_90 -->\n###### - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n\n<!-- PAGE_90 -->\n###### - 장기 효과 확인을 위한 일차 유효성 평가지표, 이차 유효성\n\n<!-- PAGE_90 -->\n###### 평가지표의 변화를 검증하기 위해 우울장애 심각도 척도 및\n\n<!-- PAGE_90 -->\n###### 해당하는 자가 보고를 작성하도록 하여 지참하게 하거나,\n\n<!-- PAGE_90 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_90 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_90 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_90 -->\n###### ※ 단, 이상반응 여부는 필요시 온라인(앱, 이메일, 문자, SNS 등)으로 대체\n\n- - 84 -\n<!-- PAGE_91 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n<!-- PAGE_91 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_91 -->\n###### - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n\n- - 85 -\n<!-- PAGE_92 -->\n##### 12.  예측되는 부작용 및 사용 시 주의사항\n\n<!-- PAGE_92 -->\n###### 가. ",
        "original_sentence": "<!-- PAGE_88 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_88 -->\n###### 이상 반응 여부를 방문일에 진찰을 통해 관찰하고, 임상시험용\n\n<!-- PAGE_88 -->\n###### ※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n<!-- PAGE_88 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n- - 82 -\n<!-- PAGE_89 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_89 -->\n###### 기간, 목적을 확인한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_741",
      "text": "<!-- PAGE_89 -->\n###### - 치료기간 동안 어플리케이션 사용도 및 컨텐츠 이용도를 수집\n\n<!-- PAGE_89 -->\n###### - 치료 후 평가 및 일차 유효성 평가지표, 이차 유효성 평가지표의\n\n<!-- PAGE_89 -->\n###### 변화를 검증하기 위해 우울장애 심각도 척도 및 해당하는 자가\n\n<!-- PAGE_89 -->\n###### 보고를 작성하도록 하여 지참하게 하거나, 애플리케이션을\n\n<!-- PAGE_89 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_89 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_89 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_89 -->\n###### ※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n<!-- PAGE_89 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n- - 83 -\n<!-- PAGE_90 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_90 -->\n###### 기간, 목적을 확인한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 740,
        "window_size": 3,
        "char_count": 653,
        "word_count": 139,
        "page_number": 89,
        "window_text": "<!-- PAGE_87 -->\n###### - 피험자 선정을 위한 한국판 우울장애 심각도 척도 정보를 수집\n\n<!-- PAGE_87 -->\n###### - 필요시 본 단계에서 수집한 정보를 Baseline 지표로 활용할\n\n<!-- PAGE_87 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n<!-- PAGE_87 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_87 -->\n###### - 일차 유효성 평가지표, 이차 임상 변수를 평가하기 위해 우울장애\n\n<!-- PAGE_87 -->\n###### 심각도 척도(BDI) 및 해당하는 자가 보고를 작성하도록 하여\n\n<!-- PAGE_87 -->\n###### 지참하게 하거나, 애플리케이션 등을 통해 평가지표에 대한\n\n<!-- PAGE_87 -->\n###### - 필요에 따라 방문 1(스크리닝 단계)에서 측정한 우울장애 심각도\n\n- - 81 -\n<!-- PAGE_88 -->\n###### 다) 임상시험 의료기기 시험방법\n\n<!-- PAGE_88 -->\n###### - OOO 애플리케이션을 실행한다.\n\n <!-- PAGE_88 -->\n###### - 회원가입 및 초기 증상 평가를 시행한다(7가지 기본 입력 정보:\n\n<!-- PAGE_88 -->\n###### 성별, 나이, 우울장애 증상의 정도, 우울장애 증상의 양상, 동반\n\n<!-- PAGE_88 -->\n###### - 정해진 기간에 상술 된 방식으로 디지털치료기기 콘텐츠를\n\n<!-- PAGE_88 -->\n###### - 우울장애 교육/우울장애 일기(예: Sham, 대면교육, 교육책자 등)\n\n<!-- PAGE_88 -->\n###### - 정해진 기간에 환자에게 해가 되지 않는 내용으로 과학적 근거에\n\n<!-- PAGE_88 -->\n###### ※ 실험 설계에 따라 대조군에 Sham을 적용하지 않고 wait-list로 대체할 수 있다.\n\n <!-- PAGE_88 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_88 -->\n###### 이상 반응 여부를 방문일에 진찰을 통해 관찰하고, 임상시험용\n\n<!-- PAGE_88 -->\n###### ※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n<!-- PAGE_88 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n- - 82 -\n<!-- PAGE_89 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_89 -->\n###### 기간, 목적을 확인한다.\n\n <!-- PAGE_89 -->\n###### - 치료기간 동안 어플리케이션 사용도 및 컨텐츠 이용도를 수집\n\n<!-- PAGE_89 -->\n###### - 치료 후 평가 및 일차 유효성 평가지표, 이차 유효성 평가지표의\n\n<!-- PAGE_89 -->\n###### 변화를 검증하기 위해 우울장애 심각도 척도 및 해당하는 자가\n\n<!-- PAGE_89 -->\n###### 보고를 작성하도록 하여 지참하게 하거나, 애플리케이션을\n\n<!-- PAGE_89 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_89 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_89 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_89 -->\n###### ※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n<!-- PAGE_89 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n- - 83 -\n<!-- PAGE_90 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_90 -->\n###### 기간, 목적을 확인한다.\n\n <!-- PAGE_90 -->\n###### - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n\n<!-- PAGE_90 -->\n###### - 장기 효과 확인을 위한 일차 유효성 평가지표, 이차 유효성\n\n<!-- PAGE_90 -->\n###### 평가지표의 변화를 검증하기 위해 우울장애 심각도 척도 및\n\n<!-- PAGE_90 -->\n###### 해당하는 자가 보고를 작성하도록 하여 지참하게 하거나,\n\n<!-- PAGE_90 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_90 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_90 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_90 -->\n###### ※ 단, 이상반응 여부는 필요시 온라인(앱, 이메일, 문자, SNS 등)으로 대체\n\n- - 84 -\n<!-- PAGE_91 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n<!-- PAGE_91 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_91 -->\n###### - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n\n- - 85 -\n<!-- PAGE_92 -->\n##### 12.  예측되는 부작용 및 사용 시 주의사항\n\n<!-- PAGE_92 -->\n###### 가.  예측되는 부작용\n\n<!-- PAGE_92 -->\n###### 본 연구에서 적용하는 치료는 디지털 우울장애 인지행동치료\n\n<!-- PAGE_92 -->\n###### (Digital CBT-D)는 행동 요법 또는 인지 요법을 포함한 교육 이외 기타\n\n<!-- PAGE_92 -->\n###### 침습적이거나, 환자에게 유해를 끼칠 수 있는 내용은 포함되어 있지\n\n<!-- PAGE_92 -->\n###### 않다. ",
        "original_sentence": "<!-- PAGE_89 -->\n###### - 치료기간 동안 어플리케이션 사용도 및 컨텐츠 이용도를 수집\n\n<!-- PAGE_89 -->\n###### - 치료 후 평가 및 일차 유효성 평가지표, 이차 유효성 평가지표의\n\n<!-- PAGE_89 -->\n###### 변화를 검증하기 위해 우울장애 심각도 척도 및 해당하는 자가\n\n<!-- PAGE_89 -->\n###### 보고를 작성하도록 하여 지참하게 하거나, 애플리케이션을\n\n<!-- PAGE_89 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_89 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_89 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_89 -->\n###### ※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n<!-- PAGE_89 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n- - 83 -\n<!-- PAGE_90 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_90 -->\n###### 기간, 목적을 확인한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_742",
      "text": "<!-- PAGE_90 -->\n###### - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n\n<!-- PAGE_90 -->\n###### - 장기 효과 확인을 위한 일차 유효성 평가지표, 이차 유효성\n\n<!-- PAGE_90 -->\n###### 평가지표의 변화를 검증하기 위해 우울장애 심각도 척도 및\n\n<!-- PAGE_90 -->\n###### 해당하는 자가 보고를 작성하도록 하여 지참하게 하거나,\n\n<!-- PAGE_90 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_90 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_90 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_90 -->\n###### ※ 단, 이상반응 여부는 필요시 온라인(앱, 이메일, 문자, SNS 등)으로 대체\n\n- - 84 -\n<!-- PAGE_91 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n<!-- PAGE_91 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_91 -->\n###### - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n\n- - 85 -\n<!-- PAGE_92 -->\n##### 12. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 741,
        "window_size": 3,
        "char_count": 708,
        "word_count": 153,
        "page_number": 90,
        "window_text": "<!-- PAGE_88 -->\n###### - 회원가입 및 초기 증상 평가를 시행한다(7가지 기본 입력 정보:\n\n<!-- PAGE_88 -->\n###### 성별, 나이, 우울장애 증상의 정도, 우울장애 증상의 양상, 동반\n\n<!-- PAGE_88 -->\n###### - 정해진 기간에 상술 된 방식으로 디지털치료기기 콘텐츠를\n\n<!-- PAGE_88 -->\n###### - 우울장애 교육/우울장애 일기(예: Sham, 대면교육, 교육책자 등)\n\n<!-- PAGE_88 -->\n###### - 정해진 기간에 환자에게 해가 되지 않는 내용으로 과학적 근거에\n\n<!-- PAGE_88 -->\n###### ※ 실험 설계에 따라 대조군에 Sham을 적용하지 않고 wait-list로 대체할 수 있다.\n\n <!-- PAGE_88 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_88 -->\n###### 이상 반응 여부를 방문일에 진찰을 통해 관찰하고, 임상시험용\n\n<!-- PAGE_88 -->\n###### ※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n<!-- PAGE_88 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n- - 82 -\n<!-- PAGE_89 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_89 -->\n###### 기간, 목적을 확인한다.\n\n <!-- PAGE_89 -->\n###### - 치료기간 동안 어플리케이션 사용도 및 컨텐츠 이용도를 수집\n\n<!-- PAGE_89 -->\n###### - 치료 후 평가 및 일차 유효성 평가지표, 이차 유효성 평가지표의\n\n<!-- PAGE_89 -->\n###### 변화를 검증하기 위해 우울장애 심각도 척도 및 해당하는 자가\n\n<!-- PAGE_89 -->\n###### 보고를 작성하도록 하여 지참하게 하거나, 애플리케이션을\n\n<!-- PAGE_89 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_89 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_89 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_89 -->\n###### ※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n<!-- PAGE_89 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n- - 83 -\n<!-- PAGE_90 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_90 -->\n###### 기간, 목적을 확인한다.\n\n <!-- PAGE_90 -->\n###### - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n\n<!-- PAGE_90 -->\n###### - 장기 효과 확인을 위한 일차 유효성 평가지표, 이차 유효성\n\n<!-- PAGE_90 -->\n###### 평가지표의 변화를 검증하기 위해 우울장애 심각도 척도 및\n\n<!-- PAGE_90 -->\n###### 해당하는 자가 보고를 작성하도록 하여 지참하게 하거나,\n\n<!-- PAGE_90 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_90 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_90 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_90 -->\n###### ※ 단, 이상반응 여부는 필요시 온라인(앱, 이메일, 문자, SNS 등)으로 대체\n\n- - 84 -\n<!-- PAGE_91 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n<!-- PAGE_91 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_91 -->\n###### - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n\n- - 85 -\n<!-- PAGE_92 -->\n##### 12.  예측되는 부작용 및 사용 시 주의사항\n\n<!-- PAGE_92 -->\n###### 가.  예측되는 부작용\n\n<!-- PAGE_92 -->\n###### 본 연구에서 적용하는 치료는 디지털 우울장애 인지행동치료\n\n<!-- PAGE_92 -->\n###### (Digital CBT-D)는 행동 요법 또는 인지 요법을 포함한 교육 이외 기타\n\n<!-- PAGE_92 -->\n###### 침습적이거나, 환자에게 유해를 끼칠 수 있는 내용은 포함되어 있지\n\n<!-- PAGE_92 -->\n###### 않다.  다만, 일반적인 우울장애 인지행동치료(CBT-D)의 부작용에 준하는\n\n<!-- PAGE_92 -->\n###### 부작용 또는 범용장비 사용으로 인한 부작용을 예상할 수 있고, 이는\n\n<!-- PAGE_92 -->\n###### 다음과 같다.\n\n",
        "original_sentence": "<!-- PAGE_90 -->\n###### - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n\n<!-- PAGE_90 -->\n###### - 장기 효과 확인을 위한 일차 유효성 평가지표, 이차 유효성\n\n<!-- PAGE_90 -->\n###### 평가지표의 변화를 검증하기 위해 우울장애 심각도 척도 및\n\n<!-- PAGE_90 -->\n###### 해당하는 자가 보고를 작성하도록 하여 지참하게 하거나,\n\n<!-- PAGE_90 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_90 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_90 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_90 -->\n###### ※ 단, 이상반응 여부는 필요시 온라인(앱, 이메일, 문자, SNS 등)으로 대체\n\n- - 84 -\n<!-- PAGE_91 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n<!-- PAGE_91 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_91 -->\n###### - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n\n- - 85 -\n<!-- PAGE_92 -->\n##### 12. "
      }
    },
    {
      "chunk_id": "chunk_743",
      "text": "예측되는 부작용 및 사용 시 주의사항\n\n<!-- PAGE_92 -->\n###### 가. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 742,
        "window_size": 3,
        "char_count": 49,
        "word_count": 11,
        "page_number": 92,
        "window_text": "<!-- PAGE_88 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_88 -->\n###### 이상 반응 여부를 방문일에 진찰을 통해 관찰하고, 임상시험용\n\n<!-- PAGE_88 -->\n###### ※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n<!-- PAGE_88 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n- - 82 -\n<!-- PAGE_89 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_89 -->\n###### 기간, 목적을 확인한다.\n\n <!-- PAGE_89 -->\n###### - 치료기간 동안 어플리케이션 사용도 및 컨텐츠 이용도를 수집\n\n<!-- PAGE_89 -->\n###### - 치료 후 평가 및 일차 유효성 평가지표, 이차 유효성 평가지표의\n\n<!-- PAGE_89 -->\n###### 변화를 검증하기 위해 우울장애 심각도 척도 및 해당하는 자가\n\n<!-- PAGE_89 -->\n###### 보고를 작성하도록 하여 지참하게 하거나, 애플리케이션을\n\n<!-- PAGE_89 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_89 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_89 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_89 -->\n###### ※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n<!-- PAGE_89 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n- - 83 -\n<!-- PAGE_90 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_90 -->\n###### 기간, 목적을 확인한다.\n\n <!-- PAGE_90 -->\n###### - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n\n<!-- PAGE_90 -->\n###### - 장기 효과 확인을 위한 일차 유효성 평가지표, 이차 유효성\n\n<!-- PAGE_90 -->\n###### 평가지표의 변화를 검증하기 위해 우울장애 심각도 척도 및\n\n<!-- PAGE_90 -->\n###### 해당하는 자가 보고를 작성하도록 하여 지참하게 하거나,\n\n<!-- PAGE_90 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_90 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_90 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_90 -->\n###### ※ 단, 이상반응 여부는 필요시 온라인(앱, 이메일, 문자, SNS 등)으로 대체\n\n- - 84 -\n<!-- PAGE_91 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n<!-- PAGE_91 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_91 -->\n###### - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n\n- - 85 -\n<!-- PAGE_92 -->\n##### 12.  예측되는 부작용 및 사용 시 주의사항\n\n<!-- PAGE_92 -->\n###### 가.  예측되는 부작용\n\n<!-- PAGE_92 -->\n###### 본 연구에서 적용하는 치료는 디지털 우울장애 인지행동치료\n\n<!-- PAGE_92 -->\n###### (Digital CBT-D)는 행동 요법 또는 인지 요법을 포함한 교육 이외 기타\n\n<!-- PAGE_92 -->\n###### 침습적이거나, 환자에게 유해를 끼칠 수 있는 내용은 포함되어 있지\n\n<!-- PAGE_92 -->\n###### 않다.  다만, 일반적인 우울장애 인지행동치료(CBT-D)의 부작용에 준하는\n\n<!-- PAGE_92 -->\n###### 부작용 또는 범용장비 사용으로 인한 부작용을 예상할 수 있고, 이는\n\n<!-- PAGE_92 -->\n###### 다음과 같다.\n\n <!-- PAGE_92 -->\n###### 1) 우울장애 인지행동치료(CBT-D)의 행동 요법 중 밤 시간의 집중\n\n<!-- PAGE_92 -->\n###### 저하를 불러일으킬 수 있어 3교대자 등 밤 시간 우울장애가 큰\n\n<!-- PAGE_92 -->\n###### 피해를 가져올 수 있는 직업군의 환자의 경우 임상시험에서\n\n<!-- PAGE_92 -->\n###### 제외한다. ",
        "original_sentence": "예측되는 부작용 및 사용 시 주의사항\n\n<!-- PAGE_92 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_744",
      "text": "예측되는 부작용\n\n<!-- PAGE_92 -->\n###### 본 연구에서 적용하는 치료는 디지털 우울장애 인지행동치료\n\n<!-- PAGE_92 -->\n###### (Digital CBT-D)는 행동 요법 또는 인지 요법을 포함한 교육 이외 기타\n\n<!-- PAGE_92 -->\n###### 침습적이거나, 환자에게 유해를 끼칠 수 있는 내용은 포함되어 있지\n\n<!-- PAGE_92 -->\n###### 않다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 743,
        "window_size": 3,
        "char_count": 228,
        "word_count": 46,
        "page_number": 92,
        "window_text": "<!-- PAGE_89 -->\n###### - 치료기간 동안 어플리케이션 사용도 및 컨텐츠 이용도를 수집\n\n<!-- PAGE_89 -->\n###### - 치료 후 평가 및 일차 유효성 평가지표, 이차 유효성 평가지표의\n\n<!-- PAGE_89 -->\n###### 변화를 검증하기 위해 우울장애 심각도 척도 및 해당하는 자가\n\n<!-- PAGE_89 -->\n###### 보고를 작성하도록 하여 지참하게 하거나, 애플리케이션을\n\n<!-- PAGE_89 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_89 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_89 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_89 -->\n###### ※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n<!-- PAGE_89 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n- - 83 -\n<!-- PAGE_90 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_90 -->\n###### 기간, 목적을 확인한다.\n\n <!-- PAGE_90 -->\n###### - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n\n<!-- PAGE_90 -->\n###### - 장기 효과 확인을 위한 일차 유효성 평가지표, 이차 유효성\n\n<!-- PAGE_90 -->\n###### 평가지표의 변화를 검증하기 위해 우울장애 심각도 척도 및\n\n<!-- PAGE_90 -->\n###### 해당하는 자가 보고를 작성하도록 하여 지참하게 하거나,\n\n<!-- PAGE_90 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_90 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_90 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_90 -->\n###### ※ 단, 이상반응 여부는 필요시 온라인(앱, 이메일, 문자, SNS 등)으로 대체\n\n- - 84 -\n<!-- PAGE_91 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n<!-- PAGE_91 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_91 -->\n###### - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n\n- - 85 -\n<!-- PAGE_92 -->\n##### 12.  예측되는 부작용 및 사용 시 주의사항\n\n<!-- PAGE_92 -->\n###### 가.  예측되는 부작용\n\n<!-- PAGE_92 -->\n###### 본 연구에서 적용하는 치료는 디지털 우울장애 인지행동치료\n\n<!-- PAGE_92 -->\n###### (Digital CBT-D)는 행동 요법 또는 인지 요법을 포함한 교육 이외 기타\n\n<!-- PAGE_92 -->\n###### 침습적이거나, 환자에게 유해를 끼칠 수 있는 내용은 포함되어 있지\n\n<!-- PAGE_92 -->\n###### 않다.  다만, 일반적인 우울장애 인지행동치료(CBT-D)의 부작용에 준하는\n\n<!-- PAGE_92 -->\n###### 부작용 또는 범용장비 사용으로 인한 부작용을 예상할 수 있고, 이는\n\n<!-- PAGE_92 -->\n###### 다음과 같다.\n\n <!-- PAGE_92 -->\n###### 1) 우울장애 인지행동치료(CBT-D)의 행동 요법 중 밤 시간의 집중\n\n<!-- PAGE_92 -->\n###### 저하를 불러일으킬 수 있어 3교대자 등 밤 시간 우울장애가 큰\n\n<!-- PAGE_92 -->\n###### 피해를 가져올 수 있는 직업군의 환자의 경우 임상시험에서\n\n<!-- PAGE_92 -->\n###### 제외한다.  이외에도 치료 시작 시점에서 밤 시간 우울장애가 악화\n\n<!-- PAGE_92 -->\n###### 될 수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통하여\n\n<!-- PAGE_92 -->\n###### 2) 우울장애 인지행동치료(CBT-D)의 인지 요법 중 왜곡된 인지 교정의\n\n<!-- PAGE_92 -->\n###### 경우 일시적인 불안감 악화를 가져올 수 있다. ",
        "original_sentence": "예측되는 부작용\n\n<!-- PAGE_92 -->\n###### 본 연구에서 적용하는 치료는 디지털 우울장애 인지행동치료\n\n<!-- PAGE_92 -->\n###### (Digital CBT-D)는 행동 요법 또는 인지 요법을 포함한 교육 이외 기타\n\n<!-- PAGE_92 -->\n###### 침습적이거나, 환자에게 유해를 끼칠 수 있는 내용은 포함되어 있지\n\n<!-- PAGE_92 -->\n###### 않다. "
      }
    },
    {
      "chunk_id": "chunk_745",
      "text": "다만, 일반적인 우울장애 인지행동치료(CBT-D)의 부작용에 준하는\n\n<!-- PAGE_92 -->\n###### 부작용 또는 범용장비 사용으로 인한 부작용을 예상할 수 있고, 이는\n\n<!-- PAGE_92 -->\n###### 다음과 같다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 744,
        "window_size": 3,
        "char_count": 135,
        "word_count": 26,
        "page_number": 92,
        "window_text": "<!-- PAGE_90 -->\n###### - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n\n<!-- PAGE_90 -->\n###### - 장기 효과 확인을 위한 일차 유효성 평가지표, 이차 유효성\n\n<!-- PAGE_90 -->\n###### 평가지표의 변화를 검증하기 위해 우울장애 심각도 척도 및\n\n<!-- PAGE_90 -->\n###### 해당하는 자가 보고를 작성하도록 하여 지참하게 하거나,\n\n<!-- PAGE_90 -->\n###### - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n\n<!-- PAGE_90 -->\n###### 이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n<!-- PAGE_90 -->\n###### 하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n<!-- PAGE_90 -->\n###### ※ 단, 이상반응 여부는 필요시 온라인(앱, 이메일, 문자, SNS 등)으로 대체\n\n- - 84 -\n<!-- PAGE_91 -->\n###### - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n\n<!-- PAGE_91 -->\n###### 하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n<!-- PAGE_91 -->\n###### - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n\n- - 85 -\n<!-- PAGE_92 -->\n##### 12.  예측되는 부작용 및 사용 시 주의사항\n\n<!-- PAGE_92 -->\n###### 가.  예측되는 부작용\n\n<!-- PAGE_92 -->\n###### 본 연구에서 적용하는 치료는 디지털 우울장애 인지행동치료\n\n<!-- PAGE_92 -->\n###### (Digital CBT-D)는 행동 요법 또는 인지 요법을 포함한 교육 이외 기타\n\n<!-- PAGE_92 -->\n###### 침습적이거나, 환자에게 유해를 끼칠 수 있는 내용은 포함되어 있지\n\n<!-- PAGE_92 -->\n###### 않다.  다만, 일반적인 우울장애 인지행동치료(CBT-D)의 부작용에 준하는\n\n<!-- PAGE_92 -->\n###### 부작용 또는 범용장비 사용으로 인한 부작용을 예상할 수 있고, 이는\n\n<!-- PAGE_92 -->\n###### 다음과 같다.\n\n <!-- PAGE_92 -->\n###### 1) 우울장애 인지행동치료(CBT-D)의 행동 요법 중 밤 시간의 집중\n\n<!-- PAGE_92 -->\n###### 저하를 불러일으킬 수 있어 3교대자 등 밤 시간 우울장애가 큰\n\n<!-- PAGE_92 -->\n###### 피해를 가져올 수 있는 직업군의 환자의 경우 임상시험에서\n\n<!-- PAGE_92 -->\n###### 제외한다.  이외에도 치료 시작 시점에서 밤 시간 우울장애가 악화\n\n<!-- PAGE_92 -->\n###### 될 수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통하여\n\n<!-- PAGE_92 -->\n###### 2) 우울장애 인지행동치료(CBT-D)의 인지 요법 중 왜곡된 인지 교정의\n\n<!-- PAGE_92 -->\n###### 경우 일시적인 불안감 악화를 가져올 수 있다.  치료 시작 시점에서\n\n<!-- PAGE_92 -->\n###### 일시적인 불안감 악화가 나타날 수 있음을 알리고, 24시간 연락\n\n- - 86 -\n<!-- PAGE_93 -->\n###### 가능한 연구자 번호를 통하여 즉시 상담과 필요하면 의료진 연결이\n\n<!-- PAGE_93 -->\n###### 가능하도록 조치한다.\n\n",
        "original_sentence": "다만, 일반적인 우울장애 인지행동치료(CBT-D)의 부작용에 준하는\n\n<!-- PAGE_92 -->\n###### 부작용 또는 범용장비 사용으로 인한 부작용을 예상할 수 있고, 이는\n\n<!-- PAGE_92 -->\n###### 다음과 같다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_746",
      "text": "<!-- PAGE_92 -->\n###### 1) 우울장애 인지행동치료(CBT-D)의 행동 요법 중 밤 시간의 집중\n\n<!-- PAGE_92 -->\n###### 저하를 불러일으킬 수 있어 3교대자 등 밤 시간 우울장애가 큰\n\n<!-- PAGE_92 -->\n###### 피해를 가져올 수 있는 직업군의 환자의 경우 임상시험에서\n\n<!-- PAGE_92 -->\n###### 제외한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 745,
        "window_size": 3,
        "char_count": 212,
        "word_count": 44,
        "page_number": 92,
        "window_text": "예측되는 부작용 및 사용 시 주의사항\n\n<!-- PAGE_92 -->\n###### 가.  예측되는 부작용\n\n<!-- PAGE_92 -->\n###### 본 연구에서 적용하는 치료는 디지털 우울장애 인지행동치료\n\n<!-- PAGE_92 -->\n###### (Digital CBT-D)는 행동 요법 또는 인지 요법을 포함한 교육 이외 기타\n\n<!-- PAGE_92 -->\n###### 침습적이거나, 환자에게 유해를 끼칠 수 있는 내용은 포함되어 있지\n\n<!-- PAGE_92 -->\n###### 않다.  다만, 일반적인 우울장애 인지행동치료(CBT-D)의 부작용에 준하는\n\n<!-- PAGE_92 -->\n###### 부작용 또는 범용장비 사용으로 인한 부작용을 예상할 수 있고, 이는\n\n<!-- PAGE_92 -->\n###### 다음과 같다.\n\n <!-- PAGE_92 -->\n###### 1) 우울장애 인지행동치료(CBT-D)의 행동 요법 중 밤 시간의 집중\n\n<!-- PAGE_92 -->\n###### 저하를 불러일으킬 수 있어 3교대자 등 밤 시간 우울장애가 큰\n\n<!-- PAGE_92 -->\n###### 피해를 가져올 수 있는 직업군의 환자의 경우 임상시험에서\n\n<!-- PAGE_92 -->\n###### 제외한다.  이외에도 치료 시작 시점에서 밤 시간 우울장애가 악화\n\n<!-- PAGE_92 -->\n###### 될 수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통하여\n\n<!-- PAGE_92 -->\n###### 2) 우울장애 인지행동치료(CBT-D)의 인지 요법 중 왜곡된 인지 교정의\n\n<!-- PAGE_92 -->\n###### 경우 일시적인 불안감 악화를 가져올 수 있다.  치료 시작 시점에서\n\n<!-- PAGE_92 -->\n###### 일시적인 불안감 악화가 나타날 수 있음을 알리고, 24시간 연락\n\n- - 86 -\n<!-- PAGE_93 -->\n###### 가능한 연구자 번호를 통하여 즉시 상담과 필요하면 의료진 연결이\n\n<!-- PAGE_93 -->\n###### 가능하도록 조치한다.\n\n <!-- PAGE_93 -->\n###### 3) 디지털 우울장애 인지행동치료(Digital CBT-D를 위한 범용 장비\n\n<!-- PAGE_93 -->\n###### (스마트폰 또는 태블릿 PC 등) 사용으로 두통, 눈의 피로, 눈 또는\n\n<!-- PAGE_93 -->\n###### 근육경련, 눈의 불수의운동, 메스꺼움, 어지럼증, 머리 또는 눈의\n\n<!-- PAGE_93 -->\n###### 불쾌감 또는 통증, 졸림, 피로감과 같은 부작용이 발생할 수 있다.\n\n",
        "original_sentence": "<!-- PAGE_92 -->\n###### 1) 우울장애 인지행동치료(CBT-D)의 행동 요법 중 밤 시간의 집중\n\n<!-- PAGE_92 -->\n###### 저하를 불러일으킬 수 있어 3교대자 등 밤 시간 우울장애가 큰\n\n<!-- PAGE_92 -->\n###### 피해를 가져올 수 있는 직업군의 환자의 경우 임상시험에서\n\n<!-- PAGE_92 -->\n###### 제외한다. "
      }
    },
    {
      "chunk_id": "chunk_747",
      "text": "이외에도 치료 시작 시점에서 밤 시간 우울장애가 악화\n\n<!-- PAGE_92 -->\n###### 될 수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통하여\n\n<!-- PAGE_92 -->\n###### 2) 우울장애 인지행동치료(CBT-D)의 인지 요법 중 왜곡된 인지 교정의\n\n<!-- PAGE_92 -->\n###### 경우 일시적인 불안감 악화를 가져올 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 746,
        "window_size": 3,
        "char_count": 210,
        "word_count": 46,
        "page_number": 92,
        "window_text": "예측되는 부작용\n\n<!-- PAGE_92 -->\n###### 본 연구에서 적용하는 치료는 디지털 우울장애 인지행동치료\n\n<!-- PAGE_92 -->\n###### (Digital CBT-D)는 행동 요법 또는 인지 요법을 포함한 교육 이외 기타\n\n<!-- PAGE_92 -->\n###### 침습적이거나, 환자에게 유해를 끼칠 수 있는 내용은 포함되어 있지\n\n<!-- PAGE_92 -->\n###### 않다.  다만, 일반적인 우울장애 인지행동치료(CBT-D)의 부작용에 준하는\n\n<!-- PAGE_92 -->\n###### 부작용 또는 범용장비 사용으로 인한 부작용을 예상할 수 있고, 이는\n\n<!-- PAGE_92 -->\n###### 다음과 같다.\n\n <!-- PAGE_92 -->\n###### 1) 우울장애 인지행동치료(CBT-D)의 행동 요법 중 밤 시간의 집중\n\n<!-- PAGE_92 -->\n###### 저하를 불러일으킬 수 있어 3교대자 등 밤 시간 우울장애가 큰\n\n<!-- PAGE_92 -->\n###### 피해를 가져올 수 있는 직업군의 환자의 경우 임상시험에서\n\n<!-- PAGE_92 -->\n###### 제외한다.  이외에도 치료 시작 시점에서 밤 시간 우울장애가 악화\n\n<!-- PAGE_92 -->\n###### 될 수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통하여\n\n<!-- PAGE_92 -->\n###### 2) 우울장애 인지행동치료(CBT-D)의 인지 요법 중 왜곡된 인지 교정의\n\n<!-- PAGE_92 -->\n###### 경우 일시적인 불안감 악화를 가져올 수 있다.  치료 시작 시점에서\n\n<!-- PAGE_92 -->\n###### 일시적인 불안감 악화가 나타날 수 있음을 알리고, 24시간 연락\n\n- - 86 -\n<!-- PAGE_93 -->\n###### 가능한 연구자 번호를 통하여 즉시 상담과 필요하면 의료진 연결이\n\n<!-- PAGE_93 -->\n###### 가능하도록 조치한다.\n\n <!-- PAGE_93 -->\n###### 3) 디지털 우울장애 인지행동치료(Digital CBT-D를 위한 범용 장비\n\n<!-- PAGE_93 -->\n###### (스마트폰 또는 태블릿 PC 등) 사용으로 두통, 눈의 피로, 눈 또는\n\n<!-- PAGE_93 -->\n###### 근육경련, 눈의 불수의운동, 메스꺼움, 어지럼증, 머리 또는 눈의\n\n<!-- PAGE_93 -->\n###### 불쾌감 또는 통증, 졸림, 피로감과 같은 부작용이 발생할 수 있다.\n\n <!-- PAGE_93 -->\n###### 해당 경우 24시간 연락 가능한 연구자 번호를 통하여 즉시 상담과\n\n<!-- PAGE_93 -->\n###### 본 연구에서 진행되는 평가는 자가 보고 설문지, 면담 등 모두\n\n<!-- PAGE_93 -->\n###### 비침습적인 검사로 이루어져 있으므로 예측되는 부작용은 없다.\n\n",
        "original_sentence": "이외에도 치료 시작 시점에서 밤 시간 우울장애가 악화\n\n<!-- PAGE_92 -->\n###### 될 수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통하여\n\n<!-- PAGE_92 -->\n###### 2) 우울장애 인지행동치료(CBT-D)의 인지 요법 중 왜곡된 인지 교정의\n\n<!-- PAGE_92 -->\n###### 경우 일시적인 불안감 악화를 가져올 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_748",
      "text": "치료 시작 시점에서\n\n<!-- PAGE_92 -->\n###### 일시적인 불안감 악화가 나타날 수 있음을 알리고, 24시간 연락\n\n- - 86 -\n<!-- PAGE_93 -->\n###### 가능한 연구자 번호를 통하여 즉시 상담과 필요하면 의료진 연결이\n\n<!-- PAGE_93 -->\n###### 가능하도록 조치한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 747,
        "window_size": 3,
        "char_count": 180,
        "word_count": 39,
        "page_number": 92,
        "window_text": "다만, 일반적인 우울장애 인지행동치료(CBT-D)의 부작용에 준하는\n\n<!-- PAGE_92 -->\n###### 부작용 또는 범용장비 사용으로 인한 부작용을 예상할 수 있고, 이는\n\n<!-- PAGE_92 -->\n###### 다음과 같다.\n\n <!-- PAGE_92 -->\n###### 1) 우울장애 인지행동치료(CBT-D)의 행동 요법 중 밤 시간의 집중\n\n<!-- PAGE_92 -->\n###### 저하를 불러일으킬 수 있어 3교대자 등 밤 시간 우울장애가 큰\n\n<!-- PAGE_92 -->\n###### 피해를 가져올 수 있는 직업군의 환자의 경우 임상시험에서\n\n<!-- PAGE_92 -->\n###### 제외한다.  이외에도 치료 시작 시점에서 밤 시간 우울장애가 악화\n\n<!-- PAGE_92 -->\n###### 될 수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통하여\n\n<!-- PAGE_92 -->\n###### 2) 우울장애 인지행동치료(CBT-D)의 인지 요법 중 왜곡된 인지 교정의\n\n<!-- PAGE_92 -->\n###### 경우 일시적인 불안감 악화를 가져올 수 있다.  치료 시작 시점에서\n\n<!-- PAGE_92 -->\n###### 일시적인 불안감 악화가 나타날 수 있음을 알리고, 24시간 연락\n\n- - 86 -\n<!-- PAGE_93 -->\n###### 가능한 연구자 번호를 통하여 즉시 상담과 필요하면 의료진 연결이\n\n<!-- PAGE_93 -->\n###### 가능하도록 조치한다.\n\n <!-- PAGE_93 -->\n###### 3) 디지털 우울장애 인지행동치료(Digital CBT-D를 위한 범용 장비\n\n<!-- PAGE_93 -->\n###### (스마트폰 또는 태블릿 PC 등) 사용으로 두통, 눈의 피로, 눈 또는\n\n<!-- PAGE_93 -->\n###### 근육경련, 눈의 불수의운동, 메스꺼움, 어지럼증, 머리 또는 눈의\n\n<!-- PAGE_93 -->\n###### 불쾌감 또는 통증, 졸림, 피로감과 같은 부작용이 발생할 수 있다.\n\n <!-- PAGE_93 -->\n###### 해당 경우 24시간 연락 가능한 연구자 번호를 통하여 즉시 상담과\n\n<!-- PAGE_93 -->\n###### 본 연구에서 진행되는 평가는 자가 보고 설문지, 면담 등 모두\n\n<!-- PAGE_93 -->\n###### 비침습적인 검사로 이루어져 있으므로 예측되는 부작용은 없다.\n\n <!-- PAGE_93 -->\n###### 나. ",
        "original_sentence": "치료 시작 시점에서\n\n<!-- PAGE_92 -->\n###### 일시적인 불안감 악화가 나타날 수 있음을 알리고, 24시간 연락\n\n- - 86 -\n<!-- PAGE_93 -->\n###### 가능한 연구자 번호를 통하여 즉시 상담과 필요하면 의료진 연결이\n\n<!-- PAGE_93 -->\n###### 가능하도록 조치한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_749",
      "text": "<!-- PAGE_93 -->\n###### 3) 디지털 우울장애 인지행동치료(Digital CBT-D를 위한 범용 장비\n\n<!-- PAGE_93 -->\n###### (스마트폰 또는 태블릿 PC 등) 사용으로 두통, 눈의 피로, 눈 또는\n\n<!-- PAGE_93 -->\n###### 근육경련, 눈의 불수의운동, 메스꺼움, 어지럼증, 머리 또는 눈의\n\n<!-- PAGE_93 -->\n###### 불쾌감 또는 통증, 졸림, 피로감과 같은 부작용이 발생할 수 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 748,
        "window_size": 3,
        "char_count": 258,
        "word_count": 53,
        "page_number": 93,
        "window_text": "<!-- PAGE_92 -->\n###### 1) 우울장애 인지행동치료(CBT-D)의 행동 요법 중 밤 시간의 집중\n\n<!-- PAGE_92 -->\n###### 저하를 불러일으킬 수 있어 3교대자 등 밤 시간 우울장애가 큰\n\n<!-- PAGE_92 -->\n###### 피해를 가져올 수 있는 직업군의 환자의 경우 임상시험에서\n\n<!-- PAGE_92 -->\n###### 제외한다.  이외에도 치료 시작 시점에서 밤 시간 우울장애가 악화\n\n<!-- PAGE_92 -->\n###### 될 수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통하여\n\n<!-- PAGE_92 -->\n###### 2) 우울장애 인지행동치료(CBT-D)의 인지 요법 중 왜곡된 인지 교정의\n\n<!-- PAGE_92 -->\n###### 경우 일시적인 불안감 악화를 가져올 수 있다.  치료 시작 시점에서\n\n<!-- PAGE_92 -->\n###### 일시적인 불안감 악화가 나타날 수 있음을 알리고, 24시간 연락\n\n- - 86 -\n<!-- PAGE_93 -->\n###### 가능한 연구자 번호를 통하여 즉시 상담과 필요하면 의료진 연결이\n\n<!-- PAGE_93 -->\n###### 가능하도록 조치한다.\n\n <!-- PAGE_93 -->\n###### 3) 디지털 우울장애 인지행동치료(Digital CBT-D를 위한 범용 장비\n\n<!-- PAGE_93 -->\n###### (스마트폰 또는 태블릿 PC 등) 사용으로 두통, 눈의 피로, 눈 또는\n\n<!-- PAGE_93 -->\n###### 근육경련, 눈의 불수의운동, 메스꺼움, 어지럼증, 머리 또는 눈의\n\n<!-- PAGE_93 -->\n###### 불쾌감 또는 통증, 졸림, 피로감과 같은 부작용이 발생할 수 있다.\n\n <!-- PAGE_93 -->\n###### 해당 경우 24시간 연락 가능한 연구자 번호를 통하여 즉시 상담과\n\n<!-- PAGE_93 -->\n###### 본 연구에서 진행되는 평가는 자가 보고 설문지, 면담 등 모두\n\n<!-- PAGE_93 -->\n###### 비침습적인 검사로 이루어져 있으므로 예측되는 부작용은 없다.\n\n <!-- PAGE_93 -->\n###### 나.  사용 시 주의사항\n\n<!-- PAGE_93 -->\n###### 본 연구에서 적용하는 우울장애 개선 디지털치료기기의 부작용,\n\n<!-- PAGE_93 -->\n###### 일반적 주의, 적용상의 주의는 다음과 같다.\n\n",
        "original_sentence": "<!-- PAGE_93 -->\n###### 3) 디지털 우울장애 인지행동치료(Digital CBT-D를 위한 범용 장비\n\n<!-- PAGE_93 -->\n###### (스마트폰 또는 태블릿 PC 등) 사용으로 두통, 눈의 피로, 눈 또는\n\n<!-- PAGE_93 -->\n###### 근육경련, 눈의 불수의운동, 메스꺼움, 어지럼증, 머리 또는 눈의\n\n<!-- PAGE_93 -->\n###### 불쾌감 또는 통증, 졸림, 피로감과 같은 부작용이 발생할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_750",
      "text": "<!-- PAGE_93 -->\n###### 해당 경우 24시간 연락 가능한 연구자 번호를 통하여 즉시 상담과\n\n<!-- PAGE_93 -->\n###### 본 연구에서 진행되는 평가는 자가 보고 설문지, 면담 등 모두\n\n<!-- PAGE_93 -->\n###### 비침습적인 검사로 이루어져 있으므로 예측되는 부작용은 없다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 749,
        "window_size": 3,
        "char_count": 181,
        "word_count": 39,
        "page_number": 93,
        "window_text": "이외에도 치료 시작 시점에서 밤 시간 우울장애가 악화\n\n<!-- PAGE_92 -->\n###### 될 수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통하여\n\n<!-- PAGE_92 -->\n###### 2) 우울장애 인지행동치료(CBT-D)의 인지 요법 중 왜곡된 인지 교정의\n\n<!-- PAGE_92 -->\n###### 경우 일시적인 불안감 악화를 가져올 수 있다.  치료 시작 시점에서\n\n<!-- PAGE_92 -->\n###### 일시적인 불안감 악화가 나타날 수 있음을 알리고, 24시간 연락\n\n- - 86 -\n<!-- PAGE_93 -->\n###### 가능한 연구자 번호를 통하여 즉시 상담과 필요하면 의료진 연결이\n\n<!-- PAGE_93 -->\n###### 가능하도록 조치한다.\n\n <!-- PAGE_93 -->\n###### 3) 디지털 우울장애 인지행동치료(Digital CBT-D를 위한 범용 장비\n\n<!-- PAGE_93 -->\n###### (스마트폰 또는 태블릿 PC 등) 사용으로 두통, 눈의 피로, 눈 또는\n\n<!-- PAGE_93 -->\n###### 근육경련, 눈의 불수의운동, 메스꺼움, 어지럼증, 머리 또는 눈의\n\n<!-- PAGE_93 -->\n###### 불쾌감 또는 통증, 졸림, 피로감과 같은 부작용이 발생할 수 있다.\n\n <!-- PAGE_93 -->\n###### 해당 경우 24시간 연락 가능한 연구자 번호를 통하여 즉시 상담과\n\n<!-- PAGE_93 -->\n###### 본 연구에서 진행되는 평가는 자가 보고 설문지, 면담 등 모두\n\n<!-- PAGE_93 -->\n###### 비침습적인 검사로 이루어져 있으므로 예측되는 부작용은 없다.\n\n <!-- PAGE_93 -->\n###### 나.  사용 시 주의사항\n\n<!-- PAGE_93 -->\n###### 본 연구에서 적용하는 우울장애 개선 디지털치료기기의 부작용,\n\n<!-- PAGE_93 -->\n###### 일반적 주의, 적용상의 주의는 다음과 같다.\n\n <!-- PAGE_93 -->\n###### 본 제품을 사용한 후 제품에 대한 부적합 반응이 전부 배제될\n\n<!-- PAGE_93 -->\n###### 사이버 보안과 관련된 사고 발생 시 임상시험 관리자 긴급\n\n<!-- PAGE_93 -->\n###### 사용 시간, 사용 횟수, 결과 작성 등 임상시험 책임자와 담당자가\n\n- - 87 -\n<!-- PAGE_94 -->\n##### 13. ",
        "original_sentence": "<!-- PAGE_93 -->\n###### 해당 경우 24시간 연락 가능한 연구자 번호를 통하여 즉시 상담과\n\n<!-- PAGE_93 -->\n###### 본 연구에서 진행되는 평가는 자가 보고 설문지, 면담 등 모두\n\n<!-- PAGE_93 -->\n###### 비침습적인 검사로 이루어져 있으므로 예측되는 부작용은 없다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_751",
      "text": "<!-- PAGE_93 -->\n###### 나. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 750,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 93,
        "window_text": "치료 시작 시점에서\n\n<!-- PAGE_92 -->\n###### 일시적인 불안감 악화가 나타날 수 있음을 알리고, 24시간 연락\n\n- - 86 -\n<!-- PAGE_93 -->\n###### 가능한 연구자 번호를 통하여 즉시 상담과 필요하면 의료진 연결이\n\n<!-- PAGE_93 -->\n###### 가능하도록 조치한다.\n\n <!-- PAGE_93 -->\n###### 3) 디지털 우울장애 인지행동치료(Digital CBT-D를 위한 범용 장비\n\n<!-- PAGE_93 -->\n###### (스마트폰 또는 태블릿 PC 등) 사용으로 두통, 눈의 피로, 눈 또는\n\n<!-- PAGE_93 -->\n###### 근육경련, 눈의 불수의운동, 메스꺼움, 어지럼증, 머리 또는 눈의\n\n<!-- PAGE_93 -->\n###### 불쾌감 또는 통증, 졸림, 피로감과 같은 부작용이 발생할 수 있다.\n\n <!-- PAGE_93 -->\n###### 해당 경우 24시간 연락 가능한 연구자 번호를 통하여 즉시 상담과\n\n<!-- PAGE_93 -->\n###### 본 연구에서 진행되는 평가는 자가 보고 설문지, 면담 등 모두\n\n<!-- PAGE_93 -->\n###### 비침습적인 검사로 이루어져 있으므로 예측되는 부작용은 없다.\n\n <!-- PAGE_93 -->\n###### 나.  사용 시 주의사항\n\n<!-- PAGE_93 -->\n###### 본 연구에서 적용하는 우울장애 개선 디지털치료기기의 부작용,\n\n<!-- PAGE_93 -->\n###### 일반적 주의, 적용상의 주의는 다음과 같다.\n\n <!-- PAGE_93 -->\n###### 본 제품을 사용한 후 제품에 대한 부적합 반응이 전부 배제될\n\n<!-- PAGE_93 -->\n###### 사이버 보안과 관련된 사고 발생 시 임상시험 관리자 긴급\n\n<!-- PAGE_93 -->\n###### 사용 시간, 사용 횟수, 결과 작성 등 임상시험 책임자와 담당자가\n\n- - 87 -\n<!-- PAGE_94 -->\n##### 13.  중지·탈락 기준\n\n<!-- PAGE_94 -->\n###### 가. ",
        "original_sentence": "<!-- PAGE_93 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_752",
      "text": "사용 시 주의사항\n\n<!-- PAGE_93 -->\n###### 본 연구에서 적용하는 우울장애 개선 디지털치료기기의 부작용,\n\n<!-- PAGE_93 -->\n###### 일반적 주의, 적용상의 주의는 다음과 같다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 751,
        "window_size": 3,
        "char_count": 120,
        "word_count": 24,
        "page_number": 93,
        "window_text": "<!-- PAGE_93 -->\n###### 3) 디지털 우울장애 인지행동치료(Digital CBT-D를 위한 범용 장비\n\n<!-- PAGE_93 -->\n###### (스마트폰 또는 태블릿 PC 등) 사용으로 두통, 눈의 피로, 눈 또는\n\n<!-- PAGE_93 -->\n###### 근육경련, 눈의 불수의운동, 메스꺼움, 어지럼증, 머리 또는 눈의\n\n<!-- PAGE_93 -->\n###### 불쾌감 또는 통증, 졸림, 피로감과 같은 부작용이 발생할 수 있다.\n\n <!-- PAGE_93 -->\n###### 해당 경우 24시간 연락 가능한 연구자 번호를 통하여 즉시 상담과\n\n<!-- PAGE_93 -->\n###### 본 연구에서 진행되는 평가는 자가 보고 설문지, 면담 등 모두\n\n<!-- PAGE_93 -->\n###### 비침습적인 검사로 이루어져 있으므로 예측되는 부작용은 없다.\n\n <!-- PAGE_93 -->\n###### 나.  사용 시 주의사항\n\n<!-- PAGE_93 -->\n###### 본 연구에서 적용하는 우울장애 개선 디지털치료기기의 부작용,\n\n<!-- PAGE_93 -->\n###### 일반적 주의, 적용상의 주의는 다음과 같다.\n\n <!-- PAGE_93 -->\n###### 본 제품을 사용한 후 제품에 대한 부적합 반응이 전부 배제될\n\n<!-- PAGE_93 -->\n###### 사이버 보안과 관련된 사고 발생 시 임상시험 관리자 긴급\n\n<!-- PAGE_93 -->\n###### 사용 시간, 사용 횟수, 결과 작성 등 임상시험 책임자와 담당자가\n\n- - 87 -\n<!-- PAGE_94 -->\n##### 13.  중지·탈락 기준\n\n<!-- PAGE_94 -->\n###### 가.  중지\n\n<!-- PAGE_94 -->\n###### - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n\n<!-- PAGE_94 -->\n###### - 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는\n\n<!-- PAGE_94 -->\n###### - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n\n<!-- PAGE_94 -->\n###### - 중지 시점까지의 검사 결과 관련 자료는 성능과 안전성 평가를\n\n- - 88 -\n<!-- PAGE_95 -->\n###### 위한 통계처리 시 삽입할 수 있다.\n\n",
        "original_sentence": "사용 시 주의사항\n\n<!-- PAGE_93 -->\n###### 본 연구에서 적용하는 우울장애 개선 디지털치료기기의 부작용,\n\n<!-- PAGE_93 -->\n###### 일반적 주의, 적용상의 주의는 다음과 같다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_753",
      "text": "<!-- PAGE_93 -->\n###### 본 제품을 사용한 후 제품에 대한 부적합 반응이 전부 배제될\n\n<!-- PAGE_93 -->\n###### 사이버 보안과 관련된 사고 발생 시 임상시험 관리자 긴급\n\n<!-- PAGE_93 -->\n###### 사용 시간, 사용 횟수, 결과 작성 등 임상시험 책임자와 담당자가\n\n- - 87 -\n<!-- PAGE_94 -->\n##### 13. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 752,
        "window_size": 3,
        "char_count": 214,
        "word_count": 50,
        "page_number": 93,
        "window_text": "<!-- PAGE_93 -->\n###### 해당 경우 24시간 연락 가능한 연구자 번호를 통하여 즉시 상담과\n\n<!-- PAGE_93 -->\n###### 본 연구에서 진행되는 평가는 자가 보고 설문지, 면담 등 모두\n\n<!-- PAGE_93 -->\n###### 비침습적인 검사로 이루어져 있으므로 예측되는 부작용은 없다.\n\n <!-- PAGE_93 -->\n###### 나.  사용 시 주의사항\n\n<!-- PAGE_93 -->\n###### 본 연구에서 적용하는 우울장애 개선 디지털치료기기의 부작용,\n\n<!-- PAGE_93 -->\n###### 일반적 주의, 적용상의 주의는 다음과 같다.\n\n <!-- PAGE_93 -->\n###### 본 제품을 사용한 후 제품에 대한 부적합 반응이 전부 배제될\n\n<!-- PAGE_93 -->\n###### 사이버 보안과 관련된 사고 발생 시 임상시험 관리자 긴급\n\n<!-- PAGE_93 -->\n###### 사용 시간, 사용 횟수, 결과 작성 등 임상시험 책임자와 담당자가\n\n- - 87 -\n<!-- PAGE_94 -->\n##### 13.  중지·탈락 기준\n\n<!-- PAGE_94 -->\n###### 가.  중지\n\n<!-- PAGE_94 -->\n###### - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n\n<!-- PAGE_94 -->\n###### - 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는\n\n<!-- PAGE_94 -->\n###### - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n\n<!-- PAGE_94 -->\n###### - 중지 시점까지의 검사 결과 관련 자료는 성능과 안전성 평가를\n\n- - 88 -\n<!-- PAGE_95 -->\n###### 위한 통계처리 시 삽입할 수 있다.\n\n <!-- PAGE_95 -->\n###### - 임상시험을 통해 얻은 자료는 성능 및 안전성 분석을 위한\n\n<!-- PAGE_95 -->\n###### 데이터가 정해져야 하며, 만약 자료에 결함이 생기면 적절한\n\n<!-- PAGE_95 -->\n###### 보정 방법을 임상시험계획서에 제시하고 보정 후 분석을 시행\n\n<!-- PAGE_95 -->\n###### 나. ",
        "original_sentence": "<!-- PAGE_93 -->\n###### 본 제품을 사용한 후 제품에 대한 부적합 반응이 전부 배제될\n\n<!-- PAGE_93 -->\n###### 사이버 보안과 관련된 사고 발생 시 임상시험 관리자 긴급\n\n<!-- PAGE_93 -->\n###### 사용 시간, 사용 횟수, 결과 작성 등 임상시험 책임자와 담당자가\n\n- - 87 -\n<!-- PAGE_94 -->\n##### 13. "
      }
    },
    {
      "chunk_id": "chunk_754",
      "text": "중지·탈락 기준\n\n<!-- PAGE_94 -->\n###### 가. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 753,
        "window_size": 3,
        "char_count": 37,
        "word_count": 7,
        "page_number": 94,
        "window_text": "<!-- PAGE_93 -->\n###### 나.  사용 시 주의사항\n\n<!-- PAGE_93 -->\n###### 본 연구에서 적용하는 우울장애 개선 디지털치료기기의 부작용,\n\n<!-- PAGE_93 -->\n###### 일반적 주의, 적용상의 주의는 다음과 같다.\n\n <!-- PAGE_93 -->\n###### 본 제품을 사용한 후 제품에 대한 부적합 반응이 전부 배제될\n\n<!-- PAGE_93 -->\n###### 사이버 보안과 관련된 사고 발생 시 임상시험 관리자 긴급\n\n<!-- PAGE_93 -->\n###### 사용 시간, 사용 횟수, 결과 작성 등 임상시험 책임자와 담당자가\n\n- - 87 -\n<!-- PAGE_94 -->\n##### 13.  중지·탈락 기준\n\n<!-- PAGE_94 -->\n###### 가.  중지\n\n<!-- PAGE_94 -->\n###### - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n\n<!-- PAGE_94 -->\n###### - 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는\n\n<!-- PAGE_94 -->\n###### - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n\n<!-- PAGE_94 -->\n###### - 중지 시점까지의 검사 결과 관련 자료는 성능과 안전성 평가를\n\n- - 88 -\n<!-- PAGE_95 -->\n###### 위한 통계처리 시 삽입할 수 있다.\n\n <!-- PAGE_95 -->\n###### - 임상시험을 통해 얻은 자료는 성능 및 안전성 분석을 위한\n\n<!-- PAGE_95 -->\n###### 데이터가 정해져야 하며, 만약 자료에 결함이 생기면 적절한\n\n<!-- PAGE_95 -->\n###### 보정 방법을 임상시험계획서에 제시하고 보정 후 분석을 시행\n\n<!-- PAGE_95 -->\n###### 나.  탈락\n\n<!-- PAGE_95 -->\n###### 시험자는 다음과 같은 경우에 연구 참여 대상자를 시험에서\n\n<!-- PAGE_95 -->\n###### - 피험자가 임상시험 중 임상시험 참여 중단을 요구하거나 시험\n\n<!-- PAGE_95 -->\n###### - 3개월 이내에 자살 시도를 한 바 있으며, 정신과 전문의에 의해\n\n<!-- PAGE_95 -->\n###### ※ 콜롬비아 자살 위험성 스케일(C-SSRS) 혹은 이와 유사한 과학적\n\n<!-- PAGE_95 -->\n###### - 피험자의 부작용(예: 두통, 눈의 피로, 눈 또는 근육경련, 눈의 불\n\n<!-- PAGE_95 -->\n###### 수의운동, 메스꺼움, 어지럼증 등)으로 인하여 임상시험 책임자\n\n<!-- PAGE_95 -->\n###### - 피험자가 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n\n<!-- PAGE_95 -->\n###### - 피험자의 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n\n- - 89 -\n<!-- PAGE_96 -->\n###### - 임상시험 중 선정/제외 기준 위반 등 중대한 계획서 위반 사항이\n\n<!-- PAGE_96 -->\n###### 발견되는 경우\n\n<!-- PAGE_96 -->\n###### - 기타 사유로 인하여 임상시험 책임자 또는 담당자가 임상\n\n<!-- PAGE_96 -->\n###### - 우울 증상이 지나치게 악화되어 다른 건강 결과 악화가 예상\n\n<!-- PAGE_96 -->\n###### - 중도 탈락 시, 시험자는 대상자의 임상시험 조기 탈락의 주요\n\n<!-- PAGE_96 -->\n###### 사유를 평가하여 증례 기록서 임상시험 완료 란에 해당 정보를\n\n<!-- PAGE_96 -->\n###### - 참여 중단 의사를 밝히지 않고 방문에 출석하지 않아 현재\n\n<!-- PAGE_96 -->\n###### 상태가 불분명한 대상자의 경우에 시험자는 대상자와 전화\n\n- - 90 -\n<!-- PAGE_97 -->\n###### 14. ",
        "original_sentence": "중지·탈락 기준\n\n<!-- PAGE_94 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_755",
      "text": "중지\n\n<!-- PAGE_94 -->\n###### - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n\n<!-- PAGE_94 -->\n###### - 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는\n\n<!-- PAGE_94 -->\n###### - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n\n<!-- PAGE_94 -->\n###### - 중지 시점까지의 검사 결과 관련 자료는 성능과 안전성 평가를\n\n- - 88 -\n<!-- PAGE_95 -->\n###### 위한 통계처리 시 삽입할 수 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 754,
        "window_size": 3,
        "char_count": 299,
        "word_count": 64,
        "page_number": 94,
        "window_text": "사용 시 주의사항\n\n<!-- PAGE_93 -->\n###### 본 연구에서 적용하는 우울장애 개선 디지털치료기기의 부작용,\n\n<!-- PAGE_93 -->\n###### 일반적 주의, 적용상의 주의는 다음과 같다.\n\n <!-- PAGE_93 -->\n###### 본 제품을 사용한 후 제품에 대한 부적합 반응이 전부 배제될\n\n<!-- PAGE_93 -->\n###### 사이버 보안과 관련된 사고 발생 시 임상시험 관리자 긴급\n\n<!-- PAGE_93 -->\n###### 사용 시간, 사용 횟수, 결과 작성 등 임상시험 책임자와 담당자가\n\n- - 87 -\n<!-- PAGE_94 -->\n##### 13.  중지·탈락 기준\n\n<!-- PAGE_94 -->\n###### 가.  중지\n\n<!-- PAGE_94 -->\n###### - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n\n<!-- PAGE_94 -->\n###### - 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는\n\n<!-- PAGE_94 -->\n###### - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n\n<!-- PAGE_94 -->\n###### - 중지 시점까지의 검사 결과 관련 자료는 성능과 안전성 평가를\n\n- - 88 -\n<!-- PAGE_95 -->\n###### 위한 통계처리 시 삽입할 수 있다.\n\n <!-- PAGE_95 -->\n###### - 임상시험을 통해 얻은 자료는 성능 및 안전성 분석을 위한\n\n<!-- PAGE_95 -->\n###### 데이터가 정해져야 하며, 만약 자료에 결함이 생기면 적절한\n\n<!-- PAGE_95 -->\n###### 보정 방법을 임상시험계획서에 제시하고 보정 후 분석을 시행\n\n<!-- PAGE_95 -->\n###### 나.  탈락\n\n<!-- PAGE_95 -->\n###### 시험자는 다음과 같은 경우에 연구 참여 대상자를 시험에서\n\n<!-- PAGE_95 -->\n###### - 피험자가 임상시험 중 임상시험 참여 중단을 요구하거나 시험\n\n<!-- PAGE_95 -->\n###### - 3개월 이내에 자살 시도를 한 바 있으며, 정신과 전문의에 의해\n\n<!-- PAGE_95 -->\n###### ※ 콜롬비아 자살 위험성 스케일(C-SSRS) 혹은 이와 유사한 과학적\n\n<!-- PAGE_95 -->\n###### - 피험자의 부작용(예: 두통, 눈의 피로, 눈 또는 근육경련, 눈의 불\n\n<!-- PAGE_95 -->\n###### 수의운동, 메스꺼움, 어지럼증 등)으로 인하여 임상시험 책임자\n\n<!-- PAGE_95 -->\n###### - 피험자가 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n\n<!-- PAGE_95 -->\n###### - 피험자의 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n\n- - 89 -\n<!-- PAGE_96 -->\n###### - 임상시험 중 선정/제외 기준 위반 등 중대한 계획서 위반 사항이\n\n<!-- PAGE_96 -->\n###### 발견되는 경우\n\n<!-- PAGE_96 -->\n###### - 기타 사유로 인하여 임상시험 책임자 또는 담당자가 임상\n\n<!-- PAGE_96 -->\n###### - 우울 증상이 지나치게 악화되어 다른 건강 결과 악화가 예상\n\n<!-- PAGE_96 -->\n###### - 중도 탈락 시, 시험자는 대상자의 임상시험 조기 탈락의 주요\n\n<!-- PAGE_96 -->\n###### 사유를 평가하여 증례 기록서 임상시험 완료 란에 해당 정보를\n\n<!-- PAGE_96 -->\n###### - 참여 중단 의사를 밝히지 않고 방문에 출석하지 않아 현재\n\n<!-- PAGE_96 -->\n###### 상태가 불분명한 대상자의 경우에 시험자는 대상자와 전화\n\n- - 90 -\n<!-- PAGE_97 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 의함)\n\n<!-- PAGE_97 -->\n###### 가. ",
        "original_sentence": "중지\n\n<!-- PAGE_94 -->\n###### - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n\n<!-- PAGE_94 -->\n###### - 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는\n\n<!-- PAGE_94 -->\n###### - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n\n<!-- PAGE_94 -->\n###### - 중지 시점까지의 검사 결과 관련 자료는 성능과 안전성 평가를\n\n- - 88 -\n<!-- PAGE_95 -->\n###### 위한 통계처리 시 삽입할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_756",
      "text": "<!-- PAGE_95 -->\n###### - 임상시험을 통해 얻은 자료는 성능 및 안전성 분석을 위한\n\n<!-- PAGE_95 -->\n###### 데이터가 정해져야 하며, 만약 자료에 결함이 생기면 적절한\n\n<!-- PAGE_95 -->\n###### 보정 방법을 임상시험계획서에 제시하고 보정 후 분석을 시행\n\n<!-- PAGE_95 -->\n###### 나. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 755,
        "window_size": 3,
        "char_count": 202,
        "word_count": 43,
        "page_number": 95,
        "window_text": "<!-- PAGE_93 -->\n###### 본 제품을 사용한 후 제품에 대한 부적합 반응이 전부 배제될\n\n<!-- PAGE_93 -->\n###### 사이버 보안과 관련된 사고 발생 시 임상시험 관리자 긴급\n\n<!-- PAGE_93 -->\n###### 사용 시간, 사용 횟수, 결과 작성 등 임상시험 책임자와 담당자가\n\n- - 87 -\n<!-- PAGE_94 -->\n##### 13.  중지·탈락 기준\n\n<!-- PAGE_94 -->\n###### 가.  중지\n\n<!-- PAGE_94 -->\n###### - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n\n<!-- PAGE_94 -->\n###### - 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는\n\n<!-- PAGE_94 -->\n###### - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n\n<!-- PAGE_94 -->\n###### - 중지 시점까지의 검사 결과 관련 자료는 성능과 안전성 평가를\n\n- - 88 -\n<!-- PAGE_95 -->\n###### 위한 통계처리 시 삽입할 수 있다.\n\n <!-- PAGE_95 -->\n###### - 임상시험을 통해 얻은 자료는 성능 및 안전성 분석을 위한\n\n<!-- PAGE_95 -->\n###### 데이터가 정해져야 하며, 만약 자료에 결함이 생기면 적절한\n\n<!-- PAGE_95 -->\n###### 보정 방법을 임상시험계획서에 제시하고 보정 후 분석을 시행\n\n<!-- PAGE_95 -->\n###### 나.  탈락\n\n<!-- PAGE_95 -->\n###### 시험자는 다음과 같은 경우에 연구 참여 대상자를 시험에서\n\n<!-- PAGE_95 -->\n###### - 피험자가 임상시험 중 임상시험 참여 중단을 요구하거나 시험\n\n<!-- PAGE_95 -->\n###### - 3개월 이내에 자살 시도를 한 바 있으며, 정신과 전문의에 의해\n\n<!-- PAGE_95 -->\n###### ※ 콜롬비아 자살 위험성 스케일(C-SSRS) 혹은 이와 유사한 과학적\n\n<!-- PAGE_95 -->\n###### - 피험자의 부작용(예: 두통, 눈의 피로, 눈 또는 근육경련, 눈의 불\n\n<!-- PAGE_95 -->\n###### 수의운동, 메스꺼움, 어지럼증 등)으로 인하여 임상시험 책임자\n\n<!-- PAGE_95 -->\n###### - 피험자가 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n\n<!-- PAGE_95 -->\n###### - 피험자의 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n\n- - 89 -\n<!-- PAGE_96 -->\n###### - 임상시험 중 선정/제외 기준 위반 등 중대한 계획서 위반 사항이\n\n<!-- PAGE_96 -->\n###### 발견되는 경우\n\n<!-- PAGE_96 -->\n###### - 기타 사유로 인하여 임상시험 책임자 또는 담당자가 임상\n\n<!-- PAGE_96 -->\n###### - 우울 증상이 지나치게 악화되어 다른 건강 결과 악화가 예상\n\n<!-- PAGE_96 -->\n###### - 중도 탈락 시, 시험자는 대상자의 임상시험 조기 탈락의 주요\n\n<!-- PAGE_96 -->\n###### 사유를 평가하여 증례 기록서 임상시험 완료 란에 해당 정보를\n\n<!-- PAGE_96 -->\n###### - 참여 중단 의사를 밝히지 않고 방문에 출석하지 않아 현재\n\n<!-- PAGE_96 -->\n###### 상태가 불분명한 대상자의 경우에 시험자는 대상자와 전화\n\n- - 90 -\n<!-- PAGE_97 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 의함)\n\n<!-- PAGE_97 -->\n###### 가.  유효성의 평가 기준\n\n<!-- PAGE_97 -->\n###### [일차 유효성 평가변수]\n\n<!-- PAGE_97 -->\n###### [이차 유효성 평가변수]\n\n<!-- PAGE_97 -->\n###### 2) 치료 전 대비 8주 및 3개월 후 우울장애 선별 도구 척도(PHQ-9) 변화량\n\n- - 91 -\n4) 치료 전 대비 8주 및 3개월 후 반응률*\n\n<!-- PAGE_98 -->\n###### * 반응 정의: 기저점 대비 일차 유효성 변수(우울장애 심각도 척도[BDI]) 변화량의\n\n**[표 시작]**\n\n**5) 삶의 질**\n\n**[표 끝]**\n\n- - 92 -\n<!-- PAGE_99 -->\n###### 나. ",
        "original_sentence": "<!-- PAGE_95 -->\n###### - 임상시험을 통해 얻은 자료는 성능 및 안전성 분석을 위한\n\n<!-- PAGE_95 -->\n###### 데이터가 정해져야 하며, 만약 자료에 결함이 생기면 적절한\n\n<!-- PAGE_95 -->\n###### 보정 방법을 임상시험계획서에 제시하고 보정 후 분석을 시행\n\n<!-- PAGE_95 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_757",
      "text": "탈락\n\n<!-- PAGE_95 -->\n###### 시험자는 다음과 같은 경우에 연구 참여 대상자를 시험에서\n\n<!-- PAGE_95 -->\n###### - 피험자가 임상시험 중 임상시험 참여 중단을 요구하거나 시험\n\n<!-- PAGE_95 -->\n###### - 3개월 이내에 자살 시도를 한 바 있으며, 정신과 전문의에 의해\n\n<!-- PAGE_95 -->\n###### ※ 콜롬비아 자살 위험성 스케일(C-SSRS) 혹은 이와 유사한 과학적\n\n<!-- PAGE_95 -->\n###### - 피험자의 부작용(예: 두통, 눈의 피로, 눈 또는 근육경련, 눈의 불\n\n<!-- PAGE_95 -->\n###### 수의운동, 메스꺼움, 어지럼증 등)으로 인하여 임상시험 책임자\n\n<!-- PAGE_95 -->\n###### - 피험자가 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n\n<!-- PAGE_95 -->\n###### - 피험자의 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n\n- - 89 -\n<!-- PAGE_96 -->\n###### - 임상시험 중 선정/제외 기준 위반 등 중대한 계획서 위반 사항이\n\n<!-- PAGE_96 -->\n###### 발견되는 경우\n\n<!-- PAGE_96 -->\n###### - 기타 사유로 인하여 임상시험 책임자 또는 담당자가 임상\n\n<!-- PAGE_96 -->\n###### - 우울 증상이 지나치게 악화되어 다른 건강 결과 악화가 예상\n\n<!-- PAGE_96 -->\n###### - 중도 탈락 시, 시험자는 대상자의 임상시험 조기 탈락의 주요\n\n<!-- PAGE_96 -->\n###### 사유를 평가하여 증례 기록서 임상시험 완료 란에 해당 정보를\n\n<!-- PAGE_96 -->\n###### - 참여 중단 의사를 밝히지 않고 방문에 출석하지 않아 현재\n\n<!-- PAGE_96 -->\n###### 상태가 불분명한 대상자의 경우에 시험자는 대상자와 전화\n\n- - 90 -\n<!-- PAGE_97 -->\n###### 14. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 756,
        "window_size": 3,
        "char_count": 990,
        "word_count": 219,
        "page_number": 95,
        "window_text": "중지·탈락 기준\n\n<!-- PAGE_94 -->\n###### 가.  중지\n\n<!-- PAGE_94 -->\n###### - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n\n<!-- PAGE_94 -->\n###### - 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는\n\n<!-- PAGE_94 -->\n###### - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n\n<!-- PAGE_94 -->\n###### - 중지 시점까지의 검사 결과 관련 자료는 성능과 안전성 평가를\n\n- - 88 -\n<!-- PAGE_95 -->\n###### 위한 통계처리 시 삽입할 수 있다.\n\n <!-- PAGE_95 -->\n###### - 임상시험을 통해 얻은 자료는 성능 및 안전성 분석을 위한\n\n<!-- PAGE_95 -->\n###### 데이터가 정해져야 하며, 만약 자료에 결함이 생기면 적절한\n\n<!-- PAGE_95 -->\n###### 보정 방법을 임상시험계획서에 제시하고 보정 후 분석을 시행\n\n<!-- PAGE_95 -->\n###### 나.  탈락\n\n<!-- PAGE_95 -->\n###### 시험자는 다음과 같은 경우에 연구 참여 대상자를 시험에서\n\n<!-- PAGE_95 -->\n###### - 피험자가 임상시험 중 임상시험 참여 중단을 요구하거나 시험\n\n<!-- PAGE_95 -->\n###### - 3개월 이내에 자살 시도를 한 바 있으며, 정신과 전문의에 의해\n\n<!-- PAGE_95 -->\n###### ※ 콜롬비아 자살 위험성 스케일(C-SSRS) 혹은 이와 유사한 과학적\n\n<!-- PAGE_95 -->\n###### - 피험자의 부작용(예: 두통, 눈의 피로, 눈 또는 근육경련, 눈의 불\n\n<!-- PAGE_95 -->\n###### 수의운동, 메스꺼움, 어지럼증 등)으로 인하여 임상시험 책임자\n\n<!-- PAGE_95 -->\n###### - 피험자가 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n\n<!-- PAGE_95 -->\n###### - 피험자의 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n\n- - 89 -\n<!-- PAGE_96 -->\n###### - 임상시험 중 선정/제외 기준 위반 등 중대한 계획서 위반 사항이\n\n<!-- PAGE_96 -->\n###### 발견되는 경우\n\n<!-- PAGE_96 -->\n###### - 기타 사유로 인하여 임상시험 책임자 또는 담당자가 임상\n\n<!-- PAGE_96 -->\n###### - 우울 증상이 지나치게 악화되어 다른 건강 결과 악화가 예상\n\n<!-- PAGE_96 -->\n###### - 중도 탈락 시, 시험자는 대상자의 임상시험 조기 탈락의 주요\n\n<!-- PAGE_96 -->\n###### 사유를 평가하여 증례 기록서 임상시험 완료 란에 해당 정보를\n\n<!-- PAGE_96 -->\n###### - 참여 중단 의사를 밝히지 않고 방문에 출석하지 않아 현재\n\n<!-- PAGE_96 -->\n###### 상태가 불분명한 대상자의 경우에 시험자는 대상자와 전화\n\n- - 90 -\n<!-- PAGE_97 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 의함)\n\n<!-- PAGE_97 -->\n###### 가.  유효성의 평가 기준\n\n<!-- PAGE_97 -->\n###### [일차 유효성 평가변수]\n\n<!-- PAGE_97 -->\n###### [이차 유효성 평가변수]\n\n<!-- PAGE_97 -->\n###### 2) 치료 전 대비 8주 및 3개월 후 우울장애 선별 도구 척도(PHQ-9) 변화량\n\n- - 91 -\n4) 치료 전 대비 8주 및 3개월 후 반응률*\n\n<!-- PAGE_98 -->\n###### * 반응 정의: 기저점 대비 일차 유효성 변수(우울장애 심각도 척도[BDI]) 변화량의\n\n**[표 시작]**\n\n**5) 삶의 질**\n\n**[표 끝]**\n\n- - 92 -\n<!-- PAGE_99 -->\n###### 나.  검사 방법\n\n<!-- PAGE_99 -->\n###### 1) 우울장애 심각도 척도(Beck Depression Inventory, BDI-II)\n\n<!-- PAGE_99 -->\n###### 우울장애 심각도 척도(BDI-II)는 우울장애의 증상 심각도에 대한\n\n<!-- PAGE_99 -->\n###### 평가를 수행할 수 있으며 질환의 호전 여부를 판단할 수 있는,\n\n<!-- PAGE_99 -->\n###### 과학적으로 검증된 자가 보고식 설문이다(Beck, 1961). ",
        "original_sentence": "탈락\n\n<!-- PAGE_95 -->\n###### 시험자는 다음과 같은 경우에 연구 참여 대상자를 시험에서\n\n<!-- PAGE_95 -->\n###### - 피험자가 임상시험 중 임상시험 참여 중단을 요구하거나 시험\n\n<!-- PAGE_95 -->\n###### - 3개월 이내에 자살 시도를 한 바 있으며, 정신과 전문의에 의해\n\n<!-- PAGE_95 -->\n###### ※ 콜롬비아 자살 위험성 스케일(C-SSRS) 혹은 이와 유사한 과학적\n\n<!-- PAGE_95 -->\n###### - 피험자의 부작용(예: 두통, 눈의 피로, 눈 또는 근육경련, 눈의 불\n\n<!-- PAGE_95 -->\n###### 수의운동, 메스꺼움, 어지럼증 등)으로 인하여 임상시험 책임자\n\n<!-- PAGE_95 -->\n###### - 피험자가 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n\n<!-- PAGE_95 -->\n###### - 피험자의 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n\n- - 89 -\n<!-- PAGE_96 -->\n###### - 임상시험 중 선정/제외 기준 위반 등 중대한 계획서 위반 사항이\n\n<!-- PAGE_96 -->\n###### 발견되는 경우\n\n<!-- PAGE_96 -->\n###### - 기타 사유로 인하여 임상시험 책임자 또는 담당자가 임상\n\n<!-- PAGE_96 -->\n###### - 우울 증상이 지나치게 악화되어 다른 건강 결과 악화가 예상\n\n<!-- PAGE_96 -->\n###### - 중도 탈락 시, 시험자는 대상자의 임상시험 조기 탈락의 주요\n\n<!-- PAGE_96 -->\n###### 사유를 평가하여 증례 기록서 임상시험 완료 란에 해당 정보를\n\n<!-- PAGE_96 -->\n###### - 참여 중단 의사를 밝히지 않고 방문에 출석하지 않아 현재\n\n<!-- PAGE_96 -->\n###### 상태가 불분명한 대상자의 경우에 시험자는 대상자와 전화\n\n- - 90 -\n<!-- PAGE_97 -->\n###### 14. "
      }
    },
    {
      "chunk_id": "chunk_758",
      "text": "유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 의함)\n\n<!-- PAGE_97 -->\n###### 가. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 757,
        "window_size": 3,
        "char_count": 63,
        "word_count": 11,
        "page_number": 97,
        "window_text": "중지\n\n<!-- PAGE_94 -->\n###### - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n\n<!-- PAGE_94 -->\n###### - 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는\n\n<!-- PAGE_94 -->\n###### - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n\n<!-- PAGE_94 -->\n###### - 중지 시점까지의 검사 결과 관련 자료는 성능과 안전성 평가를\n\n- - 88 -\n<!-- PAGE_95 -->\n###### 위한 통계처리 시 삽입할 수 있다.\n\n <!-- PAGE_95 -->\n###### - 임상시험을 통해 얻은 자료는 성능 및 안전성 분석을 위한\n\n<!-- PAGE_95 -->\n###### 데이터가 정해져야 하며, 만약 자료에 결함이 생기면 적절한\n\n<!-- PAGE_95 -->\n###### 보정 방법을 임상시험계획서에 제시하고 보정 후 분석을 시행\n\n<!-- PAGE_95 -->\n###### 나.  탈락\n\n<!-- PAGE_95 -->\n###### 시험자는 다음과 같은 경우에 연구 참여 대상자를 시험에서\n\n<!-- PAGE_95 -->\n###### - 피험자가 임상시험 중 임상시험 참여 중단을 요구하거나 시험\n\n<!-- PAGE_95 -->\n###### - 3개월 이내에 자살 시도를 한 바 있으며, 정신과 전문의에 의해\n\n<!-- PAGE_95 -->\n###### ※ 콜롬비아 자살 위험성 스케일(C-SSRS) 혹은 이와 유사한 과학적\n\n<!-- PAGE_95 -->\n###### - 피험자의 부작용(예: 두통, 눈의 피로, 눈 또는 근육경련, 눈의 불\n\n<!-- PAGE_95 -->\n###### 수의운동, 메스꺼움, 어지럼증 등)으로 인하여 임상시험 책임자\n\n<!-- PAGE_95 -->\n###### - 피험자가 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n\n<!-- PAGE_95 -->\n###### - 피험자의 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n\n- - 89 -\n<!-- PAGE_96 -->\n###### - 임상시험 중 선정/제외 기준 위반 등 중대한 계획서 위반 사항이\n\n<!-- PAGE_96 -->\n###### 발견되는 경우\n\n<!-- PAGE_96 -->\n###### - 기타 사유로 인하여 임상시험 책임자 또는 담당자가 임상\n\n<!-- PAGE_96 -->\n###### - 우울 증상이 지나치게 악화되어 다른 건강 결과 악화가 예상\n\n<!-- PAGE_96 -->\n###### - 중도 탈락 시, 시험자는 대상자의 임상시험 조기 탈락의 주요\n\n<!-- PAGE_96 -->\n###### 사유를 평가하여 증례 기록서 임상시험 완료 란에 해당 정보를\n\n<!-- PAGE_96 -->\n###### - 참여 중단 의사를 밝히지 않고 방문에 출석하지 않아 현재\n\n<!-- PAGE_96 -->\n###### 상태가 불분명한 대상자의 경우에 시험자는 대상자와 전화\n\n- - 90 -\n<!-- PAGE_97 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 의함)\n\n<!-- PAGE_97 -->\n###### 가.  유효성의 평가 기준\n\n<!-- PAGE_97 -->\n###### [일차 유효성 평가변수]\n\n<!-- PAGE_97 -->\n###### [이차 유효성 평가변수]\n\n<!-- PAGE_97 -->\n###### 2) 치료 전 대비 8주 및 3개월 후 우울장애 선별 도구 척도(PHQ-9) 변화량\n\n- - 91 -\n4) 치료 전 대비 8주 및 3개월 후 반응률*\n\n<!-- PAGE_98 -->\n###### * 반응 정의: 기저점 대비 일차 유효성 변수(우울장애 심각도 척도[BDI]) 변화량의\n\n**[표 시작]**\n\n**5) 삶의 질**\n\n**[표 끝]**\n\n- - 92 -\n<!-- PAGE_99 -->\n###### 나.  검사 방법\n\n<!-- PAGE_99 -->\n###### 1) 우울장애 심각도 척도(Beck Depression Inventory, BDI-II)\n\n<!-- PAGE_99 -->\n###### 우울장애 심각도 척도(BDI-II)는 우울장애의 증상 심각도에 대한\n\n<!-- PAGE_99 -->\n###### 평가를 수행할 수 있으며 질환의 호전 여부를 판단할 수 있는,\n\n<!-- PAGE_99 -->\n###### 과학적으로 검증된 자가 보고식 설문이다(Beck, 1961).  우울장애\n\n<!-- PAGE_99 -->\n###### 심각도 척도는 DSM-5의 우울장애 진단기준에 근거하여 우울장애를\n\n<!-- PAGE_99 -->\n###### 측정하는 문항 총 21개로 구성되어 있다. ",
        "original_sentence": "유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 의함)\n\n<!-- PAGE_97 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_759",
      "text": "유효성의 평가 기준\n\n<!-- PAGE_97 -->\n###### [일차 유효성 평가변수]\n\n<!-- PAGE_97 -->\n###### [이차 유효성 평가변수]\n\n<!-- PAGE_97 -->\n###### 2) 치료 전 대비 8주 및 3개월 후 우울장애 선별 도구 척도(PHQ-9) 변화량\n\n- - 91 -\n4) 치료 전 대비 8주 및 3개월 후 반응률*\n\n<!-- PAGE_98 -->\n###### * 반응 정의: 기저점 대비 일차 유효성 변수(우울장애 심각도 척도[BDI]) 변화량의\n\n**[표 시작]**\n\n**5) 삶의 질**\n\n**[표 끝]**\n\n- - 92 -\n<!-- PAGE_99 -->\n###### 나. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 758,
        "window_size": 3,
        "char_count": 345,
        "word_count": 78,
        "page_number": 97,
        "window_text": "<!-- PAGE_95 -->\n###### - 임상시험을 통해 얻은 자료는 성능 및 안전성 분석을 위한\n\n<!-- PAGE_95 -->\n###### 데이터가 정해져야 하며, 만약 자료에 결함이 생기면 적절한\n\n<!-- PAGE_95 -->\n###### 보정 방법을 임상시험계획서에 제시하고 보정 후 분석을 시행\n\n<!-- PAGE_95 -->\n###### 나.  탈락\n\n<!-- PAGE_95 -->\n###### 시험자는 다음과 같은 경우에 연구 참여 대상자를 시험에서\n\n<!-- PAGE_95 -->\n###### - 피험자가 임상시험 중 임상시험 참여 중단을 요구하거나 시험\n\n<!-- PAGE_95 -->\n###### - 3개월 이내에 자살 시도를 한 바 있으며, 정신과 전문의에 의해\n\n<!-- PAGE_95 -->\n###### ※ 콜롬비아 자살 위험성 스케일(C-SSRS) 혹은 이와 유사한 과학적\n\n<!-- PAGE_95 -->\n###### - 피험자의 부작용(예: 두통, 눈의 피로, 눈 또는 근육경련, 눈의 불\n\n<!-- PAGE_95 -->\n###### 수의운동, 메스꺼움, 어지럼증 등)으로 인하여 임상시험 책임자\n\n<!-- PAGE_95 -->\n###### - 피험자가 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n\n<!-- PAGE_95 -->\n###### - 피험자의 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n\n- - 89 -\n<!-- PAGE_96 -->\n###### - 임상시험 중 선정/제외 기준 위반 등 중대한 계획서 위반 사항이\n\n<!-- PAGE_96 -->\n###### 발견되는 경우\n\n<!-- PAGE_96 -->\n###### - 기타 사유로 인하여 임상시험 책임자 또는 담당자가 임상\n\n<!-- PAGE_96 -->\n###### - 우울 증상이 지나치게 악화되어 다른 건강 결과 악화가 예상\n\n<!-- PAGE_96 -->\n###### - 중도 탈락 시, 시험자는 대상자의 임상시험 조기 탈락의 주요\n\n<!-- PAGE_96 -->\n###### 사유를 평가하여 증례 기록서 임상시험 완료 란에 해당 정보를\n\n<!-- PAGE_96 -->\n###### - 참여 중단 의사를 밝히지 않고 방문에 출석하지 않아 현재\n\n<!-- PAGE_96 -->\n###### 상태가 불분명한 대상자의 경우에 시험자는 대상자와 전화\n\n- - 90 -\n<!-- PAGE_97 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 의함)\n\n<!-- PAGE_97 -->\n###### 가.  유효성의 평가 기준\n\n<!-- PAGE_97 -->\n###### [일차 유효성 평가변수]\n\n<!-- PAGE_97 -->\n###### [이차 유효성 평가변수]\n\n<!-- PAGE_97 -->\n###### 2) 치료 전 대비 8주 및 3개월 후 우울장애 선별 도구 척도(PHQ-9) 변화량\n\n- - 91 -\n4) 치료 전 대비 8주 및 3개월 후 반응률*\n\n<!-- PAGE_98 -->\n###### * 반응 정의: 기저점 대비 일차 유효성 변수(우울장애 심각도 척도[BDI]) 변화량의\n\n**[표 시작]**\n\n**5) 삶의 질**\n\n**[표 끝]**\n\n- - 92 -\n<!-- PAGE_99 -->\n###### 나.  검사 방법\n\n<!-- PAGE_99 -->\n###### 1) 우울장애 심각도 척도(Beck Depression Inventory, BDI-II)\n\n<!-- PAGE_99 -->\n###### 우울장애 심각도 척도(BDI-II)는 우울장애의 증상 심각도에 대한\n\n<!-- PAGE_99 -->\n###### 평가를 수행할 수 있으며 질환의 호전 여부를 판단할 수 있는,\n\n<!-- PAGE_99 -->\n###### 과학적으로 검증된 자가 보고식 설문이다(Beck, 1961).  우울장애\n\n<!-- PAGE_99 -->\n###### 심각도 척도는 DSM-5의 우울장애 진단기준에 근거하여 우울장애를\n\n<!-- PAGE_99 -->\n###### 측정하는 문항 총 21개로 구성되어 있다.  문항은 슬픔, 죄의식, 자살\n\n<!-- PAGE_99 -->\n###### 사고, 흥미 결여와 같은 특징적인 우울장애에 관한 것이다. ",
        "original_sentence": "유효성의 평가 기준\n\n<!-- PAGE_97 -->\n###### [일차 유효성 평가변수]\n\n<!-- PAGE_97 -->\n###### [이차 유효성 평가변수]\n\n<!-- PAGE_97 -->\n###### 2) 치료 전 대비 8주 및 3개월 후 우울장애 선별 도구 척도(PHQ-9) 변화량\n\n- - 91 -\n4) 치료 전 대비 8주 및 3개월 후 반응률*\n\n<!-- PAGE_98 -->\n###### * 반응 정의: 기저점 대비 일차 유효성 변수(우울장애 심각도 척도[BDI]) 변화량의\n\n**[표 시작]**\n\n**5) 삶의 질**\n\n**[표 끝]**\n\n- - 92 -\n<!-- PAGE_99 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_760",
      "text": "검사 방법\n\n<!-- PAGE_99 -->\n###### 1) 우울장애 심각도 척도(Beck Depression Inventory, BDI-II)\n\n<!-- PAGE_99 -->\n###### 우울장애 심각도 척도(BDI-II)는 우울장애의 증상 심각도에 대한\n\n<!-- PAGE_99 -->\n###### 평가를 수행할 수 있으며 질환의 호전 여부를 판단할 수 있는,\n\n<!-- PAGE_99 -->\n###### 과학적으로 검증된 자가 보고식 설문이다(Beck, 1961). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 759,
        "window_size": 3,
        "char_count": 264,
        "word_count": 48,
        "page_number": 99,
        "window_text": "탈락\n\n<!-- PAGE_95 -->\n###### 시험자는 다음과 같은 경우에 연구 참여 대상자를 시험에서\n\n<!-- PAGE_95 -->\n###### - 피험자가 임상시험 중 임상시험 참여 중단을 요구하거나 시험\n\n<!-- PAGE_95 -->\n###### - 3개월 이내에 자살 시도를 한 바 있으며, 정신과 전문의에 의해\n\n<!-- PAGE_95 -->\n###### ※ 콜롬비아 자살 위험성 스케일(C-SSRS) 혹은 이와 유사한 과학적\n\n<!-- PAGE_95 -->\n###### - 피험자의 부작용(예: 두통, 눈의 피로, 눈 또는 근육경련, 눈의 불\n\n<!-- PAGE_95 -->\n###### 수의운동, 메스꺼움, 어지럼증 등)으로 인하여 임상시험 책임자\n\n<!-- PAGE_95 -->\n###### - 피험자가 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n\n<!-- PAGE_95 -->\n###### - 피험자의 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n\n- - 89 -\n<!-- PAGE_96 -->\n###### - 임상시험 중 선정/제외 기준 위반 등 중대한 계획서 위반 사항이\n\n<!-- PAGE_96 -->\n###### 발견되는 경우\n\n<!-- PAGE_96 -->\n###### - 기타 사유로 인하여 임상시험 책임자 또는 담당자가 임상\n\n<!-- PAGE_96 -->\n###### - 우울 증상이 지나치게 악화되어 다른 건강 결과 악화가 예상\n\n<!-- PAGE_96 -->\n###### - 중도 탈락 시, 시험자는 대상자의 임상시험 조기 탈락의 주요\n\n<!-- PAGE_96 -->\n###### 사유를 평가하여 증례 기록서 임상시험 완료 란에 해당 정보를\n\n<!-- PAGE_96 -->\n###### - 참여 중단 의사를 밝히지 않고 방문에 출석하지 않아 현재\n\n<!-- PAGE_96 -->\n###### 상태가 불분명한 대상자의 경우에 시험자는 대상자와 전화\n\n- - 90 -\n<!-- PAGE_97 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 의함)\n\n<!-- PAGE_97 -->\n###### 가.  유효성의 평가 기준\n\n<!-- PAGE_97 -->\n###### [일차 유효성 평가변수]\n\n<!-- PAGE_97 -->\n###### [이차 유효성 평가변수]\n\n<!-- PAGE_97 -->\n###### 2) 치료 전 대비 8주 및 3개월 후 우울장애 선별 도구 척도(PHQ-9) 변화량\n\n- - 91 -\n4) 치료 전 대비 8주 및 3개월 후 반응률*\n\n<!-- PAGE_98 -->\n###### * 반응 정의: 기저점 대비 일차 유효성 변수(우울장애 심각도 척도[BDI]) 변화량의\n\n**[표 시작]**\n\n**5) 삶의 질**\n\n**[표 끝]**\n\n- - 92 -\n<!-- PAGE_99 -->\n###### 나.  검사 방법\n\n<!-- PAGE_99 -->\n###### 1) 우울장애 심각도 척도(Beck Depression Inventory, BDI-II)\n\n<!-- PAGE_99 -->\n###### 우울장애 심각도 척도(BDI-II)는 우울장애의 증상 심각도에 대한\n\n<!-- PAGE_99 -->\n###### 평가를 수행할 수 있으며 질환의 호전 여부를 판단할 수 있는,\n\n<!-- PAGE_99 -->\n###### 과학적으로 검증된 자가 보고식 설문이다(Beck, 1961).  우울장애\n\n<!-- PAGE_99 -->\n###### 심각도 척도는 DSM-5의 우울장애 진단기준에 근거하여 우울장애를\n\n<!-- PAGE_99 -->\n###### 측정하는 문항 총 21개로 구성되어 있다.  문항은 슬픔, 죄의식, 자살\n\n<!-- PAGE_99 -->\n###### 사고, 흥미 결여와 같은 특징적인 우울장애에 관한 것이다.  이들 문항\n\n<!-- PAGE_99 -->\n###### 중 19개는 증상이 없는 것에서부터 증가하여 심각도 수준(0~3)을\n\n<!-- PAGE_99 -->\n###### 나타내며, 나머지 2문항은 행동의 변화(식욕 및 수면)에 대해 반응\n\n<!-- PAGE_99 -->\n###### 하도록 구성되어 있다. ",
        "original_sentence": "검사 방법\n\n<!-- PAGE_99 -->\n###### 1) 우울장애 심각도 척도(Beck Depression Inventory, BDI-II)\n\n<!-- PAGE_99 -->\n###### 우울장애 심각도 척도(BDI-II)는 우울장애의 증상 심각도에 대한\n\n<!-- PAGE_99 -->\n###### 평가를 수행할 수 있으며 질환의 호전 여부를 판단할 수 있는,\n\n<!-- PAGE_99 -->\n###### 과학적으로 검증된 자가 보고식 설문이다(Beck, 1961). "
      }
    },
    {
      "chunk_id": "chunk_761",
      "text": "우울장애\n\n<!-- PAGE_99 -->\n###### 심각도 척도는 DSM-5의 우울장애 진단기준에 근거하여 우울장애를\n\n<!-- PAGE_99 -->\n###### 측정하는 문항 총 21개로 구성되어 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 760,
        "window_size": 3,
        "char_count": 116,
        "word_count": 22,
        "page_number": 99,
        "window_text": "유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 의함)\n\n<!-- PAGE_97 -->\n###### 가.  유효성의 평가 기준\n\n<!-- PAGE_97 -->\n###### [일차 유효성 평가변수]\n\n<!-- PAGE_97 -->\n###### [이차 유효성 평가변수]\n\n<!-- PAGE_97 -->\n###### 2) 치료 전 대비 8주 및 3개월 후 우울장애 선별 도구 척도(PHQ-9) 변화량\n\n- - 91 -\n4) 치료 전 대비 8주 및 3개월 후 반응률*\n\n<!-- PAGE_98 -->\n###### * 반응 정의: 기저점 대비 일차 유효성 변수(우울장애 심각도 척도[BDI]) 변화량의\n\n**[표 시작]**\n\n**5) 삶의 질**\n\n**[표 끝]**\n\n- - 92 -\n<!-- PAGE_99 -->\n###### 나.  검사 방법\n\n<!-- PAGE_99 -->\n###### 1) 우울장애 심각도 척도(Beck Depression Inventory, BDI-II)\n\n<!-- PAGE_99 -->\n###### 우울장애 심각도 척도(BDI-II)는 우울장애의 증상 심각도에 대한\n\n<!-- PAGE_99 -->\n###### 평가를 수행할 수 있으며 질환의 호전 여부를 판단할 수 있는,\n\n<!-- PAGE_99 -->\n###### 과학적으로 검증된 자가 보고식 설문이다(Beck, 1961).  우울장애\n\n<!-- PAGE_99 -->\n###### 심각도 척도는 DSM-5의 우울장애 진단기준에 근거하여 우울장애를\n\n<!-- PAGE_99 -->\n###### 측정하는 문항 총 21개로 구성되어 있다.  문항은 슬픔, 죄의식, 자살\n\n<!-- PAGE_99 -->\n###### 사고, 흥미 결여와 같은 특징적인 우울장애에 관한 것이다.  이들 문항\n\n<!-- PAGE_99 -->\n###### 중 19개는 증상이 없는 것에서부터 증가하여 심각도 수준(0~3)을\n\n<!-- PAGE_99 -->\n###### 나타내며, 나머지 2문항은 행동의 변화(식욕 및 수면)에 대해 반응\n\n<!-- PAGE_99 -->\n###### 하도록 구성되어 있다.  21문항에서 인지-정서적 요인과 신체화 요인\n\n<!-- PAGE_99 -->\n###### 2 요인이 확인되었다. ",
        "original_sentence": "우울장애\n\n<!-- PAGE_99 -->\n###### 심각도 척도는 DSM-5의 우울장애 진단기준에 근거하여 우울장애를\n\n<!-- PAGE_99 -->\n###### 측정하는 문항 총 21개로 구성되어 있다. "
      }
    },
    {
      "chunk_id": "chunk_762",
      "text": "문항은 슬픔, 죄의식, 자살\n\n<!-- PAGE_99 -->\n###### 사고, 흥미 결여와 같은 특징적인 우울장애에 관한 것이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 761,
        "window_size": 3,
        "char_count": 74,
        "word_count": 16,
        "page_number": 99,
        "window_text": "유효성의 평가 기준\n\n<!-- PAGE_97 -->\n###### [일차 유효성 평가변수]\n\n<!-- PAGE_97 -->\n###### [이차 유효성 평가변수]\n\n<!-- PAGE_97 -->\n###### 2) 치료 전 대비 8주 및 3개월 후 우울장애 선별 도구 척도(PHQ-9) 변화량\n\n- - 91 -\n4) 치료 전 대비 8주 및 3개월 후 반응률*\n\n<!-- PAGE_98 -->\n###### * 반응 정의: 기저점 대비 일차 유효성 변수(우울장애 심각도 척도[BDI]) 변화량의\n\n**[표 시작]**\n\n**5) 삶의 질**\n\n**[표 끝]**\n\n- - 92 -\n<!-- PAGE_99 -->\n###### 나.  검사 방법\n\n<!-- PAGE_99 -->\n###### 1) 우울장애 심각도 척도(Beck Depression Inventory, BDI-II)\n\n<!-- PAGE_99 -->\n###### 우울장애 심각도 척도(BDI-II)는 우울장애의 증상 심각도에 대한\n\n<!-- PAGE_99 -->\n###### 평가를 수행할 수 있으며 질환의 호전 여부를 판단할 수 있는,\n\n<!-- PAGE_99 -->\n###### 과학적으로 검증된 자가 보고식 설문이다(Beck, 1961).  우울장애\n\n<!-- PAGE_99 -->\n###### 심각도 척도는 DSM-5의 우울장애 진단기준에 근거하여 우울장애를\n\n<!-- PAGE_99 -->\n###### 측정하는 문항 총 21개로 구성되어 있다.  문항은 슬픔, 죄의식, 자살\n\n<!-- PAGE_99 -->\n###### 사고, 흥미 결여와 같은 특징적인 우울장애에 관한 것이다.  이들 문항\n\n<!-- PAGE_99 -->\n###### 중 19개는 증상이 없는 것에서부터 증가하여 심각도 수준(0~3)을\n\n<!-- PAGE_99 -->\n###### 나타내며, 나머지 2문항은 행동의 변화(식욕 및 수면)에 대해 반응\n\n<!-- PAGE_99 -->\n###### 하도록 구성되어 있다.  21문항에서 인지-정서적 요인과 신체화 요인\n\n<!-- PAGE_99 -->\n###### 2 요인이 확인되었다.  우울장애 심각도 척도(BDI-II)는 13세 이상의\n\n<!-- PAGE_99 -->\n###### 청소년과 성인을 대상으로 실시하며, 점수는 최대 63점이 나오고\n\n<!-- PAGE_99 -->\n###### 점수가 높을수록 우울장애가 심각함을 나타낸다. ",
        "original_sentence": "문항은 슬픔, 죄의식, 자살\n\n<!-- PAGE_99 -->\n###### 사고, 흥미 결여와 같은 특징적인 우울장애에 관한 것이다. "
      }
    },
    {
      "chunk_id": "chunk_763",
      "text": "이들 문항\n\n<!-- PAGE_99 -->\n###### 중 19개는 증상이 없는 것에서부터 증가하여 심각도 수준(0~3)을\n\n<!-- PAGE_99 -->\n###### 나타내며, 나머지 2문항은 행동의 변화(식욕 및 수면)에 대해 반응\n\n<!-- PAGE_99 -->\n###### 하도록 구성되어 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 762,
        "window_size": 3,
        "char_count": 170,
        "word_count": 34,
        "page_number": 99,
        "window_text": "검사 방법\n\n<!-- PAGE_99 -->\n###### 1) 우울장애 심각도 척도(Beck Depression Inventory, BDI-II)\n\n<!-- PAGE_99 -->\n###### 우울장애 심각도 척도(BDI-II)는 우울장애의 증상 심각도에 대한\n\n<!-- PAGE_99 -->\n###### 평가를 수행할 수 있으며 질환의 호전 여부를 판단할 수 있는,\n\n<!-- PAGE_99 -->\n###### 과학적으로 검증된 자가 보고식 설문이다(Beck, 1961).  우울장애\n\n<!-- PAGE_99 -->\n###### 심각도 척도는 DSM-5의 우울장애 진단기준에 근거하여 우울장애를\n\n<!-- PAGE_99 -->\n###### 측정하는 문항 총 21개로 구성되어 있다.  문항은 슬픔, 죄의식, 자살\n\n<!-- PAGE_99 -->\n###### 사고, 흥미 결여와 같은 특징적인 우울장애에 관한 것이다.  이들 문항\n\n<!-- PAGE_99 -->\n###### 중 19개는 증상이 없는 것에서부터 증가하여 심각도 수준(0~3)을\n\n<!-- PAGE_99 -->\n###### 나타내며, 나머지 2문항은 행동의 변화(식욕 및 수면)에 대해 반응\n\n<!-- PAGE_99 -->\n###### 하도록 구성되어 있다.  21문항에서 인지-정서적 요인과 신체화 요인\n\n<!-- PAGE_99 -->\n###### 2 요인이 확인되었다.  우울장애 심각도 척도(BDI-II)는 13세 이상의\n\n<!-- PAGE_99 -->\n###### 청소년과 성인을 대상으로 실시하며, 점수는 최대 63점이 나오고\n\n<!-- PAGE_99 -->\n###### 점수가 높을수록 우울장애가 심각함을 나타낸다.  현재 BDI-II에 대한\n\n<!-- PAGE_99 -->\n###### 우울 점수에 따라, 약간의 우울(0~13점), 경미한 우울(14~19점), 중증도\n\n<!-- PAGE_99 -->\n###### 본 연구에서는 일차 유효성 지표에 대한 검증을 위해 방문 1, 방문 2,\n\n<!-- PAGE_99 -->\n###### 방문 3, 방문 4에 각각 우울장애 심각도 척도(BDI-II) 자가 보고 설문을\n\n<!-- PAGE_99 -->\n###### 수행할 예정이다. ",
        "original_sentence": "이들 문항\n\n<!-- PAGE_99 -->\n###### 중 19개는 증상이 없는 것에서부터 증가하여 심각도 수준(0~3)을\n\n<!-- PAGE_99 -->\n###### 나타내며, 나머지 2문항은 행동의 변화(식욕 및 수면)에 대해 반응\n\n<!-- PAGE_99 -->\n###### 하도록 구성되어 있다. "
      }
    },
    {
      "chunk_id": "chunk_764",
      "text": "21문항에서 인지-정서적 요인과 신체화 요인\n\n<!-- PAGE_99 -->\n###### 2 요인이 확인되었다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 763,
        "window_size": 3,
        "char_count": 63,
        "word_count": 12,
        "page_number": 99,
        "window_text": "우울장애\n\n<!-- PAGE_99 -->\n###### 심각도 척도는 DSM-5의 우울장애 진단기준에 근거하여 우울장애를\n\n<!-- PAGE_99 -->\n###### 측정하는 문항 총 21개로 구성되어 있다.  문항은 슬픔, 죄의식, 자살\n\n<!-- PAGE_99 -->\n###### 사고, 흥미 결여와 같은 특징적인 우울장애에 관한 것이다.  이들 문항\n\n<!-- PAGE_99 -->\n###### 중 19개는 증상이 없는 것에서부터 증가하여 심각도 수준(0~3)을\n\n<!-- PAGE_99 -->\n###### 나타내며, 나머지 2문항은 행동의 변화(식욕 및 수면)에 대해 반응\n\n<!-- PAGE_99 -->\n###### 하도록 구성되어 있다.  21문항에서 인지-정서적 요인과 신체화 요인\n\n<!-- PAGE_99 -->\n###### 2 요인이 확인되었다.  우울장애 심각도 척도(BDI-II)는 13세 이상의\n\n<!-- PAGE_99 -->\n###### 청소년과 성인을 대상으로 실시하며, 점수는 최대 63점이 나오고\n\n<!-- PAGE_99 -->\n###### 점수가 높을수록 우울장애가 심각함을 나타낸다.  현재 BDI-II에 대한\n\n<!-- PAGE_99 -->\n###### 우울 점수에 따라, 약간의 우울(0~13점), 경미한 우울(14~19점), 중증도\n\n<!-- PAGE_99 -->\n###### 본 연구에서는 일차 유효성 지표에 대한 검증을 위해 방문 1, 방문 2,\n\n<!-- PAGE_99 -->\n###### 방문 3, 방문 4에 각각 우울장애 심각도 척도(BDI-II) 자가 보고 설문을\n\n<!-- PAGE_99 -->\n###### 수행할 예정이다.  단, 필요에 따라 방문 1(스크리닝 단계)에서 측정한\n\n<!-- PAGE_99 -->\n###### 우울장애 심각도 척도(BDI-II) 정보를 방문 2의 baseline 지표로 활용\n\n<!-- PAGE_99 -->\n###### 할 수 있다. ",
        "original_sentence": "21문항에서 인지-정서적 요인과 신체화 요인\n\n<!-- PAGE_99 -->\n###### 2 요인이 확인되었다. "
      }
    },
    {
      "chunk_id": "chunk_765",
      "text": "우울장애 심각도 척도(BDI-II)는 13세 이상의\n\n<!-- PAGE_99 -->\n###### 청소년과 성인을 대상으로 실시하며, 점수는 최대 63점이 나오고\n\n<!-- PAGE_99 -->\n###### 점수가 높을수록 우울장애가 심각함을 나타낸다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 764,
        "window_size": 3,
        "char_count": 141,
        "word_count": 26,
        "page_number": 99,
        "window_text": "문항은 슬픔, 죄의식, 자살\n\n<!-- PAGE_99 -->\n###### 사고, 흥미 결여와 같은 특징적인 우울장애에 관한 것이다.  이들 문항\n\n<!-- PAGE_99 -->\n###### 중 19개는 증상이 없는 것에서부터 증가하여 심각도 수준(0~3)을\n\n<!-- PAGE_99 -->\n###### 나타내며, 나머지 2문항은 행동의 변화(식욕 및 수면)에 대해 반응\n\n<!-- PAGE_99 -->\n###### 하도록 구성되어 있다.  21문항에서 인지-정서적 요인과 신체화 요인\n\n<!-- PAGE_99 -->\n###### 2 요인이 확인되었다.  우울장애 심각도 척도(BDI-II)는 13세 이상의\n\n<!-- PAGE_99 -->\n###### 청소년과 성인을 대상으로 실시하며, 점수는 최대 63점이 나오고\n\n<!-- PAGE_99 -->\n###### 점수가 높을수록 우울장애가 심각함을 나타낸다.  현재 BDI-II에 대한\n\n<!-- PAGE_99 -->\n###### 우울 점수에 따라, 약간의 우울(0~13점), 경미한 우울(14~19점), 중증도\n\n<!-- PAGE_99 -->\n###### 본 연구에서는 일차 유효성 지표에 대한 검증을 위해 방문 1, 방문 2,\n\n<!-- PAGE_99 -->\n###### 방문 3, 방문 4에 각각 우울장애 심각도 척도(BDI-II) 자가 보고 설문을\n\n<!-- PAGE_99 -->\n###### 수행할 예정이다.  단, 필요에 따라 방문 1(스크리닝 단계)에서 측정한\n\n<!-- PAGE_99 -->\n###### 우울장애 심각도 척도(BDI-II) 정보를 방문 2의 baseline 지표로 활용\n\n<!-- PAGE_99 -->\n###### 할 수 있다.  방문 1의 경우 연구자가 직접 피험자와 대면하여 연구에\n\n<!-- PAGE_99 -->\n###### 대한 설명을 수행하고 서면동의를 얻은 뒤, 독립된 방에서 설문지를\n\n<!-- PAGE_99 -->\n###### 제공하고 피험자가 스스로 설문에 답하게 5-10분간의 시간을 제공\n\n- - 93 -\n<!-- PAGE_100 -->\n###### 할 예정이며, 이는 방문 2, 3, 4에서도 동일하게 진행될 예정이다.\n\n",
        "original_sentence": "우울장애 심각도 척도(BDI-II)는 13세 이상의\n\n<!-- PAGE_99 -->\n###### 청소년과 성인을 대상으로 실시하며, 점수는 최대 63점이 나오고\n\n<!-- PAGE_99 -->\n###### 점수가 높을수록 우울장애가 심각함을 나타낸다. "
      }
    },
    {
      "chunk_id": "chunk_766",
      "text": "현재 BDI-II에 대한\n\n<!-- PAGE_99 -->\n###### 우울 점수에 따라, 약간의 우울(0~13점), 경미한 우울(14~19점), 중증도\n\n<!-- PAGE_99 -->\n###### 본 연구에서는 일차 유효성 지표에 대한 검증을 위해 방문 1, 방문 2,\n\n<!-- PAGE_99 -->\n###### 방문 3, 방문 4에 각각 우울장애 심각도 척도(BDI-II) 자가 보고 설문을\n\n<!-- PAGE_99 -->\n###### 수행할 예정이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 765,
        "window_size": 3,
        "char_count": 256,
        "word_count": 52,
        "page_number": 99,
        "window_text": "이들 문항\n\n<!-- PAGE_99 -->\n###### 중 19개는 증상이 없는 것에서부터 증가하여 심각도 수준(0~3)을\n\n<!-- PAGE_99 -->\n###### 나타내며, 나머지 2문항은 행동의 변화(식욕 및 수면)에 대해 반응\n\n<!-- PAGE_99 -->\n###### 하도록 구성되어 있다.  21문항에서 인지-정서적 요인과 신체화 요인\n\n<!-- PAGE_99 -->\n###### 2 요인이 확인되었다.  우울장애 심각도 척도(BDI-II)는 13세 이상의\n\n<!-- PAGE_99 -->\n###### 청소년과 성인을 대상으로 실시하며, 점수는 최대 63점이 나오고\n\n<!-- PAGE_99 -->\n###### 점수가 높을수록 우울장애가 심각함을 나타낸다.  현재 BDI-II에 대한\n\n<!-- PAGE_99 -->\n###### 우울 점수에 따라, 약간의 우울(0~13점), 경미한 우울(14~19점), 중증도\n\n<!-- PAGE_99 -->\n###### 본 연구에서는 일차 유효성 지표에 대한 검증을 위해 방문 1, 방문 2,\n\n<!-- PAGE_99 -->\n###### 방문 3, 방문 4에 각각 우울장애 심각도 척도(BDI-II) 자가 보고 설문을\n\n<!-- PAGE_99 -->\n###### 수행할 예정이다.  단, 필요에 따라 방문 1(스크리닝 단계)에서 측정한\n\n<!-- PAGE_99 -->\n###### 우울장애 심각도 척도(BDI-II) 정보를 방문 2의 baseline 지표로 활용\n\n<!-- PAGE_99 -->\n###### 할 수 있다.  방문 1의 경우 연구자가 직접 피험자와 대면하여 연구에\n\n<!-- PAGE_99 -->\n###### 대한 설명을 수행하고 서면동의를 얻은 뒤, 독립된 방에서 설문지를\n\n<!-- PAGE_99 -->\n###### 제공하고 피험자가 스스로 설문에 답하게 5-10분간의 시간을 제공\n\n- - 93 -\n<!-- PAGE_100 -->\n###### 할 예정이며, 이는 방문 2, 3, 4에서도 동일하게 진행될 예정이다.\n\n <!-- PAGE_100 -->\n###### 다만 방문 2, 3의 경우 애플리케이션을 통해 우울장애 심각도 척도\n\n<!-- PAGE_100 -->\n###### (BDI-II) 정보를 수집할 수 있으며, 방문 4는 내원, 애플리케이션,\n\n<!-- PAGE_100 -->\n###### 이메일, 문자, SNS를 이용하여 설문지를 제공한 뒤 회신받는 것으로\n\n<!-- PAGE_100 -->\n###### 방문 1의 설문에서 13점 이하를 기록할 때 연구 대상에서 제외\n\n<!-- PAGE_100 -->\n###### 되게 된다. ",
        "original_sentence": "현재 BDI-II에 대한\n\n<!-- PAGE_99 -->\n###### 우울 점수에 따라, 약간의 우울(0~13점), 경미한 우울(14~19점), 중증도\n\n<!-- PAGE_99 -->\n###### 본 연구에서는 일차 유효성 지표에 대한 검증을 위해 방문 1, 방문 2,\n\n<!-- PAGE_99 -->\n###### 방문 3, 방문 4에 각각 우울장애 심각도 척도(BDI-II) 자가 보고 설문을\n\n<!-- PAGE_99 -->\n###### 수행할 예정이다. "
      }
    },
    {
      "chunk_id": "chunk_767",
      "text": "단, 필요에 따라 방문 1(스크리닝 단계)에서 측정한\n\n<!-- PAGE_99 -->\n###### 우울장애 심각도 척도(BDI-II) 정보를 방문 2의 baseline 지표로 활용\n\n<!-- PAGE_99 -->\n###### 할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 766,
        "window_size": 3,
        "char_count": 134,
        "word_count": 27,
        "page_number": 99,
        "window_text": "21문항에서 인지-정서적 요인과 신체화 요인\n\n<!-- PAGE_99 -->\n###### 2 요인이 확인되었다.  우울장애 심각도 척도(BDI-II)는 13세 이상의\n\n<!-- PAGE_99 -->\n###### 청소년과 성인을 대상으로 실시하며, 점수는 최대 63점이 나오고\n\n<!-- PAGE_99 -->\n###### 점수가 높을수록 우울장애가 심각함을 나타낸다.  현재 BDI-II에 대한\n\n<!-- PAGE_99 -->\n###### 우울 점수에 따라, 약간의 우울(0~13점), 경미한 우울(14~19점), 중증도\n\n<!-- PAGE_99 -->\n###### 본 연구에서는 일차 유효성 지표에 대한 검증을 위해 방문 1, 방문 2,\n\n<!-- PAGE_99 -->\n###### 방문 3, 방문 4에 각각 우울장애 심각도 척도(BDI-II) 자가 보고 설문을\n\n<!-- PAGE_99 -->\n###### 수행할 예정이다.  단, 필요에 따라 방문 1(스크리닝 단계)에서 측정한\n\n<!-- PAGE_99 -->\n###### 우울장애 심각도 척도(BDI-II) 정보를 방문 2의 baseline 지표로 활용\n\n<!-- PAGE_99 -->\n###### 할 수 있다.  방문 1의 경우 연구자가 직접 피험자와 대면하여 연구에\n\n<!-- PAGE_99 -->\n###### 대한 설명을 수행하고 서면동의를 얻은 뒤, 독립된 방에서 설문지를\n\n<!-- PAGE_99 -->\n###### 제공하고 피험자가 스스로 설문에 답하게 5-10분간의 시간을 제공\n\n- - 93 -\n<!-- PAGE_100 -->\n###### 할 예정이며, 이는 방문 2, 3, 4에서도 동일하게 진행될 예정이다.\n\n <!-- PAGE_100 -->\n###### 다만 방문 2, 3의 경우 애플리케이션을 통해 우울장애 심각도 척도\n\n<!-- PAGE_100 -->\n###### (BDI-II) 정보를 수집할 수 있으며, 방문 4는 내원, 애플리케이션,\n\n<!-- PAGE_100 -->\n###### 이메일, 문자, SNS를 이용하여 설문지를 제공한 뒤 회신받는 것으로\n\n<!-- PAGE_100 -->\n###### 방문 1의 설문에서 13점 이하를 기록할 때 연구 대상에서 제외\n\n<!-- PAGE_100 -->\n###### 되게 된다.  방문 3, 4의 설문 점수는 방문 1의 점수와 비교 분석\n\n<!-- PAGE_100 -->\n###### 우울장애 선별 도구(PHQ-9)란 다른 우울장애 평가척도와 유의한\n\n<!-- PAGE_100 -->\n###### 공존 타당도를 나타내고 우울장애를 평가하고 선별하는 척도로서의\n\n<!-- PAGE_100 -->\n###### 신뢰도와 타당도가 입증되었다. ",
        "original_sentence": "단, 필요에 따라 방문 1(스크리닝 단계)에서 측정한\n\n<!-- PAGE_99 -->\n###### 우울장애 심각도 척도(BDI-II) 정보를 방문 2의 baseline 지표로 활용\n\n<!-- PAGE_99 -->\n###### 할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_768",
      "text": "방문 1의 경우 연구자가 직접 피험자와 대면하여 연구에\n\n<!-- PAGE_99 -->\n###### 대한 설명을 수행하고 서면동의를 얻은 뒤, 독립된 방에서 설문지를\n\n<!-- PAGE_99 -->\n###### 제공하고 피험자가 스스로 설문에 답하게 5-10분간의 시간을 제공\n\n- - 93 -\n<!-- PAGE_100 -->\n###### 할 예정이며, 이는 방문 2, 3, 4에서도 동일하게 진행될 예정이다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 767,
        "window_size": 3,
        "char_count": 231,
        "word_count": 51,
        "page_number": 99,
        "window_text": "우울장애 심각도 척도(BDI-II)는 13세 이상의\n\n<!-- PAGE_99 -->\n###### 청소년과 성인을 대상으로 실시하며, 점수는 최대 63점이 나오고\n\n<!-- PAGE_99 -->\n###### 점수가 높을수록 우울장애가 심각함을 나타낸다.  현재 BDI-II에 대한\n\n<!-- PAGE_99 -->\n###### 우울 점수에 따라, 약간의 우울(0~13점), 경미한 우울(14~19점), 중증도\n\n<!-- PAGE_99 -->\n###### 본 연구에서는 일차 유효성 지표에 대한 검증을 위해 방문 1, 방문 2,\n\n<!-- PAGE_99 -->\n###### 방문 3, 방문 4에 각각 우울장애 심각도 척도(BDI-II) 자가 보고 설문을\n\n<!-- PAGE_99 -->\n###### 수행할 예정이다.  단, 필요에 따라 방문 1(스크리닝 단계)에서 측정한\n\n<!-- PAGE_99 -->\n###### 우울장애 심각도 척도(BDI-II) 정보를 방문 2의 baseline 지표로 활용\n\n<!-- PAGE_99 -->\n###### 할 수 있다.  방문 1의 경우 연구자가 직접 피험자와 대면하여 연구에\n\n<!-- PAGE_99 -->\n###### 대한 설명을 수행하고 서면동의를 얻은 뒤, 독립된 방에서 설문지를\n\n<!-- PAGE_99 -->\n###### 제공하고 피험자가 스스로 설문에 답하게 5-10분간의 시간을 제공\n\n- - 93 -\n<!-- PAGE_100 -->\n###### 할 예정이며, 이는 방문 2, 3, 4에서도 동일하게 진행될 예정이다.\n\n <!-- PAGE_100 -->\n###### 다만 방문 2, 3의 경우 애플리케이션을 통해 우울장애 심각도 척도\n\n<!-- PAGE_100 -->\n###### (BDI-II) 정보를 수집할 수 있으며, 방문 4는 내원, 애플리케이션,\n\n<!-- PAGE_100 -->\n###### 이메일, 문자, SNS를 이용하여 설문지를 제공한 뒤 회신받는 것으로\n\n<!-- PAGE_100 -->\n###### 방문 1의 설문에서 13점 이하를 기록할 때 연구 대상에서 제외\n\n<!-- PAGE_100 -->\n###### 되게 된다.  방문 3, 4의 설문 점수는 방문 1의 점수와 비교 분석\n\n<!-- PAGE_100 -->\n###### 우울장애 선별 도구(PHQ-9)란 다른 우울장애 평가척도와 유의한\n\n<!-- PAGE_100 -->\n###### 공존 타당도를 나타내고 우울장애를 평가하고 선별하는 척도로서의\n\n<!-- PAGE_100 -->\n###### 신뢰도와 타당도가 입증되었다.  PHQ-9의 경우 기존 우울장애 평가\n\n<!-- PAGE_100 -->\n###### 도구보다 문항 수가 적고 작성 시간이 적게 걸려 일차 진료 과정\n\n<!-- PAGE_100 -->\n###### 현재 BDI에 대한 우울 점수에 따라, 경도 우울(10~14점), 중등도\n\n<!-- PAGE_100 -->\n###### 삶의 질, 우울/불안 관련 증상 유무, 직업적/사회적 기능 상태,\n\n<!-- PAGE_100 -->\n###### 등의 항목에 있어서는 자가 보고 설문 혹은 연구자와 대면 인터뷰를\n\n<!-- PAGE_100 -->\n###### 통해 측정할 수 있다. ",
        "original_sentence": "방문 1의 경우 연구자가 직접 피험자와 대면하여 연구에\n\n<!-- PAGE_99 -->\n###### 대한 설명을 수행하고 서면동의를 얻은 뒤, 독립된 방에서 설문지를\n\n<!-- PAGE_99 -->\n###### 제공하고 피험자가 스스로 설문에 답하게 5-10분간의 시간을 제공\n\n- - 93 -\n<!-- PAGE_100 -->\n###### 할 예정이며, 이는 방문 2, 3, 4에서도 동일하게 진행될 예정이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_769",
      "text": "<!-- PAGE_100 -->\n###### 다만 방문 2, 3의 경우 애플리케이션을 통해 우울장애 심각도 척도\n\n<!-- PAGE_100 -->\n###### (BDI-II) 정보를 수집할 수 있으며, 방문 4는 내원, 애플리케이션,\n\n<!-- PAGE_100 -->\n###### 이메일, 문자, SNS를 이용하여 설문지를 제공한 뒤 회신받는 것으로\n\n<!-- PAGE_100 -->\n###### 방문 1의 설문에서 13점 이하를 기록할 때 연구 대상에서 제외\n\n<!-- PAGE_100 -->\n###### 되게 된다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 768,
        "window_size": 3,
        "char_count": 291,
        "word_count": 60,
        "page_number": 100,
        "window_text": "현재 BDI-II에 대한\n\n<!-- PAGE_99 -->\n###### 우울 점수에 따라, 약간의 우울(0~13점), 경미한 우울(14~19점), 중증도\n\n<!-- PAGE_99 -->\n###### 본 연구에서는 일차 유효성 지표에 대한 검증을 위해 방문 1, 방문 2,\n\n<!-- PAGE_99 -->\n###### 방문 3, 방문 4에 각각 우울장애 심각도 척도(BDI-II) 자가 보고 설문을\n\n<!-- PAGE_99 -->\n###### 수행할 예정이다.  단, 필요에 따라 방문 1(스크리닝 단계)에서 측정한\n\n<!-- PAGE_99 -->\n###### 우울장애 심각도 척도(BDI-II) 정보를 방문 2의 baseline 지표로 활용\n\n<!-- PAGE_99 -->\n###### 할 수 있다.  방문 1의 경우 연구자가 직접 피험자와 대면하여 연구에\n\n<!-- PAGE_99 -->\n###### 대한 설명을 수행하고 서면동의를 얻은 뒤, 독립된 방에서 설문지를\n\n<!-- PAGE_99 -->\n###### 제공하고 피험자가 스스로 설문에 답하게 5-10분간의 시간을 제공\n\n- - 93 -\n<!-- PAGE_100 -->\n###### 할 예정이며, 이는 방문 2, 3, 4에서도 동일하게 진행될 예정이다.\n\n <!-- PAGE_100 -->\n###### 다만 방문 2, 3의 경우 애플리케이션을 통해 우울장애 심각도 척도\n\n<!-- PAGE_100 -->\n###### (BDI-II) 정보를 수집할 수 있으며, 방문 4는 내원, 애플리케이션,\n\n<!-- PAGE_100 -->\n###### 이메일, 문자, SNS를 이용하여 설문지를 제공한 뒤 회신받는 것으로\n\n<!-- PAGE_100 -->\n###### 방문 1의 설문에서 13점 이하를 기록할 때 연구 대상에서 제외\n\n<!-- PAGE_100 -->\n###### 되게 된다.  방문 3, 4의 설문 점수는 방문 1의 점수와 비교 분석\n\n<!-- PAGE_100 -->\n###### 우울장애 선별 도구(PHQ-9)란 다른 우울장애 평가척도와 유의한\n\n<!-- PAGE_100 -->\n###### 공존 타당도를 나타내고 우울장애를 평가하고 선별하는 척도로서의\n\n<!-- PAGE_100 -->\n###### 신뢰도와 타당도가 입증되었다.  PHQ-9의 경우 기존 우울장애 평가\n\n<!-- PAGE_100 -->\n###### 도구보다 문항 수가 적고 작성 시간이 적게 걸려 일차 진료 과정\n\n<!-- PAGE_100 -->\n###### 현재 BDI에 대한 우울 점수에 따라, 경도 우울(10~14점), 중등도\n\n<!-- PAGE_100 -->\n###### 삶의 질, 우울/불안 관련 증상 유무, 직업적/사회적 기능 상태,\n\n<!-- PAGE_100 -->\n###### 등의 항목에 있어서는 자가 보고 설문 혹은 연구자와 대면 인터뷰를\n\n<!-- PAGE_100 -->\n###### 통해 측정할 수 있다.  자가 보고 설문의 경우 우울장애 심각도\n\n<!-- PAGE_100 -->\n###### 척도(BDI-II)와 동등한 방식으로 측정할 수 있다. ",
        "original_sentence": "<!-- PAGE_100 -->\n###### 다만 방문 2, 3의 경우 애플리케이션을 통해 우울장애 심각도 척도\n\n<!-- PAGE_100 -->\n###### (BDI-II) 정보를 수집할 수 있으며, 방문 4는 내원, 애플리케이션,\n\n<!-- PAGE_100 -->\n###### 이메일, 문자, SNS를 이용하여 설문지를 제공한 뒤 회신받는 것으로\n\n<!-- PAGE_100 -->\n###### 방문 1의 설문에서 13점 이하를 기록할 때 연구 대상에서 제외\n\n<!-- PAGE_100 -->\n###### 되게 된다. "
      }
    },
    {
      "chunk_id": "chunk_770",
      "text": "방문 3, 4의 설문 점수는 방문 1의 점수와 비교 분석\n\n<!-- PAGE_100 -->\n###### 우울장애 선별 도구(PHQ-9)란 다른 우울장애 평가척도와 유의한\n\n<!-- PAGE_100 -->\n###### 공존 타당도를 나타내고 우울장애를 평가하고 선별하는 척도로서의\n\n<!-- PAGE_100 -->\n###### 신뢰도와 타당도가 입증되었다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 769,
        "window_size": 3,
        "char_count": 199,
        "word_count": 39,
        "page_number": 100,
        "window_text": "단, 필요에 따라 방문 1(스크리닝 단계)에서 측정한\n\n<!-- PAGE_99 -->\n###### 우울장애 심각도 척도(BDI-II) 정보를 방문 2의 baseline 지표로 활용\n\n<!-- PAGE_99 -->\n###### 할 수 있다.  방문 1의 경우 연구자가 직접 피험자와 대면하여 연구에\n\n<!-- PAGE_99 -->\n###### 대한 설명을 수행하고 서면동의를 얻은 뒤, 독립된 방에서 설문지를\n\n<!-- PAGE_99 -->\n###### 제공하고 피험자가 스스로 설문에 답하게 5-10분간의 시간을 제공\n\n- - 93 -\n<!-- PAGE_100 -->\n###### 할 예정이며, 이는 방문 2, 3, 4에서도 동일하게 진행될 예정이다.\n\n <!-- PAGE_100 -->\n###### 다만 방문 2, 3의 경우 애플리케이션을 통해 우울장애 심각도 척도\n\n<!-- PAGE_100 -->\n###### (BDI-II) 정보를 수집할 수 있으며, 방문 4는 내원, 애플리케이션,\n\n<!-- PAGE_100 -->\n###### 이메일, 문자, SNS를 이용하여 설문지를 제공한 뒤 회신받는 것으로\n\n<!-- PAGE_100 -->\n###### 방문 1의 설문에서 13점 이하를 기록할 때 연구 대상에서 제외\n\n<!-- PAGE_100 -->\n###### 되게 된다.  방문 3, 4의 설문 점수는 방문 1의 점수와 비교 분석\n\n<!-- PAGE_100 -->\n###### 우울장애 선별 도구(PHQ-9)란 다른 우울장애 평가척도와 유의한\n\n<!-- PAGE_100 -->\n###### 공존 타당도를 나타내고 우울장애를 평가하고 선별하는 척도로서의\n\n<!-- PAGE_100 -->\n###### 신뢰도와 타당도가 입증되었다.  PHQ-9의 경우 기존 우울장애 평가\n\n<!-- PAGE_100 -->\n###### 도구보다 문항 수가 적고 작성 시간이 적게 걸려 일차 진료 과정\n\n<!-- PAGE_100 -->\n###### 현재 BDI에 대한 우울 점수에 따라, 경도 우울(10~14점), 중등도\n\n<!-- PAGE_100 -->\n###### 삶의 질, 우울/불안 관련 증상 유무, 직업적/사회적 기능 상태,\n\n<!-- PAGE_100 -->\n###### 등의 항목에 있어서는 자가 보고 설문 혹은 연구자와 대면 인터뷰를\n\n<!-- PAGE_100 -->\n###### 통해 측정할 수 있다.  자가 보고 설문의 경우 우울장애 심각도\n\n<!-- PAGE_100 -->\n###### 척도(BDI-II)와 동등한 방식으로 측정할 수 있다.  연구자와 대면\n\n- - 94 -\n<!-- PAGE_101 -->\n###### 인터뷰 또한 우울장애 심각도 척도(BDI-II)와 유사한 방식으로 하되,\n\n<!-- PAGE_101 -->\n###### 자가 보고 설문 대신 연구자와의 인터뷰를 통해 진행되는 방식으로\n\n<!-- PAGE_101 -->\n###### 사용자 반응 평가에 대해서는 애플리케이션 사용 후 측정이 진행\n\n<!-- PAGE_101 -->\n###### 되어야 하므로 방문 3, 방문 4에 측정을 수행하여야 한다. ",
        "original_sentence": "방문 3, 4의 설문 점수는 방문 1의 점수와 비교 분석\n\n<!-- PAGE_100 -->\n###### 우울장애 선별 도구(PHQ-9)란 다른 우울장애 평가척도와 유의한\n\n<!-- PAGE_100 -->\n###### 공존 타당도를 나타내고 우울장애를 평가하고 선별하는 척도로서의\n\n<!-- PAGE_100 -->\n###### 신뢰도와 타당도가 입증되었다. "
      }
    },
    {
      "chunk_id": "chunk_771",
      "text": "PHQ-9의 경우 기존 우울장애 평가\n\n<!-- PAGE_100 -->\n###### 도구보다 문항 수가 적고 작성 시간이 적게 걸려 일차 진료 과정\n\n<!-- PAGE_100 -->\n###### 현재 BDI에 대한 우울 점수에 따라, 경도 우울(10~14점), 중등도\n\n<!-- PAGE_100 -->\n###### 삶의 질, 우울/불안 관련 증상 유무, 직업적/사회적 기능 상태,\n\n<!-- PAGE_100 -->\n###### 등의 항목에 있어서는 자가 보고 설문 혹은 연구자와 대면 인터뷰를\n\n<!-- PAGE_100 -->\n###### 통해 측정할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 770,
        "window_size": 3,
        "char_count": 315,
        "word_count": 68,
        "page_number": 100,
        "window_text": "방문 1의 경우 연구자가 직접 피험자와 대면하여 연구에\n\n<!-- PAGE_99 -->\n###### 대한 설명을 수행하고 서면동의를 얻은 뒤, 독립된 방에서 설문지를\n\n<!-- PAGE_99 -->\n###### 제공하고 피험자가 스스로 설문에 답하게 5-10분간의 시간을 제공\n\n- - 93 -\n<!-- PAGE_100 -->\n###### 할 예정이며, 이는 방문 2, 3, 4에서도 동일하게 진행될 예정이다.\n\n <!-- PAGE_100 -->\n###### 다만 방문 2, 3의 경우 애플리케이션을 통해 우울장애 심각도 척도\n\n<!-- PAGE_100 -->\n###### (BDI-II) 정보를 수집할 수 있으며, 방문 4는 내원, 애플리케이션,\n\n<!-- PAGE_100 -->\n###### 이메일, 문자, SNS를 이용하여 설문지를 제공한 뒤 회신받는 것으로\n\n<!-- PAGE_100 -->\n###### 방문 1의 설문에서 13점 이하를 기록할 때 연구 대상에서 제외\n\n<!-- PAGE_100 -->\n###### 되게 된다.  방문 3, 4의 설문 점수는 방문 1의 점수와 비교 분석\n\n<!-- PAGE_100 -->\n###### 우울장애 선별 도구(PHQ-9)란 다른 우울장애 평가척도와 유의한\n\n<!-- PAGE_100 -->\n###### 공존 타당도를 나타내고 우울장애를 평가하고 선별하는 척도로서의\n\n<!-- PAGE_100 -->\n###### 신뢰도와 타당도가 입증되었다.  PHQ-9의 경우 기존 우울장애 평가\n\n<!-- PAGE_100 -->\n###### 도구보다 문항 수가 적고 작성 시간이 적게 걸려 일차 진료 과정\n\n<!-- PAGE_100 -->\n###### 현재 BDI에 대한 우울 점수에 따라, 경도 우울(10~14점), 중등도\n\n<!-- PAGE_100 -->\n###### 삶의 질, 우울/불안 관련 증상 유무, 직업적/사회적 기능 상태,\n\n<!-- PAGE_100 -->\n###### 등의 항목에 있어서는 자가 보고 설문 혹은 연구자와 대면 인터뷰를\n\n<!-- PAGE_100 -->\n###### 통해 측정할 수 있다.  자가 보고 설문의 경우 우울장애 심각도\n\n<!-- PAGE_100 -->\n###### 척도(BDI-II)와 동등한 방식으로 측정할 수 있다.  연구자와 대면\n\n- - 94 -\n<!-- PAGE_101 -->\n###### 인터뷰 또한 우울장애 심각도 척도(BDI-II)와 유사한 방식으로 하되,\n\n<!-- PAGE_101 -->\n###### 자가 보고 설문 대신 연구자와의 인터뷰를 통해 진행되는 방식으로\n\n<!-- PAGE_101 -->\n###### 사용자 반응 평가에 대해서는 애플리케이션 사용 후 측정이 진행\n\n<!-- PAGE_101 -->\n###### 되어야 하므로 방문 3, 방문 4에 측정을 수행하여야 한다.  여기에는\n\n<!-- PAGE_101 -->\n###### 사용자의 순응도, 만족도, 난이도, 개선점 등이 포함되어야 하며\n\n<!-- PAGE_101 -->\n###### 자가 보고 설문 혹은 연구자와 대면 인터뷰를 통해 측정할 수 있다.\n\n",
        "original_sentence": "PHQ-9의 경우 기존 우울장애 평가\n\n<!-- PAGE_100 -->\n###### 도구보다 문항 수가 적고 작성 시간이 적게 걸려 일차 진료 과정\n\n<!-- PAGE_100 -->\n###### 현재 BDI에 대한 우울 점수에 따라, 경도 우울(10~14점), 중등도\n\n<!-- PAGE_100 -->\n###### 삶의 질, 우울/불안 관련 증상 유무, 직업적/사회적 기능 상태,\n\n<!-- PAGE_100 -->\n###### 등의 항목에 있어서는 자가 보고 설문 혹은 연구자와 대면 인터뷰를\n\n<!-- PAGE_100 -->\n###### 통해 측정할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_772",
      "text": "자가 보고 설문의 경우 우울장애 심각도\n\n<!-- PAGE_100 -->\n###### 척도(BDI-II)와 동등한 방식으로 측정할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 771,
        "window_size": 3,
        "char_count": 79,
        "word_count": 16,
        "page_number": 100,
        "window_text": "<!-- PAGE_100 -->\n###### 다만 방문 2, 3의 경우 애플리케이션을 통해 우울장애 심각도 척도\n\n<!-- PAGE_100 -->\n###### (BDI-II) 정보를 수집할 수 있으며, 방문 4는 내원, 애플리케이션,\n\n<!-- PAGE_100 -->\n###### 이메일, 문자, SNS를 이용하여 설문지를 제공한 뒤 회신받는 것으로\n\n<!-- PAGE_100 -->\n###### 방문 1의 설문에서 13점 이하를 기록할 때 연구 대상에서 제외\n\n<!-- PAGE_100 -->\n###### 되게 된다.  방문 3, 4의 설문 점수는 방문 1의 점수와 비교 분석\n\n<!-- PAGE_100 -->\n###### 우울장애 선별 도구(PHQ-9)란 다른 우울장애 평가척도와 유의한\n\n<!-- PAGE_100 -->\n###### 공존 타당도를 나타내고 우울장애를 평가하고 선별하는 척도로서의\n\n<!-- PAGE_100 -->\n###### 신뢰도와 타당도가 입증되었다.  PHQ-9의 경우 기존 우울장애 평가\n\n<!-- PAGE_100 -->\n###### 도구보다 문항 수가 적고 작성 시간이 적게 걸려 일차 진료 과정\n\n<!-- PAGE_100 -->\n###### 현재 BDI에 대한 우울 점수에 따라, 경도 우울(10~14점), 중등도\n\n<!-- PAGE_100 -->\n###### 삶의 질, 우울/불안 관련 증상 유무, 직업적/사회적 기능 상태,\n\n<!-- PAGE_100 -->\n###### 등의 항목에 있어서는 자가 보고 설문 혹은 연구자와 대면 인터뷰를\n\n<!-- PAGE_100 -->\n###### 통해 측정할 수 있다.  자가 보고 설문의 경우 우울장애 심각도\n\n<!-- PAGE_100 -->\n###### 척도(BDI-II)와 동등한 방식으로 측정할 수 있다.  연구자와 대면\n\n- - 94 -\n<!-- PAGE_101 -->\n###### 인터뷰 또한 우울장애 심각도 척도(BDI-II)와 유사한 방식으로 하되,\n\n<!-- PAGE_101 -->\n###### 자가 보고 설문 대신 연구자와의 인터뷰를 통해 진행되는 방식으로\n\n<!-- PAGE_101 -->\n###### 사용자 반응 평가에 대해서는 애플리케이션 사용 후 측정이 진행\n\n<!-- PAGE_101 -->\n###### 되어야 하므로 방문 3, 방문 4에 측정을 수행하여야 한다.  여기에는\n\n<!-- PAGE_101 -->\n###### 사용자의 순응도, 만족도, 난이도, 개선점 등이 포함되어야 하며\n\n<!-- PAGE_101 -->\n###### 자가 보고 설문 혹은 연구자와 대면 인터뷰를 통해 측정할 수 있다.\n\n <!-- PAGE_101 -->\n###### 다. ",
        "original_sentence": "자가 보고 설문의 경우 우울장애 심각도\n\n<!-- PAGE_100 -->\n###### 척도(BDI-II)와 동등한 방식으로 측정할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_773",
      "text": "연구자와 대면\n\n- - 94 -\n<!-- PAGE_101 -->\n###### 인터뷰 또한 우울장애 심각도 척도(BDI-II)와 유사한 방식으로 하되,\n\n<!-- PAGE_101 -->\n###### 자가 보고 설문 대신 연구자와의 인터뷰를 통해 진행되는 방식으로\n\n<!-- PAGE_101 -->\n###### 사용자 반응 평가에 대해서는 애플리케이션 사용 후 측정이 진행\n\n<!-- PAGE_101 -->\n###### 되어야 하므로 방문 3, 방문 4에 측정을 수행하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 772,
        "window_size": 3,
        "char_count": 267,
        "word_count": 57,
        "page_number": 101,
        "window_text": "방문 3, 4의 설문 점수는 방문 1의 점수와 비교 분석\n\n<!-- PAGE_100 -->\n###### 우울장애 선별 도구(PHQ-9)란 다른 우울장애 평가척도와 유의한\n\n<!-- PAGE_100 -->\n###### 공존 타당도를 나타내고 우울장애를 평가하고 선별하는 척도로서의\n\n<!-- PAGE_100 -->\n###### 신뢰도와 타당도가 입증되었다.  PHQ-9의 경우 기존 우울장애 평가\n\n<!-- PAGE_100 -->\n###### 도구보다 문항 수가 적고 작성 시간이 적게 걸려 일차 진료 과정\n\n<!-- PAGE_100 -->\n###### 현재 BDI에 대한 우울 점수에 따라, 경도 우울(10~14점), 중등도\n\n<!-- PAGE_100 -->\n###### 삶의 질, 우울/불안 관련 증상 유무, 직업적/사회적 기능 상태,\n\n<!-- PAGE_100 -->\n###### 등의 항목에 있어서는 자가 보고 설문 혹은 연구자와 대면 인터뷰를\n\n<!-- PAGE_100 -->\n###### 통해 측정할 수 있다.  자가 보고 설문의 경우 우울장애 심각도\n\n<!-- PAGE_100 -->\n###### 척도(BDI-II)와 동등한 방식으로 측정할 수 있다.  연구자와 대면\n\n- - 94 -\n<!-- PAGE_101 -->\n###### 인터뷰 또한 우울장애 심각도 척도(BDI-II)와 유사한 방식으로 하되,\n\n<!-- PAGE_101 -->\n###### 자가 보고 설문 대신 연구자와의 인터뷰를 통해 진행되는 방식으로\n\n<!-- PAGE_101 -->\n###### 사용자 반응 평가에 대해서는 애플리케이션 사용 후 측정이 진행\n\n<!-- PAGE_101 -->\n###### 되어야 하므로 방문 3, 방문 4에 측정을 수행하여야 한다.  여기에는\n\n<!-- PAGE_101 -->\n###### 사용자의 순응도, 만족도, 난이도, 개선점 등이 포함되어야 하며\n\n<!-- PAGE_101 -->\n###### 자가 보고 설문 혹은 연구자와 대면 인터뷰를 통해 측정할 수 있다.\n\n <!-- PAGE_101 -->\n###### 다.  통계분석방법\n\n<!-- PAGE_101 -->\n###### 배정된 대로 분석(Intention-to-treat, ITT) 원칙을 따르며,\n\n<!-- PAGE_101 -->\n###### 무작위배정된 모든 피험자군 중 주요한 선정기준을 위배하거나\n\n<!-- PAGE_101 -->\n###### 무작위배정된 후 우울장애 개선 디지털치료기기를 로그인하여,\n\n<!-- PAGE_101 -->\n###### 한 번이라도 사용한 로그가 존재하지 않거나, 무작위배정 이후\n\n<!-- PAGE_101 -->\n###### 일차 유효성 평가자료가 전혀 없는 경우는 제외한다. ",
        "original_sentence": "연구자와 대면\n\n- - 94 -\n<!-- PAGE_101 -->\n###### 인터뷰 또한 우울장애 심각도 척도(BDI-II)와 유사한 방식으로 하되,\n\n<!-- PAGE_101 -->\n###### 자가 보고 설문 대신 연구자와의 인터뷰를 통해 진행되는 방식으로\n\n<!-- PAGE_101 -->\n###### 사용자 반응 평가에 대해서는 애플리케이션 사용 후 측정이 진행\n\n<!-- PAGE_101 -->\n###### 되어야 하므로 방문 3, 방문 4에 측정을 수행하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_774",
      "text": "여기에는\n\n<!-- PAGE_101 -->\n###### 사용자의 순응도, 만족도, 난이도, 개선점 등이 포함되어야 하며\n\n<!-- PAGE_101 -->\n###### 자가 보고 설문 혹은 연구자와 대면 인터뷰를 통해 측정할 수 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 773,
        "window_size": 3,
        "char_count": 132,
        "word_count": 28,
        "page_number": 101,
        "window_text": "PHQ-9의 경우 기존 우울장애 평가\n\n<!-- PAGE_100 -->\n###### 도구보다 문항 수가 적고 작성 시간이 적게 걸려 일차 진료 과정\n\n<!-- PAGE_100 -->\n###### 현재 BDI에 대한 우울 점수에 따라, 경도 우울(10~14점), 중등도\n\n<!-- PAGE_100 -->\n###### 삶의 질, 우울/불안 관련 증상 유무, 직업적/사회적 기능 상태,\n\n<!-- PAGE_100 -->\n###### 등의 항목에 있어서는 자가 보고 설문 혹은 연구자와 대면 인터뷰를\n\n<!-- PAGE_100 -->\n###### 통해 측정할 수 있다.  자가 보고 설문의 경우 우울장애 심각도\n\n<!-- PAGE_100 -->\n###### 척도(BDI-II)와 동등한 방식으로 측정할 수 있다.  연구자와 대면\n\n- - 94 -\n<!-- PAGE_101 -->\n###### 인터뷰 또한 우울장애 심각도 척도(BDI-II)와 유사한 방식으로 하되,\n\n<!-- PAGE_101 -->\n###### 자가 보고 설문 대신 연구자와의 인터뷰를 통해 진행되는 방식으로\n\n<!-- PAGE_101 -->\n###### 사용자 반응 평가에 대해서는 애플리케이션 사용 후 측정이 진행\n\n<!-- PAGE_101 -->\n###### 되어야 하므로 방문 3, 방문 4에 측정을 수행하여야 한다.  여기에는\n\n<!-- PAGE_101 -->\n###### 사용자의 순응도, 만족도, 난이도, 개선점 등이 포함되어야 하며\n\n<!-- PAGE_101 -->\n###### 자가 보고 설문 혹은 연구자와 대면 인터뷰를 통해 측정할 수 있다.\n\n <!-- PAGE_101 -->\n###### 다.  통계분석방법\n\n<!-- PAGE_101 -->\n###### 배정된 대로 분석(Intention-to-treat, ITT) 원칙을 따르며,\n\n<!-- PAGE_101 -->\n###### 무작위배정된 모든 피험자군 중 주요한 선정기준을 위배하거나\n\n<!-- PAGE_101 -->\n###### 무작위배정된 후 우울장애 개선 디지털치료기기를 로그인하여,\n\n<!-- PAGE_101 -->\n###### 한 번이라도 사용한 로그가 존재하지 않거나, 무작위배정 이후\n\n<!-- PAGE_101 -->\n###### 일차 유효성 평가자료가 전혀 없는 경우는 제외한다.  1차/2차\n\n<!-- PAGE_101 -->\n###### 유효성 평가는 모든 분석 대상자군(Full Analysis Set, FAS)를\n\n<!-- PAGE_101 -->\n###### 모든 분석 대상자군(FAS)에 속한 피험자이면서 임상시험 일정\n\n<!-- PAGE_101 -->\n###### 대로 모든 수행을 완료하고, 아래의 주요한 임상시험계획 위반이\n\n<!-- PAGE_101 -->\n###### 없는 피험자로 정의한다. ",
        "original_sentence": "여기에는\n\n<!-- PAGE_101 -->\n###### 사용자의 순응도, 만족도, 난이도, 개선점 등이 포함되어야 하며\n\n<!-- PAGE_101 -->\n###### 자가 보고 설문 혹은 연구자와 대면 인터뷰를 통해 측정할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_775",
      "text": "<!-- PAGE_101 -->\n###### 다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 774,
        "window_size": 3,
        "char_count": 28,
        "word_count": 5,
        "page_number": 101,
        "window_text": "자가 보고 설문의 경우 우울장애 심각도\n\n<!-- PAGE_100 -->\n###### 척도(BDI-II)와 동등한 방식으로 측정할 수 있다.  연구자와 대면\n\n- - 94 -\n<!-- PAGE_101 -->\n###### 인터뷰 또한 우울장애 심각도 척도(BDI-II)와 유사한 방식으로 하되,\n\n<!-- PAGE_101 -->\n###### 자가 보고 설문 대신 연구자와의 인터뷰를 통해 진행되는 방식으로\n\n<!-- PAGE_101 -->\n###### 사용자 반응 평가에 대해서는 애플리케이션 사용 후 측정이 진행\n\n<!-- PAGE_101 -->\n###### 되어야 하므로 방문 3, 방문 4에 측정을 수행하여야 한다.  여기에는\n\n<!-- PAGE_101 -->\n###### 사용자의 순응도, 만족도, 난이도, 개선점 등이 포함되어야 하며\n\n<!-- PAGE_101 -->\n###### 자가 보고 설문 혹은 연구자와 대면 인터뷰를 통해 측정할 수 있다.\n\n <!-- PAGE_101 -->\n###### 다.  통계분석방법\n\n<!-- PAGE_101 -->\n###### 배정된 대로 분석(Intention-to-treat, ITT) 원칙을 따르며,\n\n<!-- PAGE_101 -->\n###### 무작위배정된 모든 피험자군 중 주요한 선정기준을 위배하거나\n\n<!-- PAGE_101 -->\n###### 무작위배정된 후 우울장애 개선 디지털치료기기를 로그인하여,\n\n<!-- PAGE_101 -->\n###### 한 번이라도 사용한 로그가 존재하지 않거나, 무작위배정 이후\n\n<!-- PAGE_101 -->\n###### 일차 유효성 평가자료가 전혀 없는 경우는 제외한다.  1차/2차\n\n<!-- PAGE_101 -->\n###### 유효성 평가는 모든 분석 대상자군(Full Analysis Set, FAS)를\n\n<!-- PAGE_101 -->\n###### 모든 분석 대상자군(FAS)에 속한 피험자이면서 임상시험 일정\n\n<!-- PAGE_101 -->\n###### 대로 모든 수행을 완료하고, 아래의 주요한 임상시험계획 위반이\n\n<!-- PAGE_101 -->\n###### 없는 피험자로 정의한다.  1차/2차 유효성 평가는 계획서 순응\n\n- - 95 -\n<!-- PAGE_102 -->\n###### 임상시험대상자군(PPS)를 보조분석군으로 분석한다.\n\n",
        "original_sentence": "<!-- PAGE_101 -->\n###### 다. "
      }
    },
    {
      "chunk_id": "chunk_776",
      "text": "통계분석방법\n\n<!-- PAGE_101 -->\n###### 배정된 대로 분석(Intention-to-treat, ITT) 원칙을 따르며,\n\n<!-- PAGE_101 -->\n###### 무작위배정된 모든 피험자군 중 주요한 선정기준을 위배하거나\n\n<!-- PAGE_101 -->\n###### 무작위배정된 후 우울장애 개선 디지털치료기기를 로그인하여,\n\n<!-- PAGE_101 -->\n###### 한 번이라도 사용한 로그가 존재하지 않거나, 무작위배정 이후\n\n<!-- PAGE_101 -->\n###### 일차 유효성 평가자료가 전혀 없는 경우는 제외한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 775,
        "window_size": 3,
        "char_count": 310,
        "word_count": 55,
        "page_number": 101,
        "window_text": "연구자와 대면\n\n- - 94 -\n<!-- PAGE_101 -->\n###### 인터뷰 또한 우울장애 심각도 척도(BDI-II)와 유사한 방식으로 하되,\n\n<!-- PAGE_101 -->\n###### 자가 보고 설문 대신 연구자와의 인터뷰를 통해 진행되는 방식으로\n\n<!-- PAGE_101 -->\n###### 사용자 반응 평가에 대해서는 애플리케이션 사용 후 측정이 진행\n\n<!-- PAGE_101 -->\n###### 되어야 하므로 방문 3, 방문 4에 측정을 수행하여야 한다.  여기에는\n\n<!-- PAGE_101 -->\n###### 사용자의 순응도, 만족도, 난이도, 개선점 등이 포함되어야 하며\n\n<!-- PAGE_101 -->\n###### 자가 보고 설문 혹은 연구자와 대면 인터뷰를 통해 측정할 수 있다.\n\n <!-- PAGE_101 -->\n###### 다.  통계분석방법\n\n<!-- PAGE_101 -->\n###### 배정된 대로 분석(Intention-to-treat, ITT) 원칙을 따르며,\n\n<!-- PAGE_101 -->\n###### 무작위배정된 모든 피험자군 중 주요한 선정기준을 위배하거나\n\n<!-- PAGE_101 -->\n###### 무작위배정된 후 우울장애 개선 디지털치료기기를 로그인하여,\n\n<!-- PAGE_101 -->\n###### 한 번이라도 사용한 로그가 존재하지 않거나, 무작위배정 이후\n\n<!-- PAGE_101 -->\n###### 일차 유효성 평가자료가 전혀 없는 경우는 제외한다.  1차/2차\n\n<!-- PAGE_101 -->\n###### 유효성 평가는 모든 분석 대상자군(Full Analysis Set, FAS)를\n\n<!-- PAGE_101 -->\n###### 모든 분석 대상자군(FAS)에 속한 피험자이면서 임상시험 일정\n\n<!-- PAGE_101 -->\n###### 대로 모든 수행을 완료하고, 아래의 주요한 임상시험계획 위반이\n\n<!-- PAGE_101 -->\n###### 없는 피험자로 정의한다.  1차/2차 유효성 평가는 계획서 순응\n\n- - 95 -\n<!-- PAGE_102 -->\n###### 임상시험대상자군(PPS)를 보조분석군으로 분석한다.\n\n <!-- PAGE_102 -->\n###### (1) 임상시험 불순응*으로 판단되는 경우\n\n<!-- PAGE_102 -->\n###### (4) 임상시험 참여 중 심적/신체적 환경 변화로 있는 것으로\n\n<!-- PAGE_102 -->\n###### * 순응도란 어플리케이션 치료 기간 내 총 노출된 모듈 횟수를 통해\n\n<!-- PAGE_102 -->\n###### 평가한다. ",
        "original_sentence": "통계분석방법\n\n<!-- PAGE_101 -->\n###### 배정된 대로 분석(Intention-to-treat, ITT) 원칙을 따르며,\n\n<!-- PAGE_101 -->\n###### 무작위배정된 모든 피험자군 중 주요한 선정기준을 위배하거나\n\n<!-- PAGE_101 -->\n###### 무작위배정된 후 우울장애 개선 디지털치료기기를 로그인하여,\n\n<!-- PAGE_101 -->\n###### 한 번이라도 사용한 로그가 존재하지 않거나, 무작위배정 이후\n\n<!-- PAGE_101 -->\n###### 일차 유효성 평가자료가 전혀 없는 경우는 제외한다. "
      }
    },
    {
      "chunk_id": "chunk_777",
      "text": "1차/2차\n\n<!-- PAGE_101 -->\n###### 유효성 평가는 모든 분석 대상자군(Full Analysis Set, FAS)를\n\n<!-- PAGE_101 -->\n###### 모든 분석 대상자군(FAS)에 속한 피험자이면서 임상시험 일정\n\n<!-- PAGE_101 -->\n###### 대로 모든 수행을 완료하고, 아래의 주요한 임상시험계획 위반이\n\n<!-- PAGE_101 -->\n###### 없는 피험자로 정의한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 776,
        "window_size": 3,
        "char_count": 238,
        "word_count": 43,
        "page_number": 101,
        "window_text": "여기에는\n\n<!-- PAGE_101 -->\n###### 사용자의 순응도, 만족도, 난이도, 개선점 등이 포함되어야 하며\n\n<!-- PAGE_101 -->\n###### 자가 보고 설문 혹은 연구자와 대면 인터뷰를 통해 측정할 수 있다.\n\n <!-- PAGE_101 -->\n###### 다.  통계분석방법\n\n<!-- PAGE_101 -->\n###### 배정된 대로 분석(Intention-to-treat, ITT) 원칙을 따르며,\n\n<!-- PAGE_101 -->\n###### 무작위배정된 모든 피험자군 중 주요한 선정기준을 위배하거나\n\n<!-- PAGE_101 -->\n###### 무작위배정된 후 우울장애 개선 디지털치료기기를 로그인하여,\n\n<!-- PAGE_101 -->\n###### 한 번이라도 사용한 로그가 존재하지 않거나, 무작위배정 이후\n\n<!-- PAGE_101 -->\n###### 일차 유효성 평가자료가 전혀 없는 경우는 제외한다.  1차/2차\n\n<!-- PAGE_101 -->\n###### 유효성 평가는 모든 분석 대상자군(Full Analysis Set, FAS)를\n\n<!-- PAGE_101 -->\n###### 모든 분석 대상자군(FAS)에 속한 피험자이면서 임상시험 일정\n\n<!-- PAGE_101 -->\n###### 대로 모든 수행을 완료하고, 아래의 주요한 임상시험계획 위반이\n\n<!-- PAGE_101 -->\n###### 없는 피험자로 정의한다.  1차/2차 유효성 평가는 계획서 순응\n\n- - 95 -\n<!-- PAGE_102 -->\n###### 임상시험대상자군(PPS)를 보조분석군으로 분석한다.\n\n <!-- PAGE_102 -->\n###### (1) 임상시험 불순응*으로 판단되는 경우\n\n<!-- PAGE_102 -->\n###### (4) 임상시험 참여 중 심적/신체적 환경 변화로 있는 것으로\n\n<!-- PAGE_102 -->\n###### * 순응도란 어플리케이션 치료 기간 내 총 노출된 모듈 횟수를 통해\n\n<!-- PAGE_102 -->\n###### 평가한다.  총 모듈 횟수 중 75% 미만(예, 총 12주의 경우 9주 미만)\n\n<!-- PAGE_102 -->\n###### 우울장애 개선 디지털치료기기로 한 번이라도 치료를 받은\n\n<!-- PAGE_102 -->\n###### 모든 피험자로 정의한다. ",
        "original_sentence": "1차/2차\n\n<!-- PAGE_101 -->\n###### 유효성 평가는 모든 분석 대상자군(Full Analysis Set, FAS)를\n\n<!-- PAGE_101 -->\n###### 모든 분석 대상자군(FAS)에 속한 피험자이면서 임상시험 일정\n\n<!-- PAGE_101 -->\n###### 대로 모든 수행을 완료하고, 아래의 주요한 임상시험계획 위반이\n\n<!-- PAGE_101 -->\n###### 없는 피험자로 정의한다. "
      }
    },
    {
      "chunk_id": "chunk_778",
      "text": "1차/2차 유효성 평가는 계획서 순응\n\n- - 95 -\n<!-- PAGE_102 -->\n###### 임상시험대상자군(PPS)를 보조분석군으로 분석한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 777,
        "window_size": 3,
        "char_count": 86,
        "word_count": 16,
        "page_number": 102,
        "window_text": "<!-- PAGE_101 -->\n###### 다.  통계분석방법\n\n<!-- PAGE_101 -->\n###### 배정된 대로 분석(Intention-to-treat, ITT) 원칙을 따르며,\n\n<!-- PAGE_101 -->\n###### 무작위배정된 모든 피험자군 중 주요한 선정기준을 위배하거나\n\n<!-- PAGE_101 -->\n###### 무작위배정된 후 우울장애 개선 디지털치료기기를 로그인하여,\n\n<!-- PAGE_101 -->\n###### 한 번이라도 사용한 로그가 존재하지 않거나, 무작위배정 이후\n\n<!-- PAGE_101 -->\n###### 일차 유효성 평가자료가 전혀 없는 경우는 제외한다.  1차/2차\n\n<!-- PAGE_101 -->\n###### 유효성 평가는 모든 분석 대상자군(Full Analysis Set, FAS)를\n\n<!-- PAGE_101 -->\n###### 모든 분석 대상자군(FAS)에 속한 피험자이면서 임상시험 일정\n\n<!-- PAGE_101 -->\n###### 대로 모든 수행을 완료하고, 아래의 주요한 임상시험계획 위반이\n\n<!-- PAGE_101 -->\n###### 없는 피험자로 정의한다.  1차/2차 유효성 평가는 계획서 순응\n\n- - 95 -\n<!-- PAGE_102 -->\n###### 임상시험대상자군(PPS)를 보조분석군으로 분석한다.\n\n <!-- PAGE_102 -->\n###### (1) 임상시험 불순응*으로 판단되는 경우\n\n<!-- PAGE_102 -->\n###### (4) 임상시험 참여 중 심적/신체적 환경 변화로 있는 것으로\n\n<!-- PAGE_102 -->\n###### * 순응도란 어플리케이션 치료 기간 내 총 노출된 모듈 횟수를 통해\n\n<!-- PAGE_102 -->\n###### 평가한다.  총 모듈 횟수 중 75% 미만(예, 총 12주의 경우 9주 미만)\n\n<!-- PAGE_102 -->\n###### 우울장애 개선 디지털치료기기로 한 번이라도 치료를 받은\n\n<!-- PAGE_102 -->\n###### 모든 피험자로 정의한다.  안전성 평가는 안전성 자료를 대상\n\n<!-- PAGE_102 -->\n###### - 치료 전 대비 Post-treatment 후 우울장애 심각도 척도(BDI)\n\n<!-- PAGE_102 -->\n###### : 각 시점에서의 우울장애 심각도 척도(BDI) 총점수와 Post-\n\n<!-- PAGE_102 -->\n###### : Post-treatment 후 변화량의 군간 차이 검정은 기저치를 공\n\n<!-- PAGE_102 -->\n###### 변량으로 한 공분산분석(ANCOVA)을 적용한다. ",
        "original_sentence": "1차/2차 유효성 평가는 계획서 순응\n\n- - 95 -\n<!-- PAGE_102 -->\n###### 임상시험대상자군(PPS)를 보조분석군으로 분석한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_779",
      "text": "<!-- PAGE_102 -->\n###### (1) 임상시험 불순응*으로 판단되는 경우\n\n<!-- PAGE_102 -->\n###### (4) 임상시험 참여 중 심적/신체적 환경 변화로 있는 것으로\n\n<!-- PAGE_102 -->\n###### * 순응도란 어플리케이션 치료 기간 내 총 노출된 모듈 횟수를 통해\n\n<!-- PAGE_102 -->\n###### 평가한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 778,
        "window_size": 3,
        "char_count": 206,
        "word_count": 42,
        "page_number": 102,
        "window_text": "통계분석방법\n\n<!-- PAGE_101 -->\n###### 배정된 대로 분석(Intention-to-treat, ITT) 원칙을 따르며,\n\n<!-- PAGE_101 -->\n###### 무작위배정된 모든 피험자군 중 주요한 선정기준을 위배하거나\n\n<!-- PAGE_101 -->\n###### 무작위배정된 후 우울장애 개선 디지털치료기기를 로그인하여,\n\n<!-- PAGE_101 -->\n###### 한 번이라도 사용한 로그가 존재하지 않거나, 무작위배정 이후\n\n<!-- PAGE_101 -->\n###### 일차 유효성 평가자료가 전혀 없는 경우는 제외한다.  1차/2차\n\n<!-- PAGE_101 -->\n###### 유효성 평가는 모든 분석 대상자군(Full Analysis Set, FAS)를\n\n<!-- PAGE_101 -->\n###### 모든 분석 대상자군(FAS)에 속한 피험자이면서 임상시험 일정\n\n<!-- PAGE_101 -->\n###### 대로 모든 수행을 완료하고, 아래의 주요한 임상시험계획 위반이\n\n<!-- PAGE_101 -->\n###### 없는 피험자로 정의한다.  1차/2차 유효성 평가는 계획서 순응\n\n- - 95 -\n<!-- PAGE_102 -->\n###### 임상시험대상자군(PPS)를 보조분석군으로 분석한다.\n\n <!-- PAGE_102 -->\n###### (1) 임상시험 불순응*으로 판단되는 경우\n\n<!-- PAGE_102 -->\n###### (4) 임상시험 참여 중 심적/신체적 환경 변화로 있는 것으로\n\n<!-- PAGE_102 -->\n###### * 순응도란 어플리케이션 치료 기간 내 총 노출된 모듈 횟수를 통해\n\n<!-- PAGE_102 -->\n###### 평가한다.  총 모듈 횟수 중 75% 미만(예, 총 12주의 경우 9주 미만)\n\n<!-- PAGE_102 -->\n###### 우울장애 개선 디지털치료기기로 한 번이라도 치료를 받은\n\n<!-- PAGE_102 -->\n###### 모든 피험자로 정의한다.  안전성 평가는 안전성 자료를 대상\n\n<!-- PAGE_102 -->\n###### - 치료 전 대비 Post-treatment 후 우울장애 심각도 척도(BDI)\n\n<!-- PAGE_102 -->\n###### : 각 시점에서의 우울장애 심각도 척도(BDI) 총점수와 Post-\n\n<!-- PAGE_102 -->\n###### : Post-treatment 후 변화량의 군간 차이 검정은 기저치를 공\n\n<!-- PAGE_102 -->\n###### 변량으로 한 공분산분석(ANCOVA)을 적용한다.  P-value와\n\n<!-- PAGE_102 -->\n###### 함께 양측 95% 신뢰구간을 제시한다. ",
        "original_sentence": "<!-- PAGE_102 -->\n###### (1) 임상시험 불순응*으로 판단되는 경우\n\n<!-- PAGE_102 -->\n###### (4) 임상시험 참여 중 심적/신체적 환경 변화로 있는 것으로\n\n<!-- PAGE_102 -->\n###### * 순응도란 어플리케이션 치료 기간 내 총 노출된 모듈 횟수를 통해\n\n<!-- PAGE_102 -->\n###### 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_780",
      "text": "총 모듈 횟수 중 75% 미만(예, 총 12주의 경우 9주 미만)\n\n<!-- PAGE_102 -->\n###### 우울장애 개선 디지털치료기기로 한 번이라도 치료를 받은\n\n<!-- PAGE_102 -->\n###### 모든 피험자로 정의한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 779,
        "window_size": 3,
        "char_count": 134,
        "word_count": 29,
        "page_number": 102,
        "window_text": "1차/2차\n\n<!-- PAGE_101 -->\n###### 유효성 평가는 모든 분석 대상자군(Full Analysis Set, FAS)를\n\n<!-- PAGE_101 -->\n###### 모든 분석 대상자군(FAS)에 속한 피험자이면서 임상시험 일정\n\n<!-- PAGE_101 -->\n###### 대로 모든 수행을 완료하고, 아래의 주요한 임상시험계획 위반이\n\n<!-- PAGE_101 -->\n###### 없는 피험자로 정의한다.  1차/2차 유효성 평가는 계획서 순응\n\n- - 95 -\n<!-- PAGE_102 -->\n###### 임상시험대상자군(PPS)를 보조분석군으로 분석한다.\n\n <!-- PAGE_102 -->\n###### (1) 임상시험 불순응*으로 판단되는 경우\n\n<!-- PAGE_102 -->\n###### (4) 임상시험 참여 중 심적/신체적 환경 변화로 있는 것으로\n\n<!-- PAGE_102 -->\n###### * 순응도란 어플리케이션 치료 기간 내 총 노출된 모듈 횟수를 통해\n\n<!-- PAGE_102 -->\n###### 평가한다.  총 모듈 횟수 중 75% 미만(예, 총 12주의 경우 9주 미만)\n\n<!-- PAGE_102 -->\n###### 우울장애 개선 디지털치료기기로 한 번이라도 치료를 받은\n\n<!-- PAGE_102 -->\n###### 모든 피험자로 정의한다.  안전성 평가는 안전성 자료를 대상\n\n<!-- PAGE_102 -->\n###### - 치료 전 대비 Post-treatment 후 우울장애 심각도 척도(BDI)\n\n<!-- PAGE_102 -->\n###### : 각 시점에서의 우울장애 심각도 척도(BDI) 총점수와 Post-\n\n<!-- PAGE_102 -->\n###### : Post-treatment 후 변화량의 군간 차이 검정은 기저치를 공\n\n<!-- PAGE_102 -->\n###### 변량으로 한 공분산분석(ANCOVA)을 적용한다.  P-value와\n\n<!-- PAGE_102 -->\n###### 함께 양측 95% 신뢰구간을 제시한다.  대조군 대비 시험군의\n\n<!-- PAGE_102 -->\n###### 평균 변화량이 우월한 방향에 있고 P-value가 유의수준\n\n- - 96 -\n<!-- PAGE_103 -->\n###### 0.05에서 작으면 통계적으로 우월하다고 판단한다. ",
        "original_sentence": "총 모듈 횟수 중 75% 미만(예, 총 12주의 경우 9주 미만)\n\n<!-- PAGE_102 -->\n###### 우울장애 개선 디지털치료기기로 한 번이라도 치료를 받은\n\n<!-- PAGE_102 -->\n###### 모든 피험자로 정의한다. "
      }
    },
    {
      "chunk_id": "chunk_781",
      "text": "안전성 평가는 안전성 자료를 대상\n\n<!-- PAGE_102 -->\n###### - 치료 전 대비 Post-treatment 후 우울장애 심각도 척도(BDI)\n\n<!-- PAGE_102 -->\n###### : 각 시점에서의 우울장애 심각도 척도(BDI) 총점수와 Post-\n\n<!-- PAGE_102 -->\n###### : Post-treatment 후 변화량의 군간 차이 검정은 기저치를 공\n\n<!-- PAGE_102 -->\n###### 변량으로 한 공분산분석(ANCOVA)을 적용한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 780,
        "window_size": 3,
        "char_count": 274,
        "word_count": 51,
        "page_number": 102,
        "window_text": "1차/2차 유효성 평가는 계획서 순응\n\n- - 95 -\n<!-- PAGE_102 -->\n###### 임상시험대상자군(PPS)를 보조분석군으로 분석한다.\n\n <!-- PAGE_102 -->\n###### (1) 임상시험 불순응*으로 판단되는 경우\n\n<!-- PAGE_102 -->\n###### (4) 임상시험 참여 중 심적/신체적 환경 변화로 있는 것으로\n\n<!-- PAGE_102 -->\n###### * 순응도란 어플리케이션 치료 기간 내 총 노출된 모듈 횟수를 통해\n\n<!-- PAGE_102 -->\n###### 평가한다.  총 모듈 횟수 중 75% 미만(예, 총 12주의 경우 9주 미만)\n\n<!-- PAGE_102 -->\n###### 우울장애 개선 디지털치료기기로 한 번이라도 치료를 받은\n\n<!-- PAGE_102 -->\n###### 모든 피험자로 정의한다.  안전성 평가는 안전성 자료를 대상\n\n<!-- PAGE_102 -->\n###### - 치료 전 대비 Post-treatment 후 우울장애 심각도 척도(BDI)\n\n<!-- PAGE_102 -->\n###### : 각 시점에서의 우울장애 심각도 척도(BDI) 총점수와 Post-\n\n<!-- PAGE_102 -->\n###### : Post-treatment 후 변화량의 군간 차이 검정은 기저치를 공\n\n<!-- PAGE_102 -->\n###### 변량으로 한 공분산분석(ANCOVA)을 적용한다.  P-value와\n\n<!-- PAGE_102 -->\n###### 함께 양측 95% 신뢰구간을 제시한다.  대조군 대비 시험군의\n\n<!-- PAGE_102 -->\n###### 평균 변화량이 우월한 방향에 있고 P-value가 유의수준\n\n- - 96 -\n<!-- PAGE_103 -->\n###### 0.05에서 작으면 통계적으로 우월하다고 판단한다.  또한,\n\n<!-- PAGE_103 -->\n###### 결과에 대한 임상적 평가를 제시한다.\n\n",
        "original_sentence": "안전성 평가는 안전성 자료를 대상\n\n<!-- PAGE_102 -->\n###### - 치료 전 대비 Post-treatment 후 우울장애 심각도 척도(BDI)\n\n<!-- PAGE_102 -->\n###### : 각 시점에서의 우울장애 심각도 척도(BDI) 총점수와 Post-\n\n<!-- PAGE_102 -->\n###### : Post-treatment 후 변화량의 군간 차이 검정은 기저치를 공\n\n<!-- PAGE_102 -->\n###### 변량으로 한 공분산분석(ANCOVA)을 적용한다. "
      }
    },
    {
      "chunk_id": "chunk_782",
      "text": "P-value와\n\n<!-- PAGE_102 -->\n###### 함께 양측 95% 신뢰구간을 제시한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 781,
        "window_size": 3,
        "char_count": 57,
        "word_count": 10,
        "page_number": 102,
        "window_text": "<!-- PAGE_102 -->\n###### (1) 임상시험 불순응*으로 판단되는 경우\n\n<!-- PAGE_102 -->\n###### (4) 임상시험 참여 중 심적/신체적 환경 변화로 있는 것으로\n\n<!-- PAGE_102 -->\n###### * 순응도란 어플리케이션 치료 기간 내 총 노출된 모듈 횟수를 통해\n\n<!-- PAGE_102 -->\n###### 평가한다.  총 모듈 횟수 중 75% 미만(예, 총 12주의 경우 9주 미만)\n\n<!-- PAGE_102 -->\n###### 우울장애 개선 디지털치료기기로 한 번이라도 치료를 받은\n\n<!-- PAGE_102 -->\n###### 모든 피험자로 정의한다.  안전성 평가는 안전성 자료를 대상\n\n<!-- PAGE_102 -->\n###### - 치료 전 대비 Post-treatment 후 우울장애 심각도 척도(BDI)\n\n<!-- PAGE_102 -->\n###### : 각 시점에서의 우울장애 심각도 척도(BDI) 총점수와 Post-\n\n<!-- PAGE_102 -->\n###### : Post-treatment 후 변화량의 군간 차이 검정은 기저치를 공\n\n<!-- PAGE_102 -->\n###### 변량으로 한 공분산분석(ANCOVA)을 적용한다.  P-value와\n\n<!-- PAGE_102 -->\n###### 함께 양측 95% 신뢰구간을 제시한다.  대조군 대비 시험군의\n\n<!-- PAGE_102 -->\n###### 평균 변화량이 우월한 방향에 있고 P-value가 유의수준\n\n- - 96 -\n<!-- PAGE_103 -->\n###### 0.05에서 작으면 통계적으로 우월하다고 판단한다.  또한,\n\n<!-- PAGE_103 -->\n###### 결과에 대한 임상적 평가를 제시한다.\n\n <!-- PAGE_103 -->\n###### - 치료 전 대비 3개월 후 우울장애 심각도 척도(BDI), 8주 후\n\n<!-- PAGE_103 -->\n###### : 각 유효성 평가변수의 각 시점의 변화량에 대해 기저치, 성,\n\n<!-- PAGE_103 -->\n###### 연령을 포함한 공분산분석을 적용하여 다른 변수를 통제한\n\n<!-- PAGE_103 -->\n###### 후 배정군간 평균 변화량 차이가 있는지 양측 유의수준 0.05\n\n<!-- PAGE_103 -->\n###### : 치료 전 대비 치료 후 각 시점에서 군간 관해율 및 반응율\n\n<!-- PAGE_103 -->\n###### 차이는 카이제곱검정(Chi-square test) 혹은 피셔정확검정\n\n<!-- PAGE_103 -->\n###### (Fisher’s exact test; 전체 셀의 20% 이상에서 기대빈도 5\n\n<!-- PAGE_103 -->\n###### 미만인 경우)을 통해 양측 유의수준 0.05에서 통계적 우월성을\n\n<!-- PAGE_103 -->\n###### : 각 시점에서 군간 답변 차이는 카이제곱검정 혹은 피셔정확\n\n<!-- PAGE_103 -->\n###### : 각 시점에서 군간 응답 빈도와 비율을 제시하고 필요 시 카이\n\n- - 97 -\n<!-- PAGE_104 -->\n###### 제곱검정 혹은 피셔정확검정을 통해 유의수준 0.05에서 통계적\n\n<!-- PAGE_104 -->\n###### 평가를 수행한다.\n\n",
        "original_sentence": "P-value와\n\n<!-- PAGE_102 -->\n###### 함께 양측 95% 신뢰구간을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_783",
      "text": "대조군 대비 시험군의\n\n<!-- PAGE_102 -->\n###### 평균 변화량이 우월한 방향에 있고 P-value가 유의수준\n\n- - 96 -\n<!-- PAGE_103 -->\n###### 0.05에서 작으면 통계적으로 우월하다고 판단한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 782,
        "window_size": 3,
        "char_count": 135,
        "word_count": 27,
        "page_number": 102,
        "window_text": "총 모듈 횟수 중 75% 미만(예, 총 12주의 경우 9주 미만)\n\n<!-- PAGE_102 -->\n###### 우울장애 개선 디지털치료기기로 한 번이라도 치료를 받은\n\n<!-- PAGE_102 -->\n###### 모든 피험자로 정의한다.  안전성 평가는 안전성 자료를 대상\n\n<!-- PAGE_102 -->\n###### - 치료 전 대비 Post-treatment 후 우울장애 심각도 척도(BDI)\n\n<!-- PAGE_102 -->\n###### : 각 시점에서의 우울장애 심각도 척도(BDI) 총점수와 Post-\n\n<!-- PAGE_102 -->\n###### : Post-treatment 후 변화량의 군간 차이 검정은 기저치를 공\n\n<!-- PAGE_102 -->\n###### 변량으로 한 공분산분석(ANCOVA)을 적용한다.  P-value와\n\n<!-- PAGE_102 -->\n###### 함께 양측 95% 신뢰구간을 제시한다.  대조군 대비 시험군의\n\n<!-- PAGE_102 -->\n###### 평균 변화량이 우월한 방향에 있고 P-value가 유의수준\n\n- - 96 -\n<!-- PAGE_103 -->\n###### 0.05에서 작으면 통계적으로 우월하다고 판단한다.  또한,\n\n<!-- PAGE_103 -->\n###### 결과에 대한 임상적 평가를 제시한다.\n\n <!-- PAGE_103 -->\n###### - 치료 전 대비 3개월 후 우울장애 심각도 척도(BDI), 8주 후\n\n<!-- PAGE_103 -->\n###### : 각 유효성 평가변수의 각 시점의 변화량에 대해 기저치, 성,\n\n<!-- PAGE_103 -->\n###### 연령을 포함한 공분산분석을 적용하여 다른 변수를 통제한\n\n<!-- PAGE_103 -->\n###### 후 배정군간 평균 변화량 차이가 있는지 양측 유의수준 0.05\n\n<!-- PAGE_103 -->\n###### : 치료 전 대비 치료 후 각 시점에서 군간 관해율 및 반응율\n\n<!-- PAGE_103 -->\n###### 차이는 카이제곱검정(Chi-square test) 혹은 피셔정확검정\n\n<!-- PAGE_103 -->\n###### (Fisher’s exact test; 전체 셀의 20% 이상에서 기대빈도 5\n\n<!-- PAGE_103 -->\n###### 미만인 경우)을 통해 양측 유의수준 0.05에서 통계적 우월성을\n\n<!-- PAGE_103 -->\n###### : 각 시점에서 군간 답변 차이는 카이제곱검정 혹은 피셔정확\n\n<!-- PAGE_103 -->\n###### : 각 시점에서 군간 응답 빈도와 비율을 제시하고 필요 시 카이\n\n- - 97 -\n<!-- PAGE_104 -->\n###### 제곱검정 혹은 피셔정확검정을 통해 유의수준 0.05에서 통계적\n\n<!-- PAGE_104 -->\n###### 평가를 수행한다.\n\n <!-- PAGE_104 -->\n###### - 모든 분석 대상자군(Full Analysis Set, FAS)에서 중도 탈락 등의\n\n<!-- PAGE_104 -->\n###### 사유로 치료 후 시점에서 발생하는 결측치는 일차/이차 유효성\n\n<!-- PAGE_104 -->\n###### 평가변수에 대해서는 마지막 관측값 선행 대체법(Last Observation\n\n<!-- PAGE_104 -->\n###### Carried Forward, LOCF) 방법으로 대치한다. ",
        "original_sentence": "대조군 대비 시험군의\n\n<!-- PAGE_102 -->\n###### 평균 변화량이 우월한 방향에 있고 P-value가 유의수준\n\n- - 96 -\n<!-- PAGE_103 -->\n###### 0.05에서 작으면 통계적으로 우월하다고 판단한다. "
      }
    },
    {
      "chunk_id": "chunk_784",
      "text": "또한,\n\n<!-- PAGE_103 -->\n###### 결과에 대한 임상적 평가를 제시한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 783,
        "window_size": 3,
        "char_count": 52,
        "word_count": 10,
        "page_number": 103,
        "window_text": "안전성 평가는 안전성 자료를 대상\n\n<!-- PAGE_102 -->\n###### - 치료 전 대비 Post-treatment 후 우울장애 심각도 척도(BDI)\n\n<!-- PAGE_102 -->\n###### : 각 시점에서의 우울장애 심각도 척도(BDI) 총점수와 Post-\n\n<!-- PAGE_102 -->\n###### : Post-treatment 후 변화량의 군간 차이 검정은 기저치를 공\n\n<!-- PAGE_102 -->\n###### 변량으로 한 공분산분석(ANCOVA)을 적용한다.  P-value와\n\n<!-- PAGE_102 -->\n###### 함께 양측 95% 신뢰구간을 제시한다.  대조군 대비 시험군의\n\n<!-- PAGE_102 -->\n###### 평균 변화량이 우월한 방향에 있고 P-value가 유의수준\n\n- - 96 -\n<!-- PAGE_103 -->\n###### 0.05에서 작으면 통계적으로 우월하다고 판단한다.  또한,\n\n<!-- PAGE_103 -->\n###### 결과에 대한 임상적 평가를 제시한다.\n\n <!-- PAGE_103 -->\n###### - 치료 전 대비 3개월 후 우울장애 심각도 척도(BDI), 8주 후\n\n<!-- PAGE_103 -->\n###### : 각 유효성 평가변수의 각 시점의 변화량에 대해 기저치, 성,\n\n<!-- PAGE_103 -->\n###### 연령을 포함한 공분산분석을 적용하여 다른 변수를 통제한\n\n<!-- PAGE_103 -->\n###### 후 배정군간 평균 변화량 차이가 있는지 양측 유의수준 0.05\n\n<!-- PAGE_103 -->\n###### : 치료 전 대비 치료 후 각 시점에서 군간 관해율 및 반응율\n\n<!-- PAGE_103 -->\n###### 차이는 카이제곱검정(Chi-square test) 혹은 피셔정확검정\n\n<!-- PAGE_103 -->\n###### (Fisher’s exact test; 전체 셀의 20% 이상에서 기대빈도 5\n\n<!-- PAGE_103 -->\n###### 미만인 경우)을 통해 양측 유의수준 0.05에서 통계적 우월성을\n\n<!-- PAGE_103 -->\n###### : 각 시점에서 군간 답변 차이는 카이제곱검정 혹은 피셔정확\n\n<!-- PAGE_103 -->\n###### : 각 시점에서 군간 응답 빈도와 비율을 제시하고 필요 시 카이\n\n- - 97 -\n<!-- PAGE_104 -->\n###### 제곱검정 혹은 피셔정확검정을 통해 유의수준 0.05에서 통계적\n\n<!-- PAGE_104 -->\n###### 평가를 수행한다.\n\n <!-- PAGE_104 -->\n###### - 모든 분석 대상자군(Full Analysis Set, FAS)에서 중도 탈락 등의\n\n<!-- PAGE_104 -->\n###### 사유로 치료 후 시점에서 발생하는 결측치는 일차/이차 유효성\n\n<!-- PAGE_104 -->\n###### 평가변수에 대해서는 마지막 관측값 선행 대체법(Last Observation\n\n<!-- PAGE_104 -->\n###### Carried Forward, LOCF) 방법으로 대치한다.  그 외 자료는 대치\n\n<!-- PAGE_104 -->\n###### - 1차 유효성 평가 결과가 피험자의 하위집단(성별, 연령별 등)에\n\n<!-- PAGE_104 -->\n###### - 1차 유효성 평가 결과가 기관에 따라 차이가 있는지를 확인하기\n\n<!-- PAGE_104 -->\n###### 위해 기관 및 기관과 그룹 간 상호작용을 공분산 분석 모형에\n\n<!-- PAGE_104 -->\n###### - 대치 처리하지 않고 결측치를 고려한 반복 측정 혼합 모형을\n\n- - 98 -\n<!-- PAGE_105 -->\n###### 9) 안전성 평가\n\n<!-- PAGE_105 -->\n###### - 안전성 평가에서는 수집된 이상 사례의 유형, 임상시험용 의료\n\n<!-- PAGE_105 -->\n###### 기기와의 인과성, 중대성 등을 발생한 환자 수, 발생 빈도 수\n\n<!-- PAGE_105 -->\n###### 및 백분율을 군별로 제시한다. ",
        "original_sentence": "또한,\n\n<!-- PAGE_103 -->\n###### 결과에 대한 임상적 평가를 제시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_785",
      "text": "<!-- PAGE_103 -->\n###### - 치료 전 대비 3개월 후 우울장애 심각도 척도(BDI), 8주 후\n\n<!-- PAGE_103 -->\n###### : 각 유효성 평가변수의 각 시점의 변화량에 대해 기저치, 성,\n\n<!-- PAGE_103 -->\n###### 연령을 포함한 공분산분석을 적용하여 다른 변수를 통제한\n\n<!-- PAGE_103 -->\n###### 후 배정군간 평균 변화량 차이가 있는지 양측 유의수준 0.05\n\n<!-- PAGE_103 -->\n###### : 치료 전 대비 치료 후 각 시점에서 군간 관해율 및 반응율\n\n<!-- PAGE_103 -->\n###### 차이는 카이제곱검정(Chi-square test) 혹은 피셔정확검정\n\n<!-- PAGE_103 -->\n###### (Fisher’s exact test; 전체 셀의 20% 이상에서 기대빈도 5\n\n<!-- PAGE_103 -->\n###### 미만인 경우)을 통해 양측 유의수준 0.05에서 통계적 우월성을\n\n<!-- PAGE_103 -->\n###### : 각 시점에서 군간 답변 차이는 카이제곱검정 혹은 피셔정확\n\n<!-- PAGE_103 -->\n###### : 각 시점에서 군간 응답 빈도와 비율을 제시하고 필요 시 카이\n\n- - 97 -\n<!-- PAGE_104 -->\n###### 제곱검정 혹은 피셔정확검정을 통해 유의수준 0.05에서 통계적\n\n<!-- PAGE_104 -->\n###### 평가를 수행한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 784,
        "window_size": 3,
        "char_count": 730,
        "word_count": 152,
        "page_number": 103,
        "window_text": "P-value와\n\n<!-- PAGE_102 -->\n###### 함께 양측 95% 신뢰구간을 제시한다.  대조군 대비 시험군의\n\n<!-- PAGE_102 -->\n###### 평균 변화량이 우월한 방향에 있고 P-value가 유의수준\n\n- - 96 -\n<!-- PAGE_103 -->\n###### 0.05에서 작으면 통계적으로 우월하다고 판단한다.  또한,\n\n<!-- PAGE_103 -->\n###### 결과에 대한 임상적 평가를 제시한다.\n\n <!-- PAGE_103 -->\n###### - 치료 전 대비 3개월 후 우울장애 심각도 척도(BDI), 8주 후\n\n<!-- PAGE_103 -->\n###### : 각 유효성 평가변수의 각 시점의 변화량에 대해 기저치, 성,\n\n<!-- PAGE_103 -->\n###### 연령을 포함한 공분산분석을 적용하여 다른 변수를 통제한\n\n<!-- PAGE_103 -->\n###### 후 배정군간 평균 변화량 차이가 있는지 양측 유의수준 0.05\n\n<!-- PAGE_103 -->\n###### : 치료 전 대비 치료 후 각 시점에서 군간 관해율 및 반응율\n\n<!-- PAGE_103 -->\n###### 차이는 카이제곱검정(Chi-square test) 혹은 피셔정확검정\n\n<!-- PAGE_103 -->\n###### (Fisher’s exact test; 전체 셀의 20% 이상에서 기대빈도 5\n\n<!-- PAGE_103 -->\n###### 미만인 경우)을 통해 양측 유의수준 0.05에서 통계적 우월성을\n\n<!-- PAGE_103 -->\n###### : 각 시점에서 군간 답변 차이는 카이제곱검정 혹은 피셔정확\n\n<!-- PAGE_103 -->\n###### : 각 시점에서 군간 응답 빈도와 비율을 제시하고 필요 시 카이\n\n- - 97 -\n<!-- PAGE_104 -->\n###### 제곱검정 혹은 피셔정확검정을 통해 유의수준 0.05에서 통계적\n\n<!-- PAGE_104 -->\n###### 평가를 수행한다.\n\n <!-- PAGE_104 -->\n###### - 모든 분석 대상자군(Full Analysis Set, FAS)에서 중도 탈락 등의\n\n<!-- PAGE_104 -->\n###### 사유로 치료 후 시점에서 발생하는 결측치는 일차/이차 유효성\n\n<!-- PAGE_104 -->\n###### 평가변수에 대해서는 마지막 관측값 선행 대체법(Last Observation\n\n<!-- PAGE_104 -->\n###### Carried Forward, LOCF) 방법으로 대치한다.  그 외 자료는 대치\n\n<!-- PAGE_104 -->\n###### - 1차 유효성 평가 결과가 피험자의 하위집단(성별, 연령별 등)에\n\n<!-- PAGE_104 -->\n###### - 1차 유효성 평가 결과가 기관에 따라 차이가 있는지를 확인하기\n\n<!-- PAGE_104 -->\n###### 위해 기관 및 기관과 그룹 간 상호작용을 공분산 분석 모형에\n\n<!-- PAGE_104 -->\n###### - 대치 처리하지 않고 결측치를 고려한 반복 측정 혼합 모형을\n\n- - 98 -\n<!-- PAGE_105 -->\n###### 9) 안전성 평가\n\n<!-- PAGE_105 -->\n###### - 안전성 평가에서는 수집된 이상 사례의 유형, 임상시험용 의료\n\n<!-- PAGE_105 -->\n###### 기기와의 인과성, 중대성 등을 발생한 환자 수, 발생 빈도 수\n\n<!-- PAGE_105 -->\n###### 및 백분율을 군별로 제시한다.  필요하면 카이제곱검정(Chi-square\n\n<!-- PAGE_105 -->\n###### test) 혹은 피셔정확검정(Fisher’s exact test; 전체 셀의 20%\n\n<!-- PAGE_105 -->\n###### 이상에서 기대빈도 5 미만인 경우)을 통해 발생 환자 비율의\n\n- - 99 -\n<!-- PAGE_106 -->\n##### 15. ",
        "original_sentence": "<!-- PAGE_103 -->\n###### - 치료 전 대비 3개월 후 우울장애 심각도 척도(BDI), 8주 후\n\n<!-- PAGE_103 -->\n###### : 각 유효성 평가변수의 각 시점의 변화량에 대해 기저치, 성,\n\n<!-- PAGE_103 -->\n###### 연령을 포함한 공분산분석을 적용하여 다른 변수를 통제한\n\n<!-- PAGE_103 -->\n###### 후 배정군간 평균 변화량 차이가 있는지 양측 유의수준 0.05\n\n<!-- PAGE_103 -->\n###### : 치료 전 대비 치료 후 각 시점에서 군간 관해율 및 반응율\n\n<!-- PAGE_103 -->\n###### 차이는 카이제곱검정(Chi-square test) 혹은 피셔정확검정\n\n<!-- PAGE_103 -->\n###### (Fisher’s exact test; 전체 셀의 20% 이상에서 기대빈도 5\n\n<!-- PAGE_103 -->\n###### 미만인 경우)을 통해 양측 유의수준 0.05에서 통계적 우월성을\n\n<!-- PAGE_103 -->\n###### : 각 시점에서 군간 답변 차이는 카이제곱검정 혹은 피셔정확\n\n<!-- PAGE_103 -->\n###### : 각 시점에서 군간 응답 빈도와 비율을 제시하고 필요 시 카이\n\n- - 97 -\n<!-- PAGE_104 -->\n###### 제곱검정 혹은 피셔정확검정을 통해 유의수준 0.05에서 통계적\n\n<!-- PAGE_104 -->\n###### 평가를 수행한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_786",
      "text": "<!-- PAGE_104 -->\n###### - 모든 분석 대상자군(Full Analysis Set, FAS)에서 중도 탈락 등의\n\n<!-- PAGE_104 -->\n###### 사유로 치료 후 시점에서 발생하는 결측치는 일차/이차 유효성\n\n<!-- PAGE_104 -->\n###### 평가변수에 대해서는 마지막 관측값 선행 대체법(Last Observation\n\n<!-- PAGE_104 -->\n###### Carried Forward, LOCF) 방법으로 대치한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 785,
        "window_size": 3,
        "char_count": 262,
        "word_count": 46,
        "page_number": 104,
        "window_text": "대조군 대비 시험군의\n\n<!-- PAGE_102 -->\n###### 평균 변화량이 우월한 방향에 있고 P-value가 유의수준\n\n- - 96 -\n<!-- PAGE_103 -->\n###### 0.05에서 작으면 통계적으로 우월하다고 판단한다.  또한,\n\n<!-- PAGE_103 -->\n###### 결과에 대한 임상적 평가를 제시한다.\n\n <!-- PAGE_103 -->\n###### - 치료 전 대비 3개월 후 우울장애 심각도 척도(BDI), 8주 후\n\n<!-- PAGE_103 -->\n###### : 각 유효성 평가변수의 각 시점의 변화량에 대해 기저치, 성,\n\n<!-- PAGE_103 -->\n###### 연령을 포함한 공분산분석을 적용하여 다른 변수를 통제한\n\n<!-- PAGE_103 -->\n###### 후 배정군간 평균 변화량 차이가 있는지 양측 유의수준 0.05\n\n<!-- PAGE_103 -->\n###### : 치료 전 대비 치료 후 각 시점에서 군간 관해율 및 반응율\n\n<!-- PAGE_103 -->\n###### 차이는 카이제곱검정(Chi-square test) 혹은 피셔정확검정\n\n<!-- PAGE_103 -->\n###### (Fisher’s exact test; 전체 셀의 20% 이상에서 기대빈도 5\n\n<!-- PAGE_103 -->\n###### 미만인 경우)을 통해 양측 유의수준 0.05에서 통계적 우월성을\n\n<!-- PAGE_103 -->\n###### : 각 시점에서 군간 답변 차이는 카이제곱검정 혹은 피셔정확\n\n<!-- PAGE_103 -->\n###### : 각 시점에서 군간 응답 빈도와 비율을 제시하고 필요 시 카이\n\n- - 97 -\n<!-- PAGE_104 -->\n###### 제곱검정 혹은 피셔정확검정을 통해 유의수준 0.05에서 통계적\n\n<!-- PAGE_104 -->\n###### 평가를 수행한다.\n\n <!-- PAGE_104 -->\n###### - 모든 분석 대상자군(Full Analysis Set, FAS)에서 중도 탈락 등의\n\n<!-- PAGE_104 -->\n###### 사유로 치료 후 시점에서 발생하는 결측치는 일차/이차 유효성\n\n<!-- PAGE_104 -->\n###### 평가변수에 대해서는 마지막 관측값 선행 대체법(Last Observation\n\n<!-- PAGE_104 -->\n###### Carried Forward, LOCF) 방법으로 대치한다.  그 외 자료는 대치\n\n<!-- PAGE_104 -->\n###### - 1차 유효성 평가 결과가 피험자의 하위집단(성별, 연령별 등)에\n\n<!-- PAGE_104 -->\n###### - 1차 유효성 평가 결과가 기관에 따라 차이가 있는지를 확인하기\n\n<!-- PAGE_104 -->\n###### 위해 기관 및 기관과 그룹 간 상호작용을 공분산 분석 모형에\n\n<!-- PAGE_104 -->\n###### - 대치 처리하지 않고 결측치를 고려한 반복 측정 혼합 모형을\n\n- - 98 -\n<!-- PAGE_105 -->\n###### 9) 안전성 평가\n\n<!-- PAGE_105 -->\n###### - 안전성 평가에서는 수집된 이상 사례의 유형, 임상시험용 의료\n\n<!-- PAGE_105 -->\n###### 기기와의 인과성, 중대성 등을 발생한 환자 수, 발생 빈도 수\n\n<!-- PAGE_105 -->\n###### 및 백분율을 군별로 제시한다.  필요하면 카이제곱검정(Chi-square\n\n<!-- PAGE_105 -->\n###### test) 혹은 피셔정확검정(Fisher’s exact test; 전체 셀의 20%\n\n<!-- PAGE_105 -->\n###### 이상에서 기대빈도 5 미만인 경우)을 통해 발생 환자 비율의\n\n- - 99 -\n<!-- PAGE_106 -->\n##### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n<!-- PAGE_106 -->\n###### 가. ",
        "original_sentence": "<!-- PAGE_104 -->\n###### - 모든 분석 대상자군(Full Analysis Set, FAS)에서 중도 탈락 등의\n\n<!-- PAGE_104 -->\n###### 사유로 치료 후 시점에서 발생하는 결측치는 일차/이차 유효성\n\n<!-- PAGE_104 -->\n###### 평가변수에 대해서는 마지막 관측값 선행 대체법(Last Observation\n\n<!-- PAGE_104 -->\n###### Carried Forward, LOCF) 방법으로 대치한다. "
      }
    },
    {
      "chunk_id": "chunk_787",
      "text": "그 외 자료는 대치\n\n<!-- PAGE_104 -->\n###### - 1차 유효성 평가 결과가 피험자의 하위집단(성별, 연령별 등)에\n\n<!-- PAGE_104 -->\n###### - 1차 유효성 평가 결과가 기관에 따라 차이가 있는지를 확인하기\n\n<!-- PAGE_104 -->\n###### 위해 기관 및 기관과 그룹 간 상호작용을 공분산 분석 모형에\n\n<!-- PAGE_104 -->\n###### - 대치 처리하지 않고 결측치를 고려한 반복 측정 혼합 모형을\n\n- - 98 -\n<!-- PAGE_105 -->\n###### 9) 안전성 평가\n\n<!-- PAGE_105 -->\n###### - 안전성 평가에서는 수집된 이상 사례의 유형, 임상시험용 의료\n\n<!-- PAGE_105 -->\n###### 기기와의 인과성, 중대성 등을 발생한 환자 수, 발생 빈도 수\n\n<!-- PAGE_105 -->\n###### 및 백분율을 군별로 제시한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 786,
        "window_size": 3,
        "char_count": 470,
        "word_count": 105,
        "page_number": 104,
        "window_text": "또한,\n\n<!-- PAGE_103 -->\n###### 결과에 대한 임상적 평가를 제시한다.\n\n <!-- PAGE_103 -->\n###### - 치료 전 대비 3개월 후 우울장애 심각도 척도(BDI), 8주 후\n\n<!-- PAGE_103 -->\n###### : 각 유효성 평가변수의 각 시점의 변화량에 대해 기저치, 성,\n\n<!-- PAGE_103 -->\n###### 연령을 포함한 공분산분석을 적용하여 다른 변수를 통제한\n\n<!-- PAGE_103 -->\n###### 후 배정군간 평균 변화량 차이가 있는지 양측 유의수준 0.05\n\n<!-- PAGE_103 -->\n###### : 치료 전 대비 치료 후 각 시점에서 군간 관해율 및 반응율\n\n<!-- PAGE_103 -->\n###### 차이는 카이제곱검정(Chi-square test) 혹은 피셔정확검정\n\n<!-- PAGE_103 -->\n###### (Fisher’s exact test; 전체 셀의 20% 이상에서 기대빈도 5\n\n<!-- PAGE_103 -->\n###### 미만인 경우)을 통해 양측 유의수준 0.05에서 통계적 우월성을\n\n<!-- PAGE_103 -->\n###### : 각 시점에서 군간 답변 차이는 카이제곱검정 혹은 피셔정확\n\n<!-- PAGE_103 -->\n###### : 각 시점에서 군간 응답 빈도와 비율을 제시하고 필요 시 카이\n\n- - 97 -\n<!-- PAGE_104 -->\n###### 제곱검정 혹은 피셔정확검정을 통해 유의수준 0.05에서 통계적\n\n<!-- PAGE_104 -->\n###### 평가를 수행한다.\n\n <!-- PAGE_104 -->\n###### - 모든 분석 대상자군(Full Analysis Set, FAS)에서 중도 탈락 등의\n\n<!-- PAGE_104 -->\n###### 사유로 치료 후 시점에서 발생하는 결측치는 일차/이차 유효성\n\n<!-- PAGE_104 -->\n###### 평가변수에 대해서는 마지막 관측값 선행 대체법(Last Observation\n\n<!-- PAGE_104 -->\n###### Carried Forward, LOCF) 방법으로 대치한다.  그 외 자료는 대치\n\n<!-- PAGE_104 -->\n###### - 1차 유효성 평가 결과가 피험자의 하위집단(성별, 연령별 등)에\n\n<!-- PAGE_104 -->\n###### - 1차 유효성 평가 결과가 기관에 따라 차이가 있는지를 확인하기\n\n<!-- PAGE_104 -->\n###### 위해 기관 및 기관과 그룹 간 상호작용을 공분산 분석 모형에\n\n<!-- PAGE_104 -->\n###### - 대치 처리하지 않고 결측치를 고려한 반복 측정 혼합 모형을\n\n- - 98 -\n<!-- PAGE_105 -->\n###### 9) 안전성 평가\n\n<!-- PAGE_105 -->\n###### - 안전성 평가에서는 수집된 이상 사례의 유형, 임상시험용 의료\n\n<!-- PAGE_105 -->\n###### 기기와의 인과성, 중대성 등을 발생한 환자 수, 발생 빈도 수\n\n<!-- PAGE_105 -->\n###### 및 백분율을 군별로 제시한다.  필요하면 카이제곱검정(Chi-square\n\n<!-- PAGE_105 -->\n###### test) 혹은 피셔정확검정(Fisher’s exact test; 전체 셀의 20%\n\n<!-- PAGE_105 -->\n###### 이상에서 기대빈도 5 미만인 경우)을 통해 발생 환자 비율의\n\n- - 99 -\n<!-- PAGE_106 -->\n##### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n<!-- PAGE_106 -->\n###### 가.  피험자 안전성\n\n<!-- PAGE_106 -->\n###### 본 임상시험은 저위험(low-risk) 치료용 의료기기의 임상적 평가\n\n<!-- PAGE_106 -->\n###### 이므로 피험자가 직접적으로 받는 인체의 위해도가 없을 수도 있다.\n\n",
        "original_sentence": "그 외 자료는 대치\n\n<!-- PAGE_104 -->\n###### - 1차 유효성 평가 결과가 피험자의 하위집단(성별, 연령별 등)에\n\n<!-- PAGE_104 -->\n###### - 1차 유효성 평가 결과가 기관에 따라 차이가 있는지를 확인하기\n\n<!-- PAGE_104 -->\n###### 위해 기관 및 기관과 그룹 간 상호작용을 공분산 분석 모형에\n\n<!-- PAGE_104 -->\n###### - 대치 처리하지 않고 결측치를 고려한 반복 측정 혼합 모형을\n\n- - 98 -\n<!-- PAGE_105 -->\n###### 9) 안전성 평가\n\n<!-- PAGE_105 -->\n###### - 안전성 평가에서는 수집된 이상 사례의 유형, 임상시험용 의료\n\n<!-- PAGE_105 -->\n###### 기기와의 인과성, 중대성 등을 발생한 환자 수, 발생 빈도 수\n\n<!-- PAGE_105 -->\n###### 및 백분율을 군별로 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_788",
      "text": "필요하면 카이제곱검정(Chi-square\n\n<!-- PAGE_105 -->\n###### test) 혹은 피셔정확검정(Fisher’s exact test; 전체 셀의 20%\n\n<!-- PAGE_105 -->\n###### 이상에서 기대빈도 5 미만인 경우)을 통해 발생 환자 비율의\n\n- - 99 -\n<!-- PAGE_106 -->\n##### 15. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 787,
        "window_size": 3,
        "char_count": 194,
        "word_count": 36,
        "page_number": 105,
        "window_text": "<!-- PAGE_103 -->\n###### - 치료 전 대비 3개월 후 우울장애 심각도 척도(BDI), 8주 후\n\n<!-- PAGE_103 -->\n###### : 각 유효성 평가변수의 각 시점의 변화량에 대해 기저치, 성,\n\n<!-- PAGE_103 -->\n###### 연령을 포함한 공분산분석을 적용하여 다른 변수를 통제한\n\n<!-- PAGE_103 -->\n###### 후 배정군간 평균 변화량 차이가 있는지 양측 유의수준 0.05\n\n<!-- PAGE_103 -->\n###### : 치료 전 대비 치료 후 각 시점에서 군간 관해율 및 반응율\n\n<!-- PAGE_103 -->\n###### 차이는 카이제곱검정(Chi-square test) 혹은 피셔정확검정\n\n<!-- PAGE_103 -->\n###### (Fisher’s exact test; 전체 셀의 20% 이상에서 기대빈도 5\n\n<!-- PAGE_103 -->\n###### 미만인 경우)을 통해 양측 유의수준 0.05에서 통계적 우월성을\n\n<!-- PAGE_103 -->\n###### : 각 시점에서 군간 답변 차이는 카이제곱검정 혹은 피셔정확\n\n<!-- PAGE_103 -->\n###### : 각 시점에서 군간 응답 빈도와 비율을 제시하고 필요 시 카이\n\n- - 97 -\n<!-- PAGE_104 -->\n###### 제곱검정 혹은 피셔정확검정을 통해 유의수준 0.05에서 통계적\n\n<!-- PAGE_104 -->\n###### 평가를 수행한다.\n\n <!-- PAGE_104 -->\n###### - 모든 분석 대상자군(Full Analysis Set, FAS)에서 중도 탈락 등의\n\n<!-- PAGE_104 -->\n###### 사유로 치료 후 시점에서 발생하는 결측치는 일차/이차 유효성\n\n<!-- PAGE_104 -->\n###### 평가변수에 대해서는 마지막 관측값 선행 대체법(Last Observation\n\n<!-- PAGE_104 -->\n###### Carried Forward, LOCF) 방법으로 대치한다.  그 외 자료는 대치\n\n<!-- PAGE_104 -->\n###### - 1차 유효성 평가 결과가 피험자의 하위집단(성별, 연령별 등)에\n\n<!-- PAGE_104 -->\n###### - 1차 유효성 평가 결과가 기관에 따라 차이가 있는지를 확인하기\n\n<!-- PAGE_104 -->\n###### 위해 기관 및 기관과 그룹 간 상호작용을 공분산 분석 모형에\n\n<!-- PAGE_104 -->\n###### - 대치 처리하지 않고 결측치를 고려한 반복 측정 혼합 모형을\n\n- - 98 -\n<!-- PAGE_105 -->\n###### 9) 안전성 평가\n\n<!-- PAGE_105 -->\n###### - 안전성 평가에서는 수집된 이상 사례의 유형, 임상시험용 의료\n\n<!-- PAGE_105 -->\n###### 기기와의 인과성, 중대성 등을 발생한 환자 수, 발생 빈도 수\n\n<!-- PAGE_105 -->\n###### 및 백분율을 군별로 제시한다.  필요하면 카이제곱검정(Chi-square\n\n<!-- PAGE_105 -->\n###### test) 혹은 피셔정확검정(Fisher’s exact test; 전체 셀의 20%\n\n<!-- PAGE_105 -->\n###### 이상에서 기대빈도 5 미만인 경우)을 통해 발생 환자 비율의\n\n- - 99 -\n<!-- PAGE_106 -->\n##### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n<!-- PAGE_106 -->\n###### 가.  피험자 안전성\n\n<!-- PAGE_106 -->\n###### 본 임상시험은 저위험(low-risk) 치료용 의료기기의 임상적 평가\n\n<!-- PAGE_106 -->\n###### 이므로 피험자가 직접적으로 받는 인체의 위해도가 없을 수도 있다.\n\n <!-- PAGE_106 -->\n###### 하지만, 치료 도중 피험자한테 문제(예: 낮 시간 졸음이 과도한 현상 등)가\n\n<!-- PAGE_106 -->\n###### 발생하면 임상시험 담당 연구진에게 연락할 수 있는 긴급 연락망을\n\n<!-- PAGE_106 -->\n###### 제공하고, 디지털 기기(애플리케이션) 사용 관련한 문제(예: 버그 문제,\n\n<!-- PAGE_106 -->\n###### 로그인 실패 등)가 발생하면 회사 측 고객센터로 연락할 수 있는\n\n<!-- PAGE_106 -->\n###### 별도의 연락망을 제공한다. ",
        "original_sentence": "필요하면 카이제곱검정(Chi-square\n\n<!-- PAGE_105 -->\n###### test) 혹은 피셔정확검정(Fisher’s exact test; 전체 셀의 20%\n\n<!-- PAGE_105 -->\n###### 이상에서 기대빈도 5 미만인 경우)을 통해 발생 환자 비율의\n\n- - 99 -\n<!-- PAGE_106 -->\n##### 15. "
      }
    },
    {
      "chunk_id": "chunk_789",
      "text": "부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n<!-- PAGE_106 -->\n###### 가. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 788,
        "window_size": 3,
        "char_count": 60,
        "word_count": 11,
        "page_number": 106,
        "window_text": "<!-- PAGE_104 -->\n###### - 모든 분석 대상자군(Full Analysis Set, FAS)에서 중도 탈락 등의\n\n<!-- PAGE_104 -->\n###### 사유로 치료 후 시점에서 발생하는 결측치는 일차/이차 유효성\n\n<!-- PAGE_104 -->\n###### 평가변수에 대해서는 마지막 관측값 선행 대체법(Last Observation\n\n<!-- PAGE_104 -->\n###### Carried Forward, LOCF) 방법으로 대치한다.  그 외 자료는 대치\n\n<!-- PAGE_104 -->\n###### - 1차 유효성 평가 결과가 피험자의 하위집단(성별, 연령별 등)에\n\n<!-- PAGE_104 -->\n###### - 1차 유효성 평가 결과가 기관에 따라 차이가 있는지를 확인하기\n\n<!-- PAGE_104 -->\n###### 위해 기관 및 기관과 그룹 간 상호작용을 공분산 분석 모형에\n\n<!-- PAGE_104 -->\n###### - 대치 처리하지 않고 결측치를 고려한 반복 측정 혼합 모형을\n\n- - 98 -\n<!-- PAGE_105 -->\n###### 9) 안전성 평가\n\n<!-- PAGE_105 -->\n###### - 안전성 평가에서는 수집된 이상 사례의 유형, 임상시험용 의료\n\n<!-- PAGE_105 -->\n###### 기기와의 인과성, 중대성 등을 발생한 환자 수, 발생 빈도 수\n\n<!-- PAGE_105 -->\n###### 및 백분율을 군별로 제시한다.  필요하면 카이제곱검정(Chi-square\n\n<!-- PAGE_105 -->\n###### test) 혹은 피셔정확검정(Fisher’s exact test; 전체 셀의 20%\n\n<!-- PAGE_105 -->\n###### 이상에서 기대빈도 5 미만인 경우)을 통해 발생 환자 비율의\n\n- - 99 -\n<!-- PAGE_106 -->\n##### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n<!-- PAGE_106 -->\n###### 가.  피험자 안전성\n\n<!-- PAGE_106 -->\n###### 본 임상시험은 저위험(low-risk) 치료용 의료기기의 임상적 평가\n\n<!-- PAGE_106 -->\n###### 이므로 피험자가 직접적으로 받는 인체의 위해도가 없을 수도 있다.\n\n <!-- PAGE_106 -->\n###### 하지만, 치료 도중 피험자한테 문제(예: 낮 시간 졸음이 과도한 현상 등)가\n\n<!-- PAGE_106 -->\n###### 발생하면 임상시험 담당 연구진에게 연락할 수 있는 긴급 연락망을\n\n<!-- PAGE_106 -->\n###### 제공하고, 디지털 기기(애플리케이션) 사용 관련한 문제(예: 버그 문제,\n\n<!-- PAGE_106 -->\n###### 로그인 실패 등)가 발생하면 회사 측 고객센터로 연락할 수 있는\n\n<!-- PAGE_106 -->\n###### 별도의 연락망을 제공한다.  긴급 연락망과 방문을 통해 이상 반응을\n\n<!-- PAGE_106 -->\n###### 수집한다.\n\n",
        "original_sentence": "부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n<!-- PAGE_106 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_790",
      "text": "피험자 안전성\n\n<!-- PAGE_106 -->\n###### 본 임상시험은 저위험(low-risk) 치료용 의료기기의 임상적 평가\n\n<!-- PAGE_106 -->\n###### 이므로 피험자가 직접적으로 받는 인체의 위해도가 없을 수도 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 789,
        "window_size": 3,
        "char_count": 137,
        "word_count": 26,
        "page_number": 106,
        "window_text": "그 외 자료는 대치\n\n<!-- PAGE_104 -->\n###### - 1차 유효성 평가 결과가 피험자의 하위집단(성별, 연령별 등)에\n\n<!-- PAGE_104 -->\n###### - 1차 유효성 평가 결과가 기관에 따라 차이가 있는지를 확인하기\n\n<!-- PAGE_104 -->\n###### 위해 기관 및 기관과 그룹 간 상호작용을 공분산 분석 모형에\n\n<!-- PAGE_104 -->\n###### - 대치 처리하지 않고 결측치를 고려한 반복 측정 혼합 모형을\n\n- - 98 -\n<!-- PAGE_105 -->\n###### 9) 안전성 평가\n\n<!-- PAGE_105 -->\n###### - 안전성 평가에서는 수집된 이상 사례의 유형, 임상시험용 의료\n\n<!-- PAGE_105 -->\n###### 기기와의 인과성, 중대성 등을 발생한 환자 수, 발생 빈도 수\n\n<!-- PAGE_105 -->\n###### 및 백분율을 군별로 제시한다.  필요하면 카이제곱검정(Chi-square\n\n<!-- PAGE_105 -->\n###### test) 혹은 피셔정확검정(Fisher’s exact test; 전체 셀의 20%\n\n<!-- PAGE_105 -->\n###### 이상에서 기대빈도 5 미만인 경우)을 통해 발생 환자 비율의\n\n- - 99 -\n<!-- PAGE_106 -->\n##### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n<!-- PAGE_106 -->\n###### 가.  피험자 안전성\n\n<!-- PAGE_106 -->\n###### 본 임상시험은 저위험(low-risk) 치료용 의료기기의 임상적 평가\n\n<!-- PAGE_106 -->\n###### 이므로 피험자가 직접적으로 받는 인체의 위해도가 없을 수도 있다.\n\n <!-- PAGE_106 -->\n###### 하지만, 치료 도중 피험자한테 문제(예: 낮 시간 졸음이 과도한 현상 등)가\n\n<!-- PAGE_106 -->\n###### 발생하면 임상시험 담당 연구진에게 연락할 수 있는 긴급 연락망을\n\n<!-- PAGE_106 -->\n###### 제공하고, 디지털 기기(애플리케이션) 사용 관련한 문제(예: 버그 문제,\n\n<!-- PAGE_106 -->\n###### 로그인 실패 등)가 발생하면 회사 측 고객센터로 연락할 수 있는\n\n<!-- PAGE_106 -->\n###### 별도의 연락망을 제공한다.  긴급 연락망과 방문을 통해 이상 반응을\n\n<!-- PAGE_106 -->\n###### 수집한다.\n\n <!-- PAGE_106 -->\n###### 나. ",
        "original_sentence": "피험자 안전성\n\n<!-- PAGE_106 -->\n###### 본 임상시험은 저위험(low-risk) 치료용 의료기기의 임상적 평가\n\n<!-- PAGE_106 -->\n###### 이므로 피험자가 직접적으로 받는 인체의 위해도가 없을 수도 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_791",
      "text": "<!-- PAGE_106 -->\n###### 하지만, 치료 도중 피험자한테 문제(예: 낮 시간 졸음이 과도한 현상 등)가\n\n<!-- PAGE_106 -->\n###### 발생하면 임상시험 담당 연구진에게 연락할 수 있는 긴급 연락망을\n\n<!-- PAGE_106 -->\n###### 제공하고, 디지털 기기(애플리케이션) 사용 관련한 문제(예: 버그 문제,\n\n<!-- PAGE_106 -->\n###### 로그인 실패 등)가 발생하면 회사 측 고객센터로 연락할 수 있는\n\n<!-- PAGE_106 -->\n###### 별도의 연락망을 제공한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 790,
        "window_size": 3,
        "char_count": 300,
        "word_count": 61,
        "page_number": 106,
        "window_text": "필요하면 카이제곱검정(Chi-square\n\n<!-- PAGE_105 -->\n###### test) 혹은 피셔정확검정(Fisher’s exact test; 전체 셀의 20%\n\n<!-- PAGE_105 -->\n###### 이상에서 기대빈도 5 미만인 경우)을 통해 발생 환자 비율의\n\n- - 99 -\n<!-- PAGE_106 -->\n##### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n<!-- PAGE_106 -->\n###### 가.  피험자 안전성\n\n<!-- PAGE_106 -->\n###### 본 임상시험은 저위험(low-risk) 치료용 의료기기의 임상적 평가\n\n<!-- PAGE_106 -->\n###### 이므로 피험자가 직접적으로 받는 인체의 위해도가 없을 수도 있다.\n\n <!-- PAGE_106 -->\n###### 하지만, 치료 도중 피험자한테 문제(예: 낮 시간 졸음이 과도한 현상 등)가\n\n<!-- PAGE_106 -->\n###### 발생하면 임상시험 담당 연구진에게 연락할 수 있는 긴급 연락망을\n\n<!-- PAGE_106 -->\n###### 제공하고, 디지털 기기(애플리케이션) 사용 관련한 문제(예: 버그 문제,\n\n<!-- PAGE_106 -->\n###### 로그인 실패 등)가 발생하면 회사 측 고객센터로 연락할 수 있는\n\n<!-- PAGE_106 -->\n###### 별도의 연락망을 제공한다.  긴급 연락망과 방문을 통해 이상 반응을\n\n<!-- PAGE_106 -->\n###### 수집한다.\n\n <!-- PAGE_106 -->\n###### 나.  시험자 안전성\n\n<!-- PAGE_106 -->\n###### 해당 임상시험용 의료기기는 소프트웨어에 속하며 비침습적이며 짧은\n\n<!-- PAGE_106 -->\n###### 기간 동안 임상시험에 참여하기 때문에 안전에 대한 위험은 없다고\n\n<!-- PAGE_106 -->\n###### 할 수 있다.\n\n",
        "original_sentence": "<!-- PAGE_106 -->\n###### 하지만, 치료 도중 피험자한테 문제(예: 낮 시간 졸음이 과도한 현상 등)가\n\n<!-- PAGE_106 -->\n###### 발생하면 임상시험 담당 연구진에게 연락할 수 있는 긴급 연락망을\n\n<!-- PAGE_106 -->\n###### 제공하고, 디지털 기기(애플리케이션) 사용 관련한 문제(예: 버그 문제,\n\n<!-- PAGE_106 -->\n###### 로그인 실패 등)가 발생하면 회사 측 고객센터로 연락할 수 있는\n\n<!-- PAGE_106 -->\n###### 별도의 연락망을 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_792",
      "text": "긴급 연락망과 방문을 통해 이상 반응을\n\n<!-- PAGE_106 -->\n###### 수집한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 791,
        "window_size": 3,
        "char_count": 55,
        "word_count": 11,
        "page_number": 106,
        "window_text": "부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n<!-- PAGE_106 -->\n###### 가.  피험자 안전성\n\n<!-- PAGE_106 -->\n###### 본 임상시험은 저위험(low-risk) 치료용 의료기기의 임상적 평가\n\n<!-- PAGE_106 -->\n###### 이므로 피험자가 직접적으로 받는 인체의 위해도가 없을 수도 있다.\n\n <!-- PAGE_106 -->\n###### 하지만, 치료 도중 피험자한테 문제(예: 낮 시간 졸음이 과도한 현상 등)가\n\n<!-- PAGE_106 -->\n###### 발생하면 임상시험 담당 연구진에게 연락할 수 있는 긴급 연락망을\n\n<!-- PAGE_106 -->\n###### 제공하고, 디지털 기기(애플리케이션) 사용 관련한 문제(예: 버그 문제,\n\n<!-- PAGE_106 -->\n###### 로그인 실패 등)가 발생하면 회사 측 고객센터로 연락할 수 있는\n\n<!-- PAGE_106 -->\n###### 별도의 연락망을 제공한다.  긴급 연락망과 방문을 통해 이상 반응을\n\n<!-- PAGE_106 -->\n###### 수집한다.\n\n <!-- PAGE_106 -->\n###### 나.  시험자 안전성\n\n<!-- PAGE_106 -->\n###### 해당 임상시험용 의료기기는 소프트웨어에 속하며 비침습적이며 짧은\n\n<!-- PAGE_106 -->\n###### 기간 동안 임상시험에 참여하기 때문에 안전에 대한 위험은 없다고\n\n<!-- PAGE_106 -->\n###### 할 수 있다.\n\n - - 100 -\n<!-- PAGE_107 -->\n###### 다. ",
        "original_sentence": "긴급 연락망과 방문을 통해 이상 반응을\n\n<!-- PAGE_106 -->\n###### 수집한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_793",
      "text": "<!-- PAGE_106 -->\n###### 나. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 792,
        "window_size": 3,
        "char_count": 28,
        "word_count": 5,
        "page_number": 106,
        "window_text": "피험자 안전성\n\n<!-- PAGE_106 -->\n###### 본 임상시험은 저위험(low-risk) 치료용 의료기기의 임상적 평가\n\n<!-- PAGE_106 -->\n###### 이므로 피험자가 직접적으로 받는 인체의 위해도가 없을 수도 있다.\n\n <!-- PAGE_106 -->\n###### 하지만, 치료 도중 피험자한테 문제(예: 낮 시간 졸음이 과도한 현상 등)가\n\n<!-- PAGE_106 -->\n###### 발생하면 임상시험 담당 연구진에게 연락할 수 있는 긴급 연락망을\n\n<!-- PAGE_106 -->\n###### 제공하고, 디지털 기기(애플리케이션) 사용 관련한 문제(예: 버그 문제,\n\n<!-- PAGE_106 -->\n###### 로그인 실패 등)가 발생하면 회사 측 고객센터로 연락할 수 있는\n\n<!-- PAGE_106 -->\n###### 별도의 연락망을 제공한다.  긴급 연락망과 방문을 통해 이상 반응을\n\n<!-- PAGE_106 -->\n###### 수집한다.\n\n <!-- PAGE_106 -->\n###### 나.  시험자 안전성\n\n<!-- PAGE_106 -->\n###### 해당 임상시험용 의료기기는 소프트웨어에 속하며 비침습적이며 짧은\n\n<!-- PAGE_106 -->\n###### 기간 동안 임상시험에 참여하기 때문에 안전에 대한 위험은 없다고\n\n<!-- PAGE_106 -->\n###### 할 수 있다.\n\n - - 100 -\n<!-- PAGE_107 -->\n###### 다.  이상 사례의 정의\n\n<!-- PAGE_107 -->\n###### 1) 이상 사례(Adverse Event, AE)란 임상시험 중 피험자에게 발생한\n\n<!-- PAGE_107 -->\n###### 모든 의도하지 않은 증후(sign), 증상(symptom) 또는 질병을 말하며,\n\n<!-- PAGE_107 -->\n###### 해당 임상시험용 의료기기와 반드시 인과관계를 가져야 하는 것은\n\n<!-- PAGE_107 -->\n###### 2) 의료기기 이상 반응(Adverse Device Effect, ADE)이란 임상시험용\n\n<!-- PAGE_107 -->\n###### 의료기기로 인하여 발생한 모든 유해하고 의도하지 않은 반응으로서\n\n<!-- PAGE_107 -->\n###### 라. ",
        "original_sentence": "<!-- PAGE_106 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_794",
      "text": "시험자 안전성\n\n<!-- PAGE_106 -->\n###### 해당 임상시험용 의료기기는 소프트웨어에 속하며 비침습적이며 짧은\n\n<!-- PAGE_106 -->\n###### 기간 동안 임상시험에 참여하기 때문에 안전에 대한 위험은 없다고\n\n<!-- PAGE_106 -->\n###### 할 수 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 793,
        "window_size": 3,
        "char_count": 167,
        "word_count": 33,
        "page_number": 106,
        "window_text": "<!-- PAGE_106 -->\n###### 하지만, 치료 도중 피험자한테 문제(예: 낮 시간 졸음이 과도한 현상 등)가\n\n<!-- PAGE_106 -->\n###### 발생하면 임상시험 담당 연구진에게 연락할 수 있는 긴급 연락망을\n\n<!-- PAGE_106 -->\n###### 제공하고, 디지털 기기(애플리케이션) 사용 관련한 문제(예: 버그 문제,\n\n<!-- PAGE_106 -->\n###### 로그인 실패 등)가 발생하면 회사 측 고객센터로 연락할 수 있는\n\n<!-- PAGE_106 -->\n###### 별도의 연락망을 제공한다.  긴급 연락망과 방문을 통해 이상 반응을\n\n<!-- PAGE_106 -->\n###### 수집한다.\n\n <!-- PAGE_106 -->\n###### 나.  시험자 안전성\n\n<!-- PAGE_106 -->\n###### 해당 임상시험용 의료기기는 소프트웨어에 속하며 비침습적이며 짧은\n\n<!-- PAGE_106 -->\n###### 기간 동안 임상시험에 참여하기 때문에 안전에 대한 위험은 없다고\n\n<!-- PAGE_106 -->\n###### 할 수 있다.\n\n - - 100 -\n<!-- PAGE_107 -->\n###### 다.  이상 사례의 정의\n\n<!-- PAGE_107 -->\n###### 1) 이상 사례(Adverse Event, AE)란 임상시험 중 피험자에게 발생한\n\n<!-- PAGE_107 -->\n###### 모든 의도하지 않은 증후(sign), 증상(symptom) 또는 질병을 말하며,\n\n<!-- PAGE_107 -->\n###### 해당 임상시험용 의료기기와 반드시 인과관계를 가져야 하는 것은\n\n<!-- PAGE_107 -->\n###### 2) 의료기기 이상 반응(Adverse Device Effect, ADE)이란 임상시험용\n\n<!-- PAGE_107 -->\n###### 의료기기로 인하여 발생한 모든 유해하고 의도하지 않은 반응으로서\n\n<!-- PAGE_107 -->\n###### 라.  이상 사례의 평가\n\n<!-- PAGE_107 -->\n###### 이상 사례 발현 시 임상시험용 의료기기와의 관련성 여부는\n\n<!-- PAGE_107 -->\n###### 시험자가 다음 기준에 의하여 평가하며, 시험자의 의견을 기술\n\n<!-- PAGE_107 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적\n\n<!-- PAGE_107 -->\n###### - 이상 반응이 다른 어떤 이유보다 임상시험용 의료기기의 사용\n\n<!-- PAGE_107 -->\n###### - 이상 반응이 임상시험용 의료기기 또는 동일 계열의 의료기기에\n\n<!-- PAGE_107 -->\n###### 대해 이미 알려진 정보와 일관된 양상을 보이는 경우\n\n- - 101 -\n<!-- PAGE_108 -->\n###### ○ 관련성이 많음(Probably related)\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n\n<!-- PAGE_108 -->\n###### - 이상 반응이 다른 원인보다 임상시험용 의료기기의 사용으로\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단으로 이상 반응이 사라지는\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n\n<!-- PAGE_108 -->\n###### - 이상 반응이 다른 가능성이 있는 원인과 같은 수준으로 임상\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단으로(실시된 경우) 이상\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단 결과(실시된 경우)가 음성\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 재사용(실시된 경우) 결과가 음성이거나\n\n- - 102 -\n<!-- PAGE_109 -->\n###### ○ 관련성이 없음(Definitely not related)\n\n<!-- PAGE_109 -->\n###### - 임상시험용 의료기기를 사용하지 않은 경우\n\n<!-- PAGE_109 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현과의 시간적\n\n<!-- PAGE_109 -->\n###### - 정보가 불충분하거나 상충하여 판단할 수 없고 이를 보완\n\n<!-- PAGE_109 -->\n###### 마. ",
        "original_sentence": "시험자 안전성\n\n<!-- PAGE_106 -->\n###### 해당 임상시험용 의료기기는 소프트웨어에 속하며 비침습적이며 짧은\n\n<!-- PAGE_106 -->\n###### 기간 동안 임상시험에 참여하기 때문에 안전에 대한 위험은 없다고\n\n<!-- PAGE_106 -->\n###### 할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_795",
      "text": "- - 100 -\n<!-- PAGE_107 -->\n###### 다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 794,
        "window_size": 3,
        "char_count": 38,
        "word_count": 9,
        "page_number": 107,
        "window_text": "긴급 연락망과 방문을 통해 이상 반응을\n\n<!-- PAGE_106 -->\n###### 수집한다.\n\n <!-- PAGE_106 -->\n###### 나.  시험자 안전성\n\n<!-- PAGE_106 -->\n###### 해당 임상시험용 의료기기는 소프트웨어에 속하며 비침습적이며 짧은\n\n<!-- PAGE_106 -->\n###### 기간 동안 임상시험에 참여하기 때문에 안전에 대한 위험은 없다고\n\n<!-- PAGE_106 -->\n###### 할 수 있다.\n\n - - 100 -\n<!-- PAGE_107 -->\n###### 다.  이상 사례의 정의\n\n<!-- PAGE_107 -->\n###### 1) 이상 사례(Adverse Event, AE)란 임상시험 중 피험자에게 발생한\n\n<!-- PAGE_107 -->\n###### 모든 의도하지 않은 증후(sign), 증상(symptom) 또는 질병을 말하며,\n\n<!-- PAGE_107 -->\n###### 해당 임상시험용 의료기기와 반드시 인과관계를 가져야 하는 것은\n\n<!-- PAGE_107 -->\n###### 2) 의료기기 이상 반응(Adverse Device Effect, ADE)이란 임상시험용\n\n<!-- PAGE_107 -->\n###### 의료기기로 인하여 발생한 모든 유해하고 의도하지 않은 반응으로서\n\n<!-- PAGE_107 -->\n###### 라.  이상 사례의 평가\n\n<!-- PAGE_107 -->\n###### 이상 사례 발현 시 임상시험용 의료기기와의 관련성 여부는\n\n<!-- PAGE_107 -->\n###### 시험자가 다음 기준에 의하여 평가하며, 시험자의 의견을 기술\n\n<!-- PAGE_107 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적\n\n<!-- PAGE_107 -->\n###### - 이상 반응이 다른 어떤 이유보다 임상시험용 의료기기의 사용\n\n<!-- PAGE_107 -->\n###### - 이상 반응이 임상시험용 의료기기 또는 동일 계열의 의료기기에\n\n<!-- PAGE_107 -->\n###### 대해 이미 알려진 정보와 일관된 양상을 보이는 경우\n\n- - 101 -\n<!-- PAGE_108 -->\n###### ○ 관련성이 많음(Probably related)\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n\n<!-- PAGE_108 -->\n###### - 이상 반응이 다른 원인보다 임상시험용 의료기기의 사용으로\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단으로 이상 반응이 사라지는\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n\n<!-- PAGE_108 -->\n###### - 이상 반응이 다른 가능성이 있는 원인과 같은 수준으로 임상\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단으로(실시된 경우) 이상\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단 결과(실시된 경우)가 음성\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 재사용(실시된 경우) 결과가 음성이거나\n\n- - 102 -\n<!-- PAGE_109 -->\n###### ○ 관련성이 없음(Definitely not related)\n\n<!-- PAGE_109 -->\n###### - 임상시험용 의료기기를 사용하지 않은 경우\n\n<!-- PAGE_109 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현과의 시간적\n\n<!-- PAGE_109 -->\n###### - 정보가 불충분하거나 상충하여 판단할 수 없고 이를 보완\n\n<!-- PAGE_109 -->\n###### 마.  안전성의 평가 기준\n\n<!-- PAGE_109 -->\n###### 본 임상시험에서 이상 반응은 임상시험 시작 전에 관찰되지 않은\n\n<!-- PAGE_109 -->\n###### 증상이 발생하는 모든 바람직하지 않은 의학적ㆍ물리적 소견을 이상\n\n<!-- PAGE_109 -->\n###### 반응으로 분류한다. ",
        "original_sentence": "- - 100 -\n<!-- PAGE_107 -->\n###### 다. "
      }
    },
    {
      "chunk_id": "chunk_796",
      "text": "이상 사례의 정의\n\n<!-- PAGE_107 -->\n###### 1) 이상 사례(Adverse Event, AE)란 임상시험 중 피험자에게 발생한\n\n<!-- PAGE_107 -->\n###### 모든 의도하지 않은 증후(sign), 증상(symptom) 또는 질병을 말하며,\n\n<!-- PAGE_107 -->\n###### 해당 임상시험용 의료기기와 반드시 인과관계를 가져야 하는 것은\n\n<!-- PAGE_107 -->\n###### 2) 의료기기 이상 반응(Adverse Device Effect, ADE)이란 임상시험용\n\n<!-- PAGE_107 -->\n###### 의료기기로 인하여 발생한 모든 유해하고 의도하지 않은 반응으로서\n\n<!-- PAGE_107 -->\n###### 라. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 795,
        "window_size": 3,
        "char_count": 381,
        "word_count": 69,
        "page_number": 107,
        "window_text": "<!-- PAGE_106 -->\n###### 나.  시험자 안전성\n\n<!-- PAGE_106 -->\n###### 해당 임상시험용 의료기기는 소프트웨어에 속하며 비침습적이며 짧은\n\n<!-- PAGE_106 -->\n###### 기간 동안 임상시험에 참여하기 때문에 안전에 대한 위험은 없다고\n\n<!-- PAGE_106 -->\n###### 할 수 있다.\n\n - - 100 -\n<!-- PAGE_107 -->\n###### 다.  이상 사례의 정의\n\n<!-- PAGE_107 -->\n###### 1) 이상 사례(Adverse Event, AE)란 임상시험 중 피험자에게 발생한\n\n<!-- PAGE_107 -->\n###### 모든 의도하지 않은 증후(sign), 증상(symptom) 또는 질병을 말하며,\n\n<!-- PAGE_107 -->\n###### 해당 임상시험용 의료기기와 반드시 인과관계를 가져야 하는 것은\n\n<!-- PAGE_107 -->\n###### 2) 의료기기 이상 반응(Adverse Device Effect, ADE)이란 임상시험용\n\n<!-- PAGE_107 -->\n###### 의료기기로 인하여 발생한 모든 유해하고 의도하지 않은 반응으로서\n\n<!-- PAGE_107 -->\n###### 라.  이상 사례의 평가\n\n<!-- PAGE_107 -->\n###### 이상 사례 발현 시 임상시험용 의료기기와의 관련성 여부는\n\n<!-- PAGE_107 -->\n###### 시험자가 다음 기준에 의하여 평가하며, 시험자의 의견을 기술\n\n<!-- PAGE_107 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적\n\n<!-- PAGE_107 -->\n###### - 이상 반응이 다른 어떤 이유보다 임상시험용 의료기기의 사용\n\n<!-- PAGE_107 -->\n###### - 이상 반응이 임상시험용 의료기기 또는 동일 계열의 의료기기에\n\n<!-- PAGE_107 -->\n###### 대해 이미 알려진 정보와 일관된 양상을 보이는 경우\n\n- - 101 -\n<!-- PAGE_108 -->\n###### ○ 관련성이 많음(Probably related)\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n\n<!-- PAGE_108 -->\n###### - 이상 반응이 다른 원인보다 임상시험용 의료기기의 사용으로\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단으로 이상 반응이 사라지는\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n\n<!-- PAGE_108 -->\n###### - 이상 반응이 다른 가능성이 있는 원인과 같은 수준으로 임상\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단으로(실시된 경우) 이상\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단 결과(실시된 경우)가 음성\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 재사용(실시된 경우) 결과가 음성이거나\n\n- - 102 -\n<!-- PAGE_109 -->\n###### ○ 관련성이 없음(Definitely not related)\n\n<!-- PAGE_109 -->\n###### - 임상시험용 의료기기를 사용하지 않은 경우\n\n<!-- PAGE_109 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현과의 시간적\n\n<!-- PAGE_109 -->\n###### - 정보가 불충분하거나 상충하여 판단할 수 없고 이를 보완\n\n<!-- PAGE_109 -->\n###### 마.  안전성의 평가 기준\n\n<!-- PAGE_109 -->\n###### 본 임상시험에서 이상 반응은 임상시험 시작 전에 관찰되지 않은\n\n<!-- PAGE_109 -->\n###### 증상이 발생하는 모든 바람직하지 않은 의학적ㆍ물리적 소견을 이상\n\n<!-- PAGE_109 -->\n###### 반응으로 분류한다.  예측되는 부작용도 이상 반응으로 분류한다.\n\n",
        "original_sentence": "이상 사례의 정의\n\n<!-- PAGE_107 -->\n###### 1) 이상 사례(Adverse Event, AE)란 임상시험 중 피험자에게 발생한\n\n<!-- PAGE_107 -->\n###### 모든 의도하지 않은 증후(sign), 증상(symptom) 또는 질병을 말하며,\n\n<!-- PAGE_107 -->\n###### 해당 임상시험용 의료기기와 반드시 인과관계를 가져야 하는 것은\n\n<!-- PAGE_107 -->\n###### 2) 의료기기 이상 반응(Adverse Device Effect, ADE)이란 임상시험용\n\n<!-- PAGE_107 -->\n###### 의료기기로 인하여 발생한 모든 유해하고 의도하지 않은 반응으로서\n\n<!-- PAGE_107 -->\n###### 라. "
      }
    },
    {
      "chunk_id": "chunk_797",
      "text": "이상 사례의 평가\n\n<!-- PAGE_107 -->\n###### 이상 사례 발현 시 임상시험용 의료기기와의 관련성 여부는\n\n<!-- PAGE_107 -->\n###### 시험자가 다음 기준에 의하여 평가하며, 시험자의 의견을 기술\n\n<!-- PAGE_107 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적\n\n<!-- PAGE_107 -->\n###### - 이상 반응이 다른 어떤 이유보다 임상시험용 의료기기의 사용\n\n<!-- PAGE_107 -->\n###### - 이상 반응이 임상시험용 의료기기 또는 동일 계열의 의료기기에\n\n<!-- PAGE_107 -->\n###### 대해 이미 알려진 정보와 일관된 양상을 보이는 경우\n\n- - 101 -\n<!-- PAGE_108 -->\n###### ○ 관련성이 많음(Probably related)\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n\n<!-- PAGE_108 -->\n###### - 이상 반응이 다른 원인보다 임상시험용 의료기기의 사용으로\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단으로 이상 반응이 사라지는\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n\n<!-- PAGE_108 -->\n###### - 이상 반응이 다른 가능성이 있는 원인과 같은 수준으로 임상\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단으로(실시된 경우) 이상\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단 결과(실시된 경우)가 음성\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 재사용(실시된 경우) 결과가 음성이거나\n\n- - 102 -\n<!-- PAGE_109 -->\n###### ○ 관련성이 없음(Definitely not related)\n\n<!-- PAGE_109 -->\n###### - 임상시험용 의료기기를 사용하지 않은 경우\n\n<!-- PAGE_109 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현과의 시간적\n\n<!-- PAGE_109 -->\n###### - 정보가 불충분하거나 상충하여 판단할 수 없고 이를 보완\n\n<!-- PAGE_109 -->\n###### 마. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 796,
        "window_size": 3,
        "char_count": 1240,
        "word_count": 251,
        "page_number": 107,
        "window_text": "시험자 안전성\n\n<!-- PAGE_106 -->\n###### 해당 임상시험용 의료기기는 소프트웨어에 속하며 비침습적이며 짧은\n\n<!-- PAGE_106 -->\n###### 기간 동안 임상시험에 참여하기 때문에 안전에 대한 위험은 없다고\n\n<!-- PAGE_106 -->\n###### 할 수 있다.\n\n - - 100 -\n<!-- PAGE_107 -->\n###### 다.  이상 사례의 정의\n\n<!-- PAGE_107 -->\n###### 1) 이상 사례(Adverse Event, AE)란 임상시험 중 피험자에게 발생한\n\n<!-- PAGE_107 -->\n###### 모든 의도하지 않은 증후(sign), 증상(symptom) 또는 질병을 말하며,\n\n<!-- PAGE_107 -->\n###### 해당 임상시험용 의료기기와 반드시 인과관계를 가져야 하는 것은\n\n<!-- PAGE_107 -->\n###### 2) 의료기기 이상 반응(Adverse Device Effect, ADE)이란 임상시험용\n\n<!-- PAGE_107 -->\n###### 의료기기로 인하여 발생한 모든 유해하고 의도하지 않은 반응으로서\n\n<!-- PAGE_107 -->\n###### 라.  이상 사례의 평가\n\n<!-- PAGE_107 -->\n###### 이상 사례 발현 시 임상시험용 의료기기와의 관련성 여부는\n\n<!-- PAGE_107 -->\n###### 시험자가 다음 기준에 의하여 평가하며, 시험자의 의견을 기술\n\n<!-- PAGE_107 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적\n\n<!-- PAGE_107 -->\n###### - 이상 반응이 다른 어떤 이유보다 임상시험용 의료기기의 사용\n\n<!-- PAGE_107 -->\n###### - 이상 반응이 임상시험용 의료기기 또는 동일 계열의 의료기기에\n\n<!-- PAGE_107 -->\n###### 대해 이미 알려진 정보와 일관된 양상을 보이는 경우\n\n- - 101 -\n<!-- PAGE_108 -->\n###### ○ 관련성이 많음(Probably related)\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n\n<!-- PAGE_108 -->\n###### - 이상 반응이 다른 원인보다 임상시험용 의료기기의 사용으로\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단으로 이상 반응이 사라지는\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n\n<!-- PAGE_108 -->\n###### - 이상 반응이 다른 가능성이 있는 원인과 같은 수준으로 임상\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단으로(실시된 경우) 이상\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단 결과(실시된 경우)가 음성\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 재사용(실시된 경우) 결과가 음성이거나\n\n- - 102 -\n<!-- PAGE_109 -->\n###### ○ 관련성이 없음(Definitely not related)\n\n<!-- PAGE_109 -->\n###### - 임상시험용 의료기기를 사용하지 않은 경우\n\n<!-- PAGE_109 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현과의 시간적\n\n<!-- PAGE_109 -->\n###### - 정보가 불충분하거나 상충하여 판단할 수 없고 이를 보완\n\n<!-- PAGE_109 -->\n###### 마.  안전성의 평가 기준\n\n<!-- PAGE_109 -->\n###### 본 임상시험에서 이상 반응은 임상시험 시작 전에 관찰되지 않은\n\n<!-- PAGE_109 -->\n###### 증상이 발생하는 모든 바람직하지 않은 의학적ㆍ물리적 소견을 이상\n\n<!-- PAGE_109 -->\n###### 반응으로 분류한다.  예측되는 부작용도 이상 반응으로 분류한다.\n\n <!-- PAGE_109 -->\n###### 바. ",
        "original_sentence": "이상 사례의 평가\n\n<!-- PAGE_107 -->\n###### 이상 사례 발현 시 임상시험용 의료기기와의 관련성 여부는\n\n<!-- PAGE_107 -->\n###### 시험자가 다음 기준에 의하여 평가하며, 시험자의 의견을 기술\n\n<!-- PAGE_107 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적\n\n<!-- PAGE_107 -->\n###### - 이상 반응이 다른 어떤 이유보다 임상시험용 의료기기의 사용\n\n<!-- PAGE_107 -->\n###### - 이상 반응이 임상시험용 의료기기 또는 동일 계열의 의료기기에\n\n<!-- PAGE_107 -->\n###### 대해 이미 알려진 정보와 일관된 양상을 보이는 경우\n\n- - 101 -\n<!-- PAGE_108 -->\n###### ○ 관련성이 많음(Probably related)\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n\n<!-- PAGE_108 -->\n###### - 이상 반응이 다른 원인보다 임상시험용 의료기기의 사용으로\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단으로 이상 반응이 사라지는\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n\n<!-- PAGE_108 -->\n###### - 이상 반응이 다른 가능성이 있는 원인과 같은 수준으로 임상\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단으로(실시된 경우) 이상\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단 결과(실시된 경우)가 음성\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 재사용(실시된 경우) 결과가 음성이거나\n\n- - 102 -\n<!-- PAGE_109 -->\n###### ○ 관련성이 없음(Definitely not related)\n\n<!-- PAGE_109 -->\n###### - 임상시험용 의료기기를 사용하지 않은 경우\n\n<!-- PAGE_109 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현과의 시간적\n\n<!-- PAGE_109 -->\n###### - 정보가 불충분하거나 상충하여 판단할 수 없고 이를 보완\n\n<!-- PAGE_109 -->\n###### 마. "
      }
    },
    {
      "chunk_id": "chunk_798",
      "text": "안전성의 평가 기준\n\n<!-- PAGE_109 -->\n###### 본 임상시험에서 이상 반응은 임상시험 시작 전에 관찰되지 않은\n\n<!-- PAGE_109 -->\n###### 증상이 발생하는 모든 바람직하지 않은 의학적ㆍ물리적 소견을 이상\n\n<!-- PAGE_109 -->\n###### 반응으로 분류한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 797,
        "window_size": 3,
        "char_count": 171,
        "word_count": 34,
        "page_number": 109,
        "window_text": "- - 100 -\n<!-- PAGE_107 -->\n###### 다.  이상 사례의 정의\n\n<!-- PAGE_107 -->\n###### 1) 이상 사례(Adverse Event, AE)란 임상시험 중 피험자에게 발생한\n\n<!-- PAGE_107 -->\n###### 모든 의도하지 않은 증후(sign), 증상(symptom) 또는 질병을 말하며,\n\n<!-- PAGE_107 -->\n###### 해당 임상시험용 의료기기와 반드시 인과관계를 가져야 하는 것은\n\n<!-- PAGE_107 -->\n###### 2) 의료기기 이상 반응(Adverse Device Effect, ADE)이란 임상시험용\n\n<!-- PAGE_107 -->\n###### 의료기기로 인하여 발생한 모든 유해하고 의도하지 않은 반응으로서\n\n<!-- PAGE_107 -->\n###### 라.  이상 사례의 평가\n\n<!-- PAGE_107 -->\n###### 이상 사례 발현 시 임상시험용 의료기기와의 관련성 여부는\n\n<!-- PAGE_107 -->\n###### 시험자가 다음 기준에 의하여 평가하며, 시험자의 의견을 기술\n\n<!-- PAGE_107 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적\n\n<!-- PAGE_107 -->\n###### - 이상 반응이 다른 어떤 이유보다 임상시험용 의료기기의 사용\n\n<!-- PAGE_107 -->\n###### - 이상 반응이 임상시험용 의료기기 또는 동일 계열의 의료기기에\n\n<!-- PAGE_107 -->\n###### 대해 이미 알려진 정보와 일관된 양상을 보이는 경우\n\n- - 101 -\n<!-- PAGE_108 -->\n###### ○ 관련성이 많음(Probably related)\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n\n<!-- PAGE_108 -->\n###### - 이상 반응이 다른 원인보다 임상시험용 의료기기의 사용으로\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단으로 이상 반응이 사라지는\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n\n<!-- PAGE_108 -->\n###### - 이상 반응이 다른 가능성이 있는 원인과 같은 수준으로 임상\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단으로(실시된 경우) 이상\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단 결과(실시된 경우)가 음성\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 재사용(실시된 경우) 결과가 음성이거나\n\n- - 102 -\n<!-- PAGE_109 -->\n###### ○ 관련성이 없음(Definitely not related)\n\n<!-- PAGE_109 -->\n###### - 임상시험용 의료기기를 사용하지 않은 경우\n\n<!-- PAGE_109 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현과의 시간적\n\n<!-- PAGE_109 -->\n###### - 정보가 불충분하거나 상충하여 판단할 수 없고 이를 보완\n\n<!-- PAGE_109 -->\n###### 마.  안전성의 평가 기준\n\n<!-- PAGE_109 -->\n###### 본 임상시험에서 이상 반응은 임상시험 시작 전에 관찰되지 않은\n\n<!-- PAGE_109 -->\n###### 증상이 발생하는 모든 바람직하지 않은 의학적ㆍ물리적 소견을 이상\n\n<!-- PAGE_109 -->\n###### 반응으로 분류한다.  예측되는 부작용도 이상 반응으로 분류한다.\n\n <!-- PAGE_109 -->\n###### 바.  이상 사례 보고 방법\n\n<!-- PAGE_109 -->\n###### ○ 시험책임자는 시험담당자 또는 임상의 등에게 임상시험용 의료\n\n<!-- PAGE_109 -->\n###### 기기 사용 후 나타날 수 있는 모든 이상 사례에 대하여 교육을\n\n<!-- PAGE_109 -->\n###### 하고 사용 후 나타나는 모든 현상에 대하여 보고하도록 교육을\n\n<!-- PAGE_109 -->\n###### ※\n\n<!-- PAGE_109 -->\n###### 본 내용은「의료기기법 시행규칙」별표 3“의료기기 임상시험 관리기준” 제8호\n\n- - 103 -\n<!-- PAGE_110 -->\n###### ○ 이외에도 시험자가 중대하다고 간주하거나, 임상시험용 의료\n\n<!-- PAGE_110 -->\n###### 기기와의 사용과 연관 지을 수 있는 유의한 위험, 금기, 부작용,\n\n<!-- PAGE_110 -->\n###### 주의사항을 시사하는 사건 등도 중대한 이상사례/의료기기\n\n<!-- PAGE_110 -->\n###### 이상반응으로 기록하고 사망을 초래하거나 생명을 위협할 때는\n\n<!-- PAGE_110 -->\n###### 의뢰자가 이 사실을 보고받거나 알게 된 날로부터 7일 이내,\n\n<!-- PAGE_110 -->\n###### 이 경우 상세한 정보를 최초 보고일로부터 8일 이내에 추가로\n\n<!-- PAGE_110 -->\n###### 보고 하여야 한다. ",
        "original_sentence": "안전성의 평가 기준\n\n<!-- PAGE_109 -->\n###### 본 임상시험에서 이상 반응은 임상시험 시작 전에 관찰되지 않은\n\n<!-- PAGE_109 -->\n###### 증상이 발생하는 모든 바람직하지 않은 의학적ㆍ물리적 소견을 이상\n\n<!-- PAGE_109 -->\n###### 반응으로 분류한다. "
      }
    },
    {
      "chunk_id": "chunk_799",
      "text": "예측되는 부작용도 이상 반응으로 분류한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 798,
        "window_size": 3,
        "char_count": 25,
        "word_count": 5,
        "page_number": 13,
        "window_text": "이상 사례의 정의\n\n<!-- PAGE_107 -->\n###### 1) 이상 사례(Adverse Event, AE)란 임상시험 중 피험자에게 발생한\n\n<!-- PAGE_107 -->\n###### 모든 의도하지 않은 증후(sign), 증상(symptom) 또는 질병을 말하며,\n\n<!-- PAGE_107 -->\n###### 해당 임상시험용 의료기기와 반드시 인과관계를 가져야 하는 것은\n\n<!-- PAGE_107 -->\n###### 2) 의료기기 이상 반응(Adverse Device Effect, ADE)이란 임상시험용\n\n<!-- PAGE_107 -->\n###### 의료기기로 인하여 발생한 모든 유해하고 의도하지 않은 반응으로서\n\n<!-- PAGE_107 -->\n###### 라.  이상 사례의 평가\n\n<!-- PAGE_107 -->\n###### 이상 사례 발현 시 임상시험용 의료기기와의 관련성 여부는\n\n<!-- PAGE_107 -->\n###### 시험자가 다음 기준에 의하여 평가하며, 시험자의 의견을 기술\n\n<!-- PAGE_107 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적\n\n<!-- PAGE_107 -->\n###### - 이상 반응이 다른 어떤 이유보다 임상시험용 의료기기의 사용\n\n<!-- PAGE_107 -->\n###### - 이상 반응이 임상시험용 의료기기 또는 동일 계열의 의료기기에\n\n<!-- PAGE_107 -->\n###### 대해 이미 알려진 정보와 일관된 양상을 보이는 경우\n\n- - 101 -\n<!-- PAGE_108 -->\n###### ○ 관련성이 많음(Probably related)\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n\n<!-- PAGE_108 -->\n###### - 이상 반응이 다른 원인보다 임상시험용 의료기기의 사용으로\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단으로 이상 반응이 사라지는\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n\n<!-- PAGE_108 -->\n###### - 이상 반응이 다른 가능성이 있는 원인과 같은 수준으로 임상\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단으로(실시된 경우) 이상\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단 결과(실시된 경우)가 음성\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 재사용(실시된 경우) 결과가 음성이거나\n\n- - 102 -\n<!-- PAGE_109 -->\n###### ○ 관련성이 없음(Definitely not related)\n\n<!-- PAGE_109 -->\n###### - 임상시험용 의료기기를 사용하지 않은 경우\n\n<!-- PAGE_109 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현과의 시간적\n\n<!-- PAGE_109 -->\n###### - 정보가 불충분하거나 상충하여 판단할 수 없고 이를 보완\n\n<!-- PAGE_109 -->\n###### 마.  안전성의 평가 기준\n\n<!-- PAGE_109 -->\n###### 본 임상시험에서 이상 반응은 임상시험 시작 전에 관찰되지 않은\n\n<!-- PAGE_109 -->\n###### 증상이 발생하는 모든 바람직하지 않은 의학적ㆍ물리적 소견을 이상\n\n<!-- PAGE_109 -->\n###### 반응으로 분류한다.  예측되는 부작용도 이상 반응으로 분류한다.\n\n <!-- PAGE_109 -->\n###### 바.  이상 사례 보고 방법\n\n<!-- PAGE_109 -->\n###### ○ 시험책임자는 시험담당자 또는 임상의 등에게 임상시험용 의료\n\n<!-- PAGE_109 -->\n###### 기기 사용 후 나타날 수 있는 모든 이상 사례에 대하여 교육을\n\n<!-- PAGE_109 -->\n###### 하고 사용 후 나타나는 모든 현상에 대하여 보고하도록 교육을\n\n<!-- PAGE_109 -->\n###### ※\n\n<!-- PAGE_109 -->\n###### 본 내용은「의료기기법 시행규칙」별표 3“의료기기 임상시험 관리기준” 제8호\n\n- - 103 -\n<!-- PAGE_110 -->\n###### ○ 이외에도 시험자가 중대하다고 간주하거나, 임상시험용 의료\n\n<!-- PAGE_110 -->\n###### 기기와의 사용과 연관 지을 수 있는 유의한 위험, 금기, 부작용,\n\n<!-- PAGE_110 -->\n###### 주의사항을 시사하는 사건 등도 중대한 이상사례/의료기기\n\n<!-- PAGE_110 -->\n###### 이상반응으로 기록하고 사망을 초래하거나 생명을 위협할 때는\n\n<!-- PAGE_110 -->\n###### 의뢰자가 이 사실을 보고받거나 알게 된 날로부터 7일 이내,\n\n<!-- PAGE_110 -->\n###### 이 경우 상세한 정보를 최초 보고일로부터 8일 이내에 추가로\n\n<!-- PAGE_110 -->\n###### 보고 하여야 한다.  그 밖의 중대하거나 예상하지 못한 모든\n\n<!-- PAGE_110 -->\n###### 이상 반응이 나타났을 때 의뢰자가 이 사실을 보고 받거나\n\n- - 104 -\n<!-- PAGE_111 -->\n##### 16. ",
        "original_sentence": "예측되는 부작용도 이상 반응으로 분류한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_800",
      "text": "<!-- PAGE_109 -->\n###### 바. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 799,
        "window_size": 3,
        "char_count": 28,
        "word_count": 5,
        "page_number": 109,
        "window_text": "이상 사례의 평가\n\n<!-- PAGE_107 -->\n###### 이상 사례 발현 시 임상시험용 의료기기와의 관련성 여부는\n\n<!-- PAGE_107 -->\n###### 시험자가 다음 기준에 의하여 평가하며, 시험자의 의견을 기술\n\n<!-- PAGE_107 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적\n\n<!-- PAGE_107 -->\n###### - 이상 반응이 다른 어떤 이유보다 임상시험용 의료기기의 사용\n\n<!-- PAGE_107 -->\n###### - 이상 반응이 임상시험용 의료기기 또는 동일 계열의 의료기기에\n\n<!-- PAGE_107 -->\n###### 대해 이미 알려진 정보와 일관된 양상을 보이는 경우\n\n- - 101 -\n<!-- PAGE_108 -->\n###### ○ 관련성이 많음(Probably related)\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n\n<!-- PAGE_108 -->\n###### - 이상 반응이 다른 원인보다 임상시험용 의료기기의 사용으로\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단으로 이상 반응이 사라지는\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n\n<!-- PAGE_108 -->\n###### - 이상 반응이 다른 가능성이 있는 원인과 같은 수준으로 임상\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단으로(실시된 경우) 이상\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 사용 중단 결과(실시된 경우)가 음성\n\n<!-- PAGE_108 -->\n###### - 임상시험용 의료기기의 재사용(실시된 경우) 결과가 음성이거나\n\n- - 102 -\n<!-- PAGE_109 -->\n###### ○ 관련성이 없음(Definitely not related)\n\n<!-- PAGE_109 -->\n###### - 임상시험용 의료기기를 사용하지 않은 경우\n\n<!-- PAGE_109 -->\n###### - 임상시험용 의료기기의 사용과 이상 반응 발현과의 시간적\n\n<!-- PAGE_109 -->\n###### - 정보가 불충분하거나 상충하여 판단할 수 없고 이를 보완\n\n<!-- PAGE_109 -->\n###### 마.  안전성의 평가 기준\n\n<!-- PAGE_109 -->\n###### 본 임상시험에서 이상 반응은 임상시험 시작 전에 관찰되지 않은\n\n<!-- PAGE_109 -->\n###### 증상이 발생하는 모든 바람직하지 않은 의학적ㆍ물리적 소견을 이상\n\n<!-- PAGE_109 -->\n###### 반응으로 분류한다.  예측되는 부작용도 이상 반응으로 분류한다.\n\n <!-- PAGE_109 -->\n###### 바.  이상 사례 보고 방법\n\n<!-- PAGE_109 -->\n###### ○ 시험책임자는 시험담당자 또는 임상의 등에게 임상시험용 의료\n\n<!-- PAGE_109 -->\n###### 기기 사용 후 나타날 수 있는 모든 이상 사례에 대하여 교육을\n\n<!-- PAGE_109 -->\n###### 하고 사용 후 나타나는 모든 현상에 대하여 보고하도록 교육을\n\n<!-- PAGE_109 -->\n###### ※\n\n<!-- PAGE_109 -->\n###### 본 내용은「의료기기법 시행규칙」별표 3“의료기기 임상시험 관리기준” 제8호\n\n- - 103 -\n<!-- PAGE_110 -->\n###### ○ 이외에도 시험자가 중대하다고 간주하거나, 임상시험용 의료\n\n<!-- PAGE_110 -->\n###### 기기와의 사용과 연관 지을 수 있는 유의한 위험, 금기, 부작용,\n\n<!-- PAGE_110 -->\n###### 주의사항을 시사하는 사건 등도 중대한 이상사례/의료기기\n\n<!-- PAGE_110 -->\n###### 이상반응으로 기록하고 사망을 초래하거나 생명을 위협할 때는\n\n<!-- PAGE_110 -->\n###### 의뢰자가 이 사실을 보고받거나 알게 된 날로부터 7일 이내,\n\n<!-- PAGE_110 -->\n###### 이 경우 상세한 정보를 최초 보고일로부터 8일 이내에 추가로\n\n<!-- PAGE_110 -->\n###### 보고 하여야 한다.  그 밖의 중대하거나 예상하지 못한 모든\n\n<!-- PAGE_110 -->\n###### 이상 반응이 나타났을 때 의뢰자가 이 사실을 보고 받거나\n\n- - 104 -\n<!-- PAGE_111 -->\n##### 16.  피험자 동의서 서식\n\n<!-- PAGE_111 -->\n###### 가. ",
        "original_sentence": "<!-- PAGE_109 -->\n###### 바. "
      }
    },
    {
      "chunk_id": "chunk_801",
      "text": "이상 사례 보고 방법\n\n<!-- PAGE_109 -->\n###### ○ 시험책임자는 시험담당자 또는 임상의 등에게 임상시험용 의료\n\n<!-- PAGE_109 -->\n###### 기기 사용 후 나타날 수 있는 모든 이상 사례에 대하여 교육을\n\n<!-- PAGE_109 -->\n###### 하고 사용 후 나타나는 모든 현상에 대하여 보고하도록 교육을\n\n<!-- PAGE_109 -->\n###### ※\n\n<!-- PAGE_109 -->\n###### 본 내용은「의료기기법 시행규칙」별표 3“의료기기 임상시험 관리기준” 제8호\n\n- - 103 -\n<!-- PAGE_110 -->\n###### ○ 이외에도 시험자가 중대하다고 간주하거나, 임상시험용 의료\n\n<!-- PAGE_110 -->\n###### 기기와의 사용과 연관 지을 수 있는 유의한 위험, 금기, 부작용,\n\n<!-- PAGE_110 -->\n###### 주의사항을 시사하는 사건 등도 중대한 이상사례/의료기기\n\n<!-- PAGE_110 -->\n###### 이상반응으로 기록하고 사망을 초래하거나 생명을 위협할 때는\n\n<!-- PAGE_110 -->\n###### 의뢰자가 이 사실을 보고받거나 알게 된 날로부터 7일 이내,\n\n<!-- PAGE_110 -->\n###### 이 경우 상세한 정보를 최초 보고일로부터 8일 이내에 추가로\n\n<!-- PAGE_110 -->\n###### 보고 하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 800,
        "window_size": 3,
        "char_count": 696,
        "word_count": 143,
        "page_number": 109,
        "window_text": "안전성의 평가 기준\n\n<!-- PAGE_109 -->\n###### 본 임상시험에서 이상 반응은 임상시험 시작 전에 관찰되지 않은\n\n<!-- PAGE_109 -->\n###### 증상이 발생하는 모든 바람직하지 않은 의학적ㆍ물리적 소견을 이상\n\n<!-- PAGE_109 -->\n###### 반응으로 분류한다.  예측되는 부작용도 이상 반응으로 분류한다.\n\n <!-- PAGE_109 -->\n###### 바.  이상 사례 보고 방법\n\n<!-- PAGE_109 -->\n###### ○ 시험책임자는 시험담당자 또는 임상의 등에게 임상시험용 의료\n\n<!-- PAGE_109 -->\n###### 기기 사용 후 나타날 수 있는 모든 이상 사례에 대하여 교육을\n\n<!-- PAGE_109 -->\n###### 하고 사용 후 나타나는 모든 현상에 대하여 보고하도록 교육을\n\n<!-- PAGE_109 -->\n###### ※\n\n<!-- PAGE_109 -->\n###### 본 내용은「의료기기법 시행규칙」별표 3“의료기기 임상시험 관리기준” 제8호\n\n- - 103 -\n<!-- PAGE_110 -->\n###### ○ 이외에도 시험자가 중대하다고 간주하거나, 임상시험용 의료\n\n<!-- PAGE_110 -->\n###### 기기와의 사용과 연관 지을 수 있는 유의한 위험, 금기, 부작용,\n\n<!-- PAGE_110 -->\n###### 주의사항을 시사하는 사건 등도 중대한 이상사례/의료기기\n\n<!-- PAGE_110 -->\n###### 이상반응으로 기록하고 사망을 초래하거나 생명을 위협할 때는\n\n<!-- PAGE_110 -->\n###### 의뢰자가 이 사실을 보고받거나 알게 된 날로부터 7일 이내,\n\n<!-- PAGE_110 -->\n###### 이 경우 상세한 정보를 최초 보고일로부터 8일 이내에 추가로\n\n<!-- PAGE_110 -->\n###### 보고 하여야 한다.  그 밖의 중대하거나 예상하지 못한 모든\n\n<!-- PAGE_110 -->\n###### 이상 반응이 나타났을 때 의뢰자가 이 사실을 보고 받거나\n\n- - 104 -\n<!-- PAGE_111 -->\n##### 16.  피험자 동의서 서식\n\n<!-- PAGE_111 -->\n###### 가.  피험자 동의서에 반드시 포함되어야 하는 사항\n\n<!-- PAGE_111 -->\n###### 3) 임상시험용 의료기기에 관한 정보 및 시험군 또는 대조군에\n\n<!-- PAGE_111 -->\n###### 4) 침습적 시술(invasive procedure)을 포함하여 임상시험에서 피험자가\n\n<!-- PAGE_111 -->\n###### 8) 기대되는 이익이 있거나 피험자에게 기대되는 이익이 없을 경우\n\n<!-- PAGE_111 -->\n###### 9) 피험자가 선택할 수 있는 다른 치료방법이나 종류 및 그 치료\n\n- - 105 -\n<!-- PAGE_112 -->\n###### 10) 임상시험과 관련한 손상이 발생하였을 경우 피험자에게 주어질\n\n<!-- PAGE_112 -->\n###### 보상이나 치료방법\n\n<!-- PAGE_112 -->\n###### 11) 피험자가 임상시험에 참여함으로써 받게 될 금전적 보상이 있는\n\n<!-- PAGE_112 -->\n###### 경우 예상 금액 및 이 금액이 임상시험 참여의 정도나 기간에\n\n<!-- PAGE_112 -->\n###### 13) 피험자의 임상시험 참여 여부 결정은 자발적이어야 하며,\n\n<!-- PAGE_112 -->\n###### 피험자가 원래 받을 수 있는 이익에 대한 손실 없이 임상시험의\n\n<!-- PAGE_112 -->\n###### 참여를 거부하거나 임상시험 도중 언제라도 참여를 포기할 수\n\n<!-- PAGE_112 -->\n###### 14) 제8호 항목에 따른 모니터 요원, 제8호 항목에 따른 점검을\n\n<!-- PAGE_112 -->\n###### 실시하는 자, 임상시험심사위원회 및 식품의약품안전처장이 관계\n\n<!-- PAGE_112 -->\n###### 법령에 따라 임상시험의 실시 절차와 자료의 품질을 검증하기\n\n<!-- PAGE_112 -->\n###### 위하여 피험자의 신상에 관한 비밀이 보호되는 범위에서 피험자의\n\n<!-- PAGE_112 -->\n###### 의무기록을 열람할 수 있다는 사실과 피험자 또는 피험자 대리인의\n\n<!-- PAGE_112 -->\n###### 15) 피험자의 신상을 파악할 수 있는 기록은 비밀로 보호될 것이며\n\n<!-- PAGE_112 -->\n###### 임상시험의 결과가 출관될 경우 피험자의 신상은 비밀로 보호\n\n<!-- PAGE_112 -->\n###### 16) 피험자의 임상시험 계속 참여 여부에 영향을 줄 수 있는 새로운\n\n<!-- PAGE_112 -->\n###### 정보를 취득하면 적시에 피험자 또는 피험자의 대리인에게 알릴\n\n<!-- PAGE_112 -->\n###### 17) 임상시험과 피험자의 권익에 관하여 추가적인 정보를 얻고자\n\n- - 106 -\n<!-- PAGE_113 -->\n###### 하거나 임상시험과 관련이 있는 손상이 발생하면 연락해야 하는\n\n<!-- PAGE_113 -->\n###### 사람\n\n<!-- PAGE_113 -->\n###### 18) 임상시험 도중 피험자의 임상시험 참여가 중지되는 경우 및 그\n\n<!-- PAGE_113 -->\n###### 나. ",
        "original_sentence": "이상 사례 보고 방법\n\n<!-- PAGE_109 -->\n###### ○ 시험책임자는 시험담당자 또는 임상의 등에게 임상시험용 의료\n\n<!-- PAGE_109 -->\n###### 기기 사용 후 나타날 수 있는 모든 이상 사례에 대하여 교육을\n\n<!-- PAGE_109 -->\n###### 하고 사용 후 나타나는 모든 현상에 대하여 보고하도록 교육을\n\n<!-- PAGE_109 -->\n###### ※\n\n<!-- PAGE_109 -->\n###### 본 내용은「의료기기법 시행규칙」별표 3“의료기기 임상시험 관리기준” 제8호\n\n- - 103 -\n<!-- PAGE_110 -->\n###### ○ 이외에도 시험자가 중대하다고 간주하거나, 임상시험용 의료\n\n<!-- PAGE_110 -->\n###### 기기와의 사용과 연관 지을 수 있는 유의한 위험, 금기, 부작용,\n\n<!-- PAGE_110 -->\n###### 주의사항을 시사하는 사건 등도 중대한 이상사례/의료기기\n\n<!-- PAGE_110 -->\n###### 이상반응으로 기록하고 사망을 초래하거나 생명을 위협할 때는\n\n<!-- PAGE_110 -->\n###### 의뢰자가 이 사실을 보고받거나 알게 된 날로부터 7일 이내,\n\n<!-- PAGE_110 -->\n###### 이 경우 상세한 정보를 최초 보고일로부터 8일 이내에 추가로\n\n<!-- PAGE_110 -->\n###### 보고 하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_802",
      "text": "그 밖의 중대하거나 예상하지 못한 모든\n\n<!-- PAGE_110 -->\n###### 이상 반응이 나타났을 때 의뢰자가 이 사실을 보고 받거나\n\n- - 104 -\n<!-- PAGE_111 -->\n##### 16. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 801,
        "window_size": 3,
        "char_count": 119,
        "word_count": 28,
        "page_number": 110,
        "window_text": "예측되는 부작용도 이상 반응으로 분류한다.\n\n <!-- PAGE_109 -->\n###### 바.  이상 사례 보고 방법\n\n<!-- PAGE_109 -->\n###### ○ 시험책임자는 시험담당자 또는 임상의 등에게 임상시험용 의료\n\n<!-- PAGE_109 -->\n###### 기기 사용 후 나타날 수 있는 모든 이상 사례에 대하여 교육을\n\n<!-- PAGE_109 -->\n###### 하고 사용 후 나타나는 모든 현상에 대하여 보고하도록 교육을\n\n<!-- PAGE_109 -->\n###### ※\n\n<!-- PAGE_109 -->\n###### 본 내용은「의료기기법 시행규칙」별표 3“의료기기 임상시험 관리기준” 제8호\n\n- - 103 -\n<!-- PAGE_110 -->\n###### ○ 이외에도 시험자가 중대하다고 간주하거나, 임상시험용 의료\n\n<!-- PAGE_110 -->\n###### 기기와의 사용과 연관 지을 수 있는 유의한 위험, 금기, 부작용,\n\n<!-- PAGE_110 -->\n###### 주의사항을 시사하는 사건 등도 중대한 이상사례/의료기기\n\n<!-- PAGE_110 -->\n###### 이상반응으로 기록하고 사망을 초래하거나 생명을 위협할 때는\n\n<!-- PAGE_110 -->\n###### 의뢰자가 이 사실을 보고받거나 알게 된 날로부터 7일 이내,\n\n<!-- PAGE_110 -->\n###### 이 경우 상세한 정보를 최초 보고일로부터 8일 이내에 추가로\n\n<!-- PAGE_110 -->\n###### 보고 하여야 한다.  그 밖의 중대하거나 예상하지 못한 모든\n\n<!-- PAGE_110 -->\n###### 이상 반응이 나타났을 때 의뢰자가 이 사실을 보고 받거나\n\n- - 104 -\n<!-- PAGE_111 -->\n##### 16.  피험자 동의서 서식\n\n<!-- PAGE_111 -->\n###### 가.  피험자 동의서에 반드시 포함되어야 하는 사항\n\n<!-- PAGE_111 -->\n###### 3) 임상시험용 의료기기에 관한 정보 및 시험군 또는 대조군에\n\n<!-- PAGE_111 -->\n###### 4) 침습적 시술(invasive procedure)을 포함하여 임상시험에서 피험자가\n\n<!-- PAGE_111 -->\n###### 8) 기대되는 이익이 있거나 피험자에게 기대되는 이익이 없을 경우\n\n<!-- PAGE_111 -->\n###### 9) 피험자가 선택할 수 있는 다른 치료방법이나 종류 및 그 치료\n\n- - 105 -\n<!-- PAGE_112 -->\n###### 10) 임상시험과 관련한 손상이 발생하였을 경우 피험자에게 주어질\n\n<!-- PAGE_112 -->\n###### 보상이나 치료방법\n\n<!-- PAGE_112 -->\n###### 11) 피험자가 임상시험에 참여함으로써 받게 될 금전적 보상이 있는\n\n<!-- PAGE_112 -->\n###### 경우 예상 금액 및 이 금액이 임상시험 참여의 정도나 기간에\n\n<!-- PAGE_112 -->\n###### 13) 피험자의 임상시험 참여 여부 결정은 자발적이어야 하며,\n\n<!-- PAGE_112 -->\n###### 피험자가 원래 받을 수 있는 이익에 대한 손실 없이 임상시험의\n\n<!-- PAGE_112 -->\n###### 참여를 거부하거나 임상시험 도중 언제라도 참여를 포기할 수\n\n<!-- PAGE_112 -->\n###### 14) 제8호 항목에 따른 모니터 요원, 제8호 항목에 따른 점검을\n\n<!-- PAGE_112 -->\n###### 실시하는 자, 임상시험심사위원회 및 식품의약품안전처장이 관계\n\n<!-- PAGE_112 -->\n###### 법령에 따라 임상시험의 실시 절차와 자료의 품질을 검증하기\n\n<!-- PAGE_112 -->\n###### 위하여 피험자의 신상에 관한 비밀이 보호되는 범위에서 피험자의\n\n<!-- PAGE_112 -->\n###### 의무기록을 열람할 수 있다는 사실과 피험자 또는 피험자 대리인의\n\n<!-- PAGE_112 -->\n###### 15) 피험자의 신상을 파악할 수 있는 기록은 비밀로 보호될 것이며\n\n<!-- PAGE_112 -->\n###### 임상시험의 결과가 출관될 경우 피험자의 신상은 비밀로 보호\n\n<!-- PAGE_112 -->\n###### 16) 피험자의 임상시험 계속 참여 여부에 영향을 줄 수 있는 새로운\n\n<!-- PAGE_112 -->\n###### 정보를 취득하면 적시에 피험자 또는 피험자의 대리인에게 알릴\n\n<!-- PAGE_112 -->\n###### 17) 임상시험과 피험자의 권익에 관하여 추가적인 정보를 얻고자\n\n- - 106 -\n<!-- PAGE_113 -->\n###### 하거나 임상시험과 관련이 있는 손상이 발생하면 연락해야 하는\n\n<!-- PAGE_113 -->\n###### 사람\n\n<!-- PAGE_113 -->\n###### 18) 임상시험 도중 피험자의 임상시험 참여가 중지되는 경우 및 그\n\n<!-- PAGE_113 -->\n###### 나.  피험자 동의의 일반적 요건\n\n<!-- PAGE_113 -->\n###### 1) 연구자는 연구를 시작하기 전에 임상시험심사위원회(Institutional\n\n<!-- PAGE_113 -->\n###### Review Board, IRB)로부터 피험자에게 제공될 설명서 및 동의서,\n\n<!-- PAGE_113 -->\n###### 2) 연구자는 임상시험심사위원회 승인 직인이 찍힌 동의서 등을\n\n<!-- PAGE_113 -->\n###### 피험자 또는 피험자의 대리인에게 제공해야 하며, 피험자(또는\n\n<!-- PAGE_113 -->\n###### 대리인)와 동의를 받은 책임연구자(또는 책임연구자의 위임을 받은\n\n<!-- PAGE_113 -->\n###### 자)는 동의서 서식에 서명하고, 자필로 해당 날짜를 기재하여야\n\n<!-- PAGE_113 -->\n###### 3) 연구자는 서명된 동의서를 보관해야 하며, 사본을 피험자(또는\n\n<!-- PAGE_113 -->\n###### 4) 동의서를 받는 과정에서 연구자는 피험자 또는 대리인에게 강제나\n\n<!-- PAGE_113 -->\n###### 부당한 영향을 미치지 않아야 하며, 피험자 또는 대리인이 연구의\n\n<!-- PAGE_113 -->\n###### 모든 정보를 이해할 수 있는 용어 및 언어로 작성된 동의서 등을\n\n<!-- PAGE_113 -->\n###### 제공하여 설명하고 질문에 대하여 대답한 후 충분히 생각할\n\n- - 107 -\n<!-- PAGE_114 -->\n###### 5) 피험자 동의서에는 피험자 또는 대리인의 법적 권리를 포기나\n\n<!-- PAGE_114 -->\n###### 제한, 연구자/의뢰자/기관 및 기관장의 과실 책임의 면제를 암시\n\n<!-- PAGE_114 -->\n###### 6) 피험자의 동의에 영향을 줄 수 있는 새로운 연구 관련정보가\n\n<!-- PAGE_114 -->\n###### 수집되면 동의서 서식, 피험자 설명서 및 기타 문서화된 정보는\n\n<!-- PAGE_114 -->\n###### 이에 따라 수정되어야 하며, 사용 전에 반드시 위원회의 승인을\n\n<!-- PAGE_114 -->\n###### 받아야 한다. ",
        "original_sentence": "그 밖의 중대하거나 예상하지 못한 모든\n\n<!-- PAGE_110 -->\n###### 이상 반응이 나타났을 때 의뢰자가 이 사실을 보고 받거나\n\n- - 104 -\n<!-- PAGE_111 -->\n##### 16. "
      }
    },
    {
      "chunk_id": "chunk_803",
      "text": "피험자 동의서 서식\n\n<!-- PAGE_111 -->\n###### 가. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 802,
        "window_size": 3,
        "char_count": 40,
        "word_count": 8,
        "page_number": 111,
        "window_text": "<!-- PAGE_109 -->\n###### 바.  이상 사례 보고 방법\n\n<!-- PAGE_109 -->\n###### ○ 시험책임자는 시험담당자 또는 임상의 등에게 임상시험용 의료\n\n<!-- PAGE_109 -->\n###### 기기 사용 후 나타날 수 있는 모든 이상 사례에 대하여 교육을\n\n<!-- PAGE_109 -->\n###### 하고 사용 후 나타나는 모든 현상에 대하여 보고하도록 교육을\n\n<!-- PAGE_109 -->\n###### ※\n\n<!-- PAGE_109 -->\n###### 본 내용은「의료기기법 시행규칙」별표 3“의료기기 임상시험 관리기준” 제8호\n\n- - 103 -\n<!-- PAGE_110 -->\n###### ○ 이외에도 시험자가 중대하다고 간주하거나, 임상시험용 의료\n\n<!-- PAGE_110 -->\n###### 기기와의 사용과 연관 지을 수 있는 유의한 위험, 금기, 부작용,\n\n<!-- PAGE_110 -->\n###### 주의사항을 시사하는 사건 등도 중대한 이상사례/의료기기\n\n<!-- PAGE_110 -->\n###### 이상반응으로 기록하고 사망을 초래하거나 생명을 위협할 때는\n\n<!-- PAGE_110 -->\n###### 의뢰자가 이 사실을 보고받거나 알게 된 날로부터 7일 이내,\n\n<!-- PAGE_110 -->\n###### 이 경우 상세한 정보를 최초 보고일로부터 8일 이내에 추가로\n\n<!-- PAGE_110 -->\n###### 보고 하여야 한다.  그 밖의 중대하거나 예상하지 못한 모든\n\n<!-- PAGE_110 -->\n###### 이상 반응이 나타났을 때 의뢰자가 이 사실을 보고 받거나\n\n- - 104 -\n<!-- PAGE_111 -->\n##### 16.  피험자 동의서 서식\n\n<!-- PAGE_111 -->\n###### 가.  피험자 동의서에 반드시 포함되어야 하는 사항\n\n<!-- PAGE_111 -->\n###### 3) 임상시험용 의료기기에 관한 정보 및 시험군 또는 대조군에\n\n<!-- PAGE_111 -->\n###### 4) 침습적 시술(invasive procedure)을 포함하여 임상시험에서 피험자가\n\n<!-- PAGE_111 -->\n###### 8) 기대되는 이익이 있거나 피험자에게 기대되는 이익이 없을 경우\n\n<!-- PAGE_111 -->\n###### 9) 피험자가 선택할 수 있는 다른 치료방법이나 종류 및 그 치료\n\n- - 105 -\n<!-- PAGE_112 -->\n###### 10) 임상시험과 관련한 손상이 발생하였을 경우 피험자에게 주어질\n\n<!-- PAGE_112 -->\n###### 보상이나 치료방법\n\n<!-- PAGE_112 -->\n###### 11) 피험자가 임상시험에 참여함으로써 받게 될 금전적 보상이 있는\n\n<!-- PAGE_112 -->\n###### 경우 예상 금액 및 이 금액이 임상시험 참여의 정도나 기간에\n\n<!-- PAGE_112 -->\n###### 13) 피험자의 임상시험 참여 여부 결정은 자발적이어야 하며,\n\n<!-- PAGE_112 -->\n###### 피험자가 원래 받을 수 있는 이익에 대한 손실 없이 임상시험의\n\n<!-- PAGE_112 -->\n###### 참여를 거부하거나 임상시험 도중 언제라도 참여를 포기할 수\n\n<!-- PAGE_112 -->\n###### 14) 제8호 항목에 따른 모니터 요원, 제8호 항목에 따른 점검을\n\n<!-- PAGE_112 -->\n###### 실시하는 자, 임상시험심사위원회 및 식품의약품안전처장이 관계\n\n<!-- PAGE_112 -->\n###### 법령에 따라 임상시험의 실시 절차와 자료의 품질을 검증하기\n\n<!-- PAGE_112 -->\n###### 위하여 피험자의 신상에 관한 비밀이 보호되는 범위에서 피험자의\n\n<!-- PAGE_112 -->\n###### 의무기록을 열람할 수 있다는 사실과 피험자 또는 피험자 대리인의\n\n<!-- PAGE_112 -->\n###### 15) 피험자의 신상을 파악할 수 있는 기록은 비밀로 보호될 것이며\n\n<!-- PAGE_112 -->\n###### 임상시험의 결과가 출관될 경우 피험자의 신상은 비밀로 보호\n\n<!-- PAGE_112 -->\n###### 16) 피험자의 임상시험 계속 참여 여부에 영향을 줄 수 있는 새로운\n\n<!-- PAGE_112 -->\n###### 정보를 취득하면 적시에 피험자 또는 피험자의 대리인에게 알릴\n\n<!-- PAGE_112 -->\n###### 17) 임상시험과 피험자의 권익에 관하여 추가적인 정보를 얻고자\n\n- - 106 -\n<!-- PAGE_113 -->\n###### 하거나 임상시험과 관련이 있는 손상이 발생하면 연락해야 하는\n\n<!-- PAGE_113 -->\n###### 사람\n\n<!-- PAGE_113 -->\n###### 18) 임상시험 도중 피험자의 임상시험 참여가 중지되는 경우 및 그\n\n<!-- PAGE_113 -->\n###### 나.  피험자 동의의 일반적 요건\n\n<!-- PAGE_113 -->\n###### 1) 연구자는 연구를 시작하기 전에 임상시험심사위원회(Institutional\n\n<!-- PAGE_113 -->\n###### Review Board, IRB)로부터 피험자에게 제공될 설명서 및 동의서,\n\n<!-- PAGE_113 -->\n###### 2) 연구자는 임상시험심사위원회 승인 직인이 찍힌 동의서 등을\n\n<!-- PAGE_113 -->\n###### 피험자 또는 피험자의 대리인에게 제공해야 하며, 피험자(또는\n\n<!-- PAGE_113 -->\n###### 대리인)와 동의를 받은 책임연구자(또는 책임연구자의 위임을 받은\n\n<!-- PAGE_113 -->\n###### 자)는 동의서 서식에 서명하고, 자필로 해당 날짜를 기재하여야\n\n<!-- PAGE_113 -->\n###### 3) 연구자는 서명된 동의서를 보관해야 하며, 사본을 피험자(또는\n\n<!-- PAGE_113 -->\n###### 4) 동의서를 받는 과정에서 연구자는 피험자 또는 대리인에게 강제나\n\n<!-- PAGE_113 -->\n###### 부당한 영향을 미치지 않아야 하며, 피험자 또는 대리인이 연구의\n\n<!-- PAGE_113 -->\n###### 모든 정보를 이해할 수 있는 용어 및 언어로 작성된 동의서 등을\n\n<!-- PAGE_113 -->\n###### 제공하여 설명하고 질문에 대하여 대답한 후 충분히 생각할\n\n- - 107 -\n<!-- PAGE_114 -->\n###### 5) 피험자 동의서에는 피험자 또는 대리인의 법적 권리를 포기나\n\n<!-- PAGE_114 -->\n###### 제한, 연구자/의뢰자/기관 및 기관장의 과실 책임의 면제를 암시\n\n<!-- PAGE_114 -->\n###### 6) 피험자의 동의에 영향을 줄 수 있는 새로운 연구 관련정보가\n\n<!-- PAGE_114 -->\n###### 수집되면 동의서 서식, 피험자 설명서 및 기타 문서화된 정보는\n\n<!-- PAGE_114 -->\n###### 이에 따라 수정되어야 하며, 사용 전에 반드시 위원회의 승인을\n\n<!-- PAGE_114 -->\n###### 받아야 한다.  피험자의 지속적인 연구 참여 의지에 영향을 줄 경우\n\n<!-- PAGE_114 -->\n###### 연구 책임자는 피험자 또는 대리인에게 즉시 알리고, 이러한\n\n<!-- PAGE_114 -->\n###### 7) 피험자 또는 대리인이 동의서 등을 읽을 수 없는 경우에는 공정한\n\n<!-- PAGE_114 -->\n###### 다. ",
        "original_sentence": "피험자 동의서 서식\n\n<!-- PAGE_111 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_804",
      "text": "피험자 동의서에 반드시 포함되어야 하는 사항\n\n<!-- PAGE_111 -->\n###### 3) 임상시험용 의료기기에 관한 정보 및 시험군 또는 대조군에\n\n<!-- PAGE_111 -->\n###### 4) 침습적 시술(invasive procedure)을 포함하여 임상시험에서 피험자가\n\n<!-- PAGE_111 -->\n###### 8) 기대되는 이익이 있거나 피험자에게 기대되는 이익이 없을 경우\n\n<!-- PAGE_111 -->\n###### 9) 피험자가 선택할 수 있는 다른 치료방법이나 종류 및 그 치료\n\n- - 105 -\n<!-- PAGE_112 -->\n###### 10) 임상시험과 관련한 손상이 발생하였을 경우 피험자에게 주어질\n\n<!-- PAGE_112 -->\n###### 보상이나 치료방법\n\n<!-- PAGE_112 -->\n###### 11) 피험자가 임상시험에 참여함으로써 받게 될 금전적 보상이 있는\n\n<!-- PAGE_112 -->\n###### 경우 예상 금액 및 이 금액이 임상시험 참여의 정도나 기간에\n\n<!-- PAGE_112 -->\n###### 13) 피험자의 임상시험 참여 여부 결정은 자발적이어야 하며,\n\n<!-- PAGE_112 -->\n###### 피험자가 원래 받을 수 있는 이익에 대한 손실 없이 임상시험의\n\n<!-- PAGE_112 -->\n###### 참여를 거부하거나 임상시험 도중 언제라도 참여를 포기할 수\n\n<!-- PAGE_112 -->\n###### 14) 제8호 항목에 따른 모니터 요원, 제8호 항목에 따른 점검을\n\n<!-- PAGE_112 -->\n###### 실시하는 자, 임상시험심사위원회 및 식품의약품안전처장이 관계\n\n<!-- PAGE_112 -->\n###### 법령에 따라 임상시험의 실시 절차와 자료의 품질을 검증하기\n\n<!-- PAGE_112 -->\n###### 위하여 피험자의 신상에 관한 비밀이 보호되는 범위에서 피험자의\n\n<!-- PAGE_112 -->\n###### 의무기록을 열람할 수 있다는 사실과 피험자 또는 피험자 대리인의\n\n<!-- PAGE_112 -->\n###### 15) 피험자의 신상을 파악할 수 있는 기록은 비밀로 보호될 것이며\n\n<!-- PAGE_112 -->\n###### 임상시험의 결과가 출관될 경우 피험자의 신상은 비밀로 보호\n\n<!-- PAGE_112 -->\n###### 16) 피험자의 임상시험 계속 참여 여부에 영향을 줄 수 있는 새로운\n\n<!-- PAGE_112 -->\n###### 정보를 취득하면 적시에 피험자 또는 피험자의 대리인에게 알릴\n\n<!-- PAGE_112 -->\n###### 17) 임상시험과 피험자의 권익에 관하여 추가적인 정보를 얻고자\n\n- - 106 -\n<!-- PAGE_113 -->\n###### 하거나 임상시험과 관련이 있는 손상이 발생하면 연락해야 하는\n\n<!-- PAGE_113 -->\n###### 사람\n\n<!-- PAGE_113 -->\n###### 18) 임상시험 도중 피험자의 임상시험 참여가 중지되는 경우 및 그\n\n<!-- PAGE_113 -->\n###### 나. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 803,
        "window_size": 3,
        "char_count": 1508,
        "word_count": 311,
        "page_number": 111,
        "window_text": "이상 사례 보고 방법\n\n<!-- PAGE_109 -->\n###### ○ 시험책임자는 시험담당자 또는 임상의 등에게 임상시험용 의료\n\n<!-- PAGE_109 -->\n###### 기기 사용 후 나타날 수 있는 모든 이상 사례에 대하여 교육을\n\n<!-- PAGE_109 -->\n###### 하고 사용 후 나타나는 모든 현상에 대하여 보고하도록 교육을\n\n<!-- PAGE_109 -->\n###### ※\n\n<!-- PAGE_109 -->\n###### 본 내용은「의료기기법 시행규칙」별표 3“의료기기 임상시험 관리기준” 제8호\n\n- - 103 -\n<!-- PAGE_110 -->\n###### ○ 이외에도 시험자가 중대하다고 간주하거나, 임상시험용 의료\n\n<!-- PAGE_110 -->\n###### 기기와의 사용과 연관 지을 수 있는 유의한 위험, 금기, 부작용,\n\n<!-- PAGE_110 -->\n###### 주의사항을 시사하는 사건 등도 중대한 이상사례/의료기기\n\n<!-- PAGE_110 -->\n###### 이상반응으로 기록하고 사망을 초래하거나 생명을 위협할 때는\n\n<!-- PAGE_110 -->\n###### 의뢰자가 이 사실을 보고받거나 알게 된 날로부터 7일 이내,\n\n<!-- PAGE_110 -->\n###### 이 경우 상세한 정보를 최초 보고일로부터 8일 이내에 추가로\n\n<!-- PAGE_110 -->\n###### 보고 하여야 한다.  그 밖의 중대하거나 예상하지 못한 모든\n\n<!-- PAGE_110 -->\n###### 이상 반응이 나타났을 때 의뢰자가 이 사실을 보고 받거나\n\n- - 104 -\n<!-- PAGE_111 -->\n##### 16.  피험자 동의서 서식\n\n<!-- PAGE_111 -->\n###### 가.  피험자 동의서에 반드시 포함되어야 하는 사항\n\n<!-- PAGE_111 -->\n###### 3) 임상시험용 의료기기에 관한 정보 및 시험군 또는 대조군에\n\n<!-- PAGE_111 -->\n###### 4) 침습적 시술(invasive procedure)을 포함하여 임상시험에서 피험자가\n\n<!-- PAGE_111 -->\n###### 8) 기대되는 이익이 있거나 피험자에게 기대되는 이익이 없을 경우\n\n<!-- PAGE_111 -->\n###### 9) 피험자가 선택할 수 있는 다른 치료방법이나 종류 및 그 치료\n\n- - 105 -\n<!-- PAGE_112 -->\n###### 10) 임상시험과 관련한 손상이 발생하였을 경우 피험자에게 주어질\n\n<!-- PAGE_112 -->\n###### 보상이나 치료방법\n\n<!-- PAGE_112 -->\n###### 11) 피험자가 임상시험에 참여함으로써 받게 될 금전적 보상이 있는\n\n<!-- PAGE_112 -->\n###### 경우 예상 금액 및 이 금액이 임상시험 참여의 정도나 기간에\n\n<!-- PAGE_112 -->\n###### 13) 피험자의 임상시험 참여 여부 결정은 자발적이어야 하며,\n\n<!-- PAGE_112 -->\n###### 피험자가 원래 받을 수 있는 이익에 대한 손실 없이 임상시험의\n\n<!-- PAGE_112 -->\n###### 참여를 거부하거나 임상시험 도중 언제라도 참여를 포기할 수\n\n<!-- PAGE_112 -->\n###### 14) 제8호 항목에 따른 모니터 요원, 제8호 항목에 따른 점검을\n\n<!-- PAGE_112 -->\n###### 실시하는 자, 임상시험심사위원회 및 식품의약품안전처장이 관계\n\n<!-- PAGE_112 -->\n###### 법령에 따라 임상시험의 실시 절차와 자료의 품질을 검증하기\n\n<!-- PAGE_112 -->\n###### 위하여 피험자의 신상에 관한 비밀이 보호되는 범위에서 피험자의\n\n<!-- PAGE_112 -->\n###### 의무기록을 열람할 수 있다는 사실과 피험자 또는 피험자 대리인의\n\n<!-- PAGE_112 -->\n###### 15) 피험자의 신상을 파악할 수 있는 기록은 비밀로 보호될 것이며\n\n<!-- PAGE_112 -->\n###### 임상시험의 결과가 출관될 경우 피험자의 신상은 비밀로 보호\n\n<!-- PAGE_112 -->\n###### 16) 피험자의 임상시험 계속 참여 여부에 영향을 줄 수 있는 새로운\n\n<!-- PAGE_112 -->\n###### 정보를 취득하면 적시에 피험자 또는 피험자의 대리인에게 알릴\n\n<!-- PAGE_112 -->\n###### 17) 임상시험과 피험자의 권익에 관하여 추가적인 정보를 얻고자\n\n- - 106 -\n<!-- PAGE_113 -->\n###### 하거나 임상시험과 관련이 있는 손상이 발생하면 연락해야 하는\n\n<!-- PAGE_113 -->\n###### 사람\n\n<!-- PAGE_113 -->\n###### 18) 임상시험 도중 피험자의 임상시험 참여가 중지되는 경우 및 그\n\n<!-- PAGE_113 -->\n###### 나.  피험자 동의의 일반적 요건\n\n<!-- PAGE_113 -->\n###### 1) 연구자는 연구를 시작하기 전에 임상시험심사위원회(Institutional\n\n<!-- PAGE_113 -->\n###### Review Board, IRB)로부터 피험자에게 제공될 설명서 및 동의서,\n\n<!-- PAGE_113 -->\n###### 2) 연구자는 임상시험심사위원회 승인 직인이 찍힌 동의서 등을\n\n<!-- PAGE_113 -->\n###### 피험자 또는 피험자의 대리인에게 제공해야 하며, 피험자(또는\n\n<!-- PAGE_113 -->\n###### 대리인)와 동의를 받은 책임연구자(또는 책임연구자의 위임을 받은\n\n<!-- PAGE_113 -->\n###### 자)는 동의서 서식에 서명하고, 자필로 해당 날짜를 기재하여야\n\n<!-- PAGE_113 -->\n###### 3) 연구자는 서명된 동의서를 보관해야 하며, 사본을 피험자(또는\n\n<!-- PAGE_113 -->\n###### 4) 동의서를 받는 과정에서 연구자는 피험자 또는 대리인에게 강제나\n\n<!-- PAGE_113 -->\n###### 부당한 영향을 미치지 않아야 하며, 피험자 또는 대리인이 연구의\n\n<!-- PAGE_113 -->\n###### 모든 정보를 이해할 수 있는 용어 및 언어로 작성된 동의서 등을\n\n<!-- PAGE_113 -->\n###### 제공하여 설명하고 질문에 대하여 대답한 후 충분히 생각할\n\n- - 107 -\n<!-- PAGE_114 -->\n###### 5) 피험자 동의서에는 피험자 또는 대리인의 법적 권리를 포기나\n\n<!-- PAGE_114 -->\n###### 제한, 연구자/의뢰자/기관 및 기관장의 과실 책임의 면제를 암시\n\n<!-- PAGE_114 -->\n###### 6) 피험자의 동의에 영향을 줄 수 있는 새로운 연구 관련정보가\n\n<!-- PAGE_114 -->\n###### 수집되면 동의서 서식, 피험자 설명서 및 기타 문서화된 정보는\n\n<!-- PAGE_114 -->\n###### 이에 따라 수정되어야 하며, 사용 전에 반드시 위원회의 승인을\n\n<!-- PAGE_114 -->\n###### 받아야 한다.  피험자의 지속적인 연구 참여 의지에 영향을 줄 경우\n\n<!-- PAGE_114 -->\n###### 연구 책임자는 피험자 또는 대리인에게 즉시 알리고, 이러한\n\n<!-- PAGE_114 -->\n###### 7) 피험자 또는 대리인이 동의서 등을 읽을 수 없는 경우에는 공정한\n\n<!-- PAGE_114 -->\n###### 다.  임상시험 실시 도중 피험자 설명문 등이 변경되었을 때 재동의\n\n<!-- PAGE_114 -->\n###### 임상시험 실시 도중 동의서 서식이 변경되거나, 피험자에게 제공된\n\n<!-- PAGE_114 -->\n###### 문서 정보의 변경이 있는 경우에는 변경일 기준 다음 방문일에 변경\n\n<!-- PAGE_114 -->\n###### 내용을 피험자에게 충분히 설명하고, 시험책임자(또는 시험담당의사)와\n\n<!-- PAGE_114 -->\n###### 피험자는 변경동의서에 서명하고 해당 날짜를 자필로 적어야 한다.\n\n",
        "original_sentence": "피험자 동의서에 반드시 포함되어야 하는 사항\n\n<!-- PAGE_111 -->\n###### 3) 임상시험용 의료기기에 관한 정보 및 시험군 또는 대조군에\n\n<!-- PAGE_111 -->\n###### 4) 침습적 시술(invasive procedure)을 포함하여 임상시험에서 피험자가\n\n<!-- PAGE_111 -->\n###### 8) 기대되는 이익이 있거나 피험자에게 기대되는 이익이 없을 경우\n\n<!-- PAGE_111 -->\n###### 9) 피험자가 선택할 수 있는 다른 치료방법이나 종류 및 그 치료\n\n- - 105 -\n<!-- PAGE_112 -->\n###### 10) 임상시험과 관련한 손상이 발생하였을 경우 피험자에게 주어질\n\n<!-- PAGE_112 -->\n###### 보상이나 치료방법\n\n<!-- PAGE_112 -->\n###### 11) 피험자가 임상시험에 참여함으로써 받게 될 금전적 보상이 있는\n\n<!-- PAGE_112 -->\n###### 경우 예상 금액 및 이 금액이 임상시험 참여의 정도나 기간에\n\n<!-- PAGE_112 -->\n###### 13) 피험자의 임상시험 참여 여부 결정은 자발적이어야 하며,\n\n<!-- PAGE_112 -->\n###### 피험자가 원래 받을 수 있는 이익에 대한 손실 없이 임상시험의\n\n<!-- PAGE_112 -->\n###### 참여를 거부하거나 임상시험 도중 언제라도 참여를 포기할 수\n\n<!-- PAGE_112 -->\n###### 14) 제8호 항목에 따른 모니터 요원, 제8호 항목에 따른 점검을\n\n<!-- PAGE_112 -->\n###### 실시하는 자, 임상시험심사위원회 및 식품의약품안전처장이 관계\n\n<!-- PAGE_112 -->\n###### 법령에 따라 임상시험의 실시 절차와 자료의 품질을 검증하기\n\n<!-- PAGE_112 -->\n###### 위하여 피험자의 신상에 관한 비밀이 보호되는 범위에서 피험자의\n\n<!-- PAGE_112 -->\n###### 의무기록을 열람할 수 있다는 사실과 피험자 또는 피험자 대리인의\n\n<!-- PAGE_112 -->\n###### 15) 피험자의 신상을 파악할 수 있는 기록은 비밀로 보호될 것이며\n\n<!-- PAGE_112 -->\n###### 임상시험의 결과가 출관될 경우 피험자의 신상은 비밀로 보호\n\n<!-- PAGE_112 -->\n###### 16) 피험자의 임상시험 계속 참여 여부에 영향을 줄 수 있는 새로운\n\n<!-- PAGE_112 -->\n###### 정보를 취득하면 적시에 피험자 또는 피험자의 대리인에게 알릴\n\n<!-- PAGE_112 -->\n###### 17) 임상시험과 피험자의 권익에 관하여 추가적인 정보를 얻고자\n\n- - 106 -\n<!-- PAGE_113 -->\n###### 하거나 임상시험과 관련이 있는 손상이 발생하면 연락해야 하는\n\n<!-- PAGE_113 -->\n###### 사람\n\n<!-- PAGE_113 -->\n###### 18) 임상시험 도중 피험자의 임상시험 참여가 중지되는 경우 및 그\n\n<!-- PAGE_113 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_805",
      "text": "피험자 동의의 일반적 요건\n\n<!-- PAGE_113 -->\n###### 1) 연구자는 연구를 시작하기 전에 임상시험심사위원회(Institutional\n\n<!-- PAGE_113 -->\n###### Review Board, IRB)로부터 피험자에게 제공될 설명서 및 동의서,\n\n<!-- PAGE_113 -->\n###### 2) 연구자는 임상시험심사위원회 승인 직인이 찍힌 동의서 등을\n\n<!-- PAGE_113 -->\n###### 피험자 또는 피험자의 대리인에게 제공해야 하며, 피험자(또는\n\n<!-- PAGE_113 -->\n###### 대리인)와 동의를 받은 책임연구자(또는 책임연구자의 위임을 받은\n\n<!-- PAGE_113 -->\n###### 자)는 동의서 서식에 서명하고, 자필로 해당 날짜를 기재하여야\n\n<!-- PAGE_113 -->\n###### 3) 연구자는 서명된 동의서를 보관해야 하며, 사본을 피험자(또는\n\n<!-- PAGE_113 -->\n###### 4) 동의서를 받는 과정에서 연구자는 피험자 또는 대리인에게 강제나\n\n<!-- PAGE_113 -->\n###### 부당한 영향을 미치지 않아야 하며, 피험자 또는 대리인이 연구의\n\n<!-- PAGE_113 -->\n###### 모든 정보를 이해할 수 있는 용어 및 언어로 작성된 동의서 등을\n\n<!-- PAGE_113 -->\n###### 제공하여 설명하고 질문에 대하여 대답한 후 충분히 생각할\n\n- - 107 -\n<!-- PAGE_114 -->\n###### 5) 피험자 동의서에는 피험자 또는 대리인의 법적 권리를 포기나\n\n<!-- PAGE_114 -->\n###### 제한, 연구자/의뢰자/기관 및 기관장의 과실 책임의 면제를 암시\n\n<!-- PAGE_114 -->\n###### 6) 피험자의 동의에 영향을 줄 수 있는 새로운 연구 관련정보가\n\n<!-- PAGE_114 -->\n###### 수집되면 동의서 서식, 피험자 설명서 및 기타 문서화된 정보는\n\n<!-- PAGE_114 -->\n###### 이에 따라 수정되어야 하며, 사용 전에 반드시 위원회의 승인을\n\n<!-- PAGE_114 -->\n###### 받아야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 804,
        "window_size": 3,
        "char_count": 1059,
        "word_count": 212,
        "page_number": 113,
        "window_text": "그 밖의 중대하거나 예상하지 못한 모든\n\n<!-- PAGE_110 -->\n###### 이상 반응이 나타났을 때 의뢰자가 이 사실을 보고 받거나\n\n- - 104 -\n<!-- PAGE_111 -->\n##### 16.  피험자 동의서 서식\n\n<!-- PAGE_111 -->\n###### 가.  피험자 동의서에 반드시 포함되어야 하는 사항\n\n<!-- PAGE_111 -->\n###### 3) 임상시험용 의료기기에 관한 정보 및 시험군 또는 대조군에\n\n<!-- PAGE_111 -->\n###### 4) 침습적 시술(invasive procedure)을 포함하여 임상시험에서 피험자가\n\n<!-- PAGE_111 -->\n###### 8) 기대되는 이익이 있거나 피험자에게 기대되는 이익이 없을 경우\n\n<!-- PAGE_111 -->\n###### 9) 피험자가 선택할 수 있는 다른 치료방법이나 종류 및 그 치료\n\n- - 105 -\n<!-- PAGE_112 -->\n###### 10) 임상시험과 관련한 손상이 발생하였을 경우 피험자에게 주어질\n\n<!-- PAGE_112 -->\n###### 보상이나 치료방법\n\n<!-- PAGE_112 -->\n###### 11) 피험자가 임상시험에 참여함으로써 받게 될 금전적 보상이 있는\n\n<!-- PAGE_112 -->\n###### 경우 예상 금액 및 이 금액이 임상시험 참여의 정도나 기간에\n\n<!-- PAGE_112 -->\n###### 13) 피험자의 임상시험 참여 여부 결정은 자발적이어야 하며,\n\n<!-- PAGE_112 -->\n###### 피험자가 원래 받을 수 있는 이익에 대한 손실 없이 임상시험의\n\n<!-- PAGE_112 -->\n###### 참여를 거부하거나 임상시험 도중 언제라도 참여를 포기할 수\n\n<!-- PAGE_112 -->\n###### 14) 제8호 항목에 따른 모니터 요원, 제8호 항목에 따른 점검을\n\n<!-- PAGE_112 -->\n###### 실시하는 자, 임상시험심사위원회 및 식품의약품안전처장이 관계\n\n<!-- PAGE_112 -->\n###### 법령에 따라 임상시험의 실시 절차와 자료의 품질을 검증하기\n\n<!-- PAGE_112 -->\n###### 위하여 피험자의 신상에 관한 비밀이 보호되는 범위에서 피험자의\n\n<!-- PAGE_112 -->\n###### 의무기록을 열람할 수 있다는 사실과 피험자 또는 피험자 대리인의\n\n<!-- PAGE_112 -->\n###### 15) 피험자의 신상을 파악할 수 있는 기록은 비밀로 보호될 것이며\n\n<!-- PAGE_112 -->\n###### 임상시험의 결과가 출관될 경우 피험자의 신상은 비밀로 보호\n\n<!-- PAGE_112 -->\n###### 16) 피험자의 임상시험 계속 참여 여부에 영향을 줄 수 있는 새로운\n\n<!-- PAGE_112 -->\n###### 정보를 취득하면 적시에 피험자 또는 피험자의 대리인에게 알릴\n\n<!-- PAGE_112 -->\n###### 17) 임상시험과 피험자의 권익에 관하여 추가적인 정보를 얻고자\n\n- - 106 -\n<!-- PAGE_113 -->\n###### 하거나 임상시험과 관련이 있는 손상이 발생하면 연락해야 하는\n\n<!-- PAGE_113 -->\n###### 사람\n\n<!-- PAGE_113 -->\n###### 18) 임상시험 도중 피험자의 임상시험 참여가 중지되는 경우 및 그\n\n<!-- PAGE_113 -->\n###### 나.  피험자 동의의 일반적 요건\n\n<!-- PAGE_113 -->\n###### 1) 연구자는 연구를 시작하기 전에 임상시험심사위원회(Institutional\n\n<!-- PAGE_113 -->\n###### Review Board, IRB)로부터 피험자에게 제공될 설명서 및 동의서,\n\n<!-- PAGE_113 -->\n###### 2) 연구자는 임상시험심사위원회 승인 직인이 찍힌 동의서 등을\n\n<!-- PAGE_113 -->\n###### 피험자 또는 피험자의 대리인에게 제공해야 하며, 피험자(또는\n\n<!-- PAGE_113 -->\n###### 대리인)와 동의를 받은 책임연구자(또는 책임연구자의 위임을 받은\n\n<!-- PAGE_113 -->\n###### 자)는 동의서 서식에 서명하고, 자필로 해당 날짜를 기재하여야\n\n<!-- PAGE_113 -->\n###### 3) 연구자는 서명된 동의서를 보관해야 하며, 사본을 피험자(또는\n\n<!-- PAGE_113 -->\n###### 4) 동의서를 받는 과정에서 연구자는 피험자 또는 대리인에게 강제나\n\n<!-- PAGE_113 -->\n###### 부당한 영향을 미치지 않아야 하며, 피험자 또는 대리인이 연구의\n\n<!-- PAGE_113 -->\n###### 모든 정보를 이해할 수 있는 용어 및 언어로 작성된 동의서 등을\n\n<!-- PAGE_113 -->\n###### 제공하여 설명하고 질문에 대하여 대답한 후 충분히 생각할\n\n- - 107 -\n<!-- PAGE_114 -->\n###### 5) 피험자 동의서에는 피험자 또는 대리인의 법적 권리를 포기나\n\n<!-- PAGE_114 -->\n###### 제한, 연구자/의뢰자/기관 및 기관장의 과실 책임의 면제를 암시\n\n<!-- PAGE_114 -->\n###### 6) 피험자의 동의에 영향을 줄 수 있는 새로운 연구 관련정보가\n\n<!-- PAGE_114 -->\n###### 수집되면 동의서 서식, 피험자 설명서 및 기타 문서화된 정보는\n\n<!-- PAGE_114 -->\n###### 이에 따라 수정되어야 하며, 사용 전에 반드시 위원회의 승인을\n\n<!-- PAGE_114 -->\n###### 받아야 한다.  피험자의 지속적인 연구 참여 의지에 영향을 줄 경우\n\n<!-- PAGE_114 -->\n###### 연구 책임자는 피험자 또는 대리인에게 즉시 알리고, 이러한\n\n<!-- PAGE_114 -->\n###### 7) 피험자 또는 대리인이 동의서 등을 읽을 수 없는 경우에는 공정한\n\n<!-- PAGE_114 -->\n###### 다.  임상시험 실시 도중 피험자 설명문 등이 변경되었을 때 재동의\n\n<!-- PAGE_114 -->\n###### 임상시험 실시 도중 동의서 서식이 변경되거나, 피험자에게 제공된\n\n<!-- PAGE_114 -->\n###### 문서 정보의 변경이 있는 경우에는 변경일 기준 다음 방문일에 변경\n\n<!-- PAGE_114 -->\n###### 내용을 피험자에게 충분히 설명하고, 시험책임자(또는 시험담당의사)와\n\n<!-- PAGE_114 -->\n###### 피험자는 변경동의서에 서명하고 해당 날짜를 자필로 적어야 한다.\n\n <!-- PAGE_114 -->\n###### 라. ",
        "original_sentence": "피험자 동의의 일반적 요건\n\n<!-- PAGE_113 -->\n###### 1) 연구자는 연구를 시작하기 전에 임상시험심사위원회(Institutional\n\n<!-- PAGE_113 -->\n###### Review Board, IRB)로부터 피험자에게 제공될 설명서 및 동의서,\n\n<!-- PAGE_113 -->\n###### 2) 연구자는 임상시험심사위원회 승인 직인이 찍힌 동의서 등을\n\n<!-- PAGE_113 -->\n###### 피험자 또는 피험자의 대리인에게 제공해야 하며, 피험자(또는\n\n<!-- PAGE_113 -->\n###### 대리인)와 동의를 받은 책임연구자(또는 책임연구자의 위임을 받은\n\n<!-- PAGE_113 -->\n###### 자)는 동의서 서식에 서명하고, 자필로 해당 날짜를 기재하여야\n\n<!-- PAGE_113 -->\n###### 3) 연구자는 서명된 동의서를 보관해야 하며, 사본을 피험자(또는\n\n<!-- PAGE_113 -->\n###### 4) 동의서를 받는 과정에서 연구자는 피험자 또는 대리인에게 강제나\n\n<!-- PAGE_113 -->\n###### 부당한 영향을 미치지 않아야 하며, 피험자 또는 대리인이 연구의\n\n<!-- PAGE_113 -->\n###### 모든 정보를 이해할 수 있는 용어 및 언어로 작성된 동의서 등을\n\n<!-- PAGE_113 -->\n###### 제공하여 설명하고 질문에 대하여 대답한 후 충분히 생각할\n\n- - 107 -\n<!-- PAGE_114 -->\n###### 5) 피험자 동의서에는 피험자 또는 대리인의 법적 권리를 포기나\n\n<!-- PAGE_114 -->\n###### 제한, 연구자/의뢰자/기관 및 기관장의 과실 책임의 면제를 암시\n\n<!-- PAGE_114 -->\n###### 6) 피험자의 동의에 영향을 줄 수 있는 새로운 연구 관련정보가\n\n<!-- PAGE_114 -->\n###### 수집되면 동의서 서식, 피험자 설명서 및 기타 문서화된 정보는\n\n<!-- PAGE_114 -->\n###### 이에 따라 수정되어야 하며, 사용 전에 반드시 위원회의 승인을\n\n<!-- PAGE_114 -->\n###### 받아야 한다. "
      }
    },
    {
      "chunk_id": "chunk_806",
      "text": "피험자의 지속적인 연구 참여 의지에 영향을 줄 경우\n\n<!-- PAGE_114 -->\n###### 연구 책임자는 피험자 또는 대리인에게 즉시 알리고, 이러한\n\n<!-- PAGE_114 -->\n###### 7) 피험자 또는 대리인이 동의서 등을 읽을 수 없는 경우에는 공정한\n\n<!-- PAGE_114 -->\n###### 다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 805,
        "window_size": 3,
        "char_count": 182,
        "word_count": 40,
        "page_number": 114,
        "window_text": "피험자 동의서 서식\n\n<!-- PAGE_111 -->\n###### 가.  피험자 동의서에 반드시 포함되어야 하는 사항\n\n<!-- PAGE_111 -->\n###### 3) 임상시험용 의료기기에 관한 정보 및 시험군 또는 대조군에\n\n<!-- PAGE_111 -->\n###### 4) 침습적 시술(invasive procedure)을 포함하여 임상시험에서 피험자가\n\n<!-- PAGE_111 -->\n###### 8) 기대되는 이익이 있거나 피험자에게 기대되는 이익이 없을 경우\n\n<!-- PAGE_111 -->\n###### 9) 피험자가 선택할 수 있는 다른 치료방법이나 종류 및 그 치료\n\n- - 105 -\n<!-- PAGE_112 -->\n###### 10) 임상시험과 관련한 손상이 발생하였을 경우 피험자에게 주어질\n\n<!-- PAGE_112 -->\n###### 보상이나 치료방법\n\n<!-- PAGE_112 -->\n###### 11) 피험자가 임상시험에 참여함으로써 받게 될 금전적 보상이 있는\n\n<!-- PAGE_112 -->\n###### 경우 예상 금액 및 이 금액이 임상시험 참여의 정도나 기간에\n\n<!-- PAGE_112 -->\n###### 13) 피험자의 임상시험 참여 여부 결정은 자발적이어야 하며,\n\n<!-- PAGE_112 -->\n###### 피험자가 원래 받을 수 있는 이익에 대한 손실 없이 임상시험의\n\n<!-- PAGE_112 -->\n###### 참여를 거부하거나 임상시험 도중 언제라도 참여를 포기할 수\n\n<!-- PAGE_112 -->\n###### 14) 제8호 항목에 따른 모니터 요원, 제8호 항목에 따른 점검을\n\n<!-- PAGE_112 -->\n###### 실시하는 자, 임상시험심사위원회 및 식품의약품안전처장이 관계\n\n<!-- PAGE_112 -->\n###### 법령에 따라 임상시험의 실시 절차와 자료의 품질을 검증하기\n\n<!-- PAGE_112 -->\n###### 위하여 피험자의 신상에 관한 비밀이 보호되는 범위에서 피험자의\n\n<!-- PAGE_112 -->\n###### 의무기록을 열람할 수 있다는 사실과 피험자 또는 피험자 대리인의\n\n<!-- PAGE_112 -->\n###### 15) 피험자의 신상을 파악할 수 있는 기록은 비밀로 보호될 것이며\n\n<!-- PAGE_112 -->\n###### 임상시험의 결과가 출관될 경우 피험자의 신상은 비밀로 보호\n\n<!-- PAGE_112 -->\n###### 16) 피험자의 임상시험 계속 참여 여부에 영향을 줄 수 있는 새로운\n\n<!-- PAGE_112 -->\n###### 정보를 취득하면 적시에 피험자 또는 피험자의 대리인에게 알릴\n\n<!-- PAGE_112 -->\n###### 17) 임상시험과 피험자의 권익에 관하여 추가적인 정보를 얻고자\n\n- - 106 -\n<!-- PAGE_113 -->\n###### 하거나 임상시험과 관련이 있는 손상이 발생하면 연락해야 하는\n\n<!-- PAGE_113 -->\n###### 사람\n\n<!-- PAGE_113 -->\n###### 18) 임상시험 도중 피험자의 임상시험 참여가 중지되는 경우 및 그\n\n<!-- PAGE_113 -->\n###### 나.  피험자 동의의 일반적 요건\n\n<!-- PAGE_113 -->\n###### 1) 연구자는 연구를 시작하기 전에 임상시험심사위원회(Institutional\n\n<!-- PAGE_113 -->\n###### Review Board, IRB)로부터 피험자에게 제공될 설명서 및 동의서,\n\n<!-- PAGE_113 -->\n###### 2) 연구자는 임상시험심사위원회 승인 직인이 찍힌 동의서 등을\n\n<!-- PAGE_113 -->\n###### 피험자 또는 피험자의 대리인에게 제공해야 하며, 피험자(또는\n\n<!-- PAGE_113 -->\n###### 대리인)와 동의를 받은 책임연구자(또는 책임연구자의 위임을 받은\n\n<!-- PAGE_113 -->\n###### 자)는 동의서 서식에 서명하고, 자필로 해당 날짜를 기재하여야\n\n<!-- PAGE_113 -->\n###### 3) 연구자는 서명된 동의서를 보관해야 하며, 사본을 피험자(또는\n\n<!-- PAGE_113 -->\n###### 4) 동의서를 받는 과정에서 연구자는 피험자 또는 대리인에게 강제나\n\n<!-- PAGE_113 -->\n###### 부당한 영향을 미치지 않아야 하며, 피험자 또는 대리인이 연구의\n\n<!-- PAGE_113 -->\n###### 모든 정보를 이해할 수 있는 용어 및 언어로 작성된 동의서 등을\n\n<!-- PAGE_113 -->\n###### 제공하여 설명하고 질문에 대하여 대답한 후 충분히 생각할\n\n- - 107 -\n<!-- PAGE_114 -->\n###### 5) 피험자 동의서에는 피험자 또는 대리인의 법적 권리를 포기나\n\n<!-- PAGE_114 -->\n###### 제한, 연구자/의뢰자/기관 및 기관장의 과실 책임의 면제를 암시\n\n<!-- PAGE_114 -->\n###### 6) 피험자의 동의에 영향을 줄 수 있는 새로운 연구 관련정보가\n\n<!-- PAGE_114 -->\n###### 수집되면 동의서 서식, 피험자 설명서 및 기타 문서화된 정보는\n\n<!-- PAGE_114 -->\n###### 이에 따라 수정되어야 하며, 사용 전에 반드시 위원회의 승인을\n\n<!-- PAGE_114 -->\n###### 받아야 한다.  피험자의 지속적인 연구 참여 의지에 영향을 줄 경우\n\n<!-- PAGE_114 -->\n###### 연구 책임자는 피험자 또는 대리인에게 즉시 알리고, 이러한\n\n<!-- PAGE_114 -->\n###### 7) 피험자 또는 대리인이 동의서 등을 읽을 수 없는 경우에는 공정한\n\n<!-- PAGE_114 -->\n###### 다.  임상시험 실시 도중 피험자 설명문 등이 변경되었을 때 재동의\n\n<!-- PAGE_114 -->\n###### 임상시험 실시 도중 동의서 서식이 변경되거나, 피험자에게 제공된\n\n<!-- PAGE_114 -->\n###### 문서 정보의 변경이 있는 경우에는 변경일 기준 다음 방문일에 변경\n\n<!-- PAGE_114 -->\n###### 내용을 피험자에게 충분히 설명하고, 시험책임자(또는 시험담당의사)와\n\n<!-- PAGE_114 -->\n###### 피험자는 변경동의서에 서명하고 해당 날짜를 자필로 적어야 한다.\n\n <!-- PAGE_114 -->\n###### 라.  피험자의 대리인이 피험자를 대신하여 임상시험 참여에 동의\n\n<!-- PAGE_114 -->\n###### 피험자의 이해능력, 의사표현능력의 결여 등의 사유로 동의를 받을\n\n<!-- PAGE_114 -->\n###### 수 없는 경우에는 대리인의 동의를 받을 수 있으며, 이와 같은 경우\n\n<!-- PAGE_114 -->\n###### 에도 피험자는 피험자 자신이 이해할 수 있는 정도까지 임상시험에\n\n<!-- PAGE_114 -->\n###### 관한 정보를 제공 받아야하며, 가능하다면 피험자는 동의서 서식에\n\n- - 108 -\n<!-- PAGE_115 -->\n###### 서명하고 자필로 날짜를 기재하여야 한다. ",
        "original_sentence": "피험자의 지속적인 연구 참여 의지에 영향을 줄 경우\n\n<!-- PAGE_114 -->\n###### 연구 책임자는 피험자 또는 대리인에게 즉시 알리고, 이러한\n\n<!-- PAGE_114 -->\n###### 7) 피험자 또는 대리인이 동의서 등을 읽을 수 없는 경우에는 공정한\n\n<!-- PAGE_114 -->\n###### 다. "
      }
    },
    {
      "chunk_id": "chunk_807",
      "text": "임상시험 실시 도중 피험자 설명문 등이 변경되었을 때 재동의\n\n<!-- PAGE_114 -->\n###### 임상시험 실시 도중 동의서 서식이 변경되거나, 피험자에게 제공된\n\n<!-- PAGE_114 -->\n###### 문서 정보의 변경이 있는 경우에는 변경일 기준 다음 방문일에 변경\n\n<!-- PAGE_114 -->\n###### 내용을 피험자에게 충분히 설명하고, 시험책임자(또는 시험담당의사)와\n\n<!-- PAGE_114 -->\n###### 피험자는 변경동의서에 서명하고 해당 날짜를 자필로 적어야 한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 806,
        "window_size": 3,
        "char_count": 286,
        "word_count": 57,
        "page_number": 114,
        "window_text": "피험자 동의서에 반드시 포함되어야 하는 사항\n\n<!-- PAGE_111 -->\n###### 3) 임상시험용 의료기기에 관한 정보 및 시험군 또는 대조군에\n\n<!-- PAGE_111 -->\n###### 4) 침습적 시술(invasive procedure)을 포함하여 임상시험에서 피험자가\n\n<!-- PAGE_111 -->\n###### 8) 기대되는 이익이 있거나 피험자에게 기대되는 이익이 없을 경우\n\n<!-- PAGE_111 -->\n###### 9) 피험자가 선택할 수 있는 다른 치료방법이나 종류 및 그 치료\n\n- - 105 -\n<!-- PAGE_112 -->\n###### 10) 임상시험과 관련한 손상이 발생하였을 경우 피험자에게 주어질\n\n<!-- PAGE_112 -->\n###### 보상이나 치료방법\n\n<!-- PAGE_112 -->\n###### 11) 피험자가 임상시험에 참여함으로써 받게 될 금전적 보상이 있는\n\n<!-- PAGE_112 -->\n###### 경우 예상 금액 및 이 금액이 임상시험 참여의 정도나 기간에\n\n<!-- PAGE_112 -->\n###### 13) 피험자의 임상시험 참여 여부 결정은 자발적이어야 하며,\n\n<!-- PAGE_112 -->\n###### 피험자가 원래 받을 수 있는 이익에 대한 손실 없이 임상시험의\n\n<!-- PAGE_112 -->\n###### 참여를 거부하거나 임상시험 도중 언제라도 참여를 포기할 수\n\n<!-- PAGE_112 -->\n###### 14) 제8호 항목에 따른 모니터 요원, 제8호 항목에 따른 점검을\n\n<!-- PAGE_112 -->\n###### 실시하는 자, 임상시험심사위원회 및 식품의약품안전처장이 관계\n\n<!-- PAGE_112 -->\n###### 법령에 따라 임상시험의 실시 절차와 자료의 품질을 검증하기\n\n<!-- PAGE_112 -->\n###### 위하여 피험자의 신상에 관한 비밀이 보호되는 범위에서 피험자의\n\n<!-- PAGE_112 -->\n###### 의무기록을 열람할 수 있다는 사실과 피험자 또는 피험자 대리인의\n\n<!-- PAGE_112 -->\n###### 15) 피험자의 신상을 파악할 수 있는 기록은 비밀로 보호될 것이며\n\n<!-- PAGE_112 -->\n###### 임상시험의 결과가 출관될 경우 피험자의 신상은 비밀로 보호\n\n<!-- PAGE_112 -->\n###### 16) 피험자의 임상시험 계속 참여 여부에 영향을 줄 수 있는 새로운\n\n<!-- PAGE_112 -->\n###### 정보를 취득하면 적시에 피험자 또는 피험자의 대리인에게 알릴\n\n<!-- PAGE_112 -->\n###### 17) 임상시험과 피험자의 권익에 관하여 추가적인 정보를 얻고자\n\n- - 106 -\n<!-- PAGE_113 -->\n###### 하거나 임상시험과 관련이 있는 손상이 발생하면 연락해야 하는\n\n<!-- PAGE_113 -->\n###### 사람\n\n<!-- PAGE_113 -->\n###### 18) 임상시험 도중 피험자의 임상시험 참여가 중지되는 경우 및 그\n\n<!-- PAGE_113 -->\n###### 나.  피험자 동의의 일반적 요건\n\n<!-- PAGE_113 -->\n###### 1) 연구자는 연구를 시작하기 전에 임상시험심사위원회(Institutional\n\n<!-- PAGE_113 -->\n###### Review Board, IRB)로부터 피험자에게 제공될 설명서 및 동의서,\n\n<!-- PAGE_113 -->\n###### 2) 연구자는 임상시험심사위원회 승인 직인이 찍힌 동의서 등을\n\n<!-- PAGE_113 -->\n###### 피험자 또는 피험자의 대리인에게 제공해야 하며, 피험자(또는\n\n<!-- PAGE_113 -->\n###### 대리인)와 동의를 받은 책임연구자(또는 책임연구자의 위임을 받은\n\n<!-- PAGE_113 -->\n###### 자)는 동의서 서식에 서명하고, 자필로 해당 날짜를 기재하여야\n\n<!-- PAGE_113 -->\n###### 3) 연구자는 서명된 동의서를 보관해야 하며, 사본을 피험자(또는\n\n<!-- PAGE_113 -->\n###### 4) 동의서를 받는 과정에서 연구자는 피험자 또는 대리인에게 강제나\n\n<!-- PAGE_113 -->\n###### 부당한 영향을 미치지 않아야 하며, 피험자 또는 대리인이 연구의\n\n<!-- PAGE_113 -->\n###### 모든 정보를 이해할 수 있는 용어 및 언어로 작성된 동의서 등을\n\n<!-- PAGE_113 -->\n###### 제공하여 설명하고 질문에 대하여 대답한 후 충분히 생각할\n\n- - 107 -\n<!-- PAGE_114 -->\n###### 5) 피험자 동의서에는 피험자 또는 대리인의 법적 권리를 포기나\n\n<!-- PAGE_114 -->\n###### 제한, 연구자/의뢰자/기관 및 기관장의 과실 책임의 면제를 암시\n\n<!-- PAGE_114 -->\n###### 6) 피험자의 동의에 영향을 줄 수 있는 새로운 연구 관련정보가\n\n<!-- PAGE_114 -->\n###### 수집되면 동의서 서식, 피험자 설명서 및 기타 문서화된 정보는\n\n<!-- PAGE_114 -->\n###### 이에 따라 수정되어야 하며, 사용 전에 반드시 위원회의 승인을\n\n<!-- PAGE_114 -->\n###### 받아야 한다.  피험자의 지속적인 연구 참여 의지에 영향을 줄 경우\n\n<!-- PAGE_114 -->\n###### 연구 책임자는 피험자 또는 대리인에게 즉시 알리고, 이러한\n\n<!-- PAGE_114 -->\n###### 7) 피험자 또는 대리인이 동의서 등을 읽을 수 없는 경우에는 공정한\n\n<!-- PAGE_114 -->\n###### 다.  임상시험 실시 도중 피험자 설명문 등이 변경되었을 때 재동의\n\n<!-- PAGE_114 -->\n###### 임상시험 실시 도중 동의서 서식이 변경되거나, 피험자에게 제공된\n\n<!-- PAGE_114 -->\n###### 문서 정보의 변경이 있는 경우에는 변경일 기준 다음 방문일에 변경\n\n<!-- PAGE_114 -->\n###### 내용을 피험자에게 충분히 설명하고, 시험책임자(또는 시험담당의사)와\n\n<!-- PAGE_114 -->\n###### 피험자는 변경동의서에 서명하고 해당 날짜를 자필로 적어야 한다.\n\n <!-- PAGE_114 -->\n###### 라.  피험자의 대리인이 피험자를 대신하여 임상시험 참여에 동의\n\n<!-- PAGE_114 -->\n###### 피험자의 이해능력, 의사표현능력의 결여 등의 사유로 동의를 받을\n\n<!-- PAGE_114 -->\n###### 수 없는 경우에는 대리인의 동의를 받을 수 있으며, 이와 같은 경우\n\n<!-- PAGE_114 -->\n###### 에도 피험자는 피험자 자신이 이해할 수 있는 정도까지 임상시험에\n\n<!-- PAGE_114 -->\n###### 관한 정보를 제공 받아야하며, 가능하다면 피험자는 동의서 서식에\n\n- - 108 -\n<!-- PAGE_115 -->\n###### 서명하고 자필로 날짜를 기재하여야 한다.  또한, 피험자의 대리인임을\n\n<!-- PAGE_115 -->\n###### 확인할 수 있는 근거자료 등을 확보하고, 피험자 동의 설명서 등에\n\n<!-- PAGE_115 -->\n###### 대리인의 동의 사유를 구체적으로 기술할 것을 권장한다.\n\n",
        "original_sentence": "임상시험 실시 도중 피험자 설명문 등이 변경되었을 때 재동의\n\n<!-- PAGE_114 -->\n###### 임상시험 실시 도중 동의서 서식이 변경되거나, 피험자에게 제공된\n\n<!-- PAGE_114 -->\n###### 문서 정보의 변경이 있는 경우에는 변경일 기준 다음 방문일에 변경\n\n<!-- PAGE_114 -->\n###### 내용을 피험자에게 충분히 설명하고, 시험책임자(또는 시험담당의사)와\n\n<!-- PAGE_114 -->\n###### 피험자는 변경동의서에 서명하고 해당 날짜를 자필로 적어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_808",
      "text": "<!-- PAGE_114 -->\n###### 라. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 807,
        "window_size": 3,
        "char_count": 28,
        "word_count": 5,
        "page_number": 114,
        "window_text": "피험자 동의의 일반적 요건\n\n<!-- PAGE_113 -->\n###### 1) 연구자는 연구를 시작하기 전에 임상시험심사위원회(Institutional\n\n<!-- PAGE_113 -->\n###### Review Board, IRB)로부터 피험자에게 제공될 설명서 및 동의서,\n\n<!-- PAGE_113 -->\n###### 2) 연구자는 임상시험심사위원회 승인 직인이 찍힌 동의서 등을\n\n<!-- PAGE_113 -->\n###### 피험자 또는 피험자의 대리인에게 제공해야 하며, 피험자(또는\n\n<!-- PAGE_113 -->\n###### 대리인)와 동의를 받은 책임연구자(또는 책임연구자의 위임을 받은\n\n<!-- PAGE_113 -->\n###### 자)는 동의서 서식에 서명하고, 자필로 해당 날짜를 기재하여야\n\n<!-- PAGE_113 -->\n###### 3) 연구자는 서명된 동의서를 보관해야 하며, 사본을 피험자(또는\n\n<!-- PAGE_113 -->\n###### 4) 동의서를 받는 과정에서 연구자는 피험자 또는 대리인에게 강제나\n\n<!-- PAGE_113 -->\n###### 부당한 영향을 미치지 않아야 하며, 피험자 또는 대리인이 연구의\n\n<!-- PAGE_113 -->\n###### 모든 정보를 이해할 수 있는 용어 및 언어로 작성된 동의서 등을\n\n<!-- PAGE_113 -->\n###### 제공하여 설명하고 질문에 대하여 대답한 후 충분히 생각할\n\n- - 107 -\n<!-- PAGE_114 -->\n###### 5) 피험자 동의서에는 피험자 또는 대리인의 법적 권리를 포기나\n\n<!-- PAGE_114 -->\n###### 제한, 연구자/의뢰자/기관 및 기관장의 과실 책임의 면제를 암시\n\n<!-- PAGE_114 -->\n###### 6) 피험자의 동의에 영향을 줄 수 있는 새로운 연구 관련정보가\n\n<!-- PAGE_114 -->\n###### 수집되면 동의서 서식, 피험자 설명서 및 기타 문서화된 정보는\n\n<!-- PAGE_114 -->\n###### 이에 따라 수정되어야 하며, 사용 전에 반드시 위원회의 승인을\n\n<!-- PAGE_114 -->\n###### 받아야 한다.  피험자의 지속적인 연구 참여 의지에 영향을 줄 경우\n\n<!-- PAGE_114 -->\n###### 연구 책임자는 피험자 또는 대리인에게 즉시 알리고, 이러한\n\n<!-- PAGE_114 -->\n###### 7) 피험자 또는 대리인이 동의서 등을 읽을 수 없는 경우에는 공정한\n\n<!-- PAGE_114 -->\n###### 다.  임상시험 실시 도중 피험자 설명문 등이 변경되었을 때 재동의\n\n<!-- PAGE_114 -->\n###### 임상시험 실시 도중 동의서 서식이 변경되거나, 피험자에게 제공된\n\n<!-- PAGE_114 -->\n###### 문서 정보의 변경이 있는 경우에는 변경일 기준 다음 방문일에 변경\n\n<!-- PAGE_114 -->\n###### 내용을 피험자에게 충분히 설명하고, 시험책임자(또는 시험담당의사)와\n\n<!-- PAGE_114 -->\n###### 피험자는 변경동의서에 서명하고 해당 날짜를 자필로 적어야 한다.\n\n <!-- PAGE_114 -->\n###### 라.  피험자의 대리인이 피험자를 대신하여 임상시험 참여에 동의\n\n<!-- PAGE_114 -->\n###### 피험자의 이해능력, 의사표현능력의 결여 등의 사유로 동의를 받을\n\n<!-- PAGE_114 -->\n###### 수 없는 경우에는 대리인의 동의를 받을 수 있으며, 이와 같은 경우\n\n<!-- PAGE_114 -->\n###### 에도 피험자는 피험자 자신이 이해할 수 있는 정도까지 임상시험에\n\n<!-- PAGE_114 -->\n###### 관한 정보를 제공 받아야하며, 가능하다면 피험자는 동의서 서식에\n\n- - 108 -\n<!-- PAGE_115 -->\n###### 서명하고 자필로 날짜를 기재하여야 한다.  또한, 피험자의 대리인임을\n\n<!-- PAGE_115 -->\n###### 확인할 수 있는 근거자료 등을 확보하고, 피험자 동의 설명서 등에\n\n<!-- PAGE_115 -->\n###### 대리인의 동의 사유를 구체적으로 기술할 것을 권장한다.\n\n - - 109 -\n<!-- PAGE_116 -->\n##### 17. ",
        "original_sentence": "<!-- PAGE_114 -->\n###### 라. "
      }
    },
    {
      "chunk_id": "chunk_809",
      "text": "피험자의 대리인이 피험자를 대신하여 임상시험 참여에 동의\n\n<!-- PAGE_114 -->\n###### 피험자의 이해능력, 의사표현능력의 결여 등의 사유로 동의를 받을\n\n<!-- PAGE_114 -->\n###### 수 없는 경우에는 대리인의 동의를 받을 수 있으며, 이와 같은 경우\n\n<!-- PAGE_114 -->\n###### 에도 피험자는 피험자 자신이 이해할 수 있는 정도까지 임상시험에\n\n<!-- PAGE_114 -->\n###### 관한 정보를 제공 받아야하며, 가능하다면 피험자는 동의서 서식에\n\n- - 108 -\n<!-- PAGE_115 -->\n###### 서명하고 자필로 날짜를 기재하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 808,
        "window_size": 3,
        "char_count": 341,
        "word_count": 72,
        "page_number": 114,
        "window_text": "피험자의 지속적인 연구 참여 의지에 영향을 줄 경우\n\n<!-- PAGE_114 -->\n###### 연구 책임자는 피험자 또는 대리인에게 즉시 알리고, 이러한\n\n<!-- PAGE_114 -->\n###### 7) 피험자 또는 대리인이 동의서 등을 읽을 수 없는 경우에는 공정한\n\n<!-- PAGE_114 -->\n###### 다.  임상시험 실시 도중 피험자 설명문 등이 변경되었을 때 재동의\n\n<!-- PAGE_114 -->\n###### 임상시험 실시 도중 동의서 서식이 변경되거나, 피험자에게 제공된\n\n<!-- PAGE_114 -->\n###### 문서 정보의 변경이 있는 경우에는 변경일 기준 다음 방문일에 변경\n\n<!-- PAGE_114 -->\n###### 내용을 피험자에게 충분히 설명하고, 시험책임자(또는 시험담당의사)와\n\n<!-- PAGE_114 -->\n###### 피험자는 변경동의서에 서명하고 해당 날짜를 자필로 적어야 한다.\n\n <!-- PAGE_114 -->\n###### 라.  피험자의 대리인이 피험자를 대신하여 임상시험 참여에 동의\n\n<!-- PAGE_114 -->\n###### 피험자의 이해능력, 의사표현능력의 결여 등의 사유로 동의를 받을\n\n<!-- PAGE_114 -->\n###### 수 없는 경우에는 대리인의 동의를 받을 수 있으며, 이와 같은 경우\n\n<!-- PAGE_114 -->\n###### 에도 피험자는 피험자 자신이 이해할 수 있는 정도까지 임상시험에\n\n<!-- PAGE_114 -->\n###### 관한 정보를 제공 받아야하며, 가능하다면 피험자는 동의서 서식에\n\n- - 108 -\n<!-- PAGE_115 -->\n###### 서명하고 자필로 날짜를 기재하여야 한다.  또한, 피험자의 대리인임을\n\n<!-- PAGE_115 -->\n###### 확인할 수 있는 근거자료 등을 확보하고, 피험자 동의 설명서 등에\n\n<!-- PAGE_115 -->\n###### 대리인의 동의 사유를 구체적으로 기술할 것을 권장한다.\n\n - - 109 -\n<!-- PAGE_116 -->\n##### 17.  피해자 보상에 대한 규약\n\n<!-- PAGE_116 -->\n###### 임상시험용 의료기기가 직접적 원인이 되어 피험자에게 손상이\n\n<!-- PAGE_116 -->\n###### 발생하여 응급조치가 필요한 경우 시험책임자가 가입한 보험에 의해\n\n<!-- PAGE_116 -->\n###### 보상한다. ",
        "original_sentence": "피험자의 대리인이 피험자를 대신하여 임상시험 참여에 동의\n\n<!-- PAGE_114 -->\n###### 피험자의 이해능력, 의사표현능력의 결여 등의 사유로 동의를 받을\n\n<!-- PAGE_114 -->\n###### 수 없는 경우에는 대리인의 동의를 받을 수 있으며, 이와 같은 경우\n\n<!-- PAGE_114 -->\n###### 에도 피험자는 피험자 자신이 이해할 수 있는 정도까지 임상시험에\n\n<!-- PAGE_114 -->\n###### 관한 정보를 제공 받아야하며, 가능하다면 피험자는 동의서 서식에\n\n- - 108 -\n<!-- PAGE_115 -->\n###### 서명하고 자필로 날짜를 기재하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_810",
      "text": "또한, 피험자의 대리인임을\n\n<!-- PAGE_115 -->\n###### 확인할 수 있는 근거자료 등을 확보하고, 피험자 동의 설명서 등에\n\n<!-- PAGE_115 -->\n###### 대리인의 동의 사유를 구체적으로 기술할 것을 권장한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 809,
        "window_size": 3,
        "char_count": 136,
        "word_count": 28,
        "page_number": 115,
        "window_text": "임상시험 실시 도중 피험자 설명문 등이 변경되었을 때 재동의\n\n<!-- PAGE_114 -->\n###### 임상시험 실시 도중 동의서 서식이 변경되거나, 피험자에게 제공된\n\n<!-- PAGE_114 -->\n###### 문서 정보의 변경이 있는 경우에는 변경일 기준 다음 방문일에 변경\n\n<!-- PAGE_114 -->\n###### 내용을 피험자에게 충분히 설명하고, 시험책임자(또는 시험담당의사)와\n\n<!-- PAGE_114 -->\n###### 피험자는 변경동의서에 서명하고 해당 날짜를 자필로 적어야 한다.\n\n <!-- PAGE_114 -->\n###### 라.  피험자의 대리인이 피험자를 대신하여 임상시험 참여에 동의\n\n<!-- PAGE_114 -->\n###### 피험자의 이해능력, 의사표현능력의 결여 등의 사유로 동의를 받을\n\n<!-- PAGE_114 -->\n###### 수 없는 경우에는 대리인의 동의를 받을 수 있으며, 이와 같은 경우\n\n<!-- PAGE_114 -->\n###### 에도 피험자는 피험자 자신이 이해할 수 있는 정도까지 임상시험에\n\n<!-- PAGE_114 -->\n###### 관한 정보를 제공 받아야하며, 가능하다면 피험자는 동의서 서식에\n\n- - 108 -\n<!-- PAGE_115 -->\n###### 서명하고 자필로 날짜를 기재하여야 한다.  또한, 피험자의 대리인임을\n\n<!-- PAGE_115 -->\n###### 확인할 수 있는 근거자료 등을 확보하고, 피험자 동의 설명서 등에\n\n<!-- PAGE_115 -->\n###### 대리인의 동의 사유를 구체적으로 기술할 것을 권장한다.\n\n - - 109 -\n<!-- PAGE_116 -->\n##### 17.  피해자 보상에 대한 규약\n\n<!-- PAGE_116 -->\n###### 임상시험용 의료기기가 직접적 원인이 되어 피험자에게 손상이\n\n<!-- PAGE_116 -->\n###### 발생하여 응급조치가 필요한 경우 시험책임자가 가입한 보험에 의해\n\n<!-- PAGE_116 -->\n###### 보상한다.  본 임상시험과 관련이 없는 부작용이 발생한 경우에도\n\n<!-- PAGE_116 -->\n###### 해당 과와의 긴밀한 협조를 통하여 신속한 검사와 처치를 시행한다.\n\n",
        "original_sentence": "또한, 피험자의 대리인임을\n\n<!-- PAGE_115 -->\n###### 확인할 수 있는 근거자료 등을 확보하고, 피험자 동의 설명서 등에\n\n<!-- PAGE_115 -->\n###### 대리인의 동의 사유를 구체적으로 기술할 것을 권장한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_811",
      "text": "- - 109 -\n<!-- PAGE_116 -->\n##### 17. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 810,
        "window_size": 3,
        "char_count": 38,
        "word_count": 9,
        "page_number": 116,
        "window_text": "<!-- PAGE_114 -->\n###### 라.  피험자의 대리인이 피험자를 대신하여 임상시험 참여에 동의\n\n<!-- PAGE_114 -->\n###### 피험자의 이해능력, 의사표현능력의 결여 등의 사유로 동의를 받을\n\n<!-- PAGE_114 -->\n###### 수 없는 경우에는 대리인의 동의를 받을 수 있으며, 이와 같은 경우\n\n<!-- PAGE_114 -->\n###### 에도 피험자는 피험자 자신이 이해할 수 있는 정도까지 임상시험에\n\n<!-- PAGE_114 -->\n###### 관한 정보를 제공 받아야하며, 가능하다면 피험자는 동의서 서식에\n\n- - 108 -\n<!-- PAGE_115 -->\n###### 서명하고 자필로 날짜를 기재하여야 한다.  또한, 피험자의 대리인임을\n\n<!-- PAGE_115 -->\n###### 확인할 수 있는 근거자료 등을 확보하고, 피험자 동의 설명서 등에\n\n<!-- PAGE_115 -->\n###### 대리인의 동의 사유를 구체적으로 기술할 것을 권장한다.\n\n - - 109 -\n<!-- PAGE_116 -->\n##### 17.  피해자 보상에 대한 규약\n\n<!-- PAGE_116 -->\n###### 임상시험용 의료기기가 직접적 원인이 되어 피험자에게 손상이\n\n<!-- PAGE_116 -->\n###### 발생하여 응급조치가 필요한 경우 시험책임자가 가입한 보험에 의해\n\n<!-- PAGE_116 -->\n###### 보상한다.  본 임상시험과 관련이 없는 부작용이 발생한 경우에도\n\n<!-- PAGE_116 -->\n###### 해당 과와의 긴밀한 협조를 통하여 신속한 검사와 처치를 시행한다.\n\n <!-- PAGE_116 -->\n###### 예상된 의료기기 이상반응에 대하여 당사자들 간에 미리 합의한\n\n<!-- PAGE_116 -->\n###### 보상액 또는 조치가 있는 경우, 당해 기준에 따라 이를 보상한다.\n\n",
        "original_sentence": "- - 109 -\n<!-- PAGE_116 -->\n##### 17. "
      }
    },
    {
      "chunk_id": "chunk_812",
      "text": "피해자 보상에 대한 규약\n\n<!-- PAGE_116 -->\n###### 임상시험용 의료기기가 직접적 원인이 되어 피험자에게 손상이\n\n<!-- PAGE_116 -->\n###### 발생하여 응급조치가 필요한 경우 시험책임자가 가입한 보험에 의해\n\n<!-- PAGE_116 -->\n###### 보상한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 811,
        "window_size": 3,
        "char_count": 167,
        "word_count": 32,
        "page_number": 116,
        "window_text": "피험자의 대리인이 피험자를 대신하여 임상시험 참여에 동의\n\n<!-- PAGE_114 -->\n###### 피험자의 이해능력, 의사표현능력의 결여 등의 사유로 동의를 받을\n\n<!-- PAGE_114 -->\n###### 수 없는 경우에는 대리인의 동의를 받을 수 있으며, 이와 같은 경우\n\n<!-- PAGE_114 -->\n###### 에도 피험자는 피험자 자신이 이해할 수 있는 정도까지 임상시험에\n\n<!-- PAGE_114 -->\n###### 관한 정보를 제공 받아야하며, 가능하다면 피험자는 동의서 서식에\n\n- - 108 -\n<!-- PAGE_115 -->\n###### 서명하고 자필로 날짜를 기재하여야 한다.  또한, 피험자의 대리인임을\n\n<!-- PAGE_115 -->\n###### 확인할 수 있는 근거자료 등을 확보하고, 피험자 동의 설명서 등에\n\n<!-- PAGE_115 -->\n###### 대리인의 동의 사유를 구체적으로 기술할 것을 권장한다.\n\n - - 109 -\n<!-- PAGE_116 -->\n##### 17.  피해자 보상에 대한 규약\n\n<!-- PAGE_116 -->\n###### 임상시험용 의료기기가 직접적 원인이 되어 피험자에게 손상이\n\n<!-- PAGE_116 -->\n###### 발생하여 응급조치가 필요한 경우 시험책임자가 가입한 보험에 의해\n\n<!-- PAGE_116 -->\n###### 보상한다.  본 임상시험과 관련이 없는 부작용이 발생한 경우에도\n\n<!-- PAGE_116 -->\n###### 해당 과와의 긴밀한 협조를 통하여 신속한 검사와 처치를 시행한다.\n\n <!-- PAGE_116 -->\n###### 예상된 의료기기 이상반응에 대하여 당사자들 간에 미리 합의한\n\n<!-- PAGE_116 -->\n###### 보상액 또는 조치가 있는 경우, 당해 기준에 따라 이를 보상한다.\n\n <!-- PAGE_116 -->\n###### 그 외의 경우에는 신체손상의 정도, 성격, 지속기간, 유사사례 등을\n\n<!-- PAGE_116 -->\n###### 종합적으로 고려하여 당사자들 간에 합의한 보상방법에 따라 이를\n\n<!-- PAGE_116 -->\n###### 보상한다. ",
        "original_sentence": "피해자 보상에 대한 규약\n\n<!-- PAGE_116 -->\n###### 임상시험용 의료기기가 직접적 원인이 되어 피험자에게 손상이\n\n<!-- PAGE_116 -->\n###### 발생하여 응급조치가 필요한 경우 시험책임자가 가입한 보험에 의해\n\n<!-- PAGE_116 -->\n###### 보상한다. "
      }
    },
    {
      "chunk_id": "chunk_813",
      "text": "본 임상시험과 관련이 없는 부작용이 발생한 경우에도\n\n<!-- PAGE_116 -->\n###### 해당 과와의 긴밀한 협조를 통하여 신속한 검사와 처치를 시행한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 812,
        "window_size": 3,
        "char_count": 93,
        "word_count": 20,
        "page_number": 116,
        "window_text": "또한, 피험자의 대리인임을\n\n<!-- PAGE_115 -->\n###### 확인할 수 있는 근거자료 등을 확보하고, 피험자 동의 설명서 등에\n\n<!-- PAGE_115 -->\n###### 대리인의 동의 사유를 구체적으로 기술할 것을 권장한다.\n\n - - 109 -\n<!-- PAGE_116 -->\n##### 17.  피해자 보상에 대한 규약\n\n<!-- PAGE_116 -->\n###### 임상시험용 의료기기가 직접적 원인이 되어 피험자에게 손상이\n\n<!-- PAGE_116 -->\n###### 발생하여 응급조치가 필요한 경우 시험책임자가 가입한 보험에 의해\n\n<!-- PAGE_116 -->\n###### 보상한다.  본 임상시험과 관련이 없는 부작용이 발생한 경우에도\n\n<!-- PAGE_116 -->\n###### 해당 과와의 긴밀한 협조를 통하여 신속한 검사와 처치를 시행한다.\n\n <!-- PAGE_116 -->\n###### 예상된 의료기기 이상반응에 대하여 당사자들 간에 미리 합의한\n\n<!-- PAGE_116 -->\n###### 보상액 또는 조치가 있는 경우, 당해 기준에 따라 이를 보상한다.\n\n <!-- PAGE_116 -->\n###### 그 외의 경우에는 신체손상의 정도, 성격, 지속기간, 유사사례 등을\n\n<!-- PAGE_116 -->\n###### 종합적으로 고려하여 당사자들 간에 합의한 보상방법에 따라 이를\n\n<!-- PAGE_116 -->\n###### 보상한다.  당사자들 간에 전항의 합의가 이루어지지 아니한 경우에는,\n\n<!-- PAGE_116 -->\n###### 법원의 판결 및 이에 준하는 결정의 확정내용에 따라 보상한다.\n\n",
        "original_sentence": "본 임상시험과 관련이 없는 부작용이 발생한 경우에도\n\n<!-- PAGE_116 -->\n###### 해당 과와의 긴밀한 협조를 통하여 신속한 검사와 처치를 시행한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_814",
      "text": "<!-- PAGE_116 -->\n###### 예상된 의료기기 이상반응에 대하여 당사자들 간에 미리 합의한\n\n<!-- PAGE_116 -->\n###### 보상액 또는 조치가 있는 경우, 당해 기준에 따라 이를 보상한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 813,
        "window_size": 3,
        "char_count": 123,
        "word_count": 26,
        "page_number": 116,
        "window_text": "- - 109 -\n<!-- PAGE_116 -->\n##### 17.  피해자 보상에 대한 규약\n\n<!-- PAGE_116 -->\n###### 임상시험용 의료기기가 직접적 원인이 되어 피험자에게 손상이\n\n<!-- PAGE_116 -->\n###### 발생하여 응급조치가 필요한 경우 시험책임자가 가입한 보험에 의해\n\n<!-- PAGE_116 -->\n###### 보상한다.  본 임상시험과 관련이 없는 부작용이 발생한 경우에도\n\n<!-- PAGE_116 -->\n###### 해당 과와의 긴밀한 협조를 통하여 신속한 검사와 처치를 시행한다.\n\n <!-- PAGE_116 -->\n###### 예상된 의료기기 이상반응에 대하여 당사자들 간에 미리 합의한\n\n<!-- PAGE_116 -->\n###### 보상액 또는 조치가 있는 경우, 당해 기준에 따라 이를 보상한다.\n\n <!-- PAGE_116 -->\n###### 그 외의 경우에는 신체손상의 정도, 성격, 지속기간, 유사사례 등을\n\n<!-- PAGE_116 -->\n###### 종합적으로 고려하여 당사자들 간에 합의한 보상방법에 따라 이를\n\n<!-- PAGE_116 -->\n###### 보상한다.  당사자들 간에 전항의 합의가 이루어지지 아니한 경우에는,\n\n<!-- PAGE_116 -->\n###### 법원의 판결 및 이에 준하는 결정의 확정내용에 따라 보상한다.\n\n - - 110 -\n<!-- PAGE_117 -->\n##### 18. ",
        "original_sentence": "<!-- PAGE_116 -->\n###### 예상된 의료기기 이상반응에 대하여 당사자들 간에 미리 합의한\n\n<!-- PAGE_116 -->\n###### 보상액 또는 조치가 있는 경우, 당해 기준에 따라 이를 보상한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_815",
      "text": "<!-- PAGE_116 -->\n###### 그 외의 경우에는 신체손상의 정도, 성격, 지속기간, 유사사례 등을\n\n<!-- PAGE_116 -->\n###### 종합적으로 고려하여 당사자들 간에 합의한 보상방법에 따라 이를\n\n<!-- PAGE_116 -->\n###### 보상한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 814,
        "window_size": 3,
        "char_count": 156,
        "word_count": 30,
        "page_number": 116,
        "window_text": "피해자 보상에 대한 규약\n\n<!-- PAGE_116 -->\n###### 임상시험용 의료기기가 직접적 원인이 되어 피험자에게 손상이\n\n<!-- PAGE_116 -->\n###### 발생하여 응급조치가 필요한 경우 시험책임자가 가입한 보험에 의해\n\n<!-- PAGE_116 -->\n###### 보상한다.  본 임상시험과 관련이 없는 부작용이 발생한 경우에도\n\n<!-- PAGE_116 -->\n###### 해당 과와의 긴밀한 협조를 통하여 신속한 검사와 처치를 시행한다.\n\n <!-- PAGE_116 -->\n###### 예상된 의료기기 이상반응에 대하여 당사자들 간에 미리 합의한\n\n<!-- PAGE_116 -->\n###### 보상액 또는 조치가 있는 경우, 당해 기준에 따라 이를 보상한다.\n\n <!-- PAGE_116 -->\n###### 그 외의 경우에는 신체손상의 정도, 성격, 지속기간, 유사사례 등을\n\n<!-- PAGE_116 -->\n###### 종합적으로 고려하여 당사자들 간에 합의한 보상방법에 따라 이를\n\n<!-- PAGE_116 -->\n###### 보상한다.  당사자들 간에 전항의 합의가 이루어지지 아니한 경우에는,\n\n<!-- PAGE_116 -->\n###### 법원의 판결 및 이에 준하는 결정의 확정내용에 따라 보상한다.\n\n - - 110 -\n<!-- PAGE_117 -->\n##### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n<!-- PAGE_117 -->\n###### 본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 OO병원\n\n<!-- PAGE_117 -->\n###### 에서 진행하던 치료절차가 임상시험 참여 전과 다름없이 진행되며,\n\n<!-- PAGE_117 -->\n###### 이후의 치료비는 피험자가 지불하여야 한다. ",
        "original_sentence": "<!-- PAGE_116 -->\n###### 그 외의 경우에는 신체손상의 정도, 성격, 지속기간, 유사사례 등을\n\n<!-- PAGE_116 -->\n###### 종합적으로 고려하여 당사자들 간에 합의한 보상방법에 따라 이를\n\n<!-- PAGE_116 -->\n###### 보상한다. "
      }
    },
    {
      "chunk_id": "chunk_816",
      "text": "당사자들 간에 전항의 합의가 이루어지지 아니한 경우에는,\n\n<!-- PAGE_116 -->\n###### 법원의 판결 및 이에 준하는 결정의 확정내용에 따라 보상한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 815,
        "window_size": 3,
        "char_count": 94,
        "word_count": 20,
        "page_number": 116,
        "window_text": "본 임상시험과 관련이 없는 부작용이 발생한 경우에도\n\n<!-- PAGE_116 -->\n###### 해당 과와의 긴밀한 협조를 통하여 신속한 검사와 처치를 시행한다.\n\n <!-- PAGE_116 -->\n###### 예상된 의료기기 이상반응에 대하여 당사자들 간에 미리 합의한\n\n<!-- PAGE_116 -->\n###### 보상액 또는 조치가 있는 경우, 당해 기준에 따라 이를 보상한다.\n\n <!-- PAGE_116 -->\n###### 그 외의 경우에는 신체손상의 정도, 성격, 지속기간, 유사사례 등을\n\n<!-- PAGE_116 -->\n###### 종합적으로 고려하여 당사자들 간에 합의한 보상방법에 따라 이를\n\n<!-- PAGE_116 -->\n###### 보상한다.  당사자들 간에 전항의 합의가 이루어지지 아니한 경우에는,\n\n<!-- PAGE_116 -->\n###### 법원의 판결 및 이에 준하는 결정의 확정내용에 따라 보상한다.\n\n - - 110 -\n<!-- PAGE_117 -->\n##### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n<!-- PAGE_117 -->\n###### 본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 OO병원\n\n<!-- PAGE_117 -->\n###### 에서 진행하던 치료절차가 임상시험 참여 전과 다름없이 진행되며,\n\n<!-- PAGE_117 -->\n###### 이후의 치료비는 피험자가 지불하여야 한다.  다만, 부작용 발생 시\n\n<!-- PAGE_117 -->\n###### 임상시험에 사용된 의료기기와의 인과관계 유무를 확인한 후,\n\n<!-- PAGE_117 -->\n###### 본 임상시험에 사용된 의료기기로 인하여 부작용이 발생한 경우\n\n<!-- PAGE_117 -->\n###### ㈜OOO에서 치료에 관한 부작용이 소실될 때까지 치료비를 지불한다.\n\n",
        "original_sentence": "당사자들 간에 전항의 합의가 이루어지지 아니한 경우에는,\n\n<!-- PAGE_116 -->\n###### 법원의 판결 및 이에 준하는 결정의 확정내용에 따라 보상한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_817",
      "text": "- - 110 -\n<!-- PAGE_117 -->\n##### 18. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 816,
        "window_size": 3,
        "char_count": 38,
        "word_count": 9,
        "page_number": 117,
        "window_text": "<!-- PAGE_116 -->\n###### 예상된 의료기기 이상반응에 대하여 당사자들 간에 미리 합의한\n\n<!-- PAGE_116 -->\n###### 보상액 또는 조치가 있는 경우, 당해 기준에 따라 이를 보상한다.\n\n <!-- PAGE_116 -->\n###### 그 외의 경우에는 신체손상의 정도, 성격, 지속기간, 유사사례 등을\n\n<!-- PAGE_116 -->\n###### 종합적으로 고려하여 당사자들 간에 합의한 보상방법에 따라 이를\n\n<!-- PAGE_116 -->\n###### 보상한다.  당사자들 간에 전항의 합의가 이루어지지 아니한 경우에는,\n\n<!-- PAGE_116 -->\n###### 법원의 판결 및 이에 준하는 결정의 확정내용에 따라 보상한다.\n\n - - 110 -\n<!-- PAGE_117 -->\n##### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n<!-- PAGE_117 -->\n###### 본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 OO병원\n\n<!-- PAGE_117 -->\n###### 에서 진행하던 치료절차가 임상시험 참여 전과 다름없이 진행되며,\n\n<!-- PAGE_117 -->\n###### 이후의 치료비는 피험자가 지불하여야 한다.  다만, 부작용 발생 시\n\n<!-- PAGE_117 -->\n###### 임상시험에 사용된 의료기기와의 인과관계 유무를 확인한 후,\n\n<!-- PAGE_117 -->\n###### 본 임상시험에 사용된 의료기기로 인하여 부작용이 발생한 경우\n\n<!-- PAGE_117 -->\n###### ㈜OOO에서 치료에 관한 부작용이 소실될 때까지 치료비를 지불한다.\n\n - - 111 -\n<!-- PAGE_118 -->\n##### 19. ",
        "original_sentence": "- - 110 -\n<!-- PAGE_117 -->\n##### 18. "
      }
    },
    {
      "chunk_id": "chunk_818",
      "text": "임상시험 후 피험자의 진료에 관한 사항\n\n<!-- PAGE_117 -->\n###### 본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 OO병원\n\n<!-- PAGE_117 -->\n###### 에서 진행하던 치료절차가 임상시험 참여 전과 다름없이 진행되며,\n\n<!-- PAGE_117 -->\n###### 이후의 치료비는 피험자가 지불하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 817,
        "window_size": 3,
        "char_count": 196,
        "word_count": 40,
        "page_number": 117,
        "window_text": "<!-- PAGE_116 -->\n###### 그 외의 경우에는 신체손상의 정도, 성격, 지속기간, 유사사례 등을\n\n<!-- PAGE_116 -->\n###### 종합적으로 고려하여 당사자들 간에 합의한 보상방법에 따라 이를\n\n<!-- PAGE_116 -->\n###### 보상한다.  당사자들 간에 전항의 합의가 이루어지지 아니한 경우에는,\n\n<!-- PAGE_116 -->\n###### 법원의 판결 및 이에 준하는 결정의 확정내용에 따라 보상한다.\n\n - - 110 -\n<!-- PAGE_117 -->\n##### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n<!-- PAGE_117 -->\n###### 본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 OO병원\n\n<!-- PAGE_117 -->\n###### 에서 진행하던 치료절차가 임상시험 참여 전과 다름없이 진행되며,\n\n<!-- PAGE_117 -->\n###### 이후의 치료비는 피험자가 지불하여야 한다.  다만, 부작용 발생 시\n\n<!-- PAGE_117 -->\n###### 임상시험에 사용된 의료기기와의 인과관계 유무를 확인한 후,\n\n<!-- PAGE_117 -->\n###### 본 임상시험에 사용된 의료기기로 인하여 부작용이 발생한 경우\n\n<!-- PAGE_117 -->\n###### ㈜OOO에서 치료에 관한 부작용이 소실될 때까지 치료비를 지불한다.\n\n - - 111 -\n<!-- PAGE_118 -->\n##### 19.  피험자의 안전보호에 대한 대책\n\n<!-- PAGE_118 -->\n###### 가. ",
        "original_sentence": "임상시험 후 피험자의 진료에 관한 사항\n\n<!-- PAGE_117 -->\n###### 본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 OO병원\n\n<!-- PAGE_117 -->\n###### 에서 진행하던 치료절차가 임상시험 참여 전과 다름없이 진행되며,\n\n<!-- PAGE_117 -->\n###### 이후의 치료비는 피험자가 지불하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_819",
      "text": "다만, 부작용 발생 시\n\n<!-- PAGE_117 -->\n###### 임상시험에 사용된 의료기기와의 인과관계 유무를 확인한 후,\n\n<!-- PAGE_117 -->\n###### 본 임상시험에 사용된 의료기기로 인하여 부작용이 발생한 경우\n\n<!-- PAGE_117 -->\n###### ㈜OOO에서 치료에 관한 부작용이 소실될 때까지 치료비를 지불한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 818,
        "window_size": 3,
        "char_count": 197,
        "word_count": 39,
        "page_number": 117,
        "window_text": "당사자들 간에 전항의 합의가 이루어지지 아니한 경우에는,\n\n<!-- PAGE_116 -->\n###### 법원의 판결 및 이에 준하는 결정의 확정내용에 따라 보상한다.\n\n - - 110 -\n<!-- PAGE_117 -->\n##### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n<!-- PAGE_117 -->\n###### 본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 OO병원\n\n<!-- PAGE_117 -->\n###### 에서 진행하던 치료절차가 임상시험 참여 전과 다름없이 진행되며,\n\n<!-- PAGE_117 -->\n###### 이후의 치료비는 피험자가 지불하여야 한다.  다만, 부작용 발생 시\n\n<!-- PAGE_117 -->\n###### 임상시험에 사용된 의료기기와의 인과관계 유무를 확인한 후,\n\n<!-- PAGE_117 -->\n###### 본 임상시험에 사용된 의료기기로 인하여 부작용이 발생한 경우\n\n<!-- PAGE_117 -->\n###### ㈜OOO에서 치료에 관한 부작용이 소실될 때까지 치료비를 지불한다.\n\n - - 111 -\n<!-- PAGE_118 -->\n##### 19.  피험자의 안전보호에 대한 대책\n\n<!-- PAGE_118 -->\n###### 가.  임상시험 실시기관\n\n<!-- PAGE_118 -->\n###### 임상시험 실시기관의 장은 해당 임상시험의 실시에 필요한 임상\n\n<!-- PAGE_118 -->\n###### 시험실, 설비와 전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를\n\n<!-- PAGE_118 -->\n###### 취할 수 있도록 하는 등 해당 임상시험을 적절하게 실시할 수 있도록\n\n<!-- PAGE_118 -->\n###### 하여야 한다.\n\n",
        "original_sentence": "다만, 부작용 발생 시\n\n<!-- PAGE_117 -->\n###### 임상시험에 사용된 의료기기와의 인과관계 유무를 확인한 후,\n\n<!-- PAGE_117 -->\n###### 본 임상시험에 사용된 의료기기로 인하여 부작용이 발생한 경우\n\n<!-- PAGE_117 -->\n###### ㈜OOO에서 치료에 관한 부작용이 소실될 때까지 치료비를 지불한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_820",
      "text": "- - 111 -\n<!-- PAGE_118 -->\n##### 19. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 819,
        "window_size": 3,
        "char_count": 38,
        "word_count": 9,
        "page_number": 118,
        "window_text": "- - 110 -\n<!-- PAGE_117 -->\n##### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n<!-- PAGE_117 -->\n###### 본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 OO병원\n\n<!-- PAGE_117 -->\n###### 에서 진행하던 치료절차가 임상시험 참여 전과 다름없이 진행되며,\n\n<!-- PAGE_117 -->\n###### 이후의 치료비는 피험자가 지불하여야 한다.  다만, 부작용 발생 시\n\n<!-- PAGE_117 -->\n###### 임상시험에 사용된 의료기기와의 인과관계 유무를 확인한 후,\n\n<!-- PAGE_117 -->\n###### 본 임상시험에 사용된 의료기기로 인하여 부작용이 발생한 경우\n\n<!-- PAGE_117 -->\n###### ㈜OOO에서 치료에 관한 부작용이 소실될 때까지 치료비를 지불한다.\n\n - - 111 -\n<!-- PAGE_118 -->\n##### 19.  피험자의 안전보호에 대한 대책\n\n<!-- PAGE_118 -->\n###### 가.  임상시험 실시기관\n\n<!-- PAGE_118 -->\n###### 임상시험 실시기관의 장은 해당 임상시험의 실시에 필요한 임상\n\n<!-- PAGE_118 -->\n###### 시험실, 설비와 전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를\n\n<!-- PAGE_118 -->\n###### 취할 수 있도록 하는 등 해당 임상시험을 적절하게 실시할 수 있도록\n\n<!-- PAGE_118 -->\n###### 하여야 한다.\n\n <!-- PAGE_118 -->\n###### 나. ",
        "original_sentence": "- - 111 -\n<!-- PAGE_118 -->\n##### 19. "
      }
    },
    {
      "chunk_id": "chunk_821",
      "text": "피험자의 안전보호에 대한 대책\n\n<!-- PAGE_118 -->\n###### 가. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 820,
        "window_size": 3,
        "char_count": 46,
        "word_count": 9,
        "page_number": 118,
        "window_text": "임상시험 후 피험자의 진료에 관한 사항\n\n<!-- PAGE_117 -->\n###### 본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 OO병원\n\n<!-- PAGE_117 -->\n###### 에서 진행하던 치료절차가 임상시험 참여 전과 다름없이 진행되며,\n\n<!-- PAGE_117 -->\n###### 이후의 치료비는 피험자가 지불하여야 한다.  다만, 부작용 발생 시\n\n<!-- PAGE_117 -->\n###### 임상시험에 사용된 의료기기와의 인과관계 유무를 확인한 후,\n\n<!-- PAGE_117 -->\n###### 본 임상시험에 사용된 의료기기로 인하여 부작용이 발생한 경우\n\n<!-- PAGE_117 -->\n###### ㈜OOO에서 치료에 관한 부작용이 소실될 때까지 치료비를 지불한다.\n\n - - 111 -\n<!-- PAGE_118 -->\n##### 19.  피험자의 안전보호에 대한 대책\n\n<!-- PAGE_118 -->\n###### 가.  임상시험 실시기관\n\n<!-- PAGE_118 -->\n###### 임상시험 실시기관의 장은 해당 임상시험의 실시에 필요한 임상\n\n<!-- PAGE_118 -->\n###### 시험실, 설비와 전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를\n\n<!-- PAGE_118 -->\n###### 취할 수 있도록 하는 등 해당 임상시험을 적절하게 실시할 수 있도록\n\n<!-- PAGE_118 -->\n###### 하여야 한다.\n\n <!-- PAGE_118 -->\n###### 나.  임상시험심사위원회\n\n<!-- PAGE_118 -->\n###### 1) 임상시험심사위원회는 국내 법규/관례에 따라 구성되어 있어야\n\n<!-- PAGE_118 -->\n###### 한다. ",
        "original_sentence": "피험자의 안전보호에 대한 대책\n\n<!-- PAGE_118 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_822",
      "text": "임상시험 실시기관\n\n<!-- PAGE_118 -->\n###### 임상시험 실시기관의 장은 해당 임상시험의 실시에 필요한 임상\n\n<!-- PAGE_118 -->\n###### 시험실, 설비와 전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를\n\n<!-- PAGE_118 -->\n###### 취할 수 있도록 하는 등 해당 임상시험을 적절하게 실시할 수 있도록\n\n<!-- PAGE_118 -->\n###### 하여야 한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 821,
        "window_size": 3,
        "char_count": 233,
        "word_count": 49,
        "page_number": 118,
        "window_text": "다만, 부작용 발생 시\n\n<!-- PAGE_117 -->\n###### 임상시험에 사용된 의료기기와의 인과관계 유무를 확인한 후,\n\n<!-- PAGE_117 -->\n###### 본 임상시험에 사용된 의료기기로 인하여 부작용이 발생한 경우\n\n<!-- PAGE_117 -->\n###### ㈜OOO에서 치료에 관한 부작용이 소실될 때까지 치료비를 지불한다.\n\n - - 111 -\n<!-- PAGE_118 -->\n##### 19.  피험자의 안전보호에 대한 대책\n\n<!-- PAGE_118 -->\n###### 가.  임상시험 실시기관\n\n<!-- PAGE_118 -->\n###### 임상시험 실시기관의 장은 해당 임상시험의 실시에 필요한 임상\n\n<!-- PAGE_118 -->\n###### 시험실, 설비와 전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를\n\n<!-- PAGE_118 -->\n###### 취할 수 있도록 하는 등 해당 임상시험을 적절하게 실시할 수 있도록\n\n<!-- PAGE_118 -->\n###### 하여야 한다.\n\n <!-- PAGE_118 -->\n###### 나.  임상시험심사위원회\n\n<!-- PAGE_118 -->\n###### 1) 임상시험심사위원회는 국내 법규/관례에 따라 구성되어 있어야\n\n<!-- PAGE_118 -->\n###### 한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를 보호해야\n\n<!-- PAGE_118 -->\n###### 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에는\n\n<!-- PAGE_118 -->\n###### 2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가\n\n<!-- PAGE_118 -->\n###### 동의가 적절하게 얻어지지 않았거나 임상시험이 임상시험계획서에\n\n<!-- PAGE_118 -->\n###### 따라 진행되지 않은 경우 또는 중대한 이상사례/의료기기 이상반응이\n\n<!-- PAGE_118 -->\n###### 나타난 경우에는 임상시험의 일부 또는 전부에 대하여 중지 명령\n\n- - 112 -\n<!-- PAGE_119 -->\n###### 다. ",
        "original_sentence": "임상시험 실시기관\n\n<!-- PAGE_118 -->\n###### 임상시험 실시기관의 장은 해당 임상시험의 실시에 필요한 임상\n\n<!-- PAGE_118 -->\n###### 시험실, 설비와 전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를\n\n<!-- PAGE_118 -->\n###### 취할 수 있도록 하는 등 해당 임상시험을 적절하게 실시할 수 있도록\n\n<!-- PAGE_118 -->\n###### 하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_823",
      "text": "<!-- PAGE_118 -->\n###### 나. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 822,
        "window_size": 3,
        "char_count": 28,
        "word_count": 5,
        "page_number": 118,
        "window_text": "- - 111 -\n<!-- PAGE_118 -->\n##### 19.  피험자의 안전보호에 대한 대책\n\n<!-- PAGE_118 -->\n###### 가.  임상시험 실시기관\n\n<!-- PAGE_118 -->\n###### 임상시험 실시기관의 장은 해당 임상시험의 실시에 필요한 임상\n\n<!-- PAGE_118 -->\n###### 시험실, 설비와 전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를\n\n<!-- PAGE_118 -->\n###### 취할 수 있도록 하는 등 해당 임상시험을 적절하게 실시할 수 있도록\n\n<!-- PAGE_118 -->\n###### 하여야 한다.\n\n <!-- PAGE_118 -->\n###### 나.  임상시험심사위원회\n\n<!-- PAGE_118 -->\n###### 1) 임상시험심사위원회는 국내 법규/관례에 따라 구성되어 있어야\n\n<!-- PAGE_118 -->\n###### 한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를 보호해야\n\n<!-- PAGE_118 -->\n###### 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에는\n\n<!-- PAGE_118 -->\n###### 2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가\n\n<!-- PAGE_118 -->\n###### 동의가 적절하게 얻어지지 않았거나 임상시험이 임상시험계획서에\n\n<!-- PAGE_118 -->\n###### 따라 진행되지 않은 경우 또는 중대한 이상사례/의료기기 이상반응이\n\n<!-- PAGE_118 -->\n###### 나타난 경우에는 임상시험의 일부 또는 전부에 대하여 중지 명령\n\n- - 112 -\n<!-- PAGE_119 -->\n###### 다.  시험자\n\n<!-- PAGE_119 -->\n###### 1) 시험자(Investigator)란 시험책임자, 시험담당자, 임상시험조정자를\n\n<!-- PAGE_119 -->\n###### 말한다. ",
        "original_sentence": "<!-- PAGE_118 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_824",
      "text": "임상시험심사위원회\n\n<!-- PAGE_118 -->\n###### 1) 임상시험심사위원회는 국내 법규/관례에 따라 구성되어 있어야\n\n<!-- PAGE_118 -->\n###### 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 823,
        "window_size": 3,
        "char_count": 102,
        "word_count": 17,
        "page_number": 118,
        "window_text": "피험자의 안전보호에 대한 대책\n\n<!-- PAGE_118 -->\n###### 가.  임상시험 실시기관\n\n<!-- PAGE_118 -->\n###### 임상시험 실시기관의 장은 해당 임상시험의 실시에 필요한 임상\n\n<!-- PAGE_118 -->\n###### 시험실, 설비와 전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를\n\n<!-- PAGE_118 -->\n###### 취할 수 있도록 하는 등 해당 임상시험을 적절하게 실시할 수 있도록\n\n<!-- PAGE_118 -->\n###### 하여야 한다.\n\n <!-- PAGE_118 -->\n###### 나.  임상시험심사위원회\n\n<!-- PAGE_118 -->\n###### 1) 임상시험심사위원회는 국내 법규/관례에 따라 구성되어 있어야\n\n<!-- PAGE_118 -->\n###### 한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를 보호해야\n\n<!-- PAGE_118 -->\n###### 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에는\n\n<!-- PAGE_118 -->\n###### 2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가\n\n<!-- PAGE_118 -->\n###### 동의가 적절하게 얻어지지 않았거나 임상시험이 임상시험계획서에\n\n<!-- PAGE_118 -->\n###### 따라 진행되지 않은 경우 또는 중대한 이상사례/의료기기 이상반응이\n\n<!-- PAGE_118 -->\n###### 나타난 경우에는 임상시험의 일부 또는 전부에 대하여 중지 명령\n\n- - 112 -\n<!-- PAGE_119 -->\n###### 다.  시험자\n\n<!-- PAGE_119 -->\n###### 1) 시험자(Investigator)란 시험책임자, 시험담당자, 임상시험조정자를\n\n<!-- PAGE_119 -->\n###### 말한다.  시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품\n\n<!-- PAGE_119 -->\n###### 의약품안전처장의 승인을 득한 임상시험 계획서를 준수하여\n\n<!-- PAGE_119 -->\n###### 2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미\n\n<!-- PAGE_119 -->\n###### 있는 시험실적 검사치의 이상을 포함하여 임상시험에서 발생한\n\n<!-- PAGE_119 -->\n###### 모든 이상반응에 대해 피험자가 적절한 의학적 처치를 받을 수\n\n<!-- PAGE_119 -->\n###### 있도록 조치하여야 하고, 시험자가 알게 된 피험자의 병발질환에\n\n<!-- PAGE_119 -->\n###### 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려주어야 한다.\n\n",
        "original_sentence": "임상시험심사위원회\n\n<!-- PAGE_118 -->\n###### 1) 임상시험심사위원회는 국내 법규/관례에 따라 구성되어 있어야\n\n<!-- PAGE_118 -->\n###### 한다. "
      }
    },
    {
      "chunk_id": "chunk_825",
      "text": "임상시험심사위원회는 피험자의 권리, 안전, 복지를 보호해야\n\n<!-- PAGE_118 -->\n###### 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에는\n\n<!-- PAGE_118 -->\n###### 2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가\n\n<!-- PAGE_118 -->\n###### 동의가 적절하게 얻어지지 않았거나 임상시험이 임상시험계획서에\n\n<!-- PAGE_118 -->\n###### 따라 진행되지 않은 경우 또는 중대한 이상사례/의료기기 이상반응이\n\n<!-- PAGE_118 -->\n###### 나타난 경우에는 임상시험의 일부 또는 전부에 대하여 중지 명령\n\n- - 112 -\n<!-- PAGE_119 -->\n###### 다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 824,
        "window_size": 3,
        "char_count": 380,
        "word_count": 73,
        "page_number": 118,
        "window_text": "임상시험 실시기관\n\n<!-- PAGE_118 -->\n###### 임상시험 실시기관의 장은 해당 임상시험의 실시에 필요한 임상\n\n<!-- PAGE_118 -->\n###### 시험실, 설비와 전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를\n\n<!-- PAGE_118 -->\n###### 취할 수 있도록 하는 등 해당 임상시험을 적절하게 실시할 수 있도록\n\n<!-- PAGE_118 -->\n###### 하여야 한다.\n\n <!-- PAGE_118 -->\n###### 나.  임상시험심사위원회\n\n<!-- PAGE_118 -->\n###### 1) 임상시험심사위원회는 국내 법규/관례에 따라 구성되어 있어야\n\n<!-- PAGE_118 -->\n###### 한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를 보호해야\n\n<!-- PAGE_118 -->\n###### 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에는\n\n<!-- PAGE_118 -->\n###### 2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가\n\n<!-- PAGE_118 -->\n###### 동의가 적절하게 얻어지지 않았거나 임상시험이 임상시험계획서에\n\n<!-- PAGE_118 -->\n###### 따라 진행되지 않은 경우 또는 중대한 이상사례/의료기기 이상반응이\n\n<!-- PAGE_118 -->\n###### 나타난 경우에는 임상시험의 일부 또는 전부에 대하여 중지 명령\n\n- - 112 -\n<!-- PAGE_119 -->\n###### 다.  시험자\n\n<!-- PAGE_119 -->\n###### 1) 시험자(Investigator)란 시험책임자, 시험담당자, 임상시험조정자를\n\n<!-- PAGE_119 -->\n###### 말한다.  시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품\n\n<!-- PAGE_119 -->\n###### 의약품안전처장의 승인을 득한 임상시험 계획서를 준수하여\n\n<!-- PAGE_119 -->\n###### 2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미\n\n<!-- PAGE_119 -->\n###### 있는 시험실적 검사치의 이상을 포함하여 임상시험에서 발생한\n\n<!-- PAGE_119 -->\n###### 모든 이상반응에 대해 피험자가 적절한 의학적 처치를 받을 수\n\n<!-- PAGE_119 -->\n###### 있도록 조치하여야 하고, 시험자가 알게 된 피험자의 병발질환에\n\n<!-- PAGE_119 -->\n###### 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려주어야 한다.\n\n <!-- PAGE_119 -->\n###### 3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의\n\n<!-- PAGE_119 -->\n###### 라. ",
        "original_sentence": "임상시험심사위원회는 피험자의 권리, 안전, 복지를 보호해야\n\n<!-- PAGE_118 -->\n###### 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에는\n\n<!-- PAGE_118 -->\n###### 2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가\n\n<!-- PAGE_118 -->\n###### 동의가 적절하게 얻어지지 않았거나 임상시험이 임상시험계획서에\n\n<!-- PAGE_118 -->\n###### 따라 진행되지 않은 경우 또는 중대한 이상사례/의료기기 이상반응이\n\n<!-- PAGE_118 -->\n###### 나타난 경우에는 임상시험의 일부 또는 전부에 대하여 중지 명령\n\n- - 112 -\n<!-- PAGE_119 -->\n###### 다. "
      }
    },
    {
      "chunk_id": "chunk_826",
      "text": "시험자\n\n<!-- PAGE_119 -->\n###### 1) 시험자(Investigator)란 시험책임자, 시험담당자, 임상시험조정자를\n\n<!-- PAGE_119 -->\n###### 말한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 825,
        "window_size": 3,
        "char_count": 106,
        "word_count": 15,
        "page_number": 119,
        "window_text": "<!-- PAGE_118 -->\n###### 나.  임상시험심사위원회\n\n<!-- PAGE_118 -->\n###### 1) 임상시험심사위원회는 국내 법규/관례에 따라 구성되어 있어야\n\n<!-- PAGE_118 -->\n###### 한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를 보호해야\n\n<!-- PAGE_118 -->\n###### 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에는\n\n<!-- PAGE_118 -->\n###### 2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가\n\n<!-- PAGE_118 -->\n###### 동의가 적절하게 얻어지지 않았거나 임상시험이 임상시험계획서에\n\n<!-- PAGE_118 -->\n###### 따라 진행되지 않은 경우 또는 중대한 이상사례/의료기기 이상반응이\n\n<!-- PAGE_118 -->\n###### 나타난 경우에는 임상시험의 일부 또는 전부에 대하여 중지 명령\n\n- - 112 -\n<!-- PAGE_119 -->\n###### 다.  시험자\n\n<!-- PAGE_119 -->\n###### 1) 시험자(Investigator)란 시험책임자, 시험담당자, 임상시험조정자를\n\n<!-- PAGE_119 -->\n###### 말한다.  시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품\n\n<!-- PAGE_119 -->\n###### 의약품안전처장의 승인을 득한 임상시험 계획서를 준수하여\n\n<!-- PAGE_119 -->\n###### 2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미\n\n<!-- PAGE_119 -->\n###### 있는 시험실적 검사치의 이상을 포함하여 임상시험에서 발생한\n\n<!-- PAGE_119 -->\n###### 모든 이상반응에 대해 피험자가 적절한 의학적 처치를 받을 수\n\n<!-- PAGE_119 -->\n###### 있도록 조치하여야 하고, 시험자가 알게 된 피험자의 병발질환에\n\n<!-- PAGE_119 -->\n###### 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려주어야 한다.\n\n <!-- PAGE_119 -->\n###### 3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의\n\n<!-- PAGE_119 -->\n###### 라.  의뢰자\n\n<!-- PAGE_119 -->\n###### 1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로\n\n<!-- PAGE_119 -->\n###### 통상의료기기 임상시험의 경우 의료기기 제조업자(수입자를 포함\n\n<!-- PAGE_119 -->\n###### 2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상\n\n<!-- PAGE_119 -->\n###### 3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상\n\n<!-- PAGE_119 -->\n###### 시험의 종류와 복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의\n\n<!-- PAGE_119 -->\n###### 정도 및 이미 확인된 임상시험 실시상의 문제점 등에 따라 결정\n\n- - 113 -\n<!-- PAGE_120 -->\n###### 마. ",
        "original_sentence": "시험자\n\n<!-- PAGE_119 -->\n###### 1) 시험자(Investigator)란 시험책임자, 시험담당자, 임상시험조정자를\n\n<!-- PAGE_119 -->\n###### 말한다. "
      }
    },
    {
      "chunk_id": "chunk_827",
      "text": "시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품\n\n<!-- PAGE_119 -->\n###### 의약품안전처장의 승인을 득한 임상시험 계획서를 준수하여\n\n<!-- PAGE_119 -->\n###### 2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미\n\n<!-- PAGE_119 -->\n###### 있는 시험실적 검사치의 이상을 포함하여 임상시험에서 발생한\n\n<!-- PAGE_119 -->\n###### 모든 이상반응에 대해 피험자가 적절한 의학적 처치를 받을 수\n\n<!-- PAGE_119 -->\n###### 있도록 조치하여야 하고, 시험자가 알게 된 피험자의 병발질환에\n\n<!-- PAGE_119 -->\n###### 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려주어야 한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 826,
        "window_size": 3,
        "char_count": 395,
        "word_count": 78,
        "page_number": 119,
        "window_text": "임상시험심사위원회\n\n<!-- PAGE_118 -->\n###### 1) 임상시험심사위원회는 국내 법규/관례에 따라 구성되어 있어야\n\n<!-- PAGE_118 -->\n###### 한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를 보호해야\n\n<!-- PAGE_118 -->\n###### 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에는\n\n<!-- PAGE_118 -->\n###### 2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가\n\n<!-- PAGE_118 -->\n###### 동의가 적절하게 얻어지지 않았거나 임상시험이 임상시험계획서에\n\n<!-- PAGE_118 -->\n###### 따라 진행되지 않은 경우 또는 중대한 이상사례/의료기기 이상반응이\n\n<!-- PAGE_118 -->\n###### 나타난 경우에는 임상시험의 일부 또는 전부에 대하여 중지 명령\n\n- - 112 -\n<!-- PAGE_119 -->\n###### 다.  시험자\n\n<!-- PAGE_119 -->\n###### 1) 시험자(Investigator)란 시험책임자, 시험담당자, 임상시험조정자를\n\n<!-- PAGE_119 -->\n###### 말한다.  시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품\n\n<!-- PAGE_119 -->\n###### 의약품안전처장의 승인을 득한 임상시험 계획서를 준수하여\n\n<!-- PAGE_119 -->\n###### 2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미\n\n<!-- PAGE_119 -->\n###### 있는 시험실적 검사치의 이상을 포함하여 임상시험에서 발생한\n\n<!-- PAGE_119 -->\n###### 모든 이상반응에 대해 피험자가 적절한 의학적 처치를 받을 수\n\n<!-- PAGE_119 -->\n###### 있도록 조치하여야 하고, 시험자가 알게 된 피험자의 병발질환에\n\n<!-- PAGE_119 -->\n###### 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려주어야 한다.\n\n <!-- PAGE_119 -->\n###### 3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의\n\n<!-- PAGE_119 -->\n###### 라.  의뢰자\n\n<!-- PAGE_119 -->\n###### 1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로\n\n<!-- PAGE_119 -->\n###### 통상의료기기 임상시험의 경우 의료기기 제조업자(수입자를 포함\n\n<!-- PAGE_119 -->\n###### 2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상\n\n<!-- PAGE_119 -->\n###### 3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상\n\n<!-- PAGE_119 -->\n###### 시험의 종류와 복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의\n\n<!-- PAGE_119 -->\n###### 정도 및 이미 확인된 임상시험 실시상의 문제점 등에 따라 결정\n\n- - 113 -\n<!-- PAGE_120 -->\n###### 마.  모니터링\n\n<!-- PAGE_120 -->\n###### 1) 모니터링(Monitoring)이란 임상시험 진행 과정을 감독하고, 해당\n\n<!-- PAGE_120 -->\n###### 임상시험이 임상시험계획서, 표준작업지침서, 임상시험 실시 기준\n\n<!-- PAGE_120 -->\n###### 및 관련 규정에 따라 실시, 기록되는지 여부를 검토, 확인하는\n\n<!-- PAGE_120 -->\n###### 2) 임상시험에 대한 모니터링은 임상시험모니터요원의 정기적인 임상\n\n<!-- PAGE_120 -->\n###### 시험 실시기관 방문과 전화 등을 통해서 이루어질 것이다. ",
        "original_sentence": "시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품\n\n<!-- PAGE_119 -->\n###### 의약품안전처장의 승인을 득한 임상시험 계획서를 준수하여\n\n<!-- PAGE_119 -->\n###### 2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미\n\n<!-- PAGE_119 -->\n###### 있는 시험실적 검사치의 이상을 포함하여 임상시험에서 발생한\n\n<!-- PAGE_119 -->\n###### 모든 이상반응에 대해 피험자가 적절한 의학적 처치를 받을 수\n\n<!-- PAGE_119 -->\n###### 있도록 조치하여야 하고, 시험자가 알게 된 피험자의 병발질환에\n\n<!-- PAGE_119 -->\n###### 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려주어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_828",
      "text": "<!-- PAGE_119 -->\n###### 3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의\n\n<!-- PAGE_119 -->\n###### 라. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 827,
        "window_size": 3,
        "char_count": 93,
        "word_count": 18,
        "page_number": 119,
        "window_text": "임상시험심사위원회는 피험자의 권리, 안전, 복지를 보호해야\n\n<!-- PAGE_118 -->\n###### 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에는\n\n<!-- PAGE_118 -->\n###### 2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가\n\n<!-- PAGE_118 -->\n###### 동의가 적절하게 얻어지지 않았거나 임상시험이 임상시험계획서에\n\n<!-- PAGE_118 -->\n###### 따라 진행되지 않은 경우 또는 중대한 이상사례/의료기기 이상반응이\n\n<!-- PAGE_118 -->\n###### 나타난 경우에는 임상시험의 일부 또는 전부에 대하여 중지 명령\n\n- - 112 -\n<!-- PAGE_119 -->\n###### 다.  시험자\n\n<!-- PAGE_119 -->\n###### 1) 시험자(Investigator)란 시험책임자, 시험담당자, 임상시험조정자를\n\n<!-- PAGE_119 -->\n###### 말한다.  시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품\n\n<!-- PAGE_119 -->\n###### 의약품안전처장의 승인을 득한 임상시험 계획서를 준수하여\n\n<!-- PAGE_119 -->\n###### 2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미\n\n<!-- PAGE_119 -->\n###### 있는 시험실적 검사치의 이상을 포함하여 임상시험에서 발생한\n\n<!-- PAGE_119 -->\n###### 모든 이상반응에 대해 피험자가 적절한 의학적 처치를 받을 수\n\n<!-- PAGE_119 -->\n###### 있도록 조치하여야 하고, 시험자가 알게 된 피험자의 병발질환에\n\n<!-- PAGE_119 -->\n###### 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려주어야 한다.\n\n <!-- PAGE_119 -->\n###### 3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의\n\n<!-- PAGE_119 -->\n###### 라.  의뢰자\n\n<!-- PAGE_119 -->\n###### 1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로\n\n<!-- PAGE_119 -->\n###### 통상의료기기 임상시험의 경우 의료기기 제조업자(수입자를 포함\n\n<!-- PAGE_119 -->\n###### 2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상\n\n<!-- PAGE_119 -->\n###### 3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상\n\n<!-- PAGE_119 -->\n###### 시험의 종류와 복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의\n\n<!-- PAGE_119 -->\n###### 정도 및 이미 확인된 임상시험 실시상의 문제점 등에 따라 결정\n\n- - 113 -\n<!-- PAGE_120 -->\n###### 마.  모니터링\n\n<!-- PAGE_120 -->\n###### 1) 모니터링(Monitoring)이란 임상시험 진행 과정을 감독하고, 해당\n\n<!-- PAGE_120 -->\n###### 임상시험이 임상시험계획서, 표준작업지침서, 임상시험 실시 기준\n\n<!-- PAGE_120 -->\n###### 및 관련 규정에 따라 실시, 기록되는지 여부를 검토, 확인하는\n\n<!-- PAGE_120 -->\n###### 2) 임상시험에 대한 모니터링은 임상시험모니터요원의 정기적인 임상\n\n<!-- PAGE_120 -->\n###### 시험 실시기관 방문과 전화 등을 통해서 이루어질 것이다.  방문 시\n\n<!-- PAGE_120 -->\n###### 모니터는 환자기록 원본, 임상시험용 의료기기 관리 기록, 자료\n\n<!-- PAGE_120 -->\n###### 3) 또한 임상시험모니터 요원은 임상시험 진행과정을 잘 살피고,\n\n<!-- PAGE_120 -->\n###### 바. ",
        "original_sentence": "<!-- PAGE_119 -->\n###### 3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의\n\n<!-- PAGE_119 -->\n###### 라. "
      }
    },
    {
      "chunk_id": "chunk_829",
      "text": "의뢰자\n\n<!-- PAGE_119 -->\n###### 1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로\n\n<!-- PAGE_119 -->\n###### 통상의료기기 임상시험의 경우 의료기기 제조업자(수입자를 포함\n\n<!-- PAGE_119 -->\n###### 2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상\n\n<!-- PAGE_119 -->\n###### 3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상\n\n<!-- PAGE_119 -->\n###### 시험의 종류와 복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의\n\n<!-- PAGE_119 -->\n###### 정도 및 이미 확인된 임상시험 실시상의 문제점 등에 따라 결정\n\n- - 113 -\n<!-- PAGE_120 -->\n###### 마. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 828,
        "window_size": 3,
        "char_count": 421,
        "word_count": 88,
        "page_number": 119,
        "window_text": "시험자\n\n<!-- PAGE_119 -->\n###### 1) 시험자(Investigator)란 시험책임자, 시험담당자, 임상시험조정자를\n\n<!-- PAGE_119 -->\n###### 말한다.  시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품\n\n<!-- PAGE_119 -->\n###### 의약품안전처장의 승인을 득한 임상시험 계획서를 준수하여\n\n<!-- PAGE_119 -->\n###### 2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미\n\n<!-- PAGE_119 -->\n###### 있는 시험실적 검사치의 이상을 포함하여 임상시험에서 발생한\n\n<!-- PAGE_119 -->\n###### 모든 이상반응에 대해 피험자가 적절한 의학적 처치를 받을 수\n\n<!-- PAGE_119 -->\n###### 있도록 조치하여야 하고, 시험자가 알게 된 피험자의 병발질환에\n\n<!-- PAGE_119 -->\n###### 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려주어야 한다.\n\n <!-- PAGE_119 -->\n###### 3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의\n\n<!-- PAGE_119 -->\n###### 라.  의뢰자\n\n<!-- PAGE_119 -->\n###### 1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로\n\n<!-- PAGE_119 -->\n###### 통상의료기기 임상시험의 경우 의료기기 제조업자(수입자를 포함\n\n<!-- PAGE_119 -->\n###### 2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상\n\n<!-- PAGE_119 -->\n###### 3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상\n\n<!-- PAGE_119 -->\n###### 시험의 종류와 복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의\n\n<!-- PAGE_119 -->\n###### 정도 및 이미 확인된 임상시험 실시상의 문제점 등에 따라 결정\n\n- - 113 -\n<!-- PAGE_120 -->\n###### 마.  모니터링\n\n<!-- PAGE_120 -->\n###### 1) 모니터링(Monitoring)이란 임상시험 진행 과정을 감독하고, 해당\n\n<!-- PAGE_120 -->\n###### 임상시험이 임상시험계획서, 표준작업지침서, 임상시험 실시 기준\n\n<!-- PAGE_120 -->\n###### 및 관련 규정에 따라 실시, 기록되는지 여부를 검토, 확인하는\n\n<!-- PAGE_120 -->\n###### 2) 임상시험에 대한 모니터링은 임상시험모니터요원의 정기적인 임상\n\n<!-- PAGE_120 -->\n###### 시험 실시기관 방문과 전화 등을 통해서 이루어질 것이다.  방문 시\n\n<!-- PAGE_120 -->\n###### 모니터는 환자기록 원본, 임상시험용 의료기기 관리 기록, 자료\n\n<!-- PAGE_120 -->\n###### 3) 또한 임상시험모니터 요원은 임상시험 진행과정을 잘 살피고,\n\n<!-- PAGE_120 -->\n###### 바.  임상시험계획서의 변경\n\n<!-- PAGE_120 -->\n###### 1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장\n\n<!-- PAGE_120 -->\n###### 으로부터 승인받은 후, 시험절차가 광범위해지거나 위험도가\n\n<!-- PAGE_120 -->\n###### 높아지거나 피험자 선정기준에 변화가 있거나 추가적인 안전성\n\n<!-- PAGE_120 -->\n###### 정보로 인해 임사시험계획서를 변경하는 경우에는 임상시험심사\n\n<!-- PAGE_120 -->\n###### 2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정\n\n<!-- PAGE_120 -->\n###### 3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한\n\n<!-- PAGE_120 -->\n###### 경우를 제외하고는, 임상시험심사위원회- 및 식품의약품안전처장의\n\n<!-- PAGE_120 -->\n###### 변경 승인 이전에는 계획서와 다르게 임상시험을 실시하여서는\n\n- - 114 -\n<!-- PAGE_121 -->\n###### 안 된다. ",
        "original_sentence": "의뢰자\n\n<!-- PAGE_119 -->\n###### 1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로\n\n<!-- PAGE_119 -->\n###### 통상의료기기 임상시험의 경우 의료기기 제조업자(수입자를 포함\n\n<!-- PAGE_119 -->\n###### 2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상\n\n<!-- PAGE_119 -->\n###### 3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상\n\n<!-- PAGE_119 -->\n###### 시험의 종류와 복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의\n\n<!-- PAGE_119 -->\n###### 정도 및 이미 확인된 임상시험 실시상의 문제점 등에 따라 결정\n\n- - 113 -\n<!-- PAGE_120 -->\n###### 마. "
      }
    },
    {
      "chunk_id": "chunk_830",
      "text": "모니터링\n\n<!-- PAGE_120 -->\n###### 1) 모니터링(Monitoring)이란 임상시험 진행 과정을 감독하고, 해당\n\n<!-- PAGE_120 -->\n###### 임상시험이 임상시험계획서, 표준작업지침서, 임상시험 실시 기준\n\n<!-- PAGE_120 -->\n###### 및 관련 규정에 따라 실시, 기록되는지 여부를 검토, 확인하는\n\n<!-- PAGE_120 -->\n###### 2) 임상시험에 대한 모니터링은 임상시험모니터요원의 정기적인 임상\n\n<!-- PAGE_120 -->\n###### 시험 실시기관 방문과 전화 등을 통해서 이루어질 것이다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 829,
        "window_size": 3,
        "char_count": 317,
        "word_count": 58,
        "page_number": 120,
        "window_text": "시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품\n\n<!-- PAGE_119 -->\n###### 의약품안전처장의 승인을 득한 임상시험 계획서를 준수하여\n\n<!-- PAGE_119 -->\n###### 2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미\n\n<!-- PAGE_119 -->\n###### 있는 시험실적 검사치의 이상을 포함하여 임상시험에서 발생한\n\n<!-- PAGE_119 -->\n###### 모든 이상반응에 대해 피험자가 적절한 의학적 처치를 받을 수\n\n<!-- PAGE_119 -->\n###### 있도록 조치하여야 하고, 시험자가 알게 된 피험자의 병발질환에\n\n<!-- PAGE_119 -->\n###### 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려주어야 한다.\n\n <!-- PAGE_119 -->\n###### 3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의\n\n<!-- PAGE_119 -->\n###### 라.  의뢰자\n\n<!-- PAGE_119 -->\n###### 1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로\n\n<!-- PAGE_119 -->\n###### 통상의료기기 임상시험의 경우 의료기기 제조업자(수입자를 포함\n\n<!-- PAGE_119 -->\n###### 2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상\n\n<!-- PAGE_119 -->\n###### 3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상\n\n<!-- PAGE_119 -->\n###### 시험의 종류와 복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의\n\n<!-- PAGE_119 -->\n###### 정도 및 이미 확인된 임상시험 실시상의 문제점 등에 따라 결정\n\n- - 113 -\n<!-- PAGE_120 -->\n###### 마.  모니터링\n\n<!-- PAGE_120 -->\n###### 1) 모니터링(Monitoring)이란 임상시험 진행 과정을 감독하고, 해당\n\n<!-- PAGE_120 -->\n###### 임상시험이 임상시험계획서, 표준작업지침서, 임상시험 실시 기준\n\n<!-- PAGE_120 -->\n###### 및 관련 규정에 따라 실시, 기록되는지 여부를 검토, 확인하는\n\n<!-- PAGE_120 -->\n###### 2) 임상시험에 대한 모니터링은 임상시험모니터요원의 정기적인 임상\n\n<!-- PAGE_120 -->\n###### 시험 실시기관 방문과 전화 등을 통해서 이루어질 것이다.  방문 시\n\n<!-- PAGE_120 -->\n###### 모니터는 환자기록 원본, 임상시험용 의료기기 관리 기록, 자료\n\n<!-- PAGE_120 -->\n###### 3) 또한 임상시험모니터 요원은 임상시험 진행과정을 잘 살피고,\n\n<!-- PAGE_120 -->\n###### 바.  임상시험계획서의 변경\n\n<!-- PAGE_120 -->\n###### 1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장\n\n<!-- PAGE_120 -->\n###### 으로부터 승인받은 후, 시험절차가 광범위해지거나 위험도가\n\n<!-- PAGE_120 -->\n###### 높아지거나 피험자 선정기준에 변화가 있거나 추가적인 안전성\n\n<!-- PAGE_120 -->\n###### 정보로 인해 임사시험계획서를 변경하는 경우에는 임상시험심사\n\n<!-- PAGE_120 -->\n###### 2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정\n\n<!-- PAGE_120 -->\n###### 3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한\n\n<!-- PAGE_120 -->\n###### 경우를 제외하고는, 임상시험심사위원회- 및 식품의약품안전처장의\n\n<!-- PAGE_120 -->\n###### 변경 승인 이전에는 계획서와 다르게 임상시험을 실시하여서는\n\n- - 114 -\n<!-- PAGE_121 -->\n###### 안 된다.  만일 피험자에게 발생한 즉각적 위험요소를 제거하기\n\n<!-- PAGE_121 -->\n###### 위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험\n\n<!-- PAGE_121 -->\n###### 계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에\n\n<!-- PAGE_121 -->\n###### 대하여 임상시험심사위원회(사후검토 승인을 위함), 의뢰자, 식품\n\n<!-- PAGE_121 -->\n###### 의약품안전처장에게 제출하여야 한다. ",
        "original_sentence": "모니터링\n\n<!-- PAGE_120 -->\n###### 1) 모니터링(Monitoring)이란 임상시험 진행 과정을 감독하고, 해당\n\n<!-- PAGE_120 -->\n###### 임상시험이 임상시험계획서, 표준작업지침서, 임상시험 실시 기준\n\n<!-- PAGE_120 -->\n###### 및 관련 규정에 따라 실시, 기록되는지 여부를 검토, 확인하는\n\n<!-- PAGE_120 -->\n###### 2) 임상시험에 대한 모니터링은 임상시험모니터요원의 정기적인 임상\n\n<!-- PAGE_120 -->\n###### 시험 실시기관 방문과 전화 등을 통해서 이루어질 것이다. "
      }
    },
    {
      "chunk_id": "chunk_831",
      "text": "방문 시\n\n<!-- PAGE_120 -->\n###### 모니터는 환자기록 원본, 임상시험용 의료기기 관리 기록, 자료\n\n<!-- PAGE_120 -->\n###### 3) 또한 임상시험모니터 요원은 임상시험 진행과정을 잘 살피고,\n\n<!-- PAGE_120 -->\n###### 바. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 830,
        "window_size": 3,
        "char_count": 157,
        "word_count": 31,
        "page_number": 120,
        "window_text": "<!-- PAGE_119 -->\n###### 3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의\n\n<!-- PAGE_119 -->\n###### 라.  의뢰자\n\n<!-- PAGE_119 -->\n###### 1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로\n\n<!-- PAGE_119 -->\n###### 통상의료기기 임상시험의 경우 의료기기 제조업자(수입자를 포함\n\n<!-- PAGE_119 -->\n###### 2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상\n\n<!-- PAGE_119 -->\n###### 3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상\n\n<!-- PAGE_119 -->\n###### 시험의 종류와 복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의\n\n<!-- PAGE_119 -->\n###### 정도 및 이미 확인된 임상시험 실시상의 문제점 등에 따라 결정\n\n- - 113 -\n<!-- PAGE_120 -->\n###### 마.  모니터링\n\n<!-- PAGE_120 -->\n###### 1) 모니터링(Monitoring)이란 임상시험 진행 과정을 감독하고, 해당\n\n<!-- PAGE_120 -->\n###### 임상시험이 임상시험계획서, 표준작업지침서, 임상시험 실시 기준\n\n<!-- PAGE_120 -->\n###### 및 관련 규정에 따라 실시, 기록되는지 여부를 검토, 확인하는\n\n<!-- PAGE_120 -->\n###### 2) 임상시험에 대한 모니터링은 임상시험모니터요원의 정기적인 임상\n\n<!-- PAGE_120 -->\n###### 시험 실시기관 방문과 전화 등을 통해서 이루어질 것이다.  방문 시\n\n<!-- PAGE_120 -->\n###### 모니터는 환자기록 원본, 임상시험용 의료기기 관리 기록, 자료\n\n<!-- PAGE_120 -->\n###### 3) 또한 임상시험모니터 요원은 임상시험 진행과정을 잘 살피고,\n\n<!-- PAGE_120 -->\n###### 바.  임상시험계획서의 변경\n\n<!-- PAGE_120 -->\n###### 1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장\n\n<!-- PAGE_120 -->\n###### 으로부터 승인받은 후, 시험절차가 광범위해지거나 위험도가\n\n<!-- PAGE_120 -->\n###### 높아지거나 피험자 선정기준에 변화가 있거나 추가적인 안전성\n\n<!-- PAGE_120 -->\n###### 정보로 인해 임사시험계획서를 변경하는 경우에는 임상시험심사\n\n<!-- PAGE_120 -->\n###### 2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정\n\n<!-- PAGE_120 -->\n###### 3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한\n\n<!-- PAGE_120 -->\n###### 경우를 제외하고는, 임상시험심사위원회- 및 식품의약품안전처장의\n\n<!-- PAGE_120 -->\n###### 변경 승인 이전에는 계획서와 다르게 임상시험을 실시하여서는\n\n- - 114 -\n<!-- PAGE_121 -->\n###### 안 된다.  만일 피험자에게 발생한 즉각적 위험요소를 제거하기\n\n<!-- PAGE_121 -->\n###### 위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험\n\n<!-- PAGE_121 -->\n###### 계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에\n\n<!-- PAGE_121 -->\n###### 대하여 임상시험심사위원회(사후검토 승인을 위함), 의뢰자, 식품\n\n<!-- PAGE_121 -->\n###### 의약품안전처장에게 제출하여야 한다.  그리고 임상시험심사위원회\n\n<!-- PAGE_121 -->\n###### 4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이\n\n<!-- PAGE_121 -->\n###### 사. ",
        "original_sentence": "방문 시\n\n<!-- PAGE_120 -->\n###### 모니터는 환자기록 원본, 임상시험용 의료기기 관리 기록, 자료\n\n<!-- PAGE_120 -->\n###### 3) 또한 임상시험모니터 요원은 임상시험 진행과정을 잘 살피고,\n\n<!-- PAGE_120 -->\n###### 바. "
      }
    },
    {
      "chunk_id": "chunk_832",
      "text": "임상시험계획서의 변경\n\n<!-- PAGE_120 -->\n###### 1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장\n\n<!-- PAGE_120 -->\n###### 으로부터 승인받은 후, 시험절차가 광범위해지거나 위험도가\n\n<!-- PAGE_120 -->\n###### 높아지거나 피험자 선정기준에 변화가 있거나 추가적인 안전성\n\n<!-- PAGE_120 -->\n###### 정보로 인해 임사시험계획서를 변경하는 경우에는 임상시험심사\n\n<!-- PAGE_120 -->\n###### 2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정\n\n<!-- PAGE_120 -->\n###### 3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한\n\n<!-- PAGE_120 -->\n###### 경우를 제외하고는, 임상시험심사위원회- 및 식품의약품안전처장의\n\n<!-- PAGE_120 -->\n###### 변경 승인 이전에는 계획서와 다르게 임상시험을 실시하여서는\n\n- - 114 -\n<!-- PAGE_121 -->\n###### 안 된다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 831,
        "window_size": 3,
        "char_count": 536,
        "word_count": 98,
        "page_number": 120,
        "window_text": "의뢰자\n\n<!-- PAGE_119 -->\n###### 1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로\n\n<!-- PAGE_119 -->\n###### 통상의료기기 임상시험의 경우 의료기기 제조업자(수입자를 포함\n\n<!-- PAGE_119 -->\n###### 2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상\n\n<!-- PAGE_119 -->\n###### 3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상\n\n<!-- PAGE_119 -->\n###### 시험의 종류와 복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의\n\n<!-- PAGE_119 -->\n###### 정도 및 이미 확인된 임상시험 실시상의 문제점 등에 따라 결정\n\n- - 113 -\n<!-- PAGE_120 -->\n###### 마.  모니터링\n\n<!-- PAGE_120 -->\n###### 1) 모니터링(Monitoring)이란 임상시험 진행 과정을 감독하고, 해당\n\n<!-- PAGE_120 -->\n###### 임상시험이 임상시험계획서, 표준작업지침서, 임상시험 실시 기준\n\n<!-- PAGE_120 -->\n###### 및 관련 규정에 따라 실시, 기록되는지 여부를 검토, 확인하는\n\n<!-- PAGE_120 -->\n###### 2) 임상시험에 대한 모니터링은 임상시험모니터요원의 정기적인 임상\n\n<!-- PAGE_120 -->\n###### 시험 실시기관 방문과 전화 등을 통해서 이루어질 것이다.  방문 시\n\n<!-- PAGE_120 -->\n###### 모니터는 환자기록 원본, 임상시험용 의료기기 관리 기록, 자료\n\n<!-- PAGE_120 -->\n###### 3) 또한 임상시험모니터 요원은 임상시험 진행과정을 잘 살피고,\n\n<!-- PAGE_120 -->\n###### 바.  임상시험계획서의 변경\n\n<!-- PAGE_120 -->\n###### 1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장\n\n<!-- PAGE_120 -->\n###### 으로부터 승인받은 후, 시험절차가 광범위해지거나 위험도가\n\n<!-- PAGE_120 -->\n###### 높아지거나 피험자 선정기준에 변화가 있거나 추가적인 안전성\n\n<!-- PAGE_120 -->\n###### 정보로 인해 임사시험계획서를 변경하는 경우에는 임상시험심사\n\n<!-- PAGE_120 -->\n###### 2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정\n\n<!-- PAGE_120 -->\n###### 3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한\n\n<!-- PAGE_120 -->\n###### 경우를 제외하고는, 임상시험심사위원회- 및 식품의약품안전처장의\n\n<!-- PAGE_120 -->\n###### 변경 승인 이전에는 계획서와 다르게 임상시험을 실시하여서는\n\n- - 114 -\n<!-- PAGE_121 -->\n###### 안 된다.  만일 피험자에게 발생한 즉각적 위험요소를 제거하기\n\n<!-- PAGE_121 -->\n###### 위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험\n\n<!-- PAGE_121 -->\n###### 계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에\n\n<!-- PAGE_121 -->\n###### 대하여 임상시험심사위원회(사후검토 승인을 위함), 의뢰자, 식품\n\n<!-- PAGE_121 -->\n###### 의약품안전처장에게 제출하여야 한다.  그리고 임상시험심사위원회\n\n<!-- PAGE_121 -->\n###### 4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이\n\n<!-- PAGE_121 -->\n###### 사.  피험자 동의\n\n<!-- PAGE_121 -->\n###### 1) 피험자 동의(Informed consent)라 함은 피험자가 임상시험 참여\n\n<!-- PAGE_121 -->\n###### 유무를 결정하기 전에 피험자를 위한 설명서를 통해 해당 임상\n\n<!-- PAGE_121 -->\n###### 시험과 관련된 모든 정보를 제공받고, 서명과 서명 날짜가 포함된\n\n<!-- PAGE_121 -->\n###### 문서를 통해 본인이 자발적으로 임상시험에 참여함을 확인하는\n\n<!-- PAGE_121 -->\n###### 2) 피험자 본인 또는 대리인이 동의서 서식, 피험자 설명서 및 기타\n\n<!-- PAGE_121 -->\n###### 문서화된 정보를 읽을 수 없는 경우에는 공정한 입회자가 동의를\n\n<!-- PAGE_121 -->\n###### 3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의\n\n<!-- PAGE_121 -->\n###### 세부 사항에 대해 질문하고 해당 임상시험의 참여 여부를 결정\n\n<!-- PAGE_121 -->\n###### 할 수 있도록 충분한 시간과 기회를 주어야 하며, 모든 임상시험\n\n<!-- PAGE_121 -->\n###### 관련 질문에 대해 피험자 또는 대리인이 만족할 수 있도록 대답\n\n- - 115 -\n<!-- PAGE_122 -->\n###### 아. ",
        "original_sentence": "임상시험계획서의 변경\n\n<!-- PAGE_120 -->\n###### 1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장\n\n<!-- PAGE_120 -->\n###### 으로부터 승인받은 후, 시험절차가 광범위해지거나 위험도가\n\n<!-- PAGE_120 -->\n###### 높아지거나 피험자 선정기준에 변화가 있거나 추가적인 안전성\n\n<!-- PAGE_120 -->\n###### 정보로 인해 임사시험계획서를 변경하는 경우에는 임상시험심사\n\n<!-- PAGE_120 -->\n###### 2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정\n\n<!-- PAGE_120 -->\n###### 3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한\n\n<!-- PAGE_120 -->\n###### 경우를 제외하고는, 임상시험심사위원회- 및 식품의약품안전처장의\n\n<!-- PAGE_120 -->\n###### 변경 승인 이전에는 계획서와 다르게 임상시험을 실시하여서는\n\n- - 114 -\n<!-- PAGE_121 -->\n###### 안 된다. "
      }
    },
    {
      "chunk_id": "chunk_833",
      "text": "만일 피험자에게 발생한 즉각적 위험요소를 제거하기\n\n<!-- PAGE_121 -->\n###### 위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험\n\n<!-- PAGE_121 -->\n###### 계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에\n\n<!-- PAGE_121 -->\n###### 대하여 임상시험심사위원회(사후검토 승인을 위함), 의뢰자, 식품\n\n<!-- PAGE_121 -->\n###### 의약품안전처장에게 제출하여야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 832,
        "window_size": 3,
        "char_count": 255,
        "word_count": 47,
        "page_number": 121,
        "window_text": "모니터링\n\n<!-- PAGE_120 -->\n###### 1) 모니터링(Monitoring)이란 임상시험 진행 과정을 감독하고, 해당\n\n<!-- PAGE_120 -->\n###### 임상시험이 임상시험계획서, 표준작업지침서, 임상시험 실시 기준\n\n<!-- PAGE_120 -->\n###### 및 관련 규정에 따라 실시, 기록되는지 여부를 검토, 확인하는\n\n<!-- PAGE_120 -->\n###### 2) 임상시험에 대한 모니터링은 임상시험모니터요원의 정기적인 임상\n\n<!-- PAGE_120 -->\n###### 시험 실시기관 방문과 전화 등을 통해서 이루어질 것이다.  방문 시\n\n<!-- PAGE_120 -->\n###### 모니터는 환자기록 원본, 임상시험용 의료기기 관리 기록, 자료\n\n<!-- PAGE_120 -->\n###### 3) 또한 임상시험모니터 요원은 임상시험 진행과정을 잘 살피고,\n\n<!-- PAGE_120 -->\n###### 바.  임상시험계획서의 변경\n\n<!-- PAGE_120 -->\n###### 1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장\n\n<!-- PAGE_120 -->\n###### 으로부터 승인받은 후, 시험절차가 광범위해지거나 위험도가\n\n<!-- PAGE_120 -->\n###### 높아지거나 피험자 선정기준에 변화가 있거나 추가적인 안전성\n\n<!-- PAGE_120 -->\n###### 정보로 인해 임사시험계획서를 변경하는 경우에는 임상시험심사\n\n<!-- PAGE_120 -->\n###### 2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정\n\n<!-- PAGE_120 -->\n###### 3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한\n\n<!-- PAGE_120 -->\n###### 경우를 제외하고는, 임상시험심사위원회- 및 식품의약품안전처장의\n\n<!-- PAGE_120 -->\n###### 변경 승인 이전에는 계획서와 다르게 임상시험을 실시하여서는\n\n- - 114 -\n<!-- PAGE_121 -->\n###### 안 된다.  만일 피험자에게 발생한 즉각적 위험요소를 제거하기\n\n<!-- PAGE_121 -->\n###### 위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험\n\n<!-- PAGE_121 -->\n###### 계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에\n\n<!-- PAGE_121 -->\n###### 대하여 임상시험심사위원회(사후검토 승인을 위함), 의뢰자, 식품\n\n<!-- PAGE_121 -->\n###### 의약품안전처장에게 제출하여야 한다.  그리고 임상시험심사위원회\n\n<!-- PAGE_121 -->\n###### 4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이\n\n<!-- PAGE_121 -->\n###### 사.  피험자 동의\n\n<!-- PAGE_121 -->\n###### 1) 피험자 동의(Informed consent)라 함은 피험자가 임상시험 참여\n\n<!-- PAGE_121 -->\n###### 유무를 결정하기 전에 피험자를 위한 설명서를 통해 해당 임상\n\n<!-- PAGE_121 -->\n###### 시험과 관련된 모든 정보를 제공받고, 서명과 서명 날짜가 포함된\n\n<!-- PAGE_121 -->\n###### 문서를 통해 본인이 자발적으로 임상시험에 참여함을 확인하는\n\n<!-- PAGE_121 -->\n###### 2) 피험자 본인 또는 대리인이 동의서 서식, 피험자 설명서 및 기타\n\n<!-- PAGE_121 -->\n###### 문서화된 정보를 읽을 수 없는 경우에는 공정한 입회자가 동의를\n\n<!-- PAGE_121 -->\n###### 3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의\n\n<!-- PAGE_121 -->\n###### 세부 사항에 대해 질문하고 해당 임상시험의 참여 여부를 결정\n\n<!-- PAGE_121 -->\n###### 할 수 있도록 충분한 시간과 기회를 주어야 하며, 모든 임상시험\n\n<!-- PAGE_121 -->\n###### 관련 질문에 대해 피험자 또는 대리인이 만족할 수 있도록 대답\n\n- - 115 -\n<!-- PAGE_122 -->\n###### 아.  피험자 기록의 비밀보장\n\n<!-- PAGE_122 -->\n###### 1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며,\n\n<!-- PAGE_122 -->\n###### 임상시험의 결과가 출관 될 경우에도 피험자의 신원을 비밀상태로\n\n<!-- PAGE_122 -->\n###### 2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의\n\n<!-- PAGE_122 -->\n###### 모니터링과 점검 및 진행사항 관리를 위한 목적으로 피험자의\n\n<!-- PAGE_122 -->\n###### 기록을 열람할 수 있다. ",
        "original_sentence": "만일 피험자에게 발생한 즉각적 위험요소를 제거하기\n\n<!-- PAGE_121 -->\n###### 위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험\n\n<!-- PAGE_121 -->\n###### 계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에\n\n<!-- PAGE_121 -->\n###### 대하여 임상시험심사위원회(사후검토 승인을 위함), 의뢰자, 식품\n\n<!-- PAGE_121 -->\n###### 의약품안전처장에게 제출하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_834",
      "text": "그리고 임상시험심사위원회\n\n<!-- PAGE_121 -->\n###### 4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이\n\n<!-- PAGE_121 -->\n###### 사. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 833,
        "window_size": 3,
        "char_count": 105,
        "word_count": 20,
        "page_number": 121,
        "window_text": "방문 시\n\n<!-- PAGE_120 -->\n###### 모니터는 환자기록 원본, 임상시험용 의료기기 관리 기록, 자료\n\n<!-- PAGE_120 -->\n###### 3) 또한 임상시험모니터 요원은 임상시험 진행과정을 잘 살피고,\n\n<!-- PAGE_120 -->\n###### 바.  임상시험계획서의 변경\n\n<!-- PAGE_120 -->\n###### 1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장\n\n<!-- PAGE_120 -->\n###### 으로부터 승인받은 후, 시험절차가 광범위해지거나 위험도가\n\n<!-- PAGE_120 -->\n###### 높아지거나 피험자 선정기준에 변화가 있거나 추가적인 안전성\n\n<!-- PAGE_120 -->\n###### 정보로 인해 임사시험계획서를 변경하는 경우에는 임상시험심사\n\n<!-- PAGE_120 -->\n###### 2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정\n\n<!-- PAGE_120 -->\n###### 3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한\n\n<!-- PAGE_120 -->\n###### 경우를 제외하고는, 임상시험심사위원회- 및 식품의약품안전처장의\n\n<!-- PAGE_120 -->\n###### 변경 승인 이전에는 계획서와 다르게 임상시험을 실시하여서는\n\n- - 114 -\n<!-- PAGE_121 -->\n###### 안 된다.  만일 피험자에게 발생한 즉각적 위험요소를 제거하기\n\n<!-- PAGE_121 -->\n###### 위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험\n\n<!-- PAGE_121 -->\n###### 계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에\n\n<!-- PAGE_121 -->\n###### 대하여 임상시험심사위원회(사후검토 승인을 위함), 의뢰자, 식품\n\n<!-- PAGE_121 -->\n###### 의약품안전처장에게 제출하여야 한다.  그리고 임상시험심사위원회\n\n<!-- PAGE_121 -->\n###### 4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이\n\n<!-- PAGE_121 -->\n###### 사.  피험자 동의\n\n<!-- PAGE_121 -->\n###### 1) 피험자 동의(Informed consent)라 함은 피험자가 임상시험 참여\n\n<!-- PAGE_121 -->\n###### 유무를 결정하기 전에 피험자를 위한 설명서를 통해 해당 임상\n\n<!-- PAGE_121 -->\n###### 시험과 관련된 모든 정보를 제공받고, 서명과 서명 날짜가 포함된\n\n<!-- PAGE_121 -->\n###### 문서를 통해 본인이 자발적으로 임상시험에 참여함을 확인하는\n\n<!-- PAGE_121 -->\n###### 2) 피험자 본인 또는 대리인이 동의서 서식, 피험자 설명서 및 기타\n\n<!-- PAGE_121 -->\n###### 문서화된 정보를 읽을 수 없는 경우에는 공정한 입회자가 동의를\n\n<!-- PAGE_121 -->\n###### 3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의\n\n<!-- PAGE_121 -->\n###### 세부 사항에 대해 질문하고 해당 임상시험의 참여 여부를 결정\n\n<!-- PAGE_121 -->\n###### 할 수 있도록 충분한 시간과 기회를 주어야 하며, 모든 임상시험\n\n<!-- PAGE_121 -->\n###### 관련 질문에 대해 피험자 또는 대리인이 만족할 수 있도록 대답\n\n- - 115 -\n<!-- PAGE_122 -->\n###### 아.  피험자 기록의 비밀보장\n\n<!-- PAGE_122 -->\n###### 1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며,\n\n<!-- PAGE_122 -->\n###### 임상시험의 결과가 출관 될 경우에도 피험자의 신원을 비밀상태로\n\n<!-- PAGE_122 -->\n###### 2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의\n\n<!-- PAGE_122 -->\n###### 모니터링과 점검 및 진행사항 관리를 위한 목적으로 피험자의\n\n<!-- PAGE_122 -->\n###### 기록을 열람할 수 있다.  시험자는 본 임상시험 계획서에 서명함\n\n<!-- PAGE_122 -->\n###### 으로써, 국내의 법규와 윤리적 측면에서 임상시험 의뢰자 또는\n\n<!-- PAGE_122 -->\n###### 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을 검증하기\n\n<!-- PAGE_122 -->\n###### 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.\n\n",
        "original_sentence": "그리고 임상시험심사위원회\n\n<!-- PAGE_121 -->\n###### 4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이\n\n<!-- PAGE_121 -->\n###### 사. "
      }
    },
    {
      "chunk_id": "chunk_835",
      "text": "피험자 동의\n\n<!-- PAGE_121 -->\n###### 1) 피험자 동의(Informed consent)라 함은 피험자가 임상시험 참여\n\n<!-- PAGE_121 -->\n###### 유무를 결정하기 전에 피험자를 위한 설명서를 통해 해당 임상\n\n<!-- PAGE_121 -->\n###### 시험과 관련된 모든 정보를 제공받고, 서명과 서명 날짜가 포함된\n\n<!-- PAGE_121 -->\n###### 문서를 통해 본인이 자발적으로 임상시험에 참여함을 확인하는\n\n<!-- PAGE_121 -->\n###### 2) 피험자 본인 또는 대리인이 동의서 서식, 피험자 설명서 및 기타\n\n<!-- PAGE_121 -->\n###### 문서화된 정보를 읽을 수 없는 경우에는 공정한 입회자가 동의를\n\n<!-- PAGE_121 -->\n###### 3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의\n\n<!-- PAGE_121 -->\n###### 세부 사항에 대해 질문하고 해당 임상시험의 참여 여부를 결정\n\n<!-- PAGE_121 -->\n###### 할 수 있도록 충분한 시간과 기회를 주어야 하며, 모든 임상시험\n\n<!-- PAGE_121 -->\n###### 관련 질문에 대해 피험자 또는 대리인이 만족할 수 있도록 대답\n\n- - 115 -\n<!-- PAGE_122 -->\n###### 아. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 834,
        "window_size": 3,
        "char_count": 669,
        "word_count": 142,
        "page_number": 121,
        "window_text": "임상시험계획서의 변경\n\n<!-- PAGE_120 -->\n###### 1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장\n\n<!-- PAGE_120 -->\n###### 으로부터 승인받은 후, 시험절차가 광범위해지거나 위험도가\n\n<!-- PAGE_120 -->\n###### 높아지거나 피험자 선정기준에 변화가 있거나 추가적인 안전성\n\n<!-- PAGE_120 -->\n###### 정보로 인해 임사시험계획서를 변경하는 경우에는 임상시험심사\n\n<!-- PAGE_120 -->\n###### 2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정\n\n<!-- PAGE_120 -->\n###### 3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한\n\n<!-- PAGE_120 -->\n###### 경우를 제외하고는, 임상시험심사위원회- 및 식품의약품안전처장의\n\n<!-- PAGE_120 -->\n###### 변경 승인 이전에는 계획서와 다르게 임상시험을 실시하여서는\n\n- - 114 -\n<!-- PAGE_121 -->\n###### 안 된다.  만일 피험자에게 발생한 즉각적 위험요소를 제거하기\n\n<!-- PAGE_121 -->\n###### 위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험\n\n<!-- PAGE_121 -->\n###### 계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에\n\n<!-- PAGE_121 -->\n###### 대하여 임상시험심사위원회(사후검토 승인을 위함), 의뢰자, 식품\n\n<!-- PAGE_121 -->\n###### 의약품안전처장에게 제출하여야 한다.  그리고 임상시험심사위원회\n\n<!-- PAGE_121 -->\n###### 4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이\n\n<!-- PAGE_121 -->\n###### 사.  피험자 동의\n\n<!-- PAGE_121 -->\n###### 1) 피험자 동의(Informed consent)라 함은 피험자가 임상시험 참여\n\n<!-- PAGE_121 -->\n###### 유무를 결정하기 전에 피험자를 위한 설명서를 통해 해당 임상\n\n<!-- PAGE_121 -->\n###### 시험과 관련된 모든 정보를 제공받고, 서명과 서명 날짜가 포함된\n\n<!-- PAGE_121 -->\n###### 문서를 통해 본인이 자발적으로 임상시험에 참여함을 확인하는\n\n<!-- PAGE_121 -->\n###### 2) 피험자 본인 또는 대리인이 동의서 서식, 피험자 설명서 및 기타\n\n<!-- PAGE_121 -->\n###### 문서화된 정보를 읽을 수 없는 경우에는 공정한 입회자가 동의를\n\n<!-- PAGE_121 -->\n###### 3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의\n\n<!-- PAGE_121 -->\n###### 세부 사항에 대해 질문하고 해당 임상시험의 참여 여부를 결정\n\n<!-- PAGE_121 -->\n###### 할 수 있도록 충분한 시간과 기회를 주어야 하며, 모든 임상시험\n\n<!-- PAGE_121 -->\n###### 관련 질문에 대해 피험자 또는 대리인이 만족할 수 있도록 대답\n\n- - 115 -\n<!-- PAGE_122 -->\n###### 아.  피험자 기록의 비밀보장\n\n<!-- PAGE_122 -->\n###### 1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며,\n\n<!-- PAGE_122 -->\n###### 임상시험의 결과가 출관 될 경우에도 피험자의 신원을 비밀상태로\n\n<!-- PAGE_122 -->\n###### 2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의\n\n<!-- PAGE_122 -->\n###### 모니터링과 점검 및 진행사항 관리를 위한 목적으로 피험자의\n\n<!-- PAGE_122 -->\n###### 기록을 열람할 수 있다.  시험자는 본 임상시험 계획서에 서명함\n\n<!-- PAGE_122 -->\n###### 으로써, 국내의 법규와 윤리적 측면에서 임상시험 의뢰자 또는\n\n<!-- PAGE_122 -->\n###### 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을 검증하기\n\n<!-- PAGE_122 -->\n###### 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.\n\n <!-- PAGE_122 -->\n###### 3) 증례기록서 등 임상시험에 관련된 모든 서류에는 피험자 이름이\n\n<!-- PAGE_122 -->\n###### 아닌 피험자 식별코드(일반적으로 피험자 이니셜)로 기록하고\n\n<!-- PAGE_122 -->\n###### 자. ",
        "original_sentence": "피험자 동의\n\n<!-- PAGE_121 -->\n###### 1) 피험자 동의(Informed consent)라 함은 피험자가 임상시험 참여\n\n<!-- PAGE_121 -->\n###### 유무를 결정하기 전에 피험자를 위한 설명서를 통해 해당 임상\n\n<!-- PAGE_121 -->\n###### 시험과 관련된 모든 정보를 제공받고, 서명과 서명 날짜가 포함된\n\n<!-- PAGE_121 -->\n###### 문서를 통해 본인이 자발적으로 임상시험에 참여함을 확인하는\n\n<!-- PAGE_121 -->\n###### 2) 피험자 본인 또는 대리인이 동의서 서식, 피험자 설명서 및 기타\n\n<!-- PAGE_121 -->\n###### 문서화된 정보를 읽을 수 없는 경우에는 공정한 입회자가 동의를\n\n<!-- PAGE_121 -->\n###### 3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의\n\n<!-- PAGE_121 -->\n###### 세부 사항에 대해 질문하고 해당 임상시험의 참여 여부를 결정\n\n<!-- PAGE_121 -->\n###### 할 수 있도록 충분한 시간과 기회를 주어야 하며, 모든 임상시험\n\n<!-- PAGE_121 -->\n###### 관련 질문에 대해 피험자 또는 대리인이 만족할 수 있도록 대답\n\n- - 115 -\n<!-- PAGE_122 -->\n###### 아. "
      }
    },
    {
      "chunk_id": "chunk_836",
      "text": "피험자 기록의 비밀보장\n\n<!-- PAGE_122 -->\n###### 1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며,\n\n<!-- PAGE_122 -->\n###### 임상시험의 결과가 출관 될 경우에도 피험자의 신원을 비밀상태로\n\n<!-- PAGE_122 -->\n###### 2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의\n\n<!-- PAGE_122 -->\n###### 모니터링과 점검 및 진행사항 관리를 위한 목적으로 피험자의\n\n<!-- PAGE_122 -->\n###### 기록을 열람할 수 있다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 835,
        "window_size": 3,
        "char_count": 302,
        "word_count": 63,
        "page_number": 122,
        "window_text": "만일 피험자에게 발생한 즉각적 위험요소를 제거하기\n\n<!-- PAGE_121 -->\n###### 위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험\n\n<!-- PAGE_121 -->\n###### 계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에\n\n<!-- PAGE_121 -->\n###### 대하여 임상시험심사위원회(사후검토 승인을 위함), 의뢰자, 식품\n\n<!-- PAGE_121 -->\n###### 의약품안전처장에게 제출하여야 한다.  그리고 임상시험심사위원회\n\n<!-- PAGE_121 -->\n###### 4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이\n\n<!-- PAGE_121 -->\n###### 사.  피험자 동의\n\n<!-- PAGE_121 -->\n###### 1) 피험자 동의(Informed consent)라 함은 피험자가 임상시험 참여\n\n<!-- PAGE_121 -->\n###### 유무를 결정하기 전에 피험자를 위한 설명서를 통해 해당 임상\n\n<!-- PAGE_121 -->\n###### 시험과 관련된 모든 정보를 제공받고, 서명과 서명 날짜가 포함된\n\n<!-- PAGE_121 -->\n###### 문서를 통해 본인이 자발적으로 임상시험에 참여함을 확인하는\n\n<!-- PAGE_121 -->\n###### 2) 피험자 본인 또는 대리인이 동의서 서식, 피험자 설명서 및 기타\n\n<!-- PAGE_121 -->\n###### 문서화된 정보를 읽을 수 없는 경우에는 공정한 입회자가 동의를\n\n<!-- PAGE_121 -->\n###### 3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의\n\n<!-- PAGE_121 -->\n###### 세부 사항에 대해 질문하고 해당 임상시험의 참여 여부를 결정\n\n<!-- PAGE_121 -->\n###### 할 수 있도록 충분한 시간과 기회를 주어야 하며, 모든 임상시험\n\n<!-- PAGE_121 -->\n###### 관련 질문에 대해 피험자 또는 대리인이 만족할 수 있도록 대답\n\n- - 115 -\n<!-- PAGE_122 -->\n###### 아.  피험자 기록의 비밀보장\n\n<!-- PAGE_122 -->\n###### 1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며,\n\n<!-- PAGE_122 -->\n###### 임상시험의 결과가 출관 될 경우에도 피험자의 신원을 비밀상태로\n\n<!-- PAGE_122 -->\n###### 2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의\n\n<!-- PAGE_122 -->\n###### 모니터링과 점검 및 진행사항 관리를 위한 목적으로 피험자의\n\n<!-- PAGE_122 -->\n###### 기록을 열람할 수 있다.  시험자는 본 임상시험 계획서에 서명함\n\n<!-- PAGE_122 -->\n###### 으로써, 국내의 법규와 윤리적 측면에서 임상시험 의뢰자 또는\n\n<!-- PAGE_122 -->\n###### 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을 검증하기\n\n<!-- PAGE_122 -->\n###### 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.\n\n <!-- PAGE_122 -->\n###### 3) 증례기록서 등 임상시험에 관련된 모든 서류에는 피험자 이름이\n\n<!-- PAGE_122 -->\n###### 아닌 피험자 식별코드(일반적으로 피험자 이니셜)로 기록하고\n\n<!-- PAGE_122 -->\n###### 자.  기록의 보존\n\n<!-- PAGE_122 -->\n###### 1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록\n\n<!-- PAGE_122 -->\n###### 하여야 하며 보안을 유지하도록 한다. ",
        "original_sentence": "피험자 기록의 비밀보장\n\n<!-- PAGE_122 -->\n###### 1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며,\n\n<!-- PAGE_122 -->\n###### 임상시험의 결과가 출관 될 경우에도 피험자의 신원을 비밀상태로\n\n<!-- PAGE_122 -->\n###### 2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의\n\n<!-- PAGE_122 -->\n###### 모니터링과 점검 및 진행사항 관리를 위한 목적으로 피험자의\n\n<!-- PAGE_122 -->\n###### 기록을 열람할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_837",
      "text": "시험자는 본 임상시험 계획서에 서명함\n\n<!-- PAGE_122 -->\n###### 으로써, 국내의 법규와 윤리적 측면에서 임상시험 의뢰자 또는\n\n<!-- PAGE_122 -->\n###### 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을 검증하기\n\n<!-- PAGE_122 -->\n###### 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 836,
        "window_size": 3,
        "char_count": 203,
        "word_count": 41,
        "page_number": 122,
        "window_text": "그리고 임상시험심사위원회\n\n<!-- PAGE_121 -->\n###### 4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이\n\n<!-- PAGE_121 -->\n###### 사.  피험자 동의\n\n<!-- PAGE_121 -->\n###### 1) 피험자 동의(Informed consent)라 함은 피험자가 임상시험 참여\n\n<!-- PAGE_121 -->\n###### 유무를 결정하기 전에 피험자를 위한 설명서를 통해 해당 임상\n\n<!-- PAGE_121 -->\n###### 시험과 관련된 모든 정보를 제공받고, 서명과 서명 날짜가 포함된\n\n<!-- PAGE_121 -->\n###### 문서를 통해 본인이 자발적으로 임상시험에 참여함을 확인하는\n\n<!-- PAGE_121 -->\n###### 2) 피험자 본인 또는 대리인이 동의서 서식, 피험자 설명서 및 기타\n\n<!-- PAGE_121 -->\n###### 문서화된 정보를 읽을 수 없는 경우에는 공정한 입회자가 동의를\n\n<!-- PAGE_121 -->\n###### 3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의\n\n<!-- PAGE_121 -->\n###### 세부 사항에 대해 질문하고 해당 임상시험의 참여 여부를 결정\n\n<!-- PAGE_121 -->\n###### 할 수 있도록 충분한 시간과 기회를 주어야 하며, 모든 임상시험\n\n<!-- PAGE_121 -->\n###### 관련 질문에 대해 피험자 또는 대리인이 만족할 수 있도록 대답\n\n- - 115 -\n<!-- PAGE_122 -->\n###### 아.  피험자 기록의 비밀보장\n\n<!-- PAGE_122 -->\n###### 1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며,\n\n<!-- PAGE_122 -->\n###### 임상시험의 결과가 출관 될 경우에도 피험자의 신원을 비밀상태로\n\n<!-- PAGE_122 -->\n###### 2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의\n\n<!-- PAGE_122 -->\n###### 모니터링과 점검 및 진행사항 관리를 위한 목적으로 피험자의\n\n<!-- PAGE_122 -->\n###### 기록을 열람할 수 있다.  시험자는 본 임상시험 계획서에 서명함\n\n<!-- PAGE_122 -->\n###### 으로써, 국내의 법규와 윤리적 측면에서 임상시험 의뢰자 또는\n\n<!-- PAGE_122 -->\n###### 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을 검증하기\n\n<!-- PAGE_122 -->\n###### 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.\n\n <!-- PAGE_122 -->\n###### 3) 증례기록서 등 임상시험에 관련된 모든 서류에는 피험자 이름이\n\n<!-- PAGE_122 -->\n###### 아닌 피험자 식별코드(일반적으로 피험자 이니셜)로 기록하고\n\n<!-- PAGE_122 -->\n###### 자.  기록의 보존\n\n<!-- PAGE_122 -->\n###### 1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록\n\n<!-- PAGE_122 -->\n###### 하여야 하며 보안을 유지하도록 한다.  제조허가/수입허가 또는\n\n<!-- PAGE_122 -->\n###### 그 변경 허가를 위한 임상시험 관련 자료는 허가일로부터 3년간\n\n<!-- PAGE_122 -->\n###### 보존하도록 하고, 그 밖의 임상시험 관련 자료는 임상시험이 끝난\n\n<!-- PAGE_122 -->\n###### 날부터 3년간 보존하도록 한다. ",
        "original_sentence": "시험자는 본 임상시험 계획서에 서명함\n\n<!-- PAGE_122 -->\n###### 으로써, 국내의 법규와 윤리적 측면에서 임상시험 의뢰자 또는\n\n<!-- PAGE_122 -->\n###### 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을 검증하기\n\n<!-- PAGE_122 -->\n###### 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_838",
      "text": "<!-- PAGE_122 -->\n###### 3) 증례기록서 등 임상시험에 관련된 모든 서류에는 피험자 이름이\n\n<!-- PAGE_122 -->\n###### 아닌 피험자 식별코드(일반적으로 피험자 이니셜)로 기록하고\n\n<!-- PAGE_122 -->\n###### 자. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 837,
        "window_size": 3,
        "char_count": 150,
        "word_count": 28,
        "page_number": 122,
        "window_text": "피험자 동의\n\n<!-- PAGE_121 -->\n###### 1) 피험자 동의(Informed consent)라 함은 피험자가 임상시험 참여\n\n<!-- PAGE_121 -->\n###### 유무를 결정하기 전에 피험자를 위한 설명서를 통해 해당 임상\n\n<!-- PAGE_121 -->\n###### 시험과 관련된 모든 정보를 제공받고, 서명과 서명 날짜가 포함된\n\n<!-- PAGE_121 -->\n###### 문서를 통해 본인이 자발적으로 임상시험에 참여함을 확인하는\n\n<!-- PAGE_121 -->\n###### 2) 피험자 본인 또는 대리인이 동의서 서식, 피험자 설명서 및 기타\n\n<!-- PAGE_121 -->\n###### 문서화된 정보를 읽을 수 없는 경우에는 공정한 입회자가 동의를\n\n<!-- PAGE_121 -->\n###### 3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의\n\n<!-- PAGE_121 -->\n###### 세부 사항에 대해 질문하고 해당 임상시험의 참여 여부를 결정\n\n<!-- PAGE_121 -->\n###### 할 수 있도록 충분한 시간과 기회를 주어야 하며, 모든 임상시험\n\n<!-- PAGE_121 -->\n###### 관련 질문에 대해 피험자 또는 대리인이 만족할 수 있도록 대답\n\n- - 115 -\n<!-- PAGE_122 -->\n###### 아.  피험자 기록의 비밀보장\n\n<!-- PAGE_122 -->\n###### 1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며,\n\n<!-- PAGE_122 -->\n###### 임상시험의 결과가 출관 될 경우에도 피험자의 신원을 비밀상태로\n\n<!-- PAGE_122 -->\n###### 2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의\n\n<!-- PAGE_122 -->\n###### 모니터링과 점검 및 진행사항 관리를 위한 목적으로 피험자의\n\n<!-- PAGE_122 -->\n###### 기록을 열람할 수 있다.  시험자는 본 임상시험 계획서에 서명함\n\n<!-- PAGE_122 -->\n###### 으로써, 국내의 법규와 윤리적 측면에서 임상시험 의뢰자 또는\n\n<!-- PAGE_122 -->\n###### 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을 검증하기\n\n<!-- PAGE_122 -->\n###### 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.\n\n <!-- PAGE_122 -->\n###### 3) 증례기록서 등 임상시험에 관련된 모든 서류에는 피험자 이름이\n\n<!-- PAGE_122 -->\n###### 아닌 피험자 식별코드(일반적으로 피험자 이니셜)로 기록하고\n\n<!-- PAGE_122 -->\n###### 자.  기록의 보존\n\n<!-- PAGE_122 -->\n###### 1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록\n\n<!-- PAGE_122 -->\n###### 하여야 하며 보안을 유지하도록 한다.  제조허가/수입허가 또는\n\n<!-- PAGE_122 -->\n###### 그 변경 허가를 위한 임상시험 관련 자료는 허가일로부터 3년간\n\n<!-- PAGE_122 -->\n###### 보존하도록 하고, 그 밖의 임상시험 관련 자료는 임상시험이 끝난\n\n<!-- PAGE_122 -->\n###### 날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이 지시\n\n<!-- PAGE_122 -->\n###### 하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을\n\n- - 116 -\n<!-- PAGE_123 -->\n###### 20. ",
        "original_sentence": "<!-- PAGE_122 -->\n###### 3) 증례기록서 등 임상시험에 관련된 모든 서류에는 피험자 이름이\n\n<!-- PAGE_122 -->\n###### 아닌 피험자 식별코드(일반적으로 피험자 이니셜)로 기록하고\n\n<!-- PAGE_122 -->\n###### 자. "
      }
    },
    {
      "chunk_id": "chunk_839",
      "text": "기록의 보존\n\n<!-- PAGE_122 -->\n###### 1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록\n\n<!-- PAGE_122 -->\n###### 하여야 하며 보안을 유지하도록 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 838,
        "window_size": 3,
        "char_count": 116,
        "word_count": 25,
        "page_number": 122,
        "window_text": "피험자 기록의 비밀보장\n\n<!-- PAGE_122 -->\n###### 1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며,\n\n<!-- PAGE_122 -->\n###### 임상시험의 결과가 출관 될 경우에도 피험자의 신원을 비밀상태로\n\n<!-- PAGE_122 -->\n###### 2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의\n\n<!-- PAGE_122 -->\n###### 모니터링과 점검 및 진행사항 관리를 위한 목적으로 피험자의\n\n<!-- PAGE_122 -->\n###### 기록을 열람할 수 있다.  시험자는 본 임상시험 계획서에 서명함\n\n<!-- PAGE_122 -->\n###### 으로써, 국내의 법규와 윤리적 측면에서 임상시험 의뢰자 또는\n\n<!-- PAGE_122 -->\n###### 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을 검증하기\n\n<!-- PAGE_122 -->\n###### 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.\n\n <!-- PAGE_122 -->\n###### 3) 증례기록서 등 임상시험에 관련된 모든 서류에는 피험자 이름이\n\n<!-- PAGE_122 -->\n###### 아닌 피험자 식별코드(일반적으로 피험자 이니셜)로 기록하고\n\n<!-- PAGE_122 -->\n###### 자.  기록의 보존\n\n<!-- PAGE_122 -->\n###### 1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록\n\n<!-- PAGE_122 -->\n###### 하여야 하며 보안을 유지하도록 한다.  제조허가/수입허가 또는\n\n<!-- PAGE_122 -->\n###### 그 변경 허가를 위한 임상시험 관련 자료는 허가일로부터 3년간\n\n<!-- PAGE_122 -->\n###### 보존하도록 하고, 그 밖의 임상시험 관련 자료는 임상시험이 끝난\n\n<!-- PAGE_122 -->\n###### 날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이 지시\n\n<!-- PAGE_122 -->\n###### 하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을\n\n- - 116 -\n<!-- PAGE_123 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n<!-- PAGE_123 -->\n###### 가. ",
        "original_sentence": "기록의 보존\n\n<!-- PAGE_122 -->\n###### 1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록\n\n<!-- PAGE_122 -->\n###### 하여야 하며 보안을 유지하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_840",
      "text": "제조허가/수입허가 또는\n\n<!-- PAGE_122 -->\n###### 그 변경 허가를 위한 임상시험 관련 자료는 허가일로부터 3년간\n\n<!-- PAGE_122 -->\n###### 보존하도록 하고, 그 밖의 임상시험 관련 자료는 임상시험이 끝난\n\n<!-- PAGE_122 -->\n###### 날부터 3년간 보존하도록 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 839,
        "window_size": 3,
        "char_count": 180,
        "word_count": 36,
        "page_number": 122,
        "window_text": "시험자는 본 임상시험 계획서에 서명함\n\n<!-- PAGE_122 -->\n###### 으로써, 국내의 법규와 윤리적 측면에서 임상시험 의뢰자 또는\n\n<!-- PAGE_122 -->\n###### 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을 검증하기\n\n<!-- PAGE_122 -->\n###### 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.\n\n <!-- PAGE_122 -->\n###### 3) 증례기록서 등 임상시험에 관련된 모든 서류에는 피험자 이름이\n\n<!-- PAGE_122 -->\n###### 아닌 피험자 식별코드(일반적으로 피험자 이니셜)로 기록하고\n\n<!-- PAGE_122 -->\n###### 자.  기록의 보존\n\n<!-- PAGE_122 -->\n###### 1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록\n\n<!-- PAGE_122 -->\n###### 하여야 하며 보안을 유지하도록 한다.  제조허가/수입허가 또는\n\n<!-- PAGE_122 -->\n###### 그 변경 허가를 위한 임상시험 관련 자료는 허가일로부터 3년간\n\n<!-- PAGE_122 -->\n###### 보존하도록 하고, 그 밖의 임상시험 관련 자료는 임상시험이 끝난\n\n<!-- PAGE_122 -->\n###### 날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이 지시\n\n<!-- PAGE_122 -->\n###### 하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을\n\n- - 116 -\n<!-- PAGE_123 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n<!-- PAGE_123 -->\n###### 가.  자료 처리\n\n<!-- PAGE_123 -->\n###### 본 임상시험에 관련된 모니터 및 점검자는 본 임상시험의\n\n<!-- PAGE_123 -->\n###### 모니터링과 점검 및 진행사항 관리를 위한 목적으로 대상자의\n\n<!-- PAGE_123 -->\n###### 임상시험용 의료기기와 연관된 유의한 위험, 금기, 부작용, 주의\n\n<!-- PAGE_123 -->\n###### 사항을 시사하는 사건 등을 포함하며, 발생시간, 정도, 처치, 경과,\n\n<!-- PAGE_123 -->\n###### 임상시험용 의료기기와의 인과관계 등에 대한 정보를 증례기록서에\n\n<!-- PAGE_123 -->\n###### 나. ",
        "original_sentence": "제조허가/수입허가 또는\n\n<!-- PAGE_122 -->\n###### 그 변경 허가를 위한 임상시험 관련 자료는 허가일로부터 3년간\n\n<!-- PAGE_122 -->\n###### 보존하도록 하고, 그 밖의 임상시험 관련 자료는 임상시험이 끝난\n\n<!-- PAGE_122 -->\n###### 날부터 3년간 보존하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_841",
      "text": "다만, 식품의약품안전처장이 지시\n\n<!-- PAGE_122 -->\n###### 하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을\n\n- - 116 -\n<!-- PAGE_123 -->\n###### 20. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 840,
        "window_size": 3,
        "char_count": 116,
        "word_count": 22,
        "page_number": 122,
        "window_text": "<!-- PAGE_122 -->\n###### 3) 증례기록서 등 임상시험에 관련된 모든 서류에는 피험자 이름이\n\n<!-- PAGE_122 -->\n###### 아닌 피험자 식별코드(일반적으로 피험자 이니셜)로 기록하고\n\n<!-- PAGE_122 -->\n###### 자.  기록의 보존\n\n<!-- PAGE_122 -->\n###### 1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록\n\n<!-- PAGE_122 -->\n###### 하여야 하며 보안을 유지하도록 한다.  제조허가/수입허가 또는\n\n<!-- PAGE_122 -->\n###### 그 변경 허가를 위한 임상시험 관련 자료는 허가일로부터 3년간\n\n<!-- PAGE_122 -->\n###### 보존하도록 하고, 그 밖의 임상시험 관련 자료는 임상시험이 끝난\n\n<!-- PAGE_122 -->\n###### 날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이 지시\n\n<!-- PAGE_122 -->\n###### 하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을\n\n- - 116 -\n<!-- PAGE_123 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n<!-- PAGE_123 -->\n###### 가.  자료 처리\n\n<!-- PAGE_123 -->\n###### 본 임상시험에 관련된 모니터 및 점검자는 본 임상시험의\n\n<!-- PAGE_123 -->\n###### 모니터링과 점검 및 진행사항 관리를 위한 목적으로 대상자의\n\n<!-- PAGE_123 -->\n###### 임상시험용 의료기기와 연관된 유의한 위험, 금기, 부작용, 주의\n\n<!-- PAGE_123 -->\n###### 사항을 시사하는 사건 등을 포함하며, 발생시간, 정도, 처치, 경과,\n\n<!-- PAGE_123 -->\n###### 임상시험용 의료기기와의 인과관계 등에 대한 정보를 증례기록서에\n\n<!-- PAGE_123 -->\n###### 나.  법규준수\n\n<!-- PAGE_123 -->\n###### 시험자는 서명록에 서명함으로써, 본 임상시험계획서, 의료기기\n\n<!-- PAGE_123 -->\n###### 임상시험 관리기준, 국내의 모든 관련 법규와 임상시험 수행에 관련된\n\n<!-- PAGE_123 -->\n###### 규칙 및 규정에 따라서 효과적이고 성실하게 연구를 수행할 것에\n\n- - 117 -\n<!-- PAGE_124 -->\n###### 동의하게 된다. ",
        "original_sentence": "다만, 식품의약품안전처장이 지시\n\n<!-- PAGE_122 -->\n###### 하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을\n\n- - 116 -\n<!-- PAGE_123 -->\n###### 20. "
      }
    },
    {
      "chunk_id": "chunk_842",
      "text": "그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n<!-- PAGE_123 -->\n###### 가. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 841,
        "window_size": 3,
        "char_count": 65,
        "word_count": 14,
        "page_number": 123,
        "window_text": "기록의 보존\n\n<!-- PAGE_122 -->\n###### 1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록\n\n<!-- PAGE_122 -->\n###### 하여야 하며 보안을 유지하도록 한다.  제조허가/수입허가 또는\n\n<!-- PAGE_122 -->\n###### 그 변경 허가를 위한 임상시험 관련 자료는 허가일로부터 3년간\n\n<!-- PAGE_122 -->\n###### 보존하도록 하고, 그 밖의 임상시험 관련 자료는 임상시험이 끝난\n\n<!-- PAGE_122 -->\n###### 날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이 지시\n\n<!-- PAGE_122 -->\n###### 하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을\n\n- - 116 -\n<!-- PAGE_123 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n<!-- PAGE_123 -->\n###### 가.  자료 처리\n\n<!-- PAGE_123 -->\n###### 본 임상시험에 관련된 모니터 및 점검자는 본 임상시험의\n\n<!-- PAGE_123 -->\n###### 모니터링과 점검 및 진행사항 관리를 위한 목적으로 대상자의\n\n<!-- PAGE_123 -->\n###### 임상시험용 의료기기와 연관된 유의한 위험, 금기, 부작용, 주의\n\n<!-- PAGE_123 -->\n###### 사항을 시사하는 사건 등을 포함하며, 발생시간, 정도, 처치, 경과,\n\n<!-- PAGE_123 -->\n###### 임상시험용 의료기기와의 인과관계 등에 대한 정보를 증례기록서에\n\n<!-- PAGE_123 -->\n###### 나.  법규준수\n\n<!-- PAGE_123 -->\n###### 시험자는 서명록에 서명함으로써, 본 임상시험계획서, 의료기기\n\n<!-- PAGE_123 -->\n###### 임상시험 관리기준, 국내의 모든 관련 법규와 임상시험 수행에 관련된\n\n<!-- PAGE_123 -->\n###### 규칙 및 규정에 따라서 효과적이고 성실하게 연구를 수행할 것에\n\n- - 117 -\n<!-- PAGE_124 -->\n###### 동의하게 된다.  임상시험 담당자 및 참여 연구진은 임상시험계획을\n\n<!-- PAGE_124 -->\n###### 정확히 분석, 숙지하도록 하며 시험책임자는 예기치 않은 이상반응\n\n<!-- PAGE_124 -->\n###### 등의 출현에 대한 충분한 대처와 필요에 따른 보고, 시험참여 연구진에\n\n<!-- PAGE_124 -->\n###### 대한 충분한 교육 등 사전조치를 취한다. ",
        "original_sentence": "그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n<!-- PAGE_123 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_843",
      "text": "자료 처리\n\n<!-- PAGE_123 -->\n###### 본 임상시험에 관련된 모니터 및 점검자는 본 임상시험의\n\n<!-- PAGE_123 -->\n###### 모니터링과 점검 및 진행사항 관리를 위한 목적으로 대상자의\n\n<!-- PAGE_123 -->\n###### 임상시험용 의료기기와 연관된 유의한 위험, 금기, 부작용, 주의\n\n<!-- PAGE_123 -->\n###### 사항을 시사하는 사건 등을 포함하며, 발생시간, 정도, 처치, 경과,\n\n<!-- PAGE_123 -->\n###### 임상시험용 의료기기와의 인과관계 등에 대한 정보를 증례기록서에\n\n<!-- PAGE_123 -->\n###### 나. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 842,
        "window_size": 3,
        "char_count": 339,
        "word_count": 67,
        "page_number": 123,
        "window_text": "제조허가/수입허가 또는\n\n<!-- PAGE_122 -->\n###### 그 변경 허가를 위한 임상시험 관련 자료는 허가일로부터 3년간\n\n<!-- PAGE_122 -->\n###### 보존하도록 하고, 그 밖의 임상시험 관련 자료는 임상시험이 끝난\n\n<!-- PAGE_122 -->\n###### 날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이 지시\n\n<!-- PAGE_122 -->\n###### 하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을\n\n- - 116 -\n<!-- PAGE_123 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n<!-- PAGE_123 -->\n###### 가.  자료 처리\n\n<!-- PAGE_123 -->\n###### 본 임상시험에 관련된 모니터 및 점검자는 본 임상시험의\n\n<!-- PAGE_123 -->\n###### 모니터링과 점검 및 진행사항 관리를 위한 목적으로 대상자의\n\n<!-- PAGE_123 -->\n###### 임상시험용 의료기기와 연관된 유의한 위험, 금기, 부작용, 주의\n\n<!-- PAGE_123 -->\n###### 사항을 시사하는 사건 등을 포함하며, 발생시간, 정도, 처치, 경과,\n\n<!-- PAGE_123 -->\n###### 임상시험용 의료기기와의 인과관계 등에 대한 정보를 증례기록서에\n\n<!-- PAGE_123 -->\n###### 나.  법규준수\n\n<!-- PAGE_123 -->\n###### 시험자는 서명록에 서명함으로써, 본 임상시험계획서, 의료기기\n\n<!-- PAGE_123 -->\n###### 임상시험 관리기준, 국내의 모든 관련 법규와 임상시험 수행에 관련된\n\n<!-- PAGE_123 -->\n###### 규칙 및 규정에 따라서 효과적이고 성실하게 연구를 수행할 것에\n\n- - 117 -\n<!-- PAGE_124 -->\n###### 동의하게 된다.  임상시험 담당자 및 참여 연구진은 임상시험계획을\n\n<!-- PAGE_124 -->\n###### 정확히 분석, 숙지하도록 하며 시험책임자는 예기치 않은 이상반응\n\n<!-- PAGE_124 -->\n###### 등의 출현에 대한 충분한 대처와 필요에 따른 보고, 시험참여 연구진에\n\n<!-- PAGE_124 -->\n###### 대한 충분한 교육 등 사전조치를 취한다.  임상시험의 진행은 의료기기\n\n<!-- PAGE_124 -->\n###### 임상시험 관리 기준에 합당하게 진행한다.\n\n",
        "original_sentence": "자료 처리\n\n<!-- PAGE_123 -->\n###### 본 임상시험에 관련된 모니터 및 점검자는 본 임상시험의\n\n<!-- PAGE_123 -->\n###### 모니터링과 점검 및 진행사항 관리를 위한 목적으로 대상자의\n\n<!-- PAGE_123 -->\n###### 임상시험용 의료기기와 연관된 유의한 위험, 금기, 부작용, 주의\n\n<!-- PAGE_123 -->\n###### 사항을 시사하는 사건 등을 포함하며, 발생시간, 정도, 처치, 경과,\n\n<!-- PAGE_123 -->\n###### 임상시험용 의료기기와의 인과관계 등에 대한 정보를 증례기록서에\n\n<!-- PAGE_123 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_844",
      "text": "법규준수\n\n<!-- PAGE_123 -->\n###### 시험자는 서명록에 서명함으로써, 본 임상시험계획서, 의료기기\n\n<!-- PAGE_123 -->\n###### 임상시험 관리기준, 국내의 모든 관련 법규와 임상시험 수행에 관련된\n\n<!-- PAGE_123 -->\n###### 규칙 및 규정에 따라서 효과적이고 성실하게 연구를 수행할 것에\n\n- - 117 -\n<!-- PAGE_124 -->\n###### 동의하게 된다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 843,
        "window_size": 3,
        "char_count": 235,
        "word_count": 47,
        "page_number": 123,
        "window_text": "다만, 식품의약품안전처장이 지시\n\n<!-- PAGE_122 -->\n###### 하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을\n\n- - 116 -\n<!-- PAGE_123 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n<!-- PAGE_123 -->\n###### 가.  자료 처리\n\n<!-- PAGE_123 -->\n###### 본 임상시험에 관련된 모니터 및 점검자는 본 임상시험의\n\n<!-- PAGE_123 -->\n###### 모니터링과 점검 및 진행사항 관리를 위한 목적으로 대상자의\n\n<!-- PAGE_123 -->\n###### 임상시험용 의료기기와 연관된 유의한 위험, 금기, 부작용, 주의\n\n<!-- PAGE_123 -->\n###### 사항을 시사하는 사건 등을 포함하며, 발생시간, 정도, 처치, 경과,\n\n<!-- PAGE_123 -->\n###### 임상시험용 의료기기와의 인과관계 등에 대한 정보를 증례기록서에\n\n<!-- PAGE_123 -->\n###### 나.  법규준수\n\n<!-- PAGE_123 -->\n###### 시험자는 서명록에 서명함으로써, 본 임상시험계획서, 의료기기\n\n<!-- PAGE_123 -->\n###### 임상시험 관리기준, 국내의 모든 관련 법규와 임상시험 수행에 관련된\n\n<!-- PAGE_123 -->\n###### 규칙 및 규정에 따라서 효과적이고 성실하게 연구를 수행할 것에\n\n- - 117 -\n<!-- PAGE_124 -->\n###### 동의하게 된다.  임상시험 담당자 및 참여 연구진은 임상시험계획을\n\n<!-- PAGE_124 -->\n###### 정확히 분석, 숙지하도록 하며 시험책임자는 예기치 않은 이상반응\n\n<!-- PAGE_124 -->\n###### 등의 출현에 대한 충분한 대처와 필요에 따른 보고, 시험참여 연구진에\n\n<!-- PAGE_124 -->\n###### 대한 충분한 교육 등 사전조치를 취한다.  임상시험의 진행은 의료기기\n\n<!-- PAGE_124 -->\n###### 임상시험 관리 기준에 합당하게 진행한다.\n\n <!-- PAGE_124 -->\n###### 다. ",
        "original_sentence": "법규준수\n\n<!-- PAGE_123 -->\n###### 시험자는 서명록에 서명함으로써, 본 임상시험계획서, 의료기기\n\n<!-- PAGE_123 -->\n###### 임상시험 관리기준, 국내의 모든 관련 법규와 임상시험 수행에 관련된\n\n<!-- PAGE_123 -->\n###### 규칙 및 규정에 따라서 효과적이고 성실하게 연구를 수행할 것에\n\n- - 117 -\n<!-- PAGE_124 -->\n###### 동의하게 된다. "
      }
    },
    {
      "chunk_id": "chunk_845",
      "text": "임상시험 담당자 및 참여 연구진은 임상시험계획을\n\n<!-- PAGE_124 -->\n###### 정확히 분석, 숙지하도록 하며 시험책임자는 예기치 않은 이상반응\n\n<!-- PAGE_124 -->\n###### 등의 출현에 대한 충분한 대처와 필요에 따른 보고, 시험참여 연구진에\n\n<!-- PAGE_124 -->\n###### 대한 충분한 교육 등 사전조치를 취한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 844,
        "window_size": 3,
        "char_count": 203,
        "word_count": 42,
        "page_number": 124,
        "window_text": "그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n<!-- PAGE_123 -->\n###### 가.  자료 처리\n\n<!-- PAGE_123 -->\n###### 본 임상시험에 관련된 모니터 및 점검자는 본 임상시험의\n\n<!-- PAGE_123 -->\n###### 모니터링과 점검 및 진행사항 관리를 위한 목적으로 대상자의\n\n<!-- PAGE_123 -->\n###### 임상시험용 의료기기와 연관된 유의한 위험, 금기, 부작용, 주의\n\n<!-- PAGE_123 -->\n###### 사항을 시사하는 사건 등을 포함하며, 발생시간, 정도, 처치, 경과,\n\n<!-- PAGE_123 -->\n###### 임상시험용 의료기기와의 인과관계 등에 대한 정보를 증례기록서에\n\n<!-- PAGE_123 -->\n###### 나.  법규준수\n\n<!-- PAGE_123 -->\n###### 시험자는 서명록에 서명함으로써, 본 임상시험계획서, 의료기기\n\n<!-- PAGE_123 -->\n###### 임상시험 관리기준, 국내의 모든 관련 법규와 임상시험 수행에 관련된\n\n<!-- PAGE_123 -->\n###### 규칙 및 규정에 따라서 효과적이고 성실하게 연구를 수행할 것에\n\n- - 117 -\n<!-- PAGE_124 -->\n###### 동의하게 된다.  임상시험 담당자 및 참여 연구진은 임상시험계획을\n\n<!-- PAGE_124 -->\n###### 정확히 분석, 숙지하도록 하며 시험책임자는 예기치 않은 이상반응\n\n<!-- PAGE_124 -->\n###### 등의 출현에 대한 충분한 대처와 필요에 따른 보고, 시험참여 연구진에\n\n<!-- PAGE_124 -->\n###### 대한 충분한 교육 등 사전조치를 취한다.  임상시험의 진행은 의료기기\n\n<!-- PAGE_124 -->\n###### 임상시험 관리 기준에 합당하게 진행한다.\n\n <!-- PAGE_124 -->\n###### 다.  임상시험 자료의 보관 및 열람\n\n<!-- PAGE_124 -->\n###### 임상시험 자료는 기밀로 보관되고 열람은 본 임상시험의 모니터링과\n\n<!-- PAGE_124 -->\n###### 점검 및 진행 사항 관리를 위한 목적으로 대상자의 기록을 열람할 수\n\n<!-- PAGE_124 -->\n###### 있다.\n\n",
        "original_sentence": "임상시험 담당자 및 참여 연구진은 임상시험계획을\n\n<!-- PAGE_124 -->\n###### 정확히 분석, 숙지하도록 하며 시험책임자는 예기치 않은 이상반응\n\n<!-- PAGE_124 -->\n###### 등의 출현에 대한 충분한 대처와 필요에 따른 보고, 시험참여 연구진에\n\n<!-- PAGE_124 -->\n###### 대한 충분한 교육 등 사전조치를 취한다. "
      }
    },
    {
      "chunk_id": "chunk_846",
      "text": "임상시험의 진행은 의료기기\n\n<!-- PAGE_124 -->\n###### 임상시험 관리 기준에 합당하게 진행한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 845,
        "window_size": 3,
        "char_count": 65,
        "word_count": 12,
        "page_number": 124,
        "window_text": "자료 처리\n\n<!-- PAGE_123 -->\n###### 본 임상시험에 관련된 모니터 및 점검자는 본 임상시험의\n\n<!-- PAGE_123 -->\n###### 모니터링과 점검 및 진행사항 관리를 위한 목적으로 대상자의\n\n<!-- PAGE_123 -->\n###### 임상시험용 의료기기와 연관된 유의한 위험, 금기, 부작용, 주의\n\n<!-- PAGE_123 -->\n###### 사항을 시사하는 사건 등을 포함하며, 발생시간, 정도, 처치, 경과,\n\n<!-- PAGE_123 -->\n###### 임상시험용 의료기기와의 인과관계 등에 대한 정보를 증례기록서에\n\n<!-- PAGE_123 -->\n###### 나.  법규준수\n\n<!-- PAGE_123 -->\n###### 시험자는 서명록에 서명함으로써, 본 임상시험계획서, 의료기기\n\n<!-- PAGE_123 -->\n###### 임상시험 관리기준, 국내의 모든 관련 법규와 임상시험 수행에 관련된\n\n<!-- PAGE_123 -->\n###### 규칙 및 규정에 따라서 효과적이고 성실하게 연구를 수행할 것에\n\n- - 117 -\n<!-- PAGE_124 -->\n###### 동의하게 된다.  임상시험 담당자 및 참여 연구진은 임상시험계획을\n\n<!-- PAGE_124 -->\n###### 정확히 분석, 숙지하도록 하며 시험책임자는 예기치 않은 이상반응\n\n<!-- PAGE_124 -->\n###### 등의 출현에 대한 충분한 대처와 필요에 따른 보고, 시험참여 연구진에\n\n<!-- PAGE_124 -->\n###### 대한 충분한 교육 등 사전조치를 취한다.  임상시험의 진행은 의료기기\n\n<!-- PAGE_124 -->\n###### 임상시험 관리 기준에 합당하게 진행한다.\n\n <!-- PAGE_124 -->\n###### 다.  임상시험 자료의 보관 및 열람\n\n<!-- PAGE_124 -->\n###### 임상시험 자료는 기밀로 보관되고 열람은 본 임상시험의 모니터링과\n\n<!-- PAGE_124 -->\n###### 점검 및 진행 사항 관리를 위한 목적으로 대상자의 기록을 열람할 수\n\n<!-- PAGE_124 -->\n###### 있다.\n\n <!-- PAGE_124 -->\n###### 라. ",
        "original_sentence": "임상시험의 진행은 의료기기\n\n<!-- PAGE_124 -->\n###### 임상시험 관리 기준에 합당하게 진행한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_847",
      "text": "<!-- PAGE_124 -->\n###### 다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 846,
        "window_size": 3,
        "char_count": 28,
        "word_count": 5,
        "page_number": 124,
        "window_text": "법규준수\n\n<!-- PAGE_123 -->\n###### 시험자는 서명록에 서명함으로써, 본 임상시험계획서, 의료기기\n\n<!-- PAGE_123 -->\n###### 임상시험 관리기준, 국내의 모든 관련 법규와 임상시험 수행에 관련된\n\n<!-- PAGE_123 -->\n###### 규칙 및 규정에 따라서 효과적이고 성실하게 연구를 수행할 것에\n\n- - 117 -\n<!-- PAGE_124 -->\n###### 동의하게 된다.  임상시험 담당자 및 참여 연구진은 임상시험계획을\n\n<!-- PAGE_124 -->\n###### 정확히 분석, 숙지하도록 하며 시험책임자는 예기치 않은 이상반응\n\n<!-- PAGE_124 -->\n###### 등의 출현에 대한 충분한 대처와 필요에 따른 보고, 시험참여 연구진에\n\n<!-- PAGE_124 -->\n###### 대한 충분한 교육 등 사전조치를 취한다.  임상시험의 진행은 의료기기\n\n<!-- PAGE_124 -->\n###### 임상시험 관리 기준에 합당하게 진행한다.\n\n <!-- PAGE_124 -->\n###### 다.  임상시험 자료의 보관 및 열람\n\n<!-- PAGE_124 -->\n###### 임상시험 자료는 기밀로 보관되고 열람은 본 임상시험의 모니터링과\n\n<!-- PAGE_124 -->\n###### 점검 및 진행 사항 관리를 위한 목적으로 대상자의 기록을 열람할 수\n\n<!-- PAGE_124 -->\n###### 있다.\n\n <!-- PAGE_124 -->\n###### 라.  점검 및 실태조사\n\n<!-- PAGE_124 -->\n###### 임상시험의 중요도, 대상자 수, 임상시험의 종류와 복잡성, 대상자\n\n<!-- PAGE_124 -->\n###### 에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n<!-- PAGE_124 -->\n###### 실시상의 문제점 등에 따라 결정된다.\n\n",
        "original_sentence": "<!-- PAGE_124 -->\n###### 다. "
      }
    },
    {
      "chunk_id": "chunk_848",
      "text": "임상시험 자료의 보관 및 열람\n\n<!-- PAGE_124 -->\n###### 임상시험 자료는 기밀로 보관되고 열람은 본 임상시험의 모니터링과\n\n<!-- PAGE_124 -->\n###### 점검 및 진행 사항 관리를 위한 목적으로 대상자의 기록을 열람할 수\n\n<!-- PAGE_124 -->\n###### 있다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 847,
        "window_size": 3,
        "char_count": 174,
        "word_count": 37,
        "page_number": 124,
        "window_text": "임상시험 담당자 및 참여 연구진은 임상시험계획을\n\n<!-- PAGE_124 -->\n###### 정확히 분석, 숙지하도록 하며 시험책임자는 예기치 않은 이상반응\n\n<!-- PAGE_124 -->\n###### 등의 출현에 대한 충분한 대처와 필요에 따른 보고, 시험참여 연구진에\n\n<!-- PAGE_124 -->\n###### 대한 충분한 교육 등 사전조치를 취한다.  임상시험의 진행은 의료기기\n\n<!-- PAGE_124 -->\n###### 임상시험 관리 기준에 합당하게 진행한다.\n\n <!-- PAGE_124 -->\n###### 다.  임상시험 자료의 보관 및 열람\n\n<!-- PAGE_124 -->\n###### 임상시험 자료는 기밀로 보관되고 열람은 본 임상시험의 모니터링과\n\n<!-- PAGE_124 -->\n###### 점검 및 진행 사항 관리를 위한 목적으로 대상자의 기록을 열람할 수\n\n<!-- PAGE_124 -->\n###### 있다.\n\n <!-- PAGE_124 -->\n###### 라.  점검 및 실태조사\n\n<!-- PAGE_124 -->\n###### 임상시험의 중요도, 대상자 수, 임상시험의 종류와 복잡성, 대상자\n\n<!-- PAGE_124 -->\n###### 에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n<!-- PAGE_124 -->\n###### 실시상의 문제점 등에 따라 결정된다.\n\n <!-- PAGE_124 -->\n###### 마. ",
        "original_sentence": "임상시험 자료의 보관 및 열람\n\n<!-- PAGE_124 -->\n###### 임상시험 자료는 기밀로 보관되고 열람은 본 임상시험의 모니터링과\n\n<!-- PAGE_124 -->\n###### 점검 및 진행 사항 관리를 위한 목적으로 대상자의 기록을 열람할 수\n\n<!-- PAGE_124 -->\n###### 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_849",
      "text": "<!-- PAGE_124 -->\n###### 라. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 848,
        "window_size": 3,
        "char_count": 28,
        "word_count": 5,
        "page_number": 124,
        "window_text": "임상시험의 진행은 의료기기\n\n<!-- PAGE_124 -->\n###### 임상시험 관리 기준에 합당하게 진행한다.\n\n <!-- PAGE_124 -->\n###### 다.  임상시험 자료의 보관 및 열람\n\n<!-- PAGE_124 -->\n###### 임상시험 자료는 기밀로 보관되고 열람은 본 임상시험의 모니터링과\n\n<!-- PAGE_124 -->\n###### 점검 및 진행 사항 관리를 위한 목적으로 대상자의 기록을 열람할 수\n\n<!-- PAGE_124 -->\n###### 있다.\n\n <!-- PAGE_124 -->\n###### 라.  점검 및 실태조사\n\n<!-- PAGE_124 -->\n###### 임상시험의 중요도, 대상자 수, 임상시험의 종류와 복잡성, 대상자\n\n<!-- PAGE_124 -->\n###### 에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n<!-- PAGE_124 -->\n###### 실시상의 문제점 등에 따라 결정된다.\n\n <!-- PAGE_124 -->\n###### 마.  임상시험용 의료기기의 사용 및 관리\n\n<!-- PAGE_124 -->\n###### 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가\n\n<!-- PAGE_124 -->\n###### 관리한다. ",
        "original_sentence": "<!-- PAGE_124 -->\n###### 라. "
      }
    },
    {
      "chunk_id": "chunk_850",
      "text": "점검 및 실태조사\n\n<!-- PAGE_124 -->\n###### 임상시험의 중요도, 대상자 수, 임상시험의 종류와 복잡성, 대상자\n\n<!-- PAGE_124 -->\n###### 에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n<!-- PAGE_124 -->\n###### 실시상의 문제점 등에 따라 결정된다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 849,
        "window_size": 3,
        "char_count": 184,
        "word_count": 39,
        "page_number": 124,
        "window_text": "<!-- PAGE_124 -->\n###### 다.  임상시험 자료의 보관 및 열람\n\n<!-- PAGE_124 -->\n###### 임상시험 자료는 기밀로 보관되고 열람은 본 임상시험의 모니터링과\n\n<!-- PAGE_124 -->\n###### 점검 및 진행 사항 관리를 위한 목적으로 대상자의 기록을 열람할 수\n\n<!-- PAGE_124 -->\n###### 있다.\n\n <!-- PAGE_124 -->\n###### 라.  점검 및 실태조사\n\n<!-- PAGE_124 -->\n###### 임상시험의 중요도, 대상자 수, 임상시험의 종류와 복잡성, 대상자\n\n<!-- PAGE_124 -->\n###### 에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n<!-- PAGE_124 -->\n###### 실시상의 문제점 등에 따라 결정된다.\n\n <!-- PAGE_124 -->\n###### 마.  임상시험용 의료기기의 사용 및 관리\n\n<!-- PAGE_124 -->\n###### 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가\n\n<!-- PAGE_124 -->\n###### 관리한다.  임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급,\n\n<!-- PAGE_124 -->\n###### 저장하며 “임상시험용”이라는 문구가 있어야 한다. ",
        "original_sentence": "점검 및 실태조사\n\n<!-- PAGE_124 -->\n###### 임상시험의 중요도, 대상자 수, 임상시험의 종류와 복잡성, 대상자\n\n<!-- PAGE_124 -->\n###### 에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n<!-- PAGE_124 -->\n###### 실시상의 문제점 등에 따라 결정된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_851",
      "text": "<!-- PAGE_124 -->\n###### 마. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 850,
        "window_size": 3,
        "char_count": 28,
        "word_count": 5,
        "page_number": 124,
        "window_text": "임상시험 자료의 보관 및 열람\n\n<!-- PAGE_124 -->\n###### 임상시험 자료는 기밀로 보관되고 열람은 본 임상시험의 모니터링과\n\n<!-- PAGE_124 -->\n###### 점검 및 진행 사항 관리를 위한 목적으로 대상자의 기록을 열람할 수\n\n<!-- PAGE_124 -->\n###### 있다.\n\n <!-- PAGE_124 -->\n###### 라.  점검 및 실태조사\n\n<!-- PAGE_124 -->\n###### 임상시험의 중요도, 대상자 수, 임상시험의 종류와 복잡성, 대상자\n\n<!-- PAGE_124 -->\n###### 에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n<!-- PAGE_124 -->\n###### 실시상의 문제점 등에 따라 결정된다.\n\n <!-- PAGE_124 -->\n###### 마.  임상시험용 의료기기의 사용 및 관리\n\n<!-- PAGE_124 -->\n###### 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가\n\n<!-- PAGE_124 -->\n###### 관리한다.  임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급,\n\n<!-- PAGE_124 -->\n###### 저장하며 “임상시험용”이라는 문구가 있어야 한다.  임상시험용 의료\n\n<!-- PAGE_124 -->\n###### 기기 관리자는 임상시험에 사용되는 의료기기에 대해 인수, 재고관리,\n\n<!-- PAGE_124 -->\n###### 반납 등의 업무를 수행하고 관련 기록을 유지하여야 한다.\n\n",
        "original_sentence": "<!-- PAGE_124 -->\n###### 마. "
      }
    },
    {
      "chunk_id": "chunk_852",
      "text": "임상시험용 의료기기의 사용 및 관리\n\n<!-- PAGE_124 -->\n###### 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가\n\n<!-- PAGE_124 -->\n###### 관리한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 851,
        "window_size": 3,
        "char_count": 113,
        "word_count": 21,
        "page_number": 124,
        "window_text": "<!-- PAGE_124 -->\n###### 라.  점검 및 실태조사\n\n<!-- PAGE_124 -->\n###### 임상시험의 중요도, 대상자 수, 임상시험의 종류와 복잡성, 대상자\n\n<!-- PAGE_124 -->\n###### 에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n<!-- PAGE_124 -->\n###### 실시상의 문제점 등에 따라 결정된다.\n\n <!-- PAGE_124 -->\n###### 마.  임상시험용 의료기기의 사용 및 관리\n\n<!-- PAGE_124 -->\n###### 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가\n\n<!-- PAGE_124 -->\n###### 관리한다.  임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급,\n\n<!-- PAGE_124 -->\n###### 저장하며 “임상시험용”이라는 문구가 있어야 한다.  임상시험용 의료\n\n<!-- PAGE_124 -->\n###### 기기 관리자는 임상시험에 사용되는 의료기기에 대해 인수, 재고관리,\n\n<!-- PAGE_124 -->\n###### 반납 등의 업무를 수행하고 관련 기록을 유지하여야 한다.\n\n - - 118 -\n<!-- PAGE_125 -->\n###### 바. ",
        "original_sentence": "임상시험용 의료기기의 사용 및 관리\n\n<!-- PAGE_124 -->\n###### 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가\n\n<!-- PAGE_124 -->\n###### 관리한다. "
      }
    },
    {
      "chunk_id": "chunk_853",
      "text": "임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급,\n\n<!-- PAGE_124 -->\n###### 저장하며 “임상시험용”이라는 문구가 있어야 한다. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 852,
        "window_size": 3,
        "char_count": 87,
        "word_count": 16,
        "page_number": 124,
        "window_text": "점검 및 실태조사\n\n<!-- PAGE_124 -->\n###### 임상시험의 중요도, 대상자 수, 임상시험의 종류와 복잡성, 대상자\n\n<!-- PAGE_124 -->\n###### 에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n<!-- PAGE_124 -->\n###### 실시상의 문제점 등에 따라 결정된다.\n\n <!-- PAGE_124 -->\n###### 마.  임상시험용 의료기기의 사용 및 관리\n\n<!-- PAGE_124 -->\n###### 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가\n\n<!-- PAGE_124 -->\n###### 관리한다.  임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급,\n\n<!-- PAGE_124 -->\n###### 저장하며 “임상시험용”이라는 문구가 있어야 한다.  임상시험용 의료\n\n<!-- PAGE_124 -->\n###### 기기 관리자는 임상시험에 사용되는 의료기기에 대해 인수, 재고관리,\n\n<!-- PAGE_124 -->\n###### 반납 등의 업무를 수행하고 관련 기록을 유지하여야 한다.\n\n - - 118 -\n<!-- PAGE_125 -->\n###### 바.  임상시험용 의료기기의 공급과 취급\n\n<!-- PAGE_125 -->\n###### 1) 의뢰자는 임상시험계획서에 대한 심사위원회와 청장의 승인을\n\n<!-- PAGE_125 -->\n###### 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는\n\n<!-- PAGE_125 -->\n###### 2) 의뢰자는 관리자 등이 임상시험용 의료기기를 취급하고 보관하는\n\n<!-- PAGE_125 -->\n###### 방법에 대해 문서화된 절차를 가지고 있어야 하며, 이 절차에는\n\n<!-- PAGE_125 -->\n###### 적절하고 안전한 수, 취급, 보관, 미사용 임상시험용 의료기기의\n\n<!-- PAGE_125 -->\n###### 피험자로부터의 반납 및 의뢰자에 대한 반납 등에 대한 방법이\n\n<!-- PAGE_125 -->\n###### 3) 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관\n\n<!-- PAGE_125 -->\n###### 으로의 공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납\n\n<!-- PAGE_125 -->\n###### 4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상\n\n<!-- PAGE_125 -->\n###### 시험의 종료 또는 사용기간의 만료 등에 의한 임상시험용 의료\n\n- - 119 -\n<!-- PAGE_126 -->\n### Ⅳ\n\n<!-- PAGE_126 -->\n### 참고문헌\n\n- 1. ",
        "original_sentence": "임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급,\n\n<!-- PAGE_124 -->\n###### 저장하며 “임상시험용”이라는 문구가 있어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_854",
      "text": "임상시험용 의료\n\n<!-- PAGE_124 -->\n###### 기기 관리자는 임상시험에 사용되는 의료기기에 대해 인수, 재고관리,\n\n<!-- PAGE_124 -->\n###### 반납 등의 업무를 수행하고 관련 기록을 유지하여야 한다.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 853,
        "window_size": 3,
        "char_count": 132,
        "word_count": 26,
        "page_number": 124,
        "window_text": "<!-- PAGE_124 -->\n###### 마.  임상시험용 의료기기의 사용 및 관리\n\n<!-- PAGE_124 -->\n###### 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가\n\n<!-- PAGE_124 -->\n###### 관리한다.  임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급,\n\n<!-- PAGE_124 -->\n###### 저장하며 “임상시험용”이라는 문구가 있어야 한다.  임상시험용 의료\n\n<!-- PAGE_124 -->\n###### 기기 관리자는 임상시험에 사용되는 의료기기에 대해 인수, 재고관리,\n\n<!-- PAGE_124 -->\n###### 반납 등의 업무를 수행하고 관련 기록을 유지하여야 한다.\n\n - - 118 -\n<!-- PAGE_125 -->\n###### 바.  임상시험용 의료기기의 공급과 취급\n\n<!-- PAGE_125 -->\n###### 1) 의뢰자는 임상시험계획서에 대한 심사위원회와 청장의 승인을\n\n<!-- PAGE_125 -->\n###### 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는\n\n<!-- PAGE_125 -->\n###### 2) 의뢰자는 관리자 등이 임상시험용 의료기기를 취급하고 보관하는\n\n<!-- PAGE_125 -->\n###### 방법에 대해 문서화된 절차를 가지고 있어야 하며, 이 절차에는\n\n<!-- PAGE_125 -->\n###### 적절하고 안전한 수, 취급, 보관, 미사용 임상시험용 의료기기의\n\n<!-- PAGE_125 -->\n###### 피험자로부터의 반납 및 의뢰자에 대한 반납 등에 대한 방법이\n\n<!-- PAGE_125 -->\n###### 3) 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관\n\n<!-- PAGE_125 -->\n###### 으로의 공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납\n\n<!-- PAGE_125 -->\n###### 4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상\n\n<!-- PAGE_125 -->\n###### 시험의 종료 또는 사용기간의 만료 등에 의한 임상시험용 의료\n\n- - 119 -\n<!-- PAGE_126 -->\n### Ⅳ\n\n<!-- PAGE_126 -->\n### 참고문헌\n\n- 1.  2020년 국민건강영양조사, 질병관리청, 2020.12\n- 2. ",
        "original_sentence": "임상시험용 의료\n\n<!-- PAGE_124 -->\n###### 기기 관리자는 임상시험에 사용되는 의료기기에 대해 인수, 재고관리,\n\n<!-- PAGE_124 -->\n###### 반납 등의 업무를 수행하고 관련 기록을 유지하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_855",
      "text": "- - 118 -\n<!-- PAGE_125 -->\n###### 바. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 854,
        "window_size": 3,
        "char_count": 38,
        "word_count": 9,
        "page_number": 125,
        "window_text": "임상시험용 의료기기의 사용 및 관리\n\n<!-- PAGE_124 -->\n###### 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가\n\n<!-- PAGE_124 -->\n###### 관리한다.  임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급,\n\n<!-- PAGE_124 -->\n###### 저장하며 “임상시험용”이라는 문구가 있어야 한다.  임상시험용 의료\n\n<!-- PAGE_124 -->\n###### 기기 관리자는 임상시험에 사용되는 의료기기에 대해 인수, 재고관리,\n\n<!-- PAGE_124 -->\n###### 반납 등의 업무를 수행하고 관련 기록을 유지하여야 한다.\n\n - - 118 -\n<!-- PAGE_125 -->\n###### 바.  임상시험용 의료기기의 공급과 취급\n\n<!-- PAGE_125 -->\n###### 1) 의뢰자는 임상시험계획서에 대한 심사위원회와 청장의 승인을\n\n<!-- PAGE_125 -->\n###### 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는\n\n<!-- PAGE_125 -->\n###### 2) 의뢰자는 관리자 등이 임상시험용 의료기기를 취급하고 보관하는\n\n<!-- PAGE_125 -->\n###### 방법에 대해 문서화된 절차를 가지고 있어야 하며, 이 절차에는\n\n<!-- PAGE_125 -->\n###### 적절하고 안전한 수, 취급, 보관, 미사용 임상시험용 의료기기의\n\n<!-- PAGE_125 -->\n###### 피험자로부터의 반납 및 의뢰자에 대한 반납 등에 대한 방법이\n\n<!-- PAGE_125 -->\n###### 3) 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관\n\n<!-- PAGE_125 -->\n###### 으로의 공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납\n\n<!-- PAGE_125 -->\n###### 4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상\n\n<!-- PAGE_125 -->\n###### 시험의 종료 또는 사용기간의 만료 등에 의한 임상시험용 의료\n\n- - 119 -\n<!-- PAGE_126 -->\n### Ⅳ\n\n<!-- PAGE_126 -->\n### 참고문헌\n\n- 1.  2020년 국민건강영양조사, 질병관리청, 2020.12\n- 2.  일차 의료용 근거 기반 우울장애 임상진료지침, 대한의학회, 2022\n- 3. ",
        "original_sentence": "- - 118 -\n<!-- PAGE_125 -->\n###### 바. "
      }
    },
    {
      "chunk_id": "chunk_856",
      "text": "임상시험용 의료기기의 공급과 취급\n\n<!-- PAGE_125 -->\n###### 1) 의뢰자는 임상시험계획서에 대한 심사위원회와 청장의 승인을\n\n<!-- PAGE_125 -->\n###### 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는\n\n<!-- PAGE_125 -->\n###### 2) 의뢰자는 관리자 등이 임상시험용 의료기기를 취급하고 보관하는\n\n<!-- PAGE_125 -->\n###### 방법에 대해 문서화된 절차를 가지고 있어야 하며, 이 절차에는\n\n<!-- PAGE_125 -->\n###### 적절하고 안전한 수, 취급, 보관, 미사용 임상시험용 의료기기의\n\n<!-- PAGE_125 -->\n###### 피험자로부터의 반납 및 의뢰자에 대한 반납 등에 대한 방법이\n\n<!-- PAGE_125 -->\n###### 3) 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관\n\n<!-- PAGE_125 -->\n###### 으로의 공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납\n\n<!-- PAGE_125 -->\n###### 4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상\n\n<!-- PAGE_125 -->\n###### 시험의 종료 또는 사용기간의 만료 등에 의한 임상시험용 의료\n\n- - 119 -\n<!-- PAGE_126 -->\n### Ⅳ\n\n<!-- PAGE_126 -->\n### 참고문헌\n\n- 1. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 855,
        "window_size": 3,
        "char_count": 702,
        "word_count": 139,
        "page_number": 125,
        "window_text": "임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급,\n\n<!-- PAGE_124 -->\n###### 저장하며 “임상시험용”이라는 문구가 있어야 한다.  임상시험용 의료\n\n<!-- PAGE_124 -->\n###### 기기 관리자는 임상시험에 사용되는 의료기기에 대해 인수, 재고관리,\n\n<!-- PAGE_124 -->\n###### 반납 등의 업무를 수행하고 관련 기록을 유지하여야 한다.\n\n - - 118 -\n<!-- PAGE_125 -->\n###### 바.  임상시험용 의료기기의 공급과 취급\n\n<!-- PAGE_125 -->\n###### 1) 의뢰자는 임상시험계획서에 대한 심사위원회와 청장의 승인을\n\n<!-- PAGE_125 -->\n###### 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는\n\n<!-- PAGE_125 -->\n###### 2) 의뢰자는 관리자 등이 임상시험용 의료기기를 취급하고 보관하는\n\n<!-- PAGE_125 -->\n###### 방법에 대해 문서화된 절차를 가지고 있어야 하며, 이 절차에는\n\n<!-- PAGE_125 -->\n###### 적절하고 안전한 수, 취급, 보관, 미사용 임상시험용 의료기기의\n\n<!-- PAGE_125 -->\n###### 피험자로부터의 반납 및 의뢰자에 대한 반납 등에 대한 방법이\n\n<!-- PAGE_125 -->\n###### 3) 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관\n\n<!-- PAGE_125 -->\n###### 으로의 공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납\n\n<!-- PAGE_125 -->\n###### 4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상\n\n<!-- PAGE_125 -->\n###### 시험의 종료 또는 사용기간의 만료 등에 의한 임상시험용 의료\n\n- - 119 -\n<!-- PAGE_126 -->\n### Ⅳ\n\n<!-- PAGE_126 -->\n### 참고문헌\n\n- 1.  2020년 국민건강영양조사, 질병관리청, 2020.12\n- 2.  일차 의료용 근거 기반 우울장애 임상진료지침, 대한의학회, 2022\n- 3.  권정혜, & 이재우. ",
        "original_sentence": "임상시험용 의료기기의 공급과 취급\n\n<!-- PAGE_125 -->\n###### 1) 의뢰자는 임상시험계획서에 대한 심사위원회와 청장의 승인을\n\n<!-- PAGE_125 -->\n###### 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는\n\n<!-- PAGE_125 -->\n###### 2) 의뢰자는 관리자 등이 임상시험용 의료기기를 취급하고 보관하는\n\n<!-- PAGE_125 -->\n###### 방법에 대해 문서화된 절차를 가지고 있어야 하며, 이 절차에는\n\n<!-- PAGE_125 -->\n###### 적절하고 안전한 수, 취급, 보관, 미사용 임상시험용 의료기기의\n\n<!-- PAGE_125 -->\n###### 피험자로부터의 반납 및 의뢰자에 대한 반납 등에 대한 방법이\n\n<!-- PAGE_125 -->\n###### 3) 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관\n\n<!-- PAGE_125 -->\n###### 으로의 공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납\n\n<!-- PAGE_125 -->\n###### 4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상\n\n<!-- PAGE_125 -->\n###### 시험의 종료 또는 사용기간의 만료 등에 의한 임상시험용 의료\n\n- - 119 -\n<!-- PAGE_126 -->\n### Ⅳ\n\n<!-- PAGE_126 -->\n### 참고문헌\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_857",
      "text": "2020년 국민건강영양조사, 질병관리청, 2020.12\n- 2. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 856,
        "window_size": 3,
        "char_count": 36,
        "word_count": 6,
        "page_number": 9,
        "window_text": "임상시험용 의료\n\n<!-- PAGE_124 -->\n###### 기기 관리자는 임상시험에 사용되는 의료기기에 대해 인수, 재고관리,\n\n<!-- PAGE_124 -->\n###### 반납 등의 업무를 수행하고 관련 기록을 유지하여야 한다.\n\n - - 118 -\n<!-- PAGE_125 -->\n###### 바.  임상시험용 의료기기의 공급과 취급\n\n<!-- PAGE_125 -->\n###### 1) 의뢰자는 임상시험계획서에 대한 심사위원회와 청장의 승인을\n\n<!-- PAGE_125 -->\n###### 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는\n\n<!-- PAGE_125 -->\n###### 2) 의뢰자는 관리자 등이 임상시험용 의료기기를 취급하고 보관하는\n\n<!-- PAGE_125 -->\n###### 방법에 대해 문서화된 절차를 가지고 있어야 하며, 이 절차에는\n\n<!-- PAGE_125 -->\n###### 적절하고 안전한 수, 취급, 보관, 미사용 임상시험용 의료기기의\n\n<!-- PAGE_125 -->\n###### 피험자로부터의 반납 및 의뢰자에 대한 반납 등에 대한 방법이\n\n<!-- PAGE_125 -->\n###### 3) 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관\n\n<!-- PAGE_125 -->\n###### 으로의 공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납\n\n<!-- PAGE_125 -->\n###### 4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상\n\n<!-- PAGE_125 -->\n###### 시험의 종료 또는 사용기간의 만료 등에 의한 임상시험용 의료\n\n- - 119 -\n<!-- PAGE_126 -->\n### Ⅳ\n\n<!-- PAGE_126 -->\n### 참고문헌\n\n- 1.  2020년 국민건강영양조사, 질병관리청, 2020.12\n- 2.  일차 의료용 근거 기반 우울장애 임상진료지침, 대한의학회, 2022\n- 3.  권정혜, & 이재우.  (2001). ",
        "original_sentence": "2020년 국민건강영양조사, 질병관리청, 2020.12\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_858",
      "text": "일차 의료용 근거 기반 우울장애 임상진료지침, 대한의학회, 2022\n- 3. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 857,
        "window_size": 3,
        "char_count": 43,
        "word_count": 10,
        "page_number": 7,
        "window_text": "- - 118 -\n<!-- PAGE_125 -->\n###### 바.  임상시험용 의료기기의 공급과 취급\n\n<!-- PAGE_125 -->\n###### 1) 의뢰자는 임상시험계획서에 대한 심사위원회와 청장의 승인을\n\n<!-- PAGE_125 -->\n###### 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는\n\n<!-- PAGE_125 -->\n###### 2) 의뢰자는 관리자 등이 임상시험용 의료기기를 취급하고 보관하는\n\n<!-- PAGE_125 -->\n###### 방법에 대해 문서화된 절차를 가지고 있어야 하며, 이 절차에는\n\n<!-- PAGE_125 -->\n###### 적절하고 안전한 수, 취급, 보관, 미사용 임상시험용 의료기기의\n\n<!-- PAGE_125 -->\n###### 피험자로부터의 반납 및 의뢰자에 대한 반납 등에 대한 방법이\n\n<!-- PAGE_125 -->\n###### 3) 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관\n\n<!-- PAGE_125 -->\n###### 으로의 공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납\n\n<!-- PAGE_125 -->\n###### 4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상\n\n<!-- PAGE_125 -->\n###### 시험의 종료 또는 사용기간의 만료 등에 의한 임상시험용 의료\n\n- - 119 -\n<!-- PAGE_126 -->\n### Ⅳ\n\n<!-- PAGE_126 -->\n### 참고문헌\n\n- 1.  2020년 국민건강영양조사, 질병관리청, 2020.12\n- 2.  일차 의료용 근거 기반 우울장애 임상진료지침, 대한의학회, 2022\n- 3.  권정혜, & 이재우.  (2001).  우울증의 인지행동치료. ",
        "original_sentence": "일차 의료용 근거 기반 우울장애 임상진료지침, 대한의학회, 2022\n- 3. "
      }
    },
    {
      "chunk_id": "chunk_859",
      "text": "권정혜, & 이재우. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 858,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 126,
        "window_text": "임상시험용 의료기기의 공급과 취급\n\n<!-- PAGE_125 -->\n###### 1) 의뢰자는 임상시험계획서에 대한 심사위원회와 청장의 승인을\n\n<!-- PAGE_125 -->\n###### 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는\n\n<!-- PAGE_125 -->\n###### 2) 의뢰자는 관리자 등이 임상시험용 의료기기를 취급하고 보관하는\n\n<!-- PAGE_125 -->\n###### 방법에 대해 문서화된 절차를 가지고 있어야 하며, 이 절차에는\n\n<!-- PAGE_125 -->\n###### 적절하고 안전한 수, 취급, 보관, 미사용 임상시험용 의료기기의\n\n<!-- PAGE_125 -->\n###### 피험자로부터의 반납 및 의뢰자에 대한 반납 등에 대한 방법이\n\n<!-- PAGE_125 -->\n###### 3) 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관\n\n<!-- PAGE_125 -->\n###### 으로의 공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납\n\n<!-- PAGE_125 -->\n###### 4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상\n\n<!-- PAGE_125 -->\n###### 시험의 종료 또는 사용기간의 만료 등에 의한 임상시험용 의료\n\n- - 119 -\n<!-- PAGE_126 -->\n### Ⅳ\n\n<!-- PAGE_126 -->\n### 참고문헌\n\n- 1.  2020년 국민건강영양조사, 질병관리청, 2020.12\n- 2.  일차 의료용 근거 기반 우울장애 임상진료지침, 대한의학회, 2022\n- 3.  권정혜, & 이재우.  (2001).  우울증의 인지행동치료.  인지행동치료, 1, 1-22.\n",
        "original_sentence": "권정혜, & 이재우. "
      }
    },
    {
      "chunk_id": "chunk_860",
      "text": "(2001). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 859,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "2020년 국민건강영양조사, 질병관리청, 2020.12\n- 2.  일차 의료용 근거 기반 우울장애 임상진료지침, 대한의학회, 2022\n- 3.  권정혜, & 이재우.  (2001).  우울증의 인지행동치료.  인지행동치료, 1, 1-22.\n - 4. ",
        "original_sentence": "(2001). "
      }
    },
    {
      "chunk_id": "chunk_861",
      "text": "우울증의 인지행동치료. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 860,
        "window_size": 3,
        "char_count": 13,
        "word_count": 2,
        "page_number": 18,
        "window_text": "일차 의료용 근거 기반 우울장애 임상진료지침, 대한의학회, 2022\n- 3.  권정혜, & 이재우.  (2001).  우울증의 인지행동치료.  인지행동치료, 1, 1-22.\n - 4.  이삼연. ",
        "original_sentence": "우울증의 인지행동치료. "
      }
    },
    {
      "chunk_id": "chunk_862",
      "text": "인지행동치료, 1, 1-22.\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 861,
        "window_size": 3,
        "char_count": 17,
        "word_count": 3,
        "page_number": 9,
        "window_text": "권정혜, & 이재우.  (2001).  우울증의 인지행동치료.  인지행동치료, 1, 1-22.\n - 4.  이삼연.  (1999). ",
        "original_sentence": "인지행동치료, 1, 1-22.\n"
      }
    },
    {
      "chunk_id": "chunk_863",
      "text": "- 4. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 862,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 29,
        "window_text": "(2001).  우울증의 인지행동치료.  인지행동치료, 1, 1-22.\n - 4.  이삼연.  (1999).  인지-행동치료의 우울증 사정과 개입전략. ",
        "original_sentence": "- 4. "
      }
    },
    {
      "chunk_id": "chunk_864",
      "text": "이삼연. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 863,
        "window_size": 3,
        "char_count": 5,
        "word_count": 1,
        "page_number": 126,
        "window_text": "우울증의 인지행동치료.  인지행동치료, 1, 1-22.\n - 4.  이삼연.  (1999).  인지-행동치료의 우울증 사정과 개입전략.  한국가족복지학, 4, 189-218.\n",
        "original_sentence": "이삼연. "
      }
    },
    {
      "chunk_id": "chunk_865",
      "text": "(1999). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 864,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 28,
        "window_text": "인지행동치료, 1, 1-22.\n - 4.  이삼연.  (1999).  인지-행동치료의 우울증 사정과 개입전략.  한국가족복지학, 4, 189-218.\n - 5. ",
        "original_sentence": "(1999). "
      }
    },
    {
      "chunk_id": "chunk_866",
      "text": "인지-행동치료의 우울증 사정과 개입전략. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 865,
        "window_size": 3,
        "char_count": 23,
        "word_count": 4,
        "page_number": 18,
        "window_text": "- 4.  이삼연.  (1999).  인지-행동치료의 우울증 사정과 개입전략.  한국가족복지학, 4, 189-218.\n - 5.  Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., ... & CANMAT\nDepression Work Group. ",
        "original_sentence": "인지-행동치료의 우울증 사정과 개입전략. "
      }
    },
    {
      "chunk_id": "chunk_867",
      "text": "한국가족복지학, 4, 189-218.\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 866,
        "window_size": 3,
        "char_count": 21,
        "word_count": 3,
        "page_number": 9,
        "window_text": "이삼연.  (1999).  인지-행동치료의 우울증 사정과 개입전략.  한국가족복지학, 4, 189-218.\n - 5.  Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., ... & CANMAT\nDepression Work Group.  (2016). ",
        "original_sentence": "한국가족복지학, 4, 189-218.\n"
      }
    },
    {
      "chunk_id": "chunk_868",
      "text": "- 5. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 867,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 29,
        "window_text": "(1999).  인지-행동치료의 우울증 사정과 개입전략.  한국가족복지학, 4, 189-218.\n - 5.  Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., ... & CANMAT\nDepression Work Group.  (2016).  Canadian Network for Mood and Anxiety Treatments (CANMAT)\n\n2016 clinical guidelines for the management of adults with major depressive disorder: section 3.\n\n",
        "original_sentence": "- 5. "
      }
    },
    {
      "chunk_id": "chunk_869",
      "text": "Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., ... & CANMAT\nDepression Work Group. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 868,
        "window_size": 3,
        "char_count": 119,
        "word_count": 22,
        "page_number": 126,
        "window_text": "인지-행동치료의 우울증 사정과 개입전략.  한국가족복지학, 4, 189-218.\n - 5.  Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., ... & CANMAT\nDepression Work Group.  (2016).  Canadian Network for Mood and Anxiety Treatments (CANMAT)\n\n2016 clinical guidelines for the management of adults with major depressive disorder: section 3.\n\n - 6. ",
        "original_sentence": "Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., ... & CANMAT\nDepression Work Group. "
      }
    },
    {
      "chunk_id": "chunk_870",
      "text": "(2016). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 869,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "한국가족복지학, 4, 189-218.\n - 5.  Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., ... & CANMAT\nDepression Work Group.  (2016).  Canadian Network for Mood and Anxiety Treatments (CANMAT)\n\n2016 clinical guidelines for the management of adults with major depressive disorder: section 3.\n\n - 6.  Gelenberg, A. J., Freeman, M. P., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H.,\n& Van Rhoads, R. S. ",
        "original_sentence": "(2016). "
      }
    },
    {
      "chunk_id": "chunk_871",
      "text": "Canadian Network for Mood and Anxiety Treatments (CANMAT)\n\n2016 clinical guidelines for the management of adults with major depressive disorder: section 3.\n\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 870,
        "window_size": 3,
        "char_count": 157,
        "word_count": 22,
        "page_number": 73,
        "window_text": "- 5.  Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., ... & CANMAT\nDepression Work Group.  (2016).  Canadian Network for Mood and Anxiety Treatments (CANMAT)\n\n2016 clinical guidelines for the management of adults with major depressive disorder: section 3.\n\n - 6.  Gelenberg, A. J., Freeman, M. P., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H.,\n& Van Rhoads, R. S.  (2010). ",
        "original_sentence": "Canadian Network for Mood and Anxiety Treatments (CANMAT)\n\n2016 clinical guidelines for the management of adults with major depressive disorder: section 3.\n\n"
      }
    },
    {
      "chunk_id": "chunk_872",
      "text": "- 6. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 871,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 29,
        "window_text": "Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., ... & CANMAT\nDepression Work Group.  (2016).  Canadian Network for Mood and Anxiety Treatments (CANMAT)\n\n2016 clinical guidelines for the management of adults with major depressive disorder: section 3.\n\n - 6.  Gelenberg, A. J., Freeman, M. P., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H.,\n& Van Rhoads, R. S.  (2010).  American Psychiatric Association practice guidelines for the treatment\n\n- 7. ",
        "original_sentence": "- 6. "
      }
    },
    {
      "chunk_id": "chunk_873",
      "text": "Gelenberg, A. J., Freeman, M. P., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H.,\n& Van Rhoads, R. S. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 872,
        "window_size": 3,
        "char_count": 120,
        "word_count": 23,
        "page_number": 126,
        "window_text": "(2016).  Canadian Network for Mood and Anxiety Treatments (CANMAT)\n\n2016 clinical guidelines for the management of adults with major depressive disorder: section 3.\n\n - 6.  Gelenberg, A. J., Freeman, M. P., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H.,\n& Van Rhoads, R. S.  (2010).  American Psychiatric Association practice guidelines for the treatment\n\n- 7.  Anderson, I. M., Ferrier, I. N., Baldwin, R. C., Cowen, P. J., Howard, L., Lewis, G., ... & Tylee, A.\n",
        "original_sentence": "Gelenberg, A. J., Freeman, M. P., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H.,\n& Van Rhoads, R. S. "
      }
    },
    {
      "chunk_id": "chunk_874",
      "text": "(2010). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 873,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "Canadian Network for Mood and Anxiety Treatments (CANMAT)\n\n2016 clinical guidelines for the management of adults with major depressive disorder: section 3.\n\n - 6.  Gelenberg, A. J., Freeman, M. P., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H.,\n& Van Rhoads, R. S.  (2010).  American Psychiatric Association practice guidelines for the treatment\n\n- 7.  Anderson, I. M., Ferrier, I. N., Baldwin, R. C., Cowen, P. J., Howard, L., Lewis, G., ... & Tylee, A.\n - (2008). ",
        "original_sentence": "(2010). "
      }
    },
    {
      "chunk_id": "chunk_875",
      "text": "American Psychiatric Association practice guidelines for the treatment\n\n- 7. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 874,
        "window_size": 3,
        "char_count": 77,
        "word_count": 10,
        "page_number": 126,
        "window_text": "- 6.  Gelenberg, A. J., Freeman, M. P., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H.,\n& Van Rhoads, R. S.  (2010).  American Psychiatric Association practice guidelines for the treatment\n\n- 7.  Anderson, I. M., Ferrier, I. N., Baldwin, R. C., Cowen, P. J., Howard, L., Lewis, G., ... & Tylee, A.\n - (2008).  Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of\nthe 2000 British Association for Psychopharmacology guidelines. ",
        "original_sentence": "American Psychiatric Association practice guidelines for the treatment\n\n- 7. "
      }
    },
    {
      "chunk_id": "chunk_876",
      "text": "Anderson, I. M., Ferrier, I. N., Baldwin, R. C., Cowen, P. J., Howard, L., Lewis, G., ... & Tylee, A.\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 875,
        "window_size": 3,
        "char_count": 102,
        "word_count": 20,
        "page_number": 73,
        "window_text": "Gelenberg, A. J., Freeman, M. P., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H.,\n& Van Rhoads, R. S.  (2010).  American Psychiatric Association practice guidelines for the treatment\n\n- 7.  Anderson, I. M., Ferrier, I. N., Baldwin, R. C., Cowen, P. J., Howard, L., Lewis, G., ... & Tylee, A.\n - (2008).  Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of\nthe 2000 British Association for Psychopharmacology guidelines.  Journal of psychopharmacology,\n\n- 8. ",
        "original_sentence": "Anderson, I. M., Ferrier, I. N., Baldwin, R. C., Cowen, P. J., Howard, L., Lewis, G., ... & Tylee, A.\n"
      }
    },
    {
      "chunk_id": "chunk_877",
      "text": "- (2008). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 876,
        "window_size": 3,
        "char_count": 10,
        "word_count": 2,
        "page_number": 9,
        "window_text": "(2010).  American Psychiatric Association practice guidelines for the treatment\n\n- 7.  Anderson, I. M., Ferrier, I. N., Baldwin, R. C., Cowen, P. J., Howard, L., Lewis, G., ... & Tylee, A.\n - (2008).  Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of\nthe 2000 British Association for Psychopharmacology guidelines.  Journal of psychopharmacology,\n\n- 8.  Andrews, G., Basu, A., Cuijpers, P., Craske, M. G., McEvoy, P., English, C. L., & Newby, J. M.\n",
        "original_sentence": "- (2008). "
      }
    },
    {
      "chunk_id": "chunk_878",
      "text": "Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of\nthe 2000 British Association for Psychopharmacology guidelines. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 877,
        "window_size": 3,
        "char_count": 160,
        "word_count": 18,
        "page_number": 18,
        "window_text": "American Psychiatric Association practice guidelines for the treatment\n\n- 7.  Anderson, I. M., Ferrier, I. N., Baldwin, R. C., Cowen, P. J., Howard, L., Lewis, G., ... & Tylee, A.\n - (2008).  Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of\nthe 2000 British Association for Psychopharmacology guidelines.  Journal of psychopharmacology,\n\n- 8.  Andrews, G., Basu, A., Cuijpers, P., Craske, M. G., McEvoy, P., English, C. L., & Newby, J. M.\n - (2018). ",
        "original_sentence": "Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of\nthe 2000 British Association for Psychopharmacology guidelines. "
      }
    },
    {
      "chunk_id": "chunk_879",
      "text": "Journal of psychopharmacology,\n\n- 8. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 878,
        "window_size": 3,
        "char_count": 37,
        "word_count": 5,
        "page_number": 29,
        "window_text": "Anderson, I. M., Ferrier, I. N., Baldwin, R. C., Cowen, P. J., Howard, L., Lewis, G., ... & Tylee, A.\n - (2008).  Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of\nthe 2000 British Association for Psychopharmacology guidelines.  Journal of psychopharmacology,\n\n- 8.  Andrews, G., Basu, A., Cuijpers, P., Craske, M. G., McEvoy, P., English, C. L., & Newby, J. M.\n - (2018).  Computer therapy for the anxiety and depression disorders is effective, acceptable and\n- 9. ",
        "original_sentence": "Journal of psychopharmacology,\n\n- 8. "
      }
    },
    {
      "chunk_id": "chunk_880",
      "text": "Andrews, G., Basu, A., Cuijpers, P., Craske, M. G., McEvoy, P., English, C. L., & Newby, J. M.\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 879,
        "window_size": 3,
        "char_count": 95,
        "word_count": 18,
        "page_number": 126,
        "window_text": "- (2008).  Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of\nthe 2000 British Association for Psychopharmacology guidelines.  Journal of psychopharmacology,\n\n- 8.  Andrews, G., Basu, A., Cuijpers, P., Craske, M. G., McEvoy, P., English, C. L., & Newby, J. M.\n - (2018).  Computer therapy for the anxiety and depression disorders is effective, acceptable and\n- 9.  Fischer, A., Schröder, J., Vettorazzi, E., Wolf, O. T., Pöttgen, J., Lau, S., ... & Gold, S. M. ",
        "original_sentence": "Andrews, G., Basu, A., Cuijpers, P., Craske, M. G., McEvoy, P., English, C. L., & Newby, J. M.\n"
      }
    },
    {
      "chunk_id": "chunk_881",
      "text": "- (2018). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 880,
        "window_size": 3,
        "char_count": 10,
        "word_count": 2,
        "page_number": 9,
        "window_text": "Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of\nthe 2000 British Association for Psychopharmacology guidelines.  Journal of psychopharmacology,\n\n- 8.  Andrews, G., Basu, A., Cuijpers, P., Craske, M. G., McEvoy, P., English, C. L., & Newby, J. M.\n - (2018).  Computer therapy for the anxiety and depression disorders is effective, acceptable and\n- 9.  Fischer, A., Schröder, J., Vettorazzi, E., Wolf, O. T., Pöttgen, J., Lau, S., ... & Gold, S. M.  (2015). ",
        "original_sentence": "- (2018). "
      }
    },
    {
      "chunk_id": "chunk_882",
      "text": "Computer therapy for the anxiety and depression disorders is effective, acceptable and\n- 9. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 881,
        "window_size": 3,
        "char_count": 92,
        "word_count": 14,
        "page_number": 9,
        "window_text": "Journal of psychopharmacology,\n\n- 8.  Andrews, G., Basu, A., Cuijpers, P., Craske, M. G., McEvoy, P., English, C. L., & Newby, J. M.\n - (2018).  Computer therapy for the anxiety and depression disorders is effective, acceptable and\n- 9.  Fischer, A., Schröder, J., Vettorazzi, E., Wolf, O. T., Pöttgen, J., Lau, S., ... & Gold, S. M.  (2015).  An\nonline programme to reduce depression in patients with multiple sclerosis: a randomised controlled\n\n- 10. ",
        "original_sentence": "Computer therapy for the anxiety and depression disorders is effective, acceptable and\n- 9. "
      }
    },
    {
      "chunk_id": "chunk_883",
      "text": "Fischer, A., Schröder, J., Vettorazzi, E., Wolf, O. T., Pöttgen, J., Lau, S., ... & Gold, S. M. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 882,
        "window_size": 3,
        "char_count": 96,
        "word_count": 18,
        "page_number": 85,
        "window_text": "Andrews, G., Basu, A., Cuijpers, P., Craske, M. G., McEvoy, P., English, C. L., & Newby, J. M.\n - (2018).  Computer therapy for the anxiety and depression disorders is effective, acceptable and\n- 9.  Fischer, A., Schröder, J., Vettorazzi, E., Wolf, O. T., Pöttgen, J., Lau, S., ... & Gold, S. M.  (2015).  An\nonline programme to reduce depression in patients with multiple sclerosis: a randomised controlled\n\n- 10.  Berger, T., Hämmerli, K., Gubser, N., Andersson, G., & Caspar, F. ",
        "original_sentence": "Fischer, A., Schröder, J., Vettorazzi, E., Wolf, O. T., Pöttgen, J., Lau, S., ... & Gold, S. M. "
      }
    },
    {
      "chunk_id": "chunk_884",
      "text": "(2015). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 883,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "- (2018).  Computer therapy for the anxiety and depression disorders is effective, acceptable and\n- 9.  Fischer, A., Schröder, J., Vettorazzi, E., Wolf, O. T., Pöttgen, J., Lau, S., ... & Gold, S. M.  (2015).  An\nonline programme to reduce depression in patients with multiple sclerosis: a randomised controlled\n\n- 10.  Berger, T., Hämmerli, K., Gubser, N., Andersson, G., & Caspar, F.  (2011). ",
        "original_sentence": "(2015). "
      }
    },
    {
      "chunk_id": "chunk_885",
      "text": "An\nonline programme to reduce depression in patients with multiple sclerosis: a randomised controlled\n\n- 10. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 884,
        "window_size": 3,
        "char_count": 109,
        "word_count": 16,
        "page_number": 1,
        "window_text": "Computer therapy for the anxiety and depression disorders is effective, acceptable and\n- 9.  Fischer, A., Schröder, J., Vettorazzi, E., Wolf, O. T., Pöttgen, J., Lau, S., ... & Gold, S. M.  (2015).  An\nonline programme to reduce depression in patients with multiple sclerosis: a randomised controlled\n\n- 10.  Berger, T., Hämmerli, K., Gubser, N., Andersson, G., & Caspar, F.  (2011).  Internet-based treatment\nof depression: a randomized controlled trial comparing guided with unguided self-help. ",
        "original_sentence": "An\nonline programme to reduce depression in patients with multiple sclerosis: a randomised controlled\n\n- 10. "
      }
    },
    {
      "chunk_id": "chunk_886",
      "text": "Berger, T., Hämmerli, K., Gubser, N., Andersson, G., & Caspar, F. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 885,
        "window_size": 3,
        "char_count": 66,
        "word_count": 11,
        "page_number": 73,
        "window_text": "Fischer, A., Schröder, J., Vettorazzi, E., Wolf, O. T., Pöttgen, J., Lau, S., ... & Gold, S. M.  (2015).  An\nonline programme to reduce depression in patients with multiple sclerosis: a randomised controlled\n\n- 10.  Berger, T., Hämmerli, K., Gubser, N., Andersson, G., & Caspar, F.  (2011).  Internet-based treatment\nof depression: a randomized controlled trial comparing guided with unguided self-help.  Cognitive\n\n- 11. ",
        "original_sentence": "Berger, T., Hämmerli, K., Gubser, N., Andersson, G., & Caspar, F. "
      }
    },
    {
      "chunk_id": "chunk_887",
      "text": "(2011). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 886,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "(2015).  An\nonline programme to reduce depression in patients with multiple sclerosis: a randomised controlled\n\n- 10.  Berger, T., Hämmerli, K., Gubser, N., Andersson, G., & Caspar, F.  (2011).  Internet-based treatment\nof depression: a randomized controlled trial comparing guided with unguided self-help.  Cognitive\n\n- 11.  Klein, J. P., Berger, T., Schröder, J., Späth, C., Meyer, B., Caspar, F., ... & Hohagen, F. ",
        "original_sentence": "(2011). "
      }
    },
    {
      "chunk_id": "chunk_888",
      "text": "Internet-based treatment\nof depression: a randomized controlled trial comparing guided with unguided self-help. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 887,
        "window_size": 3,
        "char_count": 112,
        "word_count": 13,
        "page_number": 29,
        "window_text": "An\nonline programme to reduce depression in patients with multiple sclerosis: a randomised controlled\n\n- 10.  Berger, T., Hämmerli, K., Gubser, N., Andersson, G., & Caspar, F.  (2011).  Internet-based treatment\nof depression: a randomized controlled trial comparing guided with unguided self-help.  Cognitive\n\n- 11.  Klein, J. P., Berger, T., Schröder, J., Späth, C., Meyer, B., Caspar, F., ... & Hohagen, F.  (2016).\n",
        "original_sentence": "Internet-based treatment\nof depression: a randomized controlled trial comparing guided with unguided self-help. "
      }
    },
    {
      "chunk_id": "chunk_889",
      "text": "Cognitive\n\n- 11. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 888,
        "window_size": 3,
        "char_count": 17,
        "word_count": 3,
        "page_number": 9,
        "window_text": "Berger, T., Hämmerli, K., Gubser, N., Andersson, G., & Caspar, F.  (2011).  Internet-based treatment\nof depression: a randomized controlled trial comparing guided with unguided self-help.  Cognitive\n\n- 11.  Klein, J. P., Berger, T., Schröder, J., Späth, C., Meyer, B., Caspar, F., ... & Hohagen, F.  (2016).\n Effects of a psychological internet intervention in the treatment of mild to moderate depressive\n\nsymptoms: results of the EVIDENT study, a randomized controlled trial. ",
        "original_sentence": "Cognitive\n\n- 11. "
      }
    },
    {
      "chunk_id": "chunk_890",
      "text": "Klein, J. P., Berger, T., Schröder, J., Späth, C., Meyer, B., Caspar, F., ... & Hohagen, F. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 889,
        "window_size": 3,
        "char_count": 92,
        "word_count": 17,
        "page_number": 126,
        "window_text": "(2011).  Internet-based treatment\nof depression: a randomized controlled trial comparing guided with unguided self-help.  Cognitive\n\n- 11.  Klein, J. P., Berger, T., Schröder, J., Späth, C., Meyer, B., Caspar, F., ... & Hohagen, F.  (2016).\n Effects of a psychological internet intervention in the treatment of mild to moderate depressive\n\nsymptoms: results of the EVIDENT study, a randomized controlled trial.  Psychotherapy and\n\n- 12. ",
        "original_sentence": "Klein, J. P., Berger, T., Schröder, J., Späth, C., Meyer, B., Caspar, F., ... & Hohagen, F. "
      }
    },
    {
      "chunk_id": "chunk_891",
      "text": "(2016).\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 890,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "Internet-based treatment\nof depression: a randomized controlled trial comparing guided with unguided self-help.  Cognitive\n\n- 11.  Klein, J. P., Berger, T., Schröder, J., Späth, C., Meyer, B., Caspar, F., ... & Hohagen, F.  (2016).\n Effects of a psychological internet intervention in the treatment of mild to moderate depressive\n\nsymptoms: results of the EVIDENT study, a randomized controlled trial.  Psychotherapy and\n\n- 12.  Beevers, C. G., Pearson, R., Hoffman, J. S., Foulser, A. A., Shumake, J., & Meyer, B. ",
        "original_sentence": "(2016).\n"
      }
    },
    {
      "chunk_id": "chunk_892",
      "text": "Effects of a psychological internet intervention in the treatment of mild to moderate depressive\n\nsymptoms: results of the EVIDENT study, a randomized controlled trial. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 891,
        "window_size": 3,
        "char_count": 169,
        "word_count": 24,
        "page_number": 126,
        "window_text": "Cognitive\n\n- 11.  Klein, J. P., Berger, T., Schröder, J., Späth, C., Meyer, B., Caspar, F., ... & Hohagen, F.  (2016).\n Effects of a psychological internet intervention in the treatment of mild to moderate depressive\n\nsymptoms: results of the EVIDENT study, a randomized controlled trial.  Psychotherapy and\n\n- 12.  Beevers, C. G., Pearson, R., Hoffman, J. S., Foulser, A. A., Shumake, J., & Meyer, B.  (2017).\n",
        "original_sentence": "Effects of a psychological internet intervention in the treatment of mild to moderate depressive\n\nsymptoms: results of the EVIDENT study, a randomized controlled trial. "
      }
    },
    {
      "chunk_id": "chunk_893",
      "text": "Psychotherapy and\n\n- 12. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 892,
        "window_size": 3,
        "char_count": 25,
        "word_count": 4,
        "page_number": 9,
        "window_text": "Klein, J. P., Berger, T., Schröder, J., Späth, C., Meyer, B., Caspar, F., ... & Hohagen, F.  (2016).\n Effects of a psychological internet intervention in the treatment of mild to moderate depressive\n\nsymptoms: results of the EVIDENT study, a randomized controlled trial.  Psychotherapy and\n\n- 12.  Beevers, C. G., Pearson, R., Hoffman, J. S., Foulser, A. A., Shumake, J., & Meyer, B.  (2017).\n Effectiveness of an internet intervention (Deprexis) for depression in a united states adult sample:\n\nA parallel-group pragmatic randomized controlled trial. ",
        "original_sentence": "Psychotherapy and\n\n- 12. "
      }
    },
    {
      "chunk_id": "chunk_894",
      "text": "Beevers, C. G., Pearson, R., Hoffman, J. S., Foulser, A. A., Shumake, J., & Meyer, B. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 893,
        "window_size": 3,
        "char_count": 86,
        "word_count": 16,
        "page_number": 126,
        "window_text": "(2016).\n Effects of a psychological internet intervention in the treatment of mild to moderate depressive\n\nsymptoms: results of the EVIDENT study, a randomized controlled trial.  Psychotherapy and\n\n- 12.  Beevers, C. G., Pearson, R., Hoffman, J. S., Foulser, A. A., Shumake, J., & Meyer, B.  (2017).\n Effectiveness of an internet intervention (Deprexis) for depression in a united states adult sample:\n\nA parallel-group pragmatic randomized controlled trial.  Journal of consulting and clinical psychology,\n\n- 13. ",
        "original_sentence": "Beevers, C. G., Pearson, R., Hoffman, J. S., Foulser, A. A., Shumake, J., & Meyer, B. "
      }
    },
    {
      "chunk_id": "chunk_895",
      "text": "(2017).\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 894,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "Effects of a psychological internet intervention in the treatment of mild to moderate depressive\n\nsymptoms: results of the EVIDENT study, a randomized controlled trial.  Psychotherapy and\n\n- 12.  Beevers, C. G., Pearson, R., Hoffman, J. S., Foulser, A. A., Shumake, J., & Meyer, B.  (2017).\n Effectiveness of an internet intervention (Deprexis) for depression in a united states adult sample:\n\nA parallel-group pragmatic randomized controlled trial.  Journal of consulting and clinical psychology,\n\n- 13.  Meyer, B., Bierbrodt, J., Schröder, J., Berger, T., Beevers, C. G., Weiss, M., ... & Klein, J. P.\n",
        "original_sentence": "(2017).\n"
      }
    },
    {
      "chunk_id": "chunk_896",
      "text": "Effectiveness of an internet intervention (Deprexis) for depression in a united states adult sample:\n\nA parallel-group pragmatic randomized controlled trial. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 895,
        "window_size": 3,
        "char_count": 158,
        "word_count": 20,
        "page_number": 126,
        "window_text": "Psychotherapy and\n\n- 12.  Beevers, C. G., Pearson, R., Hoffman, J. S., Foulser, A. A., Shumake, J., & Meyer, B.  (2017).\n Effectiveness of an internet intervention (Deprexis) for depression in a united states adult sample:\n\nA parallel-group pragmatic randomized controlled trial.  Journal of consulting and clinical psychology,\n\n- 13.  Meyer, B., Bierbrodt, J., Schröder, J., Berger, T., Beevers, C. G., Weiss, M., ... & Klein, J. P.\n - (2015). ",
        "original_sentence": "Effectiveness of an internet intervention (Deprexis) for depression in a united states adult sample:\n\nA parallel-group pragmatic randomized controlled trial. "
      }
    },
    {
      "chunk_id": "chunk_897",
      "text": "Journal of consulting and clinical psychology,\n\n- 13. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 896,
        "window_size": 3,
        "char_count": 54,
        "word_count": 8,
        "page_number": 18,
        "window_text": "Beevers, C. G., Pearson, R., Hoffman, J. S., Foulser, A. A., Shumake, J., & Meyer, B.  (2017).\n Effectiveness of an internet intervention (Deprexis) for depression in a united states adult sample:\n\nA parallel-group pragmatic randomized controlled trial.  Journal of consulting and clinical psychology,\n\n- 13.  Meyer, B., Bierbrodt, J., Schröder, J., Berger, T., Beevers, C. G., Weiss, M., ... & Klein, J. P.\n - (2015).  Effects of an Internet intervention (Deprexis) on severe depression symptoms: randomized\n- 14. ",
        "original_sentence": "Journal of consulting and clinical psychology,\n\n- 13. "
      }
    },
    {
      "chunk_id": "chunk_898",
      "text": "Meyer, B., Bierbrodt, J., Schröder, J., Berger, T., Beevers, C. G., Weiss, M., ... & Klein, J. P.\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 897,
        "window_size": 3,
        "char_count": 98,
        "word_count": 18,
        "page_number": 126,
        "window_text": "(2017).\n Effectiveness of an internet intervention (Deprexis) for depression in a united states adult sample:\n\nA parallel-group pragmatic randomized controlled trial.  Journal of consulting and clinical psychology,\n\n- 13.  Meyer, B., Bierbrodt, J., Schröder, J., Berger, T., Beevers, C. G., Weiss, M., ... & Klein, J. P.\n - (2015).  Effects of an Internet intervention (Deprexis) on severe depression symptoms: randomized\n- 14.  Krämer, R., & Köhler, S. ",
        "original_sentence": "Meyer, B., Bierbrodt, J., Schröder, J., Berger, T., Beevers, C. G., Weiss, M., ... & Klein, J. P.\n"
      }
    },
    {
      "chunk_id": "chunk_899",
      "text": "- (2015). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 898,
        "window_size": 3,
        "char_count": 10,
        "word_count": 2,
        "page_number": 9,
        "window_text": "Effectiveness of an internet intervention (Deprexis) for depression in a united states adult sample:\n\nA parallel-group pragmatic randomized controlled trial.  Journal of consulting and clinical psychology,\n\n- 13.  Meyer, B., Bierbrodt, J., Schröder, J., Berger, T., Beevers, C. G., Weiss, M., ... & Klein, J. P.\n - (2015).  Effects of an Internet intervention (Deprexis) on severe depression symptoms: randomized\n- 14.  Krämer, R., & Köhler, S.  (2021). ",
        "original_sentence": "- (2015). "
      }
    },
    {
      "chunk_id": "chunk_900",
      "text": "Effects of an Internet intervention (Deprexis) on severe depression symptoms: randomized\n- 14. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 899,
        "window_size": 3,
        "char_count": 95,
        "word_count": 13,
        "page_number": 28,
        "window_text": "Journal of consulting and clinical psychology,\n\n- 13.  Meyer, B., Bierbrodt, J., Schröder, J., Berger, T., Beevers, C. G., Weiss, M., ... & Klein, J. P.\n - (2015).  Effects of an Internet intervention (Deprexis) on severe depression symptoms: randomized\n- 14.  Krämer, R., & Köhler, S.  (2021).  Evaluation of the online-based self-help programme “Selfapy” in\npatients with unipolar depression: study protocol for a randomized, blinded parallel group\n\n- 15. ",
        "original_sentence": "Effects of an Internet intervention (Deprexis) on severe depression symptoms: randomized\n- 14. "
      }
    },
    {
      "chunk_id": "chunk_901",
      "text": "Krämer, R., & Köhler, S. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 900,
        "window_size": 3,
        "char_count": 25,
        "word_count": 5,
        "page_number": 126,
        "window_text": "Meyer, B., Bierbrodt, J., Schröder, J., Berger, T., Beevers, C. G., Weiss, M., ... & Klein, J. P.\n - (2015).  Effects of an Internet intervention (Deprexis) on severe depression symptoms: randomized\n- 14.  Krämer, R., & Köhler, S.  (2021).  Evaluation of the online-based self-help programme “Selfapy” in\npatients with unipolar depression: study protocol for a randomized, blinded parallel group\n\n- 15.  Schure, M. B., Lindow, J. C., Greist, J. H., Nakonezny, P. A., Bailey, S. J., Bryan, W. L., & Byerly,\n- - 120 -\nM. J. ",
        "original_sentence": "Krämer, R., & Köhler, S. "
      }
    },
    {
      "chunk_id": "chunk_902",
      "text": "(2021). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 901,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "- (2015).  Effects of an Internet intervention (Deprexis) on severe depression symptoms: randomized\n- 14.  Krämer, R., & Köhler, S.  (2021).  Evaluation of the online-based self-help programme “Selfapy” in\npatients with unipolar depression: study protocol for a randomized, blinded parallel group\n\n- 15.  Schure, M. B., Lindow, J. C., Greist, J. H., Nakonezny, P. A., Bailey, S. J., Bryan, W. L., & Byerly,\n- - 120 -\nM. J.  (2019). ",
        "original_sentence": "(2021). "
      }
    },
    {
      "chunk_id": "chunk_903",
      "text": "Evaluation of the online-based self-help programme “Selfapy” in\npatients with unipolar depression: study protocol for a randomized, blinded parallel group\n\n- 15. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 902,
        "window_size": 3,
        "char_count": 162,
        "word_count": 22,
        "page_number": 29,
        "window_text": "Effects of an Internet intervention (Deprexis) on severe depression symptoms: randomized\n- 14.  Krämer, R., & Köhler, S.  (2021).  Evaluation of the online-based self-help programme “Selfapy” in\npatients with unipolar depression: study protocol for a randomized, blinded parallel group\n\n- 15.  Schure, M. B., Lindow, J. C., Greist, J. H., Nakonezny, P. A., Bailey, S. J., Bryan, W. L., & Byerly,\n- - 120 -\nM. J.  (2019).  Use of a fully automated internet-based cognitive behavior therapy intervention in a\n\ncommunity population of adults with depression symptoms: randomized controlled trial. ",
        "original_sentence": "Evaluation of the online-based self-help programme “Selfapy” in\npatients with unipolar depression: study protocol for a randomized, blinded parallel group\n\n- 15. "
      }
    },
    {
      "chunk_id": "chunk_904",
      "text": "Schure, M. B., Lindow, J. C., Greist, J. H., Nakonezny, P. A., Bailey, S. J., Bryan, W. L., & Byerly,\n- - 120 -\nM. J. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 903,
        "window_size": 3,
        "char_count": 118,
        "word_count": 26,
        "page_number": 73,
        "window_text": "Krämer, R., & Köhler, S.  (2021).  Evaluation of the online-based self-help programme “Selfapy” in\npatients with unipolar depression: study protocol for a randomized, blinded parallel group\n\n- 15.  Schure, M. B., Lindow, J. C., Greist, J. H., Nakonezny, P. A., Bailey, S. J., Bryan, W. L., & Byerly,\n- - 120 -\nM. J.  (2019).  Use of a fully automated internet-based cognitive behavior therapy intervention in a\n\ncommunity population of adults with depression symptoms: randomized controlled trial.  Journal of\n\n- 16. ",
        "original_sentence": "Schure, M. B., Lindow, J. C., Greist, J. H., Nakonezny, P. A., Bailey, S. J., Bryan, W. L., & Byerly,\n- - 120 -\nM. J. "
      }
    },
    {
      "chunk_id": "chunk_905",
      "text": "(2019). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 904,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "(2021).  Evaluation of the online-based self-help programme “Selfapy” in\npatients with unipolar depression: study protocol for a randomized, blinded parallel group\n\n- 15.  Schure, M. B., Lindow, J. C., Greist, J. H., Nakonezny, P. A., Bailey, S. J., Bryan, W. L., & Byerly,\n- - 120 -\nM. J.  (2019).  Use of a fully automated internet-based cognitive behavior therapy intervention in a\n\ncommunity population of adults with depression symptoms: randomized controlled trial.  Journal of\n\n- 16.  Deprexis  홈페이지, https://uk.deprexis.com/\n- 17. ",
        "original_sentence": "(2019). "
      }
    },
    {
      "chunk_id": "chunk_906",
      "text": "Use of a fully automated internet-based cognitive behavior therapy intervention in a\n\ncommunity population of adults with depression symptoms: randomized controlled trial. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 905,
        "window_size": 3,
        "char_count": 172,
        "word_count": 22,
        "page_number": 29,
        "window_text": "Evaluation of the online-based self-help programme “Selfapy” in\npatients with unipolar depression: study protocol for a randomized, blinded parallel group\n\n- 15.  Schure, M. B., Lindow, J. C., Greist, J. H., Nakonezny, P. A., Bailey, S. J., Bryan, W. L., & Byerly,\n- - 120 -\nM. J.  (2019).  Use of a fully automated internet-based cognitive behavior therapy intervention in a\n\ncommunity population of adults with depression symptoms: randomized controlled trial.  Journal of\n\n- 16.  Deprexis  홈페이지, https://uk.deprexis.com/\n- 17.  Selfapy 홈페이지, https://www.selfapy.com/\n- 18. ",
        "original_sentence": "Use of a fully automated internet-based cognitive behavior therapy intervention in a\n\ncommunity population of adults with depression symptoms: randomized controlled trial. "
      }
    },
    {
      "chunk_id": "chunk_907",
      "text": "Journal of\n\n- 16. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 906,
        "window_size": 3,
        "char_count": 18,
        "word_count": 4,
        "page_number": 28,
        "window_text": "Schure, M. B., Lindow, J. C., Greist, J. H., Nakonezny, P. A., Bailey, S. J., Bryan, W. L., & Byerly,\n- - 120 -\nM. J.  (2019).  Use of a fully automated internet-based cognitive behavior therapy intervention in a\n\ncommunity population of adults with depression symptoms: randomized controlled trial.  Journal of\n\n- 16.  Deprexis  홈페이지, https://uk.deprexis.com/\n- 17.  Selfapy 홈페이지, https://www.selfapy.com/\n- 18.  Thrive 홈페이지, https://play.google.com/store/apps/details?id=com.waypointhealth.thrive&hl=ko\n- 19. ",
        "original_sentence": "Journal of\n\n- 16. "
      }
    },
    {
      "chunk_id": "chunk_908",
      "text": "Deprexis  홈페이지, https://uk.deprexis.com/\n- 17. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 907,
        "window_size": 3,
        "char_count": 47,
        "word_count": 5,
        "page_number": 28,
        "window_text": "(2019).  Use of a fully automated internet-based cognitive behavior therapy intervention in a\n\ncommunity population of adults with depression symptoms: randomized controlled trial.  Journal of\n\n- 16.  Deprexis  홈페이지, https://uk.deprexis.com/\n- 17.  Selfapy 홈페이지, https://www.selfapy.com/\n- 18.  Thrive 홈페이지, https://play.google.com/store/apps/details?id=com.waypointhealth.thrive&hl=ko\n- 19.  NOVEGO 홈페이지, https://www.novego.de\n- 20. ",
        "original_sentence": "Deprexis  홈페이지, https://uk.deprexis.com/\n- 17. "
      }
    },
    {
      "chunk_id": "chunk_909",
      "text": "Selfapy 홈페이지, https://www.selfapy.com/\n- 18. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 908,
        "window_size": 3,
        "char_count": 45,
        "word_count": 5,
        "page_number": 28,
        "window_text": "Use of a fully automated internet-based cognitive behavior therapy intervention in a\n\ncommunity population of adults with depression symptoms: randomized controlled trial.  Journal of\n\n- 16.  Deprexis  홈페이지, https://uk.deprexis.com/\n- 17.  Selfapy 홈페이지, https://www.selfapy.com/\n- 18.  Thrive 홈페이지, https://play.google.com/store/apps/details?id=com.waypointhealth.thrive&hl=ko\n- 19.  NOVEGO 홈페이지, https://www.novego.de\n- 20.  SparkRx 홈페이지, https://www.sparkrx.com\n- 21. ",
        "original_sentence": "Selfapy 홈페이지, https://www.selfapy.com/\n- 18. "
      }
    },
    {
      "chunk_id": "chunk_910",
      "text": "Thrive 홈페이지, https://play.google.com/store/apps/details?id=com.waypointhealth.thrive&hl=ko\n- 19. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 909,
        "window_size": 3,
        "char_count": 97,
        "word_count": 5,
        "page_number": 28,
        "window_text": "Journal of\n\n- 16.  Deprexis  홈페이지, https://uk.deprexis.com/\n- 17.  Selfapy 홈페이지, https://www.selfapy.com/\n- 18.  Thrive 홈페이지, https://play.google.com/store/apps/details?id=com.waypointhealth.thrive&hl=ko\n- 19.  NOVEGO 홈페이지, https://www.novego.de\n- 20.  SparkRx 홈페이지, https://www.sparkrx.com\n- 21.  SilverCloud 홈페이지, https://health.colostate.edu/silvercloud/\n- 22. ",
        "original_sentence": "Thrive 홈페이지, https://play.google.com/store/apps/details?id=com.waypointhealth.thrive&hl=ko\n- 19. "
      }
    },
    {
      "chunk_id": "chunk_911",
      "text": "NOVEGO 홈페이지, https://www.novego.de\n- 20. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 910,
        "window_size": 3,
        "char_count": 41,
        "word_count": 5,
        "page_number": 9,
        "window_text": "Deprexis  홈페이지, https://uk.deprexis.com/\n- 17.  Selfapy 홈페이지, https://www.selfapy.com/\n- 18.  Thrive 홈페이지, https://play.google.com/store/apps/details?id=com.waypointhealth.thrive&hl=ko\n- 19.  NOVEGO 홈페이지, https://www.novego.de\n- 20.  SparkRx 홈페이지, https://www.sparkrx.com\n- 21.  SilverCloud 홈페이지, https://health.colostate.edu/silvercloud/\n- 22.  디지털치료기기 허가·심사 가이드라인 민원인 안내서, 식품의약품안전처 2020.08\n- 23. ",
        "original_sentence": "NOVEGO 홈페이지, https://www.novego.de\n- 20. "
      }
    },
    {
      "chunk_id": "chunk_912",
      "text": "SparkRx 홈페이지, https://www.sparkrx.com\n- 21. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 911,
        "window_size": 3,
        "char_count": 44,
        "word_count": 5,
        "page_number": 9,
        "window_text": "Selfapy 홈페이지, https://www.selfapy.com/\n- 18.  Thrive 홈페이지, https://play.google.com/store/apps/details?id=com.waypointhealth.thrive&hl=ko\n- 19.  NOVEGO 홈페이지, https://www.novego.de\n- 20.  SparkRx 홈페이지, https://www.sparkrx.com\n- 21.  SilverCloud 홈페이지, https://health.colostate.edu/silvercloud/\n- 22.  디지털치료기기 허가·심사 가이드라인 민원인 안내서, 식품의약품안전처 2020.08\n- 23.  의료기기의 사이버 보안 허가·심사 가이드라인 민원인안내서 2022.1. ",
        "original_sentence": "SparkRx 홈페이지, https://www.sparkrx.com\n- 21. "
      }
    },
    {
      "chunk_id": "chunk_913",
      "text": "SilverCloud 홈페이지, https://health.colostate.edu/silvercloud/\n- 22. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 912,
        "window_size": 3,
        "char_count": 66,
        "word_count": 5,
        "page_number": 28,
        "window_text": "Thrive 홈페이지, https://play.google.com/store/apps/details?id=com.waypointhealth.thrive&hl=ko\n- 19.  NOVEGO 홈페이지, https://www.novego.de\n- 20.  SparkRx 홈페이지, https://www.sparkrx.com\n- 21.  SilverCloud 홈페이지, https://health.colostate.edu/silvercloud/\n- 22.  디지털치료기기 허가·심사 가이드라인 민원인 안내서, 식품의약품안전처 2020.08\n- 23.  의료기기의 사이버 보안 허가·심사 가이드라인 민원인안내서 2022.1.  21\n- 24. ",
        "original_sentence": "SilverCloud 홈페이지, https://health.colostate.edu/silvercloud/\n- 22. "
      }
    },
    {
      "chunk_id": "chunk_914",
      "text": "디지털치료기기 허가·심사 가이드라인 민원인 안내서, 식품의약품안전처 2020.08\n- 23. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 913,
        "window_size": 3,
        "char_count": 52,
        "word_count": 9,
        "page_number": 9,
        "window_text": "NOVEGO 홈페이지, https://www.novego.de\n- 20.  SparkRx 홈페이지, https://www.sparkrx.com\n- 21.  SilverCloud 홈페이지, https://health.colostate.edu/silvercloud/\n- 22.  디지털치료기기 허가·심사 가이드라인 민원인 안내서, 식품의약품안전처 2020.08\n- 23.  의료기기의 사이버 보안 허가·심사 가이드라인 민원인안내서 2022.1.  21\n- 24.  의료기기 소프트웨어 허가·심사 가이드라인, 식품의약품안전처, 2018.06\n- 25. ",
        "original_sentence": "디지털치료기기 허가·심사 가이드라인 민원인 안내서, 식품의약품안전처 2020.08\n- 23. "
      }
    },
    {
      "chunk_id": "chunk_915",
      "text": "의료기기의 사이버 보안 허가·심사 가이드라인 민원인안내서 2022.1. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 914,
        "window_size": 3,
        "char_count": 40,
        "word_count": 7,
        "page_number": 9,
        "window_text": "SparkRx 홈페이지, https://www.sparkrx.com\n- 21.  SilverCloud 홈페이지, https://health.colostate.edu/silvercloud/\n- 22.  디지털치료기기 허가·심사 가이드라인 민원인 안내서, 식품의약품안전처 2020.08\n- 23.  의료기기의 사이버 보안 허가·심사 가이드라인 민원인안내서 2022.1.  21\n- 24.  의료기기 소프트웨어 허가·심사 가이드라인, 식품의약품안전처, 2018.06\n- 25.  의료기기의 실사용증거(RWE) 적용에 대한 가이드라인 민원인 안내서 2019. ",
        "original_sentence": "의료기기의 사이버 보안 허가·심사 가이드라인 민원인안내서 2022.1. "
      }
    },
    {
      "chunk_id": "chunk_916",
      "text": "21\n- 24. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 915,
        "window_size": 3,
        "char_count": 9,
        "word_count": 3,
        "page_number": 9,
        "window_text": "SilverCloud 홈페이지, https://health.colostate.edu/silvercloud/\n- 22.  디지털치료기기 허가·심사 가이드라인 민원인 안내서, 식품의약품안전처 2020.08\n- 23.  의료기기의 사이버 보안 허가·심사 가이드라인 민원인안내서 2022.1.  21\n- 24.  의료기기 소프트웨어 허가·심사 가이드라인, 식품의약품안전처, 2018.06\n- 25.  의료기기의 실사용증거(RWE) 적용에 대한 가이드라인 민원인 안내서 2019.  02.\n",
        "original_sentence": "21\n- 24. "
      }
    },
    {
      "chunk_id": "chunk_917",
      "text": "의료기기 소프트웨어 허가·심사 가이드라인, 식품의약품안전처, 2018.06\n- 25. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 916,
        "window_size": 3,
        "char_count": 48,
        "word_count": 8,
        "page_number": 9,
        "window_text": "디지털치료기기 허가·심사 가이드라인 민원인 안내서, 식품의약품안전처 2020.08\n- 23.  의료기기의 사이버 보안 허가·심사 가이드라인 민원인안내서 2022.1.  21\n- 24.  의료기기 소프트웨어 허가·심사 가이드라인, 식품의약품안전처, 2018.06\n- 25.  의료기기의 실사용증거(RWE) 적용에 대한 가이드라인 민원인 안내서 2019.  02.\n - 26. ",
        "original_sentence": "의료기기 소프트웨어 허가·심사 가이드라인, 식품의약품안전처, 2018.06\n- 25. "
      }
    },
    {
      "chunk_id": "chunk_918",
      "text": "의료기기의 실사용증거(RWE) 적용에 대한 가이드라인 민원인 안내서 2019. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 917,
        "window_size": 3,
        "char_count": 44,
        "word_count": 8,
        "page_number": 9,
        "window_text": "의료기기의 사이버 보안 허가·심사 가이드라인 민원인안내서 2022.1.  21\n- 24.  의료기기 소프트웨어 허가·심사 가이드라인, 식품의약품안전처, 2018.06\n- 25.  의료기기의 실사용증거(RWE) 적용에 대한 가이드라인 민원인 안내서 2019.  02.\n - 26.  의료기기 소프트웨어 밸리데이션 가이드라인, 식품의약품안전처, 2007.03\n- 27. ",
        "original_sentence": "의료기기의 실사용증거(RWE) 적용에 대한 가이드라인 민원인 안내서 2019. "
      }
    },
    {
      "chunk_id": "chunk_919",
      "text": "02.\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 918,
        "window_size": 3,
        "char_count": 4,
        "word_count": 1,
        "page_number": 9,
        "window_text": "21\n- 24.  의료기기 소프트웨어 허가·심사 가이드라인, 식품의약품안전처, 2018.06\n- 25.  의료기기의 실사용증거(RWE) 적용에 대한 가이드라인 민원인 안내서 2019.  02.\n - 26.  의료기기 소프트웨어 밸리데이션 가이드라인, 식품의약품안전처, 2007.03\n- 27.  소프트웨어 밸리데이션 규격 안내서, 디지털헬스케어 소프트웨어 시험평가센터, 2018.07\n- 28. ",
        "original_sentence": "02.\n"
      }
    },
    {
      "chunk_id": "chunk_920",
      "text": "- 26. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 919,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 9,
        "window_text": "의료기기 소프트웨어 허가·심사 가이드라인, 식품의약품안전처, 2018.06\n- 25.  의료기기의 실사용증거(RWE) 적용에 대한 가이드라인 민원인 안내서 2019.  02.\n - 26.  의료기기 소프트웨어 밸리데이션 가이드라인, 식품의약품안전처, 2007.03\n- 27.  소프트웨어 밸리데이션 규격 안내서, 디지털헬스케어 소프트웨어 시험평가센터, 2018.07\n- 28.  니코틴 사용장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원\n- 29. ",
        "original_sentence": "- 26. "
      }
    },
    {
      "chunk_id": "chunk_921",
      "text": "의료기기 소프트웨어 밸리데이션 가이드라인, 식품의약품안전처, 2007.03\n- 27. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 920,
        "window_size": 3,
        "char_count": 48,
        "word_count": 8,
        "page_number": 9,
        "window_text": "의료기기의 실사용증거(RWE) 적용에 대한 가이드라인 민원인 안내서 2019.  02.\n - 26.  의료기기 소프트웨어 밸리데이션 가이드라인, 식품의약품안전처, 2007.03\n- 27.  소프트웨어 밸리데이션 규격 안내서, 디지털헬스케어 소프트웨어 시험평가센터, 2018.07\n- 28.  니코틴 사용장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원\n- 29.  알코올 사용장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원\n- 30. ",
        "original_sentence": "의료기기 소프트웨어 밸리데이션 가이드라인, 식품의약품안전처, 2007.03\n- 27. "
      }
    },
    {
      "chunk_id": "chunk_922",
      "text": "소프트웨어 밸리데이션 규격 안내서, 디지털헬스케어 소프트웨어 시험평가센터, 2018.07\n- 28. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 921,
        "window_size": 3,
        "char_count": 56,
        "word_count": 10,
        "page_number": 9,
        "window_text": "02.\n - 26.  의료기기 소프트웨어 밸리데이션 가이드라인, 식품의약품안전처, 2007.03\n- 27.  소프트웨어 밸리데이션 규격 안내서, 디지털헬스케어 소프트웨어 시험평가센터, 2018.07\n- 28.  니코틴 사용장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원\n- 29.  알코올 사용장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원\n- 30.  불면증 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원인 안내서,\n- 31. ",
        "original_sentence": "소프트웨어 밸리데이션 규격 안내서, 디지털헬스케어 소프트웨어 시험평가센터, 2018.07\n- 28. "
      }
    },
    {
      "chunk_id": "chunk_923",
      "text": "니코틴 사용장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원\n- 29. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 922,
        "window_size": 3,
        "char_count": 58,
        "word_count": 13,
        "page_number": 1,
        "window_text": "- 26.  의료기기 소프트웨어 밸리데이션 가이드라인, 식품의약품안전처, 2007.03\n- 27.  소프트웨어 밸리데이션 규격 안내서, 디지털헬스케어 소프트웨어 시험평가센터, 2018.07\n- 28.  니코틴 사용장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원\n- 29.  알코올 사용장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원\n- 30.  불면증 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원인 안내서,\n- 31.  Van Hees, M. L., Rotter, T., Ellermann, T., & Evers, S. M. ",
        "original_sentence": "니코틴 사용장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원\n- 29. "
      }
    },
    {
      "chunk_id": "chunk_924",
      "text": "알코올 사용장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원\n- 30. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 923,
        "window_size": 3,
        "char_count": 58,
        "word_count": 13,
        "page_number": 1,
        "window_text": "의료기기 소프트웨어 밸리데이션 가이드라인, 식품의약품안전처, 2007.03\n- 27.  소프트웨어 밸리데이션 규격 안내서, 디지털헬스케어 소프트웨어 시험평가센터, 2018.07\n- 28.  니코틴 사용장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원\n- 29.  알코올 사용장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원\n- 30.  불면증 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원인 안내서,\n- 31.  Van Hees, M. L., Rotter, T., Ellermann, T., & Evers, S. M.  (2013). ",
        "original_sentence": "알코올 사용장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원\n- 30. "
      }
    },
    {
      "chunk_id": "chunk_925",
      "text": "불면증 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원인 안내서,\n- 31. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 924,
        "window_size": 3,
        "char_count": 59,
        "word_count": 13,
        "page_number": 1,
        "window_text": "소프트웨어 밸리데이션 규격 안내서, 디지털헬스케어 소프트웨어 시험평가센터, 2018.07\n- 28.  니코틴 사용장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원\n- 29.  알코올 사용장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원\n- 30.  불면증 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원인 안내서,\n- 31.  Van Hees, M. L., Rotter, T., Ellermann, T., & Evers, S. M.  (2013).  The effectiveness of individual\ninterpersonal psychotherapy as a treatment for major depressive disorder in adult outpatients: a\n\n- 32. ",
        "original_sentence": "불면증 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원인 안내서,\n- 31. "
      }
    },
    {
      "chunk_id": "chunk_926",
      "text": "Van Hees, M. L., Rotter, T., Ellermann, T., & Evers, S. M. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 925,
        "window_size": 3,
        "char_count": 59,
        "word_count": 12,
        "page_number": 127,
        "window_text": "니코틴 사용장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원\n- 29.  알코올 사용장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원\n- 30.  불면증 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원인 안내서,\n- 31.  Van Hees, M. L., Rotter, T., Ellermann, T., & Evers, S. M.  (2013).  The effectiveness of individual\ninterpersonal psychotherapy as a treatment for major depressive disorder in adult outpatients: a\n\n- 32.  Andersson, G., Bergström, J., Holländare, F., Carlbring, P. E. R., Kaldo, V., & Ekselius, L. ",
        "original_sentence": "Van Hees, M. L., Rotter, T., Ellermann, T., & Evers, S. M. "
      }
    },
    {
      "chunk_id": "chunk_927",
      "text": "(2013). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 926,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "알코올 사용장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원\n- 30.  불면증 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원인 안내서,\n- 31.  Van Hees, M. L., Rotter, T., Ellermann, T., & Evers, S. M.  (2013).  The effectiveness of individual\ninterpersonal psychotherapy as a treatment for major depressive disorder in adult outpatients: a\n\n- 32.  Andersson, G., Bergström, J., Holländare, F., Carlbring, P. E. R., Kaldo, V., & Ekselius, L.  (2005).\n",
        "original_sentence": "(2013). "
      }
    },
    {
      "chunk_id": "chunk_928",
      "text": "The effectiveness of individual\ninterpersonal psychotherapy as a treatment for major depressive disorder in adult outpatients: a\n\n- 32. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 927,
        "window_size": 3,
        "char_count": 136,
        "word_count": 19,
        "page_number": 1,
        "window_text": "불면증 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성 가이드라인 민원인 안내서,\n- 31.  Van Hees, M. L., Rotter, T., Ellermann, T., & Evers, S. M.  (2013).  The effectiveness of individual\ninterpersonal psychotherapy as a treatment for major depressive disorder in adult outpatients: a\n\n- 32.  Andersson, G., Bergström, J., Holländare, F., Carlbring, P. E. R., Kaldo, V., & Ekselius, L.  (2005).\n Internet-based self-help for depression: randomised controlled trial. ",
        "original_sentence": "The effectiveness of individual\ninterpersonal psychotherapy as a treatment for major depressive disorder in adult outpatients: a\n\n- 32. "
      }
    },
    {
      "chunk_id": "chunk_929",
      "text": "Andersson, G., Bergström, J., Holländare, F., Carlbring, P. E. R., Kaldo, V., & Ekselius, L. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 928,
        "window_size": 3,
        "char_count": 93,
        "word_count": 15,
        "page_number": 127,
        "window_text": "Van Hees, M. L., Rotter, T., Ellermann, T., & Evers, S. M.  (2013).  The effectiveness of individual\ninterpersonal psychotherapy as a treatment for major depressive disorder in adult outpatients: a\n\n- 32.  Andersson, G., Bergström, J., Holländare, F., Carlbring, P. E. R., Kaldo, V., & Ekselius, L.  (2005).\n Internet-based self-help for depression: randomised controlled trial.  The British Journal of\n\n- 33. ",
        "original_sentence": "Andersson, G., Bergström, J., Holländare, F., Carlbring, P. E. R., Kaldo, V., & Ekselius, L. "
      }
    },
    {
      "chunk_id": "chunk_930",
      "text": "(2005).\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 929,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "(2013).  The effectiveness of individual\ninterpersonal psychotherapy as a treatment for major depressive disorder in adult outpatients: a\n\n- 32.  Andersson, G., Bergström, J., Holländare, F., Carlbring, P. E. R., Kaldo, V., & Ekselius, L.  (2005).\n Internet-based self-help for depression: randomised controlled trial.  The British Journal of\n\n- 33.  Twomey, C., O’Reilly, G., Bültmann, O., & Meyer, B. ",
        "original_sentence": "(2005).\n"
      }
    },
    {
      "chunk_id": "chunk_931",
      "text": "Internet-based self-help for depression: randomised controlled trial. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 930,
        "window_size": 3,
        "char_count": 70,
        "word_count": 7,
        "page_number": 29,
        "window_text": "The effectiveness of individual\ninterpersonal psychotherapy as a treatment for major depressive disorder in adult outpatients: a\n\n- 32.  Andersson, G., Bergström, J., Holländare, F., Carlbring, P. E. R., Kaldo, V., & Ekselius, L.  (2005).\n Internet-based self-help for depression: randomised controlled trial.  The British Journal of\n\n- 33.  Twomey, C., O’Reilly, G., Bültmann, O., & Meyer, B.  (2020). ",
        "original_sentence": "Internet-based self-help for depression: randomised controlled trial. "
      }
    },
    {
      "chunk_id": "chunk_932",
      "text": "The British Journal of\n\n- 33. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 931,
        "window_size": 3,
        "char_count": 30,
        "word_count": 6,
        "page_number": 29,
        "window_text": "Andersson, G., Bergström, J., Holländare, F., Carlbring, P. E. R., Kaldo, V., & Ekselius, L.  (2005).\n Internet-based self-help for depression: randomised controlled trial.  The British Journal of\n\n- 33.  Twomey, C., O’Reilly, G., Bültmann, O., & Meyer, B.  (2020).  Effectiveness of a tailored,\nintegrative Internet intervention (deprexis) for depression: Updated meta-analysis. ",
        "original_sentence": "The British Journal of\n\n- 33. "
      }
    },
    {
      "chunk_id": "chunk_933",
      "text": "Twomey, C., O’Reilly, G., Bültmann, O., & Meyer, B. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 932,
        "window_size": 3,
        "char_count": 52,
        "word_count": 9,
        "page_number": 85,
        "window_text": "(2005).\n Internet-based self-help for depression: randomised controlled trial.  The British Journal of\n\n- 33.  Twomey, C., O’Reilly, G., Bültmann, O., & Meyer, B.  (2020).  Effectiveness of a tailored,\nintegrative Internet intervention (deprexis) for depression: Updated meta-analysis.  PLoS One, 15(1),\n\n- 34. ",
        "original_sentence": "Twomey, C., O’Reilly, G., Bültmann, O., & Meyer, B. "
      }
    },
    {
      "chunk_id": "chunk_934",
      "text": "(2020). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 933,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "Internet-based self-help for depression: randomised controlled trial.  The British Journal of\n\n- 33.  Twomey, C., O’Reilly, G., Bültmann, O., & Meyer, B.  (2020).  Effectiveness of a tailored,\nintegrative Internet intervention (deprexis) for depression: Updated meta-analysis.  PLoS One, 15(1),\n\n- 34.  Meyer, B., Berger, T., Caspar, F., Beevers, C., Andersson, G., & Weiss, M. ",
        "original_sentence": "(2020). "
      }
    },
    {
      "chunk_id": "chunk_935",
      "text": "Effectiveness of a tailored,\nintegrative Internet intervention (deprexis) for depression: Updated meta-analysis. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 934,
        "window_size": 3,
        "char_count": 113,
        "word_count": 12,
        "page_number": 1,
        "window_text": "The British Journal of\n\n- 33.  Twomey, C., O’Reilly, G., Bültmann, O., & Meyer, B.  (2020).  Effectiveness of a tailored,\nintegrative Internet intervention (deprexis) for depression: Updated meta-analysis.  PLoS One, 15(1),\n\n- 34.  Meyer, B., Berger, T., Caspar, F., Beevers, C., Andersson, G., & Weiss, M.  (2009). ",
        "original_sentence": "Effectiveness of a tailored,\nintegrative Internet intervention (deprexis) for depression: Updated meta-analysis. "
      }
    },
    {
      "chunk_id": "chunk_936",
      "text": "PLoS One, 15(1),\n\n- 34. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 935,
        "window_size": 3,
        "char_count": 24,
        "word_count": 5,
        "page_number": 28,
        "window_text": "Twomey, C., O’Reilly, G., Bültmann, O., & Meyer, B.  (2020).  Effectiveness of a tailored,\nintegrative Internet intervention (deprexis) for depression: Updated meta-analysis.  PLoS One, 15(1),\n\n- 34.  Meyer, B., Berger, T., Caspar, F., Beevers, C., Andersson, G., & Weiss, M.  (2009).  Effectiveness of\na novel integrative online treatment for depression (Deprexis): randomized controlled trial. ",
        "original_sentence": "PLoS One, 15(1),\n\n- 34. "
      }
    },
    {
      "chunk_id": "chunk_937",
      "text": "Meyer, B., Berger, T., Caspar, F., Beevers, C., Andersson, G., & Weiss, M. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 936,
        "window_size": 3,
        "char_count": 75,
        "word_count": 13,
        "page_number": 127,
        "window_text": "(2020).  Effectiveness of a tailored,\nintegrative Internet intervention (deprexis) for depression: Updated meta-analysis.  PLoS One, 15(1),\n\n- 34.  Meyer, B., Berger, T., Caspar, F., Beevers, C., Andersson, G., & Weiss, M.  (2009).  Effectiveness of\na novel integrative online treatment for depression (Deprexis): randomized controlled trial.  Journal\n\n- 35. ",
        "original_sentence": "Meyer, B., Berger, T., Caspar, F., Beevers, C., Andersson, G., & Weiss, M. "
      }
    },
    {
      "chunk_id": "chunk_938",
      "text": "(2009). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 937,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "Effectiveness of a tailored,\nintegrative Internet intervention (deprexis) for depression: Updated meta-analysis.  PLoS One, 15(1),\n\n- 34.  Meyer, B., Berger, T., Caspar, F., Beevers, C., Andersson, G., & Weiss, M.  (2009).  Effectiveness of\na novel integrative online treatment for depression (Deprexis): randomized controlled trial.  Journal\n\n- 35.  Vernmark, K., Lenndin, J., Bjärehed, J., Carlsson, M., Karlsson, J., Öberg, J., ... & Andersson, G.\n",
        "original_sentence": "(2009). "
      }
    },
    {
      "chunk_id": "chunk_939",
      "text": "Effectiveness of\na novel integrative online treatment for depression (Deprexis): randomized controlled trial. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 938,
        "window_size": 3,
        "char_count": 110,
        "word_count": 13,
        "page_number": 1,
        "window_text": "PLoS One, 15(1),\n\n- 34.  Meyer, B., Berger, T., Caspar, F., Beevers, C., Andersson, G., & Weiss, M.  (2009).  Effectiveness of\na novel integrative online treatment for depression (Deprexis): randomized controlled trial.  Journal\n\n- 35.  Vernmark, K., Lenndin, J., Bjärehed, J., Carlsson, M., Karlsson, J., Öberg, J., ... & Andersson, G.\n - (2010). ",
        "original_sentence": "Effectiveness of\na novel integrative online treatment for depression (Deprexis): randomized controlled trial. "
      }
    },
    {
      "chunk_id": "chunk_940",
      "text": "Journal\n\n- 35. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 939,
        "window_size": 3,
        "char_count": 15,
        "word_count": 3,
        "page_number": 29,
        "window_text": "Meyer, B., Berger, T., Caspar, F., Beevers, C., Andersson, G., & Weiss, M.  (2009).  Effectiveness of\na novel integrative online treatment for depression (Deprexis): randomized controlled trial.  Journal\n\n- 35.  Vernmark, K., Lenndin, J., Bjärehed, J., Carlsson, M., Karlsson, J., Öberg, J., ... & Andersson, G.\n - (2010).  Internet administered guided self-help versus individualized e-mail therapy: A randomized\n- 36. ",
        "original_sentence": "Journal\n\n- 35. "
      }
    },
    {
      "chunk_id": "chunk_941",
      "text": "Vernmark, K., Lenndin, J., Bjärehed, J., Carlsson, M., Karlsson, J., Öberg, J., ... & Andersson, G.\n",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 940,
        "window_size": 3,
        "char_count": 100,
        "word_count": 16,
        "page_number": 127,
        "window_text": "(2009).  Effectiveness of\na novel integrative online treatment for depression (Deprexis): randomized controlled trial.  Journal\n\n- 35.  Vernmark, K., Lenndin, J., Bjärehed, J., Carlsson, M., Karlsson, J., Öberg, J., ... & Andersson, G.\n - (2010).  Internet administered guided self-help versus individualized e-mail therapy: A randomized\n- 36.  Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., & Erbaugh, J. ",
        "original_sentence": "Vernmark, K., Lenndin, J., Bjärehed, J., Carlsson, M., Karlsson, J., Öberg, J., ... & Andersson, G.\n"
      }
    },
    {
      "chunk_id": "chunk_942",
      "text": "- (2010). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 941,
        "window_size": 3,
        "char_count": 10,
        "word_count": 2,
        "page_number": 9,
        "window_text": "Effectiveness of\na novel integrative online treatment for depression (Deprexis): randomized controlled trial.  Journal\n\n- 35.  Vernmark, K., Lenndin, J., Bjärehed, J., Carlsson, M., Karlsson, J., Öberg, J., ... & Andersson, G.\n - (2010).  Internet administered guided self-help versus individualized e-mail therapy: A randomized\n- 36.  Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., & Erbaugh, J.  (1961). ",
        "original_sentence": "- (2010). "
      }
    },
    {
      "chunk_id": "chunk_943",
      "text": "Internet administered guided self-help versus individualized e-mail therapy: A randomized\n- 36. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 942,
        "window_size": 3,
        "char_count": 96,
        "word_count": 12,
        "page_number": 29,
        "window_text": "Journal\n\n- 35.  Vernmark, K., Lenndin, J., Bjärehed, J., Carlsson, M., Karlsson, J., Öberg, J., ... & Andersson, G.\n - (2010).  Internet administered guided self-help versus individualized e-mail therapy: A randomized\n- 36.  Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., & Erbaugh, J.  (1961).  An inventory for",
        "original_sentence": "Internet administered guided self-help versus individualized e-mail therapy: A randomized\n- 36. "
      }
    },
    {
      "chunk_id": "chunk_944",
      "text": "Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., & Erbaugh, J. ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 943,
        "window_size": 3,
        "char_count": 65,
        "word_count": 13,
        "page_number": 127,
        "window_text": "Vernmark, K., Lenndin, J., Bjärehed, J., Carlsson, M., Karlsson, J., Öberg, J., ... & Andersson, G.\n - (2010).  Internet administered guided self-help versus individualized e-mail therapy: A randomized\n- 36.  Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., & Erbaugh, J.  (1961).  An inventory for",
        "original_sentence": "Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., & Erbaugh, J. "
      }
    },
    {
      "chunk_id": "chunk_945",
      "text": "(1961). ",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 944,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 28,
        "window_text": "- (2010).  Internet administered guided self-help versus individualized e-mail therapy: A randomized\n- 36.  Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., & Erbaugh, J.  (1961).  An inventory for",
        "original_sentence": "(1961). "
      }
    },
    {
      "chunk_id": "chunk_946",
      "text": "An inventory for",
      "metadata": {
        "source": "우울장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인(민원인+안내서).pdf",
        "chunk_index": 945,
        "window_size": 3,
        "char_count": 16,
        "word_count": 3,
        "page_number": 127,
        "window_text": "Internet administered guided self-help versus individualized e-mail therapy: A randomized\n- 36.  Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., & Erbaugh, J.  (1961).  An inventory for",
        "original_sentence": "An inventory for"
      }
    }
  ],
  "chunking_analysis": {
    "total_chunks": 946,
    "avg_chunk_length": 129.20401691331924,
    "min_chunk_length": 4,
    "max_chunk_length": 1508,
    "total_characters": 122227,
    "total_words": 26011,
    "window_size": 3
  },
  "statistics": {
    "total_text_blocks": 3685,
    "heading_count": 1216,
    "paragraph_count": 154,
    "list_item_count": 170,
    "table_cell_count": 2145,
    "tables_detected": 21,
    "chunks_generated": 946
  }
}